(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
04 November 2021 (04.11.2021)

WIPO | PCT

(10) International Publication Number
WO 2021/222556 A1

(51) International Patent Classification:
C07D 487/04 (2006.01)

(21) International Application Number:
PCT/US2021/029882

(22) International Filing Date:
29 April 2021 (29.04.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

63/017,571	29 April 2020 (29.04.2020)	US
63/066,489	17 August 2020 (17.08.2020)	US

(71) Applicants: **RELAY THERAPEUTICS, INC.** [US/US]; 399 Binney Street, 2nd Floor, Cambridge, Massachusetts 02139 (US). **D.E. SHAW RESEARCH, LLC** [US/US]; 120 West 45th Street, 39th Floor, New York, New York 10036 (US).

(72) Inventors: **BOEZIO, Alessandro**; 399 Binney Street, 2nd Floor, Cambridge, Massachusetts 02139 (US). **DIPIETRO, Lucian V.**; 399 Binney Street, 2nd Floor, Cambridge, Massachusetts 02139 (US). **FRIDRICH, Cary Griffin**; 399 Binney Street, 2nd Floor, Cambridge, Massachusetts 02139 (US). **GUNAYDIN, Hakan**; 399 Binney Street, 2nd Floor, Cambridge, Massachusetts 02139 (US). **KURUKULASURIYA, Ravi**; 399 Binney Street, 2nd Floor, Cambridge, Massachusetts 02139 (US). **LESCARBEAU, Andre**; 399 Binney Street, 2nd Floor, Cambridge, Massachusetts 02139 (US). **MADER, Mary M.**; 399 Binney Street, 2nd Floor, Cambridge, Massachusetts 02139 (US). **MCLEAN, Thomas H.**; 399 Binney Street, 2nd Floor, Cambridge, Massachusetts 02139 (US). **PIERCE, Levi Charles Thomas**; 399 Binney Street, 2nd Floor, Cambridge, Massachusetts 02139 (US). **RAYNOR, Kevin David**; 399 Binney Street, 2nd Floor, Cambridge, Massachusetts 02139 (US). **SHORTSLEEVES, Kelley C.**; 399 Binney Street, 2nd Floor, Cambridge, Massachusetts 02139 (US). **TANG, Yong**; 399 Binney Street, 2nd Floor, Cambridge, Massachusetts 02139 (US). **TAYLOR, Alexander M.**; 399 Binney Street, 2nd Floor, Cambridge, Massachusetts 02139 (US). **WALTERS, W. Patrick**; 399 Binney Street, 2nd Floor, Cambridge, Massachusetts 02139 (US). **ZHANG, Hanmo**; 399 Binney Street, 2nd Floor, Cambridge, Massachusetts 02139 (US). **GIORDANETTO, Fabrizio**; 120 West 45th Street, 39th Floor, New York, New York 10036 (US). **PECHERSKY, Yakov**; 120 West 45th Street, 39th Floor, New York, New York 10036 (US). **WANG, Qi**; 120 West 45th Street, 39th Floor, New York, New York 10036 (US). **ATIENZA, Bren-Jordan**; 2525 Marie-Curie, Montreal, Québec H4S 2E1 (CA). **BERTRAND-LAPERLE, Megan**; 2525 Marie-Curie, Montreal, Québec H4S 2E1 (CA). **BURNIE, Andrew J.**; 2525 Marie-Curie, Montreal, Québec H4S 2E1 (CA). **CHEN, Fei**; 2525 Marie-Curie, Montreal, Québec H4S 2E1 (CA). **CHITALE, Sampada**; 2525 Marie-Curie, Montreal, Québec H4S 2E1 (CA). **GELOZIA, Shorena**; 2525 Marie-Curie, Montreal, Québec H4S 2E1 (CA). **GIGUERE, Jean-Benoit**; 2525 Marie-Curie, Montreal, Québec H4S 2E1 (CA). **LANDAGARAY, Elodie**; 2525 Marie-Curie, Montreal, Québec H4S 2E1 (CA). **LARIVEE, Alexandre**; 2525 Marie-Curie, Montreal, Québec H4S 2E1 (CA). **LEPITRE, Thomas**; 2525 Marie-Curie, Montreal, Québec H4S 2E1 (CA). **MAERTENS, Gaetan**; 2525 Marie-Curie, Montreal, Québec H4S 2E1 (CA). **OUTIN, Johanne**; 2525 Marie-Curie, Montreal, Québec H4S 2E1 (CA). **PAL, Mohan**; 2525 Marie-Curie, Montreal, Québec H4S 2E1 (CA). **STURINO, Claudio**; 2525 Marie-Curie, Montreal, Québec H4S 2E1 (CA). **TANVEER, Kashif**; 2525 Marie-Curie, Montreal, Québec H4S 2E1 (CA). **THORAT, Rakesh**; 2525 Marie-Curie, Montreal, Québec H4S 2E1 (CA). **VEMULA, Naresh**; 2525 Marie-Curie, Montreal, Québec H4S 2E1 (CA). **KRUEGER, Elaine B.**; 399 Binney Street, 2nd Floor, Cambridge, Massachusetts 02139 (US). **PAN, Yue**; 399 Binney Street, 2nd Floor, Cambridge, Massachusetts 02139 (US). **DENINNO, Michael Paul**; 9 Hermitage Drive, Gales Ferry, Connecticut 06335 (US). **BOUSQUET, Yves**; 2525 Marie-Curie, Montreal, Québec H4S 2E1 (CA). **JOBIN-DES LAURIERS, Antoine**; 2525 Marie-Curie, Montreal, Québec H4S 2E1 (CA). **LEE, Jessica**; 2525 Marie-Curie, Montreal, Québec H4S 2E1 (CA). **MOHAMMED, Tarek**; 2525 Marie-Curie, Montreal, Québec H4S 2E1 (CA).

(74) Agent: **REID, Andrea L.C.** et al.; c/o Dechert LLP, One International Place, 40th Floor, 100 Oliver Street, Boston, Massachusetts 02110-2605 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,

(54) Title: PI3K-α INHIBITORS AND METHODS OF USE THEREOF

(57) Abstract: The present disclosure relates to novel compounds and pharmaceutical compositions thereof, and methods for inhibiting the activity of PI3K-α enzymes with the compounds and compositions of the disclosure. The present disclosure further relates to, but is not limited to, methods for treating disorders associated with PI3K-α signaling with the compounds and compositions of the disclosure.

WO 2021/222556 A1

[Continued on next page]

SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

PI3Kα INHIBITORS AND METHODS OF USE THEREOF

CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims the benefit of U.S. Provisional Application No. 63/017,571, filed on April 29, 2020, and U.S. Provisional Application No.63/066,489, filed on August 17, 2020; the entirety of each of which is hereby incorporated by reference.

BACKGROUND

[0002] Phosphatidylinositol 3-kinases (PI3Ks) comprise a family of lipid kinases that catalyze the transfer of phosphate to the D-3' position of inositol lipids to produce phosphoinositol-3-phosphate (PIP), phosphoinositol-3,4-diphosphate (PIP_2) and phosphoinositol-3,4,5-triphosphate (PIP_3), which, in turn, act as second messengers in signaling cascades by docking proteins containing pleckstrin-homology, FYVE, Phox and other phospholipid-binding domains into a variety of signaling complexes often at the plasma membrane (Vanhaesebroeck et al., Annu. Rev. Biochem 70:535 (2001); Katso et al., Annu. Rev. Cell Dev. Biol. 17:615 (2001)). Of the two Class 1 PI3K sub-classes, Class 1A PI3Ks are heterodimers composed of a catalytic p110 subunit (alpha, beta, or delta isoforms) constitutively associated with a regulatory subunit that can be p85 alpha, p55 alpha, p50 alpha, p85 beta, or p55 gamma. The Class 1B sub-class has one family member, a heterodimer composed of a catalytic p110 gamma subunit associated with one of two regulatory subunits, p101 or p84 (Fruman et al., Annu Rev. Biochem. 67:481 (1998); Suire et al., Curr. Biol. 15:566 (2005)). The modular domains of the p85/55/50 subunits include Src Homology (SH2) domains that bind phosphotyrosine residues in a specific sequence context on activated receptor and cytoplasmic tyrosine kinases, resulting in activation and localization of Class 1A PI3Ks. Class 1B PI3K is activated directly by G protein-coupled receptors that bind a diverse repertoire of peptide and non-peptide ligands (Stephens et al., Cell 89:105 (1997); Katso et al., Annu. Rev. Cell Dev. Biol. 17:615-675 (2001)).

[0003] Consequently, the resultant phospholipid products of Class I PI3Ks link upstream receptors with downstream cellular activities including proliferation, survival, chemotaxis, cellular trafficking, motility, metabolism, inflammatory and allergic responses, transcription and translation (Cantley et al., Cell 64:281 (1991); Escobedo and Williams, Nature 335:85 (1988); Fantl et al., Cell 69:413 (1992)). In many cases, PIP_2 and PIP_3 recruit Aid, the

product of the human homologue of the viral oncogene v-Akt, to the plasma membrane where it acts as a nodal point for many intracellular signaling pathways important for growth and survival (Fantl et al., Cell 69:413-423 (1992); Bader et al., Nature Rev. Cancer 5:921 (2005); Vivanco and Sawyer, Nature Rev. Cancer 2:489 (2002)).


[0004] Aberrant regulation of PI3K, which often increases survival through Aid activation, is one of the most prevalent events in human cancer and has been shown to occur at multiple levels. The tumor suppressor gene PTEN, which dephosphorylates phosphoinositides at the 3' position of the inositol ring, and in so doing antagonizes PI3K activity, is functionally deleted in a variety of tumors. In other tumors, the genes for the p110 alpha isoform, PIK3CA, and for Akt are amplified, and increased protein expression of their gene products has been demonstrated in several human cancers. Furthermore, mutations and translocation of p85 alpha that serve to up-regulate the p85-p110 complex have been described in human cancers. Finally, somatic missense mutations in PIK3CA that activate downstream signaling pathways have been described at significant frequencies in a wide diversity of human cancers (Kang et el., Proc. Natl. Acad. Sci. USA 102:802 (2005); Samuels et al., Science 304:554 (2004); Samuels et al., Cancer Cell 7:561-573 (2005)). These observations show that deregulation of phosphoinositol-3 kinase, and the upstream and downstream components of this signaling pathway, is one of the most common deregulations associated with human cancers and proliferative diseases (Parsons et al., Nature 436:792 (2005); Hennessey at el., Nature Rev. Drug Disc. 4:988-1004 (2005)).

[0005] In view of the above, inhibitors of PI3Kα would be of particular value in the treatment of proliferative disease and other disorders. While multiple inhibitors of PI3Ks have been developed (for example, taselisib, alpelisib, buparlisib and others), these molecules inhibit multiple Class 1A PI3K isoforms. Inhibitors that are active against multiple Class 1A PI3K isoforms are known as "pan-PI3K" inhibitors. A major hurdle for the clinical development of existing PI3K inhibitors has been the inability to achieve the required level of target inhibition in tumors while avoiding toxicity in cancer patients. Pan-PI3K inhibitors share certain target-related toxicities including diarrhea, rash, fatigue, and hyperglycemia. The toxicity of PI3K inhibitors is dependent on their isoform selectivity profile. Inhibition of PI3Kα is associated with hyperglycemia and rash, whereas inhibition of PI3Kδ or PI3Kγ is associated with diarrhea, myelosuppression, and transaminitis (Hanker et al., Cancer Discovery (2019) PMID: 30837161. Therefore, selective inhibitors of PI3Kα may increase

the therapeutic window, enabling sufficient target inhibition in the tumor while avoiding dose-limiting toxicity in cancer patients.

SUMMARY


[0006] In some embodiments, the present disclosure provides a compound of formula I-1:



I-1

or a pharmaceutically acceptable salt thereof, wherein each of R^1, R^2, Q, E, X, Y, and Z is as defined in embodiments and classes and subclasses herein.

[0007] In some embodiments, the present disclosure provides a compound of formula I:



I

or a pharmaceutically acceptable salt thereof, wherein each of R^1, R^2, Q, E, X, Y, and Z is as defined in embodiments and classes and subclasses herein.

[0008] In some embodiments, the present invention provides a pharmaceutical composition comprising a compound of formula I, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant, or diluent.

[0009] In some embodiments, the present invention provides a method of treating a PI3Kα-mediated disorder comprising administering to a patient in need thereof a compound of formula I, or composition comprising said compound.


[0010] In some embodiments, the present invention provides a process for providing a compound of formula I, or synthetic intermediates thereof.

[0011] In some embodiments, the present invention provides a process for providing pharmaceutical compositions comprising compounds of formula I.

DETAILED DESCRIPTION

1. General Description of Certain Embodiments of the Invention

[0012] Compounds of the present invention, and pharmaceutical compositions thereof, are useful as inhibitors of PI3Kα. In some embodiments, the present invention provides a compound of formula I:



I

or a pharmaceutically acceptable salt thereof, wherein:

E is -C(O)-, -C(R^E)$_2$-, -C(R^E)$_2$C(R^E)$_2$-, -C(S)-, -S(O)$_2$-, -OC(O)-, -N(R^E)C(O)-, -C(O)N(R^E)-, or -C(R^E)$_2$C(O)-;

Q is CH, C(R^Q), or N;

X is CH, C(R^X), or N;

Y is CH, C(R^Y), or N;

Z is CH, C(R^Z), or N;

R^1 is -L^1-R^{1A};

R^2 is -L^2-R^{2A};

each instance of R^E is independently H or -L^E-R^{EA};

R^Q is -L^Q-R^{QA};

R^X is -L^X-R^{XA};

R^Y is -L^Y-R^{YA};

R^Z is -L^Z-R^{ZA}; or

two instances of R^E are taken together with their intervening atoms to form a 3-8 membered saturated or partially unsaturated monocyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or an 8-12 membered saturated or partially unsaturated bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein each ring is substituted with n instances of R^{EEC};

R^Q and R^1 are taken together with their intervening atoms to form a 4-8 membered saturated or partially unsaturated monocyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or an 8-12 membered saturated or partially unsaturated bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein each ring is substituted with p instances of R^{Q1C};

R^Y and R^Z are taken together with their intervening atoms to form a 4-7 membered partially unsaturated or aromatic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said ring is substituted with q instances of R^{YZC};

each of L^1, L^2, L^E, L^Q, L^X, L^Y, and L^Z is independently a covalent bond, or a C_{1-4} bivalent saturated or unsaturated, straight or branched hydrocarbon chain wherein one or two methylene units of the chain are optionally and independently replaced by $-CH(R^L)-$, $-C(R^L)_2-$, C_{3-6} cycloalkylene, C_{3-6} heterocycloalkylene, -N(R)-, -N(R)C(O)-, -N(R)C(NR)-, -N(R)C(NOR)-, -N(R)C(NCN)-, -C(O)N(R)-, $-N(R)S(O)_2-$, $-S(O)_2N(R)-$, -O-, -C(O)-, -OC(O)-, -C(O)O-, -S-, -S(O)- , or $-S(O)_2-$;

R^{1A} is R^A or R^B substituted by r^1 instances of R^{1C};

R^{2A} is R^A or R^B substituted by r^2 instances of R^{2C};

R^{EA} is R^A or R^B substituted by r^3 instances of R^{EC};

R^{QA} is R^A or R^B substituted by r^4 instances of R^{QC};

R^{XA} is R^A or R^B substituted by r^5 instances of R^{XC};

R^{YA} is R^A or R^B substituted by r^6 instances of R^{YC};

R^{ZA} is R^A or R^B substituted by r^7 instances of R^{ZC};

R^L is R^A or R^B substituted by r^8 instances of R^{LC};

each instance of R^A is independently oxo, deuterium, halogen, -CN, $-NO_2$, -OR, $-SF_5$, -SR, $-NR_2$, $-S(O)_2R$, $-S(O)_2NR_2$, $-S(O)_2F$, -S(O)R, $-S(O)NR_2$, -S(O)(NR)R, -C(O)R, -C(O)OR, $-C(O)NR_2$, -C(O)N(R)OR, -OC(O)R, $-OC(O)NR_2$, -N(R)C(O)OR, -N(R)C(O)R, $-N(R)C(O)NR_2$, $-N(R)C(NR)NR_2$, $-N(R)S(O)_2NR_2$, $-N(R)S(O)_2R$, $-P(O)R_2$, -P(O)(R)OR, or $-B(OR)_2$;

each instance of R^B is independently a C_{1-6} aliphatic chain; phenyl; naphthyl; cubanyl; adamantyl; a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; an 8-10 membered bicyclic

heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring; a 5-12 membered saturated or partially unsaturated bicyclic carbocyclic ring; a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or a 7-12 membered saturated or partially unsaturated bicyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;

each instance of R^{1C}, R^{2C}, R^{EC}, R^{QC}, R^{XC}, R^{YC}, R^{ZC}, R^{LC}, R^{EEC}, R^{Q1C}, and R^{YZC} is independently oxo, deuterium, halogen, -CN, $-NO_2$, -OR, $-SF_5$, -SR, $-NR_2$, $-S(O)_2R$, $-S(O)_2NR_2$, $-S(O)_2F$, -S(O)R, $-S(O)NR_2$, -S(O)(NR)R, -C(O)R, -C(O)OR, $-C(O)NR_2$, -C(O)N(R)OR, -OC(O)R, $-OC(O)NR_2$, -N(R)C(O)OR, -N(R)C(O)R, $-N(R)C(O)NR_2$, $-N(R)C(NR)NR_2$, $-N(R)S(O)_2NR_2$, $-N(R)S(O)_2R$, $-P(O)R_2$, -P(O)(R)OR, $-B(OR)_2$, or an optionally substituted group selected from C_{1-6} aliphatic, phenyl, a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;

each instance of R is independently hydrogen, or an optionally substituted group selected from C_{1-6} aliphatic, phenyl, a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or

two R groups on the same nitrogen are taken together with their intervening atoms to form a 4-7 membered saturated, partially unsaturated, or heteroaryl ring having 0-3 heteroatoms, in addition to the nitrogen, independently selected from nitrogen, oxygen, and sulfur; and

each of n, p, q, r^1, r^2, r^3, r^4, r^5, r^6, r^7, and r^8 is independently 0, 1, 2, 3, or 4.

2. Compounds and Definitions

[0013] Compounds of the present invention include those described generally herein, and are further illustrated by the classes, subclasses, and species disclosed herein. As used herein, the following definitions shall apply unless otherwise indicated. For purposes of this invention, the chemical elements are identified in accordance with the Periodic Table of the Elements, CAS version, Handbook of Chemistry and Physics, 75th Ed. Additionally, general principles

of organic chemistry are described in "Organic Chemistry", Thomas Sorrell, University Science Books, Sausalito: 1999, and "March's Advanced Organic Chemistry", 5th Ed., Ed.: Smith, M.B. and March, J., John Wiley & Sons, New York: 2001, the entire contents of which are hereby incorporated by reference.

[0014] The term "aliphatic" or "aliphatic group", as used herein, means a straight-chain (i.e., unbranched) or branched, substituted or unsubstituted hydrocarbon chain that is completely saturated or that contains one or more units of unsaturation, or a monocyclic hydrocarbon or bicyclic hydrocarbon that is completely saturated or that contains one or more units of unsaturation, but which is not aromatic (also referred to herein as "carbocycle" or "cycloaliphatic"), that has a single point of attachment to the rest of the molecule. Unless otherwise specified, aliphatic groups contain 1-6 aliphatic carbon atoms. In some embodiments, aliphatic groups contain 1-5 aliphatic carbon atoms. In other embodiments, aliphatic groups contain 1-4 aliphatic carbon atoms. In still other embodiments, aliphatic groups contain 1-3 aliphatic carbon atoms, and in yet other embodiments, aliphatic groups contain 1-2 aliphatic carbon atoms. In some embodiments, "cycloaliphatic" (or "carbocycle") refers to a monocyclic C_3-C_6 hydrocarbon that is completely saturated or that contains one or more units of unsaturation, but which is not aromatic, that has a single point of attachment to the rest of the molecule. Suitable aliphatic groups include, but are not limited to, linear or branched, substituted or unsubstituted alkyl, alkenyl, alkynyl groups and hybrids thereof such as (cycloalkyl)alkyl, (cycloalkenyl)alkyl or (cycloalkyl)alkenyl.

[0015] The term "alkyl", unless otherwise indicated, as used herein, refers to a monovalent aliphatic hydrocarbon radical having a straight chain, branched chain, monocyclic moiety, or polycyclic moiety or combinations thereof, wherein the radical is optionally substituted at one or more carbons of the straight chain, branched chain, monocyclic moiety, or polycyclic moiety or combinations thereof with one or more substituents at each carbon, wherein the one or more substituents are independently C_1-C_{10} alkyl. Examples of "alkyl" groups include methyl, ethyl, propyl, isopropyl, butyl, *iso*-butyl, *sec*-butyl, *tert*-butyl, pentyl, hexyl, heptyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, norbornyl, and the like.

[0016] The term "lower alkyl" refers to a C_{1-4} straight or branched alkyl group. Exemplary lower alkyl groups are methyl, ethyl, propyl, isopropyl, butyl, isobutyl, and tert-butyl.

[0017] The term "lower haloalkyl" refers to a C_{1-4} straight or branched alkyl group that is substituted with one or more halogen atoms.

[0018] The term "heteroatom" means one or more of oxygen, sulfur, nitrogen, phosphorus, or silicon (including, any oxidized form of nitrogen, sulfur, phosphorus, or silicon; the quaternized form of any basic nitrogen or; a substitutable nitrogen of a heterocyclic ring, for example N (as in 3,4-dihydro-2*H*-pyrrolyl), NH (as in pyrrolidinyl) or NR^+ (as in N-substituted pyrrolidinyl)).

[0019] The term "unsaturated," as used herein, means that a moiety has one or more units of unsaturation.

[0020] As used herein, the term "C_{1-8} (or C_{1-6}, or C_{1-4}) bivalent saturated or unsaturated, straight or branched, hydrocarbon chain", refers to bivalent alkylene, alkenylene, and alkynylene chains that are straight or branched as defined herein.

[0021] The term "alkylene" refers to a bivalent alkyl group. An "alkylene chain" is a polymethylene group, i.e., $–(CH_2)_n–$, wherein n is a positive integer, preferably from 1 to 6, from 1 to 4, from 1 to 3, from 1 to 2, or from 2 to 3. A substituted alkylene chain is a polymethylene group in which one or more methylene hydrogen atoms are replaced with a substituent. Suitable substituents include those described below for a substituted aliphatic group.


[0022] The term "alkenylene" refers to a bivalent alkenyl group. A substituted alkenylene chain is a polymethylene group containing at least one double bond in which one or more hydrogen atoms are replaced with a substituent. Suitable substituents include those described below for a substituted aliphatic group.

[0023] The term "halogen" means F, Cl, Br, or I.

[0024] The term "aryl," used alone or as part of a larger moiety as in "aralkyl," "aralkoxy," or "aryloxyalkyl," refers to monocyclic or bicyclic ring systems having a total of five to fourteen ring members, wherein at least one ring in the system is aromatic and wherein each ring in the system contains 3 to 7 ring members. The term "aryl" may be used interchangeably with the term "aryl ring." In certain embodiments of the present invention, "aryl" refers to an aromatic ring system which includes, but is not limited to, phenyl, biphenyl, naphthyl, anthracyl and the like, which may bear one or more substituents.


[0025] The terms "heteroaryl" or "heteroaromatic", unless otherwise defined, as used herein refers to a monocyclic aromatic 5-6 membered ring containing one or more heteroatoms, for example one to three heteroatoms, such as nitrogen, oxygen, and sulfur, or an 8-10 membered polycyclic ring system containing one or more heteroatoms, wherein at least one ring in the

polycyclic ring system is aromatic, and the point of attachment of the polycyclic ring system is through a ring atom on an aromatic ring. A heteroaryl ring may be linked to adjacent radicals though carbon or nitrogen. Examples of heteroaryl rings include but are not limited to furan, thiophene, pyrrole, thiazole, oxazole, isothiazole, isoxazole, imidazole, pyrazole, triazole, pyridine, pyrimidine, indole, etc. For example, unless otherwise defined, 1,2,3,4-tetrahydroquinoline is a heteroaryl ring if its point of attachment is through the benzo ring, e.g.:



[0026] The terms "heterocyclyl" or "heterocyclic group", unless otherwise defined, refer to a saturated or partially unsaturated 3-10 membered monocyclic or 7-14 membered polycyclic ring system, including bridged or fused rings, and whose ring system includes one to four heteroatoms, such as nitrogen, oxygen, and sulfur. A heterocyclyl ring may be linked to adjacent radicals through carbon or nitrogen.

[0027] The term "partially unsaturated" in the context of rings, unless otherwise defined, refers to a monocyclic ring, or a component ring within a polycyclic (e.g. bicyclic, tricyclic, etc.) ring system, wherein the component ring contains at least one degree of unsaturation in addition to those provided by the ring itself, but is not aromatic. Examples of partially unsaturated rings include, but are not limited to, 3,4-dihydro-2H-pyran, 3-pyrroline, 2-thiazoline, etc. Where a partially unsaturated ring is part of a polycyclic ring system, the other component rings in the polycyclic ring system may be saturated, partially unsaturated, or aromatic, but the point of attachment of the polycyclic ring system is on a partially unsaturated component ring. For example, unless otherwise defined, 1,2,3,4-tetrahydroquinoline is a partially unsaturated ring if its point of attachment is through the piperidino ring, e.g.:




[0028] The term "saturated" in the context of rings, unless otherwise defined, refers to a 3-10 membered monocyclic ring, or a 7-14 membered polycyclic (e.g. bicyclic, tricyclic, etc.) ring system, wherein the monocyclic ring or the component ring that is the point of attachment for


the polycyclic ring system contains no additional degrees of unsaturation in addition to that provided by the ring itself. Examples of monocyclic saturated rings include, but are not limited to, azetidine, oxetane, cyclohexane, etc. Where a saturated ring is part of a polycyclic ring system, the other component rings in the polycyclic ring system may be saturated, partially unsaturated, or aromatic, but the point of attachment of the polycyclic ring system is on a saturated component ring. For example, unless otherwise defined, 2-azaspiro[3.4]oct-6-ene is a saturated ring if its point of attachment is through the azetidino ring, e.g.:



[0029] The terms "alkylene", "arylene", "cycloalkylene", "heteroarylene", "heterocycloalkylene", and the other similar terms with the suffix "-ylene" as used herein refers to a divalently bonded version of the group that the suffix modifies. For example, "alkylene" is a divalent alkyl group connecting the groups to which it is attached.

[0030] As used herein, the term "bridged bicyclic" refers to any bicyclic ring system, i.e. carbocyclic or heterocyclic, saturated or partially unsaturated, having at least one bridge. As defined by IUPAC, a "bridge" is an unbranched chain of atoms or an atom or a valence bond connecting two bridgeheads, where a "bridgehead" is any skeletal atom of the ring system which is bonded to three or more skeletal atoms (excluding hydrogen). In some embodiments, a bridged bicyclic group has 7-12 ring members and 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. Such bridged bicyclic groups are well known in the art and include those groups set forth below where each group is attached to the rest of the molecule at any substitutable carbon or nitrogen atom. Unless otherwise specified, a bridged bicyclic group is optionally substituted with one or more substituents as set forth for aliphatic groups. Additionally or alternatively, any substitutable nitrogen of a bridged bicyclic group is optionally substituted. Exemplary bridged bicyclics include:





[0031] As described herein, compounds of the invention may contain "optionally substituted" moieties. In general, the term "substituted," whether preceded by the term "optionally" or not, means that one or more hydrogens of the designated moiety are replaced with a suitable substituent. Unless otherwise indicated, an "optionally substituted" group may have a suitable substituent at each substitutable position of the group, and when more than one position in any given structure may be substituted with more than one substituent selected from a specified group, the substituent may be either the same or different at every position. Combinations of substituents envisioned by this invention are preferably those that result in the formation of stable or chemically feasible compounds. The term "stable," as used herein, refers to compounds that are not substantially altered when subjected to conditions to allow for their production, detection, and, in certain embodiments, their recovery, purification, and use for one or more of the purposes disclosed herein.

[0032] Suitable monovalent substituents on a substitutable carbon atom of an "optionally substituted" group are independently halogen; $-(CH_2)_{0-4}R°$; $-(CH_2)_{0-4}OR°$; $-O(CH_2)_{0-4}R°$, $-O-(CH_2)_{0-4}C(O)OR°$; $-(CH_2)_{0-4}CH(OR°)_2$; $-(CH_2)_{0-4}SR°$; $-(CH_2)_{0-4}Ph$, which may be substituted with R°; $-(CH_2)_{0-4}O(CH_2)_{0-1}Ph$ which may be substituted with R°; –CH=CHPh, which may be substituted with R°; $-(CH_2)_{0-4}O(CH_2)_{0-1}$-pyridyl which may be substituted with R°; $-NO_2$; –CN; $-N_3$; $-(CH_2)_{0-4}N(R°)_2$; $-(CH_2)_{0-4}N(R°)C(O)R°$; $-N(R°)C(S)R°$; $-(CH_2)_{0-4}N(R°)C(O)NR°_2$; $-N(R°)C(S)NR°_2$; $-(CH_2)_{0-4}N(R°)C(O)OR°$; $-N(R°)N(R°)C(O)R°$; $-N(R°)N(R°)C(O)NR°_2$; $-N(R°)N(R°)C(O)OR°$; $-(CH_2)_{0-4}C(O)R°$; $-C(S)R°$; $-(CH_2)_{0-4}C(O)OR°$; $-(CH_2)_{0-4}C(O)SR°$; $-(CH_2)_{0-4}C(O)OSiR°_3$; $-(CH_2)_{0-4}OC(O)R°$; $-OC(O)(CH_2)_{0-4}SR°$; –SC(S)SR°; $-(CH_2)_{0-4}SC(O)R°$; $-(CH_2)_{0-4}C(O)NR°_2$; $-C(S)NR°_2$; $-C(S)SR°$; –SC(S)SR°, $-(CH_2)_{0-4}OC(O)NR°_2$; $-C(O)N(OR°)R°$; $-C(O)C(O)R°$; $-C(O)CH_2C(O)R°$; $-C(NOR°)R°$; $-(CH_2)_{0-4}SSR°$; $-(CH_2)_{0-4}S(O)_2R°$; $-(CH_2)_{0-4}S(O)_2OR°$;

$-(CH_2)_{0-4}OS(O)_2R°$; $-S(O)_2NR°_2$; $-(CH_2)_{0-4}S(O)R°$; $-N(R°)S(O)_2NR°_2$; $-N(R°)S(O)_2R°$; $-N(OR°)R°$; $-C(NH)NR°_2$; $-P(O)(OR°)R°$; $-P(O)R°_2$; $-OP(O)R°_2$; $-OP(O)(OR°)_2$; $-SiR°_3$; $-(C_{1-4}$ straight or branched alkylene$)O-N(R°)_2$; or $-(C_{1-4}$ straight or branched alkylene$)C(O)O-N(R°)_2$, wherein each R° may be substituted as defined below and is independently hydrogen, C_{1-6} aliphatic, $-CH_2Ph$, $-O(CH_2)_{0-1}Ph$, $-CH_2$-(5-6 membered heteroaryl ring), or a 5–6–membered saturated, partially unsaturated, or aryl ring having 0–4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or, notwithstanding the definition above, two independent occurrences of R°, taken together with their intervening atom(s), form a 3–12–membered saturated, partially unsaturated, or aryl mono– or bicyclic ring having 0–4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, which may be substituted as defined below.

[0033] Suitable monovalent substituents on R° (or the ring formed by taking two independent occurrences of R° together with their intervening atoms), are independently halogen, $-(CH_2)_{0-2}R^•$, $-(haloR^•)$, $-(CH_2)_{0-2}OH$, $-(CH_2)_{0-2}OR^•$, $-(CH_2)_{0-2}CH(OR^•)_2$; $-O(haloR^•)$, $-CN$, $-N_3$, $-(CH_2)_{0-2}C(O)R^•$, $-(CH_2)_{0-2}C(O)OH$, $-(CH_2)_{0-2}C(O)OR^•$, $-(CH_2)_{0-2}SR^•$, $-(CH_2)_{0-2}SH$, $-(CH_2)_{0-2}NH_2$, $-(CH_2)_{0-2}NHR^•$, $-(CH_2)_{0-2}NR^•_2$, $-NO_2$, $-SiR^•_3$, $-OSiR^•_3$, $-C(O)SR^•$, $-(C_{1-4}$ straight or branched alkylene$)C(O)OR^•$, or $-SSR^•$ wherein each $R^•$ is unsubstituted or where preceded by "halo" is substituted only with one or more halogens, and is independently selected from C_{1-4} aliphatic, $-CH_2Ph$, $-O(CH_2)_{0-1}Ph$, or a 5–6–membered saturated, partially unsaturated, or aryl ring having 0–4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. Suitable divalent substituents on a saturated carbon atom of R° include =O and =S.

[0034] Suitable divalent substituents on a saturated carbon atom of an "optionally substituted" group include the following: =O, =S, $=NNR^*_2$, $=NNHC(O)R^*$, $=NNHC(O)OR^*$, $=NNHS(O)_2R^*$, $=NR^*$, $=NOR^*$, $-O(C(R^*_2))_{2-3}O-$, or $-S(C(R^*_2))_{2-3}S-$, wherein each independent occurrence of R^* is selected from hydrogen, C_{1-6} aliphatic which may be substituted as defined below, or an unsubstituted 5–6–membered saturated, partially unsaturated, or aryl ring having 0–4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. Suitable divalent substituents that are bound to vicinal substitutable carbons of an "optionally substituted" group include: $-O(CR^*_2)_{2-3}O-$, wherein each independent occurrence of R^* is selected from hydrogen, C_{1-6} aliphatic which may be substituted as defined below, or an unsubstituted 5–6–membered saturated, partially

unsaturated, or aryl ring having 0–4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.

[0035] Suitable substituents on the aliphatic group of R^* include halogen, $-R^\bullet$, -(halo$R^\bullet$), -OH, $-OR^\bullet$, -O(halo$R^\bullet$), –CN, –C(O)OH, $-C(O)OR^\bullet$, $-NH_2$, $-NHR^\bullet$, $-NR^\bullet{}_2$, or $-NO_2$, wherein each $R^\bullet$ is unsubstituted or where preceded by "halo" is substituted only with one or more halogens, and is independently C_{1-4} aliphatic, $-CH_2Ph$, $-O(CH_2)_{0-1}Ph$, or a 5–6–membered saturated, partially unsaturated, or aryl ring having 0–4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.

[0036] Suitable substituents on a substitutable nitrogen of an "optionally substituted" group include $-R^\dagger$, $-NR^\dagger{}_2$, $-C(O)R^\dagger$, $-C(O)OR^\dagger$, $-C(O)C(O)R^\dagger$, $-C(O)CH_2C(O)R^\dagger$, $-S(O)_2R^\dagger$, $-S(O)_2NR^\dagger{}_2$, $-C(S)NR^\dagger{}_2$, $-C(NH)NR^\dagger{}_2$, or $-N(R^\dagger)S(O)_2R^\dagger$; wherein each $R^\dagger$ is independently hydrogen, C_{1-6} aliphatic which may be substituted as defined below, unsubstituted –OPh, or an unsubstituted 5–6–membered saturated, partially unsaturated, or aryl ring having 0–4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or, notwithstanding the definition above, two independent occurrences of $R^\dagger$, taken together with their intervening atom(s) form an unsubstituted 3–12–membered saturated, partially unsaturated, or aryl mono– or bicyclic ring having 0–4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.

[0037] Suitable substituents on the aliphatic group of $R^\dagger$ are independently halogen, $-R^\bullet$, -(halo$R^\bullet$), –OH, $-OR^\bullet$, -O(halo$R^\bullet$), –CN, –C(O)OH, $-C(O)OR^\bullet$, $-NH_2$, $-NHR^\bullet$, $-NR^\bullet{}_2$, or $-NO_2$, wherein each $R^\bullet$ is unsubstituted or where preceded by "halo" is substituted only with one or more halogens, and is independently C_{1-4} aliphatic, $-CH_2Ph$, $-O(CH_2)_{0-1}Ph$, or a 5–6–membered saturated, partially unsaturated, or aryl ring having 0–4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.

[0038] The term "isomer" as used herein refers to a compound having the identical chemical formula but different structural or optical configurations. The term "stereoisomer" as used herein refers to and includes isomeric molecules that have the same molecular formula but differ in positioning of atoms and/or functional groups in the space. All stereoisomers of the present compounds (*e.g.*, those which may exist due to asymmetric carbons on various substituents), including enantiomeric forms and diastereomeric forms, are contemplated within the scope of this disclosure. Therefore, unless otherwise stated, single stereochemical

isomers as well as mixtures of enantiomeric, diastereomeric, and geometric (or conformational) isomers of the present compounds are within the scope of the invention.

[0039] The term "tautomer" as used herein refers to one of two or more structural isomers which exist in equilibrium and which are readily converted from one isomeric form to another. It is understood that tautomers encompass valence tautomers and proton tautomers (also known as prototropic tautomers). Valence tautomers include interconversions by reorganization of some of the bonding electrons. Proton tautomers include interconversions via migration of a proton, such as keto-enol and imine-enamine isomerizations. Unless otherwise stated, all tautomers of the compounds of the invention are within the scope of the invention.

[0040] The term "isotopic substitution" as used herein refers to the substitution of an atom with its isotope. The term "isotope" as used herein refers to an atom having the same atomic number as that of atoms dominant in nature but having a mass number (neutron number) different from the mass number of the atoms dominant in nature. It is understood that a compound with an isotopic substitution refers to a compound in which at least one atom contained therein is substituted with its isotope. Atoms that can be substituted with its isotope include, but are not limited to, hydrogen, carbon, and oxygen. Examples of the isotope of a hydrogen atom include ^{2}H (also represented as D) and ^{3}H. Examples of the isotope of a carbon atom include ^{13}C and ^{14}C. Examples of the isotope of an oxygen atom include ^{18}O. Unless otherwise stated, all isotopic substitution of the compounds of the invention are within the scope of the invention. Such compounds are useful, for example, as analytical tools, as probes in biological assays, or as therapeutic agents in accordance with the present invention. In certain embodiments, for example, a warhead moiety, R^{W}, of a provided compound comprises one or more deuterium atoms.

[0041] As used herein, the term "pharmaceutically acceptable salt" refers to those salts which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response and the like, and are commensurate with a reasonable benefit/risk ratio. Exemplary pharmaceutically acceptable salts are found, *e.g.*, in Berge, *et al.* (*J. Pharm. Sci.* 1977, 66(1), 1; and Gould, P.L., *Int. J. Pharmaceutics* 1986, 33, 201-217; (each hereby incorporated by reference in its entirety).

[0042] Pharmaceutically acceptable salts of the compounds of this invention include those derived from suitable inorganic and organic acids and bases. Examples of pharmaceutically acceptable, nontoxic acid addition salts are salts of an amino group formed with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid or with organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid or malonic acid or by using other methods used in the art such as ion exchange. Other pharmaceutically acceptable salts include adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2–hydroxy–ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2–naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 3–phenylpropionate, phosphate, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, p–toluenesulfonate, undecanoate, valerate salts, and the like.

[0043] Salts derived from appropriate bases include alkali metal, alkaline earth metal, ammonium and $N^+(C_{1-4}alkyl)_4$ salts. Representative alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and the like. Further pharmaceutically acceptable salts include, when appropriate, nontoxic ammonium, quaternary ammonium, and amine cations formed using counterions such as halide, hydroxide, carboxylate, sulfate, phosphate, nitrate, loweralkyl sulfonate and aryl sulfonate.

[0044] Pharmaceutically acceptable salts are also intended to encompass hemi-salts, wherein the ratio of compound:acid is respectively 2:1. Exemplary hemi-salts are those salts derived from acids comprising two carboxylic acid groups, such as malic acid, fumaric acid, maleic acid, succinic acid, tartaric acid, glutaric acid, oxalic acid, adipic acid and citric acid. Other exemplary hemi-salts are those salts derived from diprotic mineral acids such as sulfuric acid. Exemplary preferred hemi-salts include, but are not limited to, hemimaleate, hemifumarate, and hemisuccinate.

[0045] As used herein the term “about” is used herein to mean approximately, roughly, around, or in the region of. When the term “about” is used in conjunction with a numerical range, it modifies that range by extending the boundaries above and below the numerical values set forth. In general, the term “about” is used herein to modify a numerical value above and below the stated value by a variance of 20 percent up or down (higher or lower).


[0046] An "effective amount", "sufficient amount" or "therapeutically effective amount" as used herein is an amount of a compound that is sufficient to effect beneficial or desired results, including clinical results. As such, the effective amount may be sufficient, *e.g.*, to reduce or ameliorate the severity and/or duration of afflictions related to PI3Kα signaling, or one or more symptoms thereof, prevent the advancement of conditions or symptoms related to afflictions related to PI3Kα signaling, or enhance or otherwise improve the prophylactic or therapeutic effect(s) of another therapy. An effective amount also includes the amount of the compound that avoids or substantially attenuates undesirable side effects.

[0047] As used herein and as well understood in the art, "treatment" is an approach for obtaining beneficial or desired results, including clinical results. Beneficial or desired clinical results may include, but are not limited to, alleviation or amelioration of one or more symptoms or conditions, diminution of extent of disease or affliction, a stabilized (*i.e.*, not worsening) state of disease or affliction, preventing spread of disease or affliction, delay or slowing of disease or affliction progression, amelioration or palliation of the disease or affliction state and remission (whether partial or total), whether detectable or undetectable. "Treatment" can also mean prolonging survival as compared to expected survival if not receiving treatment. In some embodiments, treatment may be administered after one or more symptoms have developed. In other embodiments, treatment may be administered in the absence of symptoms. For example, treatment may be administered to a susceptible individual prior to the onset of symptoms (e.g., in light of a history of symptoms and/or in light of genetic or other susceptibility factors). Treatment may also be continued after symptoms have resolved, for example to prevent or delay their recurrence.

[0048] The phrase "in need thereof" refers to the need for symptomatic or asymptomatic relief from conditions related to PI3Kα signaling activity or that may otherwise be relieved by the compounds and/or compositions of the disclosure.

3. Description of Exemplary Embodiments

[0049] As described above, in some embodiments, the present invention provides a compound of formula I-1:



I-1

or a pharmaceutically acceptable salt thereof, wherein:

E is -C(O)-, -C(R^E)$_2$-, -C(R^E)$_2$C(R^E)$_2$-, -C(S)-, -S(O)$_2$-, -OC(O)-, -N(R^E)C(O)-, -C(O)N(R^E)-, or -C(R^E)$_2$C(O)-;

Q is CH, C(R^Q), or N;

X is CH, C(R^X), or N;

Y is CH, C(R^Y), or N;

Z is CH, C(R^Z), or N;

R^1 is -L^1-R^{1A};

R^2 is -L^2-R^{2A};

each instance of R^E is independently H or -L^E-R^{EA};

R^Q is -L^Q-R^{QA};

R^X is -L^X-R^{XA};

R^Y is -L^Y-R^{YA};

R^Z is -L^Z-R^{ZA}; or

two instances of R^E are taken together with their intervening atoms to form a 3-8 membered saturated or partially unsaturated monocyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or an 8-12 membered saturated or partially unsaturated bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein each ring is substituted with n instances of R^{EEC};

R^Q and R^1 are taken together with their intervening atoms to form a 4-8 membered saturated or partially unsaturated monocyclic ring having 0-4 heteroatoms independently

selected from nitrogen, oxygen, and sulfur; or an 8-12 membered saturated or partially unsaturated bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein each ring is substituted with p instances of R^{Q1C};

R^Y and R^Z are taken together with their intervening atoms to form a 4-7 membered partially unsaturated or aromatic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said ring is substituted with q instances of R^{YZC};

each of L^1, L^2, L^E, L^Q, L^X, L^Y, and L^Z is independently a covalent bond, or a C_{1-4} bivalent saturated or unsaturated, straight or branched hydrocarbon chain wherein one or two methylene units of the chain are optionally and independently replaced by $-CH(R^L)-$, $-C(R^L)_2-$, C_{3-6} cycloalkylene, C_{3-6} heterocycloalkylene, -N(R)-, -N(R)C(O)-, -N(R)C(NR)-, -N(R)C(NOR)-, -N(R)C(NCN)-, -C(O)N(R)-, $-N(R)S(O)_2-$, $-S(O)_2N(R)-$, -O-, -C(O)-, -OC(O)-, -C(O)O-, -S-, -S(O)- , or $-S(O)_2-$;

R^{1A} is R^A or R^B substituted by r^1 instances of R^{1C};

R^{2A} is R^A or R^B substituted by r^2 instances of R^{2C};

R^{EA} is R^A or R^B substituted by r^3 instances of R^{EC};

R^{QA} is R^A or R^B substituted by r^4 instances of R^{QC};

R^{XA} is R^A or R^B substituted by r^5 instances of R^{XC};

R^{YA} is R^A or R^B substituted by r^6 instances of R^{YC};

R^{ZA} is R^A or R^B substituted by r^7 instances of R^{ZC};

R^L is R^A or R^B substituted by r^8 instances of R^{LC};

each instance of R^A is independently oxo, deuterium, halogen, -CN, $-NO_2$, -OR, $-SF_5$, -SR, $-NR_2$, $-S(O)_2R$, $-S(O)_2NR_2$, $-S(O)_2F$, -S(O)R, $-S(O)NR_2$, -S(O)(NR)R, -S(O)(NCN)R, -S(NCN)R, -C(O)R, -C(O)OR, $-C(O)NR_2$, -C(O)N(R)OR, -OC(O)R, $-OC(O)NR_2$, -N(R)C(O)OR, -N(R)C(O)R, $-N(R)C(O)NR_2$, $-N(R)C(NR)NR_2$, $-N(R)S(O)_2NR_2$, $-N(R)S(O)_2R$, $-P(O)R_2$, -P(O)(R)OR, or $-B(OR)_2$;

each instance of R^B is independently a C_{1-6} aliphatic chain; phenyl; naphthyl; cubanyl; adamantyl; a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; an 8-10 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring; a 5-

12 membered saturated or partially unsaturated bicyclic carbocyclic ring; a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or a 7-12 membered saturated or partially unsaturated bicyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;

each instance of R^{1C}, R^{2C}, R^{EC}, R^{QC}, R^{XC}, R^{YC}, R^{ZC}, R^{LC}, R^{EEC}, R^{Q1C}, and R^{YZC} is independently oxo, deuterium, halogen, -CN, $-NO_2$, -OR, $-SF_5$, -SR, $-NR_2$, $-S(O)_2R$, $-S(O)_2NR_2$, $-S(O)_2F$, -S(O)R, $-S(O)NR_2$, -S(O)(NR)R, -C(O)R, -C(O)OR, $-C(O)NR_2$, -C(O)N(R)OR, -OC(O)R, $-OC(O)NR_2$, -N(R)C(O)OR, -N(R)C(O)R, $-N(R)C(O)NR_2$, $-N(R)C(NR)NR_2$, $-N(R)S(O)_2NR_2$, $-N(R)S(O)_2R$, $-P(O)R_2$, -P(O)(R)OR, $-B(OR)_2$, or an optionally substituted group selected from C_{1-6} aliphatic, phenyl, a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;

each instance of R is independently hydrogen, or an optionally substituted group selected from C_{1-6} aliphatic, phenyl, a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or

two R groups on the same nitrogen are taken together with their intervening atoms to form a 4-7 membered saturated, partially unsaturated, or heteroaryl ring having 0-3 heteroatoms, in addition to the nitrogen, independently selected from nitrogen, oxygen, and sulfur; and

each of n, p, q, r^1, r^2, r^3, r^4, r^5, r^6, r^7, and r^8 is independently 0, 1, 2, 3, 4, or 5.

[0050] In some embodiments, the present invention provides a compound of Formula I-1, wherein each of E, Q, X, Y, Z, R^1, R^2, R^E, R^Q, R^X, R^Y, R^Z, R^{1A}, R^{2A}, R^{EA}, R^{QA}, R^{XA}, R^{YA}, R^{ZA}, R^L, R^A, R^B, R^{1C}, R^{2C}, R^{EC}, R^{QC}, R^{XC}, R^{YC}, R^{ZC}, R^{LC}, R^{EEC}, R^{Q1C}, R^{YZC}, R, n, p, q, r^1, r^2, r^3, r^4, r^5, r^6, r^7, and r^8 is as defined below, and described in embodiments herein, both singly and in combination.

[0051] In certain embodiments, R^{YA} is $-S(O)_2R$, $-S(O)_2NR_2$, $-S(O)_2F$, -S(O)R, $-S(O)NR_2$, -S(O)(NR)R, -S(O)(NCN)R, or -S(NCN)R. In certain embodiments, R^{YA} is -S(O)(NR)R, -S(O)(NCN)R, or -S(NCN)R. In certain embodiments, R^{YA} is -S(O)(NCN)R or -S(NCN)R.

In certain embodiments, R^{YA} is -S(O)(NCN)R. In certain embodiments, R^{YA} is -S(NCN)R. In some embodiments, R^{YA} is selected from the groups depicted in the compounds in Table 1.

[0052] In certain embodiments, R^A is $-S(O)_2R$, $-S(O)_2NR_2$, $-S(O)_2F$, -S(O)R, $-S(O)NR_2$, -S(O)(NR)R, -S(O)(NCN)R, or -S(NCN)R. In certain embodiments, R^A is -S(O)(NR)R, -S(O)(NCN)R, or -S(NCN)R. In certain embodiments, R^A is -S(O)(NCN)R or -S(NCN)R. In certain embodiments, R^A is -S(O)(NCN)R. In certain embodiments, R^A is -S(NCN)R. In some embodiments, R^A is selected from the groups depicted in the compounds in Table 1.

[0053] In certain embodiments, n is 1, 2, 3, 4, or 5. In certain embodiments, n is 2, 3, 4, or 5. In certain embodiments, n is 3, 4, or 5. In certain embodiments, n is 4 or 5. In certain embodiments, n is 5. In certain embodiments, n is selected from the values represented in the compounds in Table 1.

[0054] In certain embodiments, p is 1, 2, 3, 4, or 5. In certain embodiments, p is 2, 3, 4, or 5. In certain embodiments, p is 3, 4, or 5. In certain embodiments, p is 4 or 5. In certain embodiments, p is 5. In certain embodiments, p is selected from the values represented in the compounds in Table 1.

[0055] In certain embodiments, q is 1, 2, 3, 4, or 5. In certain embodiments, q is 2, 3, 4, or 5. In certain embodiments, q is 3, 4, or 5. In certain embodiments, q is 4 or 5. In certain embodiments, q is 5. In certain embodiments, q is selected from the values represented in the compounds in Table 1.

[0056] In certain embodiments, r^1 is 1, 2, 3, 4, or 5. In certain embodiments, r^1 is 2, 3, 4, or 5. In certain embodiments, r^1 is 3, 4, or 5. In certain embodiments, r^1 is 4 or 5. In certain embodiments, r^1 is 5. In certain embodiments, r^1 is selected from the values represented in the compounds in Table 1.

[0057] In certain embodiments, r^2 is 1, 2, 3, 4, or 5. In certain embodiments, r^2 is 2, 3, 4, or 5. In certain embodiments, r^2 is 3, 4, or 5. In certain embodiments, r^2 is 4 or 5. In certain embodiments, r^2 is 5. In certain embodiments, r^2 is selected from the values represented in the compounds in Table 1.

[0058] In certain embodiments, r^3 is 1, 2, 3, 4, or 5. In certain embodiments, r^3 is 2, 3, 4, or 5. In certain embodiments, r^3 is 3, 4, or 5. In certain embodiments, r^3 is 4 or 5. In certain embodiments, r^3 is 5. In certain embodiments, r^3 is selected from the values represented in the compounds in Table 1.

[0059] In certain embodiments, r^4 is 1, 2, 3, 4, or 5. In certain embodiments, r^4 is 2, 3, 4, or 5. In certain embodiments, r^4 is 3, 4, or 5. In certain embodiments, r^4 is 4 or 5. In certain embodiments, r^4 is 5. In certain embodiments, r^4 is selected from the values represented in the compounds in Table 1.


[0060] In certain embodiments, r^5 is 1, 2, 3, 4, or 5. In certain embodiments, r^5 is 2, 3, 4, or 5. In certain embodiments, r^5 is 3, 4, or 5. In certain embodiments, r^5 is 4 or 5. In certain embodiments, r^5 is 5. In certain embodiments, r^5 is selected from the values represented in the compounds in Table 1.

[0061] In certain embodiments, r^6 is 1, 2, 3, 4, or 5. In certain embodiments, r^6 is 2, 3, 4, or 5. In certain embodiments, r^6 is 3, 4, or 5. In certain embodiments, r^6 is 4 or 5. In certain embodiments, r^6 is 5. In certain embodiments, r^6 is selected from the values represented in the compounds in Table 1.

[0062] In certain embodiments, r^7 is 1, 2, 3, 4, or 5. In certain embodiments, r^7 is 2, 3, 4, or 5. In certain embodiments, r^7 is 3, 4, or 5. In certain embodiments, r^7 is 4 or 5. In certain embodiments, r^7 is 5. In certain embodiments, r^7 is selected from the values represented in the compounds in Table 1.

[0063] In certain embodiments, r^8 is 1, 2, 3, 4, or 5. In certain embodiments, r^8 is 2, 3, 4, or 5. In certain embodiments, r^8 is 3, 4, or 5. In certain embodiments, r^8 is 4 or 5. In certain embodiments, r^8 is 5. In certain embodiments, r^8 is selected from the values represented in the compounds in Table 1.

[0064] As described above, in some embodiments, the present invention provides a compound of formula I:



I

or a pharmaceutically acceptable salt thereof, wherein:

E is -C(O)-, -C(R^E)$_2$-, -C(R^E)$_2$C(R^E)$_2$-, -C(S)-, -S(O)$_2$-, -OC(O)-, -N(R^E)C(O)-, -C(O)N(R^E)-, or -C(R^E)$_2$C(O)-;

Q is CH, C(R^Q), or N;

X is CH, C(R^X), or N;

Y is CH, C(R^Y), or N;

Z is CH, C(R^Z), or N;

R^1 is -L^1-R^{1A};

R^2 is -L^2-R^{2A};

each instance of R^E is independently H or -L^E-R^{EA};

R^Q is -L^Q-R^{QA};

R^X is -L^X-R^{XA};

R^Y is -L^Y-R^{YA};

R^Z is -L^Z-R^{ZA}; or

two instances of R^E are taken together with their intervening atoms to form a 3-8 membered saturated or partially unsaturated monocyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or an 8-12 membered saturated or partially unsaturated bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein each ring is substituted with n instances of R^{EEC};

R^Q and R^1 are taken together with their intervening atoms to form a 4-8 membered saturated or partially unsaturated monocyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or an 8-12 membered saturated or partially unsaturated bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein each ring is substituted with p instances of R^{Q1C};

R^Y and R^Z are taken together with their intervening atoms to form a 4-7 membered partially unsaturated or aromatic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said ring is substituted with q instances of R^{YZC};

each of L^1, L^2, L^E, L^Q, L^X, L^Y, and L^Z is independently a covalent bond, or a C_{1-4} bivalent saturated or unsaturated, straight or branched hydrocarbon chain wherein one or two methylene units of the chain are optionally and independently replaced by -CH(R^L)-, -C(R^L)$_2$-, C_{3-6} cycloalkylene, C_{3-6} heterocycloalkylene, -N(R)-, -N(R)C(O)-, -N(R)C(NR)-, -N(R)C(NOR)-, -N(R)C(NCN)-, -C(O)N(R)-, -N(R)S(O)$_2$-, -S(O)$_2$N(R)-, -O-, -C(O)-, -OC(O)-, -C(O)O-, -S-, -S(O)- , or -S(O)$_2$-;

R^{1A} is R^A or R^B substituted by r^1 instances of R^{1C};

R^{2A} is R^A or R^B substituted by r^2 instances of R^{2C};

R^{EA} is R^A or R^B substituted by r^3 instances of R^{EC};

R^{QA} is R^A or R^B substituted by r^4 instances of R^{QC};

R^{XA} is R^A or R^B substituted by r^5 instances of R^{XC};

R^{YA} is R^A or R^B substituted by r^6 instances of R^{YC};

R^{ZA} is R^A or R^B substituted by r^7 instances of R^{ZC};

R^L is R^A or R^B substituted by r^8 instances of R^{LC};

each instance of R^A is independently oxo, deuterium, halogen, -CN, $-NO_2$, -OR, $-SF_5$, -SR, $-NR_2$, $-S(O)_2R$, $-S(O)_2NR_2$, $-S(O)_2F$, -S(O)R, $-S(O)NR_2$, -S(O)(NR)R, -C(O)R, -C(O)OR, $-C(O)NR_2$, -C(O)N(R)OR, -OC(O)R, $-OC(O)NR_2$, -N(R)C(O)OR, -N(R)C(O)R, $-N(R)C(O)NR_2$, $-N(R)C(NR)NR_2$, $-N(R)S(O)_2NR_2$, $-N(R)S(O)_2R$, $-P(O)R_2$, -P(O)(R)OR, or $-B(OR)_2$;

each instance of R^B is independently a C_{1-6} aliphatic chain; phenyl; naphthyl; cubanyl; adamantyl; a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; an 8-10 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring; a 5-12 membered saturated or partially unsaturated bicyclic carbocyclic ring; a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or a 7-12 membered saturated or partially unsaturated bicyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;

each instance of R^{1C}, R^{2C}, R^{EC}, R^{QC}, R^{XC}, R^{YC}, R^{ZC}, R^{LC}, R^{EEC}, R^{Q1C}, and R^{YZC} is independently oxo, deuterium, halogen, -CN, $-NO_2$, -OR, $-SF_5$, -SR, $-NR_2$, $-S(O)_2R$, $-S(O)_2NR_2$, $-S(O)_2F$, -S(O)R, $-S(O)NR_2$, -S(O)(NR)R, -C(O)R, -C(O)OR, $-C(O)NR_2$, -C(O)N(R)OR, -OC(O)R, $-OC(O)NR_2$, -N(R)C(O)OR, -N(R)C(O)R, $-N(R)C(O)NR_2$, $-N(R)C(NR)NR_2$, $-N(R)S(O)_2NR_2$, $-N(R)S(O)_2R$, $-P(O)R_2$, -P(O)(R)OR, $-B(OR)_2$, or an optionally substituted group selected from C_{1-6} aliphatic, phenyl, a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently

selected from nitrogen, oxygen, and sulfur, and a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;

each instance of R is independently hydrogen, or an optionally substituted group selected from C_{1-6} aliphatic, phenyl, a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or

two R groups on the same nitrogen are taken together with their intervening atoms to form a 4-7 membered saturated, partially unsaturated, or heteroaryl ring having 0-3 heteroatoms, in addition to the nitrogen, independently selected from nitrogen, oxygen, and sulfur; and

each of n, p, q, r^1, r^2, r^3, r^4, r^5, r^6, r^7, and r^8 is independently 0, 1, 2, 3, or 4.

[0065] As defined generally above, E is -C(O)-, $-C(R^E)_2-$, $-C(R^E)_2C(R^E)_2-$, C_{3-6} cycloalkylene, C_{3-6} heterocycloalkylene, -C(S)-, $-S(O)_2-$, -OC(O)-, $-N(R^E)C(O)-$, $-C(O)N(R^E)-$, or $-C(R^E)_2C(O)-$. In some embodiments, E is -C(O)-. In some embodiments, E is -OC(O)- or $-N(R^E)C(O)-$. In some embodiments, E is $-C(R^E)_2-$, C_{3-6} cycloalkylene, or C_{3-6} heterocycloalkylene.

[0066] In some embodiments, E is -C(O)-, -OC(O)-, $-N(R^E)C(O)-$, or $-C(R^E)_2C(O)-$. In some embodiments, E is -OC(O)-, $-N(R^E)C(O)-$, or $-C(R^E)_2C(O)-$. In some embodiments, E is -C(O)- or $-N(R^E)C(O)-$.

[0067] In some embodiments, E is -C(O)-, $-C(R^E)_2-$, -C(S)-, or $-S(O)_2-$. In some embodiments, E is -C(O)-, $-C(R^E)_2-$, or -C(S)-. In some embodiments, E is -C(O)- or -C(S)-.

[0068] In some embodiments, E is $-C(R^E)_2C(R^E)_2-$, C_{3-6} cycloalkylene, C_{3-6} heterocycloalkylene, -OC(O)-, $-N(R^E)C(O)-$, $-C(O)N(R^E)-$, or $-C(R^E)_2C(O)-$. In some embodiments, E is C_{3-6} cycloalkylene or C_{3-6} heterocycloalkylene. In some embodiments, E is $-C(R^E)_2C(R^E)_2-$, -OC(O)-, $-N(R^E)C(O)-$, $-C(O)N(R^E)-$, or $-C(R^E)_2C(O)-$. In some embodiments, E is -OC(O)-, $-N(R^E)C(O)-$, $-C(O)N(R^E)-$, or $-C(R^E)_2C(O)-$. In some embodiments, E is -OC(O)-, $-N(R^E)C(O)-$, or $-C(O)N(R^E)-$. In some embodiments, E is $-N(R^E)C(O)-$ or $-C(O)N(R^E)-$. In some embodiments, E is -N(H)C(O)- or -C(O)N(H)-. In some embodiments, E is $-N(CH_3)C(O)-$ or $-C(O)N(CH_3)-$.

[0069] In some embodiments, E is -$S(O)_2$-, -OC(O)-, -$N(R^E)$C(O)-, or -C(O)$N(R^E)$-. In some embodiments, E is -C(O)-, -$C(R^E)_2$-, -$C(R^E)_2C(R^E)_2$-, C_{3-6} cycloalkylene, C_{3-6} heterocycloalkylene, -C(S)-, or -$C(R^E)_2$C(O)-. In some embodiments, E is -C(O)-, -$C(R^E)_2$-, -$C(R^E)_2C(R^E)_2$-, -C(S)-, or -$C(R^E)_2$C(O)-. In some embodiments, E is -C(O)-, -C(S)-, or -$C(R^E)_2$C(O)-. In some embodiments, E is -$C(R^E)_2$-, -$C(R^E)_2C(R^E)_2$-, or -$C(R^E)_2$C(O)-. In some embodiments, E is -$C(R^E)_2$- or -$C(R^E)_2C(R^E)_2$-.

[0070] In some embodiments, E is -$C(R^E)_2$-. In some embodiments, E is -$C(R^E)_2C(R^E)_2$-. In some embodiments, E is C_{3-6} cycloalkylene. In some embodiments, E is C_{3-6} heterocycloalkylene. In some embodiments, E is -C(S)-. In some embodiments, E is -$S(O)_2$-. In some embodiments, E is -OC(O)-. In some embodiments, E is -$N(R^E)$C(O)-. In some embodiments, E is -N(H)C(O)-. In some embodiments, E is -$N(CH_3)$C(O)-. In some embodiments, E is -C(O)$N(R^E)$-. In some embodiments, E is -C(O)N(H)-. In some embodiments, E is -C(O)$N(CH_3)$-. In some embodiments, E is -$C(R^E)_2$C(O)-.

[0071] In some embodiments, E is selected from the groups depicted in the compounds in Table 1.

[0072] As defined generally above, Q is CH, $C(R^Q)$, or N. In some embodiments, Q is CH. In some embodiments, Q is $C(R^Q)$. In some embodiments, Q is N. In some embodiments, Q is CH or $C(R^Q)$. In some embodiments, Q is CH or N. In some embodiments, Q is $C(R^Q)$ or N. In some embodiments, Q is selected from the groups depicted in the compounds in Table 1.

[0073] As defined generally above, X is CH, $C(R^X)$, or N. In some embodiments, X is CH. In some embodiments, X is $C(R^X)$. In some embodiments, X is N. In some embodiments, X is CH or $C(R^X)$. In some embodiments, X is CH or N. In some embodiments, X is $C(R^X)$ or N. In some embodiments, X is selected from the groups depicted in the compounds in Table 1.




[0074] As defined generally above, Y is CH, $C(R^Y)$, or N. In some embodiments, Y is CH. In some embodiments, Y is $C(R^Y)$. In some embodiments, Y is N. In some embodiments, Y is CH or $C(R^Y)$. In some embodiments, Y is CH or N. In some embodiments, Y is $C(R^Y)$ or N. In some embodiments, Y is selected from the groups depicted in the compounds in Table 1.



[0075] As defined generally above, Z is CH, $C(R^Z)$, or N. In some embodiments, Z is CH. In some embodiments, Z is $C(R^Z)$. In some embodiments, Z is N. In some embodiments, Z







is CH or C(R^Z). In some embodiments, Z is CH or N. In some embodiments, Z is C(R^Z) or N. In some embodiments, Z is selected from the groups depicted in the compounds in Table 1.



[0076] As defined generally above, R^1 is -L^1-R^{1A} or R^Q and R^1 are taken together with their intervening atoms to form a 4-8 membered saturated or partially unsaturated monocyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or an 8-12 membered saturated or partially unsaturated bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein each ring is substituted with p instances of R^{Q1C}. In some embodiments, R^1 is -L^1-R^{1A}. In some embodiments, R^1 is -R^{1A}.





[0077] In some embodiments, R^Q and R^1 are taken together with their intervening atoms to form a 4-8 membered saturated or partially unsaturated monocyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or an 8-12 membered saturated or partially unsaturated bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein each ring is substituted with p instances of R^{Q1C}. In some embodiments, R^Q and R^1 are taken together with their intervening atoms to form a 4-8 membered saturated or partially unsaturated monocyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said ring is substituted with p instances of R^{Q1C}. In some embodiments, R^Q and R^1 are taken together with their intervening atoms to form an 8-12 membered saturated or partially unsaturated bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said ring is substituted with p instances of R^{Q1C}.

[0078] In some embodiments, R^1 (i.e. –L^1-R^{1A} taken together) is , wherein R^{1C} and r^1 are as defined in the embodiments and classes and subclasses herein. In some embodiments, R^1 (i.e. –L^1-R^{1A} taken together) is , wherein R^{1C} is as defined in the embodiments and classes and subclasses herein. In some embodiments, R^1 (i.e. –L^1-R^{1A} taken together) is , wherein R^{1C} is as defined in the embodiments

and classes and subclasses herein. In some embodiments, R^1 (i.e. $-L^1-R^{1A}$ taken together) is , wherein R^{1C} is as defined in the embodiments and classes and subclasses herein. In some embodiments, R^1 (i.e. $-L^1-R^{1A}$ taken together) is , wherein R^{1C} is as defined in the embodiments and classes and subclasses herein.

[0079] In some embodiments, R^1 (i.e. $-L^1-R^{1A}$ taken together) is , wherein each instance of R^{1C} is independently halogen, -CN, -O-(optionally substituted C_{1-6} aliphatic), or an optionally substituted C_{1-6} aliphatic. In some embodiments, R^1 (i.e. $-L^1-R^{1A}$ taken together) is , wherein each instance of R^{1C} is independently halogen or C_{1-3} aliphatic optionally substituted with 1-3 halogen. In some embodiments, R^1 (i.e. $-L^1-R^{1A}$ taken together) is , wherein each instance of R^{1C} is independently halogen or C_{1-3} aliphatic optionally substituted with 1-3 halogen. In some embodiments, R^1 (i.e. $-L^1-R^{1A}$ taken together) is , wherein each instance of R^{1C} is independently halogen or C_{1-3} aliphatic optionally substituted with 1-3 halogen. In some embodiments, R^1 (i.e. $-L^1-R^{1A}$ taken together) is , wherein each instance of R^{1C} is independently fluorine, chlorine, $-CH_3$, $-CHF_2$, or $-CF_3$. In some embodiments, R^1 (i.e. $-L^1-R^{1A}$ taken together) is , wherein R^{1C} is halogen or C_{1-3} aliphatic optionally substituted with 1-3 halogen.

[0080] In some embodiments, R^1 (i.e. $-L^1-R^{1A}$ taken together) is . In some embodiments, R^1 (i.e. $-L^1-R^{1A}$ taken together) is .

[0081] In some embodiments, R^1 (i.e. $-L^1-R^{1A}$ taken together) is , wherein R^{1C} and r^1 are as defined in the embodiments and classes and subclasses herein. In some embodiments, R^1 (i.e. $-L^1-R^{1A}$ taken together) is . In some embodiments, R^1 (i.e. $-L^1-R^{1A}$ taken together) is . In some embodiments, R^1 (i.e. $-L^1-R^{1A}$ taken together) is .


[0082] In some embodiments, R^1 is selected from the groups depicted in the compounds in Table 1.


[0083] As defined generally above, R^2 is $-L^2-R^{2A}$. In some embodiments, R^2 (i.e. $-L^2-R^{2A}$ taken together) is $-N(R)C(O)-R^{2A}$ or $-R^{2A}$, wherein R and R^{2A} are as defined in the embodiments and classes and subclasses herein. In some embodiments, R^2 (i.e. $-L^2-R^{2A}$ taken together) is $-N(R)C(O)-R^{2A}$, wherein R and R^{2A} are as defined in the embodiments and classes and subclasses herein. In some embodiments, R^2 (i.e. $-L^2-R^{2A}$ taken together) is $-N(H)C(O)-R^{2A}$, wherein R^{2A} is as defined in the embodiments and classes and subclasses herein. In some embodiments, R^2 (i.e. $-L^2-R^{2A}$ taken together) is $-N(H)C(O)-R^{2A}$, wherein R^{2A} is R^B substituted by r^2 instances of R^{2C}. In some embodiments, R^2 is $-R^{2A}$.

[0084] In some embodiments, R^2 is $-N(H)C(O)-R^{2A}$, $-N(H)C(O)N(H)-R^{2A}$, $-C(O)N(H)-R^{2A}$, $-N(H)-R^{2A}$, $-S(O)_2CH_2-R^{2A}$, $-CH_2S(O)_2-R^{2A}$, or $-C(H)(CH_3)OH$. In some embodiments, R^2 is $-N(H)C(O)-R^{2A}$, $-N(H)C(O)N(H)-R^{2A}$, or $-N(H)-R^{2A}$. In some embodiments, R^2 is


-C(O)N(H)-R^{2A}, -$CH_2S(O)_2$-R^{2A}, or -C(H)(CH_3)OH. In some embodiments, R^2 is -$S(O)_2CH_2$-R^{2A} or -$CH_2S(O)_2$-R^{2A}.


[0085] In some embodiments, R^2 is -N(H)C(O)N(H)-R^{2A}. In some embodiments, R^2 is -C(O)N(H)-R^{2A}. In some embodiments, R^2 is -N(H)-R^{2A}. In some embodiments, R^2 is -$S(O)_2CH_2$-R^{2A}. In some embodiments, R^2 is -$CH_2S(O)_2$-R^{2A}. In some embodiments, R^2 is -C(H)(CH_3)OH.

[0086] In some embodiments, R^2 (i.e. –L^2-R^{2A} taken together) is 


, wherein R^{2C} and r^2 are as defined in the embodiments and classes and subclasses herein. In some embodiments, R^2 (i.e. –L^2-R^{2A} taken together) is 

, wherein R^{2C} is as defined in the embodiments and classes and subclasses herein.


[0087] In some embodiments, R^2 (i.e. –L^2-R^{2A} taken together) is 


, wherein each instance of R^{2C} is independently halogen, -CN, -O-(optionally substituted C_{1-6} aliphatic), or an optionally substituted C_{1-6} aliphatic. In some embodiments, R^2 (i.e. –L^2-R^{2A} taken together) is 


, wherein each instance of R^{2C} is independently halogen or C_{1-3} aliphatic optionally substituted with 1-3 halogen. In some embodiments, R^2 (i.e. –L^2-R^{2A}





taken together) is , wherein each instance of R^{2C} is independently fluorine, chlorine, $-CH_3$, $-CHF_2$, or $-CF_3$. In some embodiments, R^2 (i.e. $-L^2-R^{2A}$ taken together) is




or . In some embodiments, R^2 (i.e. $-L^2-R^{2A}$ taken together) is




. In some embodiments, R^2 (i.e. $-L^2-R^{2A}$ taken together) is .




[0088] In some embodiments, R^2 (i.e. $-L^2-R^{2A}$ taken together) is , wherein R^{2C} and r^2 are as defined in the embodiments and classes and subclasses herein. In some




embodiments, R^2 (i.e. $-L^2-R^{2A}$ taken together) is . In some embodiments, R^2 (i.e. –




L^2-R^{2A} taken together) is , wherein R^{2C} is as defined in the embodiments and classes and subclasses herein.




[0089] In some embodiments, R^2 (i.e. $-L^2-R^{2A}$ taken together) is , wherein R^{2C} and r^2 are as defined in the embodiments and classes and subclasses herein. In some




embodiments, R^2 (i.e. $-L^2-R^{2A}$ taken together) is . In some embodiments, R^2 (i.e. –




L^2-R^{2A} taken together) is , wherein R^{2C} is as defined in the embodiments and classes and subclasses herein.





[0090] In some embodiments, R^2 (i.e. $-L^2-R^{2A}$ taken together) is , wherein R^{2C} and r^2 are as defined in the embodiments and classes and subclasses herein. In some







embodiments, R^2 (i.e. $-L^2-R^{2A}$ taken together) is . In some embodiments, R^2 (i.e. –










L^2-R^{2A} taken together) is , wherein R^{2C} is as defined in the embodiments and classes and subclasses herein.





[0091] In some embodiments, R^2 (i.e. $-L^2-R^{2A}$ taken together) is , wherein R^{2C} and r^2 are as defined in the embodiments and classes and subclasses herein. In some embodiments, R^2 (i.e. $-L^2-R^{2A}$ taken together) is , wherein R^{2C} is as defined in the embodiments and classes and subclasses herein.

[0092] In some embodiments, R^2 (i.e. $-L^2-R^{2A}$ taken together) is , wherein R^{2C} and r^2 are as defined in the embodiments and classes and subclasses herein. In some embodiments, R^2 (i.e. $-L^2-R^{2A}$ taken together) is , wherein R^{2C} is as defined in the embodiments and classes and subclasses herein.


[0093] In some embodiments, R^2 (i.e. $-L^2-R^{2A}$ taken together) is , wherein R^{2C} and r^2 are as defined in the embodiments and classes and subclasses herein. In some embodiments, R^2 (i.e. $-L^2-R^{2A}$ taken together) is , wherein R^{2C} is as defined in the embodiments and classes and subclasses herein.

[0094] In some embodiments, R^2 (i.e. $-L^2-R^{2A}$ taken together) is , wherein R^{2C} and r^2 are as defined in the embodiments and classes and subclasses herein. In some embodiments, R^2 (i.e. $-L^2-R^{2A}$ taken together) is , wherein R^{2C} is as defined in the embodiments and classes and subclasses herein.


[0095] In some embodiments, R^2 is , , , , .


, , , or .




[0096] In some embodiments, R^2 is . In some embodiments, R^2 is




. In some embodiments, R^2 is




. In some embodiments, R^2 is




. In some embodiments, R^2 is




. In some embodiments, R^2 is








. In some embodiments, R^2 is








.







[0097] In some embodiments, R^2 is . In some embodiments, R^2 is


. In some embodiments, R^2 is 
. In some embodiments, R^2 is 
. In some embodiments, R^2 is 
. In some embodiments, R^2 is 
.

[0098] In some embodiments, R^2 is 
. In some embodiments, R^2 is 
. In some embodiments, R^2 is 
.

[0099] In some embodiments, R^2 is 
. In some embodiments, R^2 is 
.

In some embodiments, R^2 is 
. In some embodiments, R^2 is 
. In

some embodiments, R^2 is  . In some embodiments, R^2 is  .

[0100] In some embodiments, R^2 is selected from the groups depicted in the compounds in Table 1.

[0101] As defined generally above, each instance of R^E is independently H or $-L^E-R^{EA}$; or two instances of R^E are taken together with their intervening atoms to form a 3-8 membered saturated or partially unsaturated monocyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or an 8-12 membered saturated or partially unsaturated bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein each ring is substituted with n instances of R^{EEC}.

[0102] In some embodiments, each instance of R^E is independently H or $-L^E-R^{EA}$. In some embodiments, R^E is H. In some embodiments, each instance of R^E is independently $-L^E-R^{EA}$. In some embodiments, each instance of R^E is independently R^{EA}. In some embodiments, each instance of R^E is independently R^A. In some embodiments, each instance of R^E is independently R^B substituted by r^3 instances of R^{EC}.

[0103] In some embodiments, each instance of R^E is independently H or C_{1-6} aliphatic substituted by r^3 instances of R^{EC}. In some embodiments, each instance of R^E is independently H or C_{1-3} aliphatic substituted by r^3 instances of R^{EC}. In some embodiments, each instance of R^E is independently H or C_{1-3} aliphatic substituted by r^3 instances of halogen. In some embodiments, each instance of R^E is independently H or C_{1-3} aliphatic. In some embodiments, each instance of R^E is independently H, $-CH_3$, $-CH_2F$, $-CHF_2$-, or $-CF_3$. In some embodiments, each instance of R^E is independently H or $-CH_3$.

[0104] In some embodiments, each instance of R^E is independently C_{1-6} aliphatic substituted by r^3 instances of R^{EC}. In some embodiments, each instance of R^E is independently C_{1-3} aliphatic substituted by r^3 instances of R^{EC}. In some embodiments, each instance of R^E is independently C_{1-3} aliphatic substituted by r^3 instances of halogen. In some embodiments, each instance of R^E is independently C_{1-3} aliphatic. In some embodiments, each instance of R^E is independently $-CH_3$, $-CH_2F$, $-CHF_2$-, or $-CF_3$. In some embodiments, R^E is $-CH_3$.

[0105] In some embodiments, two instances of R^E are taken together with their intervening atoms to form a 3-8 membered saturated or partially unsaturated monocyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or an 8-12 membered saturated or partially unsaturated bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein each ring is substituted with n instances of R^{EEC}. In some embodiments, two instances of R^E are taken together with their intervening atoms to form a 3-8 membered saturated or partially unsaturated monocyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said ring is substituted with n instances of R^{EEC}. In some embodiments, two instances of R^E are taken together with their intervening atoms to form an 8-12 membered saturated or partially unsaturated bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said ring is substituted with n instances of R^{EEC}.

[0106] In some embodiments, R^E is selected from the groups depicted in the compounds in Table 1.

[0107] As defined generally above, R^Q is $-L^Q$-R^{QA} or R^Q and R^1 are taken together with their intervening atoms to form a 4-8 membered saturated or partially unsaturated monocyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or an 8-12 membered saturated or partially unsaturated bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said ring is substituted with p instances of R^{Q1C}. In some embodiments, R^Q is $-L^Q$-R^{QA}. In some embodiments, R^Q is $-R^{QA}$.

[0108] In some embodiments, R^Q and R^1 are taken together with their intervening atoms to form a 4-8 membered saturated or partially unsaturated monocyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or an 8-12 membered saturated or partially unsaturated bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said ring is substituted with p instances of R^{Q1C}. In some embodiments, R^Q and R^1 are taken together with their intervening atoms to form a 4-8 membered saturated or partially unsaturated monocyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said ring is substituted with p instances of R^{Q1C}. In some embodiments, R^Q and R^1 are taken together with their intervening atoms to form an 8-12 membered saturated or partially unsaturated bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said ring is substituted with p instances of R^{Q1C}.

[0109] In some embodiments, R^Q is halogen, -CN, -NO_2, -OR, -SR, -NR_2, -$S(O)_2R$, -$S(O)_2NR_2$, -$S(O)_2F$, -S(O)R, -$S(O)NR_2$, -S(O)(NR)R, -C(O)R, -C(O)OR, -$C(O)NR_2$, -C(O)N(R)OR, -OC(O)R, -$OC(O)NR_2$, -N(R)C(O)OR, -N(R)C(O)R, -$N(R)C(O)NR_2$, -$N(R)C(NR)NR_2$, -$N(R)S(O)_2NR_2$, -$N(R)S(O)_2R$, -$P(O)R_2$, -P(O)(R)OR, or -$B(OR)_2$.

[0110] In some embodiments, R^Q is halogen, -CN, -OH, -O-(optionally substituted C_{1-6} aliphatic), or an optionally substituted C_{1-6} aliphatic. In some embodiments, R^Q is halogen, -OH, or C_{1-3} aliphatic optionally substituted with 1-3 halogen. In some embodiments, R^Q is fluorine, chlorine, -OH, or -CH_3. In some embodiments, R^Q is deuterium. In some embodiments, R^Q is selected from the groups depicted in the compounds in Table 1.

[0111] As defined generally above, R^X is $-L^X-R^{XA}$. In some embodiments, R^X is $-R^{XA}$. In some embodiments, R^X is oxo, halogen, -CN, -NO_2, -OR, -SR, -NR_2, -$S(O)_2R$, -$S(O)_2NR_2$, -$S(O)_2F$, -S(O)R, -$S(O)NR_2$, -S(O)(NR)R, -C(O)R, -C(O)OR, -$C(O)NR_2$, -C(O)N(R)OR, -OC(O)R, -$OC(O)NR_2$, -N(R)C(O)OR, -N(R)C(O)R, -$N(R)C(O)NR_2$, -$N(R)C(NR)NR_2$, -$N(R)S(O)_2NR_2$, -$N(R)S(O)_2R$, -$P(O)R_2$, -P(O)(R)OR, or -$B(OR)_2$.

[0112] In some embodiments, R^X is halogen, -CN, -OH, -O-(optionally substituted C_{1-6} aliphatic), or an optionally substituted C_{1-6} aliphatic. In some embodiments, R^X is halogen, -OH, -O-(C_{1-3} aliphatic), or C_{1-3} aliphatic, wherein each C_{1-3} aliphatic is optionally substituted with 1-3 halogen. In some embodiments, R^X is fluorine, chlorine, -OCH_3, or -CH_3. In some embodiments, R^X is selected from the groups depicted in the compounds in Table 1.

[0113] As defined generally above, R^Y is $-L^Y-R^{YA}$ or R^Y and R^Z are taken together with their intervening atoms to form a 4-7 membered partially unsaturated or aromatic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said ring is substituted with q instances of R^{YZC}. In some embodiments, R^Y is $-L^Y-R^{YA}$. In some embodiments, R^Y and R^Z are taken together with their intervening atoms to form a 4-7 membered partially unsaturated or aromatic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said ring is substituted with q instances of R^{YZC}. In some embodiments, R^Y is selected from the groups depicted in the compounds in Table 1.

[0114] As defined generally above, R^Z is $-L^Z-R^{ZA}$ or R^Y and R^Z are taken together with their intervening atoms to form a 4-7 membered partially unsaturated or aromatic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said ring is substituted with q instances of R^{YZC}. In some embodiments, R^Z is $-L^Z-R^{ZA}$. In some

embodiments, R^Y and R^Z are taken together with their intervening atoms to form a 4-7 membered partially unsaturated or aromatic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said ring is substituted with q instances of R^{YZC}. In some embodiments, R^Z is selected from the groups depicted in the compounds in Table 1.

[0115] As defined generally above, L^1 is a covalent bond, or a C_{1-4} bivalent saturated or unsaturated, straight or branched hydrocarbon chain wherein one or two methylene units of the chain are optionally and independently replaced by $-CH(R^L)-$, $-C(R^L)_2-$, C_{3-6} cycloalkylene, C_{3-6} heterocycloalkylene, -N(R)-, -N(R)C(O)-, -C(O)N(R)-, $-N(R)S(O)_2-$, $-S(O)_2N(R)-$, -O-, -C(O)-, -OC(O)-, -C(O)O-, -S-, -S(O)- , or $-S(O)_2-$. In some embodiments, L^1 is a covalent bond. In some embodiments, L^1 is a C_{1-4} bivalent saturated or unsaturated, straight or branched hydrocarbon chain wherein one or two methylene units of the chain are optionally and independently replaced by $-CH(R^L)-$, $-C(R^L)_2-$, C_{3-6} cycloalkylene, C_{3-6} heterocycloalkylene, -N(R)-, -N(R)C(O)-, -C(O)N(R)-, $-N(R)S(O)_2-$, $-S(O)_2N(R)-$, -O-, -C(O)-, -OC(O)-, -C(O)O-, -S-, -S(O)- , or $-S(O)_2-$. In some embodiments, L^1 is a C_{1-4} bivalent saturated or unsaturated, straight or branched hydrocarbon chain.

[0116] In some embodiments, L^1 is a C_{1-2} bivalent saturated or unsaturated hydrocarbon chain wherein one or two methylene units of the chain are optionally and independently replaced by $-CH(R^L)-$, $-C(R^L)_2-$, C_{3-6} cycloalkylene, C_{3-6} heterocycloalkylene, -N(R)-, -N(R)C(O)-, -C(O)N(R)-, $-N(R)S(O)_2-$, $-S(O)_2N(R)-$, -O-, -C(O)-, -OC(O)-, -C(O)O-, -S-, -S(O)- , or $-S(O)_2-$. In some embodiments, L^1 is a C_{1-2} bivalent saturated or unsaturated hydrocarbon chain wherein one or two methylene units of the chain are optionally and independently replaced by $-CH(R^L)-$, $-C(R^L)_2-$, -N(R)-, -N(R)C(O)-, -C(O)N(R)-, $-N(R)S(O)_2-$, $-S(O)_2N(R)-$, or -O-. In some embodiments, L^1 is a C_{1-2} bivalent saturated or unsaturated hydrocarbon chain.In some embodiments, L^1 is selected from the groups depicted in the compounds in Table 1.

[0117] As defined generally above, L^2 is a covalent bond, or a C_{1-4} bivalent saturated or unsaturated, straight or branched hydrocarbon chain wherein one or two methylene units of the chain are optionally and independently replaced by $-CH(R^L)-$, $-C(R^L)_2-$, C_{3-6} cycloalkylene, C_{3-6} heterocycloalkylene, -N(R)-, -N(R)C(O)-, -C(O)N(R)-, $-N(R)S(O)_2-$, $-S(O)_2N(R)-$, -O-, -C(O)-, -OC(O)-, -C(O)O-, -S-, -S(O)- , or $-S(O)_2-$. In some embodiments, L^2 is a covalent bond. In some embodiments, L^2 is a C_{1-4} bivalent saturated or unsaturated, straight or branched hydrocarbon chain wherein one or two methylene units of the chain are

optionally and independently replaced by -CH(R^L)-, -C(R^L)$_2$-, C_{3-6} cycloalkylene, C_{3-6} heterocycloalkylene, -N(R)-, -N(R)C(O)-, -C(O)N(R)-, -N(R)S(O)$_2$-, -S(O)$_2$N(R)-, -O-, -C(O)-, -OC(O)-, -C(O)O-, -S-, -S(O)- , or -S(O)$_2$-. In some embodiments, L^2 is a C_{1-4} bivalent saturated or unsaturated, straight or branched hydrocarbon chain.

[0118] In some embodiments, L^2 is a C_{1-2} bivalent saturated or unsaturated hydrocarbon chain wherein one or two methylene units of the chain are optionally and independently replaced by -CH(R^L)-, -C(R^L)$_2$-, C_{3-6} cycloalkylene, C_{3-6} heterocycloalkylene, -N(R)-, -N(R)C(O)-, -C(O)N(R)-, -N(R)S(O)$_2$-, -S(O)$_2$N(R)-, -O-, -C(O)-, -OC(O)-, -C(O)O-, -S-, -S(O)- , or -S(O)$_2$-. In some embodiments, L^2 is a C_{1-2} bivalent saturated or unsaturated hydrocarbon chain wherein one or two methylene units of the chain are optionally and independently replaced by -CH(R^L)-, -C(R^L)$_2$-, -N(R)-, -N(R)C(O)-, -C(O)N(R)-, -N(R)S(O)$_2$-, -S(O)$_2$N(R)-, or -O-. In some embodiments, L^2 is a C_{1-2} bivalent saturated or unsaturated hydrocarbon chain.

[0119] In some embodiments, L^2 is -N(R)C(O)- or -N(R)C(O)N(R)-. In some embodiments, L^2 is -N(H)C(O)- or -N(H)C(O)N(H)-. In some embodiments, L^2 is -N(R)C(O)-. In some embodiments, L^2 is -N(H)C(O)-. In some embodiments, L^2 is -N(R)C(O)N(R)-. In some embodiments, L^2 is -N(H)C(O)N(H)-. In some embodiments, L^2 is -N(R)-. In some embodiments, L^2 is -N(H)-. In some embodiments, L^2 is a covalent bond. In some embodiments, L^2 is selected from the groups depicted in the compounds in Table 1.

[0120] As defined generally above, L^E is a covalent bond, or a C_{1-4} bivalent saturated or unsaturated, straight or branched hydrocarbon chain wherein one or two methylene units of the chain are optionally and independently replaced by -CH(R^L)-, -C(R^L)$_2$-, C_{3-6} cycloalkylene, C_{3-6} heterocycloalkylene, -N(R)-, -N(R)C(O)-, -C(O)N(R)-, -N(R)S(O)$_2$-, -S(O)$_2$N(R)-, -O-, -C(O)-, -OC(O)-, -C(O)O-, -S-, -S(O)- , or -S(O)$_2$-. In some embodiments, L^E is a covalent bond. In some embodiments, L^E is a C_{1-4} bivalent saturated or unsaturated, straight or branched hydrocarbon chain wherein one or two methylene units of the chain are optionally and independently replaced by -CH(R^L)-, -C(R^L)$_2$-, C_{3-6} cycloalkylene, C_{3-6} heterocycloalkylene, -N(R)-, -N(R)C(O)-, -C(O)N(R)-, -N(R)S(O)$_2$-, -S(O)$_2$N(R)-, -O-, -C(O)-, -OC(O)-, -C(O)O-, -S-, -S(O)- , or -S(O)$_2$-. In some embodiments, L^E is a C_{1-4} bivalent saturated or unsaturated, straight or branched hydrocarbon chain.

[0121] In some embodiments, L^E is a C_{1-2} bivalent saturated or unsaturated hydrocarbon chain wherein one or two methylene units of the chain are optionally and independently

replaced by -CH(R^L)-, -C(R^L)$_2$-, C_{3-6} cycloalkylene, C_{3-6} heterocycloalkylene, -N(R)-, -N(R)C(O)-, -C(O)N(R)-, -N(R)S(O)$_2$-, -S(O)$_2$N(R)-, -O-, -C(O)-, -OC(O)-, -C(O)O-, -S-, -S(O)- , or -S(O)$_2$-. In some embodiments, L^E is a C_{1-2} bivalent saturated or unsaturated hydrocarbon chain wherein one or two methylene units of the chain are optionally and independently replaced by -CH(R^L)-, -C(R^L)$_2$-, -N(R)-, -N(R)C(O)-, -C(O)N(R)-, -N(R)S(O)$_2$-, -S(O)$_2$N(R)-, or -O-. In some embodiments, L^E is a C_{1-2} bivalent saturated or unsaturated hydrocarbon chain. In some embodiments, L^E is selected from the groups depicted in the compounds in Table 1.

[0122] As defined generally above, L^Q is a covalent bond, or a C_{1-4} bivalent saturated or unsaturated, straight or branched hydrocarbon chain wherein one or two methylene units of the chain are optionally and independently replaced by -CH(R^L)-, -C(R^L)$_2$-, C_{3-6} cycloalkylene, C_{3-6} heterocycloalkylene, -N(R)-, -N(R)C(O)-, -C(O)N(R)-, -N(R)S(O)$_2$-, -S(O)$_2$N(R)-, -O-, -C(O)-, -OC(O)-, -C(O)O-, -S-, -S(O)- , or -S(O)$_2$-. In some embodiments, L^Q is a covalent bond. In some embodiments, L^Q is a C_{1-4} bivalent saturated or unsaturated, straight or branched hydrocarbon chain wherein one or two methylene units of the chain are optionally and independently replaced by -CH(R^L)-, -C(R^L)$_2$-, C_{3-6} cycloalkylene, C_{3-6} heterocycloalkylene, -N(R)-, -N(R)C(O)-, -C(O)N(R)-, -N(R)S(O)$_2$-, -S(O)$_2$N(R)-, -O-, -C(O)-, -OC(O)-, -C(O)O-, -S-, -S(O)- , or -S(O)$_2$-. In some embodiments, L^Q is a C_{1-4} bivalent saturated or unsaturated, straight or branched hydrocarbon chain.

[0123] In some embodiments, L^Q is a C_{1-2} bivalent saturated or unsaturated hydrocarbon chain wherein one or two methylene units of the chain are optionally and independently replaced by -CH(R^L)-, -C(R^L)$_2$-, C_{3-6} cycloalkylene, C_{3-6} heterocycloalkylene, -N(R)-, -N(R)C(O)-, -C(O)N(R)-, -N(R)S(O)$_2$-, -S(O)$_2$N(R)-, -O-, -C(O)-, -OC(O)-, -C(O)O-, -S-, -S(O)- , or -S(O)$_2$-. In some embodiments, L^Q is a C_{1-2} bivalent saturated or unsaturated hydrocarbon chain wherein one or two methylene units of the chain are optionally and independently replaced by -CH(R^L)-, -C(R^L)$_2$-, -N(R)-, -N(R)C(O)-, -C(O)N(R)-, -N(R)S(O)$_2$-, -S(O)$_2$N(R)-, or -O-. In some embodiments, L^Q is a C_{1-2} bivalent saturated or unsaturated hydrocarbon chain. In some embodiments, L^Q is selected from the groups depicted in the compounds in Table 1.

[0124] As defined generally above, L^X is a covalent bond, or a C_{1-4} bivalent saturated or unsaturated, straight or branched hydrocarbon chain wherein one or two methylene units of the chain are optionally and independently replaced by -CH(R^L)-, -C(R^L)$_2$-, C_{3-6} cycloalkylene, C_{3-6} heterocycloalkylene, -N(R)-, -N(R)C(O)-, -C(O)N(R)-, -N(R)S(O)$_2$-,

$-S(O)_2N(R)-$, -O-, -C(O)-, -OC(O)-, -C(O)O-, -S-, -S(O)- , or $-S(O)_2-$. In some embodiments, L^X is a covalent bond. In some embodiments, L^X is a C_{1-4} bivalent saturated or unsaturated, straight or branched hydrocarbon chain wherein one or two methylene units of the chain are optionally and independently replaced by $-CH(R^L)-$, $-C(R^L)_2-$, C_{3-6} cycloalkylene, C_{3-6} heterocycloalkylene, -N(R)-, -N(R)C(O)-, -C(O)N(R)-, $-N(R)S(O)_2-$, $-S(O)_2N(R)-$, -O-, -C(O)-, -OC(O)-, -C(O)O-, -S-, -S(O)- , or $-S(O)_2-$. In some embodiments, L^X is a C_{1-4} bivalent saturated or unsaturated, straight or branched hydrocarbon chain.

[0125] In some embodiments, L^X is a C_{1-2} bivalent saturated or unsaturated hydrocarbon chain wherein one or two methylene units of the chain are optionally and independently replaced by $-CH(R^L)-$, $-C(R^L)_2-$, C_{3-6} cycloalkylene, C_{3-6} heterocycloalkylene, -N(R)-, -N(R)C(O)-, -C(O)N(R)-, $-N(R)S(O)_2-$, $-S(O)_2N(R)-$, -O-, -C(O)-, -OC(O)-, -C(O)O-, -S-, -S(O)- , or $-S(O)_2-$. In some embodiments, L^X is a C_{1-2} bivalent saturated or unsaturated hydrocarbon chain wherein one or two methylene units of the chain are optionally and independently replaced by $-CH(R^L)-$, $-C(R^L)_2-$, -N(R)-, -N(R)C(O)-, -C(O)N(R)-, $-N(R)S(O)_2-$, $-S(O)_2N(R)-$, or -O-. In some embodiments, L^X is a C_{1-2} bivalent saturated or unsaturated hydrocarbon chain. In some embodiments, L^X is selected from the groups depicted in the compounds in Table 1.

[0126] As defined generally above, L^Y is a covalent bond, or a C_{1-4} bivalent saturated or unsaturated, straight or branched hydrocarbon chain wherein one or two methylene units of the chain are optionally and independently replaced by $-CH(R^L)-$, $-C(R^L)_2-$, C_{3-6} cycloalkylene, C_{3-6} heterocycloalkylene, -N(R)-, -N(R)C(O)-, -C(O)N(R)-, $-N(R)S(O)_2-$, $-S(O)_2N(R)-$, -O-, -C(O)-, -OC(O)-, -C(O)O-, -S-, -S(O)- , or $-S(O)_2-$. In some embodiments, L^Y is a covalent bond. In some embodiments, L^Y is a C_{1-4} bivalent saturated or unsaturated, straight or branched hydrocarbon chain wherein one or two methylene units of the chain are optionally and independently replaced by $-CH(R^L)-$, $-C(R^L)_2-$, C_{3-6} cycloalkylene, C_{3-6} heterocycloalkylene, -N(R)-, -N(R)C(O)-, -C(O)N(R)-, $-N(R)S(O)_2-$, $-S(O)_2N(R)-$, -O-, -C(O)-, -OC(O)-, -C(O)O-, -S-, -S(O)- , or $-S(O)_2-$. In some embodiments, L^Y is a C_{1-4} bivalent saturated or unsaturated, straight or branched hydrocarbon chain.

[0127] In some embodiments, L^Y is a C_{1-2} bivalent saturated or unsaturated hydrocarbon chain wherein one or two methylene units of the chain are optionally and independently replaced by $-CH(R^L)-$, $-C(R^L)_2-$, C_{3-6} cycloalkylene, C_{3-6} heterocycloalkylene, -N(R)-, -N(R)C(O)-, -C(O)N(R)-, $-N(R)S(O)_2-$, $-S(O)_2N(R)-$, -O-, -C(O)-, -OC(O)-, -C(O)O-, -S-, -S(O)- , or $-S(O)_2-$. In some embodiments, L^Y is a C_{1-2} bivalent saturated or unsaturated

hydrocarbon chain wherein one or two methylene units of the chain are optionally and independently replaced by -CH(R^L)-, -C(R^L)$_2$-, -N(R)-, -N(R)C(O)-, -C(O)N(R)-, -N(R)S(O)$_2$-, -S(O)$_2$N(R)-, or -O-. In some embodiments, L^Y is a C_{1-2} bivalent saturated or unsaturated hydrocarbon chain.

[0128] In some embodiments, L^Y is -C(H)$_2$-, -CH(R^L)-, -C(R^L)$_2$-, C_{3-6} cycloalkylene, C_{3-6} heterocycloalkylene, -N(R)-, -N(R)C(O)-, -C(O)N(R)-, -N(R)S(O)$_2$-, -S(O)$_2$N(R)-, -O-, -C(O)-, -OC(O)-, -C(O)O-, -S-, -S(O)- , or -S(O)$_2$-. In some embodiments, L^Y is -C(H)$_2$-, -CH(R^L)-, -C(R^L)$_2$-, -N(R)-, -N(R)C(O)-, -C(O)N(R)-, -N(R)S(O)$_2$-, -S(O)$_2$N(R)-, or -O-. In some embodiments, L^Y is -C(H)$_2$-, -N(R)-, -N(R)C(O)-, or -C(O)N(R)-. In some embodiments, L^Y is -C(H)$_2$-, -N(H)-, -N(H)C(O)-, or -C(O)N(H)-. In some embodiments, L^Y is selected from the groups depicted in the compounds in Table 1.

[0129] As defined generally above, L^Z is a covalent bond, or a C_{1-4} bivalent saturated or unsaturated, straight or branched hydrocarbon chain wherein one or two methylene units of the chain are optionally and independently replaced by -CH(R^L)-, -C(R^L)$_2$-, C_{3-6} cycloalkylene, C_{3-6} heterocycloalkylene, -N(R)-, -N(R)C(O)-, -C(O)N(R)-, -N(R)S(O)$_2$-, -S(O)$_2$N(R)-, -O-, -C(O)-, -OC(O)-, -C(O)O-, -S-, -S(O)- , or -S(O)$_2$-. In some embodiments, L^Z is a covalent bond. In some embodiments, L^Z is a C_{1-4} bivalent saturated or unsaturated, straight or branched hydrocarbon chain wherein one or two methylene units of the chain are optionally and independently replaced by -CH(R^L)-, -C(R^L)$_2$-, C_{3-6} cycloalkylene, C_{3-6} heterocycloalkylene, -N(R)-, -N(R)C(O)-, -C(O)N(R)-, -N(R)S(O)$_2$-, -S(O)$_2$N(R)-, -O-, -C(O)-, -OC(O)-, -C(O)O-, -S-, -S(O)- , or -S(O)$_2$-. In some embodiments, L^Z is a C_{1-4} bivalent saturated or unsaturated, straight or branched hydrocarbon chain.

[0130] In some embodiments, L^Z is a C_{1-2} bivalent saturated or unsaturated hydrocarbon chain wherein one or two methylene units of the chain are optionally and independently replaced by -CH(R^L)-, -C(R^L)$_2$-, C_{3-6} cycloalkylene, C_{3-6} heterocycloalkylene, -N(R)-, -N(R)C(O)-, -C(O)N(R)-, -N(R)S(O)$_2$-, -S(O)$_2$N(R)-, -O-, -C(O)-, -OC(O)-, -C(O)O-, -S-, -S(O)- , or -S(O)$_2$-. In some embodiments, L^Z is a C_{1-2} bivalent saturated or unsaturated hydrocarbon chain wherein one or two methylene units of the chain are optionally and independently replaced by -CH(R^L)-, -C(R^L)$_2$-, -N(R)-, -N(R)C(O)-, -C(O)N(R)-, -N(R)S(O)$_2$-, -S(O)$_2$N(R)-, or -O-. In some embodiments, L^Z is a C_{1-2} bivalent saturated or unsaturated hydrocarbon chain.

[0131] In some embodiments, L^Z is -$C(H)_2$-, -$CH(R^L)$-, -$C(R^L)_2$-, C_{3-6} cycloalkylene, C_{3-6} heterocycloalkylene, -N(R)-, -N(R)C(O)-, -C(O)N(R)-, -N(R)$S(O)_2$-, -$S(O)_2$N(R)-, -O-, -C(O)-, -OC(O)-, -C(O)O-, -S-, -S(O)- , or -$S(O)_2$-. In some embodiments, L^Z is -$C(H)_2$-, -$CH(R^L)$-, -$C(R^L)_2$-, -N(R)-, -N(R)C(O)-, -C(O)N(R)-, -N(R)$S(O)_2$-, -$S(O)_2$N(R)-, or -O-. In some embodiments, L^Z is -$C(H)_2$-, -N(R)-, -N(R)C(O)-, or -C(O)N(R)-. In some embodiments, L^Z is -$C(H)_2$-, -N(H)-, -N(H)C(O)-, or -C(O)N(H)-. In some embodiments, L^Z is selected from the groups depicted in the compounds in Table 1.

[0132] As defined generally above, R^{1A} is R^A or R^B substituted by r^1 instances of R^{1C}. In some embodiments, R^{1A} is R^A. In some embodiments, R^{1A} is R^B substituted by r^1 instances of R^{1C}.

[0133] In some embodiments, R^{1A} is phenyl; naphthyl; a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; an 8-10 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring; a 5-12 membered saturated or partially unsaturated bicyclic carbocyclic ring; a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or a 7-12 membered saturated or partially unsaturated bicyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein R^{1A} is substituted by r^1 instances of R^{1C}.

[0134] In some embodiments, R^{1A} is phenyl substituted by r^1 instances of R^{1C}. In some embodiments, R^{1A} is an 8-10 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein R^{1A} is substituted by r^1 instances of R^{1C}. In some embodiments, R^{1A} is phenyl or an 8-10 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein R^{1A} is substituted by r^1 instances of R^{1C}.

[0135] In some embodiments, R^{1A} is phenyl; naphthyl; a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; an 8-10 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring; wherein R^{1A} is substituted by r^1 instances of R^{1C}.

[0136] In some embodiments, R^{1A} is phenyl substituted by r^1 instances of a group independently selected from oxo, halogen, -CN, $-NO_2$, -OR, -SR, $-NR_2$, $-S(O)_2R$, $-S(O)_2NR_2$, $-S(O)_2F$, -S(O)R, $-S(O)NR_2$, -S(O)(NR)R, -C(O)R, -C(O)OR, $-C(O)NR_2$, -C(O)N(R)OR, -OC(O)R, $-OC(O)NR_2$, -N(R)C(O)OR, -N(R)C(O)R, $-N(R)C(O)NR_2$, $-N(R)C(NR)NR_2$, $-N(R)S(O)_2NR_2$, $-N(R)S(O)_2R$, $-P(O)R_2$, -P(O)(R)OR, $-B(OR)_2$, and optionally substituted C_{1-6} aliphatic. In some embodiments, R^{1A} is an 8-10 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein R^{1A} is substituted by r^1 instances of a group independently selected from oxo, halogen, -CN, $-NO_2$, -OR, -SR, $-NR_2$, $-S(O)_2R$, $-S(O)_2NR_2$, $-S(O)_2F$, -S(O)R, $-S(O)NR_2$, -S(O)(NR)R, -C(O)R, -C(O)OR, $-C(O)NR_2$, -C(O)N(R)OR, -OC(O)R, $-OC(O)NR_2$, -N(R)C(O)OR, -N(R)C(O)R, $-N(R)C(O)NR_2$, $-N(R)C(NR)NR_2$, $-N(R)S(O)_2NR_2$, $-N(R)S(O)_2R$, $-P(O)R_2$, -P(O)(R)OR, $-B(OR)_2$, and optionally substituted C_{1-6} aliphatic. In some embodiments, R^{1A} is phenyl or an 8-10 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein R^{1A} is substituted by r^1 instances of a group independently selected from oxo, halogen, -CN, $-NO_2$, -OR, -SR, $-NR_2$, $-S(O)_2R$, $-S(O)_2NR_2$, $-S(O)_2F$, -S(O)R, $-S(O)NR_2$, -S(O)(NR)R, -C(O)R, -C(O)OR, $-C(O)NR_2$, -C(O)N(R)OR, -OC(O)R, $-OC(O)NR_2$, -N(R)C(O)OR, -N(R)C(O)R, $-N(R)C(O)NR_2$, $-N(R)C(NR)NR_2$, $-N(R)S(O)_2NR_2$, $-N(R)S(O)_2R$, $-P(O)R_2$, -P(O)(R)OR, $-B(OR)_2$, and optionally substituted C_{1-6} aliphatic.


[0137] In some embodiments, R^{1A} is phenyl substituted by 1-3 instances of R^{1C}. In some embodiments, R^{1A} is phenyl substituted by 2 instances of R^{1C}. In some embodiments, R^{1A} is phenyl substituted by 1 instance of R^{1C}.


[0138] In some embodiments, R^{1A} is phenyl substituted by 1-3 instances of a group independently selected from halogen, -CN, -O-(optionally substituted C_{1-6} aliphatic), and an optionally substituted C_{1-6} aliphatic. In some embodiments, R^{1A} is phenyl substituted by 1-3 instances of a group independently selected from halogen and C_{1-3} aliphatic optionally substituted with 1-3 halogen. In some embodiments, R^{1A} is phenyl substituted by 1-3 instances of a group independently selected from fluorine, chlorine, $-CH_3$, $-CHF_2$, and $-CF_3$.


[0139] In some embodiments, R^{1A} is phenyl substituted by 2 instances of a group independently selected from halogen, -CN, -O-(optionally substituted C_{1-6} aliphatic), and an optionally substituted C_{1-6} aliphatic. In some embodiments, R^{1A} is phenyl substituted by 2 instances of a group independently selected from halogen and C_{1-3} aliphatic optionally


substituted with 1-3 halogen. In some embodiments, R^{1A} is phenyl substituted by 2 instances of a group independently selected from fluorine, chlorine, $-CH_3$, $-CHF_2$, and $-CF_3$.


[0140] In some embodiments, R^{1A} is phenyl substituted by one group selected from halogen, -CN, -O-(optionally substituted C_{1-6} aliphatic), and an optionally substituted C_{1-6} aliphatic. In some embodiments, R^{1A} is phenyl substituted by one halogen or C_{1-3} aliphatic group optionally substituted with 1-3 halogen. In some embodiments, R^{1A} is phenyl substituted by one fluorine, chlorine, $-CH_3$, $-CHF_2$, or $-CF_3$.



[0141] In some embodiments, R^{1A} is , wherein R^{1C} and r^1 are as defined in the embodiments and classes and subclasses herein. In some embodiments, R^{1A} is









, wherein R^{1C} is as defined in the embodiments and classes and subclasses herein. In some embodiments, R^{1A} is , wherein R^{1C} is as defined in the embodiments and classes and subclasses herein. In some embodiments, R^{1A} is







, wherein R^{1C} is as defined in the embodiments and classes and subclasses herein. In some embodiments, R^{1A} is , wherein R^{1C} is as defined in the embodiments and classes and subclasses herein.

[0142] In some embodiments, R^{1A} is , wherein each instance of R^{1C} is independently halogen, -CN, -O-(optionally substituted C_{1-6} aliphatic), or an optionally substituted C_{1-6} aliphatic. In some embodiments, R^{1A} is , wherein each instance of R^{1C} is independently halogen or C_{1-3} aliphatic optionally substituted with 1-3

halogen. In some embodiments, R^{1A} is , wherein each instance of R^{1C} is independently halogen or C_{1-3} aliphatic optionally substituted with 1-3 halogen. In some embodiments, R^{1A} is , wherein each instance of R^{1C} is independently halogen or C_{1-3} aliphatic optionally substituted with 1-3 halogen. In some embodiments, R^{1A} is , wherein each instance of R^{1C} is independently fluorine, chlorine, $-CH_3$, $-CHF_2$, or $-CF_3$. In some embodiments, R^{1A} is , wherein R^{1C} is halogen or C_{1-3} aliphatic optionally substituted with 1-3 halogen.

[0143] In some embodiments, R^{1A} is . In some embodiments, R^{1A} is .

[0144] In some embodiments, R^{1A} is , wherein R^{1C} and r^1 are as defined in the embodiments and classes and subclasses herein. In some embodiments, R^{1A} is . In some embodiments, R^{1A} is . In some embodiments, R^{1A} is .

[0145] In some embodiments, R^{1A} is oxo, halogen, -CN, $-NO_2$, -OR, -SR, $-NR_2$, $-S(O)_2R$, $-S(O)_2NR_2$, $-S(O)_2F$, -S(O)R, $-S(O)NR_2$, -S(O)(NR)R, -C(O)R, -C(O)OR, $-C(O)NR_2$, -C(O)N(R)OR, -OC(O)R, $-OC(O)NR_2$, -N(R)C(O)OR, -N(R)C(O)R, $-N(R)C(O)NR_2$, $-N(R)C(NR)NR_2$, $-N(R)S(O)_2NR_2$, $-N(R)S(O)_2R$, $-P(O)R_2$, -P(O)(R)OR, $-B(OR)_2$, or deuterium.

[0146] In some embodiments, R^{1A} is oxo, halogen, -CN, -NO_2, -OR, -SR, -NR_2, -$S(O)_2R$, -$S(O)_2NR_2$, -$S(O)_2F$, -S(O)R, -$S(O)NR_2$, -S(O)(NR)R, -C(O)R, -C(O)OR, -$C(O)NR_2$, -C(O)N(R)OR, -OC(O)R, -$OC(O)NR_2$, -N(R)C(O)OR, -N(R)C(O)R, -$N(R)C(O)NR_2$, -$N(R)C(NR)NR_2$, -$N(R)S(O)_2NR_2$, -$N(R)S(O)_2R$, -$P(O)R_2$, -P(O)(R)OR, or -$B(OR)_2$.

[0147] In some embodiments, R^{1A} is oxo. In some embodiments, R^{1A} is halogen. In some embodiments, R^{1A} is –CN. In some embodiments, R^{1A} is -NO_2. In some embodiments, R^{1A} is -OR. In some embodiments, R^{1A} is -SR. In some embodiments, R^{1A} is -NR_2. In some embodiments, R^{1A} is -$S(O)_2R$. In some embodiments, R^{1A} is -$S(O)_2NR_2$. In some embodiments, R^{1A} is -$S(O)_2F$. In some embodiments, R^{1A} is -S(O)R. In some embodiments, R^{1A} is -$S(O)NR_2$. In some embodiments, R^{1A} is -S(O)(NR)R. In some embodiments, R^{1A} is -C(O)R. In some embodiments, R^{1A} is -C(O)OR. In some embodiments, R^{1A} is -$C(O)NR_2$. In some embodiments, R^{1A} is -C(O)N(R)OR. In some embodiments, R^{1A} is -OC(O)R. In some embodiments, R^{1A} is -$OC(O)NR_2$. In some embodiments, R^{1A} is -N(R)C(O)OR. In some embodiments, R^{1A} is -N(R)C(O)R. In some embodiments, R^{1A} is -$N(R)C(O)NR_2$. In some embodiments, R^{1A} is -$N(R)C(NR)NR_2$. In some embodiments, R^{1A} is -$N(R)S(O)_2NR_2$. In some embodiments, R^{1A} is -$N(R)S(O)_2R$. In some embodiments, R^{1A} is -$P(O)R_2$. In some embodiments, R^{1A} is -P(O)(R)OR. In some embodiments, R^{1A} is -$B(OR)_2$. In some embodiments, R^{1A} is deuterium.

[0148] In some embodiments, R^{1A} is halogen, -CN, -NO_2, -OR, -SR, -NR_2, -$S(O)_2R$, -$S(O)_2NR_2$, -$S(O)_2F$, -S(O)R, -$S(O)NR_2$, -S(O)(NR)R, -C(O)R, -C(O)OR, -$C(O)NR_2$, -C(O)N(R)OR, -OC(O)R, -$OC(O)NR_2$, -N(R)C(O)OR, -N(R)C(O)R, -$N(R)C(O)NR_2$, -$N(R)C(NR)NR_2$, -$N(R)S(O)_2NR_2$, -$N(R)S(O)_2R$, -$P(O)R_2$, -P(O)(R)OR, or -$B(OR)_2$.

[0149] In some embodiments, R^{1A} is halogen, -CN, or -NO_2. In some embodiments, R^{1A} is -OR, -SR, or -NR_2. In some embodiments, R^{1A} is -$S(O)_2R$, -$S(O)_2NR_2$, -$S(O)_2F$, -S(O)R, -$S(O)NR_2$, or -S(O)(NR)R. In some embodiments, R^{1A} is -C(O)R, -C(O)OR, -$C(O)NR_2$, or -C(O)N(R)OR. In some embodiments, R^{1A} is -OC(O)R or -$OC(O)NR_2$. In some embodiments, R^{1A} is -N(R)C(O)OR, -N(R)C(O)R, -$N(R)C(O)NR_2$, -$N(R)C(NR)NR_2$, -$N(R)S(O)_2NR_2$, or -$N(R)S(O)_2R$. In some embodiments, R^{1A} is -$P(O)R_2$ or -P(O)(R)OR.

[0150] In some embodiments, R^{1A} is -OR, -OC(O)R, or -$OC(O)NR_2$. In some embodiments, R^{1A} is -SR, -$S(O)_2R$, -$S(O)_2NR_2$, -$S(O)_2F$, -S(O)R, -$S(O)NR_2$, or -S(O)(NR)R. In some embodiments, R^{1A} is -NR_2, -N(R)C(O)OR, -N(R)C(O)R, -$N(R)C(O)NR_2$, -$N(R)C(NR)NR_2$, -$N(R)S(O)_2NR_2$, or -$N(R)S(O)_2R$.

[0151] In some embodiments, R^{1A} is $-S(O)_2R$, $-S(O)_2NR_2$, or $-S(O)_2F$. In some embodiments, R^{1A} is $-S(O)R$, $-S(O)NR_2$, or $-S(O)(NR)R$. In some embodiments, R^{1A} is $-SR$, $-S(O)_2R$, or $-S(O)R$. In some embodiments, R^{1A} is $-S(O)_2NR_2$, $-S(O)NR_2$, or $-S(O)(NR)R$. In some embodiments, R^{1A} is $-S(O)_2NR_2$ or $-S(O)NR_2$. In some embodiments, R^{1A} is $-SR$, $-S(O)_2R$, $-S(O)_2NR_2$, or $-S(O)R$.

[0152] In some embodiments, R^{1A} is $-N(R)C(O)OR$, $-N(R)C(O)R$, or $-N(R)C(O)NR_2$. In some embodiments, R^{1A} is $-N(R)S(O)_2NR_2$ or $-N(R)S(O)_2R$. In some embodiments, R^{1A} is $-N(R)C(O)OR$ or $-N(R)C(O)R$. In some embodiments, R^{1A} is $-N(R)C(O)NR_2$ or $-N(R)S(O)_2NR_2$. In some embodiments, R^{1A} is $-N(R)C(O)OR$, $-N(R)C(O)R$, or $-N(R)S(O)_2R$.

[0153] In some embodiments, R^{1A} is $-NR_2$, $-N(R)C(O)OR$, $-N(R)C(O)R$, or $-N(R)C(O)NR_2$. In some embodiments, R^{1A} is $-NR_2$, $-N(R)C(O)OR$, or $-N(R)C(O)R$. In some embodiments, R^{1A} is $-NR_2$, $-N(R)C(O)OR$, $-N(R)C(O)R$, or $-N(R)S(O)_2R$.

[0154] In some embodiments, R^{1A} is a C_{1-6} aliphatic chain; phenyl; naphthyl; a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; an 8-10 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring; a 5-12 membered saturated or partially unsaturated bicyclic carbocyclic ring; a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or a 7-12 membered saturated or partially unsaturated bicyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted by r^1 instances of R^{1C}.

[0155] In some embodiments, R^{1A} is a C_{1-6} aliphatic chain substituted by r^1 instances of R^{1C}. In some embodiments, R^{1A} is phenyl substituted by r^1 instances of R^{1C}. In some embodiments, R^{1A} is naphthyl substituted by r^1 instances of R^{1C}. In some embodiments, R^{1A} is a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said ring is substituted by r^1 instances of R^{1C}. In some embodiments, R^{1A} is an 8-10 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said ring is substituted by r^1 instances of R^{1C}. In some embodiments, R^{1A} is a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring substituted by r^1 instances of R^{1C}. In some

embodiments, R^{1A} is a 5-12 membered saturated or partially unsaturated bicyclic carbocyclic ring substituted by r^1 instances of R^{1C}. In some embodiments, R^{1A} is a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said ring is substituted by r^1 instances of R^{1C}. In some embodiments, R^{1A} is a 7-12 membered saturated or partially unsaturated bicyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said ring is substituted by r^1 instances of R^{1C}.

[0156] In some embodiments, R^{1A} is phenyl; naphthyl; a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or an 8-10 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted by r^1 instances of R^{1C}. In some embodiments, R^{1A} is a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring; a 5-12 membered saturated or partially unsaturated bicyclic carbocyclic ring; a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or a 7-12 membered saturated or partially unsaturated bicyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted by r^1 instances of R^{1C}.

[0157] In some embodiments, R^{1A} is phenyl; naphthyl; a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring; or a 5-12 membered saturated or partially unsaturated bicyclic carbocyclic ring; each of which is substituted by r^1 instances of R^{1C}. In some embodiments, R^{1A} is a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; an 8-10 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or a 7-12 membered saturated or partially unsaturated bicyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted by r^1 instances of R^{1C}.

[0158] In some embodiments, R^{1A} is phenyl; a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring; or a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms

independently selected from nitrogen, oxygen, and sulfur; each of which is substituted by r^1 instances of R^{1C}. In some embodiments, R^{1A} is naphthyl; an 8-10 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 5-12 membered saturated or partially unsaturated bicyclic carbocyclic ring; or a 7-12 membered saturated or partially unsaturated bicyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted by r^1 instances of R^{1C}.

[0159] In some embodiments, R^{1A} is phenyl or naphthyl; each of which is substituted by r^1 instances of R^{1C}. In some embodiments, R^{1A} is a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or an 8-10 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted by r^1 instances of R^{1C}. In some embodiments, R^{1A} is a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring or a 5-12 membered saturated or partially unsaturated bicyclic carbocyclic ring; each of which is substituted by r^1 instances of R^{1C}. In some embodiments, R^{1A} is a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or a 7-12 membered saturated or partially unsaturated bicyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted by r^1 instances of R^{1C}.

[0160] In some embodiments, R^{1A} is phenyl or a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted by r^1 instances of R^{1C}. In some embodiments, R^{1A} is a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring or a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted by r^1 instances of R^{1C}. In some embodiments, R^{1A} is naphthyl or an 8-10 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted by r^1 instances of R^{1C}. In some embodiments, R^{1A} is a 5-12 membered saturated or partially unsaturated bicyclic carbocyclic ring or a 7-12 membered saturated or partially unsaturated bicyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted by r^1 instances of R^{1C}.

[0161] In some embodiments, R^{1A} is phenyl or a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring; each of which is substituted by r^1 instances of R^{1C}. In some embodiments, R^{1A} is naphthyl or a 5-12 membered saturated or partially unsaturated bicyclic carbocyclic ring; each of which is substituted by r^1 instances of R^{1C}. In some embodiments, R^{1A} is a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted by r^1 instances of R^{1C}. In some embodiments, R^{1A} is an 8-10 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or a 7-12 membered saturated or partially unsaturated bicyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted by r^1 instances of R^{1C}.

[0162] In some embodiments, R^{1A} is a C_{1-6} aliphatic chain; a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring; a 5-12 membered saturated or partially unsaturated bicyclic carbocyclic ring; a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or a 7-12 membered saturated or partially unsaturated bicyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted by r^1 instances of R^{1C}. In some embodiments, R^{1A} is a C_{1-6} aliphatic chain; phenyl; naphthyl; a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring; or a 5-12 membered saturated or partially unsaturated bicyclic carbocyclic ring; each of which is substituted by r^1 instances of R^{1C}. In some embodiments, R^{1A} is a C_{1-6} aliphatic chain; phenyl; a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring; or a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted by r^1 instances of R^{1C}.

[0163] In some embodiments, R^{1A} is a C_{1-6} aliphatic chain, a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring, or a 5-12 membered saturated or partially unsaturated bicyclic carbocyclic ring; each of which is substituted by r^1 instances of R^{1C}. In some embodiments, R^{1A} is a C_{1-6} aliphatic chain, a 3-7 membered saturated or partially

unsaturated monocyclic carbocyclic ring, or a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted by r^1 instances of R^{1C}. In some embodiments, R^{1A} is a C_{1-6} aliphatic chain, phenyl, or a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring; each of which is substituted by r^1 instances of R^{1C}.

[0164] In some embodiments, R^{1A} is selected from the groups depicted in the compounds in Table 1.

[0165] As defined generally above, R^{2A} is R^A or R^B substituted by r^2 instances of R^{2C}. In some embodiments, R^{2A} is R^A. In some embodiments, R^{2A} is R^B substituted by r^2 instances of R^{2C}.

[0166] In some embodiments, R^{2A} is phenyl; naphthyl; cubanyl; adamantyl; a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; an 8-10 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring; a 5-12 membered saturated or partially unsaturated bicyclic carbocyclic ring; a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or a 7-12 membered saturated or partially unsaturated bicyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein R^{2A} is substituted by r^2 instances of R^{2C}.

[0167] In some embodiments, R^{2A} is phenyl; naphthyl; an 8-10 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or a 7-12 membered saturated or partially unsaturated bicyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein R^{2A} is substituted by r^2 instances of R^{2C}. In some embodiments, R^{2A} is phenyl; an 8-10 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or a 7-12 membered saturated or partially unsaturated bicyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein R^{2A} is substituted by r^2 instances of R^{2C}. In some embodiments, R^{2A} is phenyl or an 8-10 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein R^{2A} is substituted by r^2 instances of R^{2C}.

[0168] In some embodiments, R^{2A} is phenyl; naphthyl; an 8-10 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or a 7-12 membered saturated or partially unsaturated bicyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein R^{2A} is substituted by r^2 instances of a group independently selected from oxo, halogen, -CN, -NO_2, -OR, -SR, -NR_2, -$S(O)_2R$, -$S(O)_2NR_2$, -$S(O)_2F$, -S(O)R, -$S(O)NR_2$, -S(O)(NR)R, -C(O)R, -C(O)OR, -$C(O)NR_2$, -C(O)N(R)OR, -OC(O)R, -$OC(O)NR_2$, -N(R)C(O)OR, -N(R)C(O)R, -$N(R)C(O)NR_2$, -$N(R)C(NR)NR_2$, -$N(R)S(O)_2NR_2$, -$N(R)S(O)_2R$, -$P(O)R_2$, -P(O)(R)OR, -$B(OR)_2$, and optionally substituted C_{1-6} aliphatic. In some embodiments, R^{2A} is phenyl; an 8-10 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or a 7-12 membered saturated or partially unsaturated bicyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein R^{2A} is substituted by r^2 instances of a group independently selected from oxo, halogen, -CN, -NO_2, -OR, -SR, -NR_2, -$S(O)_2R$, -$S(O)_2NR_2$, -$S(O)_2F$, -S(O)R, -$S(O)NR_2$, -S(O)(NR)R, -C(O)R, -C(O)OR, -$C(O)NR_2$, -C(O)N(R)OR, -OC(O)R, -$OC(O)NR_2$, -N(R)C(O)OR, -N(R)C(O)R, -$N(R)C(O)NR_2$, -$N(R)C(NR)NR_2$, -$N(R)S(O)_2NR_2$, -$N(R)S(O)_2R$, -$P(O)R_2$, -P(O)(R)OR, -$B(OR)_2$, and optionally substituted C_{1-6} aliphatic. In some embodiments, R^{2A} is phenyl or an 8-10 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein R^{2A} is substituted by r^2 instances of a group independently selected from oxo, halogen, -CN, -NO_2, -OR, -SR, -NR_2, -$S(O)_2R$, -$S(O)_2NR_2$, -$S(O)_2F$, -S(O)R, -$S(O)NR_2$, -S(O)(NR)R, -C(O)R, -C(O)OR, -$C(O)NR_2$, -C(O)N(R)OR, -OC(O)R, -$OC(O)NR_2$, -N(R)C(O)OR, -N(R)C(O)R, -$N(R)C(O)NR_2$, -$N(R)C(NR)NR_2$, -$N(R)S(O)_2NR_2$, -$N(R)S(O)_2R$, -$P(O)R_2$, -P(O)(R)OR, -$B(OR)_2$, and optionally substituted C_{1-6} aliphatic.

[0169] In some embodiments, R^{2A} is phenyl substituted by r^2 instances of R^{2C}. In some embodiments, R^{2A} is phenyl substituted by r^2 instances of a group independently selected from oxo, halogen, -CN, -NO_2, -OR, -SR, -NR_2, -$S(O)_2R$, -$S(O)_2NR_2$, -$S(O)_2F$, -S(O)R, -$S(O)NR_2$, -S(O)(NR)R, -C(O)R, -C(O)OR, -$C(O)NR_2$, -C(O)N(R)OR, -OC(O)R, -$OC(O)NR_2$, -N(R)C(O)OR, -N(R)C(O)R, -$N(R)C(O)NR_2$, -$N(R)C(NR)NR_2$, -$N(R)S(O)_2NR_2$, -$N(R)S(O)_2R$, -$P(O)R_2$, -P(O)(R)OR, -$B(OR)_2$, and optionally substituted C_{1-6} aliphatic.

[0170] In some embodiments, R^{2A} is phenyl substituted by 1-3 instances of a group independently selected from halogen, -CN, -O-(optionally substituted C_{1-6} aliphatic), and an

optionally substituted C_{1-6} aliphatic. In some embodiments, R^{2A} is phenyl substituted by 1-3 instances of a group independently selected from halogen and C_{1-3} aliphatic optionally substituted with 1-3 halogen. In some embodiments, R^{2A} is phenyl substituted by 1-3 instances of a group independently selected from fluorine, chlorine, $-CH_3$, $-CHF_2$, and $-CF_3$.

[0171] In some embodiments, R^{2A} is phenyl substituted by 2 instances of a group independently selected from halogen, -CN, -O-(optionally substituted C_{1-6} aliphatic), and an optionally substituted C_{1-6} aliphatic. In some embodiments, R^{2A} is phenyl substituted by 2 instances of a group independently selected from halogen and C_{1-3} aliphatic optionally substituted with 1-3 halogen. In some embodiments, R^{2A} is phenyl substituted by 2 instances of a group independently selected from fluorine, chlorine, $-CH_3$, $-CHF_2$, and $-CF_3$.



[0172] In some embodiments, R^{2A} is an 8-10 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein R^{2A} is substituted by r^2 instances of R^{2C}. In some embodiments, R^{2A} is an 8-10 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein R^{2A} is substituted by r^2 instances of a group independently selected from oxo, halogen, -CN, $-NO_2$, -OR, -SR, $-NR_2$, $-S(O)_2R$, $-S(O)_2NR_2$, $-S(O)_2F$, -S(O)R, $-S(O)NR_2$, -S(O)(NR)R, -C(O)R, -C(O)OR, $-C(O)NR_2$, -C(O)N(R)OR, -OC(O)R, $-OC(O)NR_2$, -N(R)C(O)OR, -N(R)C(O)R, $-N(R)C(O)NR_2$, $-N(R)C(NR)NR_2$, $-N(R)S(O)_2NR_2$, $-N(R)S(O)_2R$, $-P(O)R_2$, -P(O)(R)OR, $-B(OR)_2$, and optionally substituted C_{1-6} aliphatic.






[0173] In some embodiments, R^{2A} is an 8-10 membered bicyclic heteroaryl ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein R^{2A} is substituted by r^2 instances of R^{2C}. In some embodiments, R^{2A} is an 8-10 membered bicyclic heteroaryl ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein R^{2A} is substituted by r^2 instances of a group independently selected from oxo, halogen, -CN, $-NO_2$, -OR, -SR, $-NR_2$, $-S(O)_2R$, $-S(O)_2NR_2$, $-S(O)_2F$, -S(O)R, $-S(O)NR_2$, -S(O)(NR)R, -C(O)R, -C(O)OR, $-C(O)NR_2$, -C(O)N(R)OR, -OC(O)R, $-OC(O)NR_2$, -N(R)C(O)OR, -N(R)C(O)R, $-N(R)C(O)NR_2$, $-N(R)C(NR)NR_2$, $-N(R)S(O)_2NR_2$, $-N(R)S(O)_2R$, $-P(O)R_2$, -P(O)(R)OR, or $-B(OR)_2$, and optionally substituted C_{1-6} aliphatic.







[0174] In some embodiments, R^{2A} is an 8-10 membered bicyclic heteroaryl ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein R^{2A} is substituted by 0-2 instances of a group independently selected from halogen, -CN, -O-(optionally substituted C_{1-6} aliphatic), and an optionally substituted C_{1-6} aliphatic. In some

embodiments, R^{2A} is an 8-10 membered bicyclic heteroaryl ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein R^{2A} is substituted by 0-2 instances of a group independently selected from halogen and C_{1-3} aliphatic optionally substituted with 1-3 halogen. In some embodiments, R^{2A} is an 8-10 membered bicyclic heteroaryl ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein R^{2A} is substituted by 0-2 instances of a group independently selected from fluorine, chlorine, $-CH_3$, $-CHF_2$, and $-CF_3$.

[0175] In some embodiments, R^{2A} is:

, wherein R^{2C} and r^2 are as defined in the embodiments and classes and subclasses herein. In some embodiments, R^{2A} is . In some embodiments, R^{2A} is . In some embodiments, R^{2A} is . In some embodiments, R^{2A} is . In some embodiments, R^{2A} is . In some embodiments, R^{2A} is


. In some embodiments, R^{2A} is 
. In some embodiments, R^{2A} is 
. In some embodiments, R^{2A} is 
. In some embodiments, R^{2A} is 
. In some embodiments, R^{2A} is 
.

[0176] In some embodiments, R^{2A} is oxo, halogen, -CN, $-NO_2$, -OR, -SR, $-NR_2$, $-S(O)_2R$, $-S(O)_2NR_2$, $-S(O)_2F$, -S(O)R, $-S(O)NR_2$, -S(O)(NR)R, -C(O)R, -C(O)OR, $-C(O)NR_2$, -C(O)N(R)OR, -OC(O)R, $-OC(O)NR_2$, -N(R)C(O)OR, -N(R)C(O)R, $-N(R)C(O)NR_2$, $-N(R)C(NR)NR_2$, $-N(R)S(O)_2NR_2$, $-N(R)S(O)_2R$, $-P(O)R_2$, -P(O)(R)OR, $-B(OR)_2$, or deuterium.

[0177] In some embodiments, R^{2A} is oxo, halogen, -CN, $-NO_2$, -OR, -SR, $-NR_2$, $-S(O)_2R$, $-S(O)_2NR_2$, $-S(O)_2F$, -S(O)R, $-S(O)NR_2$, -S(O)(NR)R, -C(O)R, -C(O)OR, $-C(O)NR_2$, -C(O)N(R)OR, -OC(O)R, $-OC(O)NR_2$, -N(R)C(O)OR, -N(R)C(O)R, $-N(R)C(O)NR_2$, $-N(R)C(NR)NR_2$, $-N(R)S(O)_2NR_2$, $-N(R)S(O)_2R$, $-P(O)R_2$, -P(O)(R)OR, or $-B(OR)_2$.

[0178] In some embodiments, R^{2A} is oxo. In some embodiments, R^{2A} is halogen. In some embodiments, R^{2A} is –CN. In some embodiments, R^{2A} is $-NO_2$. In some embodiments, R^{2A} is -OR. In some embodiments, R^{2A} is -SR. In some embodiments, R^{2A} is $-NR_2$. In some embodiments, R^{2A} is $-S(O)_2R$. In some embodiments, R^{2A} is $-S(O)_2NR_2$. In some embodiments, R^{2A} is $-S(O)_2F$. In some embodiments, R^{2A} is -S(O)R. In some embodiments, R^{2A} is $-S(O)NR_2$. In some embodiments, R^{2A} is -S(O)(NR)R. In some embodiments, R^{2A} is -C(O)R. In some embodiments, R^{2A} is -C(O)OR. In some embodiments, R^{2A} is $-C(O)NR_2$. In some embodiments, R^{2A} is -C(O)N(R)OR. In some embodiments, R^{2A} is -OC(O)R. In some embodiments, R^{2A} is $-OC(O)NR_2$. In some embodiments, R^{2A} is -N(R)C(O)OR. In some embodiments, R^{2A} is -N(R)C(O)R. In some embodiments, R^{2A} is $-N(R)C(O)NR_2$. In some embodiments, R^{2A} is $-N(R)C(NR)NR_2$. In some embodiments, R^{2A} is $-N(R)S(O)_2NR_2$. In some embodiments, R^{2A} is $-N(R)S(O)_2R$. In some embodiments, R^{2A} is $-P(O)R_2$. In some embodiments, R^{2A} is -P(O)(R)OR. In some embodiments, R^{2A} is $-B(OR)_2$. In some embodiments, R^{2A} is deuterium.

[0179] In some embodiments, R^{2A} is halogen, -CN, $-NO_2$, -OR, -SR, $-NR_2$, $-S(O)_2R$, $-S(O)_2NR_2$, $-S(O)_2F$, -S(O)R, $-S(O)NR_2$, -S(O)(NR)R, -C(O)R, -C(O)OR, $-C(O)NR_2$, -C(O)N(R)OR, -OC(O)R, $-OC(O)NR_2$, -N(R)C(O)OR, -N(R)C(O)R, $-N(R)C(O)NR_2$, $-N(R)C(NR)NR_2$, $-N(R)S(O)_2NR_2$, $-N(R)S(O)_2R$, $-P(O)R_2$, -P(O)(R)OR, or $-B(OR)_2$.

[0180] In some embodiments, R^{2A} is halogen, -CN, or $-NO_2$. In some embodiments, R^{2A} is -OR, -SR, or $-NR_2$. In some embodiments, R^{2A} is $-S(O)_2R$, $-S(O)_2NR_2$, $-S(O)_2F$, -S(O)R, $-S(O)NR_2$, or -S(O)(NR)R. In some embodiments, R^{2A} is -C(O)R, -C(O)OR, $-C(O)NR_2$, or -C(O)N(R)OR. In some embodiments, R^{2A} is -OC(O)R or $-OC(O)NR_2$. In some embodiments, R^{2A} is -N(R)C(O)OR, -N(R)C(O)R, $-N(R)C(O)NR_2$, $-N(R)C(NR)NR_2$, $-N(R)S(O)_2NR_2$, or $-N(R)S(O)_2R$. In some embodiments, R^{2A} is $-P(O)R_2$ or -P(O)(R)OR.

[0181] In some embodiments, R^{2A} is -OR, -OC(O)R, or $-OC(O)NR_2$. In some embodiments, R^{2A} is -SR, $-S(O)_2R$, $-S(O)_2NR_2$, $-S(O)_2F$, -S(O)R, $-S(O)NR_2$, or -S(O)(NR)R. In some embodiments, R^{2A} is $-NR_2$, -N(R)C(O)OR, -N(R)C(O)R, $-N(R)C(O)NR_2$, $-N(R)C(NR)NR_2$, $-N(R)S(O)_2NR_2$, or $-N(R)S(O)_2R$.

[0182] In some embodiments, R^{2A} is $-S(O)_2R$, $-S(O)_2NR_2$, or $-S(O)_2F$. In some embodiments, R^{2A} is -S(O)R, $-S(O)NR_2$, or -S(O)(NR)R. In some embodiments, R^{2A} is -SR, $-S(O)_2R$, or -S(O)R. In some embodiments, R^{2A} is $-S(O)_2NR_2$, $-S(O)NR_2$, or -S(O)(NR)R. In some embodiments, R^{2A} is $-S(O)_2NR_2$ or $-S(O)NR_2$. In some embodiments, R^{2A} is -SR, $-S(O)_2R$, $-S(O)_2NR_2$, or -S(O)R.

[0183] In some embodiments, R^{2A} is -N(R)C(O)OR, -N(R)C(O)R, or $-N(R)C(O)NR_2$. In some embodiments, R^{2A} is $-N(R)S(O)_2NR_2$ or $-N(R)S(O)_2R$. In some embodiments, R^{2A} is -N(R)C(O)OR or -N(R)C(O)R. In some embodiments, R^{2A} is $-N(R)C(O)NR_2$ or $-N(R)S(O)_2NR_2$. In some embodiments, R^{2A} is -N(R)C(O)OR, -N(R)C(O)R, or $-N(R)S(O)_2R$.

[0184] In some embodiments, R^{2A} is $-NR_2$, -N(R)C(O)OR, -N(R)C(O)R, or $-N(R)C(O)NR_2$. In some embodiments, R^{2A} is $-NR_2$, -N(R)C(O)OR, or -N(R)C(O)R. In some embodiments, R^{2A} is $-NR_2$, -N(R)C(O)OR, -N(R)C(O)R, or $-N(R)S(O)_2R$.

[0185] In some embodiments, R^{2A} is a C_{1-6} aliphatic chain; phenyl; naphthyl; cubanyl; adamantyl; a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; an 8-10 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring; a 5-12

membered saturated or partially unsaturated bicyclic carbocyclic ring; a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or a 7-12 membered saturated or partially unsaturated bicyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted by r^2 instances of R^{2C}.

[0186] In some embodiments, R^{2A} is a C_{1-6} aliphatic chain substituted by r^2 instances of R^{2C}. In some embodiments, R^{2A} is phenyl substituted by r^2 instances of R^{2C}. In some embodiments, R^{2A} is naphthyl substituted by r^2 instances of R^{2C}. In some embodiments, R^{2A} is cubanyl substituted by r^2 instances of R^{2C}. In some embodiments, R^{2A} is adamantyl substituted by r^2 instances of R^{2C}. In some embodiments, R^{2A} is a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said ring is substituted by r^2 instances of R^{2C}. In some embodiments, R^{2A} is an 8-10 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said ring is substituted by r^2 instances of R^{2C}. In some embodiments, R^{2A} is a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring substituted by r^2 instances of R^{2C}. In some embodiments, R^{2A} is a 5-12 membered saturated or partially unsaturated bicyclic carbocyclic ring substituted by r^2 instances of R^{2C}. In some embodiments, R^{2A} is a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said ring is substituted by r^2 instances of R^{2C}. In some embodiments, R^{2A} is a 7-12 membered saturated or partially unsaturated bicyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said ring is substituted by r^2 instances of R^{2C}.

[0187] In some embodiments, R^{2A} is phenyl; naphthyl; a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or an 8-10 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted by r^2 instances of R^{2C}. In some embodiments, R^{2A} is cubanyl; adamantyl; a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring; a 5-12 membered saturated or partially unsaturated bicyclic carbocyclic ring; a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or a 7-12 membered saturated or partially unsaturated bicyclic heterocyclic ring

having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted by r^2 instances of R^{2C}.

[0188] In some embodiments, R^{2A} is phenyl; naphthyl; cubanyl; adamantyl; a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring; or a 5-12 membered saturated or partially unsaturated bicyclic carbocyclic ring; each of which is substituted by r^2 instances of R^{2C}. In some embodiments, R^{2A} is a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; an 8-10 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or a 7-12 membered saturated or partially unsaturated bicyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted by r^2 instances of R^{2C}.

[0189] In some embodiments, R^{2A} is phenyl; a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring; or a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted by r^2 instances of R^{2C}. In some embodiments, R^{2A} is naphthyl; cubanyl; adamantyl; an 8-10 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 5-12 membered saturated or partially unsaturated bicyclic carbocyclic ring; or a 7-12 membered saturated or partially unsaturated bicyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted by r^2 instances of R^{2C}.

[0190] In some embodiments, R^{2A} is phenyl or naphthyl; each of which is substituted by r^2 instances of R^{2C}. In some embodiments, R^{2A} is a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or an 8-10 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted by r^2 instances of R^{2C}. In some embodiments, R^{2A} is a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring or a 5-12 membered saturated or partially unsaturated bicyclic carbocyclic ring; each of which is substituted by r^2 instances of R^{2C}. In some embodiments, R^{2A} is a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2

heteroatoms independently selected from nitrogen, oxygen, and sulfur; or a 7-12 membered saturated or partially unsaturated bicyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted by r^2 instances of R^{2C}.

[0191] In some embodiments, R^{2A} is phenyl or a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted by r^2 instances of R^{2C}. In some embodiments, R^{2A} is a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring or a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted by r^2 instances of R^{2C}. In some embodiments, R^{2A} is naphthyl or an 8-10 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted by r^2 instances of R^{2C}. In some embodiments, R^{2A} is cubanyl; adamantyl; a 5-12 membered saturated or partially unsaturated bicyclic carbocyclic ring; or a 7-12 membered saturated or partially unsaturated bicyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted by r^2 instances of R^{2C}.

[0192] In some embodiments, R^{2A} is phenyl or a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring; each of which is substituted by r^2 instances of R^{2C}. In some embodiments, R^{2A} is naphthyl; cubanyl; adamantyl; or a 5-12 membered saturated or partially unsaturated bicyclic carbocyclic ring; each of which is substituted by r^2 instances of R^{2C}. In some embodiments, R^{2A} is a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted by r^2 instances of R^{2C}. In some embodiments, R^{2A} is an 8-10 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or a 7-12 membered saturated or partially unsaturated bicyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted by r^2 instances of R^{2C}.

[0193] In some embodiments, R^{2A} is a C_{1-6} aliphatic chain; cubanyl; adamantyl; a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring; a 5-12 membered saturated or partially unsaturated bicyclic carbocyclic ring; a 3-7 membered saturated or

partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or a 7-12 membered saturated or partially unsaturated bicyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted by r^2 instances of R^{2C}. In some embodiments, R^{2A} is a C_{1-6} aliphatic chain; phenyl; naphthyl; cubanyl; adamantyl; a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring; or a 5-12 membered saturated or partially unsaturated bicyclic carbocyclic ring; each of which is substituted by r^2 instances of R^{2C}. In some embodiments, R^{2A} is a C_{1-6} aliphatic chain; phenyl; a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring; or a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted by r^2 instances of R^{2C}.

[0194] In some embodiments, R^{2A} is a C_{1-6} aliphatic chain, cubanyl, adamantyl, a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring, or a 5-12 membered saturated or partially unsaturated bicyclic carbocyclic ring; each of which is substituted by r^2 instances of R^{2C}. In some embodiments, R^{2A} is a C_{1-6} aliphatic chain, a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring, or a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted by r^2 instances of R^{2C}. In some embodiments, R^{2A} is a C_{1-6} aliphatic chain, phenyl, or a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring; each of which is substituted by r^2 instances of R^{2C}.

[0195] In some embodiments, R^{2A} is selected from the groups depicted in the compounds in Table 1.

[0196] As defined generally above, R^{EA} is R^A or R^B substituted by r^3 instances of R^{EC}. In some embodiments, R^{EA} is R^A. In some embodiments, R^{EA} is R^B substituted by r^3 instances of R^{EC}.

[0197] In some embodiments, each instance of R^{EA} is independently C_{1-6} aliphatic substituted by r^3 instances of R^{EC}. In some embodiments, each instance of R^{EA} is independently C_{1-3} aliphatic substituted by r^3 instances of R^{EC}. In some embodiments, each instance of R^{EA} is independently C_{1-3} aliphatic substituted by r^3 instances of halogen. In some embodiments,

each instance of R^{EA} is independently C_{1-3} aliphatic. In some embodiments, each instance of R^{EA} is independently $-CH_3$, $-CH_2F$, $-CHF_2$-, or $-CF_3$. In some embodiments, R^{EA} is $-CH_3$.

[0198] In some embodiments, R^{EA} is selected from the groups depicted in the compounds in Table 1.

[0199] As defined generally above, R^{QA} is R^A or R^B substituted by r^4 instances of R^{QC}. In some embodiments, R^{QA} is R^A. In some embodiments, R^{QA} is R^B substituted by r^4 instances of R^{QC}.

[0200] In some embodiments, R^{QA} is oxo, halogen, -CN, $-NO_2$, -OR, -SR, $-NR_2$, $-S(O)_2R$, $-S(O)_2NR_2$, $-S(O)_2F$, -S(O)R, $-S(O)NR_2$, -S(O)(NR)R, -C(O)R, -C(O)OR, $-C(O)NR_2$, -C(O)N(R)OR, -OC(O)R, $-OC(O)NR_2$, -N(R)C(O)OR, -N(R)C(O)R, $-N(R)C(O)NR_2$, $-N(R)C(NR)NR_2$, $-N(R)S(O)_2NR_2$, $-N(R)S(O)_2R$, $-P(O)R_2$, -P(O)(R)OR, $-B(OR)_2$, or deuterium.

[0201] In some embodiments, R^{QA} is oxo, halogen, -CN, $-NO_2$, -OR, -SR, $-NR_2$, $-S(O)_2R$, $-S(O)_2NR_2$, $-S(O)_2F$, -S(O)R, $-S(O)NR_2$, -S(O)(NR)R, -C(O)R, -C(O)OR, $-C(O)NR_2$, -C(O)N(R)OR, -OC(O)R, $-OC(O)NR_2$, -N(R)C(O)OR, -N(R)C(O)R, $-N(R)C(O)NR_2$, $-N(R)C(NR)NR_2$, $-N(R)S(O)_2NR_2$, $-N(R)S(O)_2R$, $-P(O)R_2$, -P(O)(R)OR, or $-B(OR)_2$.

[0202] In some embodiments, R^{QA} is oxo. In some embodiments, R^{QA} is halogen. In some embodiments, R^{QA} is –CN. In some embodiments, R^{QA} is $-NO_2$. In some embodiments, R^{QA} is -OR. In some embodiments, R^{QA} is -SR. In some embodiments, R^{QA} is $-NR_2$. In some embodiments, R^{QA} is $-S(O)_2R$. In some embodiments, R^{QA} is $-S(O)_2NR_2$. In some embodiments, R^{QA} is $-S(O)_2F$. In some embodiments, R^{QA} is -S(O)R. In some embodiments, R^{QA} is $-S(O)NR_2$. In some embodiments, R^{QA} is -S(O)(NR)R. In some embodiments, R^{QA} is -C(O)R. In some embodiments, R^{QA} is -C(O)OR. In some embodiments, R^{QA} is $-C(O)NR_2$. In some embodiments, R^{QA} is -C(O)N(R)OR. In some embodiments, R^{QA} is -OC(O)R. In some embodiments, R^{QA} is $-OC(O)NR_2$. In some embodiments, R^{QA} is -N(R)C(O)OR. In some embodiments, R^{QA} is -N(R)C(O)R. In some embodiments, R^{QA} is $-N(R)C(O)NR_2$. In some embodiments, R^{QA} is $-N(R)C(NR)NR_2$. In some embodiments, R^{QA} is $-N(R)S(O)_2NR_2$. In some embodiments, R^{QA} is $-N(R)S(O)_2R$. In some embodiments, R^{QA} is $-P(O)R_2$. In some embodiments, R^{QA} is -P(O)(R)OR. In some embodiments, R^{QA} is $-B(OR)_2$. In some embodiments, R^{QA} is deuterium.

[0203] In some embodiments, R^{QA} is halogen, -CN, $-NO_2$, -OR, -SR, $-NR_2$, $-S(O)_2R$, $-S(O)_2NR_2$, $-S(O)_2F$, -S(O)R, $-S(O)NR_2$, -S(O)(NR)R, -C(O)R, -C(O)OR, $-C(O)NR_2$,

-C(O)N(R)OR, -OC(O)R, -OC(O)NR_2, -N(R)C(O)OR, -N(R)C(O)R, -N(R)C(O)NR_2, -N(R)C(NR)NR_2, -N(R)S(O)$_2NR_2$, -N(R)S(O)$_2$R, -P(O)R_2, -P(O)(R)OR, or -B(OR)$_2$.

[0204] In some embodiments, R^{QA} is halogen, -CN, or -NO_2. In some embodiments, R^{QA} is -OR, -SR, or -NR_2. In some embodiments, R^{QA} is -S(O)$_2$R, -S(O)$_2NR_2$, -S(O)$_2$F, -S(O)R, -S(O)NR_2, or -S(O)(NR)R. In some embodiments, R^{QA} is -C(O)R, -C(O)OR, -C(O)NR_2, or -C(O)N(R)OR. In some embodiments, R^{QA} is -OC(O)R or -OC(O)NR_2. In some embodiments, R^{QA} is -N(R)C(O)OR, -N(R)C(O)R, -N(R)C(O)NR_2, -N(R)C(NR)NR_2, -N(R)S(O)$_2NR_2$, or -N(R)S(O)$_2$R. In some embodiments, R^{QA} is -P(O)R_2 or -P(O)(R)OR.

[0205] In some embodiments, R^{QA} is -OR, -OC(O)R, or -OC(O)NR_2. In some embodiments, R^{QA} is -SR, -S(O)$_2$R, -S(O)$_2NR_2$, -S(O)$_2$F, -S(O)R, -S(O)NR_2, or -S(O)(NR)R. In some embodiments, R^{QA} is -NR_2, -N(R)C(O)OR, -N(R)C(O)R, -N(R)C(O)NR_2, -N(R)C(NR)NR_2, -N(R)S(O)$_2NR_2$, or -N(R)S(O)$_2$R.

[0206] In some embodiments, R^{QA} is -S(O)$_2$R, -S(O)$_2NR_2$, or -S(O)$_2$F. In some embodiments, R^{QA} is -S(O)R, -S(O)NR_2, or -S(O)(NR)R. In some embodiments, R^{QA} is -SR, -S(O)$_2$R, or -S(O)R. In some embodiments, R^{QA} is -S(O)$_2NR_2$, -S(O)NR_2, or -S(O)(NR)R. In some embodiments, R^{QA} is -S(O)$_2NR_2$ or -S(O)NR_2. In some embodiments, R^{QA} is -SR, -S(O)$_2$R, -S(O)$_2NR_2$, or -S(O)R.

[0207] In some embodiments, R^{QA} is -N(R)C(O)OR, -N(R)C(O)R, or -N(R)C(O)NR_2. In some embodiments, R^{QA} is -N(R)S(O)$_2NR_2$ or -N(R)S(O)$_2$R. In some embodiments, R^{QA} is -N(R)C(O)OR or -N(R)C(O)R. In some embodiments, R^{QA} is -N(R)C(O)NR_2 or -N(R)S(O)$_2NR_2$. In some embodiments, R^{QA} is -N(R)C(O)OR, -N(R)C(O)R, or -N(R)S(O)$_2$R.

[0208] In some embodiments, R^{QA} is -NR_2, -N(R)C(O)OR, -N(R)C(O)R, or -N(R)C(O)NR_2. In some embodiments, R^{QA} is -NR_2, -N(R)C(O)OR, or -N(R)C(O)R. In some embodiments, R^{QA} is -NR_2, -N(R)C(O)OR, -N(R)C(O)R, or -N(R)S(O)$_2$R.

[0209] In some embodiments, R^{QA} is a C_{1-6} aliphatic chain; phenyl; naphthyl; a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; an 8-10 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring; a 5-12 membered saturated or partially unsaturated bicyclic carbocyclic ring; a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected

from nitrogen, oxygen, and sulfur; or a 7-12 membered saturated or partially unsaturated bicyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted by r^4 instances of R^{QC}.

[0210] In some embodiments, R^{QA} is a C_{1-6} aliphatic chain substituted by r^4 instances of R^{QC}. In some embodiments, R^{QA} is phenyl substituted by r^4 instances of R^{QC}. In some embodiments, R^{QA} is naphthyl substituted by r^4 instances of R^{QC}. In some embodiments, R^{QA} is a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said ring is substituted by r^4 instances of R^{QC}. In some embodiments, R^{QA} is an 8-10 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said ring is substituted by r^4 instances of R^{QC}. In some embodiments, R^{QA} is a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring substituted by r^4 instances of R^{QC}. In some embodiments, R^{QA} is a 5-12 membered saturated or partially unsaturated bicyclic carbocyclic ring substituted by r^4 instances of R^{QC}. In some embodiments, R^{QA} is a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said ring is substituted by r^4 instances of R^{QC}. In some embodiments, R^{QA} is a 7-12 membered saturated or partially unsaturated bicyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said ring is substituted by r^4 instances of R^{QC}.

[0211] In some embodiments, R^{QA} is phenyl; naphthyl; a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; an 8-10 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring; a 5-12 membered saturated or partially unsaturated bicyclic carbocyclic ring; a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or a 7-12 membered saturated or partially unsaturated bicyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted by r^4 instances of R^{QC}.

[0212] In some embodiments, R^{QA} is phenyl; naphthyl; a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or an 8-10 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently

selected from nitrogen, oxygen, and sulfur; each of which is substituted by r^4 instances of R^{QC}. In some embodiments, R^{QA} is a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring; a 5-12 membered saturated or partially unsaturated bicyclic carbocyclic ring; a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or a 7-12 membered saturated or partially unsaturated bicyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted by r^4 instances of R^{QC}.

[0213] In some embodiments, R^{QA} is phenyl; naphthyl; a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring; or a 5-12 membered saturated or partially unsaturated bicyclic carbocyclic ring; each of which is substituted by r^4 instances of R^{QC}. In some embodiments, R^{QA} is a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; an 8-10 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or a 7-12 membered saturated or partially unsaturated bicyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted by r^4 instances of R^{QC}.

[0214] In some embodiments, R^{QA} is phenyl; a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring; or a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted by r^4 instances of R^{QC}. In some embodiments, R^{QA} is naphthyl; an 8-10 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 5-12 membered saturated or partially unsaturated bicyclic carbocyclic ring; or a 7-12 membered saturated or partially unsaturated bicyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted by r^4 instances of R^{QC}.

[0215] In some embodiments, R^{QA} is phenyl or naphthyl; each of which is substituted by r^4 instances of R^{QC}. In some embodiments, R^{QA} is a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or an 8-10

membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted by r^4 instances of R^{QC}. In some embodiments, R^{QA} is a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring or a 5-12 membered saturated or partially unsaturated bicyclic carbocyclic ring; each of which is substituted by r^4 instances of R^{QC}. In some embodiments, R^{QA} is a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or a 7-12 membered saturated or partially unsaturated bicyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted by r^4 instances of R^{QC}.

[0216] In some embodiments, R^{QA} is phenyl or a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted by r^4 instances of R^{QC}. In some embodiments, R^{QA} is a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring or a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted by r^4 instances of R^{QC}. In some embodiments, R^{QA} is naphthyl or an 8-10 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted by r^4 instances of R^{QC}. In some embodiments, R^{QA} is a 5-12 membered saturated or partially unsaturated bicyclic carbocyclic ring or a 7-12 membered saturated or partially unsaturated bicyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted by r^4 instances of R^{QC}.

[0217] In some embodiments, R^{QA} is phenyl or a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring; each of which is substituted by r^4 instances of R^{QC}. In some embodiments, R^{QA} is naphthyl or a 5-12 membered saturated or partially unsaturated bicyclic carbocyclic ring; each of which is substituted by r^4 instances of R^{QC}. In some embodiments, R^{QA} is a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted by r^4 instances of R^{QC}. In some embodiments, R^{QA} is an 8-10 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or a 7-12 membered

saturated or partially unsaturated bicyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted by r^4 instances of R^{QC}.

[0218] In some embodiments, R^{QA} is a C_{1-6} aliphatic chain; a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring; a 5-12 membered saturated or partially unsaturated bicyclic carbocyclic ring; a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or a 7-12 membered saturated or partially unsaturated bicyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted by r^4 instances of R^{QC}. In some embodiments, R^{QA} is a C_{1-6} aliphatic chain; phenyl; naphthyl; a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring; or a 5-12 membered saturated or partially unsaturated bicyclic carbocyclic ring; each of which is substituted by r^4 instances of R^{QC}. In some embodiments, R^{QA} is a C_{1-6} aliphatic chain; phenyl; a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring; or a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted by r^4 instances of R^{QC}.

[0219] In some embodiments, R^{QA} is a C_{1-6} aliphatic chain, a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring, or a 5-12 membered saturated or partially unsaturated bicyclic carbocyclic ring; each of which is substituted by r^4 instances of R^{QC}. In some embodiments, R^{QA} is a C_{1-6} aliphatic chain, a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring, or a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted by r^4 instances of R^{QC}. In some embodiments, R^{QA} is a C_{1-6} aliphatic chain, phenyl, or a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring; each of which is substituted by r^4 instances of R^{QC}.

[0220] In some embodiments, R^{QA} is selected from the groups depicted in the compounds in Table 1.

[0221] As defined generally above, R^{XA} is R^A or R^B substituted by r^5 instances of R^{XC}. In some embodiments, R^{XA} is R^A. In some embodiments, R^{XA} is R^B substituted by r^5 instances of R^{XC}.

[0222] In some embodiments, R^{XA} is oxo, halogen, -CN, $-NO_2$, -OR, -SR, $-NR_2$, $-S(O)_2R$, $-S(O)_2NR_2$, $-S(O)_2F$, -S(O)R, $-S(O)NR_2$, -S(O)(NR)R, -C(O)R, -C(O)OR, $-C(O)NR_2$, -C(O)N(R)OR, -OC(O)R, $-OC(O)NR_2$, -N(R)C(O)OR, -N(R)C(O)R, $-N(R)C(O)NR_2$, $-N(R)C(NR)NR_2$, $-N(R)S(O)_2NR_2$, $-N(R)S(O)_2R$, $-P(O)R_2$, -P(O)(R)OR, $-B(OR)_2$, or deuterium.

[0223] In some embodiments, R^{XA} is oxo, halogen, -CN, $-NO_2$, -OR, -SR, $-NR_2$, $-S(O)_2R$, $-S(O)_2NR_2$, $-S(O)_2F$, -S(O)R, $-S(O)NR_2$, -S(O)(NR)R, -C(O)R, -C(O)OR, $-C(O)NR_2$, -C(O)N(R)OR, -OC(O)R, $-OC(O)NR_2$, -N(R)C(O)OR, -N(R)C(O)R, $-N(R)C(O)NR_2$, $-N(R)C(NR)NR_2$, $-N(R)S(O)_2NR_2$, $-N(R)S(O)_2R$, $-P(O)R_2$, -P(O)(R)OR, or $-B(OR)_2$.

[0224] In some embodiments, R^{XA} is oxo. In some embodiments, R^{XA} is halogen. In some embodiments, R^{XA} is –CN. In some embodiments, R^{XA} is $-NO_2$. In some embodiments, R^{XA} is -OR. In some embodiments, R^{XA} is -SR. In some embodiments, R^{XA} is $-NR_2$. In some embodiments, R^{XA} is $-S(O)_2R$. In some embodiments, R^{XA} is $-S(O)_2NR_2$. In some embodiments, R^{XA} is $-S(O)_2F$. In some embodiments, R^{XA} is -S(O)R. In some embodiments, R^{XA} is $-S(O)NR_2$. In some embodiments, R^{XA} is -S(O)(NR)R. In some embodiments, R^{XA} is -C(O)R. In some embodiments, R^{XA} is -C(O)OR. In some embodiments, R^{XA} is $-C(O)NR_2$. In some embodiments, R^{XA} is -C(O)N(R)OR. In some embodiments, R^{XA} is -OC(O)R. In some embodiments, R^{XA} is $-OC(O)NR_2$. In some embodiments, R^{XA} is -N(R)C(O)OR. In some embodiments, R^{XA} is -N(R)C(O)R. In some embodiments, R^{XA} is $-N(R)C(O)NR_2$. In some embodiments, R^{XA} is $-N(R)C(NR)NR_2$. In some embodiments, R^{XA} is $-N(R)S(O)_2NR_2$. In some embodiments, R^{XA} is $-N(R)S(O)_2R$. In some embodiments, R^{XA} is $-P(O)R_2$. In some embodiments, R^{XA} is -P(O)(R)OR. In some embodiments, R^{XA} is $-B(OR)_2$. In some embodiments, R^{XA} is deuterium.

[0225] In some embodiments, R^{XA} is halogen, -CN, $-NO_2$, -OR, -SR, $-NR_2$, $-S(O)_2R$, $-S(O)_2NR_2$, $-S(O)_2F$, -S(O)R, $-S(O)NR_2$, -S(O)(NR)R, -C(O)R, -C(O)OR, $-C(O)NR_2$, -C(O)N(R)OR, -OC(O)R, $-OC(O)NR_2$, -N(R)C(O)OR, -N(R)C(O)R, $-N(R)C(O)NR_2$, $-N(R)C(NR)NR_2$, $-N(R)S(O)_2NR_2$, $-N(R)S(O)_2R$, $-P(O)R_2$, -P(O)(R)OR, or $-B(OR)_2$.

[0226] In some embodiments, R^{XA} is halogen, -CN, or $-NO_2$. In some embodiments, R^{XA} is -OR, -SR, or $-NR_2$. In some embodiments, R^{XA} is $-S(O)_2R$, $-S(O)_2NR_2$, $-S(O)_2F$, -S(O)R,

-S(O)NR_2, or -S(O)(NR)R. In some embodiments, R^{XA} is -C(O)R, -C(O)OR, -C(O)NR_2, or -C(O)N(R)OR. In some embodiments, R^{XA} is -OC(O)R or -OC(O)NR_2. In some embodiments, R^{XA} is -N(R)C(O)OR, -N(R)C(O)R, -N(R)C(O)NR_2, -N(R)C(NR)NR_2, -N(R)S(O)$_2$$NR_2$, or -N(R)S(O)$_2$R. In some embodiments, R^{XA} is -P(O)R_2 or -P(O)(R)OR.

[0227] In some embodiments, R^{XA} is -OR, -OC(O)R, or -OC(O)NR_2. In some embodiments, R^{XA} is -SR, -S(O)$_2$R, -S(O)$_2$$NR_2$, -S(O)$_2$F, -S(O)R, -S(O)$NR_2$, or -S(O)(NR)R. In some embodiments, R^{XA} is -NR_2, -N(R)C(O)OR, -N(R)C(O)R, -N(R)C(O)NR_2, -N(R)C(NR)NR_2, -N(R)S(O)$_2$$NR_2$, or -N(R)S(O)$_2$R.

[0228] In some embodiments, R^{XA} is -S(O)$_2$R, -S(O)$_2$$NR_2$, or -S(O)$_2$F. In some embodiments, R^{XA} is -S(O)R, -S(O)NR_2, or -S(O)(NR)R. In some embodiments, R^{XA} is -SR, -S(O)$_2$R, or -S(O)R. In some embodiments, R^{XA} is -S(O)$_2$$NR_2$, -S(O)$NR_2$, or -S(O)(NR)R. In some embodiments, R^{XA} is -S(O)$_2$$NR_2$ or -S(O)NR_2. In some embodiments, R^{XA} is -SR, -S(O)$_2$R, -S(O)$_2$$NR_2$, or -S(O)R.

[0229] In some embodiments, R^{XA} is -N(R)C(O)OR, -N(R)C(O)R, or -N(R)C(O)NR_2. In some embodiments, R^{XA} is -N(R)S(O)$_2$$NR_2$ or -N(R)S(O)$_2$R. In some embodiments, R^{XA} is -N(R)C(O)OR or -N(R)C(O)R. In some embodiments, R^{XA} is -N(R)C(O)NR_2 or -N(R)S(O)$_2$$NR_2$. In some embodiments, R^{XA} is -N(R)C(O)OR, -N(R)C(O)R, or -N(R)S(O)$_2$R.

[0230] In some embodiments, R^{XA} is -NR_2, -N(R)C(O)OR, -N(R)C(O)R, or -N(R)C(O)NR_2. In some embodiments, R^{XA} is -NR_2, -N(R)C(O)OR, or -N(R)C(O)R. In some embodiments, R^{XA} is -NR_2, -N(R)C(O)OR, -N(R)C(O)R, or -N(R)S(O)$_2$R.

[0231] In some embodiments, R^{XA} is a C_{1-6} aliphatic chain; phenyl; naphthyl; a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; an 8-10 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring; a 5-12 membered saturated or partially unsaturated bicyclic carbocyclic ring; a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or a 7-12 membered saturated or partially unsaturated bicyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted by r^5 instances of R^{XC}.

[0232] In some embodiments, R^{XA} is a C_{1-6} aliphatic chain substituted by r^5 instances of R^{XC}. In some embodiments, R^{XA} is phenyl substituted by r^5 instances of R^{XC}. In some embodiments, R^{XA} is naphthyl substituted by r^5 instances of R^{XC}. In some embodiments, R^{XA} is a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said ring is substituted by r^5 instances of R^{XC}. In some embodiments, R^{XA} is an 8-10 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said ring is substituted by r^5 instances of R^{XC}. In some embodiments, R^{XA} is a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring substituted by r^5 instances of R^{XC}. In some embodiments, R^{XA} is a 5-12 membered saturated or partially unsaturated bicyclic carbocyclic ring substituted by r^5 instances of R^{XC}. In some embodiments, R^{XA} is a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said ring is substituted by r^5 instances of R^{XC}. In some embodiments, R^{XA} is a 7-12 membered saturated or partially unsaturated bicyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said ring is substituted by r^5 instances of R^{XC}.

[0233] In some embodiments, R^{XA} is phenyl; naphthyl; a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; an 8-10 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring; a 5-12 membered saturated or partially unsaturated bicyclic carbocyclic ring; a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or a 7-12 membered saturated or partially unsaturated bicyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted by r^5 instances of R^{XC}.

[0234] In some embodiments, R^{XA} is phenyl; naphthyl; a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or an 8-10 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted by r^5 instances of R^{XC}. In some embodiments, R^{XA} is a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring; a 5-12 membered saturated or partially unsaturated bicyclic

carbocyclic ring; a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or a 7-12 membered saturated or partially unsaturated bicyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted by r^5 instances of R^{XC}.

[0235] In some embodiments, R^{XA} is phenyl; naphthyl; a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring; or a 5-12 membered saturated or partially unsaturated bicyclic carbocyclic ring; each of which is substituted by r^5 instances of R^{XC}. In some embodiments, R^{XA} is a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; an 8-10 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or a 7-12 membered saturated or partially unsaturated bicyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted by r^5 instances of R^{XC}.

[0236] In some embodiments, R^{XA} is phenyl; a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring; or a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted by r^5 instances of R^{XC}. In some embodiments, R^{XA} is naphthyl; an 8-10 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 5-12 membered saturated or partially unsaturated bicyclic carbocyclic ring; or a 7-12 membered saturated or partially unsaturated bicyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted by r^5 instances of R^{XC}.

[0237] In some embodiments, R^{XA} is phenyl or naphthyl; each of which is substituted by r^5 instances of R^{XC}. In some embodiments, R^{XA} is a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or an 8-10 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted by r^5 instances of R^{XC}. In some embodiments, R^{XA} is a 3-7 membered saturated or partially unsaturated monocyclic

carbocyclic ring or a 5-12 membered saturated or partially unsaturated bicyclic carbocyclic ring; each of which is substituted by r^5 instances of R^{XC}. In some embodiments, R^{XA} is a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or a 7-12 membered saturated or partially unsaturated bicyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted by r^5 instances of R^{XC}.

[0238] In some embodiments, R^{XA} is phenyl or a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted by r^5 instances of R^{XC}. In some embodiments, R^{XA} is a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring or a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted by r^5 instances of R^{XC}. In some embodiments, R^{XA} is naphthyl or an 8-10 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted by r^5 instances of R^{XC}. In some embodiments, R^{XA} is a 5-12 membered saturated or partially unsaturated bicyclic carbocyclic ring or a 7-12 membered saturated or partially unsaturated bicyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted by r^5 instances of R^{XC}.

[0239] In some embodiments, R^{XA} is phenyl or a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring; each of which is substituted by r^5 instances of R^{XC}. In some embodiments, R^{XA} is naphthyl or a 5-12 membered saturated or partially unsaturated bicyclic carbocyclic ring; each of which is substituted by r^5 instances of R^{XC}. In some embodiments, R^{XA} is a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted by r^5 instances of R^{XC}. In some embodiments, R^{XA} is an 8-10 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or a 7-12 membered saturated or partially unsaturated bicyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted by r^5 instances of R^{XC}.

[0240] In some embodiments, R^{XA} is a C_{1-6} aliphatic chain; a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring; a 5-12 membered saturated or partially unsaturated bicyclic carbocyclic ring; a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or a 7-12 membered saturated or partially unsaturated bicyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted by r^5 instances of R^{XC}. In some embodiments, R^{XA} is a C_{1-6} aliphatic chain; phenyl; naphthyl; a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring; or a 5-12 membered saturated or partially unsaturated bicyclic carbocyclic ring; each of which is substituted by r^5 instances of R^{XC}. In some embodiments, R^{XA} is a C_{1-6} aliphatic chain; phenyl; a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring; or a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted by r^5 instances of R^{XC}.

[0241] In some embodiments, R^{XA} is a C_{1-6} aliphatic chain, a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring, or a 5-12 membered saturated or partially unsaturated bicyclic carbocyclic ring; each of which is substituted by r^5 instances of R^{XC}. In some embodiments, R^{XA} is a C_{1-6} aliphatic chain, a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring, or a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted by r^5 instances of R^{XC}. In some embodiments, R^{XA} is a C_{1-6} aliphatic chain, phenyl, or a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring; each of which is substituted by r^5 instances of R^{XC}.

[0242] In some embodiments, R^{XA} is selected from the groups depicted in the compounds in Table 1.

[0243] As defined generally above, R^{YA} is R^A or R^B substituted by r^6 instances of R^{YC}. In some embodiments, R^{YA} is R^A. In some embodiments, R^{YA} is R^B substituted by r^6 instances of R^{YC}.

[0244] In some embodiments, R^{YA} is oxo, halogen, -CN, -NO_2, -OR, -SR, -NR_2, -$S(O)_2R$, -$S(O)_2NR_2$, -$S(O)_2F$, -S(O)R, -$S(O)NR_2$, -S(O)(NR)R, -C(O)R, -C(O)OR, -$C(O)NR_2$, -C(O)N(R)OR, -OC(O)R, -$OC(O)NR_2$, -N(R)C(O)OR, -N(R)C(O)R, -$N(R)C(O)NR_2$, -$N(R)C(NR)NR_2$, -$N(R)S(O)_2NR_2$, -$N(R)S(O)_2R$, -$P(O)R_2$, -P(O)(R)OR, -$B(OR)_2$, or R^B selected from a C_{1-6} aliphatic chain; phenyl; a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring; and a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said R^B is substituted by r^6 instances of R^{YC}.

[0245] In some embodiments, R^{YA} is halogen, -CN, -OR, -NR_2, -C(O)R, -C(O)OR, -$C(O)NR_2$, -N(R)C(O)R, or R^B selected from a C_{1-6} aliphatic chain; phenyl; a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring; and a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said R^B is substituted by r^6 instances of R^{YC}.

[0246] In some embodiments, R^{YA} is halogen, -CN, -OR, -NR_2, -C(O)R, -C(O)OR, -$C(O)NR_2$, -N(R)C(O)R, or R^B selected from a C_{1-6} aliphatic chain; a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring; and a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said R^B is substituted by r^6 instances of R^{YC}. In some embodiments, R^{YA} is halogen or R^B selected from a C_{1-6} aliphatic chain; a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring; and a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said R^B is substituted by r^6 instances of R^{YC}.

[0247] In some embodiments, R^{YA} is halogen or R^B selected from a C_{1-4} aliphatic chain; a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 3-5 membered saturated or partially unsaturated monocyclic

carbocyclic ring; and a 3-5 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said R^B is substituted by r^6 instances of R^{YC}. In some embodiments, R^{YA} is halogen or R^B selected from a C_{1-4} aliphatic chain; a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 3-5 membered saturated or partially unsaturated monocyclic carbocyclic ring; and a 3-5 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said R^B is substituted by r^6 instances of a group independently selected from oxo, halogen, -CN, $-NO_2$, -OR, -SR, $-NR_2$, $-S(O)_2R$, $-S(O)_2NR_2$, $-S(O)_2F$, -S(O)R, $-S(O)NR_2$, -S(O)(NR)R, -C(O)R, -C(O)OR, $-C(O)NR_2$, -C(O)N(R)OR, -OC(O)R, $-OC(O)NR_2$, -N(R)C(O)OR, -N(R)C(O)R, $-N(R)C(O)NR_2$, $-N(R)C(NR)NR_2$, $-N(R)S(O)_2NR_2$, $-N(R)S(O)_2R$, $-P(O)R_2$, -P(O)(R)OR, $-B(OR)_2$, and optionally substituted C_{1-6} aliphatic.

[0248] In some embodiments, R^{YA} is halogen or R^B selected from a C_{1-4} aliphatic chain; a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 3-5 membered saturated or partially unsaturated monocyclic carbocyclic ring; and a 3-5 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said R^B is substituted by r^6 instances of a group independently selected from halogen, -CN, -OH, -O-(optionally substituted C_{1-3} aliphatic), and an optionally substituted C_{1-3} aliphatic. In some embodiments, R^{YA} is halogen or R^B selected from a C_{1-4} aliphatic chain; a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 3-5 membered saturated or partially unsaturated monocyclic carbocyclic ring; and a 3-5 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said R^B is substituted by r^6 instances of a group independently selected from halogen, -OH, -O-(C_{1-3} aliphatic), and C_{1-3} aliphatic, wherein each C_{1-3} aliphatic is optionally substituted with 1-3 halogen. In some embodiments, R^{YA} is halogen or R^B selected from a C_{1-4} aliphatic chain; a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 3-5 membered saturated or partially unsaturated monocyclic carbocyclic ring; and a 3-5 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said R^B is substituted by r^6 instances of a

group independently selected from fluorine, chlorine, -OH, $-OCH_3$, $-OCF_3$, $-CH_3$, $-CHF_2$, and $-CF_3$.

[0249] In some embodiments, R^{YA} is halogen or R^B selected from a C_{1-4} aliphatic chain and a 3-5 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said R^B is substituted by r^6 instances of a group independently selected from halogen, -OH, -O-(C_{1-3} aliphatic), and C_{1-3} aliphatic, wherein each C_{1-3} aliphatic is optionally substituted with 1-3 halogen. In some embodiments, R^{YA} is halogen or R^B selected from a C_{1-4} aliphatic chain and a 3-5 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen and oxygen; wherein said R^B is substituted by r^6 instances of a group independently selected from fluorine, chlorine, -OH, $-OCH_3$, $-OCF_3$, $-CH_3$, $-CHF_2$, and $-CF_3$.

[0250] In some embodiments, R^{YA} is halogen or a C_{1-4} aliphatic chain substituted by -OH and 0-3 fluorine.

[0251] In some embodiments, R^{YA} is halogen, -CN, -OR, $-NR_2$, -C(O)R, -C(O)OR, $-C(O)NR_2$, or -N(R)C(O)R. In some embodiments, R^{YA} is halogen.

[0252] In some embodiments, R^{YA} is a C_{1-6} aliphatic chain; phenyl; a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring; or a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein R^{YA} is substituted by r^6 instances of R^{YC}. In some embodiments, R^{YA} is a C_{1-6} aliphatic chain; a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring; or a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein R^{YA} is substituted by r^6 instances of R^{YC}.

[0253] In some embodiments, R^{YA} is a C_{1-4} aliphatic chain; a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 3-5 membered saturated or partially unsaturated monocyclic carbocyclic ring; or a 3-5 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein R^{YA} is

substituted by r^6 instances of R^{YC}. In some embodiments, R^{YA} is a C_{1-4} aliphatic chain; a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 3-5 membered saturated or partially unsaturated monocyclic carbocyclic ring; or a 3-5 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein R^{YA} is substituted by r^6 instances of a group independently selected from oxo, halogen, -CN, $-NO_2$, -OR, -SR, $-NR_2$, $-S(O)_2R$, $-S(O)_2NR_2$, $-S(O)_2F$, -S(O)R, $-S(O)NR_2$, -S(O)(NR)R, -C(O)R, -C(O)OR, $-C(O)NR_2$, -C(O)N(R)OR, -OC(O)R, $-OC(O)NR_2$, -N(R)C(O)OR, -N(R)C(O)R, $-N(R)C(O)NR_2$, $-N(R)C(NR)NR_2$, $-N(R)S(O)_2NR_2$, $-N(R)S(O)_2R$, $-P(O)R_2$, -P(O)(R)OR, $-B(OR)_2$, and optionally substituted C_{1-6} aliphatic.

[0254] In some embodiments, R^{YA} is a C_{1-4} aliphatic chain; a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 3-5 membered saturated or partially unsaturated monocyclic carbocyclic ring; or a 3-5 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein R^{YA} is substituted by r^6 instances of a group independently selected from halogen, -CN, -OH, -O-(optionally substituted C_{1-3} aliphatic), and an optionally substituted C_{1-3} aliphatic. In some embodiments, R^{YA} is a C_{1-4} aliphatic chain; a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 3-5 membered saturated or partially unsaturated monocyclic carbocyclic ring; or a 3-5 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein R^{YA} is substituted by r^6 instances of a group independently selected from halogen, -OH, -O-(C_{1-3} aliphatic), and C_{1-3} aliphatic, wherein each C_{1-3} aliphatic is optionally substituted with 1-3 halogen. In some embodiments, R^{YA} is a C_{1-4} aliphatic chain; a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 3-5 membered saturated or partially unsaturated monocyclic carbocyclic ring; or a 3-5 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein R^{YA} is substituted by r^6 instances of a group independently selected from fluorine, chlorine, -OH, $-OCH_3$, $-OCF_3$, $-CH_3$, $-CHF_2$, and $-CF_3$.

[0255] In some embodiments, R^{YA} is a C_{1-4} aliphatic chain or a 3-5 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently

selected from nitrogen, oxygen, and sulfur; wherein R^{YA} is substituted by r^6 instances of a group independently selected from halogen, -OH, -O-(C_{1-3} aliphatic), and C_{1-3} aliphatic, wherein each C_{1-3} aliphatic is optionally substituted with 1-3 halogen. In some embodiments, R^{YA} is a C_{1-4} aliphatic chain or a 3-5 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen and oxygen; wherein R^{YA} is substituted by r^6 instances of a group independently selected from fluorine, chlorine, -OH, $-OCH_3$, $-OCF_3$, $-CH_3$, $-CHF_2$, and $-CF_3$. In some embodiments, R^{YA} is a C_{1-4} aliphatic chain substituted by -OH and 0-3 fluorine.

[0256] In some embodiments, R^{YA} is oxo, halogen, -CN, $-NO_2$, -OR, -SR, $-NR_2$, $-S(O)_2R$, $-S(O)_2NR_2$, $-S(O)_2F$, -S(O)R, $-S(O)NR_2$, -S(O)(NR)R, -C(O)R, -C(O)OR, $-C(O)NR_2$, -C(O)N(R)OR, -OC(O)R, $-OC(O)NR_2$, -N(R)C(O)OR, -N(R)C(O)R, $-N(R)C(O)NR_2$, $-N(R)C(NR)NR_2$, $-N(R)S(O)_2NR_2$, $-N(R)S(O)_2R$, $-P(O)R_2$, -P(O)(R)OR, $-B(OR)_2$, or deuterium.

[0257] In some embodiments, R^{YA} is oxo, halogen, -CN, $-NO_2$, -OR, -SR, $-NR_2$, $-S(O)_2R$, $-S(O)_2NR_2$, $-S(O)_2F$, -S(O)R, $-S(O)NR_2$, -S(O)(NR)R, -C(O)R, -C(O)OR, $-C(O)NR_2$, -C(O)N(R)OR, -OC(O)R, $-OC(O)NR_2$, -N(R)C(O)OR, -N(R)C(O)R, $-N(R)C(O)NR_2$, $-N(R)C(NR)NR_2$, $-N(R)S(O)_2NR_2$, $-N(R)S(O)_2R$, $-P(O)R_2$, -P(O)(R)OR, or $-B(OR)_2$.

[0258] In some embodiments, R^{YA} is oxo. In some embodiments, R^{YA} is halogen. In some embodiments, R^{YA} is –CN. In some embodiments, R^{YA} is $-NO_2$. In some embodiments, R^{YA} is -OR. In some embodiments, R^{YA} is -SR. In some embodiments, R^{YA} is $-NR_2$. In some embodiments, R^{YA} is $-S(O)_2R$. In some embodiments, R^{YA} is $-S(O)_2NR_2$. In some embodiments, R^{YA} is $-S(O)_2F$. In some embodiments, R^{YA} is -S(O)R. In some embodiments, R^{YA} is $-S(O)NR_2$. In some embodiments, R^{YA} is -S(O)(NR)R. In some embodiments, R^{YA} is -C(O)R. In some embodiments, R^{YA} is -C(O)OR. In some embodiments, R^{YA} is $-C(O)NR_2$. In some embodiments, R^{YA} is -C(O)N(R)OR. In some embodiments, R^{YA} is -OC(O)R. In some embodiments, R^{YA} is $-OC(O)NR_2$. In some embodiments, R^{YA} is -N(R)C(O)OR. In some embodiments, R^{YA} is -N(R)C(O)R. In some embodiments, R^{YA} is $-N(R)C(O)NR_2$. In some embodiments, R^{YA} is $-N(R)C(NR)NR_2$. In some embodiments, R^{YA} is $-N(R)S(O)_2NR_2$. In some embodiments, R^{YA} is $-N(R)S(O)_2R$. In some embodiments, R^{YA} is $-P(O)R_2$. In some embodiments, R^{YA} is -P(O)(R)OR. In some embodiments, R^{YA} is $-B(OR)_2$. In some embodiments, R^{YA} is deuterium.

[0259] In some embodiments, R^{YA} is halogen, -CN, -NO_2, -OR, -SR, -NR_2, -$S(O)_2R$, -$S(O)_2NR_2$, -$S(O)_2F$, -S(O)R, -$S(O)NR_2$, -S(O)(NR)R, -C(O)R, -C(O)OR, -$C(O)NR_2$, -C(O)N(R)OR, -OC(O)R, -$OC(O)NR_2$, -N(R)C(O)OR, -N(R)C(O)R, -$N(R)C(O)NR_2$, -$N(R)C(NR)NR_2$, -$N(R)S(O)_2NR_2$, -$N(R)S(O)_2R$, -$P(O)R_2$, -P(O)(R)OR, or -$B(OR)_2$.

[0260] In some embodiments, R^{YA} is halogen, -CN, or -NO_2. In some embodiments, R^{YA} is -OR, -SR, or -NR_2. In some embodiments, R^{YA} is -$S(O)_2R$, -$S(O)_2NR_2$, -$S(O)_2F$, -S(O)R, -$S(O)NR_2$, or -S(O)(NR)R. In some embodiments, R^{YA} is -C(O)R, -C(O)OR, -$C(O)NR_2$, or -C(O)N(R)OR. In some embodiments, R^{YA} is -OC(O)R or -$OC(O)NR_2$. In some embodiments, R^{YA} is -N(R)C(O)OR, -N(R)C(O)R, -$N(R)C(O)NR_2$, -$N(R)C(NR)NR_2$, -$N(R)S(O)_2NR_2$, or -$N(R)S(O)_2R$. In some embodiments, R^{YA} is -$P(O)R_2$ or -P(O)(R)OR.

[0261] In some embodiments, R^{YA} is -OR, -OC(O)R, or -$OC(O)NR_2$. In some embodiments, R^{YA} is -SR, -$S(O)_2R$, -$S(O)_2NR_2$, -$S(O)_2F$, -S(O)R, -$S(O)NR_2$, or -S(O)(NR)R. In some embodiments, R^{YA} is -NR_2, -N(R)C(O)OR, -N(R)C(O)R, -$N(R)C(O)NR_2$, -$N(R)C(NR)NR_2$, -$N(R)S(O)_2NR_2$, or -$N(R)S(O)_2R$.

[0262] In some embodiments, R^{YA} is -$S(O)_2R$, -$S(O)_2NR_2$, or -$S(O)_2F$. In some embodiments, R^{YA} is -S(O)R, -$S(O)NR_2$, or -S(O)(NR)R. In some embodiments, R^{YA} is -SR, -$S(O)_2R$, or -S(O)R. In some embodiments, R^{YA} is -$S(O)_2NR_2$, -$S(O)NR_2$, or -S(O)(NR)R. In some embodiments, R^{YA} is -$S(O)_2NR_2$ or -$S(O)NR_2$. In some embodiments, R^{YA} is -SR, -$S(O)_2R$, -$S(O)_2NR_2$, or -S(O)R.

[0263] In some embodiments, R^{YA} is -N(R)C(O)OR, -N(R)C(O)R, or -$N(R)C(O)NR_2$. In some embodiments, R^{YA} is -$N(R)S(O)_2NR_2$ or -$N(R)S(O)_2R$. In some embodiments, R^{YA} is -N(R)C(O)OR or -N(R)C(O)R. In some embodiments, R^{YA} is -$N(R)C(O)NR_2$ or -$N(R)S(O)_2NR_2$. In some embodiments, R^{YA} is -N(R)C(O)OR, -N(R)C(O)R, or -$N(R)S(O)_2R$.

[0264] In some embodiments, R^{YA} is -NR_2, -N(R)C(O)OR, -N(R)C(O)R, or -$N(R)C(O)NR_2$. In some embodiments, R^{YA} is -NR_2, -N(R)C(O)OR, or -N(R)C(O)R. In some embodiments, R^{YA} is -NR_2, -N(R)C(O)OR, -N(R)C(O)R, or -$N(R)S(O)_2R$.

[0265] In some embodiments, R^{YA} is a C_{1-6} aliphatic chain; phenyl; naphthyl; a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; an 8-10 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring; a 5-12 membered saturated or

partially unsaturated bicyclic carbocyclic ring; a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or a 7-12 membered saturated or partially unsaturated bicyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted by r^6 instances of R^{YC}.

[0266] In some embodiments, R^{YA} is a C_{1-6} aliphatic chain substituted by r^6 instances of R^{YC}. In some embodiments, R^{YA} is phenyl substituted by r^6 instances of R^{YC}. In some embodiments, R^{YA} is naphthyl substituted by r^6 instances of R^{YC}. In some embodiments, R^{YA} is a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said ring is substituted by r^6 instances of R^{YC}. In some embodiments, R^{YA} is an 8-10 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said ring is substituted by r^6 instances of R^{YC}. In some embodiments, R^{YA} is a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring substituted by r^6 instances of R^{YC}. In some embodiments, R^{YA} is a 5-12 membered saturated or partially unsaturated bicyclic carbocyclic ring substituted by r^6 instances of R^{YC}. In some embodiments, R^{YA} is a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said ring is substituted by r^6 instances of R^{YC}. In some embodiments, R^{YA} is a 7-12 membered saturated or partially unsaturated bicyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said ring is substituted by r^6 instances of R^{YC}.

[0267] In some embodiments, R^{YA} is phenyl; naphthyl; a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; an 8-10 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring; a 5-12 membered saturated or partially unsaturated bicyclic carbocyclic ring; a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or a 7-12 membered saturated or partially unsaturated bicyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted by r^6 instances of R^{YC}.

[0268] In some embodiments, R^{YA} is phenyl; naphthyl; a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or an 8-10 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted by r^6 instances of R^{YC}. In some embodiments, R^{YA} is a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring; a 5-12 membered saturated or partially unsaturated bicyclic carbocyclic ring; a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or a 7-12 membered saturated or partially unsaturated bicyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted by r^6 instances of R^{YC}.

[0269] In some embodiments, R^{YA} is phenyl; naphthyl; a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring; or a 5-12 membered saturated or partially unsaturated bicyclic carbocyclic ring; each of which is substituted by r^6 instances of R^{YC}. In some embodiments, R^{YA} is a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; an 8-10 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or a 7-12 membered saturated or partially unsaturated bicyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted by r^6 instances of R^{YC}.

[0270] In some embodiments, R^{YA} is phenyl; a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring; or a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted by r^6 instances of R^{YC}. In some embodiments, R^{YA} is naphthyl; an 8-10 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 5-12 membered saturated or partially unsaturated bicyclic carbocyclic ring; or a 7-12 membered saturated or partially unsaturated bicyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted by r^6 instances of R^{YC}.

[0271] In some embodiments, R^{YA} is phenyl or naphthyl; each of which is substituted by r^6 instances of R^{YC}. In some embodiments, R^{YA} is a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or an 8-10 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted by r^6 instances of R^{YC}. In some embodiments, R^{YA} is a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring or a 5-12 membered saturated or partially unsaturated bicyclic carbocyclic ring; each of which is substituted by r^6 instances of R^{YC}. In some embodiments, R^{YA} is a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or a 7-12 membered saturated or partially unsaturated bicyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted by r^6 instances of R^{YC}.

[0272] In some embodiments, R^{YA} is phenyl or a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted by r^6 instances of R^{YC}. In some embodiments, R^{YA} is a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring or a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted by r^6 instances of R^{YC}. In some embodiments, R^{YA} is naphthyl or an 8-10 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted by r^6 instances of R^{YC}. In some embodiments, R^{YA} is a 5-12 membered saturated or partially unsaturated bicyclic carbocyclic ring or a 7-12 membered saturated or partially unsaturated bicyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted by r^6 instances of R^{YC}.

[0273] In some embodiments, R^{YA} is phenyl or a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring; each of which is substituted by r^6 instances of R^{YC}. In some embodiments, R^{YA} is naphthyl or a 5-12 membered saturated or partially unsaturated bicyclic carbocyclic ring; each of which is substituted by r^6 instances of R^{YC}. In some embodiments, R^{YA} is a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently

selected from nitrogen, oxygen, and sulfur; each of which is substituted by r^6 instances of R^{YC}. In some embodiments, R^{YA} is an 8-10 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or a 7-12 membered saturated or partially unsaturated bicyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted by r^6 instances of R^{YC}.

[0274] In some embodiments, R^{YA} is a C_{1-6} aliphatic chain; a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring; a 5-12 membered saturated or partially unsaturated bicyclic carbocyclic ring; a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or a 7-12 membered saturated or partially unsaturated bicyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted by r^6 instances of R^{YC}. In some embodiments, R^{YA} is a C_{1-6} aliphatic chain; phenyl; naphthyl; a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring; or a 5-12 membered saturated or partially unsaturated bicyclic carbocyclic ring; each of which is substituted by r^6 instances of R^{YC}. In some embodiments, R^{YA} is a C_{1-6} aliphatic chain; phenyl; a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring; or a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted by r^6 instances of R^{YC}.

[0275] In some embodiments, R^{YA} is a C_{1-6} aliphatic chain, a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring, or a 5-12 membered saturated or partially unsaturated bicyclic carbocyclic ring; each of which is substituted by r^6 instances of R^{YC}. In some embodiments, R^{YA} is a C_{1-6} aliphatic chain, a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring, or a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted by r^6 instances of R^{YC}. In some embodiments, R^{YA} is a C_{1-6} aliphatic chain, phenyl, or a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring; each of which is substituted by r^6 instances of R^{YC}.

[0276] In some embodiments, R^{YA} is an 8-10 membered bicyclic heteroaryl ring having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said ring is substituted by r^6 instances of R^{YC}. In some embodiments, R^{YA} is an 8-10 membered bicyclic heteroaryl ring having 2 or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said ring is substituted by r^6 instances of R^{YC}. In some embodiments, R^{YA} is an 8-10 membered bicyclic heteroaryl ring having 1, 2, or 3 nitrogen atoms; wherein said ring is substituted by r^6 instances of R^{YC}. In some embodiments, R^{YA} is an 8-10 membered bicyclic heteroaryl ring having 2 or 3 nitrogen atoms; wherein said ring is substituted by r^6 instances of R^{YC}.

[0277] In certain embodiments, R^{YA} is imidazo[1,2-*a*]pyrazinyl, [1,2,4]triazolo[1,5-*a*]pyridinyl, or pyrazolo[1,5-*a*]pyrimidinyl; each of which is substituted by r^6 instances of R^{YC}. In certain embodiments, R^{YA} is imidazo[1,2-*a*]pyrazinyl substituted by r^6 instances of R^{YC}. In certain embodiments, R^{YA} is [1,2,4]triazolo[1,5-*a*]pyridinyl substituted by r^6 instances of R^{YC}. In certain embodiments, R^{YA} is pyrazolo[1,5-*a*]pyrimidinyl substituted by r^6 instances of R^{YC}.

[0278] In certain embodiments, R^{YA} is imidazo[1,2-*a*]pyrazin-6-yl, [1,2,4]triazolo[1,5-*a*]pyridin-6-yl, or pyrazolo[1,5-*a*]pyrimidin-5-yl; each of which is substituted by r^6 instances of R^{YC}. In certain embodiments, R^{YA} is imidazo[1,2-*a*]pyrazin-6-yl substituted by r^6 instances of R^{YC}. In certain embodiments, R^{YA} is [1,2,4]triazolo[1,5-*a*]pyridin-6-yl substituted by r^6 instances of R^{YC}. In certain embodiments, R^{YA} is pyrazolo[1,5-*a*]pyrimidin-5-yl substituted by r^6 instances of R^{YC}.

[0279] In certain embodiments, R^{YA} is imidazo[1,2-*a*]pyrazin-6-yl, [1,2,4]triazolo[1,5-*a*]pyridin-6-yl, or pyrazolo[1,5-*a*]pyrimidin-5-yl. In certain embodiments, R^{YA} is imidazo[1,2-*a*]pyrazin-6-yl. In certain embodiments, R^{YA} is [1,2,4]triazolo[1,5-*a*]pyridin-6-yl. In certain embodiments, R^{YA} is pyrazolo[1,5-*a*]pyrimidin-5-yl.

[0280] In some embodiments, R^{YA} is a 5-6 membered monocyclic heteroaryl ring having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or a 5-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted by r^6 instances of R^{YC}.

[0281] In some embodiments, R^{YA} is a 5-6 membered monocyclic heteroaryl ring having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said

ring is substituted by r^6 instances of R^{YC}. In some embodiments, R^{YA} is a 5-membered monocyclic heteroaryl ring having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said ring is substituted by r^6 instances of R^{YC}. In some embodiments, R^{YA} is a 5-membered monocyclic heteroaryl ring having 1 or 2 heteroatoms independently selected from nitrogen and oxygen; wherein said ring is substituted by r^6 instances of R^{YC}. In some embodiments, R^{YA} is a 6-membered monocyclic heteroaryl ring having 1 or 2 nitrogen atoms; wherein said ring is substituted by r^6 instances of R^{YC}.







[0282] In certain embodiments, R^{YA} is pyrazolyl or imidazolyl, each of which is substituted by r^6 instances of R^{YC}. In certain embodiments, R^{YA} is pyrazolyl substituted by r^6 instances of R^{YC}. In certain embodiments, R^{YA} is imidazolyl substituted by r^6 instances of R^{YC}. In certain embodiments, R^{YA} is pyrazol-4-yl or imidazol-4-yl, each of which is substituted by r^6 instances of R^{YC}. In certain embodiments, R^{YA} is pyrazol-4-yl substituted by r^6 instances of R^{YC}. In certain embodiments, R^{YA} is imidazol-4-yl substituted by r^6 instances of R^{YC}.



















[0283] In some embodiments, R^{YA} is a 3-7 membered partially unsaturated monocyclic heterocyclic ring having 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said ring is substituted by r^6 instances of R^{YC}. In some embodiments, R^{YA} is a 3-7 membered saturated monocyclic heterocyclic ring having 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said ring is substituted by r^6 instances of R^{YC}.



[0284] In some embodiments, R^{YA} is a 5-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said ring is substituted by r^6 instances of R^{YC}. In some embodiments, R^{YA} is a 5-7 membered saturated monocyclic heterocyclic ring having 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said ring is substituted by r^6 instances of R^{YC}. In some embodiments, R^{YA} is a 5-7 membered partially unsaturated monocyclic heterocyclic ring having 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said ring is substituted by r^6 instances of R^{YC}.






[0285] In some embodiments, R^{YA} is a 6-membered saturated or partially unsaturated monocyclic heterocyclic ring having 1 or 2 heteroatoms independently selected from nitrogen and oxygen; wherein said ring is substituted by r^6 instances of R^{YC}. In some embodiments, R^{YA} is a 6-membered saturated monocyclic heterocyclic ring having 1 or 2 heteroatoms independently selected from nitrogen and oxygen; wherein said ring is substituted by r^6












instances of R^{YC}. In some embodiments, R^{YA} is a 6-membered partially unsaturated monocyclic heterocyclic ring having 1 or 2 heteroatoms independently selected from nitrogen and oxygen; wherein said ring is substituted by r^6 instances of R^{YC}. In some embodiments, R^{YA} is pyridin-2(1*H*)-onyl substituted by 0, 1, 2, or 3 instances of R^{YC}. In some embodiments, R^{YA} is pyridin-2(1*H*)-on-5-yl substituted by 0, 1, 2, or 3 instances of R^{YC}.

[0286] In some embodiments, R^{YA} is , , or , wherein R^{YC} and r^6 are as defined in the embodiments and classes and subclasses herein. In some embodiments, R^{YA} is . In some embodiments, R^{YA} is . In some embodiments, R^{YA} is .

[0287] In some embodiments, R^{YA} is , , , , , , , , , or , wherein R^{YC} is as defined in the embodiments and classes and subclasses herein. In some embodiments, R^{YA} is , , , , , or . In some embodiments, R^{YA} is , ,


, or 
.

[0288] In some embodiments, R^{YA} is 
. In some embodiments, R^{YA} is 
. In some embodiments, R^{YA} is 
. In some embodiments, R^{YA} is 
. In some embodiments, R^{YA} is 
. In some embodiments, R^{YA} is 
.

[0289] In some embodiments, R^{YA} is 
, 
, 
, or 
. In some embodiments, R^{YA} is 
, 
, or 
. In some embodiments, R^{YA} is 
. In some embodiments, R^{YA} is 
. In some embodiments, R^{YA} is 
. In some embodiments, R^{YA} is 
.

[0290] In some embodiments, R^{YA} is selected from the groups depicted in the compounds in Table 1.

[0291] As defined generally above, R^{ZA} is R^A or R^B substituted by r^7 instances of R^{ZC}. In some embodiments, R^{ZA} is R^A. In some embodiments, R^{ZA} is R^B substituted by r^7 instances of R^{ZC}.

[0292] In some embodiments, R^{ZA} is oxo, halogen, -CN, $-NO_2$, -OR, -SR, $-NR_2$, $-S(O)_2R$, $-S(O)_2NR_2$, $-S(O)_2F$, -S(O)R, $-S(O)NR_2$, -S(O)(NR)R, -C(O)R, -C(O)OR, $-C(O)NR_2$, -C(O)N(R)OR, -OC(O)R, $-OC(O)NR_2$, -N(R)C(O)OR, -N(R)C(O)R, $-N(R)C(O)NR_2$, $-N(R)C(NR)NR_2$, $-N(R)S(O)_2NR_2$, $-N(R)S(O)_2R$, $-P(O)R_2$, -P(O)(R)OR, $-B(OR)_2$, or R^B selected from a C_{1-6} aliphatic chain; phenyl; a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring; and a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said R^B is substituted by r^7 instances of R^{ZC}.

[0293] In some embodiments, R^{ZA} is halogen, -CN, -OR, $-NR_2$, -C(O)R, -C(O)OR, $-C(O)NR_2$, -N(R)C(O)R, or R^B selected from a C_{1-6} aliphatic chain; a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring; and a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said R^B is substituted by r^7 instances of R^{ZC}. In some embodiments, R^{ZA} is halogen or R^B selected from a C_{1-4} aliphatic chain; a 3-5 membered saturated or partially unsaturated monocyclic carbocyclic ring; and a 3-5 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said R^B is substituted by r^7 instances of a group independently selected from oxo, halogen, -CN, $-NO_2$, -OR, -SR, $-NR_2$, $-S(O)_2R$, $-S(O)_2NR_2$, $-S(O)_2F$, -S(O)R, $-S(O)NR_2$, -S(O)(NR)R, -C(O)R, -C(O)OR, $-C(O)NR_2$, -C(O)N(R)OR, -OC(O)R, $-OC(O)NR_2$, -N(R)C(O)OR, -N(R)C(O)R, $-N(R)C(O)NR_2$, $-N(R)C(NR)NR_2$, $-N(R)S(O)_2NR_2$, $-N(R)S(O)_2R$, $-P(O)R_2$, -P(O)(R)OR, or $-B(OR)_2$, and optionally substituted C_{1-6} aliphatic.

[0294] In some embodiments, R^{ZA} is halogen or R^B selected from a C_{1-4} aliphatic chain; a 3-5 membered saturated or partially unsaturated monocyclic carbocyclic ring; and a 3-5 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2

heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said R^B is substituted by r^7 instances of a group independently selected from halogen, -OH, -O-(C_{1-3} aliphatic), and C_{1-3} aliphatic, wherein each C_{1-3} aliphatic is optionally substituted with 1-3 halogen. In some embodiments, R^{ZA} is halogen or R^B selected from a C_{1-4} aliphatic chain; a 3-5 membered saturated or partially unsaturated monocyclic carbocyclic ring; and a 3-5 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said R^B is substituted by r^7 instances of a group independently selected from fluorine, chlorine, -OH, -OCH_3, -OCF_3, -CH_3, -CHF_2, and -CF_3.

[0295] In some embodiments, R^{ZA} is halogen, -CN, -OR, -NR_2, -C(O)R, -C(O)OR, -$C(O)NR_2$, or -N(R)C(O)R. In some embodiments, R^{ZA} is halogen.

[0296] In some embodiments, R^{ZA} is a C_{1-6} aliphatic chain; a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring; or a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein R^{ZA} is substituted by r^7 instances of R^{ZC}. In some embodiments, R^{ZA} is a C_{1-4} aliphatic chain; a 3-5 membered saturated or partially unsaturated monocyclic carbocyclic ring; or a 3-5 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein R^{ZA} is substituted by r^7 instances of a group independently selected from oxo, halogen, -CN, -NO_2, -OR, -SR, -NR_2, -$S(O)_2R$, -$S(O)_2NR_2$, -$S(O)_2F$, -S(O)R, -$S(O)NR_2$, -S(O)(NR)R, -C(O)R, -C(O)OR, -$C(O)NR_2$, -C(O)N(R)OR, -OC(O)R, -$OC(O)NR_2$, -N(R)C(O)OR, -N(R)C(O)R, -$N(R)C(O)NR_2$, -$N(R)C(NR)NR_2$, -$N(R)S(O)_2NR_2$, -$N(R)S(O)_2R$, -$P(O)R_2$, -P(O)(R)OR, -$B(OR)_2$, and optionally substituted C_{1-6} aliphatic.

[0297] In some embodiments, R^{ZA} is a C_{1-4} aliphatic chain; a 3-5 membered saturated or partially unsaturated monocyclic carbocyclic ring; or a 3-5 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein R^{ZA} is substituted by r^7 instances of a group independently selected from halogen, -OH, -O-(C_{1-3} aliphatic), and C_{1-3} aliphatic, wherein each C_{1-3} aliphatic is optionally substituted with 1-3 halogen. In some embodiments, R^{ZA} is a C_{1-4} aliphatic chain; a 3-5 membered saturated or partially unsaturated monocyclic carbocyclic ring; or a 3-5 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and

sulfur; wherein R^{ZA} is substituted by r^7 instances of a group independently selected from fluorine, chlorine, -OH, $-OCH_3$, $-OCF_3$, $-CH_3$, $-CHF_2$, and $-CF_3$.

[0298] In some embodiments, R^{ZA} is oxo, halogen, -CN, $-NO_2$, -OR, -SR, $-NR_2$, $-S(O)_2R$, $-S(O)_2NR_2$, $-S(O)_2F$, -S(O)R, $-S(O)NR_2$, -S(O)(NR)R, -C(O)R, -C(O)OR, $-C(O)NR_2$, -C(O)N(R)OR, -OC(O)R, $-OC(O)NR_2$, -N(R)C(O)OR, -N(R)C(O)R, $-N(R)C(O)NR_2$, $-N(R)C(NR)NR_2$, $-N(R)S(O)_2NR_2$, $-N(R)S(O)_2R$, $-P(O)R_2$, -P(O)(R)OR, $-B(OR)_2$, or deuterium.

[0299] In some embodiments, R^{ZA} is oxo, halogen, -CN, $-NO_2$, -OR, -SR, $-NR_2$, $-S(O)_2R$, $-S(O)_2NR_2$, $-S(O)_2F$, -S(O)R, $-S(O)NR_2$, -S(O)(NR)R, -C(O)R, -C(O)OR, $-C(O)NR_2$, -C(O)N(R)OR, -OC(O)R, $-OC(O)NR_2$, -N(R)C(O)OR, -N(R)C(O)R, $-N(R)C(O)NR_2$, $-N(R)C(NR)NR_2$, $-N(R)S(O)_2NR_2$, $-N(R)S(O)_2R$, $-P(O)R_2$, -P(O)(R)OR, or $-B(OR)_2$.

[0300] In some embodiments, R^{ZA} is oxo. In some embodiments, R^{ZA} is halogen. In some embodiments, R^{ZA} is –CN. In some embodiments, R^{ZA} is $-NO_2$. In some embodiments, R^{ZA} is -OR. In some embodiments, R^{ZA} is -SR. In some embodiments, R^{ZA} is $-NR_2$. In some embodiments, R^{ZA} is $-S(O)_2R$. In some embodiments, R^{ZA} is $-S(O)_2NR_2$. In some embodiments, R^{ZA} is $-S(O)_2F$. In some embodiments, R^{ZA} is -S(O)R. In some embodiments, R^{ZA} is $-S(O)NR_2$. In some embodiments, R^{ZA} is -S(O)(NR)R. In some embodiments, R^{ZA} is -C(O)R. In some embodiments, R^{ZA} is -C(O)OR. In some embodiments, R^{ZA} is $-C(O)NR_2$. In some embodiments, R^{ZA} is -C(O)N(R)OR. In some embodiments, R^{ZA} is -OC(O)R. In some embodiments, R^{ZA} is $-OC(O)NR_2$. In some embodiments, R^{ZA} is -N(R)C(O)OR. In some embodiments, R^{ZA} is -N(R)C(O)R. In some embodiments, R^{ZA} is $-N(R)C(O)NR_2$. In some embodiments, R^{ZA} is $-N(R)C(NR)NR_2$. In some embodiments, R^{ZA} is $-N(R)S(O)_2NR_2$. In some embodiments, R^{ZA} is $-N(R)S(O)_2R$. In some embodiments, R^{ZA} is $-P(O)R_2$. In some embodiments, R^{ZA} is -P(O)(R)OR. In some embodiments, R^{ZA} is $-B(OR)_2$. In some embodiments, R^{ZA} is deuterium.

[0301] In some embodiments, R^{ZA} is halogen, -CN, $-NO_2$, -OR, -SR, $-NR_2$, $-S(O)_2R$, $-S(O)_2NR_2$, $-S(O)_2F$, -S(O)R, $-S(O)NR_2$, -S(O)(NR)R, -C(O)R, -C(O)OR, $-C(O)NR_2$, -C(O)N(R)OR, -OC(O)R, $-OC(O)NR_2$, -N(R)C(O)OR, -N(R)C(O)R, $-N(R)C(O)NR_2$, $-N(R)C(NR)NR_2$, $-N(R)S(O)_2NR_2$, $-N(R)S(O)_2R$, $-P(O)R_2$, -P(O)(R)OR, or $-B(OR)_2$.

[0302] In some embodiments, R^{ZA} is halogen, -CN, or $-NO_2$. In some embodiments, R^{ZA} is -OR, -SR, or $-NR_2$. In some embodiments, R^{ZA} is $-S(O)_2R$, $-S(O)_2NR_2$, $-S(O)_2F$, -S(O)R, $-S(O)NR_2$, or -S(O)(NR)R. In some embodiments, R^{ZA} is -C(O)R, -C(O)OR, $-C(O)NR_2$,

or -C(O)N(R)OR. In some embodiments, R^{ZA} is -OC(O)R or -OC(O)NR_2. In some embodiments, R^{ZA} is -N(R)C(O)OR, -N(R)C(O)R, -N(R)C(O)NR_2, -N(R)C(NR)NR_2, -N(R)S(O)$_2NR_2$, or -N(R)S(O)$_2$R. In some embodiments, R^{ZA} is -P(O)R_2 or -P(O)(R)OR.

[0303] In some embodiments, R^{ZA} is -OR, -OC(O)R, or -OC(O)NR_2. In some embodiments, R^{ZA} is -SR, -S(O)$_2$R, -S(O)$_2NR_2$, -S(O)$_2$F, -S(O)R, -S(O)NR_2, or -S(O)(NR)R. In some embodiments, R^{ZA} is -NR_2, -N(R)C(O)OR, -N(R)C(O)R, -N(R)C(O)NR_2, -N(R)C(NR)NR_2, -N(R)S(O)$_2NR_2$, or -N(R)S(O)$_2$R.

[0304] In some embodiments, R^{ZA} is -S(O)$_2$R, -S(O)$_2NR_2$, or -S(O)$_2$F. In some embodiments, R^{ZA} is -S(O)R, -S(O)NR_2, or -S(O)(NR)R. In some embodiments, R^{ZA} is -SR, -S(O)$_2$R, or -S(O)R. In some embodiments, R^{ZA} is -S(O)$_2NR_2$, -S(O)NR_2, or -S(O)(NR)R. In some embodiments, R^{ZA} is -S(O)$_2NR_2$ or -S(O)NR_2. In some embodiments, R^{ZA} is -SR, -S(O)$_2$R, -S(O)$_2NR_2$, or -S(O)R.

[0305] In some embodiments, R^{ZA} is -N(R)C(O)OR, -N(R)C(O)R, or -N(R)C(O)NR_2. In some embodiments, R^{ZA} is -N(R)S(O)$_2NR_2$ or -N(R)S(O)$_2$R. In some embodiments, R^{ZA} is -N(R)C(O)OR or -N(R)C(O)R. In some embodiments, R^{ZA} is -N(R)C(O)NR_2 or -N(R)S(O)$_2NR_2$. In some embodiments, R^{ZA} is -N(R)C(O)OR, -N(R)C(O)R, or -N(R)S(O)$_2$R.

[0306] In some embodiments, R^{ZA} is -NR_2, -N(R)C(O)OR, -N(R)C(O)R, or -N(R)C(O)NR_2. In some embodiments, R^{ZA} is -NR_2, -N(R)C(O)OR, or -N(R)C(O)R. In some embodiments, R^{ZA} is -NR_2, -N(R)C(O)OR, -N(R)C(O)R, or -N(R)S(O)$_2$R.

[0307] In some embodiments, R^{ZA} is a C_{1-6} aliphatic chain; phenyl; naphthyl; a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; an 8-10 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring; a 5-12 membered saturated or partially unsaturated bicyclic carbocyclic ring; a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or a 7-12 membered saturated or partially unsaturated bicyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted by r^7 instances of R^{ZC}.

[0308] In some embodiments, R^{ZA} is a C_{1-6} aliphatic chain substituted by r^7 instances of R^{ZC}. In some embodiments, R^{ZA} is phenyl substituted by r^7 instances of R^{ZC}. In some

embodiments, R^{ZA} is naphthyl substituted by r^7 instances of R^{ZC}. In some embodiments, R^{ZA} is a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said ring is substituted by r^7 instances of R^{ZC}. In some embodiments, R^{ZA} is an 8-10 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said ring is substituted by r^7 instances of R^{ZC}. In some embodiments, R^{ZA} is a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring substituted by r^7 instances of R^{ZC}. In some embodiments, R^{ZA} is a 5-12 membered saturated or partially unsaturated bicyclic carbocyclic ring substituted by r^7 instances of R^{ZC}. In some embodiments, R^{ZA} is a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said ring is substituted by r^7 instances of R^{ZC}. In some embodiments, R^{ZA} is a 7-12 membered saturated or partially unsaturated bicyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said ring is substituted by r^7 instances of R^{ZC}.

[0309] In some embodiments, R^{ZA} is phenyl; naphthyl; a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; an 8-10 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring; a 5-12 membered saturated or partially unsaturated bicyclic carbocyclic ring; a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or a 7-12 membered saturated or partially unsaturated bicyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted by r^7 instances of R^{ZC}.

[0310] In some embodiments, R^{ZA} is phenyl; naphthyl; a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or an 8-10 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted by r^7 instances of R^{ZC}. In some embodiments, R^{ZA} is a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring; a 5-12 membered saturated or partially unsaturated bicyclic carbocyclic ring; a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or a 7-12 membered saturated or partially unsaturated bicyclic heterocyclic ring having 1-4

heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted by r^7 instances of R^{ZC}.

[0311] In some embodiments, R^{ZA} is phenyl; naphthyl; a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring; or a 5-12 membered saturated or partially unsaturated bicyclic carbocyclic ring; each of which is substituted by r^7 instances of R^{ZC}. In some embodiments, R^{ZA} is a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; an 8-10 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or a 7-12 membered saturated or partially unsaturated bicyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted by r^7 instances of R^{ZC}.

[0312] In some embodiments, R^{ZA} is phenyl; a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring; or a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted by r^7 instances of R^{ZC}. In some embodiments, R^{ZA} is naphthyl; an 8-10 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 5-12 membered saturated or partially unsaturated bicyclic carbocyclic ring; or a 7-12 membered saturated or partially unsaturated bicyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted by r^7 instances of R^{ZC}.

[0313] In some embodiments, R^{ZA} is phenyl or naphthyl; each of which is substituted by r^7 instances of R^{ZC}. In some embodiments, R^{ZA} is a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or an 8-10 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted by r^7 instances of R^{ZC}. In some embodiments, R^{ZA} is a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring or a 5-12 membered saturated or partially unsaturated bicyclic carbocyclic ring; each of which is substituted by r^7 instances of R^{ZC}. In some embodiments, R^{ZA} is a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2

heteroatoms independently selected from nitrogen, oxygen, and sulfur; or a 7-12 membered saturated or partially unsaturated bicyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted by r^7 instances of R^{ZC}.

[0314] In some embodiments, R^{ZA} is phenyl or a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted by r^7 instances of R^{ZC}. In some embodiments, R^{ZA} is a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring or a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted by r^7 instances of R^{ZC}. In some embodiments, R^{ZA} is naphthyl or an 8-10 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted by r^7 instances of R^{ZC}. In some embodiments, R^{ZA} is a 5-12 membered saturated or partially unsaturated bicyclic carbocyclic ring or a 7-12 membered saturated or partially unsaturated bicyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted by r^7 instances of R^{ZC}.

[0315] In some embodiments, R^{ZA} is phenyl or a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring; each of which is substituted by r^7 instances of R^{ZC}. In some embodiments, R^{ZA} is naphthyl or a 5-12 membered saturated or partially unsaturated bicyclic carbocyclic ring; each of which is substituted by r^7 instances of R^{ZC}. In some embodiments, R^{ZA} is a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted by r^7 instances of R^{ZC}. In some embodiments, R^{ZA} is an 8-10 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or a 7-12 membered saturated or partially unsaturated bicyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted by r^7 instances of R^{ZC}.

[0316] In some embodiments, R^{ZA} is a C_{1-6} aliphatic chain; a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring; a 5-12 membered saturated or partially unsaturated bicyclic carbocyclic ring; a 3-7 membered saturated or partially unsaturated

monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or a 7-12 membered saturated or partially unsaturated bicyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted by r^7 instances of R^{ZC}. In some embodiments, R^{ZA} is a C_{1-6} aliphatic chain; phenyl; naphthyl; a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring; or a 5-12 membered saturated or partially unsaturated bicyclic carbocyclic ring; each of which is substituted by r^7 instances of R^{ZC}. In some embodiments, R^{ZA} is a C_{1-6} aliphatic chain; phenyl; a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring; or a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted by r^7 instances of R^{ZC}.

[0317] In some embodiments, R^{ZA} is a C_{1-6} aliphatic chain, a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring, or a 5-12 membered saturated or partially unsaturated bicyclic carbocyclic ring; each of which is substituted by r^7 instances of R^{ZC}. In some embodiments, R^{ZA} is a C_{1-6} aliphatic chain, a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring, or a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted by r^7 instances of R^{ZC}. In some embodiments, R^{ZA} is a C_{1-6} aliphatic chain, phenyl, or a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring; each of which is substituted by r^7 instances of R^{ZC}.

[0318] In some embodiments, R^{ZA} is selected from the groups depicted in the compounds in Table 1.

[0319] As defined generally above, R^L is R^A or R^B substituted by r^8 instances of R^{LC}. In some embodiments, R^L is R^A. In some embodiments, R^L is R^B substituted by r^8 instances of R^{LC}.

[0320] In some embodiments, R^L is oxo, halogen, -CN, $-NO_2$, -OR, -SR, $-NR_2$, $-S(O)_2R$, $-S(O)_2NR_2$, $-S(O)_2F$, -S(O)R, $-S(O)NR_2$, -S(O)(NR)R, -C(O)R, -C(O)OR, $-C(O)NR_2$, -C(O)N(R)OR, -OC(O)R, $-OC(O)NR_2$, -N(R)C(O)OR, -N(R)C(O)R, $-N(R)C(O)NR_2$,

$-N(R)C(NR)NR_2$, $-N(R)S(O)_2NR_2$, $-N(R)S(O)_2R$, $-P(O)R_2$, $-P(O)(R)OR$, $-B(OR)_2$, or deuterium.

[0321] In some embodiments, R^L is oxo, halogen, -CN, $-NO_2$, -OR, -SR, $-NR_2$, $-S(O)_2R$, $-S(O)_2NR_2$, $-S(O)_2F$, -S(O)R, $-S(O)NR_2$, $-S(O)(NR)R$, -C(O)R, -C(O)OR, $-C(O)NR_2$, $-C(O)N(R)OR$, $-OC(O)R$, $-OC(O)NR_2$, $-N(R)C(O)OR$, $-N(R)C(O)R$, $-N(R)C(O)NR_2$, $-N(R)C(NR)NR_2$, $-N(R)S(O)_2NR_2$, $-N(R)S(O)_2R$, $-P(O)R_2$, $-P(O)(R)OR$, or $-B(OR)_2$.

[0322] In some embodiments, R^L is oxo. In some embodiments, R^L is halogen. In some embodiments, R^L is –CN. In some embodiments, R^L is $-NO_2$. In some embodiments, R^L is -OR. In some embodiments, R^L is -SR. In some embodiments, R^L is $-NR_2$. In some embodiments, R^L is $-S(O)_2R$. In some embodiments, R^L is $-S(O)_2NR_2$. In some embodiments, R^L is $-S(O)_2F$. In some embodiments, R^L is -S(O)R. In some embodiments, R^L is $-S(O)NR_2$. In some embodiments, R^L is $-S(O)(NR)R$. In some embodiments, R^L is -C(O)R. In some embodiments, R^L is -C(O)OR. In some embodiments, R^L is $-C(O)NR_2$. In some embodiments, R^L is $-C(O)N(R)OR$. In some embodiments, R^L is $-OC(O)R$. In some embodiments, R^L is $-OC(O)NR_2$. In some embodiments, R^L is $-N(R)C(O)OR$. In some embodiments, R^L is $-N(R)C(O)R$. In some embodiments, R^L is $-N(R)C(O)NR_2$. In some embodiments, R^L is $-N(R)C(NR)NR_2$. In some embodiments, R^L is $-N(R)S(O)_2NR_2$. In some embodiments, R^L is $-N(R)S(O)_2R$. In some embodiments, R^L is $-P(O)R_2$. In some embodiments, R^L is $-P(O)(R)OR$. In some embodiments, R^L is $-B(OR)_2$. In some embodiments, R^L is deuterium.

[0323] In some embodiments, R^L is halogen, -CN, $-NO_2$, -OR, -SR, $-NR_2$, $-S(O)_2R$, $-S(O)_2NR_2$, $-S(O)_2F$, -S(O)R, $-S(O)NR_2$, $-S(O)(NR)R$, -C(O)R, -C(O)OR, $-C(O)NR_2$, $-C(O)N(R)OR$, $-OC(O)R$, $-OC(O)NR_2$, $-N(R)C(O)OR$, $-N(R)C(O)R$, $-N(R)C(O)NR_2$, $-N(R)C(NR)NR_2$, $-N(R)S(O)_2NR_2$, $-N(R)S(O)_2R$, $-P(O)R_2$, $-P(O)(R)OR$, or $-B(OR)_2$.

[0324] In some embodiments, R^L is halogen, -CN, or $-NO_2$. In some embodiments, R^L is -OR, -SR, or $-NR_2$. In some embodiments, R^L is $-S(O)_2R$, $-S(O)_2NR_2$, $-S(O)_2F$, -S(O)R, $-S(O)NR_2$, or $-S(O)(NR)R$. In some embodiments, R^L is -C(O)R, -C(O)OR, $-C(O)NR_2$, or $-C(O)N(R)OR$. In some embodiments, R^L is $-OC(O)R$ or $-OC(O)NR_2$. In some embodiments, R^L is $-N(R)C(O)OR$, $-N(R)C(O)R$, $-N(R)C(O)NR_2$, $-N(R)C(NR)NR_2$, $-N(R)S(O)_2NR_2$, or $-N(R)S(O)_2R$. In some embodiments, R^L is $-P(O)R_2$ or $-P(O)(R)OR$.

[0325] In some embodiments, R^L is -OR, $-OC(O)R$, or $-OC(O)NR_2$. In some embodiments, R^L is -SR, $-S(O)_2R$, $-S(O)_2NR_2$, $-S(O)_2F$, -S(O)R, $-S(O)NR_2$, or $-S(O)(NR)R$. In some

embodiments, R^L is $-NR_2$, $-N(R)C(O)OR$, $-N(R)C(O)R$, $-N(R)C(O)NR_2$, $-N(R)C(NR)NR_2$, $-N(R)S(O)_2NR_2$, or $-N(R)S(O)_2R$.

[0326] In some embodiments, R^L is $-S(O)_2R$, $-S(O)_2NR_2$, or $-S(O)_2F$. In some embodiments, R^L is $-S(O)R$, $-S(O)NR_2$, or $-S(O)(NR)R$. In some embodiments, R^L is $-SR$, $-S(O)_2R$, or $-S(O)R$. In some embodiments, R^L is $-S(O)_2NR_2$, $-S(O)NR_2$, or $-S(O)(NR)R$. In some embodiments, R^L is $-S(O)_2NR_2$ or $-S(O)NR_2$. In some embodiments, R^L is $-SR$, $-S(O)_2R$, $-S(O)_2NR_2$, or $-S(O)R$.

[0327] In some embodiments, R^L is $-N(R)C(O)OR$, $-N(R)C(O)R$, or $-N(R)C(O)NR_2$. In some embodiments, R^L is $-N(R)S(O)_2NR_2$ or $-N(R)S(O)_2R$. In some embodiments, R^L is $-N(R)C(O)OR$ or $-N(R)C(O)R$. In some embodiments, R^L is $-N(R)C(O)NR_2$ or $-N(R)S(O)_2NR_2$. In some embodiments, R^L is $-N(R)C(O)OR$, $-N(R)C(O)R$, or $-N(R)S(O)_2R$.

[0328] In some embodiments, R^L is $-NR_2$, $-N(R)C(O)OR$, $-N(R)C(O)R$, or $-N(R)C(O)NR_2$. In some embodiments, R^L is $-NR_2$, $-N(R)C(O)OR$, or $-N(R)C(O)R$. In some embodiments, R^L is $-NR_2$, $-N(R)C(O)OR$, $-N(R)C(O)R$, or $-N(R)S(O)_2R$.

[0329] In some embodiments, R^L is a C_{1-6} aliphatic chain; phenyl; naphthyl; a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; an 8-10 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring; a 5-12 membered saturated or partially unsaturated bicyclic carbocyclic ring; a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or a 7-12 membered saturated or partially unsaturated bicyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted by r^8 instances of R^{LC}.

[0330] In some embodiments, R^L is a C_{1-6} aliphatic chain substituted by r^8 instances of R^{LC}. In some embodiments, R^L is phenyl substituted by r^8 instances of R^{LC}. In some embodiments, R^L is naphthyl substituted by r^8 instances of R^{LC}. In some embodiments, R^L is a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said ring is substituted by r^8 instances of R^{LC}. In some embodiments, R^L is an 8-10 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said ring is substituted by

r^8 instances of R^{LC}. In some embodiments, R^L is a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring substituted by r^8 instances of R^{LC}. In some embodiments, R^L is a 5-12 membered saturated or partially unsaturated bicyclic carbocyclic ring substituted by r^8 instances of R^{LC}. In some embodiments, R^L is a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said ring is substituted by r^8 instances of R^{LC}. In some embodiments, R^L is a 7-12 membered saturated or partially unsaturated bicyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said ring is substituted by r^8 instances of R^{LC}.

[0331] In some embodiments, R^L is phenyl; naphthyl; a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; an 8-10 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring; a 5-12 membered saturated or partially unsaturated bicyclic carbocyclic ring; a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or a 7-12 membered saturated or partially unsaturated bicyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted by r^8 instances of R^{LC}.

[0332] In some embodiments, R^L is phenyl; naphthyl; a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or an 8-10 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted by r^8 instances of R^{LC}. In some embodiments, R^L is a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring; a 5-12 membered saturated or partially unsaturated bicyclic carbocyclic ring; a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or a 7-12 membered saturated or partially unsaturated bicyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted by r^8 instances of R^{LC}.

[0333] In some embodiments, R^L is phenyl; naphthyl; a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring; or a 5-12 membered saturated or partially unsaturated bicyclic carbocyclic ring; each of which is substituted by r^8 instances of R^{LC}. In

some embodiments, R^L is a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; an 8-10 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or a 7-12 membered saturated or partially unsaturated bicyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted by r^8 instances of R^{LC}.

[0334] In some embodiments, R^L is phenyl; a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring; or a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted by r^8 instances of R^{LC}. In some embodiments, R^L is naphthyl; an 8-10 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 5-12 membered saturated or partially unsaturated bicyclic carbocyclic ring; or a 7-12 membered saturated or partially unsaturated bicyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted by r^8 instances of R^{LC}.

[0335] In some embodiments, R^L is phenyl or naphthyl; each of which is substituted by r^8 instances of R^{LC}. In some embodiments, R^L is a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or an 8-10 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted by r^8 instances of R^{LC}. In some embodiments, R^L is a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring or a 5-12 membered saturated or partially unsaturated bicyclic carbocyclic ring; each of which is substituted by r^8 instances of R^{LC}. In some embodiments, R^L is a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or a 7-12 membered saturated or partially unsaturated bicyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted by r^8 instances of R^{LC}.

[0336] In some embodiments, R^L is phenyl or a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted by r^8 instances of R^{LC}. In some embodiments, R^L is a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring or a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted by r^8 instances of R^{LC}. In some embodiments, R^L is naphthyl or an 8-10 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted by r^8 instances of R^{LC}. In some embodiments, R^L is a 5-12 membered saturated or partially unsaturated bicyclic carbocyclic ring or a 7-12 membered saturated or partially unsaturated bicyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted by r^8 instances of R^{LC}.

[0337] In some embodiments, R^L is phenyl or a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring; each of which is substituted by r^8 instances of R^{LC}. In some embodiments, R^L is naphthyl or a 5-12 membered saturated or partially unsaturated bicyclic carbocyclic ring; each of which is substituted by r^8 instances of R^{LC}. In some embodiments, R^L is a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted by r^8 instances of R^{LC}. In some embodiments, R^L is an 8-10 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or a 7-12 membered saturated or partially unsaturated bicyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted by r^8 instances of R^{LC}.

[0338] In some embodiments, R^L is a C_{1-6} aliphatic chain; a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring; a 5-12 membered saturated or partially unsaturated bicyclic carbocyclic ring; a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or a 7-12 membered saturated or partially unsaturated bicyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted by r^8 instances of R^{LC}. In some embodiments, R^L is a C_{1-6}

aliphatic chain; phenyl; naphthyl; a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring; or a 5-12 membered saturated or partially unsaturated bicyclic carbocyclic ring; each of which is substituted by r^8 instances of R^{LC}. In some embodiments, R^L is a C_{1-6} aliphatic chain; phenyl; a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring; or a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted by r^8 instances of R^{LC}.

[0339] In some embodiments, R^L is a C_{1-6} aliphatic chain, a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring, or a 5-12 membered saturated or partially unsaturated bicyclic carbocyclic ring; each of which is substituted by r^8 instances of R^{LC}. In some embodiments, R^L is a C_{1-6} aliphatic chain, a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring, or a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted by r^8 instances of R^{LC}. In some embodiments, R^L is a C_{1-6} aliphatic chain, phenyl, or a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring; each of which is substituted by r^8 instances of R^{LC}.

[0340] In some embodiments, R^L is selected from the groups depicted in the compounds in Table 1.

[0341] As defined generally above, each instance of R^A is independently oxo, deuterium, halogen, -CN, $-NO_2$, -OR, $-SF_5$, -SR, $-NR_2$, $-S(O)_2R$, $-S(O)_2NR_2$, $-S(O)_2F$, -S(O)R, $-S(O)NR_2$, -S(O)(NR)R, -C(O)R, -C(O)OR, $-C(O)NR_2$, -C(O)N(R)OR, -OC(O)R, $-OC(O)NR_2$, -N(R)C(O)OR, -N(R)C(O)R, $-N(R)C(O)NR_2$, $-N(R)C(NR)NR_2$, $-N(R)S(O)_2NR_2$, $-N(R)S(O)_2R$, $-P(O)R_2$, -P(O)(R)OR, or $-B(OR)_2$.

[0342] In some embodiments, each instance of R^A is independently oxo, halogen, -CN, $-NO_2$, -OR, $-SF_5$, -SR, $-NR_2$, $-S(O)_2R$, $-S(O)_2NR_2$, $-S(O)_2F$, -S(O)R, $-S(O)NR_2$, -S(O)(NR)R, -C(O)R, -C(O)OR, $-C(O)NR_2$, -C(O)N(R)OR, -OC(O)R, $-OC(O)NR_2$, -N(R)C(O)OR, -N(R)C(O)R, $-N(R)C(O)NR_2$, $-N(R)C(NR)NR_2$, $-N(R)S(O)_2NR_2$, $-N(R)S(O)_2R$, $-P(O)R_2$, -P(O)(R)OR, or $-B(OR)_2$.

[0343] In some embodiments, R^A is oxo. In some embodiments, R^A is halogen. In some embodiments, R^A is –CN. In some embodiments, R^A is $-NO_2$. In some embodiments, R^A is –OR. In some embodiments, R^A is $–SF_5$. In some embodiments, R^A is –SR. In some embodiments, R^A is $-NR_2$. In some embodiments, R^A is $-S(O)_2R$. In some embodiments, R^A is $-S(O)_2NR_2$. In some embodiments, R^A is $-S(O)_2F$. In some embodiments, R^A is -S(O)R. In some embodiments, R^A is $-S(O)NR_2$. In some embodiments, R^A is -S(O)(NR)R. In some embodiments, R^A is -C(O)R. In some embodiments, R^A is -C(O)OR. In some embodiments, R^A is $-C(O)NR_2$. In some embodiments, R^A is -C(O)N(R)OR. In some embodiments, R^A is $-OC(O)R$. In some embodiments, R^A is $-OC(O)NR_2$. In some embodiments, R^A is -N(R)C(O)OR. In some embodiments, R^A is -N(R)C(O)R. In some embodiments, R^A is $-N(R)C(O)NR_2$. In some embodiments, R^A is $-N(R)C(NR)NR_2$. In some embodiments, R^A is $-N(R)S(O)_2NR_2$. In some embodiments, R^A is $-N(R)S(O)_2R$. In some embodiments, R^A is $-P(O)R_2$. In some embodiments, R^A is -P(O)(R)OR. In some embodiments, R^A is $-B(OR)_2$. In some embodiments, R^A is deuterium.

[0344] In some embodiments, R^A is halogen, -CN, $-NO_2$, -OR, -SR, $-NR_2$, $-S(O)_2R$, $-S(O)_2NR_2$, $-S(O)_2F$, -S(O)R, $-S(O)NR_2$, -S(O)(NR)R, -C(O)R, -C(O)OR, $-C(O)NR_2$, -C(O)N(R)OR, $-OC(O)R$, $-OC(O)NR_2$, -N(R)C(O)OR, -N(R)C(O)R, $-N(R)C(O)NR_2$, $-N(R)C(NR)NR_2$, $-N(R)S(O)_2NR_2$, $-N(R)S(O)_2R$, $-P(O)R_2$, -P(O)(R)OR, or $-B(OR)_2$.

[0345] In some embodiments, R^A is halogen, -CN, or $-NO_2$. In some embodiments, R^A is -OR, -SR, or $-NR_2$. In some embodiments, R^A is $-S(O)_2R$, $-S(O)_2NR_2$, $-S(O)_2F$, -S(O)R, $-S(O)NR_2$, or -S(O)(NR)R. In some embodiments, R^A is -C(O)R, -C(O)OR, $-C(O)NR_2$, or -C(O)N(R)OR. In some embodiments, R^A is $-OC(O)R$ or $-OC(O)NR_2$. In some embodiments, R^A is -N(R)C(O)OR, -N(R)C(O)R, $-N(R)C(O)NR_2$, $-N(R)C(NR)NR_2$, $-N(R)S(O)_2NR_2$, or $-N(R)S(O)_2R$. In some embodiments, R^A is $-P(O)R_2$ or -P(O)(R)OR.

[0346] In some embodiments, R^A is -OR, $-OC(O)R$, or $-OC(O)NR_2$. In some embodiments, R^A is -SR, $-S(O)_2R$, $-S(O)_2NR_2$, $-S(O)_2F$, -S(O)R, $-S(O)NR_2$, or -S(O)(NR)R. In some embodiments, R^A is $-NR_2$, -N(R)C(O)OR, -N(R)C(O)R, $-N(R)C(O)NR_2$, $-N(R)C(NR)NR_2$, $-N(R)S(O)_2NR_2$, or $-N(R)S(O)_2R$.

[0347] In some embodiments, R^A is $-S(O)_2R$, $-S(O)_2NR_2$, or $-S(O)_2F$. In some embodiments, R^A is -S(O)R, $-S(O)NR_2$, or -S(O)(NR)R. In some embodiments, R^A is -SR, $-S(O)_2R$, or -S(O)R. In some embodiments, R^A is $-S(O)_2NR_2$, $-S(O)NR_2$, or -S(O)(NR)R. In some

embodiments, R^A is $-S(O)_2NR_2$ or $-S(O)NR_2$. In some embodiments, R^A is -SR, $-S(O)_2R$, $-S(O)_2NR_2$, or -S(O)R.

[0348] In some embodiments, R^A is -N(R)C(O)OR, -N(R)C(O)R, or $-N(R)C(O)NR_2$. In some embodiments, R^A is $-N(R)S(O)_2NR_2$ or $-N(R)S(O)_2R$. In some embodiments, R^A is -N(R)C(O)OR or -N(R)C(O)R. In some embodiments, R^A is $-N(R)C(O)NR_2$ or $-N(R)S(O)_2NR_2$. In some embodiments, R^A is -N(R)C(O)OR, -N(R)C(O)R, or $-N(R)S(O)_2R$.

[0349] In some embodiments, R^A is $-NR_2$, -N(R)C(O)OR, -N(R)C(O)R, or $-N(R)C(O)NR_2$. In some embodiments, R^A is $-NR_2$, -N(R)C(O)OR, or -N(R)C(O)R. In some embodiments, R^A is $-NR_2$, -N(R)C(O)OR, -N(R)C(O)R, or $-N(R)S(O)_2R$.

[0350] In some embodiments, R^A is selected from the groups depicted in the compounds in Table 1.

[0351] As defined generally above, each instance of R^B is independently a C_{1-6} aliphatic chain; phenyl; naphthyl; cubanyl; adamantyl; a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; an 8-10 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring; a 5-12 membered saturated or partially unsaturated bicyclic carbocyclic ring; a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or a 7-12 membered saturated or partially unsaturated bicyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0352] In some embodiments, R^B is a C_{1-6} aliphatic chain. In some embodiments, R^B is phenyl. In some embodiments, R^B is naphthyl. In some embodiments, R^B is cubanyl. In some embodiments, R^B is adamantyl. In some embodiments, R^B is a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, R^B is an 8-10 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, R^B is a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring. In some embodiments, R^B is a 5-12 membered saturated or partially unsaturated bicyclic carbocyclic ring. In some embodiments, R^B is a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, R^B is a 7-12 membered

saturated or partially unsaturated bicyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0353] In some embodiments, R^B is phenyl; naphthyl; a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; an 8-10 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring; a 5-12 membered saturated or partially unsaturated bicyclic carbocyclic ring; a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or a 7-12 membered saturated or partially unsaturated bicyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0354] In some embodiments, R^B is phenyl; naphthyl; a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or an 8-10 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, R^B is a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring; a 5-12 membered saturated or partially unsaturated bicyclic carbocyclic ring; a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or a 7-12 membered saturated or partially unsaturated bicyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0355] In some embodiments, R^B is phenyl; naphthyl; a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring; or a 5-12 membered saturated or partially unsaturated bicyclic carbocyclic ring. In some embodiments, R^B is a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; an 8-10 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or a 7-12 membered saturated or partially unsaturated bicyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0356] In some embodiments, R^B is phenyl; a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring; or a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, R^B is naphthyl; an 8-10 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 5-12 membered saturated or partially unsaturated bicyclic carbocyclic ring; or a 7-12 membered saturated or partially unsaturated bicyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0357] In some embodiments, R^B is phenyl or naphthyl. In some embodiments, R^B is a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or an 8-10 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, R^B is a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring or a 5-12 membered saturated or partially unsaturated bicyclic carbocyclic ring. In some embodiments, R^B is a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or a 7-12 membered saturated or partially unsaturated bicyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0358] In some embodiments, R^B is phenyl or a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, R^B is a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring or a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, R^B is naphthyl or an 8-10 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, R^B is a 5-12 membered saturated or partially unsaturated bicyclic carbocyclic ring or a 7-12 membered saturated or partially unsaturated bicyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0359] In some embodiments, R^B is phenyl or a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring. In some embodiments, R^B is naphthyl or a 5-12

membered saturated or partially unsaturated bicyclic carbocyclic ring. In some embodiments, R^B is a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, R^B is an 8-10 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or a 7-12 membered saturated or partially unsaturated bicyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0360] In some embodiments, R^B is a C_{1-6} aliphatic chain; a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring; a 5-12 membered saturated or partially unsaturated bicyclic carbocyclic ring; a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or a 7-12 membered saturated or partially unsaturated bicyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, R^B is a C_{1-6} aliphatic chain; phenyl; naphthyl; a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring; or a 5-12 membered saturated or partially unsaturated bicyclic carbocyclic ring. In some embodiments, R^B is a C_{1-6} aliphatic chain; phenyl; a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring; or a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0361] In some embodiments, R^B is a C_{1-6} aliphatic chain, a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring, or a 5-12 membered saturated or partially unsaturated bicyclic carbocyclic ring. In some embodiments, R^B is a C_{1-6} aliphatic chain, a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring, or a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, R^B is a C_{1-6} aliphatic chain, phenyl, or a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring.

[0362] In some embodiments, R^B is selected from the groups depicted in the compounds in Table 1.

[0363] As defined generally above, each instance of R^{1C} is independently oxo, deuterium, halogen, -CN, -NO_2, -OR, -SR, -NR_2, -$S(O)_2R$, -$S(O)_2NR_2$, -$S(O)_2F$, -S(O)R, -$S(O)NR_2$, -S(O)(NR)R, -C(O)R, -C(O)OR, -$C(O)NR_2$, -C(O)N(R)OR, -OC(O)R, -$OC(O)NR_2$, -N(R)C(O)OR, -N(R)C(O)R, -$N(R)C(O)NR_2$, -$N(R)C(NR)NR_2$, -$N(R)S(O)_2NR_2$, -$N(R)S(O)_2R$, -$P(O)R_2$, -P(O)(R)OR, -$B(OR)_2$, or an optionally substituted group selected from C_{1-6} aliphatic, phenyl, a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0364] In some embodiments, each instance of R^{1C} is independently oxo, halogen, -CN, -NO_2, -OR, -SR, -NR_2, -$S(O)_2R$, -$S(O)_2NR_2$, -$S(O)_2F$, -S(O)R, -$S(O)NR_2$, -S(O)(NR)R, -C(O)R, -C(O)OR, -$C(O)NR_2$, -C(O)N(R)OR, -OC(O)R, -$OC(O)NR_2$, -N(R)C(O)OR, -N(R)C(O)R, -$N(R)C(O)NR_2$, -$N(R)C(NR)NR_2$, -$N(R)S(O)_2NR_2$, -$N(R)S(O)_2R$, -$P(O)R_2$, -P(O)(R)OR, -$B(OR)_2$, or an optionally substituted group selected from C_{1-6} aliphatic, phenyl, a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0365] In some embodiments, each instance of R^{1C} is independently oxo, halogen, -CN, -NO_2, -OR, -SR, -NR_2, -$S(O)_2R$, -$S(O)_2NR_2$, -$S(O)_2F$, -S(O)R, -$S(O)NR_2$, -S(O)(NR)R, -C(O)R, -C(O)OR, -$C(O)NR_2$, -C(O)N(R)OR, -OC(O)R, -$OC(O)NR_2$, -N(R)C(O)OR, -N(R)C(O)R, -$N(R)C(O)NR_2$, -$N(R)C(NR)NR_2$, -$N(R)S(O)_2NR_2$, -$N(R)S(O)_2R$, -$P(O)R_2$, -P(O)(R)OR, or -$B(OR)_2$. In some embodiments, each instance of R^{1C} is independently an optionally substituted group selected from C_{1-6} aliphatic, phenyl, a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0366] In some embodiments, R^{1C} is oxo. In some embodiments, R^{1C} is deuterium. In some embodiments, each instance of R^{1C} is independently halogen. In some embodiments, R^{1C} is -CN. In some embodiments, R^{1C} is -NO_2. In some embodiments, R^{1C} is -OR. In some embodiments, R^{1C} is -SR. In some embodiments, R^{1C} is -NR_2. In some embodiments, R^{1C} is -$S(O)_2R$. In some embodiments, R^{1C} is -$S(O)_2NR_2$. In some embodiments, R^{1C} is -$S(O)_2F$. In some embodiments, R^{1C} is -S(O)R. In some embodiments, R^{1C} is -$S(O)NR_2$. In some

embodiments, R^{1C} is -S(O)(NR)R. In some embodiments, R^{1C} is -C(O)R. In some embodiments, R^{1C} is -C(O)OR. In some embodiments, R^{1C} is -C(O)NR_2. In some embodiments, R^{1C} is -C(O)N(R)OR. In some embodiments, R^{1C} is -OC(O)R. In some embodiments, R^{1C} is -OC(O)NR_2. In some embodiments, R^{1C} is -N(R)C(O)OR. In some embodiments, R^{1C} is -N(R)C(O)R. In some embodiments, R^{1C} is -N(R)C(O)NR_2. In some embodiments, R^{1C} is -N(R)C(NR)NR_2. In some embodiments, R^{1C} is -N(R)S(O)$_2NR_2$. In some embodiments, R^{1C} is -N(R)S(O)$_2$R. In some embodiments, R^{1C} is -P(O)R_2. In some embodiments, R^{1C} is -P(O)(R)OR. In some embodiments, R^{1C} is -B(OR)$_2$.

[0367] In some embodiments, each instance of R^{1C} is independently halogen, -CN, -NO_2, -OR, -SR, -NR_2, -S(O)$_2$R, -S(O)$_2NR_2$, -S(O)$_2$F, -S(O)R, -S(O)NR_2, -S(O)(NR)R, -C(O)R, -C(O)OR, -C(O)NR_2, -C(O)N(R)OR, -OC(O)R, -OC(O)NR_2, -N(R)C(O)OR, -N(R)C(O)R, -N(R)C(O)NR_2, -N(R)C(NR)NR_2, -N(R)S(O)$_2NR_2$, -N(R)S(O)$_2$R, -P(O)R_2, -P(O)(R)OR, or -B(OR)$_2$.

[0368] In some embodiments, each instance of R^{1C} is independently halogen, -CN, or -NO_2. In some embodiments, each instance of R^{1C} is independently -OR, -SR, or -NR_2. In some embodiments, each instance of R^{1C} is independently -S(O)$_2$R, -S(O)$_2NR_2$, -S(O)$_2$F, -S(O)R, -S(O)NR_2, or -S(O)(NR)R. In some embodiments, each instance of R^{1C} is independently -C(O)R, -C(O)OR, -C(O)NR_2, or -C(O)N(R)OR. In some embodiments, each instance of R^{1C} is independently -OC(O)R or -OC(O)NR_2. In some embodiments, each instance of R^{1C} is independently -N(R)C(O)OR, -N(R)C(O)R, -N(R)C(O)NR_2, -N(R)C(NR)NR_2, -N(R)S(O)$_2NR_2$, or -N(R)S(O)$_2$R. In some embodiments, each instance of R^{1C} is independently -P(O)R_2 or -P(O)(R)OR.

[0369] In some embodiments, each instance of R^{1C} is independently -OR, -OC(O)R, or -OC(O)NR_2. In some embodiments, each instance of R^{1C} is independently -SR, -S(O)$_2$R, -S(O)$_2NR_2$, -S(O)$_2$F, -S(O)R, -S(O)NR_2, or -S(O)(NR)R. In some embodiments, each instance of R^{1C} is independently -NR_2, -N(R)C(O)OR, -N(R)C(O)R, -N(R)C(O)NR_2, -N(R)C(NR)NR_2, -N(R)S(O)$_2NR_2$, or -N(R)S(O)$_2$R.

[0370] In some embodiments, each instance of R^{1C} is independently -S(O)$_2$R, -S(O)$_2NR_2$, or -S(O)$_2$F. In some embodiments, each instance of R^{1C} is independently -S(O)R, -S(O)NR_2, or -S(O)(NR)R. In some embodiments, each instance of R^{1C} is independently -SR, -S(O)$_2$R, or -S(O)R. In some embodiments, each instance of R^{1C} is independently -S(O)$_2NR_2$, -S(O)NR_2, or -S(O)(NR)R. In some embodiments, each instance of R^{1C} is independently

$-S(O)_2NR_2$ or $-S(O)NR_2$. In some embodiments, each instance of R^{1C} is independently -SR, $-S(O)_2R$, $-S(O)_2NR_2$, or -S(O)R.

[0371] In some embodiments, each instance of R^{1C} is independently -N(R)C(O)OR, -N(R)C(O)R, or $-N(R)C(O)NR_2$. In some embodiments, each instance of R^{1C} is independently $-N(R)S(O)_2NR_2$ or $-N(R)S(O)_2R$. In some embodiments, each instance of R^{1C} is independently -N(R)C(O)OR or -N(R)C(O)R. In some embodiments, each instance of R^{1C} is independently $-N(R)C(O)NR_2$ or $-N(R)S(O)_2NR_2$. In some embodiments, each instance of R^{1C} is independently -N(R)C(O)OR, -N(R)C(O)R, or $-N(R)S(O)_2R$.

[0372] In some embodiments, each instance of R^{1C} is independently $-NR_2$, -N(R)C(O)OR, -N(R)C(O)R, or $-N(R)C(O)NR_2$. In some embodiments, each instance of R^{1C} is independently $-NR_2$, -N(R)C(O)OR, or -N(R)C(O)R. In some embodiments, each instance of R^{1C} is independently $-NR_2$, -N(R)C(O)OR, -N(R)C(O)R, or $-N(R)S(O)_2R$.

[0373] In some embodiments, each instance of R^{1C} is independently an optionally substituted C_{1-6} aliphatic. In some embodiments, each instance of R^{1C} is independently an optionally substituted phenyl. In some embodiments, each instance of R^{1C} is independently an optionally substituted 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, each instance of R^{1C} is independently an optionally substituted 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0374] In some embodiments, each instance of R^{1C} is independently an optionally substituted C_{1-6} aliphatic or an optionally substituted 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, each instance of R^{1C} is independently an optionally substituted phenyl or an optionally substituted 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0375] In some embodiments, each instance of R^{1C} is independently an optionally substituted C_{1-6} aliphatic or an optionally substituted phenyl. In some embodiments, each instance of R^{1C} is independently an optionally substituted 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen,

oxygen, and sulfur, or an optionally substituted 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0376] In some embodiments, each instance of R^{1C} is independently an optionally substituted group selected from phenyl, a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0377] In some embodiments, each instance of R^{1C} is independently a C_{1-6} aliphatic. In some embodiments, R^{1C} is phenyl. In some embodiments, each instance of R^{1C} is independently a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, each instance of R^{1C} is independently a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0378] In some embodiments, each instance of R^{1C} is independently a C_{1-6} aliphatic or a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, each instance of R^{1C} is independently phenyl or a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0379] In some embodiments, each instance of R^{1C} is independently a C_{1-6} aliphatic or phenyl. In some embodiments, each instance of R^{1C} is independently a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0380] In some embodiments, each instance of R^{1C} is independently phenyl, a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0381] In some embodiments, each instance of R^{1C} is independently halogen, -CN, -O-(optionally substituted C_{1-6} aliphatic), or an optionally substituted C_{1-6} aliphatic. In some

embodiments, each instance of R^{1C} is independently halogen, -CN, -O-(C_{1-6} aliphatic), or C_{1-6} aliphatic; wherein each C_{1-6} aliphatic is optionally substituted with one or more halogen atoms. In some embodiments, each instance of R^{1C} is independently halogen or C_{1-3} aliphatic optionally substituted with 1-3 halogen. In some embodiments, each instance of R^{1C} is independently fluorine, chlorine, $-CH_3$, $-CHF_2$, or $-CF_3$.

[0382] In some embodiments, each instance of R^{1C} is independently oxo, halogen, -CN, $-NO_2$, -OR, -SR, $-NR_2$, $-S(O)_2R$, $-S(O)_2NR_2$, $-S(O)_2F$, -S(O)R, $-S(O)NR_2$, -S(O)(NR)R, -C(O)R, -C(O)OR, $-C(O)NR_2$, -C(O)N(R)OR, -OC(O)R, $-OC(O)NR_2$, -N(R)C(O)OR, -N(R)C(O)R, $-N(R)C(O)NR_2$, $-N(R)C(NR)NR_2$, $-N(R)S(O)_2NR_2$, $-N(R)S(O)_2R$, $-P(O)R_2$, -P(O)(R)OR, $-B(OR)_2$, or optionally substituted C_{1-6} aliphatic.

[0383] In some embodiments, each instance of R^{1C} is independently selected from the groups depicted in the compounds in Table 1.

[0384] As defined generally above, each instance of R^{2C} is independently oxo, deuterium, halogen, -CN, $-NO_2$, -OR, -SR, $-NR_2$, $-S(O)_2R$, $-S(O)_2NR_2$, $-S(O)_2F$, -S(O)R, $-S(O)NR_2$, -S(O)(NR)R, -C(O)R, -C(O)OR, $-C(O)NR_2$, -C(O)N(R)OR, -OC(O)R, $-OC(O)NR_2$, -N(R)C(O)OR, -N(R)C(O)R, $-N(R)C(O)NR_2$, $-N(R)C(NR)NR_2$, $-N(R)S(O)_2NR_2$, $-N(R)S(O)_2R$, $-P(O)R_2$, -P(O)(R)OR, $-B(OR)_2$, or an optionally substituted group selected from C_{1-6} aliphatic, phenyl, a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0385] In some embodiments, each instance of R^{2C} is independently oxo, halogen, -CN, $-NO_2$, -OR, -SR, $-NR_2$, $-S(O)_2R$, $-S(O)_2NR_2$, $-S(O)_2F$, -S(O)R, $-S(O)NR_2$, -S(O)(NR)R, -C(O)R, -C(O)OR, $-C(O)NR_2$, -C(O)N(R)OR, -OC(O)R, $-OC(O)NR_2$, -N(R)C(O)OR, -N(R)C(O)R, $-N(R)C(O)NR_2$, $-N(R)C(NR)NR_2$, $-N(R)S(O)_2NR_2$, $-N(R)S(O)_2R$, $-P(O)R_2$, -P(O)(R)OR, $-B(OR)_2$, or an optionally substituted group selected from C_{1-6} aliphatic, phenyl, a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0386] In some embodiments, each instance of R^{2C} is independently oxo, halogen, -CN, $-NO_2$, -OR, -SR, $-NR_2$, $-S(O)_2R$, $-S(O)_2NR_2$, $-S(O)_2F$, -S(O)R, $-S(O)NR_2$, -S(O)(NR)R,

-C(O)R, -C(O)OR, -C(O)NR_2, -C(O)N(R)OR, -OC(O)R, -OC(O)NR_2, -N(R)C(O)OR, -N(R)C(O)R, -N(R)C(O)NR_2, -N(R)C(NR)NR_2, -N(R)S(O)$_2NR_2$, -N(R)S(O)$_2$R, -P(O)R_2, -P(O)(R)OR, or -B(OR)$_2$. In some embodiments, each instance of R^{2C} is independently an optionally substituted group selected from C_{1-6} aliphatic, phenyl, a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0387] In some embodiments, R^{2C} is oxo. In some embodiments, R^{2C} is deuterium. In some embodiments, each instance of R^{2C} is independently halogen. In some embodiments, R^{2C} is -CN. In some embodiments, R^{2C} is -NO_2. In some embodiments, R^{2C} is -OR. In some embodiments, R^{2C} is -SR. In some embodiments, R^{2C} is -NR_2. In some embodiments, R^{2C} is -S(O)$_2$R. In some embodiments, R^{2C} is -S(O)$_2NR_2$. In some embodiments, R^{2C} is -S(O)$_2$F. In some embodiments, R^{2C} is -S(O)R. In some embodiments, R^{2C} is -S(O)NR_2. In some embodiments, R^{2C} is -S(O)(NR)R. In some embodiments, R^{2C} is -C(O)R. In some embodiments, R^{2C} is -C(O)OR. In some embodiments, R^{2C} is -C(O)NR_2. In some embodiments, R^{2C} is -C(O)N(R)OR. In some embodiments, R^{2C} is -OC(O)R. In some embodiments, R^{2C} is -OC(O)NR_2. In some embodiments, R^{2C} is -N(R)C(O)OR. In some embodiments, R^{2C} is -N(R)C(O)R. In some embodiments, R^{2C} is -N(R)C(O)NR_2. In some embodiments, R^{2C} is -N(R)C(NR)NR_2. In some embodiments, R^{2C} is -N(R)S(O)$_2NR_2$. In some embodiments, R^{2C} is -N(R)S(O)$_2$R. In some embodiments, R^{2C} is -P(O)R_2. In some embodiments, R^{2C} is -P(O)(R)OR. In some embodiments, R^{2C} is -B(OR)$_2$.

[0388] In some embodiments, each instance of R^{2C} is independently halogen, -CN, -NO_2, -OR, -SR, -NR_2, -S(O)$_2$R, -S(O)$_2NR_2$, -S(O)$_2$F, -S(O)R, -S(O)NR_2, -S(O)(NR)R, -C(O)R, -C(O)OR, -C(O)NR_2, -C(O)N(R)OR, -OC(O)R, -OC(O)NR_2, -N(R)C(O)OR, -N(R)C(O)R, -N(R)C(O)NR_2, -N(R)C(NR)NR_2, -N(R)S(O)$_2NR_2$, -N(R)S(O)$_2$R, -P(O)R_2, -P(O)(R)OR, or -B(OR)$_2$.

[0389] In some embodiments, each instance of R^{2C} is independently halogen, -CN, or -NO_2. In some embodiments, each instance of R^{2C} is independently -OR, -SR, or -NR_2. In some embodiments, each instance of R^{2C} is independently -S(O)$_2$R, -S(O)$_2NR_2$, -S(O)$_2$F, -S(O)R, -S(O)NR_2, or -S(O)(NR)R. In some embodiments, each instance of R^{2C} is independently -C(O)R, -C(O)OR, -C(O)NR_2, or -C(O)N(R)OR. In some embodiments, each instance of R^{2C} is independently -OC(O)R or -OC(O)NR_2. In some embodiments, each instance of R^{2C} is independently -N(R)C(O)OR, -N(R)C(O)R, -N(R)C(O)NR_2, -N(R)C(NR)NR_2,

$-N(R)S(O)_2NR_2$, or $-N(R)S(O)_2R$. In some embodiments, each instance of R^{2C} is independently $-P(O)R_2$ or $-P(O)(R)OR$.

[0390] In some embodiments, each instance of R^{2C} is independently -OR, -OC(O)R, or $-OC(O)NR_2$. In some embodiments, each instance of R^{2C} is independently -SR, $-S(O)_2R$, $-S(O)_2NR_2$, $-S(O)_2F$, -S(O)R, $-S(O)NR_2$, or -S(O)(NR)R. In some embodiments, each instance of R^{2C} is independently $-NR_2$, -N(R)C(O)OR, -N(R)C(O)R, $-N(R)C(O)NR_2$, $-N(R)C(NR)NR_2$, $-N(R)S(O)_2NR_2$, or $-N(R)S(O)_2R$.

[0391] In some embodiments, each instance of R^{2C} is independently $-S(O)_2R$, $-S(O)_2NR_2$, or $-S(O)_2F$. In some embodiments, each instance of R^{2C} is independently -S(O)R, $-S(O)NR_2$, or -S(O)(NR)R. In some embodiments, each instance of R^{2C} is independently -SR, $-S(O)_2R$, or -S(O)R. In some embodiments, each instance of R^{2C} is independently $-S(O)_2NR_2$, $-S(O)NR_2$, or -S(O)(NR)R. In some embodiments, each instance of R^{2C} is independently $-S(O)_2NR_2$ or $-S(O)NR_2$. In some embodiments, each instance of R^{2C} is independently -SR, $-S(O)_2R$, $-S(O)_2NR_2$, or -S(O)R.

[0392] In some embodiments, each instance of R^{2C} is independently -N(R)C(O)OR, -N(R)C(O)R, or $-N(R)C(O)NR_2$. In some embodiments, each instance of R^{2C} is independently $-N(R)S(O)_2NR_2$ or $-N(R)S(O)_2R$. In some embodiments, each instance of R^{2C} is independently -N(R)C(O)OR or -N(R)C(O)R. In some embodiments, each instance of R^{2C} is independently $-N(R)C(O)NR_2$ or $-N(R)S(O)_2NR_2$. In some embodiments, each instance of R^{2C} is independently -N(R)C(O)OR, -N(R)C(O)R, or $-N(R)S(O)_2R$.

[0393] In some embodiments, each instance of R^{2C} is independently $-NR_2$, -N(R)C(O)OR, -N(R)C(O)R, or $-N(R)C(O)NR_2$. In some embodiments, each instance of R^{2C} is independently $-NR_2$, -N(R)C(O)OR, or -N(R)C(O)R. In some embodiments, each instance of R^{2C} is independently $-NR_2$, -N(R)C(O)OR, -N(R)C(O)R, or $-N(R)S(O)_2R$.

[0394] In some embodiments, each instance of R^{2C} is independently an optionally substituted C_{1-6} aliphatic. In some embodiments, each instance of R^{2C} is independently an optionally substituted phenyl. In some embodiments, each instance of R^{2C} is independently an optionally substituted 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, each instance of R^{2C} is independently an optionally substituted 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0395] In some embodiments, each instance of R^{2C} is independently an optionally substituted C_{1-6} aliphatic or an optionally substituted 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, each instance of R^{2C} is independently an optionally substituted phenyl or an optionally substituted 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0396] In some embodiments, each instance of R^{2C} is independently an optionally substituted C_{1-6} aliphatic or an optionally substituted phenyl. In some embodiments, each instance of R^{2C} is independently an optionally substituted 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or an optionally substituted 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0397] In some embodiments, each instance of R^{2C} is independently an optionally substituted group selected from phenyl, a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0398] In some embodiments, each instance of R^{2C} is independently a C_{1-6} aliphatic. In some embodiments, R^{2C} is phenyl. In some embodiments, each instance of R^{2C} is independently a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, each instance of R^{2C} is independently a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0399] In some embodiments, each instance of R^{2C} is independently a C_{1-6} aliphatic or a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, each instance of R^{2C} is independently phenyl or a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0400] In some embodiments, each instance of R^{2C} is independently a C_{1-6} aliphatic or phenyl. In some embodiments, each instance of R^{2C} is independently a 3-7 membered

saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0401] In some embodiments, each instance of R^{2C} is independently phenyl, a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0402] In some embodiments, each instance of R^{2C} is independently halogen, -CN, -O-(optionally substituted C_{1-6} aliphatic), or an optionally substituted C_{1-6} aliphatic. In some embodiments, each instance of R^{2C} is independently halogen, -CN, -O-(C_{1-6} aliphatic), or C_{1-6} aliphatic; wherein each C_{1-6} aliphatic is optionally substituted with one or more halogen atoms. In some embodiments, each instance of R^{2C} is independently halogen or C_{1-3} aliphatic optionally substituted with 1-3 halogen. In some embodiments, each instance of R^{2C} is independently fluorine, chlorine, $-CH_3$, $-CHF_2$, or $-CF_3$.

[0403] In some embodiments, each instance of R^{2C} is independently oxo, halogen, -CN, $-NO_2$, -OR, -SR, $-NR_2$, $-S(O)_2R$, $-S(O)_2NR_2$, $-S(O)_2F$, -S(O)R, $-S(O)NR_2$, -S(O)(NR)R, -C(O)R, -C(O)OR, $-C(O)NR_2$, -C(O)N(R)OR, -OC(O)R, $-OC(O)NR_2$, -N(R)C(O)OR, -N(R)C(O)R, $-N(R)C(O)NR_2$, $-N(R)C(NR)NR_2$, $-N(R)S(O)_2NR_2$, $-N(R)S(O)_2R$, $-P(O)R_2$, -P(O)(R)OR, $-B(OR)_2$, or optionally substituted C_{1-6} aliphatic.

[0404] In some embodiments, each instance of R^{2C} is independently selected from the groups depicted in the compounds in Table 1.

[0405] As defined generally above, each instance of R^{EC} is independently oxo, deuterium, halogen, -CN, $-NO_2$, -OR, -SR, $-NR_2$, $-S(O)_2R$, $-S(O)_2NR_2$, $-S(O)_2F$, -S(O)R, $-S(O)NR_2$, -S(O)(NR)R, -C(O)R, -C(O)OR, $-C(O)NR_2$, -C(O)N(R)OR, -OC(O)R, $-OC(O)NR_2$, -N(R)C(O)OR, -N(R)C(O)R, $-N(R)C(O)NR_2$, $-N(R)C(NR)NR_2$, $-N(R)S(O)_2NR_2$, $-N(R)S(O)_2R$, $-P(O)R_2$, -P(O)(R)OR, $-B(OR)_2$, or an optionally substituted group selected from C_{1-6} aliphatic, phenyl, a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0406] In some embodiments, each instance of R^{EC} is independently oxo, deuterium, halogen, -CN, -NO_2, -OR, -SR, -NR_2, -$S(O)_2R$, -$S(O)_2NR_2$, -$S(O)_2F$, -S(O)R, -$S(O)NR_2$, -S(O)(NR)R, -C(O)R, -C(O)OR, -$C(O)NR_2$, -C(O)N(R)OR, -OC(O)R, -$OC(O)NR_2$, -N(R)C(O)OR, -N(R)C(O)R, -$N(R)C(O)NR_2$, -$N(R)C(NR)NR_2$, -$N(R)S(O)_2NR_2$, -$N(R)S(O)_2R$, -$P(O)R_2$, -P(O)(R)OR, or -$B(OR)_2$. In some embodiments, each instance of R^{EC} is independently oxo, deuterium, halogen, -CN, -NO_2, -OR, -NR_2, -C(O)R, -C(O)OR, -$C(O)NR_2$, -OC(O)R, -N(R)C(O)R, or -$N(R)S(O)_2R$. In some embodiments, each instance of R^{EC} is independently deuterium, halogen, -CN, -OR, or -NR_2. In some embodiments, each instance of R^{EC} is independently deuterium or halogen. In some embodiments, each instance of R^{EC} is independently halogen.

[0407] In some embodiments, each instance of R^{EC} is independently an optionally substituted group selected from C_{1-6} aliphatic, phenyl, a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0408] In some embodiments, each instance of R^{EC} is independently selected from the groups depicted in the compounds in Table 1.

[0409] As defined generally above, each instance of R^{QC} is independently oxo, deuterium, halogen, -CN, -NO_2, -OR, -SR, -NR_2, -$S(O)_2R$, -$S(O)_2NR_2$, -$S(O)_2F$, -S(O)R, -$S(O)NR_2$, -S(O)(NR)R, -C(O)R, -C(O)OR, -$C(O)NR_2$, -C(O)N(R)OR, -OC(O)R, -$OC(O)NR_2$, -N(R)C(O)OR, -N(R)C(O)R, -$N(R)C(O)NR_2$, -$N(R)C(NR)NR_2$, -$N(R)S(O)_2NR_2$, -$N(R)S(O)_2R$, -$P(O)R_2$, -P(O)(R)OR, -$B(OR)_2$, or an optionally substituted group selected from C_{1-6} aliphatic, phenyl, a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0410] In some embodiments, each instance of R^{QC} is independently oxo, halogen, -CN, -NO_2, -OR, -SR, -NR_2, -$S(O)_2R$, -$S(O)_2NR_2$, -$S(O)_2F$, -S(O)R, -$S(O)NR_2$, -S(O)(NR)R, -C(O)R, -C(O)OR, -$C(O)NR_2$, -C(O)N(R)OR, -OC(O)R, -$OC(O)NR_2$, -N(R)C(O)OR, -N(R)C(O)R, -$N(R)C(O)NR_2$, -$N(R)C(NR)NR_2$, -$N(R)S(O)_2NR_2$, -$N(R)S(O)_2R$, -$P(O)R_2$, -P(O)(R)OR, -$B(OR)_2$, or an optionally substituted group selected from C_{1-6} aliphatic, phenyl, a 3-7 membered saturated or partially unsaturated monocyclic

heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0411] In some embodiments, each instance of R^{QC} is independently oxo, halogen, -CN, $-NO_2$, -OR, -SR, $-NR_2$, $-S(O)_2R$, $-S(O)_2NR_2$, $-S(O)_2F$, -S(O)R, $-S(O)NR_2$, -S(O)(NR)R, -C(O)R, -C(O)OR, $-C(O)NR_2$, -C(O)N(R)OR, -OC(O)R, $-OC(O)NR_2$, -N(R)C(O)OR, -N(R)C(O)R, $-N(R)C(O)NR_2$, $-N(R)C(NR)NR_2$, $-N(R)S(O)_2NR_2$, $-N(R)S(O)_2R$, $-P(O)R_2$, -P(O)(R)OR, or $-B(OR)_2$. In some embodiments, each instance of R^{QC} is independently an optionally substituted group selected from C_{1-6} aliphatic, phenyl, a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0412] In some embodiments, R^{QC} is oxo. In some embodiments, R^{QC} is deuterium. In some embodiments, each instance of R^{QC} is independently halogen. In some embodiments, R^{QC} is -CN. In some embodiments, R^{QC} is $-NO_2$. In some embodiments, R^{QC} is -OR. In some embodiments, R^{QC} is -SR. In some embodiments, R^{QC} is $-NR_2$. In some embodiments, R^{QC} is $-S(O)_2R$. In some embodiments, R^{QC} is $-S(O)_2NR_2$. In some embodiments, R^{QC} is $-S(O)_2F$. In some embodiments, R^{QC} is -S(O)R. In some embodiments, R^{QC} is $-S(O)NR_2$. In some embodiments, R^{QC} is -S(O)(NR)R. In some embodiments, R^{QC} is -C(O)R. In some embodiments, R^{QC} is -C(O)OR. In some embodiments, R^{QC} is $-C(O)NR_2$. In some embodiments, R^{QC} is -C(O)N(R)OR. In some embodiments, R^{QC} is -OC(O)R. In some embodiments, R^{QC} is $-OC(O)NR_2$. In some embodiments, R^{QC} is -N(R)C(O)OR. In some embodiments, R^{QC} is -N(R)C(O)R. In some embodiments, R^{QC} is $-N(R)C(O)NR_2$. In some embodiments, R^{QC} is $-N(R)C(NR)NR_2$. In some embodiments, R^{QC} is $-N(R)S(O)_2NR_2$. In some embodiments, R^{QC} is $-N(R)S(O)_2R$. In some embodiments, R^{QC} is $-P(O)R_2$. In some embodiments, R^{QC} is -P(O)(R)OR. In some embodiments, R^{QC} is $-B(OR)_2$.

[0413] In some embodiments, each instance of R^{QC} is independently halogen, -CN, $-NO_2$, -OR, -SR, $-NR_2$, $-S(O)_2R$, $-S(O)_2NR_2$, $-S(O)_2F$, -S(O)R, $-S(O)NR_2$, -S(O)(NR)R, -C(O)R, -C(O)OR, $-C(O)NR_2$, -C(O)N(R)OR, -OC(O)R, $-OC(O)NR_2$, -N(R)C(O)OR, -N(R)C(O)R, $-N(R)C(O)NR_2$, $-N(R)C(NR)NR_2$, $-N(R)S(O)_2NR_2$, $-N(R)S(O)_2R$, $-P(O)R_2$, -P(O)(R)OR, or $-B(OR)_2$.

[0414] In some embodiments, each instance of R^{QC} is independently halogen, -CN, or -NO_2. In some embodiments, each instance of R^{QC} is independently -OR, -SR, or -NR_2. In some embodiments, each instance of R^{QC} is independently -$S(O)_2R$, -$S(O)_2NR_2$, -$S(O)_2F$, -S(O)R, -$S(O)NR_2$, or -S(O)(NR)R. In some embodiments, each instance of R^{QC} is independently -C(O)R, -C(O)OR, -$C(O)NR_2$, or -C(O)N(R)OR. In some embodiments, each instance of R^{QC} is independently -OC(O)R or -$OC(O)NR_2$. In some embodiments, each instance of R^{QC} is independently -N(R)C(O)OR, -N(R)C(O)R, -$N(R)C(O)NR_2$, -$N(R)C(NR)NR_2$, -$N(R)S(O)_2NR_2$, or -$N(R)S(O)_2R$. In some embodiments, each instance of R^{QC} is independently -$P(O)R_2$ or -P(O)(R)OR.

[0415] In some embodiments, each instance of R^{QC} is independently -OR, -OC(O)R, or -$OC(O)NR_2$. In some embodiments, each instance of R^{QC} is independently -SR, -$S(O)_2R$, -$S(O)_2NR_2$, -$S(O)_2F$, -S(O)R, -$S(O)NR_2$, or -S(O)(NR)R. In some embodiments, each instance of R^{QC} is independently -NR_2, -N(R)C(O)OR, -N(R)C(O)R, -$N(R)C(O)NR_2$, -$N(R)C(NR)NR_2$, -$N(R)S(O)_2NR_2$, or -$N(R)S(O)_2R$.

[0416] In some embodiments, each instance of R^{QC} is independently -$S(O)_2R$, -$S(O)_2NR_2$, or -$S(O)_2F$. In some embodiments, each instance of R^{QC} is independently -S(O)R, -$S(O)NR_2$, or -S(O)(NR)R. In some embodiments, each instance of R^{QC} is independently -SR, -$S(O)_2R$, or -S(O)R. In some embodiments, each instance of R^{QC} is independently -$S(O)_2NR_2$, -$S(O)NR_2$, or -S(O)(NR)R. In some embodiments, each instance of R^{QC} is independently -$S(O)_2NR_2$ or -$S(O)NR_2$. In some embodiments, each instance of R^{QC} is independently -SR, -$S(O)_2R$, -$S(O)_2NR_2$, or -S(O)R.

[0417] In some embodiments, each instance of R^{QC} is independently -N(R)C(O)OR, -N(R)C(O)R, or -$N(R)C(O)NR_2$. In some embodiments, each instance of R^{QC} is independently -$N(R)S(O)_2NR_2$ or -$N(R)S(O)_2R$. In some embodiments, each instance of R^{QC} is independently -N(R)C(O)OR or -N(R)C(O)R. In some embodiments, each instance of R^{QC} is independently -$N(R)C(O)NR_2$ or -$N(R)S(O)_2NR_2$. In some embodiments, each instance of R^{QC} is independently -N(R)C(O)OR, -N(R)C(O)R, or -$N(R)S(O)_2R$.

[0418] In some embodiments, each instance of R^{QC} is independently -NR_2, -N(R)C(O)OR, -N(R)C(O)R, or -$N(R)C(O)NR_2$. In some embodiments, each instance of R^{QC} is independently -NR_2, -N(R)C(O)OR, or -N(R)C(O)R. In some embodiments, each instance of R^{QC} is independently -NR_2, -N(R)C(O)OR, -N(R)C(O)R, or -$N(R)S(O)_2R$.

[0419] In some embodiments, each instance of R^{QC} is independently an optionally substituted C_{1-6} aliphatic. In some embodiments, each instance of R^{QC} is independently an optionally substituted phenyl. In some embodiments, each instance of R^{QC} is independently an optionally substituted 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, each instance of R^{QC} is independently an optionally substituted 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0420] In some embodiments, each instance of R^{QC} is independently an optionally substituted C_{1-6} aliphatic or an optionally substituted 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, each instance of R^{QC} is independently an optionally substituted phenyl or an optionally substituted 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0421] In some embodiments, each instance of R^{QC} is independently an optionally substituted C_{1-6} aliphatic or an optionally substituted phenyl. In some embodiments, each instance of R^{QC} is independently an optionally substituted 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or an optionally substituted 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0422] In some embodiments, each instance of R^{QC} is independently an optionally substituted group selected from phenyl, a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0423] In some embodiments, each instance of R^{QC} is independently a C_{1-6} aliphatic. In some embodiments, R^{QC} is phenyl. In some embodiments, each instance of R^{QC} is independently a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some

embodiments, each instance of R^{QC} is independently a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0424] In some embodiments, each instance of R^{QC} is independently a C_{1-6} aliphatic or a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, each instance of R^{QC} is independently phenyl or a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0425] In some embodiments, each instance of R^{QC} is independently a C_{1-6} aliphatic or phenyl. In some embodiments, each instance of R^{QC} is independently a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0426] In some embodiments, each instance of R^{QC} is independently phenyl, a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0427] In some embodiments, each instance of R^{QC} is independently selected from the groups depicted in the compounds in Table 1.

[0428] As defined generally above, each instance of R^{XC} is independently oxo, deuterium, halogen, -CN, $-NO_2$, -OR, -SR, $-NR_2$, $-S(O)_2R$, $-S(O)_2NR_2$, $-S(O)_2F$, -S(O)R, $-S(O)NR_2$, -S(O)(NR)R, -C(O)R, -C(O)OR, $-C(O)NR_2$, -C(O)N(R)OR, -OC(O)R, $-OC(O)NR_2$, -N(R)C(O)OR, -N(R)C(O)R, $-N(R)C(O)NR_2$, $-N(R)C(NR)NR_2$, $-N(R)S(O)_2NR_2$, $-N(R)S(O)_2R$, $-P(O)R_2$, -P(O)(R)OR, $-B(OR)_2$, or an optionally substituted group selected from C_{1-6} aliphatic, phenyl, a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0429] In some embodiments, each instance of R^{XC} is independently oxo, halogen, -CN, $-NO_2$, -OR, -SR, $-NR_2$, $-S(O)_2R$, $-S(O)_2NR_2$, $-S(O)_2F$, -S(O)R, $-S(O)NR_2$,

-S(O)(NR)R, -C(O)R, -C(O)OR, -C(O)NR_2, -C(O)N(R)OR, -OC(O)R, -OC(O)NR_2, -N(R)C(O)OR, -N(R)C(O)R, -N(R)C(O)NR_2, -N(R)C(NR)NR_2, -N(R)$S(O)_2NR_2$, -N(R)$S(O)_2$R, -P(O)R_2, -P(O)(R)OR, -B$(OR)_2$, or an optionally substituted group selected from C_{1-6} aliphatic, phenyl, a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0430] In some embodiments, each instance of R^{XC} is independently oxo, halogen, -CN, -NO_2, -OR, -SR, -NR_2, -$S(O)_2$R, -$S(O)_2NR_2$, -$S(O)_2$F, -S(O)R, -S(O)NR_2, -S(O)(NR)R, -C(O)R, -C(O)OR, -C(O)NR_2, -C(O)N(R)OR, -OC(O)R, -OC(O)NR_2, -N(R)C(O)OR, -N(R)C(O)R, -N(R)C(O)NR_2, -N(R)C(NR)NR_2, -N(R)$S(O)_2NR_2$, -N(R)$S(O)_2$R, -P(O)R_2, -P(O)(R)OR, or -B$(OR)_2$. In some embodiments, each instance of R^{XC} is independently an optionally substituted group selected from C_{1-6} aliphatic, phenyl, a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0431] In some embodiments, R^{XC} is oxo. In some embodiments, R^{XC} is deuterium. In some embodiments, each instance of R^{XC} is independently halogen. In some embodiments, R^{XC} is -CN. In some embodiments, R^{XC} is -NO_2. In some embodiments, R^{XC} is -OR. In some embodiments, R^{XC} is -SR. In some embodiments, R^{XC} is -NR_2. In some embodiments, R^{XC} is -$S(O)_2$R. In some embodiments, R^{XC} is -$S(O)_2NR_2$. In some embodiments, R^{XC} is -$S(O)_2$F. In some embodiments, R^{XC} is -S(O)R. In some embodiments, R^{XC} is -S(O)NR_2. In some embodiments, R^{XC} is -S(O)(NR)R. In some embodiments, R^{XC} is -C(O)R. In some embodiments, R^{XC} is -C(O)OR. In some embodiments, R^{XC} is -C(O)NR_2. In some embodiments, R^{XC} is -C(O)N(R)OR. In some embodiments, R^{XC} is -OC(O)R. In some embodiments, R^{XC} is -OC(O)NR_2. In some embodiments, R^{XC} is -N(R)C(O)OR. In some embodiments, R^{XC} is -N(R)C(O)R. In some embodiments, R^{XC} is -N(R)C(O)NR_2. In some embodiments, R^{XC} is -N(R)C(NR)NR_2. In some embodiments, R^{XC} is -N(R)$S(O)_2NR_2$. In some embodiments, R^{XC} is -N(R)$S(O)_2$R. In some embodiments, R^{XC} is -P(O)R_2. In some embodiments, R^{XC} is -P(O)(R)OR. In some embodiments, R^{XC} is -B$(OR)_2$.

[0432] In some embodiments, each instance of R^{XC} is independently halogen, -CN, -NO_2, -OR, -SR, -NR_2, -$S(O)_2$R, -$S(O)_2NR_2$, -$S(O)_2$F, -S(O)R, -S(O)NR_2, -S(O)(NR)R, -C(O)R, -C(O)OR, -C(O)NR_2, -C(O)N(R)OR, -OC(O)R, -OC(O)NR_2, -N(R)C(O)OR, -N(R)C(O)R,

$-N(R)C(O)NR_2$, $-N(R)C(NR)NR_2$, $-N(R)S(O)_2NR_2$, $-N(R)S(O)_2R$, $-P(O)R_2$, $-P(O)(R)OR$, or $-B(OR)_2$.

[0433] In some embodiments, each instance of R^{XC} is independently halogen, -CN, or $-NO_2$. In some embodiments, each instance of R^{XC} is independently -OR, -SR, or $-NR_2$. In some embodiments, each instance of R^{XC} is independently $-S(O)_2R$, $-S(O)_2NR_2$, $-S(O)_2F$, -S(O)R, $-S(O)NR_2$, or -S(O)(NR)R. In some embodiments, each instance of R^{XC} is independently -C(O)R, -C(O)OR, $-C(O)NR_2$, or -C(O)N(R)OR. In some embodiments, each instance of R^{XC} is independently -OC(O)R or $-OC(O)NR_2$. In some embodiments, each instance of R^{XC} is independently -N(R)C(O)OR, -N(R)C(O)R, $-N(R)C(O)NR_2$, $-N(R)C(NR)NR_2$, $-N(R)S(O)_2NR_2$, or $-N(R)S(O)_2R$. In some embodiments, each instance of R^{XC} is independently $-P(O)R_2$ or -P(O)(R)OR.

[0434] In some embodiments, each instance of R^{XC} is independently -OR, -OC(O)R, or $-OC(O)NR_2$. In some embodiments, each instance of R^{XC} is independently -SR, $-S(O)_2R$, $-S(O)_2NR_2$, $-S(O)_2F$, -S(O)R, $-S(O)NR_2$, or -S(O)(NR)R. In some embodiments, each instance of R^{XC} is independently $-NR_2$, -N(R)C(O)OR, -N(R)C(O)R, $-N(R)C(O)NR_2$, $-N(R)C(NR)NR_2$, $-N(R)S(O)_2NR_2$, or $-N(R)S(O)_2R$.

[0435] In some embodiments, each instance of R^{XC} is independently $-S(O)_2R$, $-S(O)_2NR_2$, or $-S(O)_2F$. In some embodiments, each instance of R^{XC} is independently -S(O)R, $-S(O)NR_2$, or -S(O)(NR)R. In some embodiments, each instance of R^{XC} is independently -SR, $-S(O)_2R$, or -S(O)R. In some embodiments, each instance of R^{XC} is independently $-S(O)_2NR_2$, $-S(O)NR_2$, or -S(O)(NR)R. In some embodiments, each instance of R^{XC} is independently $-S(O)_2NR_2$ or $-S(O)NR_2$. In some embodiments, each instance of R^{XC} is independently -SR, $-S(O)_2R$, $-S(O)_2NR_2$, or -S(O)R.

[0436] In some embodiments, each instance of R^{XC} is independently -N(R)C(O)OR, -N(R)C(O)R, or $-N(R)C(O)NR_2$. In some embodiments, each instance of R^{XC} is independently $-N(R)S(O)_2NR_2$ or $-N(R)S(O)_2R$. In some embodiments, each instance of R^{XC} is independently -N(R)C(O)OR or -N(R)C(O)R. In some embodiments, each instance of R^{XC} is independently $-N(R)C(O)NR_2$ or $-N(R)S(O)_2NR_2$. In some embodiments, each instance of R^{XC} is independently -N(R)C(O)OR, -N(R)C(O)R, or $-N(R)S(O)_2R$.

[0437] In some embodiments, each instance of R^{XC} is independently $-NR_2$, -N(R)C(O)OR, -N(R)C(O)R, or $-N(R)C(O)NR_2$. In some embodiments, each instance of R^{XC} is

independently $-NR_2$, -N(R)C(O)OR, or -N(R)C(O)R. In some embodiments, each instance of R^{XC} is independently $-NR_2$, -N(R)C(O)OR, -N(R)C(O)R, or $-N(R)S(O)_2R$.

[0438] In some embodiments, each instance of R^{XC} is independently an optionally substituted C_{1-6} aliphatic. In some embodiments, each instance of R^{XC} is independently an optionally substituted phenyl. In some embodiments, each instance of R^{XC} is independently an optionally substituted 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, each instance of R^{XC} is independently an optionally substituted 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0439] In some embodiments, each instance of R^{XC} is independently an optionally substituted C_{1-6} aliphatic or an optionally substituted 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, each instance of R^{XC} is independently an optionally substituted phenyl or an optionally substituted 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0440] In some embodiments, each instance of R^{XC} is independently an optionally substituted C_{1-6} aliphatic or an optionally substituted phenyl. In some embodiments, each instance of R^{XC} is independently an optionally substituted 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or an optionally substituted 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0441] In some embodiments, each instance of R^{XC} is independently an optionally substituted group selected from phenyl, a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0442] In some embodiments, each instance of R^{XC} is independently a C_{1-6} aliphatic. In some embodiments, R^{XC} is phenyl. In some embodiments, each instance of R^{XC} is independently a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2

heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, each instance of R^{XC} is independently a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0443] In some embodiments, each instance of R^{XC} is independently a C_{1-6} aliphatic or a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, each instance of R^{XC} is independently phenyl or a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0444] In some embodiments, each instance of R^{XC} is independently a C_{1-6} aliphatic or phenyl. In some embodiments, each instance of R^{XC} is independently a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0445] In some embodiments, each instance of R^{XC} is independently phenyl, a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0446] In some embodiments, each instance of R^{XC} is independently selected from the groups depicted in the compounds in Table 1.

[0447] As defined generally above, each instance of R^{YC} is independently oxo, deuterium, halogen, -CN, $-NO_2$, -OR, -SR, $-NR_2$, $-S(O)_2R$, $-S(O)_2NR_2$, $-S(O)_2F$, -S(O)R, $-S(O)NR_2$, -S(O)(NR)R, -C(O)R, -C(O)OR, $-C(O)NR_2$, -C(O)N(R)OR, -OC(O)R, $-OC(O)NR_2$, -N(R)C(O)OR, -N(R)C(O)R, $-N(R)C(O)NR_2$, $-N(R)C(NR)NR_2$, $-N(R)S(O)_2NR_2$, $-N(R)S(O)_2R$, $-P(O)R_2$, -P(O)(R)OR, $-B(OR)_2$, or an optionally substituted group selected from C_{1-6} aliphatic, phenyl, a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0448] In some embodiments, each instance of R^{YC} is independently oxo, halogen, -CN, $-NO_2$, -OR, -SR, $-NR_2$, $-S(O)_2R$, $-S(O)_2NR_2$, $-S(O)_2F$, -S(O)R, $-S(O)NR_2$, -S(O)(NR)R, -C(O)R, -C(O)OR, $-C(O)NR_2$, -C(O)N(R)OR, -OC(O)R, $-OC(O)NR_2$, -N(R)C(O)OR, -N(R)C(O)R, $-N(R)C(O)NR_2$, $-N(R)C(NR)NR_2$, $-N(R)S(O)_2NR_2$, $-N(R)S(O)_2R$, $-P(O)R_2$, -P(O)(R)OR, $-B(OR)_2$, or an optionally substituted group selected from C_{1-6} aliphatic, phenyl, a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0449] In some embodiments, each instance of R^{YC} is independently oxo, halogen, -CN, $-NO_2$, -OR, -SR, $-NR_2$, $-S(O)_2R$, $-S(O)_2NR_2$, $-S(O)_2F$, -S(O)R, $-S(O)NR_2$, -S(O)(NR)R, -C(O)R, -C(O)OR, $-C(O)NR_2$, -C(O)N(R)OR, -OC(O)R, $-OC(O)NR_2$, -N(R)C(O)OR, -N(R)C(O)R, $-N(R)C(O)NR_2$, $-N(R)C(NR)NR_2$, $-N(R)S(O)_2NR_2$, $-N(R)S(O)_2R$, $-P(O)R_2$, -P(O)(R)OR, or $-B(OR)_2$. In some embodiments, each instance of R^{YC} is independently an optionally substituted group selected from C_{1-6} aliphatic, phenyl, a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0450] In some embodiments, R^{YC} is oxo. In some embodiments, R^{YC} is deuterium. In some embodiments, each instance of R^{YC} is independently halogen. In some embodiments, R^{YC} is -CN. In some embodiments, R^{YC} is $-NO_2$. In some embodiments, R^{YC} is -OR. In some embodiments, R^{YC} is -SR. In some embodiments, R^{YC} is $-NR_2$. In some embodiments, R^{YC} is $-S(O)_2R$. In some embodiments, R^{YC} is $-S(O)_2NR_2$. In some embodiments, R^{YC} is $-S(O)_2F$. In some embodiments, R^{YC} is -S(O)R. In some embodiments, R^{YC} is $-S(O)NR_2$. In some embodiments, R^{YC} is -S(O)(NR)R. In some embodiments, R^{YC} is -C(O)R. In some embodiments, R^{YC} is -C(O)OR. In some embodiments, R^{YC} is $-C(O)NR_2$. In some embodiments, R^{YC} is -C(O)N(R)OR. In some embodiments, R^{YC} is -OC(O)R. In some embodiments, R^{YC} is $-OC(O)NR_2$. In some embodiments, R^{YC} is -N(R)C(O)OR. In some embodiments, R^{YC} is -N(R)C(O)R. In some embodiments, R^{YC} is $-N(R)C(O)NR_2$. In some embodiments, R^{YC} is $-N(R)C(NR)NR_2$. In some embodiments, R^{YC} is $-N(R)S(O)_2NR_2$. In some embodiments, R^{YC} is $-N(R)S(O)_2R$. In some embodiments, R^{YC} is $-P(O)R_2$. In some embodiments, R^{YC} is -P(O)(R)OR. In some embodiments, R^{YC} is $-B(OR)_2$.

[0451] In some embodiments, each instance of R^{YC} is independently halogen, -CN, -NO_2, -OR, -SR, -NR_2, -$S(O)_2R$, -$S(O)_2NR_2$, -$S(O)_2F$, -S(O)R, -$S(O)NR_2$, -S(O)(NR)R, -C(O)R, -C(O)OR, -$C(O)NR_2$, -C(O)N(R)OR, -OC(O)R, -$OC(O)NR_2$, -N(R)C(O)OR, -N(R)C(O)R, -$N(R)C(O)NR_2$, -$N(R)C(NR)NR_2$, -$N(R)S(O)_2NR_2$, -$N(R)S(O)_2R$, -$P(O)R_2$, -P(O)(R)OR, or -$B(OR)_2$.

[0452] In some embodiments, each instance of R^{YC} is independently halogen, -CN, or -NO_2. In some embodiments, each instance of R^{YC} is independently -OR, -SR, or -NR_2. In some embodiments, each instance of R^{YC} is independently -$S(O)_2R$, -$S(O)_2NR_2$, -$S(O)_2F$, -S(O)R, -$S(O)NR_2$, or -S(O)(NR)R. In some embodiments, each instance of R^{YC} is independently -C(O)R, -C(O)OR, -$C(O)NR_2$, or -C(O)N(R)OR. In some embodiments, each instance of R^{YC} is independently -OC(O)R or -$OC(O)NR_2$. In some embodiments, each instance of R^{YC} is independently -N(R)C(O)OR, -N(R)C(O)R, -$N(R)C(O)NR_2$, -$N(R)C(NR)NR_2$, -$N(R)S(O)_2NR_2$, or -$N(R)S(O)_2R$. In some embodiments, each instance of R^{YC} is independently -$P(O)R_2$ or -P(O)(R)OR.

[0453] In some embodiments, each instance of R^{YC} is independently -OR, -OC(O)R, or -$OC(O)NR_2$. In some embodiments, each instance of R^{YC} is independently -SR, -$S(O)_2R$, -$S(O)_2NR_2$, -$S(O)_2F$, -S(O)R, -$S(O)NR_2$, or -S(O)(NR)R. In some embodiments, each instance of R^{YC} is independently -NR_2, -N(R)C(O)OR, -N(R)C(O)R, -$N(R)C(O)NR_2$, -$N(R)C(NR)NR_2$, -$N(R)S(O)_2NR_2$, or -$N(R)S(O)_2R$.

[0454] In some embodiments, each instance of R^{YC} is independently -$S(O)_2R$, -$S(O)_2NR_2$, or -$S(O)_2F$. In some embodiments, each instance of R^{YC} is independently -S(O)R, -$S(O)NR_2$, or -S(O)(NR)R. In some embodiments, each instance of R^{YC} is independently -SR, -$S(O)_2R$, or -S(O)R. In some embodiments, each instance of R^{YC} is independently -$S(O)_2NR_2$, -$S(O)NR_2$, or -S(O)(NR)R. In some embodiments, each instance of R^{YC} is independently -$S(O)_2NR_2$ or -$S(O)NR_2$. In some embodiments, each instance of R^{YC} is independently -SR, -$S(O)_2R$, -$S(O)_2NR_2$, or -S(O)R.

[0455] In some embodiments, each instance of R^{YC} is independently -N(R)C(O)OR, -N(R)C(O)R, or -$N(R)C(O)NR_2$. In some embodiments, each instance of R^{YC} is independently -$N(R)S(O)_2NR_2$ or -$N(R)S(O)_2R$. In some embodiments, each instance of R^{YC} is independently -N(R)C(O)OR or -N(R)C(O)R. In some embodiments, each instance of R^{YC} is independently -$N(R)C(O)NR_2$ or -$N(R)S(O)_2NR_2$. In some embodiments, each instance of R^{YC} is independently -N(R)C(O)OR, -N(R)C(O)R, or -$N(R)S(O)_2R$.

[0456] In some embodiments, each instance of R^{YC} is independently $-NR_2$, -N(R)C(O)OR, -N(R)C(O)R, or $-N(R)C(O)NR_2$. In some embodiments, each instance of R^{YC} is independently $-NR_2$, -N(R)C(O)OR, or -N(R)C(O)R. In some embodiments, each instance of R^{YC} is independently $-NR_2$, -N(R)C(O)OR, -N(R)C(O)R, or $-N(R)S(O)_2R$.

[0457] In some embodiments, each instance of R^{YC} is independently an optionally substituted C_{1-6} aliphatic. In some embodiments, each instance of R^{YC} is independently an optionally substituted phenyl. In some embodiments, each instance of R^{YC} is independently an optionally substituted 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, each instance of R^{YC} is independently an optionally substituted 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0458] In some embodiments, each instance of R^{YC} is independently an optionally substituted C_{1-6} aliphatic or an optionally substituted 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, each instance of R^{YC} is independently an optionally substituted phenyl or an optionally substituted 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0459] In some embodiments, each instance of R^{YC} is independently an optionally substituted C_{1-6} aliphatic or an optionally substituted phenyl. In some embodiments, each instance of R^{YC} is independently an optionally substituted 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or an optionally substituted 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0460] In some embodiments, each instance of R^{YC} is independently an optionally substituted group selected from phenyl, a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0461] In some embodiments, each instance of R^{YC} is independently a C_{1-6} aliphatic. In some embodiments, R^{YC} is phenyl. In some embodiments, each instance of R^{YC} is independently a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, each instance of R^{YC} is independently a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0462] In some embodiments, each instance of R^{YC} is independently a C_{1-6} aliphatic or a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, each instance of R^{YC} is independently phenyl or a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0463] In some embodiments, each instance of R^{YC} is independently a C_{1-6} aliphatic or phenyl. In some embodiments, each instance of R^{YC} is independently a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0464] In some embodiments, each instance of R^{YC} is independently phenyl, a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0465] In some embodiments, each instance of R^{YC} is independently oxo, halogen, -CN, $-NO_2$, -OR, -SR, $-NR_2$, $-S(O)_2R$, $-S(O)_2NR_2$, $-S(O)_2F$, -S(O)R, $-S(O)NR_2$, -S(O)(NR)R, -C(O)R, -C(O)OR, $-C(O)NR_2$, -C(O)N(R)OR, -OC(O)R, $-OC(O)NR_2$, -N(R)C(O)OR, -N(R)C(O)R, $-N(R)C(O)NR_2$, $-N(R)C(NR)NR_2$, $-N(R)S(O)_2NR_2$, $-N(R)S(O)_2R$, $-P(O)R_2$, -P(O)(R)OR, $-B(OR)_2$, or optionally substituted C_{1-6} aliphatic.

[0466] In some embodiments, each instance of R^{YC} is independently halogen, -CN, -OH, -O-(optionally substituted C_{1-3} aliphatic), or an optionally substituted C_{1-3} aliphatic. In some embodiments, each instance of R^{YC} is independently halogen, -OH, -O-(C_{1-3} aliphatic), or C_{1-3} aliphatic, wherein each C_{1-3} aliphatic is optionally substituted with 1-3 halogen. In some

embodiments, each instance of R^{YC} is independently fluorine, chlorine, -OH, $-OCH_3$, $-OCF_3$, $-CH_3$, $-CHF_2$, or $-CF_3$. In some embodiments, each instance of R^{YC} is independently fluorine or -OH.

[0467] In some embodiments, each instance of R^{YC} is independently oxo, halogen, -CN, -OH, -O-(optionally substituted C_{1-3} aliphatic), or an optionally substituted C_{1-3} aliphatic. In some embodiments, each instance of R^{YC} is independently oxo, halogen, -CN, -OH, -O-(C_{1-3} aliphatic), or C_{1-3} aliphatic, wherein each C_{1-3} aliphatic is optionally substituted with one or more halogen atoms. Insome embodiments, each instance of R^{YC} is independently oxo, halogen, -CN, -OH, -O-(C_{1-3} aliphatic), or C_{1-3} aliphatic, wherein each C_{1-3} aliphatic is optionally substituted with 1-3 halogen. In some embodiments, each instance of R^{YC} is independently oxo, fluorine, chlorine, -CN, -OH, $-OCH_3$, $-OCF_3$, $-CH_3$, $-CHF_2$, or $-CF_3$. In some embodiments, each instance of R^{YC} is independently oxo, -CN, fluorine, or -OH. In some embodiments, each instance of R^{YC} is independently oxo, -CN, $-CH_3$, or $-CHF_2$. In some embodiments, each instance of R^{YC} is independently -CN, $-CH_3$, or $-CHF_2$.

[0468] In some embodiments, each instance of R^{YC} is independently selected from the groups depicted in the compounds in Table 1.

[0469] As defined generally above, each instance of R^{ZC} is independently oxo, deuterium, halogen, -CN, $-NO_2$, -OR, -SR, $-NR_2$, $-S(O)_2R$, $-S(O)_2NR_2$, $-S(O)_2F$, -S(O)R, $-S(O)NR_2$, -S(O)(NR)R, -C(O)R, -C(O)OR, $-C(O)NR_2$, -C(O)N(R)OR, -OC(O)R, $-OC(O)NR_2$, -N(R)C(O)OR, -N(R)C(O)R, $-N(R)C(O)NR_2$, $-N(R)C(NR)NR_2$, $-N(R)S(O)_2NR_2$, $-N(R)S(O)_2R$, $-P(O)R_2$, -P(O)(R)OR, $-B(OR)_2$, or an optionally substituted group selected from C_{1-6} aliphatic, phenyl, a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0470] In some embodiments, each instance of R^{ZC} is independently oxo, halogen, -CN, $-NO_2$, -OR, -SR, $-NR_2$, $-S(O)_2R$, $-S(O)_2NR_2$, $-S(O)_2F$, -S(O)R, $-S(O)NR_2$, -S(O)(NR)R, -C(O)R, -C(O)OR, $-C(O)NR_2$, -C(O)N(R)OR, -OC(O)R, $-OC(O)NR_2$, -N(R)C(O)OR, -N(R)C(O)R, $-N(R)C(O)NR_2$, $-N(R)C(NR)NR_2$, $-N(R)S(O)_2NR_2$, $-N(R)S(O)_2R$, $-P(O)R_2$, -P(O)(R)OR, $-B(OR)_2$, or an optionally substituted group selected from C_{1-6} aliphatic, phenyl, a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and

sulfur, and a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0471] In some embodiments, each instance of R^{ZC} is independently oxo, halogen, -CN, $-NO_2$, -OR, -SR, $-NR_2$, $-S(O)_2R$, $-S(O)_2NR_2$, $-S(O)_2F$, -S(O)R, $-S(O)NR_2$, -S(O)(NR)R, -C(O)R, -C(O)OR, $-C(O)NR_2$, -C(O)N(R)OR, -OC(O)R, $-OC(O)NR_2$, -N(R)C(O)OR, -N(R)C(O)R, $-N(R)C(O)NR_2$, $-N(R)C(NR)NR_2$, $-N(R)S(O)_2NR_2$, $-N(R)S(O)_2R$, $-P(O)R_2$, -P(O)(R)OR, or $-B(OR)_2$. In some embodiments, each instance of R^{ZC} is independently an optionally substituted group selected from C_{1-6} aliphatic, phenyl, a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0472] In some embodiments, R^{ZC} is oxo. In some embodiments, R^{ZC} is deuterium. In some embodiments, each instance of R^{ZC} is independently halogen. In some embodiments, R^{ZC} is -CN. In some embodiments, R^{ZC} is $-NO_2$. In some embodiments, R^{ZC} is -OR. In some embodiments, R^{ZC} is -SR. In some embodiments, R^{ZC} is $-NR_2$. In some embodiments, R^{ZC} is $-S(O)_2R$. In some embodiments, R^{ZC} is $-S(O)_2NR_2$. In some embodiments, R^{ZC} is $-S(O)_2F$. In some embodiments, R^{ZC} is -S(O)R. In some embodiments, R^{ZC} is $-S(O)NR_2$. In some embodiments, R^{ZC} is -S(O)(NR)R. In some embodiments, R^{ZC} is -C(O)R. In some embodiments, R^{ZC} is -C(O)OR. In some embodiments, R^{ZC} is $-C(O)NR_2$. In some embodiments, R^{ZC} is -C(O)N(R)OR. In some embodiments, R^{ZC} is -OC(O)R. In some embodiments, R^{ZC} is $-OC(O)NR_2$. In some embodiments, R^{ZC} is -N(R)C(O)OR. In some embodiments, R^{ZC} is -N(R)C(O)R. In some embodiments, R^{ZC} is $-N(R)C(O)NR_2$. In some embodiments, R^{ZC} is $-N(R)C(NR)NR_2$. In some embodiments, R^{ZC} is $-N(R)S(O)_2NR_2$. In some embodiments, R^{ZC} is $-N(R)S(O)_2R$. In some embodiments, R^{ZC} is $-P(O)R_2$. In some embodiments, R^{ZC} is -P(O)(R)OR. In some embodiments, R^{ZC} is $-B(OR)_2$.

[0473] In some embodiments, each instance of R^{ZC} is independently halogen, -CN, $-NO_2$, -OR, -SR, $-NR_2$, $-S(O)_2R$, $-S(O)_2NR_2$, $-S(O)_2F$, -S(O)R, $-S(O)NR_2$, -S(O)(NR)R, -C(O)R, -C(O)OR, $-C(O)NR_2$, -C(O)N(R)OR, -OC(O)R, $-OC(O)NR_2$, -N(R)C(O)OR, -N(R)C(O)R, $-N(R)C(O)NR_2$, $-N(R)C(NR)NR_2$, $-N(R)S(O)_2NR_2$, $-N(R)S(O)_2R$, $-P(O)R_2$, -P(O)(R)OR, or $-B(OR)_2$.

[0474] In some embodiments, each instance of R^{ZC} is independently halogen, -CN, or $-NO_2$. In some embodiments, each instance of R^{ZC} is independently -OR, -SR, or $-NR_2$. In some

embodiments, each instance of R^{ZC} is independently $-S(O)_2R$, $-S(O)_2NR_2$, $-S(O)_2F$, $-S(O)R$, $-S(O)NR_2$, or $-S(O)(NR)R$. In some embodiments, each instance of R^{ZC} is independently $-C(O)R$, $-C(O)OR$, $-C(O)NR_2$, or $-C(O)N(R)OR$. In some embodiments, each instance of R^{ZC} is independently $-OC(O)R$ or $-OC(O)NR_2$. In some embodiments, each instance of R^{ZC} is independently $-N(R)C(O)OR$, $-N(R)C(O)R$, $-N(R)C(O)NR_2$, $-N(R)C(NR)NR_2$, $-N(R)S(O)_2NR_2$, or $-N(R)S(O)_2R$. In some embodiments, each instance of R^{ZC} is independently $-P(O)R_2$ or $-P(O)(R)OR$.

[0475] In some embodiments, each instance of R^{ZC} is independently $-OR$, $-OC(O)R$, or $-OC(O)NR_2$. In some embodiments, each instance of R^{ZC} is independently $-SR$, $-S(O)_2R$, $-S(O)_2NR_2$, $-S(O)_2F$, $-S(O)R$, $-S(O)NR_2$, or $-S(O)(NR)R$. In some embodiments, each instance of R^{ZC} is independently $-NR_2$, $-N(R)C(O)OR$, $-N(R)C(O)R$, $-N(R)C(O)NR_2$, $-N(R)C(NR)NR_2$, $-N(R)S(O)_2NR_2$, or $-N(R)S(O)_2R$.

[0476] In some embodiments, each instance of R^{ZC} is independently $-S(O)_2R$, $-S(O)_2NR_2$, or $-S(O)_2F$. In some embodiments, each instance of R^{ZC} is independently $-S(O)R$, $-S(O)NR_2$, or $-S(O)(NR)R$. In some embodiments, each instance of R^{ZC} is independently $-SR$, $-S(O)_2R$, or $-S(O)R$. In some embodiments, each instance of R^{ZC} is independently $-S(O)_2NR_2$, $-S(O)NR_2$, or $-S(O)(NR)R$. In some embodiments, each instance of R^{ZC} is independently $-S(O)_2NR_2$ or $-S(O)NR_2$. In some embodiments, each instance of R^{ZC} is independently $-SR$, $-S(O)_2R$, $-S(O)_2NR_2$, or $-S(O)R$.

[0477] In some embodiments, each instance of R^{ZC} is independently $-N(R)C(O)OR$, $-N(R)C(O)R$, or $-N(R)C(O)NR_2$. In some embodiments, each instance of R^{ZC} is independently $-N(R)S(O)_2NR_2$ or $-N(R)S(O)_2R$. In some embodiments, each instance of R^{ZC} is independently $-N(R)C(O)OR$ or $-N(R)C(O)R$. In some embodiments, each instance of R^{ZC} is independently $-N(R)C(O)NR_2$ or $-N(R)S(O)_2NR_2$. In some embodiments, each instance of R^{ZC} is independently $-N(R)C(O)OR$, $-N(R)C(O)R$, or $-N(R)S(O)_2R$.

[0478] In some embodiments, each instance of R^{ZC} is independently $-NR_2$, $-N(R)C(O)OR$, $-N(R)C(O)R$, or $-N(R)C(O)NR_2$. In some embodiments, each instance of R^{ZC} is independently $-NR_2$, $-N(R)C(O)OR$, or $-N(R)C(O)R$. In some embodiments, each instance of R^{ZC} is independently $-NR_2$, $-N(R)C(O)OR$, $-N(R)C(O)R$, or $-N(R)S(O)_2R$.

[0479] In some embodiments, each instance of R^{ZC} is independently an optionally substituted C_{1-6} aliphatic. In some embodiments, each instance of R^{ZC} is independently an optionally substituted phenyl. In some embodiments, each instance of R^{ZC} is independently an

optionally substituted 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, each instance of R^{ZC} is independently an optionally substituted 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0480] In some embodiments, each instance of R^{ZC} is independently an optionally substituted C_{1-6} aliphatic or an optionally substituted 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, each instance of R^{ZC} is independently an optionally substituted phenyl or an optionally substituted 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0481] In some embodiments, each instance of R^{ZC} is independently an optionally substituted C_{1-6} aliphatic or an optionally substituted phenyl. In some embodiments, each instance of R^{ZC} is independently an optionally substituted 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or an optionally substituted 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0482] In some embodiments, each instance of R^{ZC} is independently an optionally substituted group selected from phenyl, a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0483] In some embodiments, each instance of R^{ZC} is independently a C_{1-6} aliphatic. In some embodiments, R^{ZC} is phenyl. In some embodiments, each instance of R^{ZC} is independently a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, each instance of R^{ZC} is independently a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0484] In some embodiments, each instance of R^{ZC} is independently a C_{1-6} aliphatic or a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some

embodiments, each instance of R^{ZC} is independently phenyl or a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0485] In some embodiments, each instance of R^{ZC} is independently a C_{1-6} aliphatic or phenyl. In some embodiments, each instance of R^{ZC} is independently a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0486] In some embodiments, each instance of R^{ZC} is independently phenyl, a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0487] In some embodiments, each instance of R^{ZC} is independently oxo, halogen, -CN, $-NO_2$, -OR, -SR, $-NR_2$, $-S(O)_2R$, $-S(O)_2NR_2$, $-S(O)_2F$, -S(O)R, $-S(O)NR_2$, -S(O)(NR)R, -C(O)R, -C(O)OR, $-C(O)NR_2$, -C(O)N(R)OR, -OC(O)R, $-OC(O)NR_2$, -N(R)C(O)OR, -N(R)C(O)R, $-N(R)C(O)NR_2$, $-N(R)C(NR)NR_2$, $-N(R)S(O)_2NR_2$, $-N(R)S(O)_2R$, $-P(O)R_2$, -P(O)(R)OR, $-B(OR)_2$, or optionally substituted C_{1-6} aliphatic.

[0488] In some embodiments, each instance of R^{ZC} is independently halogen, -CN, -OH, -O-(optionally substituted C_{1-3} aliphatic), or an optionally substituted C_{1-3} aliphatic. In some embodiments, each instance of R^{ZC} is independently halogen, -OH, -O-(C_{1-3} aliphatic), or C_{1-3} aliphatic, wherein each C_{1-3} aliphatic is optionally substituted with 1-3 halogen. In some embodiments, each instance of R^{ZC} is independently fluorine, chlorine, -OH, $-OCH_3$, $-OCF_3$, $-CH_3$, $-CHF_2$, or $-CF_3$. In some embodiments, each instance of R^{ZC} is independently fluorine or -OH.

[0489] In some embodiments, each instance of R^{ZC} is independently selected from the groups depicted in the compounds in Table 1.

[0490] As defined generally above, each instance of R^{LC} is independently oxo, deuterium, halogen, -CN, $-NO_2$, -OR, -SR, $-NR_2$, $-S(O)_2R$, $-S(O)_2NR_2$, $-S(O)_2F$, -S(O)R, $-S(O)NR_2$, -S(O)(NR)R, -C(O)R, -C(O)OR, $-C(O)NR_2$, -C(O)N(R)OR, -OC(O)R, $-OC(O)NR_2$, -N(R)C(O)OR, -N(R)C(O)R, $-N(R)C(O)NR_2$, $-N(R)C(NR)NR_2$, $-N(R)S(O)_2NR_2$,

$-N(R)S(O)_2R$, $-P(O)R_2$, $-P(O)(R)OR$, $-B(OR)_2$, or an optionally substituted group selected from C_{1-6} aliphatic, phenyl, a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0491] In some embodiments, each instance of R^{LC} is independently oxo, halogen, $-CN$, $-NO_2$, $-OR$, $-SR$, $-NR_2$, $-S(O)_2R$, $-S(O)_2NR_2$, $-S(O)_2F$, $-S(O)R$, $-S(O)NR_2$, $-S(O)(NR)R$, $-C(O)R$, $-C(O)OR$, $-C(O)NR_2$, $-C(O)N(R)OR$, $-OC(O)R$, $-OC(O)NR_2$, $-N(R)C(O)OR$, $-N(R)C(O)R$, $-N(R)C(O)NR_2$, $-N(R)C(NR)NR_2$, $-N(R)S(O)_2NR_2$, $-N(R)S(O)_2R$, $-P(O)R_2$, $-P(O)(R)OR$, $-B(OR)_2$, or an optionally substituted group selected from C_{1-6} aliphatic, phenyl, a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0492] In some embodiments, each instance of R^{LC} is independently oxo, halogen, $-CN$, $-NO_2$, $-OR$, $-SR$, $-NR_2$, $-S(O)_2R$, $-S(O)_2NR_2$, $-S(O)_2F$, $-S(O)R$, $-S(O)NR_2$, $-S(O)(NR)R$, $-C(O)R$, $-C(O)OR$, $-C(O)NR_2$, $-C(O)N(R)OR$, $-OC(O)R$, $-OC(O)NR_2$, $-N(R)C(O)OR$, $-N(R)C(O)R$, $-N(R)C(O)NR_2$, $-N(R)C(NR)NR_2$, $-N(R)S(O)_2NR_2$, $-N(R)S(O)_2R$, $-P(O)R_2$, $-P(O)(R)OR$, or $-B(OR)_2$. In some embodiments, each instance of R^{LC} is independently an optionally substituted group selected from C_{1-6} aliphatic, phenyl, a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0493] In some embodiments, R^{LC} is oxo. In some embodiments, R^{LC} is deuterium. In some embodiments, each instance of R^{LC} is independently halogen. In some embodiments, R^{LC} is $-CN$. In some embodiments, R^{LC} is $-NO_2$. In some embodiments, R^{LC} is $-OR$. In some embodiments, R^{LC} is $-SR$. In some embodiments, R^{LC} is $-NR_2$. In some embodiments, R^{LC} is $-S(O)_2R$. In some embodiments, R^{LC} is $-S(O)_2NR_2$. In some embodiments, R^{LC} is $-S(O)_2F$. In some embodiments, R^{LC} is $-S(O)R$. In some embodiments, R^{LC} is $-S(O)NR_2$. In some embodiments, R^{LC} is $-S(O)(NR)R$. In some embodiments, R^{LC} is $-C(O)R$. In some embodiments, R^{LC} is $-C(O)OR$. In some embodiments, R^{LC} is $-C(O)NR_2$. In some embodiments, R^{LC} is $-C(O)N(R)OR$. In some embodiments, R^{LC} is $-OC(O)R$. In some embodiments, R^{LC} is $-OC(O)NR_2$. In some embodiments, R^{LC} is $-N(R)C(O)OR$. In some

embodiments, R^{LC} is -N(R)C(O)R. In some embodiments, R^{LC} is -N(R)C(O)NR_2. In some embodiments, R^{LC} is -N(R)C(NR)NR_2. In some embodiments, R^{LC} is -N(R)S(O)$_2NR_2$. In some embodiments, R^{LC} is -N(R)S(O)$_2$R. In some embodiments, R^{LC} is -P(O)R_2. In some embodiments, R^{LC} is -P(O)(R)OR. In some embodiments, R^{LC} is -B(OR)$_2$.

[0494] In some embodiments, each instance of R^{LC} is independently halogen, -CN, -NO_2, -OR, -SR, -NR_2, -S(O)$_2$R, -S(O)$_2NR_2$, -S(O)$_2$F, -S(O)R, -S(O)NR_2, -S(O)(NR)R, -C(O)R, -C(O)OR, -C(O)NR_2, -C(O)N(R)OR, -OC(O)R, -OC(O)NR_2, -N(R)C(O)OR, -N(R)C(O)R, -N(R)C(O)NR_2, -N(R)C(NR)NR_2, -N(R)S(O)$_2NR_2$, -N(R)S(O)$_2$R, -P(O)R_2, -P(O)(R)OR, or -B(OR)$_2$.

[0495] In some embodiments, each instance of R^{LC} is independently halogen, -CN, or -NO_2. In some embodiments, each instance of R^{LC} is independently -OR, -SR, or -NR_2. In some embodiments, each instance of R^{LC} is independently -S(O)$_2$R, -S(O)$_2NR_2$, -S(O)$_2$F, -S(O)R, -S(O)NR_2, or -S(O)(NR)R. In some embodiments, each instance of R^{LC} is independently -C(O)R, -C(O)OR, -C(O)NR_2, or -C(O)N(R)OR. In some embodiments, each instance of R^{LC} is independently -OC(O)R or -OC(O)NR_2. In some embodiments, each instance of R^{LC} is independently -N(R)C(O)OR, -N(R)C(O)R, -N(R)C(O)NR_2, -N(R)C(NR)NR_2, -N(R)S(O)$_2NR_2$, or -N(R)S(O)$_2$R. In some embodiments, each instance of R^{LC} is independently -P(O)R_2 or -P(O)(R)OR.

[0496] In some embodiments, each instance of R^{LC} is independently -OR, -OC(O)R, or -OC(O)NR_2. In some embodiments, each instance of R^{LC} is independently -SR, -S(O)$_2$R, -S(O)$_2NR_2$, -S(O)$_2$F, -S(O)R, -S(O)NR_2, or -S(O)(NR)R. In some embodiments, each instance of R^{LC} is independently -NR_2, -N(R)C(O)OR, -N(R)C(O)R, -N(R)C(O)NR_2, -N(R)C(NR)NR_2, -N(R)S(O)$_2NR_2$, or -N(R)S(O)$_2$R.

[0497] In some embodiments, each instance of R^{LC} is independently -S(O)$_2$R, -S(O)$_2NR_2$, or -S(O)$_2$F. In some embodiments, each instance of R^{LC} is independently -S(O)R, -S(O)NR_2, or -S(O)(NR)R. In some embodiments, each instance of R^{LC} is independently -SR, -S(O)$_2$R, or -S(O)R. In some embodiments, each instance of R^{LC} is independently -S(O)$_2NR_2$, -S(O)NR_2, or -S(O)(NR)R. In some embodiments, each instance of R^{LC} is independently -S(O)$_2NR_2$ or -S(O)NR_2. In some embodiments, each instance of R^{LC} is independently -SR, -S(O)$_2$R, -S(O)$_2NR_2$, or -S(O)R.

[0498] In some embodiments, each instance of R^{LC} is independently -N(R)C(O)OR, -N(R)C(O)R, or -N(R)C(O)NR_2. In some embodiments, each instance of R^{LC} is

independently -N(R)S(O)$_2$NR$_2$ or -N(R)S(O)$_2$R. In some embodiments, each instance of R^{LC} is independently -N(R)C(O)OR or -N(R)C(O)R. In some embodiments, each instance of R^{LC} is independently -N(R)C(O)NR$_2$ or -N(R)S(O)$_2$NR$_2$. In some embodiments, each instance of R^{LC} is independently -N(R)C(O)OR, -N(R)C(O)R, or -N(R)S(O)$_2$R.

[0499] In some embodiments, each instance of R^{LC} is independently -NR$_2$, -N(R)C(O)OR, -N(R)C(O)R, or -N(R)C(O)NR$_2$. In some embodiments, each instance of R^{LC} is independently -NR$_2$, -N(R)C(O)OR, or -N(R)C(O)R. In some embodiments, each instance of R^{LC} is independently -NR$_2$, -N(R)C(O)OR, -N(R)C(O)R, or -N(R)S(O)$_2$R.

[0500] In some embodiments, each instance of R^{LC} is independently an optionally substituted C_{1-6} aliphatic. In some embodiments, each instance of R^{LC} is independently an optionally substituted phenyl. In some embodiments, each instance of R^{LC} is independently an optionally substituted 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, each instance of R^{LC} is independently an optionally substituted 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0501] In some embodiments, each instance of R^{LC} is independently an optionally substituted C_{1-6} aliphatic or an optionally substituted 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, each instance of R^{LC} is independently an optionally substituted phenyl or an optionally substituted 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0502] In some embodiments, each instance of R^{LC} is independently an optionally substituted C_{1-6} aliphatic or an optionally substituted phenyl. In some embodiments, each instance of R^{LC} is independently an optionally substituted 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or an optionally substituted 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0503] In some embodiments, each instance of R^{LC} is independently an optionally substituted group selected from phenyl, a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and

sulfur, and a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0504] In some embodiments, each instance of R^{LC} is independently a C_{1-6} aliphatic. In some embodiments, R^{LC} is phenyl. In some embodiments, each instance of R^{LC} is independently a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, each instance of R^{LC} is independently a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0505] In some embodiments, each instance of R^{LC} is independently a C_{1-6} aliphatic or a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, each instance of R^{LC} is independently phenyl or a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0506] In some embodiments, each instance of R^{LC} is independently a C_{1-6} aliphatic or phenyl. In some embodiments, each instance of R^{LC} is independently a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0507] In some embodiments, each instance of R^{LC} is independently phenyl, a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0508] In some embodiments, each instance of R^{LC} is independently selected from the groups depicted in the compounds in Table 1.

[0509] As defined generally above, each instance of R^{EEC} is independently oxo, deuterium, halogen, -CN, $-NO_2$, -OR, -SR, $-NR_2$, $-S(O)_2R$, $-S(O)_2NR_2$, $-S(O)_2F$, -S(O)R, $-S(O)NR_2$, -S(O)(NR)R, -C(O)R, -C(O)OR, $-C(O)NR_2$, -C(O)N(R)OR, -OC(O)R, $-OC(O)NR_2$, -N(R)C(O)OR, -N(R)C(O)R, $-N(R)C(O)NR_2$, $-N(R)C(NR)NR_2$, $-N(R)S(O)_2NR_2$, $-N(R)S(O)_2R$, $-P(O)R_2$, -P(O)(R)OR, $-B(OR)_2$, or an optionally substituted group selected

from C_{1-6} aliphatic, phenyl, a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0510] In some embodiments, each instance of R^{EEC} is independently oxo, deuterium, halogen, -CN, -NO_2, -OR, -SR, -NR_2, -$S(O)_2R$, -$S(O)_2NR_2$, -$S(O)_2F$, -S(O)R, -$S(O)NR_2$, -S(O)(NR)R, -C(O)R, -C(O)OR, -$C(O)NR_2$, -C(O)N(R)OR, -OC(O)R, -$OC(O)NR_2$, -N(R)C(O)OR, -N(R)C(O)R, -$N(R)C(O)NR_2$, -$N(R)C(NR)NR_2$, -$N(R)S(O)_2NR_2$, -$N(R)S(O)_2R$, -$P(O)R_2$, -P(O)(R)OR, or -$B(OR)_2$. In some embodiments, each instance of R^{EEC} is independently oxo, deuterium, halogen, -CN, -NO_2, -OR, -NR_2, -C(O)R, -C(O)OR, -$C(O)NR_2$, -OC(O)R, -N(R)C(O)R, or -$N(R)S(O)_2R$. In some embodiments, each instance of R^{EEC} is independently deuterium, halogen, -CN, -OR, or -NR_2. In some embodiments, each instance of R^{EEC} is independently deuterium or halogen. In some embodiments, each instance of R^{EEC} is independently halogen.

[0511] In some embodiments, each instance of R^{EEC} is independently an optionally substituted group selected from C_{1-6} aliphatic, phenyl, a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0512] In some embodiments, each instance of R^{EEC} is independently selected from the groups depicted in the compounds in Table 1.

[0513] As defined generally above, each instance of R^{Q1C} is independently oxo, deuterium, halogen, -CN, -NO_2, -OR, -SR, -NR_2, -$S(O)_2R$, -$S(O)_2NR_2$, -$S(O)_2F$, -S(O)R, -$S(O)NR_2$, -S(O)(NR)R, -C(O)R, -C(O)OR, -$C(O)NR_2$, -C(O)N(R)OR, -OC(O)R, -$OC(O)NR_2$, -N(R)C(O)OR, -N(R)C(O)R, -$N(R)C(O)NR_2$, -$N(R)C(NR)NR_2$, -$N(R)S(O)_2NR_2$, -$N(R)S(O)_2R$, -$P(O)R_2$, -P(O)(R)OR, -$B(OR)_2$, or an optionally substituted group selected from C_{1-6} aliphatic, phenyl, a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0514] In some embodiments, each instance of R^{Q1C} is independently oxo, halogen, -CN, -NO_2, -OR, -SR, -NR_2, -$S(O)_2R$, -$S(O)_2NR_2$, -$S(O)_2F$, -S(O)R, -$S(O)NR_2$,

-S(O)(NR)R, -C(O)R, -C(O)OR, -C(O)NR_2, -C(O)N(R)OR, -OC(O)R, -OC(O)NR_2, -N(R)C(O)OR, -N(R)C(O)R, -N(R)C(O)NR_2, -N(R)C(NR)NR_2, -N(R)$S(O)_2NR_2$, -N(R)$S(O)_2$R, -P(O)R_2, -P(O)(R)OR, -B$(OR)_2$, or an optionally substituted group selected from C_{1-6} aliphatic, phenyl, a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0515] In some embodiments, each instance of R^{Q1C} is independently oxo, halogen, -CN, -NO_2, -OR, -SR, -NR_2, -$S(O)_2$R, -$S(O)_2NR_2$, -$S(O)_2$F, -S(O)R, -S(O)NR_2, -S(O)(NR)R, -C(O)R, -C(O)OR, -C(O)NR_2, -C(O)N(R)OR, -OC(O)R, -OC(O)NR_2, -N(R)C(O)OR, -N(R)C(O)R, -N(R)C(O)NR_2, -N(R)C(NR)NR_2, -N(R)$S(O)_2NR_2$, -N(R)$S(O)_2$R, -P(O)R_2, -P(O)(R)OR, or -B$(OR)_2$. In some embodiments, each instance of R^{Q1C} is independently an optionally substituted group selected from C_{1-6} aliphatic, phenyl, a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0516] In some embodiments, R^{Q1C} is oxo. In some embodiments, R^{Q1C} is deuterium. In some embodiments, each instance of R^{Q1C} is independently halogen. In some embodiments, R^{Q1C} is -CN. In some embodiments, R^{Q1C} is -NO_2. In some embodiments, R^{Q1C} is -OR. In some embodiments, R^{Q1C} is -SR. In some embodiments, R^{Q1C} is -NR_2. In some embodiments, R^{Q1C} is -$S(O)_2$R. In some embodiments, R^{Q1C} is -$S(O)_2NR_2$. In some embodiments, R^{Q1C} is -$S(O)_2$F. In some embodiments, R^{Q1C} is -S(O)R. In some embodiments, R^{Q1C} is -S(O)NR_2. In some embodiments, R^{Q1C} is -S(O)(NR)R. In some embodiments, R^{Q1C} is -C(O)R. In some embodiments, R^{Q1C} is -C(O)OR. In some embodiments, R^{Q1C} is -C(O)NR_2. In some embodiments, R^{Q1C} is -C(O)N(R)OR. In some embodiments, R^{Q1C} is -OC(O)R. In some embodiments, R^{Q1C} is -OC(O)NR_2. In some embodiments, R^{Q1C} is -N(R)C(O)OR. In some embodiments, R^{Q1C} is -N(R)C(O)R. In some embodiments, R^{Q1C} is -N(R)C(O)NR_2. In some embodiments, R^{Q1C} is -N(R)C(NR)NR_2. In some embodiments, R^{Q1C} is -N(R)$S(O)_2NR_2$. In some embodiments, R^{Q1C} is -N(R)$S(O)_2$R. In some embodiments, R^{Q1C} is -P(O)R_2. In some embodiments, R^{Q1C} is -P(O)(R)OR. In some embodiments, R^{Q1C} is -B$(OR)_2$.

[0517] In some embodiments, each instance of R^{Q1C} is independently halogen, -CN, -NO_2, -OR, -SR, -NR_2, -$S(O)_2$R, -$S(O)_2NR_2$, -$S(O)_2$F, -S(O)R, -S(O)NR_2, -S(O)(NR)R, -C(O)R,

-C(O)OR, -C(O)NR_2, -C(O)N(R)OR, -OC(O)R, -OC(O)NR_2, -N(R)C(O)OR, -N(R)C(O)R, -N(R)C(O)NR_2, -N(R)C(NR)NR_2, -N(R)S(O)$_2$$NR_2$, -N(R)S(O)$_2$R, -P(O)$R_2$, -P(O)(R)OR, or -B(OR)$_2$.

[0518] In some embodiments, each instance of R^{Q1C} is independently halogen, -CN, or -NO_2. In some embodiments, each instance of R^{Q1C} is independently -OR, -SR, or -NR_2. In some embodiments, each instance of R^{Q1C} is independently -S(O)$_2$R, -S(O)$_2$$NR_2$, -S(O)$_2$F, -S(O)R, -S(O)$NR_2$, or -S(O)(NR)R. In some embodiments, each instance of R^{Q1C} is independently -C(O)R, -C(O)OR, -C(O)NR_2, or -C(O)N(R)OR. In some embodiments, each instance of R^{Q1C} is independently -OC(O)R or -OC(O)NR_2. In some embodiments, each instance of R^{Q1C} is independently -N(R)C(O)OR, -N(R)C(O)R, -N(R)C(O)NR_2, -N(R)C(NR)NR_2, -N(R)S(O)$_2$$NR_2$, or -N(R)S(O)$_2$R. In some embodiments, each instance of R^{Q1C} is independently -P(O)R_2 or -P(O)(R)OR.

[0519] In some embodiments, each instance of R^{Q1C} is independently -OR, -OC(O)R, or -OC(O)NR_2. In some embodiments, each instance of R^{Q1C} is independently -SR, -S(O)$_2$R, -S(O)$_2$$NR_2$, -S(O)$_2$F, -S(O)R, -S(O)$NR_2$, or -S(O)(NR)R. In some embodiments, each instance of R^{Q1C} is independently -NR_2, -N(R)C(O)OR, -N(R)C(O)R, -N(R)C(O)NR_2, -N(R)C(NR)NR_2, -N(R)S(O)$_2$$NR_2$, or -N(R)S(O)$_2$R.

[0520] In some embodiments, each instance of R^{Q1C} is independently -S(O)$_2$R, -S(O)$_2$$NR_2$, or -S(O)$_2$F. In some embodiments, each instance of R^{Q1C} is independently -S(O)R, -S(O)NR_2, or -S(O)(NR)R. In some embodiments, each instance of R^{Q1C} is independently -SR, -S(O)$_2$R, or -S(O)R. In some embodiments, each instance of R^{Q1C} is independently -S(O)$_2$$NR_2$, -S(O)$NR_2$, or -S(O)(NR)R. In some embodiments, each instance of R^{Q1C} is independently -S(O)$_2$$NR_2$ or -S(O)NR_2. In some embodiments, each instance of R^{Q1C} is independently -SR, -S(O)$_2$R, -S(O)$_2$$NR_2$, or -S(O)R.

[0521] In some embodiments, each instance of R^{Q1C} is independently -N(R)C(O)OR, -N(R)C(O)R, or -N(R)C(O)NR_2. In some embodiments, each instance of R^{Q1C} is independently -N(R)S(O)$_2$$NR_2$ or -N(R)S(O)$_2$R. In some embodiments, each instance of R^{Q1C} is independently -N(R)C(O)OR or -N(R)C(O)R. In some embodiments, each instance of R^{Q1C} is independently -N(R)C(O)NR_2 or -N(R)S(O)$_2$$NR_2$. In some embodiments, each instance of R^{Q1C} is independently -N(R)C(O)OR, -N(R)C(O)R, or -N(R)S(O)$_2$R.

[0522] In some embodiments, each instance of R^{Q1C} is independently -NR_2, -N(R)C(O)OR, -N(R)C(O)R, or -N(R)C(O)NR_2. In some embodiments, each instance of R^{Q1C} is

independently -NR_2, -N(R)C(O)OR, or -N(R)C(O)R. In some embodiments, each instance of R^{Q1C} is independently -NR_2, -N(R)C(O)OR, -N(R)C(O)R, or -N(R)$S(O)_2$R.

[0523] In some embodiments, each instance of R^{Q1C} is independently an optionally substituted C_{1-6} aliphatic. In some embodiments, each instance of R^{Q1C} is independently an optionally substituted phenyl. In some embodiments, each instance of R^{Q1C} is independently an optionally substituted 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, each instance of R^{Q1C} is independently an optionally substituted 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0524] In some embodiments, each instance of R^{Q1C} is independently an optionally substituted C_{1-6} aliphatic or an optionally substituted 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, each instance of R^{Q1C} is independently an optionally substituted phenyl or an optionally substituted 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0525] In some embodiments, each instance of R^{Q1C} is independently an optionally substituted C_{1-6} aliphatic or an optionally substituted phenyl. In some embodiments, each instance of R^{Q1C} is independently an optionally substituted 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or an optionally substituted 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0526] In some embodiments, each instance of R^{Q1C} is independently an optionally substituted group selected from phenyl, a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0527] In some embodiments, each instance of R^{Q1C} is independently a C_{1-6} aliphatic. In some embodiments, R^{Q1C} is phenyl. In some embodiments, each instance of R^{Q1C} is independently a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic

ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, each instance of R^{Q1C} is independently a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0528] In some embodiments, each instance of R^{Q1C} is independently a C_{1-6} aliphatic or a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, each instance of R^{Q1C} is independently phenyl or a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0529] In some embodiments, each instance of R^{Q1C} is independently a C_{1-6} aliphatic or phenyl. In some embodiments, each instance of R^{Q1C} is independently a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0530] In some embodiments, each instance of R^{Q1C} is independently phenyl, a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0531] In some embodiments, each instance of R^{Q1C} is independently selected from the groups depicted in the compounds in Table 1.

[0532] As defined generally above, each instance of R^{YZC} is independently oxo, deuterium, halogen, -CN, $-NO_2$, -OR, -SR, $-NR_2$, $-S(O)_2R$, $-S(O)_2NR_2$, $-S(O)_2F$, -S(O)R, $-S(O)NR_2$, -S(O)(NR)R, -C(O)R, -C(O)OR, $-C(O)NR_2$, -C(O)N(R)OR, -OC(O)R, $-OC(O)NR_2$, -N(R)C(O)OR, -N(R)C(O)R, $-N(R)C(O)NR_2$, $-N(R)C(NR)NR_2$, $-N(R)S(O)_2NR_2$, $-N(R)S(O)_2R$, $-P(O)R_2$, -P(O)(R)OR, $-B(OR)_2$, or an optionally substituted group selected from C_{1-6} aliphatic, phenyl, a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0533] In some embodiments, each instance of R^{YZC} is independently oxo, halogen, -CN, $-NO_2$, -OR, -SR, $-NR_2$, $-S(O)_2R$, $-S(O)_2NR_2$, $-S(O)_2F$, -S(O)R, $-S(O)NR_2$, -S(O)(NR)R, -C(O)R, -C(O)OR, $-C(O)NR_2$, -C(O)N(R)OR, -OC(O)R, $-OC(O)NR_2$, -N(R)C(O)OR, -N(R)C(O)R, $-N(R)C(O)NR_2$, $-N(R)C(NR)NR_2$, $-N(R)S(O)_2NR_2$, $-N(R)S(O)_2R$, $-P(O)R_2$, -P(O)(R)OR, $-B(OR)_2$, or an optionally substituted group selected from C_{1-6} aliphatic, phenyl, a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0534] In some embodiments, each instance of R^{YZC} is independently oxo, halogen, -CN, $-NO_2$, -OR, -SR, $-NR_2$, $-S(O)_2R$, $-S(O)_2NR_2$, $-S(O)_2F$, -S(O)R, $-S(O)NR_2$, -S(O)(NR)R, -C(O)R, -C(O)OR, $-C(O)NR_2$, -C(O)N(R)OR, -OC(O)R, $-OC(O)NR_2$, -N(R)C(O)OR, -N(R)C(O)R, $-N(R)C(O)NR_2$, $-N(R)C(NR)NR_2$, $-N(R)S(O)_2NR_2$, $-N(R)S(O)_2R$, $-P(O)R_2$, -P(O)(R)OR, or $-B(OR)_2$. In some embodiments, each instance of R^{YZC} is independently an optionally substituted group selected from C_{1-6} aliphatic, phenyl, a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0535] In some embodiments, R^{YZC} is oxo. In some embodiments, R^{YZC} is deuterium. In some embodiments, each instance of R^{YZC} is independently halogen. In some embodiments, R^{YZC} is -CN. In some embodiments, R^{YZC} is $-NO_2$. In some embodiments, R^{YZC} is -OR. In some embodiments, R^{YZC} is -SR. In some embodiments, R^{YZC} is $-NR_2$. In some embodiments, R^{YZC} is $-S(O)_2R$. In some embodiments, R^{YZC} is $-S(O)_2NR_2$. In some embodiments, R^{YZC} is $-S(O)_2F$. In some embodiments, R^{YZC} is -S(O)R. In some embodiments, R^{YZC} is $-S(O)NR_2$. In some embodiments, R^{YZC} is -S(O)(NR)R. In some embodiments, R^{YZC} is -C(O)R. In some embodiments, R^{YZC} is -C(O)OR. In some embodiments, R^{YZC} is $-C(O)NR_2$. In some embodiments, R^{YZC} is -C(O)N(R)OR. In some embodiments, R^{YZC} is -OC(O)R. In some embodiments, R^{YZC} is $-OC(O)NR_2$. In some embodiments, R^{YZC} is -N(R)C(O)OR. In some embodiments, R^{YZC} is -N(R)C(O)R. In some embodiments, R^{YZC} is $-N(R)C(O)NR_2$. In some embodiments, R^{YZC} is $-N(R)C(NR)NR_2$. In some embodiments, R^{YZC} is $-N(R)S(O)_2NR_2$. In some embodiments, R^{YZC} is $-N(R)S(O)_2R$. In some embodiments, R^{YZC} is $-P(O)R_2$. In some embodiments, R^{YZC} is -P(O)(R)OR. In some embodiments, R^{YZC} is $-B(OR)_2$.

[0536] In some embodiments, each instance of R^{YZC} is independently halogen, -CN, -NO_2, -OR, -SR, -NR_2, -$S(O)_2R$, -$S(O)_2NR_2$, -$S(O)_2F$, -S(O)R, -$S(O)NR_2$, -S(O)(NR)R, -C(O)R, -C(O)OR, -$C(O)NR_2$, -C(O)N(R)OR, -OC(O)R, -$OC(O)NR_2$, -N(R)C(O)OR, -N(R)C(O)R, -$N(R)C(O)NR_2$, -$N(R)C(NR)NR_2$, -$N(R)S(O)_2NR_2$, -$N(R)S(O)_2R$, -$P(O)R_2$, -P(O)(R)OR, or -$B(OR)_2$.

[0537] In some embodiments, each instance of R^{YZC} is independently halogen, -CN, or -NO_2. In some embodiments, each instance of R^{YZC} is independently -OR, -SR, or -NR_2. In some embodiments, each instance of R^{YZC} is independently -$S(O)_2R$, -$S(O)_2NR_2$, -$S(O)_2F$, -S(O)R, -$S(O)NR_2$, or -S(O)(NR)R. In some embodiments, each instance of R^{YZC} is independently -C(O)R, -C(O)OR, -$C(O)NR_2$, or -C(O)N(R)OR. In some embodiments, each instance of R^{YZC} is independently -OC(O)R or -$OC(O)NR_2$. In some embodiments, each instance of R^{YZC} is independently -N(R)C(O)OR, -N(R)C(O)R, -$N(R)C(O)NR_2$, -$N(R)C(NR)NR_2$, -$N(R)S(O)_2NR_2$, or -$N(R)S(O)_2R$. In some embodiments, each instance of R^{YZC} is independently -$P(O)R_2$ or -P(O)(R)OR.

[0538] In some embodiments, each instance of R^{YZC} is independently -OR, -OC(O)R, or -$OC(O)NR_2$. In some embodiments, each instance of R^{YZC} is independently -SR, -$S(O)_2R$, -$S(O)_2NR_2$, -$S(O)_2F$, -S(O)R, -$S(O)NR_2$, or -S(O)(NR)R. In some embodiments, each instance of R^{YZC} is independently -NR_2, -N(R)C(O)OR, -N(R)C(O)R, -$N(R)C(O)NR_2$, -$N(R)C(NR)NR_2$, -$N(R)S(O)_2NR_2$, or -$N(R)S(O)_2R$.

[0539] In some embodiments, each instance of R^{YZC} is independently -$S(O)_2R$, -$S(O)_2NR_2$, or -$S(O)_2F$. In some embodiments, each instance of R^{YZC} is independently -S(O)R, -$S(O)NR_2$, or -S(O)(NR)R. In some embodiments, each instance of R^{YZC} is independently -SR, -$S(O)_2R$, or -S(O)R. In some embodiments, each instance of R^{YZC} is independently -$S(O)_2NR_2$, -$S(O)NR_2$, or -S(O)(NR)R. In some embodiments, each instance of R^{YZC} is independently -$S(O)_2NR_2$ or -$S(O)NR_2$. In some embodiments, each instance of R^{YZC} is independently -SR, -$S(O)_2R$, -$S(O)_2NR_2$, or -S(O)R.

[0540] In some embodiments, each instance of R^{YZC} is independently -N(R)C(O)OR, -N(R)C(O)R, or -$N(R)C(O)NR_2$. In some embodiments, each instance of R^{YZC} is independently -$N(R)S(O)_2NR_2$ or -$N(R)S(O)_2R$. In some embodiments, each instance of R^{YZC} is independently -N(R)C(O)OR or -N(R)C(O)R. In some embodiments, each instance of R^{YZC} is independently -$N(R)C(O)NR_2$ or -$N(R)S(O)_2NR_2$. In some embodiments, each instance of R^{YZC} is independently -N(R)C(O)OR, -N(R)C(O)R, or -$N(R)S(O)_2R$.

[0541] In some embodiments, each instance of R^{YZC} is independently $-NR_2$, -N(R)C(O)OR, -N(R)C(O)R, or $-N(R)C(O)NR_2$. In some embodiments, each instance of R^{YZC} is independently $-NR_2$, -N(R)C(O)OR, or -N(R)C(O)R. In some embodiments, each instance of R^{YZC} is independently $-NR_2$, -N(R)C(O)OR, -N(R)C(O)R, or $-N(R)S(O)_2R$.

[0542] In some embodiments, each instance of R^{YZC} is independently an optionally substituted C_{1-6} aliphatic. In some embodiments, each instance of R^{YZC} is independently an optionally substituted phenyl. In some embodiments, each instance of R^{YZC} is independently an optionally substituted 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, each instance of R^{YZC} is independently an optionally substituted 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0543] In some embodiments, each instance of R^{YZC} is independently an optionally substituted C_{1-6} aliphatic or an optionally substituted 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, each instance of R^{YZC} is independently an optionally substituted phenyl or an optionally substituted 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0544] In some embodiments, each instance of R^{YZC} is independently an optionally substituted C_{1-6} aliphatic or an optionally substituted phenyl. In some embodiments, each instance of R^{YZC} is independently an optionally substituted 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or an optionally substituted 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0545] In some embodiments, each instance of R^{YZC} is independently an optionally substituted group selected from phenyl, a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0546] In some embodiments, each instance of R^{YZC} is independently a C_{1-6} aliphatic. In some embodiments, R^{YZC} is phenyl. In some embodiments, each instance of R^{YZC} is independently a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, each instance of R^{YZC} is independently a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0547] In some embodiments, each instance of R^{YZC} is independently a C_{1-6} aliphatic or a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, each instance of R^{YZC} is independently phenyl or a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0548] In some embodiments, each instance of R^{YZC} is independently a C_{1-6} aliphatic or phenyl. In some embodiments, each instance of R^{YZC} is independently a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0549] In some embodiments, each instance of R^{YZC} is independently phenyl, a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0550] In some embodiments, each instance of R^{YZC} is independently selected from the groups depicted in the compounds in Table 1.

[0551] As defined generally above, each instance of R is independently hydrogen, or an optionally substituted group selected from C_{1-6} aliphatic, phenyl, a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or two R groups on the same nitrogen are taken together with their intervening atoms to form a 4-7

membered saturated, partially unsaturated, or heteroaryl ring having 0-3 heteroatoms, in addition to the nitrogen, independently selected from nitrogen, oxygen, and sulfur.

[0552] In some embodiments, R is hydrogen or an optionally substituted group selected from C_{1-6} aliphatic, phenyl, a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, two R groups on the same nitrogen are taken together with their intervening atoms to form a 4-7 membered saturated, partially unsaturated, or heteroaryl ring having 0-3 heteroatoms, in addition to the nitrogen, independently selected from nitrogen, oxygen, and sulfur.

[0553] In some embodiments, R is hydrogen. In some embodiments, R is an optionally substituted group selected from C_{1-6} aliphatic, phenyl, a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, R is hydrogen, C_{1-6} aliphatic, phenyl, a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0554] In some embodiments, R is an optionally substituted C_{1-6} aliphatic. In some embodiments, R is an optionally substituted phenyl. In some embodiments, R is an optionally substituted 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, R is an optionally substituted 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0555] In some embodiments, R is an optionally substituted C_{1-6} aliphatic or an optionally substituted 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, R is an optionally substituted phenyl or an optionally substituted 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0556] In some embodiments, R is an optionally substituted C_{1-6} aliphatic or an optionally substituted phenyl. In some embodiments, R is an optionally substituted 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or an optionally substituted 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0557] In some embodiments, R is an optionally substituted group selected from phenyl, a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0558] In some embodiments, R is a C_{1-6} aliphatic. In some embodiments, R is phenyl. In some embodiments, R is a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, R is a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0559] In some embodiments, R is a C_{1-6} aliphatic or a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, R is phenyl or a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0560] In some embodiments, R is a C_{1-6} aliphatic or phenyl. In some embodiments, R is a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0561] In some embodiments, R is phenyl, a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0562] In some embodiments, two R groups on the same nitrogen are taken together with their intervening atoms to form a 4-7 membered saturated, partially unsaturated, or heteroaryl

ring having 1-3 heteroatoms, in addition to the nitrogen, independently selected from nitrogen, oxygen, and sulfur. In some embodiments, two R groups on the same nitrogen are taken together with their intervening atoms to form a 4-7 membered saturated, partially unsaturated, or heteroaryl ring having no additional heteroatoms other than said nitrogen.

[0563] In some embodiments, two R groups on the same nitrogen are taken together with their intervening atoms to form a 4-7 membered saturated ring having 0-3 heteroatoms, in addition to the nitrogen, independently selected from nitrogen, oxygen, and sulfur. In some embodiments, two R groups on the same nitrogen are taken together with their intervening atoms to form a 4-7 membered partially unsaturated ring having 0-3 heteroatoms, in addition to the nitrogen, independently selected from nitrogen, oxygen, and sulfur. In some embodiments, two R groups on the same nitrogen are taken together with their intervening atoms to form a 4-7 membered heteroaryl ring having 0-3 heteroatoms, in addition to the nitrogen, independently selected from nitrogen, oxygen, and sulfur.

[0564] In some embodiments, two R groups on the same nitrogen are taken together with their intervening atoms to form a 4-7 membered saturated ring having 1-3 heteroatoms, in addition to the nitrogen, independently selected from nitrogen, oxygen, and sulfur. In some embodiments, two R groups on the same nitrogen are taken together with their intervening atoms to form a 4-7 membered partially unsaturated ring having 1-3 heteroatoms, in addition to the nitrogen, independently selected from nitrogen, oxygen, and sulfur. In some embodiments, two R groups on the same nitrogen are taken together with their intervening atoms to form a 4-7 membered heteroaryl ring having 1-3 heteroatoms, in addition to the nitrogen, independently selected from nitrogen, oxygen, and sulfur.

[0565] In some embodiments, two R groups on the same nitrogen are taken together with their intervening atoms to form a 4-7 membered saturated ring having no additional heteroatoms other than said nitrogen. In some embodiments, two R groups on the same nitrogen are taken together with their intervening atoms to form a 4-7 membered partially unsaturated ring having no additional heteroatoms other than said nitrogen. In some embodiments, two R groups on the same nitrogen are taken together with their intervening atoms to form a 4-7 membered heteroaryl ring having no additional heteroatoms other than said nitrogen.

[0566] In some embodiments, R is selected from the groups depicted in the compounds in Table 1.

[0567] As defined generally above, n is 0, 1, 2, 3, or 4. In some embodiments, n is 0. In some embodiments, n is 1. In some embodiments, n is 2. In some embodiments, n is 3. In some embodiments, n is 4. In some embodiments, n is 0 or 1. In some embodiments, n is 0, 1, or 2. In some embodiments, n is 0, 1, 2, or 3. In some embodiments, n is 1 or 2. In some embodiments, n is 1, 2, or 3. In some embodiments, n is 1, 2, 3, or 4. In some embodiments, n is 2 or 3. In some embodiments, n is 2, 3, or 4. In some embodiments, n is 3 or 4. In some embodiments, n is selected from the values represented in the compounds in Table 1.

[0568] As defined generally above, p is 0, 1, 2, 3, or 4. In some embodiments, p is 0. In some embodiments, p is 1. In some embodiments, p is 2. In some embodiments, p is 3. In some embodiments, p is 4. In some embodiments, p is 0 or 1. In some embodiments, p is 0, 1, or 2. In some embodiments, p is 0, 1, 2, or 3. In some embodiments, p is 1 or 2. In some embodiments, p is 1, 2, or 3. In some embodiments, p is 1, 2, 3, or 4. In some embodiments, p is 2 or 3. In some embodiments, p is 2, 3, or 4. In some embodiments, p is 3 or 4. In some embodiments, p is selected from the values represented in the compounds in Table 1.

[0569] As defined generally above, q is 0, 1, 2, 3, or 4. In some embodiments, q is 0. In some embodiments, q is 1. In some embodiments, q is 2. In some embodiments, q is 3. In some embodiments, q is 4. In some embodiments, q is 0 or 1. In some embodiments, q is 0, 1, or 2. In some embodiments, q is 0, 1, 2, or 3. In some embodiments, q is 1 or 2. In some embodiments, q is 1, 2, or 3. In some embodiments, q is 1, 2, 3, or 4. In some embodiments, q is 2 or 3. In some embodiments, q is 2, 3, or 4. In some embodiments, q is 3 or 4. In some embodiments, q is selected from the values represented in the compounds in Table 1.

[0570] As defined generally above, r^1 is 0, 1, 2, 3, or 4. In some embodiments, r^1 is 0. In some embodiments, r^1 is 1. In some embodiments, r^1 is 2. In some embodiments, r^1 is 3. In some embodiments, r^1 is 4. In some embodiments, r^1 is 0 or 1. In some embodiments, r^1 is 0, 1, or 2. In some embodiments, r^1 is 0, 1, 2, or 3. In some embodiments, r^1 is 1 or 2. In some embodiments, r^1 is 1, 2, or 3. In some embodiments, r^1 is 1, 2, 3, or 4. In some embodiments, r^1 is 2 or 3. In some embodiments, r^1 is 2, 3, or 4. In some embodiments, r^1 is 3 or 4. In some embodiments, r^1 is selected from the values represented in the compounds in Table 1.

[0571] As defined generally above, r^2 is 0, 1, 2, 3, or 4. In some embodiments, r^2 is 0. In some embodiments, r^2 is 1. In some embodiments, r^2 is 2. In some embodiments, r^2 is 3. In some embodiments, r^2 is 4. In some embodiments, r^2 is 0 or 1. In some embodiments, r^2 is 0,

1, or 2. In some embodiments, r^2 is 0, 1, 2, or 3. In some embodiments, r^2 is 1 or 2. In some embodiments, r^2 is 1, 2, or 3. In some embodiments, r^2 is 1, 2, 3, or 4. In some embodiments, r^2 is 2 or 3. In some embodiments, r^2 is 2, 3, or 4. In some embodiments, r^2 is 3 or 4. In some embodiments, r^2 is selected from the values represented in the compounds in Table 1.

[0572] As defined generally above, r^3 is 0, 1, 2, 3, or 4. In some embodiments, r^3 is 0. In some embodiments, r^3 is 1. In some embodiments, r^3 is 2. In some embodiments, r^3 is 3. In some embodiments, r^3 is 4. In some embodiments, r^3 is 0 or 1. In some embodiments, r^3 is 0, 1, or 2. In some embodiments, r^3 is 0, 1, 2, or 3. In some embodiments, r^3 is 1 or 2. In some embodiments, r^3 is 1, 2, or 3. In some embodiments, r^3 is 1, 2, 3, or 4. In some embodiments, r^3 is 2 or 3. In some embodiments, r^3 is 2, 3, or 4. In some embodiments, r^3 is 3 or 4. In some embodiments, r^3 is selected from the values represented in the compounds in Table 1.

[0573] As defined generally above, r^4 is 0, 1, 2, 3, or 4. In some embodiments, r^4 is 0. In some embodiments, r^4 is 1. In some embodiments, r^4 is 2. In some embodiments, r^4 is 3. In some embodiments, r^4 is 4. In some embodiments, r^4 is 0 or 1. In some embodiments, r^4 is 0, 1, or 2. In some embodiments, r^4 is 0, 1, 2, or 3. In some embodiments, r^4 is 1 or 2. In some embodiments, r^4 is 1, 2, or 3. In some embodiments, r^4 is 1, 2, 3, or 4. In some embodiments, r^4 is 2 or 3. In some embodiments, r^4 is 2, 3, or 4. In some embodiments, r^4 is 3 or 4. In some embodiments, r^4 is selected from the values represented in the compounds in Table 1.

[0574] As defined generally above, r^5 is 0, 1, 2, 3, or 4. In some embodiments, r^5 is 0. In some embodiments, r^5 is 1. In some embodiments, r^5 is 2. In some embodiments, r^5 is 3. In some embodiments, r^5 is 4. In some embodiments, r^5 is 0 or 1. In some embodiments, r^5 is 0, 1, or 2. In some embodiments, r^5 is 0, 1, 2, or 3. In some embodiments, r^5 is 1 or 2. In some embodiments, r^5 is 1, 2, or 3. In some embodiments, r^5 is 1, 2, 3, or 4. In some embodiments, r^5 is 2 or 3. In some embodiments, r^5 is 2, 3, or 4. In some embodiments, r^5 is 3 or 4. In some embodiments, r^5 is selected from the values represented in the compounds in Table 1.


[0575] As defined generally above, r^6 is 0, 1, 2, 3, or 4. In some embodiments, r^6 is 0. In some embodiments, r^6 is 1. In some embodiments, r^6 is 2. In some embodiments, r^6 is 3. In some embodiments, r^6 is 4. In some embodiments, r^6 is 0 or 1. In some embodiments, r^6 is 0,

1, or 2. In some embodiments, r^6 is 0, 1, 2, or 3. In some embodiments, r^6 is 1 or 2. In some embodiments, r^6 is 1, 2, or 3. In some embodiments, r^6 is 1, 2, 3, or 4. In some embodiments, r^6 is 2 or 3. In some embodiments, r^6 is 2, 3, or 4. In some embodiments, r^6 is 3 or 4. In some embodiments, r^6 is selected from the values represented in the compounds in Table 1.

[0576] As defined generally above, r^7 is 0, 1, 2, 3, or 4. In some embodiments, r^7 is 0. In some embodiments, r^7 is 1. In some embodiments, r^7 is 2. In some embodiments, r^7 is 3. In some embodiments, r^7 is 4. In some embodiments, r^7 is 0 or 1. In some embodiments, r^7 is 0, 1, or 2. In some embodiments, r^7 is 0, 1, 2, or 3. In some embodiments, r^7 is 1 or 2. In some embodiments, r^7 is 1, 2, or 3. In some embodiments, r^7 is 1, 2, 3, or 4. In some embodiments, r^7 is 2 or 3. In some embodiments, r^7 is 2, 3, or 4. In some embodiments, r^7 is 3 or 4. In some embodiments, r^7 is selected from the values represented in the compounds in Table 1.

[0577] As defined generally above, r^8 is 0, 1, 2, 3, or 4. In some embodiments, r^8 is 0. In some embodiments, r^8 is 1. In some embodiments, r^8 is 2. In some embodiments, r^8 is 3. In some embodiments, r^8 is 4. In some embodiments, r^8 is 0 or 1. In some embodiments, r^8 is 0, 1, or 2. In some embodiments, r^8 is 0, 1, 2, or 3. In some embodiments, r^8 is 1 or 2. In some embodiments, r^8 is 1, 2, or 3. In some embodiments, r^8 is 1, 2, 3, or 4. In some embodiments, r^8 is 2 or 3. In some embodiments, r^8 is 2, 3, or 4. In some embodiments, r^8 is 3 or 4. In some embodiments, r^8 is selected from the values represented in the compounds in Table 1.


[0578] In some embodiments, the present invention provides a compound of formula I wherein E is -C(O)-, thereby forming a compound of formula II:



II

or a pharmaceutically acceptable salt thereof, wherein each of Q, R^1, R^2, X, Y, and Z is as defined in embodiments and classes and subclasses herein.


[0579] In some embodiments, the present invention provides a compound of formula II wherein Q is CH, thereby forming a compound of formula III:



III

or a pharmaceutically acceptable salt thereof, wherein each of R^1, R^2, X, Y, and Z is as defined in embodiments and classes and subclasses herein.


[0580] In some embodiments, the present invention provides a compound of formula II wherein Q is N, thereby forming a compound of formula IV:




IV

or a pharmaceutically acceptable salt thereof, wherein each of R^1, R^2, X, Y, and Z is as defined in embodiments and classes and subclasses herein.


[0581] In some embodiments, the present invention provides a compound of formula II wherein X, Y, or Z is CH, thereby forming a compound of formula V, VI, or VII:



V




VI



VII

or a pharmaceutically acceptable salt thereof, wherein each of R^1, R^2, Q, X, Y, and Z is as defined in embodiments and classes and subclasses herein.


[0582] In some embodiments, the present invention provides a compound of formula II wherein X, Y, or Z is N, thereby forming a compound of formula VIII, IX, or X:



VIII



IX




X

or a pharmaceutically acceptable salt thereof, wherein each of R^1, R^2, Q, X, Y, and Z is as defined in embodiments and classes and subclasses herein.


[0583] In some embodiments, the present invention provides a compound of formula III wherein X, Y, or Z is CH, thereby forming a compound of formula XI, XII, or XIII:



XI



XII



XIII

or a pharmaceutically acceptable salt thereof, wherein each of R^1, R^2, X, Y, and Z is as defined in embodiments and classes and subclasses herein.


[0584] In some embodiments, the present invention provides a compound of formula III wherein X, Y, or Z is N, thereby forming a compound of formula XIV, XV, or XVI:



XIV



XV




XVI

or a pharmaceutically acceptable salt thereof, wherein each of R^1, R^2, X, Y, and Z is as defined in embodiments and classes and subclasses herein.

[0585] In some embodiments, the present invention provides a compound of formulas XII, XIII, XV, and XVI wherein X is CH, thereby forming a compound of formula XVII, XVIII, XIX, or XX:




XVII



XVIII




XIX




XX

or a pharmaceutically acceptable salt thereof, wherein each of R^1, R^2, X, Y, and Z is as defined in embodiments and classes and subclasses herein.


[0586] In some embodiments, the present invention provides a compound of formula I wherein E is -OC(O)-, -N(R^E)C(O)-, or -C(R^E)$_2$C(O)-, thereby forming a compound of formula XXI, XXII, or XXIII, respectively:



XXI




XXII



XXIII

or a pharmaceutically acceptable salt thereof, wherein each of Q, R^1, R^2, R^E, X, Y, and Z is as defined in embodiments and classes and subclasses herein.


[0587] In some embodiments, the present invention provides a compound of formula XXI, XXII, or XXIII wherein Q is CH, thereby forming a compound of formula XXIV, XXV, or XXVI respectively:



XXIV




XXV



XXVI

or a pharmaceutically acceptable salt thereof, wherein each of R^1, R^2, R^E, X, Y, and Z is as defined in embodiments and classes and subclasses herein.


[0588] In some embodiments, the present invention provides a compound of formula III, XI, XII, XIII, XIV, XV, XVI, XVII, XVIII, XIX, XX, XXIV, XXV, or XXVI, having the depicted stereochemistry at Q when Q is CH, thereby forming a compound of formula XXVII, XXVIII, XXIX, XXX, XXXI, XXXII, XXXIII, XXXIV, XXXV, XXXVI, XXXVII, XXXVIII, XXXIX, or XXXX respectively:




XXVII



XXVIII



XXIX



XXX




XXXI




XXXII




XXXIII




XXXIV




XXXV




XXXVI




XXXVII



XXXVIII



XXXIX



XXXX

or a pharmaceutically acceptable salt thereof, wherein each of R^1, R^2, R^E, X, Y, and Z is as defined in embodiments and classes and subclasses herein.


[0589] In some embodiments, the present invention provides a compound of formula XXVIII:



XXVIII

or a pharmaceutically acceptable salt thereof, wherein each of R^1, R^2, Y, and Z is as defined in embodiments and classes and subclasses herein.


[0590] In some embodiments, the present invention provides a compound of formula XXXV:



XXXV

or a pharmaceutically acceptable salt thereof, wherein each of R^1, R^2, and Y is as defined in embodiments and classes and subclasses herein.

[0591] In some embodiments, the present invention provides a compound of formula XXXVII:



XXXVII

or a pharmaceutically acceptable salt thereof, wherein each of R^1, R^2, and Y is as defined in embodiments and classes and subclasses herein.

[0592] In some embodiments, the present invention provides a compound of formula I, II, III, IV, V, VI, VII, VIII, IX, X, XI, XII, XIII, XIV, XV, XVI, XVII, XVIII, XIX, XX, XXI, XXII, XXIII, XXIV, XXV, XXVI, XXVII, XXVIII, XXIX, XXX, XXXI, XXXII, XXXIII, XXXIV, XXXV, XXXVI, XXXVII, XXXVIII, XXXIX, or XXXX, wherein L^1 is a covalent bond, and R^2 is $-N(R)C(O)-R^{2A}$, $-N(R)-R^{2A}$, or $-R^{2A}$.

[0593] In some embodiments, the present invention provides a compound of formula I, II, III, IV, V, VI, VII, VIII, IX, X, XI, XII, XIII, XIV, XV, XVI, XVII, XVIII, XIX, XX, XXI, XXII, XXIII, XXIV, XXV, XXVI, XXVII, XXVIII, XXIX, XXX, XXXI, XXXII, XXXIII, XXXIV, XXXV, XXXVI, XXXVII, XXXVIII, XXXIX, or XXXX, wherein L^1 is a covalent bond, and R^2 is $-N(R)C(O)-R^{2A}$. In some embodiments, the present invention provides a compound of formula I, II, III, IV, V, VI, VII, VIII, IX, X, XI, XII, XIII, XIV, XV, XVI, XVII, XVIII, XIX, XX, XXI, XXII, XXIII, XXIV, XXV, XXVI, XXVII, XXVIII, XXIX, XXX, XXXI, XXXII, XXXIII, XXXIV, XXXV, XXXVI, XXXVII, XXXVIII, XXXIX, or XXXX, wherein L^1 is a covalent bond, and R^2 is $-N(R)-R^{2A}$. In some embodiments, the present invention provides a compound of formula I, II, III, IV, V, VI, VII, VIII, IX, X, XI, XII, XIII, XIV, XV, XVI, XVII, XVIII, XIX, XX, XXI, XXII, XXIII, XXIV, XXV, XXVI, XXVII, XXVIII, XXIX, XXX, XXXI, XXXII, XXXIII, XXXIV, XXXV, XXXVI, XXXVII, XXXVIII, XXXIX, or XXXX, wherein L^1 is a covalent bond, and R^2 is $-R^{2A}$.

[0594] In some embodiments, the present invention provides a compound of formula I, II, III, IV, V, VI, VII, VIII, IX, X, XI, XII, XIII, XIV, XV, XVI, XVII, XVIII, XIX, XX, XXI, XXII, XXIII, XXIV, XXV, XXVI, XXVII, XXVIII, XXIX, XXX, XXXI, XXXII, XXXIII, XXXIV, XXXV, XXXVI, XXXVII, XXXVIII, XXXIX, or XXXX, wherein L^1 is a covalent bond, and R^2 is $-N(H)C(O)-R^{2A}$, $-N(H)-R^{2A}$, or $-R^{2A}$. In some embodiments, the present invention provides a compound of formula I, II, III, IV, V, VI, VII, VIII, IX, X, XI, XII, XIII, XIV, XV, XVI, XVII, XVIII, XIX, XX, XXI, XXII, XXIII, XXIV, XXV, XXVI, XXVII, XXVIII, XXIX, XXX, XXXI, XXXII, XXXIII, XXXIV, XXXV, XXXVI, XXXVII, XXXVIII, XXXIX, or XXXX, wherein L^1 is a covalent bond, and R^2 is $-N(H)C(O)-R^{2A}$. In some embodiments, the present invention provides a compound of formula I, II, III, IV, V, VI, VII, VIII, IX, X, XI, XII, XIII, XIV, XV, XVI, XVII, XVIII, XIX, XX, XXI, XXII, XXIII, XXIV, XXV, XXVI, XXVII, XXVIII, XXIX, XXX, XXXI, XXXII, XXXIII,

XXXIV, XXXV, XXXVI, XXXVII, XXXVIII, XXXIX, or XXXX, wherein L^1 is a covalent bond, and R^2 is -N(H)-R^{2A}.

[0595] In some embodiments, the present invention provides a compound of formula I, II, III, IV, V, VI, VII, VIII, IX, X, XI, XII, XIII, XIV, XV, XVI, XVII, XVIII, XIX, XX, XXI, XXII, XXIII, XXIV, XXV, XXVI, XXVII, XXVIII, XXIX, XXX, XXXI, XXXII, XXXIII, XXXIV, XXXV, XXXVI, XXXVII, XXXVIII, XXXIX, or XXXX, wherein Y is C(R^{YA}), L^1 is a covalent bond, and R^2 is -N(R)C(O)-R^{2A}. In some embodiments, the present invention provides a compound of formula I, II, III, IV, V, VI, VII, VIII, IX, X, XI, XII, XIII, XIV, XV, XVI, XVII, XVIII, XIX, XX, XXI, XXII, XXIII, XXIV, XXV, XXVI, XXVII, XXVIII, XXIX, XXX, XXXI, XXXII, XXXIII, XXXIV, XXXV, XXXVI, XXXVII, XXXVIII, XXXIX, or XXXX, wherein Y is C(R^{YA}), L^1 is a covalent bond, and R^2 is -N(R)-R^{2A}. In some embodiments, the present invention provides a compound of formula I, II, III, IV, V, VI, VII, VIII, IX, X, XI, XII, XIII, XIV, XV, XVI, XVII, XVIII, XIX, XX, XXI, XXII, XXIII, XXIV, XXV, XXVI, XXVII, XXVIII, XXIX, XXX, XXXI, XXXII, XXXIII, XXXIV, XXXV, XXXVI, XXXVII, XXXVIII, XXXIX, or XXXX, wherein Y is C(R^{YA}), L^1 is a covalent bond, and R^2 is -R^{2A}.

[0596] In some embodiments, the present invention provides a compound of formula I, II, III, IV, V, VI, VII, VIII, IX, X, XI, XII, XIII, XIV, XV, XVI, XVII, XVIII, XIX, XX, XXI, XXII, XXIII, XXIV, XXV, XXVI, XXVII, XXVIII, XXIX, XXX, XXXI, XXXII, XXXIII, XXXIV, XXXV, XXXVI, XXXVII, XXXVIII, XXXIX, or XXXX, wherein Y is C(R^{YA}), L^1 is a covalent bond, and R^2 is -N(H)C(O)-R^{2A}, -N(H)-R^{2A}, or -R^{2A}. In some embodiments, the present invention provides a compound of formula I, II, III, IV, V, VI, VII, VIII, IX, X, XI, XII, XIII, XIV, XV, XVI, XVII, XVIII, XIX, XX, XXI, XXII, XXIII, XXIV, XXV, XXVI, XXVII, XXVIII, XXIX, XXX, XXXI, XXXII, XXXIII, XXXIV, XXXV, XXXVI, XXXVII, XXXVIII, XXXIX, or XXXX, wherein Y is C(R^{YA}), L^1 is a covalent bond, and R^2 is -N(H)C(O)-R^{2A}. In some embodiments, the present invention provides a compound of formula I, II, III, IV, V, VI, VII, VIII, IX, X, XI, XII, XIII, XIV, XV, XVI, XVII, XVIII, XIX, XX, XXI, XXII, XXIII, XXIV, XXV, XXVI, XXVII, XXVIII, XXIX, XXX, XXXI, XXXII, XXXIII, XXXIV, XXXV, XXXVI, XXXVII, XXXVIII, XXXIX, or XXXX, wherein Y is C(R^{YA}), L^1 is a covalent bond, and R^2 is -N(H)-R^{2A}.

[0597] In some embodiments, the present invention provides a compound of formula I, II, III, IV, V, VI, VII, VIII, IX, X, XI, XII, XIII, XIV, XV, XVI, XVII, XVIII, XIX, XX, XXI,

XXII, XXIII, XXIV, XXV, XXVI, XXVII, XXVIII, XXIX, XXX, XXXI, XXXII, XXXIII, XXXIV, XXXV, XXXVI, XXXVII, XXXVIII, XXXIX, or XXXX, wherein Y is $C(R^{YA})$.

[0598] In some embodiments, the present invention provides a compound of formula I, II, III, IV, V, VI, VII, VIII, IX, X, XI, XII, XIII, XIV, XV, XVI, XVII, XVIII, XIX, XX, XXI, XXII, XXIII, XXIV, XXV, XXVI, XXVII, XXVIII, XXIX, XXX, XXXI, XXXII, XXXIII, XXXIV, XXXV, XXXVI, XXXVII, XXXVIII, XXXIX, or XXXX, wherein L^1 is a covalent bond (i.e. R^1 is $-R^{1A}$).

[0599] In some embodiments, the present invention provides a compound of formula I, II, III, IV, V, VI, VII, VIII, IX, X, XI, XII, XIII, XIV, XV, XVI, XVII, XVIII, XIX, XX, XXI, XXII, XXIII, XXIV, XXV, XXVI, XXVII, XXVIII, XXIX, XXX, XXXI, XXXII, XXXIII, XXXIV, XXXV, XXXVI, XXXVII, XXXVIII, XXXIX, or XXXX, wherein R^2 is $-N(R)C(O)-R^{2A}$, $-N(R)-R^{2A}$, or $-R^{2A}$. In some embodiments, the present invention provides a compound of formula I, II, III, IV, V, VI, VII, VIII, IX, X, XI, XII, XIII, XIV, XV, XVI, XVII, XVIII, XIX, XX, XXI, XXII, XXIII, XXIV, XXV, XXVI, XXVII, XXVIII, XXIX, XXX, XXXI, XXXII, XXXIII, XXXIV, XXXV, XXXVI, XXXVII, XXXVIII, XXXIX, or XXXX, wherein R^2 is $-N(R)C(O)-R^{2A}$. In some embodiments, the present invention provides a compound of formula I, II, III, IV, V, VI, VII, VIII, IX, X, XI, XII, XIII, XIV, XV, XVI, XVII, XVIII, XIX, XX, XXI, XXII, XXIII, XXIV, XXV, XXVI, XXVII, XXVIII, XXIX, XXX, XXXI, XXXII, XXXIII, XXXIV, XXXV, XXXVI, XXXVII, XXXVIII, XXXIX, or XXXX, wherein R^2 is $-N(R)-R^{2A}$. In some embodiments, the present invention provides a compound of formula I, II, III, IV, V, VI, VII, VIII, IX, X, XI, XII, XIII, XIV, XV, XVI, XVII, XVIII, XIX, XX, XXI, XXII, XXIII, XXIV, XXV, XXVI, XXVII, XXVIII, XXIX, XXX, XXXI, XXXII, XXXIII, XXXIV, XXXV, XXXVI, XXXVII, XXXVIII, XXXIX, or XXXX, wherein R^2 is $-R^{2A}$.


[0600] In some embodiments, the present invention provides a compound of formula I, II, III, IV, V, VI, VII, VIII, IX, X, XI, XII, XIII, XIV, XV, XVI, XVII, XVIII, XIX, XX, XXI, XXII, XXIII, XXIV, XXV, XXVI, XXVII, XXVIII, XXIX, XXX, XXXI, XXXII, XXXIII, XXXIV, XXXV, XXXVI, XXXVII, XXXVIII, XXXIX, or XXXX, wherein R^2 is $-N(H)C(O)-R^{2A}$, $-N(H)-R^{2A}$, or $-R^{2A}$. In some embodiments, the present invention provides a compound of formula I, II, III, IV, V, VI, VII, VIII, IX, X, XI, XII, XIII, XIV, XV, XVI, XVII, XVIII, XIX, XX, XXI, XXII, XXIII, XXIV, XXV, XXVI, XXVII, XXVIII, XXIX, XXX, XXXI, XXXII, XXXIII, XXXIV, XXXV, XXXVI, XXXVII, XXXVIII, XXXIX, or XXXX, wherein R^2 is $-N(H)C(O)-R^{2A}$. In some embodiments, the present invention provides





a compound of formula I, II, III, IV, V, VI, VII, VIII, IX, X, XI, XII, XIII, XIV, XV, XVI, XVII, XVIII, XIX, XX, XXI, XXII, XXIII, XXIV, XXV, XXVI, XXVII, XXVIII, XXIX, XXX, XXXI, XXXII, XXXIII, XXXIV, XXXV, XXXVI, XXXVII, XXXVIII, XXXIX, or XXXX, wherein R^2 is -N(H)-R^{2A}.





[0601] In some embodiments, the present invention provides a compound of formula I, II, III, IV, V, VI, VII, VIII, IX, X, XI, XII, XIII, XIV, XV, XVI, XVII, XVIII, XIX, XX, XXI, XXII, XXIII, XXIV, XXV, XXVI, XXVII, XXVIII, XXIX, XXX, XXXI, XXXII, XXXIII, XXXIV, XXXV, XXXVI, XXXVII, XXXVIII, XXXIX, or XXXX, wherein Y is C(R^{YA}).






[0602] Examples of compounds of the present invention include those listed in the Tables and exemplification herein, or a pharmaceutically acceptable salt, stereoisomer, or mixture of stereoisomers thereof. In some embodiments, the present invention comprises a compound selected from those depicted in Table 1, below, or a pharmaceutically acceptable salt, stereoisomer, or mixture of stereoisomers thereof. In some embodiments, the present invention provides a compound set forth in Table 1, below, or a pharmaceutically acceptable salt thereof. In some embodiments, the present invention provides a compound set forth in Table 1, below.





Table 1. Representative Compounds of the Invention with Bioactivity Data.






Ex. No.	Structure	SMILES	^{1}H NMR	MS	ADP-Glo IC_{50}	MCF 10A IC_{50}
I-1		Cc1ccccc1C1NC(=O)c2cccc(NC(=O)c3csc4ccccc34)c12	1H NMR (400 MHz, DMSO-d6) 10.09 (s, 1H), 9.02 (s, 1H), 7.94-8.07 (m, 2H), 7.52 - 7.72 (m, 4H), 7.32-7.46 (m, 2H), 7.04-7.15 (m, 1H), 6.91-7.00 (m, 2H), 6.62 (br s, 1H), 6.02 (s, 1H), 2.07-2.30 (m, 3 H)	399.2	B	B







I-2		Cc1ccccc1C1NC(=O)c2cccc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	1H NMR (400 MHz, DMSO-d6) 10.37 (s, 1 H) 9.06 (s, 1H) 7.88 (br d, 8.59 Hz, 1 H) 7.65 - 7.69 (m, 1 H) 7.61 (t, 7.58 Hz, 1 H) 7.51 (d, 7.58 Hz, 1 H) 7.47 (br d, 8.84 Hz, 1 H) 7.33 (br d, 1.26 Hz, 1 H) 7.02 - 7.08 (m, 1 H) 6.91 - 7.00 (m, 2H) 5.89 (br s, 1 H) 1.93 - 2.35 (m, 3H)	429.3	B	
I-3		O=C(Nc1cccc2C(=O)NCc12)c1csc2ccccc12	1H NMR (400 MHz, DMSO-d6) 10.33 (s, 1 H) 8.53 - 8.67 (m, 2 H) 8.31 - 8.47 (m, 1 H) 8.09 (br d, 6.57 Hz, 1 H) 7.79 (br dd, 3.54, 2.53 Hz, 1 H) 7.36 - 7.63 (m, 4 H) 4.43 (s, 2 H)	309.17	E	
I-4		Cc1ccccc1[C@H]1NC(=O)c2cccc(NC(=O)c3csc4ccccc34)c12	1H NMR (400 MHz, DMSO-d6) 10.10 (s, 1 H) 9.04 (s, 1 H) 7.96 - 8.14 (m, 2 H) 7.54 - 7.74 (m, 4 H) 7.31 - 7.53 (m, 2 H) 6.89 - 7.16 (m, 3H) 6.46 - 6.83 (m, 1 H) 6.04 (s, 1 H) 2.19 (br s, 2 H)	399.23	C	
I-5		Cc1ccccc1[C@@H]1NC(=O)c2cccc(NC(=O)c3csc4ccccc34)c12	1H NMR (400 MHz, DMSO-d6) 10.10 (s, 1 H) 9.04 (s, 1 H) 7.99 - 8.09 (m, 2 H) 7.57 - 7.69 (m, 4 H) 7.37 - 7.45 (m, 2 H) 7.07 - 7.13 (m, 1H) 7.02 (d, 7.33 Hz, 1 H) 6.95 - 7.01 (m, 1 H) 6.53 - 6.72 (m, 1 H) 6.04 (s, 1 H) 2.05 - 2.32 (m, 3 H)	399.23	A	B





I-6		CNC(=O)c1cc2C(=O)NC(c2c(NC(=O)c2csc3ccccc23)c1)c1ccccc1C	1H NMR (400 MHz, DMSO-d6) 10.15-10.31 (m, 1H), 9.11-9.22 (m, 1H), 8.63-8.81 (m, 1H), 8.12-8.15 (m, 1H), 8.08-8.18 (m, 2H), 8.04-8.10 (m, 2H), 8.04-8.09 (m, 2H), 7.97-8.03 (m, 1H), 7.70 (s, 1H), 7.33-7.49 (m, 2H), 6.91-7.17 (m, 5H), 5.96-6.18 (m, 1H), 2.73-3.00 (m, 4H), 2.11-2.26 (m, 3H)	456	A	A
I-7		Cc1ccccc1C1NC(=O)c2nccc(NC(=O)c3csc4ccccc34)c12	^{1}H NMR (400 MHz, DMSO-d_6) δ 10.41 (s, 1H), 9.43 (s, 1H), 8.77 (d, J = 5.3 Hz, 1H), 8.01-8.06 (m, 1H), 7.98 (br d, J = 7.1 Hz, 1H), 7.75 (s, 1H), 7.64 (d, J = 5.3 Hz, 1H), 7.36-7.45 (m, 2H), 6.98-7.16 (m, 4H), 6.09 (s, 1H), 2.26 (br s, 3H).	400.3	B	
I-8		O=C(Nc1ccccc2C(=O)NC(c12)c1ccccc1)c1csc2ccccc12	1H NMR (400 MHz, DMSO-d6) 10.13 (s, 1 H), 9.06 (s, 1 H), 8.16-8.25 (m, 1 H), 8.03-8.11 (m, 1 H), 7.94 (s, 1 H), 7.55-7.71 (m, 3 H), 7.40-7.51 (m, 2 H), 7.12-7.26 (m, 3 H), 6.98-7.10 (m, 2 H), 5.86 (s, 1 H)	385.3	B	
I-9		Clc1ccccc1C1NC(=O)c2nccc(NC(=O)c3csc4ccccc34)c12	^{1}H NMR (400 MHz, DMSO-d_6) δ 10.50 (s, 1H), 9.46 (br s, 1H), 8.76 (d, J = 5.3 Hz, 1H), 8.08-8.14 (m, 1H), 8.02-8.07 (m, 1H), 7.95 (s, 1H), 7.58 (d, J = 5.3 Hz, 1H), 7.39-7.47 (m, 2H), 7.29-7.33 (m, 1H), 7.24 (td, J = 7.6, 1.6 Hz, 1H), 7.10-7.17 (m, 1H), 6.16-6.27 (m, 1H), 5.75 (s, 1H).	420.2	B	
I-10		Cc1ccccc1C1NC(=O)Oc2ccccc(Br)c12		318.2	E	





I-11		Cc1ccccc1C1NC(=O)c2cccc(NC(=O)c3cccc4OCCCc34)c12	1H NMR (400 MHz, DMSO-d6) 9.94 (s, 1H), 9.03 (s, 1H), 7.63-7.54 (m, 3H), 7.24-7.16 (m, 2H), 7.05 (td, 7.3, 1.4 Hz, 1H), 6.94 (t, 7.8 Hz, 1H), 6.76 (dd, 8.2, 1.2 Hz, 1H), 6.53 (br. s, 1H), 6.10 (dd, 7.5, 1.1 Hz, 1H), 6.05 (br. s, 1H), 4.14-3.99 (m, 2H), 2.30 (br. s, 3H), 2.17 (t, 5.9 Hz, 1H), 2.13 (t, 5.7 Hz, 1H), 1.80-1.62 (m, 2H).	399.3	E	
I-12		Cc1ccccc1C1NC(=O)c2cccc(NC(=O)c3cccc(c3F)C(F)(F)F)c12	1H NMR (400 MHz, DMSO-d6) 10.32 (s, 1H), 9.07 (s, 1H), 7.87 (t, 6.8 Hz, 1H), 7.68 (dd, 7.5, 1.1 Hz, 1H), 7.61 (t, 7.6 Hz, 1H), 7.52 (dd, 7.7, 0.8 Hz, 1H), 7.35 (t, 7.8 Hz, 1H), 7.19 (td, 7.4, 1.3 Hz, 1H), 7.13 (d, 6.9 Hz, 1H), 7.08-6.96 (m, 2H), 6.59 (br s, 1H), 5.96 (s, 1H), 2.43-2.08 (br s, 3H).	429.3	E	
I-13		Cc1ccccc1C1NC(=O)c2cccc(NC(=O)c3nsc4ccccc34)c12	1H NMR (400 MHz, DMSO-d6) 10.15 (s, 1H), 9.05 (s, 1H), 8.58 (d, 8.2 Hz, 1H), 8.29 (d, 8.2 Hz, 1H), 7.80 (dd, 7.6, 1.2 Hz, 1H), 7.74-7.55 (m, 4H), 7.06-6.93 (m, 2H), 6.89 (t, 13.3 Hz, 1H), 6.68 (br s, 1H), 6.12 (s, 1H), 2.40-2.10 (br s, 3H).	400.3	B	B
I-14		COc1cccc(n1)-c1cccc2C(=O)NC(c12)c1ccccc1C		331.4	E	
I-15		Fc1cccc(C2NC(=O)c3nccc(NC(=O)c4csc5ccccc45)c23)c1F	^{1}H NMR (400 MHz, DMSO-d_6) δ 10.61 (s, 1H), 9.49 (s, 1H), 8.76 (d, J = 5.1 Hz, 1H), 8.11-8.17 (m, 1H), 8.05-8.09 (m, 1H), 8.05 (s, 1H), 7.61 (d, J = 5.3	422.5	B	





			Hz, 1H), 7.41-7.48 (m, 2H), 7.25-7.34 (m, 1H), 6.98-7.05 (m, 1H), 6.82 (br t, *J* = 7.1 Hz, 1H), 6.11 (s, 1H).			
I-16		Cc1ccccc1C1NC(=O)c2cccc(NC(=O)C(F)(F)F)c12	1H NMR (400 MHz, DMSO-d6) 11.05 (s, 1H), 9.08 (s, 1H), 7.71 (d, 7.3 Hz, 1H), 7.61 (t, 7.6 Hz, 1H), 7.48 (dd, 7.8, 0.8 Hz, 1H), 7.24-7.08 (m, 2H), 7.10-6.95 (m, 1H), 6.53 (br. s, 1H), 5.86 (s, 1H), 2.27 (br. s, 3H).	335	E	
I-17		Cc1ccccc1C1NC(=O)c2cccc(NC(=O)c3nn(C)c4ccccc34)c12	1H NMR (400 MHz, DMSO-d6) 9.35 (s, 2H), 9.02 (s, 2H), 8.07 (d, 8.3 Hz, 2H), 7.98 (p, 3.8 Hz, 2H), 7.72 (d, 8.6 Hz, 2H), 7.60-7.52 (m, 4H), 7.45 (dd, 11.4, 4.0 Hz, 2H), 7.31-7.25 (m, 2H), 7.13-7.01 (m, 4H), 6.98 (t, 7.3 Hz, 2H), 6.87-6.49 (m, 2H), 6.12 (s, 2H), 4.08 (s, 6H), 2.30 (br s, 3H)	397	E	
I-18		COc1ccccc1C1NC(=O)c2cccc(NC(=O)c3csc4ccccc34)c12	1H NMR (400 MHz, DMSO-d6) 10.00 (br s, 1H), 8.86 (s, 1H), 8.38 (br s, 1H), 8.18 (dd, 6.1, 3.0 Hz, 1H), 8.01-8.07 (m, 1H), 7.98 (s, 1H), 7.59-7.65 (m, 2H), 7.50-7.58 (m, 1H), 7.35-7.44 (m, 2H), 7.07-7.21 (m, 1H), 6.80 (d, 8.3 Hz, 1H), 6.63-6.76 (m, 2H), 6.15 (s, 1H), 3.20-3.50 (m, 3H)	415.4	D	
I-19		Cc1ccccc1C1NC(=O)c2cccc(NC(=O)c3coc4ccc(F)cc34)c12		401.4	C	B





I-20		Cc1ccccc1C1NC(=O)c2cccc(NC(=O)c3coc4cc(F)ccc34)c12		401.5	C	
I-21		Cc1ccccc1C1NC(=O)c2cccc(NC(=O)c3noc4ccc(F)cc34)c12		402.5	D	
I-22		Fc1cccc([C@@H]2NC(=O)c3nccc(NC(=O)c4csc5ccccc45)c23)c1F	^{1}H NMR (400 MHz, DMSO-d_6) δ 10.60 (s, 1H), 9.49 (s, 1H), 8.77 (d, J = 5.4 Hz, 1H), 8.11-8.16 (m, 1H), 8.05-8.09 (m, 1H), 8.05 (s, 1H), 7.60 (d, J = 5.4 Hz, 1H), 7.41-7.48 (m, 2H), 7.25-7.34 (m, 1H), 6.98-7.05 (m, 1H), 6.82 (br t, J = 7.0 Hz, 1H), 6.12 (s, 1H).	422.4	C	B
I-23		Fc1cccc([C@H]2NC(=O)c3nccc(NC(=O)c4csc5ccccc45)c23)c1F	^{1}H NMR (400 MHz, DMSO-d_6) δ 10.60 (br s, 1H), 9.49 (s, 1H), 8.76 (br d, J = 5.4 Hz, 1H), 8.10-8.18 (m, 1H), 8.07 (br d, J = 3.9 Hz, 1H), 8.05 (s, 1H), 7.61 (br d, J = 5.1 Hz, 1H), 7.44 (dt, J = 4.6, 2.3 Hz, 2H), 7.24-7.35 (m, 1H), 6.97-7.06 (m, 1H), 6.82 (br t, J = 6.8 Hz, 1H), 6.12 (s, 1H).	422.4	D	
I-24		Cc1ccccc1C1NC(=O)c2cccc(NC(=O)c3n[nH]c4ccccc34)c12	1H NMR (400 MHz, DMSO-d6) 13.65 (s, 1H), 9.62 (s, 1H), 9.00 (s, 1H), 8.07 (d, 8.2 Hz, 1H), 7.87 (dd, 6.7, 2.2 Hz, 1H), 7.62-7.52 (m, 3H), 7.44-7.37 (m, 1H), 7.28-7.20 (m, 1H), 7.02-6.96 (m, 2H), 6.96-6.88 (br s, 1H), 6.66 (br s, 1H), 6.15 (s, 1H), 2.30 (br s,3H) (formate salt)	383.3	E	






I-25		[2H]C1(NC(=O)c2cccc(NC(=O)c3csc4ccccc34)c12)c1ccccc1C	1H NMR (400 MHz, DMSO-d6) 10.09 (s, 1H), 9.01 (s, 1H), 8.03-7.95 (m, 2H), 7.66-7.51 (m, 4H), 7.43-7.32 (m, 2H), 7.07 (td, 7.4, 1.4 Hz, 1H), 7.02-6.88 (m, 2H), 6.55 (br s, 1H), 2.16 (br s, 3H).	400.4	A	B
I-26		Cc1ccccc1C1NC(=O)c2cccc(NC(=O)c3csc4ccc(F)cc34)c12		417.5	B	B
I-27		Cc1ccccc1C1NC(=O)c2cccc(Nc3cc4ccccc4nn3)c12		367.4	E	
I-28		Cc1ccccc1C1NC(=O)c2cccc(Nc3nc(C)c4ccccc4n3)c12		381.4	E	
I-29		Cc1ccccc1C1NC(=O)c2cc(Br)cc(NC(=O)c3csc4ccccc34)c12	1H NMR (400 MHz, DMSO-d6) 10.12-10.35 (m, 1H), 9.13-9.35 (m, 1H), 7.96-8.08 (m, 2H), 7.80-7.87 (m, 1H), 7.71-7.78 (m, 1H), 7.56-7.68 (m, 1H), 7.32-7.49 (m, 2H), 7.05-7.14 (m, 1H), 6.88-7.05 (m, 2H), 6.44-6.82 (m, 1H), 5.91-6.11 (m, 1H), 1.82-2.38 (m, 3H)	477	A	A
I-30		Cc1ccccc1C1NC(=O)c2cccc(NC(=O)c3cc(=O)[nH]c4ccccc34)c12	1H NMR (400 MHz, DMSO-d6) 11.91 (s, 1H), 10.54 (s, 1H), 9.10 (s, 1H), 7.69 (dd, 7.5, 1.1 Hz, 1H), 7.62 (t, 7.6 Hz, 1H), 7.55-7.46 (m, 2H), 7.30 (d, 7.7 Hz, 1H), 7.27- 7.15 (m, 3H), 7.12-7.02 (m, 2H), 6.55 (br. s, 1H), 6.06 (s,	410	E	





			1H), 5.63 (d, 2.0 Hz, 1H), 2.33 (br. s, 3H).			
I-31		OC1(NC(=O)c2nccc(NC(=O)c3csc4ccccc34)c12)c1cccc(F)c1F		438.5	E	
I-32		Clc1ccccc1[C@H]1NC(=O)c2nccc(NC(=O)c3csc4ccccc34)c12	^{1}H NMR (400 MHz, DMSO-d_6) δ 10.50 (s, 1H), 9.46 (br s, 1H), 8.76 (d, J = 5.3 Hz, 1H), 8.08-8.14 (m, 1H), 8.02-8.07 (m, 1H), 7.95 (s, 1H), 7.58 (d, J = 5.3 Hz, 1H), 7.39-7.47 (m, 2H), 7.29-7.33 (m, 1H), 7.24 (td, J = 7.6, 1.6 Hz, 1H), 7.10-7.17 (m, 1H), 6.16-6.27 (m, 1H), 5.75 (s, 1H).	420.5	D	
I-33		Clc1ccccc1[C@@H]1NC(=O)c2nccc(NC(=O)c3csc4ccccc34)c12	^{1}H NMR (400 MHz, DMSO-d_6) δ 10.50 (s, 1H), 9.46 (br s, 1H), 8.76 (d, J = 5.3 Hz, 1H), 8.08-8.14 (m, 1H), 8.02-8.07 (m, 1H), 7.95 (s, 1H), 7.58 (d, J = 5.3 Hz, 1H), 7.39-7.47 (m, 2H), 7.29-7.33 (m, 1H), 7.24 (td, J = 7.6, 1.6 Hz, 1H), 7.10-7.17 (m, 1H), 6.16-6.27 (m, 1H), 5.75 (s, 1H).	420.4	B	B
I-34		Cc1ccccc1C1NC(=O)c2cc(N)cc(NC(=O)c3csc4ccccc34)c12	1H NMR (400 MHz, DMSO-d6) 9.70-9.85 (m, 1H), 8.68-8.80 (m, 1H), 8.42-8.56 (m, 1H), 7.93-8.08 (m, 2H), 7.55 (s, 1H), 7.31-7.45 (m, 2H), 6.87-7.11 (m, 3H), 6.73-6.85 (m, 2H), 6.56-6.73 (m, 1H), 5.76-5.90 (m, 1H), 5.38-5.61 (m, 2H), 2.03-2.24 (m, 2H)	414	A	B






I-35		COc1ccc(NC(=O)c2csc3cccc23)c2C(NC(=O)c12)c1ccccc1C		429.4	A	B
I-36		Cc1ccccc1C1NC(=O)c2cccc(NC(=O)c3csc4c(F)cccc34)c12	1H NMR (400 MHz, DMSO-d6) 10.20 (s, 1H), 9.02 (s, 1H), 7.85 (br d, 8.34 Hz, 1H), 7.76 (s, 1H), 7.64-7.67 (m, 1H), 7.60 (t, 7.45 Hz, 1H), 7.53-7.57 (m, 1H), 7.43 (dt, 5.43, 8.02 Hz, 1H), 7.30 (dd, 7.83, 10.10 Hz, 1H), 7.05-7.10 (m, 1H), 6.94-7.01 (m, 2H), 6.55-6.67 (m, 1H), 6.00 (s, 1H)	417.303	B	
I-37		Cc1ccccc1[C@H]1NC(=O)c2cccc(NC(=O)c3csc4c(F)ccc34)c12	1H NMR (400 MHz, DMSO-d6) 10.20 (s, 1H), 9.02 (s, 1H), 7.85 (br d, 8.34 Hz, 1H), 7.76 (s, 1H), 7.63-7.68 (m, 1H), 7.59-7.62 (m, 1H), 7.51-7.57 (m, 1H), 7.43 (dt, 5.43, 8.02 Hz, 1H), 7.28-7.34 (m, 1H), 7.04-7.11 (m, 1H), 6.93-7.02 (m, 2H), 6.55-6.66 (m, 1H), 6.00 (s, 1H), 2.07-2.25 (m, 3H)	417.25	E	
I-38		Cc1ccccc1[C@@H]1NC(=O)c2cccc(NC(=O)c3csc4c(F)cccc34)c12	1H NMR (400 MHz, DMSO-d6) 10.20 (s, 1H), 9.02 (s, 1H), 7.85 (br d, 8.34 Hz, 1H), 7.76 (s, 1H), 7.63-7.68 (m, 1H), 7.59-7.62 (m, 1H), 7.51-7.57 (m, 1H), 7.43 (dt, 5.43, 8.02 Hz, 1H), 7.28-7.34 (m, 1H), 7.04-7.11 (m, 1H), 6.93-7.02 (m, 2H), 6.55-6.66 (m, 1H), 6.00 (s, 1H), 2.07-2.25 (m, 3H)	417.25	B	B





I-39		CNc1cc2C(=O)NC(c2c(NC(=O)c2csc3ccccc23)c1)c1ccccc1C	1H NMR (400 MHz, DMSO-d6) 9.76-9.94 (m, 1H), 8.71-8.85 (m, 1H), 8.39-8.52 (m, 1H), 7.93-8.08 (m, 2H), 7.52-7.66 (m, 1H), 7.26-7.46 (m, 3H), 6.90-7.16 (m, 4H), 6.59-6.85 (m, 4H), 6.00-6.18 (m, 2H), 5.77-5.90 (m, 1H), 2.70-2.85 (m, 3H), 2.03-2.29 (m, 3H)	428	A	B
I-40		Cc1ccccc1C1NC(=O)c2cc(N)cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	1H NMR (400 MHz, DMSO-d6) 9.98-10.14 (m, 1H), 8.68-8.84 (m, 1H), 8.44-8.59 (m, 1H), 7.75-7.93 (m, 1H), 7.36-7.51 (m, 1H), 7.22-7.36 (m, 1H), 6.98-7.08 (m, 1H), 6.85-6.97 (m, 1H), 6.68-6.85 (m, 2H), 6.43-6.68 (m, 2H), 5.62-5.79 (m, 1H), 5.42-5.60 (m, 1H), 2.01-2.26 (m, 3H)	444	A	B
I-41		Cc1ccccc1C1NC(=O)c2cccc(NC(=O)c3noc4ccccc34)c12	1H NMR (400 MHz, DMSO-d6) 9.07 (s, 1H), 7.86 (d, 8.8 Hz, 2H), 7.77-7.67 (m, 2H), 7.63 (d, 4.3 Hz, 2H), 7.49 (t, 7.8 Hz, 1H), 7.03-6.84 (m, 3H), 6.61 (br s, 1H), 6.05 (s, 1H), 2.42-1.87 (m, 3H).	384.3	E	
I-42		COc1ccc2scc(C(=O)Nc3ccccc4C(=O)NC(c34)c3ccccc3C)c2c1	1H NMR (400 MHz, DMSO-d6) 10.08 (s, 1H), 9.04 (s, 1H), 7.89 (d, 8.9 Hz, 1H), 7.78 (d, 2.5 Hz, 1H), 7.66 (dd, 7.1, 1.5 Hz, 1H)., 7.62 (s, 1H), 7.60 (d, 7.2 Hz, 1H), 7.57 (dd, 7.7, 1.5 Hz, 1H), 7.12-7.03 (m, 2H), 7.03-6.90 (m, 2H), 6.61 (s, 1H), 6.03 (s, 1H), 3.79 (s, 3H), 2.18 (br s, 3H).	429.3	D	





I-43		Cc1ccccc1C1NC(=O)c2cccc(NC(=O)N3CCc4ccccc34)c12	1H NMR (400 MHz, DMSO-d6) 8.95 (s, 1H), 8.37 (s, 1H), 7.68 (d, 8.0 Hz, 1H), 7.60-7.50 (m, 2H), 7.47-7.35 (m, 1H), 7.19-7.06 (m, 3H), 7.02 (d, 7.3 Hz, 1H), 6.95 (t, 7.1 Hz, 1H), 6.88 (td, 7.4, 1.0 Hz, 1H), 6.54 (s, 1H), 5.88 (s, 1H), 3.68-3.50 (m, 1H), 3.01-2.80 (m, 3H), 2.07 (s, 3H).	384.3	A	B
I-44		Cc1ccccc1C1NC(=O)c2cccc(NC(=O)N3CC(=O)Nc4ccccc34)c12	1H NMR (400 MHz, DMSO-d6) 10.63 (s, 1H), 8.87 (s, 1H), 7.52 (dd, 7.4, 1.2 Hz, 1H), 7.47 (t, 7.5 Hz, 1H), 7.32 (dd, 7.6, 1.0 Hz, 1H), 7.19-7.06 (m, 3H), 7.01-6.94 (m, 1H), 6.90 (dd, 8.0, 1.4 Hz, 1H), 6.60 (t, 7.8 Hz, 1H), 5.91 (s, 1H), 5.84 (d, 7.3 Hz, 1H), 4.30 (d, 16.3 Hz, 1H), 3.75 (t, 12.4 Hz, 1H), 2.42-2.10 (m, 3H)	411.4	E	
I-45		Cc1ccccc1C1NC(=O)c2cccc(NC(=O)N3CC(C)(C)c4ccccc34)c12	1H NMR (400 MHz, DMSO-d6) 8.96 (s, 1H), 8.31 (s, 1H), 7.71 (d, 8.1 Hz, 1H), 7.56-7.51 (m, 2H), 7.50-7.44 (m, 1H), 7.19-7.07 (m, 3H), 7.03 (d, 7.4 Hz, 1H), 6.99-6.89 (m, 2H), 6.56 (br. s, 1H), 5.93 (s, 1H), 3.36 (d, 9.9 Hz, 1H), 2.78 (d, 9.8 Hz, 1H), 2.19 (br. s, 3H), 1.17 (s, 3H), 1.13 (s, 3H).	412.3	D	D
I-46		Cc1ccccc1C1NC(=O)c2cccc(NC(=O)c3csc4ncccc34)c12		400	B	D






I-47		Cc1ccccc1C1NC(=O)c2cccc(NC(=O)c3cnc4ccc(Cl)cn34)c12		417.2	E	
I-48		Cc1ccccc1C1NC(=O)c2cccc(NC(=O)c3cnn4ccc(Cl)cc34)c12		417.2	D	
I-49		Cc1ccccc1C1NC(=O)c2cccc(NC(=O)c3csc4ccccc34)c12	^{1}H NMR (400 MHz, DMSO-d_6) δ 10.13 (s, 1H), 9.03 (s, 1H), 8.18 (dd, J = 4.7, 1.4 Hz, 1H), 8.11-8.16 (m, 1H), 8.01-8.07 (m, 1H), 7.89 (s, 1H), 7.78-7.85 (m, 3H), 7.60-7.65 (m, 1H), 7.51-7.59 (m, 2H), 7.13 (dd, J = 7.7, 4.7 Hz, 1H), 6.18 (s, 1H), 2.17-2.26 (m, 3H)	400.4	D	
I-50		Cc1ccccc1C1NC(=O)c2cc(N)cc(NC(=O)c3nsc4ccccc34)c12	1H NMR (400 MHz, DMSO-d6) 9.6-9.9 (m, 1H), 8.7-8.9 (m, 1H), 8.4-8.6 (m, 1H), 8.2-8.3 (m, 1H), 7.6-7.8 (m, 1H), 7.5-7.6 (m, 1H), 7.1-7.2 (m, 1H), 6.9-7.0 (m, 3H), 6.7-6.8 (m, 1H), 6.5-6.7 (m, 1H), 5.8-6.0 (m, 1H), 5.4-5.6 (m, 2H), 2.1-2.4 (m, 3H)	415	A	A
I-51		Cc1ccccc1C1NC(=O)c2cc(NC3COC3)cc(NC(=O)c3csc4ccccc34)c12	1H NMR (400 MHz, DMSO-d6) 9.8-9.9 (m, 1H), 8.8-9.0 (m, 1H), 7.9-8.1 (m, 2H), 7.6-7.7 (m, 1H), 7.3-7.5 (m, 2H), 6.9-7.1 (m, 2H), 6.7-6.9 (m, 2H), 6.5-6.7 (m, 2H), 5.8-5.9 (m, 1H), 4.8-5.0 (m, 2H), 4.6-4.7 (m, 1H), 4.4-4.5 (m, 1H), 3.9-4.3 (m, 2H), 2.1-2.3 (m, 3H)	470	A	A





I-52		CC(=O)Nc1cc2C(=O)NC(c2c(NC(=O)c2csc3ccccc23)c1)c1ccccc1C	1H NMR (400 MHz, DMSO-d6) 10.2-10.4 (m, 1H), 10.0-10.2 (m, 1H), 8.9-9.1 (m, 1H), 8.0-8.1 (m, 1H), 7.9-8.0 (m, 1H), 7.8-7.9 (m, 1H), 7.5-7.7 (m, 2H), 7.3-7.5 (m, 1H), 6.9-7.2 (m, 1H), 6.5-6.8 (m, 1H), 5.9-6.0 (m, 1H), 2.3-2.4 (m, 1H), 2.1-2.2 (m, 1H), 2.1-2.1 (m, 1H), 2.1-2.2 (m, 6H)	456	A	A
I-53		CC(C)Nc1cc2C(=O)NC(c2c(NC(=O)c2csc3ccccc23)c1)c1ccccc1C	1H NMR (400 MHz, DMSO-d6) 9.8-9.9 (m, 1H), 8.7-8.8 (m, 1H), 8.2-8.4 (m, 1H), 7.9-8.1 (m, 3H), 7.6-7.8 (m, 3H), 7.3-7.5 (m, 2H), 6.9-7.2 (m, 2H), 6.5-6.7 (m, 1H), 5.7-6.0 (m, 2H), 2.1-2.3 (m, 3H), 1.0-1.2 (m, 6H)	456	A	A
I-54		Cc1ccccc1C1NC(=O)c2cc(Br)cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	1H NMR (400 MHz, DMSO-d6) 10.0-10.1 (m, 1H), 8.6-8.8 (m, 1H), 7.7-7.9 (m, 1H), 7.4-7.5 (m, 1H), 7.2-7.3 (m, 1H), 6.9-7.1 (m, 3H), 6.8-6.8 (m, 1H), 6.7-6.8 (m, 1H), 6.5-6.6 (m, 1H), 5.6-5.8 (m, 1H), 1.8-2.3 (m, 3H)	507	B	B
I-55		Cc1ccccc1C1NC(=O)c2cccc(NC(=O)N3CCCc4ccccc34)c12	1H NMR (400 MHz, DMSO-d6) 8.92 (s, 1H), 8.57 (s, 1H), 7.52-7.41 (m, 2H), 7.41-7.32 (m, 1H), 7.22-6.99 (m, 4H), 6.86 (td, 7.4, 1.2 Hz, 1H), 6.78 (t, 7.7 Hz, 1H), 6.47 (br s, 1H), 6.32 (d, 8.0 Hz, 1H), 5.90 (s, 1H), 3.44-3.35 (m, 1H), 3.15-3.06 (m, 1H), 2.67-2.49 (m, 2H), 2.40-2.07 (br s, 3H), 1.74-1.47 (m, 2H).	397.9	D	





I-56		Cc1ccccc1C1NC(=O)c2cc(NS(C)(=O)=O)cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	1H NMR (400 MHz, DMSO-d6) 10.2-10.5 (m, 1H), 8.8-9.1 (m, 1H), 8.3-8.5 (m, 1H), 7.7-7.9 (m, 1H), 7.4-7.5 (m, 1H), 7.3-7.4 (m, 1H), 7.2-7.3 (m, 1H), 7.0-7.1 (m, 1H), 6.9-7.0 (m, 2H), 6.6-6.7 (m, 2H), 5.7-5.9 (m, 1H), 2.8-3.1 (m, 3H), 2.1-2.3 (m, 3H)	522	B	
I-57		Clc1cccnc1C1NC(=O)c2cccc(NC(=O)c3csc4ccccc34)c12	^{1}H NMR (400 MHz, DMSO-d_6) δ 10.14 (s, 1H), 9.08 (s, 1H), 8.28 (dd, J = 1.52, 4.55 Hz, 1H), 8.17-8.24 (m, 1H), 7.98-8.06 (m, 2H), 7.72 (dd, J = 1.39, 8.21 Hz, 1H), 7.60-7.66 (m, 1H), 7.56 (t, J = 7.58 Hz, 1H), 7.47 (dd, J = 1.01, 7.58 Hz, 1H), 7.38-7.44 (m, 2H), 7.25 (dd, J = 4.55, 8.08 Hz, 1H), 6.30-6.57 (m, 1H).	420.3	D	
I-58		Cc1ccccc1C1NC(=O)c2cccc(NC(=O)c3coc4c(F)cc(F)cc34)c12		419.4	B	
I-59		Cc1ccccc1C1NC(=O)c2cccc(NC(=O)c3cc(F)cc(OC(F)F)c3)c12		427.4	D	
I-60		Cc1ccccc1C1NC(=O)c2cccc(NC(=O)N3CCNC(C3)C(F)(F)F)c12	1H NMR (400 MHz, DMSO-d6) 8.93 (d, 3.3 Hz, 1H), 8.56 (s, 1H), 8.47 (s, 1H), 7.52-7.45 (m, 2H), 7.32-7.24 (m, 1H), 7.21-7.11 (m, 2H), 7.07-6.97 (m, 1H), 6.47 (br s, 1H), 5.89 (s, 1H), 3.72-3.59 (m, 1H), 3.53 (d, 10.8 Hz, 1H), 3.20-3.40 (m., 2 H), 2.85-2.70 (m, 1H), 2.70-2.62	418.9	E	






			(m, 1H), 2.62-2.52 (m, 1H), 2.40-2.25 (m, 3H).			
I-61		Cc1ccccc1C1NC(=O)c2cccc(NC(=O)c3ccn4cccc34)c12	1H NMR (400 MHz, DMSO-d6) 9.24 (s, 1H), 8.97 (s, 1H), 8.36 (dt, 6.9, 1.1 Hz, 1H), 8.04 (d, 9.1 Hz, 1H), 7.68 (dd, 6.2, 2.7 Hz, 1H), 7.56 (s, 1H), 7.58-7.53 (m, 1H), 7.45 (d, 3.0 Hz, 1H), 7.05-7.00 (m, 2H), 6.99-6.96 (m, 1H), 6.92 (td, 7.4, 1.4 Hz, 1H), 6.89 (d, 3.1 Hz, 1H), 6.77 (td, 6.8, 1.3 Hz, 1H), 6.61 (br s, 1H), 6.15 (s, 1H), 2.22 (br s, 3H)	382.3	B	
I-62		Cc1ccccc1C1NC(=O)c2cccc(N)c12	1H NMR (400 MHz, DMSO-d6) 8.79 (s, 1H), 7.23 (t, 7.6 Hz, 1H), 7.21-7.19 (m, 2H), 7.09 (dt, 8.5, 4.3 Hz, 1H), 6.96 (dd, 7.4, 0.8 Hz, 1H), 6.79 (dd, 7.9, 0.8 Hz, 1H), 6.78 (br s, 1H), 5.68 (s, 1H), 4.62 (s, 2H), 2.35 (br s, 3H).	239.2	E	
I-63		Cc1ccccc1C1NC(=O)c2cccc(NC(=O)c3csc4ncncc34)c12	1H NMR (400 MHz, DMSO-d6) 10.53 (s, 1H), 9.63 (s, 1H), 9.19 (s, 1H), 9.13 (s, 1H), 8.91 (s, 1H), 8.25 (d, 5.8 Hz, 1H), 7.76-7.58 (m, 2H), 7.13 (d, 7.5 Hz, 1H), 7.04 (t, 7.5 Hz, 1H), 6.90 (t, 7.2 Hz, 1H), 6.54 (br s, 1H), 6.12 (s, 1H), 2.49-2.24 (br s, 3H).	400.46	E	
I-64		Cc1ccccc1-n1[nH]c(=O)c2cccc(N)c12	1H NMR (400 MHz, CDCl3) 8.03 (s, 1H), 7.43-7.37 (m, 1H), 7.36-7.33 (m, 1H), 7.29 (d, 3.5 Hz, 2H), 7.21 (dd, 7.9, 0.7 Hz, 1H), 6.96 (t, 7.5 Hz, 1H), 6.62 (dd, 7.4, 0.7 Hz, 1H), 2.19 (s, 3H).	239.9	D	






I-65		Cc1ccccc1[C@H]1NC(=O)c2cc(N)cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	1H NMR (400 MHz, DMSO-d6) 10.0-10.1 (m, 1H), 8.7-8.9 (m, 1H), 8.3-8.6 (m, 1H), 7.7-8.0 (m, 2H), 7.2-7.5 (m, 2H), 7.0-7.1 (m, 1H), 6.9-7.0 (m, 1H), 6.81 (s, 1H), 6.72 (br s, 1H), 6.6-6.7 (m, 1H), 5.6-5.7 (m, 1H), 5.4-5.6 (m, 1H), 2.1-2.3 (m, 3H)	444	D	
I-66		Cc1ccccc1[C@@H]1NC(=O)c2cc(N)cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	1H NMR (400 MHz, DMSO-d6) 10.0-10.1 (m, 1H), 8.7-8.9 (m, 1H), 8.3-8.6 (m, 1H), 7.7-8.0 (m, 2H), 7.2-7.5 (m, 2H), 7.0-7.1 (m, 1H), 6.9-7.0 (m, 1H), 6.81 (s, 1H), 6.72 (br s, 1H), 6.6-6.7 (m, 1H), 5.6-5.7 (m, 1H), 5.4-5.6 (m, 1H), 2.1-2.3 (m, 3H)	444	A	
I-67		Cc1ccccc1C1NC(=O)c2cccc(NC(=O)c3csc4cccc(F)c34)c12	1H NMR (400 MHz, DMSO-d6) 10.22 (s, 1H), 9.05 (s, 1H), 7.87 (d, 8.1 Hz, 1H), 7.64 (t, 7.4 Hz, 1H), 7.60 (d, 7.4 Hz, 1H), 7.54 (d, 7.4 Hz, 1H), 7.44 (td, 8.0, 4.8 Hz, 1H), 7.23 (dd, 9.3, 6.3 Hz, 2H), 7.18 (t, 6.0 Hz,1H), 7.08 (t, 7.5 Hz, 1H), 6.70 (br s, 1H), 6.65 (br s, 1H), 6.00 (s, 1H), 2.22 (br s, 3H).	417.2	D	
I-68		Cc1ccccc1-n1[nH]c(=O)c2cccc(NC(=O)c3csc4ccccc34)c12	1H NMR (400 MHz, DMSO-d6) 11.01 (s, 1H), 9.70 (s, 1H), 8.23-8.12 (m, 1H), 8.02-7.93 (m, 1H), 7.70 (dd, 8.0, 0.9 Hz,1H), 7.59 (s, 1H), 7.44-7.34 (m, 2H), 7.31 (d, 7.1 Hz, 1H), 7.18-7.11 (m, 2H), 7.09-7.04 (m, 1H), 7.03-6.93 (m, 2H), 2.06 (s, 3H).	400.2	C	





I-69		Cc1ccccc1C1NC(=O)c2cccc(NC(=O)c3cc(Cl)n4ccccc34)c12	1H NMR (400 MHz, DMSO-d6) 9.43 (s, 1H), 8.98 (s, 1H), 8.24 (d, 6.9 Hz, 1H), 8.14 (d, 8.9 Hz, 1H), 7.64-7.54 (m, 3H), 7.15 (dd, 9.0, 6.6 Hz, 1H), 7.05-6.89 (m, 5H), 6.60 (br s, 1H), 6.11 (s, 1H), 2.20 (br s, 3H).	416.2	B	
I-70		FC(F)(F)Oc1ccccc1C1NC(=O)c2nccc(NC(=O)c3csc4ccccc34)c12	1H NMR(400 MHz, CD3CN) 8.75 (d, 5.3 Hz, 1H), 8.53 (s, 1H), 8.27-8.21 (m, 1H), 7.99-7.93 (m, 1H), 7.72 (d, 5.4 Hz, 1H), 7.66 (s, 1H), 7.50-7.42 (m, 3H), 7.38-7.32 (m, 1H), 7.27-7.18 (m, 2H), 7.15 (td, 7.6, 1.2 Hz, 1H), 6.11 (s, 1H).	470.2	D	
I-71		Fc1ccc(F)c(c1)C1NC(=O)c2nccc(NC(=O)c3csc4ccccc34)c12	1H NMR (400 MHz, CD3CN) 8.76 (dd, 5.2, 0.5 Hz, 1H), 8.70 (s, 1H), 8.29-8.26 (m, 1H), 7.99-7.96 (m, 1H), 7.81 (s, 1H), 7.64 (d, 5.3 Hz, 1H), 7.51-7.45 (m, 3H), 7.01-6.96 (m, 2H), 6.85-6.79 (m, 1H), 6.09 (s, 1H).	422.2	C	
I-72		Cc1ccccc1[C@@H]1NC(=O)c2cccc(NC(=O)c3nsc4ccccc34)c12	1H NMR (400 MHz, DMSO-d6) 10.15 (s, 1H), 9.05 (s, 1H), 8.58 (d, 8.2 Hz, 1H), 8.29 (d, 8.2 Hz, 1H), 7.80 (dd, 7.6, 1.2 Hz, 1H), 7.74-7.55 (m, 4H), 7.06-6.93 (m, 2H), 6.89 (t, 13.3 Hz, 1H), 6.68 (br s, 1H), 6.12 (s, 1H), 2.40-2.10 (br s, 3H).	400.2	A	
I-73		Cc1ccccc1[C@H]1NC(=O)c2cccc(NC(=O)c3nsc4ccccc34)c12	1H NMR (400 MHz, DMSO-d6) 10.15 (s, 1H), 9.05 (s, 1H), 8.58 (d, 8.2 Hz, 1H), 8.29 (d, 8.2 Hz, 1H), 7.80 (dd, 7.6, 1.2 Hz, 1H), 7.74-7.55 (m, 4H), 7.06-6.93 (m, 2H), 6.89 (t, 13.3 Hz, 1H), 6.68 (br s, 1H), 6.12 (s, 1H), 2.40-2.10 (br s, 3H).	400.2	C	





I-74		Cc1ccccc1C1NC(=O)c2cccc(NC(=O)c3csc4ccncc34)c12	1H NMR (400 MHz, DMSO-d6) 10.27 (s, 1H), 9.29 (d, 0.7 Hz, 1H), 9.04 (s, 1H), 8.46 (d, 5.6 Hz, 1H), 8.10 (dd, 5.6, 1.0 Hz, 1H), 7.85 (s, 1H), 7.68 (dd, 7.4, 1.2 Hz, 1H), 7.62 (t, 7.5 Hz, 1H), 7.54 (dd, 7.7, 1.2 Hz, 1H), 7.07-7.00 (m, 1H), 6.95 (dt, 11.5, 5.2 Hz, 2H), 6.62 (br s, 1H), 6.01 (s, 1H), 2.06 (m, 3H)+89% pure by LC	400.3	D	
I-75		CNC(=O)c1cc2C(=O)N[C@@H](c2c(NC(=O)c2csc3ccccc23)c1)c1ccccc1C	1H NMR (400 MHz, DMSO-d6) δ 10.24 (s, 1H) 9.17 (s, 1H) 8.76 (q, J=4.21 Hz, 1H) 8.15 (d, J=1.52 Hz, 1H) 8.06 - 8.10 (m, 2H) 8.01 - 8.05 (m, 1H) 7.71 (s, 1H) 7.36 - 7.48 (m, 2H) 7.08 - 7.13 (m, 1H) 6.96 - 7.05 (m, 2H) 6.08 (s, 1H) 2.84 (d, J=4.55 Hz, 3H) 1.99 - 2.34 (m, 2H)	456.1	D	
I-76		CNC(=O)c1cc2C(=O)N[C@H](c2c(NC(=O)c2csc3ccccc23)c1)c1ccccc1C	1H NMR (400 MHz, DMSO-d6) δ 10.24 (s, 1H) 9.17 (s, 1H) 8.76 (q, J=4.21 Hz, 1H) 8.15 (d, J=1.52 Hz, 1H) 8.06 - 8.10 (m, 2H) 8.01 - 8.05 (m, 1H) 7.71 (s, 1H) 7.36 - 7.48 (m, 2H) 7.08 - 7.13 (m, 1H) 6.96 - 7.05 (m, 2H) 6.08 (s, 1H) 2.84 (d, J=4.55 Hz, 3H) 1.99 - 2.34 (m, 2H)	456.1	A	A
I-77		CNc1cc(Nc2csc3ccccc23)cc2C(NC(=O)c12)c1ccccc1C	1H NMR(400 MHz, DMSO-d6) 8.35 (s, 1H), 8.15 (s, 1H), 7.93-7.85 (m, 1H), 7.82-7.76 (m, 1H), 7.37-7.29 (m, 2H), 7.19 (s, 1H), 7.16-7.07 (m, 3H), 6.97 (d, 7.0 Hz, 1H), 6.51 (q, 5.1 Hz, 1H), 6.17 (d, 1.5 Hz, 1H), 6.02 (s, 1H), 5.64 (s, 1H), 2.74	400.3	D	






			(d, 5.1 Hz, 3H), 2.33 (s, 3H).			
I-78		COc1ccc c2scc(C(=O)Nc3c ccc4C(= O)NC(c3 4)c3cccc c3C)c12	1H NMR (400 MHz, DMSO-d6) 9.96 (s, 1H), 9.04 (s, 1H), 7.66-7.58 (m, 2H), 7.55 (ddd, 5.2, 4.5, 1.1 Hz, 2H), 7.36 (t, 8.0 Hz, 1H), 7.28-7.18 (m, 2H), 7.10 (t, 7.1 Hz, 1H), 6.94 (d, 7.6 Hz, 1H), 6.67 (s, 1H), 6.44 (s, 1H), 6.04 (s, 1H), 3.81 (s, 3H), 2.41-2.00 (m, 3H).	429.3	E	
I-79		COc1ccc 2c(csc2c 1)C(=O) Nc1cccc2 C(=O)N C(c12)c1 ccccc1C	1H NMR (400 MHz, DMSO-d6) 10.04 (s, 1H), 9.03 (s, 1H), 7.92 (d, 8.9 Hz, 1H), 7.65 (dd, 6.5, 2.2 Hz, 1H), 7.61 (d, 7.7 Hz, 1H), 7.57 (m,2H), 7.48 (s, 1H), 7.09 (td, 7.4, 1.3 Hz, 1H), 6.98 (m, 3H), 6.60 (br s, 1H), 6.03 (s, 1H), 3.82 (s, 3H), 2.34-1.92 (m, 3H).	429.3	E	
I-80		Cc1ccccc 1C1(C)N C(=O)c2 cccc(NC(=O)c3csc 4ccccc34)c12	1H NMR (400 MHz, DMSO-d6) 8.96 (s, 1H), 8.88 (s, 1H), 8.11-8.05 (m, 1H), 8.05-7.99 (m, 1H), 7.73 (dd, 7.8, 0.7 Hz, 1H), 7.71-7.65 (m, 3H), 7.58 (t, 7.6 Hz, 1H), 7.43-7.37 (m, 2H), 7.12-7.05 (m, 2H), 7.05-7.00 (m, 1H), 1.98 (s, 3H), 1.63 (s, 3H).	413.3	E	
I-81		Cc1ccccc 1C1NC(= O)c2cccc (NC(=O) c3coc4c(F)cc(Cl)c c34)c12	1H NMR (400 MHz, DMSO-d6) 10.20 (s, 1H), 9.05 (s, 1H), 8.28 (s, 1H), 7.68 (dd, 7.5, 1.1 Hz, 1H), 7.62 (t, 7.6 Hz, 1H), 7.57 (dd, 10.6, 1.9 Hz, 1H), 7.49 (m, 2H), 7.04 (td, 7.5, 1.3 Hz, 1H), 6.94 (dd, 12.8, 6.9 Hz, 2H), 6.60 (br s, 1H), 5.96 (s, 1H), 2.16 (br s, 3H).	435.2	A	





I-82		CN1C(c2c(cccc2NC(=O)c2csc3ccccc23)C1=O)c1ccccc1C	1H NMR (400 MHz, DMSO-d6) 10.18 (s, 1H), 10.10 (s, 0.62H), 8.31-8.16 (m, 0.65H), 8.13-7.97 (m, 13.1, 7.0, 2.5 Hz, 3H), 7.78 (s, 0.64 H), 7.76 (s, 1H), 7.68 (td, 7.2, 0.9 Hz, 1.78H), 7.64-7.55 (m, 1.8H), 7.51 (d, 7.0 Hz, 0.67H), 7.49-7.35 (m, 5H), 7.21-6.94 (m, 5H), 6.83 (t, 7.5 Hz, 0.65 H), 6.29 (dd, 7.7, 1.2 Hz, 1H), 6.00 (s, 1H), 5.78 (s, 0.65H), 2.77 (s, 1.84H), 2.74 (s, 3H), 2.32 (s, 3H), 1.39 (s, 1.87H).	413.3	E	
I-83		Fc1ccc(Cl)c(c1)C1NC(=O)c2cccc(NC(=O)c3nsc4ccccc34)c12	^{1}H NMR (400 MHz, DMSO-d_6) δ 10.38 (br s, 1H), 9.12 (br s, 1H), 8.63 (d, J = 8.08 Hz, 1H), 8.30 (d, J = 8.34 Hz, 1H), 7.53-7.82 (m, 6H), 7.16-7.31 (m, 1H), 6.92-7.06 (m, 1H), 6.07-6.29 (m, 1H).	438.3	A	A
I-84		Fc1cccc(F)c1C1NC(=O)c2cccc(NC(=O)c3nsc4ccccc34)c12	^{1}H NMR (400 MHz, DMSO-d_6) δ 10.49 (s, 1H), 9.01 (s, 1H), 8.64 (d, J =8.1 Hz, 1H), 8.30 (d, J =8.3 Hz, 1H), 7.50-7.76 (m, 5H), 7.18 (tt, J =8.3, 6.6 Hz, 1H), 6.78 (br t, J =7.8 Hz, 2H), 6.21 (s, 1H).	422.3	D	
I-85		Cn1ncc(C2NC(=O)c3cccc(NC(=O)c4nsc5ccccc45)c23)c1C(F)(F)F	^{1}H NMR (400 MHz, DMSO-d_6) δ 10.45 (s, 1H), 9.08 (s, 1H), 8.61 (d, J =8.1 Hz, 1H), 8.16-8.39 (m, 1H), 7.47-7.81 (m, 5H), 7.01 (s, 1H), 6.07 (s, 1H), 3.69 (d, J =0.8 Hz, 3H).	458.4	D	
I-86		Cc1ccccc1C1NC(=O)c2cccc(NC(=O)c3c[nH]c(=O)c(F)c3)c12	1H NMR (400 MHz, DMSO-d6) 12.48 (br s, 1H), 9.85 (s, 1H), 9.00 (s, 1H), 7.50-7.70 (m, 2H), 7.26-7.47 (m, 3H), 6.88-7.14 (m, 3H), 6.53 (br d, 3.90 Hz, 1H),	378.28	E	





			5.84 (br s, 1H), 1.86-2.35 (m, 3H)			
I-87		Cc1ccccc1C1NC(=O)c2cc(CNC(=O)OC(C)(C)C)cc(NC(=O)c3csc4ccccc34)c12		528	A	B
I-88		Cc1ccccc1C1NC(=O)c2cc(CN)cc(NC(=O)c3csc4ccccc34)c12		428	A	
I-89		C[C@@H](NC(=O)OC(C)(C)C)c1cc2C(=O)NC(c2c(NC(=O)c2csc3ccccc23)c1)c1ccccc1C		542	B	
I-90		C[C@@H](N)c1cc2C(=O)NC(c2c(NC(=O)c2csc3ccccc23)c1)c1ccccc1C		442	A	
I-91		Cc1ccccc1[C@H]1NC(=O)c2cc(N)cc(NC(=O)c3nsc4ccccc34)c12	1H NMR (400 MHz, DMSO-d6) 9.6-9.9 (m, 1H), 8.7-8.9 (m, 1H), 8.4-8.6 (m, 1H), 8.2-8.3 (m, 1H), 7.6-7.8 (m, 1H), 7.5-7.6 (m, 1H), 7.1-7.2 (m, 1H), 6.9-7.0 (m, 3H), 6.7-6.8 (m, 1H), 6.5-6.7 (m, 1H), 5.8-6.0 (m, 1H), 5.4-5.6 (m, 2H), 2.1-2.4 (m, 3H)	415	C	





I-92		Cc1ccccc1[C@@H]1NC(=O)c2cc(N)cc(NC(=O)c3nsc4ccccc34)c12	1H NMR (400 MHz, DMSO-d6) 9.6-9.9 (m, 1H), 8.7-8.9 (m, 1H), 8.4-8.6 (m, 1H), 8.2-8.3 (m, 1H), 7.6-7.8 (m, 1H), 7.5-7.6 (m, 1H), 7.1-7.2 (m, 1H), 6.9-7.0 (m, 3H), 6.7-6.8 (m, 1H), 6.5-6.7 (m, 1H), 5.8-6.0 (m, 1H), 5.4-5.6 (m, 2H), 2.1-2.4 (m, 3H)	415	A	A
I-93		Clc1cc(NC(=O)c2nsc3ccccc23)c2C(NC(=O)c2n1)c1ccccc1Cl	^{1}H NMR (400 MHz, DMSO-d_6) δ 10.53 (s, 1H), 9.65 (s, 1H), 8.67 (d, 1H), 8.32 (d, 1H), 7.98 (s, 1H), 7.69 (t, 1H), 7.62 (t, 1H), 7.33 (d, 1H), 7.22 (t, 1H), 7.14 (t, 1H).	455.26	A	
I-94		Clc1ccccc1C1NC(=O)c2nc(cc(NC(=O)c3nsc4ccccc34)c12)-c1cn[nH]c1	^{1}H NMR (400 MHz, DMSO-d_6) δ 13.20 (br s, 1H), 10.48 (s, 1H), 9.46 (s, 1H), 8.69 (d, J = 8.1 Hz, 1H), 8.41 (br s, 1H), 8.33 (d, J = 8.1 Hz, 1H), 8.10 (br s, 1H), 8.07 (s, 1H), 7.60-7.73 (m, 3H), 7.30 (d, J = 7.8 Hz, 1H), 7.15-7.21 (m, 1H), 7.09-7.14 (m, 1H), 6.29 ppm (br s, 1H).	487.33	B	
I-95		CC1CN(C(=O)Nc2cccc3C(=O)NC(c23)c2ccccc2C)c2ccccc12	1H NMR (400 MHz, DMSO-d6) 8.92 (s, 1H), 8.39 (s, 1H), 8.33 (s, 1H), 8.27 (s, 1H), 7.70 (d, 8.1 Hz, 1H), 7.62 (m, 1H), 7.53-7.48 (m, 2H), 7.46-7.32 (m, 2H), 7.22 (t, 7.4 Hz, 1H), 7.15-7.03 (m, 3H), 6.99 (d, 7.4 Hz, 1H), 6.96-6.84 (m, 2H), 6.79 (d, 8.7 Hz, 1), 6.54 (br s, 1H), 6.25 (t, 12.4 Hz, 1H), 6.17 (s, 0.24H), 5.87 (s, 1H), 3.79 (t, 9.8 Hz, 1H), 3.74 (s, 1H), 3.66 (s, 1H), 3.22-3.01 (m, 2H), 2.04 (s, 3H), 1.33 (d, 6.8 Hz, 1H), 1.18 (d, 6.2 Hz, 1H), 1.11 (d, 6.4 Hz,	398.3	B	





			2H), 1.07 (d, 6.7 Hz, 1H).			
I-96		Cc1ccccc1C1NC(=O)c2cccc(NC(=O)N3CCc4ccc(F)cc34)c12	1H NMR (400 MHz, DMSO-d6) 8.97 (s, 1H), 8.49 (s, 1H), 7.60-7.51 (m, 2H), 7.43 (dd, 11.1, 2.1 Hz, 1H), 7.39 (dd, 7.1, 1.7 Hz, 1H), 7.13 (ddd, 7.4, 6.7, 3.5 Hz, 2H), 7.02 (d, 7.4 Hz, 1H), 6.95 (t, 7.3 Hz, 1H), 6.69 (ddd, 9.2, 8.3, 2.5 Hz, 1H), 6.57 (br s, 1H), 5.86 (s, 1H), 3.83-3.55 (m, 1H), 3.01-2.78 (m, 3H), 2.15 (m, 3H).	402.3	B	
I-97		Cc1ccccc1[C@H]1NC(=O)c2cccc(NC(=O)c3coc4c(F)cc(F)cc34)c12	1H NMR (400 MHz, DMSO-d6) 10.08 (s, 1H), 8.98 (s, 1H), 8.18 (s, 1H), 7.61 (d, 7.6 Hz, 1H), 7.55 (t, 7.6 Hz, 1H), 7.45 (d, 7.6 Hz, 1H), 7.37 (t, 7.6 Hz, 1H), 7.25 (d, 7.6 Hz, 1H), 6.99-6.87 (m, 3H), 5.90 (s, 1H), 2.10 (s, 3H)	417.3	E	
I-98		Cc1ccccc1[C@@H]1NC(=O)c2cccc(NC(=O)c3coc4c(F)cc(F)cc34)c12	1H NMR (400 MHz, DMSO-d6) 10.08 (s, 1H), 8.98 (s, 1H), 8.18 (s, 1H), 7.61 (d, 7.6 Hz, 1H), 7.55 (t, 7.6 Hz, 1H), 7.45 (d, 7.6 Hz, 1H), 7.37 (t, 7.6 Hz, 1H), 7.25 (d, 7.6 Hz, 1H), 6.99 - 6.87 (m, 3H), 5.90 (s, 1H), 2.10 (s, 3H)	417.3	B	
I-99		Fc1cccc(Cl)c1C1NC(=O)c2cccc(NC(=O)c3nsc4ccccc34)c12	^{1}H NMR (400 MHz, DMSO-d_6) δ 10.25-10.42 (m, 1H), 8.82-9.15 (m, 1H), 8.22-8.71 (m, 2H), 7.47-7.73 (m, 4H), 6.77-7.24 (m, 3H), 6.25-6.42 (m, 1H), 3.97-4.18 (m, 1H).	438.2	C	




I-100		Cc1ccccc1C1NC(=O)c2cc(C=C)cc(NC(=O)c3csc4ccccc34)c12	1H NMR (400 MHz, CD3CN) 8.27 (brs, 1H), 8.23-8.14 (m, 1H), 8.00-7.91 (m, 1H), 7.83-7.76 (m, 2H), 7.49-7.40 (m, 2H), 7.34 (s, 1H), 7.28 (s, 1H), 7.16 (m, 1H), 7.05 (m, 2H), 6.91 (dd, 17.6, 11.0 Hz, 1H), 6.04 (s, 1H), 5.97 (d, 17.6 Hz, 1H), 5.41 (d, 10.9 Hz, 1H), 2.18 (s, 3H).	425.3	A	C
I-101		Clc1cnccc1C1NC(=O)c2cccc(NC(=O)c3csc4ccccc34)c12	1H NMR (400 MHz, DMSO-d6) 10.23 (s, 1H), 9.13 (s, 1H), 8.40 (s, 1H), 8.24 (d, 4.9 Hz, 1H), 8.18-8.13 (m, 1H), 8.04-7.99 (m, 1H), 7.97 (s, 1H), 7.67 (dd, 7.5, 1.2 Hz, 1H), 7.61 (t, 7.6 Hz, 1H), 7.49 (dd, 7.7, 1.1 Hz, 1H), 7.42-7.37 (m, 2H), 6.86 (br s, 1H), 6.09 (s, 1H).	420.2	D	
I-102		Fc1ccc(C2NC(=O)c3cccc(NC(=O)c4csc5ccccc45)c23)c(Cl)c1	1H NMR (400 MHz, DMSO-d6) 10.19 (s, 1H), 9.06 (s, 1H), 8.36 (s, 1H), 8.12-8.06 (m, 1H), 8.03-7.98 (m, 1H), 7.96 (s, 1H), 7.66-7.55 (m, 2H), 7.49 (dd, 7.8, 1.0 Hz, 1H), 7.42-7.34 (m, 2H), 7.22 (dd, 8.9, 2.7 Hz, 1H), 6.97 (s, 1H), 6.11 (s, 1H).	437.2	A	
I-103		Nc1cccc2c1n(Cc1ccccc1)[nH]c2=O	1H NMR (400 MHz, DMSO-d6) 10.57 (s, 1H), 7.26-7.14 (m, 3H), 7.14-7.09 (m, 2H), 6.85 (dd, 7.9, 0.9 Hz, 1H), 6.77 (t, 7.6 Hz, 1H), 6.61 (d, 7.5 Hz, 1H), 5.32 (s, 2H), 5.16 (s, 2H).	240.2	E	
I-104		Cc1ccccc1C1NC(=O)c2cccc(NC(=O)N3CCc4c3cc(F)cc4F)c12	1H NMR (400 MHz, DMSO-d6) 8.94 (s, 1H), 8.58 (s, 1H), 7.54 (dd, 7.5, 1.5 Hz, 1H), 7.51 (t, 7.4 Hz, 1H), 7.34 (dd, 7.4, 1.5 Hz, 1H), 7.27 (d, 10.5 , 1.8 Hz, 1H), 7.10 (td, 8.3,	420.3	B	






			4.1 Hz, 1H), 7.01 (d, 7.3 Hz, 1H), 6.93 (t, 7.8 Hz, 1H), 6.70 (td, 9.5, 2.2 Hz, 1H), 6.61-6.38 (m, 1H), 5.80 (s, 1H), 3.75-3.62 (m, 1H), 2.97-2.78 (m, 3H), 2.34-1.80 (m, 3H).			
I-105		Cc1ccccc1C1NC(=O)c2cccc(NC(=O)c3nsc4ccc(F)cc34)c12		418	B	
I-106		Cc1c(F)ccccc1C1NC(=O)c2ccccc(NC(=O)c3nsc4ccccc34)c12	^{1}H NMR (400 MHz, DMSO-d_6) δ 10.17 (s, 1H), 9.07 (s, 1H), 8.56 (br d, J =8.1 Hz, 1H), 8.29 (d, J =8.3 Hz, 1H), 7.78 (br d, J =7.3 Hz, 1H), 7.50-7.70 (m, 4H), 6.76-7.01 (m, 2H), 6.30-6.65 (m, 1H), 6.02-6.25 (m, 1H), 1.67-2.42 (m, 3H).	418.3	B	
I-107		CCOc1ncc(cc1F)C(=O)Nc1cccc2C(=O)NC(c12)c1ccccc1C	1H NMR (400 MHz, DMSO-d6) 10.10 (s, 1H), 9.02 (s, 1H), 7.96 (s, 1H), 7.45-7.70 (m, 4H), 7.03-7.10 (m, 1H), 6.91-7.02 (m, 2H), 6.47-6.67 (m, 1H), 5.89 (br s, 1H), 4.42 (q, 6.91 Hz, 2H), 1.98-2.31 (m, 3H), 1.34 (t, 7.08 Hz, 3H)	406.39	E	
I-108		Cn1cc(cn1)-c1cc(NC(=O)c2nsc3ccccc23)c2C(NC(=O)c2n1)c1ccccc1Cl	^{1}H NMR (400 MHz, DMSO-d_6) δ 10.44 (s, 1H), 9.46 (br s, 1H), 8.68 (br d, J = 8.1 Hz, 1H), 8.40 (s, 1H), 8.33 (br d, J = 8.5 Hz, 1H), 8.04 (d, J = 7.3 Hz, 2H), 7.35-7.75 (m, 3H), 7.31 (br d, J = 7.8 Hz, 1H), 7.19 (br t, J = 8.3 Hz, 1H), 7.08-7.15 (m, 1H), 6.30 (br s, 1H), 3.94 (s, 3H).	501.4	B	






I-109		CC(C)Oc1ncc(cc1F)C(=O)Nc1cccc2C(=O)NC(c12)c1ccccc1C	1H NMR (400 MHz, DMSO-d6) 10.09 (s, 1H), 9.02 (s, 1H), 7.95 (s, 1H), 7.63-7.68 (m, 1H), 7.59 (t, 7.57 Hz, 1H), 7.46-7.55 (m, 2H), 7.03-7.10 (m, 1H), 6.90-7.02 (m, 2H), 6.45-6.68 (m, 1H), 5.89 (br s, 1H), 5.34 (td, 6.13, 12.39 Hz, 1H), 1.94-2.28 (m, 3H), 1.33 (d, 6.10 Hz, 6H)	420.45	E	
I-110		Cc1ccccc1C1NC(=O)c2cccc(NC(=O)N3CCc4ccc(Cl)cc34)c12	1H NMR (400 MHz, DMSO-d6) 8.93 (s, 1H), 8.48 (s, 1H), 7.63 (d, 1.5 Hz, 1H), 7.55-7.47 (m, 2H), 7.35 (dd, 7.2, 1.7 Hz, 1H), 7.14-7.06 (m, 2H), 6.98 (d, 7.4 Hz, 1H), 6.95-6.86 (m, 2H), 6.60 (br s, 1H), 5.82 (s, 1H), 3.71-3.56 (m, 1H), 2.96-2.76 (m, 3H), 2.11 (s, 3H).	418.3	B	
I-111		CC(C)COc1ncc(c1F)C(=O)Nc1cccc2C(=O)NC(c12)c1ccccc1C	1H NMR (400 MHz, DMSO-d6) 10.10 (s, 1H), 9.02 (s, 1H), 7.96 (s, 1H), 7.62-7.67 (m, 1H), 7.47-7.62 (m, 3H), 7.04-7.12 (m, 1H), 6.89-7.02 (m, 2H), 6.42-6.68 (m, 1H), 5.89 (br s, 1H), 4.16 (d, 6.83 Hz, 2H), 1.93-2.29 (m, 4H), 0.97 (d, 6.59 Hz, 6H)	434.45	E	
I-112		Cc1ccccc1C1NC(=O)c2cccc(NC(=O)c3cc(F)cc(c3)C(F)F)c12	1H NMR (400 MHz, DMSO-d6) 10.25 (s, 1H), 9.04 (s, 1H), 7.64-7.69 (m, 1H), 7.55-7.62 (m, 2H), 7.52 (d, 7.57 Hz, 1H), 7.39 (s, 1H), 7.15-7.26 (m, 1H), 6.86-7.10 (m, 4H), 6.59 (br d, 7.08 Hz, 1H), 5.91 (br s, 1H), 3.31 (s, 1H), 1.94-2.35 (m, 3H)	411.39	D	





I-113		Cn1cc(cn1)-c1cc(NC(=O)c2nsc3ccccc23)c2[C@@H](NC(=O)c2n1)c1ccccc1Cl	^{1}H NMR (400 MHz, DMSO-d_6) δ 10.43 (br s, 1H), 9.45 (br s, 1H), 8.67 (br d, J = 5.9 Hz, 1H), 8.39 (s, 1H), 8.32 (br d, J = 8.1 Hz, 1H), 8.04 (d, J = 11.5 Hz, 2H), 7.66-7.74 (m, 1H), 7.62 (br d, J = 7.1 Hz, 1H), 7.31 (br d, J = 7.8 Hz, 1H), 7.16-7.23 (m, 1H), 7.13 (br t, J = 7.1 Hz, 1H), 6.29 (br s, 1H), 3.94 (s, 3H).	501.3	B	
I-114		Cn1cc(cn1)-c1cc(NC(=O)c2nsc3ccccc23)c2[C@H](NC(=O)c2n1)c1ccccc1Cl	^{1}H NMR (400 MHz, DMSO-d_6) δ 10.44 (br s, 1H), 9.46 (br s, 1H), 8.68 (br d, J = 7.6 Hz, 1H), 8.39 (s, 1H), 8.32 (br d, J = 8.3 Hz, 1H), 8.04 (d, J = 9.0 Hz, 2H), 7.66-7.74 (m, 1H), 7.57-7.66 (m, 1H), 7.31 (br d, J = 7.8 Hz, 1H), 7.16-7.23 (m, 1H), 7.13 (br t, J = 7.3 Hz, 1H), 6.30 (br s, 1H), 3.94 (s, 3H).	501.4	D	
I-115		Cc1ccccc1C1NC(=O)c2cc(cc(NC(=O)c3csc4ccccc34)c12)-c1cnn(C)c1	1H NMR (400 MHz, CDCl3) 8.46 (br s, 1H), 8.26 (br s, 1H), 7.88 (s, 1H), 7.86 (d, 1.4 Hz, 1H), 7.76 (s, 1H), 7.49-7.40 (m, 3H), 7.36 (d, 7.3 Hz, 1H), 7.24-7.21 (m, 1H), 6.85 (s, 1H), 6.35 (s, 1H), 5.87 (s, 1H), 3.97 (s, 3H), 1.55 (s, 3H)	479.6	A	
I-116		Cc1ccccc1C1NC(=O)c2cc(cc(NC(=O)c3nsc4ccccc34)c12)C#N	1H NMR (400 MHz, DMSO-d6) 10.37 (s, 1H), 9.38 (s, 1H), 8.61 (d, 8.2 Hz, 1H), 8.31 (d, 8.2 Hz, 1H), 8.22 (d, 1.4 Hz, 1H), 8.11 (d, 1.3 Hz, 1H), 7.73-7.64 (m, 1H), 7.63-7.57 (m, 1H), 7.02-6.95 (m, 2H), 6.91 (t, 7.0 Hz, 1H), 6.63 (br s, 1H), 6.23 (s, 1H), 2.27 (br s, 3H).	425.2	A	





I-117		Cc1ccccc1-n1[nH]c(=O)c2cccc(NC(=O)c3nsc4ccccc34)c12	1H NMR (400 MHz, DMSO-d6) 11.71-11.31 (m, 1H), 9.89 (s, 1H), 8.57-8.50 (m, 1H), 8.24 (dt, 8.3, 0.8 Hz, 1H), 7.70 (dd, 8.0, 0.7 Hz, 1H), 7.63 (ddd, 8.2, 7.0, 1.2 Hz, 1H), 7.55 (ddd, 7.0, 4.7, 1.1 Hz, 2H), 7.18 (dd, 7.7, 1.4 Hz, 1H), 7.13 (t, 7.7 Hz, 1H), 6.98 (d, 7.4 Hz, 1H), 6.88 (dt, 7.6, 3.9 Hz, 1H), 6.83 (td, 7.4, 1.4 Hz, 1H), 2.06 (s, 3H).	401.2	D	
I-118		O=C(Nc1cccc2c1n(Cc1ccccc1)[nH]c2=O)c1csc2ccccc12	1H NMR (400 MHz, DMSO-d6) 11.05 (br s, 1H), 10.48 (s, 1H), 8.54 (s, 1H), 8.42-8.33 (m, 1H), 8.11-8.03 (m, 1H), 7.60 (dd, 8.0, 1.0 Hz, 1H), 7.48-7.42 (m, 2H), 7.28 (d, 7.0 Hz, 1H), 7.19-7.11 (m, 3H), 7.10-7.03 (m, 1H), 7.01-6.94 (m, 2H), 5.34 (s, 2H).	400.3	E	
I-119		Cc1ccccc1C1NC(=O)c2c1c(NC(=O)c1csc3ccccc13)ccc2CCO	1H NMR (400 MHz, DMSO-d6) 9.97 (s, 1H), 8.96 (s, 1H), 8.06-7.98 (m, 2H), 7.60 (s, 1H), 7.45 (d, 8.0 Hz, 1H), 7.43-7.35 (m, 3H), 7.09 (td, 7.5, 1.3 Hz, 1H), 6.99 (dd, 16.6, 7.3 Hz, 2H), 6.62 (s, 1H), 5.94 (s, 1H), 4.68 (t, 5.3 Hz, 1H), 3.75-3.63 (m, 2H), 3.39 (dt, 13.3, 6.8 Hz, 1H), 3.30-3.21 (m, 1H), 2.18 (s, 2H).	443.3	A	
I-120		Cc1ccccc1C1NC(=O)c2c1c(NC(=O)c1csc3ccccc13)ccc2C(O)CO	1H NMR (400 MHz, DMSO-d6) 10.04 (s, 0.8 H), 10.03 (s, 1H), 9.21 (s, 1H), 9.16 (s, 0.8H), 8.02 (dd, 6.5, 2.5 Hz, 4H), 7.68-7.57 (m, 4H), 7.52 (dd, 8.1, 4.3 Hz, 2H), 7.45-7.35 (m, 4H), 7.16-7.06 (m, 2H), 6.99 (dd, 16.2, 7.3 Hz, 4H), 6.61 (br s,	459.2	B	






			1H), 6.00 (d, 6.7 Hz, 2H), 5.77 (d, 5.9 Hz, 1H), 5.68 (d, 6.3 Hz, 0.8H), 5.56 (td, 6.6, 4.6 Hz, 0.8H), 5.47 (td, 6.7, 4.9 Hz, 1H), 4.77 (dd, 9.8, 5.6 Hz, 2H), 4.57 (s, 1H), 3.66-3.56 (m, 2H), 3.56-3.42 (m, 2H), 2.19 (br s, 5H)..			
I-121		Cc1ccccc1C1NC(=O)c2cc(cc(NC(=O)c3nsc4ccccc34)c12)C(=O)NCC(F)F	1H NMR (400 MHz, DMSO-d6) 10.25 (s, 1H), 9.16 (s, 1H), 8.69-8.81 (m, 1H), 8.54-8.62 (m, 1H), 8.24-8.34 (m, 2H), 8.13 (d, 1.22 Hz, 1H), 7.63-7.71 (m, 1H), 7.53-7.62 (m, 1H), 6.85-7.02 (m, 3H), 6.60-6.79 (m, 1H), 6.15 (br s, 1H), 2.82 (d, 4.39 Hz, 3H), 2.10-2.41 (m, 3H)	507.38	A	A
I-122		FC(F)c1ccccc1C1NC(=O)c2cccc(NC(=O)c3nsc4ccccc34)c12	^{1}H NMR (400 MHz, DMSO-d_6) δ 10.14 (s, 1H), 9.16 (s, 1H), 8.56 (d, J =8.08 Hz, 1H), 8.22-8.33 (m, 1H), 7.82 (dd, J =1.14, 7.71 Hz, 1H), 7.59-7.72 (m, 3H), 7.56 (ddd, J =0.88, 7.07, 8.21 Hz, 1H), 7.39-7.59 (m, 1H), 7.35 (d, J =7.83 Hz, 1H), 7.21-7.32 (m, 2H), 6.75 (br s, 1H), 6.18 (s, 1H).	436.3	A	B
I-123		CNC(=O)c1cc2C(=O)NC(c2c(NC(=O)c2nsc3ccccc23)c1)c1ccccc1C	1H NMR (400 MHz, DMSO-d6) 10.28 (s, 1H), 9.13-9.25 (m, 2H), 8.52-8.64 (m, 1H), 8.26-8.36 (m, 2H), 8.20 (s, 1H), 7.67 (br t, 7.57 Hz, 1H), 7.54-7.61 (m, 1H), 6.86-7.01 (m, 3H), 6.66-6.78 (m, 1H), 6.10-6.24 (m, 2H), 3.72 (tt, 4.76, 15.38 Hz, 2H), 2.10-2.40 (m, 3H)	457.41	A	





I-124		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	1H NMR (400 MHz, DMSO-d6) 10.3-11.0 (m, 1H), 9.0-9.4 (m, 1H), 8.3-8.6 (m, 1H), 7.5-8.1 (m, 3H), 7.2-7.4 (m, 1H), 7.0-7.2 (m, 1H), 6.5-6.9 (m, 2H), 5.7-6.1 (m, 1H)	545	A	B
I-125		Nc1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	1H NMR (500 MHz, DMSO-d6) 10.1-10.3 (m, 1H), 8.8-8.9 (m, 1H), 7.9-8.0 (m, 1H), 7.6-7.8 (m, 1H), 7.6-7.6 (m, 1H), 7.2-7.4 (m, 2H), 7.0-7.1 (m, 1H), 6.8-6.9 (m, 1H), 6.66 (s, 1H), 5.7-5.9 (m, 1H), 5.5-5.7 (m, 2H)	482	A	A
I-126		NCc1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	1H NMR (400 MHz, DMSO-d6) 10.3-10.6 (m, 1H), 9.0-9.3 (m, 1H), 7.9-8.0 (m, 1H), 7.7-7.8 (m, 1H), 7.6-7.7 (m, 2H), 7.4-7.5 (m, 1H), 7.2-7.3 (m, 2H), 7.0-7.1 (m, 1H), 6.6-6.8 (m, 1H), 5.8-6.1 (m, 1H), 5.3-5.6 (m, 1H), 4.4-4.8 (m, 2H)	496	A	
I-127		CC(=O)c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	1H NMR (400 MHz, DMSO-d6) 10.5-10.8 (m, 1H), 9.2-9.5 (m, 1H), 8.4-8.6 (m, 1H), 8.2-8.3 (m, 1H), 7.93 (br d, 1H, 8.1 Hz), 7.6-7.8 (m, 2H), 7.2-7.5 (m, 1H), 6.9-7.2 (m, 1H), 6.6-6.9 (m, 1H), 5.9-6.2 (m, 1H), 2.7-2.8 (m, 3H)	509	A	
I-128		CC(C)(O)c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	1H NMR (400 MHz, DMSO-d6) 10.4-10.6 (m, 1H), 8.9-9.2 (m, 1H), 7.9-8.0 (m, 1H), 7.7-7.8 (m, 2H), 7.6-7.7 (m, 1H), 7.5-7.6 (m, 1H), 7.2-7.4 (m, 1H), 6.9-7.1 (m, 1H), 6.3-6.9 (m, 1H), 5.9-6.1 (m, 1H), 5.2-5.4 (m, 1H), 1.4-1.6 (m, 6H)	525	A	





I-129		COc1ccc2snc(C(=O)Nc3ccc4C(=O)NC(c34)c3ccccc3C)c2c1	1H NMR (400 MHz, DMSO-d6) 10.07 (s, 1H), 9.05 (s, 1H), 8.17 (d, 9.0 Hz, 1H), 8.10 (d, 2.4 Hz, 1H), 7.83 (dd, 7.6, 1.1 Hz, 1H), 7.68-7.55 (m, 2H), 7.32 (dd, 9.0, 2.5 Hz, 1H), 7.02-6.83 (m, 3H), 6.69 (br s, 1H), 6.13 (s, 1H), 3.86 (s, 3H), 2.42-2.02 (m, 3H).	430.2	E	
I-130		CC1(NC(=O)c2cccc(NC(=O)c3csc4ccccc34)c12)c1ccccc1	1H NMR (400 MHz, DMSO-d6) 9.23 (s, 1H), 9.13 (s, 1H), 8.14-8.09 (m, 2H), 8.07-8.02 (m, 1H), 7.68 (dd, 7.0, 1.6 Hz, 1H), 7.64-7.56 (m, 2H), 7.43-7.39 (m, 2H), 7.28-7.18 (m, 5H), 1.97 (s, 3H).	399.3	E	
I-131		Cc1ccccc1C1NC(=O)c2cc(CO)cc(NC(=O)c3nsc4ccccc34)c12	1H NMR (400 MHz, DMSO-d6) 10.11 (s, 1H), 9.02 (s, 1H), 8.57 (d, 8.2 Hz, 1H), 8.29 (d, 8.2 Hz, 1H), 7.78 (s, 1H), 7.67 (ddd, 8.2, 7.1, 1.1 Hz, 1H), 7.61 (s, 1H), 7.58 (t, 7.6 Hz, 1H), 7.02-6.95 (m, 2H), 6.91 (t, 7.1 Hz, 1H), 6.68 (br s, 1H), 6.09 (s, 1H), 5.45 (s, 1H), 2.25 (br s, 3H).	430.2	A	
I-132		Cc1ccccc1C1NC(=O)c2c1c(NC(=O)c1csc3ccccc13)ccc2C#N	1H NMR (400 MHz, DMSO-d6) 10.45 (br s, 1H), 9.48 (s, 1H), 8.08 (d, 8.2 Hz, 1H), 8.02 (dd, 12.5, 5.5 Hz, 2H), 7.81 (d, 8.2 Hz, 1H), 7.65 (s, 1H), 7.46 7.33 (m, 2H), 7.12 (dd, 13.8, 6.8 Hz, 1H), 7.01 (dd, 15.2, 7.3 Hz, 1H), 6.58 (br s, 1H), 6.10 (s, 1H), 2.23 (br s, 3H).	424.2	A	
I-133		Cc1cc(Cl)ccc1C1NC(=O)c2cccc(NC(=O)c3nsc4ccccc34)c12	1H NMR (400 MHz, DMSO-d6) 10.27 (s, 1H), 9.06 (s, 1H), 8.55 (d, 8.2 Hz, 1H), 8.31 (d, 8.3 Hz, 1H), 7.75 (dd, 7.6, 1.1 Hz, 1H), 7.73-7.55 (m, 4H), 7.01	433.7	D	






			(d, 2.0 Hz, 1H), 6.95 (d, 7.3 Hz, 1H), 6.65 (br s, 1H), 6.07 (s, 1H), 2.22 (br s, 3H).			
I-134		COCc1cc2C(=O)NC(c2c(c1)N(C)C(=O)c1nsc2ccccc12)c1ccccc1C	1H NMR (400 MHz, CD3OD) (s, 1H), 8.13 (d, 7.8 Hz, 0.40H), 7.98 (d, 7.9 Hz, 1H), 7.90 (s, 0.33H), 7.66 (s, 1H), 7.64-7.47 (m, 2H), 7.44-7.01 (m, 4H), 6.73 (br s, 0.55H), 6.37 (br s, 0.53H), 6.03 (br s, 0.31H), 4.67 (s, 0.35H), 4.58-4.48 (m, 0.34H), 4.36 (s, 1.37H), 3.50 (d, 8.6 Hz, 1H), 3.08 (br s, 2H), 2.94 (br s, 0.56H), 2.64 (br s, 2H), 1.29 (s, 1.12H).	458.3	E	
I-135		CC(=O)c1cc2C(=O)NC(c2c(NC(=O)c2nsc3ccccc23)c1)c1cc(F)ccc1Cl	1H NMR (400 MHz, DMSO-d6) 10.1-10.5 (m, 1H), 8.9-9.2 (m, 1H), 8.5-8.7 (m, 1H), 8.2-8.3 (m, 1H), 7.8-7.9 (m, 1H), 7.7-7.8 (m, 1H), 7.6-7.7 (m, 1H), 7.5-7.6 (m, 1H), 7.1-7.3 (m, 1H), 6.9-7.0 (m, 1H), 6.0-6.3 (m, 1H), 5.6-5.8 (m, 1H), 2.5 (m, 3H)	480	C	
I-136		CC(C)(O)c1cc2C(=O)NC(c2c(NC(=O)c2nsc3ccccc23)c1)c1cc(F)ccc1Cl	^{1}H NMR (400 MHz, DMSO-d_6) δ 10.1-10.5 (m, 1H), 8.9-9.2 (m, 1H), 8.5-8.7 (m, 1H), 8.2-8.3 (m, 1H), 7.8-7.8 (m, 1H), 7.6-7.7 (m, 1H), 7.5-7.6 (m, 1H), 7.2-7.3 (m, 1H), 6.9-7.0 (m, 1H), 6.4-6.9 (m, 1H), 6.0-6.2 (m, 1H), 5.6-5.7 (m, 1H), 5.1-5.3 (m, 1H), 1.3-1.6 (m, 6H).	496	A	
I-137		FC(F)c1ccc(F)cc1C1NC(=O)c2cccc(NC(=O)c3nsc4ccccc34)c12	^{1}H NMR (400 MHz, DMSO-d_6) δ 10.25 (s, 1H), 9.17 (s, 1H), 8.54 (d, J =8.05 Hz, 1H), 8.26 (d, J =8.30 Hz, 1H), 7.11-8.09 (m, 7H), 7.05 (dt, J =2.44, 8.42	454.4	A	






			Hz, 1H), 6.35-6.65 (m, 1H), 6.13 (s, 1H).			
I-138		FC(F)c1ccc(F)cc1C1NC(=O)c2cccc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	^{1}H NMR (400 MHz, DMSO-d_6) δ 10.44 (s, 1H), 9.14 (s, 1H), 7.90-8.00 (m, 1H), 7.83-7.90 (m, 1H), 7.67-7.74 (m, 1H), 7.58-7.67 (m, 2H), 7.52-7.57 (m, 1H), 7.47-7.52 (m, 1H), 7.40-7.47 (m, 1H), 7.16 (dt, J =2.44, 8.42 Hz, 1H), 6.24-6.62 (m, 1H), 5.77-6.15 (m, 1H).	483.4	A	
I-139		Cc1ccccc1C1NC(=O)c2cc(cc(NC(=O)c3csc4ccccc34)c12)C(O)CO	1H NMR (400 MHz, DMSO-d6) 10.09 (s, 0.5H), 10.07 (s, 0.5H), 8.95 (s, 1H), 7.98 (m, 2H), 7.64 (s, 0.5H), 7.62 (s, 0.5H), 7.55 (d, 14.9 Hz, 2H), 7.36 (m, 2H), 7.05 (d, 7.5 Hz, 1H), 6.96 (m, 12.5, 5.3 Hz, 2H), 6.56 (br s, 1H), 5.97 (s, 1H), 5.46 (d, 4.4 Hz, 1H), 4.80 (sets of d, 5.8 Hz, 1H), 4.65 (m, 1H), 3.50 (m, 2H), 2.15 (s, 3H).	458.7	A	
I-140		Cc1ccccc1C1NC(=O)c2c1c(NC(=O)c1csc3ccccc13)ccc2CN	1H NMR (400 MHz, DMSO-d6) 10.25-10.10 (m, 1H), 9.38 (s, 1H), 8.02 (d, 7.2 Hz, 2H), 7.62 (d, J = 16.0 Hz, 3H), 7.46-7.35 (m, 2H), 7.11 (t, 7.2 Hz, 1H), 7.06-6.95 (m, 2H), 6.61 (s, 1H), 6.07 (s, 1H), 4.47 (s, 2H), 2.23 (s, 3H).	429.3	A	
I-141		Cc1ccccc1C1NC(=O)c2cc(cc(NC(=O)c3csc4ccccc34)c12)-c1cnoc1	1H NMR (400 MHz, DMSO-d6) 10.19 (s, 1H), 9.61 (s, 1H), 9.29 (s, 1H), 9.08 (s, 1H), 8.09-8.03 (m, 1H), 8.02-7.97 (m, 2H), 7.84 (d, 1.5 Hz, 1H), 7.66 (s, 1H), 7.42-7.34 (m, 2H), 7.05 (td, 7.4, 1.3 Hz, 1H), 7.01-6.91 (m, 2H), 6.00 (s, 1H), 1.20 (s, 3H).	465.8	A	






I-142		Cc1ccccc1C1NC(=O)c2nccc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12		430.4	B	
I-143		CN(C)c1ncc(NC(=O)c2nsc3ccccc23)c2C(NC(=O)c12)c1ccccc1C		444.45	B	
I-144		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(NC(=O)c3nsc4ccccc34)c12	1H NMR (400 MHz, DMSO-d6) 10.3-10.6 (m, 1H), 9.2-9.4 (m, 1H), 8.5-8.7 (m, 1H), 8.2-8.3 (m, 1H), 7.9-8.0 (m, 1H), 7.75 (s, 1H), 7.6-7.7 (m, 1H), 7.5-7.6 (m, 1H), 7.2-7.3 (m, 1H), 6.9-7.0 (m, 1H), 6.5-6.9 (m, 1H), 6.0-6.2 (m, 1H)	518.29	A	C
I-145		Cc1ccccc1C1NC(=O)c2cccc(NCc3nsc4ccccc34)c12	1H NMR (400 MHz, DMSO-d6) 8.87 (s, 1H), 8.13 (d, 8.2 Hz, 1H), 7.83 (d, 8.2 Hz, 1H), 7.55 (t, 7.7 Hz, 1H), 7.31 (t, 7.7 Hz, 2H), 7.23 (d, 4.2 Hz, 2H), 7.04-7.02 (m, 2 Hz, 2H), 6.89 (d, 8.2 Hz, 1H), 6.74 (m, 1H), 6.82-6.60 (m, 1H), 5.80 (s, 1H), 5.30 (s, 1H), 4.71 (ddd, 21.1, 16.1, 5.4 Hz, 2H), 2.40 (br s, 3H).	386.3	E	
I-146		COCc1cc2C(=O)NC(c2c(NC(=O)c2nsc3ccccc23)c1)c1ccccc1C	1H NMR (400 MHz, CDCl3) 8.93 (d, 7.5 Hz, 1H), 8.81 (s, 1H), 8.45 (s, 1H), 7.95 (d, 7.8 Hz, 1H), 7.77 (s, 1H), 7.56 (dtd, 16.2, 7.0, 1.2 Hz, 2H), 7.23 (s, 1H), 7.15 (s, 1H), 6.52 (s, 1H), 5.98 (br s, 1H), 4.62 (s, 2H), 3.47 (s, 3H), 1.78 (br s, 3H).	444.2	A	C







I-147		Cc1ccccc1C1NC(=O)c2nccc(NC(=O)N3CCc4ccccc34)c12	1H NMR (400 MHz, DMSO-d6) 9.34 (s, 1H), 8.83 (br s, 1H), 8.64 (d, 5.3 Hz, 1H), 7.64 (d, 7.8 Hz, 1H), 7.42 (d, 5.4 Hz, 1H), 7.18-7.07 (m, 3H), 7.04-6.95 (m, 2H), 6.92 (t, 7.1 Hz, 1H), 6.55 (br s, 1H), 5.90 (s, 1H), 3.62-3.52 (m, 1H), 3.01-2.78 (m, 3H), 2.11 (br s, 3H)	385.4	B	
I-148		Cc1ccccc1C1NC(=O)c2nccc(NC(=O)N3CCc4c3cc(F)cc4F)c12	1H NMR (400 MHz, DMSO-d6) 9.33 (s, 1H), 9.06 (br s, 1H), 8.63 (d, 5.3 Hz, 1H), 7.33 (d, 5.3 Hz, 1H), 7.26 (d, 10.3 Hz, 1H), 7.12 (td, 7.4, 1.0 Hz, 1H), 6.96 (dd, 17.5, 7.5 Hz, 2H), 6.75 (td, 9.5, 2.2 Hz, 1H), 6.63-6.40 (m, 1H), 5.82 (s, 1H), 3.74-3.57 (m, 1H), 3.02-2.82 (m, 2H), 2.76 (m, 1H), 2.13 (m, 3H).	421.2	C	
I-149		Cc1ccccc1C1NC(=O)c2c1c(NC(=O)c1csc3cccc13)ccc2C(N)=O	1H NMR (400 MHz, DMSO-d6) 10.78 (s, 1H), 10.25 (Br s, 1H), 9.80 (s, 1H), 8.33 (d, 8.3 Hz, 1H), 8.06-8.01 (m, 2H), 7.78 (d, 8.4 Hz, 1H), 7.73 (s, 1H), 7.68-7.58 (m, 1H), 7.45-7.36 (m, 2H), 7.12 (td, 7.7, 0.9 Hz, 1H), 7.07-6.97 (m, 2H), 6.60 (Br s, 1H), 6.12 (s, 1H), 2.23 (Br s, 3H).	442.3	A	
I-150		CNC(=O)c1ccc(NC(=O)c2csc3ccccc23)c2C(NC(=O)c12)c1ccccc1C	1H NMR (400 MHz, DMSO-d6) 11.20 (s, 1H), 10.22 (s, 1H), 9.82 (s, 1H), 8.33 (d, 7.9 Hz, 1H), 8.03 (d, 6.2 Hz, 2H), 7.77 (d, 8.1 Hz, 1H), 7.62 (s, 1H), 7.41 (s, 2H), 7.11 (d, 7.1 Hz, 1H), 7.07-6.93 (m, 2H), 6.61 (Br s, 1H), 6.13 (s, 1H), 2.91 (s, 3H), 2.23 (br s, 3H).	456.3	A	





I-151		Cc1ccccc1C1NC(=O)c2cccc(NC(=O)c3ncc4ccc(Cl)cn34)c12	1H NMR (400 MHz, DMSO-d6) 9.90 (s, 1H), 9.31 (dt, 1.7, 0.8 Hz, 1H), 9.03 (s, 1H), 7.87 (dd, 9.6, 0.9 Hz, 1H), 7.82 (dd, 7.5, 1.3 Hz, 1H), 7.64-7.56 (m, 3H), 7.19 (dd, 9.5, 1.8 Hz, 1H), 6.99-6.93 (m, 2H), 6.91-6.86 (m, 1H), 6.67 (br s, 1H), 6.11 (s, 1H), 2.26 (br. s, 3H).	417.2	E	
I-152		Cc1ccccc1-n1[nH]c(=O)c2cccc(NC(=O)c3nsc4ccc(F)cc34)c12	1H NMR (400 MHz, DMSO-d6) 11.12 (br s, 1H), 9.98 (s, 1H), 8.28 (dd, 9.1, 4.8 Hz, 1H), 8.11 (dd, 9.7, 2.5 Hz, 1H), 7.66 (dd, 8.0, 0.7 Hz, 1H), 7.55 (td, 8.8, 2.6 Hz, 1H), 7.45 (d, 7.2 Hz, 1H), 7.15-7.08 (m, 2H), 6.92 (d, 7.5 Hz, 1H), 6.81 (td, 7.5, 1.3 Hz, 1H), 6.74 (td, 7.5, 1.3 Hz, 1H), 2.04 (s, 3H).	419.2	D	
I-153		Cc1ccc(NC(=O)c2csc3ccccc23)c2C(NC(=O)c12)c1ccccc1C	1H NMR (400 MHz, DMSO-d6) 9.98 (s, 1H), 8.93 (s, 1H), 8.06-7.99 (m, 2H), 7.61 (s, 1H), 7.45-7.35 (m, 3H), 7.34 (d, 8.0 Hz, 1H), 7.08 (td, 7.5, 1.3 Hz, 1H), 6.98 (m, 2H), 6.62 (br s, 1H), 5.95 (s, 1H), 2.69 (s, 3H), 2.19 (br s, 3H).	413.3	B	
I-154		OCc1cc2C(=O)NC(c2c(NC(=O)c2nsc3ccccc23)c1)c1cc(F)ccc1Cl	1H NMR (400 MHz, DMSO-d6) 10.2-10.6 (m, 1H), 8.9-9.3 (m, 1H), 8.5-8.8 (m, 1H), 8.2-8.3 (m, 1H), 8.1-8.4 (m, 1H), 7.5-7.8 (m, 4H), 7.2-7.4 (m, 1H), 6.9-7.1 (m, 1H), 5.9-6.3 (m, 1H), 5.4-5.6 (m, 1H), 4.5-4.8 (m, 2H)	468	A	





I-155		COc1ccc(CNCc2cc3C(=O)NC(c3c(NC(=O)c3nsc4ccccc34)c2)c2cc(F)ccc2Cl)cc1	1H NMR (500 MHz, DMSO-d6) 3.64-3.77 (m, 2H), 3.79-3.91 (m, 1H), 5.98-6.24 (m, 1H), 6.78-6.95 (m, 1H), 6.95-7.06 (m, 1H), 7.17-7.33 (m, 1H), 7.48-7.63 (m, 1H), 7.63-7.81 (m, 1H), 8.05-8.19 (m, 1H), 8.23-8.37 (m, 1H), 8.53-8.74 (m, 1H), 8.93-9.22 (m, 1H) 10.21-10.57 (m, 1H)	587	A	B
I-156		CNC(=O)c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1ccccc1C	1H NMR (400 MHz, CDCl3) 8.60 (s, 1H), 8.15 (d, 1.4 Hz, 1H), 7.51-7.42 (m, 2H), 7.34 (d, 7.5 Hz, 1H), 7.22 (d, 8.3 Hz, 5H), 6.43 (s, 1H), 6.33 (s, 1H), 5.93 (s, 1H), 3.06 (d, 4.8 Hz, 3H)	486.37	A	
I-157		Clc1ccc(Cl)c(c1)C1NC(=O)c2cccc(NC(=O)c3nsc4ccccc34)c12	^{1}H NMR (400 MHz, DMSO-d_6) δ 10.17-10.60 (m, 1H), 8.89-9.28 (m, 1H), 8.65 (br d, J =8.05 Hz, 1H), 8.30 (d, J =8.05 Hz, 1H), 6.82-8.02 (m, 7H), 5.74-6.69 (m, 2H).	454.3	A	
I-158		Clc1nccc1C1NC(=O)c2cccc(NC(=O)c3nsc4ccccc34)c12	^{1}H NMR (400 MHz, DMSO-d_6) δ 10.32-10.59 (m, 1H), 8.97-9.31 (m, 1H), 8.62 (br d, J =8.30 Hz, 1H), 8.22-8.37 (m, 1H), 8.04-8.22 (m, 1H), 6.82-7.88 (m, 7H), 5.87-6.53 (m, 1H).	421.3	D	
I-159		Fc1cc(Cl)c(cc1F)C1NC(=O)c2cccc(NC(=O)c3nsc4ccccc34)c12	^{1}H NMR (400 MHz, DMSO-d_6) δ 10.21-10.54 (m, 1H), 8.95-9.30 (m, 1H), 8.62 (d, J =8.05 Hz, 1H), 8.31 (d, J =8.30 Hz, 1H), 6.86-7.83 (m, 7H), 6.00-6.27 (m, 1H).	456.4	A	






I-160		Clc1ccnc c1C1NC(=O)c2ccc c(NC(=O)c3nsc4c cccc34)c 12	^{1}H NMR (400 MHz, DMSO-d_6) δ 10.53 (s, 1H), 9.10 (br s, 1H), 8.63 (d, J =8.30 Hz, 1H), 7.91-8.40 (m, 3H), 7.44-7.78 (m, 5H), 7.30 (d, J =5.13 Hz, 1H), 6.01-6.31 (m, 1H).	421. 3	C	
I-161		Fc1ccc(C l)c(c1)C1 NC(=O)c 2nc(cc(N C(=O)c3 cc(F)cc(c 3)C(F)(F) F)c12)- c1cn[nH] c1	^{1}H NMR (400 MHz, DMSO-d_6) δ 13.21 (br s, 1H), 10.85 (br s, 1H), 9.44 (br s, 1H), 8.43 (br s, 1H), 8.12 (br s, 1H), 7.97 (br d, J = 4.1 Hz, 1H), 7.63-7.87 (m, 3H), 7.34 (br dd, J = 8.8, 5.1 Hz, 1H), 7.09 (td, J = 8.4, 2.9 Hz, 1H), 6.75-6.96 (m, 1H), 5.98 (br s, 1H).	534. 4	A	B
I-162		Cn1cc(cn 1)- c1cc(NC(=O)c2cc(F)cc(c2) C(F)(F)F)c2C(NC (=O)c2n1)c1cc(F)c cc1Cl	^{1}H NMR (400 MHz, DMSO-d_6) δ 10.84 (br s, 1H), 9.44 (br s, 1H), 8.40 (s, 1H), 8.05 (s, 1H), 7.97 (br d, J = 6.6 Hz, 1H), 7.62-7.79 (m, 3H), 7.34 (br dd, J = 8.8, 5.1 Hz, 1H), 7.09 (td, J = 8.4, 2.9 Hz, 1H), 6.81-6.97 (m, 1H), 5.98 (br s, 1H), 3.93 (s, 3H).	548. 4	A	
I-163		CNC(=O)c1cc2C(=O)N[C @H](c2c (NC(=O) c2nsc3cc ccc23)c1) c1ccccc1 C	1H NMR (400 MHz, DMSO-d6) 10.28 (s, 1H), 9.13-9.25 (m, 2H), 8.52-8.64 (m, 1H), 8.26-8.36 (m, 2H), 8.20 (s, 1H), 7.67 (br t, 7.57 Hz, 1H), 7.54-7.61 (m, 1H), 6.86-7.01 (m, 3H), 6.66-6.78 (m, 1H), 6.10-6.24 (m, 2H), 3.72 (tt, 4.76, 15.38 Hz, 2H), 2.10-2.40 (m, 3H)	457. 41	A	
I-164		CNC(=O)c1cc2C(=O)N[C @@H](c 2c(NC(= O)c2nsc3 ccccc23) c1)c1ccc cc1C	1H NMR (400 MHz, DMSO-d6) 10.28 (s, 1H), 9.13-9.25 (m, 2H), 8.52-8.64 (m, 1H), 8.26-8.36 (m, 2H), 8.20 (s, 1H), 7.67 (br t, 7.57 Hz, 1H), 7.54-7.61 (m, 1H), 6.86-7.01 (m, 3H), 6.66-6.78 (m, 1H),	457. 41	D	D





			6.10-6.24 (m, 2H), 3.72 (tt, 4.76, 15.38 Hz, 2H), 2.10-2.40 (m, 3H)			
I-165		Cc1ccccc1[C@H]1NC(=O)c2cc(cc(NC(=O)c3nsc4ccccc34)c12)C(=O)NCC(F)F		507.38	B	
I-166		Cc1ccccc1[C@@H]1NC(=O)c2cc(cc(NC(=O)c3nsc4ccccc34)c12)C(=O)NCC(F)F		507.38	A	A
I-167		FC(F)c1ccc(F)cc1[C@H]1NC(=O)c2cccc(NC(=O)c3nsc4ccccc34)c12	1H NMR (400 MHz, DMSO-d6) 10.25 (s, 1H), 9.17 (s, 1H), 8.54 (d, 8.05 Hz, 1H), 8.26 (d, 8.30 Hz, 1H), 7.74 (d, 7.32 Hz, 1H), 7.65 (td, 7.38, 15.01 Hz, 2H), 7.47-7.56 (m, 1H), 7.35 (br dd, 5.61, 8.54 Hz, 1H), 7.05 (dt, 2.44, 8.42 Hz, 1H), 6.34-6.62 (m, 1H), 6.13 (s, 1H)	452	A	B
I-168		FC(F)c1ccc(F)cc1[C@@H]1NC(=O)c2cccc(NC(=O)c3nsc4ccccc34)c12	1H NMR (400 MHz, DMSO-d6) 10.25 (s, 1H), 9.17 (s, 1H), 8.54 (d, 8.05 Hz, 1H), 8.26 (d, 8.30 Hz, 1H), 7.74 (d, 7.32 Hz, 1H), 7.65 (td, 7.38, 15.01 Hz, 2H), 7.47-7.56 (m, 1H), 7.35 (br dd, 5.61, 8.54 Hz, 1H), 7.05 (dt, 2.44, 8.42 Hz, 1H), 6.34-6.62 (m, 1H), 6.13 (s, 1H)	452	A	
I-169		FC(F)c1ccc(F)cc1[C@H]1NC(=O)c2cccc(NC(=O)c3cc(F)cc(c3)	1H NMR (400 MHz, DMSO-d6) 10.44 (s, 1H), 9.14 (s, 1H), 7.90-8.00 (m, 1H), 7.83-7.90 (m, 1H), 7.67-7.74 (m, 1H), 7.58-7.67 (m, 2H), 7.52-7.57 (m, 1H), 7.47-7.52 (m, 1H),	483	D	






		C(F)(F)F)c12	7.40-7.47 (m, 1H), 7.16 (dt, 2.44, 8.42 Hz, 1H), 6.24-6.62 (m, 1H), 5.77-6.15 (m, 1H)			
I-170		FC(F)c1c cc(F)cc1[C@@H] 1NC(=O) c2cccc(N C(=O)c3 cc(F)cc(c 3)C(F)(F) F)c12	1H NMR (400 MHz, DMSO-d6) 10.44 (s, 1H), 9.14 (s, 1H), 7.90-8.00 (m, 1H), 7.83-7.90 (m, 1H), 7.67-7.74 (m, 1H), 7.58-7.67 (m, 2H), 7.52-7.57 (m, 1H), 7.47-7.52 (m, 1H), 7.40-7.47 (m, 1H), 7.16 (dt, 2.44, 8.42 Hz, 1H), 6.24-6.62 (m, 1H), 5.77-6.15 (m, 1H)	483	A	
I-171		Fc1cc(Cl)cc(c1)C(=O)Nc1c cnc2C(= O)NC(c1 2)c1cccc c1Cl		416. 2	D	
I-172		Clc1cccc c1C1NC(=O)c2ncc c(NC(=O)c3nsc4c cccc34)c 12		421	B	
I-173		Fc1cc(Cl)cc(c1)C(=O)Nc1c cnc2C(= O)NC(c1 2)c1cccc(F)c1F		418	D	
I-174		Fc1cc(cc(c1)C(F)(F)F)C(= O)Nc1cc nc2C(=O)NC(c12) c1cccc(F) c1F		452. 2	D	
I-175		Fc1cccc(C2NC(= O)c3nccc (NC(=O) c4nsc5cc ccc45)c2 3)c1F		421	C	





I-176		Cc1ccccc1C1NC(=O)c2ccnc(NC(=O)c3nsc4ccccc34)c12	1H NMR (400 MHz, DMSO-d6) 9.45 (s, 1H), 8.70 (d, 4.9 Hz, 1H), 8.42 (d, 8.4 Hz, 1H), 8.37 (s, 1H), 8.30 (d, 8.2 Hz, 1H), 7.72 (d, 4.9 Hz, 1H), 7.67 (t, 7.0 Hz, 1H), 7.58 (t, 7.7 Hz, 1H), 7.04-6.92 (m, 2H), 6.92-6.83 (m, 1H), 6.60 (br s, 1H), 6.23 (s, 1H), 2.22 (br s, 3H).	401.2	D	
I-177		Cc1ccccc1C1NC(=O)c2nccc(NC(=O)N3CCc4ccc(F)cc34)c12	1H NMR (400 MHz, DMSO-d6) 9.35 (s, 1H), 8.95 (br s, 1H), 8.66 (d, 5.3 Hz, 1H), 7.43-7.38 (m, 2H), 7.20-7.09 (m, 2H), 7.01-6.96 (m, 2H), 6.79-6.70 (m, 1H), 6.55(br s, 1H), 5.88 (s, 1H), 3.68-3.61 (m, 1H), 3.03-2.75 (m, 3H), 2.29-2.00 (m, 3H).	403.3	C	
I-178		Cc1ccccc1-n1[nH]c(=O)c2cccc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	1H NMR (400 MHz, DMSO-d6) 11.08 (s, 1H), 10.13 (s, 1H), 7.84 (d, 8.5 Hz, 1H), 7.72 (dd, 8.0, 0.9 Hz, 1H), 7.48 (s, 1H), 7.44 (d, 9.1 Hz, 1H), 7.25 (dd, 7.3, 0.8 Hz, 1H), 7.14 (t, 7.8 Hz, 1H), 7.11-7.06 (m, 2H), 7.01-6.92 (m, 2H), 2.03 (s, 3H).	428.3	C	
I-179		Cc1ccccc1C1NC(=O)c2cccc(NC(=O)C34CCC(CC3)CC4)c12	1H NMR (400 MHz, DMSO-d6) 8.97 (s, 1H), 8.75 (s, 1H), 7.57-7.54 (m, 1H), 7.53-7.49 (m, 1H), 7.45 (dd, 7.5, 1.4 Hz, 1H), 7.18 (d, 4.0 Hz, 2H), 7.06-6.98 (m, 1H), 6.47 (br. s, 1H), 5.94 (s, 1H), 2.32 (br. s, 3H), 1.50-1.45 (m, 1H), 1.42-1.33 (m, 6H), 1.32-1.21 (m, 6H).	375.3	D	





I-180		Cc1ccccc1C1NC(=O)c2cccc(NC(=O)c3ncc4c(F)cc(F)cn34)c12	1H NMR (400 MHz, DMSO-d6) 10.02 (br s, 1H), 9.14 (d, 4.0 Hz, 1H), 9.03 (s, 1H), 7.84 (d, 0.8 Hz, 1H), 7.78 (dd, 7.6, 1.2 Hz, 1H), 7.65-7.62 (m, 1H), 7.62-7.57 (m, 1H), 7.44 (ddd, 10.6, 8.8, 1.8 Hz, 1H), 6.99-6.92 (m, 2H), 6.90-6.85 (m, 1H), 6.68 (br s, 1H), 6.10 (s, 1H), 2.23 (br s, 3H).	419.3	E	
I-181		Cc1ccccc1C1NC(=O)c2cc(CCO)cc(NC(=O)c3csc4ccccc34)c12	1H NMR (400 MHz, DMSO-d6) 10.06 (s, 1H), 8.93 (s, 1H), 8.62-8.38 (m, 2H), 8.03-7.95 (m, 2H), 7.62 (s, 1H), 7.47 (s, 1H), 7.41-7.32 (m, 3H), 7.05 (t, 7.8 Hz, 1H), 6.99-6.90 (m, 1H), 6.57 (br s, 1H), 5.95 (s, 1H), 4.71 (br s, 1H), 3.71-3.61 (m, 2H), 2.92-2.77 (m, 2H), 2.14 (s, 3H).	442.8	A	
I-182		Fc1ccc(Cl)c(c1)C1NC(=O)c2nc(cc(NC(=O)c3cc(F)cc(Cl)c3)c12)-c1cn[nH]c1	^{1}H NMR (500 MHz, DMSO-d_6) δ 13.20 (br s, 1H), 10.69 (br s, 1H), 9.44 (br s, 1H), 8.42 (br s, 1H), 8.11 (br s, 1H), 7.88 (br s, 1H), 7.57-7.83 (m, 3H), 7.36-7.43 (m, 2H), 7.14 (td, J = 8.4, 3.1 Hz, 1H), 5.99 (br s, 1H).	500.4	B	
I-183		CSc1nc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)n1)c1ccccc1Cl	1H NMR (400 MHz, DMSO-d6) 9.63 (br s, 1H), 7.84 (br d, 7.58 Hz, 1H), 7.64 (br d, 9.09 Hz, 1H), 7.59 (s, 1H), 7.15-7.23 (m, 1H),7.07-7.15 (m, 1H), 7.03 (br t, 6.95 Hz, 1H), 6.83-6.97 (m, 1H), 6.51 (s, 1H), 5.98 (br s, 1H), 2.60 (s, 3H)	497.3	D	





I-184		Nc1nc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)n1)c1ccccc1Cl		466.4	C	
I-185		OCc1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	1H NMR (DMSO-d6, 400 MHz) 10.4-10.6 (m, 1H), 9.0-9.2 (m, 1H), 7.9-8.0 (m, 1H), 7.7-7.8 (m, 1H), 7.5-7.7 (m, 2H), 7.4-7.5 (m, 1H), 7.2-7.4 (m, 1H), 7.0-7.1 (m, 1H), 6.5-6.8 (m, 1H), 5.9-6.2 (m, 1H), 5.3-5.6 (m, 1H), 4.4-4.9 (m, 2H)	497	A	
I-186		Cn1cc(cn1)-c1cc(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c2[C@H](NC(=O)c2n1)c1cc(F)ccc1Cl	^{1}H NMR (400 MHz, DMSO-d_6) δ 10.84 (br s, 1H), 9.44 (br s, 1H), 8.40 (s, 1H), 8.05 (s, 1H), 7.97 (br d, J = 6.6 Hz, 1H), 7.62-7.79 (m, 3H), 7.34 (br dd, J = 8.8, 5.1 Hz, 1H), 7.09 (td, J = 8.4, 2.9 Hz, 1H), 6.81-6.97 (m, 1H), 5.98 (br s, 1H), 3.93 (s, 3H).	548.3	C	
I-187		Cn1cc(cn1)-c1cc(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c2[C@@H](NC(=O)c2n1)c1cc(F)ccc1Cl	^{1}H NMR (400 MHz, DMSO-d_6) δ 10.84 (br s, 1H), 9.44 (br s, 1H), 8.40 (s, 1H), 8.05 (s, 1H), 7.97 (br d, J = 6.6 Hz, 1H), 7.62-7.79 (m, 3H), 7.34 (br dd, J = 8.8, 5.1 Hz, 1H), 7.09 (td, J = 8.4, 2.9 Hz, 1H), 6.81-6.97 (m, 1H), 5.98 (br s, 1H), 3.93 (s, 3H).	548.4	A	
I-188		Fc1cc(cc(c1)C(F)(F)F)C(=O)Nc1ccccc2C(=O)NC3(CCc4ccccc34)c12	1H NMR (500 MHz, DMSO-d6) 11.55 (s, 1H), 9.47 (s, 1H), 8.34 (d, 8.24 Hz, 1H), 8.12 (s, 1H), 8.06 (br dd, 6.71, 7.93 Hz, 2H), 7.57 (t, 7.93 Hz, 1H), 7.40 (d, 7.63 Hz, 1H), 7.26-7.33 (m, 1H), 7.15 (t, 7.32 Hz, 1H), 7.01	441.07	E	






			(d, 7.32 Hz, 1H), 6.79 (d, 7.32 Hz, 1H), 3.12-3.27 (m, 2H), 2.51-2.57 (m, 1H), 2.39-2.46 (m, 1H)			
I-189		CC(C)(O)c1cc2C(=O)N[C@H](c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	1H NMR (400 MHz, DMSO-d6) 10.4-10.6 (m, 1H), 8.9-9.2 (m, 1H), 7.9-8.0 (m, 1H), 7.7-7.8 (m, 2H), 7.6-7.7 (m, 1H), 7.5-7.6 (m, 1H), 7.2-7.4 (m, 1H), 6.9-7.1 (m, 1H), 6.3-6.9 (m, 1H), 5.9-6.1 (m, 1H), 5.2-5.4 (m, 1H), 1.4-1.6 (m, 6H)	525	A	A
I-190		CC(C)(O)c1cc2C(=O)N[C@@H](c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	1H NMR (400 MHz, DMSO-d6) 10.4-10.6 (m, 1H), 8.9-9.2 (m, 1H), 7.9-8.0 (m, 1H), 7.7-7.8 (m, 2H), 7.6-7.7 (m, 1H), 7.5-7.6 (m, 1H), 7.2-7.4 (m, 1H), 6.9-7.1 (m, 1H), 6.3-6.9 (m, 1H), 5.9-6.1 (m, 1H), 5.2-5.4 (m, 1H), 1.4-1.6 (m, 6H)	525	D	
I-191		CC(C)(O)c1cc2C(=O)N[C@@H](c2c(NC(=O)c2nsc3ccccc23)c1)c1cc(F)ccc1Cl	^{1}H NMR (400 MHz, DMSO-d_6) δ 10.1-10.5 (m, 1H), 8.9-9.2 (m, 1H), 8.5-8.7 (m, 1H), 8.2-8.3 (m, 1H), 7.8-7.8 (m, 1H), 7.6-7.7 (m, 1H), 7.5-7.6 (m, 1H), 7.2-7.3 (m, 1H), 6.9-7.0 (m, 1H), 6.4-6.9 (m, 1H), 6.0-6.2 (m, 1H), 5.6-5.7 (m, 1H), 5.1-5.3 (m, 1H), 1.3-1.6 (m, 6H).	496	C	
I-192		CC(C)(O)c1cc2C(=O)N[C@H](c2c(NC(=O)c2nsc3ccccc23)c1)c1cc(F)ccc1Cl	1H NMR (400 MHz, DMSO-d6) 10.1-10.5 (m, 1H), 8.9-9.2 (m, 1H), 8.5-8.7 (m, 1H), 8.2-8.3 (m, 1H), 7.8-7.8 (m, 1H), 7.6-7.7 (m, 1H), 7.5-7.6 (m, 1H), 7.2-7.3 (m, 1H), 6.9-7.0 (m, 1H), 6.4-6.9 (m, 1H), 6.0-6.2 (m, 1H), 5.6-5.7 (m, 1H), 5.1-5.3 (m, 1H), 1.3-1.6 (m, 6H)	496	A	A






I-193		Fc1ccc(Cl)c(c1)[C@H]1NC(=O)c2nc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1cn[nH]c1	^{1}H NMR (400 MHz, DMSO-d_6) δ 13.21 (br s, 1H), 10.85 (br s, 1H), 9.44 (br s, 1H), 8.43 (br s, 1H), 8.12 (br s, 1H), 7.97 (br d, J = 4.1 Hz, 1H), 7.63-7.87 (m, 3H), 7.34 (br dd, J = 8.8, 5.1 Hz, 1H), 7.09 (td, J = 8.4, 2.9 Hz, 1H), 6.75-6.96 (m, 1H), 5.98 (br s, 1H).	534.4	D	
I-194		Fc1ccc(Cl)c(c1)[C@@H]1NC(=O)c2nc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1cn[nH]c1	^{1}H NMR (400 MHz, DMSO-d_6) δ 13.21 (br s, 1H), 10.85 (br s, 1H), 9.44 (br s, 1H), 8.43 (br s, 1H), 8.12 (br s, 1H), 7.97 (br d, J = 4.1 Hz, 1H), 7.63-7.87 (m, 3H), 7.34 (br dd, J = 8.8, 5.1 Hz, 1H), 7.09 (td, J = 8.4, 2.9 Hz, 1H), 6.75-6.96 (m, 1H), 5.98 (br s, 1H).	534.4	A	
I-195		Fc1ccc(Cl)c(c1)[C@H]1NC(=O)c2nc(cc(NC(=O)c3cc(F)cc(Cl)c3)c12)-c1cn[nH]c1	^{1}H NMR (500 MHz, DMSO-d_6) δ 13.20 (br s, 1H), 10.69 (br s, 1H), 9.44 (br s, 1H), 8.42 (br s, 1H), 8.11 (br s, 1H), 7.88 (br s, 1H), 7.57-7.83 (m, 3H), 7.36-7.43 (m, 2H), 7.14 (td, J = 8.4, 3.1 Hz, 1H), 5.99 (br s, 1H).	500.4	D	
I-196		Fc1ccc(Cl)c(c1)[C@@H]1NC(=O)c2nc(cc(NC(=O)c3cc(F)cc(Cl)c3)c12)-c1cn[nH]c1	^{1}H NMR (500 MHz, DMSO-d_6) δ 13.20 (br s, 1H), 10.69 (br s, 1H), 9.44 (br s, 1H), 8.42 (br s, 1H), 8.11 (br s, 1H), 7.88 (br s, 1H), 7.57-7.83 (m, 3H), 7.36-7.43 (m, 2H), 7.14 (td, J = 8.4, 3.1 Hz, 1H), 5.99 (br s, 1H).	500.4	A	
I-197		O=C(Nc1cccc2C(=O)NC(c12)c1ccccc1C#N)c1nsc2cccc12	1H NMR (400 MHz, DMSO-d6) 10.46 (s, 1H), 9.21 (s, 1H), 8.65 (dt, 8.1, 0.9 Hz, 1H), 8.31 (dt, 8.2, 0.9 Hz, 1H), 7.72-7.62 (m, 4H), 7.62-7.56 (m, 2H), 7.35 (td, 7.6, 1.2 Hz, 1H),	411.2	D	





			7.27 (td, 7.6, 1.3 Hz, 1H), 7.23-7.12 (br s), 6.15 (s).			
I-198		COc1ccc c2c(csc1 2)C(=O) Nc1cccc2 C(=O)N C(c12)c1 ccccc1C	1H NMR (400 MHz, DMSO-d6) 10.10 (s, 1H), 9.03 (s, 1H), 7.70-7.52 (m, 5H), 7.35 (t, 8.0 Hz, 1H), 7.09 (td, 7.4, 1.0, 1H), 7.01-6.95 (m, 3H), 6.55 (br s, 1H), 6.00 (s, 1H), 3.96 (s, 3H), 2.12 (br s, 3H).	429.3	E	
I-199		Cc1ccccc 1C1NC(= O)c2nccc (NC(=O) N3CCc4 ncccc34) c12	1H NMR (400 MHz, DMSO-d6) 9.35 (s, 1H), 9.00 (br s, 1H), 8.66 (d, 5.3 Hz, 1H), 8.04 (dd, 4.9, 1.4 Hz, 1H), 7.85 (d, 7.8 Hz, 1H), 7.39 (d, 5.3 Hz, 1H), 7.22-7.07 (m, 2H), 6.98 (d, 7.5 Hz, 2H), 6.54 (br s, 1H), 5.87 (s, 1H), 3.71-3.60 (m, 1H), 3.10-2.81 (m, 3H), 2.29-1.94 (m, 3H).	386.3	E	
I-200		Cc1ccccc 1C1NC(= O)c2cccc (NC(=O) c3noc4cc c(Cl)cc34)c12	1H NMR (400 MHz, DMSO-d6) 10.72 (br s, 1H), 9.07 (s, 1H), 7.94 (dd, 9.0, 0.4 Hz, 1H), 7.79 (dd, 9.0, 2.1 Hz, 1H), 7.73 (br s, 1H), 7.71 (dd, 7.2, 1.3 Hz, 1H), 7.63 (t, 7.5 Hz, 1H), 7.59 (dd, 7.8, 1.2 Hz, 1H), 7.02-6.93 (m, 2H), 6.93-6.85 (m, 1H), 6.64 (br s, 1H), 6.02 (s, 1H), 2.20 (br s, 3H).	835.3	D	
I-201		Cc1ccccc 1C1NCc 2cccc(N C(=O)c3 nsc4cccc c34)c12	1H NMR (400 MHz, DMSO-d6) 8.85-8.80 (m, 1H), 8.77 (s, 1H), 8.10 (dt, 8.2, 0.8 Hz, 1H), 7.90 (d, 8.2 Hz, 1H), 7.62 (ddd, 8.2, 7.0, 1.2 Hz, 1H), 7.56 (ddd, 8.2, 7.0, 1.2 Hz, 1H), 7.40 (t, 7.5 Hz, 1H), 7.23 (dd, 7.5, 0.8 Hz, 1H), 7.14-7.02 (m, 3 H), 6.96 (dd, 7.5, 1.2 Hz, 1H), 5.91 (s, 1H), 4.42 (d, 14.0 Hz, 1H),	386.2	D	




			4.32 (d, 14.0 Hz, 1H), 2.42 (s, 3H)..			
I-202		Cc1ccccc1C1NC(=O)c2cc(CS(C)(=O)=O)cc(NC(=O)c3nsc4ccccc34)c12	1H NMR (400MHz, CDCl3) 8.90 (d, 7.7 Hz, 1H), 8.87 (s, 1H), 8.59 (s, 1H), 7.94 (d, 7.8 Hz, 1H), 7.79 (d, 1.2 Hz, 1H), 7.72-7.62 (m, 1H), 7.60-7.50 (m, 3H), 7.46 (td, 7.4, 3.0 Hz, 1H), 7.17 (br s, 1H), 6.65 (s, 1H), 6.00 (br s, 1H), 4.41 (s, 2H), 2.89 (s, 3H), 2.16 (s, 1H), 1.24 (br s, 3H).	492.3	A	A
I-203		Cc1ccccc1C1NC(=O)c2c1c(NC(=O)c1nsc3ccccc13)ccc2Br	1H NMR (400 MHz, DMSO-d6) 10.10 (s, 1H), 9.22 (s, 1H), 8.58 (d, 8.2 Hz, 1H), 8.30 (d, 8.2 Hz, 1H), 7.76 (dd, 21.4, 8.4 Hz, 2H), 7.70-7.64 (m, 1H), 7.61-7.54 (m, 1 H), 7.01-6.94 (m, 2H), 6.91 (m, 1 H), 6.69 (br s, 1H), 6.08 (s, 1H), 2.24 (br s, 3H).	480.1	A	
I-204		O=C(Nc1cccc2C(=O)NC(C3CCCCC3)c12)c1nsc2ccccc12	1H NMR (400 MHz, DMSO-d6) 10.90 (s, 1H), 8.72 (s, 1H), 8.70 (d, 8.3 Hz, 1H), 8.37 (d, 8.2 Hz, 1H), 7.75-7.69 (m, 2H), 7.64 (t, 7.6 Hz, 1H), 7.57-7.50 (m, 2H), 4.89 (s, 1H), 2.09-1.97 (m, 1H), 1.62 (m, 2H), 1.48 (d, 8.6 Hz, 2H), 1.34 (qd, 12.2, 9.4 Hz, 1H), 0.91 (t, 8.6 Hz, 2H), 0.87 (m, 1H), 0.71 (t, 8.7 Hz, 2H).	392.2	B	
I-205		Cc1ccccc1C1NC(=O)c2c1c(NC(=O)c1nsc3ccccc13)ccc2C=C	1H NMR (400 MHz, DMSO-d6) 10.03 (br s, 1H), 9.06 (s, 1H), 8.59 (d, 8.1 Hz, 1H), 8.29 (d, 8.2 Hz, 1H), 8.11 (dd, 17.9, 11.2 Hz, 1H), 7.90 (d, 8.4 Hz, 1H), 7.79 (d, 8.3 Hz, 1H), 7.67 (t, 7.2 Hz, 1H), 7.58 (t, 7.4 Hz, 1 H), 7.06-6.94 (m, 2H), 6.93-6.90 (m, 1H), 6.71	426.3	B	





			(br s, 1H), 6.14-5.98 (m, 2H), 5.45 (d, 11.9 Hz, 1H), 2.25 (br s, 3H).			
I-206		FC(F)c1ccc(F)cc1C1NC(=O)c2cc(Br)cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	1H NMR (400 MHz, DMSO-d6) 10.55 (s, 1H), 9.33 (s, 1H), 7.94 (d, 8.2 Hz, 1H), 7.87 (d, 1.7 Hz, 1H), 7.78 (d, 1.7 Hz, 1H), 7.67 (d, 8.9 Hz, 1H), 7.58 (s, 1H), 7.50 (dd, 8.8, 5.6 Hz, 1H), 7.22 (td, 8.4, 2.7 Hz, 1H), 7.11 (s, 1H), 6.57 (s, 1H), 6.02 (s, 1H).	561.05	A	
I-207		CC(=O)NCc1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	1H NMR (400 MHz, DMSO-d6) 10.3-10.7 (m, 1H), 8.8-9.3 (m, 1H), 7.9-8.0 (m, 1H), 7.7-7.8 (m, 1H), 7.6-7.7 (m, 2H), 7.4-7.5 (m, 2H), 7.3-7.3 (m, 1H), 7.0-7.1 (m, 1H), 5.8-6.1 (m, 1H), 5.2-5.6 (m, 1H), 4.4-4.8 (m, 2H), 2.0-2.1 (m, 3H)	538	B	
I-208		Fc1cc(cc(c1)C(F)(F)F)C(=O)Nc1ccnc2C(=O)NC(c12)c1ccccc1Cl	1H NMR (400 MHz, DMSO-d6) 10.75 (br s, 1H), 9.48 (br s, 1H), 8.78 (d, 5.13 Hz, 1H), 7.94 (br d, 8.54 Hz, 1H), 7.63 (br d, 8.79 Hz, 1H), 7.48-7.57 (m, 2H), 7.26-7.33 (m, 1H), 7.18-7.25 (m, 1H), 7.11 (br t, 7.20 Hz, 1H), 6.70-6.99 (m, 1H), 6.06 (br s, 1H)	450.36	C	
I-209		Fc1cc(F)c2occ(C(=O)Nc3ccnc4C(=O)NC(c34)c3ccccc3Cl)c2c1	1H NMR (400 MHz, DMSO-d6) 10.55 (s, 1H), 9.46 (br s, 1H), 8.72-8.85 (m, 1H), 8.45 (s, 1H), 7.38-7.56 (m, 4H), 7.22-7.29 (m, 1H), 7.15-7.21 (m, 1H), 7.09 (br t, 7.20 Hz, 1H), 6.15 (br s, 1H)	440.35	C	






I-210		Fc1cc(F)c2occ(C(=O)Nc3ccnc4C(=O)NC(c34)c3cccc(F)c3F)c2c1	1H NMR (400 MHz, DMSO-d6) 10.62 (br s, 1H), 9.49 (s, 1H), 8.77 (d, 5.37 Hz, 1H), 8.53 (s, 1H), 7.54 (d, 5.37 Hz, 1H), 7.39-7.50 (m, 2H), 7.19-7.30 (m, 1H), 6.93-7.01 (m, 1H), 6.82 (br t, 6.96 Hz, 1H), 6.06 (s, 1H)	442.4	D	
I-211		CNC(=O)c1cc2C(=O)N[C@@H](c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1ccccc1C		486.37	E	
I-212		CNC(=O)c1cc2C(=O)N[C@H](c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1ccccc1C		486.37	A	
I-213		Nc1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(Cl)c2)c1)c1cc(F)ccc1Cl	1H NMR (400 MHz, DMSO-d6) 5.43-5.68 (m, 2H), 5.74-5.91 (m, 1H), 6.37-6.60 (m, 1H), 6.63-6.72 (m, 1H), 6.76-6.87 (m, 1H), 6.93-7.17 (m, 1H), 7.21-7.44 (m, 3H), 7.51-7.79 (m, 1H), 8.70-8.97 (m, 1H), 9.84-10.17 (m, 1H)	448	A	A
I-214		CC(C)(O)c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(Cl)c2)c1)c1cc(F)ccc1Cl	1H NMR (400 MHz, DMSO-d6) 10.2-10.4 (m, 1H), 9.0-9.2 (m, 1H), 7.7-7.8 (m, 1H), 7.66 (br d, 8.3 Hz, 2H), 7.5-7.6 (m, 1H), 7.3-7.5 (m, 2H), 7.0-7.2 (m, 1H), 6.6-6.7 (m, 1H), 5.8-6.1 (m,1H), 5.2-5.4 (m, 1H), 1.4-1.6 (m, 6H)	491	A	





I-215		CC(=O)c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(Cl)c2)c1)c1cc(F)ccc1Cl	1H NMR (400 MHz, DMSO-d6) 10.3-10.7 (m, 1H), 9.1-9.4 (m, 1H), 8.4-8.6 (m, 1H), 8.0-8.3 (m, 1H), 7.6-7.8 (m, 1H), 7.3-7.5 (m, 3H), 7.0-7.2 (m, 1H), 6.5-6.9 (m, 1H), 5.8-6.2 (m, 1H), 3.8-4.3 (m, 3H)	475	B	
I-216		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(NC(=O)c3cc(F)cc(Cl)c3)c12	1H NMR (400 MHz, DMSO-d6) 10.2-10.7 (m, 1H), 9.1-9.5 (m, 1H), 8.3-8.5 (m, 1H), 7.6-8.0 (m, 2H), 7.3-7.4 (m, 2H), 7.0-7.2 (m, 1H), 6.5-6.8 (m, 1H), 5.5-6.3 (m, 2H)	513	A	
I-217		Nc1cc2C(=O)N[C@@H](c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	1H NMR (500 MHz, DMSO-d6) 10.1-10.3 (m, 1H), 8.8-8.9 (m, 1H), 7.9-8.0 (m, 1H), 7.6-7.8 (m, 1H), 7.6-7.6 (m, 1H), 7.2-7.4 (m, 2H), 7.0-7.1 (m, 1H), 6.8-6.9 (m, 1H), 6.66 (s, 1H), 5.7-5.9 (m, 1H), 5.5-5.7 (m, 2H)	482	D	
I-218		Nc1cc2C(=O)N[C@H](c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	1H NMR (500 MHz, DMSO-d6) 10.1-10.3 (m, 1H), 8.8-8.9 (m, 1H), 7.9-8.0 (m, 1H), 7.6-7.8 (m, 1H), 7.6-7.6 (m, 1H), 7.2-7.4 (m, 2H), 7.0-7.1 (m, 1H), 6.8-6.9 (m, 1H), 6.66 (s, 1H), 5.7-5.9 (m, 1H), 5.5-5.7 (m, 2H)	482	A	A
I-219		Cc1ccccc1C1NC(=O)c2c1c(NC(=O)c1nsc3ccccc13)ccc2C(=O)N1CC(C1)C#N	1H NMR (400 MHz, DMSO-d6) 10.20 (br s, 1H), 9.25 (s, 1H), 8.59 (d, 8.3 Hz, 1H), 8.30 (d, 8.2 Hz, 1H), 7.88 (dd, 8.1, 2.2 Hz, 1H), 7.71-7.64 (m, 1H), 7.59 (t, 7.5 Hz, 1H), 7.53 (d, 8.1 Hz, 1H), 7.03-6.95 (m, 2H), 6.92 (s, 1H), 6.68 (br s, 1H), 6.15 (s, 1H), 4.37 (t, 9.4 Hz, 1H), 4.23 (dd, 9.6, 6.2 Hz, 1H), 4.20-4.07 (m, 2H), 3.91-3.81	508.2	C	





			(m, 1H), 2.27 (br s, 3H).			
I-220		Cn1cc(cn1)-c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1C(F)F	1H NMR (400 MHz, DMSO-d6) δ 10.53 (br s, 1H) 9.14 (s, 1H) 8.33 (s, 1H) 8.00 (s, 1H) 7.85 - 7.94 (m, 2H) 7.65 - 7.74 (m, 2H) 7.62 (s, 1H) 7.47 (dd, J=8.72, 5.68 Hz, 1H) 7.19 (td, J=8.46, 2.53 Hz, 1H) 6.46 - 6.61 (m, 1H) 5.98 (s, 1H) 3.74 - 4.02 (m, 1H) 3.88 (s, 2H)	563.1	A	A
I-221		FC(F)(F)c1ccccc1C1NC(=O)c2cccc(NC(=O)c3nsc4ccccc34)c12	1H NMR (400 MHz, DMSO-d6) 11.10 (s, 1H), 9.24 (s, 1H), 8.77 (d, 8.1 Hz, 1H), 8.39 (t, 4.4 Hz, 1H), 8.36 (d, 8.2 Hz, 1H), 7.99 (dt, 15.6, 7.8 Hz, 1H), 7.83 (d, 7.9 Hz, 1H), 7.76-7.68 (m, 1H), 7.67-7.63 (m, 1H), 7.61 (dd, 11.0, 4.2 Hz, 1H), 7.53 (t, 7.4 Hz, 1H), 7.18 (d, 8.2 Hz, 1H), 7.09 (d, 7.7 Hz, 1H), 5.91 (s, 1H).	454.2	E	
I-222		COC(=O)c1cc(NC(=O)c2nsc3ccccc23)c2C(NC(=O)c2n1)c1ccccc1Cl	1H NMR (400 MHz, DMSO-d6) 10.61 (br s, 1H), 9.70 (br s, 1H), 8.70 (d, 7.9 Hz, 1H), 8.60 (s, 1H), 8.33 (d, 8.2 Hz, 1H), 7.70 (ddd, 8.3, 7.0, 1.2 Hz, 1H), 7.67-7.52 (m, 1H), 7.33 (d, 7.7 Hz, 1H), 7.23 (td, 7.9, 1.6 Hz, 1H), 7.15 (td, 7.4, 1.1 Hz, 1H), 6.40 (br s, 1H), 3.97 (s, 3H).	479.2	B	
I-223		Cc1ccccc1C1NC(=O)c2c1c(NC(=O)c1csc3ccccc13)ccc2CNC(=O)C(F)(F)F	1H NMR (400 MHz, DMSO-d6) 10.11-10.04 (m, 2H), 9.17 (s, 1H), 8.05-7.97 (m, 2H), 7.62 (s, 1H), 7.55 (d, 8.1 Hz, 1H), 7.42-7.37 (m, 3 H), 7.10 (td, 7.6, 1.1 Hz, 1H), 7.05-6.95 (m, 2H), 6.62 (br s, 1H), 6.02 (s, 1H), 5.02	524.2	B	





			(d, 5.8 Hz, 2H), 2.20 (br s, 3H).			
I-224		Cc1ccccc1C1NC(=O)c2c1c(NC(=O)c1csc3ccccc13)ccc2CO	1H NMR (400 MHz, DMSO-d6) 10.07 (s, 1H), 9.11 (s, 1H), 8.08-7.99 (m, 2H), 7.63 (d, 8.0 Hz, 2H), 7.53 (d, 8.1 Hz, 1H), 7.43-7.35 (m, 2H), 7.09 (t, 7.4 Hz, 1H), 7.03-6.94 (m, 2H), 6.62 (br s, 1H), 6.02 (s, 1H), 5.04 (s, 2H), 2.19 (br s, 3H).	429.3	A	
I-225		Cc1ccccc1C1NC(=O)c2c1c(NC(=O)c1nsc3ccccc13)ccc2C(=O)N1CC(C1)S(C)(=O)=O	1H NMR (400 MHz, DMSO-d6) 10.22 (br s, 1H), 9.26 (d, 5.2 Hz, 1H), 8.59 (d, 8.1 Hz, 1H), 8.30 (d, 8.2 Hz, 1H), 7.89 (t, 8.1 Hz, 1H), 7.71-7.64 (m, 1H), 7.59 (t, 7.6 Hz, 1H), 7.52 (dd, 8.1, 4.1 Hz, 1H), 7.06-6.95 (m, 2H), 6.92 (br s, 1H), 6.67 (br s, 1H), 6.15 (s, 1H), 4.43-4.32 (m, 2H), 4.23-4.19 (m, 2H), 4.06 (ddd, 13.1, 9.2, 3.5 Hz, 1H), 3.08 (d, 6.8 Hz, 3H), 2.27 (br s, 3H).	561.3	B	
I-226		Cc1ccccc1C1NC(=O)c2cccc(NC(=O)C34CCC(C3)c3ccccc43)c12	1H NMR (400 MHz, DMSO-d6) 9.02 (br s, 1H), 8.99 (br s, 1H), 8.80 (br s, 2H), 7.67-7.53 (m, 6H), 7.23-7.10 (m, 6H), 7.09-6.91 (m, 6H), 6.85 (d, 7.2 Hz, 1H), 6.66-6.58 (m, 3H), 6.07 (s, 2H), 3.31 (dd, 11.4, 3.4 Hz, 2H), 2.29 (br. s, 6H), 1.93-1.84 (m, 2H), 1.81-1.76 (m, 1H), 1.76-1.64 (m, 3H), 1.44 (d, 8.7 Hz, 1H), 1.36 (d, 8.7 Hz, 1H), 1.22-1.14 (m, 1H), 1.14-1.08 (m, 1H), 1.08-0.99 (m, 2H). Spectrum recorded at 70 ºC (343K).	409.4	D	




I-227		Cc1ccccc1[C@@H]1NC(=O)c2nccc(NC(=O)N3CCc4ccccc34)c12	1H NMR (400 MHz, DMSO-d6) 9.34 (s, 1H), 8.83 (br s, 1H), 8.64 (d, 5.3 Hz, 1H), 7.64 (d, 7.8 Hz, 1H), 7.42 (d, 5.4 Hz, 1H), 7.18-7.07 (m, 3H), 7.04-6.95 (m, 2H), 6.92 (t, 7.1 Hz, 1H), 6.55 (br s, 1H), 5.90 (s, 1H), 3.62-3.52 (m, 1H), 3.01-2.78 (m, 3H), 2.11 (br s, 3H)	385.2	B	
I-228		Cc1ccccc1[C@H]1NC(=O)c2nccc(NC(=O)N3CCc4ccccc34)c12	1H NMR (400 MHz, DMSO-d6) 9.34 (s, 1H), 8.83 (br s, 1H), 8.64 (d, 5.3 Hz, 1H), 7.64 (d, 7.8 Hz, 1H), 7.42 (d, 5.4 Hz, 1H), 7.18-7.07 (m, 3H), 7.04-6.95 (m, 2H), 6.92 (t, 7.1 Hz, 1H), 6.55 (br s, 1H), 5.90 (s, 1H), 3.62-3.52 (m, 1H), 3.01-2.78 (m, 3H), 2.11 (br s, 3H)	385.4	E	
I-229		Cc1ccccc1[C@@H]1NC(=O)c2nccc(NC(=O)N3CCc4c3cc(F)cc4F)c12	1H NMR (400 MHz, DMSO-d6) 9.33 (s, 1H), 9.06 (br s, 1H), 8.63 (d, 5.3 Hz, 1H), 7.33 (d, 5.3 Hz, 1H), 7.26 (d, 10.3 Hz, 1H), 7.12 (td, 7.4, 1.0 Hz, 1H), 6.96 (dd, 17.5, 7.5 Hz, 2H), 6.75 (td, 9.5, 2.2 Hz, 1H), 6.63-6.40 (m, 1H), 5.82 (s, 1H), 3.74-3.57 (m, 1H), 3.02-2.82 (m, 2H), 2.76 (ddd, 25.2, 16.0, 11.6 Hz, 1H), 2.13 (m, 3H).	421.2	C	
I-230		Cc1ccccc1[C@H]1NC(=O)c2nccc(NC(=O)N3CCc4c3cc(F)cc4F)c12	1H NMR (400 MHz, DMSO-d6) 9.33 (s, 1H), 9.06 (br s, 1H), 8.63 (d, 5.3 Hz, 1H), 7.33 (d, 5.3 Hz, 1H), 7.26 (d, 10.3 Hz, 1H), 7.12 (td, 7.4, 1.0 Hz, 1H), 6.96 (dd, 17.5, 7.5 Hz, 2H), 6.75 (td, 9.5, 2.2 Hz, 1H), 6.63-6.40 (m, 1H), 5.82 (s, 1H), 3.74-3.57 (m, 1H),	421.3	E	





			3.02-2.82 (m, 2H), 2.76 (ddd, 25.2, 16.0, 11.6 Hz, 1H), 2.13 (m, 3H).			
I-231		CS(=O)(=O)Cc1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(Cl)c2)c1)c1cc(F)ccc1Cl	1H NMR (400 MHz, DMSO-d6) 2.84-3.03 (m, 3H), 3.97-4.15 (m, 1 H), 4.59-4.78 (m, 2H), 5.81-6.08 (m, 1H), 6.54-6.76 (m, 1H), 7.05-7.17 (m, 1H), 7.31-7.36 (m, 1H), 7.36-7.40 (m, 2H), 7.49-7.69 (m, 5H), 7.71-7.79 (m, 1H), 8.99-9.36 (m, 1 H), 10.24-10.55 (m, 1H)	525	A	
I-232		Cc1ccccc1C1NC(=O)c2c1c(NC(=O)c1cc(F)cc(c1)C(F)(F)F)cnc2Cl		464.36	B	
I-233		Cc1ccccc1C1NC(=O)c2cncc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	1H NMR (400 MHz, DMSO-d6) 10.65 (s, 1H), 9.28 (s, 1H), 8.88 (s, 1H), 8.69 (s, 1H), 7.91 (br d, 8.54 Hz, 1H), 7.53 (br d, 8.54 Hz, 1H), 7.40 (br s, 1H), 7.03-7.11 (m, 1H), 6.93-7.02 (m, 2H), 6.50-6.64 (m, 1H), 5.95 (br s, 1H), 2.01-2.33 (m, 3H)	430.45	B	
I-234		Fc1cc(OC(F)(F)F)cc(c1)C(=O)Nc1ccnc2C(=O)NC(c12)c1ccccc1Cl	^{1}H NMR (400 MHz, DMSO-d_6) δ 10.48-10.87 (m, 1H), 9.35-9.58 (m, 1H), 8.77 (d, J =5.13 Hz, 1H), 7.65 (br d, J =8.79 Hz, 1H), 7.54 (d, J =5.37 Hz, 1H), 6.57-7.42 (m, 6H), 5.91-6.20 (m, 1H).	466.3	D	
I-235		Fc1cc(cc(c1)C(=O)Nc1ccnc2C(=O)NC(c12)c1ccccc1Cl)C#N	^{1}H NMR (400 MHz, DMSO-d_6) δ 10.49-10.99 (m, 1H), 9.46 (br s, 1H), 8.75 (d, J =5.13 Hz, 1H), 8.08 (br d, J =7.81 Hz, 1H), 7.46-7.75 (m, 3H), 6.63-7.39	407.3	E	





			(m, 4H), 5.86-6.20 (m, 1H).			
I-236		Cc1ccccc1C1NC(=O)c2c1c(NC(=O)c1cc(F)cc(c1)C(F)(F)F)cnc2C#N	1H NMR (400 MHz, DMSO-d6) 10.99 (br s, 1H), 9.67 (s, 1H), 8.84 (s, 1H), 7.93 (br d, 8.30 Hz, 1H), 7.51 (br d, 8.79 Hz, 1H), 7.35 (br s, 1H), 7.05-7.12 (m, 1H), 6.93-7.03 (m, 2H), 6.61 (br s, 1H), 6.01 (s, 1H), 2.07-2.37 (m, 3H)	455.41	D	
I-237		FC(F)c1ccc(F)cc1C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)C#N			A	
I-238		CC(=O)c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1C(F)F	^{1}H NMR (400 MHz, DMSO-d_6) δ 10.61 (s, 1 H) 9.33 (s, 1 H) 8.24 (d, J =1.52 Hz, 1 H) 8.07 (d, J =1.52 Hz, 1 H) 7.92 (br d, J =8.34 Hz, 1 H) 7.69 (br d, J =9.09 Hz, 1 H) 7.60 (s, 1 H) 7.49 (dd, J =8.84, 5.56 Hz, 1 H) 7.21 (td, J =8.40, 2.65 Hz, 2 H) 6.50 (br s, 1 H) 6.10 (s, 1 H) 2.71 (s, 3 H).		A	
I-239		CC(C)(O)c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1C(F)F	^{1}H NMR (400 MHz, DMSO-d_6) δ 10.47 (s, 1 H) 9.10 (s, 1 H) 7.89 (br d, J =8.08 Hz, 1 H) 7.80 (s, 1 H) 7.68 (br d, J =9.09 Hz, 1 H) 7.55 - 7.63 (m, 2 H) 7.47 (dd, J =8.59, 5.56 Hz, 1 H) 7.19 (td, J =8.46, 2.53 Hz, 1 H) 6.44 (br d, J =2.53 Hz, 1 H) 5.95 (s, 1 H) 5.31 (s, 1 H) 1.51 (s, 6 H).		A	





I-240		Clc1cccc c1C1NC(=O)c2ncc c(NC(=O)c3ccnc4 CCCc34) c12	^{1}H NMR (500 MHz, DMSO-d_6) δ 10.36-10.57 (m, 1H), 8.66-8.87 (m, 1H), 8.30-8.47 (m, 1H), 7.44-7.54 (m, 1H), 7.24-7.39 (m, 2H), 6.79-7.09 (m, 2H), 6.38-6.57 (m, 2H), 5.67-5.83 (m, 1H), 4.68-4.91 (m, 1H), 2.74-3.00 (m, 3H), 2.25-2.44 (m, 1H), 1.78-2.07 (m, 2H).	405.3	E	
I-241		Cn1ncc(C2NC(= O)c3cccc (NC(=O) c4nsc5cc ccc45)c2 3)c1C(F) F	^{1}H NMR (400 MHz, DMSO-d_6) δ 10.23-10.40 (m, 1H), 8.83-9.08 (m, 1H), 8.61 (d, J =8.30 Hz, 1H), 8.31 (d, J =8.30 Hz, 1H), 7.80 (dd, J =1.22, 7.08 Hz, 1H), 7.49-7.73 (m, 4H), 6.90-7.32 (m, 2H), 6.08 (s, 1H), 3.67 (s, 3H).	440.4	E	
I-242		CC(C)(O)c1cc(NC (=O)c2cc (F)cc(c2) C(F)(F)F)c2C(NC (=O)c2n1)c1cc(F)c cc1Cl	1H NMR (400 MHz, DMSO-d6) 10.86 (s, 1H), 9.46 (s, 1H), 7.97 (d, 7.4 Hz, 1H), 7.80 (s, 1H), 7.75 (d, 8.8 Hz, 1H), 7.64 (s, 1H), 7.33 (dd, 8.9, 5.2 Hz, 1H), 7.17-7.02 (m, 1H), 6.77 (br s, 1H), 5.99 (br s, 1H), 5.47 (s, 1H), 1.56 (s, 3H), 1.51 (s, 3H).	526.4	B	
I-243		CN(C)c1 ncc(NC(=O)c2cc(F)cc(c2) C(F)(F)F)c2C(NC (=O)c12) c1ccccc1 C	1H NMR (400 MHz, DMSO-d6) 10.12 (s, 1H), 8.82 (s, 1H), 8.43 (br s, 1H), 8.13 (s, 1H), 7.86 (br d, 8.54 Hz, 1H), 7.48 (br d, 9.27 Hz, 1H), 7.37 (s, 1H), 7.00-7.08 (m, 1H), 6.89-6.98 (m, 1H), 6.66 (br s, 1H), 6.61 (br s, 1H), 5.74 (s, 1H), 3.19 (s, 3H), 2.11 (br s, 3H)	473.52	C	





I-244		Cc1ccccc1C1NC(=O)c2c1c(NC(=O)c1cc(F)cc(c1)C(F)(F)F)cnc2C	1H NMR (400 MHz, DMSO-d6) 10.50 (br s, 1H), 9.16 (br s, 1H), 8.48-8.54 (m, 1H), 7.89 (br d, 8.30 Hz, 1H), 7.51 (br d, 8.54 Hz, 1H), 7.39 (br s, 1H), 7.03-7.10 (m, 1H), 6.91-7.02 (m, 2H), 6.58 (br s, 1H), 5.86 (br s, 1H), 3.29 (s, 3H), 2.83 (s, 3H)	444.45	B	
I-245		Fc1ccc(NC(=O)Nc2ccnc3C(=O)NC(c23)c2cccc2Cl)c(F)c1	^{1}H NMR (400 MHz, DMSO-d_6) δ 9.39 (br s, 1H), 8.79 (br s, 2H), 8.63 (br d, J = 5.4 Hz, 1H), 7.79-7.87 (m, 1H), 7.76 (br d, J = 3.9 Hz, 1H), 7.46 (br d, J = 7.6 Hz, 1H), 7.32-7.37 (m, 1H), 7.20-7.31 (m, 2H), 7.04 (br t, J = 8.2 Hz, 1H), 6.76-6.91 (m, 1H), 6.10 ppm (br s, 1H).	415.3	D	
I-246		Cc1ccccc1[C@@H]1NC(=O)c2nccc(NC(=O)N3CCc4ccc(F)cc34)c12	1H NMR (400 MHz, DMSO-d6) 9.35 (s, 1H), 8.95 (br s, 1H), 8.66 (d, 5.3 Hz, 1H), 7.43-7.38 (m, 2H), 7.20-7.09 (m, 2H), 7.01-6.96 (m, 2H), 6.79-6.70 (m, 1H), 6.55(br s, 1H), 5.88 (s, 1H), 3.68-3.61 (m, 1H), 3.03-2.75 (m, 3H), 2.29-2.00 (br s, 3H).	403.3	B	
I-247		Cc1ccccc1[C@H]1NC(=O)c2nccc(NC(=O)N3CCc4ccc(F)cc34)c12	1H NMR (400 MHz, DMSO-d6) 9.35 (s, 1H), 8.95 (br s, 1H), 8.66 (d, 5.3 Hz, 1H), 7.43-7.38 (m, 2H), 7.20-7.09 (m, 2H), 7.01-6.96 (m, 2H), 6.79-6.70 (m, 1H), 6.55(br s, 1H), 5.88 (s, 1H), 3.68-3.61 (m, 1H), 3.03-2.75 (m, 3H), 2.29-2.00 (br s, 3H).	403.3	E	





I-248		Cc1ccccc1C1NC(=O)c2nccc(NC(=O)N3CCc4cnccc34)c12	1H NMR (400 MHz, DMSO-d6) 9.36 (s, 1H), 9.10 (br s, 1H), 8.67 (d, 5.3 Hz, 1H), 8.27 (s, 1H), 8.24 (d, 5.4 Hz, 1H), 7.50 (d, 5.4 Hz, 1H), 7.41 (d, 5.3 Hz, 1H), 7.14 (td, 7.5, 1.1 Hz, 1H), 7.01 (d, 7.7 Hz, 1H), 6.97 (t, 7.4 H, 1Hz), 6.55 (br s, 1H), 5.86 (s,1H), 370-3.63 (m, 1H), 3.11-2.79 (m, 3H), 2.16 (br s, 3H).	386.3	E	
I-249		CC1CN(C(=O)Nc2ccnc3C(=O)NC(c23)c2ccccc2C)c2ccccc12	1H NMR (400 MHz, DMSO-d6) 9.31 (s, 2H), 8.78 (br s, 1H), 8.67 (br s, 1H), 8.61 (s, 1H), 8.60 (s, 1H), 7.64 (d, 8.0 Hz, 1H), 7.59 (d, 8.1 Hz, 1H), 7.46 (d, 5.4 Hz, 1H), 7.40 (d, 5.3 Hz, 1H), 7.17-7.05 (m, 6H), 7.03-6.87 (m, 6H), 6.49 (br s, 2H), 5.89 (s, 1H), 5.88 (s, 1H), 3.79-3.65 (m, 2H), 3.25-3.08 (m, 2H), 2.99 (dd, 8.9, 5.9 Hz, 1H), 2.51 (dd, 10.0, 6.7 Hz, 1H), 2.15 (br s, 6H), 1.09 (d, 7.6 Hz, 3H), 1.04 (d, 6.8 Hz, 3H).	397.4	B	
I-250		CC(C)(O)c1cc(NC(=O)c2nsc3ccccc23)c2C(NC(=O)c2n1)c1ccccc1Cl	1H NMR (400 MHz, DMSO-d6) 10.40 (s, 1H), 9.47 (s, 1H), 8.65 (d, 8.1 Hz, 1H), 8.32 (d, 8.2 Hz, 1H), 8.23 (s, 1H), 7.72-7.66 (m, 1H), 7.65-7.59 (m, 1H), 7.58-7.54 (m, 1H), 7.33 (d, 7.7 Hz, 1H), 7.22 (td, 7.7, 1.8 Hz, 1H), 7.15 (td, 7.6, 1.2 Hz, 1H), 6.31 (br s, 1H), 5.44 (s, 1H), 1.56 (s, 3H), 1.52 (s, 3H).	479.2	A	





I-251		Cc1ccccc1C1NC(=O)c2nccc(NC(=O)N3CCc4ccncc34)c12	1H NMR (400 MHz, DMSO-d6) 9.36 (s, 1H), 9.02 (s, 1H), 8.84 (s, 1H), 8.67 (d, 5.3 Hz, 1H), 8.15 (d, 4.9 Hz, 1H), 7.39 (d, 5.4 Hz, 1H), 7.24 (d, 4.7 Hz, 1H), 7.13 (td, 7.5, 1.2 Hz, 1H), 6.97 (m,, 2H), 6.54 (br s, 1H), 5.88 (s, 1H), 3.71-3.55 (m, 1H), 3.09-2.77 (m, 3H), 2.11 (br s, 3H).	386.4	E	
I-252		Cc1ccccc1-n1[nH]c(=O)c2ccc(NC(=O)c3coc4c(F)cc(Cl)cc34)c12	1H NMR (400 MHz, DMSO-d6) 11.15 (br s, 1H), 9.85 (s, 1H), 8.17 (s, 1H), 7.72 (dd, 8.0, 3.9 Hz, 1H), 7.59 (d, 1.8 Hz, 1H), 7.53 (dd, 10.7, 1.9 Hz, 1H), 7.26 (d, 7.0 Hz, 1H), 7.14 (dd, 7.9, 7.4 Hz, 1H), 7.07 (dd, 7.7, 1.1 Hz, 1H), 6.97-6.92(m, 2H), 6.87 (td, 7.5, 1.1 Hz, 1H), 2.06 (s, 3H).	436.1	B	
I-253		Cc1ccccc1C1NC(=O)c2c1c(NC(=O)c1cc(F)cc(c1)C(F)(F)F)cnc2N1CCOCC1	1H NMR (400 MHz, DMSO-d6) 10.19 (s, 1H), 8.98 (s, 1H), 8.17 (s, 1H), 7.85 (d, 8.4 Hz, 1H), 7.45 (d, 8.8 Hz, 1H), 7.33 (s, 1H), 7.06-6.83 (m, 3H), 6.60 (s, J, 1H), 5.75 (s), 3.80-3.66 (m, 6H), 3.63-3.51 (m, 2H), 2.15 (s, 3H).	515.3	D	
I-254		Cc1ccccc1C1NC(=O)c2c1c(NC(=O)c1cc(F)cc(c1)C(F)(F)F)cnc2-c1cnn(C)c1	1H NMR (400 MHz, DMSO-d6) 9.24 (s, 1H), 8.90 (s, 1H), 8.59 (s, 1H), 8.38 (s, 1H), 7.87 (d, 8.7 Hz, 1H), 7.49 (d, 8.8 Hz, 1H), 7.36 (s, 1H), 7.08-7.01 (m, 1H), 7.0-6.90 (m, 2H), 6.64 (s, 1H), 5.88 (s, 1H), 3.91 (s, 3H), 2.33-2.00 (m, 60.5 Hz, 3H).	510.2	B	





I-255		Fc1ccc(Cl)c(c1)C1NC(=O)c2c1c(NC(=O)c1cc(F)cc(c1)C(F)(F)F)cnc2N1CCOCC1	1H NMR (400 MHz, CD3OD) 8.16 (s, 1H), 7.74-7.55 (m, 3H), 7.24 (dd, 8.9, 5.0 Hz, 1H), 7.10-6.91 (m, 1H), 6.80-6.61 (bs, 1H), 6.03 (bs, 1H), 3.93-3.71 (m, 6H), 3.71-3.57 (m, 2H),	553.3	D	
I-256		Cc1ccccc1C1NC(=O)c2ccccc(NC(=O)C3CCc4ccccc34)c12	1H NMR (400 MHz, DMSO-d6) 9.87 (s, 0.6H), 9.85 (s, 0.4H), 9.01 (s, 0.4H), 8.98 (s, 0.6H), 7.65-7.53 (m, 2.4H), 7.47 (d, 1.2 Hz, 0.6H), 7.28-7.16 (m, 2.4H), 7.16-7.09 (m, 1.7H), 7.08-6.91 (m, 2H), 6.61 (d, 7.5 Hz, 0.4H), 6.45 (br s, 1.3H), 6.02 (s, 1H), 3.79-3.68 (m, 1H), 2.95-2.82 (m, 1H), 2.81-2.66 (m, 1H), 2.33 (br s, 1H), 2.16 (s, 2H), 2.06-1.94 (m, 1H), 1.94-1.82 (m, 1H).	383.3	D	
I-257		Fc1ccc(Cl)c(c1)C1NC(=O)c2nccc(NC(=O)N3CCc4ccccc34)c12	1H NMR (400 MHz, DMSO-d6) 9.37 (s, 1H), 9.11 (s, 1H), 8.64 (s, 1H), 8.50 (s, 1H), 7.67 (d, 7.7 Hz, 1H), 7.41 (s, 1H), 7.35 (dd, 8.8, 5.2 Hz, 1H), 7.21-7.14 (m, 2H), 7.14-7.07 (m, 1H), 6.92 (t, 7.1 Hz, 1H), 6.72 (br s, 1H), 5.97 (br s, 1H), 3.89-3.75 (m, 1H), 3.25-3.16 (m, 1H), 3.08-2.87 (m, 2H)	423.6	C	
I-258		Cc1ccccc1C1NC(=O)c2cccc(NC(=O)c3ncn4ccc(Cl)cc34)c12	1H NMR (400 MHz, DMSO-d6) 9.29 (s, 1H), 9.02 (s, 1H), 8.52 (dd, 7.4, 0.8 Hz, 1H), 8.42 (s, 1H), 8.03-7.98 (m, 2H), 7.56 (d, 1.7 Hz, 1H), 7.55 (s, 1H), 7.09-7.02 (m, 2H), 7.01-6.94 (m, 2H), 6.69 (br. s, 1H), 6.15 (s, 1H), 2.35 (br. s, 3H).	417.2	D	





I-259		Fc1cc(cc(c1)C(F)(F)F)C(=O)Nc1ccc c2C(=O)NC(C3CC3)c12	1H NMR (400 MHz, DMSO-d6) 10.68 (s, 1H), 8.70 (s, 1H), 8.23 (s, 1H), 8.16 (d, 9.2 Hz, 1H), 8.04 (d, 8.5 Hz, 1H), 7.62 (dd, 6.9, 2.1 Hz, 1H), 7.58-7.54 (m, 2H), 4.37 (d, 7.4 Hz, 1H), 0.84-0.74 (m, 1H), 0.42-0.24 (m, 3H), 0.16 (m, 1H).	379.2	E	
I-260		Cc1ccccc1C1NC(=O)c2cc(CN)cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	1H NMR (400 MHz, CD3OD) 7.89 (s, 1H), 7.67-7.65 (m, 2H), 7.40-7.37 (m, 2H), 7.13 (td, 1.2, 7.7 Hz, 1H), 7.04 (d, 7.5 Hz, 1H), 6.99 (br t, 6.0 Hz, 1H), 6.60 (br s, 1H), 6.05 (s, 1H), 4.29 (br s, 2H), 2.30 (br s, 3H).	458.3	B	
I-261		Cc1ccccc1C1NC(=O)c2c1c(NC(=O)c1nsc3ccccc13)ccc2C(=O)NCC(N)=O	1H NMR (400 MHz, DMSO-d6) 10.59 (t, 5.8 Hz, 1H), 10.14 (br s, 1H), 9.66 (s, 1 H), 8.60 (d, 8.1 Hz, 1H), 8.31 (d, 8.2 Hz, 1H), 8.05 (d, 8.3 Hz, 1H), 7.96 (d, 8.3 Hz, 1H), 7.91 (s, 1H), 7.68 (ddd, 8.2, 7.0, 1.2 Hz, 1H), 7.59 (ddd, 8.0, 7.0, 0.9 Hz, 1H), 7.18 (s, 1 H), 7.04-6.97 (m, 2H), 6.97-6.90 (m, 1 H), 6.70 (br s, 1H), 6.22 (s, 1H), 3.90 (d, 6.2 Hz, 2H), 2.35 (br s, 3H).	500.3	A	
I-262		Cc1ccccc1C1NC(=O)c2c1c(NC(=O)c1cc(F)cc(c1)C(F)(F)F)cnc2N	1H NMR (400 MHz, DMSO-d6) 10.03 (s, 1H), 8.83 (s, 1H), 7.90-8.00 (m, 1H), 7.79 (br d, 8.34 Hz, 1H), 7.41-7.52 (m, 1H), 7.36 (s, 1H), 6.97-7.04 (m, 1H), 6.84-6.95 (m, 2H), 6.58-6.75 (m, 3H), 5.73 (s, 1H), 1.97-2.19 (m, 3H)	445.35	B	





I-263		CC(C)(O)c1cc2C(=O)N[C@@H](c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1C(F)F	^{1}H NMR (400 MHz, DMSO-d_6) δ 10.47 (s, 1 H) 9.10 (s, 1 H) 7.89 (br d, J =8.08 Hz, 1 H) 7.80 (s, 1 H) 7.68 (br d, J =9.09 Hz, 1 H) 7.55 - 7.63 (m, 2 H) 7.47 (dd, J =8.59, 5.56 Hz, 1 H) 7.19 (td, J =8.46, 2.53 Hz, 1 H) 6.44 (br d, J =2.53 Hz, 1 H) 5.95 (s, 1 H) 5.31 (s, 1 H) 1.51 (s, 6 H).		E	
I-264		CC(C)(O)c1cc2C(=O)N[C@H](c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1C(F)F	^{1}H NMR (400 MHz, DMSO-d_6) δ 10.47 (s, 1 H) 9.10 (s, 1 H) 7.89 (br d, J =8.08 Hz, 1 H) 7.80 (s, 1 H) 7.68 (br d, J =9.09 Hz, 1 H) 7.55 - 7.63 (m, 2 H) 7.47 (dd, J =8.59, 5.56 Hz, 1 H) 7.19 (td, J =8.46, 2.53 Hz, 1 H) 6.44 (br d, J =2.53 Hz, 1 H) 5.95 (s, 1 H) 5.31 (s, 1 H) 1.51 (s, 6 H).		A	B
I-265		Cc1ccccc1C1NC(=O)c2c1c(NC(=O)c1cc(F)cc(c1)C(F)(F)F)cnc2C(N)=O	1H NMR (400 MHz, DMSO-d6) 10.68 (br s, 1H), 9.47 (s, 1H), 8.79-8.91 (m, 1H), 8.71 (br s, 1H), 7.90 (br d, 6.83 Hz, 1H), 7.70 (br s, 1H), 7.53 (br d, 9.03 Hz, 1H), 7.39 (br s, 1H), 6.94-7.12 (m, 2H), 6.52-6.65 (m, 1H), 5.95 (br s, 1H), 2.07-2.35 (m, 3H)	473.4	B	
I-266		CC(C)c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1ccccc1C	1H NMR (400 MHz, DMSO-d6) 1.29 (d, 6.82 Hz, 6H), 2.17 (br d, 1.26 Hz, 3H), 3.02-3.14 (m, 1H), 5.85 (s, 1H), 6.60 (s, 1H), 6.87-6.99 (m, 2H), 7.01-7.09 (m, 1H), 7.33-7.41 (m, 2H), 7.49 (br d, 8.84 Hz, 1H), 7.55 (d, 1.26 Hz, 1H), 7.87 (br d, 8.59 Hz, 1H), 8.99 (s, 1H), 10.33 (s, 1H)	471.4	B	






I-267		CC(C)(O)c1cc2C(=O)NC(c2c(NC(=O)c2cc(Cl)n3ccccc23)c1)c1cc(F)ccc1C(F)F	^{1}H NMR (400 MHz, DMSO-d_6) δ 9.67 (s, 1 H) 9.05 (s, 1 H) 8.15 - 8.28 (m, 2 H) 7.72 (d, *J* =1.52 Hz, 1 H) 7.62 (d, *J* =1.52 Hz, 1 H) 7.38 (dd, *J* =8.72, 5.68 Hz, 1 H) 7.07 - 7.24 (m, 4 H) 7.00 (td, *J* =6.95, 1.26 Hz, 1 H) 6.39 (br d, *J* =9.35 Hz, 1 H) 6.08 (s, 1 H) 5.27 (s, 1 H) 1.51 (s, 6 H).		A	
I-268		CC(C)Cc1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1ccccc1C	1H NMR (400 MHz, DMSO-d6) 0.91 (dd, 6.57, 1.26 Hz, 6H), 1.91 (tt, 13.45, 6.63 Hz, 1H), 2.04-2.24 (m, 2H), 2.51-2.70 (m, 3H), 5.85 (br s, 1H), 6.62 (s, 1H), 6.90-7.07 (m, 3H), 7.30 (s, 1H), 7.36 (br s, 1H), 7.42-7.50 (m, 2H), 7.86 (br d, 8.59 Hz, 1H), 8.98 (s, 1H), 10.30 (s, 1H)	485.4	A	
I-269		Nc1cc(NC(=O)c2cc(F)cc(c2)C(F)(F)F)cc2C(=O)NC(c12)c1cc(F)ccc1C(F)F			E	
I-270		OC(c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl)C(F)(F)F	1H NMR (400 MHz, DMSO-d6) 5.44 (dt, 13.07, 6.47 Hz, 1H), 5.97 (br s, 1H), 7.05-7.15 (m, 2H), 7.30 (dd, 8.84, 5.31 Hz, 1H), 7.60-7.68 (m, 2H), 7.74 (br d, 8.59 Hz, 1H), 7.82 (br d, 4.29 Hz, 1H), 7.93 (br d, 8.34 Hz, 1H), 9.19 (br s, 1H), 10.57 (br d, 8.34 Hz, 1H)	565	A	






I-271		CC(C)(O)c1cc(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c2[C@H](NC(=O)c2n1)c1cc(F)ccc1Cl	^{1}H NMR (400 MHz, DMSO-d_6) δ 10.86 (s, 1H), 9.46 (s, 1H), 7.97 (d, J = 7.4 Hz, 1H), 7.80 (s, 1H), 7.75 (d, J = 8.8 Hz, 1H), 7.64 (s, 1H), 7.33 (dd, J = 8.9, 5.2 Hz, 1H), 7.17 – 7.02 (m, 1H), 6.77 (br s, 1H), 5.99 (br s, 1H), 5.47 (s, 1H), 1.56 (s, 3H), 1.51 (s, 3H).	526.4	D	
I-272		CC(C)(O)c1cc(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c2[C@@H](NC(=O)c2n1)c1cc(F)ccc1Cl	^{1}H NMR (400 MHz, DMSO-d_6) δ 10.86 (s, 1H), 9.46 (s, 1H), 7.97 (d, J = 7.4 Hz, 1H), 7.80 (s, 1H), 7.75 (d, J = 8.8 Hz, 1H), 7.64 (s, 1H), 7.33 (dd, J = 8.9, 5.2 Hz, 1H), 7.17 – 7.02 (m, 1H), 6.77 (br s, 1H), 5.99 (br s, 1H), 5.47 (s, 1H), 1.56 (s, 3H), 1.51 (s, 3H).	526.4	B	
I-273		Nc1cc(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c2C(NC(=O)c2n1)c1cc(F)ccc1Cl	^{1}H NMR (400 MHz, DMSO-d_6) δ 10.47 (s, 1H), 9.14 (br s, 1H), 7.94 (br d, J = 8.3 Hz, 1H), 7.67 (br d, J = 8.8 Hz, 1H), 7.56 (s, 1H), 7.31 (dd, J = 8.8, 5.1 Hz, 1H), 7.07 (td, J = 8.1, 2.4 Hz, 1H), 6.76-6.89 (m, 1H), 6.41-6.67 (m, 3H), 5.83 (br s, 1H).	483.4	B	
I-274		Fc1ccc(Cl)c(c1)C1(Cl)NC(=O)c2c1c(NC(=O)c1cc(F)cc(c1)C(F)(F)F)cnc2N1CC(F)(F)C1	1H NMR (400 MHz, CD3OD) 8.71 (s, 1H), 7.87 (s, 1H), 7.77 (d, 8.6 Hz, 1H), 7.68-7.58 (m, 2H), 7.49-7.32 (m, 1H), 7.14-6.97 (m, 1H), 3.82-3.56 (m, 4H).	593.1	D	





I-275		FC(F)CNc1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	1H NMR (400 MHz, DMSO-d6) 3.49-3.66 (m, 2H), 5.82 (br s, 1H), 5.98-6.31 (m, 2H), 6.52 (br t, 6.35 Hz, 1H), 6.80 (s, 1H), 6.94 (d, 1.71 Hz, 1H), 7.05 (td, 8.36, 3.05 Hz, 1H), 7.27 (dd, 8.79, 5.13 Hz, 1H), 7.61 (s, 1H), 7.69 (br d, 8.79 Hz, 1H), 7.90 (br d, 8.30 Hz, 1H), 8.92 (br s, 1H), 10.29 (s, 1H)	546.26	A	
I-276		Cc1ccccc1C1NC(=O)c2c1c(NC(=O)c1nsc3ccccc13)ccc2C(=O)NCC(F)F	1H NMR (400 MHz, DMSO-d6) 11.78 (t, 5.5 Hz, 1H), 10.09 (s, 1H), 9.91 (s, 1H), 8.60 (d, 8.3 Hz, 1H), 8.38 (d, 8.4 Hz, 1H), 8.33-8.29 (m, 1H), 8.08 (d, 8.5 Hz, 1H), 7.68 (ddd, 8.2, 7.0, 1.2 Hz, 1H), 7.59 (ddd, 8.0, 7.0, 0.9 Hz, 1H), 7.05-7.00 (m, 2H), 6.98-6.90 (m, 1H), 6.64 (br s, 1H), 6.26 (s, 1H), 6.23 (tt, 55.7, 3.7 Hz, 1H), 3.85 (tdd, 16.4, 5.5, 4.0 Hz, 2H), 2.29 (br s, 3H).	507.2	A	
I-277		Cc1nc(C(=O)Nc2cccc3C(=O)NC(c23)c2ccccc2C)c2cc(Cl)ccn12	1H NMR (400 MHz, DMSO-d6) 9.05 (s, 1H), 9.04 (s, 1H), 8.33 (dd, 7.6, 0.5 Hz, 1H), 8.17 (dd, 7.4, 1.3 Hz, 1H), 7.98 (dd, 2.1, 0.7 Hz), 7.59-7.50 (m, 2H), 7.17 (br. d, 7.4 Hz, 1H), 7.14-7.08 (m, 1H), 7.03 (br. t, 7.2 Hz, 1H), 6.97 (dd, 7.5, 2.1 Hz, 1H), 6.72 (br. s, 1H), 6.12 (s, 1H), 2.61 (s, 3H), 2.45 (br. s, 3H).	431.3	E	
I-278		Cc1ccccc1C1NC(=O)c2c1c(NC(=O)c1nsc3ccccc13)ccc2C(O)=O	1H NMR (400 MHz, DMSO-d6) 10.31 (br s, 1H), 8.61 (d, 8.1 Hz, 1 H), 8.31 (d, 8.2 Hz, 1H), 8.28 (d, 8.2 Hz, 1H), 8.10 (d, 8.3 Hz, 1H), 7.68 (ddd, 8.2, 7.0, 1.1 Hz, 1H), 7.63-	444.2	C	




			7.57 (m, 1H), 7.43-7.27 (m), 7.11-7.02 (m , 2 H), 6.96 (d, 6.1 Hz, 1H), 6.85 (br s, 1H), 6.38 (s, 1H), 2.39 (br s, 3H).			
I-279		Cc1ccccc1C1NC(=O)c2c1c(NC(=O)c1cc(F)cc(c1)C(F)(F)F)ccc2Br	1H NMR (400 MHz, DMSO-d6) 10.37 (s, 1H), 9.25 (s, 1H), 7.89 (d, 8.5 Hz, 1H), 7.79 (d, 8.3 Hz, 1 H), 7.46 (8.4 Hz, 1H), 7.31 (s, 1H), 7.07 (td, 7.5, 1.2 Hz, 1H), 7.03-6.91 (m, 2H), 6.53 (br s, 1H), 5.87 (s, 1H), 2.22 (br s, 3H).	507.2	B	
I-280		CC(O)c1cc(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c2C(NC(=O)c2n1)c1cc(F)ccc1Cl	1H NMR (400 MHz, DMSO-d6) 10.84 (br s, 1H), 9.41 (s, 1H), 8.08 -7.84 (m, 1H), 7.85-7.70 (m, 2H), 7.67 (s, 1H), 7.34 (dd, 8.8, 5.2 Hz, 1H), 7.09 (td, 8.3, 3.0 Hz, 1H), 6.78 (br s, 1H), 5.98 (s, 1H), 5.61 (br s, 1H), 4.96-4.76 (m, 1H), 1.46 (d, 6.5 Hz, 1.5H), 1.42 (d, 6.6 Hz, 1.5H).	512.2	B	
I-281		Cc1ccc(F)cc1C1NC(=O)c2ccccc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	1H NMR (400 MHz, DMSO-d6) 10.47 (s, 1H), 9.11 (s, 1H), 7.92 (d, 8.5 Hz, 1H), 7.70 (m, 1H), 7.65 (t, 7.6 Hz, 1H), 7.60 (d, 8.8 Hz, 1H), 7.52 (dd, 7.7, 1.1 Hz, 1H), 7.45 (s, 1H), 7.02 (dd, 8.5, 6.0 Hz, 1H), 6.89 (td, 8.5, 2.8 Hz, 1H), 6.35 (br s, 1H), 5.85 (s, 1H), 2.01 (br s, 3H).	445.3	B	
I-282		Cc1ccccc1C1NC(=O)c2nccc(NC(=O)N3CCc4ccccnc34)c12	1H NMR (400 MHz, DMSO-d6) 11.04 (s, 1H), 9.47 (s, 1H), 8.68 (d, 5.9 Hz, 1H), 8.41 (d, 5.6 Hz, 1H), 7.59 (d, 6.4 Hz, 1H), 7.46 (br s, 1H), 7.32 (d, 10.7,1H), 7.17 (t, 7.2 Hz, 1H), 7.01 (t, 7.5 Hz, 1H), 6.88 (dd, 7.1,	386.3	D	





			5.7 Hz, 1H), 6.56 (br s, 1H), 6.10 (s, 1H), 3.96 (t, 8.6 Hz, 2H), 3.02 (t, 8.6 Hz, 2H), 2.64 (br s, 3H).			
I-283		FC(F)c1ccc(F)cc1C1NC(=O)c2ccc(F)c(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	1H NMR (400 MHz, CD3CN) 8.53 (s, 1H), 7.83 (dd, 8.4, 4.6 Hz, 1H), 7.64 (d, 8.7 Hz, 1H), 7.59-7.40 (m, 4H), 7.24 (s, 1H), 7.10 (td, 8.9, 2.8 Hz, 1H), 6.62 (s, 1H), 6.02 (s, 1H).	499.2	C	
I-284		Fc1ccc(Cl)c(c1)C1NC(=O)c2nc(NC3CC(F)(F)C3)cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	1H NMR (400 MHz, DMSO-d6) 10.49 (br s, 1H), 9.15 (br s, 1H), 7.93 (br s, 1H), 7.68 (d, 8.9 Hz, 1H), 7.58 (br s, 1H), 7.33 (dd, 8.9, 5.1 Hz, 1H), 7.07 (td, 8.4, 3.1 Hz, 1H), 6.85-6.45 (m, 2H), 5.84 (br s, 1H), 4.38-4.15 (m, 1H), 3.13-2.88 (m, 2H), 2.65-2.52 (m, 2H).	573.2	A	
I-285		Cc1nc(C(=O)Nc2ccc3C(=O)NC(c23)c2ccccc2C)n2cc(Cl)ccc12	1H NMR (400 MHz, DMSO-d6) 9.60 (s, 1H), 9.24 (dd, 1.7, 0.9 Hz, 1H), 9.04 (s, 1H), 7.94 (dd, 6.1, 2.8 Hz, 1H), 7.86 (dd, 9.5, 0.9 Hz, 1H), 7.61-7.57 (m, 2H), 7.10 (dd, 9.6, 1.7 Hz, 1H), 7.07-7.00 (m, 2H), 6.98-6.92 (m, 1H), 6.69 (br s, 1H), 6.11 (s, 1H), 2.47 (s, 3H), 2.34 (br s, 3H).	431.2	E	
I-286		Fc1ccc(Cl)c(c1)C1NC(=O)c2nc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)N1CC(F)(F)C1	1H NMR (400 MHz, DMSO-d6) 10.72 (br s, 1H), 9.30 (br s, 1H), 7.94 (d, 6.5 Hz, 1H), 7.71 (d, 9.0 Hz, 1H), 7.62 (s, 1H), 7.34 (dd, 8.9, 5.2 Hz, 1H), 7.17-6.97 (m, 1H), 6.94-6.56 (m, 2H), 5.91 (br s, 1H), 4.65-4.33 (m, 4H).	559.3	A	




I-287		Fc1ccc(Cl)c(c1)C1NC(=O)c2c1c(NC(=O)c1cc(F)cc(c1)C(F)(F)F)cnc2-c1cn[nH]c1	1H NMR (400 MHz, CD3OD) 8.80 (s, 1H), 8.92-8.44 (bs, 2H), 8.57 (s, 1H), 7.71-7.62 (m, 3H), 7.27 (dd, 8.9, 5.1 Hz, 1H), 6.99 (td, 7.9, 3.0 Hz, 1H), 6.83-6.65 (bs, 1H), 6.30-6.02 (bs, 1H).	534.2	B	
I-288		COCCNc1cc(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c2C(NC(=O)c2n1)c1cc(F)ccc1Cl	^{1}H NMR (400 MHz, DMSO-d_6) δ 10.49 (s, 1H), 9.14 (s, 1H), 7.95 (d, J = 8.6 Hz, 1H), 7.67 (d, J = 8.7 Hz, 1H), 7.55 (s, 1H), 7.31 (dd, J = 8.9, 5.2 Hz, 1H), 7.21 (br s, 1H), 7.07 (td, J = 8.4, 3.1 Hz, 1H), 6.82 (br s, 1H), 6.65 (s, 1H), 5.82 (br s, 1H), 3.60 – 3.44 (m, 4H), 3.30 (s, 3H).	541.2	B	
I-289		Nc1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1C(F)F	^{1}H NMR (500 MHz, DMSO-d6) δ 10.21 (s, 1H) 8.89 (s, 1H) 7.88 (br d, J=8.24 Hz, 1H) 7.61 (br d, J=8.85 Hz, 1H) 7.38 - 7.58 (m, 2H) 7.15 (td, J=8.31, 2.29 Hz, 1H) 6.86 (d, J=1.83 Hz, 1H) 6.69 (d, J=1.22 Hz, 1H) 6.50 (br s, 1H) 5.77 (br s, 1H) 5.66 (s, 2H)	498.1	A	A
I-290		CC(C)(O)c1cc2C(=O)NC(c2c(NC(=O)c2coc3c(F)cc(F)cc23)c1)c1cc(F)ccc1C(F)F	^{1}H NMR (500 MHz, DMSO-d_6) δ 10.28 (s, 1 H) 9.11 (s, 1 H) 8.46 (s, 1 H) 7.78 (s, 1 H) 7.60 (d, J =1.22 Hz, 1 H) 7.36 - 7.49 (m, 2 H) 7.16 (td, J =8.31, 2.29 Hz, 1 H) 6.42 (br s, 1 H) 6.03 (s, 1 H) 5.31 (s, 1 H) 1.51 (s, 6 H).		A	
I-291		CN1CCN(CC1)c1cc(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c2C(NC(=O)c2n1)c1c	^{1}H NMR (400 MHz, DMSO-d_6) δ 10.63 (br s, 1H), 9.22 (br s, 1H), 8.34 (br s, 1H), 7.93 (br d, J = 8.1 Hz, 1H), 7.71 (br d, J = 8.8 Hz, 1H), 7.63 (s, 1H), 7.31 (br dd, J = 8.8, 5.1 Hz,	566.5	B	




		c(F)ccc1Cl	1H), 7.06 (td, *J* = 8.3, 2.9 Hz, 1H), 6.92 (br s, 1H), 6.63-6.79 (m, 1H), 5.87 (br s, 1H), 3.47-3.66 (m, 4H), 2.32-2.47 (m, *J* = 4.6 Hz, 3H), 2.24 (s, 3H).			
I-292		Cc1ccccc1C1NC(=O)c2cccc(NC(=O)c3noc4CCCCCc34)c12		402.4	E	
I-293		CC(C)Cc1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	1H NMR (400 MHz, DMSO-d6) 0.71-1.13 (m, 6H), 1.91 (dt, 13.36, 6.62 Hz, 1H), 2.55-2.67 (m, 2H), 5.92 (br s, 1H), 7.07 (td, 8.36, 3.05 Hz, 1H), 7.18-7.37 (m, 2H), 7.47 (s, 1H), 7.65 (s, 1H), 7.72 (br d, 9.03 Hz, 1H), 7.92 (br d, 8.54 Hz, 1H), 9.06 (br s, 1H), 10.44 (s, 1H)	523.4	A	
I-294		Cc1ccccc1C1NC(=O)Oc2ccccc(NC(=O)c3csc4ccccc34)c12			B	
I-295		Cc1ccccc1C1NC(=O)Nc2ccccc(OC(=O)c3csc4ccccc34)c12			D	
I-296		Clc1ccccc1NC(=O)Nc1ccnc2C(=O)NC(c12)c1ccccc1Cl	^{1}H NMR (400 MHz, DMSO-d_6) δ 9.40 (br s, 1H), 9.25 (br s, 1H), 8.65 (br d, *J* = 5.4 Hz, 1H), 8.47 (br s, 1H), 7.87 (br d, *J* = 7.8 Hz, 1H), 7.66 (br d, *J* = 5.1 Hz, 1H), 7.44 (br d, *J* = 8.1 Hz, 2H), 7.27-7.36 (m, 2H), 7.22 (br t, *J* = 7.4 Hz, 1H), 7.04-7.11	413.3	D	





			(m, 1H), 6.81-6.95 (m, 1H), 6.15 (br s, 1H).			
I-297		CS(=O)(=O)CC(O)c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(Cl)c2)c1)c1cc(F)ccc1Cl	1H NMR (500 MHz, DMSO-d6) 2.89-3.11 (m, 3H), 3.56-3.86 (m, 1H), 5.06-5.29 (m, 1H), 5.79-6.06 (m, 1H), 6.12-6.28 (m, 1H), 6.54-6.72 (m, 1H), 7.00-7.21 (m, 1H), 7.26-7.44 (m, 2H), 7.48-7.96 (m, 4H), 8.93-9.42 (m, 2H), 10.18-10.55 (m, 1H)	555	B	
I-298		CC(C)(O)c1cc2C(=O)N[C@H](c2c(NC(=O)c2cc(F)cc(Cl)c2)c1)c1cc(F)ccc1Cl	1H NMR (500 MHz, DMSO-d6) 10.3-10.4 (m, 1H), 8.9-9.2 (m, 1H), 7.7-7.8 (m, 1H), 7.6-7.7 (m, 1H), 7.5-7.6 (m, 1H), 7.3-7.5 (m, 3H), 7.1-7.2 (m, 1H), 6.3-6.9 (m, 1H), 5.6-6.2 (m, 1H), 5.2-5.4 (m, 1H), 1.4-1.6 (m, 6H)	492	A	A
I-299		CC(C)(O)c1cc2C(=O)N[C@@H](c2c(NC(=O)c2cc(F)cc(Cl)c2)c1)c1cc(F)ccc1Cl	1H NMR (500 MHz DMSO-d6) 10.3-10.4 (m, 1H), 8.9-9.2 (m, 1H), 7.7-7.8 (m, 1H), 7.6-7.7 (m, 1H), 7.5-7.6 (m, 1H), 7.3-7.5 (m, 3H), 7.1-7.2 (m, 1H), 6.3-6.9 (m, 1H), 5.6-6.2 (m, 1H), 5.2-5.4 (m, 1H), 1.4-1.6 (m, 6H)	492	E	
I-300		C[C@H]1CN(C(=O)Nc2ccnc3C(=O)N[C@H](c23)c2ccccc2C)c2ccccc12	1H NMR (400 MHz, DMSO-d6) 9.31 (s, 2H), 8.78 (br s, 1H), 8.67 (br s, 1H), 8.61 (s, 1H), 8.60 (s, 1H), 7.64 (d, 8.0 Hz, 1H), 7.59 (d, 8.1 Hz, 1H), 7.46 (d, 5.4 Hz, 1H), 7.40 (d, 5.3 Hz, 1H), 7.17-7.05 (m, 6H), 7.03-6.87 (m, 6H), 6.49 (br s, 2H), 5.89 (s, 1H), 5.88 (s, 1H), 3.79-3.65 (m, 2H), 3.25-3.08 (m, 2H), 2.99 (dd, 8.9, 5.9 Hz, 1H), 2.51 (dd, 10.0, 6.7 Hz, 1H), 2.15 (br s, 6H), 1.09 (d, 7.6 Hz,	398.5	B	





			3H), 1.04 (d, 6.8 Hz, 3H)			
I-301		C[C@@H]1CN(C(=O)Nc2ccnc3C(=O)N[C@@H](c23)c2ccccc2C)c2cccc12	1H NMR (400 MHz, DMSO-d6) 9.31 (s, 2H), 8.78 (br s, 1H), 8.67 (br s, 1H), 8.61 (s, 1H), 8.60 (s, 1H), 7.64 (d, 8.0 Hz, 1H), 7.59 (d, 8.1 Hz, 1H), 7.46 (d, 5.4 Hz, 1H), 7.40 (d, 5.3 Hz, 1H), 7.17-7.05 (m, 6H), 7.03-6.87 (m, 6H), 6.49 (br s, 2H), 5.89 (s, 1H), 5.88 (s, 1H), 3.79-3.65 (m, 2H), 3.25-3.08 (m, 2H), 2.99 (dd, 8.9, 5.9 Hz, 1H), 2.51 (dd, 10.0, 6.7 Hz, 1H), 2.15 (br s, 6H), 1.09 (d, 7.6 Hz, 3H), 1.04 (d, 6.8 Hz, 3H)	398.5	C	
I-302		C[C@H]1CN(C(=O)Nc2ccnc3C(=O)N[C@H](c23)c2ccccc2C)c2ccccc12	1H NMR (400 MHz, DMSO-d6) 9.31 (s, 2H), 8.78 (br s, 1H), 8.67 (br s, 1H), 8.61 (s, 1H), 8.60 (s, 1H), 7.64 (d, 8.0 Hz, 1H), 7.59 (d, 8.1 Hz, 1H), 7.46 (d, 5.4 Hz, 1H), 7.40 (d, 5.3 Hz, 1H), 7.17-7.05 (m, 6H), 7.03-6.87 (m, 6H), 6.49 (br s, 2H), 5.89 (s, 1H), 5.88 (s, 1H), 3.79-3.65 (m, 2H), 3.25-3.08 (m, 2H), 2.99 (dd, 8.9, 5.9 Hz, 1H), 2.51 (dd, 10.0, 6.7 Hz, 1H), 2.15 (br s, 6H), 1.09 (d, 7.6 Hz, 3H), 1.04 (d, 6.8 Hz, 3H)	398.5	C	
I-303		C[C@@H]1CN(C(=O)Nc2ccnc3C(=O)N[C@H](c23)c2ccccc2C)c2ccccc12	1H NMR (400 MHz, DMSO-d6) 9.31 (s, 2H), 8.78 (br s, 1H), 8.67 (br s, 1H), 8.61 (s, 1H), 8.60 (s, 1H), 7.64 (d, 8.0 Hz, 1H), 7.59 (d, 8.1 Hz, 1H), 7.46 (d, 5.4 Hz, 1H), 7.40 (d, 5.3 Hz, 1H), 7.17-7.05 (m, 6H), 7.03-6.87 (m, 6H), 6.49 (br s, 2H), 5.89 (s, 1H), 5.88	398.5	E	





			(s, 1H), 3.79-3.65 (m, 2H), 3.25-3.08 (m, 2H), 2.99 (dd, 8.9, 5.9 Hz, 1H), 2.51 (dd, 10.0, 6.7 Hz, 1H), 2.15 (br s, 6H), 1.09 (d, 7.6 Hz, 3H), 1.04 (d, 6.8 Hz, 3H)			
I-304		CN1CCN(CC1)c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	1H NMR (400 MHz, DMSO-d6) 2.87 (br s, 2 H), 3.02-3.25 (m, 3H), 3.53 (br s, 2H), 3.98 (br d, 4.15 Hz, 2H), 5.73 - 6.03 (m, 2H) 6.53 (br s, 1H), 7.00-7.19 (m, 2H), 7.22-7.40 (m, 2H), 7.60-7.80 (m, 2H) 7.95 (br d, 8.30 Hz, 1H) 9.07 (br s, 1H) 9.69 (br s, 1H) 10.41 (s, 1H)	565.36	A	
I-305		Fc1ccc(Cl)c(c1)C1NC(=O)c2nccc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	1H NMR (400 MHz, DMSO-d6) 10.75 (br s, 1H), 9.46 (s, 1H), 8.75 (d, 4.4 Hz, 1H), 7.94 (d, 7.0 Hz, 1H), 7.73 (d, 9.1 Hz, 1H), 7.64 (s, 1H), 7.58 (s, 1H), 7.35 (dd, 8.9, 5.2 Hz, 1H), 7.10 (ddd, 8.8, 8.0, 3.1 Hz, 1H), 7.02-6.55 (br s, 1H), 6.06-5.92 (br s, 1H)	468.2	B	
I-306		Cc1ccccc1[C@@H]1NC(=O)c2cc(CO)cc(NC(=O)c3nsc4ccccc34)c12	1H NMR (400 MHz, DMSO-d6) 10.12 (s, 1H), 9.01 (s, 1H), 8.55 (d, 7.8 Hz, 1H), 8.29 (d, 8.3 Hz, 1H), 7.78 (s, 1H), 7.66 (t, 7.2 Hz, 1H), 7.59 (s, 1H), 7.55 (m, 1H), 7.02-6.95 (m, 2H), 6.91 (t, 6.5 Hz, 1H), 6.68 (br s, 1H), 6.09 (s, 1H), 5.45 (s, 1H), 4.65 (s, 2H), 2.25 (br s, 3H).	430.3	A	
I-307		Cc1ccccc1[C@H]1NC(=O)c2cc(CO)cc(NC(=O)c3nsc4	1H NMR (400 MHz, DMSO-d6) 10.12 (s, 1H), 9.02 (s, 1H), 8.56 (d, 8.2 Hz, 1H), 8.29 (d, 8.2 Hz, 1H), 7.78 (d, 0.9 Hz, 1H), 7.67 (ddd, 8.2, 7.0, 1.1 Hz,	430.3	D	





		ccccc34)c12	1H), 7.60 (s, 1H), 7.57 (t, 7.6 Hz, 1H), 7.02-6.95 (m, 2H), 6.91 (t, 6.6 Hz, 1H), 6.69 (br s, 1H), 6.09 (s, 1H), 5.46 (t, 5.7 Hz, 1H), 4.65 (d, 5.1 Hz, 2H), 2.26 (br s, 3H).			
I-308		CC(C)(O)c1cc2C(=O)NC(c2c(NC(=O)N2CCc3ccccc23)c1)c1cc(F)ccc1Cl	1H NMR (400 MHz, DMSO-d6) 8.99 (s, 1H), 8.55 (s, 1H), 7.71 (d, 7.9 Hz, 1H), 7.65 (d, 1.4 Hz, 1H), 7.49 (d, 1.4 Hz, 1H), 7.36 (dd, 8.9, 5.2 Hz, 1H), 7.20-7.11 (m, 2H), 7.09 (t, 7.7 Hz, 1H), 6.88 (td, 7.4, 1.0 Hz, 1H), 6.54 (br s, 1H), 5.97 (br s, 1H), 5.25 (br s, 1H), 3.93-3.83 (m, 1H), 3.09-2.93 (m, 3H), 1.49 (s, 6H) .	480.5	A	
I-309		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(NC(=O)N3CCc4ccccc34)c12	1H NMR (400 MHz, DMSO-d6) 9.20 (s, 1H), 8.66 (s, 1H), 7.74-7.64 (m, 2H), 7.59 (s, 1H), 7.37 (dd, 8.8, 5.3 Hz, 1H), 7.22-7.05 (m, 3H), 6.90 (t, 7.4 Hz, 1H), 6.64 (br s, 1H), 5.99 (br s, 1H), 3.80 (dd, 17.2, 9.7 Hz, 1H), 3.27-3.13 (m, 1H), 3.10-2.92 (m, 2H)	500.1	A	
I-310		CS(=O)(=O)Cc1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	1H NMR (400 MHz, DMSO-d6) 10.62 (s, 1H), 9.22 (s, 1H), 7.95 (d, 8.5 Hz, 1H), 7.77 (s, 1H), 7.74 (d, 8.9 Hz, 1H), 7.64 (s, 1H), 7.52 (s, 1H), 7.32 (dd, 8.9, 5.2 Hz, 1H), 7.10 (td, 8.4, 3.0 Hz, 1H), 6.65 (br s, 1H), 5.98 (br s, 1H), 4.72 (s, 2H), 2.98 (s, 3H).	559	A	






I-311		CN1CC[C@@H](C1)Nc1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	1H NMR (400 MHz, DMSO-d6) 10.28 (s, 1H), 8.91 (br. s, 1H), 7.92 (dt, 8.4 and 1.6 Hz, 1H), 7.69 (d, 9.4 Hz, 1H), 7.60 (s, 1H), 7.28 (dd, 8.9, 5.2 Hz, 1H), 7.06 (td, 8.3, 3.1 Hz, 1H), 6.77 (t, 1.7 Hz, 1H), 6.68 - 6.64 (m, 1H), 6.36 (d, 6.6 Hz, 1H), 5.82 (br. s, 1H), 3.96-3.89 (m, 1H), 2.76-2.72 (m, 1H), 2.64-2.59 (m, 1H), 2.43-2.36 (m, 2H), 2.27 (s, 3H), 2.27-2.20 (m, 1H), 1.67-1.58 (m, 1H).	565.4	A	
I-312		CN1CC[C@H](C1)Nc1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	1H NMR (400 MHz, DMSO-d6) 10.27 (s, 1H), 8.91 (br s, 1H), 8.22 (s, 1H), 7.92 (dt, 8.4 and 1.6 Hz, 1H), 7.69 (d, 9.2 Hz, 1H), 7.60 (s, 1H), 7.28 (dd, 8.9, 5.2 Hz, 1H), 7.06 (td, 8.4, 3.0 Hz, 1H), 6.77 (t, 1.7 Hz, 1H), 6.71-6.59 (m, 1H), 6.57 (br. s, 1H), 6.37 (d, 6.6 Hz, 1H), 5.82 (br. s, 1H), 3.98-3.90 (m, 1H), 2.77 (ddd, 9.1, 6.7, 2.4 Hz, 1H), 2.69-2.57 (m, 1H), 2.47-2.39 (m, 2H), 2.28 (s, 3H), 2.27-2.20 (m, 1H), 1.68-1.59 (m, 1H).	565.3	A	
I-313		Cc1ccccc1C1NC(=O)c2c1c(NC(=O)c1cc(F)cc(c1)C(F)(F)F)ccc2C#N	1H NMR (400 MHz, DMSO-d6) 10.64 (br s, 1H), 9.48 (s, 1H), 8.08 (d, 8.1 Hz, 1H), 7.90 (d, 8.3 Hz, 1H), 7.77 (d, 8.0 Hz, 1H), 7.49 - 7.43 (m, 1H), 7.30 (br s, 1H), 7.08 (td, 7.5, 1.2 Hz, 1H), 7.01 (d, 7.2 Hz, 1H), 6.97 (t, 7.3 Hz, 1H), 6.52 (br s, 1H), 5.96 (s, 1H), 2.28 (s, 3 H).	454.2	B	




I-314		COC(=O)c1cc2C(=O)NC(c2c(NC(=O)c2nsc3ccccc23)c1)c1ccccc1C	1H NMR (400 MHz, DMSO-d6) 10.28 (s, 1H), 9.29 (s, 1H), 8.62 (d, 8.2 Hz, 1H), 8.45 (d, 1.4 Hz, 1H), 8.31 (dt, 8.2, 0.8 Hz, 1H), 8.13 (d, 1.4 Hz, 1H), 7.68 (ddd, 8.2, 7.0, 1.2 Hz, 1H), 7.59 (ddd, 8.1, 7.0, 1.0 Hz, 1H), 7.02-6.98 (m, 2H), 6.96-6.87 (m, 2H), 6.22 (br s, 1H), 3.94 (s, 3H), 2.26 (br s, 3H).	458.3	C	
I-315		Cc1ccccc1C1NC(=O)c2cc(cc(NC(=O)c3nsc4ccccc34)c12)C1(O)CC1	1H NMR (400 MHz, DMSO-d6) 10.13 (s, 1H), 9.00 (s, 1H), 8.56 (d, 8.1 Hz, 1H), 8.28 (dd, 5.0, 4.1 Hz, 1H), 7.66 (ddd, 8.2, 7.0, 1.2 Hz, 1H), 7.64 (d, 1.5 Hz, 1H), 7.57 (ddd, 8.1, 7.0, 1.0 Hz, 1H), 7.49 (d, 1.6 Hz, 1H), 7.01-6.85 (m, 3H), 6.67 (brs, 1H), 6.18 (s, 1H), 6.07 (br s, 1H), 2.23 (br s, 3H), 1.24-1.16 (m, 2H), 1.09-1.03 (m, 2H).	456.3	A	
I-316		Cc1ccccc1C1NC(=O)c2cccc(NC(=O)c3cc(F)n4ccccc34)c12	1H NMR (400 MHz, CD3CN) 8.09 (d, 9.2 Hz, 1H), 7.93 (d, 7.0 Hz, 1H), 7.88 (d, 7.9 Hz, 1H), 7.66-7.54 (m, 3H), 7.19-7.08 (m, 3H), 7.05 (t, 7.6 Hz, 1H), 6.99 (ddd, 9.3, 6.6, 1.0 Hz, 1H), 6.83 (td, 6.9, 1.2 Hz, 1H), 6.06 (br s, 1H), 5.94 (d, 3.1 Hz, 1H), 2.15 (br s, 3H)	400.1	C	
I-317		COc1cc(cc(F)c1F)C(=O)Nc1cccc2C(=O)NC(c12)c1ccccc1C	1H NMR (400 MHz, DMSO-d6) 10.14 (s, 1H), 9.05 (s, 1H), 7.67 (dd, 7.4, 1.2 Hz, 1H), 7.61 (t, 7.5 Hz, 1H), 7.53 (dd, 7.7, 1.1 Hz, 1H), 7.10 (td, 7.4, 1.3 Hz, 1H), 7.03 (d, 7.1 Hz, 1H), 7.00-6.96 (m, 2H), 6.94-6.89 (mt, 1H), 6.57 (br. s, 1H),	409.2	C	





			5.92 (s, 1H), 3.84 (s, 3H), 2.19 (br. s, 3H).			
I-318		Cc1ccccc1C1NC(=O)c2cccc(NC(=O)c3cc(F)cc(OC(F)(F)F)c3)c12	1H NMR (400 MHz, DMSO-d6) 10.29 (s, 1H), 9.06 (s, 1H), 7.68 (dd, 7.5, 1.1 Hz, 1H), 7.61 (t, 7.5 Hz, 1H), 7.61 (mt, 1H, 1H), 7.53 (dd, 7.6, 0.7 Hz, 1H), 7.19 (br. d, 8.6 Hz, 1H), 7.11 (br. s, 1H), 7.07 (td, 7.5, 1.3 Hz, 1H), 7.00 (d, 7.0 Hz, 1H), 6.95 (br. t, 7.2 Hz, 1H), 6.55 (br. s, 1H), 5.90 (s, 1H), 2.19 (br. s, 3H).	445.2	C	
I-319		CCCNc1cc(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c2C(NC(=O)c2n1)c1cc(F)ccc1Cl	1H NMR (400 MHz, DMSO-d6) 10.45 (br s, 1H), 9.12 (br s, 1H), 7.93 (d, 8.4 Hz, 1H), 7.67 (d, 9.4 Hz, 1H), 7.57 (s, 1H), 7.30 (dd, 8.9, 5.2 Hz, 1H), 7.11 (br s, 1H), 7.06 (ddd, 8.8, 8.1, 3.1 Hz, 1H), 6.74 (br s, 1H), 6.62 (s, 1H), 5.82 (br s, 1H), 3.28-3.25 (m, 2H), 1.59 (sx, 7.4 Hz, 2H), 0.95 (t, 7.4 Hz, 3H).	525.2	A	
I-320		Fc1ccc(Cl)c(c1)C1NC(=O)c2c1c(NC(=O)c1cc(F)cc(c1)C(F)(F)F)cnc2N1CC(F)(F)C1	1H NMR (400 MHz, CD_3CN) 8.46 (br s, 1H), 8.20 (s, 1H), 7.66-7.58 (m, 3H), 7.23 (dd, 8.9, 5.1 Hz, 1H), 7.05 (br s, 1H), 6.98 (ddd, 8.8, 8.0, 3.1 Hz, 1H), 6.76 (br s, 1H), 6.05 (br s, 1H), 4.80-4.31 (m, 4H).	559.2	B	
I-321		Fc1ccc(Cl)c(c1)C1NC(=O)c2nc(NCC(F)(F)F)cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	1H NMR (400 MHz, DMSO-d6) 10.38 (br s, 1H), 9.22 (s, 1H), 7.93 (d, 8.3 Hz, 1H), 7.73-7.66 (m, 2H), 7.57 (s, 1H), 7.32 (dd, 8.9, 5.2 Hz, 1H), 7.07 (ddd, 8.7, 8.0, 3.1 Hz, 1H), 6.83 (s, 1H), 6.75 (br s, 1H), 5.85 (br s, 1H), 4.43-4.16 (m, 2H).	565.1	A	





I-322		CC1(O)CN(C1)c1cc(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c2C(NC(=O)c2n1)c1cc(F)ccc1Cl	1H NMR (400 MHz, DMSO-d6) 10.59 (s, 1H), 9.22 (s, 1H), 8.10-7.84 (m, 1H), 7.70 (d, 9.6 Hz, 1H), 7.61 (s, 1H), 7.45-7.22 (m, 1H), 7.07 (t, 7.9 Hz, 1H), 6.71 (br s, 1H), 6.61-6.30 (m, 1H), 5.87 (br s, 1H), 5.66 (s, 1H), 3.94-3.85 (m, 4H), 1.47 (s, 3H).	553.2	B	
I-323		Fc1ccc(Cl)c(c1)-n1[nH]c(=O)c2cccc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	1H NMR (400 MHz, DMSO-d6) 11.43 (br s, 1H), 10.42 (s, 1H), 7.92 (d, 8.1 Hz, 1H), 7.73 (d, 8.0 Hz, 1H), 7.70-7.62 (m, 2H), 7.37 (dd, 8.8, 5.6 Hz, 1H), 7.30 (d, 7.3 Hz, 1H), 7.25 (dd, 9.0, 2.9 Hz, 1H), 7.20 (t, 7.6 Hz, 1H), 6.97 (td, 8.4, 3.0 Hz, 1H).	466.2	D	
I-324		COc1cc2CCN(C(=O)Nc3ccnc4C(=O)NC(c34)c3ccccc3C)c2cn1	1H NMR (400 MHz, DMSO-d6) 9.37 (s, 1H), 8.94 (s, 1H), 8.65 (d, 5.4 Hz, 1H), 8.36 (s, 1H), 7.39 (d, 5.4 Hz, 1H), 7.14 (td, 7.6, 1.2 Hz, 1H), 7.03-6.94 (m, 2H), 6.68 (s, 1H), 6.54 (br s, 1H), 5.89 (s, 1H), 3.80 (s, 3H), 3.65-3.55 (m, 1H), 3.02-2.78 (m, 3H), 2.13 (br s, 3H)	416.3	E	
I-325		Fc1cc(cc(c1)C(F)(F)F)C(=O)Nc1ccc2C(=O)NC(c12)c1ccccc1Br	1H NMR (400 MHz, DMSO-d6) 10.43 (s, 1H), 9.19 (br s, 1H), 7.92 (d, 8.6 Hz, 1H), 7.74-7.59 (m, 3H), 7.54 (s, 1H), 7.48 (d, 6.7 Hz, 1H), 7.42 (d, 8.6 Hz, 1H), 7.24-7.08 (m, 2H, 6.56 (br s, 1H), 6.15 (br s, 1H).	493.3	B	
I-326		CN(C)\C=N\c1cc(Br)cc2C(=O)NC(c12)c1cc(F)ccc1Cl			E	





I-327		Cc1cc(F)ccc1C1NC(=O)c2cccc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	1H NMR (400 MHz, CD3CN) 8.52 (s, 1H), 7.74 (dd, 7.5, 1.2 Hz, 1H), 7.64-7.62 (m, 3H), 7.57 (dd, 7.5, 1.2 Hz, 1H), 7.47 (d, 9.1 Hz, 1H), 7.37 (s, 1H), 7.16 (s, 1H), 6.78 (dd, 9.9, 2.1 Hz, 1H), 6.73 (s, 1H), 5.94 (s, 1H), 2.22 (s, 3H).	445.3	C	
I-328		Cc1ccccc1C1NC(=O)c2cccc(NC(=O)c3nnc4ccccn34)c12	1H NMR (400 MHz, DMSO-d6)-10.61 (br. s, 1H), 9.07 (dt, 7.0, 1.1 Hz, 1H), 9.05 (s, 1H), 7.98 (dt, 9.3, 1.1 Hz, 1H), 7.69 (dd, 2.7, 1.2 Hz, 1H), 7.67 (dd, 3.0, 1.2 Hz, 1H), 7.64-7.58 (m, 2H), 7.24 (td, 6.9, 1.1 Hz, 1H), 6.93-6.86 (m, 2H), 6.82 (br. s, 1H), 6.66 (br. s, 1H), 6.09 (s, 1H), 2.19 (br. s, 3H).	384.3	E	
I-329		C[C@@]1(O)C[C@@H](C1)Nc1cc(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c2C(NC(=O)c2n1)c1cc(F)ccc1Cl	1H NMR (400 MHz, DMSO-d6) 10.49 (s, 1H), 9.14 (s, 1H), 7.94 (d, 8.5 Hz, 1H), 7.67 (d, 8.9 Hz, 1H), 7.56 (s, 1H), 7.34 (br s, 1H), 7.31 (dd, 8.9, 5.2 Hz, 1H), 7.06 (td, 8.4, 3.1 Hz, 1H), 6.68 (br s, 1H), 6.55 (s, 1H), 5.82 (br s, 1H), 5.01 (s, 1H), 4.04-3.77 (m, 1H), 2.40 (dd, 11.0, 7.2 Hz, 2H), 2.03-1.87 (m, 2H), 1.30 (s, 3H).	567.3	B	
I-330		FC(F)c1cc(F)c(F)cc1C1NC(=O)c2cccc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	^{1}H NMR (400 MHz, DMSO-d_6) δ 10.47 (s, 1H), 9.16 (s, 1H), 7.87-8.05 (m, 3H), 7.64-7.77 (m, 2H), 7.42-7.58 (m, 2H), 6.64-7.38 (m, 2H), 5.96 (s, 1H).	501.4	A	






I-331		FC(F)c1cc(F)c(F)cc1C1NC(=O)c2cccc(NC(=O)c3cc(F)cc(Cl)c3)c12	^{1}H NMR (400 MHz, DMSO-d_6) δ 10.31 (s, 1H), 9.15 (s, 1H), 7.61-7.79 (m, 3H), 7.47-7.58 (m, 2H), 7.29-7.38 (m, 2H), 6.59-7.24 (m, 2H), 5.90-6.01 (m, 1H).	467.4	B	
I-332		FC(F)c1cc(F)c(F)cc1C1NC(=O)c2cccc(NC(=O)c3nsc4ccc(F)cc34)c12	^{1}H NMR (400 MHz, DMSO-d_6) δ 10.36 (s, 1H), 9.20 (s, 1H), 8.37 (br dd, J =4.88, 9.03 Hz, 1H), 8.20 (br dd, J =2.20, 9.52 Hz, 1H), 6.95-7.98 (m, 6H), 6.65-6.91 (m, 1H), 5.97-6.17 (m, 1H).	490.4	A	
I-333		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(C=O)cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	^{1}H NMR (400 MHz, DMSO-d_6) δ 10.67 (s, 1H), 10.08-10.21 (m, 1H), 9.26-9.52 (m, 1H), 8.18-8.32 (m, 1H), 7.88-7.89 (m, 1H), 7.84-8.09 (m, 1H), 7.63-7.79 (m, 1H), 7.56-7.82 (m, 1H), 7.25-7.38 (m, 1H), 6.98-7.15 (m, 1H), 5.90-6.23 (m, 2H).	495.3	A	
I-334		OC(CN1CC(F)(F)C1)c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(Cl)c2)c1)c1cc(F)ccc1Cl	1H NMR (DMSO-d6, 500 MHz) 10.3-10.5 (m, 1H), 8.9-9.3 (m, 1H), 8.3-8.5 (m, 1H), 7.6-7.8 (m, 1H), 7.2-7.6 (m, 3H), 7.0-7.2 (m, 1H), 6.5-6.8 (m, 1H), 5.8-6.2 (m, 2H), 5.4-5.6 (m, 1H), 4.4-4.9 (m, 2H), 3.5-3.8 (m, 3H), 2.7-3.0 (m, 2H)	568	B	
I-335		COc1nccc2C(=O)NC(c2c1NC(=O)c1cc(F)cc(c1)C(F)(F)F)c1ccccc1Cl	1H NMR (400 MHz, DMSO-d6) 10.24 (s, 1H), 9.05 (br s, 1H), 8.54 (s, 1H), 7.91 (br d, 8.30 Hz, 1H), 7.63 (br d, 8.79 Hz, 1H), 7.58 (br s, 1H), 7.19-7.31 (m, 2H), 7.03-7.17 (m, 1H), 6.60 (br s, 1H), 5.87-6.02 (m, 1H), 3.97 (s, 3H)	480.42	E	



I-336		Cn1cc(cn1)C(=O)Nc1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	1H NMR (400 MHz, DMSO-d6) 3.91 (s, 3H), 5.81-6.04 (m, 2H), 7.08 (td, 8.36, 3.05 Hz, 1H), 7.31 (dd, 8.91, 5.25 Hz, 1H), 7.64 (s, 1H), 7.73 (br d, 8.79 Hz, 1H), 7.91-7.99 (m, 2H), 8.03-8.10 (m, 2H), 8.36 (s, 1H), 9.13 (br s, 1H), 10.16 (s, 1H), 10.52 (s, 1H)	590.28	A	
I-337		Cc1ccccc1C1NC(=O)c2cccc(NC(=O)c3cc(ccn3)C(F)(F)F)c12	1H NMR (400 MHz, DMSO-d6) 10.07 (s, 1H), 9.08 (s, 1H), 8.83 (d, 7.1 Hz, 1H), 8.14 (s, 1H), 8.06-8.00 (m, 2H), 7.67-7.58 (m, 2H), 7.13-7.02 (m, 2H), 7.01-6.95 (m, 1H), 6.69 (br s, 1H), 6.08 (s, 1H), 2.26 (br s, 3H).	412.3	E	
I-338		FC(F)CNc1cc(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c2C(NC(=O)c2n1)c1cc(F)ccc1Cl	1H NMR (400 MHz, DMSO-d6) 10.55 (s, 1H), 9.21 (s, 1H), 7.96 (d, 8.1 Hz, 1H), 7.67 (d, 8.9 Hz, 1H), 7.55 (br s,2H), 7.32 (dd, 8.8, 5.2 Hz, 1H), 7.07 (td, 8.5, 3.0 Hz, 1H), 6.75 (s, 1H), 6.72 (br s, 1H), 6.18 (tt, 56.5, 4.0 Hz, 1H), 5.86 (br s, 1H), 4.09-3.55 (m, 2H).	547.2	A	
I-339		Cc1ccccc1C1NC(=O)c2c1c(NC(=O)c1cc(F)cc(c1)C(F)(F)F)ccc2C(N)=O	1H NMR (400 MHz, DMSO-d6) 10.73 (s, 1H), 10.48 (br s, 1H), 9.80 (s, 1H), 8.33 (d, 8.3 Hz, 1H), 7.90 (d, 8.5 Hz, 1H), 7.75 (s, 1H), 7.71 (d, 8.3 Hz,1H), 7.47 (d, 8.6 Hz, 1H), 7.31 (br s, 1H), 7.09 (td, 7.6, 0.9 Hz, 1H), 7.01 (d, 7.3 Hz, 1 H), 6.99-6.93 (m, 1H), 6.47 (br s, 1H), 6.00 (br s, 1H), 2.30 (br s, 3H).	472.3	B	





I-340		COc1cc(F)cc(c1)C(=O)Nc1cccc2C(=O)NC(c12)c1ccccc1C	1H NMR (400 MHz, DMSO-d6) 10.07 (s, 1H), 9.04 (s, 1H), 7.65 (dd, 7.4, 1.2 Hz, 1H), 7.60 (t, 7.5 Hz, 1), 7.53 (dd, 7.7, 1.1 Hz, 1H), 7.10 (td, 7.4, 1.4 Hz, 1H), 7.04 (br. d, 7.0 Hz, 1H), 6.99 (t, 2.3 Hz, 1H), 6.98-6.94 (m, 1H), 6.76 (s, 1H), 6.68 (br. d, 8.4 Hz, 1H), 6.56 (br s, 1H), 5.94 (s, 1H), 3.75 (s, 3H), 2.20 (br s, 3H)	391.3	D	
I-341		COc1cc(F)c(F)c(c1)C(=O)Nc1cccc2C(=O)NC(c12)c1ccccc1C	1H NMR (400 MHz, DMSO-d6) 10.26 (s, 1H), 9.07 (s, 1H), 7.67 (dd, 7.5, 1.0 Hz, 1H), 7.60 (t, 7.6 Hz, 1H), 7.49 (dd, 7.7, 0.5 Hz, 1H), 7.21-7.14 (m, 3H), 7.03 (td, 7.6, 1.6 Hz, 1H), 6.55 (br. s, 1H), 6.02 (s, 1H), 5.97 (s, 1H), 3.69 (s, 3H), 2.26 (br s, 3H)	409.3	E	
I-342		Cc1nc(C(=O)Nc2ccc3C(=O)NC(c23)c2ccccc2C)n2cc(F)cc(F)c12	1H NMR (400 MHz, DMSO-d6) 9.69 (s, 1H), 9.06 (dd, 5.1, 1.7 Hz, 1H), 9.05 (s, 1H), 7.91 (dd, 7.0, 1.7 Hz, 1H), 7.62-7.56 (m, 2H), 7.30 (ddd, 10.7, 8.8, 1.6 Hz, 1H), 7.07-7.01 (m, 2H), 6.97-6.92 (m, 1H), 6.69 (br s, 1H), 6.10 (s, 1H), 2.55 (s, 3H), 2.32 (br. s, 3H).	433.3	E	
I-343		CN1C[C@@H](CC1=O)Nc1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	1H NMR (400 MHz, DMSO-d6) 10.29 (d, 4.0 Hz, 1H), 8.95 (s, 1H), 7.92 (d, 8.6 Hz, 1H), 7.69 (d, 9.3 Hz, 1H), 7.60 (s, 1H), 7.28 (dd, 8.9, 5.2 Hz, 1H), 7.06 (td, 8.5, 3.1 Hz, 1H), 6.80 (d, 1.9 Hz, 1H), 6.69 (s, 1H), 6.62 (br. s, 1H), 6.58 (d, 6.2 Hz, 1H), 5.84 (br. s, 1H), 4.19-4.08 (m, 1H), 3.79-3.74 (m, 1H),	579.3	A	





			3.24-3.16 (m, 1H), 2.79-2.73 (m, 1H), 2.75 (s, 3H), 2.22-2.15 (m, 1H).			
I-344		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(NC(=O)C3COC3)cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	1H NMR (400 MHz, DMSO-d6) 2.87 (br s, 1H), 3.99 (dt, 14.89, 7.44 Hz, 2H), 4.68-4.81 (m, 2H), 5.84-6.04 (m, 2H), 6.51 (br s, 1H), 7.03-7.13 (m, 1H), 7.30 (br dd, 8.79, 5.13 Hz, 1H), 7.62 (br s, 1H), 7.67-7.76 (m, 1H), 7.82 (br s, 1H), 7.93 (br d, 11.71 Hz, 1H), 9.13 (s, 1H), 10.32 (br s, 1H), 10.50 (br s, 1H)	566.31	A	
I-345		OCC(=O)Nc1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	1H NMR (400 MHz, DMSO-d6) 4.04 (br d, 4.39 Hz, 2H), 5.73 (br s, 1H), 5.79-6.03 (m, 2H), 6.63 (br s, 1H), 7.07 (td, 8.24, 2.81 Hz, 1H), 7.29 (br dd, 8.91, 5.25 Hz, 1H), 7.62 (s, 1H), 7.71 (br d, 9.03 Hz, 1H), 7.83-8.00 (m, 2H), 8.06 (s, 1H), 8.47 (s, 1H), 9.10 (br s, 1H), 10.13(br s, 1H), 10.52 (s, 1H)	540.25	A	
I-346		COCC(=O)Nc1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	1H NMR (400 MHz, DMSO-d6) 2.53 (s, 3H), 4.06 (s, 2H), 5.85-5.96 (m, 1H), 7.07 (br d, 2.68 Hz, 2H), 7.29 (br dd, 8.79, 5.13 Hz, 1 H)7.62 (s, 1H) 7.71 (br d, 9.27 Hz, 1 H), 7.88-7.93 (m, 1H) 8.02 (s, 1 H) 9.01 - 9.21 (m, 2) 10.20 (s, 1 H) 10.51 (s, 1 H)	554.31	A	
I-347		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(NC(=O)C3CCOCC3)cc(NC(=O)c3cc(F)cc(c3)C(	1H NMR (400 MHz, DMSO-d6) 1.54 - 1.91 (m, 4H) 2.56 - 2.71 (m, 2H) 3.91 (br d, 11.23 Hz, 2 H) 5.84 - 5.99 (m, 1H) 7.07 (td, 8.30, 2.93 Hz, 1H) 7.29 (br dd, 8.79, 5.13 Hz, 1H) 7.62 (s, 1H) 7.68 -	594.28	A	





		F)(F)F)c1 2	7.78 (m, 1H) 7.82 (s, 1H) 7.89 - 7.94 (m, 1H) 9.10 (br s, 2H) 10.27 (s, 1H) 10.48 (s, 1H)			
I-348		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(CN3CC(F)(F)C3)cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	^{1}H NMR (400 MHz, DMSO-d_6) δ 10.33-10.66 (m, 1H), 9.11 (br s, 1H), 8.43 (br s, 1H), 6.17-8.11 (m, 7H), 5.80-6.08 (m, 1H), 3.76-3.99 (m, 1H), 3.58-3.72 (m, 1H), 3.13-3.31 (m, 4H).	572.2	A	
I-349		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(CNC3CC(F)(F)C3)cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	^{1}H NMR (400 MHz, DMSO-d_6) δ 10.48 (s, 1H), 9.09 (br s, 1H), 8.33 (s, 1H), 7.40-7.97 (m, 3H), 7.25-7.35 (m, 1H), 7.07 (dt, J = 3.05, 8.36 Hz, 1H), 6.24-6.89 (m, 2H), 5.79-6.10 (m, 1H), 3.77 (s, 1H), 3.01-3.23 (m, 2H), 2.61-2.93 (m, 2H), 2.15-2.44 (m, 2H).	586.2	A	
I-350		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(CN3CCNCC3)cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	^{1}H NMR (400 MHz, DMSO-d_6) δ 10.49 (br s, 1H), 9.10 (br s, 1H), 8.34 (s, 1H), 6.11-8.09 (m, 6H), 5.68-6.05 (m, 1H), 3.33-3.74 (m, 10H), 2.60-2.85 (m, 1H), 2.24-2.44 (m, 1H).	565.2	A	
I-351		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(NC(=O)C3CS(=O)(=O)C3)cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	1H NMR (400 MHz, DMSO-d6) 3.48-3.62 (m, 2H), 4.35-4.49 (m, 3H), 5.92 (br d, 6.35 Hz, 1H), 7.07 (td, 8.30, 2.93 Hz, 1H), 7.30 (br dd, 8.79, 5.13 Hz, 1H), 7.61 (s, 1H), 7.71 (br d, 8.79 Hz, 1H), 7.79 (s, 1H), 7.93 (s, 1H), 9.14 (br s, 3H), 10.51 (s, 1H), 10.64 (s, 1H)	614.34	A	





I-352		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(CNC3COC3)cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	^{1}H NMR (400 MHz, DMSO-d_6) δ 10.47 (br s, 1H), 9.08 (br s, 1H), 8.36 (br d, J =4.88 Hz, 1H), 6.19-8.08 (m, 7H), 5.74-6.11 (m, 1H), 4.45-4.63 (m, 1H), 4.16-4.38 (m, 1H), 3.82-3.99 (m, 1H), 3.66-3.82 (m, 1H), 2.83-3.30 (m, 3H).	552.1	A	
I-353		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(CN3CCC(F)(F)C3)cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	^{1}H NMR (400 MHz, DMSO-d_6) δ 10.33-10.72 (m, 1H), 8.96-9.33 (m, 1H), 8.27-8.55 (m, 1H), 6.32-8.09 (m, 6H), 5.62-6.23 (m, 2H), 3.66-3.90 (m, 1H), 3.12-3.30 (m, 2H), 2.81-3.02 (m, 1H), 2.62-2.81 (m, 1H), 2.13-2.37 (m, 1H), 1.18-1.61 (m, 2H).	586.2	A	
I-354		Fc1cnn(c1)-c1cc(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c2C(NC(=O)c2n1)c1cc(F)ccc1Cl	^{1}H NMR (400 MHz, DMSO-d_6) δ 9.34 (br s, 1H), 8.68 (br d, J = 3.9 Hz, 1H), 8.59 (br s, 1H), 8.25 (br s, 1H), 7.92 (br d, J = 3.7 Hz, 1H), 7.65-7.84 (m, 3H), 7.41 (br dd, J = 8.7, 5.0 Hz, 1H), 7.12 (td, J = 8.4, 2.9 Hz, 1H), 6.77-6.93 (m, 1H), 6.00 (br s, 1H).	552.4	B	
I-355		CC(C)(O)c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1ccccc1C(F)F	1H NMR (DMSO-d6, 400 MHz) Shift 10.4-10.5 (m, 1H), 9.0-9.2 (m, 1H), 7.88 (br d, 1H, 8.3 Hz), 7.78 (d, 1H, 1.2 Hz), 7.5-7.7 (m, 2H), 7.4-7.5 (m, 1H), 7.3-7.4 (m, 2H), 6.5-6.8 (m, 2H), 5.9-6.1 (m, 1H), 5.2-5.4 (m, 1H), 1.4-1.7 (m, 6H)	523	A	
I-356		CC(C)(O)c1cc2C(=O)NC(c2c(NC(=O)c2nsc3ccccc23)	^{1}H NMR (400 MHz, DMSO-d_6) δ 10.0-10.3 (m, 1H), 9.1-9.2 (m, 1H), 9.0-9.2 (m, 1H), 8.5-8.7 (m, 1H), 8.2-8.4 (m, 1H), 8.1-8.1 (m, 1H), 7.94 (s, 1H), 7.7-	494	A	







		c1)c1ccc cc1C(F)F	7.8 (m, 1H), 7.7-7.7 (m, 1H), 7.6-7.7 (m, 1H), 7.5-7.4 (m, 1H), 7.2-7.3 (m, 1H), 6.7-6.8 (m, 1H), 6.1-6.2 (m, 1H), 5.2-5.4 (m, 1H), 1.4-1.6 (m, 6H).			
I-357		Fc1ccc(Cl)c(c1)C1NC(=O)c2nc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)N1CCC(F)(F)C1	^{1}H NMR (400 MHz, DMSO-d_6) δ 10.61-10.73 (m, 1H), 9.08-9.25 (m, 1H), 8.42 (s, 1H), 7.82-7.98 (m, 1H), 7.72 (br d, J = 9.0 Hz, 1H), 7.65 (s, 1H), 7.33 (br dd, J = 8.5, 5.1 Hz, 1H), 7.07 (td, J = 8.3, 2.9 Hz, 1H), 6.62-6.73 (m, 1H), 5.88 (s, 1H), 3.82-4.02 (m, 2H), 3.60-3.77 (m, 2H), 2.54-2.63 (m, 2H).	573.5	A	
I-358		Fc1ccc(Cl)c(c1)C1NC(=O)c2nc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)N1CCOCC1	^{1}H NMR (400 MHz, DMSO-d_6) δ 10.57-10.72 (m, 1H), 9.16-9.28 (m, 1H), 8.42 (br s, 1H), 7.85-8.00 (m, 1H), 7.71 (br d, J = 8.5 Hz, 1H), 7.65 (br s, 1H), 7.32 (br dd, J = 8.9, 5.2 Hz, 1H), 7.07 (td, J = 8.4, 3.1 Hz, 1H), 6.88-6.99 (m, 1H), 5.88 (br s, 1H), 3.65-3.79 (m, 4H), 3.54 (br s, 4H).	553.5	A	
I-359		OC1CCC(C1)Nc1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	1H NMR (400 MHz, DMSO-d6) 1.23 (br s, 1 H) 1.39 (td, 12.45, 5.86 Hz, 1 H) 1.62 (br dd, 14.64, 7.08 Hz, 1 H) 1.73 (br d, 3.66 Hz, 1H) 1.96 (br d, 6.35 Hz, 1 H) 2.28 (br d, 6.59 Hz, 1 H) 3.64 - 3.76 (m, 1 H) 4.12 (br d, 4.88 Hz, 1 H) 4.63 (br d, 2.68 Hz, 1 H) 5.76 - 5.90 (m, 1 H) 6.19 (br d, 6.83 Hz, 1 H) 6.47 - 6.59 (m, 1 H) 6.65 (br s, 1 H) 6.77 (br d, 1.71 Hz, 1 H) 7.05 (td, 8.42, 2.93 Hz, 1 H) 7.26 (br dd, 8.79, 5.13		A	






			Hz, 1 H) 7.60 (br s, 1 H) 7.68 (br d, 9.27 Hz, 1 H) 7.90 (br d, 8.05 Hz, 1 H) 8.87 (br s, 1 H) 10.23 (s, 1 H)			
I-360		FC(F)CCC(=O)Nc1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	1H NMR (400 MHz, DMSO-d6) 2.06 - 2.25 (m, 3H) 2.52 - 2.57 (m, 2 H) 5.91 (br d, 9.27 Hz, 2H) 7.07 (td, 8.36, 2.81 Hz, 1H) 7.29 (br dd, 8.91, 5.25 Hz, 1H) 7.61 (s, 1H) 7.71 (br d,8.79 Hz, 1 H) 7.78 (s, 1H) 7.86 - 7.96 (m, 2 H) 9.11 (br s, 1H) 10.40 (s, 1H) 10.49 (s, 1H)	588.22	A	
I-361		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(NC(=O)C3CCO3)cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	1H NMR (400 MHz, DMSO-d6) 2.92 - 3.05 (m, 2 H) 4.66 (br t, 7.81 Hz, 2H) 5.13 (ddd, 9.09, 6.41, 2.81 Hz, 1H) 5.86 - 5.97 (m, 1H) 7.08 (br d, 2.68 Hz, 1H) 7.30 (dd, 8.79, 5.13 Hz, 1 H) 7.63 (s, 1H) 7.71 (br d, 9.03 Hz, 1H) 7.91 - 8.00 (m, 2H) 8.09 (br d, 5.12 Hz, 1H) 9.13 (br s, 1H) 10.32 (s, 1H) 10.52 (s, 1H)	566.16	A	
I-362		OB(O)c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	1H NMR (400 MHz, DMSO-d6) 5.81 - 6.14 (m, 2H) 6.45 - 6.63 (m, 1H) 6.90 - 7.13 (m, 2H) 7.20 - 7.37 (m, 1 H) 7.57 - 7.78 (m, 2H) 7.84 (s, 1 H) 7.88 - 7.98 (m, 1H) 8.10 - 8.23 (m, 1H) 8.37 - 8.54 (m, 2H) 8.99 - 9.19 (m, 1H) 10.41 - 10.54 (m, 1H)	511	A	
I-363		Oc1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	1H NMR (DMSO-d6, 400 MHz) 10.3-10.5 (m, 1H), 10.0-10.2 (m, 1H), 8.9-9.1 (m, 1H), 7.9-8.0 (m, 1H), 7.6-7.8 (m, 1H), 7.5-7.6 (m, 1H), 7.2-7.4 (m, 1H), 7.0-7.1 (m, 1H), 6.8-6.9	483	A	





			(m, 1H), 6.4-6.7 (m, 1H), 6.3-6.8 (m, 1H), 5.5-6.0 (m, 1H)			
I-364		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)C1CCCO1	1H NMR (400 MHz, CD3CN) 8.63 (s, 1H), 7.69 (dd, 8.3, 0.8 Hz, 1H), 7.64 (dd, 8.4, 1.6 Hz, 1H), 7.61-7.52 (m, 3H), 7.25 (ddd, 8.9, 5.1, 1.2 Hz, 2H), 7.01-6.92 (m, 1H), 6.62 (br s, 1H), 6.11 (br s, 1H), 5.00 (q, 7.4 Hz, 1H), 4.12-4.04 (m, 1H), 3.95-3.86 (m, 1H), 2.48-2.38 (m, 1H), 2.06-1.97 (m, 2H), 1.84-1.72 (m, 1H).	537.2	A	
I-365		Cc1ccccc1C1NC(=O)c2c1c(NC(=O)c1cc(F)cc(c1)C(F)(F)F)ccc2P(C)(C)=O	1H NMR (400 MHz, DMSO-d6) 10.48 (br s, 1 H), 9.38 (s, 1 H), 8.17 (dd, 11.6, 8.1 Hz, 1 H), 7.88 (d, 8.5 Hz, 1 H), 7.70 (d, 8.0 Hz, 1 H), 7.44 (d, 8.2 Hz, 1 H), 7.28 (s, 1 H), 7.06 (td, 7.5, 1.2 Hz, 1 H), 7.00 - 6.90 (m, 2 H), 6.47 (br s, 1H), 5.94 (s, 1 H), 2.25 (br s, 3 H), 1.91 (d, 6.9 Hz, 3 H), 1.87 (d, 6.9 Hz, 3 H).	503.3	D	
I-366		Fc1ccc(Cl)c(c1)[C@@H]1NC(=O)c2nc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)N1CC(F)(F)C1	^{1}H NMR (400 MHz, DMSO-d_6) δ 10.72 (br s, 1H), 9.30 (br s, 1H), 7.94 (d, J = 6.5 Hz, 1H), 7.71 (d, J = 9.0 Hz, 1H), 7.62 (s, 1H), 7.34 (dd, J = 8.9, 5.2 Hz, 1H), 7.17 – 6.97 (m, 1H), 6.94 – 6.56 (m, 2H), 5.91 (br s, 1H), 4.65 – 4.33 (m, 4H).	559.3	A	
I-367		Fc1ccc(Cl)c(c1)[C@H]1NC(=O)c2nc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)N1CC(F)(F)C1	^{1}H NMR (400 MHz, DMSO-d_6) δ 10.72 (br s, 1H), 9.30 (br s, 1H), 7.94 (d, J = 6.5 Hz, 1H), 7.71 (d, J = 9.0 Hz, 1H), 7.62 (s, 1H), 7.34 (dd, J = 8.9, 5.2 Hz, 1H), 7.17 – 6.97 (m, 1H), 6.94 – 6.56	559.2	D	





		2)N1CC(F)(F)C1	(m, 2H), 5.91 (br s, 1H), 4.65 – 4.33 (m, 4H).			
I-368		CC1(F)CN(C1)c1cc(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c2C(NC(=O)c2n1)c1cc(F)ccc1Cl	1H NMR (400 MHz, DMSO-d6) 10.64 (s, 1H), 9.27 (s, 1H), 7.96 (d, 8.1 Hz, 1H), 7.70 (d, 8.9 Hz, 1H), 7.60 (s, 1H), 7.32 (dd, 8.9, 5.2 Hz, 1H), 7.13-7.00 (m, 1H), 6.75 (br s, 1H), 6.53 (s, 1H), 5.89 (s, 1H), 4.27-4.01 (m, 4H), 1.67 (d, 22.2 Hz, 3H).	555.3	B	
I-369		Cc1ccccc1C1NC(=O)c2cccc(NC(=O)c3cc(ccc3F)C(F)(F)F)c12	1H NMR (400 MHz, DMSO-d6) 10.42 (s, 1H), 9.09 (s, 1H), 7.90 (mt, 1H), 7.68 (dd, 7.5, 1.0 Hz, 1H), 7.62 (t, 7.6 Hz, 1H), 7.58-7.45 (m, 2H), 7.17 (td, 7.2, 0.8 Hz, 1H), 7.12 (d, 6.8 Hz, 1H), 7.03 (td, 7.6, 1.2 Hz, 1H), 6.76 (s, 1H), 6.56 (br. s, 1H), 5.95 (s, 1H), 2.26 (br. s, 3H).	429.3	D	
I-370		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)N1CC(F)(F)C1	1H NMR (400 MHz, CD3CN) 8.55 (s, 1H), 7.66 (d, 8.9 Hz, 1H), 7.60 (d, 8.9 Hz, 1H), 7.57 (s, 1H), 7.27 (dd, 8.9, 5.1 Hz, 1H), 7.18 (s, 1H), 7.01-6.94 (m, 1H), 6.92 (d, 2.2 Hz, 1H), 6.78 (d, 2.2 Hz, 1H), 6.66 (br s, 1H), 6.05 (br s, 1H), 4.37 (t, 12.1 Hz, 4H).	558.3	A	
I-371		Fc1cc(cc(c1)C(F)(F)F)C(=O)Nc1ccccc2C(=O)NC(c12)c1ccc2ccccc2c1	1H NMR (400 MHz, DMSO-d6) 10.35 (s, 1H), 9.18 (s, 1H), 7.84 (d, 8.1 Hz, 1H), 7.78 (d, 8.0 Hz, 1H), 7.72 (dd, 7.2, 0.4 Hz, 1H), 7.70 (d, 8.4 Hz, 1H), 7.66-7.55 (m, 3H), 7.52 (s, 1H), 7.49-7.39 (m, 3H), 7.35 (m, 1H), 6.87 (dd, 8.6, 1.4 Hz, 1H), 5.88 (s, 1H)	465.2	E	





I-372		Fc1ccc(Cl)c(c1)C1NC(=O)c2cccc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	1H NMR (400 MHz, CD3CN) 8.63 (s, 1H), 7.77 (dd, 7.5, 0.9 Hz, 1H), 7.67-7.52 (m, 5H), 7.25 (dd, 8.9, 5.1 Hz, 2H), 6.97 (ddd, 8.9, 8.0, 3.1 Hz, 1H), 6.62 (br s, 1H), 6.13 (br s, 1H).	467	A	
I-373		COC(=O)c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	1H NMR (400 MHz, d6-DMSO) 10.66 (s, 1H), 9.35 (br s, 1H), 8.13 (dd, 16.4, 1.2 Hz, 2H), 7.96 (d, 8.3 Hz, 1H), 7.76 (d, 8.8 Hz, 1H), 7.68 (s, 1H), 7.33 (dd, 8.9, 5.2 Hz, 1H), 7.10 (td, 8.5, 3.1 Hz, 1H), 6.04 (br s, 1H), 3.93 (s, 3H).	525.3	A	
I-374		OC1(CC1)c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	1H NMR (400 MHz, CD3CN) 8.61 (s, 1H), 7.67-7.56 (m, 4H), 7.55 (d, 1.6 Hz, 1H), 7.51 (d, 1.3 Hz, 1H), 7.25 (dd, 8.9, 5.1 Hz, 1H), 7.20 (br s, 1H), 6.96 (ddd, 8.9, 8.0, 3.1 Hz, 1H), 6.63 (br s, 1H), 6.09 (s, 1H), 1.30-1.26 (m, 2H), 1.14-1.10 (m, 2H).	523.4	A	
I-375		CN1C[C@H](CC1=O)Nc1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	NMR (400 MHz,) 10.30 (br. s, 1H), 8.95 (br. s, 1H), 7.93 (d, 8.5 Hz, 1H), 7.69 (d, 9.0 Hz, 1H), 7.60 (s, 1H), 7.28 (dd, 8.7, 5.1 Hz, 1H), 7.07 (td, 8.1, 2.8 Hz, 1H), 6.80 (d, 1.3 Hz, 1H), 6.69 (s, 1H), 6.58 (d, 6.2 Hz, 1H), 5.84 (br. s, 1H), 4.17 - 4.12 (m, 1H), 3.79-3.74 (m, 1H), 3.21 (m, 1H), 2.79-2.73 (m, 1H), 2.75 (s, 3H), 2.25-2.13 (m, 1H)	579.4	A	






I-376		Cc1ccccc1C1NC(=O)c2cccc(NC(=O)c3nsc4ccc(Br)cc34)c12		478.3	C	
I-377		Cc1ccccc1C1NC(=O)c2cccc(NC(=O)c3nsc4ccc(cc34)C#N)c12		425.4	D	
I-378		Cc1ccccc1C1NC(=O)c2cccc(NC(=O)c3nsc4ccc(cc34)-c3ccccc3)c12		476.5	D	
I-379		Cn1cc(cn1)-c1cc(NC(=O)c2cc(F)cc(Cl)c2)c2C(NC(=O)c2n1)c1cc(F)ccc1Cl	1H NMR (400 MHz, DMSO-d6) 10.67 (s, 1H), 9.43 (br s, 1H), 8.38 (s, 1H), 8.03 (s, 1H), 7.63-7.76 (m, 2H), 7.27-7.43 (m, 3H), 7.13 (td, 8.4, 3.1 Hz, 1H), 6.79-6.95 (m, 1H), 5.98 (br s, 1H), 3.92 (s, 3H)	514.4	B	
I-380		Cc1nn(C)cc1-c1cc(NC(=O)c2cc(F)cc(Cl)c2)c2C(NC(=O)c2n1)c1cc(F)ccc1Cl	1H NMR (DMSO-d6, 400 MHz) 10.65 (br s, 1H), 9.43 (br s, 1H), 8.26 (s, 1H), 7.61-7.75 (m, 2H), 7.29-7.44 (m, 3H), 7.15 (td, 8.4, 3.1 Hz, 1H), 6.81-6.97 (m, 1H), 6.00 (br s, 1H), 3.84 (s, 3H), 3.30 (br s, 3H)	528.4	B	
I-381		Cc1c(cnn1C)-c1cc(NC(=O)c2cc(F)cc(Cl)c2)c2C(NC(=O)c2n1)c1cc(F)ccc1Cl	1H NMR (DMSO-d6, 400 MHz) 10.66 (br s, 1H), 9.33-9.45 (m, 1H), 7.90 (br s, 1H), 7.57-7.76 (m, 2H), 7.38 (br d, 8.8 Hz, 3H), 7.13 (td, 8.4, 3.1 Hz, 1H), 6.80-6.90 (m, 1H), 5.98 (s, 1H), 3.81 (s, 3H), 2.70 (s, 3H)	528.4	B	







I-382		CC(O)(CO)c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	1H NMR (DMSO-d6, 400 MHz) Shift 10.4-10.7 (m, 1H), 8.9-9.2 (m, 1H), 7.8-8.0 (m, 1H), 7.7-7.8 (m, 1H), 7.66 (s, 1H), 7.5-7.6 (m, 1H), 7.2-7.4 (m, 1H), 6.9-7.2 (m, 1H), 6.5-6.7 (m, 1H), 5.8-6.1 (m, 2H), 5.1-5.3 (m, 1H), 4.7-5.0 (m, 1H), 3.4-3.7 (m, 2H), 1.3-1.6 (m, 3H)	541	B	
I-383		Oc1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(Cl)c2)c1)c1cc(F)ccc1Cl	1H NMR (400 MHz, DMSO-d6) 5.43 - 6.14 (m, 2H), 6.82 - 6.95 (m, 1H), 7.00 (d, 1.95 Hz, 1H), 7.10 (td, 8.36, 3.05 Hz, 1H), 7.25 - 7.47 (m, 2H), 7.53 - 7.88 (m, 1 H), 8.82 - 9.39 (m, 2H), 10.00 - 10.41 (m, 2H)	450	A	
I-384		Cn1cc(cn1)-c1cc(NC(=O)c2cc(F)cc(Cl)c2)c2[C@H](NC(=O)c2n1)c1cc(F)ccc1Cl	^{1}H NMR (400 MHz, DMSO-d_6) δ 10.67 (s, 1H), 9.43 (br s, 1H), 8.38 (s, 1H), 8.03 (s, 1H), 7.63-7.76 (m, 2H), 7.27-7.43 (m, 3H), 7.13 (td, J = 8.4, 3.1 Hz, 1H), 6.79-6.95 (m, 1H), 5.98 (br s, 1H), 3.92 (s, 3H).	514.4	D	
I-385		OB(O)c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(Cl)c2)c1)c1cc(F)ccc1Cl	1H NMR (400 MHz, DMSO-d6) 5.78 - 6.22 (m, 1H), 6.46-6.65 (m, 1H), 6.93 - 7.22 (m, 1H), 7.25-7.49 (m, 1H), 7.55-7.71 (m, 1H), 7.81 - 7.91 (m, 1H), 8.11 - 8.23 (m, 1H), 8.36 - 8.58 (m, 1H), 8.88 - 9.35 (m, 1H), 10.16 - 10.67 (m, 1H)	478	A	
I-386		Cn1cc(cn1)-c1cc(NC(=O)c2cc(F)cc(Cl)c2)c2[C@@H](NC(=O)c2n1	^{1}H NMR (400 MHz, DMSO-d_6) δ 10.67 (s, 1H), 9.43 (br s, 1H), 8.38 (s, 1H), 8.03 (s, 1H), 7.63-7.76 (m, 2H), 7.27-7.43 (m, 3H), 7.13 (td, J = 8.4, 3.1 Hz, 1H), 6.79-6.95 (m, 1H),	514.4	A	




		)c1cc(F)ccc1Cl	5.98 (br s, 1H), 3.92 (s, 3H).			
I-387		Fc1ccc(Cl)c(c1)[C@H]1NC(=O)c2cc(Br)cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	1H NMR (DMSO-d6, 500 MHz) 10.4-10.7 (m, 1H), 9.1-9.4 (m, 1H), 7.9-8.0 (m, 1H), 7.8-7.9 (m, 1H), 7.7-7.8 (m, 2H), 7.6-7.7 (m, 1H), 7.2-7.4 (m, 1H), 7.0-7.1 (m, 1H), 6.3-6.8 (m, 1H), 5.8-6.1 (m, 1H)	546	D	
I-388		Fc1ccc(Cl)c(c1)[C@@H]1NC(=O)c2cc(Br)cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	1H NMR (DMSO-d6, 500 MHz) 10.4-10.7 (m, 1H), 9.1-9.4 (m, 1H), 7.9-8.0 (m, 1H), 7.8-7.9 (m, 1H), 7.7-7.8 (m, 2H), 7.6-7.7 (m, 1H), 7.2-7.4 (m, 1H), 7.0-7.1 (m, 1H), 6.3-6.8 (m, 1H), 5.8-6.1 (m, 1H)	546	A	A
I-389		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(NC(=O)C3CNC3)cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	1H NMR (400 MHz, DMSO-d6) 3.73 - 3.81 (m, 1H), 3.94 - 4.21 (m, 4H), 5.80 - 6.02 (m, 2H) 6.52 (s, 1H), 7.08 (td,8.36, 2.81 Hz, 1 H), 7.31 (br dd, 8.79, 5.13 Hz, 1 H), 7.61 (s, 1H), 7.67 - 7.80 (m, 2H), 7.90 - 8.03 (m, 2H), 8.46 - 8.56 (m, 1H), 9.15 (br s, 1H), 10.49 (br d, 3.17 Hz, 1H)	565.5	B	
I-390		Fc1cccc(c1)C1NC(=O)c2cccc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	1H NMR (400 MHz, DMSO-d6) 10.44 (s, 1H), 9.12 (s, 1H), 8.01-7.93(m, 1H), 7.77-7.72(m, 1H), 7.69 (dd, 7.5, 1.0 Hz, 1H), 7.66 (br s, 1H), 7.61 (t, 7.6 Hz, 1H), 7.54-7.49 (m, 1H), 7.19 (td, 8.0, 6.0 Hz, 1H), 7.07-6.98 (m, 1H), 6.83-6.74 (m, 2H), 5.74 (s, 1H).	431.3	D	





I-391		Cc1ccccc1C1NC(=O)c2cccc(NC(=O)c3cc(F)cc(Br)c3)c12	1H NMR (400 MHz, DMSO-d6) 10.22 (s, 1H), 9.06 (s, 1H), 7.74 (td, 8.3, 2.0 Hz, 1H), 7.67 (dd, 7.4, 1.1 Hz, 1H), 7.61 (t, 7.5 Hz, 1H), 7.53 (dd, 7.7, 0.9 Hz, 1H), 7.21 -7.14 (m, 2H), 7.10 (dd, 7.4, 1.2 Hz, 1H), 7.04 (d, 7.1 Hz, 1H), 6.98 (t, 7.2 Hz, 1H), 6.54 (br s, 1H), 5.90 (s, 1H), 2.20 (br s, 3H).	439.2	C	
I-392		O=C(Nc1cccc2C(=O)NC(c12)c1ccc2ccccc2c1)c1nsc2ccccc12	1H NMR (400 MHz, DMSO-d6) 10.22 (s, 1H), 9.18 (s, 1H), 8.56 (dt, 8.2, 1.0 Hz, 1H), 8.25 (dt, 8.3, 0.9 Hz, 1H), 7.85 (s, 1H), 7.77 (dd, 7.8, 0.9 Hz, 1H), 7.69 (d, 8.0 Hz, 1H), 7.66-7.60 (m, 3H), 7.57 (t, 7.7 Hz, 1H), 7.50 (ddd, 8.0, 7.0, 1.0 Hz, 1H), 7.39 (d, 8.1 Hz, 1H), 7.33 (ddd, 8.2, 6.9, 1.4 Hz, 1H), 7.26 (ddd, 8.1, 6.9, 1.2 Hz, 1H), 6.93 (dd, 8.5, 1.7 Hz, 1H), 6.09 (s, 1H)	436.3	E	
I-393		Nc1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1ccccc1Cl	1H NMR (400 MHz, CD3CN) 8.34 (s, 1H), 7.61 (d, 8.5 Hz, 1H), 7.52-7.44 (m, 3H), 7.28-7.23 (m, 2H), 7.19 (td, 7.6, 1.7 Hz, 1H), 7.12 (t, 7.4 Hz, 1H), 7.06 (s, 1H), 6.99-6.87 (m, 3H), 6.03 (s, 1H).	464	A	
I-394		Fc1cc(cc(c1)C(F)(F)F)C(=O)Nc1cc(Br)cc2C(=O)NC(c12)c1ccccc1Cl	1H NMR (400 MHz, CD3CN) 8.62 (br s, 1H), 7.88 (d, 1.7 Hz, 1H), 7.80 (br s, 1H), 7.67-7.61 (m, 1H), 7.53-7.46 (m, 2H), 7.32 (br s, 1H), 7.28 (dd, 8.0, 1.6 Hz, 1H), 7.24-7.19 (m, 1H), 7.12 (br t, 7.0 Hz, 1H), 6.90 (br s, 1H), 6.13 (br s, 1H).	527	B	





I-395		CP(C)(=O)c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	1H NMR (400 MHz, DMSO-d6) 9.29 (br s, 1 H), 8.34 (br s, 1 H), 8.08 (d, 10.5 Hz, 1 H), 7.96 (d, 8.6 Hz, 1 H), 7.91 (d, 11.5 Hz, 1 H), 7.76 (d, 8.8 Hz, 1 H), 7.69 (s, 1 H), 7.32 (dd, 8.9, 5.1 Hz, 1 H), 7.10 (td, 8.5, 3.0 Hz, 1 H), 6.67 (br s, 1H), 6.04 (br s, 1 H), 1.80-1.70 (m, 6H).	543.3	A	
I-396		Cc1ccccc1[C@@H]1NC(=O)c2c1c(NC(=O)c1cc(F)cc(c1)C(F)(F)F)ccc2C#N	1H NMR (400 MHz, DMSO-d6) 10.64 (br s, 1 H), 9.48 (s, 1 H), 8.08 (d, 8.1 Hz, 1 H), 7.90 (d, 8.3 Hz, 1 H), 7.77 (d, 8.0 Hz, 1 H), 7.49 - 7.43 (m, 1H), 7.30 (br s, 1 H), 7.08 (td, 7.5, 1.2 Hz, 1 H), 7.01 (d, 7.2 Hz, 1 H), 6.97 (t, 7.3 Hz, 1 H), 6.52 (br s, 1 H), 5.96 (s, 1 H), 2.28 (s, 3 H).	454.3	A	
I-397		Cc1ccccc1[C@H]1NC(=O)c2c1c(NC(=O)c1cc(F)cc(c1)C(F)(F)F)ccc2C#N	(400 MHz, DMSO-D6) 10.64 (br s, 1 H), 9.48 (s, 1 H), 8.08 (d, 8.1 Hz, 1 H), 7.90 (d, 8.3 Hz, 1 H), 7.77 (d, 8.0 Hz, 1 H), 7.49 - 7.43 (m, 1 H), 7.30 (br s, 1 H), 7.08 (td, 7.5, 1.2 Hz, 1 H), 7.01 (d, 7.2 Hz, 1 H), 6.97 (t, 7.3 Hz, 1 H), 6.52 (br s, 1 H), 5.96 (s, 1 H), 2.28 (s, 3 H).	454.3	B	
I-398		Cc1ccccc1C1NC(=O)c2cccc(-c3nnc([nH]3)-c3ccccc3)c12	NMR (400 MHz, DMSO-d6) 8.29 (br. s, 1H), 8.02-8.01 (m, 2H), 7.82-7.81 (m, 2H), 7.58 (br. s, 1H), 7.28-7.24 (m, 4H), 7.21-7.15 (m, 4H), 6.67 (br. s, 1H), 2.10 (br. s, 3H) - 0.88-0.82	366.2	E	






I-399		OC(=O)Cc1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	1H-NMR (400 MHz, DMSO-d6) 10.51 (br. s, 1H), 9.11 (s, 1H), 7.93 (dt, 8.5, 1.7 Hz, 1H), 7.73 (br. d, 8.8 Hz, 1H), 7.66 (s, 1H), 7.58 (s, 1H), 7.37 (s, 1H), 7.31 (dd, 8.9, 5.2 Hz, 1H), 7.09 (td, 8.5, 3.1 Hz, 1H), 6.58 (br. s, 1H), 5.95 (br. s, 1H), 3.71 (d, A of AB, JAB = 15.9 Hz, 1H), 3.66 (d, B of AB, JAB = 15.6 Hz, 1H).	525.3	A	
I-400		Cc1ccccc1C1NC(=O)c2cccc(NC(=O)c3nnc4ccc(Cl)cn34)c12	1H-NMR (400 MHz, DMSO-d6) 10.70 (s, 1H), 9.08 (dd, 1.9, 0.9 Hz, 1H), 9.05 (s, 1H), 8.06 (dd, 9.7, 1.0 Hz, 1H), 7.71-7.66 (m, 3H), 7.65-7.59 (m, 1H), 6.94-6.86 (m, 2H), 6.85-6.79 (m, 1H), 6.67 (br. s, 1H), 6.07 (s, 1H), 2.18 (br. s, 3H).	418.3	E	
I-401		Fc1cc(cc(c1)C(F)(F)F)C(=O)Nc1ccc2C(=O)NC(c12)c1cc(Cl)cc(F)c1F	1H NMR (400 MHz, CD3CN) 8.84 (s, 1H), 7.77 (d, 7.5 Hz, 1H), 7.74-7.66 (m, 3H), 7.63 (t, 7.7 Hz, 1H), 7.50 (d, 7.7 Hz, 1H), 7.26-7.15 (m, 2H), 6.89-6.79 (m, 1H), 5.93 (s, 1H).	485.2	B	
I-402		Clc1ccc2occ(C(=O)Nc3ccccc4C(=O)NCc34)c2c1			E	
I-403		Cn1cc(C(=O)Nc2cccc3C(=O)NCc23)c2ccccc12			E	






I-404		O=C(Nc1cccc2C(=O)NCc12)c1csc2CCCCc12			E	
I-405		CN1Cc2c(cccc2NC(=O)N2CCc3ccc(C)cc23)C1=O			E	
I-406		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(NC(=O)C=C)cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12		536.25	A	
I-407		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(NC(=O)CCl)cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12		558.26	A	
I-408		Cc1ccccc1C1NC(=O)c2cccc(NC(=O)c3cc(F)cc4c(c[nH]c34)C(=O)C(F)(F)F)c12	1H NMR (400 MHz, DMSO-d6) Shift 12.68 (br s, 1H), 10.36 (br s, 1H), 9.06 (s, 1H), 8.28 (br s, 1H), 8.01 (br d, 5.86 Hz, 1H), 7.47-7.72 (m, 3H), 6.84-7.06 (m, 3H), 6.44-6.73 (m, 2H), 6.00 (br s, 1H), 1.94-2.28 (m, 3H)	496.28	E	
I-409		Fc1cc(cc(c1)C(F)(F)F)C(=O)Nc1cccc2C(=O)NC(c12)c1ccc(Br)cc1Cl			D	




I-410		Cc1nn(C)c(C)c1-c1cc(NC(=O)c2cc(F)cc(Cl)c2)c2C(NC(=O)c2n1)c1cc(F)ccc1Cl		542.4	C	
I-411		Cc1ccccc1C1NC(=O)c2cccc(NC(=O)c3n[nH]cc3Br)c12	1H NMR (400 MHz, DMSO-d6) 13.52 - 13.93 (m, 1H), 9.42 (br s, 1H), 8.98 (s, 1H), 8.03 (s, 1H), 7.79 (dd, 7.20, 1.10 Hz, 1H), 7.50 - 7.60 (m, 2H), 7.02 - 7.13 (m, 2H), 6.96 (dt, 7.87, 4.24 Hz, 1H), 6.54 - 6.73 (m, 1H), 6.06 (s, 1H), 2.14 - 2.40 (m, 3H)	411.19	E	
I-412		Cc1ccccc1C1NC(=O)c2cccc(NC(=O)c3n[nH]cc3-c3ccccc3)c12	1H NMR (400 MHz, DMSO-d6) 13.43 (br s, 1 H), 9.37 (br s, 1H), 8.97 (s, 1H) 7.99 (s, 1H) 7.85 (br d, 5.37 Hz, 1H) 7.48-7.61 (m, 2 H), 7.43 (br s, 2H) 7.26 - 7.35 (m, 2H) 7.19 - 7.26 (m, 1H) 7.06 - 7.16 (m, 2H) 6.95 - 7.05 (m, 1H) 6.57 - 6.77 (m, 1H) 6.07 (s, 1H) 2.14 - 2.42 (m, 3H)	409.39	E	
I-413		Cc1ccccc1C1NC(=O)c2cccc(NC(=O)c3nscc3-c3ccccc3)c12	1H NMR (400 MHz, DMSO-d6) 9.99 (s, 1 H), 9.05 (s, 1 H), 8.98 (s, 1 H), 7.68 (d, 7.32 Hz, 1 H) 7.50 - 7.62 (m, 2 H) 7.29 - 7.38 (m, 3 H), 7.17 - 7.27 (m, 2 H) 7.07 - 7.13 (m, 2 H), 6.97 - 7.04 (m, 1 H), 6.64 (br d, 3.17 Hz, 1 H), 6.03 (s, 1 H), 2.13 - 2.30 (m, 3 H)	426.3	D	





I-414		Oc1cc(cc(c1)C(F)(F)F)C(=O)Nc1ccc c2C(=O)NC(c12)c1cc(Br)ccc1Cl		525	B	
I-415		Oc1ccc(Cl)c(c1)C1NC(=O)c2cccc(NC(=O)c3cc(O)cc(c3)C(F)(F)F)c12	1H NMR (400 MHz, DMSO-d6) 5.81 - 6.28 (m, 2 H), 6.47 - 6.72 (m, 1 H), 6.90 - 7.06 (m, 1 H), 7.17 (s, 1 H), 7.25 - 7.35 (m, 1 H), 7.38 - 7.52 (m, 1 H), 7.54 - 7.90 (m, 1 H), 8.90 - 9.20 (m, 1 H), 9.29 - 9.81 (m, 1 H), 10.09 - 10.38 (m, 1 H)	463	E	
I-416		FC(F)(F)c1cc(Br)cc(c1)C(=O)Nc1ccc c2C(=O)NC(c12)c1cc(Br)ccc1Cl	1H NMR (400 MHz, DMSO-d6) 5.59 - 6.12 (m, 1 H), 6.47 - 6.69 (m, 1 H), 7.16 - 7.29 (m, 1 H), 7.31 - 7.52 (m, 1 H), 7.53 - 7.73 (m, 1 H), 7.75 - 7.86 (m, 1 H), 7.89 - 8.03 (m, 1 H), 8.14 - 8.32 (m, 1 H), 8.79 - 9.36 (m, 1 H), 10.34 - 10.85 (m, 1 H)	589	C	
I-417		NC1CN(C1)c1cc(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c2C(NC(=O)c2n1)c1cc(F)ccc1Cl	1H NMR (400 MHz, DMSO-d6) 10.62 (br s, 1H), 9.23 (s, 1H), 8.25 (s, 1H), 7.95 (d, 8.2 Hz, 1H), 7.71 (d, 8.9 Hz, 1H), 7.61 (s, 1H), 7.32 (dd, 8.8, 5.1 Hz, 1H), 7.07 (td, 8.5, 3.0 Hz, 1H), 6.70 (br s, 1H), 6.46 (s, 1H), 5.88 (s, 1H), 4.22 (d, 8.1 Hz, 2H), 3.95-3.85 (m, 1H), 3.69 (dd, 14.1, 8.4 Hz, 2H).	538.3	B	





I-418		CS(=O)(=O)C1CN(C1)c1cc(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c2C(NC(=O)c2n1)c1cc(F)ccc1Cl	1H NMR (400 MHz, DMSO-d6) 10.51 (br s, 1H), 9.26 (s, 1H), 8.34 (s, 1H), 7.92 (d, 14.2 Hz, 1H), 7.71 (d, 9.0 Hz, 1H), 7.62 (s, 1H), 7.33 (dd, 8.8, 5.2 Hz, 1H), 7.08 (td, 8.3, 3.0 Hz, 1H), 6.75 (br s, 1H), 6.63 (s, 1H), 5.89 (s, 1H), 4.53-4.41 (m, 1H), 4.36 (q, 8.4 Hz, 2H), 4.24 (td, 8.9, 5.2 Hz, 2H), 3.10 (s, 1H).	601.1	B	
I-419		Cc1ccccc1C1NC(=O)c2cc(cc(NC(=O)c3nsc4ccccc34)c12)C1(O)CCC1	1H NMR (400 MHz, CD3CN) 8.93 (s, 1H), 8.85 (d, 8.1 Hz, 1H), 8.26 (t, 1.5 Hz, 1H), 8.13 (dt, 8.2, 1.0 Hz, 1H), 8.10 (s, 2.8 Hz, 1H), 7.65 (ddd, 7.1, 6.4, 1.3 Hz, 2H), 7.59 (ddd, 8.1, 7.0, 1.1 Hz, 1H), 7.23-7.10 (m, 4H), 7.05 (td, 8.2, 3.5 Hz, 1H), 6.05 (brs, 1H), 1.01 (t, 6.1 Hz, 1H), 0.90 (t, 7.3 Hz, 1H), 0.82 (dd, 6.4, 1.6 Hz, 4H)	470.3	A	
I-420		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)C1COC1	1H NMR (400 MHz, DMSO-d6) 2.07 (s, 3 H) 4.43 (dt, 15.13, 7.32 Hz, 1 H) 4.59 - 4.76 (m, 2 H) 4.98 - 5.04 (m, 1 H) 5.98 (br d, 4.39 Hz, 1 H) 7.09 (td, 8.36, 3.05 Hz, 1 H) 7.31 (br dd, 8.79, 5.13 Hz, 1 H) 7.56 (s, 1 H) 7.65 - 7.78 (m, 2 H) 7.94 (br d, 8.30 Hz, 1 H) 9.15 (br s, 1 H) 10.52 (s, 1 H)	523.25	A	
I-421		Fc1cc(cc(c1)C(F)(F)F)C(=O)Nc1ccccc2C(=O)NC(c12)c1ccc(cc1Cl)-c1ccccc1			D	





I-422		Fc1cc(cc(c1)C(F)(F)F)C(=O)Nc1ccc c2C(=O)NC(c12)c1ccc(cc1Cl)C#N			E	
I-423		CC(=O)Nc1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl		524.25	A	
I-424		Fc1cc(cc(c1)C(F)(F)F)C(=O)Nc1ccc c2C(=O)NC(c12)c1ccc(cc1Cl)C1CC1			D	
I-425		Cn1cc(cn1)-c1ccc(C2NC(=O)c3cccc(NC(=O)c4cc(F)cc(c4)C(F)(F)F)c23)c(Cl)c1			E	
I-426		CC(C)(CO)c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	1H NMR (400 MHz, DMSO-d6) 1.13 - 1.41 (m, 6 H), 4.66 - 4.88 (m, 1 H), 5.79 - 6.13 (m, 1 H), 6.61 - 6.80 (m, 1 H), 6.99 - 7.15 (m, 1 H), 7.18 - 7.35 (m, 1 H), 7.44 - 7.52 (m, 1 H), 7.58 - 7.81 (m, 4 H), 7.87 - 8.01 (m, 1 H), 8.41 - 8.54 (m, 1 H), 8.99 - 9.23 (m, 1 H), 10.39 - 10.63 (m, 1 H)	563	A	







I-427		CC(C)(C(O)=O)c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	1H NMR (400 MHz, DMSO-d6) 1.41 - 1.64 (m, 6 H), 5.82 - 6.07 (m, 1 H), 7.02 - 7.14 (m, 1 H), 7.24 - 7.34 (m, 1 H), 7.41 - 7.48 (m, 1 H), 7.60 - 7.67 (m, 2 H), 7.70 - 7.80 (m, 1 H), 7.88 - 7.98 (m, 1 H), 8.32 - 8.45 (m, 1 H), 9.03 - 9.25 (m, 1 H), 10.42 - 10.65 (m, 1 H)	553	B	
I-428		Oc1ccc(Cl)c(c1)C1NC(=O)c2cccc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12		465	D	
I-429		Nc1ccc(Cl)c(c1)C1NC(=O)c2cccc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12		464	D	
I-430		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(NC(=O)N3CCC(CC3)C(F)(F)F)c12	1H NMR (400 MHz, DMSO-d6) 9.19 (s, 1H), 8.68 (s, 1H), 7.59 (d, 1.4 Hz, 1H), 7.50 (d, 1.4 Hz, 1H), 7.48-7.40 (m, 1H), 7.22 (td, 8.4, 3.0 Hz, 1H), 6.55 (br s, 1H), 6.03 (br s, 1H), 3.93 (d, 13.4 Hz, 1H), 3.78 (d, 13.6 Hz, 1H), 2.70 (d, 12.7 Hz, 1H), 2.55-2.38 (m, 2H), 1.72 (d, 12.3 Hz, 1H), 1.64 (d, 12.3 Hz, 1H), 1.25-1.09 (m, 1H), 0.89-0.65 (m, 1H) .	534.2	D	
I-431		Fc1cc(cc(c1)C(F)(F)F)C(=O)Nc1ccc2C(=O)NC(c12)c1cccc2ccccc12	1H NMR (400 MHz, DMSO-d6) 10.03 (s, 1H), 8.99 (s, 1H), 8.01 (s, 1H), 7.92 (d, 7.9 Hz, 1H), 7.83-7.77 (m, 2H), 7.75 (d, 8.3 Hz, 2H), 7.68 (m, 1H), 7.63 (t, 7.6 Hz, 1H), 7.48 (d,	463.3	D	





			7.6 H, 1Hz), 7.39-7.19 (m, 4H), 6.48 (br s, 1H).			
I-432		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(NC(=O)N3CCCC(C3)C(F)(F)F)c12	1H NMR (400 MHz, DMSO-d6) 9.20 (s, 2H), 8.80 (s, 1H), 8.77 (s, 1H), 7.57 (s, 1H), 7.57 (s, 1H), 7.54-7.42 (m, 4H), 7.25-7.15 (m, 2H), 6.52 (br s, 2H), 5.98 (br s, 2H), 4.03-3.87 (m, 2H), 3.71 (d, 13.0 Hz, 1H), 3.57 (d, 13.2 Hz, 1H), 2.70-2.54 (m, 2H), 2.36 (t, 12.3 Hz, 1H), 2.10 (br s, 1H), 1.83-1.70 (m, 2H), 1.68-1.11 (m, 7H), 0.6 (br s, 1H) . [1:1 mixture of diastereomers]	534.2	C	
I-433		Cc1ccccc1C1NC(=O)c2cccc(NC(=O)N3CCCCC3)c12	1H NMR (400 MHz, DMSO-d6) 8.90 (s, 1H), 8.24 (s, 1H), 7.46-7.42 (m, 2H), 7.31 (dd, 6.2, 2.7 Hz, 1H), 7.19-7.12 (m, 2H), 7.07-6.98 (m, 1H), 6.53 (br s, 1H), 5.94 (s, 1H), 3.11-3.00 (m, 2H), 2.97-2.85 (m, 2H), 2.33 (br s, 3H), 1.43-1.32 (m, 2H), 1.28-1.14 (m, 2H), 1.13-0.98 (m, 2H) .	350.3	E	
I-434		Cc1ccccc1C1NC(=O)c2c1c(NC(=O)c1nsc3ccccc13)ccc2CCO	1H NMR (400 MHz, DMSO-d6) 10.03 (s, 1 H), 8.96 (s, 1 H), 8.56 (d, 8.1 Hz, 1 H), 8.29 (d, 8.2 Hz, 1 H), 7.69-7.63 (m, 2 H), 7.57 (t, 7.6 Hz, 1 H), 7.39 (d, 8.1 Hz, 1 H), 6.99-6.84 (m, 3 H), 6.68 (br s, 1 H), 6.02 (s, 1 H), 4.69 (s, 1 H), 3.75 - 3.65 (m, 2 H), 3.43-3.22 (m, 2 H), 2.23 (s, 3 H).	444.3	A	






I-435		Cc1ccccc1C1NC(=O)c2cccc(NC(=O)c3cccc(c3)C(F)(F)F)c12	NMR (400 MHz, DMSO-d6) 10.29 (s, 1H), 9.05 (s, 1H), 7.87 (d, 7.6 Hz, 1H), 7.74 (d, 8.0 Hz, 1H), 7.69-7.58 (m, 3H), 7.53 (d, 7.8 Hz, 1H), 7.45 (s, 1H), 7.06 (td, 7.2 and 0.8 Hz, 1H), 6.99-6.93 (m, 2H), 6.55 (br. s, 1H), 5.94 (s, 1H), 2.18 (br. s, 3H).	411.3	D	
I-436		COc1cc(cc(F)c1F)C(=O)Nc1cc(Br)cc2C(=O)NC(c12)c1cc(F)ccc1C(F)F	1H NMR (400 MHz, DMSO-d6) 10.33 (br. s, 1H), 9.32 (s, 1H), 7.84 (d, 1.7 Hz, 1H), 7.76 (d, 1.7 Hz, 1H), 7.53 (dd, 8.7, 5.7 Hz, 1H), 7.24 (td, 8.5, 2.6 Hz, 1H), 7.45-7.00 (1 H submerged), 7.16-7.10 (m, 2H), 6.55 (br. s, 1H), 6.01 (s, 1H), 3.86 (s, 3H).	539.2	B	
I-437		CC(C)(O)Cc1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	1H-NMR (400 MHz, DMSO-d6) as a ca. 9:1 mixture of rotamers; assignment for major rotamer-´ 10.49 (s, 1H), 9.07 (br. s, 1H), 7.93 (d, 8.6 Hz, 1H), 7.73 (d, 8.9 Hz, 1H), 7.65 (s, 1H), 7.56 (s, 1H), 7.34-7.31 (m, 1H), 7.31-7.28 (m, 1H), 7.09 (td, 8.4, 3.0 Hz, 1H), 6.60 (br. s, 1H), 5.94 (br. s, 1H), 4.47 (br. s, 1H), 2.83 (d, A of AB, JAB = 13.2 Hz, 1H), 2.78 (d, B of AB, JAB = 12.9 Hz), 1.12 (s, 3H), 1.10 (s, 3H).	539.4	A	
I-438		CNC(=O)Cc1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	1H-NMR (400 MHz, DMSO-d6) 10.52 (br. s, 1H), 9.13 (s, 1H), 8.10 (q, 4.0 Hz, 1H), 7.94 (d, 8.5 Hz, 1H), 7.73 (d, 9.1 Hz, 1H), 7.65 (s, 1H), 7.59 (s, 1H), 7.37 (s, 1H), 7.31 (dd, 8.9, 5.2 Hz, 1H), 7.09 (td, 8.4, 3.1 Hz,	538.3	A	






			1H), 6.58 (br. s, 1H), 5.95 (br. s, 1H), 3.59 (d, A of AB, JAB = 14.3 Hz, 1H), 3.55 (d, B of AB, JAB = 14.3 Hz, 1H), 2.60 (d, 4.6 Hz, 3H)..			
I-439		CC(C)(O)c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1ccccc1Cl	NMR (400 MHz, CD3CN) 8.57 (br s, 1H), 7.81 (d, 1.5 Hz, 1H), 7.75 (br s, 1H), 7.67-7.63 (m, 1H), 7.62-7.58 (m, 1H), 7.54 (s, 1H), 7.51 (m, 2H), 7.26 (dd, 8.0, 1.4 Hz, 1H), 7.20 (td, 7.6, 1.7 Hz, 1H) overlapped with (s, 1H), 7.12 (t, 7.0 Hz, 1H), 6.87 (s, 1H), 6.15 (s, 1H), 1.57 (s, 3H), 1.56 (s, 3H).	507	B	
I-440		Fc1ccc(Cl)c(c1)C1NC(=O)c2c1c(NC(=O)c1cc(F)cc(c1)C(F)(F)F)cnc2NC1COC1	NMR (400 MHz, MeOD4) 8.55 (s, 1H), 8.06 (s,1H), 7.74-7.58 (m, 3H), 7.28 (dd, 8.9, 5.1 Hz, 1H), 7.01 (ddd, 8.9, 5.1 and 3.0 Hz, 1H), 6.74 (br. s,1H), 6.12 (br. s,1H), 5.49 (s, 1H), 5.32-5.18 (m, 1H), 5.02 (td, 6.9, 2.0 Hz, 2H), 4.72 (q, 6.6 Hz, 2H).	539.3	D	
I-441		Fc1ccc(Cl)c(c1)C1NC(=O)c2nc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)N1CCC1	NMR (400 MHz, DMSO-d6) 10.57 (br. s, 1H), 9.22 (br. s, 1H), 7.95 (d, 8.6 Hz, 1H), 7.70 (d, 9.0 Hz, 1H), 7.60 (s, 1H), 7.32 (dd, 8.9, 5.2 Hz 1H), 7.10-7.05 (m, 1H), 6.67 (br.s, 1H), 6.45 (br. s, 1H), 5.88 (br. s, 1H), 4.13-3.97 (m, 4H), 2.38 (qt, 8.9, 7.6 Hz, 2H).	523.2	A	
I-442		CC(C)CC1NC(=O)c2cccc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	NMR (400 MHz, DMSO-d6) 10.78 (s, 1H), 8.93 (s, 1H), 8.18 (s, 1H), 8.12 (d, 8.9 Hz, 1H), 8.04 (d, 8.4 Hz, 1H), 7.62-7.50 (m, 3H), 4.81 (d, 9.0 Hz, 1H), 1.73 (m, 1H), 1.68-1.58	395.3	D	






			(ddd, 13.1, 10.4, 2.1Hz, 1H), 1.10 (ddd, 13.2, 6.4, 2.2 Hz, 1H), 0.78 (d, 6.3 Hz, 3H), 0.72 (d, 6.5 Hz, 3H).			
I-443		Fc1ccc(Cl)c(c1)C1NC(=O)c2nc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)N1CC(C1)C#N	1H NMR (400 MHz, ACN-d3) 8.62 (s, 1H), 7.66 (d, 8.4 Hz, 1H), 7.55 (d, 8.9 Hz, 1H), 7.52 (s, 1H), 7.42 (s, 1H), 7.31 (dd, 8.9, 5.1 Hz, 1H), 6.99 (td, 8.4, 3.0 Hz, 1H), 6.72 (s, 2H), 6.04 (s, 1H), 4.37 (td, 8.4, 3.9 Hz, 2H), 4.26 (ddd, 8.3, 5.9, 2.7 Hz, 2H), 3.75 (tt, 8.8, 5.9 Hz, 1H). contains grease at 1.2 and 0.8 and trace impurities at 3.4 to 3.5 .	548.3	A	
I-444		Fc1ccc(Cl)c(c1)C1NC(=O)c2nc(CNCc3ccccc3)cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	(400 MHz, CD3CN) 8.10 (s, 1H), 7.76 (s, 1H), 7.66 (d, 8.3 Hz, 1H), 7.59 (d, 13.5 Hz, 3H), 7.41 (d, 7.3 Hz, 2H), 7.36 - 7.25 (m, 4H), 6.99 (td, 8.3, 2.8 Hz, 1H), 6.78 - 6.70 (m, 1 H), 6.15 (s, 1H), 4.08 (s, 2H), 3.89 (s, 2H).	587.3	B	
I-445		Cc1ccccc1C1NC(=O)c2cccc(NC(=O)c3nsc4ccc(cc34)-c3cnn(C)c3)c12		480.5	D	
I-446		Fc1cc(cc(c1)C(F)(F)F)C(=O)Nc1ccc2C(=O)NC(c12)c1cc(Br)ccc1Cl		527	A	





I-447		Fc1ccc(Cl)c(c1)C1NC(=O)c2cccc(NC(=O)c3cc(Br)cc(c3)C(F)(F)F)c12		527	D	
I-448		Oc1cc(cc(c1)C(F)(F)F)C(=O)Nc1ccc2C(=O)NC(c12)c1cc(F)ccc1Cl		465	C	
I-449		Nc1cc(cc(c1)C(F)(F)F)C(=O)Nc1ccc2C(=O)NC(c12)c1cc(F)ccc1Cl		464	D	
I-450		OB(O)c1cc(cc(c1)C(F)(F)F)C(=O)Nc1cccc2C(=O)NC(c12)c1cc(F)ccc1Cl		493	D	
I-451		Cc1ccccc1C1NC(=O)c2cccc(NC(=O)c3ccsn3)c12	1H NMR (400 MHz, DMSO-d6) Shift 9.87 (s, 1H), 9.11 (d, 4.64 Hz, 1H), 9.01 (s, 1H), 7.76 (d, 7.32 Hz, 1H), 7.67 (d, 4.64 Hz, 1H), 7.54-7.64 (m, 2H), 6.99-7.07 (m, 2H), 6.89-6.96 (m, 1H), 6.57-6.79 (m, 1H), 6.05 (br s, 1H), 2.10-2.39 (m, 3H)	350.31	E	
I-452		Cc1ccccc1C1NC(=O)c2cccc(NC(=O)c3ncsc3Br)c12	1H NMR (400 MHz, DMSO-d6) Shift 9.69 (s, 1H), 9.07 (s, 1H), 9.01 (s, 1H), 7.84 (d, 7.08 Hz, 1H), 7.49-7.64 (m, 2H), 7.07 (br d, 4.39 Hz, 2H), 6.92-7.02 (m, 1H), 6.57-6.79 (m,	428.2	D	



			1H), 6.03 (br s, 1H), 2.03-2.40 (m, 3H)			
I-453		Cc1ccccc1C1NC(=O)c2cccc(NC(=O)c3cc(Br)sn3)c12	1H NMR (400 MHz, DMSO-d6) Shift 9.97 (s, 1H), 9.01 (s, 1H), 7.79 (s, 1H), 7.69 (d, 7.57 Hz, 1H), 7.61-7.66 (m, 1H), 7.54-7.61 (m, 1H), 6.99-7.08 (m, 2H), 6.94 (br t, 7.32 Hz, 1H), 6.50-6.80 (m, 1H), 6.01 (br s, 1H), 2.02-2.40 (m, 3H)	428.25	E	
I-454		Cc1ccccc1C1NC(=O)c2cccc(NC(=O)c3cc(F)cc4cc[nH]c34)c12	1H NMR (400 MHz, DMSO-d6) Shift 11.17 (br s, 1H), 10.06 (s, 1H), 9.03 (s, 1H), 7.64-7.70 (m, 1H), 7.60 (d, 4.39 Hz, 1H), 7.50 (dd, 2.07, 9.40 Hz, 1H), 7.40 (br t, 2.68 Hz, 1H), 7.02-7.09 (m, 1H), 6.97 (br d, 7.32 Hz, 1H), 6.91 (br t, 7.20 Hz, 1H), 6.75 (br d, 9.52 Hz, 1H), 6.57-6.71 (m, 1H), 6.41-6.54 (m, 1H), 6.04 (s, 1H), 1.99-2.25 (m, 3H)	400.33	B	
I-455		Fc1ccc(Cl)c(c1)C1NC(=O)c2nc(cc(NC(=O)c3cc(F)cc(Cl)c3)c12)-c1cccnc1		511.4	B	
I-456		Cn1cc(ccc1=O)-c1cc(NC(=O)c2cc(F)cc(Cl)c2)c2C(NC(=O)c2n1)c1cc(F)ccc1Cl		541.4	A	





I-457		Cc1ncc(s1)-c1cc(NC(=O)c2cc(F)cc(Cl)c2)c2C(NC(=O)c2n1)c1cc(F)ccc1Cl		531.3	A	
I-458		Fc1ccc(Cl)c(c1)C1NC(=O)c2nc(cc(NC(=O)c3cc(F)cc(Cl)c3)c12)-c1ccncc1		511.4	B	
I-459		Cc1nc(C)c(s1)-c1cc(NC(=O)c2cc(F)cc(Cl)c2)c2C(NC(=O)c2n1)c1cc(F)ccc1Cl		545.3	A	
I-460		Cc1ncc(cn1)-c1cc(NC(=O)c2cc(F)cc(Cl)c2)c2C(NC(=O)c2n1)c1cc(F)ccc1Cl		526.4	B	
I-461		CC(=O)Nc1cc2C(=O)N[C@H](c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl		524.2	A	






I-462		CC(=O)Nc1cc2C(=O)N[C@@H](c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl		524.2	D	
I-463		Cc1ccccc1C1NC(=O)c2cccc(NC(=O)c3nscc3Br)c12	1H NMR (400 MHz, DMSO-d6) 10.05 (s, 1 H) 9.22 (s, 1 H) 9.01 (s, 1 H) 7.52 - 7.71 (m, 3 H) 7.02 - 7.10 (m, 2 H) 6.91 - 6.98 (m, 1 H) 6.58 -6.78 (m, 1 H) 6.03 (s, 1 H) 2.03 - 2.35 (m, 3 H)	428.2	D	
I-464		Cc1ccccc1C(=O)Nc1cc(Br)cc2C(=O)NC(c12)c1cc(F)ccc1Cl	1H NMR (400 MHz, Methanol-d4) 7.93 (d, 1.7 Hz, 1H), 7.80 (s, 1H), 7.47 (dd, 8.8, 5.0 Hz, 1H), 7.35 (td, 7.5, 1.4 Hz, 1H), 7.25 (d, 7.6 Hz, 1H), 7.22 - 7.09 (m, 2H), 6.74 (d, 7.7 Hz, 2H), 6.26 (s, 1H), 2.27 (s, 3H).	475.15	E	
I-465		COc1ccc(cc1)C(=O)Nc1cc(Br)cc2C(=O)NC(c12)c1cc(F)ccc1Cl	1H NMR (400 MHz, Methanol-d4) 7.92 (d, 1.7 Hz, 1H), 7.74 (d, 1.7 Hz, 1H), 7.62 - 7.54 (m, 2H), 7.29 (dd, 8.9, 5.1 Hz, 1H), 7.00 (ddd, 8.9, 7.8, 3.1 Hz, 1H), 6.99 - 6.91 (m, 2H), 6.66 (s, 1H), 6.18 (s, 1H), 3.87 (s, 3H).	491	E	
I-466		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(NC(=O)c3ccccc3F)c12	1H NMR (400 MHz, Methanol-d4) 7.94 (d, 1.7 Hz, 1H), 7.83 - 7.78 (m, 1H), 7.56 (dddd, 8.3, 7.2, 5.1, 1.9 Hz, 1H), 7.46 (td, 7.5, 1.9 Hz, 1H), 7.38 (dd, 8.9, 5.1 Hz, 1H), 7.25 (td, 7.6, 1.1 Hz, 1H), 7.17 (ddd, 11.0, 8.4, 1.1 Hz, 1H), 7.08 (ddd, 8.9, 7.8, 3.1 Hz, 1H), 6.71 (s, 1H), 6.22 (s, 1H).	478.95	E	





I-467		FC(F)C(=O)Nc1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	1H NMR (400 MHz, DMSO-d6) 5.93 (br s, 1 H) 6.29 - 6.51 (m, 2 H) 7.08 (td, 8.42, 2.93 Hz, 1 H) 7.30 (br dd, 8.79, 5.13 Hz, 1 H) 7.61 (s, 1 H) 7.71 (br d, 9.03 Hz, 1 H) 7.87 (s, 1 H) 7.93 (br d, 6.35 Hz, 1 H) 8.00 (s, 1 H) 9.19 (br s, 1 H) 10.56 (s, 1 H) 11.11 (s, 1 H)	560.26	A	
I-468		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(NC(=O)c3cc(F)cc(F)c3)c12	1H NMR (400 MHz, DMSO-d6) 10.39 (s, 1H), 9.29 (s, 1H), 7.82 (d, 1.7 Hz, 1H), 7.74 (t, 2.0 Hz, 1H), 7.52 (tt, 9.1, 2.4 Hz, 1H), 7.36 (dd, 8.9, 5.2 Hz, 1H), 7.24 (h, 4.8 Hz, 2H), 7.14 (td, 8.4, 3.1 Hz, 1H), 6.80 (s, 1H), 5.98 (s, 1H).	495	B	
I-469		COc1ccccc(c1)C(=O)Nc1cc(Br)cc2C(=O)NC(c12)c1cc(F)ccc1Cl	1H NMR (400 MHz, DMSO-d6) 9.79 (s, 1H), 9.27 (s, 1H), 7.87 (s, 1H), 7.75 (d, 1.8 Hz, 1H), 7.53 - 7.45 (m, 1H), 7.45 -7.35 (m, 2H), 7.18 (td, 8.4, 3.1 Hz, 1H), 7.10 (d, 8.4 Hz, 1H), 6.99 (t, 7.5 Hz, 1H), 6.74 (s, 1H), 6.11 (s, 1H), 3.74 (s, 3H).	489	E	
I-470		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(NC(=O)c3ccccc3)c12	1H NMR (400 MHz, DMSO-d6) 10.22 (s, 1H), 9.27 (s, 1H), 7.80 - 7.73 (m, 2H), 7.55 (d, 8.0 Hz, 3H), 7.44 (t, 7.6 Hz, 2H), 7.35 (dd, 8.9, 5.2 Hz, 1H), 7.12 (td, 8.4, 3.1 Hz, 1H),7.00-6.55 (br,1H), 6.04 (s, 1H).	459.1	E	
I-471		COc1ccccc1C(=O)Nc1cc(Br)cc2C(=O)NC(c12)c1cc(F)ccc1Cl	1H NMR (400 MHz, DMSO-d6) 9.79 (s, 1H), 9.26 (s, 1H), 7.88 (t, 3.0 Hz, 1H), 7.75 (d, 1.8 Hz, 1H), 7.48 (ddd, 8.6, 7.3, 1.8 Hz, 1H), 7.45-7.34 (m, 2H), 7.18 (td, 8.4, 3.1 Hz, 1H),	489	E	





			7.10 (d, 8.3 Hz, 1H), 6.98 (t, 7.5 Hz, 1H), 6.74 (s, 1H), 6.11 (s, 1H), 3.73 (s, 3H).			
I-472		Fc1cc(cc(c1)C(F)(F)F)C(=O)Nc1ccc2c1C(=O)NS2(=O)=O	NMR (400 MHz, DMSO) 12.14 (s, 1H), 8.57 (d, 8.2 Hz, 1H), 8.10-7.98 (m, 3H), 7.76 (t, 7.9 Hz, 1H), 7.58 (d, 7.5 Hz, 1H), 6.44 (br s, 1H).	387.3	E	
I-473		Cc1ccccc1C1NC(=O)c2cc(CO)cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	NMR (400 MHz, DMSO) 10.33 (s, 1H), 9.00 (s, 1H), 7.84 (d, 8.3 Hz, 1H), 7.58 (s, 1H), 7.45 (t, 4.1 Hz, 2H), 7.32 (s, 1H), 7.01 (t, 7.7 Hz, 1H), 6.97-6.86 (m, 2H), 6.51 (br s, 1H), 5.84 (s, 1H), 5.41 (s, 1H), 4.62 (d, 2.4 Hz, 2H), 2.15 (br s, 3H).	459.1	A	
I-474		COc1cc(cc(F)c1N)C(=O)Nc1cc(N)cc2C(=O)NC(c12)c1cc(F)ccc1C(F)F	1H NMR (400 MHz, DMSO-d6) 8.08 (br. d, 7.4 Hz, 1H), 7.96 (ddd, 8.4, 7.0, 1.9 Hz, 1H), 7.85 (dd, 8.7, 5.4 Hz, 1H), 7.74 (s, 1H), 7.46 (td, 8.2, 2.3 Hz, 1H), 7.12 (d, 2.1 Hz, 1H), 7.09 (s, 2H), 7.06 (d, 2.5 Hz, 1H), 7.05 (t, 54.4 Hz, 1H), 6.99 (d, 2.2 Hz, 1H), 7.20-6.8 (2 submerged H), 6.72 (br. s, 2H), 3.97 (s, 3H).	475.3	E	
I-475		Cc1ccccc1C1NC(=O)c2cccc(NC(=O)c3cccc(F)c3)c12	1H NMR (400 MHz, DMSO-d6) 10.09 (s, 1H), 9.04 (s, 1H), 7.66 (dd, 7.3, 1.3 Hz, 1H), 7.60 (t, 7.5 Hz, 1H), 7.54 (dd, 7.7, 1.3 Hz, 1H), 7.44 (td, 8.0, 5.9 Hz, 1H), 7.35 (tdd, 8.7, 2.6, 1.0 Hz, 1H), 7.25 (d, 7.6 Hz, 1H), 7.09 (td, 7.4, 1.3 Hz, 1H), 7.03-6.99 (m, 2H), 6.97 (t, 7.5 Hz, 1H), 6.58	361.3	D	






			(br. s, 1H), 5.95 (s, 1H), 2.18 (br. s, 3H).			
I-476		CN(C)C(=O)Cc1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	1H-NMR (400 MHz, DMSO-d6)-10.51 (br. s, 1H), 9.12 (s, 1H), 7.94 (d, 8.5 Hz, 1H), 7.73 (d, 9.1 Hz, 1H), 7.65 (s, 1H), 7.56 (s, 1H), 7.33 (s, 1H), 7.31 (dd, 8.9, 5.2 Hz, 1H), 7.09 (td, 8.4, 3.1 Hz, 1H), 6.58 (br. s, 1H), 5.95 (br. s, 1H), 3.91 (d, A of AB, JAB = 15.6 Hz, 1H), 3.86 (d, B of AB, JAB = 15.6 Hz, 1H), 3.06 (s, 3H), 2.86 (s, 3H). Contains traces of n-hexane (1.27 and 0.86) and grease (1.54 and 1.03).	552.3	A	
I-477		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(NC(=O)c3ccccc3Cl)c12	1H NMR (400 MHz, DMSO-d6) 10.42 (s, 1H), 9.30 (s, 1H), 7.8-7.75 (m, 2H), 7.55-7.43 (m, 3H), 7.38-7.24 (m, 2H), 6.82 (m, 2H), 6.11 (s, 1H).	493	E	
I-478		O[C@H]1C[C@H](C1)Nc1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	1H NMR (400 MHz, DMSO-d6) 10.26 (br s, 1H), 8.90 (br s, 1H), 7.92 (d, 7.6 Hz, 1H), 7.69 (d, 8.0 Hz, 1H), 7.61 (s, 1H), 7.27 (dd, 8.7, 5.3 Hz, 1H), 7.06 (td, 8.3, 2.8 Hz, 1H), 6.73 (d, 1.7 Hz, 1H), 6.60 (s, 1H), 6.58 (br. s, 1H), 6.43 (d, 6.0 Hz, 1H), 5.82 (br s, 1H), 5.12 (d, 6.2 Hz, 1H), 3.95-3.86 (m, 1H), 3.39-3.30 (m, 1H), 2.75-2.67 (m, 2H), 1.75-1.66 (m, 2H); DMSO satellites at 2.67 and 2.33 ; multiplet at 3.39-3.30 overlaps with water peak at 3.30 .	552.3	A	






I-479		Cc1ccccc1C1NC(=O)c2cccc(-c3cc4c(F)cc(F)cc4[nH]3)c12	1H NMR (400 MHz, DMSO-d6) 11.87 (br. s, 1H), 9.15 (br. s, 1H), 7.87 (d, 7.6 Hz, 1H), 7.79 (d, 7.5 Hz, 1H), 7.71 (t, 7.5 Hz, 1H), 7.02-6.93 (m, 3H), 6.83 (t, 7.4 Hz, 1H), 6.74 (td, 10.2, 1.6 Hz, 1H), 6.46 (s, 1H), 6.43 (s, 1H), 2.36 (br. s, 3H); DMSO satellites at 2.67 and 2.33 ; residual acetonitrile at 2.07 ; sample contains 18% of formate salt (peak at 8.51).	375.3	D	
I-480		NCc1ncc(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c2C(NC(=O)c12)c1cc(F)ccc1Cl	1H NMR (400 MHz, MeOD4) 8.68 (s, 1H), 8.54 (br. s, 1H), 7.76-7.65 (m, 3H), 7.31 (dd, 9.0, 5.0 Hz, 1H), 7.04 (ddd, 8.9, 7.9, 3.0 Hz, 1H), 6.76 (br. s, 1H), 6.25 (br. s, 1H), 4.82-4.69 (m, 2H).	497.1	C	
I-481		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(NC(=O)N3CCCC3)c12	(400 MHz, DMSO-d6) 9.16 (br. s, 1H), 8.20 (s, 1H), 7.58 (d, 1.6 Hz, 1H), 7.49 (d, 1.6 Hz, 1H), 7.47 (br. s, 1H), 7.24 (td, 8.4, 3.0 Hz, 1H), 5.95 (br. s, 1H), 3.18 (m, 2H), 2.77 (m, 2H), 1.78-1.59 (m, 4H).	452.2	E	
I-482		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(NC(=O)N3CCC(F)(F)C3)c12	(400 MHz, CD3CN) 7.73 (d, 1.5 Hz, 1H), 7.60 (s, 1H), 7.44 (dd, 8.5, 5.2 Hz, 1H), 7.24 (s, 1H), 7.10 (td, 8.5, 3.1 Hz, 1H), 6.76 (s, 1H), 6.08 (s, 1H), 3.59 (q, 13.4 Hz, 1H), 3.46-3.28 (m, 2H), 3.13 (s, 1H), 2.36-2.23 (m, 2H).	488.2	D	





I-483		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(OS(F)(=O)=O)cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	1H NMR (400 MHz, DMSO-d6) 5.73 - 6.32 (m, 1 H), 6.40 - 7.00 (m, 1 H), 7.04 - 7.16 (m, 1 H), 7.27 - 7.40 (m, 1 H), 7.59 - 7.66 (m, 1 H), 7.67 - 7.76 (m, 1 H), 7.77 - 7.85 (m, 1 H), 7.89 - 8.03 (m, 2 H), 9.05 - 9.62 (m, 1 H), 10.50 - 11.01 (m, 1 H)	565	A	
I-484		OC(O)(c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl)C(F)(F)F	1H NMR (400 MHz, DMSO-d6) 5.77 - 6.12 (m, 2 H), 6.41 - 6.62 (m, 1 H), 6.99 - 7.20 (m, 1 H), 7.25 - 7.46 (m, 2 H), 7.54 - 7.71 (m, 1 H), 7.79 - 7.92 (m, 1 H), 8.05 - 8.22 (m, 1 H), 8.30 - 8.54 (m, 2 H), 8.93 - 9.14 (m, 1 H), 10.28 - 10.43 (m, 1 H)	581	B	
I-485		Fc1cc(cc(c1)C(F)(F)F)C(=O)Nc1cccc2C(=O)NC(c12)c1cc(ccc1Cl)C#N		474.3	E	
I-486		Fc1cc(cc(c1)C(F)(F)F)C(=O)Nc1cccc2C(=O)NC(c12)c1cc(ccc1Cl)-c1ccccc1		525.4	D	
I-487		FC(F)C1CN(C1)c1cc(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c2C(NC(=O)c2n1)c1cc(F)ccc1Cl	1H NMR (400 MHz, DMSO-d6) 10.62 (br s, 1H), 9.26 (br s, 1H), 7.96 (d, 7.9 Hz, 1H), 7.70 (d, 8.9 Hz, 1H), 7.60 (s, 1H), 7.32 (dd, 8.5, 5.1 Hz, 1H), 7.11-7.04 (m, 1H), 6.76 (br s,1 H), 6.50 (s, 1H), 6.42 (td, 56.3, 3.4 Hz, 1H), 5.88 (br s, 1H), 4.17 (q, 8.8 Hz, 1H),	573.3	A	






			4.00-3.95 (m, 2H), 3.56-3.37 (m, 1H).			
I-488		FC1CN(C1)c1cc(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c2C(NC(=O)c2n1)c1cc(F)ccc1Cl	1H NMR (400 MHz, DMSO-d6) 10.64 (s, 1H), 9.27 (s, 1H), 7.97 (d, 8.2 Hz, 1H), 7.70 (d, 8.8 Hz, 1H), 7.60 (s, 1H), 7.32 (dd, 8.8, 5.1 Hz, 1H), 7.08 (td, 8.5, 3.0 Hz, 1H), 6.75 (br s, 1H), 6.54 (s, 1H), 5.89 (br s, 1H), 5.73-5.34 (m, 1H), 4.55-4.27 (m, 2H), 4.25-3.96 (m, 2H).	541.1	A	
I-489		Cn1cc(cn1)-c1ccc(Cl)c(c1)C1NC(=O)c2cccc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12		529.4	E	
I-490		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)C#N	(400 MHz, CD3CN) 8.76 (br s, 1 H), 8.10 (d, 1.2 Hz, 1H), 7.90 (s, 1H), 7.67 (d, 8.4 Hz, 1H), 7.59 (d, 9.0 Hz, 1H), 7.55 (s, 1H), 7.45 (br s, 1H), 7.27 (dd, 8.9, 5.1 Hz, 1H), 6.99 (ddd, 8.8, 8.1, 3.1 Hz, 1H), 6.64 (br s, 1H), 6.18 (br s, 1H).	490.3	A	
I-491		FC1CCCN(C1)C(=O)Nc1cc(Br)cc2C(=O)NC(c12)c1cc(F)ccc1Cl	NMR (400 MHz, CD3CN) 7.69 (d, 1.6 Hz, 1H), 7.64-7.54 (m, 1H), 7.44 (dd, 8.2, 5.0 Hz, 1H), 7.23 (d, 1.3 Hz, 1H), 7.15-7.04 (m, 1H), 7.04-6.90 (m, 1H), 6.69 (br s, 1H), 6.06 (s, 1H), 4.72-4.05 (m, 1H), 3.52-2.79 (m, 4H), 1.89-1.68 (m, 2H), 1.67-1.16 (m, 2H).	484.1	E	






I-492		Cc1ccccc1C1NC(=O)c2cccc(NC3(COC3)c3cc(F)cc(c3)C(F)(F)F)c12	NMR (400 MHz, DMSO-d6) 8.92 (s, 1H), 7.69-7.62 (m, 1H), 7.48-7.45 (m, 2H), 7.26-7.23 (m, 2H), 7.20 (d, 7.7 Hz, 1H), 7.16-7.08 (m, 1H), 7.06 (d, 7.3 Hz, 1H), 6.72 (br s, 1H), 6.13 (d, 7.9 Hz, 1H), 5.90 (s, 1H), 5.38 (s, 1H), 5.18 (d, 6.8 Hz, 1H), 4.87 (d, 6.5 Hz, 1H), 4.67 (d, 6.2 Hz, 1H), 4.50 (d, 7.0 Hz, 1H), 2.40-2.27 (br s, 3H).	457.2	D	
I-493		CNC(=O)c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	(400 MHz, CD3CN) 8.82 (s, 1H), 8.09 (d, 1.4 Hz, 1H), 8.02 (s, 1H), 7.69 (d, 8.4 Hz 1H), 7.60 (d, 8.9 Hz 1H), 7.58 (s, 1H) 7.37 (s, 1H), 7.26 (dd, 8.9, 5.1 Hz, 1H), 7.26 (br s, 1H), 6.97 (ddd, 8.8, 8.0, 3.1 Hz, 1H), 6.67 (br s, 1H), 6.16 (br s, 1H), 2.90 (d, 4.7 Hz, 3H).	524.3	A	A
I-494		OC(=O)c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	(400 MHz, d6-DMSO) 10.64 (br s, 1H), 9.24 (br s,1H), 8.31 (br s, 1H), 8.13 (s, 1H), 8.03 (d, 10.0 Hz, 1H), 7.95 (d, 8.3 Hz, 1H), 7.76 (d, 8.9 Hz, 1H), 7.68 (s, 1H), 7.32 (dd, 8.9, 5.2 Hz, 1H), 7.09 (td, 8.0, 2.7 Hz, 1H), 6.04 (br s, 1H).	509.2	A	
I-495		CC(C)(O)c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc3cc[nH]c23)c1)c1cc(F)ccc1Cl	1H NMR (400 MHz, DMSO-d6) 11.21 (br s, 1H), 10.21 (s, 1H), 9.06 (br s, 1H), 7.75 (s, 1H), 7.67 (s, 1H), 7.53 (br dd, 2.20, 9.27 Hz, 1H), 7.43 (br t, 2.56 Hz, 1H), 7.27 (br dd, 5.25, 8.91 Hz, 1H), 7.13 (br dd, 2.20, 10.25 Hz, 1H), 7.04 (dt, 2.93, 8.30 Hz, 1H), 6.58-6.76 (m, 1H), 6.45-6.51 (m,	496.38	A	






			1H), 6.10 (br s, 1H), 5.28 (s, 1H), 1.50 (d, 1.95 Hz, 3H), 0.75-1.19 (m, 3H)			
I-496		Fc1ccc(Cl)c(c1)C1NC(=O)c2nc(cc(NC(=O)c3cc(F)cc(Cl)c3)c12)-c1cnc(s1)C(F)(F)F		585.4	A	
I-497		Cc1ccc(cn1)-c1cc(NC(=O)c2cc(F)cc(Cl)c2)c2C(NC(=O)c2n1)c1cc(F)ccc1Cl		525.4	B	
I-498		Cn1ccc(cc1=O)-c1cc(NC(=O)c2cc(F)cc(Cl)c2)c2C(NC(=O)c2n1)c1cc(F)ccc1Cl		541.4	B	
I-500		Fc1ccc(Cl)c(c1)[C@@H]1NC(=O)c2cccc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	1H NMR (DMSO-d6, 400 MHz) Shift 10.3-10.7 (m, 1H), 8.9-9.3 (m, 1H), 7.93 (br d, 1H, 8.5 Hz), 7.6-7.8 (m, 4H), 7.4-7.5 (m, 1H), 7.2-7.4 (m, 1H), 7.0-7.2 (m, 1H), 6.4-6.8 (m, 1H), 5.7-6.2 (m, 1H)	467.1	A	A
I-501		COc1cc(C)c(cn1)C(=O)Nc1cccc2C(=O)NC(c12)c1ccccc1C		388	E	





I-502		Fc1ccc(Cl)c(c1)C1NC(=O)c2nc(cc(NC(=O)c3cc(F)cc(Cl)c3)c12)-c1ccncc1F		529.4	A	
I-503		Cc1cnccc1-c1cc(NC(=O)c2cc(F)cc(Cl)c2)c2C(NC(=O)c2n1)c1cc(F)ccc1Cl		525.4	A	
I-504		Cc1ccccc1C1NC(=O)c2cccc(NC(=O)c3c[nH]c(=O)c(Br)c3C)c12		452	E	
I-505		COc1cnccc1-c1cc(NC(=O)c2cc(F)cc(Cl)c2)c2C(NC(=O)c2n1)c1cc(F)ccc1Cl		541.4	B	
I-506		Fc1ccc(Cl)c(c1)C1NC(=O)c2nc(cc(NC(=O)c3cc(F)cc(Cl)c3)c12)-c1ccncc1C#N		536.4	A	





I-507		NC(=O)c1cnccc1-c1cc(NC(=O)c2cc(F)cc(Cl)c2)c2C(NC(=O)c2n1)c1cc(F)ccc1Cl		554.4	D	
I-508		Cc1ccccc1[C@@H]1NC(=O)c2c1c(NC(=O)c1cc(F)cc(c1)C(F)(F)F)ccc2C(N)=O	(400 MHz, DMSO-D6) 10.73 (s, 1 H), 10.48 (br s, 1 H), 9.80 (s, 1 H), 8.33 (d, 8.3 Hz, 1 H), 7.90 (d, 8.5 Hz, 1 H), 7.75 (s, 1 H), 7.71 (d, 8.3 Hz,1 H), 7.47 (d, 8.6 Hz, 1 H), 7.31 (br s, 1 H), 7.09 (td, 7.6, 0.9 Hz, 1 H), 7.01 (d, 7.3 Hz, 1 H), 6.99 - 6.93 (m, 1 H), 6.47 (br s, 1 H), 6.00 (br s, 1 H), 2.30 (br s, 3 H).	472.3	A	
I-509		Cc1ccccc1[C@H]1NC(=O)c2c1c(NC(=O)c1cc(F)cc(c1)C(F)(F)F)ccc2C(N)=O	(400 MHz, DMSO-D6) 10.73 (s, 1 H), 10.48 (br s, 1 H), 9.80 (s, 1 H), 8.33 (d, 8.3 Hz, 1 H), 7.90 (d, 8.5 Hz, 1 H), 7.75 (s, 1 H), 7.71 (d, 8.3 Hz,1 H), 7.47 (d, 8.6 Hz, 1 H), 7.31 (br s, 1 H), 7.09 (td, 7.6, 0.9 Hz, 1 H), 7.01 (d, 7.3 Hz, 1 H), 6.99 - 6.93 (m, 1 H), 6.47 (br s, 1 H), 6.00 (br s, 1 H), 2.30 (br s, 3 H).	472.3	B	
I-510		FC(F)CNC(=O)Nc1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	1H NMR (400 MHz, DMSO-d6) 3.48 - 3.62 (m, 2 H) 5.92 - 6.26 (m, 3 H) 6.70 (br t, 5.86 Hz, 1 H) 7.08 (td, 8.30, 2.93 Hz, 1 H) 7.30 (br dd, 8.79, 5.13 Hz, 1 H) 7.61 (br d, 15.62 Hz, 2 H) 7.68 - 7.79 (m, 2 H) 7.93 (br d, 8.30 Hz, 1 H) 9.07 (br s, 1 H) 9.21 (s, 1 H) 10.46 (s, 1 H)	589.28	A	





I-511		OCC(=O)Nc1cc2C(=O)N[C@H](c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl		540.3	A	
I-512		OCC(=O)Nc1cc2C(=O)N[C@@H](c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl		540.3	B	
I-513		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(NC(=O)N3CC(F)(F)C3)cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	1H NMR (400 MHz, DMSO-d6) 4.41 (br t, 12.69 Hz, 4 H) 5.90 (br s, 1 H) 6.75 (br s, 1 H) 7.07 (td, 8.36, 3.05 Hz, 1 H) 7.29 (br dd, 8.91, 5.25 Hz, 1 H) 7.62 (br s, 1 H) 7.70 (br s, 1 H) 7.86 (br s, 1 H) 7.92 (br d, 7.57 Hz, 1 H) 8.50 (br s, 1 H) 9.07 (br s, 1 H) 9.26 (br s, 1 H) 10.48 (s, 1 H)	601.33	A	
I-514		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(NC(=O)c3cccc(OC(F)(F)F)c3)c12	1H NMR (400 MHz, Methanol-d4) 7.96 (d, 1.7 Hz, 1H), 7.77 - 7.72 (m, 1H), 7.61 (dt, 7.7, 1.5 Hz, 1H), 7.56 (dd, 8.7, 7.7 Hz, 1H), 7.52 - 7.46 (m, 2H), 7.29 (dd, 8.9, 5.1 Hz, 1H), 7.01 (ddd, 8.9, 7.8, 3.1 Hz, 1H), 6.63 (s, 1H), 6.18 (s, 1H).	541	C	
I-515		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(NC(=O)c3cc(ccc3F)C(F)(F)F)c12	1H NMR (400 MHz, DMSO-d6) 10.55 (s, 1H), 9.31 (s, 1H), 8.0 (s, 1H), 7.82 (d, 1.7 Hz, 1H), 7.73 (s, 1H), 7.56 (t, 9.2 Hz, 1H), 7.45 (dd, 8.9, 5.1 Hz, 1H), 7.38 (d, 5.8 Hz, 1H), 7.21 (td, 8.4, 3.1 Hz,	545	D	





			1H),6.67(s, 1H), 6.01 (s, 1H).			
I-516		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(NC(=O)c3ccc(F)c(OC(F)(F)F)c3)c12	1H NMR (400 MHz, DMSO-d6) 10.44 (s, 1H), 9.28 (s, 1H), 7.82 (d, 1.8 Hz, 1H), 7.79 - 7.70 (m, 2H), 7.70 (d, 7.4 Hz, 1H), 7.70 - 7.61 (m, 1H), 7.31 (dd, 8.9, 5.1 Hz, 1H), 7.09 (td, 8.4, 3.0 Hz, 1H), 6.73 (s, 1H), 5.97 (s, 1H).	561	B	
I-517		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(NC(=O)c3ccc(cc3)C#N)c12	1H NMR (400 MHz, DMSO-d6) 10.45 (s, 1H), 9.29 (s, 1H), 7.88 - 7.79 (m, 2H), 7.73 (d, 1.8 Hz, 1H), 7.49 (d, 1.9 Hz, 3H), 7.37 (dd, 8.9, 5.2 Hz, 1H), 7.15 (td, 8.5, 3.1 Hz, 1H), 6.77 (s, 1H), 5.97 (s, 1H).	484	E	
I-518		FC(F)c1ccccc1C(=O)Nc1cc(Br)cc2C(=O)NC(c12)c1cc(F)ccc1Cl	1H NMR (400 MHz, DMSO-d6) 10.50 (s, 1H), 9.30 (s, 1H), 7.81 (d, 9.4 Hz, 2H), 7.73 (d, 7.8 Hz, 1H), 7.66 (t, 7.6 Hz, 1H), 7.51 (q, 6.5, 5.6 Hz, 2H), 7.27 (td, 8.5, 3.2 Hz, 1H), 7.14 (s, 1H), 6.79 (d, 7.2 Hz, 2H), 6.04 (s, 1H).	509	E	
I-519		Cc1ccc(cc1)C(=O)Nc1cc(Br)cc2C(=O)NC(c12)c1cc(F)ccc1Cl	1H NMR (400 MHz, Methanol-d4) 7.93 (d, 1.7 Hz, 1H), 7.75 (d, 1.7 Hz, 1H), 7.53-7.45 (m, 2H), 7.33-7.21 (m, 3H), 7.00 (ddd, 8.8, 7.7, 3.1 Hz, 1H), 6.66 (s, 1H), 6.18 (s, 1H), 2.41 (s, 3H).	473	E	
I-520		Cc1cccc(c1)C(=O)Nc1cc(Br)cc2C(=O)NC(c12)c1cc(F)ccc1Cl	1H NMR (400 MHz, Chloroform-d) 8.53 (s, 1H), 7.92 (d, 1.7 Hz, 1H), 7.47 - 7.25 (m, 6H), 7.07 (ddd, 8.9, 7.3, 3.0 Hz, 1H), 6.72 (s, 1H), 6.56 (s, 1H), 6.18 (s, 1H), 2.40 (s, 3H).	473	D	





I-521		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(NC(=O)c3cc(Cl)cc(Cl)c3)c12	1H NMR (400 MHz, DMSO-d6) 10.49 (s, 1H), 9.28 (s, 1H), 7.96 (d, 8.2 Hz, 2H), 7.81 (d, 1.8 Hz, 1H), 7.71 (d, 8.3 Hz, 3H), 7.34 (dd, 8.9, 5.1 Hz, 1H), 7.12 (td, 8.4, 3.1 Hz, 1H), 6.00 (s, 1H).	527	A	
I-522		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(NC(=O)c3cccc(c3)C#N)c12	1H NMR (400 MHz, Chloroform-d) 8.52 (s, 1H), 7.97 (d, 1.7 Hz, 1H), 7.93-7.83 (m, 2H), 7.63 (t, 7.8 Hz, 1H), 7.58-7.50 (m, 2H), 7.37 (s, 1H), 7.15 (ddd, 8.9, 7.3, 3.0 Hz, 1H), 6.74 (s, 1H), 6.41 (s, 1H), 6.19 (s, 1H), 0.87 (s, 0H).	486	D	
I-523		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(NC(=O)c3ccnc(c3)C(F)(F)F)c12	1H NMR (400 MHz, Methanol-d4) 8.86 (d, 4.9 Hz, 1H), 7.99 (d, 1.7 Hz, 1H), 7.90-7.78 (m, 2H), 7.75 (s, 1H), 7.31 (dd, 8.9, 5.1 Hz, 1H), 7.03 (ddd, 8.9, 7.7, 3.1 Hz, 1H), 6.66 (s, 1H), 6.12 (s, 1H).	528	E	
I-524		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(NC(=O)c3ccc(OC(F)(F)F)cc3)c12	1H NMR (400 MHz, Methanol-d4) 7.95 (d, 1.7 Hz, 1H), 7.76-7.66 (m, 3H), 7.38-7.26 (m, 3H), 7.02 (ddd, 8.9, 7.8, 3.0 Hz, 1H), 6.79 (s, 1H), 6.17 (s, 1H).	541	D	
I-525		Fc1ccc(cc1)C(=O)Nc1cc(Br)cc2C(=O)NC(c12)c1cc(F)ccc1Cl	1H NMR (400 MHz, Methanol-d4) 7.94 (d, 1.7 Hz, 1H), 7.73 (d, 1.7 Hz, 1H), 7.70-7.61 (m, 2H), 7.30 (dd, 8.9, 5.1 Hz, 1H), 7.22-7.12 (m, 2H), 7.01 (ddd, 8.9, 7.7, 3.0 Hz, 1H), 6.65 (s, 1H), 6.17 (s, 1H).	477	E	






I-526		Fc1cccc(c1)C(=O)Nc1cc(Br)cc2C(=O)NC(c12)c1cc(F)ccc1Cl	1H NMR (400 MHz, DMSO-d6) 10.31 (s, 1H), 9.27 (s, 1H), 7.80 (d, 1.8 Hz, 1H), 7.74 (d, 1.9 Hz, 1H), 7.56 - 7.46 (m, 1H), 7.46 - 7.38 (m, 2H), 7.38 - 7.27 (m, 2H), 7.13 (td, 8.4, 3.1 Hz, 1H), 6.95 - 6.40 (br, 1H), 6.01 (s, 1H).	476.9	D	
I-527		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(NC(=O)c3ccc(Cl)cc3)c12	1H NMR (400 MHz, Methanol-d4)7.95 (d, 1.7 Hz, 1H), 7.73 (d, 1.7 Hz, 1H), 7.62-7.54 (m, 2H), 7.50-7.43 (m, 2H), 7.31 (dd, 8.9, 5.1 Hz, 1H), 7.02 (ddd, 8.8, 7.7, 3.0 Hz, 1H), 6.65 (s, 1H), 6.18 (s, 1H).	492.9	D	
I-528		Cc1ccccc1C1NC(=O)c2cc(Br)cc(NC(=O)c3cncc(c3)C(F)(F)F)c12	1H NMR (400 MHz, DMSO-d6) 10.22 (br. s, 1H), 9.26 (s, 1H), 9.10 (s, 1H), 8.78 (s, 1H), 7.83 (overlap s, 1H), 7.80 (d, 1.7 Hz, 1H), 7.78 (d, 1.7 Hz, 1H), 7.07 (td, 7.5, 1.3 Hz, 1H), 7.00 (d, 6.8 Hz, 1H), 6.96 (br. t, 7.2 Hz, 1H), 6.57 (br. s, 1H), 5.89 (s, 1H), 2.23 (br. s, 3H), 10 % of impurities at 1.98, 1.23 and 0.85	488.3	D	
I-529		Fc1ccc(Cl)c(c1)C1NC(=O)c2nc(CCC(F)(F)F)cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	1H NMR (400 MHz, DMSO-d6) 10.61 (br s, 1H), 9.47 (s, 1H), 7.96 (d, 7.8 Hz, 1H), 7.73 (d, 8.5 Hz, 1H), 7.62 (s, 1H), 7.51 (s, 1H), 7.34 (dd, 8.9, 5.2 Hz, 1H), 7.10 (td, 8.4, 3.1 Hz, 1H), 6.81 (br s, 1H), 5.97 (br s, 1H), 3.22-3.09 (m, 2H), 2.94-2.70 (m, 2H). contains 5%-10%	564.3	A	





I-530		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(NC3CCC3(F)F)cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	1H NMR (400 MHz, DMSO-d6) 10.32 (d, 4.5 Hz, 1H), 8.96 (s, 1H), 7.92 (d, 8.4 Hz, 1H), 7.69 (d, 9.2 Hz, 1H), 7.60 (s, 1H), 7.28 (ddd, 8.8, 5.2, 1.7 Hz, 1H), 7.14-7.00 (m, 1H), 6.90 (d, 1.8 Hz, 1H), 6.77 (s, 1H), 6.74 (d, 7.3 Hz, 1H), 6.57 (br s, 1H), 5.82 (br s, 1H), 4.57-4.22 (m, 1H), 2.47-2.32 (m, 2H), 2.31-2.17 (m, 1H), 1.71 (p, 9.9 Hz, 1H).	572.5	A	
I-531		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(Cl)c3)c12)C#N	NMR (400 MHz, DMSO-d6i) 9.42 (s, 1H), 8.10 (s, 1H), 8.03 (s, 1H), 7.69 (d, 8.5 Hz, 1H), 7.44-7.33 (m, 4H), 7.16 (td, 8.3, 2.8 Hz, 1H), 6.77 (br s, 1H), 6.06 (s, 1H).	458	A	
I-532		Fc1ccc(Cl)c(c1)C1NC(=O)c2nc(NC3CCC3(F)F)cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	1H NMR (400 MHz, DMSO-d6) 10.55 (s, 1H), 9.21 (s, 1H), 7.96 (d, 8.3 Hz, 1H), 7.66 (d, 7.8 Hz, 2H), 7.54 (s, 1H), 7.31 (ddd, 8.7, 5.2, 1.9 Hz, 1H), 7.07 (td, 8.4, 3.0 Hz, 1H), 6.77 (br s, 1H), 6.73 (d, 1.9 Hz, 1H), 5.85 (br s, 1H), 5.09 (br s, 1H), 2.54-2.30 (m, 2H), 2.30-2.18 (m, 1H), 1.82-1.57 (m, 1H).	573.4	A	
I-533		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(CC#N)cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	1H-NMR (400 MHz, DMSO-d6) 10.61 (br. s, 1H), 9.22 (br. s, 1H), 7.95 (d, 7.7 Hz, 1H), 7.74 (d, 8.8 Hz, 1H), 7.70-7.63 (m, 2H), 7.51 (, 1Hs), 7.32 (dd, 8.9, 5.2 Hz, 1H), 7.09 (td, 8.5, 3.1 Hz, 1H), 6.63 (br. s, 1H), 5.98 (br. s, 1H), 4.26 (s, 2H). Partial formate salt (peak at 8.47).	504.3	A	






I-534		Cc1ccccc1C1NC(=O)c2cc(Br)cc(NC(=O)c3cc(F)cc(c3)C3CC3)c12	10.11 (s, 1H), 9.23 (s, 1H), 7.81 (d, 1.7 Hz, 1H), 7.76 (d, 1.7 Hz, 1H), 7.14-7.06 (m, 3H), 6.99 (td, 7.5, 1.3 Hz, 1H), 6.86 (br. d, 9.5 Hz, 1H), 6.74 (s, 1H), 6.55 (br. s, 1H), 5.95 (s, 1H), 2.28 (br. s, 3H), 1.95-1.85 (m, 1H), 1.03-0.95 (m, 2H), 0.71-0.62 (m, 2H), traces of impurities 1.98, 1.23 and 0.85 .	479.3	D	
I-535		Cc1ccccc1C1NS(=O)(=O)c2cccc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	NMR (400 MHz, DMSO) 10.41 (s, 1H), 8.45 (d, 4.5 Hz, 1H), 7.85 (dt, 8.3 and 1.6 Hz, 1H), 7.81 (d, 7.6 Hz, 1H), 7.72 (t, 7.7 Hz, 1H), 7.59 (d, 7.4 Hz, 1H), 7.39 (d, 8.8 Hz, 1H), 7.22 (s, 1H), 7.03 (t, 7.3 Hz, 1H), 6.90 - 6.99 (m, 2H), 6.55 (br s, 1H), 5.97 (s, 1H), 2.16 (br. s, 3H).	465.1	D	
I-536		Cc1ccccc1C1NC(=O)c2cc(CF)cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	NMR (400 MHz, DMSO) 10.44 (s, 1H), 9.15 (s, 1H), 7.90 (d, 8.5 Hz, 1H), 7.72 (s, 1H), 7.60 (s, 1H), 7.49 (d, 9.0 Hz, 1H), 7.36 (s, 1H), 7.07 (t, 7.5 Hz, 1H), 7.00 (d, 7.3 Hz, 1H), 6.95 (t, 7.0 Hz, 1H), 6.59 (br s, 1H), 5.93 (s, 1H), 5.61 (d, 47.4 Hz, 2H), 2.21 (br s, 3H).	461.2	A	
I-537		Fc1cc(cc(c1)C(F)(F)F)C(=O)Nc1ccccc2C(=O)NC(N3CCCCC3)c12	NMR (400 MHz, DMSO-d6) 10.48 (s, 1H), 8.96 (s, 1H), 8.26 (dd, 8.0, 0.7 Hz, 1H), 8.12 (s, 1H), 8.11-8.04 (m, 2H), 7.57 (t, 7.7 Hz, 1H), 7.47 (dd, 7.5, 0.9 Hz, 1H), 5.68 (s, 1H), 2.53 (m, 2H), 2.33-2.24 (m, 2H), 1.38 (m, 4H), 1.35-1.27 (m, 2H)	422.3	E	






I-538		Fc1ccc(Cl)c(c1)C1NC(=O)c2nc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)N1CCCC(F)(F)C1	(400 MHz, CD3CN) 8.63 (s, 1H), 7.66 (d, 8.9 Hz, 1H), 7.57 (d, 8.5 Hz, 1H), 7.55 (br. s, 1H), 7.39 (br. s, 1H), 7.33-7.27 (m, 1H), 7.10 (s, 1H), 6.98 (td, 8.4, 3.1 Hz, 1H), 6.75 (br. s, 1H), 6.04 (s, 1H), 4.06-3.94 (m, 2H), 3.73-3.65 (m, 2H), 1.91-1.81 (m, 4H).	587.3	A	
I-539		Fc1ccc(Cl)c(c1)C1NC(=O)c2nc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)N1CCC(F)(F)CC1	(400 MHz, CD3CN) 8.64 (br. s, 1H), 7.66 (d, 8.4 Hz, 1H), 7.61-7.50 (m, 2H), 7.39 (s, 1H), 7.30 (dd, 8.9, 5.1 Hz, 1H), 7.13 (s, 1H), 6.98 (ddd, 8.9, 8.0, 3.0 Hz, 1H), 6.75 (br. s, 1H), 6.05 (s, 1H), 3.84-3.81 (m, 4 H), 2.10-2.03 (m, 4H).	587.3	A	
I-540		F[C@H]1C[C@@H](C1)Nc1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	1H NMR (400 MHz, DMSO-d6) 10.28 br. (s, 1H), 8.94 (br. s, 1H), 7.92 (d, 8.5 Hz, 1H), 7.69 (d, 9.0 Hz, 1H), 7.60 (s, 1H), 7.28 (dd, 8.9, 5.2 Hz, 1H), 7.06 (td, 8.4, 3.1 Hz, 1H), 6.70 (d, 2.0 Hz, 1H), 6.61 (s, 1H), 6.58 (d, 4.3 Hz, 1H), 6.74 - 6.42 (1H submerged), 5.83 (br. s, 1H), 5.38-5.18 (m, 1H), 4.07-4.03 (m, 1H), 2.64-2.54 (m, 2H), 2.37-2.26 (m, 2H)	554.3	A	
I-541		F[C@H]1C[C@H](C1)Nc1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	1H NMR (400 MHz,) 10.28 (br. s, 1H), 8.93 (br. s, 1H), 7.92 (d, 8.5 Hz, 1H), 7.69 (d, 9.2 Hz, 1H), 7.61 (s, 1H), 7.28 (dd, 8.9, 5.2 Hz, 1H), 7.06 (td, 8.4, 3.1 Hz, 1H), 6.75 (d, 2.0 Hz, 1H), 6.63 (d, 1.4 Hz, 1H), 6.55 (d, 6.8 Hz, 1H), 6.74 - 6.42 (1H submerged), 5.82 (br. s, 1H), 4.92 (dp, 56.2, 6.8 Hz, 1H), 3.53-	554.2	A	






			3.43 (m, 1H), 2.94-2.86 (m, 2H), 2.12-1.96 (m, 2H);			
I-542		FC1CCN(C1)C(=O)Nc1cc(Br)cc2C(=O)NC(c12)c1cc(F)ccc1Cl	NMR (400 MHz, CD3CN) 7.74-7.60 (m, 2H), 7.47-7.37 (m, 1H), 7.25 (s, 1H), 7.13-7.03 (m, 1H), 6.68 (s, 1H), 6.10 (s, 1H), 5.31-5.08 (m, 1H), 3.65-2.89 (m, 5H), 2.09-2.02 (m, 1H), 1.90-1.80 (m, 1H): possible mixture of rotamers and disatereomers+grease	470.1	E	
I-543		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(NC(=O)N3CCC(C3)C(F)(F)F)c12	NMR (400 MHz, CD3CN) 7.73-7.69 (m, 1H), 7.66 (d, 7.3 Hz, 1H), 7.44 (dd, 8.7, 5.1 Hz, 1H), 7.25 (s,1H), 7.15-7.03 (m, 1H), 6.72 (br s, 1H), 6.67 (d, 14.4 Hz, 1H), 6.20-5.95 (m, 1H), 3.71-3.37 (m, 2H), 3.31-3.14 (m, 1H), 3.12-2.86 (m, 2H), 2.14-2.05 (m, 1H), 2.02-1.96 (m, 1H).	518.2	D	
I-544		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(NC(=O)N3CCCC(F)(F)C3)c12	NMR (400 MHz, CD3CN) 7.71 (d, 1.7 Hz, 1H), 7.58 (d, 1.6 Hz, 1H), 7.42 (dd, 17.2, 8.7 Hz, 1H), 7.23 (d, 1.6 Hz, 1H), 7.08 (ddd, 8.9, 8.0, 3.1 Hz 1H), 7.03 (s, 1H), 6.71 (br s, 1H), 6.06 (br s, 1H), 3.60-3.46 (m, 1H), 3.46-3.31 (m, 1H), 3.22-3.10 (m, 1H), 3.05-2.91 (m, 1H), 2.13-2.09 (m, 1H), 2.02-1.97 (m, 1H), 1.66-1.45 (m, 2H). approx 10 % impurity by NMR	502.1	D	
I-545		Fc1ccc(Cl)c(c1)C1NC(=O)c2nc(Cl)cc(NC(=O)c3cc(F)cc		502.3	A	






		(c3)C(F)(F)F)c12				
I-546		Cc1ncc(s1)-c1cc(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c2C(NC(=O)c2n1)c1cc(F)ccc1Cl		565.4	A	
I-547		Cn1cc(ccc1=O)-c1cc(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c2C(NC(=O)c2n1)c1cc(F)ccc1Cl		575.5	A	
I-548		Fc1ccc(Cl)c(c1)C1NC(=O)c2nc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1ccncc1F		563.4	A	
I-549		Fc1ccc(Cl)c(c1)C1NC(=O)c2nc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1ccncc1C#N		570.4	A	
I-550		Fc1cc(cc(Cl)c1F)C(=O)Nc1ccnc2C(=O)NC(c12)c1ccccc1Cl		434.3	C	





I-551		NC1(CC1)c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	NMR (400 MHz, CD3CN) 8.73 (s, 1H), 8.27 (d, 1.4 Hz, 1H), 8.12 (s, 1H), 7.66 (dd, 6.8, 1.8 Hz, 1H), 7.64-7.57 (m, 2H), 7.35 (s, 1H), 7.27 (dd, 8.9, 5.1 Hz, 1H), 6.98 (ddd, 8.9, 8.0, 3.1 Hz, 1H), 6.66 (br s, 1H), 6.17 (br s, 1H), 3.15 (qd, 7.1, 0.9 Hz, 2H), 1.19 (t, 7.2 Hz, 4H).	523.1	A	
I-552		CCC(=O)Nc1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	1H NMR (400 MHz, DMSO-d6) 1.12 (t, 7.44 Hz, 3 H) 2.29 - 2.45 (m, 2 H) 5.91 (br s, 1 H) 6.83 (br s, 1 H) 7.08 (td, 8.30, 2.93 Hz, 1 H) 7.31 (br dd, 8.91, 5.25 Hz, 1 H) 7.58 - 7.97 (m, 4 H) 8.50 (s, 1 H) 9.10 (br s, 1 H) 10.28 (br s, 1 H) 10.52 (br s, 1 H)	538.25	A	
I-553		Fc1ccc(Cl)c(c1)C1NC(=O)c2cncc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	NMR (400 MHz, DMSO-d6) 10.70 (br. s, 1H), 9.33 (s, 1H), 8.89 (s, 1H), 8.69 (s, 1H), 7.97 (d, 8.7 Hz, 1H), 7.76 (d, 9.1 Hz, 1H), 7.68 (s, 1H), 7.34 (dd, 8.9, 5.2 Hz, 1H), 7.16-7.05 (m, 1H), 6.85 (br. s, 1H), 6.02 (br. s, 1H).	468	A	
I-554		CCC(N)(CC)c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	(400 MHz, CD3CN) 8.65 (br s, 1H), 8.10 (s, 1H), 7.82 (d, 1.6 Hz, 1H), 7.64 (s, 1H), 7.64-7.59 (m, 1H), 7.57 (s, 1H), 7.25 (dd, 8.8, 5.1 Hz, 1H), 7.19 (s, 1H), 6.96 (ddd, 8.8, 7.9, 3.0 Hz, 1H), 6.61 (br s, 1H), 6.09 (br s, 1H), 3.93 (t, 6.0 Hz, 1H), 3.28 (t, 5.9 Hz, 1H), 1.87 (br q, 7.0 Hz, 2H), 1.71 (br q, 7.3 Hz, 2H), 0.73 (td, 7.4, 2.0 Hz, 6H).	550.4	A	







I-555		NC(=O)c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	(400 MHz, d6-DMSO) 10.63 (s, 1H), 9.26 (s, 1H), 8.30 (s, 1H), 8.25 (s, 1H), 8.01 (d, 0.9 Hz, 1H), 7.96 (d, 8.5 Hz, 1H), 7.75 (d, 9.1 Hz, 1H), 7.68 (s, 1H), 7.59 (s, 1H), 7.32 (dd, 8.9, 5.2 Hz, 1H), 7.10 (ddd, 8.8, 3.2, 3.2 Hz, 1H), 6.02 (br s, 1H).	510.2	A	
I-556		CCOc1cc(ccc1F)C(=O)Nc1cc(Br)cc2C(=O)NC(c12)c1cc(F)ccc1Cl	1H NMR (400 MHz, Methanol-d4)7.94 (d, 1.7 Hz, 1H), 7.73 (s, 1H), 7.32 (ddd, 10.1, 7.5, 3.5 Hz, 2H), 7.21-7.10 (m, 2H), 7.02 (ddd, 8.8, 7.7, 3.1 Hz, 1H), 6.42 (d, 201.1 Hz, 2H), 4.13 (qd, 7.0, 4.9 Hz, 2H), 1.46 (t, 7.0 Hz, 3H).	520.95	D	
I-557		Fc1cccc(c1)C1(CC1)C(=O)Nc1cc(Br)cc2C(=O)NC(c12)c1cc(F)ccc1Cl	1H NMR (400 MHz, Methanol-d4) 7.85 (d, 1.8 Hz, 1H), 7.68 (s, 1H), 7.59 (s, 1H), 7.35-7.20 (m, 2H), 7.02 (td, 8.3, 2.6 Hz, 1H), 6.87 (dt, 7.7, 1.3 Hz, 1H), 6.76 (dt, 9.9, 2.1 Hz, 1H), 6.44 (s, 1H), 6.08 (s, 1H), 1.62 (s, 1H), 1.34 (ddd, 10.1, 7.0, 4.0 Hz, 1H), 1.20-1.11 (m, 1H), 0.98 (ddd, 9.6, 7.0, 3.8 Hz, 1H).	516.9	D	
I-558		FC(F)Oc1cc(ccc1F)C(=O)Nc1cc(Br)cc2C(=O)NC(c12)c1cc(F)ccc1Cl	1H NMR (400 MHz, Methanol-d4)7.95 (d, 1.7 Hz, 1H), 7.72 (s, 1H), 7.61-7.48 (m, 2H), 7.41-7.24 (m, 2H), 7.11-6.50 (m, 3H), 6.16 (s, 1H).	542.85	D	
I-559		COc1cc(ccc1F)C(=O)Nc1cc(Br)cc2C(=O)NC(c12)c1cc(F)ccc1Cl	1H NMR (400 MHz, Chloroform-d) 8.41 (s, 1H), 7.95 (d, 1.6 Hz, 1H), 7.44-7.33 (m, 3H), 7.13-7.01 (m, 2H), 6.83 (s, 1H), 6.71 (s, 1H), 6.49 (s, 1H), 6.18 (s, 1H), 3.94 (s, 3H), 2.03 (s, 0H).	508.9	D	





I-560		Fc1ccc(c(CC(=O)Nc2cc(Br)cc3C(=O)NC(c23)c2cc(F)ccc2Cl)c1)C(F)(F)F	1H NMR (400 MHz, Chloroform-d) 8.38 (s, 1H), 7.90 (d, 1.7 Hz, 1H), 7.64 (dd, 8.8, 5.4 Hz, 1H), 7.45 (dd, 8.9, 4.9 Hz, 1H), 7.15-7.01 (m, 3H), 6.85 (s, 1H), 6.53 (d, 8.3 Hz, 1H), 6.38 (s, 1H), 6.02 (s, 1H), 3.76-3.65 (m , 2H), 3.50 (d, 16.0 Hz, 1H).	561	D	
I-561		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(NC(=O)c3cnn(c3)-c3ccccc3)c12	1H NMR (400 MHz, Chloroform-d) 8.52 (s, 1H), 8.36 (s, 1H), 7.93 (d, 1.7 Hz, 1H), 7.75-7.68 (m, 2H), 7.65 (s, 1H), 7.58-7.47 (m, 3H), 7.42 (t, 7.4 Hz, 1H), 7.09 (ddd, 12.2, 6.8, 3.1 Hz, 2H), 6.72 (s, 1H), 6.42 (s, 1H), 6.22 (s, 1H).	527	E	
I-562		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(NC(=O)c3cccn4ccnc34)c12	1H NMR (400 MHz, DMSO-d6) 11.99 (s, 1H), 9.41 (s, 1H), 8.83 - 8.77 (m, 2H), 8.12 - 8.05 (m, 2H), 7.73 (d, 1.8 Hz, 1H), 7.53 (s, 2H), 7.13 (t, 7.0 Hz, 1H), 7.12 (s, 1H), 6.54 (s, 1H), 6.19 (s, 1H).	499	E	
I-563		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(NC(=O)Cc3c(F)ccc(F)c3F)c12	1H NMR (400 MHz, Methanol-d4) 7.90 (d, 1.7 Hz, 1H), 7.68 (d, 1.6 Hz, 1H), 7.48 - 7.40 (m, 1H), 7.25 (qd, 9.4, 5.1 Hz, 1H), 7.13 (ddd, 8.9, 7.8, 3.1 Hz, 1H), 6.96 (ddt, 9.6, 6.6, 3.4 Hz, 1H), 6.14 (s, 1H), 3.64 - 3.51 (m, 2H).	527	E	
I-564		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(NC(=O)c3cc(F)c(F)c(Cl)c3)c12	1H NMR (400 MHz, Methanol-d4) 7.96 (d, 1.7 Hz, 2H), 7.73 (s, 2H), 7.58 - 7.47 (m, 4H), 7.34 (dd, 8.9, 5.0 Hz, 2H), 7.06 (ddd, 8.9, 7.7, 3.1 Hz, 2H), 6.65 (s, 3H), 6.14 (s, 2H), 4.63 (s, 2H).	530.9	A	






I-565		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(NC(=O)c3ccc(F)c(Cl)c3)c12	1H NMR (400 MHz, Chloroform-d) 8.45 (s, 1H), 7.94 (d, 1.6 Hz, 1H), 7.55-7.43 (m, 3H), 7.34 (s, 1H), 7.23 (t, 8.4 Hz, 1H), 7.10 (ddd, 8.9, 7.3, 3.0 Hz, 1H), 6.72 (s, 1H), 6.60 (s, 1H), 6.18 (s, 1H).	510.95	C	
I-566		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(NC(=O)c3ccc(F)c(c3)C(F)(F)F)c12	1H NMR (400 MHz, Chloroform-d) 8.39 (s, 1H), 7.95 (s, 1H), 7.87 (s, 1H), 7.68 (d, 6.3 Hz, 1H), 7.40 (s, 2H), 7.31 (d, 8.8 Hz, 1H), 7.07 (s, 1H), 6.70 (s, 2H), 6.21 (s, 1H).	545	C	
I-567		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(NC(=O)c3cccc(n3)C(F)(F)F)c12	1H NMR (400 MHz, Chloroform-d) 9.30 (s, 1H), 8.74 (s, 1H), 8.45 (d, 7.9 Hz, 1H), 8.13 (t, 7.8 Hz, 1H), 7.96 (d, 1.7 Hz, 1H), 7.87 (d, 7.8 Hz, 1H), 7.48 (dd, 8.8, 4.8 Hz, 1H), 7.03 (s, 1H), 6.60 (s, 1H), 6.47 (s, 1H), 6.22 (s, 1H).	529.9	D	
I-568		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(NC(=O)Cc3ccccc3C(F)(F)F)c12	1H NMR (400 MHz, DMSO-d6) 10.01 (s, 1H), 9.22 (s, 1H), 7.75 - (m, 2H), 7.69 - 7.59 (m, 1H), 7.59 (d, 7.6 Hz, 1H), 7.47 (t, 7.5 Hz, 2H), 7.30 -7.21 (m, 2H), 7.23-6.08 (m, 1H),5.98 (s, 1H), 3.65 - 3.49 (m, 2H).	541.05	D	
I-569		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(NC(=O)c3cccc(c3)C3CC3)c12	1H NMR (400 MHz, DMSO-d6) 10.16 (s, 1H), 9.27 (s, 1H), 7.82-7.73 (m, 2H), 7.37 (dd, 8.9, 5.2 Hz, 1H), 7.36 - 7.26 (m, 2H), 7.28 (s, 1H), 7.18 - 7.08 (m, 2H), 6.78 (s, 1H), 6.04 (s, 1H), 1.98 - 1.87 (m, 1H), 0.99 (dq, 8.3, 1.5 Hz, 2H), 0.73 - 0.60 (m, 2H).	499.05	D	




I-570		FC(F)c1ccc(c1)C(=O)Nc1cc(Br)cc2C(=O)NC(c12)c1cc(F)ccc1Cl	1H NMR (400 MHz, DMSO-d6) 10.42 (s, 1H), 9.28 (s, 1H), 7.80 (d, 1.7 Hz, 1H), 7.78 - 7.69 (m, 4H), 7.60 (t, 7.8 Hz, 1H), 7.33 (dd, 8.8, 5.1 Hz, 1H), 7.15 - 7.05 (m, 2H), 6.71 (s, 1H), 6.02 (s, 1H).	509	D	
I-571		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(NC(=O)c3ccccc3OC(F)(F)F)c12	1H NMR (400 MHz, DMSO-d6) 10.40 (s, 1H), 9.29 (s, 1H), 7.79 (d, 1.7 Hz, 1H), 7.69 (d, 1.9 Hz, 1H), 7.67 - 7.59 (m, 1H), 7.48 (t, 8.4 Hz, 2H), 7.39 (td, 7.6, 1.1 Hz, 1H), 7.27 (td, 8.4, 3.1 Hz, 1H), 6.83 (dt, 7.7, 2.2 Hz, 2H), 6.05 (s, 1H).	542.95	D	
I-572		FC(F)c1ccc(cc1)C(=O)Nc1cc(Br)cc2C(=O)NC(c12)c1cc(F)ccc1Cl	1H NMR (400 MHz, Chloroform-d) 7.96 (d, 1.7 Hz, 1H), 6.72 (t, 56.1 Hz, 2H), 8.46 (s, 1H), 7.60 (s, 4H), 7.41 (dd, 8.1, 4.3 Hz, 2H), 7.12 - 7.03 (m, 1H), 6.45 (s, 1H), 6.20 (s, 1H).	509	D	
I-573		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(NC(=O)c3cccc(Cl)c3)c12	1H NMR (400 MHz, DMSO-d6) 10.36 (s, 1H), 9.29 (s, 1H), 7.80 (d, 1.8 Hz, 1H), 7.74 (d, 1.8 Hz, 1H), 7.64 (dt, 7.8, 1.6 Hz, 1H), 7.55 (dt, 7.9, 1.5 Hz, 1H), 7.52 - 7.45 (m, 2H), 7.36 (dd, 8.9, 5.2 Hz, 1H), 7.14 (td, 8.4, 3.1 Hz, 1H), 7.11 - 6.25 (br, 1H), 6.00 (s, 1H).	492.85	C	
I-574		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(NC(=O)N3CCCOCC3)c12	(400 MHz, CDCl3) 8.14 (s, 1H), 7.81 (dd, 1.6, 0.4 Hz, 1H), 7.45 (dd, 8.9, 4.9 Hz, 1H), 7.06 (ddd, 8.9, 7.4, 3.0 Hz 1H), 6.62 (br s, 1H), 6.45 (dd, 20.1, 8.5 Hz, 1H), 6.11 (s, 1H), 5.89 (s, 1H), 3.69-3.52 (m, 4H), 3.44-3.36 (m, 2H), 3.32 (t, 5.2 Hz, 2H), 1.83-1.67 (m, 2H)	482.2	E	





I-575		OC1CN(C1)c1cc(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c2C(NC(=O)c2n1)c1cc(F)ccc1Cl	1H NMR (400 MHz, DMSO-d6) 10.68 (br s, 1H), 9.16 (s, 1H), 8.45 (s, 1H), 7.88 (s, 1H), 7.72 (d, 9.2 Hz, 1H), 7.66 (s, 1H), 7.33 (dd, 8.8, 5.2 Hz, 1H), 7.07 (td, 8.5, 2.9 Hz, 1H), 6.60 (br s, 1H), 5.86 (s, 1H), 5.65 (br s, 1H), 4.69-4.58 (m, 1H), 4.23 (dd, 15.5, 8.3 Hz, 2H), 3.77-3074 (m, 2H).	539.5	A	
I-576		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(NC(=O)N3CCOCC3)c12	NMR (400 MHz, CD3CN) 7.70 (d, 1.7 Hz, 1H), 7.52 (d, 1.6 Hz, 1H), 7.46 (dd, 7.8, 5.5 Hz, 1H), 7.24 (s, 1H), 7.11 (ddd, 8.9, 8.0, 3.1 Hz, 1H), 7.00 (s 1H), 6.69 (br s, 1H), 6.08 (s, 1H), 3.48 (ddd, 11.3, 6.5, 3.2 Hz, 2H), 3.42-3.34 (m, 2H), 3.19 (ddd, 13.1, 6.5, 3.3 Hz, 2H), 2.99 (ddd, 13.2, 6.5, 3.2 Hz, 2H).	466.3	E	
I-577		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(NC(=O)N3CCCCCC3)c12	NMR (400 MHz, CD3CN) 7.68 (s, 2H), 7.44 (dd, 8.9, 5.2 Hz, 1H), 7.23 (s, 1H), 7.09 (ddd, 8.8, 8.0, 3.1 Hz, 1H), 6.74 (s, 1H), 6.64 (br s, 1H), 6.16 (s, 1H), 3.33-2.98 (m, 4H), 1.54-1.44 (m, 4H), 1.43-1.36 (m, 2H), 1.33-1.22 (m, 2H).	480.2	E	
I-578		NC(=O)Cc1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	1H-NMR (400 MHz, DMSO-d6) 10.52 (s, 1H), 9.12 (br. s, 1H), 7.94 (d, 8.5 Hz, 1H), 7.73 (d, 9.0 Hz, 1H), 7.65 (s, 1H), 7.61 (s, 2H), 7.38 (s, 1H), 7.31 (dd, 8.9, 5.2 Hz, 1H), 7.09 (td, 8.4, 3.0 Hz, 1H), 7.01 (br. s, 1H), 6.59 (br. s, 1H), 5.95 (br. s, 1H), 3.62-3.51 (m, 2H).	524.2	A	





I-579		OCCc1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	NMR (400 MHz, DMSO-d6) 10.49 (br. s, 1H), 9.09 (br. s, 1H), 7.94 (d, 8.5 Hz, 1H), 7.73 (d, 9.1 Hz, 1H), 7.65 (s, 1H), 7.56 (s, 1H), 7.34 (s, 1H), 7.30 (dd, 8.9, 5.2 Hz, 1H), 7.09 (td, 8.4, 3.1 Hz, 1H), 6.58 (br. s, 1H), 5.94 (br. s, 1H), 4.74 (br. s, 1H), 3.70 (t, 6.4 Hz, 2H), 2.95-2.82 (m, 2H).	511.2	A	
I-580		Fc1ccc(Cl)c(c1)C1NC(=O)c2cccc(NC(=O)c3cc(F)c(F)c(c3)C(F)(F)F)c12		485.1	A	
I-581		CC(=O)c1cc(F)cc(c1)C(=O)Nc1cccc2C(=O)NC(c12)c1cc(F)ccc1Cl		441.4	D	
I-582		Cn1cc(Br)c(n1)C(=O)Nc1cccc2C(=O)NC(c12)c1cc(F)ccc1Cl		463.22	E	
I-583		Cn1ncc(Br)c1C(=O)Nc1cccc2C(=O)NC(c12)c1cc(F)ccc1Cl		463.22	E	
I-584		Cc1ncc(cn1)-c1cc(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c2C(NC(=O)c2n1	1H NMR (DMSO-d6, 400 MHz) 11.04 (br s, 1H), 9.63 (br s, 1H), 9.38 (s, 2H), 8.14 (s, 1H), 8.00 (br d, 8.1 Hz, 1H), 7.76 (br d, 8.8 Hz, 1H), 7.67 (s, 1H), 7.35 (dd, 8.9, 5.2 Hz, 1H), 7.10 (td, 8.4, 2.9 Hz,	560.5	A	





		)c1cc(F)ccc1Cl	1H), 6.83-7.02 (m, 1H), 6.08 (br s, 1H), 2.74 (s, 3H)			
I-585		Fc1ccc(Cl)c(c1)C1NC(=O)c2nc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1cncc(F)c1	1H NMR (DMSO-d6, 400 MHz) 11.03 (s, 1H), 9.63 (br s, 1H), 9.21 (s, 1H), 8.74 (br d, 2.4 Hz, 1H), 8.39 (br d, 9.8 Hz, 1H), 8.19 (br s, 1H), 8.00 (br d, 7.6 Hz, 1H), 7.77 (br d, 9.0 Hz, 1H), 7.68 (br s, 1H), 7.36 (br dd, 8.8, 5.1 Hz, 1H), 7.11 (td, 8.4, 3.1 Hz, 1H), 6.83-7.03 (m, 1H), 6.08 (br s, 1H)	563.5	A	
I-586		CCn1cc(ccc1=O)-c1cc(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c2C(NC(=O)c2n1)c1cc(F)ccc1Cl	1H NMR (DMSO-d6, 400 MHz) 10.91 (s, 1H), 9.52 (br s, 1H), 8.62 (d, 2.2 Hz, 1H), 8.20 (dd, 9.5, 2.4 Hz, 1H), 7.99 (br d, 8.1 Hz, 1H), 7.90 (s, 1H), 7.76 (br d, 9.0 Hz, 1H), 7.68 (s, 1H), 7.34 (dd, 9.0, 5.1 Hz, 1H), 7.10 (td, 8.4, 2.9 Hz, 1H), 6.79-6.98 (m, 1H), 6.57 (d, 9.5 Hz, 1H), 6.02 (br s, 1H), 4.07 (q, 7.1 Hz, 2H), 1.30 (t, 7.1 Hz, 3H)	589.5	A	
I-587		Cn1cc(ccc1=O)-c1cc(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c2[C@H](NC(=O)c2n1)c1cc(F)ccc1Cl		575.2	D	
I-588		Cn1cc(ccc1=O)-c1cc(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c2[C@@H](NC(=O)c2n1		575.2	A	




		)c1cc(F)ccc1Cl				
I-589		Fc1ccc(Cl)c(c1)[C@H]1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)C1COC1		523.4	A	
I-590		Fc1ccc(Cl)c(c1)[C@@H]1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)C1COC1		523.4	A	
I-591		CC(C)(O)C(=O)Nc1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl		568.27	A	
I-592		OC1(CC1)C(=O)Nc1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl		566.21	A	
I-593		CC(C)n1cc(ccc1=O)-c1cc(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c2C(NC(=O)c2n1)c1cc(F)ccc1Cl	1H NMR (DMSO-d6, 400 MHz) 10.94 (br s, 1H), 9.51 (br s, 1H), 8.48 (br d, 2.2 Hz, 1H), 8.20 (br dd, 9.6, 2.3 Hz, 1H), 7.98 (br s, 2H), 7.76 (br d, 8.8 Hz, 1H), 7.69 (s, 1H), 7.34 (dd, 8.9, 5.2 Hz, 1H), 7.09 (td, 8.4, 2.9 Hz, 1H), 6.77-6.96 (m, 1H), 6.58	603.6	A	





			(d, 9.5 Hz, 1H), 6.01 (br s, 1H), 5.13 (dt, 13.6, 6.7 Hz, 1H), 1.41 (dd, 6.6, 4.9 Hz, 6H)			
I-594		Fc1ccc(Cl)c(c1)C1NC(=O)c2cccc(NC(=O)c3cc(F)cc4cn[nH]c34)c12		439.33	C	
I-595		Fc1ccc(Cl)c(c1)C1NC(=O)c2cccc(NC(=O)c3cc(F)cc4nc[nH]c34)c12		439.38	D	
I-596		Fc1ccc(Cl)c(c1)C1NC(=O)c2cccc(NC(=O)c3cc(Cl)cc4CCOc34)c12		457.4	D	
I-597		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(NC(=O)N3CCCC(C3)c3ccccc3)c12	(400 MHz, DMSO-d6) 9.19 (s, 1H), 8.71 (s, 0.5H), 8.67 (s, 0.5H), 7.61-7.57 (m, 1H), 7.56-7.50 (m, 1H), 7.47 (d, 1.6 Hz, 0.5H), 7.46 (d, 1.6 Hz, 0.5H) 7.38-7.28 (m, 3H), 7.28-7.19 (m, 3H), 7.12 (d, 7.1 Hz, 1H), 6.60 (br s, 1H), 6.07 (br s, 1H), 3.96 (d, 12.1 Hz, 0.5H), 3.86 (d, 7.6 Hz, 0.5H), 3.76 (t, 14.4 Hz, 1H), 2.75-2.57 (m, 1H), 2.48-2.40 (m, 1H), 1.99-1.82 (m, 0.5H), 1.82-1.68 (m, 1H), 1.68-1.43 (m, 2H), 1.43-1.27 (m, 0.5H)	542.3	D	






I-598		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(NC(=O)N3CCC(C3)c3ccccc3)c12	(400 MHz, DMSO-d6) 9.15 (s, 1H), 8.28 (s, 0.5H), 8.19 (s, 0.5H), 7.56 (dd, 2.7, 1.8 Hz, 1H), 7.51 (d, (t, 1.7 Hz, 1H), 7.46 (d, (t, 1.7 Hz, 1H), 7.31 (t, 7.7 Hz, 2H), 7.28-7.13 (m, 5H), 5.94 (br s, 1H), 3.79-3.57 (m, 0.5H), 3.56-3.37 (m, 1H), 3.25-3.11 (m, 2.5H), 3.10-2.99 (m, 1H), 2.17-2.04 (m, 1H), 1.89-1.65 (m, 1H)	528.3	D	
I-599		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(NC(=O)CC3CCc4ccccc34)c12	1H NMR (400 MHz, Chloroform-d) 8.46 (s, 1H), 7.89 (t, 1.9 Hz, 1H), 7.42 (ddd, 22.3, 8.9, 4.9 Hz, 1H), 7.26 (d, 8.7 Hz, 1H), 7.22 (d, 6.6 Hz, 1H), 7.19-6.97 (m, 3H), 6.88 (s, 1H), 6.66 (dd, 8.5, 3.0 Hz, 1H), 6.42 (d, 5.1 Hz, 1H), 6.06 (s, 1H), 3.59-3.51 (m, 1H),2.72-2.57 (m, 2H), 2.40 - 2.30 (m, 1H), 2.34-2.23 (m, 2H), 1.69 (dt, 13.3, 7.4 Hz, 1H).	515	E	
I-600		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(NC(=O)CCc3ccccc3C(F)(F)F)c12	1H NMR (400 MHz, DMSO-d6) 9.87 (s, 1H), 9.25 (s, 1H), 7.75 - 7.57 (m, 4H), 7.44 (q, 7.7 Hz, 2H), 7.37 (d, 7.7 Hz, 1H), 7.22 (ddd, 8.9, 7.9, 3.1 Hz, 1H), 6.71 (s, 1H), 6.00 (s, 1H), 2.81 (dd, 20.3, 10.4 Hz, 2H), 2.34-2.19 (m, 2H).	555	D	
I-601		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(NC(=O)c3cccc4CCCOc34)c12	1H NMR (400 MHz, DMSO-d6) 9.73 (s, 1H), 9.27 (s, 1H), 7.89 (d, 16.6 Hz, 1H), 7.74 (d, 1.8 Hz, 1H), 7.44 (s, 1H), 7.27 - 7.15 (m, 3H), 6.85 (t, 7.6 Hz, 2H), 6.11 (s, 1H), 4.18 - 4.10 (m, 1H), 4.04 (dt, 10.6, 5.2 Hz, 1H), 2.76 (t, 6.5 Hz, 2H), 1.90 (q, 5.9 Hz, 2H).	515.05	E	






I-602		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(NC(=O)c3cccc4ccncc34)c12	1H NMR (400 MHz, DMSO-d6) 12.91 (s, 1H), 9.34 (s, 1H), 8.93 (s, 1H), 8.58 (ddd, 14.9, 7.9, 1.7 Hz, 2H), 8.39 (s, 1H), 8.26 (dd, 8.1, 1.6 Hz, 1H), 7.82 - 7.68 (m, 3H), 7.29 (dd, 8.8, 5.1 Hz, 1H), 6.98 (d, 8.9 Hz, 1H), 6.80 (s, 1H), 6.26 (s, 1H).	510	D	
I-603		Cc1nc2ccccn2c1CC(=O)Nc1cc(Br)cc2C(=O)NC(c12)c1cc(F)ccc1Cl	1H NMR (400 MHz, DMSO-d6) 10.12 (s, 1H), 9.21 (s, 1H), 8.06 (d, 6.9 Hz, 1H), 7.71 (dd, 13.5, 1.8 Hz, 2H), 7.44 (d, 9.0 Hz, 1H), 7.34 (dd, 8.8, 5.1 Hz, 1H), 7.23 - 7.14 (m, 1H), 7.15 (s, 1H), 6.83 (td, 6.8, 1.2 Hz, 1H), 6.54 (s, 1H), 5.98 (s, 1H), 3.72 (s, 2H), 2.17 (s, 3H).	527	E	
I-604		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(NC(=O)C3(CCCC3)c3ccccc3)c12	1H NMR (400 MHz, DMSO-d6) 9.23 (s, 1H), 9.16 (s, 1H), 7.69 (d, 1.8 Hz, 1H), 7.53 (d, 1.8 Hz, 2H), 7.30 - 7.13 (m, 6H), 6.17 (s, 1H), 2.14 (s, 2H), 1.89 (d, 23.1 Hz, 1H), 1.68 (dt, 13.1, 7.1 Hz, 1H), 1.48 (s, 2H), 1.26 (s, 2H).	527.05	D	
I-605		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(NC(=O)C3CCOc4ccccc34)c12	1H NMR (400 MHz, DMSO-d6) 10.21 - 10.11 (m, 1H), 9.26 (d, 15.1 Hz, 1H), 7.82 - 7.69 (m, 2H), 7.60 (s, 1H), 7.46-7.33 (m, 1H), 7.21-7.05 (m, 1H), 6.78- 6.67 (m, 3H), 6.56 (s, 1H), 6.08 (s, 1H), 4.23-3.97 (m, 2H), 3.65 -3.58 (m, 1H), 1.86 - 1.79 (m, 1H), 1.71 - 1.63 (m, 1H).	515	E	





I-606		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(NC(=O)c3ccnc4ccc(Cl)cc34)c12	1H NMR (400 MHz, DMSO-d6) 10.30 (s, 1H), 9.34 (s, 1H), 8.99 (d, 4.3 Hz, 1H), 8.13 (d, 9.0 Hz, 1H), 7.92 (d, 2.3 Hz, 1H), 7.86 (ddd, 8.3, 3.4, 2.0 Hz, 3H), 7.49 (dd, 8.9, 5.1 Hz, 1H), 7.24 (td, 8.4, 3.1 Hz, 1H), 7.14 (s, 1H), 6.70 (s, 1H), 6.13 (s, 1H).	543.95	E	
I-607		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(NC(=O)c3ccnc(c3F)C(F)(F)F)c12	1H NMR (400 MHz, Chloroform-d) 8.70 (d, 4.8 Hz, 1H), 8.45-8.40 (m, 1H), 8.10 (t, 5.0 Hz, 1H), 7.98 (d, 1.6 Hz, 1H), 7.86 (d, 11.0 Hz, 1H), 7.42 (dd, 8.9, 4.9 Hz, 1H), 7.08 (ddd, 8.9, 7.4, 3.0 Hz, 1H), 6.94 (s, 1H), 6.65 (s, 1H), 6.17 (s, 1H).	545.95	E	
I-608		CCc1cc(F)cc(c1)C(=O)Nc1cc(Br)cc2C(=O)NC(c12)c1ccccc1C	NMR (400 MHz, DMSO-d6) 10.12 (br. s, 1H), 9.23 (s, 1H), 7.85 (d, 1.7 Hz, 1H), 7.76 (d, 1.7 Hz, 1H), 7.25-7.21 (m, 1H), 7.12 (td, 7.6, 1.2 Hz, 1H), 7.07-7.06 (m, 1H), 6.99 (td, 7.6, 1.2 Hz, 1H), 6.91-6.88 (m, 2H), 6.58 (br. s, 1H), 5.96 (s, 1H), 2.58 (q, 7.5 Hz, 2H), 2.26 (br. s, 3H), 1.15 (t, 7.6 Hz, 3H), traces of impurities at 3.63, 1.99, 1.22, 0.86 .	465.3	C	
I-609		O[C@H]1C[C@@H](C1)Nc1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	NMR (400 MHz, DMSO-d6) 10.25 (br. s, 1H), 8.88 (br. s, 1H), 8.43 (br. s, 1H), 7.88 (d, 8.4 Hz, 1H), 7.65 (d, 8.6 Hz, 1H), 7.56 (s, 1H), 7.24 (dd, 8.9, 5.2 Hz, 1H), 7.02 (td, 8.5, 2.4 Hz, 1H), 6.63 (d, 1.9 Hz, 1H), 6.54 (s, 1H), 6.44 (d, 5.1 Hz, 1H), 5.79 (br. s, 1H), 5.07 (br. s, 1H), 4.37-4.20 (m, 1H), 3.84	552.2	A	





			(ddd, 11.5, 7.6, 4.3 Hz, 1H), 2.24-2.01 (m, 3H).			
I-610		CC1(COC1)Nc1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	NMR (400 MHz, DMSO-d6) 10.24 (s, 1H), 8.91 (br. s, 1H), 7.88 (td, 8.4, 1.6 Hz, 1H), 7.64 (d, 9.0 Hz, 1H), 7.55 (s, 1H), 7.25 (dd, 8.9, 5.2 Hz, 1H), 7.03 (td, 8.4, 3.1 Hz, 1H), 6.64 (s, 1H), 6.57 (br. s, 1.6 Hz, 1H), 6.52 (d, 2.1 Hz, 1H), 6.47 (br. d, 1H), 5.80 (s, 1H), 4.63 (d, 5.7 Hz, 2H), 4.48 (d, 5.8 Hz, 2H), 1.57 (s, 3H).6% as formate salt at 8.32 .	552.2	A	
I-611		COCc1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	NMR (400 MHz, ACN) 8.61 (s, 1H), 7.69 (s, 1H), 7.65 (d, 8.5 Hz, 1H), 7.61-7.55 (m, 2H), 7.53 (s, 1H), 7.25 (dd, 8.9, 5.1 Hz, 1H), 7.22 (br s, 1H), 6.97 (ddd, 8.8, 8.0, 3.1 Hz, 1H), 6.64 (br s, 1H), 6.11 (br s, 1H), 4.59 (s, 2H), 3.41 (s, 3H).	511.1	A	
I-612		FC(F)c1ccc(F)cc1C1NC(=O)c2cc(Br)cc(NC(=O)c3nsc4ccccc34)c12	NMR (400 MHz, DMSO) 10.31 (br s, 1H), 9.38 (s, 1H), 8.60 (d, 8.2 Hz, 1H), 8.31 (dt, 8.3, 0.9 Hz, 1H), 8.01 (d, 1.7 Hz, 1H), 7.83 (d, 1.7 Hz, 1H), 7.67 (ddd, 8.2, 7.0, 1.2 Hz, 1H), 7.59 (ddd, 8.1, 7.0, 1.0 Hz, 1H), 7.42 (dd, 8.6, 5.7 Hz, 1H), 7.11 (td, 8.5, 2.6 Hz, 1H), 6.63 (br s, 1H), 6.16 (s, 1H). contains 9% formate salt (8.34) and residual acetone from NMR tube (2.05).	532.1	A	






I-613		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(NC3COC3)cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	NMR (400 MHz, DMSO-d6) 10.30 (s, 1H), 8.95 (br. s, 1H), 7.92 (d, 8.6 Hz, 1H), 7.69 (d, 8.9 Hz, 1H), 7.60 (s, 1H), 7.28 (dd, 8.9, 5.2 Hz, 1H), 7.06 (td, 8.4, 3.1 Hz, 1H), 6.94 (d, 6.3 Hz, 1H), 6.69 (d, 2.0 Hz, 1H), 6.62 (s, 1H), 6.57 (br. s, 1H), 5.82 (br. s, 1H), 4.89 (t, 6.5 Hz, 2H), 4.62 (dd, 12.7, 6.4 Hz, 1H), 4.45 (q, 6.1 Hz, 2H). 6% of formate salt at 8.36	538.2	A	
I-614		CCn1cc(ccc1=O)-c1cc(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c2[C@H](NC(=O)c2n1)c1cc(F)ccc1Cl		589.3	D	
I-615		CCn1cc(ccc1=O)-c1cc(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c2[C@@H](NC(=O)c2n1)c1cc(F)ccc1Cl		589.3	A	
I-616		Fc1ccc(Cl)c(c1)[C@H]1NC(=O)c2nc(Cl)cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12		502.2	B	





I-617		Fc1ccc(Cl)c(c1)[C@@H]1NC(=O)c2nc(Cl)cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12		502.2	A	
I-618		CS(=O)(=O)Cc1cc2C(=O)N[C@H](c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	1H NMR (DMSO-d6, 500 MHz) 10.5-10.7 (m, 1H), 9.0-9.3 (m, 1H), 7.9-8.0 (m, 1H), 7.7-7.8 (m, 2H), 7.6-7.7 (m, 1H), 7.4-7.6 (m, 1H), 7.2-7.4 (m, 1H), 6.9-7.2 (m, 1H), 6.5-7.0 (m, 2H), 5.7-6.2 (m, 1H), 4.5-4.9 (m, 2H), 2.9-3.1 (m, 3H)	559	A	
I-619		CS(=O)(=O)Cc1cc2C(=O)N[C@@H](c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	1H NMR (DMSO-d6, 500 MHz) 10.5-10.7 (m, 1H), 9.1-9.4 (m, 1H), 7.92 (br d, 1H, 8.2 Hz), 7.7-7.8 (m, 2H), 7.6-7.7 (m, 1H), 7.5-7.6 (m, 1H), 7.2-7.4 (m, 1H), 7.0-7.2 (m, 1H), 6.2-7.0 (m, 1H), 5.7-6.2 (m, 1H), 4.5-4.8 (m, 2H), 2.9-3.1 (m, 3H)	559	D	
I-620		CC(=O)Cc1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1C(F)F		539	A	
I-621		CC(C)(O)Cc1cc2C(=O)N[C@H](c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl		539	A	




I-622		CC(C)(O)Cc1cc2C(=O)N[C@@H](c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl		539	B	
I-623		CC(=O)Cc1cc2C(=O)N[C@H](c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl		523	A	
I-624		CC(=O)Cc1cc2C(=O)N[C@@H](c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl		523	B	
I-625		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(NC(=O)C3CC3)cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	1H NMR (500 MHz, DMSO-d6) 0.81 - 0.87 (m, 4 H) 1.81 (dt, 12.53, 6.19 Hz, 1 H) 5.85 - 5.95 (m, 1 H) 6.56 (br s, 1 H) 7.06 (td, 8.35, 3.15 Hz, 1 H) 7.29 (dd, 8.83, 5.04 Hz, 1 H) 7.62 (s, 1 H) 7.70 (br d, 9.14 Hz, 1 H) 7.80 (s, 1 H) 7.88 - 7.96 (m, 2 H) 9.08 (br s, 1 H) 10.47 (s, 1 H) 10.56 (s, 1 H)	550.4	A	
I-626		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(NC(=O)c3csc4cccc34)c12		517.3	A	






I-627		CC(C)(O)c1cc(F)cc(c1)C(=O)Nc1ccccc2C(=O)NC(c12)c1cc(F)ccc1Cl		457.4	E	
I-628		Fc1ccc(Br)c(c1)C1NC(=O)c2cccc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	(400 MHz, DMSO-d6) 10.34 (s, 1H), 8.99 (s, 1H), 7.86 (d, 8.5 Hz, 1H), 7.75-7.68 (m, 3H), 7.65 (t, 7.6 Hz, 1H), 7.51 (d, 7.5 Hz, 1H), 7.46 (dd, 8.9, 5.4 Hz, 1H), 7.00 (dt, 8.5, 3.1 Hz, 1H), 6.55 (br s, 1H), 6.01 (s, 1H) [T = 60 °C].	509.3	A	
I-629		Fc1cc(cc(c1)C(F)(F)F)C(=O)Nc1ccccc2c1n([nH]c2=O)C1CCCCC1	NMR (400 MHz, DMSO-d6) 10.61 (s, 2H), 8.26 (s, 1H), 8.15 (d, 8.7 Hz, 1H), 8.05 (d, 8.6 Hz, 1H), 7.59 (d, 7.9, 0.7 Hz, 1H), 7.23 (d, 7.2 Hz, 1H), 7.01 (t, 17.2, 9.5 Hz, 1H), 4.40 (m, 1H), 1.88-1.77 (m, 2H), 1.77-1.64 (m, 4H), 1.56-1.43 (m, 1H), 1.15-1.00 (m, 1H), 1.00-0.81 (m, 2H).	422.5	D	
I-630		Fc1cc(cc(c1)C(F)(F)F)C(=O)Nc1ccccc2C(=O)NC(c12)c1ccnc(Cl)c1	(400 MHz, d6-DMSO) 10.52 (s, 1H), 9.17 (s, 1H), 8.19 (d, 5.1 Hz, 1H), 8.01 (d, 8.5 Hz, 1H), 7.86 (d, 8.5 Hz, 1H), 7.84 (s 1H), 7.72 (dd, 7.5, 1.0 Hz, 1H), 7.64 (t, 7.6 Hz, 1H), 7.51 (dd, 7.8, 1.0 Hz, 1H), 7.18 (s, 1H), 6.93 (dd, 5.2, 1.4 Hz, 1H), 5.75 (s, 1H). With traces of aliphatic impurity.	448.3	E	






I-631		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(NC(=O)C3CCCc4ccccc34)c12	1H NMR (400 MHz, DMSO-d6) 9.99 (d, 52.3 Hz, 1H), 9.25 (s, 1H), 7.79 (d, 12.1 Hz, 1H), 7.72 (s, 1H), 7.65 - 7.24 (m, 2H), 7.16 - 6.93 (m, 3H), 6.59 (d, 59.8 Hz, 1H), 6.10 (s, 1H), 3.59 (s, 1H), 2.66 (d, 6.3 Hz, 2H), 1.95 - 1.67 (m, 2H), 1.64 (s, 2H), .	512.95	D	
I-632		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(NC(=O)C3(COC3)c3ccccc3)c12	1H NMR (400 MHz, DMSO-d6) 9.89 (s, 1H), 9.29 (s, 1H), 7.76 (d, 1.7 Hz, 1H), 7.51 (s, 2H), 7.39 - 7.18 (m, 6H), 6.11 (s, 1H), 4.87 (d, 6.4 Hz, 1H), 4.69 (d, 6.3 Hz, 1H), 4.62 (d, 6.4 Hz, 1H), 4.51 (s, 1H).	514.95	E	
I-633		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(NC(=O)Cn3ncc4ccccc34)c12	1H NMR (400 MHz, DMSO-d6) 10.19 (s, 1H), 9.22 (s, 1H), 8.06 (s, 1H), 7.75 (dd, 18.4, 8.9 Hz, 3H), 7.54 (s, 1H), 7.41 - 7.23 (m, 3H), 7.16 (t, 7.4 Hz, 1H), 5.95 (s, 1H), 4.99 (s, 2H).	512.95	E	
I-634		CC1(CCCc2ccccc12)C(=O)Nc1cc(Br)cc2C(=O)NC(c12)c1cc(F)ccc1Cl	1H NMR (400 MHz, Chloroform-d) 855 - 8.25 (d, 111.5 Hz, 1H), 7.84 (dd, 9.8, 1.7 Hz, 1H), 7.44 (dt, 9.2, 4.9 Hz, 1H), 7.23 - 6.95 (m, 4H), 6.92 - 6.81 (m, 1H), 6.57 (d, 8.1 Hz, 1H), 6.41 (d, 7.0 Hz, 1H), 6.33 - 6.23 (m, 1H), 5.82 - 5.46 (m, 1H), 2.72 (ddt, 22.0, 10.5, 5.9 Hz, 2H), 2.24 - 2.05 (m, 1H), 1.89 - 1.72 (m, 1H), 1.71 - 1.61 (m, 1H), 1.51 (d, 6.8 Hz, 4H).	527.1	D	





I-635		Cc1cc2ccccc(C(=O)Nc3cc(Br)cc4C(=O)NC(c34)c3cc(F)ccc3Cl)c2o1	1H NMR (400 MHz, DMSO-d6) 10.14 (s, 1H), 9.27 (s, 1H), 7.77 (dd, 17.9, 1.8 Hz, 2H), 7.69 (dd, 6.8, 2.3 Hz, 1H), 7.33 (dd, 8.9, 5.1 Hz, 1H), 7.28 -7.18 (m, 2H), 7.11 (td, 8.4, 3.1 Hz, 1H), 6.65 (d, 1.3 Hz, 2H), 6.06 (s, 1H), 2.41 (s, 3H).	513	D	
I-636		Cn1ccc2c(ccnc12)C(=O)Nc1cc(Br)cc2C(=O)NC(c12)c1cc(F)ccc1Cl	1H NMR (400 MHz, DMSO-d6) 10.40 (s, 1H), 9.29 (s, 1H), 8.32 (d, 4.9 Hz, 1H), 7.80 (s, 2H), 7.63 (d, 3.5 Hz, 1H), 7.37 (dd, 8.8, 5.1 Hz, 1H), 7.14 (td, 8.5, 3.1 Hz, 1H), 7.01 (d, 4.9 Hz, 1H), 6.72 (s, 1H), 6.45 (d, 3.5 Hz, 1H), 6.10 (s, 1H), 3.85 (s, 3H).	513	E	
I-637		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(NC(=O)c3ccc4nncn4c3)c12	1H NMR (400 MHz, DMSO-d6) 10.46 (s, 1H), 9.42 (d, 0.8 Hz, 1H), 9.29 (s, 1H), 8.94 (t, 1.4 Hz, 1H), 7.88 - 7.80 (m, 2H), 7.71 (d, 1.7 Hz, 1H), 7.46 (dd, 9.6, 1.7 Hz, 1H), 7.34 (dd, 8.9, 5.2 Hz, 1H), 7.11 (td, 8.4, 3.0 Hz, 1H), 6.70 (s, 1H), 6.00 (s, 1H).	500	E	
I-638		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(NC(=O)c3nccc4ccccc34)c12	1H NMR (400 MHz, DMSO-d6) 10.51 (s, 1H), 9.34 (s, 1H), 9.05 (d, 8.8 Hz, 1H), 8.50 (d, 5.5 Hz, 1H), 8.28 (d, 6.4 Hz, 1H), 8.12 (dd, 13.7, 6.9 Hz, 2H), 7.82 (dt, 40.5, 7.6 Hz, 3H), 7.45 (s, 1H), 7.15 (t, 8.5 Hz, 1H), 6.24 (s, 1H).	510	E	
I-639		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(NC(=O)c3ccccc3C#N)c12	1H NMR (400 MHz, Chloroform-d) 8.20 (s, 1H), 7.93 (s, 1H), 7.73 (s, 4H), 6.96 (s, 1H), 6.73 (t, 8.3 Hz, 1H), 6.61 (s, 1H), 6.55 (s, 1H), 6.17 (s, 1H).	484	E	





I-640		CCc1cc(ccc1F)C(=O)Nc1cc(Br)cc2C(=O)NC(c12)c1ccccc1C	NMR (400 MHz, DMSO-d6) 10.04 (s, 1H), 9.22 (s, 1H), 7.84 (d, 1.6 Hz, 1H), 7.75 (d, 1.6 Hz, 1H), 7.30 (ddd, 7.6, 5.0, 2.2 Hz, 1H), 7.16 (dd, 9.6, 8.4, Hz, 1H), 7.13-7.09 (m, 2H), 7.06 (br. d, 6.9 Hz, 1H), 6.99 (td, 7.3, 1.2 Hz, 1H), 6.57 (br. s, 1H), 5.96 (s, 1H), 2.57 (q, 7.6 Hz, 2H), 2.25 (br. s, 3H), 1.14 (t, 7.5 Hz, 3H), impurities at 3.7, 1.2 and 0.9 .	467.4	D	
I-641		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(F)cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	NMR (400 MHz, DMSO-d6) 10.59 (br. s, 1H), 9.30 (s, 1H), 7.96 (d, 7.6 Hz, 1H), 7.72 (d, 8.9 Hz, 1H), 7.63 (s, 1H), 7.49 (d, 6.5 Hz, 1H), 7.44 (d, 10.0 Hz, 1H), 7.33 (dd, 8.9, 5.2 Hz, 1H), 7.10 (td, 8.5, 2.5 Hz, 1H), 6.65 (br. s, 1H), 5.98 (br. s, 1H). 9% of formate salt at 8.36 .	485.1	A	
I-642		CN1CCN(CC1)C(=O)Nc1cc(Br)cc2C(=O)NC(c12)c1cc(F)ccc1Cl	1H-NMR (400 MHz, DMSO-d6) 9.17 (br. s, 1H), 8.64 (s, 1H), 7.58 (d, 1.7 Hz, 1H), 7.54-7.48 (m, 1H), 7.47 (d, 1.7 Hz, 1H), 7.25 (ddd, 8.7, 8.1, 3.1 Hz, 1H), 6.57 (br. s, 1H), 5.97 (br. s, 1H), 3.22-3.11 (m, 2H), 3.03-2.93 (m, 2H), 2.18-2.09 (m, 2H), 2.12 (s, 3H), 2.05-1.95 (m, 2H). Compound is a partial salt (peak at 8.22).	473.2	E	
I-643		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)C1=CCOC1	NMR (400 MHz, MeCN-d3) 8.64 (s, 1H), 7.74 (s, 1H), 7.63 (d, 8.7 Hz, 1H), 7.58 (d, 8.7 Hz, 1H), 7.58-7.53 (m, 2H), 7.26 (dd, 8.9, 5.2 Hz, 2H), 6.97 (td, 8.5, 2.9 Hz, 1H), 6.66 (br. s, 1H), 6.54 (s,	535.2	A	





			1H), 6.13 (br. s, 1H), 5.04-4.99 (m, 2H), 4.81 (t, 4.1 Hz, 2H).			
I-644		OC1(Cc2cc3C(=O)NC(c3c(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c2)c2cc(F)ccc2Cl)CC1	NMR (400 MHz, DMSO-d6) 10.51 (s, 1H), 9.09 (br. s, 1H), 7.94 (d, 8.5 Hz, 1H), 7.74 (d, 9.0 Hz, 1H), 7.66 (s, 1H), 7.64 (s, 1H), 7.40 (s, 1H), 7.32 (dd, 8.9, 5.2 Hz, 1H), 7.10 (td, 8.3, 3.0 Hz, 1H), 6.58 (br. s, 1H), 5.96 (br. s, 1H), 5.29 (s, 1H), 2.93 (s, 2H), 0.66 - 0.62 (m, 2H), 0.60 - 0.56 (m, 2H).	537.2	A	
I-645		CC(C)(O)Cc1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(Cl)c2)c1)c1cc(F)ccc1Cl	NMR (400 MHz, CD3CN) 8.46 (s, 1H), 7.60 (s, 1H), 7.42 (s, 1H), 7.39 (m, 1H), 7.32-7.27 (m, 3H), 7.24 (dd, 9.0, 1.8 Hz, 1H), 7.00 (ddd, 11.5, 5.7, 2.8 Hz, 1H), 6.63 (br s, 1H), 6.10 (br s, 1H), 2.92-2.82 (m, 2H), 1.19 (s, 3H), 1.17 (s, 3H).	505	A	
I-646		Fc1ccc(Cl)c(c1)C1NC(=O)c2cccc(NC(=O)c3cc(F)cc4cc[nH]c34)c12		438.46	A	
I-647		Fc1ccc(Cl)c(c1)C1NC(=O)c2nc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1ccc(=O)n(c1)C1CC1	1H NMR (DMSO-d6, 500 MHz) 10.90 (br s, 1H), 9.50 (br s, 1H), 8.32 (d, 2.2 Hz, 1H), 8.18 (dd, 9.6, 2.7 Hz, 1H), 7.85-8.03 (m, 2H), 7.76 (br d, 9.1 Hz, 1H), 7.68 (s, 1H), 7.34 (dd, 8.8, 5.0 Hz, 1H), 7.09 (td, 8.4, 3.2 Hz, 1H), 6.76-6.99 (m, 1H), 6.55 (d, 9.5 Hz, 1H), 6.01 (br s, 1H), 3.39-3.45 (m, 1H), 1.04-1.12 (m, 2H), 0.90-1.01 (m, 2H)	601.6	A	






I-648		Cn1cc(ccc1=O)-c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl		574.5	A	
I-649		CCn1cc(ccc1=O)-c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl		588.5	A	
I-650		CC(C)n1cc(ccc1=O)-c1cc(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c2[C@H](NC(=O)c2n1)c1cc(F)ccc1Cl		603.4	C	
I-651		CC(C)n1cc(ccc1=O)-c1cc(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c2[C@@H](NC(=O)c2n1)c1cc(F)ccc1Cl		603.4	A	
I-652		Cc1ncc(cn1)-c1cc(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c2[C@H](NC(=O)c2n1)c1		560.2	C	






		cc(F)ccc1Cl				
I-653		Cc1ncc(cn1)-c1cc(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c2[C@@H](NC(=O)c2n1)c1cc(F)ccc1Cl		560.2	A	
I-654		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)C1CNC1		522.4	A	
I-655		CC(=O)N1CC(C1)c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl		564.51	A	
I-656		CC(C)(COS(C)(=O)=O)c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl		617	A	
I-657		Cc1ccccc1C1NC(=O)c2cccc(NC(=O)c3cc(F)cc(c3)C3COC3)c12		417.45	D	






I-658		Oc1cc(ccn1)C1NC(=O)c2ccccc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	(400 MHz, d6-DMSO) 11.39 (br s, 1H), 10.58 (br s, 1H), 9.07 (s, 1H), 7.99 (d, 8.2 Hz, 1H), 7.91 (s, 1H), 7.87 (d, 9.1 Hz, 1H), 7.68 (dd, 7.4, 0.9 Hz, 1H), 7.62 (app t, 7.6 Hz, 1H), 7.53 (d, 6.8 Hz, 1H), 7.15 (d, 6.8 Hz, 1H), 6.06 (s, 1H), 5.52 (s, 1H), 5.45 (d, 6.6 Hz, 1H).	430.4	E	
I-659		Fc1cc(cc(c1)C(F)(F)F)C(=O)Nc1ccccc2C(=O)NC(c12)c1cccc(c1)C#N	(400 MHz, d6-DMSO) 10.44 (br s, 1H), 9.13 (s, 1H), 7.98 (d, 8.5 Hz, 1H), 7.77 (d, 8.9 Hz, 1H), 7.71 (dd, 7.5, 1.0 Hz, 1H), 7.67 (s, 1H), 7.66 (d, 7.2 Hz, 1H), 7.63 (app t, 6.6 Hz, 1H), 7.49 (dd, 7.7, 1.0 Hz, 1H), 7.45 (app t, 1.5 Hz, 1H), 7.38 (app t, 7.8 Hz, 1H), 7.22 (br d, 8.0 Hz, 1H), 5.77 (s, 1H).	438.4	E	
I-660		Fc1cc(cc(c1)C(F)(F)F)C(=O)Nc1ccccc2C(=O)NC(c12)c1cccc2CCNc12	1H NMR (400 MHz, CD3CN) 8.93 (br. s, 1H), 7.90 (d, 7.8 Hz, 1H), 7.69-7.65 (m, 3H), 7.59-7.54 (m, 2H), 7.08 (br. s, 1H), 6.95 (dd, 7.2, 0.9 Hz, 1H), 6.62 (br. d, 7.3 Hz, 1H), 6.54 (t, 7.5 Hz, 1H), 5.74 (s, 1H), 4.21 (br. s, 1H), 3.30-3.22 (m, 1H), 2.93-2.79 (m, 2H), 2.54-2.44 (m, 1H); acetonitrile satellites at 2.11 and 1.77 .	456.2	E	
I-661		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(NC(=O)N3CC(CC(C3)C(F)(F)F)C(F)(F)F)c12	(400 MHz, DMSO-d6) 9.18 (br s, 1H), 8.82 (s, 0.3 H), 8.65 (s, 0.6 H), 7.69-7.58 (m, 2H), 7.53-7.42 (m, 1H), 7.27-7.17 (m, 1H), 6.67 (br s, 1H), 5.98 (s, 1H), 3.45-3.34 (m, 4H), 2.65-2.53 (m, 2H), 1.92 (t, 6.5 Hz, 2H)	602.2	D	



I-662		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)C1CCO1	(400 MHz, DMSO-d6) 10.53 (s, 1H), 9.09 (s, 1H), 7.94 (d, 8.4 Hz, 1H), 7.90 (d, 8.1 Hz, 1H), 7.73 (d, 8.4 Hz, 1H), 7.66 (s, 1H), 7.55 (d, 8.0 Hz, 1H), 7.30 (ddd, 7.7, 5.1, 2.8 Hz, 1H), 7.13-7.05 (m, 1H), 6.62 (t, 7.4 Hz, 0.3H), 6.57 (t, 7.4 Hz, 0.7H), 6.00 (br s, 1H), 4.74 (dd, 13.7, 7.9 Hz, 1H), 4.65-4.55 (m, 1H), 3.52-3.46 (m, 1H), 3.24-3.11 (m, 1H) .	523.4	B	
I-663		Fc1cc(cc(c1)C(F)(F)F)C(=O)Nc1ccc2C(=O)NC(c12)c1cccc(Br)c1	(400 MHz, d6-DMSO) 10.47 (s, 1H), 9.10 (s, 1H), 7.98 (d, 8.5 Hz, 1H), 7.77 (d, 8.9 Hz, 1H), 7.72 (s, 1H), 7.69 (d, 7.3 Hz, 1H), 7.61 (app t, 7.6 Hz, 1H), 7.48 (d, 7.6 Hz, 1H), 7.38 (d, 7.9 Hz, 1H), 7.15 (d, 1.3 Hz, 1H), 7.13 (app t, 9.2 Hz, 1H), 6.89 (d, 7.8 Hz, 1H), 5.69 (s, 1H).	493.3	E	
I-664		CC(O)c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	NMR (400 MHz, DMSO-d6) 10.50 (2xs, 1H), 9.11 (s, 1H), 7.94 (d, 8.5 Hz, 1H), 7.74 (d, 8.6 Hz, 1H), 7.69-7.64 (m, 2H), 7.47 (2xs, 1H), 7.31 (dd, 8.9, 5.1 Hz, 1H), 7.09 (td, 8.4, 3.0 Hz, 1H), 6.60 (br. s, 1H), 5.96 (br. s, 1H), 5.44 (2xs, 1H), 4.94-4.83 (m, 1H), 1.40 (2xd, 2.1 Hz, 3H).	511.1	A	
I-665		CC(O)Cc1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	NMR (400 MHz, DMSO-d6) 10.47 (s, 1H), 9.08 (s, 1H), 7.93 (d, 8.3 Hz, 1H), 7.73 (d, 8.9 Hz, 1H), 7.65 (s, 1H), 7.54 (s, 1H), 7.36-7.26 (m, 2H), 7.09 (td, 8.4, 3.0 Hz, 1H), 6.61 (br. s, 1H), 5.94 (br. s, 1H), 4.68 (2xd, 1.2 Hz, 1H), 3.95-3.85 (m, 1H),	525.1	A	





			2.86-2.72 (m, 2H), 1.09 (2xd, 2.9 Hz, 3H).			
I-666		Fc1cc(cc(c1)C(F)(F)F)C(=O)Nc1ccc2C(=O)NC(c12)c1cccc2cn[nH]c12	1H NMR (400 MHz, DMSO-d6) 13.02 (s, 1H), 10.28 (s, 1H), 9.16 (s, 1H), 7.86 (s, 1H), 7.78 (d, 8.5 Hz, 1H), 7.72 (d, 7.4 Hz, 1H), 7.63 (t, 7.7 Hz, 1H), 7.57 (d, 7.9 Hz, 1H), 7.45 (d, 7.7 Hz, 1H), 7.20 (d, 8.8 Hz, 1H), 7.14 (s, 1H), 6.89 (t, 7.6 Hz, 1H), 6.64 (d, 7.2 Hz, 1H), 6.31 (s, 1H)	455.3	E	
I-667		Fc1cc(cc(c1)C(F)(F)F)C(=O)Nc1cc(Br)cc2C(=O)N[C@@H](c12)c1cccc(F)c1Cl	1H NMR (400 MHz, DMSO-d6) 10.55 (s, 1H), 9.33 (s, 1H), 7.96 (d, 8.4 Hz, 1H), 7.84 (d, 1.7 Hz, 1H), 7.76 (s, 1H), 7.69 (d, 9.0 Hz, 1H), 7.56 (s, 1H), 7.26 (t, 8.7 Hz, 1H), 7.17 (s, 1H), 6.67 (s, 1H), 6.07 (s, 1H).	545	D	
I-668		Cn1ccc2ccc(cc12)C(=O)Nc1cc(Br)cc2C(=O)NC(c12)c1cc(F)ccc1Cl	1H NMR (400 MHz, Chloroform-d) 7.80 (s, 1H), 7.64 (d, 8.3 Hz, 1H), 7.48 (d, 1.6 Hz, 1H), 7.46 (s, 1H), 7.28 (s, 1H), 7.25 - 7.16 (m, 1H), 7.09 - 6.97 (m, 2H), 6.87 (d, 15.2 Hz, 2H), 6.66 - 6.26 (m, 1H), 3.85 (s, 3H).	512.05	D	
I-669		Fc1cc(cc(c1)C(F)(F)F)C(=O)Nc1cc(Br)cc2C(=O)N[C@H](c12)c1cccc(F)c1Cl	1H NMR (400 MHz, DMSO-d6) 10.55 (s, 1H), 9.33 (s, 1H), 7.96 (d, 8.4 Hz, 1H), 7.84 (d, 1.7 Hz, 1H), 7.76 (s, 1H), 7.69 (d, 9.0 Hz, 1H), 7.56 (s, 1H), 7.26 (t, 8.7 Hz, 1H), 7.17 (s, 1H), 6.67 (s, 1H), 6.07 (s, 1H).	545	A	





I-670		Cn1ccc2c(cccc12)C(=O)Nc1cc(Br)cc2C(=O)NC(c12)c1cc(F)ccc1Cl	1H NMR (400 MHz, Methanol-d4) 7.61 (dt, 8.2, 0.9 Hz, 1H), 7.56 - 7.35 (m, 2H), 7.35 - 7.16 (m, 3H), 7.18 - 6.50 (m, 5H), 3.86 (s, 3H).	512.05	E	
I-671		Fc1ccc(F)c(c1)[C@H]1NC(=O)c2cc(Br)cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	1H NMR (400 MHz, DMSO-d6) 10.59 (s, 1H), 9.27 (s, 1H), 7.98 (d, 8.6 Hz, 1H), 7.82 (d, 1.8 Hz, 1H), 7.78 - 7.70 (m, 2H), 7.68 (s, 1H), 7.09 (dt, 9.7, 4.0 Hz, 2H), 6.88 (dd, 8.1, 4.7 Hz, 1H), 5.85 (s, 1H).	529	D	
I-672		Fc1cc(cc(c1)C(F)(F)F)C(=O)Nc1cc(Br)cc2C(=O)NC(c12)c1cccc(F)c1Cl	1H NMR (400 MHz, DMSO-d6) 10.55 (s, 1H), 9.33 (s, 1H), 7.96 (d, 8.4 Hz, 1H), 7.84 (d, 1.7 Hz, 1H), 7.76 (s, 1H), 7.69 (d, 9.0 Hz, 1H), 7.56 (s, 1H), 7.26 (t, 8.7 Hz, 1H), 7.17 (s, 1H), 6.67 (s, 1H), 6.07 (s, 1H).	545	A	
I-673		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(NC(=O)c3cncc4ccccc34)c12	1H NMR (400 MHz, Methanol-d4) 9.35 (d, 0.8 Hz, 1H), 8.20 (dd, 7.7, 1.4 Hz, 1H), 8.10 (d, 8.5 Hz, 1H), 7.98 (d, 1.7 Hz, 2H), 7.82 (dddd, 26.6, 8.1, 6.9, 1.3 Hz, 3H), 7.45 (dd, 8.9, 5.0 Hz, 1H), 7.17 (ddd, 8.9, 7.7, 3.0 Hz, 1H), 6.69 (s, 1H), 6.30 (s, 1H).	510	D	
I-674		Fc1ccc(F)c(c1)[C@@H]1NC(=O)c2cc(Br)cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	1H NMR (400 MHz, DMSO-d6) 10.59 (s, 1H), 9.27 (s, 1H), 7.98 (d, 8.5 Hz, 1H), 7.82 (d, 1.7 Hz, 1H), 7.78 - 7.70 (m, 2H), 7.68 (s, 1H), 7.14- 7.02 (m, 2H), 6.92 - 6.84 (m, 1H), 5.85 (s, 1H).	531	B	





I-675		Fc1ccc(F)c(c1)C1NC(=O)c2cc(Br)cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	1H NMR (400 MHz, DMSO-d6) 10.58 (s, 1H), 9.27 (s, 1H), 7.98 (d, 8.5 Hz, 1H), 7.82 (d, 1.8 Hz, 1H), 7.78-7.71 (m, 2H), 7.68 (s, 1H), 7.09 (dq, 8.0, 3.0 Hz, 2H), 6.88 (s, 1H), 5.85 (s, 1H).	529	A	
I-676		Fc1cc(cc(c1)C(F)(F)F)C(=O)Nc1cc(Br)cc2C(=O)N[C@@H](c12)c1cc(F)c(F)cc1Cl	1H NMR (400 MHz, DMSO-d6) 10.58 (s, 1H), 9.29 (s, 1H), 7.99 (d, 8.5 Hz, 1H), 7.83 (d, 1.7 Hz, 1H), 7.81 - 7.71 (m, 2H), 7.63 (s, 1H), 7.57 (dd, 10.4, 7.3 Hz, 1H), 6.98 (s, 1H), 5.94 (s, 1H).	562.9	D	
I-677		Fc1cc(cc(c1)C(F)(F)F)C(=O)Nc1cc(Br)cc2C(=O)N[C@H](c12)c1cc(F)c(F)cc1Cl	1H NMR (400 MHz, DMSO-d6) 10.58 (s, 1H), 9.32 - 9.27 (m, 1H), 7.98 (d, 8.8 Hz, 1H), 7.83 (d, 1.7 Hz, 1H), 7.81 - 7.71 (m, 2H), 7.63 (s, 1H), 7.57 (dd, 10.4, 7.2 Hz, 1H), 6.91 (s, 1H), 5.94 (s, 1H).	562.9	A	
I-678		Fc1cc(cc(c1)C(F)(F)F)C(=O)Nc1cc(Br)cc2C(=O)NC(c12)c1cc(F)c(F)cc1Cl	1H NMR (400 MHz, DMSO-d6) 10.58 (s, 1H), 9.29 (s, 1H), 7.99 (d, 8.4 Hz, 1H), 7.86 - 7.81 (m, 1H), 7.81 - 7.72 (m, 2H), 7.63 (s, 1H), 7.57 (dd, 10.4, 7.3 Hz, 1H), 6.91 (s, 1H), 5.93 (s, 1H).	562.95	A	
I-679		Fc1cc(cc(c1)C(F)(F)F)C(=O)Nc1cc(Br)cc2C(=O)N[C@@H](c12)c1c(F)cccc1Cl	1H NMR (400 MHz, DMSO-d6) 10.61 (d, 15.9 Hz, 1H), 9.24 (d, 57.4 Hz, 1H), 8.00 - 7.93 (m, 1H), 7.83 (dd, 5.3, 1.7 Hz, 1H), 7.74 - 7.60 (m, 3H), 7.27 (qd, 8.2, 5.9 Hz, 1H), 7.20 - 6.91 (m, 2H), 6.16 (d, 1.9 Hz, 1H).	544.9	D	





I-680		Fc1cc(cc(c1)C(F)(F)F)C(=O)Nc1cc(Br)cc2C(=O)N[C@H](c12)c1c(F)cccc1Cl	1H NMR (400 MHz, DMSO-d6) 10.61 (d, 15.9 Hz, 1H), 9.24 (d, 57.5 Hz, 1H), 7.97 (d, 8.4 Hz, 1H), 7.83 (dd, 5.3, 1.7 Hz, 1H), 7.74 - 7.60 (m, 3H), 7.27 (qd, 8.1, 5.9 Hz, 1H), 7.20 - 6.92 (m, 2H), 6.16 (d, 2.0 Hz, 1H).	544.9	A	
I-681		Fc1cc(cc(c1)C(F)(F)F)C(=O)Nc1cc(Br)cc2C(=O)NC(c12)c1c(F)cccc1Cl	1H NMR (400 MHz, DMSO-d6) 10.62 (d, 15.8 Hz, 1H), 9.25 (d, 57.4 Hz, 1H), 7.96 (d, 8.5 Hz, 1H), 7.83 (dd, 5.4, 1.8 Hz, 1H), 7.75 - 7.59 (m, 3H), 7.28 (td, 8.4, 6.1 Hz, 1H), 7.20 - 6.91 (m, 2H), 6.16 (s, 1H).	544.95	D	
I-682		Fc1cc(cc(c1)C(F)(F)F)C(=O)Nc1cc(Br)cc2C(=O)N[C@H](c12)c1cccc(F)c1F	1H NMR (400 MHz, DMSO-d6) 10.58 (s, 1H), 9.30 (s, 1H), 7.98 (d, 8.4 Hz, 1H), 7.84 (d, 1.7 Hz, 1H), 7.79 (d, 1.8 Hz, 1H), 7.73 (d, 9.0 Hz, 1H), 7.63 (s, 1H), 7.35 - 7.24 (m, 1H), 7.05 - 6.95 (m, 1H), 6.80 (t, 7.0 Hz, 1H), 5.95 (s, 1H).	528.95	B	
I-683		Fc1cc(cc(c1)C(F)(F)F)C(=O)Nc1cc(Br)cc2C(=O)N[C@@H](c12)c1cccc(F)c1F	1H NMR (400 MHz, DMSO-d6) 10.58 (s, 1H), 9.30 (s, 1H), 8.02 - 7.95 (m, 1H), 7.84 (d, 1.8 Hz, 1H), 7.79 (d, 1.8 Hz, 1H), 7.73 (d, 8.8 Hz, 1H), 7.63 (s, 1H), 7.29 (q, 8.9 Hz, 1H), 7.00 (q, 7.9 Hz, 1H), 6.80 (t, 7.0 Hz, 1H), 5.95 (s, 1H).	528.95	D	
I-684		Fc1cc(cc(c1)C(F)(F)F)C(=O)Nc1cc(Br)cc2C(=O)NC(c12)c1cccc(F)c1F	1H NMR (400 MHz, DMSO-d6) 10.58 (s, 1H), 9.31 (s, 1H), 7.99 (d, 8.5 Hz, 1H), 7.84 (d, 1.7 Hz, 1H), 7.79 (t, 2.2 Hz, 1H), 7.73 (d, 9.0 Hz, 1H), 7.62 (s, 1H), 7.29 (q, 8.8 Hz, 1H), 7.03 - 6.95 (m, 1H), 6.84 - 6.76 (m, 1H), 5.95 (s, 1H).	528.95	D	





I-685		CN1CCN(CC1(C)C)C(=O)Nc1cc(Br)cc2C(=O)NC(c12)c1cc(F)ccc1Cl	1H-NMR (400 MHz, DMSO-d6) 9.16 (s, 1H), 8.49 (s, 1H), 7.59 (d, 1.4 Hz, 1H), 7.53 (d, 1.5 Hz, 1H), 7.51-7.44 (m, 1H), 7.23 (td, 8.4, 3.0 Hz, 1H), 6.61 (br. s, 1H), 6.01 (br. s, 1H), 3.23-3.16 (m, 1H), 3.02-2.96 (m, 1H), 2.92 (d, 13.4 Hz, 1H), 2.76 (d, 12.6 Hz, 1H), 2.32-2.20 (m, 2H), 2.06 (s, 3H), 0.84 (s, 3H), 0.69 (s, 3H). Partial formate salt. Presence of racemic impurity derived from piperazine (possibly the carbamic acid), includes-´ 4.01 (t, 6.2 Hz, 2H), 3.66 (t, 6.4 Hz, 2H), 2.10 (s, 3H), 0.90 (s, 3H).	511.3	E	
I-686		CC1CN(CCN1C)C(=O)Nc1cc(Br)cc2C(=O)NC(c12)c1cc(F)ccc1Cl	1H-NMR (400 MHz, DMSO-d6) as a ca. 1:1 mixture of diastereomers, 9.16 (br. s, 2H), 8.63 (br. s, 1H), 8.61 (br. s, 1H), 7.58 (d, 1.4 Hz, 2H), 7.49 (br. d, 1.5 Hz, 2H), 7.48 (br. d, 1.3 Hz, 2H), 7.25 (td, 8.5, 3.0 Hz, 2H), 6.56 (br. s, 2H), 5.97 (br. s, 2H), 3.69-3.64 (m, 1H), 3.64-3.43 (m, 4H), 2.79-2.70 (m, 1H), 2.62-2.52 (m, 1H), 2.34 (dd, 12.9, 10.6 Hz, 1H), 2.18-2.12 (m, 1H), 2.11 (s, 6H), 1.90-1.82 (m, 1H), 1.80-1.72 (m, 1H), 1.72-1.65 (m, 1H), 1.62-1.52 (m, 1H), 1.49-1.36 (m, 1H), 0.89 (d, 6.2 Hz, 3H), 0.87 (d, 6.3 Hz, 3H).	497.3	E	





I-687		COc1ccc c(c1)C1N C(=O)c2 cccc(NC(=O)c3cc(F)cc(c3) C(F)(F)F)c12	NMR (400 MHz, DMSOd6) 10.42 (s, 1H), 9.07 (s, 1H), 7.96 (d, 8.5 Hz, 1H), 7.70 (d, 8.2 Hz, 1H), 7.67 (m, 2H), 7.59 (t, 7.6 Hz, 1H), 7.49 (d, 7.7 Hz, 1 H), 7.08 (t, 7.9 Hz, 1H), 6.75 (dd, 8.2, 2.4 Hz, 1H), 6.53 (bs, 1H), 6.48 (d, 7.7 Hz, 1H), 5.68 (s, 1H), 3.48 (s, 3H).	445.2	E	
I-688		Fc1ccc(C l)c(c1)C1 NC(=O)c 2cc(Cl)cc (NC(=O) c3cc(F)cc (c3)C(F)(F)F)c12	NMR (400 MHz, CD3CN) 8.64 (br s,1H), 7.74 (d, 1.8 Hz, 1H), 7.63 (d, 6.0 Hz, 1H), 7.60 (s, 1H), 7.56 (d, 6.0 Hz, 1H), 7.53 (s, 1H), 7.30 (br s, 1H), 7.25 (dd, 8.8, 5.2 Hz, 1H), 6.96 (td, 8.4, 3.1 Hz, 1H), 6.66 (br s, 1H), 6.09 (br s, 1H).	542.3	A	
I-689		Fc1ccc(C l)c(c1)C1 NC(=O)c 2nc(cc(N C(=O)c3 cc(F)cc(c 3)C(F)(F) F)c12)C1 COC1	1H NMR (400 MHz, DMSO-d6) 9.29 (s, 1H), 8.40 (s,1H), 7.89-7.64 (m, 4H), 7.37 (dd, 8.9, 5.2 Hz, 1H), 7.09 (td, 8.4, 3.1 Hz, 1H), 6.75 (br s, 1H), 5.96 (s, 1H), 4.94 (dd, 8.5, 5.5 Hz , 2H), 4.89 (dd, 6.7, 5.7 Hz, 1H), 4.83 (dd, 6.7, 5.7 Hz, 1H), 4.53 - 4.40 (m, 1H).	524.1	B	
I-690		COCc1cc 2C(=O)N [C@@H] (c2c(NC(=O)c2cc(F)cc(c2) C(F)(F)F)c1)c1cc(F)ccc1Cl	NMR (400 MHz, ACN) 8.61 (s, 1H), 7.69 (s, 1H), 7.65 (d, 8.5 Hz, 1H), 7.61-7.55 (m, 2H), 7.53 (s, 1H), 7.25 (dd, 8.9, 5.1 Hz, 1H), 7.22 (br s, 1H), 6.97 (ddd, 8.8, 8.0, 3.1 Hz, 1H), 6.64 (br s, 1H), 6.11 (br s, 1H), 4.59 (s, 2H), 3.41 (s, 3H).	511.2	B	





I-691		COCc1cc2C(=O)N[C@H](c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	NMR (400 MHz, ACN) 8.61 (s, 1H), 7.69 (s, 1H), 7.65 (d, 8.5 Hz, 1H), 7.61-7.55 (m, 2H), 7.53 (s, 1H), 7.25 (dd, 8.9, 5.1 Hz, 1H), 7.22 (br s, 1H), 6.97 (ddd, 8.8, 8.0, 3.1 Hz, 1H), 6.64 (br s, 1H), 6.11 (br s, 1H), 4.59 (s, 2H), 3.41 (s, 3H).	511.2	A	A
I-692		Cc1ccccc1C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)C(F)F	NMR (400 MHz, DMSO) 10.49 (s, 1H), 9.24 (s, 1H), 7.87 (d, 8.6 Hz, 1H), 7.82 (d, 0.8 Hz, 1H), 7.73 (s, 1H), 7.46 (d, 8.5 Hz, 1H), 7.31 (s, 1H), 7.21 (t, 55.6 Hz, 1H), 7.04 (td, 7.5, 1.3 Hz, 1H), 6.97 (d, 6.7 Hz, 1H), 6.92 (t, 7.6 Hz, 1H), 6.48 (br s, 1H), 5.94 (s, 1H), 2.20 (br s, 3H).	479.2	B	
I-693		Cc1ccccc1C1NC(=O)c2cc(Br)cc(NC(=O)c3cncc(n3)C(F)(F)F)c12	NMR (400 MHz, CDCl3) 9.65 (s, 1H), 9.15 (s, 1H), 8.92 (s, 1H), 8.37 (br. d, 7.7 Hz, 1H), 7.86 (dd, 7.6, 0.8 Hz, 1H), 7.69 (t, 7.8 Hz, 1H), 7.42 (dd, 8.8, 4.9 Hz, 1H), 7.00 (ddd, 8.9, 7.5, 3.0 Hz, 1H), 6.68 (s, 1H), 6.59 (br. s, 1H), 6.26 (s, 1H), 1.63 (br. s, 3H).	492.3	E	
I-694		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(NC(=O)c3cc(Cl)cc(F)c3Cl)c12	NMR (400 MHz, DMSO-d6) 10.46 (br. s, 1H), 9.31 (br. s, 1H), 7.84 (d, 9.6 Hz, 1H), 7.80 (d, 1.6 Hz, 1H), 7.72 (d, 1.4 Hz, 1H), 7.46 (dd, 8.3, 5.3 Hz, 1H), 7.30 (d, 6.7 Hz, 1H), 7.24 (ddd, 8.8, 8.0, 3.1 Hz, 1H), 6.67 (br. s, 1H), 5.98 (br. s, 1H),	547	D	





I-695		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(NCC3(CC3)C#N)cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	1H NMR (400 MHz, DMSO-d6) 10.32 (s, 1H), 8.94 (s, 1H), 7.92 (d, 8.3 Hz, 1H), 7.70 (d, 8.9 Hz, 1H), 7.62 (s, 1H), 7.28 (dd, 8.8, 5.2 Hz, 1H), 7.06 (td, 8.5, 2.9 Hz, 1H), 6.92 (d, 1.6 Hz, 1H), 6.79 (s, 1H), 6.62 (br s, 1H), 6.57 (br t, 5.6 Hz, 1H), 5.84 (br s, 1H), 3.30 (m, 2H), 1.33-1.17 (m, 2H), 1.14-0.98 (m, 2H).	559.5	A	
I-696		CC(C)(O)Cc1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(CC(C)(C)O)c2)c1)c1cc(F)ccc1Cl	NMR (400 MHz, DMSO) 10.13 (s, 1H), 9.03 (s, 1H), 7.52 (s, 1H), 7.37-7.28 (m, 3H), 7.22 (d, 9.7 Hz, 1H), 7.11 (m, 2H), 6.61 (s, 1H), 6.00 (s, 1H), 4.45 (s, 1H), 4.42 (s, 1H), 2.82 (d, 12.7 Hz, 1H), 2.77 (d, 13.4 Hz, 1H)., 2.67 (s, 2H), 1.12 (s, 3H), 1.09 (s, 3H), 1.05 (s, 3H), 1.04 (s, 3H).	543	E	
I-697		CCOC(=O)Cc1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(CC(=O)OCC)c2)c1)c1cc(F)ccc1Cl	NMR (400 MHz, DMSO) 10.23 (s, 1H), 9.12 (s, 1H), 7.59 (s, 1H), 7.41 (s, 1H), 7.36-7.32 (m, 3H), 7.18 (m, 1H), 7.12 (td, 8.5, 3.2 Hz, 1H), 6.58 (br s, 1H), 5.99 (br s, 1H), 4.12 (q, 7.1, 2H), 4.11 (q, 7.1, 2H), 3.90 (d, A of AB, 16 Hz, 1H), 3.85 (d, B of AB, 16 Hz, 1H), 3.74 (s, 2H), 1.21 (t, 7.1, 3H), 1.20 (tt, 7.1, 3H).	571	D	
I-698		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(NC(=O)N3CCOCC(F)(F)C3)c12	1H-NMR (400 MHz, DMSO-d6)-9.22 (s, 1H), 8.66 (s, 1H), 7.66 (d, 1.6 Hz, 1H), 7.55 (d, 1.7 Hz, 1H), 7.53-7.47 (m, 1H), 7.23 (td, 8.4, 3.1 Hz, 1H), 6.57 (br. s, 1H), 6.04 (br s, 1H), 4.17 (dt, 15.4, 11.2 Hz, 1H), 3.77-3.53 (m, 4H), 3.52-3.41 (m,	518.2	E	




			2H), 3.19 (ddd, 14.6, 8.0, 3.6 Hz, 1H).			
I-699		CC(C)n1cc(ccc1=O)-c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	1H NMR (DMSO-d6, 500 MHz):-′ = 10.54 (s, 1H), 9.17 (br s, 1H), 8.17 (d, 2.7 Hz, 1H), 7.94-7.98 (m, 2H), 7.88 (dd, 9.5, 2.6 Hz, 1H), 7.68-7.78 (m, 3H), 7.32 (dd, 8.9, 5.2 Hz, 1H), 7.10 (td, 8.4, 3.1 Hz, 1H), 6.55-6.84 (m, 1H), 6.52 (d, 9.5 Hz, 1H), 6.00 (br s, 1H), 5.12 (quin, 6.8 Hz, 1H), 1.40 (dd, 6.9, 2.9 Hz, 6H)	602.1	A	
I-700		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1ccc(=O)n(c1)C1CC1	1H NMR (DMSO-d6, 500 MHz) 10.53 (s, 1H), 9.16 (br s, 1H), 7.93-7.98 (m, 2H), 7.91 (d, 1.2 Hz, 1H), 7.88 (dd, 9.5, 2.7 Hz, 1H), 7.76 (br d, 8.2 Hz, 1H), 7.70 (s, 2H), 7.32 (dd, 8.9, 5.1 Hz, 1H), 7.10 (td, 8.4, 3.1 Hz, 1H), 6.54-6.76 (m, 1H), 6.51 (d, 9.3 Hz, 1H), 6.01 (br s, 1H), 3.38-3.43 (m, 1H), 0.99-1.05 (m, 4H)	600.1	A	
I-701		Cn1cc(ccc1=O)-c1cc2C(=O)N[C@@H](c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	^{1}H NMR (400 MHz, DMSO-d_6) δ 10.90 (s, 1H), 9.52 (s, 1H), 8.62 (d, *J* = 1.5 Hz, 1H), 8.18 (dd, *J* = 8.6, 1.6 Hz, 1H), 7.98 (d, *J* = 8.7, 1H), 7.87 (s, 1H), 7.75 (d, *J* = 8.5, 1H), 7.67 (s, 1H), 7.35 (m, 1H), 7.10 (td, 8.6, 1.6 Hz, 1H), 6.57 (d, *J* = 8.8 Hz, 1H), 6.02 (s, 1H), 3.59 (s, 3H).	574.3	C	
I-702		Cn1cc(ccc1=O)-c1cc2C(=O)N[C@H](c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1c	^{1}H NMR (400 MHz, DMSO-d_6) δ 10.90 (s, 1H), 9.52 (s, 1H), 8.62 (d, *J* = 1.5 Hz, 1H), 8.18 (dd, *J* = 8.6, 1.6 Hz, 1H), 7.98 (d, *J* = 8.7, 1H), 7.87 (s, 1H), 7.75 (d, *J* = 8.5, 1H), 7.67 (s, 1H), 7.35 (m,	574.2	A	





		c(F)ccc1Cl	1H), 7.10 (td, 8.6, 1.6 Hz, 1H), 6.57 (d, *J* = 8.8 Hz, 1H), 6.02 (s, 1H), 3.59 (s, 3H).			
I-703		CCn1cc(ccc1=O)-c1cc2C(=O)N[C@@H](c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl		588.2	E	
I-704		CCn1cc(ccc1=O)-c1cc2C(=O)N[C@H](c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl		588.4	A	
I-705		COc1ccc(cn1)-c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl		574	A	
I-706		OC1(Cc2cc3C(=O)NC(c3c(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c2)c2cc(F)ccc2Cl)CCC1	1H NMR (500 MHz, DMSO-d6) 1.48 - 1.67 (m, 2H), 1.88 - 2.03 (m, 4H), 2.94 (d, 15.26 Hz, 2H), 5.10 (s, 1H), 5.79 - 6.05 (m, 1H), 7.07 (td, 8.32, 3.05 Hz, 1H), 7.29 (dd, 8.85, 5.19 Hz, 1H), 7.38 (s, 1H), 7.63 (d, 17.85 Hz, 2H), 7.72 (br d, 8.85 Hz, 1H), 7.91 (br d, 8.39 Hz, 1H), 9.04 (br s, 1H), 10.44 (s, 1H)	551.41	A	





I-707		OCCNc1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	1H NMR (500 MHz, DMSO-d6) 3.16 (q, 5.80 Hz, 2 H) 3.55 - 3.63 (m, 2 H) 4.75 (br t, 4.43 Hz, 1 H) 6.13 - 6.18 (m, 1 H) 6.69 (s, 1 H) 6.75 (br s, 1 H) 6.82 (d, 1.83 Hz, 1 H) 7.04 (td, 8.28, 2.98 Hz, 1 H) 7.26 (dd, 8.85, 5.19 Hz, 1 H) 7.61 (s, 1 H) 7.66 - 7.71 (m, 1 H) 7.89 (br d, 8.09 Hz, 1 H) 8.50 (s, 1 H) 8.87 (br s, 1 H) 10.26 (s, 1 H)	526.4	A	
I-708		CC(=O)COc1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	1H NMR (DMSO-d6, 500 MHz) 10.3-10.6 (m, 1H), 9.0-9.2 (m, 1H), 7.8-8.0 (m, 1H), 7.63 (s, 2H), 7.2-7.4 (m, 1H), 7.1-7.2 (m, 1H), 7.0-7.1 (m, 2H), 5.8-6.1 (m, 1H), 4.9-5.2 (m, 2H), 2.1-2.3 (m, 3H), 1.0-1.3 (m, 3H)	539	A	
I-709		CC(C)(O)COc1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1ccc(F)ccc1Cl	1H NMR (DMSO-d6, 500 MHz) 10.3-10.5 (m, 1H), 9.0-9.2 (m, 1H), 7.9-8.1 (m, 1H), 7.7-7.8 (m, 1H), 7.6-7.7 (m, 1H), 7.3-7.4 (m, 1H), 7.1-7.2 (m, 1H), 7.0-7.1 (m, 2H), 6.3-6.8 (m, 1H), 5.7-6.1 (m, 1H), 4.5-4.8 (m, 1H), 3.7-3.9 (m, 2H), 1.1-1.4 (m, 6H)	555	A	
I-710		CC1(Cc2cc3C(=O)NC(c3c(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c2)c2cc(F)ccc2Cl)COC1	1H NMR (400 MHz, DMSO-d6) 1.24 (s, 2 H) 1.25 - 1.25 (m, 1 H) 2.83 - 3.16 (m, 3 H) 4.23 (d, 5.56 Hz, 2 H) 4.58 (t, 5.68 Hz, 2 H) 5.76 - 6.07 (m, 1 H) 7.09 (td, 8.46, 3.03 Hz, 1 H) 7.28 - 7.33 (m, 2 H) 7.51 (s, 1 H) 7.65 (s, 1 H) 7.73 (br d, 8.59 Hz, 1 H) 7.94 (br d, 8.59 Hz, 1 H) 9.10 (br s, 1 H) 10.45 (s, 1 H)	551.41	A	






I-711		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(NC(=O)c3cc(F)cc4cc[nH]c34)c12			A	
I-712		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1ncc[nH]1	1H NMR (400 MHz, DMSO-d6) 12.83 (br. s, 1H), 10.65 (s, 1H), 9.22 (s, 1H), 8.37 (s, 1H), 8.27 (d, 0.7 Hz, 1H), 8.14 (d, 1.0 Hz, 1H), 7.96 (d, 8.3 Hz, 1H), 7.77 (d, 8.6 Hz), 7.69 (s, 1H), 7.32 (dd, 8.9, 5.2 Hz, 1H), 7.34-7.07 (m, 1H), 7.09 (td, 8.5, 3.0 Hz, 1H), 6.66 (br. s, 1H), 6.02 (br. s, 1H).	533.2	A	
I-713		CC(C)(O)c1cc2C(=O)N[C@H](c2c(NC(=O)N2CCc3ccccc23)c1)c1cc(F)ccc1Cl	(400 MHz, DMSO-d6) 8.99 (s, 1H), 8.55 (s, 1H), 7.71 (d, 7.9 Hz, 1H), 7.65 (d, 1.4 Hz, 1H), 7.49 (d, 1.4 Hz, 1H), 7.36 (dd, 8.9, 5.2 Hz, 1H), 7.20-7.11 (m, 2H), 7.09 (t, 7.7 Hz, 1H), 6.88 (td, 7.4, 1.0 Hz, 1H), 6.54 (br s, 1H), 5.97 (br s, 1H), 5.25 (br s, 1H), 3.93-3.83 (m, 1H), 3.09-2.93 (m, 3H), 1.49 (s, 6H) .	480.2	A	
I-714		CC(C)(O)c1cc2C(=O)N[C@@H](c2c(NC(=O)N2CCc3ccccc23)c1)c1cc(F)ccc1Cl	(400 MHz, DMSO-d6) 8.99 (s, 1H), 8.55 (s, 1H), 7.71 (d, 7.9 Hz, 1H), 7.65 (d, 1.4 Hz, 1H), 7.49 (d, 1.4 Hz, 1H), 7.36 (dd, 8.9, 5.2 Hz, 1H), 7.20-7.11 (m, 2H), 7.09 (t, 7.7 Hz, 1H), 6.88 (td, 7.4, 1.0 Hz, 1H), 6.54 (br s, 1H), 5.97 (br s, 1H), 5.25 (br s, 1H), 3.93-3.83 (m, 1H), 3.09-2.93 (m, 3H), 1.49 (s, 6H)	480.2	E	





I-715		CC(C)c1cc(F)cc(c1)C(=O)Nc1cccc2C(=O)NC(c12)c1ccccc1C	1H NMR (400 MHz, DMSO-d6) 10.03 (s, 1H), 9.05 (s, 1H), 7.65 (dd, 6.8, 1.8 Hz, 1H), 7.62-7.55 (m, 2H), 7.24 (dt, 9.9, 2.0 Hz, 1H), 7.09 (td, 7.3, 1.2 Hz, 1H), 7.03 (d, 7.1 Hz, 1H), 7.00 - 6.94 (m, 2H), 6.92 (d, 9.1 Hz, 1H), 6.55 (br s, 1H), 5.96 (s, 1H), 2.86 (sept, 6.8 Hz, 1H), 2.21 (br s, 3H), 1.18 (d, 1.7 Hz, 3H), 1.16 (d, 1.7 Hz, 3H) .	403.3	D	
I-716		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(NC(=O)N3CCNc4ccccc34)c12	(400 MHz, DMSO-d6) 9.20 (br s, 1H), 8.70 (s, 1H), 7.66-7.57 (m, 2H), 7.48 (dd, 8.7, 5.0 Hz, 1H), 7.22 (td, 8.4, 2.9 Hz, 1H), 6.76 (ddd, 8.1, 7.3, 1.4 Hz, 1H), 6.54 (dd, 8.1, 1.3 Hz, 1H), 6.19 (ddd, 8.4, 7.4, 1.4 Hz, 1H), 6.12-5.97 (m, 3H), 4.07-3.95 (m, 1H), 3.31-3.24 (m, 2H), 3.03 (t, 9.0 Hz, 1H), 2.91 (t, 9.0 Hz, 1H) .	515.1	D	
I-717		OB(O)c1cccc(c1)C1NC(=O)c2cccc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	1H NMR (400 MHz, d6-DMSO) 10.35 (s, 1H), 9.05 (s, 1H), 7.92 (s, 1H), 7.90 (s, 2H), 7.68 (dd, 7.4, 0.9 Hz, 1H), 7.66-7.61 (m, 3H), 7.58 (t, 7.6 Hz, 1H), 7.47 (d, 7.7 Hz, 1H), 7.44 (s, 1H), 7.07 (t, 7.5 Hz, 1H), 6.99 (m, 1H), 5.71 (s, 1H).	457.4	E	
I-718		Fc1cc(cc(c1)C(F)(F)F)C(=O)Nc1cccc2C(=O)NC(c12)c1cccc(c1)C1CC1	(400 MHz, d6-DMSO) 10.40 (s, 1H), 9.03 (s, 1H), 7.97 (d, 8.3 Hz, 1H), 7.70 (s, 1H), 7.69-7.64 (m, 2H), 7.59 (app t, 7.6 Hz, 1H), 7.45 (d, 7.1 Hz, 1H), 7.03 (app t, 7.7 Hz, 1H), 6.85 (d, 7.7 Hz, 1H), 6.71 (s, 1H), 6.61 (d, 7.6 Hz, 1H), 5.65 (s, 1H), 1.63-1.52 (m, 1H),	455.2	E	





			0.75-0.60 (m, 2H), 0.40-0.30 (m, 1H), 0.23-0.13 (m, 1H).			
I-719		Nc1ccc(cc1C(F)(F)F)C(=O)Nc1cc(Br)cc2C(=O)NC(c12)c1cc(F)ccc1Cl	1H NMR (400 MHz, DMSO-d6) 9.99 (s, 1H), 9.22 (s, 1H), 7.76 - 7.67 (m, 2H), 7.59 - 7.51 (m, 2H), 7.31 (dd, 8.9, 5.2 Hz, 1H), 7.08 (td, 8.4, 3.1 Hz, 1H), 6.78 (d, 8.6 Hz, 2H), 6.27 (s, 2H), 5.99 (s, 1H).	542	D	
I-720		F[C@H]1CCN(C[C@@H]1F)C(=O)Nc1cc(Br)cc2C(=O)NC(c12)c1cc(F)ccc1Cl	1H-NMR (400 MHz, DMSO-d6) as a ca. 1:1 mixture of diastereomers-´ 9.18 (br. s, 2H), 8.74 (s, 1H), 8.70 (s, 1H), 7.62-7.59 (m, 2H), 7.55 (d, 1.7 Hz, 1H), 7.48 (d, 1.7 Hz, 1H), 7.51-7.43 (m, 2H), 7.27-7.18 (m, 2H), 6.64 (br. s, 2H), 5.96 (br. s, 2H), 4.98-4.86 (m, 1H), 4.85-4.61 (m, 2H), 4.60-4.39 (m, 1H), 3.67-3.57 (m, 1H), 3.57-3.47 (m, 1H), 3.28-3.18 (m, 2H), 3.12-3.02 (m, 1H), 2.96-2.88 (m, 1H), 1.85-1.66 (m, 3H), 1.63-1.50 (m, 1H).	504.2	E	
I-721		O[C@@H]1CC[C@H]1Nc1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	1H NMR (400 MHz, CD3CN) 8.49 (d, 11.1 Hz, 1H), 7.63 (d, 8.6 Hz, 1H), 7.56 (m, 3H), 7.23 (dd, 8.8, 5.1 Hz, 1H), 7.08 (s, 1H), 7.00 (t, 1.9 Hz, 1H), 6.97-6.92 (m, 1H), 6.85 (s, 1H), 6.64 (s, 1H), 5.96 (s, 1H), 5.19 (d, 6.1 Hz, 1H), 3.90 (dd, 15.2, 7.9 Hz, 1H), 3.67 (m, 1H), 1.62-1.44 (m 1H), 1.35-1.18 (m, 3H).	552.2	A	





I-722		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(NC(=O)N3CCCC4CCCC34)c12	1H NMR (400 MHz, CDCl3) 8.15 (d, 7.2 Hz, 1H), 7.78 (d, 1.3 Hz, 1H), 7.44 (dd, 8.7, 5.1 Hz, 1H), 7.08-7.04 (m, 1H), 6.64 (s, 1H), 6.42 (s, 1H), 6.09 (s, 1H), 5.99-5.96 (m, 1H), 3.81-3.61 (m, 2H), 2.72-2.58 (m, 1H), 1.86-1.71 (m, 3H), 1.69-1.52 (m, 11H), 1.51-1.39 (m, 4H), 1.37-1.24 (m, 3H), 1.21-1.12 (m, 1H).	508	B	
I-723		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)N1CC(C1)C#N	NMR (400 MHz, CD3CN) 8.49 (s, 1H), 7.62 (d, 8.5 Hz, 1H), 7.55 (d, 8.9 Hz, 1H), 7.52 (s, 1H), 7.22 (dd, 8.9, 5.1 Hz, 1H), 7.12 (br s, 1H), 6.97-6.90 (m), 6.79 (d, 2.0 Hz, 1H), 6.65 (s, 1H), 6.59 (br s, 1H), 5.99 (br s, 1H), 4.24-4.17 (m, 2H), 4.13-4.07 (m, 2H), 3.68 (m, 1H).	547.3	A	
I-724		Fc1ccc(Cl)c(c1)C1NC(=O)c2cccc(NC(=O)c3cc(cc(Cl)n3)C(F)(F)F)c12	1H-NMR (400 MHz, DMSO-d6) 10.29 (br. s, 1H), 9.14 (br. s, 1H), 8.33 (s, 1H), 8.15 (s, 1H), 7.75 (dd, 7.5, 0.9 Hz, 1H), 7.70-7.60 (m, 1H), 7.32 (dd, 8.8, 5.0 Hz, 1H), 7.07 (td, 8.5, 2.9 Hz, 1H), 6.58 (br. s, 1H), 6.11 (br. s, 1H).	484.2	D	
I-725		Fc1ccc(Cl)c(c1)C1NC(=O)c2cccc(NC(=O)c3cc(Cl)cc(c3)C(F)(F)F)c12	1H NMR (400 MHz, DMSO-d6) 10.52 (br. s, 1H), 9.15 (br. s, 1H), 8.11 (s, 1H), 7.87 (s, 1H), 7.76 (s, 1H), 7.71 (d, 7.1 Hz, 1H), 7.64 (t, 7.6 Hz, 1H), 7.49 (d, 7.5 Hz, 1H), 7.32 (dd, 8.9, 5.2 Hz, 1H), 7.10 (td, 8.4, 3.0 Hz, 1H), 6.52 (br. s, 1H), 5.98 (br. s, 1H).	483.1	C	






I-726		Nc1cc(cc(n1)C(=O)Nc1cccc2C(=O)NC(c12)c1cc(F)ccc1Cl)C(F)(F)F	1H NMR (400 MHz, DMSO-d6) 9.86 (s, 1H), 9.14 (s, 1H), 7.86 (dd, 6.7, 2.2 Hz, 1H), 7.64-7.60 (m, 2H), 7.41-7.32 (m, 1H), 7.22 (s, 1H), 7.11 (td, 8.4, 3.0 Hz, 1H), 6.97-6.95 (m, 1H), 6.63 (br. s, 2H), 6.63 (br. s, 1H), 6.12 (br. s, 1H).	465.2	D	
I-727		Cn1c2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)cc1=O)c1cc(F)ccc1Cl	(400 MHz, DMSO-d6) 8.35 (s, 1H), 8.12-8.01 (m, 1H), 7.95 (d, 8.7 Hz, 1H), 7.83 (br. s, 2H), 7.57 (br. s, 1H), 7.27 (ddd, 8.8, 8.0, 3.1 Hz, 1H), 6.42 (br. s, 1H), 5.68 (s, 1H), 3.56 (s, 3H)	498.3	E	
I-728		COC1CN(C1)c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	NMR (400 MHz, CD3CN) 8.49 (s, 1H), 7.63 (d, 8.6 Hz, 1H), 7.57 (d, 9.2 Hz, 1H), 7.55 (s, 1H), 7.24 (dd, 8.8, 5.2 Hz, 1H), 7.11 (br s, 1H), 6.99-6.89 (m, 1H), 6.76 (d, 2.0 Hz, 1H), 6.63 (br s, 2H), 6.01 (br s, 1H), 4.39-4.33 (m, 1H), 4.27-4.07 (m, 2H), 3.95-3.65 (m, 2H), 3.31 (s, 3H).	552.3	B	
I-729		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)N1CC2(COC2)C1	NMR (400 MHz, DMSO-d6) 10.35 (s, 1H), 9.00 (br. s, 1H), 7.93 (d, 8.4 Hz, 1H), 7.71 (d, 8.9 Hz, 1H), 7.64 (s, 1H), 7.29 (dd, 8.9, 5.2 Hz, 1H), 7.06 (td, 8.3, 3.1 Hz, 1H), 6.67 (d, 2.0 Hz, 1H), 6.52 (d, 1.5 Hz, 1H), 6.63-6.44 (br. s, 1H) 5.87 (br. s, 1H), 4.77-4.71 (m, 4H), 4.12-4.03 (m, 4H).	564.3	A	






I-730		CC(C)(O)CNc1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	1H NMR (500 MHz, DMSO-d6) 1.19 (s, 6 H) 3.02 (dd, 5.72, 1.30 Hz, 2 H) 5.82 (br s, 1 H) 5.96 (br t, 5.19 Hz, 1 H) 6.78 (d, 1.37 Hz, 1 H) 6.90 (d, 1.98 Hz, 1 H) 7.05 (td, 8.39, 3.05 Hz, 1 H) 7.27 (dd, 8.85, 5.19 Hz, 1 H) 7.63 (s, 1 H) 7.69 (br d, 9.77 Hz, 1 H) 7.90 (br d, 8.39 Hz, 1 H) 8.86 (br s, 1 H) 10.18 - 10.31 (m, 1 H)	554.36	A	
I-731		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(NC(=O)c3coc4c(F)cc(F)cc34)c12	1H NMR (500 MHz, DMSO-d6) 6.03 (br s, 1 H) 7.05 (td, 8.35, 3.13 Hz, 1 H) 7.29 (dd, 8.85, 5.19 Hz, 1 H) 7.38 - 7.55 (m, 2 H) 7.70 (s, 1 H) 7.80 (d, 1.53 Hz, 1 H) 8.48 (s, 1 H) 9.26 (br s, 1 H) 10.32 (br s, 1 H)	537.25	A	
I-732		Cc1ncc(cn1)-c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl		559	A	
I-733		Fc1ccc(Cl)c(c1)[C@H]1NC(=O)c2cc(Br)cc(NC(=O)c3csc4ccccc34)c12		517.3	D	
I-734		Fc1ccc(Cl)c(c1)[C@@H]1NC(=O)c2cc(Br)cc(NC(=O)c3csc4ccccc34)c12		517.3	A	






I-735		CS(=O)(=O)CCCOc1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	1H NMR (DMSO-d6, 400 MHz) 10.3-10.4 (m, 1H), 10.0-10.1 (m, 1H), 7.8-8.0 (m, 1H), 7.6-7.7 (m, 1H), 7.5-7.6 (m, 1H), 7.2-7.3 (m, 1H), 7.1-7.1 (m, 1H), 7.0-7.0 (m, 1H), 6.9-7.0 (m, 1H), 6.8-6.9 (m, 1H), 6.2-6.6 (m, 1H), 5.8-6.1 (m, 1H), 4.3-4.5 (m, 2H), 3.2-3.5 (m,2H) 3.0-3.0 (m, 3H), 2.1-2.3 (m, 2H)	603	B	
I-736		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1ccc2nccn2c1		583	A	
I-737		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1ccc2nccccc2c1		594	A	
I-738		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1ccc2OC(F)(F)Oc2c1		623	B	





I-739		CC(C)(O)COc1cc2C(=O)N[C@@H](c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	1H NMR (DMSO-d6, 400 MHz) 10.3-10.5 (m, 1H), 8.9-9.2 (m, 1H), 7.8-8.1 (m, 1H), 7.7-7.8 (m, 1H), 7.6-7.7 (m, 1H), 7.2-7.3 (m, 1H), 7.1-7.2 (m, 1H), 7.0-7.1 (m, 2H), 6.2-6.9 (m, 1H), 5.7-6.1 (m, 1H), 4.6-4.7 (m, 1H), 4.0-4.1 (m, 2H), 1.1-1.3 (m, 6H)	555	D	
I-740		CC(C)(O)COc1cc2C(=O)N[C@H](c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	1H NMR (DMSO-d6, 400 MHz) 10.3-10.6 (m, 1H), 8.9-9.3 (m, 1H), 7.9-8.0 (m, 1H), 7.7-7.8 (m, 1H), 7.6-7.7 (m, 1H), 7.2-7.4 (m, 1H), 7.1-7.2 (m, 1H), 7.0-7.1 (m, 2H), 6.2-6.9 (m, 1H), 5.7-6.1 (m, 1H), 4.6-4.8 (m, 1H), 4.0-4.2 (m, 2H), 1.1-1.3 (m, 6H)	555	A	
I-741		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1ccc2OCOc2c1		587	A	
I-742		CC(C)n1cc(ccc1=O)-c1cc2C(=O)N[C@@H](c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl		602.4	D	





I-743		CC(C)n1cc(ccc1=O)-c1cc2C(=O)N[C@H](c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl		602.3	A	
I-744		Fc1ccc(Cl)c(c1)[C@H]1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1ccc(=O)n(c1)C1CC1		600.4	D	
I-745		Fc1ccc(Cl)c(c1)[C@@H]1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1ccc(=O)n(c1)C1CC1		600.4	A	
I-746		Fc1ccc(Cl)c(c1)[C@H]1NC(=O)c2nc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1ccc(=O)n(c1)C1CC1		601.3	D	




I-747		Fc1ccc(Cl)c(c1)[C@@H]1NC(=O)c2nc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1ccc(=O)n(c1)C1CC1		601.3	A	A
I-748		CC1(COc2cc3C(=O)NC(c3c(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c2)c2cc(F)ccc2Cl)COC1		567	A	
I-749		Cc1c(F)cccc1[C@H]1NC(=O)c2cc(Br)cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	1H NMR (400 MHz, DMSO-d6) 10.51 (s, 1H), 9.28 (s, 1H), 7.97-7.90 (m, 1H), 7.84-7.78 (m, 2H), 7.55 (d, 9.0 Hz, 1H), 7.34 (s, 1H), 7.02-6.93 (m, 2H), 6.36 (s, 1H), 5.93 (s, 1H), 2.19 (s, 3H).	527	D	
I-750		Cc1c(F)cccc1[C@@H]1NC(=O)c2cc(Br)cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	1H NMR (400 MHz, DMSO-d6) 10.50 (s, 1H), 9.28 (s, 1H), 7.93 (dt, 8.7, 2.0 Hz, 1H), 7.84-7.77 (m, 2H), 7.55 (d, 8.8 Hz, 1H), 7.35 (s, 1H), 7.03-6.92 (m, 2H), 6.38 (s, 1H), 5.93 (s, 1H), 2.17 (s, 3H).	527	B	
I-751		Cc1c(F)cccc1C1NC(=O)c2cc(Br)cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	1H NMR (400 MHz, DMSO-d6) 10.50 (s, 1H), 9.28 (s, 1H), 7.93 (d, 8.4 Hz, 1H), 7.87-7.75 (m, 2H), 7.55 (d, 8.9 Hz, 1H), 7.35 (s, 1H), 7.08-6.90 (m, 2H), 6.38 (s, 1H), 5.94 (s, 1H), 2.17 (s, 3H).	525.15	B	





I-752		Fc1ccc(Cl)c(c1)-n1[nH]c(=O)c2cc(Br)cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	1H NMR (400 MHz, CD3CN) 8.65 (s, 1H), 7.92 (d, 1.7 Hz, 1H), 7.68-7.61 (m, 1H), 7.54 7.50 (m, 3H), 7.31 (dd, 9.0, 5.5 Hz, 1H), 7.25 (dd, 8.8, 3.0 Hz, 1H), 6.92 (ddd, 9.0, 8.0, 3.0 Hz, 1H)	544.3	D	
I-753		Fc1ccc(Cl)c(c1)C1NC(=O)c2cccc(NC(=S)c3cc(F)cc(c3)C(F)(F)F)c12	(400 MHz, DMSO-d6) 7.86 (d, 7.1 Hz, 1H), 7.69 (t, 7.7 Hz, 1H), 7.60 (app d, 8.2 Hz, 1H), 7.55 (app d, 8.3 Hz, 2H), 7.38 (s, 1H), 7.33 (dd, 8.9, 5.1 Hz, 1H), 7.28-7.19 (m, 1H), 7.06 (ddd, 8.8, 8.1, 3.1 Hz, 1H), 6.69 (br s, 1H), 6.15 (br s, 1H).	481.3	C	
I-754		Fc1ccc([C@H]2NC(=O)c3cc(Br)cc(NC(=O)c4cc(F)cc(c4)C(F)(F)F)c23)c(Cl)c1	1H NMR (400 MHz, Chloroform-d) 8.46 (s, 1H), 7.93 (d, 1.6 Hz, 1H), 7.58 - 7.49 (m, 2H), 7.47 (s, 1H), 7.38 (s, 1H), 7.25 - 7.18 (m, 1H), 7.00 (s, 2H), 6.70 (s, 1H), 6.19 (s, 1H).	547	D	
I-755		Fc1ccc([C@@H]2NC(=O)c3cc(Br)cc(NC(=O)c4cc(F)cc(c4)C(F)(F)F)c23)c(Cl)c1	1H NMR (400 MHz, Chloroform-d) 8.46 (s, 1H), 7.93 (d, 1.7 Hz, 1H), 7.58 - 7.49 (m, 2H), 7.45 (s, 1H), 7.38 (s, 1H), 7.21 (dd, 7.9, 1.9 Hz, 1H), 7.01 (s, 2H), 6.69 (s, 1H), 6.19 (s, 1H).	547	B	
I-756		Fc1ccc(C2NC(=O)c3cc(Br)cc(NC(=O)c4cc(F)cc(c4)C(F)(F)F)c23)c(Cl)c1	1H NMR (400 MHz, Methanol-d4) 7.96 (d, 1.7 Hz, 1H), 7.81 - 7.68 (m, 2H), 7.69 - 7.50 (m, 2H), 7.11 (dd, 8.7, 2.5 Hz, 1H), 6.93 (s, 2H), 6.22 (s, 1H).	547	B	





I-757		Cc1ccc(F)cc1[C@H]1NC(=O)c2cc(Br)cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	1H NMR (400 MHz, DMSO-d6) 10.53 (s, 1H), 9.26 (s, 1H), 7.97-7.90 (m, 1H), 7.82 (d, 1.7 Hz, 1H), 7.77 (t, 2.0 Hz, 1H), 7.59 (d, 9.0 Hz, 1H), 7.46 (s, 1H), 7.04 (dd, 8.5, 5.9 Hz, 1H), 6.90 (td, 8.4, 2.8 Hz, 1H), 6.40 (s, 1H), 5.86 (s, 1H), 2.33 (s, 3H).	525	D	
I-758		Cc1ccc(F)cc1[C@@H]1NC(=O)c2cc(Br)cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	1H NMR (400 MHz, DMSO-d6) 10.53 (s, 1H), 9.26 (s, 1H), 7.97-7.90 (m, 1H), 7.82 (d, 1.7 Hz, 1H), 7.77 (t, 2.0 Hz, 1H), 7.59 (d, 9.0 Hz, 1H), 7.46 (s, 1H), 7.04 (dd, 8.5, 5.9 Hz, 1H), 6.90 (td, 8.4, 2.8 Hz, 1H), 6.40 (s, 1H), 5.86 (s, 1H), 2.33 (s, 3H).	525	A	
I-759		Cc1ccc(F)cc1C1NC(=O)c2cc(Br)cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	1H NMR (400 MHz, DMSO-d6) 10.53 (s, 1H), 9.26 (s, 1H), 7.97-7.90 (m, 1H), 7.82 (d, 1.7 Hz, 1H), 7.77 (t, 2.0 Hz, 1H), 7.59 (d, 9.0 Hz, 1H), 7.46 (s, 1H), 7.04 (dd, 8.5, 5.9 Hz, 1H), 6.90 (td, 8.4, 2.8 Hz, 1H), 6.40 (s, 1H), 5.86 (s, 1H), 2.33 (s, 3H).	525	A	
I-760		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(Nc3nncc4ccccc34)c12	1H NMR (400 MHz, DMSO-d6) 11.16 - 9.18 (d, 750.6 Hz, 1H), 9.13 (d, 29.5 Hz, 1H), 8.02 (d, 8.5 Hz, 1H), 7.98 - 7.80 (m, 2H), 7.80 - 7.60 (m, 3H), 7.55 - 7.13 (m, 1H), 6.95 (s, 2H), 6.73 - 6.19 (m, 1H), 5.81 (s, 1H).	483	E	
I-761		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(Nc3nccc	1H NMR (400 MHz, DMSO-d6) 9.30 (s, 1H), 9.04 (s, 1H), 8.89 (s, 1H), 8.76 (dd, 4.2, 1.6 Hz, 1H), 8.31 (dd, 8.3, 1.7 Hz, 1H), 8.13	483	E	





		4cccnc34)c12	(dd, 5.8, 1.7 Hz, 1H), 7.78 (dd, 8.3, 4.2 Hz, 1H), 7.58 (d, 1.8 Hz, 1H), 7.47 (s, 1H), 7.27 (d, 5.8 Hz, 1H), 7.16 (td, 8.3, 3.0 Hz, 1H), 6.73 (s, 1H), 6.22 (s, 1H).			
I-762		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(Nc3nccc4ccccc34)c12	1H NMR (400 MHz, Chloroform-d) 8.40 (s, 1H), 8.10 (s, 1H), 7.85 (d, 1.7 Hz, 1H), 7.77 (d, 8.3 Hz, 1H), 7.66 (ddd, 8.1, 6.8, 1.1 Hz, 1H), 7.45 (ddd, 8.3, 6.9, 1.3 Hz, 2H), 7.28 (s, 3H), 6.97 - 6.87 (m, 1H), 6.67 (dd, 8.7, 3.0 Hz, 1H), 6.49 (s, 1H), 6.17 (s, 1H).	482	D	
I-763		Fc1cc(cc(c1)C(F)(F)F)C(=O)Nc1cc(Br)cc2C(=O)NC(c12)c1cc(Cl)ccc1Cl	1H NMR (400 MHz, Methanol-d4) 7.97 (d, 1.7 Hz, 1H), 7.83-7.58 (m, 4H), 7.39 -7.18 (m, 2H), 7.00 (s, 1H), 6.07 (s, 1H).	562.85	A	
I-764		Fc1cc(cc(c1)C(F)(F)F)C(=O)Nc1cc(Br)cc2C(=O)N[C@@H](c12)c1cc(Cl)ccc1Cl	1H NMR (400 MHz, Chloroform-d) 8.40 (s, 1H), 7.98 (d, 1.7 Hz, 1H), 7.59-7.50 (m, 2H), 7.43 (s, 2H), 7.39 (d, 8.6 Hz, 1H), 7.33 (dd, 8.6, 2.4 Hz, 1H), 6.98 (s, 1H), 6.52 (s, 1H), 6.17 (s, 1H).	563.05	D	
I-765		Fc1cc(cc(c1)C(F)(F)F)C(=O)Nc1cc(Br)cc2C(=O)N[C@H](c12)c1cc(Cl)ccc1Cl	1H NMR (400 MHz, Chloroform-d) 8.40 (s, 1H), 7.98 (d, 1.7 Hz, 1H), 7.55 (td, 8.4, 7.2, 4.1 Hz, 2H), 7.43 (s, 2H), 7.39 (d, 8.6 Hz, 1H), 7.33 (dd, 8.6, 2.4 Hz, 1H), 6.98 (s, 1H), 6.49 (s, 1H), 6.17 (s, 1H).	563	A	






I-766		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(NC(=O)N3CC4CCCN4C(=O)C3)c12	NMR (400 MHz, DMSO-d6) 9.19 (s, 1H), 8.75-8.71 (m, 1H), 7.63 (dd, 6.6, 1.6 Hz, 1H), 7.46 (d, 1.6 Hz, 1H), 7.24 (ddd, 8.9, 8.1, 3.1 Hz, 1H), 7.18 (ddd, 8.9, 8.1, 3.1 Hz, 1H), 6.59 (br. s, 1H), 5.96-5.91 (m, 1H), 4.20-3.98 (m, 2H), 3.46-3.25 (m, 5H under water peak), 2.04-1.95 (m, 1H), 1.95-1.86 (m, 2H), 1.81-1.66 (m, 1H), 1.42-1.30 (m, 1H)	521.3	E	
I-767		Fc1ccc(Cl)c(c1)C1NC(=O)c2cccc(NC(=O)c3cc(Cl)cc(F)c3F)c12	NMR (400 MHz, DMSO-d6) 10.49 (br. s, 1H), 9.16 (s, 1H), 7.91 (ddd, 10.0, 6.6, 2.6 Hz, 1H), 7.70 (dd, 7.6, 0.8 Hz, 1H), 7.64 (t, 8.0 Hz, 1H), 7.50-7.46 (m, 2H), 7.25 (ddd, 8.8, 8.1, 3.1 Hz, 1H), 6.88 (dt, 4.8, 2.0 Hz, 1H), 6.56 (br. s, 1H), 6.02 (br. s, 1H)	451.2	B	
I-768		Fc1ccc(Cl)c(c1)C1NC(=O)c2cccc(NC(=O)c3cc(F)cnc3NC3CCC3)c12	NMR (400 MHz, DMSO-d6) 10.16 (s, 1H), 9.14 (s, 1H), 8.20 (d, 2.9 Hz, 1H), 8.04 (d, 7.0 Hz, 1H), 7.69 (d, 6.9 Hz, 1H), 7.63 (t, 7.6 Hz, 1H), 7.46 (d, 7.7 Hz, 1H), 7.40 (br. d, 8.9 Hz, 1H), 7.34 (dd, 8.9, 5.2 Hz, 1H), 7.12 (ddd, 8.8, 8.1, 3.1 Hz, 1H), 6.59 (br. s submerged, 1H), 6.01 (br. s, 1H), 4.47-4.36 (sx, 7.6 Hz, 1H), 2.36 - 2.25 (m, 2H), 1.91-1.77 (m, 2H), 1.77-1.62 (m, 2H).	469.4	D	
I-769		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(NC(=O)N3CCCC	NMR (400 MHz, DMSO) 9.37 (s, 1H), 9.24 - 9.16 (m, 1H), 7.81 (s, 1H), 7.67 (d, 1.6 Hz, 1H), 7.60 (d, 1.5 Hz, 1H), 7.58 (d, 1.6 Hz, 1H), 7.54-48	528	D	






		3c3ccccc3)c12	(m, 1H), 7.33-7.27 (m, 2H), 7.26-7.16 (m, 1H), 7.09-7.03 (m, 1H), 6.57 (s, 1H), 6.04 (s, 1H), 4.74 (s, 1H), 3.98 (t, 6.0 Hz, 1H), 3.62 (t, 6.3 Hz, 1H), 3.46-3.38 (m, 1H), 2.11-2.01 (m, 1H), 1.77-1.54 (m, 3H).			
I-770		Fc1ccc(Cl)c(c1)[C@H]1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)C#N		490.3	A	
I-771		Fc1ccc(Cl)c(c1)[C@@H]1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)C#N		490.3	A	
I-772		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(NC(=O)N3CCCCC3c3ccccc3)c12	NMR (400 MHz, DMSO) 9.19 (s, 2H), 8.67 (s, 1H), 8.59 (s, 1H), 7.68-7.64 (m, 1H), 7.60 (dt, 3.5, 1.8 Hz, 3H), 7.55 (br s, 1H), 7.40-7.31 (m, 4H), 7.30-7.19 (m, 4H), 7.13-7.05 (m, 4H), 6.12 (s, 1H), 5.46 (s, 1H), 5.07 (s, 1H), 3.77 (d, 12.9 Hz, 1H), 3.50 (d, 12.4 Hz, 1H), 2.71-2.58 (m, 1H), 2.46-2.42 (m, 1H), 2.32 (dd, 7.6, 5.8 Hz, 1H), 2.22 (dd, 9.9, 1.7 Hz, 1H), 1.77-1.55 (m, 2H), 1.51-1.13 (m, 8H), 0.95-0.77 (m, 1H).	544	D	






I-773		COc1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	NMR (400 MHz, DMSO-d6) 10.48 (br. s, 1H), 9.13 (s, 1H), 7.94 (d, 8.5 Hz, 1H), 7.72 (d, 9.0 Hz, 1H), 7.64 (s, 1H), 7.30 (dd, 8.8, 5.2 Hz, 1H), 7.21 (d, 2.1 Hz, 1H), 7.12-7.04 (m, 2H), 6.59 (br. s, 1H), 5.93 (br. s, 1H), 3.88 (s, 3H)	497.2	A	
I-774		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(NC(=O)c3cc(F)cc(c3)S(F)(F)(F)(F)F)c12	NMR (400 MHz, DMSO D6) 10.64 (s, broad, 1H), 9.30 (s, broad, 1H,), 8.21 (dd, 8.7, 1.9 Hz, 1H), 7.83 (s, 2H), 7.76 (d, 8.5 Hz, 1H), 7.73 (s, 1H), 7.31 (dd, 8.9, 5.2 Hz, 1H), 7.09 (td, 8.5, 3.0 Hz, 1H), 7.25-6.25 (m, broad, 1H), 6.20-5.60 (m, broad, 1H).	603.1	A	
I-775		CP(C)(=O)Cc1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	NMR (400 MHz, DMSO-d6) 10.55 (br. s, 1H), 9.14 (s, 1H), 7.94 (d, 8.6 Hz, 1H), 7.73 (d, 9.0 Hz, 1H), 7.63 (s, 1H), 7.60 (br. t, 2.0 Hz 1H), 7.37 (s, 1H), 7.31 (dd, 8.9, 5.2 Hz, 1H), 7.09 (td, 8.4, 3.0 Hz, 1H), 6.66 (br. s, 1H), 5.95 (br. s, 1H), 3.45-3.23 (s, 2H), 1.40 (d, 7.7 Hz, 1H), 1.37 (d, 7.7 Hz, 1H).	557.2	A	
I-776		Fc1ccc(Cl)c(c1)[C@@H]1NC(=O)c2cc(Cl)cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	NMR (400 MHz, CD3CN) 8.64 (br s,1H), 7.74 (d, 1.8 Hz, 1H), 7.63 (d, 6.0 Hz, 1H), 7.60 (s, 1H), 7.56 (d, 6.0 Hz, 1H), 7.53 (s, 1H), 7.30 (br s, 1H), 7.25 (dd, 8.8, 5.2 Hz, 1H), 6.96 (td, 8.4, 3.1 Hz, 1H), 6.66 (br s, 1H), 6.09 (br s, 1H).	542.3	A	A





I-777		Fc1ccc(Cl)c(c1)[C@H]1NC(=O)c2cc(Cl)cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	NMR (400 MHz, CD3CN) 8.64 (br s,1H), 7.74 (d, 1.8 Hz, 1H), 7.63 (d, 6.0 Hz, 1H), 7.60 (s, 1H), 7.56 (d, 6.0 Hz, 1H), 7.53 (s, 1H), 7.30 (br s, 1H), 7.25 (dd, 8.8, 5.2 Hz, 1H), 6.96 (td, 8.4, 3.1 Hz, 1H), 6.66 (br s, 1H), 6.09 (br s, 1H).	542.3	D	
I-778		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)C1CCOC1	NMR (400 MHz, CD3CN) 8.58 (s, 1H), 7.63-7.50 (m, 4H), 7.42 (s, 1H), 7.20 (dd, 8.9, 5.1 Hz, 1H), 7.16 (br s, 1H), 6.93 (ddd, 11.9, 8.9, 5.1 Hz, 1H), 6.56 (br s, 1H), 6.04 (br s, 1H), 4.10-4.03 (m, 1H), 3.99 (td, 8.5, 4.7 Hz, 1H), 3.82 (q, 7.5 Hz, 1H), 3.67 (dd, 14.9, 7.8 Hz, 1H), 3.58-3.49 (m, 1H), 2.39 (ddd, 12.4, 10.1, 6.1 Hz, 1H), 2.01-1.94 (m, 1H).	537.3	A	
I-779		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)C1CC(F)(F)C1	NMR (400 MHz, CD3CN) 8.62 (s, 1H), 7.71-7.54 (m, 4H), 7.47 (s, 1H), 7.25 (dd, 8.9, 5.1 Hz, 2H), 6.96 (ddd, 8.9, 8.0, 3.1 Hz, 1H), 6.59 (br s, 1H), 6.10 (br s, 1H), 3.66-3.54 (m, 1H), 3.15-3.02 (m, 2H), 2.85-2.67 (m, 2H).	598.3	A	
I-780		CO[C@@H]1CC[C@H]1Nc1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	NMR (400 MHz, DMSO-d6) 10.28 (s, 1H), 8.96 (s, 1H), 7.92 (d, 8.6 Hz, 1H), 7.67 (d, 16.1Hz, 1H), 7.61 (s, 1H), 7.28 (dd, 8.9, 5.2 Hz, 1H), 7.06 (td, 8.4, 3.1 Hz, 1H), 6.69 (d, 2.0 Hz, 1H), 6.60 (s, 1H), 6.54 (d, 5.3 Hz, 1H), 5.88 (s, 1H), 4.10-3.99 (m, 1H), 3.95-3.87 (m, 1H), 3.16 (s, 3H), 2.31 (ddd, 12.5, 7.6, 4.8 Hz, 2H), 2.18-2.09 (m, 2H).	566.3	A	






I-781		CO[C@H]1CC(C1)Nc1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	NMR (400 MHz, CD3CN) 8.46 (s, 1H), 7.63 (d, 8.5 Hz, 2.0 Hz, 1H), 7.59-7.53 (m, 2H), 7.23 (dd, 8.9, 5.1 Hz, 1H), 7.09 (s, 1H), 6.95 (ddd, 8.8 Hz, 8.1 Hz, 3.1 Hz, 1H), 6.84 (d, 2.1 Hz, 1H), 6.76 (s, 1H), 6.63 (br, s, 1H), 5.98 (s, 1H), 5.09 (d, 6.9 Hz, 1H), 3.69 (p, 7.3 Hz, 1H), 3.62-3.53 (m, 1H), 3.20 (s, 3H), 2.86-2.79 (m, 2H), 1.77-1.69 (m, 2H).	566.3	A	
I-782		COc1ncc(cn1)-c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	1H NMR (DMSO-d6, 400 MHz) 10.63 (s, 1H), 9.24 (br s, 1H), 9.05 (s, 2H), 8.06 (d, 1.5 Hz, 1H), 7.96 (br d, 8.3 Hz, 1H), 7.84 (d, 1.3 Hz, 1H), 7.76 (br d, 8.8 Hz, 1H), 7.70 (s, 1H), 7.33 (dd, 8.8, 5.3 Hz, 1H), 7.11 (td, 8.5, 3.0 Hz, 1H), 6.43-6.91 (m, 1H), 6.04 (br s, 1H), 4.00 (s, 3H)	575	A	
I-783		Cc1ncc(cn1)-c1cc2C(=O)N[C@@H](c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl		559.2	D	
I-784		Cc1ncc(cn1)-c1cc2C(=O)N[C@H](c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl		559.2	A	





I-785		Fc1cc(cc(c1)C(F)(F)F)C(=O)Nc1cc(Br)cc2C(=O)NC(c12)c1cc(Cl)cc(F)c1F	1H NMR (400 MHz, DMSO-d6) 10.61 (s, 1H), 9.28 (s, 1H), 8.01 (d, 8.5 Hz, 1H), 7.87 - 7.73 (m, 4H), 7.59 (ddd, 9.7, 6.7, 2.6 Hz, 1H), 6.99 (s, 1H), 5.86 (s, 1H).	563	A	
I-786		Fc1cc(cc(c1)C(F)(F)F)C(=O)Nc1cc(Br)cc2C(=O)N[C@H](c12)c1cc(Cl)cc(F)c1F	1H NMR (400 MHz, DMSO-d6) 10.61 (s, 1H), 9.28 (s, 1H), 8.00 (d, 8.5 Hz, 1H), 7.87 - 7.78 (m, 2H), 7.78 - 7.73 (m, 2H), 7.59 (ddd, 9.7, 6.6, 2.6 Hz, 1H), 6.99 (s, 1H), 5.86 (s, 1H).	563	A	
I-787		Fc1cc(cc(c1)C(F)(F)F)C(=O)Nc1cc(Br)cc2C(=O)N[C@@H](c12)c1cc(Cl)cc(F)c1F	1H NMR (400 MHz, DMSO-d6) 10.61 (s, 1H), 9.28 (s, 1H), 8.01 (d, 8.4 Hz, 1H), 7.87 - 7.79 (m, 2H), 7.79 - 7.73 (m, 2H), 7.59 (ddd, 9.5, 6.7, 2.6 Hz, 1H), 6.99 (s, 1H), 5.86 (s, 1H).	563	D	
I-788		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(NC(=O)c3cc(F)ccc3OC(F)(F)F)c12	1H NMR (400 MHz, DMSO-d6) 10.50 (s, 1H), 9.33 - 9.29 (m, 1H), 7.81 (d, 1.7 Hz, 1H), 7.72 (d, 1.8 Hz, 1H), 7.60 - 7.47 (m, 3H), 7.29 (td, 8.4, 3.1 Hz, 1H), 6.78 (s, 1H), 6.58 (dd, 8.2, 3.0 Hz, 1H), 6.03 (s, 1H).	563	D	
I-789		FC(F)c1ccccc1[C@@H]1NC(=O)c2cc(Br)cc(NC(=O)c3cc(F)ccc(c3)C(F)(F)F)c12	1H NMR (400 MHz, DMSO-d6) 10.50 (s, 1H), 9.29 (s, 1H), 7.92 (d, 8.7 Hz, 1H), 7.85 (d, 1.8 Hz, 1H), 7.78 (d, 1.8 Hz, 1H), 7.67-7.00 (m, 6H), 6.72 (s, 1H), 6.02 (s, 1H).	545.15	A	





I-790		FC(F)c1ccccc1[C@H]1NC(=O)c2cc(Br)cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	1H NMR (400 MHz, DMSO-d6) 10.50 (s, 1H), 9.29 (s, 1H), 7.92 (dt, 8.6, 1.9 Hz, 1H), 7.85 (d, 1.7 Hz, 1H), 7.78 (d, 1.8 Hz, 1H), 7.63-7.09 (m, 6H), 6.72 (s, 1H), 6.02 (s, 1H).	545.15	D	
I-791		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(NC(=O)c3cc(F)ccc3Cl)c12	1H NMR (400 MHz, Methanol-d4) 7.95 (d, 1.7 Hz, 1H), 7.88 - 7.73 (m, 1H), 7.66 - 7.36 (m, 2H), 7.21 (dddd, 20.0, 8.8, 7.9, 3.0 Hz, 2H), 6.63 (d, 3.1 Hz, 1H), 6.61 (d, 3.1 Hz, 1H), 6.27 (s, 1H).	512.95	E	
I-792		FC(F)c1ccccc1C1NC(=O)c2cc(Br)cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	1H NMR (400 MHz, DMSO-d6) 10.50 (s, 1H), 9.29 (s, 1H), 7.92 (d, 8.4 Hz, 1H), 7.85 (d, 1.8 Hz, 1H), 7.78 (d, 1.9 Hz, 1H), 7.62-7.04 (m, 6H), 6.72 (s, 1H), 6.02 (s, 1H).	545.15	A	
I-793		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(NC(=O)c3cc(F)ccc3F)c12	1H NMR (400 MHz, DMSO-d6) 10.36 (s, 1H), 9.30 (s, 1H), 7.80 (d, 1.7 Hz, 1H), 7.74 (d, 1.8 Hz, 1H), 7.45 (ddt, 11.9, 7.4, 3.1 Hz, 2H), 7.36 (td, 9.3, 4.3 Hz, 1H), 7.28-7.19 (m, 1H), 6.98 (ddd, 8.5, 5.4, 3.2 Hz, 1H), 6.74 (s, 1H), 6.02 (s, 1H).	496.9	D	
I-794		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(NC(=O)c3cc(Cl)ccc3F)c12	1H NMR (400 MHz, DMSO-d6) 10.43 (s, 1H), 9.30 (s, 1H), 7.80 (d, 1.7 Hz, 1H), 7.76 - 7.71 (m, 1H), 7.63 (ddd, 8.9, 4.3, 2.8 Hz, 1H), 7.51 - 7.43 (m, 1H), 7.36 (t, 9.3 Hz, 1H), 7.25 (td, 8.4, 3.0 Hz, 1H), 7.06 (dd, 6.0, 2.8 Hz, 1H), 6.71 (s, 1H), 6.00 (s, 1H).	512.95	D	






I-795		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(NC(=O)c3cc(Cl)ccc3Cl)c12	1H NMR (400 MHz, Chloroform-d) 8.45 (s, 1H), 7.95 (d, 1.6 Hz, 1H), 7.64 (s, 1H), 7.45-7.32 (m, 4H), 7.08 (td, 8.9, 8.2, 3.0 Hz, 1H), 6.66-6.59 (m, 2H), 6.16 (s, 1H).	528.85	D	
I-796		COc1ccc(F)cc1C(=O)Nc1cc(Br)cc2C(=O)NC(c12)c1cc(F)ccc1Cl	1H NMR (400 MHz, DMSO-d6) 9.89 (s, 1H), 9.28 (s, 1H), 7.83 (d, 1.7 Hz, 1H), 7.77 (d, 1.8 Hz, 1H), 7.42 (dd, 8.8, 5.1 Hz, 1H), 7.35 (ddd, 9.1, 7.9, 3.3 Hz, 1H), 7.23 - 7.05 (m, 3H), 6.73 (s, 1H), 6.07 (s, 1H), 3.73 (s, 3H).	509	D	
I-797		FC(F)c1ccc(F)cc1[C@@H]1NC(=O)c2cc(Br)cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	1H NMR (400 MHz, DMSO-d6) 10.55 (s, 1H), 9.33 (s, 1H), 7.94 (d, 8.2 Hz, 1H), 7.87 (d, 1.7 Hz, 1H), 7.78 (d, 1.7 Hz, 1H), 7.67 (d, 8.9 Hz, 1H), 7.58 (s, 1H), 7.50 (dd, 8.8, 5.6 Hz, 1H), 7.22 (td, 8.4, 2.7 Hz, 1H), 7.11 (s, 1H), 6.57 (s, 1H), 6.02 (s, 1H).	561.05	A	
I-798		FC(F)c1ccc(F)cc1[C@H]1NC(=O)c2cc(Br)cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	1H NMR (400 MHz, DMSO-d6) 10.55 (s, 1H), 9.33 (s, 1H), 7.94 (d, 8.2 Hz, 1H), 7.87 (d, 1.7 Hz, 1H), 7.78 (d, 1.7 Hz, 1H), 7.67 (d, 8.9 Hz, 1H), 7.58 (s, 1H), 7.50 (dd, 8.8, 5.6 Hz, 1H), 7.22 (td, 8.4, 2.7 Hz, 1H), 7.11 (s, 1H), 6.57 (s, 1H), 6.02 (s, 1H).	561.05	D	
I-799		COc1ccc(Cl)cc1C(=O)Nc1cc(Br)cc2C(=O)NC(c12)c1cc(F)ccc1Cl	1H NMR (400 MHz, DMSO-d6) 9.95 (s, 1H), 9.28 (s, 1H), 7.82-7.74 (m, 2H), 7.52 (dd, 8.9, 2.8 Hz, 1H), 7.44 (dd, 8.8, 5.1 Hz, 1H), 7.21 (ddd, 8.9, 8.0, 3.1 Hz, 1H), 7.16 -7.10 (m, 2H), 6.74 (s, 1H), 6.06 (s, 1H), 3.74 (s, 3H).	522.95	D	






I-800		COc1cc(F)cc(c1)C(=O)Nc1cc(Br)cc2C(=O)NC(c12)c1cc(F)ccc1Cl	1H NMR (400 MHz, DMSO-d6) 10.29 (s, 1H), 9.31-9.26 (m, 1H), 7.82-7.77 (m, 1H), 7.74 (d, 2.0 Hz, 1H), 7.37 (dd, 8.8, 5.1 Hz, 1H), 7.14 (td, 8.4, 3.0 Hz, 1H), 7.05 (dt, 10.7, 2.5 Hz, 1H), 6.97 (s, 1H), 6.92 (d, 9.0 Hz, 1H), 6.70 (s, 1H), 6.01 (s, 1H), 3.80 (s, 3H).	506.9	C	
I-801		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(NC(=O)c3cccc(c3)C(F)(F)F)c12	1H NMR (400 MHz, DMSO-d6) 10.51 (s, 1H), 9.29 (s, 1H), 7.93 (t, 9.0 Hz, 2H), 7.81 (d, 1.7 Hz, 1H), 7.78-7.67 (m, 3H), 7.32 (dd, 8.8, 5.1 Hz, 1H), 7.09 (td, 8.3, 3.0 Hz, 1H), 6.91 - 6.24 (m, 1H), 5.99 (s, 1H).	526.9	B	
I-802		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(NC(=O)c3cc(Cl)cc4ccncc34)c12	1H NMR (400 MHz, Chloroform-d) 13.17 (s, 1H), 8.82 (d, 2.5 Hz, 2H), 8.61 (dd, 4.4, 1.8 Hz, 1H), 8.22 (dd, 8.4, 1.8 Hz, 1H), 8.00 (d, 2.5 Hz, 1H), 7.95 (d, 1.7 Hz, 1H), 7.51 (dd, 8.4, 4.3 Hz, 1H), 7.34 (dd, 8.8, 4.9 Hz, 1H), 6.89 -6.80 (m, 1H), 6.64 (s, 1H), 6.59 (dd, 8.8, 2.9 Hz, 1H), 6.27 (s, 1H).	543.95	E	
I-803		O[C@H](C(=O)Nc1cc(Br)cc2C(=O)NC(c12)c1cc(F)ccc1Cl)c1cc(F)cc(F)c1	1H NMR (400 MHz, DMSO-d6) 9.54 (s, 1H), 9.25 (s, 1H), 8.01 (s, 1H), 7.70 (d, 1.7 Hz, 1H), 7.41 (s, 1H), 7.16 - 7.04 (m, 2H), 6.84 (s, 1H), 6.81 - 6.74 (m, 2H), 6.56 (s, 1H), 6.18 (s, 1H), 5.04 (d, 3.1 Hz, 1H).	525.15	E	





I-804		O[C@@H](C(=O)Nc1cc(Br)cc2C(=O)NC(c12)c1cc(F)ccc1Cl)c1cc(F)cc(F)c1	1H NMR (400 MHz, DMSO-d6) 9.72 (s, 1H), 9.20 (s, 1H), 7.91 (s, 1H), 7.71 (d, 1.7 Hz, 1H), 7.31 (dd, 8.8, 5.1 Hz, 1H), 7.13 (ddt, 10.9, 8.5, 4.2 Hz, 2H), 6.92 (d, 7.6 Hz, 2H), 6.75 (d, 4.5 Hz, 1H), 6.51 (s, 1H), 6.06 (s, 1H), 4.97 (d, 4.2 Hz, 1H).	525.15	E	
I-805		Fc1cc(F)c(Cl)c(c1)[C@@H]1NC(=O)c2cc(Br)cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	1H NMR (400 MHz, DMSO-d6) 10.60 (s, 1H), 9.33 (s, 1H), 7.99 (dt, 8.6, 2.1 Hz, 1H), 7.85 (d, 1.7 Hz, 1H), 7.81 - 7.74 (m, 2H), 7.68 (s, 1H), 7.41 (td, 8.9, 2.9 Hz, 1H), 6.63 (s, 1H), 6.02 (s, 1H).	563	A	
I-806		Fc1cc(F)c(Cl)c(c1)[C@H]1NC(=O)c2cc(Br)cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	1H NMR (400 MHz, DMSO-d6) 10.58 (s, 1H), 9.32 (s, 1H), 7.98 (dd, 8.5, 2.4 Hz, 1H), 7.85 (d, 1.7 Hz, 1H), 7.81 - 7.74 (m, 2H), 7.68 (s, 1H), 7.41 (td, 9.0, 2.9 Hz, 1H), 6.66 (s, 1H), 6.01 (s, 1H).	562.85	C	
I-807		Fc1cc(F)c(Cl)c(c1)C1NC(=O)c2cc(Br)cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	1H NMR (400 MHz, DMSO-d6) 10.58 (s, 1H), 9.32 (s, 1H), 7.98 (d, 8.4 Hz, 1H), 7.85 (d, 1.7 Hz, 1H), 7.81 - 7.74 (m, 2H), 7.68 (s, 1H), 7.40 (td, 8.9, 2.9 Hz, 1H), 6.65 (s, 1H), 6.01 (s, 1H).	562.9	A	
I-808		CNC(=O)c1cc(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c2n([nH]c(=O)c2c1)-c1cc(F)ccc1Cl	NMR (400 MHz, CD3CN) 8.78 (s, 1H), 8.38 (s, 1H), 7.81 (s, 1H), 7.63 (d, 8.3 Hz, 1H), 7.58-7.49 (m, 2H), 7.37 (br s, 1H), 7.33-7.18 (m, 2H), 6.89 (td, 9.2, 3.7 Hz, 1H), 2.87 (d, 4.5 Hz, 3H).	523.3	D	






I-809		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(NC(=O)c3cc(F)cc(c3Cl)C(F)(F)F)c12	(400 MHz, DMSO-d6) 10.65 (br s, 1H), 9.33 (s, 1H), 7.97 (dd, 8.5, 3.0 Hz, 1H), 7.86 (d, 1.7 Hz, 1H), 7.81 (d, 1.5 Hz, 1H), 7.60-7.48 (m, 1H), 7.30 (td, 8.4, 3.0 Hz, 1H), 7.16 (d, 5.8 Hz, 1H), 6.67 (br s, 1H), 6.09 (br s, 1H)	577.3	D	
I-810		Fc1cc(cc(c1)C(F)(F)F)C(=O)Nc1ccc2C(=O)NC(c12)c1cccc2CC(=O)Nc12	1H NMR (400 MHz, DMSO-d6) 10.53 (br. s, 1H), 10.37 (br. s, 1H), 9.00 (s, 1H), 7.91 (d, 8.5 Hz, 1H), 7.67 (dd, 7.5, 1.0 Hz, 1H), 7.61 (t, 7.6 Hz, 1H), 7.52-7.46 (m, 2H), 7.43 (s, 1H), 6.99 (d, 6.6 Hz, 1H), 6.76 (t, 7.6 Hz, 1H), 6.31 (d, 7.5 Hz, 1H), 5.94 (br. s, 1H), 3.38 (d, 22.7 Hz, 1H), 2.70 (d, 22.7 Hz, 1H).	470.2	E	
I-811		Cn1cc(cn1)-c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	1h NMR (400 MHz, DMSO-d6) 10.52 (s, 1H), 9.14 (br. s, 1H), 8.34 (s, 1H), 8.01 (s, 1H), 7.95 (dt, 9.9, 1.5 Hz, 1H), 7.88 (d, 1.0 Hz, 1H), 7.75 (d, 8.0 Hz, 1H), 7.71-7.66 (m, 8.8 Hz, 2H), 7.31 (dd, 8.9, 5.1 Hz, 1H), 7.09 (td, 8.5, 3.0 Hz, 1H), 6.61 (br. s, 1H), 5.96 (br. s, 1H), 3.89 (s, 3H).	547.2	A	A
I-812		FC(F)Oc1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	NMR (400 MHz, MeCN-d3) 8.70 (br. s, 1H), 7.68-7.63 (m, 1H), 7.61-7.57 (m, 1H), 7.56 (s, 1H), 7.49 (d, 2.1 Hz, 1H), 7.40 (d, 1.4 Hz, 1H), 7.34 (s, 1H), 7.27 (dd, 8.9, 5.1 Hz, 1H), 6.98 (ddd, 8.8, 8.1, 3.1 Hz, 1H), 6.91 (t, 73.6 Hz, 1H), 6.66 (br.s, 1H), 6.12 (br. s, 1H). Contains 4% of formate salt at 8.17	531.4	A	





I-813		CC1(COC1)Nc1cc2C(=O)N[C@H](c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	NMR (400 MHz, DMSO-d6) 10.24 (s, 1H), 8.91 (br. s, 1H), 7.88 (td, 8.4, 1.6 Hz, 1H), 7.64 (d, 9.0 Hz, 1H), 7.55 (s, 1H), 7.25 (dd, 8.9, 5.2 Hz, 1H), 7.03 (td, 8.4, 3.1 Hz, 1H), 6.64 (s, 1H), 6.57 (br. s, 1.6 Hz, 1H), 6.52 (d, 2.1 Hz, 1H), 6.47 (br. d, 1H), 5.80 (s, 1H), 4.63 (d, 5.7 Hz, 2H), 4.48 (d, 5.8 Hz, 2H), 1.57 (s, 3H).	552.1	A	
I-814		Fc1ccc(Cl)c(c1)[C@@H]1NC(=O)c2cc(NC3COC3)cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	NMR (400 MHz, DMSO-d6) 10.30 (s, 1H), 8.95 (br. s, 1H), 7.92 (d, 8.6 Hz, 1H), 7.69 (d, 8.9 Hz, 1H), 7.60 (s, 1H), 7.28 (dd, 8.9, 5.2 Hz, 1H), 7.06 (td, 8.4, 3.1 Hz, 1H), 6.94 (d, 6.3 Hz, 1H), 6.69 (d, 2.0 Hz, 1H), 6.62 (s, 1H), 6.57 (br. s, 1H), 5.82 (br. s, 1H), 4.89 (t, 6.5 Hz, 2H), 4.62 (dd, 12.7, 6.4 Hz, 1H), 4.45 (q, 6.1 Hz, 2H).	538.3	A	A
I-815		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1ccn[nH]1	NMR (400 MHz, CD3CN) 8.67 (br s, 1H), 8.10 (d, 1.3 Hz, 1H), 8.05 (s, 1H), 7.68 (d, 2.4 Hz, 1H), 7.63 (d, 8.5 Hz, 1H), 7.59 (d, 9.0 Hz, 1H), 7.57 (s, 1H), 7.24 (dd, 8.9, 5.1 Hz, 2H), 6.99-6.91 (m, 1H), 6.79 (d, 2.4 Hz, 1H), 6.68 (br s, 1H), 6.14 (br s, 1H).	533.3	A	
I-816		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(NC(=O)c3cc(F)cc(Cl)c3Cl)c12	NMR (400 MHz, DMSO) 9.29 (s, 1H), 7.81 (d, 1.6 Hz, 1H), 7.75 (d, 1.6 Hz, 1H), 7.60 (m, 3H), 7.36 (dd, 8.7, 5.2 Hz, 1H), 7.17-7.11 (m, 1H), 5.96 (br s, 1H).	545	B	





I-817		CC1(Cc2cc3C(=O)N[C@@H](c3c(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c2)c2cc(F)ccc2Cl)COC1		551.31	D	
I-818		CC1(Cc2cc3C(=O)N[C@H](c3c(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c2)c2cc(F)ccc2Cl)COC1		551.31	A	
I-819		CC(C)(O)COc1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(Cl)c2)c1)c1cc(F)ccc1Cl		521	A	
I-820		COC(C)(C)Cc1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl		553.31	A	
I-821		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1ccc2nncn2c1	1H NMR (DMSO-d6, 400 MHz):-′ = 10.64 (s, 1H), 9.28 (d, 0.8 Hz, 1H), 9.22-9.27 (m, 1H), 9.14 (s, 1H), 8.05 (s, 1H), 7.97 (br d, 8.1 Hz, 1H), 7.88-7.94 (m, 2H), 7.83-7.88 (m, 1H), 7.78 (br d, 8.8 Hz, 1H), 7.73 (s, 1H), 7.35 (dd, 8.8, 5.3 Hz, 1H), 7.12 (td, 8.3, 3.0 Hz, 1H), 6.50-7.03 (m, 1H), 6.07 (br s, 1H)	584	A	






I-822		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1cnc(nc1)C1CC1		585	A	
I-823		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1cnc(nc1)C(F)(F)F		613.1	A	
I-824		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1ccc2nnnn2c1		584	A	
I-825		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1cnc2nccn2c1		584	A	
I-826		Fc1ccc(Cl)c(c1)[C@H]1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1ccc2nccn2c1			C	






I-827		Fc1ccc(Cl)c(c1)[C@@H]1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1ccc2nccn2c1		583.3	A	
I-828		Nc1cc(ccn1)C1NC(=O)c2cccc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	(400 MHz, d6-DMSO) 10.51 (s, 1H), 9.06 (s, 1H), 8.35 (s, 1H), 7.97 (d, 8.3 Hz, 1H), 7.83 (br s, 1H), 7.79 (br d, 8.7 Hz, 1H), 7.66 (dd, 7.4, 1.0 Hz, 1H), 7.62 (dd, 5.7, 0.8 Hz, 1H) 7.58 (t, 7.5 Hz, 1H), 7.50 (dd, 7.7, 0.9 Hz, 1H), 6.06 (dd, 5.2, 1.4 Hz, 1H), 6.05 (s, 1H) 5.78 (br s, 2H), 5.54 (s, 1H).	431.2	E	
I-829		CC1(COC1)Nc1cc2C(=O)N[C@@H](c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1ccc(F)ccc1Cl	NMR (400 MHz, DMSO-d6) 10.24 (s, 1H), 8.91 (br. s, 1H), 7.88 (td, 8.4, 1.6 Hz, 1H), 7.64 (d, 9.0 Hz, 1H), 7.55 (s, 1H), 7.25 (dd, 8.9, 5.2 Hz, 1H), 7.03 (td, 8.4, 3.1 Hz, 1H), 6.64 (s, 1H), 6.57 (br. s, 1.6 Hz, 1H), 6.52 (d, 2.1 Hz, 1H), 6.47 (br. d, 1H), 5.80 (s, 1H), 4.63 (d, 5.7 Hz, 2H), 4.48 (d, 5.8 Hz, 2H), 1.57 (s, 3H).	552.1	C	
I-830		Fc1ccc(Cl)c(c1)[C@H]1NC(=O)c2cc(NC3COC3)cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	NMR (400 MHz, DMSO-d6) 10.30 (s, 1H), 8.95 (br. s, 1H), 7.92 (d, 8.6 Hz, 1H), 7.69 (d, 8.9 Hz, 1H), 7.60 (s, 1H), 7.28 (dd, 8.9, 5.2 Hz, 1H), 7.06 (td, 8.4, 3.1 Hz, 1H), 6.94 (d, 6.3 Hz, 1H), 6.69 (d, 2.0 Hz, 1H), 6.62 (s, 1H), 6.57 (br. s, 1H), 5.82 (br. s, 1H), 4.89 (t, 6.5 Hz, 2H),	538.3	D	






			4.62 (dd, 12.7, 6.4 Hz, 1H), 4.45 (q, 6.1 Hz, 2H).			
I-831		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(NC(=O)c3cc(F)cc(OC(F)(F)F)c3)c12	1H NMR (400 MHz, Chloroform-d) 8.40 (s, 1H), 7.94 (d, 1.6 Hz, 1H), 7.54-7.40 (m, 2H), 7.22-7.15 (m, 2H), 7.14-7.04 (m, 2H), 6.73 (d, 14.7 Hz, 2H), 6.18 (s, 1H).	563.1	B	
I-832		[O-][N+](=O)c1cc(F)cc(c1)C(=O)Nc1cc(Br)cc2C(=O)NC(c12)c1cc(F)ccc1Cl	1H NMR (400 MHz, CDCl3) 8.47 (s, 1H), 8.16 (dt, 7.7, 2.2 Hz, 1H), 8.03-7.97 (m, 2H), 7.82-7.75 (m, 1H), 7.51 (dd, 8.7, 4.3 Hz, 2H), 7.14 (ddd, 8.9, 7.3, 3.0 Hz, 1H), 6.74 (s, 1H), 6.46 (s, 1H), 6.21 (s, 1H).	524	A	
I-833		FC(F)Oc1cc(F)cc(c1)C(=O)Nc1cc(Br)cc2C(=O)NC(c12)c1cc(F)ccc1Cl	1H NMR (400 MHz, Chloroform-d) 8.45 (s, 1H), 7.96 (d, 1.6 Hz, 1H), 7.45 (dd, 8.9, 4.9 Hz, 1H), 7.34 (s, 1H), 7.08 (dddd, 20.4, 10.1, 7.8, 2.5 Hz, 4H), 6.72 (s, 1H), 6.58-6.43 (m, 2H), 6.18 (s, 1H).	545	B	
I-834		COc1c(Cl)cc(F)cc1C(=O)Nc1cc(Br)cc2C(=O)NC(c12)c1cc(F)ccc1Cl	1H NMR (400 MHz, DMSO-d6) 10.29 (s, 1H), 9.31 (s, 1H), 7.84 (d, 1.8 Hz, 1H), 7.80 (d, 1.7 Hz, 1H), 7.70 (dd, 8.1, 3.1 Hz, 1H), 7.50 (t, 6.3 Hz, 1H), 7.27 (ddd, 8.9, 7.9, 3.1 Hz, 1H), 6.60 (dd, 8.3, 3.2 Hz, 2H), 6.07 (s, 1H), 3.64 (s, 3H), 1.59 (s, 1H).	540.95	D	
I-835		FC(F)c1cc(F)cc(c1)C(=O)Nc1cc(Br)cc2C(=O)NC(c12)c1cc(F)ccc1Cl	1H NMR (400 MHz, Methanol-d4) 7.96 (d, 1.6 Hz, 1H), 7.74 (s, 1H), 7.61-7.45 (m, 3H), 7.31 (dd, 8.9, 5.0 Hz, 1H), 7.08-6.95 (m, 1H), 6.84 (s, 1H), 6.71 (s, 1H), 6.19 (s, 1H).	526.85	B	





I-836		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(NC(=O)c3cc(F)cc(Cl)c3F)c12	1H NMR (400 MHz, DMSO-d6) 10.51 (s, 1H), 9.31 (s, 1H), 7.86 (ddd, 8.4, 5.5, 3.2 Hz, 1H), 7.81 (d, 1.7 Hz, 1H), 7.74 (d, 1.8 Hz, 1H), 7.47 (t, 7.0 Hz, 1H), 7.25 (ddd, 8.8, 7.9, 3.1 Hz, 1H), 7.03 (ddd, 7.9, 4.5, 2.9 Hz, 1H), 6.84 (s, 1H), 6.00 (s, 1H).	528.9	C	
I-837		FC(F)c1ccc(F)cc1C(=O)Nc1cc(Br)cc2C(=O)NC(c12)c1cc(F)ccc1Cl	1H NMR (400 MHz, Methanol-d4) 7.95 (d, 1.7 Hz, 1H), 7.84-7.72 (m, 2H), 7.47 (dd, 8.9, 5.0 Hz, 1H), 7.39 (td, 8.4, 2.7 Hz, 1H), 7.26-6.93 (m, 2H), 6.54 (s, 2H), 6.19 (s, 1H).	526.9	D	
I-838		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1cnc[nH]1	NMR (400 MHz, DMSO-d6) : Presence of the 2 tautomeric forms of the imidazole (4 and 5 substituted imidazoles) in a 3:1 ratio. Major tautomer:-′ 12.32 (br. s, 1H), 10.55 (s, 1H), 9.12 (s, 1H), 8.07 (d, 0.8 Hz, 1H), 7.96 (s, 1H), 7.93 (s, 1H), 7.84 (br. s, 1H), 7.79-7.74 (m, 2H), 7.70 (s, 1H), 7.31 (dd, 8.9, 5.2 Hz, 1H), 7.11-7.06 (m, 1H), 6.63 (br. s, 1H), 5.97 (br. s, 1H). 24 % of formate salt at 8.24 .	533.2	A	
I-839		CNc1cc(cc(n1)C(=O)Nc1cccc2C(=O)NC(c12)c1cc(F)ccc1Cl)C(F)(F)F	1H-NMR (400 MHz, DMSO-d6) 9.90 (s, 1H), 9.13 (s, 1H), 7.80 (d, 6.2 Hz, 1H), 7.69-7.60 (m, 2H), 7.36-7.27 (m, 2H), 7.18 (d, 1.0 Hz, 1H), 7.07 (td, 8.4, 3.1 Hz, 1H), 6.93-6.91 (m, 1H), 6.62 (br. s, 1H), 6.17 (br. s, 1H), 2.84 (d, 4.4 Hz, 3H).	479.3	E	





I-840		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1c[nH]nn1	NMR (400 MHz, DMSO-d6) 10.63 (br. s, 1H), 9.21 (br. s, 1H), 8.59 (br. s, 1H), 8.17 (s, 1H), 8.05 (s, 1H), 7.96 (d, 8.5 Hz, 1H), 7.77 (d, 9.0 Hz, 1H), 7.70 (s, 1H), 7.32 (dd, 8.8, 5.1 Hz, 1H), 7.09 (td, 9.16, 9.02, 3.04 Hz, 1H), 6.69 (br. s, 1H), 6.02 (br. s, 1H).	534.2	A	A
I-841		Cc1ccccc1CC1NC(=O)c2cccc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	NMR (400 MHz, DMSOd6) 10.75 (s, 1H), 8.57 (s, 1H), 8.21 (s, 1H), 8.14 (d, 9.0 Hz, 1H), 8.03 (d, 8.4 Hz, 1H), 7.62 (m, 1H), 7.55 (d, 2.8 Hz, 1H), 7.54 (s, 1H), 7.01-6.92 (m, 4H), 5.14-5.06 (m, 1H), 3.16 (dd, 14.0, 4.4 Hz, 1H), 2.56 (dd, 14.0, 7.8 Hz, 1H), 2.12 (s, 3H).	443.4	D	
I-842		Fc1ccc(Cl)c(c1)C1NC(=O)c2cccc(-c3nc4c(cc(F)cc4[nH]3)C(F)(F)F)c12	NMR (400 MHz, DMSO-D6) 9.23 (br s, 1 H), 8.39-8.15 (m, 2 H), 7.92 (dd, 7.5, 0.7 Hz, 1 H), 7.82 (t, 7.6 Hz, 1 H), 7.61 (dd, 8.8, 2.1 Hz, 1 H), 7.43-7.12 (m, 2 H), 6.95 (ddd, 8.7, 8.2, 3.1 Hz, 1 H), 6.60 (br s, 1 H), 6.29 (br s, 1 H).	464.2	B	
I-843		Nc1c(Cl)cc(F)cc1C(=O)Nc1cc(Br)cc2C(=O)NC(c12)c1cc(F)ccc1Cl	(400 MHz, DMSO-d6) 10.20 (br s, 1H), 9.29 (s, 1H), 7.78 (d, 1.4 Hz, 1H), 7.73 (d, 1.4 Hz, 1H), 7.48 (dd, 8.1, 2.9 Hz, 1H), 7.39 (dd, 8.8, 5.2 Hz, 1H), 7.16 (td, 8.4, 3.1 Hz, 1H), 6.97 - 6.47 (m, 1H), 6.71 (dd, 9.3, 2.1 Hz, 1H), 6.31 (s, 2H), 5.97 (br s, 1H) .	524.3	B	





I-844		Fc1cc(cc(c1)C(F)(F)F)C(=O)Nc1ccc2C(=O)NC(c12)c1ccc2cn[nH]c2c1	1H NMR (400 MHz, DMSO-d6) 12.76 (s, 1H), 10.35 (s, 1H), 9.13 (s, 1H), 7.95 (s, 1H), 7.88 (d, 8.3 Hz, 1H), 7.70 (dd, 7.5, 0.9 Hz, 1H), 7.60 (t, 7.6 Hz, 1H), 7.53 (d, 8.4 Hz, 1H), 7.51-7.45 (m, 8.1 Hz, 2H), 7.42 (s, 1H), 7.15 (s, 1H), 6.56 (d, 8.4 Hz, 1H), 5.82 (s, 1H). DMSO satellites at 2.67 and 2.33 .	455.3	E	
I-845		Oc1c(Cl)cc(F)cc1C(=O)Nc1cc(Br)cc2C(=O)NC(c12)c1cc(F)ccc1Cl	(400 MHz, DMSO-d6) 12.35 (br s, 1H), 9.25 (s, 1H), 8.04 (s, 1H), 7.72 (s, 1H), 7.48 (d, 4.8 Hz, 1H), 7.38-7.26 (m, 2H), 7.10 (td, 8.4, 3.1 Hz, 1H), 6.90 (br s, 1H), 5.98 (s, 1H)	525.2	C	
I-846		O\N=C(/Nc1cccc2C(=S)NC(c12)c1cc(F)ccc1Cl)c1cc(F)cc(c1)C(F)(F)F		498	C	
I-847		Fc1ccc(Cl)c(c1)C1NC(=O)c2c1c(NC(=O)c1cc(F)cc(c1)C(F)(F)F)cc(Br)c2Cl			A	
I-848		CC(C)(O)CN(CC(C)(C)O)c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl		626.39	D	




I-849		Cc1ncc(cn1)-c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(Cl)c2)c1)c1cc(F)ccc1Cl		525	A	
I-850		COc1cc(C)c(cn1)C(=O)Nc1cc(Br)cc2C(=O)NC(c12)c1cc(F)ccc1Cl	1H NMR (400 MHz, DMSO-d6) 2.17 (s, 3 H) 3.83 (s, 3 H) 6.03 (br d, 4.80 Hz, 1 H) 6.64 - 6.74 (m, 2 H) 7.20 - 7.32 (m, 1 H) 7.43 - 7.52 (m, 1 H) 7.57 (s, 1 H) 7.71 - 7.79 (m, 2 H) 9.27 (br s, 1 H) 10.25 (s, 1 H)	506.29	E	
I-851		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1ccc2OCCCOc2c1		615.39	A	
I-852		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1cncc2ccccc12		594.33	A	
I-853		Cn1ccc2cc(ccc12)-c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl		596.33	B	





I-854		COc1cnc c(c1)-c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl		574.32	A	
I-855		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1ccc2cc[nH]c2c1		582.27	B	
I-856		Cc1nocc1Nc1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	(400 MHz, DMSO-d6) 10.36 (s, 1H), 9.02 (s, 1H), 9.01 (s, 1H), 7.96 (s, 1H), 7.93 (d, 8.4 Hz, 1H), 7.70 (d, 9.2 Hz, 1H), 7.60 (s, 1H), 7.30 (dd, 8.9, 5.2 Hz, 1H), 7.07 (td, 8.4, 3.1 Hz, 1H), 6.99 (d, 2.0 Hz, 1H), 6.90 (d, 1.5 Hz, 1H), 6.63 (br s, 1H), 5.88 (br s, 1H), 2.20 (s, 3H).	561.4	A	A
I-857		CC1(CCCCC1)n1[nH]c(=O)c2cccc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	1H NMR (400 MHz, DSMO-d6) 10.66 (s, 1H), 10.52 (br s, 1H), 8.21 (s, 1H), 8.11 (d, 9.2 Hz. 1H), 8.03 (d, 8.6 Hz, 1H), 7.66 (d, 7.9 Hz, 1H), 7.24 (d, 7.2 Hz, 1H), 7.08 (t, 7.6 Hz, 1H), 2.45-2.34 (m, 2H), 1.81-1.70 (m, 1H), 1.55-1.21 (m, 6H), 1.40 (s, 3H).	434.5	D	
I-858		COc1c(F)cc(Cl)cc1C(=O)Nc1cc(Br)cc2C(=O)NC(c12)c1cc(F)ccc1Cl	1H NMR (400 MHz, Chloroform-d) 9.16 (s, 1H), 8.35 (s, 1H), 7.97 (d, 1.7 Hz, 1H), 7.85 (dd, 2.7, 1.7 Hz, 1H), 7.42 (dd, 8.9, 5.0 Hz, 1H), 7.31 (d, 2.7 Hz, 1H), 7.02 (ddd, 8.8,	541	D	





			7.4, 3.0 Hz, 1H), 6.58 (d, 11.2 Hz, 2H), 6.15 (s, 1H), 3.75 (d, 2.3 Hz, 3H).			
I-859		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(NC(=O)c3cc(Cl)ccc3OC(F)(F)F)c12	1H NMR (400 MHz, Chloroform-d) 8.28 (s, 1H), 7.98 (d, 1.7 Hz, 1H), 7.72 (s, 1H), 7.67 (d, 2.7 Hz, 1H), 7.55 (dd, 8.8, 2.7 Hz, 1H), 7.35 (dd, 8.9, 4.9 Hz, 1H), 7.27 (dt, 8.8, 1.5 Hz, 1H), 7.03 (ddd, 8.9, 7.4, 3.0 Hz, 1H), 6.66 (s, 1H), 6.55 (s, 1H), 6.17 (s, 1H).	578.95	D	
I-860		Fc1ccc(Cl)c(c1)[C@H]1NC(=O)c2ccccc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	1H NMR (400 MHz, DMSO-d6) 10.49 (s, 1H), 9.14 (s, 1H), 7.99-7.91 (m, 1H), 7.77-7.69 (m, 2H), 7.69-7.61 (m, 2H), 7.50 (d, 7.8 Hz, 1H), 7.32 (dd, 8.9, 5.2 Hz, 1H), 7.10 (td, 8.4, 3.1 Hz, 1H), 6.60 (s, 1H), 5.99 (s, 1H).	467.37	D	
I-861		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)C1CCC(=O)N1	1H NMR (400 MHz, DMSO-d6) 10.55 (d, 5.1 Hz, 1H), 9.17 (s, 1H), 8.23 (d, 7.5 Hz, 1H), 7.95 (d, 8.5 Hz, 1H), 7.75 (d, 9.2 Hz, 1H), 7.70-7.62 (m, 2H), 7.45 (s, 1H), 7.32 (dd, 8.9, 5.1 Hz, 1H), 7.10 (td, 8.4, 2.9 Hz, 1H), 5.99 (s, 1H), 4.87 (q, 6.4 Hz, 1H), 2.59 (dd, 12.7, 7.4 Hz, 1H), 2.54 (s, 1H), 2.28 (dd, 10.6, 5.7 Hz, 2H), 1.88-1.80 (m, 1H).	550.25	A	
I-862		COc1ccc(cc1)[C@H](C)N1[C@@H](c2c(cc(Br)cc2N)C1=O)c1cc(F)ccc1Cl	1H NMR (400 MHz, DMSO-d6) 7.59 (dd, 8.9, 5.1 Hz, 1H), 7.35 - 7.20 (m, 2H), 7.15 - 7.02 (m, 3H), 7.01 - 6.84 (m, 3H), 6.62 (dd, 9.3, 3.1 Hz, 1H), 5.64 - 5.24 (m, 2H), 5.02 (d, 8.2 Hz, 1H), 4.77 (d, 13.1 Hz, 1H), 3.75 (d,	491.05	D	






			15.2 Hz, 3H), 1.18 (dd, 16.3, 7.3 Hz, 3H).			
I-863		COc1ccc(cc1)[C@H](C)N1[C@H](c2c(cc(Br)cc2N)C1=O)c1cc(F)ccc1Cl	1H NMR (400 MHz, DMSO-d6) 7.66 -7.43 (m, 1H), 7.15 - 6.95 (m, 4H), 6.91 (d, 1.7 Hz, 1H), 6.68 - 6.59 (m, 2H), 6.05 (dd, 9.3, 3.1 Hz, 1H), 5.97 -5.70 (m, 1H), 5.26 (q, 7.2 Hz, 1H), 5.11 (q, 7.2 Hz, 1H), 4.95-4.78 (m, 1H), 3.66 (d, 3.7 Hz, 3H), 1.65 (dd, 9.2, 7.2 Hz, 3H).	491	D	
I-864		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(Nc3ncnc4ccccc34)c12	1H NMR (400 MHz, DMSO-d6) 9.84 (s, 1H), 9.21 (d, 35.3 Hz, 1H), 8.52 (s, 1H), 7.96 (d, 8.3 Hz, 1H), 7.89 - 7.67 (m, 4H), 7.52 (td, 7.4, 6.7, 1.4 Hz, 1H), 7.24 - 6.86 (m, 2H), 6.77 - 6.39 (m, 1H), 6.03 (s, 1H).	483	E	
I-865		Fc1ccc(Cl)c(c1)[C@@H]1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1ccn[nH]1	NMR (400 MHz, CD3CN) 8.67 (br s, 1H), 8.10 (d, 1.3 Hz, 1H), 8.05 (s, 1H), 7.68 (d, 2.4 Hz, 1H), 7.63 (d, 8.5 Hz, 1H), 7.59 (d, 9.0 Hz, 1H), 7.57 (s, 1H), 7.24 (dd, 8.9, 5.1 Hz, 2H), 6.99-6.91 (m, 1H), 6.79 (d, 2.4 Hz, 1H), 6.68 (br s, 1H), 6.14 (br s, 1H).	533.3	A	A
I-866		Fc1ccc(Cl)c(c1)[C@H]1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1ccn[nH]1	1H NMR (400 MHz, CD3CN) 8.67 (br s, 1H), 8.10 (d, 1.3 Hz, 1H), 8.05 (s, 1H), 7.68 (d, 2.4 Hz, 1H), 7.63 (d, 8.5 Hz, 1H), 7.59 (d, 9.0 Hz, 1H), 7.57 (s, 1H), 7.24 (dd, 8.9, 5.1 Hz, 2H), 6.99-6.91 (m, 1H), 6.79 (d, 2.4 Hz, 1H), 6.68 (br s, 1H), 6.14 (br s, 1H).	533.3	D	





I-867		Cn1ccc(Nc2cc3C(=O)NC(c3c(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c2)c2cc(F)ccc2Cl)n1	NMR (400 MHz, DMSO-d6) 10.41 (s, 1H), 8.98 (br. s, 1H), 8.92 (s, 1H), 7.92 (d, 8.4 Hz, 1H), 7.72 (d, 1.9 Hz, 1H), 7.70 (d, 8.6 Hz, 1H), 7.61 (s, 1H), 7.56 (d, 2.2 Hz, 1H), 7.39 (d, 1.5 Hz, 1H), 7.29 (dd, 8.9, 5.2 Hz, 1H), 7.07 (td, 8.4, 3.0 Hz, 1H), 6.59 (br. s, 1H), 5.85 (br. s, 1H), 5.82 (d, 2.2 Hz, 1H), 3.77 (s, 3H).	562.3	A	
I-868		Fc1ccc(Cl)c(c1)[C@@H]1NC(=O)c2cc(NCC3(CC3)C#N)cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	(400 MHz, DMSO-d6) 10.32 (s, 1H), 8.94 (s, 1H), 7.92 (d, 8.3 Hz, 1H), 7.70 (d, 8.9 Hz, 1H), 7.62 (s, 1H), 7.28 (dd, 8.8, 5.2 Hz, 1H), 7.06 (td, 8.5, 2.9 Hz, 1H), 6.92 (d, 1.6 Hz, 1H), 6.79 (s, 1H), 6.62 (br s, 1H), 6.57 (br t, 5.6 Hz, 1H), 5.84 (br s, 1H), 3.30 (m, 2H), 1.33-1.17 (m, 2H), 1.14-0.98 (m, 2H).	561.4	A	A
I-869		Fc1ccc(Cl)c(c1)[C@H]1NC(=O)c2cc(NCC3(CC3)C#N)cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	(400 MHz, DMSO-d6) 10.32 (s, 1H), 8.94 (s, 1H), 7.92 (d, 8.3 Hz, 1H), 7.70 (d, 8.9 Hz, 1H), 7.62 (s, 1H), 7.28 (dd, 8.8, 5.2 Hz, 1H), 7.06 (td, 8.5, 2.9 Hz, 1H), 6.92 (d, 1.6 Hz, 1H), 6.79 (s, 1H), 6.62 (br s, 1H), 6.57 (br t, 5.6 Hz, 1H), 5.84 (br s, 1H), 3.30 (m, 2H), 1.33-1.17 (m, 2H), 1.14-0.98 (m, 2H).	561.4	B	
I-870		Cn1cc2c(cc(F)cc2n1)C(=O)Nc1cccc2C(=O)NC(c12)c1cc(F)ccc1Cl	NMR (400 MHz, CD3CN) 8.51 (s, 1H), 8.25 (s, 1H), 7.76 (dd, 7.2, 1.3 Hz, 1H), 7.65 (t, 7.4 Hz, 1H), 7.60 (dd, 7.7, 1.0 Hz, 1H), 7.46 (ddd, 9.8, 2.1, 1.0 Hz, 1H), 7.22 (dd, 8.9, 5.1 Hz, 1H), 7.24-7.20 (m, 1H), 6.98-6.91 (m,	453.5	E	





			2H), 6.64 (br. s, 1H), 6.18 (br. s, 1H), 4.15 (s, 3H).			
I-871		Cn1ncc2c(cc(F)cc12)C(=O)Nc1cccc2C(=O)NC(c12)c1cc(F)ccc1Cl	NMR (400 MHz, CD3CN) 8.54 (s, 1H), 8.06 (s, 1H), 7.76 (dd, 7.1, 1.3 Hz, 1H), 7.65 (t, 7.5 Hz, 1H), 7.61 (dd, 7.9, 1.4 Hz, 1H), 7.43 (ddd, 9.2, 2.0, 1.0 Hz, 1H), 7.24 (dd, 8.9, 5.2 Hz, 1H), 7.25-7.22 (submerged signal, 1H), 6.99-6.92 (m, 2H), 6.66 (br. s, 1H), 6.20 (br. s, 1H), 4.02 (s, 3H).	453.3	E	
I-872		Fc1ccc(Cl)c(c1)C1NC(=O)c2cccc(NC(=O)c3cc(F)ccc3NC3CCC3)c12	NMR (400 MHz, DMSO-d6) 10.02 (s, 1H), 9.11 (s, 1H), 7.66 (dd, 7.3, 0.7 Hz, 1H), 7.61 (t, 7.5 Hz, 1H), 7.47 (dd, 7.6, 0.9 Hz, 1H), 7.39 (d, 6.1 Hz, 1H), 7.36 (dd, 8.9, 5.2 Hz, 1H), 7.16-7.13 m, 2H), 6.82 (dd, 9.9, 2.2 Hz, 1H), 6.54 (dd, 9.3, 4.7 Hz, 1H), 6.70-6.40 (m, 1H), 6.01 (s, 1H), 3.94-3.81 (m, 1H), 2.44-2.29 (m, 2H), 1.82-1.68 (m, 4H)	468.4	D	
I-873		CC1(C)CC(COc2cc3C(=O)NC(c3c(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c2)c2cc(F)ccc2Cl)O1	1H NMR (400 MHz, DMSO-d6) 10.44 (s, 1H), 9.10 (s, 1H), 7.92 (d, 7.6 Hz, 1H), 7.72 (d, 8.8 Hz, 1H), 7.65 (s, 1H), 7.35-7.28 (m, 1H), 7.23 (s, 1H), 7.14 (s, 1H), 7.11-7.03 (m, 1H), 6.63 (s (br), 1H), 5.92 (s (br), 1H), 4.90-4.77 (m, 1H), 4.27-4.12 (m, 2H), 2.47-2.32 (m, 2H), 1.42 (s, 3H), 1.40-1.37 (m, 3H).	581.2	B	






I-874		CNc1cc(ccn1)C1NC(=O)c2cccc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	(400 MHz, d6-DMSO) 9.05 (br s, 2H), 7.86 (s, 1H), 7.83 (d, 8.3 Hz, 1H), 7.79 (br d, 9.4 Hz, 1H), 7.71 (d, 5.2 Hz, 1H), 7.63-7.56 (m, 1H), 7.49 (s, 1H), 7.48 (d, 5.0 Hz, 1H), 6.28-6.21 (m, 1H), 6.09 (s, 1H), 6.04 (dd, 5.3, 1.0 Hz, 1H), 5.50 (s, 1H), 2.54 (d, 4.8 Hz, 3H).	445.4	E	
I-875		Cc1ccc(cc1C(F)(F)F)C(=O)Nc1cc(Br)cc2C(=O)NC(c12)c1cc(F)ccc1Cl	NMR (400 MHz, CD3CN) 8.57 (s, 1H), 7.87 (d, 1.7 Hz, 1H), 7.75 (s, 1H), 7.72-7.66 (m, 2H), 7.44 (d, 7.9 Hz, 1H), 7.30 (br s, 1H), 7.25 (dd, 8.9, 5.1 Hz, 1H), 6.97 (ddd, 8.8, 8.0, 3.1 Hz, 1H), 6.67 (br s, 1H), 6.09 (s, 1H), 2.52 (d, 1.6 Hz, 3H).	541	B	
I-876		Fc1ccc(Cl)c(c1)C1NC(=O)c2cccc(NC(=O)C34CC5CC(CC(C5)C3)C4)c12	1H NMR (400 MHz, DMSO-d6) 9.09 (s, 1H), 9.06 (br. s, 1H), 7.60-7.53 (m, 2H), 7.52-7.46 (m, 1H), 7.40 (dd, 7.4, 1.5 Hz, 1H), 7.24 (ddd, 8.7, 8.2, 3.1 Hz, 1H), 6.45 (br. s, 1H), 6.04 (br. s, 1H), 1.92-1.85 (m, 3H), 1.66-1.60 (m, 3H), 1.58-1.47 (m, 9H).	439.4	B	
I-877		COc1ccc(cc1C(F)(F)F)C(=O)Nc1cc(Br)cc2C(=O)NC(c12)c1cc(F)ccc1Cl	NMR (400 MHz, DMSO-d6) 10.34 (s, 1H), 9.27 (br s, 1H), 7.93 (dd, 8.8, 1.9 Hz, 1H), 7.78 (d, 1.6 Hz, 1H), 7.74 (d, 2.0 Hz, 1H), 7.70 (d, 1.5 Hz, 1H), 7.34 (d, 8.9 Hz, 1H), 7.30 (dd, 8.9, 5.2 Hz, 1H), 7.13-7.02 (m, 1H), 5.98 (s, 1H), 3.96 (s, 3H).	555	C	





I-878		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1cn[nH]c1	NMR (400 MHz, DMSO-d6) 13.07 (br.s, 1H), 10.56 (br. s, 1H), 9.12 (br. s, 1H), 8.41-8.11 (m, 2H), 7.95 (br. d, 6.5 Hz, 1H), 7.94 (s, 1H), 7.76 (br.d, 9.8 Hz, 1H), 7.73 (s, 1H), 7.71 (s, 1H), 7.31 (dd, 8.9, 5.2 Hz, 1H), 7.09 (td, 8.5, 3.1 Hz, 1H), 6.65 (br. s, 1H), 5.97 (br. s, 1H).	533.2	A	A
I-879		Cn1cc(nn1)-c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	NMR (400 MHz, MeCN-D3) Major rotamer: 8.72 (s, 1H), 8.23 (s, 1H), 8.12 (d, 1.3 Hz, 1H), 8.10 (d, 1.3 Hz, 1H), 7.67 - 7.60 (m, 2H), 7.59 (s, 1H), 7.28 - 7.25 (m, 1H), 7.26 (dd, 8.9, 5.1 Hz, 1H), 6.98 (ddd, 8.9, 8.0, 3.1 Hz, 1H), 6.71 (br. s, 1H), 6.16 (br. s, 1H), 4.11 (s, 3H).	548.1	A	
I-880		Cn1c(Nc2cccc3C(=O)NC(c23)c2cc(F)ccc2Cl)nnc1C1CC1	1H-NMR (400 MHz, DMSO-d6) 8.95 (br. s, 1H), 8.47 (br. s, 1H), 7.50 (t, 7.4 Hz, 1H), 7.44-7.38 (m, 2H), 7.32 (d, 7.7 Hz, 1H), 7.20 (td, 8.5, 3.1 Hz, 1H), 6.30-6.24 (m, 1H), 5.76 (br. s, 1H), 2.94 (s, 3H), 1.83-1.74 (m, 1H), 0.98-0.86 (m, 4H). Peak at 8.38 suspected to be due to presence of formate salt. Multiplet at 0.83-0.75 may be due to grease.	398.4	E	
I-881		COc1ncc(cn1)-c1cc2C(=O)N[C@@H](c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl		575.2	D	





I-882		COc1ncc(cn1)-c1cc2C(=O)N[C@H](c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl		575.2	A	A
I-883		Fc1ccc(Cl)c(c1)[C@H]1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1cnc2nccn2c1		584.2	D	
I-884		Fc1ccc(Cl)c(c1)[C@@H]1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1cnc2nccn2c1		584.3	A	A
I-885		Nc1ncc(cn1)-c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	1H NMR (400 MHz, DMSO-d6) 10.50-10.59 (m, 1H), 9.13-9.21 (m, 1H), 8.66-8.71 (m, 2H), 7.90-7.96 (m, 2H), 7.71-7.80 (m, 2H), 7.69 (s, 1H), 7.31 (dd, 5.18, 8.97 Hz, 1H), 7.09 (dt, 3.03, 8.34 Hz, 1H), 6.90 (s, 2H), 2.92-3.04 (m, 2H)	560.31	A	
I-886		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-	1H NMR (400 MHz, DMSO-d6) Shift 10.72 (br s, 1H), 9.44-9.55 (m, 2H), 9.30 (br s, 1H), 8.24 (s, 1H), 8.04 (s, 1H), 7.95 (br d, 8.08 Hz, 1H), 7.76 (br d, 8.84 Hz, 1H), 7.70 (s, 1H), 7.33 (dd, 5.31,	570.31	A	






		c1cnc(nc1)C#N	8.84 Hz, 1H), 7.10 (dt, 3.16, 8.40 Hz, 1H), 5.97-6.15 (m, 1H)			
I-887		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1ccncc1F	1H NMR (400 MHz, DMSO-d6) Shift 10.66 (br s, 1H), 9.29 (br s, 1H), 8.73 (d, 2.78 Hz, 1H), 8.56 (dd, 0.76, 5.05 Hz, 1H), 7.90-8.02 (m, 2H), 7.73-7.86 (m, 3H), 7.68 (s, 1H), 7.33 (dd, 5.18, 8.97 Hz, 1H), 7.11 (dt, 3.16, 8.40 Hz, 1H), 5.96-6.14 (m, 1H)	562.41	A	A
I-888		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1cccnc1	1H NMR (400 MHz, DMSO-d6) Shift 10.62 (s, 1H), 9.24 (br s, 1H), 8.99 (d, 2.02 Hz, 1H), 8.63 (dd, 1.52, 4.80 Hz, 1H), 8.17-8.25 (m, 1H), 8.01 (d, 1.52 Hz, 1H), 7.95 (br d, 8.59 Hz, 1H), 7.86 (s, 1H), 7.76 (br d, 8.84 Hz, 1H), 7.69 (s, 1H), 7.57-7.67 (m, 2H), 7.49-7.57 (m, 3H), 7.33 (dd, 5.05, 8.84 Hz, 1H), 7.10 (dt, 3.16, 8.40 Hz, 1H), 5.95-6.15 (m, 1H)	544.45	A	
I-889		Cn1ccc(cc1=O)-c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	1H NMR (400 MHz, DMSO-d6) 10.59 (br s, 1H), 9.24 (br s, 1H), 7.92-7.97 (m, 2H), 7.84 (s, 1H), 7.82 (s, 1H), 7.75 (br d, 8.84 Hz, 1H), 7.69 (s, 1H), 7.32 (dd, 5.18, 8.97 Hz, 1H), 7.09 (dt, 3.03, 8.34 Hz, 1H), 6.75 (d, 2.02 Hz, 1H), 6.68 (dd, 2.02, 7.07 Hz, 1H), 5.97-6.10 (m, 1H), 3.47 (s, 3H)	574.36	A	
I-890		Cc1cnccc1-c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c	1H NMR (400 MHz, DMSO-d6) 10.59 (s, 1H), 9.25 (br s, 1H), 8.56 (s, 1H), 8.50 (d, 4.80 Hz, 1H), 8.26 (s, 1H), 7.94 (br d, 8.34 Hz, 1H), 7.73 (br d, 9.09 Hz, 1H), 7.62-7.69	558.41	A	





		1cc(F)ccc 1Cl	(m, 2H), 7.52 (s, 1H), 7.28-7.38 (m, 2H), 7.10 (dt, 3.03, 8.34 Hz, 1H), 5.96-6.14 (m, 1H), 2.31 (s, 3H)			
I-891		COc1ccc c(n1)-c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	1H NMR (400 MHz, DMSO-d6) 10.58 (s, 1H), 9.23 (br s, 1H), 8.53 (s, 1H), 8.33 (d, 4.80 Hz, 1H), 7.94 (br d, 8.34 Hz, 1H), 7.86 (d, 1.01 Hz, 1H), 7.70-7.80 (m, 2H), 7.67 (s, 1H), 7.46 (d, 4.80 Hz, 1H), 7.33 (dd, 5.18, 8.97 Hz, 1H), 7.10 (dt, 3.03, 8.46 Hz, 1H), 5.98-6.13 (m, 1H), 3.95 (s, 3H)	574.41	A	
I-892		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1cccnc1C(F)(F)F	1H NMR (400 MHz, DMSO-d6) Shift 10.62 (s, 1H), 9.21-9.35 (m, 1H), 8.83 (dd, 1.14, 4.67 Hz, 1H), 8.04 (d, 7.58 Hz, 1H), 7.93 (br d, 8.59 Hz, 1H), 7.83 (dd, 4.67, 7.96 Hz, 1H), 7.73 (br d, 8.84 Hz, 1H), 7.64 (br d, 6.06 Hz, 2H), 7.48 (br s, 1H), 7.34 (dd, 5.18, 8.97 Hz, 1H), 7.11 (dt, 3.16, 8.40 Hz, 1H), 5.94-6.12 (m, 1H)	612.38	A	
I-893		Fc1ccc(Cl)c(c1)[C@H]1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1ccc2nccc2c1		594.3	D	
I-894		Fc1ccc(Cl)c(c1)[C@@H]1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)		594.3	A	A





		F)c12)-c1ccc2nccccc2c1				
I-895		Cc1ncc(cn1)-c1cc2C(=O)N[C@@H](c2c(NC(=O)c2cc(F)cc(Cl)c2)c1)c1cc(F)ccc1Cl		525.2	E	
I-896		Cc1ncc(cn1)-c1cc2C(=O)N[C@H](c2c(NC(=O)c2cc(F)cc(Cl)c2)c1)c1cc(F)ccc1Cl		525.2	A	
I-897		OC1(Cc2cc3C(=O)N[C@@H](c3c(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c2)c2cc(F)ccc2Cl)CCC1		549.2	D	
I-898		OC1(Cc2cc3C(=O)N[C@H](c3c(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c2)c2cc(F)ccc2Cl)CCC1		549.2	A	
I-899		CC(C)(O)CNc1cc2C(=O)N[C@@H](c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl		554.3	E	





I-900		CC(C)(O)CNc1cc2C(=O)N[C@H](c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl		554.3	A	A
I-901		Cn1cccc(-c2cc3C(=O)NC(c3c(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c2)c2cc(F)ccc2Cl)c1=O	1H NMR (500 MHz, DMSO-d6) 10.57 (s, 1H), 9.10-9.18 (m, 1H), 8.04 (s, 1H), 7.89-7.99 (m, 2H), 7.83 (dt, 2.29, 4.65 Hz, 2H), 7.76 (br d, 8.85 Hz, 1H), 7.70 (s, 1H), 7.34 (dd, 5.19, 8.85 Hz, 1H), 7.08-7.14 (m, 1H), 6.40 (t, 6.87 Hz, 1H), 5.93-6.09 (m, 1H), 3.56 (s, 3H)	574.32	B	B
I-902		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1cccc2cnccc12	1H NMR (500 MHz, DMSO-d6) 10.63 (s, 1H), 9.45 (s, 1H), 9.25-9.32 (m, 1H), 8.58 (d, 6.10 Hz, 1H), 8.25 (d, 8.24 Hz, 1H), 7.93-7.98 (m, 1H), 7.87-7.90 (m, 1H), 7.84 (d, 7.93 Hz, 1H), 7.73-7.80 (m, 3H), 7.63-7.71 (m, 2H), 7.38 (dd, 5.19, 8.85 Hz, 1H), 7.11-7.17 (m, 1H), 6.08-6.18 (m, 1H)	594.32	A	A
I-903		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1cnn(c1)C1CNC1	1H NMR (500 MHz, DMSO) 10.51 (s, 1H), 9.14 (s, 1H), 8.95 (d, 89.5 Hz, 2H), 8.54 (s, 1H), 8.28 (s, 1H), 7.98-7.89 (m, 2H), 7.76-7.68 (m, 3H), 7.31 (dd, 8.8, 5.2 Hz, 1H), 7.09 (td, 8.4, 3.1 Hz, 1H), 5.97 (s, 1H), 5.46-5.36 (m, 1H), 4.47-4.34 (m, 4H).	588.375	A	D





I-904		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1cnn(c1)C1COC1	1H NMR (500 MHz, DMSO) 10.51 (s, 1H), 9.12 (s, 1H), 8.60 (s, 1H), 8.17 (s, 1H), 7.98-7.90 (m, 2H), 7.79-7.67 (m, 3H), 7.30 (dd, 8.9, 5.2 Hz, 1H), 7.09 (qd, 8.4, 2.0 Hz, 1H), 5.96 (s, 1H), 5.63-5.55 (m, 1H), 4.98-4.89 (m, 4H).	589.38	A	A
I-905		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1ccc2nccn2n1	1H NMR (500 MHz, DMSO) 10.68 (s, 1H), 9.28 (s, 1H), 8.40-8.32 (m, 2H), 8.29-8.21 (m, 2H), 8.00-7.94 (m, 2H), 7.86 (d, 1.2 Hz, 1H), 7.78 (dd, 9.2, 2.5 Hz, 1H), 7.72 (s, 1H), 7.33 (dd, 8.9, 5.1 Hz, 1H), 7.10 (td, 8.4, 3.0 Hz, 1H), 6.08 (s, 1H).	584.37	A	A
I-906		Cn1nccc1-c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	NMR (400 MHz, CD3CN) 8.76 (br. s, 1H), 7.84 (d, 1.5 Hz, 1H), 7.68-7.64 (m, 2H), 7.64-7.57 (m, 2H), 7.49 (d, 1.9 Hz, 1H), 7.36 (br. s, 1H), 7.27 (dd, 8.9, 5.1 Hz, 1H), 6.99 (ddd, 8.9, 8.0, 3.1 Hz, 1H), 6.70 (br. s, 1H), 6.47 (d, 1.9 Hz, 1H), 6.19 (br. s, 1H), 3.93 (s, 3H).	547.4	A	A
I-907		Fc1cc(cc(c1)C(F)(F)F)C(=O)Nc1ccccc2C(=O)NC(c12)c1ccccc1C1COC1	1H NMR (400 MHz, DMSO-d6) 10.44 (br. s, 1H), 9.06 (s, 1H), 7.90 (d, 8.4 Hz, 1H), 7.71 (d, 5.2 Hz, 1H), 7.63 (t, 7.6 Hz, 1H), 7.53-7.22 (m, 5H), 7.09 (br. s, 1H), 6.41 (br. s, 1H), 5.74 (s, 1H), 5.03-4.43 (m, 4H), 4.16 (m, 1H); DMSO satellites at 2.67 and 2.33 ; TMS containing minor impurities in 0.08 - 0.03 region.	471.2	E	





I-908		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(NC(=O)c3cc(cc(F)c3F)C(F)(F)F)c12	1H NMR (400 MHz, Methanol-d4) 7.97 (d, 1.7 Hz, 1H), 7.90 (ddd, 9.5, 6.8, 2.3 Hz, 1H), 7.76 (s, 1H), 7.41 (dt, 8.2, 4.1 Hz, 2H), 7.11 (ddd, 8.9, 7.8, 3.1 Hz, 1H), 6.69 (s, 1H), 6.20 (s, 1H).	565	D	
I-909		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(NC(=O)c3cncc(Cl)c3)c12	1H NMR (400 MHz, Chloroform-d) 8.76 (s, 1H), 8.55 (s, 1H), 8.43 (s,1H), 7.97 (d, 1.6 Hz, 1H), 7.88 (s, 1H), 7.47 (dd, 8.4, 4.3 Hz, 2H), 7.11 (m, 1H), 6.72 (s, 1H), 6.53 (s, 1H), 6.20 (s, 1H).	495.95	D	
I-910		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(NC(=O)c3cc(F)cc(c3)C#N)c12	1H NMR (400 MHz, Chloroform-d) 8.50 (s, 1H), 7.97 (d, 1.6 Hz, 1H), 7.57 (td, 10.5, 9.9, 6.3 Hz, 3H), 7.42-7.38 (m, 2H), 7.22-7.12 (m, 1H), 6.74 (s, 1H), 6.52 (s, 1H), 6.19 (s, 1H).		D	
I-911		FC(F)c1ccc(Cl)cc1C(=O)Nc1cc(Br)cc2C(=O)NC(c12)c1cc(F)ccc1Cl	1H NMR (400 MHz, Chloroform-d) 8.45 (s, 1H), 7.96 (q, 1.8 Hz, 1H), 7.73 (d, 8.4 Hz, 1H), 7.61 (dd, 8.4, 2.0 Hz, 1H), 7.45-7.22 (m, 2H), 7.18-7.06 (m, 2H), 6.95 (d, 4.1 Hz, 1H), 6.72 (d, 8.5 Hz, 1H), 6.58 (s, 1H), 6.17 (s, 1H).	544.95	D	
I-912		CS(=O)(=O)c1cc(F)cc(c1)C(=O)Nc1cc(Br)cc2C(=O)NC(c12)c1cc(F)ccc1Cl	1H NMR (400 MHz, Chloroform-d) 8.34 (s, 1H), 7.94 (d, 1.6 Hz, 1H), 7.87-7.81 (m, 3H), 7.67 (ddd, 8.3, 2.4, 1.5 Hz, 1H), 7.46 (dd, 8.9, 4.9 Hz, 1H), 7.07 (ddd, 8.9, 7.4, 3.0 Hz, 1H), 6.73-6.64 (m, 2H), 6.21 (s, 1H), 3.12 (s, 3H).	557	E	






I-913		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(I)cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	(400 MHz, DMSO-d6) 10.54 (s, 1 H), 9.22 (s, 1 H), 8.03-7.80 (m, 3 H), 7.72 (d, 9.0 Hz, 1 H), 7.66 (s, 1 H), 7.32 (dd, 8.9, 5.2 Hz, 1 H), 7.09 (td, 8.5, 3.0 Hz, 1 H), 6.66 (br s, 1 H), 5.93 (br s, 1 H).	591.3	A	A
I-914		CSCc1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	NMR (400 MHz, DMSO-d6) 10.52 (s, 1H), 9.14 (s, 1H), 7.93 (t, 8.7 Hz, 1H), 7.74 (d, 9.2 Hz, 1H), 7.64 (d, 6.4 Hz, 2H), 7.44 (s, 1H), 7.31 (dd, 8.9, 5.2 Hz, 1H), 7.09 (td, 8.4, 3.0 Hz, 1H), 5.97 (br, s, 1H), 4.00-3.75 (m, 2H), 1.99 (s,3H).	527.3	A	A
I-915		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1ncco1	NMR (400 MHz, DMSO) 10.69 (s, 1H), 9.33 (s, 1H), 8.33 (s, 1H), 8.16 (s, 2H), 7.96 (d, 8.3 Hz, 1H), 7.77 (d, 8.9 Hz, 1H), 7.68 (s, 1H), 7.48 (s, 1H), 7.34 (dd, 8.8, 5.2 Hz, 1H), 7.10 (td, 8.5, 3.1 Hz, 1H), 6.08 (s, 1H).Ortho proton of the B-ring is missing	534	A	A
I-916		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1ccc[nH]c1=O	NMR (400 MHz, DMSO) 12.00 (s, 1H), 10.59 (s, 1H), 9.15 (s, 1H), 8.07 (m, 1H), 7.94 (m, 2H), 7.85 (dd, 7.0, 2.0 Hz, 1H), 7.75 (d, 8.7 Hz, 1H), 7.68 (s, 1H), 7.47 (dd, 6.3, 1.4 Hz, 1H), 7.33 (dd, 8.9, 5.2 Hz, 1H), 7.10 (td, 8.4, 3.1 Hz, 1H), 6.36 (t, 6.7 Hz, 1H), 5.99 (s, 1H). Ortho proton of B-ring is missing	560	A	A





I-917		Cn1cc(Nc2cc3C(=O)NC(c3c(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c2)c2cc(F)ccc2Cl)cn1	NMR (400 MHz, DMSO-d6) 10.30 (s, 1H), 8.96 (bs, 1H), 7.95 (s, 1H), 7.92 (d, 8.5 Hz, 1H), 7.74 (s, 1H), 7.69 (d, 9.1 Hz, 1H), 7.60 (s, 1H), 7.38 (s, 1H), 7.28 (dd, 8.8, 5.1 Hz, 1H), 7.06 (td, 8.3, 2.9 Hz, 1H), 6.96 (d, 1.6 Hz, 1H), 6.84 (d, 1.5 Hz, 1H), 6.69 (bs, 1H), 5.85 (bs, 1H), 3.83 (s, 3H).	262.4	A	A
I-918		Fc1ccc(Cl)c(c1)[C@H]1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1ncc[nH]1	NMR (400 MHz, DMSO-d6) 12.83 (br. s, 1H), 10.65 (s, 1H), 9.22 (s, 1H), 8.37 (s, 1H), 8.27 (d, 0.7 Hz, 1H), 8.14 (d, 1.0 Hz, 1H), 7.96 (d, 8.3 Hz, 1H), 7.77 (d, 8.6 Hz), 7.69 (s, 1H), 7.32 (dd, 8.9, 5.2 Hz, 1H), 7.34-7.07 (m, sumerged 1H), 7.09 (td, 8.5, 3.0 Hz, 1H), 6.66 (br. s, 1H), 6.02 (br. s, 1H).	533.2	C	
I-919		Fc1ccc(Cl)c(c1)[C@@H]1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1ncc[nH]1	NMR (400 MHz, DMSO-d6) 12.83 (br. s, 1H), 10.65 (s, 1H), 9.22 (s, 1H), 8.37 (s, 1H), 8.27 (d, 0.7 Hz, 1H), 8.14 (d, 1.0 Hz, 1H), 7.96 (d, 8.3 Hz, 1H), 7.77 (d, 8.6 Hz), 7.69 (s, 1H), 7.32 (dd, 8.9, 5.2 Hz, 1H), 7.34-7.07 (m, sumerged 1H), 7.09 (td, 8.5, 3.0 Hz, 1H), 6.66 (br. s, 1H), 6.02 (br. s, 1H).	533.2	A	A
I-920		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1cscn1	NMR (400 MHz, CD3CN) 9.01 (d, 1.9 Hz, 1H), 8.76 (br s, 1H), 8.29 (d, 1.4 Hz, 1H), 8.25 (s, 1H), 8.02 (d, 1.9 Hz, 1H), 7.70-7.59 (m, 3H), 7.32 (br s, 1H), 7.27 (dd, 8.9, 5.1 Hz, 1H), 6.98 (ddd, 8.8, 8.0, 3.1 Hz, 1H), 6.72 (br s, 1H), 6.18 (br s, 1H).	550.3	A	A





I-921		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1nccs1	NMR (400 MHz, CD3CN) 8.76 (s, 1H), 8.20 (m, 2H), 7.93 (d, 3.6, 1H), 7.65-7.55 (m, 4H), 7.35 (br s, 1H), 7.25 (dd, 8.9, 5.1 Hz, 1H), 6.99 (ddd, 8.8, 8.0, 3.1 Hz, 1H), 6.69 (br s, 1H), 6.16 (br s, 1H).	550.3	A	A
I-922		Cn1nccc1Nc1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	NMR (400 MHz, DMSOd6) 10.37 (s, 1H), 9.04 (s, 1H), 8.45 (s, 1H), 7.93 (d, 8.5 Hz, 1H), 7.69 (d, 9.2 Hz, 1H), 7.59 (s, 1H), 7.42 (d, 1.9 Hz, 1H), 7.30 (dd, 8.9, 5.2 Hz, 1H), 7.07 (td, 8.3, 3.1 Hz, 1H), 7.02 (d, 2.0 Hz, 1H), 6.93 (d, 1.64 Hz, 1H), 6.63 (bs, not well resolved, 1H), 6.12 (d, 1.9 Hz, 1H), 5.90 (bs, 1H), 3.68 (s, 3H).	562.3	A	A
I-923		Cc1noc(C)c1Nc1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	NMR (400 MHz, CD3CN) 8.47 (br s, 1H), 7.60 (br d, 1H), 7.55 (d, 12.2 Hz, 1H), 7.51 (s, 1H), 7.22 (dd, 8.9, 5.1 Hz, 1H), 7.15 (br s, 1H), 6.93 (ddd, 11.1, 7.0, 3.1 Hz, 1H), 6.86 (d, 2.1 Hz, 1H), 6.76 (d, 1.8 Hz, 1H), 6.62 (br s, 1H), 6.17 (s, 1H), 5.99 (br s, 1H), 2.26 (s, 3H), 2.08 (s, 3H).	577.5	A	A
I-924		Cc1nn(C)cc1Nc1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	NMR (400 MHz, DMSOd6) 10.29 (s, 1H), 8.94 (s, 1H), 7.91 (d, 8.7 Hz, 1H), 7.68 (submerged br. d, 1H), 7.67 (s, 1H), 7.60-7.58 (m, 1H), 7.28 (dd, 8.9, 5.2 Hz, 1H), 7.06 (td, 8.3, 3.1 Hz, 1H), 6.82 (d, 2.0 Hz, 1H), 6.72 (d, 1.8 Hz, 1H), 6.60 (bs, not well resolved, 1H), 5.83 (bs, 1H), 3.76 (s, 3H), 2.02 (s, 3H).	576.3	A	A





			Presence of 20% formate salt (8.38).			
I-925		Fc1cc(cc(c1)C(F)(F)F)C(=O)Nc1ccc2C(=O)NC(c12)c1ccccc1C1CC1	1H NMR (400 MHz, DMSO-d6) 10.15 (br. s, 1H), 8.85 (s, 1H), 7.79 (d, 8.4 Hz, 1H), 7.69 (d, 7.5 Hz, 1H), 7.61 (t, 7.6 Hz, 1H), 7.54-7.47 (m, 3H), 7.08 (t, 7.8 Hz, 1H), 6.95 (t, 7.7 Hz, 1H), 6.85 (d, 7.6 Hz, 1H), 6.66 (br. s, 1H), 6.21 (br. s, 1H), 1.88 (s), 0.74-0.47 (m, 1H), 0.70 - 0.50 (m, 3H), 0.47-0.39 (m, 1H); DMSO satellites at 2.68 and 2.33 .	455.3	B	
I-926		OC1(Cc2cc3C(=O)NC(c3c(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c2)c2cc(F)ccc2Cl)CNC1	NMR (400 MHz, DMSO-d6) 10.54 (s, 1H), 9.07 (s, 1H), 8.34 (s, 1H), 7.90 (d, 8.6 Hz, 1H), 7.69 (d, 8.7 Hz, 1H), 7.59 (d, 4.4 Hz, 2H), 7.36 (s, 1H), 7.27 (dd, 8.9, 5.2 Hz, 1H), 7.05 (td, 8.4, 3.1 Hz, 1H), 6.58 (br., 1H), 6.21 (br, 1H), 5.90 (s, 1H), 3.65 (d, 9.6 Hz, 2H), 3.58 (d, 9.8 Hz, 2H)3.13 (dd, 13.9 Hz, 9.6Hz, 2H).	552.3	A	D
I-927		Cc1cc(cc2cnn(C)c12)-c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl			B	C
I-928		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-			A	A






		c1ccc(nc1)C#N				
I-929		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1ccc(nc1)N1CCOCC1			A	A
I-930		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1cnc(nc1)N1CCOCC1			A	B
I-931		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1cccc2ncccc12			A	A
I-932		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1ccc2OCCOc2c1			B	B






I-933		Cc1cc2cnn(C)c2cc1-c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl			B	C
I-934		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1ccnc2ccccc12			A	A
I-935		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1cnoc1			A	A
I-936		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1n[nH]c2cccnc12			A	A
I-937		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1n[nH]c2ccccc12			B	B





I-938		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1n[nH]c2ccncc12			B	
I-939		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1n[nH]c2ncccc12			A	A
I-940		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1cnc2cnccn12			A	A
I-941		CC(C)(O)c1ncc(cn1)-c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl		603.5	B	A
I-942		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1cnn(c1)C1CC1		573.4	A	A





I-943		Fc1ccc(Cl)c(c1)[C@H]1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1ccc2ncnn2c1	^{1}H NMR (DMSO-d_6, 400 MHz): δ = 10.64 (s, 1H), 9.48 (s, 1H), 9.26 (br s, 1H), 8.58 (s, 1H), 8.10-8.19 (m, 2H), 7.99 (br d, J = 9.9 Hz, 3H), 7.75-7.83 (m, 1H), 7.73 (s, 1H), 7.35 (dd, J = 8.8, 5.3 Hz, 1H), 7.12 (td, J = 8.3, 3.0 Hz, 1H), 6.51-6.97 (m, 1H), 6.07 (br s, 1H).	584.3	C	
I-944		CC(C)(C)OC(=O)N1CC(C1)n1cc(cn1)-c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl		588.37	A	C
I-945		Fc1ccc(Cl)c(c1)[C@@H]1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1ccc2ncnn2c1	^{1}H NMR (DMSO-d_6, 400 MHz): δ = 10.64 (s, 1H), 9.48 (s, 1H), 9.26 (br s, 1H), 8.58 (s, 1H), 8.10-8.19 (m, 2H), 7.99 (br d, J = 9.9 Hz, 3H), 7.75-7.83 (m, 1H), 7.73 (s, 1H), 7.35 (dd, J = 8.8, 5.3 Hz, 1H), 7.12 (td, J = 8.3, 3.0 Hz, 1H), 6.51-6.97 (m, 1H), 6.07 ppm (br s, 1H).	584.3	A	A
I-946		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1cn2ccnc2cn1	1H NMR (500 MHz, DMSO) 10.64 (s, 1H), 9.51 (d, 1.5 Hz, 1H), 9.27-9.12 (m, 2H), 8.29 (d, 26.2 Hz, 2H), 8.15 (t, 0.9 Hz, 1H), 7.94 (d, 8.4 Hz, 1H), 7.91-7.84 (m, 1H), 7.78 (d, 9.0 Hz, 1H), 7.72 (s, 1H), 7.33 (dd, 8.9, 5.2 Hz, 1H), 7.09 (td, 8.3, 3.1 Hz, 1H), 6.06 (s, 1H).	584.37	A	A





I-947		Cn1ccc(n1)-c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	1H NMR (500 MHz, DMSO) 10.52 (s, 1H), 9.13 (s, 1H), 8.04 (d, 1.5 Hz, 1H), 7.98-7.88 (m, 2H), 7.83-7.66 (m, 3H), 7.31 (dd, 8.9, 5.1 Hz, 1H), 7.08 (td, 8.4, 3.2 Hz, 1H), 6.86 (d, 2.3 Hz, 1H), 5.99 (s, 1H), 3.91 (s, 3H).	547.41	A	A
I-948		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1cnc2ccccc2n1	1H NMR (500 MHz, DMSO-d6) 6.04 - 6.18 (m, 1 H) 6.52 (br d, 1.53 Hz, 1 H) 7.12 (td, 8.32, 2.90 Hz, 1 H) 7.36 (dd, 9.00, 5.04 Hz, 1 H) 7.73 - 7.78 (m, 1 H) 7.82 (br d, 8.85 Hz, 1 H) 7.89 - 8.03 (m, 3 H) 8.19 (td, 7.55, 1.68 Hz, 2 H) 8.52 (s, 1 H) 8.67 (s, 1 H) 9.31 (br d, 3.05 Hz, 1 H) 9.77 (s, 1 H) 10.76 (s, 1 H)	595.33	A	A
I-949		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1cc2cnccc2[nH]1	1H NMR (500 MHz, DMSO-d6) 7.09 - 7.14 (m, 1 H) 7.33 - 7.37 (m, 1 H) 7.66 (s, 1 H) 7.73 (s, 1 H) 7.78 (br d, 9.16 Hz, 1 H) 7.93 - 8.04 (m, 3 H) 8.18 (s, 1 H) 8.38 (s, 1 H) 8.45 (d, 6.71 Hz, 1 H) 9.27 - 9.38 (m, 2 H) 10.69 (s, 1 H) 13.57 (s, 1 H) 14.65 - 14.98 (m, 1 H)	583.32	A	B
I-950		Fc1cc(cc(c1)C(F)(F)F)C(=O)Nc1ccccc2c1n([nH]c2=O)-c1cccc(Cl)c1	1H NMR (400 MHz, DMSO-d6) 11.50 (br s, 1H), 10.65 (s, 1H), 7.94 (d, 12.7 Hz. 1H), 7.74 (m, 3H), 7.38 (d, 7.4 Hz, 1H), 7.33 (d, 8.2 Hz, 1H), 7.23(m, 3H), 7.05 (d, 8.0 Hz, 1H).	450.3	D	





I-951		Cc1cc(F)cc(c1)C(=O)Nc1cc(Br)cc2C(=O)NC(c12)c1cc(F)ccc1Cl	1H NMR (400 MHz, Chloroform-d) 8.52 (s, 1H), 7.94 (d, 1.7 Hz, 1H), 7.46 (dd, 8.9, 4.9 Hz, 1H), 7.32 (s, 1H), 7.15-7.04 (m, 3H), 6.97 (d, 8.7 Hz, 1H), 6.73 (s, 1H), 6.49 (s, 1H), 6.18 (s, 1H), 2.41 (d, 0.8 Hz, 3H).	493	D	
I-952		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(NC(=O)c3ccc(Cl)c(c3)C(F)(F)F)c12	1H NMR (400 MHz, Chloroform-d) 8.41 (s, 1H), 7.98 (d, 1.7 Hz, 1H), 7.74 (d, 5.3 Hz, 2H), 7.63 (d, 8.9 Hz, 1H), 7.45 - 7.36 (m, 2H), 7.13 - 7.03 (m, 1H), 6.71 (s, 1H), 6.44 (s, 1H), 6.18 (s, 1H).	560.85	B	
I-953		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(NC(=O)Cc3c[nH]c4ccccc34)c12	1H NMR (400 MHz, DMSO-d6) 10.87 (s, 1H), 9.71 (s, 1H), 9.20 (s, 1H), 7.71 (dd, 16.6, 1.7 Hz, 2H), 7.40 (dd, 8.9, 5.2 Hz, 1H), 7.36 - 7.30 (m, 1H), 7.35 - 7.25 (m, 1H), 7.15 (td, 8.5, 2.9 Hz, 1H), 7.11 - 7.03 (m, 1H), 7.01 (d, 2.4 Hz, 1H), 6.94 (ddd, 7.9, 6.9, 1.1 Hz, 1H), 6.65 (s, 1H), 6.02 (s, 1H), 3.46 (s, 2H).	512	E	
I-954		OC(=O)c1cc(F)cc(c1)C(=O)Nc1cc(Br)cc2C(=O)NC(c12)c1cc(F)ccc1Cl	1H NMR (400 MHz, DMSO-d6) 13.51 (s, 1H), 10.53 (s, 1H), 9.28 (s, 1H), 8.00 (d, 1.5 Hz, 1H), 7.89 - 7.79 (m, 2H), 7.72 (d, 1.9 Hz, 1H), 7.60 (dt, 9.2, 2.0 Hz, 1H), 7.33 (dd, 8.9, 5.2 Hz, 1H), 7.09 (td, 8.4, 3.1 Hz, 1H), 6.73 (s, 1H), 5.99 (s, 1H).	523	E	
I-955		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(NC(=O)Cc3n[nH]c4ccccc34)c12	1H NMR (400 MHz, DMSO-d6) 12.78 (s, 1H), 10.04 (s, 1H), 9.20 (s, 1H), 7.76 - 7.69 (m, 2H), 7.53 - 7.44 (m, 2H), 7.42 - 7.29 (m, 2H), 7.16 (t, 7.2 Hz, 1H), 7.10 - 6.30 (m,	513.05	E	





			2H), 6.00 (s, 1H), 3.70 (s, 2H), .			
I-956		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(NC(=O)c3c[nH]c4cccc(Cl)c34)c12	1H NMR (400 MHz, DMSO-d6) 11.89 (s, 1H), 9.93 (s, 1H), 9.23 (s, 1H), 7.80 (d, 1.9 Hz, 1H), 7.72 (d, 1.7 Hz, 1H), 7.49 - 7.40 (m, 2H), 7.27 - 7.10 (m, 4H), 6.78 (s, 1H), 6.11 (s, 1H).	532	D	
I-957		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(NC(=O)c3cncc(c3)C(F)(F)F)c12	1H NMR (400 MHz, DMSO-d6) 10.68 (s, 1H), 9.31 (s, 1H), 9.18 (s, 1H), 9.02 (s, 1H), 8.18 (s, 1H), 7.85 (s, 1H), 7.75 (s, 1H), 7.33 (dd, 8.9, 5.0 Hz, 1H), 7.10 (dd, 8.7, 3.0 Hz, 1H), 6.82 (t, 9.0 Hz, 1H), 5.97 (s, 1H).	530.1	D	
I-958		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(NC(=O)c3cncc(F)c3)c12	1H NMR (400 MHz, DMSO-d6) 10.52 (s, 1H), 9.30 (s, 1H), 8.78 (d, 2.8 Hz, 1H), 8.56 (d, 1.8 Hz, 1H), 7.87 - 7.79 (m, 2H), 7.75 (d, 1.8 Hz, 1H), 7.36 (dd, 8.8, 5.2 Hz, 1H), 7.19 - 7.09 (m, 1H), 6.76 (s, 1H), 5.99 (s, 1H).	479.95	E	
I-959		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(Nc3nccc4c(Cl)cc(F)cc34)c12	1H NMR (400 MHz, DMSO-d6) 9.27 (s, 1H), 9.14 (s, 1H), 8.09 (d, 6.0 Hz, 1H), 7.98 (dd, 8.6, 2.4 Hz, 1H), 7.73-7.66 (m, 2H), 7.65 (d, 9.8 Hz, 1H), 7.39 (d, 6.0 Hz, 1H), 7.06 (s, 1H), 6.93-6.84 (m, 1H), 6.30 (s, 1H), 5.80 (s, 1H).	533.95	B	A
I-960		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-n1cccn1	(400 MHz, DMSO-D6) 10.67 (s, 1 H), 9.29 (s, 1 H), 8.76 (d, 2.5 Hz, 1 H), 8.14 (d, 1.6 Hz, 1 H), 8.09 (d, 1.6 Hz, 1 H), 7.96 (d, 8.4 Hz, 1 H), 7.82 (d, 1.6 Hz, 1 H), 7.76 (d, 8.9 Hz, 1 H), 7.69 (s, 1 H), 7.33 (dd, 8.9, 5.2 Hz, 1 H), 7.10 (td, 8.5, 3.0 Hz, 1	533.3	A	A





			H), 6.66-6.58 (m, 1 H), 6.03 (br s, 1 H). Ortho-proton of the B-ring is missing/submerged.			
I-961		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Nc3ncco3)cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	NMR (400 MHz, DMSOd6) 10.58 (s, 1H), 10.53 (s, 1H), 9.08 (Presence of Formate salt), 7.98 (s, 1H), 7.94 (d, 8.6 Hz, 1H), 7.76 (s, 1H), 7.69 (m, 2H including d, 1.01 Hz, 1H), 7.62 (s, 1H), 7.30 (dd, 8.9, 5.2 Hz, 1H), 7.08 (submerged td, 8.38, 3.04 Hz, 1H), 7.05 (submerged s, 1H), 6.60 (bs, 1H), 5.90 (bs, 1H).	549.3	A	A
I-962		CS(=O)Cc1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	NMR (400 MHz, Cd3CN) 8.75 (s, 1H), 7.67 (s, 1H), 7.65 (d, 8.5 Hz, 1H), 7.61-7.55 (m, 2H), 7.51 (s, 1H), 7.32 (s, 1H), 7.25 (dd, 8.9, 5.1 Hz, 1H), 6.97 (td, 8.4, 3.0 Hz, 1H), 6.65 (br, s, 1H), 6.11 (s, 1H), 4.21 (dd, 13.0, 1.2 Hz, 1H), 4.01 (dd, 13.1, 1.1 Hz, 1H), 2.49 (d, 3.6 Hz, 3H).	543.2	A	A
I-963		CC(C)(O)Cc1cc2C(=O)N[C@H](c2c(NC(=O)c2cc(F)cc(Cl)c2)c1)c1cc(F)ccc1Cl		505	C	
I-964		Cc1coc(Nc2cc3C(=O)NC(c3c(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c2)c2cc(F)ccc2Cl)n1	NMR (400 MHz, DMSOd6) 10.53 (s, 1H), 10.47 (s, 1H), 9.10 (br s, 1H), 8.02 (d, 1.8 Hz, 1H), 7.94 (d, 8.2 Hz, 1H), 7.71 (d, 9.6 Hz, 1H), 7.68 (s, 1H), 7.61 (s, 1H), 7.40 (d, 1.4 Hz, 1H), 7.30 (dd, 8.9, 5.2 Hz, 1H), 7.08 (td, 8.5, 3.0 Hz, 1H), 6.61 (br s, 1H), 5.87 (br	563.4	A	A





			s, 1H), 2.07 (d, 1.3 Hz, 3H).			
I-965		Cn1cc(Nc2cc3C(=O)NC(c3c(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c2)c2cc(F)ccc2Cl)nn1	1H-NMR (400 MHz, DMSO-d6) 10.42 (s, 1H), 9.01 (br. s, 1H), 8.98 (s, 1H), 7.93 (br. d, 8.4 Hz, 1H), 7.84 (s, 1H), 7.71 (br. d, 8.8 Hz, 1H), 7.62 (s, 1H), 7.39 (d, 2.0 Hz, 1H), 7.29 (dd, 8.9, 5.2 Hz, 1H), 7.24 (d, 1.8 Hz, 1H), 7.07 (app. td, 8.4, 3.1 Hz, 1H), 6.60 (br. s, 1H), 5.87 (br. s, 1H), 4.04 (s, 3H).	563.4	A	A
I-966		Cc1nc(Nc2cc3C(=O)NC(c3c(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c2)c2cc(F)ccc2Cl)oc1C	NMR (400 MHz, DMSOd6) 10.52 (s, 1H), 10.33 (s, 1H), 9.08 (br s, 1H), 7.99 (d, 1.8 Hz, 1H), 7.93 (d, 8.2 Hz, 1H), 7.71 (d, 8.8 Hz, 1H), 7.66 (s, 1H), 7.61 (s, 1H), 7.29 (dd, 8.8, 5.2 Hz, 1H), 7.07 (td, 8.5, 3.1 Hz, 1H), 6.68 (br s, 1H), 5.88 (br s, 1H), 2.19 (d, 0.9 Hz, 3H), 2.00 (d, 0.9 Hz, 3H).	577.4	A	A
I-967		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1cncnc1		545.4	A	A
I-968		CC(C)(O)Cn1cc(cn1)-c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl		605.6	A	A





I-969		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1cnc2nccnn2c1		585.4	A	A
I-970		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1cc2nccccc2[nH]1		582.27	A	A
I-971		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1cc2ccccc2[nH]1	1H NMR (400 MHz, DMSO-d6) 6.01 (br s, 1 H) 6.37 - 6.91 (m, 1 H) 6.99 - 7.15 (m, 4 H) 7.32 (dd, 8.84, 5.05 Hz, 1 H) 7.41 (dd, 8.08, 0.76 Hz, 1 H) 7.56 (d, 7.83 Hz, 1 H) 7.69 - 7.80 (m, 2 H) 7.92 - 8.02 (m, 2 H) 8.21 (s, 1 H) 9.20 (br s, 1 H) 10.60 (s, 1 H) 11.81 (s, 1 H)	582.27	A	A
I-972		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1cc2ccccnc2[nH]1	1H NMR (400 MHz, DMSO-d6) 5.90 - 6.12 (m, 1 H) 6.86 - 6.98 (m, 1 H) 7.05 - 7.13 (m, 3 H) 7.32 (dd, 8.84, 5.05 Hz, 1 H) 7.72 (s, 1 H) 7.77 (br d, 9.35 Hz, 1 H) 7.91 - 7.99 (m, 2 H) 8.08 (br s, 1 H) 8.24 (dd, 4.55, 1.52 Hz, 1 H) 8.29 (br s, 1 H) 8.47 (s, 1 H) 9.10 - 9.32 (m, 1 H) 10.68 (br s, 1 H) 12.24 - 12.42 (m, 1 H)	583.27	A	A





I-974		Cn1ncnc1Nc1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	1H NMR (400 MHz, DMSO-d6) 10.50 (br. s, 1H), 9.39 (s, 1H), 9.09 (br. s, 1H), 8.00 (d, 1.8 Hz, 1H), 7.94 (d, 8.5 Hz, 1H), 7.82 (d, 1.6 Hz, 1H), 7.72 (d, 9.1 Hz, 1H), 7.69 (s, 1H), 7.63 (s, 1H), 7.31 (dd, 8.9, 5.2 Hz, 1H), 7.08 (td, 8.5, 3.0 Hz, 1H), 6.61 (br. s, 1H), 5.91 (br. s, 1H), 3.37 (s, 3H)	563.3	A	A
I-975		Cc1cc2nccnc2cc1-c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl		609.3	B	
I-976		Cn1cnc(Nc2cc3C(=O)NC(c3c(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c2)c2cc(F)ccc2Cl)n1	1H NMR (400 MHz, DMSO-d6) 10.47 (s, 1H), 9.67 (s, 1H), 9.02 (br. s, 1H), 8.26 (s, 1H), 7.96 (d, 1.9 Hz, 1H), 7.93 (dt, 8.5 Hz, 1H), 7.71 (d, 8.7 Hz, 1H), 7.61 (s, 1H), 7.58 (d, 1.5 Hz, 1H), 7.28 (dd, 8.8, 5.2 Hz, 1H), 7.07 (td, 8.6, 3.0 Hz, 1H), 6.54 (br. s, 1H), 5.86 (br. s, 1H), 3.81 (s, 3H);	563.3	A	A
I-977		COCCOc1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	(400 MHz, DMSO-d6) 10.50 (br s, 1H), 9.13 (s, 1H), 7.94 (d, 8.5 Hz, 1H), 7.71 (d, 8.7 Hz, 1H), 7.63 (s, 1H), 7.31 (dd, 8.9, 5.2 Hz, 1H), 7.25-7.16 (m, 1H), 7.08 (td, 8.9, 3.1 Hz, 2H), 5.92 (br s, 1H), 4.28-4.17 (m, 2H), 3.70 (t, 4.4 Hz, 2H), 3.33 (s, 3H)	541.3	B	





I-978		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(Nc3nccc4c(cc(F)cc34)C(F)(F)F)c12	1H NMR (400 MHz, DMSO-d6) 9.40 (s, 1H), 9.15 (s, 1H), 8.20 - 8.10 (m, 2H), 7.95 (d, 9.9 Hz, 1H), 7.70 (dd, 14.7, 1.7 Hz, 2H), 7.28 (s, 1H), 7.03 (s, 1H), 6.91 - 6.82 (m, 1H), 6.29 (s, 1H), 5.76 (s, 1H).	568.15	A	A
I-979		Fc1ccc(Cl)c(c1)[C@@H]1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1cnc(nc1)C#N		570.1	B	
I-980		Fc1ccc(Cl)c(c1)[C@H]1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1cnc(nc1)C#N		570.1	A	A
I-981		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1ccc2OC(=O)NCc2c1	1H NMR (400 MHz, DMSO-d6) 4.49 (s, 2 H) 5.93 - 6.10 (m, 1 H) 7.05 - 7.17 (m, 2 H) 7.32 (dd, 8.84, 5.05 Hz, 1 H) 7.66 - 7.82 (m, 6 H) 7.89 - 7.98 (m, 2 H) 8.03 (s, 1 H) 9.19 (br s, 1 H) 10.57 (s, 1 H)	614.3	A	A





I-982		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1ccc2CC(=O)Nc2c1		598.2	A	A
I-983		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1cccn2nccc12	1H NMR (400 MHz, DMSO-d6) 4.08 (q, 5.14 Hz, 1 H) 6.01 - 6.17 (m, 1 H) 6.83 (d, 1.52 Hz, 1 H) 7.04 (t, 6.95 Hz, 1 H) 7.11 (td, 8.46, 3.03 Hz, 1 H) 7.35 (dd, 8.84, 5.31 Hz, 1 H) 7.48 (dd, 6.82, 0.76 Hz, 1 H) 7.67 (s, 1 H) 7.75 (br d, 8.59 Hz, 1 H) 7.87 - 8.00 (m, 3 H) 8.12 (d, 2.27 Hz, 1 H) 8.76 (d, 7.07 Hz, 1 H) 9.26 (br s, 1 H) 10.60 (s, 1 H)	583.2	A	A
I-984		Cc1nc2ccc(cc2o1)-c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	1H NMR (400 MHz, DMSO-d6) 2.65 (s, 3 H) 5.84 - 6.18 (m, 1 H) 6.50 - 6.94 (m, 1 H) 7.10 (td, 8.34, 3.03 Hz, 1 H) 7.33 (dd, 8.84, 5.05 Hz, 1 H) 7.70 (s, 1 H) 7.73 - 7.78 (m, 3 H) 7.86 (s, 1 H) 7.95 (br d, 8.34 Hz, 1 H) 7.99 (s, 1 H) 8.11 (s, 1 H) 9.15 - 9.25 (m, 1 H) 10.59 (s, 1 H)	598.2	A	A
I-985		Cc1ncncc1-c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl		559.4	A	A






I-986		Fc1ccc(Cl)c(c1)[C@H]1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1ccncc1F		562.1	A	A
I-987		Fc1ccc(Cl)c(c1)[C@@H]1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1ccncc1F		562.15	D	
I-988		O=C(Nc1cccc2C(=O)NCc12)N1CCCC[C@H]1Cc1ccccc1	1H NMR (400 MHz, DMSO-d6) 8.39 (d, 26.3 Hz, 2H), 7.37 - 7.31 (m, 3H), 7.27 (d, 6.2 Hz, 4H), 7.19 (tt, 5.4, 2.4 Hz, 1H), 4.53 (p, 4.1 Hz, 1H), 4.26 - 3.81 (m, 3H), 3.09 (td, 13.3, 2.7 Hz, 1H), 2.92 (qd, 13.3, 7.7 Hz, 2H), 1.86 - 1.61 (m, 2H), 1.60 (s, 2H), 1.57 - 1.51 (m, 3H), 1.40 (qt, 12.5, 3.9 Hz, 1H).	350.15	E	
I-989		O=C(Nc1cccc2C(=O)NCc12)N1CCCC[C@@H]1Cc1ccccc1	1H NMR (400 MHz, DMSO-d6) 8.39 (d, 26.3 Hz, 2H), 7.37 - 7.31 (m, 3H), 7.27 (d, 6.2 Hz, 4H), 7.19 (tt, 5.4, 2.4 Hz, 1H), 4.53 (p, 4.1 Hz, 1H), 4.26 - 3.81 (m, 3H), 3.09 (td, 13.3, 2.7 Hz, 1H), 2.92 (qd, 13.3, 7.7 Hz, 2H), 1.86 - 1.61 (m, 2H), 1.60 (s, 2H), 1.57 - 1.51 (m, 3H), 1.40 (qt, 12.5, 3.9 Hz, 1H).	350.2	E	






I-990		O=C(Nc1cccc2C(=O)NCc12)N1CCCCC1Cc1ccccc1	1H NMR (400 MHz, DMSO-d6) 8.39 (d, 26.3 Hz, 2H), 7.37 - 7.31 (m, 3H), 7.27 (d, 6.2 Hz, 4H), 7.19 (tt, 5.4, 2.4 Hz, 1H), 4.53 (p, 4.1 Hz, 1H), 4.26 - 3.81 (m, 3H), 3.09 (td, 13.3, 2.7 Hz, 1H), 2.92 (qd, 13.3, 7.7 Hz, 2H), 1.86 - 1.61 (m, 2H), 1.60 (s, 2H), 1.57 - 1.51 (m, 3H), 1.40 (qt, 12.5, 3.9 Hz, 1H).	350.15	E	
I-991		COc1cc(cc(Cl)c1F)C(=O)Nc1cc(Br)cc2C(=O)NC(c12)c1cc(F)ccc1Cl	1H NMR (400 MHz, DMSO-d6) 10.34 (s, 1H), 9.29 (s, 1H), 7.81 (d, 1.7 Hz, 1H), 7.74 (d, 1.8 Hz, 1H), 7.37 (td, 9.2, 5.9 Hz, 2H), 7.24 (dd, 6.1, 2.0 Hz, 1H), 7.15 (ddd, 8.9, 7.9, 3.1 Hz, 1H), 6.66 (s, 1H), 5.98 (s, 1H), 3.90 (s, 3H).	541	B	
I-992		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(NC(=O)N3CCCc4ccc(Cl)cc34)c12	1H NMR (400 MHz, DMSO-d6) 11.59 (s, 1H), 10.32 (s, 1H), 8.11 (s, 1H), 8.03 (d, 9.1 Hz, 1H), 7.95 (d, 8.4 Hz, 1H), 7.75 (dd, 7.5, 1.8 Hz, 1H), 7.67 (dd, 7.8, 1.5 Hz, 1H), 7.50 - 7.39 (m, 3H), 7.16 (d, 7.3 Hz, 1H), 7.00 (t, 7.8 Hz, 1H), 6.75 (d, 2.0 Hz, 1H).	550	D	
I-993		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Nc3nc4ccccc4[nH]3)cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	1H-NMR (400 MHz, DMSO-d6)-11.36 (br. s, 1H), 10.55 (s, 1H), 10.10 (br. s, 1H), 9.09 (br. s, 1H), 8.19 (d, 1.8 Hz, 1H), 7.97-7.95 (m, 1H), 7.95-7.92 (m, 1H), 7.73 (br. d, 8.9 Hz, 1H), 7.64 (s, 1H), 7.40 (br. s, 1H), 7.32 (d, 5.2 Hz, 1H), 7.30 (d, 5.2 Hz, 1H), 7.09 (app. td, 8.5, 3.1 Hz, 1H), 7.04-7.00 (m, 2H), 6.61 (br. s, 1H), 5.91 (br. s, 1H).	598.4	A	B





I-994		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Nc3cn[nH]c3)cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	1H-NMR (400 MHz, DMSO-d6) 12.73 (br. s, 1H), 10.30 (br. s, 1H), 8.95 (s, 1H), 7.94-7.89 (m, 2H), 7.69 (br. d, 8.7 Hz, 1H), 7.73-7.52 (m, 2H), 7.59 (s, 1H), 7.28 (dd, 8.9, 5.2 Hz, 1H), 7.06 (app. td, 8.4, 3.1 Hz, 1H), 6.95 (d, 2.1 Hz, 1H), 6.84 (d, 2.0 Hz, 1H), 6.58 (br. s, 1H), 5.85 (br. s, 1H).	548.3	A	A
I-995		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-n1ccnn1	(400 MHz, DMSO-D6) 10.77 (br s, 1 H), 9.37 (s, 1 H), 8.26 (d, 1.5 Hz, 1 H), 8.23 (s, 2 H), 8.20 (d, 1.7 Hz, 1 H), 7.96 (d, 8.4 Hz, 1 H), 7.77 (d, 8.9 Hz, 1 H), 7.69 (s, 1 H), 7.34 (dd, 8.9, 5.2 Hz, 1 H), 7.10 (td, 8.5, 3.0 Hz, 1 H), 6.71 (br s, 1 H), 6.08 (br s, 1 H).	532.4	A	A
I-996		Fc1ccc(Cl)c(c1)[C@@H]1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1ccc(nc1)C#N		569.3	C	
I-997		Cn1cc(Nc2cc3C(=O)N[C@H](c3c(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c2)c2cc(F)ccc2Cl)cn1	1H NMR (400 MHz, DMSO-d6) 11.02 (br s, 1H), 10.44 (s, 1H), 9.19 (br s, 1H), 9.00 (s, 1H), 7.92 (d, 8.5 Hz, 1H), 7.75 (s, 1H), 7.71 (d, 9.2 Hz, 1H), 7.63 (s, 1H), 7.58 (s, 1H), 7.29 (dd, 8.8, 5.2 Hz, 1H), 7.07 (td, 8.4, 2.9 Hz, 1H), 6.81 (s, 1H), 6.68 (s, 1H), 5.87 (br s, 1H).	562.4	A	A





I-998		Cn1cc(Nc2cc3C(=O)N[C@@H](c3c(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c2)c2cc(F)ccc2Cl)cn1	1H NMR (400 MHz, DMSOD6) 10.33 (br s, 1H), 8.95 (br s, 1H), 8.54 (s, residual salt), 7.94 (submerged s, 1H), 7.91 (submerged d, 8.03 Hz, 1H), 7.73 (s, 1H), 7.69 (d, 9.3 Hz, 1H), 7.61 (s, 1H), 7.38 (s, 1H), 7.29 (dd, 8.9, 5.2 Hz, 1H), 7.06 (td, 8.4, 3.2 Hz, 1H), 6.94 (br s, 1H), 6.86 (br s, 1H), 6.57 (br s, 1H), 5.85 (br s, 1H), 3.83 (s, 3H).	562.4	C	
I-999		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Nc3nccnH3)cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	NMR (400 MHz, DMSOD6) 11.02 (br s, 1H), 10.44 (s, 1H), 9.19 (br s, 1H), 9.00 (s, 1H), 7.92 (d, 8.5 Hz, 1H), 7.75 (s, 1H), 7.71 (d, 9.2 Hz, 1H), 7.63 (s, 1H), 7.58 (s, 1H), 7.29 (dd, 8.8, 5.2 Hz, 1H), 7.07 (td, 8.4, 2.9 Hz, 1H), 6.81 (s, 1H), 6.68 (s, 1H), 5.87 (br s, 1H).	548.4	A	B
I-1000		Fc1ccc(Cl)c(c1)[C@H]1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1ccc(nc1)C#N		569.3	A	A
I-1001		Cn1ccc(cc1=O)-c1cc2C(=O)N[C@H](c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl		574.1	D	






I-1002		Cn1ccc(cc1=O)-c1cc2C(=O)N[C@@H](c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl		574.15	A	A
I-1003		Nc1ncc(cn1)-c1cc2C(=O)N[C@@H](c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl		560.15	A	A
I-1004		Nc1ncc(cn1)-c1cc2C(=O)N[C@H](c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl		560.15	D	
I-1005		Cn1ccc2c(F)cc(cc12)C(=O)Nc1cc(Br)cc2C(=O)NC(c12)c1cc(F)ccc1Cl	1H NMR (400 MHz, DMSO-d6) 10.19 (s, 1H), 9.27 (s, 1H), 7.79 (dt, 4.5, 2.1 Hz, 2H), 7.59 (d, 2.9 Hz, 2H), 7.34 (dd, 8.9, 5.1 Hz, 1H), 7.10 (td, 8.4, 3.1 Hz, 1H), 7.02 (d, 11.4 Hz, 1H), 6.78 -6.56 (s, 2H), , 6.08 (s, 1H), 3.85 (s, 3H).	529.9	D	
I-1006		COc1cccc(n1)-c1cc2C(=O)N[C@H](c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1c		574.05	A	A






		c(F)ccc1Cl				
I-1007		COc1cccc(n1)-c1cc2C(=O)N[C@@H](c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl		574.05	D	
I-1008		Fc1ccc(Cl)c(c1)[C@@H]1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1ccccnc1		544.1	D	
I-1009		Fc1ccc(Cl)c(c1)[C@H]1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1ccccnc1		544.1	A	A
I-1010		Cc1cnccc1-c1cc2C(=O)N[C@H](c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl		558.15	A	A
I-1011		Cc1cnccc1-c1cc2C(=O)N[C@@H](c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c		558.15	D	






		1cc(F)ccc1Cl				
I-1012		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1ccc2nccnc2c1		595.4	A	A
I-1013		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1cccc2nccn12	1H NMR (400 MHz, DMSO-d6) 5.94 - 6.19 (m, 1 H) 6.96 - 7.17 (m, 2 H) 7.30 - 7.43 (m, 2 H) 7.62 - 7.82 (m, 5 H) 7.85 - 8.02 (m, 4 H) 8.68 (br d, 6.57 Hz, 1 H) 9.16 - 9.40 (m, 1 H) 10.68 (br s, 1 H)	583.27	A	A
I-1014		Fc1ccc(c(c1)C1NC(=O)c2cc(Br)cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)C(F)(F)F	1H NMR (400 MHz,Chloroform-d) 8.63 (d, 1.7 Hz, 1H), 7.98 (d, 1.6 Hz, 1H), 7.85 (dd, 8.9, 5.1 Hz, 1H), 7.50 (dd, 13.0, 8.2 Hz, 2H), 7.26 (d, 22.8 Hz, 2H), 7.14 (s, 1H), 6.71 (dd, 8.8, 2.6 Hz, 1H), 6.58 (s, 1H), 6.05 (s, 1H).	581.05	A	A
I-1015		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-n1ccnc1	(400 MHz, DMSO-D6) 10.71 (br s, 1 H), 9.31 (s, 1 H), 8.45 (s, 1 H), 8.03 - 7.90 (m, 3 H), 7.84 (s, 1 H), 7.76 (d, 8.8 Hz, 1 H), 7.69 (s, 1 H), 7.33 (dd, 8.9, 5.1 Hz, 1 H), 7.16 (s, 1 H), 7.10 (td, 8.4, 2.9 Hz, 1 H), 6.67 (br s, 1 H), 6.02 (br s, 1 H).	531.4	A	A
I-1016		Cn1cc(ncc1=O)-c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c	NMR (400 MHz, DMSO) 10.59 (s, 1H), 9.19 (s, 1H), 8.67 (s, 1H), 8.16 (s, 1H), 8.14 (s, 1H), 8.06 (s, 1H), 7.95 (d, 8.3 Hz, 1H), 7.77 (d, 8.5 Hz, 1H), 7.70 (s, 1H), 7.32 (dd, 8.9, 5.1 Hz, 1H), 7.09	573	A	A






		1cc(F)ccc1Cl	(td, 8.6, 2.9 Hz, 1H), 6.01 (s, 1H), 3.55 (s, 3H)			
I-1017		Cc1[nH]ncc1Nc1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	NMR (400 MHz, DMSO-d6) 10.27 (s, 1H), 8.94 (s, 1H), 7.91 (d, 8.4 Hz, 1H), 7.68 (d, 8.8 Hz, 1H), 7.58 (d, 5.8 Hz, 2H), 7.32-7.24 (m, 1H), 7.06 (td, 8.4, 3.2 Hz, 1H), 6.81 (d, 1.9 Hz, 1H), 6.70 (s, 1H), 5.84 (s, 1H), 2.08 (s, 3H).	562.3	A	A
I-1018		CS(=N)(=O)Cc1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	NMR (400 MHz, DMSO-d6) 10.60 (s, 1H), 9.19 (br. s, 1H), 7.94 (d, 8.5 Hz, 1H), 7.81 (d, 0.5 Hz, 1H), 7.73 (d, 9.1 Hz, 1H), 7.64 (d, 3.3 Hz, 1H), 7.54 (d, 2.1 Hz, 1H), 7.32 (dd, 8.9, 5.2 Hz, 1H), 7.14-7.06 (m, 1H), 6.65 (br. s, 1H), 5.98 (br. s, 1H), 4.66-4.47 (m, 2H), 3.77 (d, 4.4 Hz, 1H), 2.84 (s, 3H).	558.2	A	A
I-1019		OC1CC(C1)c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	1H NMR (400 MHz, DMSO-d6) 10.42 (s, 1H), 9.07 (br. s, 1H), 7.90 (d, 8.5 Hz, 1H), 7.70 (d, 8.9 Hz, 1H), 7.62 (s, 1H), 7.54 (s, 1H), 7.31 (s, 1H), 7.26 (dd, 8.9, 5.2 Hz, 1H), 7.04 (td, 8.4, 3.1 Hz, 1H), 6.61 (br. s, 1H), 5.91 (br. s, 1H), 5.12 (d, 7.5 Hz, 1H), 4.11-3.94 (m, 1H), 3.07-2.95 (m, 1H), 2.65 (ddd, 14.5, 7.2, 3.8 Hz, 2H), 1.93 (ddd, 21.2, 7.3, 2.2 Hz, 2H).	537.1	A	A
I-1020		COCCc1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c	NMR (400 MHz, CD3CN) 8.58 (br s, 1H), 7.64-7.52 (m, 4H), 7.39 (s, 1H), 7.21 (m, 2H), 6.94 (td, 8.4, 3.1 Hz, 1H), 6.58 (br s, 1H), 6.04 (br s, 1H), 3.63 (t, 6.5 Hz, 2H),	525.4	A	A






		1cc(F)ccc 1Cl	3.28 (s, 3H), 2.98 (td, 6.7, 1.7 Hz, 2H).			
I-1021		Fc1ccc(C l)c(c1)[C @H]1NC (=O)c2cc (cc(NC(= O)c3cc(F)cc(c3)C(F)(F)F)c1 2)- c1cnn(c1)C1CC1		573. 2	E	
I-1022		Fc1ccc(C l)c(c1)[C @@H]1 NC(=O)c 2cc(cc(N C(=O)c3 cc(F)cc(c 3)C(F)(F) F)c12)- c1cnn(c1)C1CC1		573. 3	A	A
I-1023		Fc1ccc(C l)c(c1)[C @H]1NC (=O)c2cc (cc(NC(= O)c3cc(F)cc(c3)C(F)(F)F)c1 2)- c1cnc2nc nn2c1		585. 4	C	
I-1024		Fc1ccc(C l)c(c1)[C @@H]1 NC(=O)c 2cc(cc(N C(=O)c3 cc(F)cc(c 3)C(F)(F) F)c12)- c1cnc2nc nn2c1		585. 2	A	A






I-1025		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1nc2cnccc2[nH]1		584.32	A	B
I-1026		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1nc2nccc2[nH]1		584.32	A	A
I-1027		Cn1cnc2ccc(cc12)-c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl		597.38	A	
I-1028		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1cccc2NC(=O)CCc12		612.34	A	A
I-1029		Cn1cc2cc(ccc2n1)-c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl		597.33	A	A





I-1030		Cn1nncc1-c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl		548.31	A	A
I-1031		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1cccc2nonc12		585.27	A	A
I-1032		Cc1cc2ncc(cn2n1)-c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl		598.38	A	A
I-1033		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1ccc2[nH]ncc2c1		583.37	A	A
I-1034		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1cccc2NC(=O)Cc12		598.38	A	





I-1035		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1ccc2nc[nH]c2c1		583.32	A	
I-1036		Cc1nc2cc(ccc2o1)-c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl		598.33	A	
I-1037		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1ccnn1C1COC1		589.33	A	
I-1038		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1ccnn1CC1CC1		587.32	A	A
I-1039		Cc1noc2ncc(cc12)-c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl		599.33	A	A






I-1040		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)N1CCn2ncnc2C1		589.33	A	B
I-1041		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1ccc2NC(=O)Cc2c1		598.23	A	
I-1042		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1cccc2C(=O)NCCc12		612.39	A	A
I-1043		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1ccc2NC(=O)COCc2c1		628.34	A	A
I-1044		Cn1c2cc(ccc2[nH]c1=O)-c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c		613.34	A	





		1cc(F)ccc1Cl				
I-1045		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1cccc2ccccnc12		594.33	A	
I-1046		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1cnn2ccccnc12		584.32	A	A
I-1047		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1cnc2ccnn2c1		584.32	A	A
I-1048		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1ccc2OCCNC(=O)c2c1		628.34	A	A
I-1049		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1ccnc2[nH]ccc12		583.32	A	A





I-1050		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(NC(=O)Nc3ccc(F)cc3C(F)(F)F)c12	(400 MHz, DMSO-d6) 9.31 (br s, 1H), 9.21 (s, 1H), 8.56 (br s, 1H), 7.80 (d, 1.3 Hz, 1H), 7.62 (d, 1.3 Hz, 1H), 7.61-7.42 (m, 4H), 7.22 (td, 8.5, 3.0 Hz, 1H), 6.82 (br s, 1H), 6.06 (s, 1H)	558.3	B	
I-1051		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(NC(=O)Nc3cc(ccc3C(F)(F)F)C#N)c12	1H NMR (400 MHz, DMSO-d6, 60 Â°C) 9.06 (br s, 1H), 8.39 (s, 1H), 8.24 (s, 1H), 7.81 (d, 7.4 Hz, 2H), 7.64 (s, 2H), 7.44 (dd, 8.8, 5.1 Hz, 1H), 7.18 (td, 8.4, 3.1 Hz, 1H), 6.78 (br s, 1H), 6.05 (s, 1H)	565.3	D	
I-1052		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Oc3ccncn3)cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	(400 MHz, DMSO-d6) 10.52 (br s, 1H), 9.29 (s, 1H), 8.82 (s, 1H), 8.75 (d, 6.0 Hz, 1H), 7.95 (d, 8.4 Hz, 1H), 7.72 (d, 8.9 Hz, 1H), 7.64 (s, 1H), 7.54 (d, 1.9 Hz, 1H), 7.41 (s, 1H), 7.34 (dd, 8.9, 5.2 Hz, 1H), 7.28 (dd, 5.7, 0.7 Hz, 1H), 7.12 (td, 8.5, 3.0 Hz, 1H), 6.70 (br s, 1H), 6.01 (br s, 1H)	559.4	B	
I-1053		Fc1cc(cc(c1)C(F)(F)F)C(=O)Nc1cc(cc2C(=O)N[C@H](c12)c1cc(Cl)ccc1Cl)-c1ccc2ncnn2c1	1H NMR (400 MHz, Chloroform-d) 8.96 (s, 1H), 8.56 (s, 1H), 8.45 (s, 1H), 8.09 (d, 1.6 Hz, 1H), 7.97-7.87 (m, 2H), 7.58-7.51(m , 4H), 7.43 (d, 8.6 Hz, 1H), 7.36 (dd, 8.6, 2.4 Hz, 1H), 7.06 (s, 1H), 6.50 (s, 1H), 6.30 (s, 1H)	600.05	C	
I-1054		Fc1cc(cc(c1)C(F)(F)F)C(=O)Nc1cc(cc2C(=O)N[C@@H](c12)c1cc(Cl)ccc1Cl)-	1H NMR (400 MHz, Chloroform-d) 8.96 (s, 1H), 8.56 (s, 1H), 8.45 (s, 1H), 8.09 (d, 1.5 Hz, 1H), 7.97-7.87 (m, 2H), 7.58-7.53 (m,3H), 7.49 (s, 1H), 7.43 (d, 8.6 Hz, 1H), 7.36 (dd, 8.7, 2.4 Hz, 1H), 7.06 (s, 1H),	600.05	A	A




		c1ccc2nc nn2c1	6.51 (s, 1H), 6.30 (s, 1H).			
I-1055		FC(F)c1c cc(F)cc1[C@H]1N C(=O)c2 cc(cc(NC (=O)c3cc (F)cc(c3) C(F)(F)F)c12)- c1ccc2nc nn2c1	1H NMR (400 MHz, DMSO-d6) 10.62 (s, 1H), 9.50 (s, 1H), 9.30 (s, 1H), 8.59 (s, 1H), 8.16 (dd, 11.3, 1.8 Hz, 2H), 8.00 (dd, 5.5, 3.8 Hz, 2H), 7.95 (d, 8.5 Hz, 1H), 7.72 (d, 8.9 Hz, 1H), 7.65 (s, 1H), 7.52 (dd, 8.9, 5.6 Hz, 1H), 7.23 (td, 8.4, 2.7 Hz, 1H), 6.57 (s, 1H), 6.11 (s, 1H).	600.2	D	
I-1056		FC(F)c1c cc(F)cc1[C@@H] 1NC(=O) c2cc(cc(NC(=O)c 3cc(F)cc(c3)C(F)(F)F)c12)- c1ccc2nc nn2c1	1H NMR (400 MHz, DMSO-d6) 10.62 (s, 1H), 9.50 (s, 1H), 9.30 (s, 1H), 8.59 (s, 1H), 8.16 (dd, 11.3, 1.8 Hz, 2H), 8.00 (dd, 5.5, 3.8 Hz, 2H), 7.95 (d, 8.5 Hz, 1H), 7.72 (d, 8.9 Hz, 1H), 7.65 (s, 1H), 7.52 (dd, 8.9, 5.6 Hz, 1H), 7.23 (td, 8.4, 2.7 Hz, 1H), 6.57 (s, 1H), 6.11 (s, 1H).	600.2	A	A
I-1057		FC(F)c1c cc(F)cc1 C1NC(= O)c2cc(c c(NC(=O)c3cc(F)c c(c3)C(F) (F)F)c12) - c1ccc2nc nn2c1	1H NMR (400 MHz, DMSO-d6) 10.62 (s, 1H), 9.50 (s, 1H), 9.30 (s, 1H), 8.59 (s, 1H), 8.16 (dd, 11.3, 1.8 Hz, 2H), 8.00 (dd, 5.5, 3.8 Hz, 2H), 7.95 (d, 8.5 Hz, 1H), 7.72 (d, 8.9 Hz, 1H), 7.65 (s, 1H), 7.52 (dd, 8.9, 5.6 Hz, 1H), 7.23 (td, 8.4, 2.7 Hz, 1H), 6.57 (s, 1H), 6.11 (s, 1H).	600.2	A	A
I-1058		Fc1ccc(C l)c(c1)C1 NC(=O)c 2cc(Br)cc (Nc3noc4 ccccc34) c12	1H NMR (400 MHz, DMSO-d6) 9.24 (s, 1H), 9.12 (s, 1H), 7.98 (d, 1.8 Hz, 1H), 7.65 (d, 1.7 Hz, 1H), 7.63-7.55 (m, 3H), 7.35-7.21 (m, 2H), 7.02 (td, 8.4, 3.0 Hz, 1H), 6.81 (s, 1H), 6.16 (s, 1H).	472.05	E	





I-1059		Fc1cc(cc(c1)C(F)(F)F)C(=O)Nc1cc(cc2C(=O)N[C@H](c12)c1cc(F)c(F)cc1Cl)-c1ccc2ncnn2c1	1H NMR (400 MHz, DMSO-d6) 10.65 (s, 1H), 9.48 (t, 1.4 Hz, 1H), 9.26 (s, 1H), 8.58 (s, 1H), 8.18 - 8.11 (m, 2H), 8.03 -7.95 (m, 3H), 7.84 (d, 9.0 Hz, 1H), 7.72 (s, 1H), 7.59 (dd, 10.4, 7.3 Hz, 1H), 7.00 (s, 1H) , 6.04 (s, 1H).	602.1	D	
I-1060		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(Nc3nsc4ccccc34)c12	1H NMR (400 MHz, DMSO-d6) 9.29 (s, 1H), 9.17 (s, 1H), 8.07-7.97 (m, 2H), 7.81 (d, 8.1 Hz, 1H), 7.65 (d, 1.7 Hz, 1H), 7.61-7.52 (m, 1H), 7.40 (dd, 8.2, 6.9 Hz, 1H), 7.21 (dd, 8.9, 5.1 Hz, 1H), 6.97 (td, 8.4, 3.1 Hz, 1H), 6.57 (s, 1H), 6.11-6.07 (m, 1H).	488	E	
I-1061		Fc1cc(cc(c1)C(F)(F)F)C(=O)Nc1cc(cc2C(=O)N[C@@H](c12)c1cc(F)c(F)cc1Cl)-c1ccc2ncnn2c1	1H NMR (400 MHz, DMSO-d6) 10.64 (s, 1H), 9.48 (t, 1.4 Hz, 1H), 9.26 (s, 1H), 8.58 (s, 1H), 8.18 - 8.11 (m, 2H), 8.03 - 7.95 (m, 3H), 7.83 (d, 8.9 Hz, 1H), 7.71 (s, 1H), 7.59 (dd, 10.4, 7.2 Hz, 1H), 7.00 (s, 1H), 6.04 (s, 1H).	602.1	A	A
I-1062		Fc1cc(cc(c1)C(F)(F)F)C(=O)Nc1cc(cc2C(=O)N[C@H](c12)c1cc(F)cc(F)c1Cl)-c1ccc2ncnn2c1	1H NMR (400 MHz, Chloroform-d) 8.95 (s, 1H), 8.45 (s, 1H), 8.39 (s, 1H), 8.11 (d, 1.6 Hz, 1H), 7.97 - 7.86 (m, 2H), 7.58 (d, 8.1 Hz, 2H), 7.51 (d, 9.0 Hz, 2H), 6.99 (dd, 8.1, 2.9 Hz, 1H), 6.65 (s, 1H), 6.47 (s, 1H), 6.35 (s, 1H).	602.1	A	A





I-1063		Fc1cc(cc(c1)C(F)(F)F)C(=O)Nc1cc(cc2C(=O)N[C@@H](c12)c1cc(F)cc(F)c1Cl)-c1ccc2ncnn2c1	1H NMR (400 MHz, Chloroform-d) 8.96 (s, 1H), 8.45 (s, 1H), 8.38 (s, 1H), 8.11 (s, 1H), 7.91 (q, 9.1 Hz, 2H), 7.61 - 7.52 (m, 3H), 7.50 (s, 1H), 6.99 (d, 8.0 Hz, 1H), 6.64 (s, 1H), 6.51 (s, 1H), 6.34 (s, 1H).	602.1	E	
I-1064		OCCOc1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)cccc1Cl	NMR (400 MHz, DMSO-d6) 10.49-10.36 (s, 1H), 9.13 (s, 1H), 7.94 (d, 8.3 Hz, 1H), 7.71 (d, 8.7 Hz, 1H), 7.63 (s, 1H), 7.31 (dd, 8.9, 5.2 Hz, 1H), 7.20 (s), 7.12-7.05 (m, 2H), 5.90 (br, s, 1H), 4.94 (t, 5.5 Hz, 1H), 4.15-4.08 (m, 2H), 3.76 (q, 5.0 Hz, 2H).	527.2	A	A
I-1065		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1cncs1	NMR (400 MHz, CD3CN) 8.88 (s, 1H), 8.73 (br s, 1H), 8.25 (d, 5.4 Hz, 1H), 7.95 (br s, 1H), 7.80 (s, 1H), 7.68-7.52 (m, 3H), 7.31 (m, 1H), 7.26-7.19 (m, 1H), 6.95 (td, 8.8, 2.7 Hz, 1H), 6.67 (br s, 1H), 6.13 (br s, 1H).	550	A	A
I-1066		COc1nc(cs1)-c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)cccc1Cl	NMR (400 MHz, CD3CN) 8.67 (br s, 1H), 8.16 (s,1H), 8.03 (s, 1H), 7.61 (dd, 18.1, 9.7 Hz, 3H), 7.29 (d, 1.3 Hz, 1H), 7.23 (dd, 8.9, 5.0 Hz, 2H), 6.94 (td, 8.5, 3.4 Hz, 1H), 6.67 (br s, 1H), 6.12 (br s, 1H), 4.12 (s, 3H).	580	A	B
I-1067		NC(=O)c1nc(cs1)-c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)cccc1Cl	NMR (400 MHz, CD3CN/DMSO) 10.49 (br s, 1H), 8.88 (br s, 1H), 8.43 (br s, 1H), 8.36 (d, 14.5 Hz, 2H), 8.15 (br s, 1H), 7.97 (br s, 1H), 7.78-7.64 (m, 3H), 7.59 (m, 1H), 7.20 (dd, 8.7, 5.2 Hz, 1H),	591	A	A






			6.94 (td, 8.4, 3.0 Hz, 1H), 6.06 (br s, 1H).			
I-1068		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1cnsc1	NMR (400 MHz, CD3CN) 9.14 (s, 1H), 8.94 (s, 1H), 8.77 (br s, 1H), 8.08 (s, 1H), 7.89 (s, 1H), 7.66 (br d, 8.2 Hz, 1H), 7.61 (submerged br d, 8.3 Hz, 1H), 7.61-7.58 (m, 1H), 7.25 (dd, 8.2, 4.8 Hz), 7.29-7.26 (submerged m, 1H), 7.01-6.95 (m, 1H), 6.69 (br s, 1H), 6.16 (br s, 1H).	548	A	A
I-1069		Fc1ccc(Cl)c(c1)[C@@H]1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-n1cccn1	(400 MHz, DMSO-D6) 10.67 (s, 1 H), 9.29 (s, 1 H), 8.76 (d, 2.5 Hz, 1 H), 8.14 (d, 1.6 Hz, 1 H), 8.09 (d, 1.6 Hz, 1 H), 7.96 (d, 8.4 Hz, 1 H), 7.82 (d, 1.6 Hz, 1 H), 7.76 (d, 8.9 Hz, 1 H), 7.69 (s, 1 H), 7.33 (dd, 8.9, 5.2 Hz, 1 H), 7.10 (td, 8.5, 3.0 Hz, 1 H), 6.66-6.58 (m, 1 H), 6.03 (br s, 1 H). \.	533.3	A	A
I-1070		Fc1ccc(Cl)c(c1)[C@H]1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-n1cccn1	(400 MHz, DMSO-D6) 10.67 (s, 1 H), 9.29 (s, 1 H), 8.76 (d, 2.5 Hz, 1 H), 8.14 (d, 1.6 Hz, 1 H), 8.09 (d, 1.6 Hz, 1 H), 7.96 (d, 8.4 Hz, 1 H), 7.82 (d, 1.6 Hz, 1 H), 7.76 (d, 8.9 Hz, 1 H), 7.69 (s, 1 H), 7.33 (dd, 8.9, 5.2 Hz, 1 H), 7.10 (td, 8.5, 3.0 Hz, 1 H), 6.66-6.58 (m, 1 H), 6.03 (br s, 1 H).	533.3	D	
I-1071		Cn1ccc(Nc2cc3C(=O)N[C@H](c3c(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c2)c2cc(F)ccc2Cl)n1	1H-NMR (400 MHz, DMSO-d6) 10.41 (s, 1H), 8.96 (br. s, 1H), 8.90 (br. s, 1H), 7.91 (br. s, 1H), 7.73-7.68 (m, 2H), 7.62 (br. s, 1H), 7.56 (d, 2.1 Hz, 1H), 7.40 (br. s, 1H), 7.29 (dd, 8.9, 5.2 Hz, 1H), 7.07 (app. td, 8.6, 3.0 Hz, 1H), 6.60 (br. s,	562.4	A	A






			1H), 5.85 (br. s, 1H), 5.82 (d, 2.3 Hz, 1H), 3.77 (s, 3H).			
I-1072		Cn1ccc(Nc2cc3C(=O)N[C@@H](c3c(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c2)c2cc(F)ccc2Cl)n1	1H-NMR (400 MHz, DMSO-d6) 10.43 (br. s, 1H), 8.97 (br. s, 1H), 8.90 (br. s, 1H), 7.91 (br. d, 6.5 Hz, 1H), 7.73-7.68 (m, 2H), 7.62 (br. s, 1H),7.56 (d, 2.2 Hz, 1H), 7.41 (br. s, 1H), 7.29 (dd, 8.9, 5.2 Hz, 1H), 7.07 (app. td, 8.5, 3.0 Hz, 1H), 6.58 (br. s, 1H), 5.85 (s, 1H), 5.82 (d, 2.3 Hz, 1H), 3.77 (s, 3H).	562.4	C	
I-1073		Fc1ccc(Cl)c(c1)C1NC(=O)c2cccc(NC(=O)C34CC5CC(C3)CC(C5)(C4)C(F)(F)F)c12	1H-NMR (400 MHz, DMSO-d6) 9.37 (s, 1H), 9.09 (br. s, 1H), 7.61 (dd, 7.4, 1.1 Hz, 1H), 7.57 (t, 7.5 Hz, 1H), 7.52-7.45 (m, 1H), 7.36 (dd, 7.4, 1.0 Hz, 1H), 7.21 (app. td, 8.4, 3.1 Hz, 1H), 6.39 (br. s, 1H), 6.01 (br. s, 1H), 2.11-2.04 (m, 2H), 1.69-1.44 (m, 11H), 1.37-1.31 (m, 1H).	507.4	A	A
I-1074		CC12CC3CC(C)(C1)CC(C3)(C2)C(=O)Nc1cccc2C(=O)NC(c12)c1cc(F)ccc1Cl	1H-NMR (400 MHz, DMSO-d6) 9.09 (s, 1H), 9.07 (br. s, 1H), 7.61-7.53 (m, 2H), 7.53-7.47 (m, 1H), 7.41 (dd, 7.3, 1.5 Hz, 1H), 7.24 (ddd, 8.8, 8.1, 3.1 Hz, 1H), 6.41 (br. s, 1H), 6.03 (br. s, 1H), 1.98 (dt, 6.0, 3.0 Hz, 1H), 1.44-1.35 (m, 2H), 1.35-1.18 (m, 5H), 1.16-0.95 (m, 5H), 0.75 (s, 3H), 0.75 (s, 3H).	467.4	B	
I-1075		Cn1ccnc1Nc1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1c	1H NMR (400 MHz, DMSO-d6) 10.42 (s, 1H), 9.01 (br. s, 1H), 8.75 (s, 1H), 8.15 (s, 1H), 7.93 (br. d, 8.9 Hz, 1H), 7.72 (d, 1.9 Hz, 1H), 7.71 (br. d, 8.9 Hz, 1H), 7.62 (s, 1H), 7.58 (d, 1.6 Hz),	562.3	A	A





		c(F)ccc1Cl	1H, 7.30 (dd, 8.9, 5.2 Hz, 1H), 7.06 (td, 8.1, 3.1 Hz, 1H), 6.91 (d, 1.4 Hz, 1H), 6.70 (d, 1.4 Hz, 1H), 5.88 (br. s, 1H), 3.54 (s, 3H)			
I-1076		Cn1nc(ccc1=O)-c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	NMR (400 MHz, DMSO) 10.65 (s, 1H), 9.26 (br s, 1H), 8.23 (d, 9.8 Hz, 1H), 8.18 (d, 1.0 Hz, 1H), 8.04 (s, 1H), 7.96 (d, 8.2 Hz, 1H), 7.77 (d, 9.4 Hz, 1H), 7.70 (s, 1H), 7.33 (dd, 8.9, 5.2 Hz, 1H), 7.14-7.06 (m, 2H), 6.04 (br s, 1H), 3.78 (s, 3H)	573	A	A
I-1077		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Oc3ccccn3)cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	NMR (400 MHz, CD3CN) 8.62 (s, 1H), 8.17 (ddd, 5.0, 2.0, 0.8 Hz, 1H), 7.85 (ddd, 8.3, 7.2, 2.0 Hz, 1H), 7.67-7.62 (m, 1H), 7.60-7.54 (m, 2H), 7.49 (d, 2.1 Hz, 1H), 7.38-7.34 (m, 1H), 7.32-7.29 (m overlapped with dd, 1H), 7.28 (dd, 8.9, 5.1 Hz, 1H), 7.15 (ddd, 7.2, 5.0, 0.9 Hz, 1H), 7.09 (dt, 8.3, 0.8 Hz, 1H), 6.99 (ddd, 8.8, 8.0, 3.1 Hz, 1H), 6.71 (br s, 1H), 6.14 (br s, 1H)	558	B	
I-1078		Fc1ccc(Cl)c(c1)[C@@H]1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1cn[nH]c1		533	A	A





I-1079		Fc1ccc(Cl)c(c1)[C@H]1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1cn[nH]c1		531	A	
I-1080		CC(C)(O)Cc1cc2C(=O)N[C@H](c2c(NC(=O)c2cc(F)cc(Cl)c2)c1)c1cc(F)ccc1Cl		505	A	A
I-1081		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(CS(=O)(=O)C3CC3)cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	NMR (400 MHz, DMSO-d6) 10.61 (br. s, 1H), 9.21 (br. s, 1H), 7.95 (br. d, 8.3 Hz, 1H), 7.79 (d, 0.5 Hz, 1H), 7.74 (br. d, 9.0 Hz, 1H), 7.65 (s, 1H), 7.54 (s, 1H), 7.32 (dd, 8.9, 5.2 Hz, 1H), 7.10 (td, 8.5, 3.0 Hz, 1H), 6.59 (br. s, 1H), 5.98 (br. s, 1H), 4.77 (s, 2H), 2.71-2.61 (m, 1H), 1.02-0.91 (m, 2H), 0.89-0.79 (m, 2H). Presence of 2w% of OPPh3 (signals between 7.55 and 7.64). Partial formate salt at 8.41 .	585.2	A	A
I-1082		Cn1nccc1CNc1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	NMR (400 MHz, DMSO-d6) 10.31 (s, 1H), 8.93 (br. s, 1H), 7.92 (br. d, 8.5 Hz, 1H), 7.69 (br. d, 9.0 Hz, 1H), 7.61 (s, 1H), 7.32 (d, 1.8 Hz, 1H), 7.28 (dd, 8.9, 5.2 Hz, 1H), 7.06 (td, 8.4, 3.1 Hz, 1H), 6.91 (d, 2.0 Hz, 1H), 6.79 (d, 1.6 Hz, 1H), 6.66 (br. t, 5.4 Hz, 1H), 6.59 (br. s,	576.2	A	A





			1H), 6.22 (d, 1.7 Hz, 1H), 5.82 (br. s, 1H), 4.40 (d, 5.6 Hz, 2H), 3.83 (s, 3H).			
I-1083		Cn1cnnc1Nc1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	1H NMR (400 MHz, DMSO-d6) 10.50 (s, 1H), 9.12 (s, 1H), 9.08 (br. s, 1H), 8.22 (s, 1H), 7.93 (br. d, 9.5 Hz, 1H), 7.92 (d, 1.9 Hz, 1H), 7.84 (d, 1.8 Hz, 1H), 7.72 (br. d, 9.5 Hz, 1H), 7.63 (s, 1H), 7.31 (dd, 8.9, 5.2 Hz, 1H), 7.08 (td, 8.5, 3.0 Hz, 1H), 6.59 (br. s, 1H), 5.91 (br. s, 1H), 3.59 (s, 3H).	563.3	A	B
I-1084		Fc1ccc(Cl)c(c1)[C@@H]1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1cscn1	NMR (400 MHz, CD3CN) 9.01 (d, 1.9 Hz, 1H), 8.76 (br s, 1H), 8.29 (d, 1.4 Hz, 1H), 8.25 (s, 1H), 8.02 (d, 1.9 Hz, 1H), 7.70-7.59 (m, 3H), 7.32 (br s, 1H), 7.27 (dd, 8.9, 5.1 Hz, 1H), 6.98 (ddd, 8.8, 8.0, 3.1 Hz, 1H), 6.72 (br s, 1H), 6.18 (br s, 1H).	550.3	A	A
I-1085		Fc1ccc(Cl)c(c1)[C@H]1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1cscn1	NMR (400 MHz, CD3CN) 9.01 (d, 1.9 Hz, 1H), 8.76 (br s, 1H), 8.29 (d, 1.4 Hz, 1H), 8.25 (s, 1H), 8.02 (d, 1.9 Hz, 1H), 7.70-7.59 (m, 3H), 7.32 (br s, 1H), 7.27 (dd, 8.9, 5.1 Hz, 1H), 6.98 (ddd, 8.8, 8.0, 3.1 Hz, 1H), 6.72 (br s, 1H), 6.18 (br s, 1H).	550.3	D	
I-1086		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-n1cncn1	(400 MHz, DMSO-D6) 10.73 (s, 1 H), 9.55 (s, 1 H), 9.35 (s, 1 H), 8.32 (s, 1 H), 8.24 (d, 1.1 Hz, 1 H), 8.09 (s, 1 H), 7.96 (d, 8.5 Hz, 1 H), 7.76 (d, 8.9 Hz, 1 H), 7.68 (s, 1 H), 7.34 (dd, 8.9, 5.2 Hz, 1 H), 7.11 (td, 8.4, 3.1 Hz, 1 H),	532.3	A	A





			6.65 (br s, 1 H), 6.05 (br s, 1 H).			
I-1087		Fc1ccc(Cl)c(c1)[C@H]1NC(=O)c2cc(CC#N)cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12		504.2	B	
I-1088		Fc1ccc(Cl)c(c1)[C@@H]1NC(=O)c2cc(CC#N)cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12		506.2	A	A
I-1089		Nc1cc(ncn1)-c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	1H NMR (400 MHz, DMSO) 10.64 (s, 1H), 9.24 (s, 1H), 8.48 (d, 1.1 Hz, 1H), 8.19 (s, 2H), 7.94 (d, 8.4 Hz, 1H), 7.76 (d, 9.0 Hz, 1H), 7.70 (s, 1H), 7.65-7.51 (m, 1H), 7.32 (dd, 8.9, 5.2 Hz, 1H), 7.09 (td, 8.3, 3.1 Hz, 1H), 7.06-6.99 (m, 3H), 6.65 (s, 1H), 6.05 (s, 1H).	560.36	A	
I-1090		Nc1nccc(n1)-c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	1H NMR (400 MHz, DMSO) 10.67 (s, 1H), 9.23 (s, 1H), 8.42-8.31 (m, 2H), 8.22 (s, 1H), 7.94 (d, 8.5 Hz, 1H), 7.77 (d, 9.2 Hz, 1H), 7.71 (s, 1H), 7.31 (dd, 8.9, 5.2 Hz, 1H), 7.27 (d, 5.2 Hz, 1H), 7.09 (td, 8.4, 3.1 Hz, 1H), 6.77 (s, 3H).	560.31	A	
I-1091		COc1nccccc1-c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c	1H NMR (400 MHz, DMSO) 10.62 (s, 1H), 9.23 (s, 1H), 8.28 (d, 5.3 Hz, 1H), 8.01 (d, 1.6 Hz, 1H), 7.94 (d, 5.5 Hz, 2H), 7.75 (dd, 8.8, 2.4 Hz, 1H), 7.70 (s, 1H), 7.41 (dd, 5.4, 1.6 Hz, 1H), 7.33 (dd,	574.32	A	A




		1cc(F)ccc 1Cl	8.9, 5.2 Hz, 1H), 7.20 (d, 1.8 Hz, 1H), 7.09 (ddd, 8.8, 7.9, 3.1 Hz, 1H), 6.63 (s, 1H), 6.04 (s, 1H), 3.91 (s, 3H).			
I-1092		Cc1ncc(c (C)n1)-c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl		573	B	
I-1093		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1ccc2ncncc2c1		595.5	A	A
I-1094		Fc1ccc(Cl)c(c1)[C@H]1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1cncnc1		545.2	C	
I-1095		Fc1ccc(Cl)c(c1)[C@@H]1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1cncnc1		545.2	A	A
I-1096		CC(C)(O)Cn1cc(cn1)-c1cc2C(=O)N[C@@H](c2c(NC(=O)c2cc(F)cc		605.4	E	





		(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl				
I-1097		CC(C)(O)Cn1cc(cn1)-c1cc2C(=O)N[C@H](c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl		605.4	A	A
I-1098		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1ccncc1C#N		569.26	A	A
I-1099		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Nc3nnco3)cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	1H-NMR (400 MHz, DMSO-d6) 11.00 (br. s, 1H), 10.59 (br. s, 1H), 9.15 (br. s, 1H), 8.82 (s, 1H), 7.94 (br. d, 8.7 Hz, 1H), 7.92 (d, 1.5 Hz, 1H), 7.77 (s, 1H), 7.73 (br. d, 9.0 Hz, 1H), 7.62 (s, 1H), 7.31 (dd, 8.9, 5.2 Hz, 1H), 7.09 (app. td, 8.4, 3.0 Hz, 1H), 6.62 (br. s, 1H), 5.93 (br. s, 1H).	550.3	A	A
I-1100		O\N=C(/Nc1cccc2C(=O)NC(c12)c1cc(F)ccc1Cl)c1cc(F)cc(c1)C(F)(F)F		482.4	A	





I-1101		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1nc2cccc2[nH]1	1H NMR (500 MHz, DMSO) 13.23 (s, 1H), 10.68 (s, 1H), 9.28 (s, 1H), 8.52-8.38 (m, 2H), 7.95 (d, 8.5 Hz, 1H), 7.79 (d, 8.8 Hz, 1H), 7.75-7.52 (m, 4H), 7.34-7.30 (m, 1H), 7.23 (s, 2H), 7.10 (dt, 8.7, 4.4 Hz, 1H), 6.64 (s, 1H), 6.08 (s, 1H).	583.27	A	A
I-1102		Nc1cnc(cn1)-c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	1H NMR (500 MHz, DMSO) 10.55 (s, 1H), 9.14 (s, 1H), 8.66 (d, 1.5 Hz, 1H), 8.19 (d, 1.6 Hz, 1H), 8.08 (d, 1.6 Hz, 1H), 7.98 (d, 1.5 Hz, 1H), 7.93 (d, 8.6 Hz, 1H), 7.76 (d, 9.2 Hz, 1H), 7.70 (s, 1H), 7.31 (dd, 8.9, 5.2 Hz, 1H), 7.08 (td, 8.4, 3.1 Hz, 1H), 6.70 (s, 2H), 6.01 (s, 1H).	560.36	A	A
I-1103		COc1cnc(cn1)-c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	1H NMR (500 MHz, DMSO) 10.64 (s, 1H), 9.21 (s, 1H), 8.98 (d, 1.5 Hz, 1H), 8.44 (d, 1.4 Hz, 1H), 8.32 (d, 1.6 Hz, 1H), 8.20 (s, 1H), 7.94 (d, 8.5 Hz, 1H), 7.76 (d, 9.1 Hz, 1H), 7.70 (s, 1H), 7.32 (dd, 8.9, 5.1 Hz, 1H), 7.09 (td, 8.4, 3.1 Hz, 1H), 6.68 (s, 1H), 6.04 (s, 1H), 3.99 (s, 3H).	575.31	A	
I-1104		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)C1CN(C1)c1ccncn1		600.33	A	A






I-1105		COc1nccc(n1)-c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	1H NMR (500 MHz, DMSO) 10.68 (s, 1H), 9.27 (s, 1H), 8.73 (d, 5.2 Hz, 1H), 8.47-8.31 (m, 2H), 7.92 (dd, 23.2, 6.7 Hz, 2H), 7.80-7.65 (m, 2H), 7.32 (dd, 8.9, 5.2 Hz, 1H), 7.09 (td, 8.4, 3.0 Hz, 1H), 6.59 (s, 1H), 6.05 (s, 1H), 4.02 (s, 3H).	575.31	A	A
I-1106		Nc1ncncc1-c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl		560.5	A	
I-1107		Fc1ccc(Cl)c(c1)[C@@H]1NC(=O)c2cc(cc(NC(=O)c3ccc(F)c(OC(F)(F)F)c3)c12)-c1ccc2ncnn2c1	1H NMR (400 MHz, DMSO-d6) 10.50 (s, 1H), 9.48 (t, 1.4 Hz, 1H), 9.25 (s, 1H), 8.58 (s, 1H), 8.18 - 8.10 (m, 2H), 8.02 - 7.92 (m, 2H), 7.85 - 7.74 (m, 2H), 7.67 (dd, 10.1, 8.7 Hz, 1H), 7.34 (dd, 8.9, 5.1 Hz, 1H), 7.11 (td, 8.4, 3.1 Hz, 1H), 6.68 (s, 1H), 6.08 (s, 1H).	600.1	B	
I-1108		Fc1ccc(Cl)c(c1)[C@H]1NC(=O)c2cc(cc(NC(=O)c3ccc(F)c(OC(F)(F)F)c3)c12)-c1ccc2ncnn2c1	1H NMR (400 MHz, DMSO-d6) 10.50 (s, 1H), 9.48 (t, 1.4 Hz, 1H), 9.25 (s, 1H), 8.58 (s, 1H), 8.18 - 8.10 (m, 2H), 8.02 - 7.92 (m, 2H), 7.85 - 7.74 (m, 2H), 7.67 (dd, 10.1, 8.7 Hz, 1H), 7.34 (dd, 8.9, 5.1 Hz, 1H), 7.11 (td, 8.4, 3.1 Hz, 1H), 6.68 (s, 1H), 6.08 (s, 1H).	600.05	D	





I-1109		Fc1ccc(Cl)c(c1)[C@@H]1NC(=O)c2cc(Br)cc(Nc3nccc4c(cc(F)cc34)C(F)(F)F)c12	1H NMR (400 MHz, Chloroform-d) 8.35 (s, 1H), 8.21 (s, 1H), 7.88-7.83 (m, 2H), 7.50 (s, 1H), 7.34 (s, 1H), 7.10 (s, 1H), 6.99 (s, 1H), 6.68 (dd, 8.7, 3.0 Hz, 1H), 6.57-6.44 (m, 2H), 6.14 (s, 1H).	569.9	A	A
I-1110		Fc1ccc(Cl)c(c1)[C@H]1NC(=O)c2cc(Br)cc(Nc3nccc4c(cc(F)cc34)C(F)(F)F)c12	1H NMR (400 MHz, Chloroform-d) 8.34 (s, 1H), 8.22 (d, 6.2 Hz, 1H), 7.90-7.85(s,1H),7.80-7.85(s,1H) 7.53-7.46 (m, 1H), 7.32 (dd, 8.9, 4.9 Hz, 1H), 7.14-7.07 (m, 1H), 6.99 (s, 1H), 6.67-6.57 (m, 3H), 6.14 (s, 1H)	569.9	D	
I-1111		Fc1ccc(Cl)c(c1)[C@@H]1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(OC(F)(F)F)c3)c12)-c1ccc2ncnn2c1	1H NMR (400 MHz, DMSO-d6) 10.55 (s, 1H), 9.48 (dd, 1.9, 1.0 Hz, 1H), 9.26 (s, 1H), 8.58 (s, 1H), 8.18-8.03 (m, 2H), 8.03-7.95 (m, 2H), 7.68 (d, 8.8 Hz, 1H), 7.53 (d, 8.8 Hz, 1H), 7.46-7.42 (m, 1H), 7.36 (dd, 8.9, 5.2 Hz, 1H), 7.13 (td, 8.4, 3.1 Hz, 1H), 6.08 (s, 1H).	600.1	A	A
I-1112		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Nc3cc[nH]n3)cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	1H NMR (400 MHz, DMSO-d6) 12.12 (s, 1H), 10.39 (s, 1H), 8.96 (br. s, 1H), 8.91 (s, 1H), 7.92 (d, 8.5 Hz, 1H), 7.74 (d, 0.9 Hz, 1H), 7.71 (br. d, 8.5 Hz, 1H), 7.62 (s, 1H), 7.47 (br. s, 1H), 7.29 (dd, 8.9, 5.2 Hz, 1H), 7.07 (td, 8.4, 3.1 Hz, 1H), 6.63 (br. s, 1H), 5.90 (m, 1H)	548.3	A	A




I-1113		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(OCC3(CC3)C#N)cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	(400 MHz, DMSO-D6) 10.51 (br s, 1 H), 9.15 (br s, 1 H), 7.94 (d, 8.5 Hz, 1 H), 7.71 (d, 9.1 Hz, 1 H), 7.64 (s, 1 H), 7.31 (dd, 8.9, 5.2 Hz, 1 H), 7.22 (d, 2.1 Hz, 1 H), 7.13 (s, 1 H), 7.08 (td, 8.4, 3.1 Hz, 1 H), 6.61 (br s, 1 H), 5.93 (br s, 1 H), 4.18 (dd, 28.4, 10.4 Hz, 2 H), 1.40 (dd, 7.3, 4.7 Hz, 2 H), 1.20 (dd, 7.4, 4.9 Hz, 2 H).	562.4	A	
I-1114		OC1(COC1)c1c(F)cc(cc1C(=O)Nc1ccc2C(=O)NC(c12)c1cc(F)ccc1Cl)C(F)(F)F	NMR (400 MHz, DMSO-d6) 10.62 (br. s, 1H), 9.16 (br. s, 1H), 7.90 (d, 10.6 Hz, 1H), 7.70 (d, 7.4 Hz, 1H), 7.65 (t, 7.5 Hz, 1H), 7.55-7.44 (m, 2H), 7.23 (td, 8.4, 2.9 Hz, 1H), 6.51 (s, 1H), 6.33 (br. s, 1H), 6.00 (br. s, 1H), 4.91 (dd, 7.3, 1.8 Hz, 1H), 4.79 (d, 7.5 Hz, 1H), 4.65 (d, 7.4 Hz, 1H), 4.43 (d, 7.5 Hz, 1H)	539.2	D	
I-1115		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Nc3ccno3)cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	1H-NMR (400 MHz, DMSO-d6) 10.65 (br. s, 1H), 9.28 (br. s, 1H), 8.00 (br. d, 10.2 Hz, 1H), 7.95 (d, 8.1 Hz, 1H), 7.79 (d, 4.4 Hz, 1H), 7.74 (br. d, 8.3 Hz, 1H), 7.67 (br. s, 1H), 7.64 (s, 1H), 7.58 (s, 1H), 7.32 (dd, 8.7, 5.1 Hz, 1H), 7.10 (app. td, 8.4, 3.0 Hz, 1H), 6.63 (br. s, 1H), 5.99 (br. s, 1H), 5.33 (s, 1H).	549.2	A	





I-1116		Fc1ccc(Cl)c(c1)[C@H]1NC(=O)c2cc(cc(NC(=O)c3cccc(c3)C(F)(F)F)c12)-c1ccc2ncnn2c1	1H NMR (400 MHz, DMSO-d6) 10.57 (s, 1H), 9.48 (t, 1.3 Hz, 1H), 9.25 (s, 1H), 8.58 (s, 1H), 8.18 - 8.04 (m, 2H), 8.03-7.90 (m, 4H), 7.83 (s, 1H), 7.74 (t, 7.8 Hz, 1H), 7.34 (dd, 8.9, 5.1 Hz, 1H), 7.11 (td, 8.4, 3.1 Hz, 1H), 6.11 (s, 1H), 1.24 (s, 1H).	566.05	E	
I-1117		Fc1ccc(Cl)c(c1)[C@H]1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(OC(F)(F)F)c3)c12)-c1ccc2ncnn2c1	1H NMR (400 MHz, DMSO-d6) 10.55 (s, 1H), 9.48 (dd, 1.9, 1.0 Hz, 1H), 9.26 (s, 1H), 8.58 (s, 1H), 8.18-8.03 (m, 2H), 8.03-7.95 (m, 2H), 7.68 (d, 8.8 Hz, 1H), 7.53 (d, 8.8 Hz, 1H), 7.46-7.42 (m, 1H), 7.36 (dd, 8.9, 5.2 Hz, 1H), 7.13 (td, 8.4, 3.1 Hz, 1H), 6.08 (s, 1H).	600.1	D	
I-1118		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(Nc3ncc(cc3F)C(F)(F)F)c12	1H NMR (400 MHz, DMSO-d6) 10.10 (s, 1H), 10.04 (s, 1H), 9.06 (s, 1H), 8.72 (dd, 11.2, 2.1 Hz, 1H), 8.58-8.50 (m, 2H), 8.12 (dd, 8.9, 5.1 Hz, 1H), 7.90 (ddd, 8.8, 7.9, 3.1 Hz, 1H), 7.34 (s, 1H), 6.76 (s, 1H).	518	C	
I-1119		FCc1cc(F)cc(c1)C(=O)Nc1cc(Br)cc2C(=O)NC(c12)c1cc(F)ccc1Cl	1H NMR (400 MHz, Chloroform-d) 8.49 (s, 1H), 7.96 (s, 1H), 7.45 (dd, 8.9, 4.9 Hz, 2H), 7.38 (s, 1H), 7.26 -7.18 (m, 2H), 7.14 - 7.05 (m, 1H), 6.72 (s, 1H), 6.50 (s, 1H), 6.19 (s, 1H), 5.48 (s, 1H), 5.37 (s, 1H).	509	C	




I-1120		Cn1cc(Oc2cc3C(=O)NC(c3c(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c2)c2cc(F)ccc2Cl)cn1	NMR (400 MHz, DMSO) 10.50 (s, 1H), 8.52 (s, 1H), 7.98 (s, 1H), 7.84 (d, 9.2 Hz, 1H), 7.83 (s, 1H), 7.79 (s, 1H), 7.54 (d, 0.6 Hz, 1H), 7.51 (dd, 9.2, 3.0 Hz, 1H), 7.22 (dd, 8.8, 5.2 Hz, 1H), 7.08 (d, 1.7 Hz, 1H), 7.02 (td, 8.5, 3.1 Hz, 1H), 6.92 (br s, 1H), 6.04 (s, 1H), 3.74 (s, 3H).	563	D	
I-1121		Fc1ccc(Cl)c(c1)[C@@H]1NC(=O)c2cc(cc(NC(=O)c3cccc(c3)C(F)(F)F)c12)-c1ccc2nccnn2c1	1H NMR (400 MHz, DMSO-d6)10.57 (s, 1H), 9.48 (t, 1.3 Hz, 1H), 9.25 (s, 1H), 8.58 (s, 1H), 8.18 - 8.04 (m, 2H), 8.03-7.90 (m, 4H), 7.83 (s, 1H), 7.74 (t, 7.8 Hz, 1H), 7.34 (dd, 8.9, 5.1 Hz, 1H), 7.11 (td, 8.4, 3.1 Hz, 1H), 6.11 (s, 1H), 1.24 (s, 1H).	566.05	A	
I-1122		Cc1ncc(c(N)n1)-c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl		574.4	A	
I-1123		Cc1nc2ccc(cn2n1)-c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl		598.6	A	A





I-1124		Cc1nc2ncc(cn2n1)-c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl		599.5	A	A
I-1125		Fc1ccc(Cl)c(c1)[C@H]1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-n1ccnc1	(400 MHz, DMSO-D6) 10.71 (br s, 1 H), 9.31 (s, 1 H), 8.45 (s, 1 H), 8.03 - 7.90 (m, 3 H), 7.84 (s, 1 H), 7.76 (d, 8.8 Hz, 1 H), 7.69 (s, 1 H), 7.33 (dd, 8.9, 5.1 Hz, 1 H), 7.16 (s, 1 H), 7.10 (td, 8.4, 2.9 Hz, 1 H), 6.67 (br s, 1 H), 6.02 (br s, 1 H).	533.3	B	
I-1126		Fc1ccc(Cl)c(c1)[C@@H]1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-n1ccnc1	(400 MHz, DMSO-D6) 10.71 (br s, 1 H), 9.31 (s, 1 H), 8.45 (s, 1 H), 8.03 - 7.90 (m, 3 H), 7.84 (s, 1 H), 7.76 (d, 8.8 Hz, 1 H), 7.69 (s, 1 H), 7.33 (dd, 8.9, 5.1 Hz, 1 H), 7.16 (s, 1 H), 7.10 (td, 8.4, 2.9 Hz, 1 H), 6.67 (br s, 1 H), 6.02 (br s, 1 H).	533.3	A	
I-1127		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-n1cnc(c1)C#N	(400 MHz, DMSO-D6) 9.36 (s, 1 H), 8.90 (d, 1.1 Hz, 1 H), 8.67 (d, 0.9 Hz, 1 H), 8.06 (s, 1 H), 7.94 (d, 6.7 Hz, 2 H), 7.79-7.62 (m, 3 H), 7.34 (dd, 8.9, 5.2 Hz, 1 H), 7.11 (td, 8.4, 3.0 Hz, 1 H), 6.67 (br s, 1 H), 6.03 (br s, 1 H).	556.3	A	
I-1128		Fc1cncn1-c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	(400 MHz, DMSO-D6) 9.33 (s, 1 H), 8.39 (br s, 1 H), 8.23 (s, 1 H), 8.00 (s, 1 H), 7.96 (d, 8.3 Hz, 1 H), 7.88 (s, 1 H), 7.80-7.73 (m, 2 H), 7.71 (s, 1 H), 7.33 (dd, 8.8, 5.1 Hz, 1 H), 7.10 (td, 8.4, 2.7 Hz, 1 H),	551.3	A	





			6.71 (br s, 1 H), 6.03 (br s, 1 H).			
I-1129		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(OC3CC(C3)C#N)cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	1H NMR (400 MHz, DMSO-d6) 10.44 (s, 1H), 9.14 (s, 1H), 7.94 (dt, 8.5, 1.2 Hz, 1H), 7.71 (br. d, 8.9 Hz, 1H), 7.62 (s, 1H), 7.31 (dd, 8.9, 5.2 Hz, 1H), 7.12-7.05 (m, 2H), 7.03 d, 1.6 Hz, 1H), 6.58 (br. s, 1H), 5.92 (br. s, 1H), 5.19-5.08 (m, 1H), 3.53-3.44 (m, 1H), 2.92-2.80 (m, 2H), 2.62-2.52 (m, 2H)	562.3	A	
I-1130		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Oc3ccnc(c3)C#N)cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	(400 MHz, DMSO-d6) 10.68 (br s, 1H), 9.31 (s, 1H), 8.67 (d, 5.7 Hz, 1H), 7.91 (d, 6.8 Hz, 1H), 7.86 (s, 1H), 7.71 (d, 8.4 Hz, 1H), 7.63 (s, 1H), 7.52 - 7.43 (m, 2H), 7.40 - 7.31 (m, 2H), 7.11 (td, 8.5, 3.0 Hz, 1H), 6.87 (br s, 1H), 6.05 (s, 1H) .	583.4	A	
I-1131		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(OC3COC3)cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	(400 MHz, DMSO-d6) 10.52 (br s, 1H), 9.15 (s, 1H), 7.94 (d, 8.4 Hz, 1H), 7.71 (d, 8.9 Hz, 1H), 7.63 (s, 1H), 7.30 (dd, 8.8, 5.2 Hz, 1H), 7.08 (td, 8.5, 3.0 Hz, 1H), 7.00 (s, 1H), 6.97 (d, 2.1 Hz, 1H), 6.65 (br s, 1H), 5.92 (s, 1H), 5.44 (p, 5.2 Hz, 1H), 4.98 (t, 6.6 Hz, 2H), 4.64-4.57 (m, 2H) .	537.3	A	
I-1132		OC1CC(C1)Oc1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	NMR (400 MHz, DMSO-d6) 8.60 (br. d, 7.9 Hz, 1H), 7.67-7.55 (m, 3H), 7.30-7.23 (m, 2H), 7.21 (br. s, 1H), 7.13 (dd, 5.6, 2.1 Hz, 2H), 6.96 (ddd, 8.8, 8.0, 3.1 Hz), 6.64 (br. s, 1H), 6.05 (br. s, 1H), 4.77-4.68 (m, 1H), 3.69-3.62 (m, 1H), 1.36 (dd, 6.0, 5.2 Hz, 2H),	555.3	B	





			1.28-1.25 (m, 1H), 1.19 (d, 6.2 Hz, 1H)			
I-1133		Fc1ccc(Cl)c(c1)C1NC(=O)c2cccc(NC(=O)C34CC5CC(CC(F)(C5)C3)C4)c12	1H-NMR (400MHz, DMSO-d6)-9.29 (s, 1H), 9.08 (br. s, 1H), 7.61 (dd, 7.3, 1.1 Hz, 1H), 7.57 (t, 7.5 Hz, 1H), 7.54-7.47 (m, 1H), 7.37 (dd, 7.5, 1.3 Hz, 1H), 7.24 (ddd, 8.8, 8.1, 3.1 Hz, 1H), 6.42 (br. s, 1H), 6.02 (br. s, 1H), 2.24-2.15 (m, 2H), 1.78 (d, 2.8 Hz, 1H), 1.77-1.72 (m, 1H), 1.71-1.64 (m, 3H), 1.62-1.56 (m, 1H), 1.53-1.39 (m, 5H), 1.37-1.31 (m, 1H).	457.4	C	
I-1134		OCCOCC(O)c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	NMR (400 MHz, DMSO-d6) 10.55 (br s, 1H), 9.19 (br s 1H), 7.91 (d, 7.1 Hz, 1H), 7.79-7.69 (m, 2H), 7.66 (s, 2H), 7.54-7.48 (m, 1H), 7.31 (dd, 8.8, 5.2 Hz, 1H), 7.09 (tt, 8.7, 4.3 Hz, 1H), 5.96 (br s, 1H), 5.62 (d, 8.0 Hz, 1H), 4.88 (ddd, 16.6, 11.5, 5.0 Hz, 1H), 4.60 (dd, 5.0, 3.7 Hz, 1H), 3.62-3.52 (m, 2H), 3.52-3.43 (m, 4H).	571.3	B	
I-1135		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(OC3CCOCC3)cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	NMR (400 MHz, DMSO-d6) 10.41 (br. s, 1H), 9.12 (s, 1H), 7.94 (dt, 8.4, 1.6 Hz, 1H), 7.71 (br. d, 9.2 Hz), 7.63 (s, 1H), 7.30 (dd, 8.9, 5.2 Hz, 1H), 7.26 (d, 2.2 Hz, 1H), 7.11-7.07 (m, 2H), 6.64 (br. s, 1H), 5.92 (br. s, 1H), 4.75 (tt, 8.4, 4.0 Hz, 1H), 3.93-3.81 (m, 2H), 3.57-3.46 (m, 2H), 2.07-1.94 (m, 2H), 1.72-1.54 (m, 2H).	567.3	A	





I-1136		Cn1nccc1-c1cc2C(=O)N[C@H](c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	NMR (400 MHz, DMSO-d6) 10.61 (s, 1H), 9.27 (br. s, 1H), 7.96 (br. d, 7.6 Hz, 1H), 7.79 (s, 1H), 7.74 (br. d, 7.9 Hz, 1H), 7.67 (s, 2H), 7.53 (d, 1.9 Hz, 1H), 7.34 (dd, 8.9, 5.2 Hz, 1H), 7.11 (td, 8.4, 3.1 Hz, 1H), 6.80 (s, 1H), 6.57 (d, 1.9 Hz, 1H), 6.05 (s, 1H), 3.94 (s, 3H).	547.4	A	
I-1137		Cn1nccc1-c1cc2C(=O)N[C@@H](c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	NMR (400 MHz, DMSO-d6) 10.60 (s, 1H), 9.28 (br. s, 1H), 7.96 (br. d, 8.5 Hz, 1H), 7.80 (d, 1.3 Hz, 1H), 7.74 (br. d, 9.4 Hz, 1H), 7.66-7.65 (m, 2H), 7.53 (d, 1.9 Hz, 1H), 7.34 (dd, 8.9, 5.2 Hz, 1H), 7.11 (td, 8.5, 3.0 Hz, 1H), 6.75 (s, 1H), 6.57 (d, 1.9 Hz, 1H), 6.05 (s, 1H), 3.94 (s, 3H).	547.4	D	
I-1138		CNC1(NC(=O)c2cc(CS(C)=O)cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)c1cc(F)ccc1Cl	NMR (400 MHz, MeCNd3) 9.81 (br. s, 1H), 8.46 (dd, 1.6, 2.0 Hz, 1H), 7.78 (s, 1H), 7.70 (d, 0.8 Hz, 1H), 7.68 (d, 0.8 Hz, 1H), 7.51 (dd, 1.6, 2.0 Hz, 1H), 7.43 (dd, 8.8, 5.4 Hz, 1H), 7.30 (dt, 10.4, 3.1 Hz, 1H), 7.20 (br. s, 1H), 7.06 (dddd, 10.8, 7.2, 2.8, 0.4 Hz, 1H), 4.20 (dd, 12.9, 1.2 Hz, 1H), 4.03 (d, 12.9 Hz, 1H), 3.31 (br. s, 1H) 2.49 (d, 2.5 Hz, 3H), 2.18 (s, 3H).	572.2	D	
I-1139		CC(C)(C)C(=O)Nc1cc(Br)cc2C(=O)NC(c12)c1cc(F)ccc1Cl	1H-NMR (400 MHz, Solvent) 9.30 (s, 1H), 9.24 (br. s, 1H), 7.71 (d, 1.7 Hz, 1H), 7.58 (d, 1.7 Hz, 1H), 7.54-7.47 (m, 1H), 7.24 (ddd, 8.8, 8.1, 3.1 Hz, 1H), 6.56 (br. s, 1H),	439.3	D	





			6.03 (s, 1H), 0.89 (s, 9H).			
I-1140		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-n1cc(cn1)C#N	(400 MHz, DMSO-D6) 10.71 (br s, 1 H), 9.57 (s, 1 H), 9.36 (s, 1 H), 8.44 (s, 1 H), 8.18 (s, 1 H), 8.12 (s, 1 H), 7.96 (d, 7.8 Hz, 1 H), 7.76 (d, 8.6 Hz, 1 H), 7.68 (s, 1 H), 7.34 (dd, 8.9, 5.2 Hz, 1 H), 7.11 (td, 8.5, 3.1 Hz, 1 H), 6.66 (br s, 1 H), 6.05 (br s, 1 H).	556.3	A	
I-1141		OC1COCC1(O)c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	NMR (400 MHz, DMSO-d6) 10.65 (br s, 1H), 9.13 (br s, 1H), 7.94 (d, 8.7 Hz, 1H), 7.85 (s, 1H) 7.77 (d , 8.7 Hz, 1H), 7.69 (s, 1H), 7.64-7.62 (m, 1H), 7.30 (dd, 8.9, 5.1 Hz, 1H), 7.11-7.06 (m, 1H), 6.58 (br s, 1H), 5.99 (br s, 1H), 5.51-5.46 (m, 1H), 5.40 (d, 6.0 Hz, 1H), 4.31 (ddd, 20.5, 13.2, 6.7 Hz, 1H), 4.14-4.01 (m, 1H), 3.98 (d, 9.3 Hz, 1H), 3.90 (dd, 9.3, 4.6 Hz, 1H), 3.70-3.59 (m, 1H).	569.3	B	
I-1142		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)C1CCCOC1	NMR (400 MHz, DMSO-d6) 9.11 (br s, 1H), 8.44 (br s, 1H), 7.94 (d, 8.4 Hz, 1H), 7.74 (d, 9.1 Hz, 1H), 7.67 (s, 1H), 7.61 (s, 1H), 7.40 (s, 1H), 7.30 (dd, 8.9, 5.2 Hz, 1H), 7.08 (td, 8.5, 2.9 Hz, 1H), 6.61 (br s, 1H), 5.95 (br s, 1H), 3.92-3.86 (m, 2H), 3.47-3.3 (m. 2H), 3.10-2.94 (m. 1H), 2.05-1.99 (m, 1H), 1.89-1.74 (m, 1H), 1.77-1.65 (m, 2H).	551.3	A	





I-1143		COc1ccnc(Oc2cc3C(=O)NC(c3c(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c2)c2cc(F)ccc2Cl)n1	NMR (400 MHz, CD3CN) 8.76 (br s, 1H), 8.21 (d, 5.7 Hz, 1H), 7.66-7.62 (m, 1H), 7.60-7.53 (m, 3H), 7.42 (d, 1.6 Hz, 1H), 7.40 (br s, 1H), 7.26 (dd, 8.9, 5.1 Hz, 1H), 6.98 (ddd, 8.8, 8.0, 3.1 Hz, 1H), 6.68 (br s, 1H), 6.58 (d, 5.7 Hz, 1H), 6.13 (s, 1H), 3.90 (s, 3H).	591	B	
I-1144		Cn1nccc1Nc1cc2C(=O)N[C@H](c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	1H NMR (400 MHz, DMSO-D6) 10.37 (s, 1H), 9.04 (s, 1H), 8.45 (s, 1H), 7.92 (d, 8.5 Hz, 1H), 7.69 (d, 8.9 Hz, 1H), 7.59 (s, 1H), 7.42 (d, 1.4 Hz, 1H), 7.30 (dd, 8.9, 5.1 Hz, 1H), 7.07 (td, 8.4, 2.9 Hz, 1H), 7.02 (d, 1.6 Hz, 1H), 6.94 (s, 1H), 6.66 (br s, 1H), 6.12 (d, 1.6 Hz, 1H), 5.89 (br s, 1H), 3.68 (s, 3H).	562.3	A	
I-1145		Cn1nccc1Nc1cc2C(=O)N[C@@H](c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	1H NMR (400 MHz, DMSO-d6) 10.36 (s, 1H), 9.04 (br s, 1H), 8.44 (s, 1H), 7.93 (d, 8.6 Hz, 1H), 7.69 (d, 9.0 Hz, 1H), 7.59 (s, 1H), 7.42 (d, 1.9 Hz, 1H), 7.30 (dd, 8.9, 5.2 Hz, 1H), 7.07 (td, 8.4, 3.1 Hz, 1H), 7.02 (d, 2.0 Hz, 1H), 6.93 (br s, 1H), 6.64 (br s, 1H), 6.12 (d, 1.8 Hz, 1H), 5.89 (br s, 1H), 3.68 (s, 3 H).	562.3	D	
I-1146		Fc1cnn(c1)-c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	(400 MHz, DMSO-D6) 10.69 (br s, 1 H), 9.30 (br s, 1 H), 8.96 (d, 4.4 Hz, 1 H), 8.12 - 8.02 (m, 2 H), 7.96 (d, 8.7 Hz, 1 H), 7.93 (d, 4.3 Hz, 1 H), 7.76 (d, 8.9 Hz, 1 H), 7.68 (s, 1 H), 7.33 (dd, 8.9, 5.2 Hz, 1 H), 7.10 (td, 8.5, 3.0	549.3	A	A





			Hz, 1 H), 6.66 (br s, 1 H), 6.02 (br s, 1 H).			
I-1147		COc1ccc(Oc2cc3C(=O)NC(c3c(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c2)c2cc(F)ccc2Cl)nn1	NMR (400 MHz, DMSO) 10.66 (br s, 1H), 9.24 (br s, 1H), 8.49 (s, 1H), 7.92 (br d, 7.0 Hz, 1H), 7.73 (br d, 8.9 Hz, 1H), 7.65 (s, 1H), 7.57 (d, 9.4 Hz, 1H), 7.41-7.39 (m, 2H), 7.34 (dd, 8.9, 5.2 Hz, 1H), 7.11 (td, 8.3, 3.0 Hz, 1H), 6.71 (br s, 1H), 6.01 (br s, 1H), 3.97 (s, 3H).	591	A	
I-1148		COc1nccc(Oc2cc3C(=O)NC(c3c(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c2)c2cc(F)ccc2Cl)n1	NMR (400 MHz, CD3CN) 8.72 (br s, 1H), 8.42 (d, 5.6 Hz, 1H), 7.65 (d, 8.4 Hz, 1H), 7.62-7.54 (m, 3H), 7.42 (d, 1.2 Hz, 1H), 7.35 (s, 1H), 7.28 (dd, 8.9, 5.1 Hz, 1H), 7.02-6.96 (m, 1H), 6.71 (br d, 5.6 Hz, 2H), 6.15 (br s, 1H), 3.86 (s, 3H).	591	A	
I-1149		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(OC3CS(=O)(=O)C3)cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	NMR (400 MHz, DMSO-d6) Major rotamer:-′ 10.40 (br. s, 1H), 10.32 (br. s, 1H), 7.98 (br. d, 8.2 Hz, 1H), 7.78 (br. d, 8.8 Hz, 1H), 7.69 (s, 1H), 7.36-7.31 (m, 2H), 7.14-7.08 (m, 1H), 7.03 (d, 2.2 Hz, 1H), 6.86 (d, 2.2 Hz, 1H), 5.83 (s, 1H), 4.88-4.81 (m, 1H), 4.81-4.74 (m, 1H), 4.38-4.27 (m, 2H), 4.20-4.11 (m, 1H)	587.1	D	
I-1150		CS(=O)c1ccccc1-c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	1H NMR (400 MHz, DMSO-d6) 2.53 - 2.56 (m, 4 H) 5.98 - 6.19 (m, 1 H) 7.12 - 7.20 (m, 1 H) 7.39 (ddd, 8.84, 5.18, 2.15 Hz, 1 H) 7.50 - 7.62 (m, 2 H) 7.68 - 7.75 (m, 3 H) 7.76 - 7.83 (m, 2 H) 7.99 (br d, 8.34 Hz, 1 H) 8.09 (ddd, 7.77, 2.97, 1.14	605.28	A	





			Hz, 1 H) 9.31 (br s, 1 H) 10.65 (br d, 16.67 Hz, 1 H)			
I-1151		COc1ncc(c(N)n1)-c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl		590.5	B	
I-1152		Cc1ncccc1-c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl		558.36	A	
I-1153		Nc1ncc(cn1)C#Cc1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	1H NMR (DMSO-d6, 400 MHz):-′ = 10.53 (s, 1H), 9.26 (br s, 1H), 8.49 (s, 2H), 7.96 (br d, 8.3 Hz, 1H), 7.60-7.77 (m, 4H), 7.33 (dd, 8.8, 5.3 Hz, 1H), 7.22 (s, 2H), 7.10 (td, 8.3, 3.0 Hz, 1H), 6.02 (br s, 1H), 2.99 (br s, 1H)	584.5	A	
I-1154		OC1(COC1)C#Cc1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	1H NMR (DMSO-d6, 400 MHz):-′ = 10.52 (s, 1H), 9.28 (br s, 1H), 7.96 (br d, 8.3 Hz, 1H), 7.69-7.76 (m, 2H), 7.66 (s, 1H), 7.61 (d, 1.0 Hz, 1H), 7.33 (dd, 8.8, 5.3 Hz, 1H), 7.10 (td, 8.4, 3.2 Hz, 1H), 6.70 (s, 1H), 6.01 (br s, 1H), 4.80 (d, 6.6 Hz, 2H), 4.63 (d, 6.6 Hz, 2H), 4.31-4.58 (m, 1H), 3.13 (s, 1H)	563.4	A	




I-1155		Cn1cc(cn1)C#Cc1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	1H NMR (DMSO-d6, 400 MHz):-′ = 10.51 (s, 1H), 9.26 (br s, 1H), 8.13 (s, 1H), 7.96 (br d, 8.6 Hz, 1H), 7.71-7.77 (m, 2H), 7.69 (d, 1.0 Hz, 1H), 7.66 (s, 1H), 7.60 (s, 1H), 7.33 (dd, 9.0, 5.2 Hz, 1H), 7.10 (td, 8.3, 3.0 Hz, 1H), 6.01 (br s, 1H), 3.87 (s, 3H), 2.98 (br s, 1H)	571.4	A	
I-1156		COc1c(F)cccc1-c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	1H NMR (500 MHz, DMSO-d6) 3.74 (d, 1.37 Hz, 3 H) 6.06 (br s, 1 H) 6.74 (br d, 3.36 Hz, 1 H) 7.09 (td, 8.39, 3.05 Hz, 1 H) 7.21 - 7.27 (m, 1 H) 7.28 - 7.37 (m, 3 H) 7.66 (s, 1 H) 7.69 - 7.81 (m, 3 H) 7.88 (br d, 8.39 Hz, 1 H) 9.09 (s, 1 H) 10.47 (br s, 1 H)	591.33	A	A
I-1157		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)C1CN(C1)C#N	1H NMR (500 MHz, DMSO-d6) 4.14 - 4.21 (m, 1 H) 4.23 - 4.32 (m, 2 H) 4.53 - 4.62 (m, 2 H) 6.00 (br s, 1 H) 6.56 - 6.72 (m, 1 H) 7.07 (td, 8.39, 3.05 Hz, 1 H) 7.30 (dd, 8.85, 5.19 Hz, 1 H) 7.54 (d, 1.22 Hz, 1 H) 7.67 - 7.76 (m, 3 H) 7.89 (br d, 8.39 Hz, 1 H) 9.04 (s, 1 H) 10.42 (s, 1 H)	547.31	A	C
I-1158		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)C1CN(CC#N)C1	1H NMR (500 MHz, DMSO-d6) 3.34 - 3.40 (m, 2 H) 3.70 (s, 2 H) 3.74 - 3.80 (m, 2 H) 3.80 - 3.87 (m, 1 H) 5.97 (br s, 1 H) 6.50 - 6.72 (m, 1 H) 7.06 (td, 8.39, 3.05 Hz, 1 H) 7.28 (dd, 8.85, 5.19 Hz, 1 H) 7.49 (s, 1 H) 7.66 - 7.75 (m, 3 H) 7.87 (br d, 8.39 Hz, 1 H) 8.99 (s, 1 H) 10.40 (br s, 1 H)	534.4	A	A




I-1159		CS(=O)(=O)Nc1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	1H NMR (400 MHz, DMSO-d6) 3.07 (s, 3 H) 5.92 (br s, 1 H) 6.58 (br s, 1 H) 7.08 (td, 8.40, 3.16 Hz, 1 H) 7.27 - 7.36 (m, 2 H) 7.49 (d, 1.77 Hz, 1 H) 7.60 (s, 1 H) 7.71 (br d, 9.09 Hz, 1 H) 7.94 (br d, 8.34 Hz, 1 H) 9.15 (br s, 1 H) 10.18 - 10.47 (m, 1 H) 10.54 (br s, 1 H)	560.31	A	A
I-1160		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(OCC#N)cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12		522.4	A	A
I-1161		Fc1ccc(Cl)c(c1)C1NC(=O)c2cccc(NC(=O)c3cc(F)cc4c(Cl)c[nH]c34)c12		472	B	B
I-1162		COc1nccc(n1)N1CC(C1)c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	1H NMR (400 MHz, DMSO-d6) 3.80 (s, 3 H) 4.08 (ddd, 11.87, 8.72, 5.94 Hz, 2 H) 4.15 - 4.25 (m, 1 H) 4.45 - 4.55 (m, 2 H) 6.16 (d, 5.81 Hz, 1 H) 6.70 - 6.82 (m, 1 H) 7.10 (td, 8.40, 2.91 Hz, 1 H) 7.32 (dd, 8.97, 5.18 Hz, 1 H) 7.56 (s, 1 H) 7.64 - 7.79 (m, 3 H) 7.94 (br d, 8.08 Hz, 1 H) 8.03 (d, 5.56 Hz, 1 H) 8.47 (s, 1 H) 9.16 (br s, 1 H) 10.53 (br s, 1 H)	630.39	A	A





I-1163		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1ccccc1C#C	1H NMR (400 MHz, DMSO-d6) 4.22 (s, 1 H) 5.99 - 6.12 (m, 1 H) 7.11 (td, 8.46, 3.03 Hz, 1 H) 7.34 (dd, 8.84, 5.05 Hz, 1 H) 7.43 - 7.49 (m, 1 H) 7.51 - 7.59 (m, 2 H) 7.63 - 7.70 (m, 3 H) 7.75 (br d, 9.09 Hz, 1 H) 7.86 (d, 1.26 Hz, 1 H) 7.95 (br d, 8.34 Hz, 1 H) 9.23 (br s, 1 H) 10.60 (s, 1 H)	567.32	A	A
I-1164		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)N1CCOCC1	1H NMR (400 MHz, DMSO-d6) 3.22 (q, 4.46 Hz, 4 H) 3.76 (t, 4.80 Hz, 4 H) 5.83 - 5.94 (m, 1 H) 7.02 - 7.10 (m, 2 H) 7.17 (d, 2.02 Hz, 1 H) 7.28 (dd, 8.84, 5.05 Hz, 1 H) 7.65 (s, 1 H) 7.71 (br d, 8.84 Hz, 1 H) 7.92 (br d, 8.59 Hz, 1 H) 9.01 (br s, 1 H) 10.38 (s, 1 H)	552.36	A	A
I-1165		Fc1ccc(Cl)c(c1)[C@@H]1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(Cl)c3)c12)-c1ccc2nnn2c1	1H NMR (400 MHz, DMSO-d6) 10.50 (s, 1H), 9.48 (dd, 1.9, 1.0 Hz, 1H), 9.27 (s, 1H), 8.58 (s, 1H), 8.18 - 8.10 (m, 2H), 8.03 - 7.94 (m, 2H), 7.72 (dt, 8.6, 2.2 Hz, 1H), 7.48 - 7.36 (m, 3H), 7.17 (td, 8.4, 3.1 Hz, 1H), 6.08 (s, 1H).	550.1	A	
I-1166		Fc1ccc(Cl)c(c1)[C@H]1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(Cl)c3)c12)-c1ccc2nnn2c1	1H NMR (400 MHz, DMSO-d6) 10.50 (s, 1H), 9.48 (d, 1.6 Hz, 1H), 9.27 (s, 1H), 8.58 (s, 1H), 8.14 (dd, 9.4, 1.8 Hz, 2H), 8.03 - 7.94 (m, 2H), 7.75 - 7.68 (m, 1H), 7.47 - 7.36 (m, 3H), 7.17 (td, 8.4, 3.1 Hz, 1H), 6.08 (s, 1H), 1.24 (s, 0H).	550.1	D	




I-1167		Cc1ccc(cc1C(F)(F)F)C(=O)Nc1cc(cc2C(=O)N[C@H](c12)c1cc(F)ccc1Cl)-c1ccc2ncnn2c1	1H NMR (400 MHz, Chloroform-d) 8.96 (t, 1.4 Hz, 1H), 8.60 (s, 1H), 8.44 (s, 1H), 8.05 (d, 1.6 Hz, 1H), 7.91 (t, 1.3 Hz, 2H), 7.77 - 7.67 (m, 2H), 7.52 (s, 1H), 7.49 -7.40 (m, 2H), 7.10 (ddd, 8.9, 7.3, 3.0 Hz, 1H), 6.79 (d, 8.3 Hz, 1H), 6.56 (s, 1H), 6.31 (s, 1H), 2.60 (d, 1.9 Hz, 3H).	580.15	A	
I-1168		Cc1ccc(cc1C(F)(F)F)C(=O)Nc1cc(cc2C(=O)N[C@@H](c12)c1cc(F)ccc1Cl)-c1ccc2ncnn2c1	1H NMR (400 MHz, Chloroform-d) 8.97 (s, 1H), 8.60 (s, 1H), 8.44 (s, 1H), 8.05 (d, 1.6 Hz, 1H), 7.92 (s, 2H), 7.76 - 7.68 (m, 2H), 7.54 (s, 1H), 7.49 - 7.40 (m, 2H), 7.10 (ddd, 8.9, 7.2, 3.0 Hz, 1H), 6.79 (d, 8.4 Hz, 1H), 6.62 (s, 1H), 6.31 (s, 1H), 2.60 (q, 1.9 Hz, 3H).	580.05	E	
I-1169		FC(F)Oc1cc(F)cc(c1)C(=O)Nc1cc(cc2C(=O)N[C@H](c12)c1cc(F)ccc1Cl)-c1ccc2ncnn2c1	1H NMR (400 MHz, DMSO-d6) 10.45 (s, 1H), 9.47 (t, 1.3 Hz, 1H), 9.25 (s, 1H), 8.58 (s, 1H), 8.17 - 8.10 (m, 2H), 8.02 - 7.94 (m, 2H), 7.44 - 7.27 (m, 5H), 7.14 (td, 8.9, 8.0, 3.1 Hz, 1H), 6.10 (s, 2H).	582.1	B	
I-1170		FC(F)Oc1cc(F)cc(c1)C(=O)Nc1cc(cc2C(=O)N[C@@H](c12)c1cc(F)ccc1Cl)-c1ccc2ncnn2c1	1H NMR (400 MHz, DMSO-d6) 10.45 (s, 1H), 9.48 (d, 1.3 Hz, 1H), 9.25 (s, 1H), 8.58 (s, 1H), 8.17 - 8.10 (m,2H), 8.02 - 7.94 (m, 2H), 7.42 - 7.27 (m, 5H), 7.14 (td, 8.8, 8.1, 3.0 Hz, 1H), 6.10 (s, 2H).	582.05	E	






I-1171		FC(F)c1cc(F)cc(c1)C(=O)Nc1cc(cc2C(=O)N[C@H](c12)c1cc(F)ccc1Cl)-c1ccc2ncnn2c1	1H NMR (400 MHz, DMSO-d6) 10.55 (s, 1H), 9.48 (s, 2H), 9.26 (s, 1H), 8.58 (d, 1.3 Hz, 1H), 8.14 (d, 10.2 Hz, 2H), 8.02 - 7.94 (m, 1H), 7.70 (d, 2.1 Hz, 1H), 7.68 (s, 2H), 7.58 (d, 9.3 Hz, 1H), 7.36 (dd, 9.0, 5.1 Hz, 1H), 7.12 (d, 5.7 Hz, 2H), 6.73 (s, 1H) ,6.10 (s, 1H).	566.15	B	
I-1172		FC(F)c1cc(F)cc(c1)C(=O)Nc1cc(cc2C(=O)N[C@@H](c12)c1cc(F)ccc1Cl)-c1ccc2ncnn2c1	1H NMR (400 MHz, DMSO-d6) 10.55 (s, 1H), 9.48 (s, 1H), 9.25 (s, 1H), 8.58 (s, 1H), 8.14 (d, 10.1 Hz, 2H), 8.02 - 7.94 (m, 2H), 7.69 (d, 9.4 Hz, 2H), 7.58 (d, 9.2 Hz, 1H), 7.36 (dd, 8.9, 5.1 Hz, 1H), 7.12 (d, 8.0 Hz, 2H), 6.73 (s, 1H), 6.09 (s, 1H).	566.2	E	
I-1173		Fc1ccc(Cl)c(c1)[C@@H]1NC(=O)c2cc(cc(NC(=O)c3cc(F)c(F)c(Cl)c3)c12)-c1ccc2ncnn2c1	1H NMR (400 MHz, DMSO-d6) 10.49 (s, 1H), 9.47 (t, 1.4 Hz, 1H), 9.28-9.23 (m, 1H), 8.58 (s, 1H), 8.17-8.10 (m, 2H), 8.02-7.94 (m, 2H), 7.75-7.66 (m, 1H), 7.63 (dt, 6.1, 1.9 Hz, 1H), 7.39 (dd, 8.9, 5.2 Hz, 1H), 7.16 (td, 8.4, 3.1 Hz, 1H), 6.65 (s, 1H), 6.07 (s, 1H).	568.1	A	
I-1174		Fc1ccc(Cl)c(c1)[C@H]1NC(=O)c2cc(cc(NC(=O)c3cc(F)c(F)c(Cl)c3)c12)-c1ccc2ncnn2c1	1H NMR (400 MHz, DMSO-d6) 10.49 (s, 1H), 9.47 (t, 1.4 Hz, 1H), 9.28-9.23 (m, 1H), 8.58 (s, 1H), 8.17-8.10 (m, 2H), 8.02-7.94 (m, 2H), 7.75-7.66 (m, 1H), 7.63 (dt, 6.1, 1.9 Hz, 1H), 7.39 (dd, 8.9, 5.2 Hz, 1H), 7.16 (td, 8.4, 3.1 Hz, 1H), 6.65 (s, 1H), 6.07 (s, 1H).	568.1	D	





I-1175		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)C1CC(C1)C#N	NMR (400 MHz, CD3CN) 8.64 (s,1H), 7.68-7.56 (m, 4H), 7.42 (d, 6.9 Hz,1H), 7.30-7.22 (m, 2H), 7.02-6.92 (m,1H), 6.60 (br, s,1H), 6.09 (br, s, 1H), 3.78-3.67 (m,1H), 3.31-3.19 (m,1H), 2.88-2.80 (m,1H), 2.78-2.70 (m,1H), 2.69-2.59 (m,1H), 2.56-2.44 (m,1H).	546.3	A	
I-1176		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(NC(=O)Nc3cc(ccc3Cl)C(F)(F)F)c12	(400 MHz, DMSO-d6) 9.27 (s, 1H), 9.09 (s, 1H), 8.46 (s, 1H), 8.35 (d, 1.9 Hz, 1H), 7.74-7.66 (m, 3H), 7.46-7.36 (m, 2H), 7.17 (dt, 8.6, 2.3 Hz, 1H), 6.71 (br s, 1H), 6.06 (br s, 1H) .	574.2	B	
I-1177		Fc1cc(cc(c1)C(F)(F)F)C(=O)Nc1ccc2C(NC(=O)Cc2c1)c1ccccc1Cl	NMR (400 MHz, DMSO) 10.56 (s, 1H), 8.45 (d, 2.3 Hz, 1H), 8.16 (s, 1H), 8.10 (d, 9.1 Hz, 1H), 7.98 (d, 8.5 Hz, 1H), 7.67 (d, 2.0 Hz, 1H), 7.53 (dd, 8.5, 2.1 Hz, 1H), 7.51-7.47 (m, 1H), 7.36-7.26 (m, 3H), 7.00 (d, 8.6 Hz, 1H), 6.07 (d, 1.7 Hz, 1H), 3.79 (d, 20.4 Hz, 1H), 3.61 (d, 19.6 Hz, 1H).	463.1	D	
I-1178		Fc1cc(cc(c1)C(F)(F)F)C(=O)Nc1ccccc2CC(=O)NC(c3ccccc3Cl)c12	NMR (400 MHz, DMSO) 10.18 (s, 1H), 8.59 (d, 3.8 Hz, 1H), 7.98-7.91 (m, 2H), 7.87 (d, 9.0 Hz, 1H), 7.40 (t, 7.7 Hz, 1H), 7.31-7.25 (m, 2H), 7.20 (td, 7.6, 1.7 Hz, 1H), 7.18-7.09 (m, 2H), 6.90 (dd, 7.7, 1.4 Hz, 1H), 6.23 (d, 3.7 Hz, 1H), 3.90 (d, 20.6 Hz, 1H), 3.62 (d, 20.7 Hz, 1H).	463.1	D	





I-1179		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(NC(=O)C34CC5CC(CC(Cl)(C5)C3)C4)c12	1H-NMR (400 MHz, DMSO-d6) 9.38 (s, 1H), 9.24 (br. s, 1H), 7.72 (d, 1.7 Hz, 1H), 7.58 (d, 1.7 Hz, 1H), 7.55-7.47 (m, 1H), 7.25 (ddd, 8.8, 8.1, 3.1 Hz, 1H), 6.52 (br. s, 1H), 6.00 (br. s, 1H), 2.15-2.09 (m, 2H), 2.06-1.99 (m, 2H), 1.95-1.85 (m, 3H), 1.81-1.75 (m, 1H), 1.61-1.55 (m, 1H), 1.52-1.40 (m, 5H).	551.3	A	
I-1180		Fc1ccc(Cl)c(c1)C1NC(=O)c2cccc(NC(=O)C34CC5CC(F)(CC(F)(C5)C3)C4)c12	1H-NMR (400 MHz, DMSO-d6) 9.45 (s, 1H), 9.11 (br. s, 1H), 7.63 (d, 6.8 Hz, 1H), 7.58 (t, 7.6 Hz, 1H), 7.56-7.49 (m, 1H), 7.39-7.35 (m, 1H), 7.25 (app. td, 8.4, 3.0 Hz, 1H), 6.38 (br. s, 1H), 6.01 (br. s, 1H), 2.42-2.35 (m, 1H), 2.07-1.99 (m, 1H), 1.94-1.87 (m, 1H), 1.81-1.73 (m, 2H), 1.71-1.59 (m, 5H), 1.58-1.52 (m, 1H), 1.42-1.29 (m, 2H).	473.4	B	
I-1181		OC1(CNc2cc3C(=O)NC(c3c(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c2)c2cc(F)ccc2Cl)CC1	(400 MHz, CD3CN) 8.48 (s, 1 H), 7.63 (d, 8.4 Hz, 1 H), 7.57 (d, 9.0 Hz, 1 H), 7.54 (s, 1 H), 7.23 (dd, 8.9, 5.1 Hz, 1 H), 7.09 (s, 1 H), 6.98-6.91 (m, 2 H), 6.86 (d, 1.9 Hz, 1 H), 6.64 (br s, 1 H), 5.98 (br s, 1 H), 5.08 (t, 5.5 Hz, 1 H), 3.60 (br s, 1 H), 3.28 (d, 5.6 Hz, 2 H), 0.73 - 0.69 (m, 2 H), 0.63 - 0.59 (m, 2 H). Contains small grease peaks at 0.86 and 1.27 .	552.4	A	





I-1182		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(NC(=O)C34C5C6C7C5C3C7C46)c12	1H-NMR (400MHz, DMSO-d6) 9.44 (s, 1H), 9.22 (br. s, 1H), 7.71 (d, 1.5 Hz, 1H), 7.62 (d, 1.7 Hz, 1H), 7.52-7.43 (m, 1H), 7.24 (app. td, 8.4, 3.1 Hz, 1H), 6.69 (br. s, 1H), 5.97 (br. s, 1H), 3.94-3.90 (m, 4H), 3.89-3.84 (m, 3H).	485.3	D	
I-1183		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(NC(=O)C34CC5CC(C3)CC(C5)(C4)C(F)(F)F)c12	1H-NMR (400 MHz, DMSO-d6) 9.44 (s, 1H), 9.25 (br. s, 1H), 7.72 (d, 1.6 Hz, 1H), 7.57 (d, 1.7 Hz, 1H), 7.52-7.44 (m, 1H), 7.22 (app. td, 8.4, 3.1 Hz, 1H), 6.48 (br. s, 1H), 5.99 (br. s, 1H), 2.11-2.04 (m, 2H), 1.69-1.62 (m, 2H), 1.61-1.41 (m, 9H), 1.38-1.32 (m, 1H).	585.3	A	
I-1184		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(OC3CCOC3)cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	NMR (400 MHz, DMSO) 10.49 (br s, 1H), 9.14 (br s, 1H), 7.94 (d, 8.1 Hz, 1H), 7.71 (d, 9.0 Hz, 1H), 7.63 (s, 1H), 7.31 (dd, 8.9, 5.2 Hz, 1H), 7.18 (s, 1H), 7.09 (td overlapped with s, 8.2, 2.9 Hz, 1H), 7.06 (s overlapped with td, 1H), 6.64 (br s, 1H), 5.93 (br s, 1H), 5.20 (m, 1H), 3.90 (m, 3H), 3.79 (td, 8.4, 4.6 Hz, 1H), 2.34-2.21 (m, 1H), 2.09-1.97 (m, 1H).	553	A	
I-1185		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)C#Cc1ccccn1	NMR (400 MHz, DMSO-d6) 10.53 (br. s, 1H), 9.31 (s, 1H), 8.65 (ddd, 4.8, 1.7, 0.9 Hz, 1H), 7.96 (br. d, 8.5 Hz, 1H), 7.90 (td, 7.7, 1.8 Hz, 1H), 7.85 (d, 0.9 Hz, 1H), 7.77-7.70 (m, 3H), 7.67 (s, 1H), 7.46 (ddd, 7.6, 4.9, 1.2 Hz, 1H), 7.34 (dd, 8.9, 5.2 Hz, 1H), 7.11 (td, 8.4, 3.0 Hz,	568.3	A	





			1H), 6.74 (br. s, 1H), 6.03 (br. s, 1H).			
I-1186		CCCCC(C)(O)c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	NMR (400 MHz, DMSO-d6) 10.53 (s, 1H), 9.09 (s, 1H), 7.93 (br. d, 8.4 Hz, 1H), 7.76 (br. d, 8.9 Hz, 1H), 7.73-7.70 (m, 1H), 7.68 (s, 1H), 7.54 (s, 1H), 7.31 (dd, 8.9, 5.2 Hz, 1H), 7.09 (td, 8.4, 3.0 Hz, 1H), 6.57 (br. s, 1H), 5.93 (br. s, 1H), 5.14 (s, 1H), 1.81-1.64 (m, 2H), 1.50 (s, 3H), 1.33-1.12 (m, 3H), 1.05-0.89 (m, 1H), 0.84 - 0.76 (m, 3H).	567.2	A	
I-1187		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)C1CCOCC1	NMR (400 MHz, DMSO-D6) 10.52 (br s, 1H), 9.12 (br s, 1H), 7.94 (d, 9.2 Hz, 1H), 7.74 (d, 8.3 Hz, 1H), 7.66 (s, 1H), 7.57 (s, 1H), 7.38 (s, 1H), 7.30 (dd, 8.8, 5.2 Hz, 1H), 7.08 (td, 8.2, 2.6 Hz, 1H), 6.61 (br s, 1H), 5.97 (br s, 1H), 3.98 (dd, 11.1, 3.6 Hz, 2H), 3.47 (t, 11.5 Hz, 2H), 3.01-2.95 (m, 1H), 1.89-1.56 (m, 4H).	551.3	A	
I-1188		CC(O)(c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl)c1ccccn1	NMR (400 MHz, DMSO-d6) 10.50 (br. s, 1H), 9.10 (s, 1H), 8.55 - 8.50 (m, 1H), 7.93 (br. d, 8.5 Hz, 1H), 7.82-7.77 (m, 2H), 7.76-7.70 (m, 2H), 7.64 (s, 1H), 7.60 (s, 1H), 7.31-7.22 (m, 2H), 6.55 (br. s, 1H), 6.25 (s, 1H), 5.90 (br. s, 1H), 1.94 (s, 3H).	588.2	A	





I-1189		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)N1CCOc2ccccc12		600.38	A	
I-1190		Cc1cnc2ccc(nn12)-c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl		598.38	A	
I-1191		CC(C)(O)C#Cc1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl		549.4	A	
I-1192		O[C@@H]1COC[C@H]1Oc1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl		569.4	A	
I-1193		Cn1ccnc1-c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	(400 MHz, DMSO-d6) 9.15 (s, 1H), 8.51 (s, 1H), 8.08 (br s, 1H), 7.87-7.70 (m, 4H), 7.35 (dd, 8.8, 5.2 Hz, 1H), 7.31 (s, 1H), 7.09 (td, 8.4, 2.9 Hz, 1H), 7.03 (s, 1H), 6.70 (br s, 1H), 6.04 (s, 1H), 3.85 (s, 3H)	547.2	B	





I-1194		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)C#CC1CC(F)(F)C1		581.5	B	
I-1195		CS(=O)(=O)c1ccccc1-c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	1H NMR (400 MHz, DMSO-d6) 2.97 (s, 3 H) 6.05 (br s, 1 H) 7.11 (td, 8.34, 3.03 Hz, 1 H) 7.34 (dd, 8.97, 5.18 Hz, 1 H) 7.46 - 7.54 (m, 2 H) 7.63 - 7.83 (m, 5 H) 7.93 (br d, 8.34 Hz, 1 H) 8.13 (dd, 7.83, 1.26 Hz, 1 H) 9.25 (br s, 1 H) 10.62 (s, 1 H)	621.34	A	
I-1196		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)C1CS(=O)(=O)C1	1H NMR (500 MHz, DMSO-d6) 4.04 - 4.14 (m, 1 H) 4.32 - 4.49 (m, 2 H) 4.62 - 4.73 (m, 2 H) 5.98 (br d, 1.98 Hz, 1 H) 6.73 - 6.89 (m, 1 H) 7.09 (td, 8.39, 2.90 Hz, 1 H) 7.31 (dd, 8.85, 5.19 Hz, 1 H) 7.51 - 7.57 (m, 1 H) 7.67 (s, 1 H) 7.71 - 7.81 (m, 2 H) 7.94 (br d, 8.24 Hz, 1 H) 9.17 (br s, 1 H) 10.59 (br s, 1 H)	571.32	A	
I-1197		COc1ccccc1-c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	1H NMR (500 MHz, DMSO-d6) 3.81 (s, 3 H) 6.02 (br s, 1 H) 7.04 - 7.14 (m, 2 H) 7.18 (d, 8.24 Hz, 1 H) 7.32 (dd, 8.85, 5.19 Hz, 1 H) 7.36 - 7.44 (m, 2 H) 7.60 (s, 1 H) 7.67 (s, 1 H) 7.70 - 7.80 (m, 2 H) 7.93 (br d, 8.24 Hz, 1 H) 9.16 (br s, 1 H) 10.51 (s, 1 H)	573.37	B	




I-1198		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(OC3CCC3(F)F)cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	1H NMR (400 MHz, DMSO) 10.55 (br. s, 1H), 9.24 (s, 1H), 7.95 (d, 8.2 Hz, 1H), 7.72 (d, 9.7 Hz, 1H), 7.64 (s, 1H), 7.43 (s, 1H), 7.37-7.26 (m, 2H), 7.09 (td, 8.5, 3.1 Hz, 1H), 6.61 (submerged br. s, 1H), 6.43 (ddd, 59.9, 16.9, 11.9 Hz, 1H), 5.96 (s, 1H), 1.37-1.14 (m, 2H), 1.15-0.99 (m, 2H)	573.2	A	
I-1199		Cn1ccnc1C(C)(O)c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	NMR (400 MHz, DMSO-d6) 10.56 (br. s, 1H), 9.13 (br. s, 1H), 8.26 (s, 1H), 7.92 (br. d, 8.3 Hz, 1H), 7.72 (app. t, 8.4 Hz, 1H), 7.64-7.59 (m, 1H), 7.43 (s, 1H), 7.30 (dd, 8.9, 5.2 Hz, 1H), 7.11-7.04 (m, 2H), 6.85-6.82 (m, 1H), 6.43 (br. s, 1H), 5.93 (br. s, 1H), 3.33 (s, 3H), 1.90 (s, 3H).	591.2	A	
I-1200		OC(Cc1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl)C(F)(F)F	NMR (400 MHz, DMSO-d6) 10.50 (br s, 1H), 9.12 (br s, 1H), 7.94 (d, 8.3 Hz, 1H), 7.74 (d, 8.7 Hz, 1H), 7.70-7.63 (m, 2H), 7.43 (s, 1H), 7.31 (dd, 8.9, 5.1 Hz, 1H), 7.10 (td, 8.9, 2.1 Hz, 1H), 6.65 (submerged br s, 1H), 6.35 (br s, 1H), 5.94 (br s, 1H), 4.28 (br s, 1H), 3.18-3.03 (m, 1H), 2.97-2.79 (m, 1H).	579.2	A	
I-1201		OC(=O)c1nc(cs1)-c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	NMR (400 MHz, DMSO-d6) 10.65 (br s, 1H), 9.20 (br s, 1H), 8.43 (br s, 1H), 8.26 (s, 1H), 8.18 (s, 1H), 7.94 (dd, 9.0, 1.2 Hz, 1H), 7.79 (dd, 9.0, 1.2 Hz, 1H), 7.72 (br s, 1H), 7.32 (dd, 9.0, 5.1 Hz, 1H), 7.17 (br s, 1H), 7.13-7.05 (m, 1H), 6.03 (br s, 1H).	594.1	A	






I-1202		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Oc3ncccn3)cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	NMR (400 MHz, DMSO-d6) 10.56 (s, 1H), 9.27 (s, 1H), 8.71 (d, 4.8 Hz, 2 X 1H), 7.95 (dt, 8.4, 2.0 Hz, 1H), 7.72 (br. d, 9.2 Hz, 1H), 7.64 (s, 1H), 7.52 (d, 1.9 Hz, 1H), 7.37 (s, 1H), 7.36-7.32 (m, 2H), 7.12 (td, 8.5, 3.1 Hz, 1H), 6.69 (br. s, 1H), 6.00 (br. s, 1H).	561.1	B	
I-1203		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(NC(=O)C34CC5CC(C3)C(F)(F)C(C5)C4)c12	1H-NMR (400 MHz, DMSO-d6) 9.42 (s, 1H), 9.25 (br. s, 1H), 7.72 (d, 1.6 Hz, 1H), 7.59 (d, 1.7 Hz, 1H), 7.55-7.45 (m, 1H), 7.25 (app. td, 8.4, 3.0 Hz, 1H), 6.56 (br. s, 1H), 5.99 (br. s, 1H), 2.18-2.10 (m, 2H), 1.92-1.86 (m, 1H), 1.79-1.66 (m, 3H), 1.65-1.57 (m, 5H), 1.56-1.51 (m, 2H).	555.2	B	
I-1204		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(NC(=O)C3(CC3)C(F)(F)F)c12	1H-NMR (400 MHz, DMSO-d6) 9.51 (br. s, 1H), 9.25 (s, 1H), 7.75 (s, 1H), 7.62 (s, 1H), 7.55-7.44 (m, 1H), 7.25 (app. td, 8.5, 3.1 Hz, 1H), 6.55 (br. s, 1H), 5.90 (br. s, 1H), 1.22-1.08 (m, 3H), 0.81-0.73 (m, 1H).	493.1	E	
I-1205		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(OC3CN(C3)C#N)cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	NMR (400 MHz, DMSO) 10.47 (s, 1H), 9.17 (s, 1H), 7.95 (d, 8.5 Hz, 1H), 7.70 (d, 9.6 Hz, 1H), 7.62 (s, 1H), 7.31 (dd, 8.9, 5.2 Hz, 1H), 7.09 (td, 8.5, 3.3 Hz, 1H), 7.02 (s, 2H), 5.92 (s, 1H), 5.27-5.20 (m, 1H), 4.68-4.64 (m, 2H), 4.24 (m, 2H). B-pocket ortho proton missing. By LC, approx. 12-13% impurity which is oxidized product.	563	A	





I-1206		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(NC(=O)Oc3ccc4CCNc4n3)c12	1H NMR (400 MHz, DMSO-d6) 10.65 (s, 1H), 9.26 (s, 1H), 7.89 (s, 1H), 7.71 (s, 1H), 7.47 (d, 8.0 Hz, 1H), 7.29 (dd, 9.0, 5.1 Hz, 1H), 7.04 (t, 8.5 Hz, 1H), 6.18 (d, 8.1 Hz, 2H), 3.92 (q, 9.3 Hz, 1H), 3.80 (q, 10.3, 9.6 Hz, 1H), 2.89 (t, 8.6 Hz, 2H).	517.1	E	
I-1207		Fc1ccc(Cl)c(c1)[C@H]1NC(=O)c2cc(cc(NC(=O)c3cc(Cl)cc(Cl)c3)c12)-c1ccc2nccnn2c1	1H NMR (400 MHz, DMSO-d6) 10.51 (s, 1H), 9.47 (dd, 1.9, 1.0 Hz, 1H), 9.25 (s, 1H), 8.58 (s, 1H), 8.13 (dd, 9.1, 1.8 Hz, 2H), 8.03 - 7.93 (m, 2H), 7.86 (t, 1.9 Hz, 1H), 7.57 (d, 1.9 Hz, 2H), 7.40 (dd, 8.9, 5.1 Hz, 1H), 7.17 (td, 8.3, 3.0 Hz, 1H), 6.71 (s, 1H), 6.08 (s, 1H).	565.8	D	
I-1208		Fc1ccc(Cl)c(c1)[C@@H]1NC(=O)c2cc(cc(NC(=O)c3cc(Cl)cc(Cl)c3)c12)-c1ccc2nccnn2c1	1H NMR (400 MHz, DMSO-d6) 10.51 (s, 1H), 9.47 (dd, 1.9, 0.9 Hz, 1H), 9.25 (s, 1H), 8.58 (s, 1H), 8.13 (dd, 9.2, 1.8 Hz, 2H), 8.03 - 7.93 (m, 2H), 7.86 (t, 1.9 Hz, 1H), 7.57 (d, 1.9 Hz, 2H), 7.40 (dd, 8.9, 5.1 Hz, 1H), 7.17 (td, 8.4, 3.0 Hz, 1H), 6.08 (s, 1H).	565.95	A	
I-1209		Cn1c(Cl)cc(cc1=O)C(=O)Nc1cc(Br)cc2C(=O)NC(c12)c1cc(F)ccc1Cl	1H NMR (400 MHz, DMSO-d6) 10.44 (s, 1H), 9.30 (s, 1H), 7.82 (d, 1.7 Hz, 1H), 7.71 (d, 1.6 Hz, 1H), 7.43 (d, 8.2 Hz, 1H), 7.19 (td, 8.5, 8.1, 2.8 Hz, 1H), 6.86 (s, 1H), 6.47 (q, 1.9 Hz, 2H), 5.97 (s, 1H), 3.57 (d, 1.3 Hz, 3H)	525.85	E	






I-1210		O[C@@H]1CC[C@@H]1Oc1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	1H NMR (400 MHz, DMSO-d6) 10.45 (s, 1H), 9.11 (s, 1H), 7.94 (d, 8.4 Hz, 1H), 7.71 (d, 8.2 Hz, 1H), 7.62 (s, 1H), 7.31 (dd, 8.5, 5.0 Hz, 1H), 7.11 (d, 2.2 Hz, 1H), 7.07 (td, 8.5, 2.9 Hz, 1H), 7.04 (br. s, 1H), 6.49 (br. s, 1H), 5.92 (br. s, 1H), 5.23 (t, 7.35 Hz, 1H), 4.88-4.72 (m, 1H), 4.44 (br. s, 1H), 2.23-2.02 (m, 3H), 2.01-1.86 (m, 1H);	553.2	A	
I-1211		CC(O)(C#N)c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	(400 MHz, DMSO-d6) 10.56 (s, 1H), 9.16 (s, 1H), 7.94 (d, 8.4 Hz, 1H), 7.84 (s, 1H), 7.75 (d, 9.0 Hz, 1H), 7.68 (s, 2H), 7.31 (dd, 8.8, 5.2 Hz, 1H), 7.10 (td, 8.4, 3.0 Hz, 1H), 6.58 (br s, 1H), 6.08 (s, 1H), 5.96 (br s, 1H), 3.14-3.07 (m, 2H), 1.63 (s, 3H)	550.2	A	
I-1212		Fc1cc(cc(c1)C(F)(F)F)C(=O)Nc1ccc2NC(=O)NC(c3ccccc3Cl)c12	NMR (400 MHz, DMSO) 10.15 (s, 1H), 9.49 (d, 1.7 Hz, 1H), 8.00-7.91 (m, 2H), 7.89 (d, 9.2 Hz, 1H), 7.55-7.49 (m, 2H), 7.31-7.23 (m, 2H), 7.23-7.16 (m, 2H), 7.06 (dd, 5.9, 3.5 Hz, 1H), 6.89 (d, 7.3 Hz, 1H), 6.80 (d, 7.8 Hz, 1H), 6.14 (d, 3.0 Hz, 1H).	464.1	D	
I-1213		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Nc3ccccc3)cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12		558.36	A	





I-1214		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1cccnc1C#N		569.31	A	
I-1215		NC(=O)c1cnccc1-c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl		587.27	B	
I-1216		OC(=O)c1ccccc1-c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	1H NMR (500 MHz, DMSO-d6) 5.95 - 6.11 (m, 1 H) 7.10 (td, 8.32, 2.90 Hz, 1 H) 7.33 (dd, 8.85, 5.04 Hz, 1 H) 7.44 - 7.53 (m, 3 H) 7.56 - 7.63 (m, 2 H) 7.66 (s, 1 H) 7.76 (br dd, 15.49, 8.32 Hz, 2 H) 7.93 (br d, 8.39 Hz, 1 H) 9.18 (br s, 1 H) 10.58 (s, 1 H)	587.37	B	
I-1217		OC(=O)c1cnccc1-c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	1H NMR (500 MHz, DMSO-d6) 5.96 - 6.12 (m, 1 H) 7.10 (td, 8.32, 2.90 Hz, 1 H) 7.33 (dd, 8.85, 5.19 Hz, 1 H) 7.49 - 7.57 (m, 5 H) 7.58 - 7.68 (m, 6 H) 7.74 (br d, 8.39 Hz, 1 H) 7.93 (br d, 8.39 Hz, 1 H) 8.75 (d, 5.04 Hz, 1 H) 8.90 - 8.95 (m, 1 H) 9.23 (br s, 1 H) 10.62 (s, 1 H)	588.32	B	





I-1218		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)C1CCCN1	1H NMR (500 MHz, DMSO-d6) 1.54 - 1.65 (m, 1 H) 1.73 - 1.93 (m, 2 H) 2.25 (quind, 7.78, 7.78, 7.78, 7.78, 4.43 Hz, 1 H) 2.96 - 3.13 (m, 3 H) 4.25 - 4.34 (m, 1 H) 5.95 (br s, 1 H) 7.01 - 7.14 (m, 1 H) 7.29 (ddd, 8.66, 5.23, 1.68 Hz, 1 H) 7.51 (br d, 9.77 Hz, 1 H) 7.61 - 7.78 (m, 3 H) 7.92 (br d, 7.93 Hz, 1 H) 8.24 (s, 1 H) 9.08 (br s, 1 H) 10.50 (br d, 3.97 Hz, 1 H)	536.45	A	
I-1219		COc1cnccc1-c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	1H NMR (500 MHz, DMSO-d6) 3.95 (s, 3 H) 6.04 (br s, 1 H) 7.10 (td, 8.35, 2.98 Hz, 1 H) 7.33 (dd, 8.93, 5.11 Hz, 1 H) 7.47 (d, 4.88 Hz, 1 H) 7.57 - 7.65 (m, 1 H) 7.65 - 7.76 (m, 3 H) 7.88 (s, 1 H) 7.94 (br d, 8.39 Hz, 1 H) 8.33 (d, 4.88 Hz, 1 H) 8.54 (s, 1 H) 9.22 (br s, 1 H) 10.57 (s, 1 H)	574.37	A	
I-1220		OC(=O)Cc1ccncc1-c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	1H NMR (500 MHz, DMSO-d6) 2.33 (s, 2 H) 5.94 - 6.13 (m, 1 H) 7.11 (td, 8.35, 2.98 Hz, 1 H) 7.34 (dd, 8.85, 5.34 Hz, 1 H) 7.37 - 7.40 (m, 1 H) 7.51 (s, 1 H) 7.65 - 7.69 (m, 2 H) 7.74 (br d, 8.85 Hz, 1 H) 7.94 (br d, 8.39 Hz, 1 H) 8.45 - 8.51 (m, 2 H) 9.23 (br s, 1 H) 10.56 (s, 1 H)	602.33	A	





I-1221		Cn1ncnc1COc1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	1H NMR (DMSO-d6, 400 MHz):-′ = 10.48 (s, 1H), 9.15 (br s, 1H), 7.97 (s, 1H), 7.92-7.96 (m, 1H), 7.71 (br d, 9.1 Hz, 1H), 7.63 (s, 1H), 7.43 (d, 2.0 Hz, 1H), 7.31 (dd, 8.8, 5.1 Hz, 1H), 7.17 (d, 1.8 Hz, 1H), 7.09 (td, 8.3, 3.0 Hz, 1H), 5.92 (br s, 1H), 5.46 (d, 2.0 Hz, 2H), 3.94 (s, 3H)	578.1	A	
I-1222		CN(C)c1ncc(cn1)-c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	1H NMR (DMSO-d6, 400 MHz): 10.59 (s, 1H), 9.19 (br s, 1H), 8.80 (s, 2H), 7.91-7.98 (m, 2H), 7.72-7.78 (m, 2H), 7.69 (s, 1H), 7.32 (dd, 8.8, 5.1 Hz, 1H), 7.10 (td, 8.3, 3.3 Hz, 1H), 5.99 (br s, 1H), 3.19 (s, 6H), 2.84-3.07 (m, 1H)	588.1	A	
I-1223		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)C#CC1COC1		547.4	A	
I-1224		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)C#Cc1ccncc1		568.4	A	
I-1225		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)C#		568.1	A	





		Cc1cccnc1				
I-1226		Fc1ccc(Cl)c(c1)C1NC(=O)c2nc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1ccc2ncnn2c1		585.4	A	
I-1227		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)N1CCCc2nccc12	1H NMR (400 MHz, DMSO-d6) 2.06 (quin, 6.13 Hz, 2 H) 2.92 (t, 6.57 Hz, 2 H) 3.63 - 3.76 (m, 2 H) 5.84 - 6.14 (m, 1 H) 7.00 (dd, 8.08, 4.55 Hz, 1 H) 7.09 (td, 8.46, 3.03 Hz, 1 H) 7.16 (br d, 7.58 Hz, 1 H) 7.28 - 7.38 (m, 2 H) 7.46 (d, 1.77 Hz, 1 H) 7.62 (s, 1 H) 7.70 (br d, 9.09 Hz, 1 H) 7.87 - 7.99 (m, 2 H) 9.15 (br s, 1 H) 10.46 (s, 1 H)	599.33	A	
I-1228		CS(=O)(=O)N1CC(C1)c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	1H NMR (400 MHz, DMSO-d6) 3.09 (s, 3 H) 3.92 - 4.09 (m, 3 H) 4.25 - 4.33 (m, 2 H) 5.98 (br s, 1 H) 7.09 (td, 8.34, 3.03 Hz, 1 H) 7.31 (dd, 8.97, 5.18 Hz, 1 H) 7.52 (s, 1 H) 7.66 (s, 1 H) 7.70 - 7.77 (m, 2 H) 7.95 (br d, 8.34 Hz, 1 H) 9.16 (br s, 1 H) 10.55 (s, 1 H)	600.33	A	
I-1229		Fc1ccc(Cl)c(c1)[C@@H]1NC(=O)c2nc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1ccc2ncnn2c1		585.4	A	





I-1230		Fc1ccc(Cl)c(c1)[C@H]1NC(=O)c2nc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1ccc2nnn2c1		585.4	B	
I-1231		Fc1ccc(Cl)c(c1)[C@H]1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1ccncc1C#N			C	
I-1232		Fc1ccc(Cl)c(c1)[C@@H]1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1ccncc1C#N		569.08	A	
I-1233		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-n1cnc2nccccc12		584.32	A	
I-1234		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(OCCCC=C)cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	1H NMR (400 MHz, DMSO-d6) 10.43 (s, 1H), 9.12 (br. s, 1H), 7.94 (d, 8.4 Hz, 1H), 7.71 (d, 9.2 Hz, 1H), 7.63 (s, 1H), 7.31 (dd, 8.7, 5.2 Hz, 1H), 7.18 (d, 1.8 Hz, 1H), 7.14-7.01 (m, 2H), 6.63 (br. s, 1H), 5.89 (ddt, 17.0,	551.2	C	





			10.3, 6.6 Hz, 2H), 5.08 (ddd, 17.3, 3.4, 1.7 Hz, 1H), 5.01 (ddd, 10.3, 3.0, 1.4 Hz, 1H), 4.22-3.98 (m, 2H), 2.21 (dd, 14.5, 6.7 Hz, 2H), 1.92-1.80 (m, 1H).			
I-1235		CN1CCN(Cc2cc3C(=O)NC(c3c(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c2)c2cc(F)ccc2Cl)CC1=O	NMR (400 MHz, CD3CN) 8.73 (s, 1H), 7.72-7.50 (m, 5H), 7.28 (s, 1H), 7.24 (dd, 8.9, 5.1 Hz, 1H), 6.96 (ddd, 8.8, 8.1, 3.1 Hz, 1H), 6.61 (br, s, 1H), 6.11 (br, s, 1H), 3.70 (s, 2H), 3.32-3.27 (m,, 2H), 3.04 (s, 2H), 2.86 (s, 3H), 2.75-2.70 (m, 2H).	593.3	B	
I-1236		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)N1CCn2ccnc2C1	(400 MHz, CD3CN) 8.83 (s, 1 H), 8.08 (s, 1 H), 7.66 - 7.55 (m, 4 H), 7.37 - 7.17 (m, 4 H), 6.95 (td, 8.4, 2.9 Hz, 1 H), 6.63 (br s, 1 H), 6.04 (br s, 1 H), 4.55 (app d, 9.3 Hz, 2 H), 4.20 - 4.12 (m, 2 H), 3.83 (t, 5.1 Hz, 2 H).	586.3	A	
I-1237		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)N1CCn2cncc2C1	(400 MHz, CD3CN) 8.66 (s, 1 H), 8.09 (s, 1 H), 7.67 - 7.56 (m, 4 H), 7.32 (d, 2.0 Hz, 1 H), 7.26-7.17 (m, 3 H), 6.95 (td, 8.4, 3.0 Hz, 1 H), 6.64 (br s, 1 H), 6.04 (br s, 1 H), 4.57 (s, 2 H), 4.19 (t, 5.2 Hz, 2 H), 3.80 (t, 5.3 Hz, 2 H).	588.3	A	
I-1238		COC(=O)c1cc(Nc2cccc3C(=O)NC(c23)c2cc(F)ccc2Cl)ncc1C(F)(F)F	(400 MHz, CD3CN) 8.88 (s, 1 H), 8.61 (s, 1 H), 7.78-7.71 (m, 1 H), 7.49 (br s, 1 H), 7.46 (dd, 5.0, 1.8 Hz, 1 H), 7.37 (t, 7.6 Hz, 1 H), 7.30 (d, 7.3 Hz, 1 H), 7.01 (app t, 7.0 Hz, 1 H), 6.94 (d, 7.8 Hz, 1 H), 6.85 (br s, 1 H), 6.65 (br s, 1 H), 4.19 (s, 1 H), 3.93 (s, 3 H).	480.3	D	





I-1239		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(OC3CCCOC3)cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	1H NMR (400 MHz, DMSO-d6) 10.43 (br. s, 1H), 9.13 (br. s, 1H), 7.94 (d, 8.5 Hz, 1H), 7.71 (d, 9.1 Hz, 1H), 7.63 (s, 1H), 7.31 (dd, 8.9, 5.2 Hz, 1H), 7.22 (d, 1.2 Hz, 1H), 7.13-7.03 (m, 2H), 6.64 (br. s, 1H), 5.91 (br. s, 1H), 4.64-4.43 (m, 1H), 3.84 (dd, 11.6, 2.4 Hz, 1H), 3.68-3.49 (m, 3H), 2.05 (m, 1H), 1.88-1.68 (m, 2H), 1.64-1.47 (m, 1H)	567.3	A	
I-1240		Cc1cc(=O)[nH]cc1C(=O)Nc1cc(Br)cc2C(=O)NC(c12)c1cc(F)ccc1Cl	1H NMR (400 MHz, DMSO-d6) 11.75 (s, 1H), 10.06 (s, 1H), 9.26 (s, 1H), 7.75 (d, 1.7 Hz, 1H), 7.64 (s, 1H), 7.46 (dd, 8.8, 5.1 Hz, 1H), 7.21 (ddd, 8.9, 7.9, 3.1 Hz, 1H), 6.89 (s, 1H), 6.65 (s, 1H), 6.16 (s, 1H), 5.96 (s, 1H), 2.13 - 2.06 (m, 3H).	489.9	E	
I-1241		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(NC(=O)c3cc(F)cc(COC(F)(F)F)c3)c12	1H NMR (400 MHz, DMSO-d6) 10.40 (s, 1H), 9.28 (s, 1H), 7.81 (d, 1.7 Hz, 1H), 7.74 (d, 1.9 Hz, 1H), 7.57-7.46 (m, 2H), 7.38-7.30 (m, 2H), 7.11 (td, 8.4, 3.1 Hz, 1H), 6.76 (s, 1H), 6.03-5.97 (m, 1H), 5.22 (s, 2H).	575	D	
I-1242		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(NC(=O)c3cc(Cl)cc4OCCNc34)c12	1H NMR (400 MHz, Chloroform-d) 8.46 (s, 1H), 7.92 (d, 1.6 Hz, 1H), 7.55 (dd, 9.0, 4.9 Hz, 1H),7.4-7.3(S,1H), 7.18 (s, 1H), 7.13 (ddd, 8.9, 7.4, 3.0 Hz, 1H), 6.87 (d, 2.3 Hz, 1H), 6.70 (s, 1H), 6.42 (s, 1H), 6.28 (d, 2.3 Hz, 1H), 6.16 (s, 1H), 4.22 (t, 4.5 Hz, 2H), 3.54-3.47 (m, 2H).	551.9	D	





I-1243		OC(CC#N)c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	(400 MHz, DMSO-d6) 10.58 (s, 0.5H), 10.56 (s, 0.5H), 9.16 (s, 1H), 7.96 (s, 0.5H), 7.94 (s, 0.5H), 7.79 (s, 0.5H), 7.77-7.71 (m, 1.5H), 7.66 (s, 1H), 7.59 (s, 0.5H), 7.52 (s, 0.5H), 7.32 (dd, 5.2, 1.4 Hz, 0.5H), 7.30 (dd, 5.2, 1.4 Hz, 0.5H), 7.13-7.06 (m, 1H), 6.55 (br s, 1H), 6.24 (s, 0.5H), 6.22 (s, 0.5H), 5.97 (br s, 1H), 5.12 (q, 5.0 Hz, 0.5H), 5.07 (q, 5.1 Hz, 0.5H), 3.07-2.90 (m, 4H)	536.2	A	
I-1244		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)C#Cc1ccn[nH]1	NMR (400 MHz, ACN-d3) : 8.79 (br. s, 1H), 7.89 (d, 0.8 Hz, 1H), 7.69 (s, 1H), 7.66-7.64 (m, 2H), 7.59 (mt, 1H), 7.57 (s, 1H), 7.41 (br. s, 1H), 7.26 (dd, 8.8, 5.1 Hz, 1H), 6.98 (td, 8.6, 3.0 Hz, 1H), 6.70 (br. s, 1H), 6.57 (s, 1H), 6.15 (br. s, 1H)	557.1	A	
I-1245		Cc1ncc(Nc2cc3C(=O)NC(c3c(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c2)c2cc(F)ccc2Cl)cn1	1H-NMR (400 MHz, DMSO-d6) 10.39 (br. s, 1H), 9.09 (br. s, 1H), 8.78 (s, 1H), 8.60 (s, 2H), 7.94 (br. d, 8.3 Hz, 1H), 7.71 (br. d, 8.9 Hz, 1H), 7.61 (br. s, 1H), 7.31 (dd, 8.9, 5.2 Hz, 1H), 7.23 (d, 2.0 Hz, 1H), 7.19 (d, 1.7 Hz, 1H), 7.11-7.05 (m, 1H), 6.67 (br. s, 1H), 5.93 (br. s, 1H), 2.56 (s, 3H).	574.4	A	
I-1246		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Oc3ncncc3F)cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	NMR (400 MHz, CD3CN) 8.71 (br. s, 1H), 8.61 (d, 2.9 Hz, 1H), 8.51 (d, 1.4 Hz, 1H), 7.66-7.64 (m, 1H), 7.63 (d, 2.1 Hz, 1H), 7.61-7.58 (m, 1H), 7.57 (s, 1H), 7.51 (d, 1.5 Hz, 1H), 7.36 (br. s, 1H), 7.29 (dd, 8.9, 5.1 Hz,	577.3	A	





			1H), 7.00 (ddd, 8.6, 8.2, 3.1 Hz, 1H), 6.73 (br. s, 1H), 6.17 (br. s, 1H)			
I-1247		Cn1cncc1C#Cc1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	NMR (400 MHz, ACN-d3) : 8.80 (br. s, 1H), 7.89 (s, 1H), 7.69 (s, 1H), 7.66 (dt, 24.4, 8.4 Hz, 1H), 7.61-7.58 (m, 2H), 7.57 (s, 1H), 7.43 (br. s, 1H), 7.34 (br. s, 1H), 7.26 (dd, 9.0, 5.0 Hz, 1H), 6.98 (td, 8.7, 3.0 Hz, 1H), 6.69 (br. s, 1H), 6.14 (br. s, 1H), 3.75 (s, 3H).	571.4	A	
I-1248		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)N1CCS(=O)(=O)CC1	(400 MHz, CD3CN) 8.59 (br. s, 1H), 7.64 (br. d, 8.0 Hz, 1H), 7.58 (br. d, 8.0 Hz, 1H), 7.57 (br. s, 1H), 7.32 (d, 2.3 Hz, 1H), 7.25 (dd, 8.9, 5.1 Hz, 1H), 7.17 (d, 2.0 Hz, 2H), 6.96 (td, 8.0, 3.1 Hz, 1H), 6.64 (br. s, 1H), 6.06 (br. s, 1H), 3.97-3.88 (m, 4H), 3.14-3.07 (m, 4H).	600.2	A	
I-1249		CN1CCN(CC1=O)c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	(400 MHz, CD3CN) 8.54 (br. s, 1H), 7.65-7.53 (m, 3H), 7.23-7.19 (m, 2H), 7.13 (s, 1H), 7.05 (d, 2.1 Hz, 1H), 6.93 (ddd, 8.8, 8.0, 3.1 Hz, 1H), 6.60 (br. s, 1H), 6.00 (br. s, 1H), 3.84 (s, 2H), 3.62-3.50 (m, 2H), 3.49-3.39 (m, 2H), 2.93 (s, 3H).	579.4	A	
I-1250		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-n1ccc2nccc2c1=O	(400 MHz, CD3CN) 8.92 (dd, 4.6, 1.7 Hz, 1H), 8.75 (br. s, 1H), 8.60 (dd, 8.0, 1.3 Hz, 1H), 7.80 (d, 1.8 Hz, 1H), 7.71 (s, 1H), 7.65-7.57 (m, 3H), 7.56-7.53 (m, 1H), 7.49 (dd, 8.1, 4.6 Hz, 1H), 7.34 (s, 1H), 7.26 (dd, 8.9, 5.2 Hz, 1H), 7.00-6.94 (m, 1H), 6.82 (d, 7.6 Hz,	611.3	A	





			1H), 6.71 (br. s, 1H), 6.18 (br. s, 1H).			
I-1251		CC(=O)N1CC(C1)Oc1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	NMR (400 MHz, CD3CN) 8.68 (s, 1H), 7.64 (br d, 8.3 Hz, 1H), 7.58 (d overlapped with m, 8.3 Hz, 1H), 7.56 (s, 1H) 7.31 (s, 1H), 7.25 (dd, 8.9, 5.1 Hz, 1H), 7.08 (s, 2H), 6.96 (ddd, 8.8, 8.0, 3.1 Hz, 1H), 6.64 (br s, 1H), 6.07 (br s, 1H), 5.13-5.06 (m, 1H), 4.61-4.53 (m, 1H), 4.33 (dd, 10.5, 6.6 Hz, 1H), 4.16 (ddd, 6.6, 5.6, 2.7 Hz, 1H), 3.88 (dd, 10.6, 3.5 Hz, 1H), 1.81 (s, 3H).	580	B	
I-1252		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(OC3CNC3)cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	NMR (400 MHz, CD3CN) 9.04 (s, 1H), 7.72-7.54 (m, 4H), 7.45 (s, 1H), 7.24 (dd, 8.9, 5.1 Hz, 1H), 7.11 (d, 5.8 Hz, 1H), 6.95 (td, 8.4, 3.0 Hz, 1H), 6.65 (br s, 1H), 6.08 (br s, 1H), 5.30-5.18 (m, 1H), 4.64-4.47 (m, 2H), 4.30-4.10 (m, 2H), 3.89 (dd, 11.8, 5.3 Hz).	538	B	
I-1253		CC(C)Oc1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	1H NMR (400 MHz, DMSO-d6) 10.41 (s, 1H), 9.11 (s, 1H), 7.94 (d, 8.0 Hz, 1H), 7.71 (d, 9.6 Hz, 1H), 7.62 (s, 1H), 7.31 (dd, 8.9, 5.2 Hz, 1H), 7.17 (d, 2.1 Hz, 1H), 7.08 (td, 8.5, 3.1 Hz, 1H), 7.02 (s, 1H), 6.59 (br. s, 1H), 5.92 (br. s, 1H), 4.75 (m, 1H), 1.32 (dd, 6.0, 3.5 Hz, 6H)	525.2	A	
I-1254		CS(C)(=O)=Nc1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c	NMR (400 MHz, DMSO-d6) 10.40 (br. s, 1H), 9.03 (br. s, 1H), 7.93 (br. d, 8.5 Hz, 1H), 7.71 (br. d, 9.0 Hz, 1H), 7.61 (s, 1H), 7.30 (dd, 8.9, 5.2 Hz, 1H), 7.19 (d, 1.8 Hz, 1H), 7.07 (td, 8.4, 3.0	558.2	B	





		1cc(F)ccc1Cl	Hz, 1H), 7.02 (d, 1.8 Hz, 1H), 6.62 (br. s, 1H), 5.89 (br. s, 1H), 3.29 (s, 6H).			
I-1255		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)C1CNCCS1(=O)=O	NMR (400 MHz, CD3CN) 8.71 (br s, 1H), 7.77 (d, 2.6 Hz, 1H), 7.71-7.56 (m, 5H), 7.38-7.29 (m, 1H), 7.25 (dd, 8.9, 5.1 Hz, 1H), 6.97 (td, 8.4, 3.0 Hz, 1H), 6.65 (br s, 1H), 6.14 (br s, 1H), 4.33-4.38 (m, 1H), 3.43-3.51 (m, 3H), 3.24-3.26 (m, 1H), 3.12-3.14 (m, 2H).	600.2	A	
I-1256		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(NC(=O)NC34CC5CC(C3)CC(C5)(C4)C(F)(F)F)c12	1H-NMR (400 MHz, DMSO-d6) 9.14 (br. s, 1H), 7.99 (s, 1H), 7.66 (br. s, 1H), 7.53 (d, 1.7 Hz, 1H), 7.46 (dd, 8.2, 5.0 Hz, 1H), 7.23 (ddd, 8.8, 8.1, 3.1 Hz, 1H), 6.68 (br. s, 1H), 6.24 (s, 1H), 6.02 (br. s, 1H), 2.18-2.12 (m, 2H), 1.96 (d, 11.9 Hz, 1H), 1.93-1.84 (m, 2H), 1.80 (d, 11.8 Hz, 1H), 1.66-1.54 (m, 8H).	602.2	B	
I-1257		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(NC(=O)NC34CC5CC(CC(C5)C3)C4)c12	1H-NMR (400 MHz, DMSO-d6) 9.12 (br. s, 1H), 8.24 (br. s, 1H), 7.70 (br. s, 1H), 7.49 (d, 1.7 Hz, 1H), 7.46 (dd, 8.2, 5.2 Hz, 1H), 7.23 (ddd, 8.7, 8.4, 3.1 Hz, 1H), 6.76 (br. s, 1H), 6.23 (s, 1H), 6.03 (br. s, 1H), 2.02-1.95 (m, 3H), 1.86-1.77 (m, 6H), 1.64-1.55 (m, 6H).	534.2	B	
I-1258		Fc1ccc(Cl)c(c1)[C@@H]1NC(=O)c2cc(Nc3cn[nH]c3)cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	1H-NMR (400 MHz, DMSO-d6) 12.73 (br. s, 1H), 10.30 (s, 1H), 8.94 (br. s, 1H), 7.94-7.86 (m, 2H), 7.69 (br. d, 9.0 Hz, 1H), 7.60 (s, 1H), 7.65-7.55 (m, 2H), 7.29 (dd, 8.9, 5.2 Hz, 1H), 7.06 (app. td, 8.4, 3.1 Hz, 1H), 6.93 (br. s, 1H), 6.86 (br. s, 1H),	548.3	A	




			6.58 (br. s, 1H), 5.85 (br. s, 1H).			
I-1259		Fc1ccc(Cl)c(c1)[C@H]1NC(=O)c2cc(Nc3cn[nH]c3)cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	1H-NMR (400 MHz, DMSO-d6) 12.73 (br. s, 1H), 10.29 (s, 1H), 8.95 (br. s, 1H), 7.94-7.88 (m, 2H), 7.69 (br. d, 9.3 Hz, 1H), 7.78-7.43 (m, 2H), 7.60 (s, 1H), 7.29 (dd, 8.9, 5.2 Hz, 1H), 7.06 (app. td, 8.4, 3.1 Hz, 1H), 6.94 (s, 1H), 6.85 (br. s, 1H), 6.59 (br. s, 1H), 5.85 (br. s, 1H).	548.4	D	
I-1260		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)N1CCc2nccccc12			A	
I-1261		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)N1CCc2cnccc12			A	
I-1262		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)N1CCCc2cc(ccc12)C#N			A	






I-1263		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)N1CCc2cc(ccc12)C#N			A	
I-1264		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1ccccc1S(F)(=O)=O	1H NMR (400 MHz, DMSO-d6) 5.96 - 6.13 (m, 1 H) 7.12 (td, 8.46, 3.03 Hz, 1 H) 7.34 (dd, 8.84, 5.05 Hz, 1 H) 7.48 (s, 1 H) 7.65 (s, 2 H) 7.69 - 7.76 (m, 2 H) 7.85 (t, 7.71 Hz, 1 H) 7.93 (br d, 8.08 Hz, 1 H) 8.02 (td, 7.58, 1.26 Hz, 1 H) 8.29 (dd, 8.08, 1.01 Hz, 1 H) 9.28 (br s, 1 H) 10.63 (s, 1 H)	625.29	A	
I-1265		OC(=O)Cc1ccccc1-c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	1H NMR (400 MHz, DMSO-d6) 3.56 - 3.60 (m, 2 H) 5.93 - 6.14 (m, 1 H) 7.11 (td, 8.34, 3.03 Hz, 1 H) 7.30 - 7.45 (m, 7 H) 7.57 (d, 1.26 Hz, 1 H) 7.65 (s, 1 H) 7.73 (br d, 9.09 Hz, 1 H) 7.94 (br d, 8.34 Hz, 1 H) 9.21 (br s, 1 H) 10.57 (s, 1 H)	601.28	B	
I-1266		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)C1CC11CC1	1H NMR (400 MHz, DMSO-d6) 0.68 (br d, 4.29 Hz, 1 H) 0.95 - 1.03 (m, 3 H) 1.15 (dt, 15.22, 4.39 Hz, 1 H) 1.61 (dt, 8.08, 4.04 Hz, 1 H) 2.43 (s, 1 H) 5.83 - 6.05 (m, 1 H) 7.04 - 7.12 (m, 1 H) 7.24 (br d, 6.82 Hz, 1 H) 7.30 (dt, 8.91, 5.40 Hz, 1 H) 7.42 (dd, 4.29, 1.26 Hz, 1 H) 7.65 (br s, 1 H) 7.72 (br d, 8.84 Hz, 1 H) 7.94 (br d, 8.34 Hz, 1 H) 9.08 (br s, 1	533.35	A	





			H) 10.42 (d, 6.82 Hz, 1 H)			
I-1267		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)N1CCC2(CNC(=O)C2)C1	(400 MHz, DMSO-d6) 10.37 (s, 1 H), 8.96 (s, 1 H), 7.92 (d, 8.6 Hz, 1 H), 7.72 (d, 8.9 Hz, 1 H) 7.68 (s, 1 H), 7.65 (s, 1 H), 7.29 (dd, 8.9, 5.2 Hz, 1 H), 7.06 ((ddd, 8.8, 8.1, 3.1 Hz), 1 H), 6.74 (d, 1.9 Hz, 1 H), 6.71-6.51 (submerged br. s, 1H), 6.63 (d, 1.3 Hz, 1 H), 5.87 (br s, 1 H), 3.33 - 3.25 (m, 6 H, submerged under water peak), 3.35 - 2.20 (m, 2 H), 2.12 - 1.98 (m, 2 H). Partial formate salt.	603.4	A	
I-1268		CC(C)(C#N)c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	(400 MHz, DMSO-d6) 10.64 (s, 1H), 9.22 (s, 1H), 7.93 (d, 7.5 Hz, 1H), 7.84-7.72 (m, 2H), 7.72-7.63 (m, 2H), 7.32 (dd, 8.9, 5.2 Hz, 1H), 7.10 (td, 8.5, 3.1 Hz, 1H), 6.67 (br s, 1H), 5.98 (br s, 1H), 1.79 (s, 3H), 1.78 (s, 3H) .	534.3	A	
I-1269		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(NC(=O)N3CCc4cc(Cl)ccc34)c12	1H NMR (400 MHz, DMSO-d6) 9.21 (s, 1H), 8.72 (s, 1H), 7.73 - 7.67 (m, 2H), 7.57 (d, 1.8 Hz, 1H), 7.39 (dd, 8.9, 5.2 Hz, 1H), 7.24 (d, 2.2 Hz, 1H), 7.22 - 7.12 (m, 2H), 6.69 (s, 1H), 5.97 (s, 1H), 3.84 (td, 10.1, 7.0 Hz, 2H), 3.03 (dqd, 20.1, 10.0, 4.8 Hz, 2H).	536	D	
I-1270		Fc1ccc2N(CCc2c1)C(=O)Nc1cc(Br)cc2C(=O)NC(c12)c1cc(F)ccc1Cl	1H NMR (400 MHz, DMSO-d6) 9.20 (s, 1H), 8.67 (s, 1H), 7.69 (p, 4.4 Hz, 2H), 7.58 (d, 1.8 Hz, 1H), 7.38 (dd, 8.9, 5.1 Hz, 1H), 7.17 (ddd, 8.8, 7.9, 3.1 Hz, 1H), 7.06 (dd, 8.5, 2.7 Hz, 1H), 6.94 (td, 9.0, 2.8 Hz, 1H), 6.70 (s, 1H), 5.97 (s, 1H),	520.05	A	





			3.84 (td, 10.1, 7.0 Hz, 1H), 3.33 (s, 1H), 3.13 - 2.89 (m, 2H).			
I-1271		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(NC(=O)c3cccc4c(Cl)c[nH]c34)c12	1H NMR (400 MHz, DMSO-d6) 11.40 (s, 1H), 10.31 (s, 1H), 9.27 (s, 1H), 7.85 (dd, 2.8, 1.8 Hz, 1H), 7.79 (d, 1.8 Hz, 1H), 7.71 (d, 7.9 Hz, 1H), 7.51 (d, 2.6 Hz, 1H), 7.34 - 7.25 (m, 2H), 7.13 (t, 7.7 Hz, 1H), 7.06 (td, 8.4, 3.0 Hz, 1H),6.92 (s, 1H), 6.12 (s, 1H).	533.9	C	
I-1272		Cn1cncc1-c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	NMR (400 MHz, DMSO) 10.60 (br s, 1H), 9.23 (br s, 1H), 7.96 (d, 8.3 Hz, 1H), 7.80-7.72 (m, , 3H), 7.67 (s, 1H), 7.62 (s, 1H), 7.33 (dd, 8.8, 5.1 Hz, 1H), 7.23 (s, 1H), 7.10 (td, 8.3, 2.8 Hz, 1H), 6.70 (br s, 1H), 6.03 (br s, 1H), 3.78 (s, 3H). contains 0.48 mol eq. of formate at 8.30 .	547.1	A	
I-1273		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)N1CCCC1=O	NMR (400 MHz, ACN) 8.65 (s, 1H), 8.02 (d, 1.9 Hz, 1H), 7.89 (d, 1.9 Hz, 1H), 7.64-7.59 (m, 1H), 7.59-7.53 (m, 2H), 7.26-7.19 (m, 2H), 6.93 (ddd, 8.9, 8.0, 3.1 Hz, 1H), 6.62 (br s, 1H), 6.06 (br s, 1H), 3.95-3.88 (m, 2H), 2.53 (t, 8.0 Hz, 2H), 2.12-2.08 (m, 2H). 2.10 peak shadowed by water signal.	550	A	
I-1274		Fc1cc(cc(c1)C(F)(F)F)C(=O)Nc1ccc2OC(=O)NC(c3ccccc3Cl)c12	NMR (400 MHz, DMSO) 10.26 (s, 1H), 8.70 (d, 2.8 Hz, 1H), 7.97 (br. d, 8.2 Hz, 1H), 7.91 (s, 1H), 7.87 (d, 9.1 Hz, 1H), 7.44 (t, 8.1 Hz, 1H), 7.31 (dd, 8.0, 1.3 Hz, 1H), 7.27-7.23 (m, 1H), 7.18-7.13 (m, 2H), 7.07 (br. d, 7.8	465.1	C	




			Hz, 1H), 7.02 (dd, 7.7, 1.4 Hz, 1H), 6.15 (d, 2.7 Hz, 1H).			
I-1275		CN(C)S(=O)(=O)Cc1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	NMR (400 MHz, DMSO-d6) 10.60 (br. s, 1H), 9.21 (br. s, 1H), 7.95 (dt, 8.5, 2.0 Hz, 1H), 7.77 (s, 1H), 7.75 (br. d, 8.4 Hz, 1H) 7.66 (s, 1H), 7.55 (s, 1H), 7.32 (dd, 8.9, 5.2 Hz, 1H), 7.10 (td, 8.5, 3.1 Hz, 1H), 6.58 (br. s, 1H), 5.97 (br. s, 1H), 4.70-4.58 (m, 2H), 2.76 (s, 6H).	588.2	A	
I-1276		CS(=O)(=O)c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	NMR (400 MHz, CD3CN) 8.81 (br s, 1H), 8.21 (d, 1.5 Hz, 1H), 8.14 (s, 1H), 7.70-7.65 (m, 1H), 7.63-7.58 (m, 1H), 7.55-7.58 (m, 1H), 7.46 (br s, 1H), 7.29 (dd, 8.9, 5.1 Hz, 1H), 7.00 (ddd, 8.9, 8.0, 3.1 Hz, 1H), 6.69 (br s, 1H), 6.23 (br s, 1H), 3.18 (s, 3H).	543	A	
I-1277		CN1CC(NCC1=O)c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	NMR (400 MHz, CD3CN) 8.85 (br s, 1H), 7.76 (s,1H), 7.68-7.56 (m, 4H), 7.39 (s, 1H), 7.25 (dd, 8.9, 5.1 Hz, 1H), 6.96 (td, 8.4, 3.0 Hz, 1H), 6.60 (br s, 1H), 6.11 (br s, 1H), 4.27 (dt, 10.2, 4.0 Hz, 1H), 3.55-3.43 (m, 3H), 3.37 (dd, 20.5, 10.7 Hz, 1H), 2.89 (s, 3H). DMSO peak observed @ 2.5	579.2	A	
I-1278		OC(c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl)c1ccccn1	NMR (400 MHz, DMSO-d6) Description for the major diastereomer.-′ 10.49 (br. s, 1Hs), 9.12 (br. s, 1H), 8.50 (ddd, 4.8, 1.7, 0.9 Hz, 1H), 7.93 (br. d, 8.3 Hz, 1H), 7.83 (td, 7.7, 1.8 Hz, 1H), 7.72 (app. d, 9.8 Hz, 2H), 7.66-7.62	574.2	A	





			(m, 5.9 Hz, 2H), 7.50 (s, 1H), 7.33-7.24 (m, 2H), 7.08 (td, 8.5, 3.1 Hz, 1H), 6.60 (br. s, 1H), 6.40 (br. s, 1H), 5.92 (submerged br. s, 1H), 5.87 (s, 1H). 2:1 mixture in the 2 diastereomers. Presence of grease in the aliphatic region.			
I-1279		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(CC3COC3)cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	1H NMR (400 MHz, DMSO-d6) 3.12 (dd, 7.71, 4.42 Hz, 2 H) 3.32 - 3.38 (m, 2 H) 4.38 (td, 6.06, 3.79 Hz, 2 H) 4.65 (ddd, 7.64, 6.00, 1.26 Hz, 2 H) 5.83 - 5.97 (m, 1 H) 7.07 (td, 8.46, 3.03 Hz, 1 H) 7.26 - 7.31 (m, 2 H) 7.50 (s, 1 H) 7.63 (s, 1 H) 7.71 (br d, 8.84 Hz, 1 H) 7.93 (br d, 8.59 Hz, 1 H) 9.09 (br s, 1 H) 10.45 (s, 1 H)	537.35	A	
I-1280		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)C1CN(C1)C1COC1	1H NMR (400 MHz, DMSO-d6) 2.29 (s, 1 H) 3.56 - 3.82 (m, 2 H) 3.92 - 4.31 (m, 4 H) 4.42 - 4.52 (m, 2 H) 4.67 (br t, 6.57 Hz, 2 H) 5.97 (br s, 1 H) 7.03 - 7.13 (m, 1 H) 7.30 (dd, 8.84, 5.31 Hz, 1 H) 7.50 (s, 1 H) 7.66 (s, 1 H) 7.69 - 7.82 (m, 2 H) 7.94 (br d, 8.34 Hz, 1 H) 9.15 (br s, 1 H) 10.53 (s, 1 H)	578.22	A	
I-1281		OC1(COC1)c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	NMR (400 MHz, DMSO-d6) 10.56 (br. s, 1H), 9.15 (s, 1H), 7.93 (submerged br. d, 8.7 Hz, 1H), 7.91 (d, 1.5 Hz, 1H), 7.76 (d, 1.4 Hz, 1H), 7.75 (submerged br. d, 1H), 7.68 (s, 1H), 7.32 (dd, 8.9, 5.2 Hz, 1H), 7.09 (td, 8.4, 3.1 Hz, 1H), 6.82 - 6.50 (m, 2H), 6.01 (br. s, 1H), 4.86 (d, 6.6 Hz, 2H), 4.76	539.2	A	





			(d, 6.5 Hz, 1H), 4.71 (d, 6.5 Hz, 1H).			
I-1282		Oc1cc(Cl)cc(c1)C(=O)Nc1cc(Br)cc2C(=O)NC(c12)c1cc(F)ccc1Cl	1H NMR (400 MHz, DMSO-d6) 10.24 (s,2H), 9.26 (s, 1H), 7.78-7.73 (d, 1.8 Hz, 2H), 7.38 (dd, 8.8, 5.2 Hz, 1H), 7.15 (ddd, 8.8, 7.9, 3.1 Hz, 1H), 6.96 (d, 1.6 Hz, 2H), 6.87 (t, 1.7 Hz, 1H), 6.66 (s, 1H), 6.00 (s, 1H)	510.09	B	
I-1283		Oc1cc(F)cc(c1)C(=O)Nc1cc(Br)cc2C(=O)NC(c12)c1cc(F)ccc1Cl	1H NMR (400 MHz, DMSO-d6) 10.24-10.19 (m, 2H), 9.26 (s, 1H), 7.78-7.72 (m, 2H), 7.38 (dd, 8.9, 5.1 Hz, 1H), 7.14 (ddd, 8.8, 7.9, 3.1 Hz, 1H), 6.90-6.84 (m, 1H), 6.79-6.66 (m, 2H), 6.00 (s, 1H).	495	D	
I-1284		[O-][n+]1cccc(c1)C(=O)Nc1cc(Br)cc2C(=O)NC(c12)c1cc(F)ccc1Cl	1H NMR (400 MHz, DMSO-d6) 10.51 (s, 1H), 9.29 (s, 1H), 8.40-8.34 (m, 1H), 8.29-8.24 (m, 1H), 7.82 (s, 1H), 7.72 (s, 1H), 7.56-7.43 (m, 2H), 7.38 (dd, 8.9, 5.2 Hz, 1H), 7.20-7.10 (m, 1H), 5.97 (s, 1H).	477.85	E	
I-1285		FC(F)Oc1cc(F)cc(c1)C(=O)Nc1cc(Br)cc2C(=O)NC(c12)c1cc(F)ccc1Cl	1H NMR (400 MHz, DMSO-d6) 9.37 (d, 60.3 Hz, 1H), 8.08 (s, 2H), 7.59 (s, 1H), 7.44-7.00 (m, 4H), 6.80 (d, 53.5 Hz, 1H), 6.30 (d, 149.1 Hz, 1H), 5.46 (t, 5.6 Hz, 1H), 4.51 (d, 5.7 Hz, 2H).	557	E	
I-1286		FC(F)Oc1ccc(cc1F)C(=O)Nc1cc(Br)cc2C(=O)NC(c12)c1cc(F)ccc1Cl	1H NMR (400 MHz, DMSO-d6) 10.33 (s, 1H), 9.28 (s, 1H), 7.81 (d, 1.7 Hz, 1H), 7.73 (d, 1.7 Hz, 1H), 7.59 - 7.31 (m, 5H), 7.13 (td, 8.4, 3.1 Hz, 1H), 6.34 - 6.87(s, 1H), 6.00 (s, 1H).	544.9	D	





I-1287		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(NS(=O)(=O)N3CCc4ccccc34)c12	1H NMR (400 MHz, DMSO-d6) 9.93 (s, 1H), 9.24 (s, 1H), 7.61 (s, 1H), 7.48 (s, 1H), 7.27 - 7.16 (m, 3H), 7.04 - 6.90 (m, 3H), 6.76 (s, 1H), 6.08 (s, 1H), 3.81 - 3.72 (m, 1H), 3.65 (td, 10.1, 6.6 Hz, 1H), 3.09 - 2.88 (m, 2H).	536	E	
I-1288		CC(F)c1cc(F)cc(c1)C(=O)Nc1cc(Br)cc2C(=O)NC(c12)c1cc(F)ccc1Cl	1H NMR (400 MHz, DMSO-d6) 10.38 (s, 1H), 9.28 (s, 1H), 7.81 (d, 1.7 Hz, 1H), 7.75 (d, 1.7 Hz, 1H), 7.43 (dd, 19.9, 9.3 Hz, 2H), 7.38 - 7.27 (m, 2H), 7.12 (tt, 8.7, 3.2 Hz, 1H), 6.72 (s, 2H), 6.00 (s, 1H), 5.85 - 5.65 (m, 1H), 2.08 (s, 0H), 1.59 (ddd, 24.4, 6.4, 1.9 Hz, 3H).	523	B	
I-1289		O[C@H]1CC[C@@H]1Oc1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	1H NMR (400 MHz, DMSO-d6) 10.46 (br. s, 1H), 9.12 (br. s, 1H), 7.95 (d, 8.4 Hz, 1H), 7.71 (d, 9.1 Hz, 1H), 7.62 (s, 1H), 7.33 - 7.28 (m, 2H), 7.15-7.01 (m, 2H), 6.58 (br. s, 1H), 5.91 (br. s, 1H), 5.75 (t, 8.0 Hz, 1H), 4.44 (q, 7.5 Hz, 1H), 4.15-3.95 (m, 1H), 2.25-2.19 (m, 1H), 2.12 - 2.03 (m, 1H), 1.56-1.35 (m, 2H)	553.2	B	
I-1290		NCC(O)c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	NMR (400 MHz, DMSO) 10.58 (br s, 1H), 9.13 (br s, 1H), 8.23 (s, 1H), 7.91 (d, 8.3 Hz, 1H), 7.75-7.68 (m, 1 H), 7.64 (d, 7.5 Hz, 1 H), 7.49 (d, 16.8 Hz, 1H), 7.31-7.25 (m, 1 H), 7.35-6.94 (m, 2 H), 7.09-7.02 (m, 1 H), 5.96 (br s, 1H), 4.87 (ddd, 12.6, 8.9, 3.1 Hz, 1H), 3.10-2.99 (m, 1H), 2.88-2.78 (m, 1H).	526.1	B	




I-1291		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)N1CC2CNCC2C1=O	(400 MHz, CD3CN) 8.70 (br. s, 1H), 8.14 (s, 1H), 8.11 (dd, 6.0, 1.9 Hz, 1H), 7.93 (dd, 9.9, 1.8 Hz, 1H), 7.65 (d, 7.5 Hz, 1H), 7.59 (d, 7.5 Hz, 1H), 7.58 (s, 1H), 7.27 (br. s, 1H), 7.25 (dd, 9.0, 5.1 Hz, 1H), 6.96 (td, 8.5, 3.0 Hz, 1H), 6.65 (br. s, 1H), 6.09 (br. s, 1H), 4.17 (dd, 17.2, 9.0 Hz, 1H), 3.65 (ddd, 9.8, 6.7, 2.8 Hz, 1H), 3.28 (d, 10.8 Hz, 1H), 3.18 (t, 8.3 Hz, 1H), 3.04-2.91 (m, 4H).	591.3	A	
I-1292		CC(c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl)S(C)(=O)=O	NMR (400 MHz, CD_3CN) 8.68 (s, 1H), 7.79 - 7.72 (m, 1H), 7.65 (d, J = 7.9 Hz, 1H), 7.62 - 7.56 (m, 3H), 7.32 - 7.22 (m, 2H), 6.97 (td, J = 8.4, 2.6 Hz, 1H), 6.63 (br, s, 1H), 6.11 (br, s, 1H), 5.55- 5.46 (m, 1H), 2.68- 2.61 (m, 3H), 1.68-1.63 (m, 3H).	573	A	
I-1293		Cn1nccc1Cc1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	1H-NMR (400 MHz, DMSO-d6) 10.51 (br. s, 1H), 9.15 (br. s, 1H), 7.94 (br. d, 9.0 Hz, 1H), 7.71 (br. d, 9.7 Hz, 1H), 7.62 (br. s, 1H), 7.53 (br. s, 1H), 7.34 (d, 1.8 Hz, 1H), 7.31 (dd, 8.9, 5.1 Hz, 1H), 7.30-7.28 (m, 1H), 7.08 (app. td, 8.5, 3.1 Hz, 1H), 6.59 (br. s, 1H), 6.09 (s, 1H), 5.94 (br. s, 1H), 4.27-4.18 (m, 2H), 3.71 (s, 3H).	561.3	A	
I-1294		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(NC(=O)NC3(CC3)C(F)(F)F)c12	1H-NMR (400 MHz, DMSO-d6) 9.19 (br. s, 1H), 8.11 (s, 1H), 7.72 (br. s, 1H), 7.59 (d, 1.6 Hz, 1H), 7.53-7.43 (m, 1H), 7.36 (s, 1H), 7.23 (app. td, 8.5, 3.1 Hz, 1H), 6.69 (br. s, 1H),	506.2	D	






			5.97 (br. s, 1H), 1.22-1.17 (m, 1H), 1.16-1.09 (m, 1H), 1.07-0.99 (m, 1H), 0.87-0.78 (m, 1H).			
I-1295		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(O[C@H]3C[C@H](C3)C#N)cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	1H NMR (400 MHz, DMSO) 10.44 (br. s, 1H), 9.14 (br. s, 1H), 7.94 (br. d, 8.5 Hz, 1H), 7.73-7.68 (m, 1H), 7.62 (s, 1H), 7.31 (dd, 8.9, 5.2 Hz, 1H), 7.13-7.04 (m, 2H), 7.01 (d, 1.9 Hz, 1H), 6.62 (br. s, 1H), 5.91 (s, 1H), 4.90-4.80 (m, 1H), 3.22-3.05 (m, 1H), 3.02-2.89 (m, 2H), 2.48-2.32 (m, 2H)	562.2	A	
I-1296		CS(=O)(=O)c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)(c1cc(F)ccc1Cl)S(O)(=O)=O	(400 MHz, DMSO-d6) 10.93 (s, 1 H), 9.87 (s, 1 H), 8.77 (dd, 11.7, 3.1 Hz, 1 H), 8.66 (d, 1.5 Hz, 1 H), 8.02 (d, 8.5 Hz, 1 H), 8.00 (d, 1.6 Hz, 1 H), 7.79 (s, 1 H), 7.71 (d, 9.0 Hz, 1 H), 7.26 (dd, 8.8, 5.6 Hz, 1 H), 7.24-7.16 (m, 1 H), 7.10 (ddd, 8.8, 7.5, 3.1 Hz, 1 H), 6.95 (br s, 1 H), 3.35 (s, 3 H).	623.3	D	
I-1297		CC(C)(C)OC(=O)NCCSc1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	NMR (400 MHz, CD3CN) 8.70 (brs, 1H), 7.70 (d, 1.4 Hz, 1H), 7.64 (br d, 8.3 Hz, 1H), 7.59 (br d, 8.4 Hz, 1H), 7.58 (s, 1H), 7.27 (br s, 1H), 7.25 (dd, 8.9, 5.1 Hz, 1H), 6.96 (td, 8.4, 3.0 Hz, 1H), 6.67 (brs, 1H), 6.09 (brs, 1H), 5.57 (brs, 1H), 3.30 (q, 6.5 Hz, 2H), 3.18-3.11 (m, 2H), 1.39 (s, 9H).	642.2	B	





I-1298		NCCOc1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	(400 MHz, DMSO-d6) 10.47 (br s, 1H), 9.12 (s, 1H), 7.94 (d, 8.3 Hz, 1H), 7.71 (d, 8.9 Hz, 1H), 7.64 (s, 1H), 7.31 (dd, 8.9, 5.2 Hz, 1H), 7.22 (d, 2.2 Hz, 1H), 7.12-7.03 (m, 2H), 6.57 (br s, 1H), 5.93 (br s, 1H), 4.19-4.06 (m, 2H), 3.35 (br s, 3H), 3.02 (t, 5.3 Hz, 2H)	526.2	B	
I-1299		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)N1CC2(CNC2)C1	NMR (400 MHz, DMSO-d6) 10.46 (br. s, 1H), 9.00 (br. s, 1H), 7.92 (br. d, 9.2 Hz, 1H), 7.72 (br. d, 8.3 Hz, 1H), 7.64 (s, 1H), 7.28 (dd, 8.7, 5.1 Hz, 1H), 7.06 (td, 8.3, 3.2 Hz, 1H), 6.66 (d, 1.7 Hz, 1H), 6.52 (d, 1.2 Hz, 1H), 6.75-6.40 (br. s, 1H), 5.87 (br. s, 1H), 4.04-3.99 (m, 4H), 3.94-3.86 (m, 4H)	561.3	B	
I-1300		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1cn2ccncc2n1	NMR (400 MHz, ACN-d3) 9.00 (s, 1H), 8.88 (br. s, 1H), 8.41 (s, 1H), 8.32 (dd, 4.5, 1.1 Hz, 1H), 8.29 (m, 2H), 7.86 (d, 4.6 Hz, 1H), 7.68-7.61 (m, 2H), 7.60 (s, 1H), 7.41 (s, 1H), 7.27 (dd, 8.9, 5.1 Hz, 1H), 6.98 (td, 8.5, 3.1 Hz, 1H), 6.73 (br. s, 1H), 6.18 (br. s, 1H)	582.4	A	
I-1301		CC(=O)N1CC2(C1)CN(C2)c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	NMR (400 MHz, DMSO-d6) 10.43 (br. s, 1H), 9.02 (br. s, 1H), 7.93 (br. d, 8.6 Hz, 1H), 7.72 (br. d, 9.2 Hz, 1H), 7.64 (s, 1H), 7.29 (dd, 9.0, 5.1 Hz, 1H), 7.07 (td, 8.3, 3.3 Hz, 1H), 6.67 (d, 1.7 Hz, 1H), 6.54 (br. s, 1H), 6.75-6.40 (br. s, 1H), 5.87 (br. s, 1H), 4.35-4.29 (m, 2H), 4.10-4.01 (m, 6H), 1.76 (s, 3H)	603.3	B	




I-1302		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(CC3CCO3)cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	1H NMR (400 MHz, DMSO-d6) 2.37 - 2.45 (m, 1 H) 2.59 - 2.69 (m, 1 H) 3.04 - 3.22 (m, 2 H) 4.38 (tt, 9.00, 5.78 Hz, 1 H) 4.45 - 4.56 (m, 1 H) 4.92 - 5.04 (m, 1 H) 5.79 - 6.08 (m, 1 H) 7.09 (td, 8.34, 3.03 Hz, 1 H) 7.26 - 7.39 (m, 2 H) 7.55 - 7.79 (m, 3 H) 7.95 (br d, 8.59 Hz, 1 H) 9.12 (br s, 1 H) 10.45 - 10.56 (m, 1 H)	537.25	A	
I-1303		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1ccnn1CC#N	1H NMR (400 MHz, DMSO-d6) 5.57 (s, 2 H) 5.91 - 6.22 (m, 1 H) 6.66 (d, 2.02 Hz, 1 H) 7.11 (td, 8.40, 2.91 Hz, 1 H) 7.33 (dd, 8.84, 5.05 Hz, 1 H) 7.59 - 7.67 (m, 2 H) 7.70 - 7.76 (m, 2 H) 7.79 (d, 1.52 Hz, 1 H) 7.96 (br d, 8.34 Hz, 1 H) 9.23 - 9.40 (m, 1 H)	572.17	A	
I-1304		Fc1ccc(Cl)c(c1)[C@H]1NC(=O)c2cc(O[C@H]3C[C@@H](C3)C#N)cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12			D	
I-1305		Fc1ccc(Cl)c(c1)[C@@H]1NC(=O)c2cc(O[C@H]3C[C@@H](C3)C#N)cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12			A	





I-1306		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1cn2ncccc2n1	NMR (400 MHz, DMSO-d6) 10.65 (br. s, 1H), 9.22 (br. s, 1H), 9.11 (s, 1H), 8.54 (dd, 4.5, 1.6 Hz, 1H), 8.37 (s, 1H), 8.25 (d, 0.8 Hz, 1H), 8.17 (ddd, 9.6, 1.2, 0.8 Hz, 1H), 7.97 (br. d, 8.3 Hz, 1H), 7.79 (br. d, 9.6 Hz, 1H), 7.72 (s, 1H), 7.33 (dd, 8.9, 5.2 Hz, 1H), 7.28 (dd, 9.2, 4.5 Hz, 1H), 7.10 (td, 8.6, 3.0 Hz, 1H), 6.68 (br. s, 1H), 6.03 (br. s, 1H)	584.3	A	
I-1307		CC(C)(O)C(O)c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	NMR (400 MHz, DMSO d6) 10.50 (br. s, 1H), 9.09 (br. s, 1H), 7.94 (br. d, 8.2 Hz, 1H), 7.73 (br. d, 7.6 Hz, 1H), 7.70 (s, 1H), 7.64 (s,1H), 7.46 (s, 1H), 7.32-7.28 (m, 1H), 7.09 (td, 8.4, 3.0 Hz, 1H), 6.50 (br s, 1H), 5.97 (br s, 1H), 5.54 (d, 4.5 Hz, 1H), 4.45-4.44 (m, 2H), 1.15 (s, 3H), 0.97 (s, 3H)	555.3	B	
I-1308		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)C1CNC(=O)CO1	NMR (400 MHz, MeOD) 8.54 (s, 1H), 7.90 (d, 3.7 Hz, 1H), 7.73-7.59 (m, 4H), 7.28 (dd, 8.9, 5.1 Hz, 1H), 7.03-6.96 (m, 1H), 6.57 (br s, 1H) 6.19 (br s, 1H), 5.08-5.00 (m, 1H), 4.40 (s, 2H), 3.68-3.62 (m, 1H), 3.52-3.42 (m, 1H).	566.1	A	
I-1309		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)N1CC2CNC(=O)C2C1	NMR (400 MHz, CD3CN) 8.53 (br. s, 1H), 7.64 (d, 8.3 Hz, 1H), 7.58 (d, 8.3 Hz, 1H), 7.57 (s, 1H), 7.26-7.21(m, 1H), 7.11 (br. s, 1H), 6.98-6.90 (m, 2H), 6.81 (s, 1H), 6.62 (br. s, 1H), 6.09 (s, 1H), 6.01 (br. s, 1H), 3.68-3.61 (m, 2H), 3.58 (dd, 9.9, 6.6 Hz,	591.3	A	





			1H), 3.45 (t, 7.8 Hz, 1H), 3.32-3.17 (m, 3H), 3.08 (t, 7.7 Hz, 1H)			
I-1310		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)N1CC2(CCO2)C1	NMR (400 MHz, DMSO-d6) 10.40 (s, 1H), 9.01 (br. s, 1H), 7.93 (br. d, 8.3 Hz, 1H), 7.71 (br. d, 8.6 Hz, 1H), 7.64 (s, 1H), 7.29 (dd, 8.8, 5.1 Hz, 1H), 7.06 (td, 8.5, 3.0 Hz, 1H), 6.69 (d, 1.6 Hz, 1H), 6.55 (submerged br. s, 1H), 6.53 (s, 1H), 5.86 (br. s, 1H), 4.46 (t, 7.4 Hz, 2H), 4.18 (dd, 14.8, 9.0 Hz, 2), 3.96 (dd, 15.1, 8.9 Hz, 2H), 2.90 (t, 7.5 Hz, 2H).	564.3	B	
I-1311		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1csc(n1)C#N	NMR (400 MHz, CDC3CN/DMSO-d6) 10.27 (br s, 1H), 8.59 (br s, 1H), 8.53 (s, 1H), 8.28 (s, 1H), 8.19 (s, 1H), 7.69-7.77 (m, 2H), 7.67 (br d, 1H), 7.24 (dd, 8.6, 5.3 Hz, 1H), 6.95 (td, 7.9, 3.1 Hz, 1H), 6.66 (br s, 1H), 6.16 (br s, 1H).	575	A	
I-1312		CS(=O)(=N#N)Cc1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	NMR (400 MHz, DMSO-d6) 10.68 (br. s, 1H), 9.29 (s, 1H), 7.95 (br. d, 8.3 Hz, 1H), 7.84 (s, 1H), 7.73 (br. d, 8.9 Hz, 1H), 7.63 (s, 1H), 7.58 (s, 1H), 7.32 (dd, 8.9, 5.2 Hz, 1H), 7.10 (td, 8.4, 2.9 Hz, 1H), 6.65 (br. s, 1H), 6.03 (br. s, 1H), 5.29-5.18 (m, 2H), 3.45 (s, 3H).	583.1	A	





I-1313		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(NC(=O)c3ccc(OC(F)(F)F)c(F)c3)c12	1H NMR (400 MHz, DMSO-d6) 10.41 (s, 1H), 9.27 (s, 1H), 7.81 (d, 1.7 Hz, 1H), 7.75 - 7.67 (m, 2H), 7.62 (dd, 11.0, 2.1 Hz, 1H), 7.54 (dd, 8.3, 2.0 Hz, 1H), 7.35 (dd, 8.9, 5.2 Hz, 1H), 7.12 (td, 8.4, 3.1 Hz, 1H), 6.75 (s, 1H), 5.97 (s, 1H).	560.8	D	
I-1314		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(NC(=O)c3cccc(SC(F)(F)F)c3)c12	1H NMR (400 MHz, DMSO-d6) 10.44 (s, 1H), 9.27 (s, 1H), 7.91 (d, 7.6 Hz, 1H), 7.86 - 7.77 (m, 3H), 7.74 (d, 1.8 Hz, 1H), 7.63 (t, 7.8 Hz, 1H), 7.31 (dd, 8.9, 5.2 Hz, 1H), 7.09 (td, 8.4, 3.1 Hz, 1H), 6.69 (s, 1H), 6.01 (s, 1H).	558.95	D	
I-1315		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(Nc3n[nH]c4ccccc34)c12	1H NMR (400 MHz, DMSO-d6) 12.28 (s, 1H), 9.13 (s, 1H), 8.18 (s, 1H), 8.08-8.03 (m, 1H), 7.42-7.35 (m, 2H), 7.31 (ddt, 7.7, 4.7, 2.1 Hz, 3H), 7.14-7.02 (m, 1H), 6.97 (ddd, 7.9, 6.8, 0.9 Hz, 1H), 6.79 (s, 1H), 6.08 (s, 1H).	471	E	
I-1316		COCc1cc(F)cc(c1)C(=O)Nc1cc(Br)cc2C(=O)NC(c12)c1cc(F)ccc1Cl	1H NMR (400 MHz, DMSO-d6) 10.34 (s, 1H), 9.27 (s, 1H), 7.80 (s, 1H), 7.74 (s, 1H), 7.40 - 7.31 (m, 3H), 7.23 (d, 9.4 Hz, 1H), 7.14 (td, 8.4, 3.0 Hz, 1H), 6.66 (s, 1H), 6.00 (s, 1H), 4.44 (s, 2H), 3.29 - 3.32 (m, 3H)	521	D	
I-1317		Fc1ccc(Cl)c(c1)C1NC(=O)c2cccc(-c3cc4c(Cl)cc(F)cc4[nH]3)c12	1H NMR (400 MHz, DMSO-d6) 11.85 (s, 1H), 9.28 (s, 1H), 7.90 (d, 7.4 Hz, 1H), 7.82 (dd, 7.6, 1.2 Hz, 1H), 7.75 (t, 7.5 Hz, 1H), 7.31 (s, 1H), 7.09 (ddd, 9.4, 2.2, 0.9 Hz, 1H), 7.05-6.95 (m, 2H), 6.56-6.50 (m, 2H), 6.35 (s, 1H).	428.95	B	





I-1318		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(NC(=O)n3ccc4ccccc34)c12	1H NMR (400 MHz, DMSO-d6) 10.07 (s, 1H), 9.30 (s, 1H), 8.02 (d, 8.1 Hz, 1H), 7.82 (m, 2H), 7.76 (s, 1H), 7.59 (d, 7.6 Hz, 1H), 7.38 - 7.06 (m, 5H), 6.65 (d, 3.7 Hz, 1H), 6.05 (s, 1H).	499.9	A	
I-1319		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(NC(=O)c3cc(F)cc4oc(=O)[nH]c34)c12	1H NMR (400 MHz, DMSO-d6) 11.85 (s, 1H), 10.40 (s, 1H), 9.27 (s, 1H), 8.52 - 7.59 (m, 3H), 7.30 (s, 1H), 7.10 - 6.90 (m, 3H), 5.98 (s, 1H).	535.95	D	
I-1320		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(OC3CN(C3)C(=O)C(F)(F)F)cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	(400 MHz, DMSO-d6) 10.48 (s, 1H), 9.20 (br s, 1H), 7.96 (d, 8.5 Hz, 1H), 7.71 (d, 8.9 Hz, 1H), 7.61 (s, 1H), 7.32 (dd, 8.9, 5.2 Hz, 1H), 7.12-7.06 (m, 2H), 7.06-7.01 (m, 1H), 6.56 (br s, 1H), 5.94 (br s, 1H), 5.33-5.24 (m, 1H), 5.00-4.90 (m, 1H), 4.62 (dd, 11.3, 6.7 Hz, 1H), 4.52-4.41 (m, 1H), 4.19-4.10 (m, 1H).	634.2	B	
I-1321		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(C[n+]3ccccc3)cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	(400 MHz, CD3CN) 8.95 (d, 6.0 Hz, 2H), 8.52 (t, 7.8 Hz, 1H), 8.39 (s, 2H), 8.05 (t, 6.9 Hz, 2H), 7.85 (s, 1H), 7.80 (s, 1H), 7.76-7.70 (m, 2H), 7.60 (d, 8.4 Hz, 1H), 7.55 (s, 1H), 7.20 (dd, 8.8, 5.1 Hz, 1H), 6.91 (td, 8.4, 2.9 Hz, 1H), 6.67 (br s, 1H), 6.19 (s, 1H), 5.86 (s, 2H).	558.3	A	




I-1322		CC(=O)NCCOc1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	(400 MHz, DMSO-d6) 10.47 (s, 1H), 9.14 (s, 1H), 8.16 (t, 5.2 Hz, 1H), 7.95 (d, 8.1 Hz, 1H), 7.71 (d, 8.7 Hz, 1H), 7.63 (s, 1H), 7.31 (dd, 8.8, 5.1 Hz, 1H), 7.20 (s, 1H), 7.08 (d, 8.3 Hz, 2H), 6.54 (br s, 1H), 5.92 (br s, 1H), 4.18-4.04 (m, 2H), 3.45 (dd, 11.0, 5.6 Hz, 2H), 1.83 (s, 3H).	568.1	B	
I-1323		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(NC(=O)C3CCCC(C3)C(F)(F)F)c12	1H-NMR (400 MHz, DMSO-d6) as a ca. 1:1 mixture of diastereomers-′ 9.98 (br. s, 1H), 9.91 (br. s, 1H), 9.26 (br. s, 2H), 7.72-7.69 (m, 2H), 7.61 (d, 1.7 Hz, 1H), 7.58 (d, 1.7 Hz, 1H), 7.53-7.41 (m, 2H), 7.25-7.17 (m, 2H), 6.54 (br. s, 2H), 6.01 (br. s, 2H), 2.30-2.20 (m, 2H), 2.19-2.09 (m, 2H), 1.81-1.68 (m, 4H), 1.58 (d, 12.8 Hz, 1H), 1.50 (d, 12.8 Hz, 1H), 1.42-1.31 (m, 2H), 1.27-1.16 (m, 2H), 1.13-0.93 (m, 6H).	533.2	B	
I-1324		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(NC(=O)C3CCC(CC3)C(F)(F)F)c12	1H-NMR (400 MHz, DMSO-d6) 9.78 (br. s, 1H), 9.26 (br. s, 1H), 7.75 (d, 1.6 Hz, 1H), 7.69 (d, 1.6 Hz, 1H), 7.53-7.45 (m, 1H), 7.23 (app. td, 8.4, 3.1 Hz, 1H), 6.52 (br. s, 1H), 6.08 (br. s, 1H), 2.38-2.34 (m, 1H), 2.24-2.12 (m, 1H), 1.66-1.58 (m, 1H), 1.57-1.31 (m, 5H), 1.29-1.14 (m, 2H).	533.2	D	





I-1325		Fc1ccc(Cl)c(c1)[C@H]1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)[C@H]1C[C@@H](C1)C#N	NMR (400 MHz, CD3CN) 8.64 (s,1H), 7.68-7.56 (m, 4H), 7.42 (d, 6.9 Hz,1H), 7.30-7.22 (m, 2H), 7.02-6.92 (m,1H), 6.60 (br, s,1H), 6.09 (br, s, 1H), 3.78-3.67 (m,1H), 3.31-3.19 (m,1H), 2.88-2.80 (m,1H), 2.78-2.70 (m,1H), 2.69-2.59 (m,1H), 2.56-2.44 (m,1H)	546	B	
I-1326		Fc1ccc(Cl)c(c1)[C@@H]1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)[C@H]1C[C@@H](C1)C#N	NMR (400 MHz, CD3CN) 8.64 (s,1H), 7.68-7.56 (m, 4H), 7.42 (d, 6.9 Hz,1H), 7.30-7.22 (m, 2H), 7.02-6.92 (m,1H), 6.60 (br, s,1H), 6.09 (br, s, 1H), 3.78-3.67 (m,1H), 3.31-3.19 (m,1H), 2.88-2.80 (m,1H), 2.78-2.70 (m,1H), 2.69-2.59 (m,1H), 2.56-2.44 (m,1H)	546	A	
I-1327		Fc1ccc(Cl)c(c1)[C@H]1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)[C@@H]1C[C@@H](C1)C#N	NMR (400 MHz, CD3CN) 8.64 (s,1H), 7.68-7.56 (m, 4H), 7.42 (d, 6.9 Hz,1H), 7.30-7.22 (m, 2H), 7.02-6.92 (m,1H), 6.60 (br, s,1H), 6.09 (br, s, 1H), 3.78-3.67 (m,1H), 3.31-3.19 (m,1H), 2.88-2.80 (m,1H), 2.78-2.70 (m,1H), 2.69-2.59 (m,1H), 2.56-2.44 (m,1H)	546	A	
I-1328		Fc1ccc(Cl)c(c1)[C@@H]1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)[C@@H]1C[C@@H](C1)C#N	NMR (400 MHz, CD3CN) 8.64 (s,1H), 7.68-7.56 (m, 4H), 7.42 (d, 6.9 Hz,1H), 7.30-7.22 (m, 2H), 7.02-6.92 (m,1H), 6.60 (br, s,1H), 6.09 (br, s, 1H), 3.78-3.67 (m,1H), 3.31-3.19 (m,1H), 2.88-2.80 (m,1H), 2.78-2.70 (m,1H), 2.69-2.59 (m,1H), 2.56-2.44 (m,1H)	546	B	





I-1329		Fc1ccc(Cl)c(c1)[C@H]1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1cn2ccnc2cn1		584.2	D	
I-1330		Fc1ccc(Cl)c(c1)[C@@H]1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1cn2ccnc2cn1		584.2	A	
I-1331		Fc1ccc(Cl)c(c1)[C@H]1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1ccc2nccn2n1		584.2	D	
I-1332		Fc1ccc(Cl)c(c1)[C@@H]1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1ccc2nccn2n1		584.2	A	





I-1333		Fc1ccc(Cl)c(c1)[C@H]1NC(=O)c2cc(O[C@H]3C[C@H](C3)C#N)cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12		561	D	
I-1334		Fc1ccc(Cl)c(c1)[C@@H]1NC(=O)c2cc(O[C@H]3C[C@H](C3)C#N)cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12		561	A	
I-1335		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1cn2ncnc2cn1		585.5	A	
I-1336		CS(=O)(=O)Cn1cc(cn1)-c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	1H NMR (500 MHz, DMSO-d6) 3.06 (s, 3 H) 5.77 (d, 0.92 Hz, 2 H) 5.89 - 6.10 (m, 1 H) 7.08 (td, 8.35, 2.98 Hz, 1 H) 7.31 (dd, 8.85, 5.19 Hz, 1 H) 7.69 (s, 1 H) 7.71 - 7.78 (m, 2 H) 7.94 (br s, 2 H) 8.27 (s, 1 H) 8.47 (s, 1 H) 9.14 (br s, 1 H) 10.53 (s, 1 H)	625.24	A	




I-1337		OC(c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl)C1(O)COC1		569.22	B	
I-1338		OC1(COc2cc3C(=O)NC(c3c(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c2)c2cc(F)ccc2Cl)COC1		569.17	B	
I-1339		OCC1(Cc2cc3C(=O)NC(c3c(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c2)c2cc(F)ccc2Cl)COC1	1H NMR (500 MHz, DMSO) 10.45 (s, 1H), 9.08 (s, 1H), 7.92 (dt, 8.6, 2.1 Hz, 1H), 7.72 (d, 9.1 Hz, 1H), 7.64 (s, 1H), 7.54 (d, 1.5 Hz, 1H), 7.35-7.25 (m, 2H), 7.12-6.98 (m, 1H), 6.59 (s, 1H), 5.93 (s, 1H), 5.02 (s, 1H), 4.45 (dd, 12.2, 5.8 Hz, 2H), 4.28 (dd, 20.6, 5.8 Hz, 2H), 3.52 (d, 10.9 Hz, 1H), 3.47 (d, 11.0 Hz, 1H), 3.13 (d, 13.4 Hz, 1H), 3.06 (d, 13.4 Hz, 1H).	567.22	A	
I-1340		OCCn1nccc1-c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl		577.22	A	





I-1341		OCC(O)COc1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	NMR (400 MHz, DSMO-d6) 10.50 (br s, 1H), 9.17 (s, 1H), 7.95 (d, 9.2 Hz, 1H), 7.71 (d, 8.8 Hz, 1H), 7.63 (s, 1H), 7.31 (dd, 8.8, 5.2 Hz, 1H), 7.19 (d, 1.9 Hz, 1H), 7.13-7.04 (m, 2H), 6.49 (br s, 1H), 5.97 (br s, 1H), 5.05 (d, 5.1 Hz, 1H), 4.74 (t, 5.4 Hz, 1H), 4.13 (td, 9.5, 3.9 Hz, 1H), 4.06-3.90 (m, 1H), 3.90-3.75 (m, 1H), 3.47 (t, 5.5 Hz, 2H).	557.2	A	
I-1342		OCN1C(c2c(cc(cc2NC(=O)c2cc(F)cc(c2)C(F)(F)F)-c2ccc3ncnn3c2)C1=O)c1cc(F)ccc1Cl	(400 MHz, DMSO) 10.67 (d, 35.5 Hz, 1H), 9.50 (s, 1H), 8.58 (s, 1H), 8.30-8.11 (m, 2H), 8.07-7.91 (m, 3H), 7.89-7.74 (m, 2H), 7.42-7.27 (m, 1H), 7.19-7.07 (m, 1H), 6.47-6.37 (m, 1H), 6.18 (t, 7.0 Hz, 1H), 6.09-5.98 (m, 1H), 5.30-5.17 (m, 1H), 4.18-4.07 (m, 1H) .	614.4	B	
I-1343		CC(C)[C@H](N)C(=O)N1C(c2c(cc(cc2NC(=O)c2cc(F)cc(c2)C(F)(F)F)-c2ccc3ncnn3c2)C1=O)c1cc(F)ccc1Cl	(400 MHz, DMSO-d6, 60Â°C) 9.48-9.40 (m, 1H), 8.57-8.51 (m, 1H), 8.34-8.24 (m, 1H), 8.16-8.07 (m, 2H), 8.00-7.73 (m, 4H), 7.25 (dd, 8.9, 5.2 Hz, 1H), 7.10-7.00 (m, 1H), 6.63-6.41 (m, 1H), 6.14-6.02 (m, 1H), 4.54 (d, 3.7 Hz, 0.5H), 4.44 (d, 4.9 Hz, 0.5H), 2.14-1.93 (m, 1H), 1.01 (d, 6.7 Hz, 1.5H), 0.94 (d, 6.5 Hz, 1.5H), 0.85 (d, 6.6 Hz, 1.5H), 0.42 (br d, 5.5 Hz, 1.5H)	683.4	A	





I-1344		C[C@@](O)(C#N)c1cc2C(=O)N[C@H](c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	(400 MHz, DMSO-d6) 10.69 (br s, 1H), 9.10 (br s, 1H), 7.95-7.83 (m, 1H), 7.82 - 7.66 (m, 4H), 7.32 (dd, 8.8, 5.2 Hz, 1H), 7.09 (td, 8.4, 3.0 Hz, 1H), 6.52 (br s, 1H), 6.07 (br s, 1H), 5.95 (br s, 1H), 3.08 (s, 2H), 1.60 (s, 3H) .	550.3	C	
I-1345		C[C@](O)(C#N)c1cc2C(=O)N[C@H](c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	(400 MHz, DMSO-d6) 10.66 (br s, 1H), 9.13 (br s, 1H), 8.02-7.88 (m, 1H), 7.88-7.80 (m, 1H), 7.76 (d, 9.1 Hz, 1H), 7.73-7.62 (m, 2H), 7.31 (dd, 8.9, 5.2 Hz, 1H), 7.09 (td, 8.4, 2.9 Hz, 1H), 6.52 (br s, 1H), 6.09 (s, 1H), 5.95 (br s, 1H), 3.09 (s, 2H), 1.60 (s, 3H) [	550.2	A	
I-1346		CS(=O)(=O)N1CC(C1)Oc1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	(400 MHz,) 10.47 (s, 1H), 9.18 (br s, 1H), 7.95 (d, 7.8 Hz, 1H), 7.71 (d, 8.5 Hz, 1H), 7.62 (s, 1H), 7.31 (dd, 8.8, 5.2 Hz, 1H), 7.14-7.00 (m, 3H), 6.58 (br s, 1H), 5.94 (br s, 1H), 5.21 (p, 5.3 Hz, 1H), 4.37 (t, 6.6 Hz, 2H), 4.00 (td, 9.7, 4.6 Hz, 2H), 3.10 (s, 3H) .	616.3	A	
I-1347		CN1C(COc2cc3C(=O)NC(c3c(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c2)c2cc(F)ccc2Cl)CCC1=O	1H NMR (400 MHz, DMSO-d6) 10.44 (s, 1H), 9.14 (s, 1H), 7.95 (d, 8.3 Hz, 1H), 7.72 (d, 8.6 Hz, 1H), 7.64 (s, 1H), 7.31 (dd, 8.8, 5.1 Hz, 1H), 7.27 (s, 1H), 7.16-7.02 (m, 2H), 6.61 (br. s, 1H), 5.94 (br. s, 1H), 4.35 - 4.26 (m, 1H), 4.21 - 4.13 (m, 1H), 3.97-3.85 (m, 1H), 2.79 (s, 3H), 2.46-2.27 (m, 1H), 2.28-2.08 (m, 2H), 1.96-1.77 (m, 1H)	594.2	A	





I-1348		CN1CC(COc2cc3C(=O)NC(c3c(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c2c)c(F)ccc2Cl)CC1=O	1H NMR (400 MHz, DMSO-d6) mixture of diastereomers:-′ 10.44 (br. s, 1H), 9.11 (br. s, 1H), 7.92 (br. d, 7.1 Hz, 1H), 7.71 (br. d, 8.9 Hz, 1H), 7.65 (s, 1H), 7.31 (dd, 8.9, 5.2 Hz, 1H), 7.20 (s, 1H), 7.13 (s, 1H), 7.08 (dt, 5.6, 3.0 Hz, 1H), 6.58 (br. s, 1H), 5.92 (br. s, 1H), 4.20-3.98 (m, 2H), 3.54 (dd, 9.7, 8.3 Hz, 1H), 3.24 (dd, 9.6, 5.0 Hz, 1H), 2.90-2.76 (m, 1H), 2.73 (s, 3H), 2.44 (dd, overlapped with solvent peak, 17.0, 9.2 Hz, 1H), 2.17 (dd, 16.8, 6.4 Hz, 1H)	594.2	A	
I-1349		Cn1nc(Nc2cc(Br)cc3C(=O)NC(c23)c2cc(F)ccc2Cl)c2ccccc12	1H NMR (400 MHz, DMSO-d6) 9.14 (s, 1H), 8.39 (s, 1H), 7.87 (s, 1H), 7.47 (d, 8.5 Hz, 1H), 7.39 (d, 1.7 Hz, 1H), 7.33 (ddd, 8.3, 6.8, 1.1 Hz, 1H), 7.27 (d, 8.1 Hz, 1H), 7.20 (dd, 8.9, 5.1 Hz, 1H), 7.05-6.91 (m, 2H), 6.67 (s, 1H), 6.01 (s, 1H), 3.91 (s, 3H).	485	E	
I-1350		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(NC(=O)c3cc(F)cc(CC4CCC4)c3)c12	1H NMR (400 MHz, DMSO-d6) 10.25 (s, 1H), 9.28 (s, 1H), 7.81-7.74 (m, 2H), 7.36 (dd, 8.9, 5.1 Hz, 1H), 7.22 (dt, 9.7, 1.8 Hz, 1H), 7.13 (ddt, 9.4, 4.7, 2.5 Hz, 3H), 6.71 (s, 1H), 6.01 (s, 1H), 2.69 (d, 7.7 Hz, 2H), 2.02-1.89 (m, 2H), 1.89-1.77 (m, 2H), 1.74-1.61 (m, 2H).	545	D	
I-1351		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(NC(=O)c3cc(F)cc(c3)C3CCC3)c12	1H NMR (400 MHz, DMSO-d6) 10.30 (s, 1H), 9.28 (s, 1H), 7.79 (d, 1.7 Hz, 1H), 7.74 (d, 1.8 Hz, 1H), 7.36 (dd, 8.8, 5.1 Hz, 1H), 7.26 (dd, 9.8, 2.3 Hz, 1H), 7.20-7.09 (m, 3H),	531	D	






			6.73 (s, 1H), 6.00 (s, 1H), 3.53 (p, 8.6 Hz, 1H), 2.30 (qt, 7.7, 2.5 Hz, 2H), 2.15-2.06 (m, 1H), 2.06 (ddd, 8.4, 6.9, 2.3 Hz, 1H), 2.05-1.89 (m, 1H), 1.88-1.73 (m, 1H).			
I-1352		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(NS(=O)(=O)c3cc(F)cc(c3)C(F)(F)F)c12	1H NMR (400 MHz, DMSO-d6) 10.42 (s, 1H), 9.21 (s, 1H), 8.13-8.03 (s, 1H), 7.92-7.61 (m, 3H), 7.52-7.34 (s, 1H), 7.31-7.12 (tt, 8.5, 4.9 Hz, 2H) , 6.39-6.71 (s, 1H), 6.02 (s, 1H).	581.15	E	
I-1353		Fc1ccc(Cl)c(c1)C1NC(=O)c2cccc(C(=O)Nc3cc(F)cc(c3)C(F)(F)F)c12	1H NMR (400 MHz, DMSO-d6) 10.84 (s, 1H), 9.30 (s, 1H), 8.00 - 7.90 (m, 2H), 7.77 (t, 7.6 Hz, 1H), 7.63 (s, 1H), 7.57 (d, 11.3 Hz, 1H), 7.38 (d, 8.7 Hz, 2H), 7.10 (td, 8.4, 3.1 Hz, 1H), 6.39 (s, 1H).	467.05	D	
I-1354		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)N1CCn2cnnc2C1	(400 MHz, DMSO-d6) 10.50 (br s, 1 H), 8.78 (br s, 1 H), 8.51 (d, 13.2 Hz, 1 H), 8.50 (s, 1 H), 7.83 (s, 1 H), 7.75 (d, 9.1 Hz, 1 H), 7.55 (br s, 1 H), 7.36 (dd, 8.8, 5.2 Hz, 1 H), 7.06 (td, 8.4, 3.1 Hz, 1 H), 6.87 (br s, 1 H), 6.51 (br s, 1 H), 5.87 (s, 1 H), 4.57 (s, 2 H), 4.18 (t, 5.2 Hz, 2 H), 3.80 - 3.72 (m, 2 H).	589.3	A	
I-1355		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1cn2cccnc2n1	NMR (400 MHz, DMSO-d6) 10.70 (br. s, 1H), 9.23 (br. s, 1H), 9.00 (dd, 6.8, 1.9 Hz, 1H), 8.61 (s, 1H), 8.57 (dd, 4.1, 2.0 Hz, 1H), 8.27 (s, 1H), 8.21 (s, 1H), 7.96 (br. d, 8.3 Hz, 1H), 7.79 (br. d, 9.1 Hz, 1H), 7.72 (s, 1H), 7.33 (dd, 8.8, 5.1 Hz, 1H), 7.13-7.08 (m,	584.1	A	




			2H), 6.60 (br. s, 1H), 6.07 (br. s, 1H).			
I-1356		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(NC(=O)c3cccnc3)cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	NMR (400 MHz, DMSO) 10.86 (s, 1H), 10.63 (s, 1H), 9.19 (s, 1H), 9.15 (d, 2.1 Hz, 1H), 8.79 (dd, 4.8, 1.6 Hz, 1H), 8.37-8.30 (m, 1H), 8.15 (d, 1.4 Hz, 1H), 8.03 (d, 1.1 Hz, 1H), 7.95 (d, 8.0 Hz, 1H), 7.74 (d, 8.6 Hz, 1H), 7.65 (s, , 1H), 7.61 (dd, 8.5, 4.8 Hz, 1H), 7.32 (dd, 8.8, 5.2 Hz, 1H), 7.10 (td, 8.4, 2.9 Hz 1H), 6.57 (br s, 1H), 5.96 (br s, 1H).	587.3	A	
I-1357		OCC1(COc2cc3C(=O)NC(c3c(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c2)c2cc(F)ccc2Cl)COC1	NMR (400 MHz, DMSO) 10.45 (br s, 1H), 9.15 (br s, 1H), 7.95 (d, 7.8 Hz, 1H), 7.72 (d, 8.8 Hz, 1H), 7.64 (s, 1H), 7.31 (dd, 8.8, 5.2 Hz, 1H), 7.26 (d, 2.0 Hz, 1H), 7.13 (d, 1.6 Hz, 1H), 7.09 (td, 8.5, 3.1 Hz, 1H), 6.59 (br s, 1H), 5.94 (br s, 1H), 5.04 (s, 1H), 4.50-4.38 (m, 4H), 4.30 (d, 9.5 Hz, 1H), 4.25 (d, 9.5 Hz, 1H), 3.74 (s, 2H).	583.3	A	
I-1358		CC1(CCCC(C1)C(F)(F)F)C(=O)Nc1cc(Br)cc2C(=O)NC(c12)c1cc(F)ccc1Cl	1H-NMR (400 MHz, DMSO-d6) as a mixture of diastereomers-′ 9.58 (br. s, 2H), 9.30 (br. s, 2H), 7.74 (br. d, 1.3 Hz, 2H), 7.66 (d, 1.7 Hz, 1H), 7.64 (d, 1.7 Hz, 1H), 7.57-7.48 (m, 2H), 7.27-7.22 (m, 1H), 7.22-7.17 (m, 1H), 6.40 (br. s, 2H), 6.22 (br. s, 1H), 6.15 (br. s, 1H), 2.22-2.13 (m, 2H), 2.10-2.00 (m, 2H), 1.58-1.44 (m, 5H), 1.36-1.29 (m, 1H), 1.10-0.93 (m, 8H), 0.93 (s, 3H), 0.89 (s, 3H).	547.2	B	





I-1359		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)C1CNC(=O)O1	NMR (400 MHz, DMSO) 10.60 (s, 1H), 9.23 (s, 1H), 7.95 (d, 8.4 Hz, 1H), 7.82 (s, 0.5H), 7.81 (s, 0.5H), 7.74 (d, 9.1 Hz, 1H), 7.71 (s, 1H), 7.65 (s, 1H), 7.54 (s, 0.5H), 7.53 (s, 0.5H), 7.32 (dd, 8.8, 5.1 Hz, 1H), 7.14-7.06 (m, 1H), 6.59 (br s, 1H), 6.00 (br s, 1H), 5.81 (dd, 15.3, 7.8 Hz, 1H), 3.99 (td, 8.8, 6.7 Hz, 1H), 3.45-3.37 (m, 1H)	552.1	A	
I-1360		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)C1CNC(=O)C1	(400 MHz, CD3CN) 8.65 (br. s, 1H), 7.88-7.55 (m, 5H), 7.48 (s, 1H), 7.32-7.23 (m, 2H), 7.04-6.92 (m, 1H), 6.61 (br. s, 1H), 6.11 (br. s, 1H), 3.91-3.72 (m, 2H), 3.44-3.33 (m, 1H), 2.66 (dtd, 11.2, 8.6, 2.5 Hz, 1H), 2.46-2.33 (m, 1H).	548.3	A	
I-1361		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)C1COCCO1	NMR (400 MHz, CD3CN) 8.60 (br s, 1H), 7.77 (d, 8.0 Hz, 1H), 7.65 (d, 7.9 Hz, 1H), 7.62-7.46 (m, 3H), 7.24 (dd, 9.7, 4.5 Hz, 2H), 7.09-6.92 (m, 1H), 6.63 (br s, 1H), 6.08 (br s, 1H), 5.75 (d, 7.7 Hz, 1H), 4.09 (t, 15.0 Hz, 1H), 3.95 (dd, 11.0, 4.4 Hz, 2H), 3.79 (d, 11.4 Hz, 1H), 3.69 (dt, 12.1, 4.0 Hz, 1H), 3.27 (dt, 16.6, 11.2 Hz, 1H).	553.3	B	
I-1362		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(NC(=O)C3CC4(CCC4)C3)c12	1H-NMR (400 MHz, DMSO-d6) 9.58 (s, 1H), 9.22 (br. s, 1H), 7.68 (d, 1.5 Hz, 1H), 7.58 (d, 1.6 Hz, 1H), 7.52-7.45 (m, 1H), 7.24 (app. td, 8.4, 3.1 Hz, 1H), 6.64 (br. s, 1H), 6.00 (br. s, 1H), 2.74 (p, 8.5 Hz, 1H), 1.96-1.64 (m, 10H).	477.3	D	





I-1363		OC12CC3CC(C1)CC(C3)(C2)C(=O)Nc1cc(Br)cc2C(=O)NC(c12)c1cc(F)ccc1Cl	1H-NMR (400 MHz, DMSO-d6) 9.24 (br. s, 2H), 7.70 (d, 1.6 Hz, 1H), 7.59 (d, 1.7 Hz, 1H), 7.53-7.45 (m, 1H), 7.24 (app. td, 8.5, 3.1 Hz, 1H), 6.51 (br. s, 1H), 6.01 (br. s, 1H), 4.48 (br. s, 1H), 2.07-2.01 (m, 2H), 1.53-1.29 (m, 12H).	533.3	D	
I-1364		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(CS(=O)(=O)N3CCOCC3)cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	NMR (400 MHz, DMSO-d6) 10.61 (s, 1H), 9.23 (br. s, 1H), 7.96 (br. d, 8.3 Hz, 1H), 7.79 (s, 1H), 7.75 (br. d, 9.2 Hz, 1H), 7.65 (s, 1H), 7.55 (s, 1H), 7.33 (dd, 8.9, 5.2 Hz, 1H), 7.11 (td, 8.5, 2.9 Hz, 1H), 6.44 (br. s, 1H), 5.98 (br. s, 1H), 4.71 (d, 13.7 Hz, 1H), 4.67 (d, 13.6 Hz, 1H), 3.64-3.53 (m, 4H), 3.21-3.09 (m, 4H).	630.2	A	
I-1365		CNS(=O)(=O)Cc1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	NMR (400 MHz, CD3CN) 8.74 (s,1H), 7.75 (d, 1.4 Hz,1H), 7.68-7.53 (m, 1H), 7.62--7.54 (m,3H)7.32-7.23 (m, 2H), 6.98 (ddd, 8.9, 8.0, 3.1 Hz,1H), 6.64 (br, s,1H), 6.25-6.04 (br, s,1H), 5.22 (q, 4.8Hz,1H), 4.45 (s,2H), 2.71 (d, 5.0 Hz,3H).	574	A	
I-1366		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(OCC3CCO3)cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	1H NMR (400 MHz, DMSO-d6) 10.47 (br. s, 1H), 9.14 (br. s, 1H), 7.95 (d, 8.4 Hz, 1H), 7.72 (d, 9.1 Hz, 1H), 7.64 (s, 1H), 7.31 (dd, 8.9, 5.2 Hz, 1H), 7.26 (s, 1H), 7.13 (s, 1H), 7.09 (td, 8.5, 3.0 Hz, 1H), 6.58 (br. s, 1H), 5.93 (br. s, 1H), 5.10 - 5.00 (m, 1H), 4.61-4.41 (m, 2H), 4.27 m, 2H), 2.79 - 2.65 (m, 1H), 2.63-2.53 (m, 1H).	553.1	A	




I-1367		NS(=O)(=O)Cc1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	NMR (400 MHz, DMSO-d6) 10.65 (br. s, 1H), 9.20 (br. s, 1H), 7.94 (br. d, 8.3 Hz, 1H), 7.74 (br. d, 8.9 Hz, 1H), 7.72 (s, 1H), 7.63 (s, 1H), 7.47 (s, 1H), 7.32 (dd, 8.9, 5.2 Hz, 1H), 7.11 (td, 8.6, 3.0 Hz, 1H), 6.97 (s, 2H), 6.60 (br. s, 1H), 6.00 (br. s, 1H), 4.51 (d, 13.7 Hz, 1H), 4.45 (d, 13.6 Hz, 1H).	560.1	A	
I-1368		Nc1nc2ccc(cn2n1)-c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	^{1}H NMR (500 MHz, DMSO) δ 10.79 (s, 1H), 9.21 (s, 1H), 9.03 (dd, J = 2.0, 0.9 Hz, 1H), 8.01 (d, J = 1.7 Hz, 1H), 7.97 – 7.92 (m, 1H), 7.89 (d, J = 1.7 Hz, 1H), 7.86 (dd, J = 9.2, 1.9 Hz, 1H), 7.83 (s, 1H), 7.75 (s, 1H), 7.48 – 7.45 (m, 1H), 7.31 (dd, J = 8.9, 5.1 Hz, 1H), 7.08 (td, J = 8.3, 3.0 Hz, 1H), 6.13 (s, 2H), 6.08 (s, 1H).	599.23	A	
I-1369		Cc1nccc(C#N)c(n1)-c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl			A	
I-1370		Nc1nc2ccc(ccn2n1)-c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	^{1}H NMR (500 MHz, DMSO) δ 10.61 (s, 1H), 9.25 (s, 1H), 8.64 (d, J = 7.0 Hz, 1H), 8.06 (d, J = 1.8 Hz, 1H), 7.98 – 7.91 (m, 2H), 7.79 – 7.66 (m, 4H), 7.37 – 7.27 (m, 2H), 7.10 (td, J = 8.3, 3.2 Hz, 1H), 6.10 (s, 2H).	599.13	A	





I-1371		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1ccn2ncnc2c1			A	
I-1372		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1ccn2ccnc2c1			A	
I-1373		Nc1nnc2ccc(cn12)-c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl			A	
I-1374		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1ccc2nnnn2c1		585.4	A	
I-1375		CS(=O)(=O)N1CCC[C@H]1COc1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c	NMR (400 MHz, DMSO-d6) 10.45 (s, 1H), 9.14 (br. s, 1H), 7.95 (br. d, 8.5 Hz, 1H), 7.72 (br. d, 8.7 Hz, 1H), 7.64 (s, 1H), 7.31 (dd, 8.9, 5.2 Hz, 1H), 7.21 (d, 1.6 Hz, 1H), 7.11-7.05 (m, 2H), 6.57 (br. s, 1H), 5.94 (br. s, 1H), 4.16-4.00	644.2	A	





		1cc(F)ccc1Cl	(m, 3H), 3.32-3.30 (m, 2H), 2.99 (d, 0.8 Hz, 3H), 2.09-1.87 (m, 4H).			
I-1376		OCC(O)Cc1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	NMR (400 MHz, DMSO-d6) 10.48 (br s, 1H), 9.09 (s, 1H), 7.94 (d, 8.3 Hz, 1H), 7.73 (d, 8.9 Hz, 1H), 7.65 (s, 1H), 7.56 (s, 1H), 7.37-7.26 (m, 2H), 7.08 (td, 13.5, 6.7 Hz, 1H), 6.59 (br s, 1H), 5.95 (br s, 1H), 4.73 (d, 4.5 Hz, 1H), 4.67 (br s, 1H), 3.70 (br s, 1H), 3.31-3.25 (m, 2H), 3.01-2.89 (m, 1H), 2.67 (tt, 17.1, 8.5 Hz, 1H).	541.3	A	
I-1377		OCc1cc(Nc2cccc3C(=O)NC(c23)c2cc(F)ccc2Cl)ncc1C(F)(F)F	(400 MHz, CD3CN) 8.92 (s, 1 H), 8.41 (s, 1 H), 7.48 (br s, 1 H), 7.35 (app t, 7.6 Hz, 1 H), 7.31 - 7.26 (m, 1 H), 6.99 (br t, 7.1 Hz, 1 H), 6.92 (d, 7.8 Hz, 1 H), 6.88 (br s, 1 H), 6.75 - 6.48 (br s, 1 H)), 6.69 - 6.61 (m, 1 H), 4.80 (d, 16.2 Hz, 1 H), 4.80 (d, 16.2 Hz, 1 H), 4.18 (s, 1 H), 3.68 (s, 1 H).	452.2	E	
I-1378		CS(=O)(=O)N1CCC[C@@H]1COc1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	NMR (400 MHz, DMSO-d6) 10.45 (s, 1H), 9.14 (br. s, 1H), 7.95 (br. d, 8.5 Hz, 1H), 7.72 (br. d, 8.7 Hz, 1H), 7.64 (s, 1H), 7.31 (dd, 8.9, 5.2 Hz, 1H), 7.21 (d, 1.6 Hz, 1H), 7.13-7.03 (m, 2H), 6.58 (br. s, 1H), 5.93 (br. s, 1H), 4.19-3.98 (m, 3H), 3.32-3.30 (m, 2H), 2.99 (d, 0.8 Hz, 3H), 2.10-1.84 (m, 4H).	644.2	A	





I-1379		Cn1nccc1C(F)c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	NMR (400 MHz, DMSO-d6) as a ca. 1.2:1 mixture of diastereomers-′ 10.59 (br. s, 2H), 9.27 (br. s, 2H), 7.95 (br. d, 8.2 Hz, 2H), 7.77-7.68 (m, 4H), 7.64 (s, 2H), 7.59 (s, 1H), 7.55 (s, 1H), 7.43 (dd, 6.9, 1.8 Hz, 2H), 7.34 (dd, 5.2, 1.8 Hz, 1H), 7.33-7.29 (m, 2H), 7.22 (d, 7.7 Hz, 1H), 7.13-7.07 (m, 3H), 6.69 (br. s, 2H), 6.12-5.93 (m, 4H), 3.90 (s, 3H), 3.89 (s, 3H).	579.3	A	
I-1380		Cn1nccc1C(=O)c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	1H-NMR (400 MHz, DMSO-d6) 10.71 (br. s, 1H), 9.38 (br. s, 1H), 8.03 (s, 1H), 8.00 (s, 1H), 7.97 (br. d, 8.3 Hz, 1H), 7.76 (br. d, 9.1 Hz, 1H), 7.67 (br. s, 1H), 7.66 (d, 2.0 Hz, 1H), 7.35 (dd, 8.9, 5.1 Hz, 1H), 7.12 (td, 8.5, 3.1 Hz, 1H), 6.90 (s, 1H), 6.58 (br. s, 1H), 6.10 (br. s, 1H), 4.14 (s, 3H).	575.3	A	
I-1381		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(NC(=O)c3cc(F)cc4c3NC(=O)C4(F)F)c12	1H NMR (400 MHz, DMSO-d6) 11.11 (s, 1H), 10.49 (s, 1H), 9.30 (s, 1H), 7.99 (s, 1H), 7.79 (d, 21.8 Hz, 2H), 7.23 (d, 87.9 Hz, 4H), 6.0(s, 1H)	570	B	
I-1382		CN(Cc1ccc(O)c1)C(=O)Nc1cc(Br)cc2C(=O)NC(c12)c1cc(F)ccc1Cl	1H NMR (400 MHz, Chloroform-d) 8.16 (s, 1H), 7.77 (d, 1.6 Hz, 1H), 7.36 (dd, 8.9, 4.9 Hz, 1H), 7.19 (t, 7.8 Hz, 1H), 7.02 (ddd, 8.9, 7.4, 3.1 Hz, 1H), 6.78 (ddd, 8.2, 2.6, 0.9 Hz, 1H), 6.65 (dd, 16.5, 7.1 Hz, 3H), 6.57 (s, 1H), 6.04 (s, 1H), 5.93 (d, 6.8 Hz, 2H), 4.41- 4.12 (m, 2H), 2.74 (s, 3H).	520	E	




I-1383		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(NC(=O)N3CC4(CCC4)c4ccccc34)c12	1H NMR (400 MHz, DMSO-d6) 9.21 (s, 1H), 8.64 (s, 1H), 7.69 - 7.62 (m, 3H), 7.46 (dd, 7.6, 1.3 Hz, 1H), 7.37 (dd, 8.9, 5.1 Hz, 1H), 7.14 (ddt, 11.0, 6.2, 3.1 Hz, 2H), 7.00 (td, 7.4, 1.1 Hz, 1H), 5.99 (s, 1H), 3.86 (d, 10.5 Hz, 1H), 3.40 (d, 10.4 Hz, 1H), 2.37 - 2.25 (m, 2H), 2.15 - 2.01 (m, 1H), 2.04 - 1.87 (m, 3H).	540.05	B	
I-1384		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(NC(=O)c3cc(Cl)c(Cl)s3)c12	1H NMR (400 MHz, DMSO-d6) 10.42 (s, 1H), 9.29 (s, 1H), 7.82 (d, 1.7 Hz, 1H), 7.71 (d, 1.7 Hz, 1H), 7.55 (s, 1H), 7.37 (dd, 8.9, 5.1 Hz, 1H), 7.14 (ddd, 8.8, 7.9, 3.1 Hz, 1H), 7.01-5.62 (m, 2H).	534.85	C	
I-1385		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(NC(=O)c3cc(F)cc4CCCNc34)c12	1H NMR (400 MHz, DMSO-d6) 9.95 (s, 1H), 9.28 (s, 1H), 7.97 - 7.67 (m, 2H), 7.39 (t, 7.0 Hz, 1H), 7.30 (s, 1H), 7.16 (td, 8.4, 3.1 Hz, 1H), 6.92 (dd, 8.9, 2.9 Hz, 1H), 6.56 (dd, 10.1, 3.0 Hz, 1H), 6.01 (s, 1H), 3.28 (s, 2H), 2.70 (q, 6.2 Hz, 2H), 1.83 - 1.67 (m, 2H).	534.05	C	
I-1386		FC(F)Sc1ccccc1)C(=O)Nc1cc(Br)cc2C(=O)NC(c12)c1cc(F)ccc1Cl	1H NMR (400 MHz, DMSO-d6) 10.37 (s, 1H), 9.27 (s, 1H), 7.85-7.80 (s, 1H), 7.80-7.72 (m, 2H),7.71-7.69 (s, 1H), 7.67 (s, 1H), 7.54 (s, 1H), 7.49-7.31 (m, 1H), 7.30-7.15 (m, 1H), 7.10 (ddd, 8.8, 7.9, 3.1 Hz, 1H), 6.99-6.23 (s, 1H), 6.16 (s, 1H).	540.95	D	





I-1387		CC(=O)N1CCC11CN(C1)c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	NMR (400 MHz, DMSO-d6), 10.39 (br. s, 1H), 9.01 (br. s, 1H), 7.93 (br. d, 8.5 Hz, 1H), 7.72 (br. d, 8.8 Hz, 1H), 7.64 (s, 1H), 7.29 (dd, 8.9, 5.2 Hz, 1H), 7.06 (td, 8.4, 3.0 Hz, 1H), 6.67 (d, 2.0 Hz, 1H), 6.51 (d, 1.4 Hz, 1H), 6.9-6.4 (br. s, 1H), 5.87 (br. s, 1H), 4.47 (dd, 7.8, 3.4 Hz, 2H), 4.04-4.00 (m, 4H), 2.54 (t, 7.4 Hz, 2H), 1.76 (s, 3H).	603.3	B	
I-1388		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)N1CCC2(CCN2)C1	NMR (400 MHz, DMSO-d6) 10.35 (s, 1H), 8.99 (s, 1H), 7.93 (br. d, 8.4 Hz, 1H), 7.71 (br. d, 8.8 Hz, 1H), 7.63 (s, 1H), 7.28 (dd, 8.9, 5.2 Hz, 1H), 7.06 (td, 8.5, 3.0 Hz, 1H), 6.65 (d, 1.9 Hz, 1H), 6.50 (d, 0.7 Hz), 6.70-6.40 (submerged br. s, 1H), 5.86 (br. s, 1H), 4.08 (dd, 12.3, 8.0 Hz, 2H), 3.83 (t, 8.3 Hz, 2H), 3.32 (t, 6.9 Hz, 2H), 2.48-2.46 (m, 2H)	563.2	B	
I-1389		Cn1nccc1C(O)c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	1H-NMR (400 MHz, DMSO-d6) 10.53 (br. s, 2H), 9.17 (br. s, 2H), 7.94 (br. d, 8.4 Hz, 2H), 7.73 (d, 9.2 Hz, 2H), 7.72 (s, 2H), 7.65 (d, 10.6 Hz, 2H), 7.64 (s, 2H), 7.50 (s, 12.6 Hz, 1H), 7.47 (br. s, 1H), 7.34-7.28 (m, 4H), 7.13-7.05 (m, 2H), 6.40-6.34 (m, 2H), 6.09 (d, 5.1 Hz, 1H), 6.06 (d, 4.6 Hz, 1H), 5.99 (br. s, 1H), 5.97 (br. s, 2H), 5.95 (br. s, 1H), 3.78 (s, 3H), 3.76 (s, 3H).	577.3	A	






I-1390		OC(=O)COc1ncc(cn1)-c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	(400 MHz, CD3CN) 8.86 (s, 3H), 8.00 (s, 1H), 7.77 (s, 1H), 7.70-7.57 (m, 4H), 7.32 (br. s, 1H), 7.26 (dd, 9.0, 5.0 Hz, 1H), 6.98 (td, 8.3, 2.8 Hz, 1H), 6.66 (br. s, 1H), 6.16 (br. s, 1H), 4.92 (s, 2H).	619.2	A	
I-1391		O[C@H](CC#N)c1cc2C(=O)N[C@@H](c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	(400 MHz, DMSO-d6) 10.58 (s, 1H), 9.16 (br s, 1H), 7.94 (d, 7.4 Hz, 1H), 7.81-7.70 (m, 2H), 7.66 (s, 1H), 7.54 (s, 1H), 7.32 (dd, 8.9, 5.2 Hz, 1H), 7.10 (td, 8.5, 3.0 Hz, 1H), 6.52 (br s, 1H), 6.23 (d, 4.0 Hz, 1H), 5.96 (br s, 1H), 5.07 (app q, 4.9 Hz, 1H), 3.03 (dd, 16.8, 4.7 Hz, 1H), 2.95 (dd, 16.8, 6.5 Hz, 1H).	536.2	D	
I-1392		O[C@@H](CC#N)c1cc2C(=O)N[C@@H](c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	(400 MHz, DMSO-d6) 10.60 (s, 1H), 9.15 (s, 1H), 7.93 (d, 7.8 Hz, 1H), 7.79-7.69 (m, 2H), 7.67 (s, 1H), 7.61 (s, 1H), 7.31 (dd, 8.9, 5.2 Hz, 1H), 7.09 (td, 8.5, 2.9 Hz, 1H), 6.55 (br s, 1H), 6.24 (d, 3.5 Hz, 1H), 5.97 (br s, 1H), 5.12 (app q, 3.6 Hz, 1H), 3.01 (dd, 16.8, 4.9 Hz, 1H), 2.94 (dd, 16.7, 6.4 Hz, 1H).	536.2	D	
I-1393		O[C@H](CC#N)c1cc2C(=O)N[C@H](c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	(400 MHz, DMSO-d6) 10.58 (s, 1H), 9.16 (br s, 1H), 7.94 (d, 7.4 Hz, 1H), 7.83-7.70 (m, 2H), 7.66 (s, 1H), 7.54 (s, 1H), 7.32 (dd, 8.9, 5.2 Hz, 1H), 7.10 (td, 8.5, 3.0 Hz, 1H), 6.54 (br s, 1H), 6.23 (d, 4.0 Hz, 1H), 5.96 (br s, 1H), 5.07 (app q, 5.0 Hz, 1H), 3.02 (dd, 16.8, 4.7 Hz, 1H), 2.95 (dd, 16.8, 6.5 Hz, 1H).	536.2	A	





I-1394		O[C@@H](CC#N)c1cc2C(=O)N[C@H](c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	(400 MHz, DMSO-d6) 10.59 (s, 1H), 9.15 (br s, 1H), 7.93 (d, 7.9 Hz, 1H), 7.78-7.69 (m, 2H), 7.67 (s, 1H), 7.61 (s, 1H), 7.31 (dd, 8.9, 5.2 Hz, 1H), 7.09 (td, 8.5, 3.0 Hz, 1H), 6.51 (br s, 1H), 6.23 (d, 3.3 Hz, 1H), 5.97 (br s, 1H), 5.11 (app q, 4.2 Hz, 1H), 3.00 (dd, 16.7, 4.9 Hz, 1H), 2.93 (dd, 16.7, 6.4 Hz, 1H).	536.2	A	
I-1395		C[C@@](O)(CC#N)c1cc2C(=O)N[C@H](c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	(400 MHz, DMSO-d6) 10.69 (br s, 1H), 9.10 (br s, 1H), 7.95-7.83 (m, 1H), 7.81 (br s, 1H), 7.76 - 7.66 (m, 3H), 7.32 (dd, 8.8, 5.2 Hz, 1H), 7.09 (td, 8.4, 3.0 Hz, 1H), 6.52 (br s, 1H), 6.07 (br s, 1H), 5.95 (br s, 1H), 3.08 (s, 2H), 1.60 (s, 3H).	550.3	A	
I-1396		C[C@](O)(CC#N)c1cc2C(=O)N[C@@H](c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	(400 MHz, DMSO-d6) 10.59 (s, 1H), 9.14 (br s, 1H), 7.98-7.87 (m, 1H), 7.81 (s, 1H), 7.78-7.64 (m, 3H), 7.31 (dd, 8.9, 5.2 Hz, 1H), 7.09 (td, 8.6, 2.9 Hz, 1H), 6.53 (br s, 1H), 6.07 (s, 1H), 5.96 (br s, 1H), 3.08 (s, 2H), 1.62 (s, 3H) .	550.3	D	
I-1397		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1cnn(CCC#N)c1	NMR (400 MHz, DMSO-d6) 10.56 (s, 1H), 9.17 (br s, 1H), 8.48 (s, 1H), 8.14 (s, 1H), 7.96 (br d, 8.4 Hz, 1H), 7.91 (s, 1H), 7.76 (br d, 9.1 Hz, 1H), 7.70 (s, 2H), 7.32 (dd, 8.9, 5.2 Hz, 1H), 7.09 (td, 8.5, 2.9 Hz, 1H), 6.65 (br s, 1H), 5.99 (br s, 1H), 4.44 (t, 6.3 Hz, 2H), 3.13 (t, 6.3 Hz, 2H).	586.3	A	





I-1398		CS(=O)(=O)CCn1cc(cn1)-c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	NMR (400 MHz, DMSO-d6) 10.58 (br s, 1H), 9.15 (br s, 1H), 8.48 (s, 1H), 8.12 (s, 1H), 7.96 (br d, 8.4 Hz, 1H), 7.90 (s, 1H), 7.76 (br d, 8.9 Hz, 1H), 7.70 (s, 2H), 7.31 (dd, 8.9, 5.2 Hz, 1H), 7.09 (td, 8.5, 3.0 Hz, 1H), 6.68 (br s, 1H), 5.96 (br s, 1H), 4.60 (t, 6.8 Hz, 2H), 3.76 (t, 6.8 Hz, 2H), 2.90 (s, 3H).	639.2	A	
I-1399		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(CS(=O)(=O)N3CCC3)cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	NMR (400 MHz, DMSOd6) 10.63 (br. s, 1H), 9.22 (br. s, 1H), 7.95 (br. d, 8.3 Hz, 1H), 7.80 (s, 1H), 7.75 (br. d, 8.7 Hz, 1H), 7.66 (s, 1H), 7.56 (s, 1H), 7.32 (dd, 8.8, 5.2 Hz, 1H), 7.10 (td, 8.3, 2.8 Hz, 1H), 6.55 (br. s, 1H), 5.97 (br. s, 1H), 4.81-4.69 (m, 2H), 3.90 (t, 7.7 Hz, 4H), 2.19 (p, 7.8, 2H).	600.3	A	
I-1400		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(CN3CCn4ncnc4C3)cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	(400 MHz, DMSO-D6) 10.58 (br s, 1 H), 9.16 (s, 1 H), 7.94 (d, 9.7 Hz, 1 H), 7.74 (d, 8.9 Hz, 1 H), 7.69 (s, 1 H), 7.65 (s, 1 H), 7.52 (s, 1 H), 7.31 (dd, 8.9, 5.2 Hz, 1 H), 7.08 (td, 8.5, 3.0 Hz, 1 H), 6.64 (br s, 1 H), 5.98 (br s, 1 H), 4.17 (t, 5.3 Hz, 2 H), 3.99 - 3.87 (m, 2 H), 3.75 (s, 2 H), 3.10-3.01 (m, 2 H).	603.4	A	
I-1401		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(CN3CCn4cnnc4C3)cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	(400 MHz, DMSO-D6) 10.61 (br s, 1 H), 9.17 (s, 1 H), 8.45 (s, 1 H), 7.95 - 7.91 (m, 1 H), 7.74 (d, 8.9 Hz, 1 H), 7.69 (s, 1 H), 7.65 (s, 1 H), 7.51 (s, 1 H), 7.31 (dd, 8.9, 5.2 Hz, 1 H), 7.09 (td, 8.5, 3.0 Hz, 1 H), 6.67 (br s, 1 H), 5.99 (br s, 1 H), 4.08(t,	603.4	A	





			5.4 Hz, 2 H), 3.97 - 3.86 (m, 2 H), 3.76 (s, 2 H), 2.98-2.89 (m, 2 H)..			
I-1402		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(CS(=O)(=O)Nc3cccnc3)cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	NMR (400 MHz, DMSO-d6) 10.61 (s, 1H), 10.47 (br. s, 1H), 9.20 (br. s, 1H), 8.37 (d, 2.4 Hz, 1H), 8.24 (dd, 4.6, 1.2 Hz, 1H), 7.95 (br. d, 8.3 Hz, 1H), 7.73 (br. d, 8.7 Hz, 1H), 7.66 (d, 0.8 Hz, 1H), 7.62 (s, 1H), 7.56 (ddd, 8.3, 2.7, 1.4 Hz, 1H), 7.46 (s, 1H), 7.36-7.28 (m, 2H), 7.11 (td, 8.5, 3.0 Hz), 6.48 (br. s, 1H), 5.98 (br. s, 1H), 4.79 (d, 13.9 Hz, 1H), 4.74 (d, 14.1 Hz, 1H).	637.3	A	
I-1403		CC(O)(c1ccncc1)c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	NMR (400 MHz, DMSO-d6) 10.53 (s, 0.5H), 10.51 (s, 0.5H) 9.15 (br. s, 1H), 8.53-8.50 (m, 2H), 7.93 (br. d, 8.5 Hz, 1H), 7.78 (d, 1.3 Hz, 0.5H), 7.74 (d, 1.3 Hz, 0.5H) 7.73 (br. d, 9.0, 1H), 7.64 (d, 6.4 Hz, 1H), 7.56 (s, 0.5H), 7.52 (s, 0.5H), 7.51 (s, 1H), 7.49 (s, 1H), 7.29 (dd, 8.9, 5.2 Hz, 1H), 7.08 (td, 8.6, 3.0 Hz, 1H), 6.54 (br. s, 1H), 6.29 (br. s, 1H), 5.92 (br. s, 1H), 1.94 (s, 1.5H), 1.93 (s, 1.5H).	588.2	A	
I-1404		Cn1cc(cnc1=O)-c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	1H NMR (400 MHz, DMSO-d6) 10.61 (s, 1H), 9.22 (br. s, 1H), 9.03 (d, 5.8 Hz, 1H), 8.84 (d, 3.4 Hz, 1H), 7.98 (s, 1H), 7.96 (submerged br.d, 5.8 Hz, 1H), 7.77 (s, 1H), 7.76 (submerged br. d, 5.5 Hz, 1H), 7.70 (s, 1H), 7.33 (dd, 8.9, 5.2 Hz, 1H), 7.10 (td, 8.6, 3.0 Hz, 1H), 6.63 (br. s,	575.2	A	






			1H), 5.99 (br. s, 1H), 3.54 (s, 3H);			
I-1405		COCCn1nccc1-c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl		606.23	B	
I-1406		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1ccnn1C[C@H]1CCOC1		617.24	A	
I-1407		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1ccnn1C[C@@H]1CCOC1		617.29	A	
I-1408		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1ncccc1C#N		569.27	A	




I-1409		Nc1cnc2ccc(cn12)-c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl		598.28	A	
I-1410		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1ccc2ncc(C#N)n2c1		608.23	A	
I-1411		Nc1cn2cc(ccc2n1)-c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl		598.28	A	
I-1412		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(OCc3cccnc3)cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12		574.27	A	
I-1413		[2H]C1(NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1ccc2ncnn2c1)c1	1H NMR (500 MHz, DMSO-d6) 6.50 (s, 1 H) 7.10 (td, 8.20, 3.13 Hz, 1 H) 7.33 (dd, 8.85, 5.19 Hz, 1 H) 7.70 - 7.72 (m, 1 H) 7.74 - 7.79 (m, 1 H) 7.96 (d, 8.70 Hz, 2 H) 7.98 (s, 1 H) 8.11 -	585.23	A	




		cc(F)ccc1Cl	8.15 (m, 2 H) 8.56 (s, 1 H) 9.46 (d, 0.76 Hz, 1 H) 10.62 (s, 1 H)			
I-1414		OCCC(O)COc1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	1H NMR (400 MHz, DMSO-d6) 10.48 (br s, 1H), 9.15 (br s, 1H), 7.96 (d, 7.5 Hz, 1H), 7.72 (d, 8.9 Hz, 1H), 7.63 (s, 1H), 7.31 (dd, 8.9, 5.2 Hz, 1H), 7.20 (s, 1H), 7.13-7.03 (m, 2H), 6.57 (br s, 1H), 5.93 (br s, 1H), 4.93 (d, 3.8 Hz, 1H), 4.52-4.43 (m, 1H), 4.07-3.89 (m, 3H), 3.63-3.50 (m, 2H), 1.77-1.50 (m, 2H).	571.2	A	
I-1415		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1ccc2ocnc2c1	NMR (400 MHz, DMSO-d6) 10.62 (br s, 1H), 9.24 (s, 1H), 8.84 (s, 1H), 8.19 (d, 1.5 Hz, 1H), 8.00 (d, 1.5 Hz, 1H), 7.97 (d, 8.4 Hz, 1H), 7.92 (d, 8.6 Hz, 1H), 7.90-7.84 (m, 1H), 7.78 (d, 9.1 Hz, 1H), 7.71 (s, 1H), 7.34 (dd, 8.9, 5.2 Hz, 1H), 7.11 (td, 8.4, 3.1 Hz, 1H), 6.86-6.56 (br s), 1H, 6.07 (br s, 1H).	582.2	A	
I-1416		NC(=O)COc1ncc(cn1)-c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	(400 MHz, DMSO-d6) 10.66 (br s, 1H), 9.25 (br s, 1H), 9.05 (s, 2H), 8.06 (s, 1H), 7.97 (d, 8.5 Hz, 1H), 7.86 (s, 1H), 7.76 (d, 9.0 Hz, 1H), 7.69 (s, 1H), 7.55 (s, 1H), 7.33 (dd, 8.9, 5.2 Hz, 1H), 7.25 (s, 1H), 7.11 (td, 8.4, 3.1 Hz, 1H), 6.67 (br s, 1H), 6.04 (br s, 1H), 4.80 (s, 2H) .	618.1	A	
I-1417		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(NC(=O)c3csc(Cl)c3Cl)c12	1H NMR (400 MHz, DMSO-d6) 10.35 (s, 1H), 9.28 (s, 1H), 7.85-7.79 (s, 1H), 7.78 (d, 1.8 Hz, 1H), 7.70 (s, 1H), 7.56-7.39 (s, 1H), 7.30-7.12 (s, 1H), 7.09-6.20 (s, 1H), 6.00 (s, 1H).	534.9	D	





I-1418		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1cnn(c1)-c1ncccn1	NMR (400 MHz, DMSO-d6) 10.57 (br s, 1H), 9.29 (s, 1H), 9.20 (br s, 1H), 8.93 (s, 1H), 8.92 (s, 1H), 8.54 (s, 1H), 8.14 (s, 1H), 7.99 (br d, 7.1 Hz, 1H), 7.96 (s, 1H), 7.78 (br d, 9.6 Hz, 1H), 7.73 (s, 1H), 7.53 (t, 4.8 Hz, 1H), 7.33 (dd, 8.9, 5.2 Hz, 1H), 7.10 (td, 8.5, 3.1 Hz, 1H), 6.65 (br s, 1H), 6.01 (br s, 1H).	611.2	A	A
I-1419		COc1ncc(cc1F)-c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	1H NMR (400 MHz, DMSO-d6) 10.64 (br. s, 1H), 9.25 (s, 1H), 8.45 (d, 1.9 Hz, 1H), 8.22 (dd, 11.8, 1.9 Hz, 1H), 8.01 (s, 1H), 7.97 (d, 8.8 Hz, 1H), 7.84 (s, 1H), 7.76 (d, 9.0 Hz, 1H), 7.70 (s, 1H), 7.33 (dd, 8.9, 5.2 Hz, 1H), 7.11 (td, 8.5, 3.0 Hz, 1H), 6.69 (br. s, 1H), 6.04 (br. s, 1H), 4.01 (s, 3H)	592.2	A	
I-1420		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1cnn(CC#N)c1	NMR (400 MHz, DMSO-d6) 10.64 (br s, 1H), 9.18 (br s, 1H), 8.48 (s, 1H), 8.22 (s, 1H), 7.95 (d, 8.5 Hz, 1H), 7.92 (s, 1H), 7.76 (d, 8.0 Hz, 1H), 7.73 (overlapping d, 12.0 Hz, 1H), 7.32 (dd, 8.9, 5.2 Hz, 1H), 7.09 (td, 8.4, 2.9 Hz, 1H), 6.61 (br s, 1H), 5.98 (br s, 1H), 5.55 (s, 2H).	570.3	A	
I-1421		CC(C)(O)COc1cc(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c2C(NC(=O)c2n1)c1cc(F)ccc1Cl	NMR (400 MHz, DMSOd6) 9.35 (s, 1H), 7.92 (d, 8.3 Hz, 1H), 7.70 (d, 9.0 Hz, 1H), 7.61 (s, H), 7.35 (dd, 8.9, 5.2 Hz, 1H), 7.17-7.00 (td, 1H, 8.3, 3.0 Hz), 7.09 (s, 1H), 6.83 (br s, 1H), 5.95 (s, 1H), 4.73 (br s, 1H), 4.20-4.10 (m, 2H), 1.23 (s, 6H).	556.3	B	





I-1422		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)C(=O)NCCC=C	(400 MHz, DMSO-d6) 10.64 (br s, 1 H), 9.27 (s, 1 H), 8.85 (t, 5.6 Hz, 1 H), 8.21 (s, 1 H), 7.99 (d, 0.7 Hz, 1 H), 7.96 (d, 8.4 Hz, 1 H), 7.76 (d, 8.9 Hz, 1 H), 7.68 (s, 1 H), 7.32 (dd, 8.9, 5.2 Hz, 1 H), 7.09 (td, 8.5, 3.0 Hz, 1 H), 6.53 (br s, 1 H), 6.03 (br s, 1 H), 5.85 (ddt, 17.0, 10.3, 6.7 Hz, 1 H), 5.15-5.07 (m, 1 H), 5.06-5.01 (m, 1 H), 3.37 (app dd, 12.9, 6.8 Hz, 2 H), 2.32 (app q, 6.9 Hz, 2 H).	564.3	A	
I-1423		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(NC(=O)c3ccc(o3)C(F)(F)F)c12	1H NMR (400 MHz, Chloroform-d) 8.58 (s, 1H), 7.94 (d, 1.7 Hz, 1H), 7.57 (s, 1H), 7.50 (dd, 9.0, 4.9 Hz, 1H), 7.27 (dd, 3.6, 0.9 Hz, 1H), 7.07 (ddd, 8.9, 7.4, 3.0 Hz, 1H), 6.95 (dt, 3.7, 1.1 Hz, 1H), 6.70 - 6.65 (m, 2H), 6.23 (s, 1H).	518.95	D	
I-1424		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(NC(=O)c3cc(F)cc4ccc(=O)[nH]c34)c12	1H NMR (400 MHz, DMSO-d6) 11.53 (s, 1H), 10.62 (s, 1H), 9.33 (s, 1H), 7.98 (d, 9.7 Hz, 1H), 7.86 (d, 11.8 Hz, 3H), 7.32 (s, 2H), 7.10 (s, 1H), 6.70 (d, 9.7 Hz, 1H), 6.03 (s, 1H).	544	D	
I-1425		Nc1csnc1C(=O)Nc1cc(Br)cc2C(=O)NC(c12)c1cc(F)ccc1Cl	1H NMR (400 MHz, DMSO-d6) 9.98 (s, 1H), 9.27 (s, 1H), 7.97 (s, 1H), 7.70 (d, 16.1 Hz, 2H), 7.35 (s, 1H), 7.12 (dt, 9.4, 4.8 Hz, 1H), 6.12 (s, 1H), 5.75 (s, 2H).	480.95	E	





I-1426		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(NC(=O)c3nsc(Cl)c3Cl)c12	1H NMR (400 MHz, DMSO-d6) 10.51 (s, 1H), 9.30 (s, 1H), 7.81 (q, 1.8 Hz, 2H), 7.42 - 7.34 (m, 1H), 7.15 (ddd, 8.9, 7.9, 3.1 Hz, 1H), 6.95- 6.20 (s, 1H), 6.05 (s, 1H).	535.9	D	
I-1427		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(NC(=O)c3ccc(s3)C(F)(F)F)c12	1H NMR (400 MHz, DMSO-d6) 10.60 (s, 1H), 9.30 (s, 1H), 7.83 (d, 1.7 Hz, 1H), 7.79 - 7.70 (m, 2H), 7.60 (dt, 4.0, 1.4 Hz, 1H), 7.33 (dd, 8.9, 5.1 Hz, 1H), 7.10 (ddd, 8.9, 7.9, 3.1 Hz, 1H), 6.82 (s, 1H), 5.99 (s, 1H).	534.95	D	
I-1428		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(NC(=O)c3cc(cs3)C(F)(F)F)c12	1H NMR (400 MHz, DMSO-d6) 10.43 (s, 1H), 9.29 (s, 1H), 8.56-8.51 (m, 1H), 7.81 (d, 1.7 Hz, 1H), 7.73 (dd, 2.7, 1.5 Hz, 2H), 7.31 (dd, 8.9, 5.2 Hz, 1H), 7.13-7.03 (m, 1H), 7.00-6.10(s, 1H),5.98 (s, 1H).	534.9	D	
I-1429		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(NC(=O)N3CCc4ccc(=O)[nH]c34)c12	1H NMR (400 MHz, DMSO-d6) 10.66 (s, 2H), 9.27 (s, 1H), 7.89 (s, 1H), 7.76 - 7.63 (m, 1H), 7.47 (d, 8.0 Hz, 1H), 7.29 (dd, 8.9, 5.1 Hz, 1H), 7.04 (td, 8.4, 3.0 Hz, 1H), 6.18 (d, 8.1 Hz, 2H), 3.92 (q, 9.3 Hz, 1H), 3.80 (q, 10.0, 9.3 Hz, 1H), 3.17 (d, 5.2 Hz, 1H), 2.89 (t, 8.6 Hz, 1H).	519	E	
I-1430		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Cn3ccnc3)cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	1H-NMR (400 MHz, DMSO-d6) 10.55 (br. s, 1H), 9.19 (br. s, 1H), 7.94 (br. d, 8.5 Hz, 1H), 7.84 (s, 1H), 7.71 (br. d, 8.7 Hz, 1H), 7.62 (s, 1H), 7.58 (d, 0.6 Hz, 1H), 7.34 (s, 1H), 7.30 (dd, 8.9, 5.2 Hz, 1H), 7.28 (s, 1H), 7.09 (app. td, 8.4, 3.1 Hz, 1H), 6.95 (s, 1H),	547.3	A	





			6.57 (br. s, 1H), 5.95 (br. s, 1H), 5.44-5.33 (m, 2H).			
I-1431		CC(=O)N1CCC[C@H](C1)Oc1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	(400 MHz, DMSO-d6) 10.43 (br s, 1H), 9.14 (s, 1H), 7.95 (d, 8.4 Hz, 1H), 7.71 (d, 8.2 Hz, 1H), 7.64 (s, 1H), 7.31 (dd, 8.8, 5.2 Hz, 1H), 7.25 (ddd, 13.6, 6.3, 2.1 Hz, 1H), 7.13-7.02 (m, 2H), 6.54 (br s, 1H), 5.91 (br s, 1H), 4.79-4.68 (m, 0.5H), 4.54-4.43 (m, 0.5H), 4.00-3.87 (m, 0.5H), 3.83-3.46 (m, 2.5H), 3.24-3.10 (m, 1H), 2.09-1.40 (m, 7H)	608.3	A	
I-1432		Fc1ccc(Cl)c(c1)[C@H]1NC(=O)c2cc(NC(=O)c3cccnc3)cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	(400 MHz, DMSO-d6) 10.46 (br s, 1H), 9.16 (s, 1H), 7.95 (d, 8.4 Hz, 1H), 7.70 (d, 8.9 Hz, 1H), 7.62 (s, 1H), 7.35-7.28 (m, 1H), 7.26-7.19 (m, 1H), 7.12-7.03 (m, 2H), 6.60 (br s, 1H), 5.93 (br s, 1H), 5.34-5.24 (m, 0.5H), 5.22-5.14 (m, 0.5H), 3.85 (dd, 11.9, 4.4 Hz, 0.5H), 3.69-3.51 (m, 3.5H), 2.29-2.06 (m, 2H), 1.98 (s, 1.8H), 1.96 (s, 0.6H), 1.95 (s, 0.6H)	594.2	A	
I-1433		Cc1ccccc1S(=O)(=O)Cc1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	NMR (400 MHz, CD3CN) 8.64 (s,1H), 7.70 (d, 7.8, 0.9 Hz,1H), 7.65 (dt, 8.8 Hz, 1.5Hz,1H), 7.61-7.56 (m, 2H), 7.55 (d, 0.8 Hz, 1H), 7.41 (d., 7.0Hz, 1H), 7.33 (app. t, 7.7 Hz, 1H), 7.26 (dd, 8.9, 5.1 Hz, 1H), 7.25 - 7.22 (submerged m, 1H), 6.57 (br, s, 1H), 6.13 (br, s, 1H), 4.60 (s, 2H), 2.63 (s,3H).	635	A	






I-1434		CN=S(C)(=O)Cc1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	NMR (400 MHz, DMSO-d6) 10.60 (s, 1H), 9.20 (br. s, 1H), 7.95 (br. d, 8.2 Hz, 1H), 7.79 (s, 1H), 7.74 (br. d, 8.7 Hz, 1H), 7.64 (s, 1H), 7.51 (s, 0.5H), 7.50 (s, 0.5H), 7.32 (dd, 8.7, 5.1 Hz, 1H), 7.13-7.06 (m, 1H), 6.73 (br. s, 1H), 5.98 (br. s, 1H), 4.70 (d, 13.5 Hz, 1H), 4.64 (d, 13.6 Hz, 1H), , 2.83 (s, 1.5H), 2.82 (s, 1.5H), 2.69 (s, 1.5H), 2.67 (s, 1.5H).	572.1	A	
I-1435		CS(=O)(Cc1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl)=Nc1ccccc1	NMR (400 MHz, DMSO-d6) 10.63 (br. s, 1H), 9.21 (br. s, 1H), 7.96 (br. d, 8.3 Hz, 1H), 7.81 (s, 0.5H), 7.79 (s, 0.5H), 7.73 (br. d, 8.9 Hz, 1H), 7.64 (s, 1H), 7.56 (s, 0.5H), 7.50 (s, 0.5H), 7.32 (dd, 8.3, 5.2 Hz, 2 x 0.5H), 7.21-7.15 (m, 2H), 7.10 (td, 8.2, 2.3 Hz, 1H), 7.01-6.94 (m, 2H), 6.90-6.85 (m, 1H), 6.61 (br. s, 1H), 5.98 (br. s, 1H), 4.99-4.81 (m, 2H), 3.07 (s, 3H)..	634.2	A	
I-1436		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(CS(=O)(=O)c3ccccc3)cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	NMR (400 MHz, CD3CN) 8.72 (d, 23.5 Hz, 1H), 7.75-7.71 (m, 2H), 7.69 (dt, 2.5, 1.5Hz, 1H) 7.67 - 7.63 (m, 1H) 7.61-7.52 (m, 4H), 7.46 (s, 1H), 7.43-7.39 (s, 1H), 7.34-7.29 (m, 1H), 7.26 (dd, 8.9, 5.1 Hz, 1H), 7.01-6.95 (m, 1H), 6.61 (br, s, 1H), 6.15 (br, s, 1H), 4.69-4.33 (m, 2H).	621	A	





I-1437		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1cn2ccnc2cc1C#N	1H NMR (400 MHz, DMSO-d6) 10.71 (br. s, 1H), 9.33 (br. s, 1H), 8.98 (d, 0.8 Hz, 1H), 8.55 (app.t, 0.8 Hz 1H), 8.19 (s, 1H), 7.98 (d, 8.1 Hz, 1H), 7.95 - 7.92 (submerged m, 1H), 7.93 (d, 1.1 Hz, 1H), 7.81-7.70 (m, 2H), 7.68 (s, 1H), 7.36 (dd, 8.9, 5.2 Hz, 1H), 7.13 (td, 8.1, 2.9 Hz, 1H), 6.68 (br. s, 1H), 6.07 (br. s, 1H)	608.1	A	
I-1438		COc1ccc(nn1)-c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	1H NMR (400 MHz, DMSO-d6) 10.70 (s, 1H), 9.29 (br. s, 1H), 8.40-8.30 (m, 2H), 8.26 (s, 1H), 7.96 (br. d, 8.2 Hz, 1H), 7.76 (br. d, 8.9 Hz, 1H), 7.68 (s, 1H), 7.38 (d, 9.3 Hz, 1H), 7.33 (dd, 9.0, 5.2 Hz, 1H), 7.10 (td, 8.4, 2.7 Hz, 1H), 6.61 (br. s, 1H), 6.06 (br. s, 1H), 4.10 (s, 3H)	575.2	A	
I-1439		CN(C)S(=O)(=O)n1nccc1-c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl		640.24	A	
I-1440		Fc1ccc(Cl)c(c1)[C@H]1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1cn2ncnc2cn1		585.4	D	




I-1441		Fc1ccc(Cl)c(c1)[C@@H]1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1cn2ncnc2cn1		585.4	A	A
I-1442		Fc1ccc(Cl)c(c1)[C@H]1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1ccc2ncc(C#N)n2c1		608.2	B	
I-1443		Fc1ccc(Cl)c(c1)[C@@H]1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1ccc2ncc(C#N)n2c1		608.2	A	
I-1444		Nc1nc2ccc(cn2n1)-c1cc2C(=O)N[C@@H](c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl		599.2	A	




I-1445		Nc1nc2ccc(cn2n1)-c1cc2C(=O)N[C@H](c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl		599.2	A	
I-1446		Nc1nc2ccc(ccn2n1)-c1cc2C(=O)N[C@@H](c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl		599.2	A	
I-1447		Nc1nc2ccc(ccn2n1)-c1cc2C(=O)N[C@H](c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl		599.2	A	
I-1448		Nc1nnc2ccc(cn12)-c1cc2C(=O)N[C@@H](c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl			C	




I-1449		Nc1nnc2ccc(cn12)-c1cc2C(=O)N[C@H](c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	^{1}H NMR (500 MHz, DMSO) δ 10.65 (s, 1H), 9.25 (s, 1H), 8.66 (t, J = 1.4 Hz, 1H), 8.04 (d, J = 1.7 Hz, 1H), 7.96 (dt, J = 8.6, 2.0 Hz, 1H), 7.83 (s, 1H), 7.77 (d, J = 9.1 Hz, 1H), 7.70 (s, 1H), 7.55 (qd, J = 9.7, 1.4 Hz, 2H), 7.33 (dd, J = 8.9, 5.2 Hz, 1H), 7.10 (td, J = 8.4, 3.1 Hz, 1H), 6.53 (s, 2H), 6.04 (s, 1H).	599.19	A	
I-1450		Fc1ccc(Cl)c(c1)[C@@H]1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1ccn2ccnc2c1			A	
I-1451		Fc1ccc(Cl)c(c1)[C@H]1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1ccn2ccnc2c1			B	
I-1452		Fc1ccc(Cl)c(c1)[C@H]1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1ccc2nnnn2c1		585.5	D	





I-1453		Fc1ccc(Cl)c(c1)[C@@H]1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1ccc2nnnn2c1		585.5	A	
I-1454		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1nccn1CC#N		572.22	B	
I-1455		CS(=O)(=O)c1ccc(cn1)-c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl		622.19	A	
I-1456		CS(=O)(=O)c1ccc(nc1)-c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl		622.14	A	
I-1457		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(OC[C@H]3CCCN3)cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	NMR (400 MHz, DMSO-d6) 10.53 (br. s, 1H), 9.15 (br. s, 1H), 7.95 (br. d, 8.3 Hz, 1H), 7.73 (br. d, 9.1 Hz, 1H), 7.65 (s, 1H), 7.31 (dd, 8.9, 5.2 Hz, 1H), 7.22 (br. t, 2.1 Hz, 1H), 7.11-7.06 (m, 2H), 6.57 (br. s, 1H), 5.93	566.3	B	




			(br. s, 1H), 4.17-4.03 (m, 2H), 3.65 (m, 1H), 3.06-2.93 (m, 2H), 2.04-1.91 (m, 1H), 1.91-1.69 (m, 2H), 1.65-1.56 (m, 1H)			
I-1458		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1ccc2ncnn2n1	(400 MHz, DMSO-d6) 10.74 (s, 1H), 9.34 (br s, 1H), 8.76 (s, 1H), 8.61 (d, 9.5 Hz, 1H), 8.47 (d, 9.5 Hz, 1H), 8.42 (s, 1H), 8.33 (s, 1H), 7.98 (d, 8.3 Hz, 1H), 7.80 (d, 8.9 Hz, 1H), 7.72 (s, 1H), 7.35 (dd, 8.8, 5.1 Hz, 1H), 7.12 (td, 8.4, 2.9 Hz, 1H), 6.62 (br s, 1H), 6.10 (br s, 1H) .	583.3	A	
I-1459		CC(N(C)C(=O)Nc1cc(Br)cc2C(=O)NC(c12)c1cc(F)ccc1Cl)c1ccccc1O	1H NMR (400 MHz, DMSO-d6) 9.73 (s, 1H), 9.12 (d, 9.4 Hz, 1H), 8.42 (s, 1H), 7.76-7.67 (m, 1H), 7.58 (td, 9.7, 8.9, 5.1 Hz, 1H), 7.50-7.44 (s, 1H), 7.29-7.18 (m, 2H), 7.19-7.08 (s, 1H), 6.92-6.68 (m, 3H), 6.15-5.71 (s, 1H), 5.20 (q, 7.0 Hz, 1H), 2.45 (s, 2H), 2.25 (s, 1H), 1.40-1.15 (m, 3H).	534	E	
I-1460		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(Nc3nccc4cc[nH]c34)c12	1H NMR (400 MHz, DMSO-d6) 10.78 (s, 1H), 9.09 (s, 1H), 8.42 (s, 1H), 7.78 (d, 1.8 Hz, 1H), 7.67 (d, 5.6 Hz, 1H), 7.55 (d, 1.7 Hz, 1H), 7.39 (t, 2.7 Hz, 1H), 7.18 (dd, 8.8, 5.2 Hz, 1H), 7.08 (d, 5.6 Hz, 1H), 6.95 (td, 8.4, 3.1 Hz, 1H), 6.42-6.36 (m, 1H), 6.28 (d, 9.2 Hz, 1H), 6.02 (s, 1H).	471	E	
I-1461		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(Nc3nccc4ccsc34)c12	1H NMR (400 MHz, DMSO-d6) 9.10 (s, 1H), 8.88 (s, 1H), 8.03 (d, 5.6 Hz, 1H), 7.92 (d, 5.3 Hz, 1H), 7.72 (d, 1.7 Hz, 1H), 7.60 (d, 1.8 Hz, 1H), 7.43 (d, 5.3 Hz, 1H), 7.36	487.95	E	




			(d, 5.5 Hz, 1H), 7.12 (dd, 8.8, 5.1 Hz, 1H), 6.94 (td, 8.3, 3.1 Hz, 1H), 6.25 (s, 1H), 5.85 (s, 1H).			
I-1462		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(NC(=O)N3CC4(CC4)c4ccccc34)c12	1H NMR (400 MHz, DMSO-d6) 9.19 (s, 1H), 8.58 (s, 1H), 7.69 - 7.60 (m, 3H), 7.37 (dd, 8.9, 5.1 Hz, 1H), 7.17 (td, 8.4, 3.0 Hz, 1H), 7.07 (t, 7.8 Hz, 1H), 6.89 - 6.42 (m, 3H), 5.96 (s, 1H), 3.78 (d, 9.9 Hz, 1H), 3.22 (s, 1H), 1.09 - 0.89 (m, 4H).	526	B	
I-1463		OCCC(O)Cc1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	NMR (400 MHz, DMSO-d6) 10.48 (br s, 1H), 9.08 (s, 1H), 7.93 (d, 8.4 Hz, 1H), 7.73 (dd, 8.9 Hz, 1H), 7.65 (s, 1H), 7.55 (s, 1H), 7.32 (s, 1H), 7.33 (dd, 8.9, 5.2 Hz, 1H), 7.13-7.05 (m, 1H), 6.61 (br s, 1H), 5.95 (br s, 1H), 4.62 (d, 4.7 Hz, 1H), 4.38 (br t, 4.3 Hz, 1H), 3.92-3.82 (m, 1H), 3.57-3.49 (m, 2H), 2.92-2.71 (m, 2H), 1.65-1.43 (m, 2H).	555.3	A	
I-1464		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1cnc(nc1)-c1ncco1	NMR (400 MHz, DMSO-d6) 10.74 (br s, 1H), 9.44 (s, 2H), 9.31 (br s, 1H), 8.43 (s, 1H), 8.25 (d, 0.7 Hz, 1H), 8.03 (s, 1H), 7.98 (d, 8.4 Hz, 1H), 7.78 (d, 9.3 Hz, 1H), 7.71 (s, 1H), 7.59 (s, 1H), 7.34 (dd, 8.9, 5.2 Hz, 1H), 7.12 (td, 8.7, 3.0 Hz, 1H), 6.64 (br s), 6.07 (br s).	612.2	A	




I-1465		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1cnn(c1)-c1ccncn1	NMR (400 MHz, DMSO-d6) 10.59 (br s, 1H), 9.37 (s, 1H), 9.21 (br s, 1H), 9.15 (d, 0.8 Hz, 1H), 8.94 (d, 5.6 Hz, 1H), 8.66 (s, 1H), 8.18 (s, 1H), 8.00 (dd, 5.9, 0.9, 1H), 8.00-7.95 (m, 2H), 7.78 (d, 8.8 Hz, 1H), 7.73 (s, 1H), 7.33 (dd, 8.9, 5.2 Hz, 1H), 7.10 (td, 8.5, 3.1 Hz, 1H), 6.81 (br s, 1H), 6.01 (br s, 1H).	611.3	A	
I-1466		CC(=O)N1CCC[C@H]1COc1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	NMR (400 MHz, CD3CN), ´ 8.63 (br. s, 1H), 7.64 (br. d, 8.5 Hz, 1H), 7.58 (br. d, 9.8 Hz, 1H),7.55 (s, 1H), 7.37 (d, 1.9 Hz, 1H), 7.36 (d, 2.1 Hz, 1H), 7.24 (dd, 8.8, 5.2 Hz, 1H), 7.19-7.11 (m, 1H), 6.96 (td, 8.4, 2.8 Hz, 1H), 6.63 (br. s, 1H), 6.05 (br. s, 1H), 4.34-4.30 (m, 1H), 4.29-4.24 (m, 1H), 4.09-4.00 (m, 2H), 3.55-3.31 (m, 2H), 2.12-2.01(m, 4H), 1.98 (s, 3H)	608.3	A	
I-1467		CC(=O)N1CCC[C@@H]1COc1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	NMR (400 MHz, CD3CN) mixture of rotamers, ´ 8.94 (br. s, 1H), 7.63 (br. d, 8.5 Hz, 1H), 7.59-7.56 (m, 2H), 7.36 (d, 1.9 Hz, 1H), 7.35 (d, 2.1 Hz, 1H), 7.24 (dd, 8.8, 5.2 Hz, 1H), 7.19-7.11 (m, 1H), 6.95 (td, 8.4, 2.8 Hz, 1H), 6.63 (br. s, 1H), 6.04 (br. s, 1H), 4.35-4.27 (m, 1H), 4.25 (dd, 9.8, 2.9 Hz, 1H), 4.03 (dd, 9.6, 7.8 Hz, 1H), 3.55-3.31 (m, 2H), 2.14-1.98 (m, 4H), 1.97 (s, 3H)	608.3	A	




I-1468		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(OC[C@@H]3CCCN3)cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	NMR (400 MHz, DMSO-d6) 10.58 (br. s, 1H), 9.16 (br. s, 1H), 8.34 (s, 1H), 7.95 (br. d, 8.3 Hz, 1H), 7.73 (br. d, 9.1 Hz, 1H), 7.65 (s, 1H), 7.31 (dd, 8.9, 5.2 Hz, 1H), 7.22 (br. t, 2.1 Hz, 1H), 7.11-7.06 (m, 2H), 6.54 (submerged br. s, 1H), 5.93 (br. s, 1H), 4.20-4.03 (m, 2H), 3.72-3.66 (m, 1H), 3.07-2.96 (m, 2H), 2.04-1.91 (m, 1H), 1.91-1.72 (m, 2H), 1.65-1.56 (m, 1H)	566.1	B	
I-1469		NS(=O)(=O)CCNC(=O)c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	(400 MHz, DMSO-D6) 10.67 (br s, 1 H), 9.29 (br s, 1 H), 8.99 (t, 5.5 Hz, 1 H), 8.21 (s, 1 H), 7.99 (s, 1 H), 7.96 (br d, 8.6 Hz, 1 H), 7.76 (br d, 8.9 Hz, 1 H), 7.68 (s, 1 H), 7.33 (dd, 8.8, 5.2 Hz, 1 H), 7.10 (td, 8.5, 2.8 Hz, 1 H), 6.98 (s, 2 H), 6.50 (br s, 1 H), 6.03 (br s, 1 H), 3.72 - 3.65 (m, 2 H), 3.28 (t, 7.2 Hz, 2H).	615.2	A	
I-1470		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(CS(=O)(=O)Cc3ccncc3)cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	NMR (400 MHz, DMSO-d6) 10.64 (br s, 1H), 9.24 (br s, 1H), 8.60 (d, 4.6 Hz, 2H), 7.95 (d, 8.3 Hz, 1H), 7.74 (s, 1H), 7.74 (br d, 7.8 Hz, 1H), 7.64 (s, 1H), 7.51 (s, 1H), 7.41 (d, 4.8 Hz, 2H), 7.32 (dd, 8.8, 5.0 Hz, 1H), 7.11 (td, 8.0, 3.6 Hz, 1H), 6.60 (br s, 1H), 5.99 (br s, 1H), 4.79 (s, 2H), 4.64 (s, 2H)	636	A	




I-1471		[O-][n+]1ccc(CS(=O)(=O)Cc2cc3C(=O)NC(c3c(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c2)c2cc(F)ccc2Cl)cc1	NMR (400 MHz, DMSO-d6) 10.62 (br s, 1H), 9.24 (br s, 1H), 8.25 (m, 2H), 7.95 (d, 8.5 Hz, 1H), 7.73 (m, 2H), 7.64 (s, 1H), 7.50 (s, 1H), 7.41 (m, 2H), 7.32 (dd, 8.8, 5.2 Hz, 1H), 7.11 (td, 8.4, 2.9 Hz, 1H), 6.65 (br s, 1H), 6.00 (br s, 1H), 4.81-4.69 (m, 2H), 4.64 (s, 2H).	652	A	
I-1472		CC(c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl)S(C)=O	NMR (400 MHz, DMSO-d6) 10.67 (br. s, 1H), 9.20 (s, 1H), 7.95 (br. d, 8.3 Hz, 1H), 7.74 (br. d, 9.1 Hz, 1H), 7.70-7.63 (m, 2H), 7.44 (s, 0.5H), 7.41 (s, 0.5H), 7.35-7.28 (m, 1H), 7.14-7.06 (m, 1H), 6.6 (br. s, 1H), 5.98 (br, s, 1H), 4.30-4.23 (m, 0.5H), 4.22-4.15 (m, 0.5H), 2.42-2.37 (m, 1.5H), 2.27-2.21 (m, 1.5H), 1.67-1.63 (m, 1.5H), 1.63-1.58 (m, 1.5H)	557	B	
I-1473		CC(c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl)S(C)(=O)=O	NMR (400 MHz, DMSO-d6) 10.64 (s, 1H), 9.28 (s, 1H), 7.95 (d, 8.1 Hz, 1H), 7.80 (d, 2.7 Hz, 1H), 7.74 (d, 9.3 Hz, 1H), 7.64 (s, 1H), 7.55 (s, 1H), 7.32 (dd, 8.8, 5.1 Hz, 1H), 7.10 (m, 1H), 6.59 (br, s, 1H), 6.00 (br, s, 1H), 4.87- 4.78 (m, 1H), 2.91 (s, 3H), 1.71 (d, 7.1 Hz, 3H)	573	A	
I-1474		OCCOc1ncc(cn1)-c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	1H-NMR (400 MHz, DMSO-d6) 10.54 (br. s, 1H), 9.26 (br. s, 1H), 9.04 (s, 2H), 8.05 (d, 0.8 Hz, 1H), 7.96 (br. d, 7.9 Hz, 1H), 7.86 (s, 1H), 7.77 (br. d, 8.8 Hz, 1H), 7.70 (s, 1H), 7.33 (dd, 8.8, 5.2 Hz, 1H), 7.11 (app. td, 8.4,	605.3	A	




			3.0 Hz, 1H), 6.63 (br. s, 1H), 6.04 (br. s, 1H), 4.96 (br. s, 1H), 4.42-4.38 (t, 5.0 Hz, 2H), 3.76 (t, 5.0 Hz, 2H).			
I-1475		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Cc3ccc4C(=O)NCCc4c3)cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	1H-NMR (400 MHz, DMSO-d6) 9.13 (br. s, 1H), 8.36 (br. s, 1H), 7.93 (br. d, 8.4 Hz, 1H), 7.88 (t, 2.5 Hz 1H), 7.79 (d, 7.9 Hz, 1H), 7.72 (br. d, 8.9 Hz, 1H), 7.63 (s, 1H), 7.60 (s, 1H), 7.35 (s, 1H), 7.32-7.27 (m, 2H), 7.25 (s, 1H), 7.08 (app. td, 8.5, 3.1 Hz, 1H), 6.58 (br. s, 1H), 5.92 (br. s, 1H), 4.17 (d, A of AB, JAB = 14.6 Hz, 1H), 4.12 (d, B of AB, JAB = 14.7 Hz, 1H), 3.35 (td, 6.6, 2.7 Hz, 2H), 2.87 (t, 6.5 Hz, 2H).	626.3	A	
I-1476		CS(=O)(=O)CCc1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	NMR (400 MHz, DMSO) 10.53 (br s, 1H), 9.14 (br s, 1H), 7.95 (d, 8.2 Hz, 1H), 7.73 (d, 9.1 Hz, 1H), 7.68 (s, 1H), 7.66 (s, 1H). 7.44 (s, 1H), 7.31 (dt, 9.7, 4.9 Hz, 1H), 7.09 (td, 8.3, 3.0 Hz, 1H), 6.59 (br s, 1H), 5.96 (br s, 1H), 3.54 (t, 7.9 Hz, 2H), 3.22-3.15 (m, 2H), 3.02 (s, 2H).	573.1	A	
I-1477		Fc1ccc(Cl)c(c1)[C@@H]1NC(=O)c2cc(NC(=O)c3cccnc3)cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	NMR (400 MHz, DMSO) 10.86 (s, 1H), 10.63 (s, 1H), 9.19 (s, 1H), 9.15 (d, 2.1 Hz, 1H), 8.79 (dd, 4.8, 1.6 Hz, 1H), 8.37-8.30 (m, 1H), 8.15 (d, 1.4 Hz, 1H), 8.03 (d, 1.1 Hz, 1H), 7.95 (d, 8.0 Hz, 1H), 7.74 (d, 8.6 Hz, 1H), 7.65 (s, , 1H), 7.61 (dd, 8.5, 4.8 Hz, 1H), 7.32 (dd, 8.8, 5.2 Hz, 1H), 7.10 (td, 8.4, 2.9	587.2	A	




			Hz 1H), 6.57 (br s, 1H), 5.96 (br s, 1H).			
I-1478		Fc1ccc(Cl)c(c1)[C@H]1NC(=O)c2cc(NC(=O)c3cccnc3)cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	NMR (400 MHz, DMSO) 10.86 (s, 1H), 10.63 (s, 1H), 9.19 (s, 1H), 9.15 (d, 2.1 Hz, 1H), 8.79 (dd, 4.8, 1.6 Hz, 1H), 8.37-8.30 (m, 1H), 8.15 (d, 1.4 Hz, 1H), 8.03 (d, 1.1 Hz, 1H), 7.95 (d, 8.0 Hz, 1H), 7.74 (d, 8.6 Hz, 1H), 7.65 (s, , 1H), 7.61 (dd, 8.5, 4.8 Hz, 1H), 7.32 (dd, 8.8, 5.2 Hz, 1H), 7.10 (td, 8.4, 2.9 Hz 1H), 6.57 (br s, 1H), 5.96 (br s, 1H).	587.3	B	
I-1479		NS(=O)(=O)Cc1cc2C(=O)N[C@@H](c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	NMR (400 MHz, DMSO-d6) 10.65 (br. s, 1H), 9.20 (br. s, 1H), 7.94 (br. d, 8.3 Hz, 1H), 7.74 (submerged br. d, 8.9 Hz, 1H), 7.72 (s, 1H), 7.63 (s, 1H), 7.47 (s, 1H), 7.32 (dd, 8.9, 5.2 Hz, 1H), 7.11 (td, 8.6, 3.0 Hz, 1H), 6.97 (s, 2H), 6.60 (br. s, 1H), 6.00 (br. s, 1H), 4.48 (app. q, 13.6 Hz, 2H).	560.1	D	
I-1480		NS(=O)(=O)Cc1cc2C(=O)N[C@H](c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	NMR (400 MHz, DMSO-d6) 10.65 (br. s, 1H), 9.20 (br. s, 1H), 7.94 (br. d, 8.3 Hz, 1H), 7.74 (submerged br. d, 8.9 Hz, 1H), 7.72 (s, 1H), 7.63 (s, 1H), 7.47 (s, 1H), 7.32 (dd, 8.9, 5.2 Hz, 1H), 7.11 (td, 8.6, 3.0 Hz, 1H), 6.97 (s, 2H), 6.60 (br. s, 1H), 6.00 (br. s, 1H), 4.48 (app. q, 13.6 Hz, 2H).	560.1	A	





I-1481		NC(=O)Cn1cc(cn1)-c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	NMR (400 MHz, DMSO-d6) 10.56 (br s, 1H), 9.15 (br s, 1H), 8.33 (s, 1H), 8.05 (s, 1H), 7.95 (br d, 8.6 Hz, 1H), 7.89 (s, 1H), 7.76 (br d, 9.5 Hz, 1H), 7.70 (s, 1H), 7.66-7.51 (m, 10H), 7.32 (dd, 8.8, 5.2 Hz, 2H), 7.09 (td, 8.7, 3.0 Hz, 1H), 6.61 (br s, 1H), 5.98 (br s, 1H), 4.80 (s, 2H).	590.2	A	
I-1482		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1cnc(nc1)-n1ccnc1	NMR (400 MHz, DMSO-d6) 10.76 (br s, 1H), 9.32 (s, 2H), 9.29 (submerged br s, 1H), 8.67 (s, 1H), 8.19 (s, 1H), 8.03 (s, 1H), 7.97 (s, 1H), 7.96 (submerged br d, 8.1 Hz, 1H), 7.77 (br d, 8.1 Hz, 1H), 7.71 (s, 1H), 7.34 (dd, 8.9, 5.2 Hz, 1H), 7.20 (s, 1H), 7.11 (td, 8.5, 3.0 Hz, 1H), 6.68 (br s, 1H), 6.04 (br s, 1H).	611.2	A	
I-1483		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1cnc(nc1)-n1cccn1	NMR (400 MHz, DMSO-d6) 10.73 (br s, 1H), 9.32 (s, 2H), 9.29 (submerged br s, 1H), 8.74 (d, 2.4 Hz, 1H), 8.20 (s, 1H), 7.98 (s, 1H), 7.97 (submerged br d, 7.7 Hz, 1H), 7.92 (d, 0.9 Hz, 1H), 7.78 (br d, 9.0 Hz, 1H), 7.71 (s, 1H), 7.34 (dd, 8.9, 5.2 Hz, 1H), 7.11 (td, 8.6, 3.1 Hz, 1H), 6.75 (submerged br s, 1H), 6.65 (dd, 2.6, 1.6 Hz, 1H), 6.07 (br s, 1H).	611.2	A	






I-1484		Fc1ccc(Cl)c(c1)[C@H]1NC(=O)c2cc(CS(=O)(=O)N3CCOCC3)cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	NMR (400 MHz, DMSO-d6) 10.61 (s, 1H), 9.23 (br. s, 1H), 7.96 (br. d, 8.3 Hz, 1H), 7.79 (s, 1H), 7.75 (br. d, 9.2 Hz, 1H), 7.65 (s, 1H), 7.55 (s, 1H), 7.33 (dd, 8.9, 5.2 Hz, 1H), 7.11 (td, 8.5, 2.9 Hz, 1H), 6.44 (br. s, 1H), 5.98 (br. s, 1H), 4.69 (s, 2H), 3.64-3.53 (m, 4H), 3.21-3.09 (m, 4H).	630.2	D	
I-1485		Fc1ccc(Cl)c(c1)[C@@H]1NC(=O)c2cc(CS(=O)(=O)N3CCOCC3)cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	NMR (400 MHz, DMSO-d6) 10.61 (s, 1H), 9.23 (br. s, 1H), 7.96 (br. d, 8.3 Hz, 1H), 7.79 (s, 1H), 7.75 (br. d, 9.2 Hz, 1H), 7.65 (s, 1H), 7.55 (s, 1H), 7.33 (dd, 8.9, 5.2 Hz, 1H), 7.11 (td, 8.5, 2.9 Hz, 1H), 6.44 (br. s, 1H), 5.98 (br. s, 1H), 4.69 (s, 2H), 3.64-3.53 (m, 4H), 3.21-3.09 (m, 4H).	630.2	A	
I-1486		CS(=O)(Cc1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl)=Nc1ccccnc1	NMR (400 MHz, DMSO-d6) 10.61 (br. s, 1H), 9.21 (br. s, 1H), 8.20 (d, 1.6 Hz, 0.5H), 8.19 (d, 1.7 Hz, 0.5H), 8.07 (app br. t, 4.0 Hz, 1H), 7.96 (br. d, 8.3 Hz, 1H), 7.81 (s, 0.5H), 7.79 (s, 0.5H), 7.73 (br. d, 8.4 Hz, 1H), 7.63 (s, 1H), 7.57 (s, 0.5H), 7.53 (s, 0.5H), 7.36-7.31 (submerged m, 1H), 7.32 (dd, 8.9, 5.2 Hz, 1H), 7.21-7.14 (m, 1H), 7.10 (td, 8.5, 2.7 Hz, 1H), 6.66 (br. s, 1H), 5.97 (br. s, 1H), 5.05-4.90 (m, 2H), 3.16 (s, 3H).	635.3	A	





I-1487		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(CS(=O)c3ccccc(c3)C#N)cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	NMR (400 MHz, CD3CN) ′ 8.63 (br. s 0.5H), 8.58 (br. s, 0.5H), 7.84 (dt, 3.3, 1.5 Hz, 0.5H), 7.82 (dt, 3.2, 1.6 Hz, 0.5H), 7.80 (br. t, 1.2 Hz, 0.5H), 7.77 (br. t, 1.2 Hz, 0.5H), 7.69-7.61 (m, 3H), 7.61-7.55 (m, 1H), 7.54 (s, 0.5H), 7.53 (s, 0.5H), 7.34 (d, 0.8 Hz, 0.5 H), 7.30-7.20 (m, 3.5H), 6.98 (dt, 8.8, 2.8 Hz, 0.5H), 6.97 (dt, 8.8, 2.8 Hz, 0.5H), 6.61 (br, s, 1H), 6.08 (br, s, 1H), 4.40 (d, 12.8 Hz, 0.5H), 4.37 (d, 12.8 Hz, 0.5H), 4.17 (d, 12.7 Hz, 0.5H), 4.14 (d, 12.9 Hz, 0.5H).	630	A	
I-1488		CN(C)S(=O)(=O)Cc1cc2C(=O)N[C@@H](c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	NMR (400 MHz, DMSO-d6) 10.60 (br. s, 1H), 9.21 (br. s, 1H), 7.95 (dt, 8.5, 2.0 Hz, 1H), 7.77 (s, 1H), 7.75 (br. d, 8.4 Hz, 1H) 7.66 (s, 1H), 7.55 (s, 1H), 7.32 (dd, 8.9, 5.2 Hz, 1H), 7.10 (td, 8.5, 3.1 Hz, 1H), 6.58 (br. s, 1H), 5.97 (br. s, 1H), 4.70-4.58 (m, 2H), 2.76 (s, 6H).	588.2	D	
I-1489		CN(C)S(=O)(=O)Cc1cc2C(=O)N[C@H](c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	NMR (400 MHz, DMSO-d6) 10.60 (br. s, 1H), 9.21 (br. s, 1H), 7.95 (dt, 8.5, 2.0 Hz, 1H), 7.77 (s, 1H), 7.75 (submerged br. d, 8.4 Hz, 1H) 7.66 (s, 1H), 7.55 (s, 1H), 7.32 (dd, 8.9, 5.2 Hz, 1H), 7.10 (td, 8.5, 3.1 Hz, 1H), 6.58 (br. s, 1H), 5.97 (br. s, 1H), 4.70-4.58 (m, 2H), 2.76 (s, 6H).		A	





I-1490		CSC(C)c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	NMR (400 MHz, DMSO-d6) ′ 10.51 (br. s, 0.5 H), 10.5 (br. s, 0.5 H), 9.11 (br. s, 1H), 7.90 (br. d, 8.7 Hz, 1H), 7.70 (br. d, 9.2 Hz, 1H), 7.62-7.60 (m, 2H), 7.44 (br. s, 0.5H), 7.42 (br. s, 0.5 H), 7.27 (dd, 8.9, 5.1 Hz, 1H), 7.05 (td, 8.6, 3.1 Hz, 1H), 6.59 (br. s, 1H), 5.90 (br. s, 1H), 4.12 (q, 6.9 Hz, 0.5H), 4.12 (q, 6.9 Hz, 0.5H), 1.88 (s, 1.5H), 1.87 (s, 1.5H), 1.54 (d, 6.9 Hz, 1.5H), 1.53 (d, 6.9 Hz, 1.5H).	541	A	
I-1491		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(CS(=O)(=O)c3ccccc3)C#N)cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	NMR (400 MHz, CD3CN) 8.62 (s, 1H), 8.13 (t, 1.1Hz, 1H), 8.03 (dt, 7.9, 1.2 Hz, 1H), 7.94 (dt, 8.0, 1.3Hz, 1H), 7.70 (t, 7.9 Hz, 1H), 7.66 (br, d, 8.5 Hz, 1H), 7.58 (td, 9.1 Hz, 1.7Hz, 1H), 7.54 (s, 1H), 7.50 (s, 1H), 7.42 (s, 1H), 7.27 (dd, 8.9, 5.1 Hz, 1H), 7.27 (NH, 1H), 6.98 (td, 8.1, 3.0 Hz, 1H), 6.62 (br, s, 1H), 6.12 (br, s, 1H), 4.66 (s, 2H).	646	A	
I-1492		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1cnc(OC2CC2)nc1	1H NMR (400 MHz, DMSO-d6) 10.66 (br. s, 1H), 9.26 (br. s, 1H), 9.06 (s, 2H), 8.06 (d, 1.3 Hz, 1H), 7.97 (d, 8.5 Hz, 1H), 7.85 (s, 1H), 7.76 (d, 8.8 Hz, 1H), 7.69 (s, 1H), 7.33 (dd, 8.9, 5.2 Hz, 1H), 7.11 (td, 8.4, 3.0 Hz, 1H), 6.59 (br. s, 1H), 6.02 (br. s, 1H), 4.38 (tt, 6.2, 3.2 Hz, 1H), 0.86-0.80 (m, 2H), 0.80 - 0.74 (m, 2H).	601.2	A	





I-1493		OCC(O)CCNC(=O)c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	(400 MHz, DMSO-D6) 10.65 (br s, 1 H), 9.27 (br s, 1 H), 8.79 (t, 5.3 Hz, 1 H), 8.21 (s, 1 H), 7.99 (s, 1 H), 7.96 (d, 8.5 Hz, 1 H), 7.76 (d, 8.8 Hz, 1 H), 7.68 (s, 1 H), 7.32 (dd, 8.9, 5.2 Hz, 1 H), 7.09 (td, 8.5, 2.9 Hz, 1 H), 6.52 (br s, 1 H), 6.03 (br s, 1 H), 4.64 - 4.50 (m, 2 H), 3.57-3.49 (m, 1 H), 3.47-3.23 (m, 4 H), 1.84-1.72 (m, 1 H), 1.54 - 1.43 (m, 1 H).	598.2	A	
I-1494		C\S(Cc1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl)=N/C#N	NMR (400 MHz, DMSOO-d6) 10.64 (br. s, 1H), 9.26 (br. s, 1H), 7.95 (br. d, 8.4 Hz, 1H), 7.77 (s, 0.5H), 7.76 (s, 0.5H), 7.73 (br. d, 9.0 Hz, 1H), 7.63 (s, 1H), 7.55 (s, 0.5H), 7.53 (s, 0.5H), 7.33 (dd, 5.3, 2.6 Hz, 0.5H), 7.31 (dd, 5.2, 2.6 Hz, 0.5H), 7.15-7.06 (m, 1H), 6.59 (br. s, 1H), 6.01 (br. s, 1H), 4.71 (d, 12.9 Hz, 0.5H), 4.67 (d, 13.0 Hz, 0.5H), 4.50 (d, 11.9 Hz, 0.5H), 4.47 (d, 12.2 Hz, 0.5H), 2.90 (s, 1.5H), 2.89 (s, 1.5H).	567.2	A	
I-1495		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(CS(=O)(=O)c3ccncc3)cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	NMR (400 MHz, DMSO-d6) 10.59 (s, 1H), 9.19 (br. s, 1H), 8.89 (dd, 4.5, 1.6 Hz, 2H), 7.95 (br. d, 8.5 Hz, 1H), 7.76 (dd, 5.8, 1.9 Hz, 2H), 7.73 (br. d, 9.1 Hz, 1H), 7.63 (s, 1H), 7.52 (br. s, 1H), 7.44 (s, 1H), 7.33 (dd, 8.9, 5.2 Hz, 1H), 7.11 (td, 8.5, 2.9 Hz, 1H), 6.53 (br. s, 1H), 5.95 (br. s, 1H), 5.08 (s, 2H).	622.1	A	




I-1496		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Cc3ccc4C(=O)NCc4c3)cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	1H-NMR (400 MHz, DMSO-d6) 10.48 (br. s, 1H), 9.13 (br. s, 1H), 8.50 (s, 1H), 7.93 (br. d, 8.5 Hz, 1H), 7.71 (br. d, 8.8 Hz, 1H), 7.65-7.61 (m, 3H), 7.52 (s, 1H), 7.44 (d, 7.9 Hz, 1H), 7.36 (s, 1H), 7.30 (dd, 8.9, 5.2 Hz, 1H), 7.08 (app. td, 8.4, 3.0 Hz, 1H), 6.57 (br. s, 1H), 5.93 (br. s, 1H), 4.35 (s, 2H), 4.26 (d, A of AB, JAB = 14.5 Hz, 1H), 4.22 (d, JAB = 14.7 Hz, 1H).	612.3	A	
I-1497		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Cn3ccnn3)cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	1H-NMR (400 MHz, DMSO-d6) 10.52 (br. s, 1H), 9.17 (br. s, 1H), 7.97-7.93 (m, 1H), 7.93 (d, 2.0 Hz, 1H), 7.71 (br. d, 8.8 Hz, 1H), 7.62 (s, 1H), 7.52 (d, 1.6 Hz, 1H), 7.50 (s, 1H), 7.32-7.28 (m, 2H), 7.09 (app. td, 8.3, 2.9 Hz, 1H), 6.56 (br. s, 1H), 6.32 (t, 2.0 Hz, 1H), 5.94 (br. s, 1H), 5.57-5.48 (m, 2H).	547.3	A	
I-1498		CS(=O)(=O)n1ccc(cn1)-c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl		610.99	A	
I-1499		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1ccc2ccnn2c1		583.126	A	




I-1500		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1ccc2cncn2c1		583.12	A	
I-1501		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1ccn2cnnc2c1		584.17	A	
I-1502		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(N\C(Nc3ccc(F)cc3C(F)(F)F)=N\C#N)c12		584.3	D	
I-1503		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1ccn2cncc2c1		583.12	A	
I-1504		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1cnn2ccnc2c1		584.17	A	



I-1505		CNC(=O)n1cc(cn1)-c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)ccc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl		590.13	A	
I-1506		CNC(=O)c1ncc(cn1)-c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)ccc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	NMR (400 MHz, DMSO-d6) 10.59 (br s, 1H), 9.39 (s, 2H), 9.31 (br s, 1H), 9.01 (q, 4.6 Hz, 1H), 8.24 (d, 1.1 Hz, 1H), 8.02 (s, 1H), 7.98 (d, 8.5 Hz, 1H), 7.78 (d, 8.3 Hz, 1H), 7.71 (s, 1H), 7.34 (dd, 8.9, 5.2 Hz, 1H), 7.12 (td, 8.5, 2.9 Hz, 1H), 6.65 (br s, 1H), 6.07 (br s, 1H), 2.85 (d, 4.8 Hz, 2H).	602.2	B	
I-1507		CC(C)(CNC(=O)Nc1cc(Br)cc2C(=O)NC(c12)c1cc(F)ccc1Cl)C1(O)CCC1	1H NMR (400 MHz, DMSO-d6) 9.16 (s, 1H), 8.13 (s, 1H), 7.83 (s, 1H), 7.52 (d, 1.7 Hz, 1H), 7.50 - 7.43 (m, 1H), 7.21 (td, 8.4, 3.1 Hz, 1H), 6.70 (s, 1H), 6.20 (t, 6.1 Hz, 1H), 5.99 (s, 1H), 4.86 (s, 1H), 3.03 (d, 8.7 Hz, 1H), 2.82 (dd, 13.5, 5.2 Hz, 1H), 2.16 - 2.06 (m, 3H), 1.82 - 1.71 (m, 2H), 1.44 - 1.34 (m, 1H), 0.69 (d, 10.8 Hz, 6H).	526.25	E	
I-1508		CC1(O)CN(C(=O)Nc2cc(Br)cc3C(=O)NC(c23)c2cc(F)ccc2Cl)c2ccccc12	1H NMR (400 MHz, DMSO-d6) 9.20 (s, 1H), 8.68 (s, 1H), 7.82 (d, 8.1 Hz, 1H), 7.68 (d, 1.8 Hz, 1H), 7.59 (d, 1.8 Hz, 1H), 7.37 (dd, 8.8, 5.1 Hz, 1H), 7.31 (d, 7.4 Hz, 1H), 7.27 - 7.12 (m, 2H), 7.00 (t, 7.4 Hz, 1H), 6.68 (s, 1H), 5.97 (s, 1H), 5.53 (s, 1H), 3.78	532	D	




			(d, 10.7 Hz, 1H), 2.96 (s, 1H), 1.39 (s, 3H).			
I-1509		Fc1ccc2N(CC3(CC3)c2c1)C(=O)Nc1cc(Br)cc2C(=O)N[C@H](c12)c1cc(F)ccc1Cl	1H NMR (400 MHz, DMSO-d6) 9.19 (s, 1H), 8.61 (s, 1H), 7.66 (s, 2H), 7.59 (d, 1.8 Hz, 1H), 7.37 (dd, 8.9, 5.0 Hz, 1H), 7.18 (t, 7.7 Hz, 1H), 6.89 (t, 8.9 Hz, 1H), 6.67 (dd, 8.8, 2.7 Hz, 1H), 5.94 (s, 1H), 3.81 (d, 10.0 Hz, 1H), 3.18 (s, 1H), 1.09 (s, 2H), 0.97 (t, 9.6 Hz, 2H).	544	A	
I-1510		Fc1ccc2N(CC3(CC3)c2c1)C(=O)Nc1cc(Br)cc2C(=O)N[C@@H](c12)c1cc(F)ccc1Cl	1H NMR (400 MHz, DMSO-d6) 9.19 (s, 1H), 8.61 (s, 1H), 7.65 (d, 10.6 Hz, 2H), 7.59 (d, 1.8 Hz, 1H), 7.37 (dd, 9.0, 5.1 Hz, 1H), 7.18 (td, 8.3, 3.0 Hz, 1H), 6.88 (td, 9.1, 2.6 Hz, 1H), 6.67 (dd, 8.7, 2.7 Hz, 1H), 5.93 (s, 1H), 3.81 (d, 10.0 Hz, 1H), 3.18 (s, 1H), 1.09 (d, 3.0 Hz, 2H), 1.02 - 0.90 (m, 2H).	544	D	
I-1511		C[C@@]1(O)CN(C(=O)Nc2cc(Br)cc3C(=O)NC(c23)c2cc(F)ccc2Cl)c2cccc12	1H NMR (400 MHz, DMSO-d6) 9.20 (s, 1H), 8.68 (s, 1H), 7.82 (d, 8.1 Hz, 1H), 7.68 (d, 1.8 Hz, 1H), 7.59 (d, 1.8 Hz, 1H), 7.37 (dd, 8.8, 5.1 Hz, 1H), 7.31 (d, 7.4 Hz, 1H), 7.27 - 7.12 (m, 2H), 7.00 (t, 7.4 Hz, 1H), 6.68 (s, 1H), 5.97 (s, 1H), 5.53 (s, 1H), 3.78 (d, 10.7 Hz, 1H), 2.96 (s, 1H), 1.39 (s, 3H).	514	A	
I-1512		Fc1ccc2N(CC3(CC3)c2c1)C(=O)Nc1cc(Br)cc2C(=O)NC(c12)c1cc(F)ccc1Cl	1H NMR (400 MHz, DMSO-d6) 9.20 (s, 1H), 8.61 (s, 1H), 7.63 (dd, 29.2, 1.7 Hz, 3H), 7.38 (dd, 8.8, 5.1 Hz, 1H), 7.18 (td, 8.4, 3.1 Hz, 1H), 7.06 - 6.24 (m, 3H), 5.94 (s, 1H), 3.81 (d, 10.0 Hz, 1H), 3.19 (s, 1H), 1.15 -	543.95	B	





			1.04 (m, 2H), 1.03 - 0.91 (m, 2H).			
I-1513		O[C@H]1CN(C(=O)Nc2cc(Br)cc3C(=O)N[C@@H](c23)c2cc(F)ccc2Cl)c2ccccc12	1H NMR (400 MHz, DMSO-d6) 9.20 (s, 1H), 8.72 (s, 1H), 7.82 (d, 8.2 Hz, 1H), 7.71 - 7.66 (m, 1H), 7.60 (d, 1.8 Hz, 1H), 7.40 - 7.30 (m, 2H), 7.24 (t, 7.8 Hz, 1H), 7.16 (td, 8.4, 3.1 Hz, 1H), 6.99 (t, 7.4 Hz, 1H), 6.67 (s, 1H), 5.98 (s, 1H), 5.66 (d, 6.0 Hz, 1H), 5.12 - 5.03 (m, 1H), 3.62 (dd, 11.2, 3.5 Hz, 1H), 3.23 (s, 1H).	518	B	
I-1514		O[C@@H]1CN(C(=O)Nc2cc(Br)cc3C(=O)N[C@H](c23)c2cc(F)ccc2Cl)c2ccccc12	1H NMR (400 MHz, DMSO-d6) 9.20 (s, 1H), 8.72 (s, 1H), 7.82 (d, 8.2 Hz, 1H), 7.71 - 7.66 (m, 1H), 7.60 (d, 1.8 Hz, 1H), 7.40 - 7.30 (m, 2H), 7.24 (t, 7.8 Hz, 1H), 7.16 (td, 8.4, 3.1 Hz, 1H), 6.99 (t, 7.4 Hz, 1H), 6.67 (s, 1H), 5.98 (s, 1H), 5.66 (d, 6.0 Hz, 1H), 5.12 - 5.03 (m, 1H), 3.62 (dd, 11.2, 3.5 Hz, 1H), 3.23 (s, 1H).	518	A	B
I-1515		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(NC(=O)c3cccc4c(Cl)n[nH]c34)c12	1H NMR (400 MHz, DMSO-d6) 13.44 (s, 1H), 10.49 (s, 1H), 9.29 (s, 1H), 7.90 (d, 8.1 Hz, 1H), 7.81 (q, 1.8 Hz, 2H), 7.59 (d, 7.3 Hz, 1H), 7.31-7.21 (m, 2H), 7.08-6.99 (m, 1H), 6.08 (s, 1H).	522.95	D	
I-1516		Fc1ccc(Cl)c(c1)C1NC(=O)c2cccc(c12)-n1cnc2cccc2c1=O	1H NMR (400 MHz, DMSO-d6) 9.30 (s, 1H), 8.60-8.05 (s, 1H), 8.02-7.31 (m, 7H), 7.32-6.80(m, 2H), 6.80-5.39 (m, 2H).	406.05	E	





I-1517		Fc1ccc(Cl)c(c1)[C@@H]1NC(=O)c2cc(OC[C@@H]3CCO3)cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	1H NMR (400 MHz, DMSO-d6) 10.47 (br. s, 1H), 9.14 (br. s, 1H), 7.95 (d, 8.4 Hz, 1H), 7.72 (d, 9.1 Hz, 1H), 7.64 (s, 1H), 7.31 (dd, 8.9, 5.2 Hz, 1H), 7.26 (s, 1H), 7.13 (s, 1H), 7.09 (dt, 8.5, 3.0 Hz, 1H), 6.58 (br. s, 1H), 5.93 (br. s, 1H), 5.10 - 5.00 (m, 1H), 4.61-4.41 (m, 2H), 4.27 m, 2H), 2.79 - 2.65 (m, 1H), 2.63-2.53 (m, 1H).	553.1	A	
I-1518		Fc1ccc(Cl)c(c1)[C@@H]1NC(=O)c2cc(OC[C@H]3CCO3)cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	1H NMR (400 MHz, DMSO-d6) 10.47 (br. s, 1H), 9.14 (br. s, 1H), 7.95 (d, 8.4 Hz, 1H), 7.72 (d, 9.1 Hz, 1H), 7.64 (s, 1H), 7.31 (dd, 8.9, 5.2 Hz, 1H), 7.26 (s, 1H), 7.13 (s, 1H), 7.09 (dt, 8.5, 3.0 Hz, 1H), 6.58 (br. s, 1H), 5.93 (br. s, 1H), 5.10 - 5.00 (m, 1H), 4.61-4.41 (m, 2H), 4.27 m, 2H), 2.79 - 2.65 (m, 1H), 2.63-2.53 (m, 1H).	553.1	A	
I-1519		Fc1ccc(Cl)c(c1)[C@H]1NC(=O)c2cc(OC[C@@H]3CCO3)cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	1H NMR (400 MHz, DMSO-d6) 10.47 (br. s, 1H), 9.14 (br. s, 1H), 7.95 (d, 8.4 Hz, 1H), 7.72 (d, 9.1 Hz, 1H), 7.64 (s, 1H), 7.31 (dd, 8.9, 5.2 Hz, 1H), 7.26 (s, 1H), 7.13 (s, 1H), 7.09 (dt, 8.5, 3.0 Hz, 1H), 6.58 (br. s, 1H), 5.93 (br. s, 1H), 5.10 - 5.00 (m, 1H), 4.61-4.41 (m, 2H), 4.27 m, 2H), 2.79 - 2.65 (m, 1H), 2.63-2.53 (m, 1H).	553.1	E	





I-1520		Fc1ccc(Cl)c(c1)[C@H]1NC(=O)c2cc(OC[C@H]3CCO3)cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	1H NMR (400 MHz, DMSO-d6) 10.47 (br. s, 1H), 9.14 (br. s, 1H), 7.95 (d, 8.4 Hz, 1H), 7.72 (d, 9.1 Hz, 1H), 7.64 (s, 1H), 7.31 (dd, 8.9, 5.2 Hz, 1H), 7.26 (s, 1H), 7.13 (s, 1H), 7.09 (dt, 8.5, 3.0 Hz, 1H), 6.58 (br. s, 1H), 5.93 (br. s, 1H), 5.10 - 5.00 (m, 1H), 4.61-4.41 (m, 2H), 4.27 m, 2H), 2.79 - 2.65 (m, 1H), 2.63-2.53 (m, 1H).	553.1	E	
I-1521		CN1C[C@H](COc2cc3C(=O)N[C@@H](c3c(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c2)c2cc(F)ccc2Cl)CC1=O	1H NMR (400 MHz, DMSO-d6) 10.44 (br. s, 1H), 9.11 (br. s, 1H), 7.92 (br. d, 7.1 Hz, 1H), 7.71 (br. d, 8.9 Hz, 1H), 7.65 (s, 1H), 7.31 (dd, 8.9, 5.2 Hz, 1H), 7.20 (s, 1H), 7.13 (s, 1H), 7.08 (dt, 5.6, 3.0 Hz, 1H), 6.58 (br. s, 1H), 5.92 (br. s, 1H), 4.20-3.98 (m, 2H), 3.54 (dd, 9.7, 8.3 Hz, 1H), 3.24 (dd, 9.6, 5.0 Hz, 1H), 2.90-2.76 (m, 1H), 2.73 (s, 3H), 2.44 (dd, 17.0, 9.2 Hz, 1H), 2.17 (dd, 16.8, 6.4 Hz, 1H)	594.2	A	
I-1522		CN1C[C@H](COc2cc3C(=O)N[C@H](c3c(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c2)c2cc(F)ccc2Cl)CC1=O	1H NMR (400 MHz, DMSO-d6) 10.44 (br. s, 1H), 9.11 (br. s, 1H), 7.92 (br. d, 7.1 Hz, 1H), 7.71 (br. d, 8.9 Hz, 1H), 7.65 (s, 1H), 7.31 (dd, 8.9, 5.2 Hz, 1H), 7.20 (s, 1H), 7.13 (s, 1H), 7.08 (dt, 5.6, 3.0 Hz, 1H), 6.58 (br. s, 1H), 5.92 (br. s, 1H), 4.20-3.98 (m, 2H), 3.54 (dd, 9.7, 8.3 Hz, 1H), 3.24 (dd, 9.6, 5.0 Hz, 1H), 2.90-2.76 (m, 1H), 2.73 (s, 3H), 2.44 (dd, overlapped with solvent peak, 17.0, 9.2 Hz, 1H), 2.17 (dd, 16.8, 6.4 Hz, 1H); DMSO satellites at 2.67 and 2.33 ;	594.2	A	




			signal at 7.13 (s, 1H) is partially overlapped with signal at 7.08 (dt, 5.6, 3.0 Hz, 1H).			
I-1523		CN1C[C@@H](COc2cc3C(=O)N[C@@H](c3c(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c2)c2cc(F)ccc2Cl)CC1=O	1H NMR (400 MHz, DMSO-d6) 10.44 (br. s, 1H), 9.11 (br. s, 1H), 7.92 (br. d, 7.1 Hz, 1H), 7.71 (br. d, 8.9 Hz, 1H), 7.65 (s, 1H), 7.31 (dd, 8.9, 5.2 Hz, 1H), 7.20 (s, 1H), 7.13 (s, 1H), 7.08 (dt, 5.6, 3.0 Hz, 1H), 6.58 (br. s, 1H), 5.92 (br. s, 1H), 4.20-3.98 (m, 2H), 3.54 (dd, 9.7, 8.3 Hz, 1H), 3.24 (dd, 9.6, 5.0 Hz, 1H), 2.90-2.76 (m, 1H), 2.73 (s, 3H), 2.44 (dd, overlapped with solvent peak, 17.0, 9.2 Hz, 1H), 2.17 (dd, 16.8, 6.4 Hz, 1H); DMSO satellites at 2.67 and 2.33 ; signal at 7.13 (s, 1H) is partially overlapped with signal at 7.08 (dt, 5.6, 3.0 Hz, 1H).	594.2	D	
I-1524		CN1C[C@@H](COc2cc3C(=O)N[C@H](c3c(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c2)c2cc(F)ccc2Cl)CC1=O	1H NMR (400 MHz, DMSO-d6) 10.44 (br. s, 1H), 9.11 (br. s, 1H), 7.92 (br. d, 7.1 Hz, 1H), 7.71 (br. d, 8.9 Hz, 1H), 7.65 (s, 1H), 7.31 (dd, 8.9, 5.2 Hz, 1H), 7.20 (s, 1H), 7.13 (s, 1H), 7.08 (dt, 5.6, 3.0 Hz, 1H), 6.58 (br. s, 1H), 5.92 (br. s, 1H), 4.20-3.98 (m, 2H), 3.54 (dd, 9.7, 8.3 Hz, 1H), 3.24 (dd, 9.6, 5.0 Hz, 1H), 2.90-2.76 (m, 1H), 2.73 (s, 3H), 2.44 (dd, 17.0, 9.2 Hz, 1H), 2.17 (dd, 16.8, 6.4 Hz, 1H)	594.2	E	





I-1525		CC(=O)N1CCC[C@@H](C1)Oc1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	(400 MHz, DMSO-D6) 10.44 (s, 1 H), 9.14 (s, 1 H), 7.95 (d, 8.3 Hz, 1 H), 7.71 (d, 8.4 Hz, 1 H), 7.64 (s, 1 H), 7.31 (dd, 8.8, 5.2 Hz, 1 H), 7.26 (ddd, 13.7, 6.3, 2.1 Hz, 1 H), 7.14-7.02 (m, 2 H), 6.60 (br s, 1 H), 5.92 (br s, 1 H), 4.78-4.68 (m, 0.5 H), 4.54-4.43 (m, 0.5 H), 3.93 (ddd, 15.8, 12.7, 2.6 Hz, 0.5 H), 3.84-3.35 (m, 2.5 H), 3.25-3.09 (m, 1 H), 2.10 - 1.85 (m, 4.5 H), 1.84 - 1.40 (m, 2.5 H).	608.3	B	
I-1526		CS(=O)(=O)N1CCC[C@@H](C1)Oc1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	(400 MHz, DMSO-D6) 10.47 (s, 0.5 H), 10.45 (s, 0.5 H), 9.15 (s, 1 H), 7.95 (br d, 8.5 Hz, 1 H), 7.71 (br d, 8.9 Hz, 1 H), 7.63 (s, 1 H), 7.31 (ddd, 8.8, 5.2, 0.7 Hz, 1 H), 7.27 (dd, 4.6, 2.1 Hz, 1 H), 7.13-7.04 (m, 2 H), 6.56 (br s, 1 H), 5.92 (br s, 1 H), 4.78-4.62 (m, 1 H), 3.54-3.44 (m, 1 H), 3.32 - 3.10 (m, 3 H), 2.93 (s, 1.5 H), 2.92 (s, 1.5 H), 2.02 - 1.96 (m, 1 H), 1.92-1.80 (m, 1 H), 1.78 - 1.68 (m, 1 H), 1.67 - 1.59 (m, 1 H).	644.2	B	
I-1527		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(O[C@H]3CCCNC3)cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	(400 MHz, DMSO-D6+D2O) 7.92 (d, 8.5 Hz, 1 H), 7.66 (d, 9.1 Hz, 1 H), 7.57 (s, 1 H), 7.35 (app dd, 3.3, 2.3 Hz, 1 H), 7.30 (dd, 8.7, 5.2 Hz, 1 H), 7.17 (dd, 7.0, 1.5 Hz, 1 H), 7.07 (td, 8.3, 2.8 Hz, 1 H), 6.62 (br s, 1 H), 5.90 (br s, 1 H), 4.87 (s, 1 H), 3.37 - 3.27 (m, 2 H), 3.18-3.09 (m, 1 H), 3.09-2.98 (m, 1 H), 1.98 - 1.82 (m, 3 H), 1.76-1.61 (m, 1 H).	566.3	B	





I-1528		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Cc3ccc4nncn4c3)cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	1H-NMR (400 MHz, DMSO-d6) 10.48 (br. s, 1H), 9.24 (s, 1H), 9.14 (br. s, 1H), 8.55 (s, 1H), 7.93 (br. d, 8.6 Hz, 1H), 7.74 (d, 9.5 Hz, 1H), 7.70 (br. d, 8.7 Hz, 1H), 7.68 (s, 1H), 7.65-7.59 (m, 1H), 7.39 (s, 1H), 7.31 (d, 9.6 Hz, 1H), 7.30 (dd, 8.9, 5.3 Hz, 1H), 7.08 (app. td, 8.3, 2.9 Hz, 1H), 6.58 (br. s, 1H), 5.94 (br. s, 1H), 4.17 (d, A of AB, JAB = 16.1 Hz, 1H), 4.12 (d, B of AB, JAB = 15.6 Hz, 1H).	598.3	A	
I-1529		CC(C)(O)COc1ncc(cn1)-c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	1H-NMR (400 MHz, DMSO-d6) 10.50 (br. s, 1H), 9.26 (br. s, 1H), 9.04 (s, 2H), 8.06 (d, 1.4 Hz, 1H), 7.97 (br. d, 8.4 Hz, 1H), 7.86 (s, 1H), 7.77 (br. d, 8.8 Hz, 1H), 7.70 (s, 1H), 7.33 (dd, 8.9, 5.2 Hz, 1H), 7.11 (app. td, 8.5, 3.1 Hz, 1H), 6.61 (br. s, 1H), 6.04 (br. s, 1H), 4.74 (br. s, 1H), 4.15 (s, 2H), 1.23 (s, 6H).	633.3	A	
I-1530		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1cnc(OCC#N)nc1	(400 MHz, DMSO-d6) 10.75 (br s, 1H), 9.26 (br s, 1H), 9.17 (s, 1H), 9.16 (s, 1H), 8.10 (s, 1H), 7.96 (d, 7.5 Hz, 1H), 7.91 (s, 1H), 7.77 (d, 8.7 Hz, 1H), 7.71 (s, 1H), 7.37-7.29 (m, 1H), 7.11 (t, 8.2 Hz, 1H), 6.68 (br s, 1H), 6.04 (br s, 1H), 5.35 (s, 2H)	598.3	A	
I-1531		Nc1nc2cc(ccc2o1)-c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c	(400 MHz, CD3CN) 8.73 (s, 1H), 7.99 (d, 1.4 Hz, 1H), 7.80 (s, 1H), 7.69-7.59 (m, 4H), 7.40 (s, 2H), 7.30 (br. s, 1H), 7.27 (dd, 8.9, 5.1 Hz, 1H), 6.98 (ddd, 8.7, 8.1, 3.1 Hz, 1H), 6.68	599.2	A	





		1cc(F)ccc1Cl	(br. s, 1H), 6.18 (br. s, 1H), 5.85 (br. s, 2H).			
I-1532		CN(C)C(=O)OCc1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	NMR (400 MHz, DMSO) 10.54 (br s, 1H), 9.19 (br s, 1H), 7.95 (d, 8.6 Hz, 1H), 7.73 (d, 8.9 Hz, 1H), 7.67 (s, 1H), 7.64 (s, 1H), 7.47 (s, 1H), 7.31 (dd, 8.7, 5.2 Hz, 1H), 7.09 (td, 8.5, 2.7 Hz, 1H), 6.61 (br s, 1H), 5.97 (br s, 1H), 5.23 (s, 2H), 2.92 (s, 3H), 2.86 (s, 3H).	568.1	A	
I-1533		CNS(=O)(=O)Cc1cc2C(=O)N[C@@H](c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	NMR (400 MHz, CD3CN) 8.74 (s,1H), 7.75 (d, 1.4 Hz,1H), 7.68-7.53 (m, 1H), 7.62--7.54 (m,3H)7.32-7.23 (m, 2H), 6.98 (ddd, 8.9, 8.0, 3.1 Hz,1H), 6.64 (br, s,1H), 6.25-6.04 (br, s,1H), 5.22 (q, 4.8Hz,1H), 4.45 (s,2H), 2.71 (d, 5.0 Hz,3H).	574	B	
I-1534		CNS(=O)(=O)Cc1cc2C(=O)N[C@H](c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl		574	A	
I-1535		Cn1cc(NS(=O)(=O)Cc2cc3C(=O)NC(c3c(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c2)c2cc(F)ccc2Cl)cn1	NMR (400 MHz, CD3CN) 8.78 (s, 1H), 7.71 (s, 1H), 7.65 (d, 8.4 Hz, 1H), 7.61 (s, 1H), 7.58 (d, 9.0 Hz, 1H), 7.55 (s, 1H)7.52 (s, 1H), 7.34 (s, 1H), 7.30 (br, s, 1H), 7.27 (dd, 8.9, 5.1 Hz, 1H), 6.98 (td, 8.4, 3.0 Hz, 1H), 6.67 (br, s, 1H), 6.11 (br, s, 1H), 4.49 (d, 14.1 Hz, 1H), 4.45 (d, 14.1 Hz, 1H), 3.82 (s, 3H).	640	A	





I-1536		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(CS(=O)(=O)c3ccccnc3)cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	NMR (400 MHz, CD3CN) 8.84 (s, 1H), 8.83 (s, 1H), 8.65 (s, 1H), 8.03 (d, 7.9 Hz, 1H), 7.65 (d, 8.2 Hz, 1H), 7.58 (d, 9.1 Hz, 1H), 7.55-7.50 (m, 2H), 7.48 (s, 2H), 7.27 (dd, 8.8, 5.1 Hz, 1H), 7.27 (NH, s, 1H), 6.98 (td, 8.4, 3.0 Hz, 1H), 6.68 (br, s, 1H), 6.11 (br, s, 1H), 4.68 (s, 2H).	622	A	
I-1537		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1cnccc1C#N			A	
I-1538		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1ccc2nccnn2c1C#N			A	
I-1539		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1cn2ncnc2cc1C#N			A	




I-1540		CC(C)(O)c1cnc2ccc(cc2c1)-c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl		652.6	A	
I-1541		CC(=O)N1CC[C@@H](C1)Oc1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	(400 MHz, DMSO-D6) 9.17 (s, 1 H), 7.94 (br d, 8.4 Hz, 1 H), 7.72 (br d, 9.0 Hz, 1 H), 7.64 (s, 1 H), 7.31 (dd, 8.8, 5.2 Hz, 1 H), 7.24 (app t, 2.0 Hz, 0.5 H), 7.22 (d, 2.1 Hz, 0.25 H), 7.21 (d, 2.1 Hz, 0.25 H), 7.12 - 7.04 (m, 2 H), 6.54 (br s, 1 H), 5.94 (br s, 1 H), 5.27 (s, 0.5 H), 5.18 (s, 0.5 H), 3.85 (dd, 11.8, 4.4 Hz, 0.5 H), 3.69-3.62 (m, 1 H), 3.62-3.51 (m, 2 H), 3.33 (td, 10.4, 2.3 Hz, 0.5 H), 2.34 - 2.18 (m, 1 H), 2.17-2.01 (m, 1 H), 1.98 (s, 1.5 H), 1.96 (s, 0.75 H), 1.94 (s, 0.75 H).	594.3	B	
I-1542		OCC(O)c1ncc(cn1)-c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	NMR (400 MHz, DMS-d6) 10.75 (br s, 1H), 9.27 (br s, 1H), 9.24 (s, 2H), 8.14 (s, 1H), 7.97 (d, 8.8 Hz, 1H), 7.94 (s, 1H), 7.77 (d, 8.4 Hz), 7.70 (s, 1H), 7.34 (dd, 8.9, 5.1 Hz, 1H), 7.11 (td, 8.6, 3.0 Hz, 1H), 6.63 (br s, 1H), 6.04 (br s, 1H), 5.36 (d, 6.2 Hz, 1H), 4.75-4.69 (m, 2H), 3.91-3.67 (m, 2H).	605.2	A	





I-1543		CS(=O)(=O)Oc1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	(400 MHz, DMSO-D6) 10.68 (br s, 1 H), 9.36 (br s, 1 H), 7.96 (br d, 8.4 Hz, 1 H), 7.73 (br d, 9.0 Hz, 1 H), 7.66 (d, 1.8 Hz, 1 H), 7.64 (s, 1 H), 7.52 (s, 1 H), 7.33 (dd, 8.9, 5.2 Hz, 1 H), 7.11 (td, 8.5, 3.0 Hz, 1 H), 6.71 (br s, 1 H), 6.02 (br s, 1 H), 3.50 (s, 3 H).	559.2	A	
I-1544		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1cnc2ocnc2c1	NMR (400 MHz, DMSO-d6) 10.65 (br s, 1H), 9.26 (br s, 1H), 9.00 (s, 1H), 8.84 (d, 2.2 Hz, 1H), 8.72 (d, 2.1 Hz, 1H), 8.09 (d, 1.3 Hz, 1H), 7.97 (d, 8.4 Hz, 1H), 7.93 (s, 1H), 7.77 (d, 9.0 Hz, 1H), 7.71 (s, 1H), 7.34 (dd, 8.9, 5.2 Hz, 1H), 7.11 (td, 8.6, 3.0 Hz, 1H), 6.66 (br s, 1H), 6.06 (br s, 1H).	583.2	A	
I-1545		Fc1ccc(Cl)c(c1)C1NC(=O)c2cccc(NC(=O)c3cc(F)cc4CCC(=O)Nc34)c12	1H NMR (400 MHz, DMSO-d6) 10.35 (s, 1H), 10.16 (s, 1H), 9.15 (s, 1H), 7.72 (d, 7.4 Hz, 1H), 7.65 (t, 7.6 Hz, 1H), 7.51 (d, 7.7 Hz, 1H), 7.40-7.32 (m, 2H), 7.13 (td, 8.4, 3.1 Hz, 1H), 6.97-6.89 (m, 1H), 6.53 (s, 1H), 6.01 (s, 1H), 2.96 (q, 9.6, 8.6 Hz, 2H), 2.52 (s, 2H).	468.1	E	
I-1546		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(NC(=O)c3cc(F)cc4CCC(=O)Nc34)c12	1H NMR (400 MHz, DMSO-d6) 10.41 (s, 1H), 10.08 (s, 1H), 9.30 (s, 1H), 7.83 (s, 1H), 7.78 (d, 1.7 Hz, 1H), 7.37 (dt, 8.5, 4.3 Hz, 2H), 7.15 (td, 8.4, 3.1 Hz, 1H), 6.84 (d, 9.4 Hz, 1H), 6.68 (s, 1H), 5.99 (s, 1H), 2.96 (q, 8.5, 8.0 Hz, 2H), 2.52 (s, 2H).	546	E	




I-1547		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc4c3NC(=O)C4(F)F)c12)-c1ccc2nnnn2c1	1H NMR (400 MHz, DMSO-d6)11.30-10.90(s,1H),10.56 (s, 1H), 9.48 (d, 1.7 Hz, 1H), 9.27 (s, 1H), 8.59 (s, 1H), 8.17-8.10 (m, 2H), 8.00 (d, 9.6 Hz, 3H), 7.38 (d, 9.1 Hz, 2H), 7.14 (s, 1H),6.20-5.90 (s, 1H).	607.05	A	
I-1548		CNC(=O)c1cc2C(=O)NC(c2c(NC(=O)c2ccccc2)c1)c1cc(F)ccc1Cl	1H NMR (400 MHz, DMSO-d6)10.27 (s, 1H), 9.22 (s, 1H), 8.76 (d, 4.8 Hz, 1H), 8.16 (d, 1.5 Hz, 1H), 8.02 (d, 1.6 Hz, 1H), 7.62-7.51 (m, 3H), 7.44 (t, 7.6 Hz, 2H), 7.35 (dd, 8.9, 5.1 Hz, 1H), 7.12 (td, 8.3, 3.0 Hz, 1H), 6.70 (s, 1H), 6.10 (s, 1H), 2.83 (d, 4.4 Hz, 3H).	438.1	E	
I-1549		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)C3CCCCC3)c12)-c1ccc2nnnn2c1	1H NMR (400 MHz, DMSO-d6) 9.70 (s, 1H), 9.43 (dd, 1.9, 0.9 Hz, 1H), 9.19 (s, 1H), 8.57 (s, 1H), 8.09 (dd, 9.3, 1.9 Hz, 1H), 8.02 - 7.94 (m, 2H), 7.81 (d, 1.7 Hz, 1H), 7.51 (s, 1H), 7.25 (td, 8.4, 3.1 Hz, 1H), 6.13 (s, 1H), 2.06 (s, 1H), 1.62 (d, 16.2 Hz, 3H), 1.48 (s, 1H), 1.33 (s, 1H), 1.17 (d, 10.8 Hz, 1H), 1.13 (s, 4H).	504.2	D	
I-1550		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3ccccc3)c12)-c1ccc2nnnn2c1	1H NMR (400 MHz, DMSO-d6) 10.28 (s, 1H), 9.47 (d, 1.7 Hz, 1H), 9.23 (s, 1H), 8.58 (s, 1H), 8.14 (dd, 9.3, 2.0 Hz, 1H), 8.09 (d, 1.7 Hz, 1H), 8.02-7.95 (m, 2H), 7.66-7.59 (m, 2H), 7.56 (t, 7.3 Hz, 1H), 7.45 (t, 7.6 Hz, 2H), 7.37 (dd, 8.9, 5.2 Hz, 1H), 7.14 (td, 8.3, 3.1 Hz, 1H), 6.15 (s, 1H).	498	D	





I-1551		[2H]C([2H])(c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl)S(C)(=O)=O	NMR (400 MHz, CD3CN) 8.72 (br, s, 1H), 7.78 (d, 1.4 Hz, 1H), 7.65 (br, d, 8.5 Hz, 1H), 7.63 (s, 1H), 7.60 (br, d, 9.1 Hz, 1H), 7.56 (s, 1H), 7.30 (br, s, 1H), 7.26 (dd, 8.9, 5.1 Hz, 1H), 6.98 (ddd, 8.8, 8.1, 3.1 Hz,1H), 6.66 (br, s, 1H), 6.14 (br, s, 1H), 2.89 (s, 3H).	561	A	
I-1552		Oc1ccc(nc1NC=O)-c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	(400 MHz, DMSO-D6) 10.59 (br s, 1 H), 9.92 (br s, 1 H), 9.40 (s, 1 H), 9.18 (s, 1 H), 8.21 (s, 1 H), 8.15 (s, 1 H), 7.95 (d, 8.4 Hz, 1 H), 7.79 - 7.73 (m, 2 H), 7.68 (s, 1 H), 7.35-7.30 (m, 1 H), 7.29 (d, 10.0 Hz, 1 H), 7.09 (td, 8.4, 3.0 Hz, 1 H), 6.67 (br s, 1 H), 6.00 (br s, 1 H).	601.2	A	
I-1553		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1ccc2ocnc2n1	(400 MHz, DMSO-D6) 9.26 (br s, 1 H), 9.12 (s, 1 H), 8.70 (br s, 1 H), 8.41 (d, 8.5 Hz, 1 H), 8.40 (s, 1 H), 8.36 (d, 1.2 Hz, 1 H), 8.29 (d, 8.6 Hz, 1 H), 7.96 (d, 8.4 Hz, 1 H), 7.80 (d, 9.1 Hz, 1 H), 7.74 (s, 1 H), 7.34 (dd, 8.9, 5.2 Hz, 1 H), 7.11 (td, 8.5, 3.0 Hz, 1 H), 6.69 (br s, 1 H), 6.07 (br s, 1 H).	585.2	A	
I-1554	 **Isomer 1**	Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1cnn(c1)-c1ncccn1	NMR (400 MHz, DMSO-d6) 10.57 (br s, 1H), 9.29 (s, 1H), 9.20 (br s, 1H), 8.93 (d, 4.8 Hz, 2H), 8.54 (s, 1H), 8.14 (s, 1H), 7.97 (br d, 7.1 Hz, 1H), 7.96 (s, 1H), 7.78 (br d, 9.6 Hz, 1H), 7.73 (s, 1H), 7.53 (t, 4.8 Hz, 1H), 7.33 (dd, 8.9, 5.2 Hz, 1H), 7.10 (td, 8.5, 3.1 Hz, 1H), 6.65 (br s, 1H), 6.01 (br s, 1H).	611	D	





I-1555	 Isomer 2	Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1cnn(c1)-c1ncccn1	NMR (400 MHz, DMSO-d6) 10.57 (br s, 1H), 9.29 (s, 1H), 9.20 (br s, 1H), 8.93 (d, 4.8 Hz, 2H), 8.54 (s, 1H), 8.14 (s, 1H), 7.97 (br d, 7.1 Hz, 1H), 7.96 (s, 1H), 7.78 (br d, 9.6 Hz, 1H), 7.73 (s, 1H), 7.53 (t, 4.8 Hz, 1H), 7.33 (dd, 8.9, 5.2 Hz, 1H), 7.10 (td, 8.5, 3.1 Hz, 1H), 6.65 (br s, 1H), 6.01 (br s, 1H).	611	A	
I-1556		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(CS(=O)(=O)N3CC(C3)C#N)cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	NMR (400 MHz, DMSO-d6) 10.60 (s, 1H), 9.22 (br. s, 1H), 7.95 (br. d, 8.5 Hz, 1H), 7.79 (s, 1H), 7.74 (br. d, 8.8 Hz, 1H), 7.65 (s, 1H), 7.55 (s, 1H), 7.32 (dd, 8.9, 5.2 Hz, 1H), 7.10 (td, 8.4, 3.0 Hz, 1H), 6.66 (br. s, 1H), 5.97 (br. s, 1H), 4.85 (s, 2H), 4.22-4.11 (m, 3H), 4.10-4.04 (m, 1H), 3.87-3.78 (m, 1H).	625.2	A	
I-1557		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Cn3ccnc3C#N)cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	1H-NMR (400 MHz, DMSO-d6) 10.57 (br. s, 1H), 9.24 (br. s, 1H), 7.95 (br. d, 8.5 Hz, 1H), 7.85 (d, 1.0 Hz, 1H), 7.71 (br. d, 8.9 Hz, 1H), 7.62-7.59 (m, 2H), 7.37-7.33 (m, 1H), 7.31 (dd, 8.9, 5.2 Hz, 1H), 7.31 (d, 1.0 Hz, 1H), 7.09 (td, 8.4, 3.1 Hz, 1H), 6.58 (br. s, 1H), 5.97 (br. s, 1H), 5.66-5.58 (m, 2H).	572.1	A	
I-1558		Fc1ccc(Cl)c(c1)[C@H]1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)[C@H]1CNC(=O)O1	NMR (400 MHz, DMSO) 10.60 (s, 1H), 9.23 (s, 1H), 7.95 (d, 8.4 Hz, 1H), 7.82 (s, 0.5H), 7.81 (s, 0.5H), 7.74 (d, 9.1 Hz, 1H), 7.71 (s, 1H), 7.65 (s, 1H), 7.54 (s, 0.5H), 7.53 (s, 0.5H), 7.32 (dd, 8.8, 5.1 Hz, 1H), 7.14-7.06 (m, 1H), 6.59	552.1	B	




			(br s, 1H), 6.00 (br s, 1H), 5.81 (dd, 15.3, 7.8 Hz, 1H), 3.99 (td, 8.8, 6.7 Hz, 1H), 3.45-3.37 (m, 1H).			
I-1559		Fc1ccc(Cl)c(c1)[C@@H]1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)[C@H]1CNC(=O)O1	NMR (400 MHz, DMSO) 10.60 (s, 1H), 9.23 (s, 1H), 7.95 (d, 8.4 Hz, 1H), 7.82 (s, 0.5H), 7.81 (s, 0.5H), 7.74 (d, 9.1 Hz, 1H), 7.71 (s, 1H), 7.65 (s, 1H), 7.54 (s, 0.5H), 7.53 (s, 0.5H), 7.32 (dd, 8.8, 5.1 Hz, 1H), 7.14-7.06 (m, 1H), 6.59 (br s, 1H), 6.00 (br s, 1H), 5.81 (dd, 15.3, 7.8 Hz, 1H), 3.99 (td, 8.8, 6.7 Hz, 1H), 3.45-3.37 (m, 1H).	552.1	A	
I-1560		Fc1ccc(Cl)c(c1)[C@H]1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)[C@@H]1CNC(=O)O1	NMR (400 MHz, DMSO) 10.60 (s, 1H), 9.23 (s, 1H), 7.95 (d, 8.4 Hz, 1H), 7.82 (s, 0.5H), 7.81 (s, 0.5H), 7.74 (d, 9.1 Hz, 1H), 7.71 (s, 1H), 7.65 (s, 1H), 7.54 (s, 0.5H), 7.53 (s, 0.5H), 7.32 (dd, 8.8, 5.1 Hz, 1H), 7.14-7.06 (m, 1H), 6.59 (br s, 1H), 6.00 (br s, 1H), 5.81 (dd, 15.3, 7.8 Hz, 1H), 3.99 (td, 8.8, 6.7 Hz, 1H), 3.45-3.37 (m, 1H).	552.1	C	
I-1561		CS(=O)(Cc1cc2C(=O)N[C@@H](c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl)=NC#N	NMR (187) (400 MHz, DMSO-d6) 10.68 (br. s, 1H), 9.29 (s, 1H), 7.95 (br. d, 8.3 Hz, 1H), 7.84 (s, 1H), 7.73 (br. d, 8.9 Hz, 1H), 7.63 (s, 1H), 7.58 (s, 1H), 7.32 (dd, 8.9, 5.2 Hz, 1H), 7.10 (td, 8.4, 2.9 Hz, 1H), 6.65 (br. s, 1H), 6.03 (br. s, 1H), 5.29-5.18 (m, 2H), 3.45 (s, 3H).	583.1	B	





I-1562		Fc1ccc(Cl)c(c1)[C@@H]1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)[C@@H]1CNC(=O)O1	NMR (400 MHz, DMSO) 10.60 (s, 1H), 9.23 (s, 1H), 7.95 (d, 8.4 Hz, 1H), 7.82 (s, 0.5H), 7.81 (s, 0.5H), 7.74 (d, 9.1 Hz, 1H), 7.71 (s, 1H), 7.65 (s, 1H), 7.54 (s, 0.5H), 7.53 (s, 0.5H), 7.32 (dd, 8.8, 5.1 Hz, 1H), 7.14-7.06 (m, 1H), 6.59 (br s, 1H), 6.00 (br s, 1H), 5.81 (dd, 15.3, 7.8 Hz, 1H), 3.99 (td, 8.8, 6.7 Hz, 1H), 3.45-3.37 (m, 1H).	552.1	A	
I-1563		CS(=O)(Cc1cc2C(=O)N[C@@H](c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl)=NC#N	NMR (187) (400 MHz, DMSO-d6) 10.68 (br. s, 1H), 9.29 (s, 1H), 7.95 (br. d, 8.3 Hz, 1H), 7.84 (s, 1H), 7.73 (br. d, 8.9 Hz, 1H), 7.63 (s, 1H), 7.58 (s, 1H), 7.32 (dd, 8.9, 5.2 Hz, 1H), 7.10 (td, 8.4, 2.9 Hz, 1H), 6.65 (br. s, 1H), 6.03 (br. s, 1H), 5.29-5.18 (m, 2H), 3.45 (s, 3H).	583.1	A	
I-1564		CS(=O)(Cc1cc2C(=O)N[C@H](c2c(NC(=O)c2cc(F)ccc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl)=NC#N	NMR (187) (400 MHz, DMSO-d6) 10.68 (br. s, 1H), 9.29 (s, 1H), 7.95 (br. d, 8.3 Hz, 1H), 7.84 (s, 1H), 7.73 (br. d, 8.9 Hz, 1H), 7.63 (s, 1H), 7.58 (s, 1H), 7.32 (dd, 8.9, 5.2 Hz, 1H), 7.10 (td, 8.4, 2.9 Hz, 1H), 6.65 (br. s, 1H), 6.03 (br. s, 1H), 5.29-5.18 (m, 2H), 3.45 (s, 3H).	583.1	A	
I-1565		CS(=O)(Cc1cc2C(=O)N[C@H](c2c(NC(=O)c2cc(F)ccc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl)=NC#N	NMR (187) (400 MHz, DMSO-d6) 10.68 (br. s, 1H), 9.29 (s, 1H), 7.95 (br. d, 8.3 Hz, 1H), 7.84 (s, 1H), 7.73 (br. d, 8.9 Hz, 1H), 7.63 (s, 1H), 7.58 (s, 1H), 7.32 (dd, 8.9, 5.2 Hz, 1H), 7.10 (td, 8.4, 2.9 Hz, 1H), 6.65 (br. s, 1H), 6.03 (br. s, 1H),	583.1	A	





			5.29-5.18 (m, 2H), 3.45 (s, 3H).			
I-1566		CN1[C@H](COc2cc3C(=O)N[C@H](c3c(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c2)c2cc(F)ccc2Cl)CCC1=O	1H NMR (400 MHz, DMSO-d6) 10.44 (s, 1H), 9.14 (s, 1H), 7.95 (d, 8.3 Hz, 1H), 7.72 (d, 8.6 Hz, 1H), 7.64 (s, 1H), 7.31 (dd, 8.8, 5.1 Hz, 1H), 7.27 (s, 1H), 7.16-7.02 (m, 2H), 6.61 (br. s, 1H), 5.94 (br. s, 1H), 4.35 - 4.26 (m, 1H), 4.21 - 4.13 (m, 1H), 3.97-3.85 (m, 1H), 2.79 (s, 3H), 2.46-2.27 (m, 1H), 2.28-2.08 (m, 2H), 1.96-1.77 (m, 1H)	594.2	A	
I-1567		CN1[C@@H](COc2cc3C(=O)N[C@H](c3c(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c2)c2cc(F)ccc2Cl)CCC1=O	1H NMR (400 MHz, DMSO-d6) 10.44 (s, 1H), 9.14 (s, 1H), 7.95 (d, 8.3 Hz, 1H), 7.72 (d, 8.6 Hz, 1H), 7.64 (s, 1H), 7.31 (dd, 8.8, 5.1 Hz, 1H), 7.27 (s, 1H), 7.16-7.02 (m, 2H), 6.61 (br. s, 1H), 5.94 (br. s, 1H), 4.35 - 4.26 (m, 1H), 4.21 - 4.13 (m, 1H), 3.97-3.85 (m, 1H), 2.79 (s, 3H), 2.46-2.27 (m, 1H), 2.28-2.08 (m, 2H), 1.96-1.77 (m, 1H)	594.2	A	
I-1568		CN1[C@H](COc2cc3C(=O)N[C@@H](c3c(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c2)c2cc(F)ccc2Cl)CCC1=O	1H NMR (400 MHz, DMSO-d6) 10.44 (s, 1H), 9.14 (s, 1H), 7.95 (d, 8.3 Hz, 1H), 7.72 (d, 8.6 Hz, 1H), 7.64 (s, 1H), 7.31 (dd, 8.8, 5.1 Hz, 1H), 7.27 (s, 1H), 7.16-7.02 (m, 2H), 6.61 (br. s, 1H), 5.94 (br. s, 1H), 4.35 - 4.26 (m, 1H), 4.21 - 4.13 (m, 1H), 3.97-3.85 (m, 1H), 2.79 (s, 3H), 2.46-2.27 (m, 1H), 2.28-2.08 (m, 2H), 1.96-1.77 (m, 1H)	594.2	D	





I-1569		CN1[C@@H](COc2cc3C(=O)N[C@@H](c3c(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c2)c2cc(F)ccc2Cl)CCC1=O	1H NMR (400 MHz, DMSO-d6) 10.44 (s, 1H), 9.14 (s, 1H), 7.95 (d, 8.3 Hz, 1H), 7.72 (d, 8.6 Hz, 1H), 7.64 (s, 1H), 7.31 (dd, 8.8, 5.1 Hz, 1H), 7.27 (s, 1H), 7.16-7.02 (m, 2H), 6.61 (br. s, 1H), 5.94 (br. s, 1H), 4.35 - 4.26 (m, 1H), 4.21 - 4.13 (m, 1H), 3.97-3.85 (m, 1H), 2.79 (s, 3H), 2.46-2.27 (m, 1H), 2.28-2.08 (m, 2H), 1.96-1.77 (m, 1H)	594.2	E	
I-1570		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(CS(=O)(=O)c3ncccn3)cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	NMR (400 MHz, CD3CN) 8.99 (s, 1H), 8.98 (s, 1H), 8.68 (s, 1H), 7.69 (t, 4.9 Hz, 2H), 7.70 (br, s, 1H), 7.67-7.63 (m, 1H), 7.60 (s, 1H), 7.60-7.56 (m, 1H), 7.55 (m, 1H), 7.32 (s, 1H), 7.24 (dd, 8.9, 5.1 Hz, 1H), 6.97 (ddd, 8.8, 8.0, 3.1 Hz, 1H), 6.54 (br, s, 1H), 6.09 (br, s, 1H), 5.00 (d, 2.1 Hz, 2H).	623	A	
I-1571		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1cnn(c1)-c1cscn1	NMR (400 MHz, DMSO-d6) 10.57 (br s, 1H), 9.24 (d, 2.2 Hz, 1H), 9.17 (br s, 1H), 9.04 (s, 1H), 8.44 (s, 1H), 8.10 (s, 1H), 7.96 (br d, 8.4 Hz, 1H), 7.91 (s, 1H), 7.81 (d, 2.2 Hz, 1H), 7.77 (br d, 8.9 Hz, 1H), 7.73 (s, 1H), 7.32 (dd, 8.9, 5.2 Hz, 1H), 7.10 (td, 8.5, 3.0 Hz, 1H), 6.61 (br s, 1H), 6.00 (br s, 1H).	616	A	
I-1572		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1cnn(c1)-c1nccs1	NMR (400 MHz, DMSO-d6) 10.59 (br s, 1H), 9.20 (s, 1H), 9.20 (br s, 1H), 8.55 (s, 1H), 8.16 (s, 1H), 7.97 (br d, 8.6 Hz, 1H), 7.94 (br s, 1H), 7.77 (br d, 9.1 Hz, 1H), 7.72 (br s, 1H), 7.71 (d, 3.5 Hz, 1H), 7.60 (d, 3.5 Hz,	616	A	




			1H), 7.32 (dd, 8.9, 5.2 Hz, 1H), 7.10 (td, 8.5, 3.0 Hz, 1H), 6.62 (br s, 1H), 6.01 (br s, 1H).			
I-1573		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1ccc2nc(Cl)nn2c1	1H NMR (500 MHz, DMSO) 10.65 (s, 1H), 9.46 (d, 1.9 Hz, 1H), 9.25 (s, 1H), 8.22 (dd, 9.3, 1.9 Hz, 1H), 8.12 (s, 1H), 7.99-7.91 (m, 3H), 7.76 (d, 9.2 Hz, 1H), 7.71 (s, 1H), 7.33 (dd, 8.8, 5.2 Hz, 1H), 7.10 (td, 8.3, 3.0 Hz, 1H), 6.61 (s, 1H), 6.06 (s, 1H).	618.18	A	
I-1574		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1ccc2nnc(Cl)n2c1		618.04	A	
I-1575		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1ccn2nc(Cl)nc2c1	1H NMR (500 MHz, DMSO) 10.68 (s, 1H), 9.26 (s, 1H), 9.05 (d, 7.0 Hz, 1H), 8.26 (s, 1H), 8.15 (s, 1H), 8.04 (s, 1H), 7.94 (s, 1H), 7.78-7.71 (m, 3H), 7.34 (dd, 8.9, 5.1 Hz, 1H), 7.10 (td, 8.4, 3.1 Hz, 1H), 6.70 (s, 1H), 6.27 (s, 1H), 6.08 (s, 1H).	618.13	A	
I-1576		O[C@H]1CN(C(=O)Nc2cc(cc3C(=O)N[C@H](c23)c2cc(F)ccc2Cl)-c2ccc3ncnn3c2)c2ccccc12	1H NMR (400 MHz, DMSO-d6) 9.43 (dd, 1.9, 0.9 Hz, 1H), 9.17 (s, 1H), 8.76 (s, 1H), 8.58 (s, 1H), 8.11 (dd, 9.3, 1.9 Hz, 1H), 8.05-7.91 (m, 2H), 7.87 (d, 8.1 Hz, 1H), 7.82 (d, 1.7 Hz, 1H), 7.43-7.31 (m, 2H), 7.30-7.21 (m, 1H), 7.24-7.13 (m, 1H), 7.00 (td, 7.4, 1.0 Hz, 1H), 6.66 (s, 1H), 6.11 (s, 1H), 5.68 (d, 6.0 Hz, 1H), 5.12 (td, 8.3, 7.0,	555.35	B	





			3.5 Hz, 1H), 3.72 (dd, 11.3, 3.6 Hz, 1H), 3.31 (s, 1H).			
I-1577		O[C@@H]1CN(C(=O)Nc2cc(cc3C(=O)N[C@H](c23)c2cc(F)ccc2Cl)-c2ccc3ncnn3c2)c2ccccc12	1H NMR (400 MHz, DMSO-d6) 9.43 (dd, 1.9, 0.9 Hz, 1H), 9.17 (s, 1H), 8.76 (s, 1H), 8.58 (s, 1H), 8.11 (dd, 9.3, 1.9 Hz, 1H), 8.05-7.91 (m, 2H), 7.87 (d, 8.1 Hz, 1H), 7.82 (d, 1.7 Hz, 1H), 7.43-7.31 (m, 2H), 7.30-7.21 (m, 1H), 7.24-7.13 (m, 1H), 7.00 (td, 7.4, 1.0 Hz, 1H), 6.66 (s, 1H), 6.11 (s, 1H), 5.68 (d, 6.0 Hz, 1H), 5.12 (td, 8.3, 7.0, 3.5 Hz, 1H), 3.72 (dd, 11.3, 3.6 Hz, 1H), 3.31 (s, 1H).	555.3	A	
I-1578		O[C@H]1CN(C(=O)Nc2cc(cc3C(=O)N[C@@H](c23)c2cc(F)ccc2Cl)-c2ccc3ncnn3c2)c2ccccc12	1H NMR (400 MHz, DMSO-d6) 9.43 (dd, 1.9, 0.9 Hz, 1H), 9.17 (s, 1H), 8.76 (s, 1H), 8.58 (s, 1H), 8.11 (dd, 9.3, 1.9 Hz, 1H), 8.05-7.91 (m, 2H), 7.87 (d, 8.1 Hz, 1H), 7.82 (d, 1.7 Hz, 1H), 7.43-7.31 (m, 2H), 7.30-7.21 (m, 1H), 7.24-7.13 (m, 1H), 7.00 (td, 7.4, 1.0 Hz, 1H), 6.66 (s, 1H), 6.11 (s, 1H), 5.68 (d, 6.0 Hz, 1H), 5.12 (td, 8.3, 7.0, 3.5 Hz, 1H), 3.72 (dd, 11.3, 3.6 Hz, 1H), 3.31 (s, 1H).	555.1	E	
I-1579		O[C@@H]1CN(C(=O)Nc2cc(cc3C(=O)N[C@@H](c23)c2cc(F)ccc2Cl)-c2ccc3ncnn3c2)c2ccccc12	1H NMR (400 MHz, DMSO-d6) 9.43 (dd, 1.9, 0.9 Hz, 1H), 9.17 (s, 1H), 8.76 (s, 1H), 8.58 (s, 1H), 8.11 (dd, 9.3, 1.9 Hz, 1H), 8.05-7.91 (m, 2H), 7.87 (d, 8.1 Hz, 1H), 7.82 (d, 1.7 Hz, 1H), 7.43-7.31 (m, 2H), 7.30-7.21 (m, 1H), 7.24-7.13 (m, 1H), 7.00 (td, 7.4, 1.0 Hz, 1H), 6.66 (s, 1H), 6.11 (s, 1H), 5.68 (d, 6.0 Hz, 1H), 5.12 (td, 8.3, 7.0,	555.35	C	





			3.5 Hz, 1H), 3.72 (dd, 11.3, 3.6 Hz, 1H), 3.31 (s, 1H).			
I-1580		Fc1ccc(Cl)c(c1)C1NC(=O)c2cccc(c12)-n1cc2cccc2cc1=O	1H NMR (400 MHz, Chloroform-d) 8.10 (d, 7.6 Hz, 1H), 7.77-7.53 (m, 3H), 7.39 (s, 1H), 7.23 (s, 1H), 7.01-6.90 (m, 2H), 6.85 (t, 7.4 Hz, 1H), 6.76 (s, 1H), 6.65 (s, 2H), 6.44 (s, 1H), 6.20 (s, 1H).	405.15	E	
I-1581		CC(=O)Nc1cccc2C(=O)NC(c12)c1cc(F)ccc1Cl	1H NMR (400 MHz, Chloroform-d) 8.10 (d, 7.9 Hz, 1H), 7.76 (d, 7.5 Hz, 1H), 7.58 (t, 7.8 Hz, 1H), 7.48 (dd, 8.9, 4.9 Hz, 1H), 7.06 (ddd, 8.9, 7.3, 3.0 Hz, 1H), 6.99 (s, 1H), 6.69 (d, 8.8 Hz, 1H), 6.63 (s, 1H), 6.19 (s, 1H), 2.03 (s, 3H).	319	E	
I-1582		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(NC(=O)c3cc(F)cc(CC(F)(F)F)c3)c12	1H NMR (400 MHz, DMSO-d6) 10.35 (s, 1H), 9.28 (s, 1H), 7.81 (d, 1.7 Hz, 1H), 7.75 (d, 1.8 Hz, 1H), 7.47 (s, 2H), 7.34 (dd, 8.9, 5.2 Hz, 1H), 7.28 (d, 9.2 Hz, 1H), 7.12 (td, 8.4, 3.1 Hz, 1H), 5.99 (s, 1H), 3.78-3.72 (d, 2H).	560.9	C	
I-1583		Fc1ccc(Cl)c(c1)[C@H]1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc4c3NC(=O)C4(F)F)c12)-c1ccc2ncnn2c1	1H NMR (400 MHz, DMSO-d6) 11.08 (s, 1H), 10.55 (s, 1H), 9.47 (dd, 1.9, 1.0 Hz, 1H), 9.26 (s, 1H), 8.58 (s, 1H), 8.17-8.10 (m, 2H), 8.03-7.95 (m, 3H), 7.38 (t, 7.0 Hz, 2H), 7.19-7.10 (m, 1H), 6.07 (s, 1H), 1.29-1.24 (m, 2H), 1.20-1.12 (m, 1H),1.00-0.70 (s,1H)	607	D	





I-1584		Fc1ccc(Cl)c(c1)[C@@H]1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc4c3NC(=O)C4(F)F)c12)-c1ccc2nccnn2c1	1H NMR (400 MHz, DMSO-d6) 11.08 (s, 1H), 10.57 (s, 1H), 9.47 (t, 1.4 Hz, 1H), 9.26 (s, 1H), 8.58 (s, 1H), 8.17-8.10 (m, 2H), 8.03-7.95 (m, 3H), 7.80-7.50 (m,2H),7.50-7.30 (m,2H),7.30-7.00 (m,2H),6.08 (s, 1H),1.30-1.22 (s, 3H), 1.20-1.13 (m, 1H),0.90-0.80 (m,1H).	607	B	
I-1585		Fc1ccc(Cl)c(c1)[C@H]1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1cn2ccnc2cc1C#N	1H NMR (400 MHz, DMSO-d6) 10.71 (br. s, 1H), 9.33 (br. s, 1H), 8.98 (d, 0.8 Hz, 1H), 8.55 (app.t, 0.8 Hz 1H), 8.19 (s, 1H), 7.98 (d, 8.1 Hz, 1H), 7.95 - 7.92 (m, 1H), 7.93 (d, 1.1 Hz, 1H), 7.81-7.70 (m, 2H), 7.68 (s, 1H), 7.36 (dd, 8.9, 5.2 Hz, 1H), 7.13 (td, 8.1, 2.9 Hz, 1H), 6.68 (br. s, 1H), 6.07 (br. s, 1H)	608.1	C	
I-1586		Fc1ccc(Cl)c(c1)[C@@H]1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1cn2ccnc2cc1C#N	1H NMR (400 MHz, DMSO-d6) 10.71 (br. s, 1H), 9.33 (br. s, 1H), 8.98 (d, 0.8 Hz, 1H), 8.55 (t, 0.8 Hz 1H), 8.19 (s, 1H), 7.98 (d, 8.1 Hz, 1H), 7.95 - 7.92 (m, 1H), 7.93 (d, 1.1 Hz, 1H), 7.81-7.70 (m, 2H), 7.68 (s, 1H), 7.36 (dd, 8.9, 5.2 Hz, 1H), 7.13 (td, 8.1, 2.9 Hz, 1H), 6.68 (br. s, 1H), 6.07 (br. s, 1H)	608.1	A	
I-1587		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)C1=CC(=O)OC1	(400 MHz, DMSO-d6) 10.68 (s, 1H), 9.32 (br s, 1H), 8.06 (s, 1H), 7.98 (d, 8.5 Hz, 1H), 7.83 (s, 1H), 7.79-7.71 (m, 1H), 7.69 (s, 1H), 7.33 (dd, 8.9, 5.2 Hz, 1H), 7.11 (td, 8.4, 3.1 Hz, 1H), 6.95 (s, 1H), 6.50 (br s, 1H), 6.04 (br s, 1H), 5.55-5.43 (m, 2H) .	547.2	A	





I-1588		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Cn3cc(cn3)C#N)cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	1H-NMR (400 MHz, DMSO-d6) 10.53 (br. s, 1H), 9.21 (br. s, 1H), 8.79 (d, 0.4 Hz, 1H), 8.15 (d, 0.5 Hz, 1H), 7.95 (br. d, 8.3 Hz, 1H), 7.71 (br. d, 8.8 Hz, 1H), 7.62 (s, 1H), 7.61 (s, 1H), 7.37 (br. s, 1H), 7.30 (dd, 8.9, 5.2 Hz, 1H), 7.09 (app. td, 8.4, 3.1 Hz, 1H), 6.57 (br. s, 1H), 5.95 (br. s, 1H), 5.64-5.56 (m, 2H).	570.2	A	
I-1589		[2H]c1nc2ccc(cn2n1)-c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	1H NMR (400 MHz, DMSO-d6) 10.64 (s, 1H), 9.51-9.46 (m, 1H), 9.26 (s, 1H), 8.18 -8.07 (m, 2H), 8.03 - 7.94 (m, 3H), 7.78 (d, 9.3 Hz, 1H), 7.73 (s, 1H), 7.35 (dd, 8.9, 5.2 Hz, 1H), 7.12 (td, 8.4, 3.0 Hz, 1H), 6.67 (s, 1H), 6.08 (s, 1H).	585.15	A	
I-1590		Fc1ccc(Cl)c(c1)C1NC(=O)c2cccc(c12)-n1ccc2ccccc2c1=O	1H NMR (400 MHz, DMSO-d6) 9.21 (s, 1H), 8.26 (d, 8.0 Hz, 1H), 7.90 (d, 7.5 Hz, 1H), 7.76 (dt, 19.1, 7.6 Hz, 2H), 7.62 (dd, 22.6, 7.7 Hz, 2H), 7.55 (d, 7.5 Hz, 1H), 7.14 (s, 1H), 6.99 (s, 1H), 6.83 (d, 7.4 Hz, 1H), 6.66 (s, 1H), 6.49 (s, 1H), 6.34 (d, 7.4 Hz, 1H), 6.01 (s, 1H).	405.05	E	
I-1591		Fc1ccc(Cl)c(c1)[C@@H]1NC(=O)c2cc(CS(=O)(=O)c3ccccc3)cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	NMR (400 MHz, CD3CN) 8.72 (br s, 1H), 7.75-7.71 (m, 2H), 7.69 (dt, 2.5, 1.5Hz, 1H) 7.67 - 7.63 (m, 1H) 7.61-7.52 (m, 4H), 7.46 (s, 1H), 7.43-7.39 (s, 1H), 7.34-7.29 (m, 1H), 7.26 (dd, 8.9, 5.1 Hz, 1H), 7.01-6.95 (m, 1H), 6.61 (br, s, 1H), 6.15 (br, s, 1H), 4.69-4.33 (m, 2H).	621	A	




I-1592		CN(C)S(=O)(=O)n1cc(cn1)-c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	(400 MHz, DMSO-D6) 10.56 (br s, 1 H), 9.18 (br s, 1 H), 8.97 (s, 1 H), 8.57 (s, 1 H), 8.14 (s, 1 H), 7.97 (br d, 8.4 Hz, 1 H), 7.92 (s, 1 H), 7.77 (br d, 8.7 Hz, 1 H), 7.73 (s, 1 H), 7.32 (dd, 8.9, 5.2 Hz, 1 H), 7.10 (td, 8.5, 2.8 Hz, 1 H), 6.58 (br s, 1 H), 6.00 (br s, 1 H), 2.90 (s, 6 H).	638.2	A	
I-1593		Fc1ccc(Cl)c(c1)[C@H]1NC(=O)c2cc(CS(=O)(=O)c3ccccc3)cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	NMR (400 MHz, CD3CN) 8.72 (d, 23.5 Hz, 1H), 7.75-7.71 (m, 2H), 7.69 (dt, 2.5, 1.5Hz, 1H) 7.67 - 7.63 (m, 1H) 7.61-7.52 (m, 4H), 7.46 (s, 1H), 7.43-7.39 (s, 1H), 7.34-7.29 (m, 1H), 7.26 (dd, 8.9, 5.1 Hz, 1H), 7.01-6.95 (m, 1H), 6.61 (br, s, 1H), 6.15 (br, s, 1H), 4.69-4.33 (m, 2H).	621	D	
I-1594		Fc1ccc(Cl)c(c1)[C@@H]1NC(=O)c2cc(CS(=O)(=O)c3ccccc3)C#N)cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	NMR (400 MHz, CD3CN) 8.62 (s, 1H), 8.13 (t, 1.1Hz, 1H), 8.03 (dt, 7.9, 1.2 Hz, 1H), 7.94 (dt, 8.0, 1.3Hz, 1H), 7.70 (t, 7.9 Hz, 1H), 7.66 (br, d, 8.5 Hz, 1H), 7.58 (td, 9.1 Hz, 1.7Hz, 1H), 7.54 (s, 1H), 7.50 (s, 1H), 7.42 (s, 1H), 7.27 (dd, 8.9, 5.1 Hz, 1H), 7.27 (NH, 1H), 6.98 (td, 8.1, 3.0 Hz, 1H), 6.62 (br, s, 1H), 6.12 (br, s, 1H), 4.66 (s, 2H).	646	A	





I-1595		Fc1ccc(Cl)c(c1)[C@H]1NC(=O)c2cc(CS(=O)(=O)c3ccc(c3)C#N)cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	NMR (400 MHz, CD3CN) 8.62 (s, 1H), 8.13 (t, 1.1Hz, 1H), 8.03 (dt, 7.9, 1.2 Hz, 1H), 7.94 (dt, 8.0, 1.3Hz, 1H), 7.70 (t, 7.9 Hz, 1H), 7.66 (br, d, 8.5 Hz, 1H), 7.58 (td, 9.1 Hz, 1.7Hz, 1H), 7.54 (s, 1H), 7.50 (s, 1H), 7.42 (s, 1H), 7.27 (dd, 8.9, 5.1 Hz, 1H), 7.27 (NH, 1H), 6.98 (td, 8.1, 3.0 Hz, 1H), 6.62 (br, s, 1H), 6.12 (br, s, 1H), 4.66 (s, 2H).	646	D	
I-1596		Fc1ccc(Cl)c(c1)[C@H]1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1ccn2ncnc2c1		584.2	D	
I-1597		Fc1ccc(Cl)c(c1)[C@@H]1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1ccn2ncnc2c1		584.2	A	
I-1598		CN(C)S(=O)(=O)n1nccc1-c1cc2C(=O)N[C@@H](c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl		640.14	C	






I-1599		CN(C)S(=O)(=O)n1nccc1-c1cc2C(=O)N[C@H](c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl		640.14	A	
I-1600		[2H][C@@]1(NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1ccc2ncnn2c1)c1cc(F)ccc1Cl		585.08	A	
I-1601		[2H][C@]1(NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1ccc2ncnn2c1)c1cc(F)ccc1Cl		585.08	A	
I-1602		COc1cnc2ccc(cc2c1)-c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl		624.5	A	




I-1603		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1ccc2ncc(cc2c1)C#N	1H NMR (DMSO-d6, 500 MHz) 10.66 (s, 1H), 9.24-9.33 (m, 1H), 9.21 (d, 2.1 Hz, 1H), 9.14 (d, 1.8 Hz, 1H), 8.59 (d, 2.0 Hz, 1H), 8.43 (dd, 8.8, 2.1 Hz, 1H), 8.26 (d, 8.7 Hz, 1H), 8.16 (d, 1.1 Hz, 1H), 8.00 (s, 1H), 7.97 (br d, 8.2 Hz, 1H), 7.78 (br d, 9.0 Hz, 1H), 7.72 (s, 1H), 7.34 (dd, 8.9, 5.2 Hz, 1H), 7.11 (td, 8.4, 3.0 Hz, 1H), 6.42-6.97 (m, 1H), 5.95-6.25 (m, 1H)	619.5	A	
I-1604		CC(C)(O)c1cnc2ccc(cc2c1)-c1cc2C(=O)N[C@H](c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl		652.2	A	
I-1605		CC(C)(O)c1cnc2ccc(cc2c1)-c1cc2C(=O)N[C@@H](c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl		652.2	E	
I-1606		Fc1ccc(Cl)c(c1)[C@H]1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1ccn2nc		619.2	B	




		(Cl)nc2c1				
I-1607		Fc1cc(cc(c1)C(F)(F)F)C(=O)Nc1cc(nc2C(=O)NC(C3CCCC3)c12)-c1ccc2ncnn2c1			C	
I-1608		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1cnn(c1)-c1cnccn1	NMR (400 MHz, DMSO-d6) 10.57 (s, 1H), 9.30 (s, 1H), 9.29 (s, 1H), 9.19 (s, 1H), 8.67 (d, 2.5 Hz, 1H), 8.63-8.60 (m, 2H), 8.17 (s, 1H), 8.00-7.94 (m, 2H), 7.78 (d, 9.3 Hz, 1H), 7.73 (s, 1H), 7.33 (dd, 8.9, 5.2 Hz, 1H), 7.10 (td, 8.4, 2.8 Hz, 1H), 6.58 (br s, 1H), 5.96 (br s, 1H).	609.1	A	
I-1609		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc4ccccc4[nH]3)c12)-c1ccc2ncnn2c1	NMR (400 MHz,) 11.72 (s, 1H), 10.29 (s, 1H), 9.49 (s, 1H), 9.25 (s, 1H), 8.58 (s, 1H), 8.15 (dd, 9.3, 1.5 Hz, 1H), 8.09 (d, 0.9 Hz, 1H), 8.02-9.98 (m, 2H), 7.62 (d, 8.0 Hz, 1H), 7.44 (d, 8.2 Hz, 1H), 7.32 (dd, 8.8, 5.2 Hz, 1H), 7.21 (t, 7.5 Hz, 1H), 7.12-6.98 (m, 3H), 6.72 (br s, 1H), 6.26 (br s, 1H).	535.2	D	
I-1610		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(NC(=O)c3cc4ccccc4[nH]3)c12	NMR (400 MHz, DMSO-d6) 11.71 (s, 1H), 10.18 (s, 1H), 9.28 (s, 1H), 7.81 (d, 1.5 Hz, 1H), 7.78 (d, 1.4 Hz, 1H), 7.61 (d, 7.9 Hz, 1H), 7.42 (d, 8.2 Hz, 1H), 7.30 (dd, 8.8, 5.2 Hz, 1H), 7.20 (td, 11.7, 4.4 Hz, 1H), 7.09-7.01 (m, 2H), 6.93 (d, 1.4 Hz, 1H), 6.64 (br s, 1H), 6.13 (br s, 1H).	496.1	D	





I-1611		Fc1cc(cc(c1)C(F)(F)F)C(=O)Nc1ccc2C(=O)NC(C3CCCCC3)c12	NMR (400 MHz, DMSO-d6) 10.74 (br. s, 1H), 8.74 (s, 1H), 8.13 (s, 1H), 8.08 (br. d, 9.0 Hz, 1H), 8.04 (br. d, 8.5 Hz, 1H), 7.62-7.49 (m, 3H), 4.73 (d, 1.3 Hz, 1H), 1.90-1.80 (m, 1H), 1.73-1.64 (m, 1H), 1.59 - 1.50 (m, 3H), 1.39-1.27 (m, 1H), 1.06-0.86 (m, 3H), 0.79-0.61 (m, 2H).	421.2	D	
I-1612		Fc1ccc(Cl)c(c1)[C@@H]1NC(=O)c2cc(Cc3ccc4C(=O)NCc4c3)cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	1H-NMR (400 MHz, DMSO-d6) 10.57 (br. s, 1H), 9.07 (br. s, 1H), 8.49 (s, 1H), 7.87 (br. d, 7.9 Hz, 1H), 7.71 (br. d, 8.6 Hz, 1H), 7.66 (s, 1H), 7.62 (d, 7.7 Hz, 1H), 7.56-7.50 (m, 2H), 7.46-7.41 (m, 2H), 7.30 (dd, 8.9, 5.2 Hz, 1H), 7.07 (app. td, 8.4, 3.1 Hz, 1H), 6.62 (br. s, 1H), 5.92 (br. s, 1H), 4.34 (s, 2H), 4.24 (d, A of AB, JAB = 14.9 Hz, 1H), 4.20 (d, B of AB, JAB = 14.7 Hz, 1H).	612.2	A	
I-1613		Fc1ccc(Cl)c(c1)[C@H]1NC(=O)c2cc(Cc3ccc4C(=O)NCc4c3)cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	1H-NMR (400 MHz, DMSO-d6) 10.47 (br. s, 1H), 9.11 (br. s, 1H), 8.48 (s, 1H), 7.92 (br. d, 8.4 Hz, 1H), 7.71 (br. d, 8.8 Hz, 1H), 7.64-7.60 (m, 3H), 7.52 (s, 1H), 7.44 (d, 7.8 Hz, 1H), 7.37 (s, 1H), 7.29 (dd, 8.9, 5.2 Hz, 1H), 7.08 (app. td, 8.4, 3.0 Hz, 1H), 6.60 (br. s, 1H), 5.92 (br. s, 1H), 4.35 (s, 2H), 4.26 (d, A of AB, JAB = 14.5 Hz, 1H), 4.22 (d, B of AB, JAB = 14.4 Hz, 1H).	612.2	B	





I-1614		Fc1ccc(Cl)c(c1)[C@H]1NC(=O)c2cc(Cn3cccn3)cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	1H-NMR (400 MHz, DMSO-d6) 10.63 (br. s, 1H), 9.09 (br. s, 1H), 7.91 (d, 2.0 Hz, 1H), 7.88-7.82 (m, 1H), 7.72 (br. d, 9.7 Hz, 1H), 7.67 (s, 1H), 7.51 (d, 1.8 Hz, 1H), 7.47-7.35 (m, 2H), 7.31 (dd, 8.8, 5.2 Hz, 1H), 7.08 (app. td, 8.5, 3.0 Hz, 1H), 6.60 (br. s, 1H), 6.31 (t, 2.0 Hz, 1H), 5.93 (br. s, 1H), 5.53-5.45 (m, 2H).	547.2	B	
I-1615		Fc1ccc(Cl)c(c1)[C@@H]1NC(=O)c2cc(Cn3cccn3)cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	1H-NMR (400 MHz, DMSO-d6) 10.68 (br. s, 1H), 9.08 (br. s, 1H), 7.91 (d, 2.1 Hz, 1H), 7.87-7.81 (m, 1H), 7.72 (br. d, 9.4 Hz, 1H), 7.68 (s, 1H), 7.51 (d, 1.7 Hz, 1H), 7.49-7.43 (m, 1H), 7.37 (br. s, 1H), 7.31 (dd, 8.8, 5.2 Hz, 1H), 7.07 (app. td, 8.5, 3.1 Hz, 1H), 6.62 (br. s, 1H), 6.31 (t, 2.0 Hz, 1H), 5.93 (br. s, 1H), 5.53-5.44 (m, 2H).	547.2	A	
I-1616		Fc1cnc(nc1)-n1cc(cn1)-c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	NMR (400 MHz, DMSO-d6) 9.25 (s, 1H), 9.19 (br s, 1H), 9.04-9.01 (m, 2H), 8.54 (s, 1H), 8.36 (br s, 1H), 8.14 (s, 1H), 7.98-7.92 (m. 2H), 7.78 (br d, 8.6 Hz, 1H), 7.73 (s 1H), 7.32 (dd, 8.8, 5.1 Hz, 1H), 7.10 (td, 8.3, 2.7 Hz, 1H), 6.60 (br s, 1H), 6.02 (br s, 1H).	629	A	
I-1617		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(NC(=O)c3nc4ccccc4[nH]3)c12	NMR (400 MHz, DMSO-d6) 9.32 (br s,1H), 8.38 (s, 1H), 7.99 (br s, 1H), 7.78 (s, 1H), 7.65-7.60 (m, 2H), 7.32 (dd, 6.0, 3.1 Hz, 3H), 7.07 (td, 8.5, 2.9 Hz, 1H), 6.93-6.72 (m, 1H), 6.19 (br s, 1H)	501	D	




I-1618		CC(C)(C#N)n1cc(cn1)-c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	(400 MHz, DMSO-D6) 10.56 (br s, 1 H), 9.16 (br s, 1 H), 8.77 (s, 1 H), 8.25 (s, 1 H), 8.04 (s, 1 H), 7.96 (br d, 8.3 Hz, 1 H), 7.79 (s, 1 H), 7.77 (br d, 13.5 Hz, 1 H), 7.72 (s, 1 H), 7.32 (dd, 8.8, 5.2 Hz, 1 H), 7.09 (td, 8.5, 2.8 Hz, 1 H), 6.60 (br s, 1 H), 5.97 (br s, 1 H), 2.03 (s, 6 H).	598.3	A	
I-1619		CC(C)(CC(F)(F)F)C(=O)Nc1cc(Br)cc2C(=O)NC(c12)c1cc(F)ccc1Cl	1H NMR (400 MHz, DMSO):-′ 9.40 (s, 1H), 9.28 (s, 1H), 7.75 (d, 1.2 Hz, 1H), 7.59 (d, 1.5 Hz, 1H), 7.51 (br s, 1H), 7.24 (td, 8.4, 3.0 Hz, 1H), 6.07 (br s, 1H), 2.52-2.47 (m, 2H), 0.98 (s, 3H), 0.90 (s, 3H).	509.1	E	
I-1620		CC(C)(C(=O)Nc1cc(Br)cc2C(=O)NC(c12)c1cc(F)ccc1Cl)C(F)(F)F	1H NMR (400 MHz, DMSO):-′ 9.73 (s, 1H), 9.29 (s, 1H), 7.79 (d, 1.6 Hz, 1H), 7.59 (s, 1H), 7.52 (br s, 1H), 7.25 (td, 8.4, 3.0 Hz, 1H), 6.00 (br s, 1H), 1.12 (s, 6H).	495.1	E	
I-1621		FC(F)C1CCCC1C(=O)Nc1cc(Br)cc2C(=O)NC(c12)c1cc(F)ccc1Cl	1H NMR (400 MHz, DMSO):-′ 10.26 (s, 0.5H), 10.16 (s, 0.5H), 9.25 (s, 1H), 7.77 (d, 1.5 Hz, 0.5H), 7.70 (d, 1.4 Hz, 0.5H), 7.68 (d, 1.3 Hz, 0.5H), 7.62 (d, 1.6 Hz, 0.5H), 7.47 (br s, 1H), 7.26-7.19 (m, 1H), 6.14 (s, 0.5H), 6.10 (br s, 0.5H), 5.89 (td, 57.0, 3.9 Hz, 1H), 2.68-2.30 (m, 2H), 1.77-0.92 (m, 6H).	503	E	
I-1622		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(NC(=O)C3CC4(C3)CC(F	1H NMR (400 MHz, DMSO):-′ 9.70 (s, 1H), 9.24 (s, 1H), 7.70 (d, 1.5 Hz, 1H), 7.57 (d, 1.7 Hz, 1H), 7.50 (br s, 1H), 7.24 (td, 8.4, 3.1 Hz, 1H), 6.00 (br s, 1H), 2.84 (pentet, 8.4	515	D	





		)(F)C4)c12	Hz, 1H), 2.59 (td, 12.6, 2.0 Hz, 2H), 2.43 (td, 12.5, 1.9 Hz, 2H), 2.10-1.94 (m, 3H), 1.82 (br s, 1H).			
I-1623		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(NC(=O)C3CCC4C(C3)C4(F)F)c12	1H NMR (400 MHz, DMSO):-´ 9.82 (s, 0.5H), 9.77 (d, 5.7 Hz, 0.5H), 9.25 (s, 1H), 7.71-7.68 (m, 1H), 7.66 (d, 1.3 Hz, 0.25H), 7.61 (d, 1.5 Hz, 0.25H), 7.58 (d, 1.7 Hz, 0.25H), 7.57 (d, 1.7 Hz, 0.25H), 7.49 (br s, 1H), 7.29-7.20 (m, 1H), 6.00 (br s, 1H), 2.03-0.72 (m, 9H).	515.1	D	
I-1624		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1ccc2nc(nn2c1)C1CC1			A	
I-1625		Fc1ccc(Cl)c(c1)[C@@H]1NC(=O)c2cc(Cc3ccc4C(=O)NCCc4c3)cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	1H-NMR (400 MHz, DMSO-d6) 10.49 (br. s, 1H), 9.12 (br. s, 1H), 7.92 (br. d, 8.1 Hz, 1H), 7.87 (t, 2.7 Hz, 1H), 7.79 (d, 7.9 Hz, 1H), 7.71 (br. d, 9.1 Hz, 1H), 7.63 (s, 1H), 7.58 (s, 1H), 7.36 (s, 1H), 7.32-7.27 (m, 2H), 7.25 (s, 1H), 7.08 (app. td, 8.5, 3.0 Hz, 1H), 6.61 (br. s, 1H), 5.92 (br. s, 1H), 4.17 (d, A of AB, JAB = 14.7 Hz, 1H), 4.12 (d, B of AB, JAB = 14.6 Hz, 1H), 3.36 (td, 6.8, 2.8 Hz, 2H), 2.87 (t, 6.5 Hz, 2H).	626.3	C	





I-1626		Fc1ccc(Cl)c(c1)[C@H]1NC(=O)c2cc(Cc3ccc4C(=O)NCCc4c3)cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	1H-NMR (400 MHz, DMSO-d6) 10.48 (s, 1H), 9.13 (br. s, 1H), 7.93 (br. d, 8.5 Hz, 1H), 7.88 (br. t, 2.5 Hz, 1H), 7.79 (d, 7.9 Hz, 1H), 7.71 (br. d, 9.1 Hz, 1H), 7.63 (s, 1H), 7.59 (s, 1H), 7.35 (br. s, 1H), 7.33-7.27 (m, 2H), 7.25 (s, 1H), 7.08 (app. td, 8.4, 3.0 Hz, 1H), 6.57 (br. s, 1H), 5.92 (br. s, 1H), 4.17 (d, Aof AB, JAB = 14.6 Hz, 1H), 4.12 (d, B of AB JAB = 14.6 Hz, 1H), 3.35 (td, 6.5, 2.8 Hz, 2H), 2.87 (t, 6.5 Hz, 2H).	626.2	A	
I-1627		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)CC3CCCCC3)c12)-c1ccc2ncnn2c1	NMR (400 MHz, DMSO-d6) 9.78 (s, 1H), 9.44 (s, 1H), 9.22 (s, 1H), 8.58 (s, 1H), 8.08 (dd, 9.3, 1.6 Hz, 1H), 7.97 (d, 9.3 Hz, 1H), 7.87 (d, 1.4 Hz, 1H), 7.58-7.49 (m, 1H), 7.24 (tt, 5.8, 2.9 Hz, 1H), 6.53 (br s, 1H), 6.16 (s, 1H), 1.93 (d, 6.9 Hz, 2H), 1.56 (d, 9.0 Hz, 3H), 1.51-1.44 (m, 1H), 1.38 (t, 13.5 Hz, 2H), 1.16-1.01 (m, 3H), 0.80-0.65 (m, 2H).	518.2	D	
I-1628		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)CCc3ccccc3)c12)-c1ccc2ncnn2c1	1H-NMR (400 MHz, DMSO-d6) 9.88 (br. s, 1H), 9.44 (s, 1H), 9.23 (br. s, 1H), 8.57 (s, 1H), 8.08 (d, 9.1 Hz, 1H), 8.02 (s, 1H), 7.97 (d, 9.2 Hz, 1H), 7.78 (s, 1H), 7.58-7.49 (m, 1H), 7.33-7.23 (m, 3H), 7.22-7.09 (m, 3H), 6.65 (br. s, 1H), 6.09 (br. s, 1H), 2.69-2.55 (m, 2H), 2.41-2.19 (m, 2H).	526.3	D	




I-1629		Fc1cc(cc(c1)C(F)(F)F)C(=O)Nc1ccc c2C(=O)NC(c12)C1=CCCCC1	NMR (400 MHz, DMSO-d6) 10.58 (s, 1H), 8.66 (s, 1H), 8.11 (s, 1H), 8.04 (s, 1H), 8.02 (s, 1H), 7.63-7.50 (m, 3H), 5.69-5.64 (m, 1H), 5.12 (s, 1H), 1.90-1.78 (m, 1H), 1.52-1.27 (m, 5H), 1.26-1.16 (m, 1H), 1.13-1.01 (m, 1H).	419.2	D	
I-1630		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)C(Cl)c3ccccc3)c12)-c1ccc2ncnn2c1	NMR (400 MHz, DMSO-d6) 10.43 (br s, 1H), 9.47 (d, 6.0 Hz, 1H), 9.23 (br s, 1H), 8.57 (d, 3.1 Hz, 1H), 8.10 (ddd, 9.2, 7.3, 1.7 Hz, 1H), 8.05 (dd, 5.9, 1.6 Hz, 1H), 7.99-7.94 (m, 1H), 7.93-7.88 (m, 1H), 7.43 (br s, 1H), 7.40-7.29 (m, 6H), 7.16 (dtd, 11.6, 8.6, 3.0 Hz, 1H), 6.49 (br s, 1H), 6.14 (br s, 1H), 5.54 (s, 0.5H), 5.49 (s, 0.5 H).	546	D	
I-1631		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3nc4ccccc4s3)c12)-c1ccc2ncnn2c1	NMR (400 MHz, DMSO-d6) 9.48 (s, 1H), 9.30 (br s, 1H), 8.58 (s, 1H), 8.30-8.23 (m, 2H), 8.21-8.07 (m, 4H), 7.99 (d, 9.2 Hz, 1H), 7.76-7.52 (m, 2H), 7.33 (dd, 8.8, 5.2 Hz, 1H), 7.06 (td, 8.5, 3.0 Hz, 1H), 6.62 (br s, 1H), 6.24 (br s, 1H).	555	D	
I-1632		NC1(CCC1)C(=O)Nc1cc(Br)cc2C(=O)NC(c12)c1cc(F)ccc1Cl)C(F)(F)F	1H NMR (400 MHz, DMSO):-′ 9.79 (s, 0.4H), 9.76 (s, 0.6H), 9.22 (s, 1H), 7.71-7.64 (m, 1H), 7.61 (d, 1.7 Hz, 0.6H), 7.59 (d, 1.7 Hz, 0.4H), 7.51-7.39 (m, 1H), 7.19 (td, 8.3, 3.1 Hz, 1H), 7.09-6.10 (br m, 1H), 5.95 (br s, 1H), 3.13-3.00 (m, 0.4H), 2.69-2.61 (m, 0.6H), 2.32-2.14 (m, 2.4H), 2.10-1.80 (m, 2H), 1.72-1.54 (m, 0.6H).	520.1	E	






I-1633		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(NC(=O)CC3CC(F)(F)C3(F)F)c12	1H NMR (400 MHz, DMSO):-′ 10.00 (s, 1H), 9.25 (s, 1H), 7.74-7.69 (m, 1H), 7.65 (d, 1.7 Hz, 0.5H), 7.62 (d, 1.4 Hz, 0.5H), 7.56-7.41 (m, 1H), 7.29-7.19 (m, 1H), 7.12-6.14 (br m, 1H), 5.95 (br s, 1H), 2.95 (br s, 1H), 2.80-2.63 (m, 1H), 2.49-2.05 (m, 3H).	523	D	
I-1634		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(NC(=O)C3CC4(CC4(F)F)C3)c12	1H NMR (400 MHz, DMSO):-′ 9.87 (s, 1H), 9.27 (s, 1H), 7.74-7.68 (m, 1H), 7.62 (d, 1.7 Hz, 0.5H), 7.60 (d, 1.7 Hz, 0.5H), 7.57-7.39 (m, 1H), 7.19 (td, 8.8, 3.1 Hz, 1H), 7.12-6.22 (br m, 1H), 6.03 (br s, 1H), 3.17-2.96 (m, 1H), 2.20-1.77 (m, 4H), 1.38 (t, 8.7 Hz, 1H), 1.29 (td, 8.7, 2.3 Hz, 1H).	499	E	
I-1635		CC12CC3CC(F)(C1)CC(C3)(C2)C(=O)Nc1cc(Br)cc2C(=O)NC(c12)c1cc(F)ccc1Cl	1H NMR (400 MHz, DMSO):-′ 9.38 (s, 0.5H), 9.37 (s, 0.5H), 9.26 (s, 1H), 7.72 (d, 1.6 Hz, 1H), 7.59 (d, 1.7 Hz, 0.5H), 7.58 (d, 1.7 Hz, 0.5H), 7.52 (br s, 1H), 7.26 (td, 8.4, 3.1 Hz, 1H), 7.11-6.18 (br m, 1H), 5.99 (br s, 1H), 2.22 (br s, 1H), 1.72-1.47 (m, 5H), 1.45-0.94 (m, 7H), 0.84 (s, 1.5H), 0.83 (s, 1.5H).	549.2	B	
I-1636		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(NC(=O)C3(CCCC3)c3ccc(Cl)c(Cl)c3)c12	1H NMR (400 MHz, DMSO):-′ 9.37 (s, 1H), 9.25 (s, 1H), 7.71 (d, 1.7 Hz, 1H), 7.55 (d, 1.7 Hz, 1H), 7.49-7.42 (m, 2H), 7.40 (d, 2.2 Hz, 1H), 7.18 (td, 8.4, 3.0 Hz, 1H), 7.07 (dd, 8.5, 2.2 Hz, 1H), 6.70-6.16 (br m, 1H), 6.10 (s, 1H), 2.33-2.12 (m, 2H), 1.84-1.63 (m, 2H), 1.56-1.41 (m, 2H), 1.40-1.22 (m, 2H).	595.1	E	






I-1637		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(NC(=O)C3(CCCC3)c3cccc(Cl)c3)c12	1H NMR (400 MHz, DMSO):-′ 9.30 (s, 1H), 9.25 (s, 1H), 7.70 (d, 1.6 Hz, 1H), 7.51 (d, 1.7 Hz, 1H), 7.51-7.46 (m, 1H), 7.29-7.26 (m, 2H), 7.26-7.24 (m, 1H), 7.21 (dt, 8.3, 2.9 Hz, 1H), 7.10-7.03 (m, 1H), 6.82-6.22 (br m, 1H), 6.11 (br s, 1H), 2.25-2.09 (m, 2H), 1.86-1.75 (m, 1H), 1.74-1.62 (m, 1H), 1.54-1.40 (m, 2H), 1.33-1.19 (m, 2H).	561.1	E	
I-1638		Fc1cccc(c1)C1(CCCC1)C(=O)Nc1cc(Br)cc2C(=O)NC(c12)c1cc(F)ccc1Cl	1H NMR (400 MHz, DMSO) 9.35-9.19 (m, 2H), 7.69 (d, 1.6 Hz, 1H), 7.52 (d, 1.7 Hz, 1H), 7.52-7.46 (m, 1H), 7.28 (dd, 14.4, 7.9 Hz, 1H), 7.22 (td, 8.5, 3.1 Hz, 1H), 7.07-6.97 (m, 2H), 6.95 (d, 7.9 Hz, 1H), 6.72-6.23 (br m, 1H), 6.14 (br s, 1H), 2.23-2.09 (m, 2H), 1.88-1.77 (m, 1H), 1.73-1.63 (m, 1H), 1.54-1.40 (m, 2H), 1.34-1.20 (m, 2H).	545	E	
I-1639		Cc1cccc(c1)C1(CCCC1)C(=O)Nc1cc(Br)cc2C(=O)NC(c12)c1cc(F)ccc1Cl	1H NMR (400 MHz, DMSO):-′ 9.23 (s, 1H), 9.11 (s, 1H), 7.68 (d, 1.1 Hz, 1H), 7.53 (d, 1.2 Hz, 1H), 7.53-7.46 (m, 1H), 7.23 (td, 8.3, 2.9 Hz, 1H), 7.13 (t, 7.7 Hz, 1H), 7.05 (s, 1H), 7.01 (d, 7.3 Hz, 1H), 6.92 (d, 7.8 Hz, 1H), 6.76-6.24 (br s, 1H), 6.15 (br s, 1H), 2.27 (s, 3H), 2.19-2.08 (m, 2H), 1.87-1.75 (m, 1H), 1.72-1.62 (m, 1H), 1.53-1.38 (m, 2H), 1.31-1.14 (m, 2H).	541.1	E	




I-1640		C[C@@H](c1cc2C(=O)N[C@@H](c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl)S(C)(=O)=O	NMR (400 MHz, DMSO-d6) ′ 10.64 (s, 1H), 9.28 (s, 1H), 7.95 (d, 8.1 Hz, 1H), 7.80 (d, 2.7 Hz, 1H), 7.74 (d, 9.3 Hz, 1H), 7.64 (s, 1H), 7.55 (s, 1H), 7.32 (dd, 8.8, 5.1 Hz, 1H), 7.10 (m, 1H), 6.59 (br, s, 1H), 6.00 (br, s, 1H), 4.87- 4.78 (m, 1H), 2.91 (s, 3H), 1.71 (d, 7.1 Hz, 3H)	573	D	
I-1641		C[C@@H](c1cc2C(=O)N[C@H](c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl)S(C)(=O)=O	NMR (400 MHz, DMSO-d6) 10.64 (s, 1H), 9.28 (s, 1H), 7.95 (d, 8.1 Hz, 1H), 7.80 (d, 2.7 Hz, 1H), 7.74 (d, 9.3 Hz, 1H), 7.64 (s, 1H), 7.55 (s, 1H), 7.32 (dd, 8.8, 5.1 Hz, 1H), 7.10 (m, 1H), 6.59 (br, s, 1H), 6.00 (br, s, 1H), 4.87- 4.78 (m, 1H), 2.91 (s, 3H), 1.71 (d, 7.1 Hz, 3H)	573	A	
I-1642		C[C@H](c1cc2C(=O)N[C@H](c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl)S(C)(=O)=O	NMR (400 MHz, DMSO-d6) 10.64 (s, 1H), 9.28 (s, 1H), 7.95 (d, 8.1 Hz, 1H), 7.80 (d, 2.7 Hz, 1H), 7.74 (d, 9.3 Hz, 1H), 7.64 (s, 1H), 7.55 (s, 1H), 7.32 (dd, 8.8, 5.1 Hz, 1H), 7.10 (m, 1H), 6.59 (br, s, 1H), 6.00 (br, s, 1H), 4.87- 4.78 (m, 1H), 2.91 (s, 3H), 1.71 (d, 7.1 Hz, 3H)	573	A	
I-1643		C[C@H](c1cc2C(=O)N[C@@H](c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl)S(C)(=O)=O	NMR (400 MHz, DMSO-d6) 10.64 (s, 1H), 9.28 (s, 1H), 7.95 (d, 8.1 Hz, 1H), 7.80 (d, 2.7 Hz, 1H), 7.74 (d, 9.3 Hz, 1H), 7.64 (s, 1H), 7.55 (s, 1H), 7.32 (dd, 8.8, 5.1 Hz, 1H), 7.10 (m, 1H), 6.59 (br, s, 1H), 6.00 (br, s, 1H), 4.87- 4.78 (m, 1H), 2.91 (s, 3H), 1.71 (d, 7.1 Hz, 3H)	573	D	





I-1644		CS(=O)(=O)Cc1cc(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c2C(NC(=O)c2n1)c1cc(F)ccc1Cl	1H NMR (400 MHz, DMSO-d6) 10.93 (br. s, 1H), 9.59 (s, 1H), 7.98 (d, 8.2 Hz, 1H), 7.74 (d, 8.9 Hz, 1H), 7.63 (s, 1H), 7.60 (s, 1H), 7.35 (dd, 8.9, 5.2 Hz, 1H), 7.11 (td, 8.1, 3.1 Hz, 1H), 6.86 (br. s, 1H), 6.02 (br. s, 1H), 4.88 (s, 2H), 3.12 (s, 3H).	560.1	A	
I-1645		Fc1ccc(Cl)c(c1)[C@H]1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1cn2ncnc2cc1C#N	^{1}H NMR (500 MHz, DMSO-d_6) δ 10.69 (s, 1H), 9.41 (d, J = 1.0 Hz, 1H), 9.31 (s, 1H), 8.85 (d, J = 0.9 Hz, 1H), 8.81 (s, 1H), 7.96 (d, J = 20.0 Hz, 2H), 7.76 (s, 2H), 7.68 (s, 1H), 7.35 (dd, J = 8.9, 5.2 Hz, 1H), 7.12 (s, 2H), 6.10 (s, 1H).	609.2	D	
I-1646		Fc1ccc(Cl)c(c1)[C@@H]1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1cn2ncnc2cc1C#N	^{1}H NMR (500 MHz, DMSO-d_6) δ 10.69 (s, 1H), 9.41 (d, J = 1.0 Hz, 1H), 9.31 (s, 1H), 8.85 (d, J = 0.9 Hz, 1H), 8.81 (s, 1H), 7.96 (d, J = 20.0 Hz, 2H), 7.76 (s, 2H), 7.68 (s, 1H), 7.35 (dd, J = 8.9, 5.2 Hz, 1H), 7.12 (s, 2H), 6.10 (s, 1H).	609.2	A	
I-1647		Fc1ccc(Cl)c(c1)[C@H]1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1ccc2ncnn2c1C#N	^{1}H NMR (500 MHz, DMSO-d_6) δ 10.71 (s, 1H), 9.33 (s, 1H), 8.80 (s, 1H), 8.34 (d, J = 9.2 Hz, 1H), 8.07 (s, 1H), 7.97 (t, J = 9.9 Hz, 2H), 7.83 (s, 1H), 7.75 (d, J = 9.2 Hz, 1H), 7.68 (s, 1H), 7.35 (dd, J = 8.8, 5.1 Hz, 1H), 7.13 (d, J = 8.0 Hz, 1H).	609.1	B	B





I-1648		Fc1ccc(Cl)c(c1)[C@@H]1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1ccc2ncnn2c1C#N	^{1}H NMR (500 MHz, DMSO-d_6) δ 10.71 (s, 1H), 9.33 (s, 1H), 8.80 (s, 1H), 8.34 (d, J = 9.2 Hz, 1H), 8.07 (s, 1H), 7.97 (t, J = 9.9 Hz, 2H), 7.83 (s, 1H), 7.75 (d, J = 9.2 Hz, 1H), 7.68 (s, 1H), 7.35 (dd, J = 8.8, 5.1 Hz, 1H), 7.13 (d, J = 8.0 Hz, 1H).	609.1	A	A
I-1649		Fc1ccc(Cl)c(c1)[C@H]1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1ccc2ncnn2n1	1H NMR (500 MHz, DMSO) δ 10.71 (s, 1H), 9.31 (s, 1H), 8.74 (s, 1H), 8.59 (d, J = 9.5 Hz, 1H), 8.45 (d, J = 9.5 Hz, 1H), 8.41 (d, J = 1.6 Hz, 1H), 8.32 (d, J = 1.6 Hz, 1H), 7.96 (d, J = 8.3 Hz, 1H), 7.79 (d, J = 9.0 Hz, 1H), 7.72 (s, 1H), 7.34 (dd, J = 8.9, 5.2 Hz, 1H), 7.11 (td, J = 8.4, 3.0 Hz, 1H), 6.13 (s, 1H).	585.2	D	
I-1650		Fc1ccc(Cl)c(c1)[C@@H]1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1ccc2ncnn2n1	1H NMR (500 MHz, DMSO) δ 10.71 (s, 1H), 9.31 (s, 1H), 8.74 (s, 1H), 8.59 (d, J = 9.5 Hz, 1H), 8.45 (d, J = 9.5 Hz, 1H), 8.41 (d, J = 1.6 Hz, 1H), 8.32 (d, J = 1.7 Hz, 1H), 7.96 (d, J = 8.3 Hz, 1H), 7.79 (d, J = 8.9 Hz, 1H), 7.72 (s, 1H), 7.34 (dd, J = 8.9, 5.1 Hz, 1H), 7.11 (td, J = 8.4, 3.1 Hz, 1H), 6.08 (s, 1H).	585.2	A	





I-1651		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1ccn2nc(nc2c1)C1CC1		624.24	A	
I-1652		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1cn2ncnc2cc1F		602.18	A	
I-1653		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1cc(F)c2ncnn2c1	1H NMR (400 MHz, DMSO) 10.65 (s, 1H), 9.39 (d, 7.1 Hz, 1H), 9.29 (s, 1H), 8.58 (s, 1H), 8.13 (s, 0.5H), 8.00 (s, 0.5H), 7.96 (d, 5.6 Hz, 2H), 7.75 (d, 8.7 Hz, 2H), 7.68 (s, 1H), 7.34 (dd, 8.9, 5.1 Hz, 1H), 7.12 (t, 6.8 Hz, 2H), 6.05 (s, 1H).	602.13	A	
I-1654		Fc1cc(cc(c1)C(F)(F)F)C(=O)Nc1cc(nc2C(=O)NC(C3CCCC3)c12)-c1ccc2ncnn2c1		98	E	
I-1655		Oc1ccc(F)cc1C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1ccn2ncnc2c1		566.22	D	





I-1656		Cn1cc(c(n1)C#N)-c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl		572.4	A	
I-1657		FC(F)n1ccc(cn1)-c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl		583.5	A	
I-1658		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(NCc3ccccc3)c12	NMR (400 MHz, DMSO-d6) 9.10 (s, 1H), 7.57 (dd, 8.7, 5.1 Hz, 1H), 7.34-7.28 (m, 1H), 7.27-7.19 (m, 3H), 7.08-7.03 (m, 3H), 6.79 (d, 1.4 Hz, 1H), 5.86 (s, 1H), 5.65 (br s, 1H), 4.36-4.21 (m,, 2H).	445	E	
I-1659		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(Nc3nc4ccccc4s3)c12)-c1ccc2ncnn2c1	NMR (400 MHz, DMSO-d6) 10.08 (br s, 1H), 9.48 (s, 1H), 9.25 (s, 1H), 8.58 (s, 1H), 8.14 (dd, 9.3, 1.8 Hz, 1H), 8.08 (br s, 1H), 8.00 (s, 1H), 7.98 (d, 9.3 Hz, 1H), 7.71 (br s, 1H), 7.53 (br s, 1H), 7.36 (dd, 8.8, 5.2 Hz, 1H), 7.29 (t, 7.7 Hz, 1H), 7.16-7.06 (m, 2H), 6.53 (br s, 1H), 6.26 (br s, 1H).	525.2	B	
I-1660		CC(C)(C#N)n1cc(cn1)-c1cc2C(=O)N[C@@H](c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c	(400 MHz, DMSO-D6) 10.57 (s, 1 H), 9.16 (br s, 1 H), 8.77 (s, 1 H), 8.25 (s, 1 H), 8.04 (s, 1 H), 7.96 (d, 8.3 Hz, 1 H), 7.83-7.74 (m, 2 H), 7.72 (s, 1 H), 7.32 (dd, 8.9, 5.2 Hz, 1 H), 7.09 (td, 8.5, 2.8 Hz, 1 H), 6.57 (br s, 1 H), 5.98	598.3	C	






		1cc(F)ccc 1Cl	(br s, 1 H), 2.03 (s, 6 H).			
I-1661		CC(C)(C #N)n1cc(cn1)- c1cc2C(= O)N[C@ H](c2c(N C(=O)c2 cc(F)cc(c 2)C(F)(F F)c1)c1c c(F)ccc1 Cl	(400 MHz, DMSO-D6) 10.57 (s, 1 H), 9.16 (br s, 1 H), 8.77 (s, 1 H), 8.25 (s, 1 H), 8.04 (s, 1 H), 7.96 (d, 8.3 Hz, 1 H), 7.83-7.74 (m, 2 H), 7.72 (s, 1 H), 7.32 (dd, 8.9, 5.2 Hz, 1 H), 7.09 (td, 8.5, 2.8 Hz, 1 H), 6.57 (br s, 1 H), 5.98 (br s, 1 H), 2.03 (s, 6 H).	598. 3	A	
I-1662		CC(C)O C(C(=O) Nc1cc(cc 2C(=O)N C(c12)c1 cc(F)ccc1 Cl)- c1ccc2nc nn2c1)c1 ccccc1	NMR (400 MHz, DMSO-d6) 9.60-9.53 (m, 1H), 9.45-9.40 (m, 1H), 9.31-9.21 (m, 1H), 8.57 (s, 1H), 8.49 (s, 2H), 8.15 (d, 1.4 Hz, 1H), 8.09-8.03 (m, 1H), 8.02-7.99 (m, 1H), 7.99-7.94 (m, 1H), 7.35-7.26 (m, 4H), 7.25-7.19 (m, 1H), 7.01 (br s, 1H), 6.27 (br s, 1H), 4.87-4.80 (m, 1H), 3.19-3.07 (m, 1H), 1.06-0.99 (m, 6H).	570	D	
I-1663		Fc1ccc(C l)c(c1)C1 NC(=O)c 2cc(cc(N C(=O)N3 CCCCC3)c12)- c1ccc2nc nn2c1	1H-NMR (400 MHz, DMSO-d6) 9.39-9.38 (m, 1H), 9.13 (br. s, 1H), 8.58-8.55 (m, 2H), 8.06 (dd, 9.3, 1.7 Hz, 1H), 7.97 (d, 9.3 Hz, 1H), 7.88 (d, 1.5 Hz, 1H), 7.69 (d, 1.4 Hz, 1H), 7.54-7.48 (m, 1H), 7.25 (app. td, 8.3, 3.0 Hz, 1H), 6.63 (br. s, 1H), 6.11 (br. s, 1H), 3.21 (ddd, 11.7, 7.2, 3.1 Hz, 2H), 3.07 (ddd, 12.6, 7.0, 3.3 Hz, 2H), 1.49-1.42 (m, 2H), 1.38-1.28 (m, 2H), 1.21-1.11 (m, 2H).	505. 3	D	





I-1664		OC1CC(C1)C(=O)Nc1cc(cc2C(=O)NC(c12)c1cc(F)ccc1Cl)-c1ccc2ncnn2c1	NMR (400 MHz, DMSO-d6) 9.77 (s, 1H), 9.45-9.43 (m, 1H), 9.22 (br. s, 1H), 8.57 (s, 1H), 8.09 - 8.07 (m, 1H), 8.01 - 7.99 (m, 1H), 7.97 (dd, 3.0, 0.7 Hz, 1H), 7.78 (d, 1.6 Hz, 1H), 7.56-7.46 (m, 1H), 7.29-7.20 (m, 1H), 6.61 (br. s, 1H), 6.16 (br. s, 1H), 5.05 (d, 6.3 Hz, 1H), 4.17-4.03 (m, 1H), 2.81-2.74 (m, 1H), 2.39-2.18 (m, 1H), 2.07-2.15 (m, 1H), 1.93-1.82 (m, 2H).	492	E	
I-1665		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)Cc3ccccc3)c12)-c1ccc2ncnn2c1	NMR (400 MHz, DMSO-d6) 9.46-9.43 (m, 1H), 8.57 (s, 1H), 8.09 (dd, 9.3, 1.8 Hz, 1H), 8.00 (d, 1.5 Hz, 1H), 7.96 (dd, 9.3, 0.7 Hz, 1H), 7.90 (d, 1.6 Hz, 1H), 7.54-7.43 (m, 1H), 7.34-7.15 (m, 5H), 7.04 (br d, 6.5 Hz, 2H), 6.63 (br s, 1H), 6.12 (br s, 1H), 3.45-3.33 (m, 2H).	512	E	
I-1666		OCC1NC(=O)c2cccc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	NMR (400 MHz, DMSO-d6) 11.08 (br. s, 1H), 8.71 (s, 1H), 8.13 (s, 1H), 8.08 (dd, 7.6, 1.2 Hz, 1H), 8.07 (br. d, 8.4 Hz, 1H), 8.03 (br. d, 8.5 Hz, 1H), 7.57-7.49 (m, 2H), 6.21 (br. s, 1H), 4.83 (dd, 6.4, 5.7 Hz, 1H), 3.73 (dd, 10.5, 4.9 Hz, 1H), 3.49 (dd, 10.4, 7.2 Hz, 1H).	369.2	E	
I-1667		Fc1ccc(Cl)c(c1)C1NC(=O)c2c1c(NC(=O)c1cc(F)cc(c1)C(F)(F)F)cc(c2Cl)-	(400 MHz, DMSO-D6) 10.99-10.14 (br s, 1 H), 9.38 (br s, 1 H), 9.18 (s, 1 H), 8.60 (s, 1 H), 7.99 (app d, 9.2 Hz, 1 H), 7.98-7.92 (m, 1 H), 7.83 (dd, 9.2, 1.6 Hz, 1 H), 7.80-7.68 (m, 2 H), 7.66 (s, 1 H), 7.36 (dd, 8.9, 5.1 Hz, 1 H), 7.13	616.2	A	




		c1ccc2nc nn2c1	(td, 8.4, 2.9 Hz, 1 H), 6.77 (br s, 1 H), 6.05 (br s, 1 H).			
I-1668		Fc1ccc(C l)c(c1)C1 NC(=O)c 2cc(cc(N c3cn4ccc cc4n3)c1 2)- c1ccc2nc nn2c1	1H NMR (400 MHz, DMSO-d6) 9.40 (s, 1H), 9.12 (s, 1H), 8.57 (s, 1H), 8.37 (d, 6.7 Hz, 1H), 8.11 (br. s, 1H), 8.08 (dd, 9.3, 1.8 Hz, 1H), 8.00 (d, 1.5 Hz, 1H), 7.97 (dd, 9.2, 0.9 Hz, 1H), 7.66 (d, 1.0 Hz, 1H), 7.53 (s, 1H), 7.43 (dd, 8.8, 5.2 Hz, 1H), 7.36 (d, 8.9 Hz, 1H), 7.22-7.10 (m, 2H), 6.82 (t, 6.5 Hz, 1H), 6.69 (br. s, 1H), 6.21 (s, 1H)	510. 2	D	
I-1669		Fc1ccc(C l)c(c1)C1 NC(=O)c 2cc(cc(N C(=O)c3 cc(F)cc(c 3)C(F)(F F)c12)- c1ccn2nc cc2c1	1H NMR (400 MHz, DMSO) 10.62 (s, 1H), 9.24 (s, 1H), 8.79 (dt, 7.3, 1.0 Hz, 1H), 8.22-8.17 (m, 1H), 8.11-8.04 (m, 2H), 7.95 (d, 9.6 Hz, 2H), 7.77 (d, 9.1 Hz, 1H), 7.71 (s, 1H), 7.36-7.30 (m, 2H), 7.10 (td, 8.4, 3.1 Hz, 1H), 6.70 (dd, 2.3, 0.9 Hz, 1H), 6.06 (s, 1H).	583. 126	A	
I-1670		Fc1ccc(C l)c(c1)C1 NC(=O)c 2cc(cc(N C(=O)c3 cc(F)cc(c 3)C(F)(F F)c12)- c1ccn2nn cc2c1	1H NMR (400 MHz, DMSO) 10.65 (s, 1H), 9.27 (s, 1H), 9.19 (d, 7.4 Hz, 1H), 8.50-8.41 (m, 1H), 8.27 (d, 1.0 Hz, 1H), 8.13 (s, 1H), 7.96 (dd, 13.1, 5.0 Hz, 2H), 7.77 (d, 9.0 Hz, 1H), 7.71 (s, 1H), 7.64 (dd, 7.4, 2.0 Hz, 1H), 7.34 (dd, 8.9, 5.2 Hz, 1H), 7.10 (td, 8.4, 3.0 Hz, 1H), 6.06 (s, 1H).	584. 127	A	
I-1671		Nc1cc(cc 2C(=O)N C(c12)c1 cc(F)ccc1 Cl)- c1ccc2nc nn2c1	1H NMR (500 MHz, DMSO) 9.24 (dd, 1.8, 1.0 Hz, 1H), 8.98 (s, 1H), 8.53 (s, 1H), 7.98 (dd, 9.3, 1.8 Hz, 1H), 7.92 (dd, 9.2, 1.0 Hz, 1H), 7.56 (dd, 8.9, 5.1 Hz, 1H), 7.34 (d, 1.5 Hz, 1H), 7.26 (ddd, 8.8,	394. 26	E	





			7.9, 3.1 Hz, 1H), 7.19 (d, 1.6 Hz, 1H), 6.81 (s, 1H), 5.88 (s, 1H), 5.00 (s, 2H)			
I-1672		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(Br)c12)-c1ccc2nccnn2c1	1H NMR (500 MHz, DMSO) 9.52 (dd, 1.9, 0.9 Hz, 1H), 9.42 (s, 1H), 8.56 (s, 1H), 8.28 (s, 1H), 8.20-8.13 (m, 2H), 7.94 (dd, 9.2, 0.9 Hz, 1H), 7.62 (s, 1H), 7.28 (td, 8.4, 3.0 Hz, 1H), 6.55 (s, 1H), 6.09 (s, 1H).	457.12	E	
I-1673		Fc1cc(cc(c1)C(F)(F)F)C(=O)Nc1ccccc2C(=O)NC(Cc3ccccc3)c12	NMR (400 MHz, DMSO-d6) 10.87 (s, 1H), 8.65 (s, 1H), 8.23 (s), 8.17 (d, 8.9 Hz, 1H), 8.01 (d, 8.2 Hz, 1H), 7.55 (dd, 7.8, 1.0 Hz, 1H), 7.42 (t, 7.6 Hz, 1H), 7.33 (dd, 7.4, 0.9 Hz, 1H), 7.00 (m, 3H), 6.91-6.87 (m, 2H), 5.10 (t, 4.6 Hz, 1H), 3.03 (dd, 13.7, 4.1 Hz, 1H), 2.81 (dd, 13.8, 4.7 Hz, 1H).	429	E	
I-1674		CC(=O)N1CCCCC1C1NC(=O)c2cccc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	(400 MHz, DMSO-d6) 10.67 (br s, 1H), 8.88 (s, 1H), 8.25 (s, 1H), 8.21 (d, 9.8 Hz, 1H), 7.98 (d, 8.2 Hz, 1H), 7.82 (d, 6.1 Hz, 1H), 7.65-7.52 (m, 2H), 5.11 (s, 1H), 4.79-4.70 (m, 1H), 3.74-3.54 (m, 2H), 1.98 (s, 3H), 1.61-1.36 (m, 4H), 1.29-1.18 (m, 1H), 1.03-0.91 (m, 1H)	464.3	E	
I-1675		Fc1cc(cc(c1)C(F)(F)F)C(=O)Nc1ccccc2C(=O)NC(C3CCCCN3)c12	(400 MHz, DMSO-d6) 8.87 (s, 1H), 8.76 (s, 1H), 8.52 (d, 8.0 Hz, 0.5H), 8.44 (d, 7.2 Hz, 0.5H), 8.06-7.95 (m, 3H), 7.52 (t, 7.7 Hz, 1H), 7.43 (d, 6.7 Hz, 1H), 4.74 (s, 0.5H), 4.53 (d, 7.1 Hz, 0.5H), 3.08-2.98 (m, 0.5H), 2.72 (br. d, 10.9 Hz, 0.5H), 2.65 - 2.60 (m, 0.5H), 2.59-2.54 (m,	422.3	D	





			1H), 1.83-1.74 (m, 0.5H), 1.74-1.66 (m, 0.5H), 1.60 - 1.54 (m, 0.5H), 1.46 (br. d, 9.7 Hz, 1H), 1.40-1.07 (m, 4H)			
I-1676		Fc1ccc(Cl)c(c1)[C@H]1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1ccc2nnc(Cl)n2c1		618.09	B	
I-1677		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1ccn2ncnc2n1		585.13	A	
I-1678		Fc1cc(cc(c1)C(F)(F)F)C(=O)Nc1ccc2C(=O)NC(CN3CCCCC3)c12	NMR (400 MHz, DMSO-d6) 11.28 (s, 1H), 8.68 (s, 1H), 8.14-8.06 (m, 3H), 8.03 (br. d, 8.6 Hz, 1H), 7.56-7.48 (m, 2H), 4.96 (t, 6.1 Hz, 1H), 2.48 (submerged d, 6.3 Hz, 2H), 2.44-2.24 (m, 4H), 1.21-1.13 (m, 6H).	436.2	E	
I-1679		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(Nc3cc4cccn4n3)c12)-c1ccc2ncnn2c1	1H NMR (400 MHz, DMSO-d6) 9.40 (s, 1H), 9.14 (s, 1H), 8.57 (s, 1H), 8.51-8.32 (m, 2H), 8.08 (td, 4.8, 1.8 Hz, 2H), 7.97 (d, 9.2 Hz, 1H), 7.72 (d, 1.5 Hz, 1H), 7.42-7.35 (m, 2H), 7.19-7.08 (m, 2H), 6.67 (td, 6.9, 1.3 Hz, 1H), 6.59 (br. s, 1H), 6.28 (s, 1H), 5.95 (s, 1H)	510.2	E	





I-1680		Fc1ccc(Cl)c(c1)C1NC(=O)c2cccc(NC(=O)C3CCCCC3)c12		387.2	D	
I-1681		Fc1ccc(Cl)c(c1)C1NC(=O)c2cccc(NC(=O)c3ccccc3)c12	1H NMR (400 MHz, DMSO-d6) 10.13 (s, 1H), 9.10 (s, 1H), 7.70-7.49 (m, 6H), 7.43 (t, 7.6 Hz, 2H), 7.34 (dd, 8.9, 5.2 Hz, 1H), 7.12 (td, 8.4, 3.1 Hz, 1H), 6.07 (s, 1H).	381.15	E	
I-1682		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(Nc3cccc4ccccc34)c12	NMR (400 MHz, DMSO-d6) 9.09 (br s, 1H), 8.16 (s, 1H), 7.84 (d, 8.2 Hz, 1H), 7.59 (d, 8.2 Hz, 1H), 7.47 (d, 9.1 Hz, 1H), 7.45-7.37 (m, 3H), 7.28 (t, 7.3 Hz, 1H), 7.20 (s, 1H), 7.09-7.02 (m, 1H), 6.97 (d, 7.2 Hz, 1H), 6.93-6.84 (m, 1H), 6.31 (br s, 1H), 5.58 (br s, 1H).	481.1	D	
I-1683		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(Nc3cc4ccccc4cn3)c12	NMR (400 MHz, DMSO-d6) 9.17 (s, 1H), 8.97 (s, 1H), 8.69 (s, 1H), 7.92 (d, 8.2 Hz, 1H), 7.77 (d, 1.0 Hz, 1H), 7.68 (d, 8.4 Hz, 1H), 7.57 (t., 7.1 Hz, 1H), 7.54 (d, 0.9 Hz, 1H), 7.342 (app t, 7.6 Hz, 1H), 7.24 (dd, 8.8, 5.1 Hz, 1H), 7.03 (td, 8.3, 3.0 Hz, 1H), 6.83 (s, 1H), 6.52 (br s, 1H), 6.01 (s, 1H).	482.1	E	
I-1684		Fc1ccc(Cl)c(c1)[C@@H]1NC(=O)c2cc(cc(NC(=O)c3csc4ccccc34)c12)-c1ccc2nnn2c1	1H NMR (400 MHz, DMSO-d6) 10.36 (s, 1H), 9.48 (t, 1.4 Hz, 1H), 9.24 (s, 1H), 8.58 (s, 1H), 8.29 - 8.22 (m, 1H), 8.15 (dd, 9.3, 1.8 Hz, 1H), 8.10 (d, 1.6 Hz, 1H), 8.06 (q, 3.2, 2.8 Hz, 2H), 8.06 - 7.96 (m, 2H), 7.49 - 7.40 (m, 2H), 7.36 (dd, 8.9,	554.1	A	A





			5.2 Hz, 1H), 7.12 (td, 8.4, 3.1 Hz, 1H), 6.72 (s, 1H), 6.21 (s, 1H).			
I-1685		Fc1ccc(Cl)c(c1)[C@H]1NC(=O)c2cc(cc(NC(=O)c3csc4ccccc34)c12)-c1ccc2ncnn2c1	1H NMR (400 MHz, DMSO-d6) 10.35 (s, 1H), 9.48 (t, 1.4 Hz, 1H), 9.24 (s, 1H), 8.58 (s, 1H), 8.30 - 8.22 (m, 1H), 8.15 (dd, 9.3, 1.9 Hz, 1H), 8.10 (d, 1.6 Hz, 1H), 8.06 (q, 3.3, 2.7 Hz, 2H), 8.06 - 7.96 (m, 2H), 7.49 - 7.40 (m, 2H), 7.36 (dd, 8.9, 5.2 Hz, 1H), 7.12 (td, 8.4, 3.1 Hz, 1H), 6.72 (s, 1H), 6.22 (s, 1H).	554.1	D	
I-1686		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(NC(=O)c3cc(F)cc4c(Cl)n[nH]c34)c12	1H NMR (400 MHz, DMSO-d6) 11.80 (s, 2H), 10.44 (s, 1H), 9.29 (s, 1H), 7.81 (d, 1.7 Hz, 1H), 7.74 (d, 1.8 Hz, 1H), 7.56 (d, 9.7 Hz, 1H), 7.46 (dd, 8.8, 5.1 Hz, 1H), 7.30 (d, 5.3 Hz, 1H), 7.23 (td, 8.4, 3.1 Hz, 1H), 6.73 (s, 1H), 6.05 (s, 1H).	550.95	D	
I-1687		CN1CC(CC1=O)c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	1H NMR (400 MHz, DMSO-d6) 10.54 (br s, 1H), 9.15 (s, 1H), 7.95 (d, 8.9 Hz, 1H), 7.73 (d, 8.7 Hz, 1H), 7.65 (s, 1H), 7.62 (s, 1H), 7.42 (s, 1H), 7.31 (dd, 8.8, 5.1 Hz, 1H), 7.09 (td, 8.7, 3.5 Hz, 1H), 5.96 (br s, 1H), 3.83-3.72 (m, 2H), 2.79 (s, 3H), 2.77-2.70 (m, 1H), 2.45-2.37 (m, 2H)	564.1	A	
I-1688		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)COc3ccccc3)c12)-c1ccc2ncnn2c1	1H-NMR (400 MHz, DMSO-d6) 9.90 (s, 1H), 9.45 (dd, 1.7, 0.8 Hz, 1H), 9.24 (br. s, 1H), 8.58 (s, 1H), 8.10 (dd, 9.3, 1.8 Hz, 1H), 8.06 (d, 1.5 Hz, 1H), 8.00-7.96 (m, 2H), 7.50 (dd, 8.3, 5.1 Hz, 1H), 7.32-7.27 (m, 2H), 7.23 (ddd, 8.8, 8.0, 3.1 Hz, 1H), 6.98 (tt, 7.3, 1.0	528.2	E	




			Hz, 1H), 6.86-6.82 (m, 2H), 6.68 (br. s, 1H), 6.17 (br. s, 1H), 4.42 (s, 2H).			
I-1689		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(NC(=O)C3CC(CCN3)C(F)(F)F)c12	1H NMR (400 MHz, CD3CN):-′ 8.48 (br s, 1H), 8.37 (d, 1.7 Hz, 0.5H), 8.24 (d, 1.7 Hz, 0.5H), 7.73 (d, 1.7 Hz, 0.5H), 7.72 (d, 1.7 Hz, 0.5H), 7.50 (br s, 1H), 7.32 (br s, 1H), 7.13 (td, 8.4, 3.1 Hz, 1H), 6.62 (br s, 1H), 6.09 (br s, 1H), 3.15-2.95 (m, 2H), 2.56 (td, 12.6, 2.9 Hz, 1H), 1.91-1.70 (m, 3H), 1.40-1.29 (m, 1H), 1.21-0.82 (m, 2H).	534.1	E	
I-1690		OC1CCC(CC1)C(=O)Nc1cc(cc2C(=O)NC(c12)c1cc(F)ccc1Cl)-c1ccc2ncnn2c1	NMR (400 MHz, DMSO-d6) 9.78 (br s, 1H),9.43 (dd, 1.7, 0.8 Hz, 1H), 9.20 (br s, 1H), 8.57 (s, 1H), 8.09 (dd, 9.3, 1.8 Hz, 1H), 8.01-7.94 (m, 2H), 7.80 (d, 1.6 Hz, , 1H), 7.57-7.45 (m, 1H), 7.32-7.19 (m, 1H), 6.58 (br s, 1H), 6.11 (br s, 1H), 4.57 (br s, 1H), 2.02-1.91 (m, 1H), 1.83-1.68 (m, 2H), 1.54-1.42 (m, 1H), 1.38-1.27 (m, 1H), 1.26-1.10 (m, 2H), 1.10-0.96 (m, 1H).	520	E	
I-1691		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(Nc3coc4ccccc34)c12	(400 MHz, DMSO-D6) 9.17 (s, 1 H), 7.92 (s, 1 H), 7.65 (br s, 1 H), 7.54 (d, 8.3 Hz, 1 H), 7.37-7.28 (m, 3 H), 7.16 (t, 7.4 Hz, 1 H), 7.10 (td, 8.3, 3.0 Hz, 1 H), 7.08 (d, 8.1 Hz, 1 H), 7.05 (d, 1.2 Hz, 1 H), 6.67 (br s, 1 H), 5.88 (s, 1 H).	469.2	D	




I-1692		Fc1ccc(Cl)c(c1)[C@H]1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1ccc2nc(Cl)nn2c1		618.4	D	
I-1693		Fc1ccc(Cl)c(c1)[C@@H]1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1ccc2nc(Cl)nn2c1		618.2	A	
I-1694		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1ccc2ncc(Cl)n2c1		617.13	A	
I-1695		Fc1ccc(Cl)c(c1)[C@H]1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1ccn2nc(Cl)nc2c1		618.2	D	





I-1696		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1ccc2nc(Cl)cn2c1		617.08	A	
I-1697		Fc1ccc(Cl)c(c1)[C@@H]1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1ccn2nc(Cl)nc2c1		618.2	A	
I-1698		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1ccn2ncnc2c1F		602.18	A	
I-1699		Cn1ncc(c1C#N)-c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl		572.4	A	




I-1700		COc1cc2ncnn2cc1-c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl		614.08	A	
I-1701		Fc1ccc(Cl)c(c1)[C@H]1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1cn2ncnc2cc1F		602.2	D	
I-1702		Fc1ccc(Cl)c(c1)[C@@H]1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1cn2ncnc2cc1F		602.2	A	
I-1703		Fc1ccc(Cl)c(c1)[C@H]1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1cc(F)c2ncnn2c1		602.2	E	



I-1704		Fc1ccc(Cl)c(c1)[C@@H]1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1cc(F)c2ncnn2c1		602.2	A	
I-1705		Fc1cc(cc(c1)C(F)(F)F)C(=O)Nc1cc(nc2C(=O)NC(C3CCOCC3)c12)-c1ccc2ncnn2c1		541.7	E	
I-1706		Fc1cc(cc(c1)C(F)(F)F)C(=O)Nc1cc(nc2C(=O)NC(C3CCCCO3)c12)-c1ccc2ncnn2c1		541.7	E	
I-1707		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1ccc2nc(nn2c1)C#N		609.13	A	





I-1708		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1ccc2nnc(C#N)n2c1		609.08	A	
I-1709		Fc1ccc(Cl)c(c1)[C@@H]1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)[C@@H]1CNC(=O)C1	(400 MHz, CD3CN) 8.79 (s, 1H), 7.68 (d, 1.2 Hz, 1H), 7.66-7.62 (m, 1H), 7.62-7.59 (m, 1H), 7.58 (s, 1H), 7.48 (s, 1H), 7.32 (br s, 1H), 7.24 (dd, 8.9, 5.1 Hz, 1H), 6.96 (td, 8.5, 3.2 Hz, 1H), 6.61 (br s, 1H), 6.19 (s, 1H), 6.10 (br s, 1H), 3.89-3.79 (m, 1H), 3.79-3.73 (m, 1H), 3.37 (dd, 9.2, 7.1 Hz, 1H), 2.66 (dd, 16.5, 8.6 Hz, 1H), 2.41 (dd, 16.5, 8.5 Hz, 1H) .	548.2	A	
I-1710		Fc1ccc(Cl)c(c1)[C@@H]1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)[C@H]1CNC(=O)C1	(400 MHz, CD3CN) 8.73 (s, 1H), 7.68 (d, 1.3 Hz, 1H), 7.65 (d, 8.4 Hz, 1H), 7.67-7.58 (m, 1H), 7.57 (s, 1H), 7.48 (s, 1H), 7.28 (s, 1H), 7.24 (dd, 8.9, 5.1 Hz, 1H), 6.96 (td, 8.5, 3.2 Hz, 1H), 6.60 (br s, 1H), 6.15 (s, 1H), 6.11 (s, 1H), 3.90-3.80 (m, 1H), 3.77 (t, 8.4 Hz, 1H), 3.39 (dd, 9.2, 6.9 Hz, 1H), 2.67 (dd, 16.5, 8.6 Hz, 1H), 2.39 (dd, 16.5, 8.3 Hz, 1H).	548.2	A	




I-1711		Fc1ccc(Cl)c(c1)[C@H]1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)[C@@H]1CNC(=O)C1	(400 MHz, CD3CN) 8.75 (s, 1H), 7.69 (d, 1.2 Hz, 1H), 7.67-7.63 (m, 1H), 7.63-7.59 (m, 1H), 7.58 (s, 1H), 7.48 (s, 1H), 7.30-7.22 (m, 2H), 6.96 (td, 8.5, 3.1 Hz, 1H), 6.63 (br s, 1H), 6.13 (br s, 2H), 3.90-3.80 (m, 1H), 3.77 (app t, 8.4 Hz, 1H), 3.37 (dd, 9.2, 7.1 Hz, 1H), 2.67 (dd, 16.5, 8.6 Hz, 1H), 2.42 (dd, 16.5, 8.5 Hz, 1H).	548.2	D	
I-1712		Fc1ccc(Cl)c(c1)[C@H]1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)[C@H]1CNC(=O)C1	(400 MHz, CD3CN) 8.74 (br s, 1H), 7.68 (d, 1.3 Hz, 1H), 7.67-7.63 (m, 1H), 7.63-7.59 (m, 1H), 7.58 (s, 1H), 7.49 (s, 1H), 7.27-7.22(m, 2H), 6.96 (td, 8.6, 3.2 Hz, 1H), 6.61 (br s, 1H), 6.12 (br s, 2H), 3.90-3.80 (m, 1H), 3.77 (app t, 8.5 Hz, 1H), 3.39 (dd, 9.2, 6.9 Hz, 1H), 2.67 (dd, 16.5, 8.7 Hz, 1H), 2.39 (dd, 16.5, 8.4 Hz, 1H).	548.3	D	
I-1713		CN1CCCC[C@@H]1[C@@H]1NC(=O)c2cccc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	(400 MHz, DMSO-d6) 8.60 (s, 1H), 8.35 (d, 7.2 Hz, 1H), 8.04 (d, 8.6 Hz, 1H), 7.92 (s, 1H), 7.89 (d, 8.4 Hz, 1H), 7.53 (t, 7.7 Hz, 1H), 7.45 (dd, 7.4, 1.0 Hz, 1H), 5.22 (s, 1H), 2.39-2.34 (m, 1H), 2.21 (s, 3H), 2.13-2.04 (m, 1H), 1.60-1.56 (m, 1H), 1.56-1.50 (m, 1H), 1.45-1.39 (m, 1H), 1.36-1.29 (m, 1H), 1.26-1.21 (m, 1H), 1.13-1.07 (m, 1H), 0.63 (qd, 14.3, 4.7 Hz, 1H)	436.2	E	





I-1714		Fc1ccc(Cl)c(c1)C1NC(=O)c2cccc(c12)-n1[nH]c(=O)c2ccccc12	1H NMR (400 MHz, DMSO-d6) 10.97 (s, 1H), 9.17 (s, 1H), 7.82 (dd, 6.5, 2.5 Hz, 1H), 7.81-7.72 (m, 2H), 7.55 (d, 8.0 Hz, 1H), 7.30 (d, 3.9 Hz, 2H), 7.12 (s, 1H), 7.02 (dt, 7.8, 3.8 Hz, 1H), 6.81 (td, 8.4, 3.1 Hz, 1H), 6.36 (s, 1H), 6.25 (s, 1H).	394.05	E	
I-1715		Fc1ccc(Cl)c(c1)[C@@H]1NC(=O)c2cc(cc(NC(=O)N3CCc4ccccc34)c12)-c1ccc2ncnn2c1	1H NMR (400 MHz, DMSO-d6) 9.43 (dd, 1.9, 0.9 Hz, 1H), 9.16 (s, 1H), 8.67 (s, 1H), 8.57 (s, 1H), 8.10 (dd, 9.3, 1.9 Hz, 1H), 8.02-7.95 (m, 2H), 7.81 (d, 1.7 Hz, 1H), 7.73 (d, 8.0 Hz, 1H), 7.40 (dd, 8.8, 5.2 Hz, 1H), 7.22-7.14 (m, 2H), 7.17-7.07 (m, 1H), 6.91 (td, 7.4, 1.1 Hz, 1H), 6.69 (s, 1H), 6.10 (s, 1H), 3.88 (td, 10.0, 7.4 Hz, 1H), 3.04 (dt, 16.6, 7.5 Hz, 2H).	539.3	A	A
I-1716		Fc1ccc(Cl)c(c1)[C@H]1NC(=O)c2cc(cc(NC(=O)N3CCc4ccccc34)c12)-c1ccc2ncnn2c1	1H NMR (400 MHz, DMSO-d6) 9.42 (d, 1.8 Hz, 1H), 9.15 (s, 1H), 8.69 (s, 1H), 8.57 (s, 1H), 8.10 (dd, 9.3, 1.8 Hz, 1H), 8.04-7.95 (m, 2H), 7.82 (d, 2.0 Hz, 1H), 7.73 (d, 8.0 Hz, 1H), 7.40 (dd, 8.9, 5.1 Hz, 1H), 7.30 (d, 9.9 Hz, 1H), 7.28-7.15 (m, 3H),7.15-7.00 (m , 2H), 6.99-6.85(m,1H), 6.69 (s, 1H), 6.11 (s, 1H), 3.95-3.84 (m, 1H), 3.35-3.28(m,1H), 3.14-2.95 (m, 2H).	539	D	
I-1717		Fc1ccc2CCN(C(=O)Nc3cc(Br)cc4C(=O)NC(c34)c3cc(F)ccc3Cl)c2c1	1H-NMR (400 MHz, DMSO-d6) 9.23 (br. s, 1H), 8.79 (s, 1H), 7.69 (s, 1H), 7.57 (s, 1H), 7.45 (br. d, 10.6 Hz, 1H), 7.38 (dd, 8.8, 5.1 Hz, 1H), 7.19-7.13 (m, 2H), 6.71 (app. td, 9.0,	520.1	A	





			2.5 Hz, 1H), 6.65 (br. s, 1H), 5.97 (br. s, 1H), 3.87 (td, 10.0, 7.5 Hz, 1H), 3.29-3.17 (m, 1H), 3.07-2.89 (m, 2H).			
I-1718		OC1CCN(C1)C(=O)Nc1cc(cc2C(=O)NC(c12)c1cc(F)ccc1Cl)-c1ccc2ncnn2c1	1H-NMR (400 MHz, DMSO-d6) 9.38 (dd, 1.6, 0.9 Hz, 2H), 9.14 (br. s, 2H), 8.57 (s, 2H), 8.23 (br. s, 1H), 8.19 (br. s, 1H), 8.06 (dd, 9.3, 1.8 Hz, 2H), 7.97 (dd, 9.3, 0.5 Hz, 2H), 7.89 (s, 2H), 7.73 (br. s, 1H), 7.71 (br. s, 1H), 7.51-7.44 (m, 2H), 7.27-7.20 (m, 2H), 6.68 (br. s, 2H), 6.07 (br. s, 2H), 4.99 (br. s, 2H), 4.24-4.19 (m, 1H), 4.18-4.13 (m, 1H), 3.39-3.26 (m, 6H), 3.08-3.03 (m, 2H), 1.83-1.75 (m, 1H), 1.75-1.64 (m, 3H).	507.3	E	
I-1719		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Cn3cnc(c3)C#N)cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	1H-NMR (400 MHz, DMSO-d6) 10.56 (br. s, 1H), 9.16 (br. s, 1H), 8.31(s, 1H), 8.12 (s), 7.93-7.85 (m, 1H), 7.71 (br. d, 8.6 Hz, 1H), 7.65 (s, 1H), 7.61 (br. s, 1H), 7.48 (br. s, 1H), 7.31 (dd, 8.9, 5.3 Hz, 1H), 7.08 (app. td, 8.5, 3.2 Hz, 1H), 6.62 (br. s, 1H), 5.95 (br. s, 1H), 5.47 (d, A of AB, JAB = 15.5 Hz, 1H), 5.42 (d, B of AB, JAB = 15.1 Hz, 1H).	572.2	A	
I-1720		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)N3CCCC3)c12)-c1ccc2ncnn2c1	1H-NMR (400 MHz, DMSO-d6) 9.38 (dd, 1.7, 0.9 Hz, 1H), 9.13 (br. s, 1H), 8.57 (s, 1H), 8.25 (br. s, 1H), 8.05 (dd, 9.3, 1.8 Hz, 1H), 7.97 (dd, 9.3, 0.8 Hz, 1H), 7.89 (d, 1.6 Hz, 1H), 7.68 (d, 1.5 Hz, 1H), 7.53-7.46 (m, 1H), 7.25 (ddd, 8.7, 8.2, 3.1 Hz, 1H), 6.67 (br. s, 1H), 6.06 (br. s,	491.3	E	






			1H), 3.25-3.21 (m, 4H), 1.76-1.71 (m, 4H).			
I-1721		OC1CCCN(C1)C(=O)Nc1cc(cc2C(=O)NC(c12)c1cc(F)ccc1Cl)-c1ccc2ncnn2c1	1H-NMR (400 MHz, DMSO-d6)-9.38 (dd, 1.6, 0.8 Hz, 2H), 9.12 (br. s, 2H), 8.66 (br. s, 1H), 8.61 (br. s, 1H), 8.56 (s, 2H), 8.07 (d, 1.7 Hz, 1H), 8.05 (d, 1.7 Hz, 1H), 7.98 (d, 0.6 Hz, 1H), 7.96 (d, 0.7 Hz, 1H), 7.88 (d, 1.6 Hz, 2H), 7.69 (d, 1.6 Hz, 1H), 7.66 (d, 1.6 Hz, 1H), 7.54-7.47 (m, 2H), 7.28-7.21 (m, 2H), 6.59 (br. s, 1H), 6.08 (br. s, 2H), 4.85 (br. s, 2H), 3.82-3.73 (m, 2H), 3.63 (br. d, 12.8 Hz, 1H), 3.50 (br. d, 12.6 Hz, 1H), 2.99-2.89 (m, 1H), 2.63-2.54 (m, 1H), 2.44-2.34 (m, 2H), 2.27 (dd, 12.2, 9.9 Hz, 1H), 1.84-1.73 (m, 2H), 1.61-1.45 (m, 2H), 1.32-1.10 (m, 4H), 0.92-0.78 (m, 1H).	521.3	E	
I-1722		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)N3CCC4(CC4(F)F)C3)c12)-c1ccc2ncnn2c1	1H-NMR (400 MHz, DMSO-d6) ´ 9.39-9.38 (m, 1H), 9.16 (br. s, 1H), 8.57 (s, 1H), 8.41 (d, 2.2 Hz, 1H), 8.08-8.04 (m, 1H), 7.97 (dd, 9.3, 0.8 Hz, 1H), 7.92 (d, 1.4 Hz, 1H), 7.68 (dd, 5.4, 1.6 Hz, 1H), 7.53-7.45 (m, 1H), 7.30-7.20 (m, 1H), 6.66 (br. s, 1H), 6.06 (br. s, 1H), 3.54-3.37 (m, 2H), 3.11-3.02 (m, 1H), 3.00-2.86 (m, 1H), 2.02-1.85 (m, 2H), 1.64-1.49 (m, 2H).	553.3	D	




I-1723		OC1CCCC(C1)C(=O)Nc1cc(cc2C(=O)NC(c12)c1cc(F)ccc1Cl)-c1ccc2ncnn2c1	1H-NMR (400 MHz, DMSO-d6) 9.84 (br. s, 1H), 9.78 (br. s, 1H), 9.45-9.42 (m, 2H), 9.20 (br. s, 2H), 8.57 (s, 2H), 8.10 (dd, 3.8, 1.5 Hz, 1H), 8.07 (dd, 3.6, 1.5 Hz, 1H), 7.99-7.96 (m, 3H), 7.96 (s, 1H), 7.85 (d, 0.8 Hz, 1H), 7.76 (d, 0.6 Hz, 1H), 7.55-7.48 (m, 2H), 7.24 (app. td, 8.3, 2.9 Hz, 2H), 6.56 (br. s, 2H), 6.15 (br. s, 2H), 4.42 (br. s, 2H), 3.90-3.86 (m, 1H), 3.85-3.82 (m, 1H), 1.58-1.44 (m, 5H), 1.43-1.23 (m, 8H), 1.20-1.11 (m, 2H), 1.10-1.01 (m, 1H).	520.3	E	
I-1724		OC(C(=O)Nc1cc(cc2C(=O)NC(c12)c1cc(F)ccc1Cl)-c1ccc2ncnn2c1)c1ccccc1	NMR (400 MHz, DMSO-d6) 9.62 (br s, 1H), 9.41 (s, 1Hz), 9.20 (s, 1H), 8.57 (d, 1.7 Hz, 1H), 8.30 (s, 1H), 8.05 (td, 9.2, 1.6 Hz, 1H), 7.98 (d, 3.5 Hz, 1H), 7.62- 7.50 (m, 1H), 7.46-7.39 (m, 1H), 7.35-7.17 (m, 5H), 7.06 (d, 2.2 Hz, 1H), 6.63 (br s, 1H), 6.21 (br s, 1H), 4.95 (s, 1H).	528	E	
I-1725		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(Nc3ccc4ccccc4c3)c12	NMR (400 MHz, DMSO-d6) 9.15 (br s, 1H), 8.15 (s, 1H), 7.76 (d, 8.1 Hz, 1H), 7.71 (d, 8.8 Hz, 2H), 7.49-7.46 (m, 2H), 7.39 (t, 7.0 Hz, 1H), 7.32-7.24 (m, 2H), 7.13 (d, 1.7 Hz, 1H), 7.10-7.03 (m, 1H), 6.92 (dd, 8.8, 2.1 Hz, 1H), 6.48 (dd, 9.3, 2.8 Hz, 1H), 5.82 (s, 1H)	481.1	D	
I-1726		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(NCC3C	NMR (400 MHz, DMSO-d6) 9.06 (s, 1H), 7.60-7.49 (m, 1H), 7.26 (td, 8.4, 3.1 Hz, 1H), 7.03 (d, 1.2 Hz, 1H), 6.87 (s, 1H), 6.76	451.1	E	





		CCCC3)c12	(br s, 1H), 5.82 (s, 1H), 4.65-4.56 (m, 1H), 2.97-2.87 (m, 1H), 2.83-2.74 (m, 1H), 1.55 (d, 6.8 Hz, 3H), 1.45-1.24 (m, 3H), 1.15-0.96 (m, 3H), 0.78-0.58 (m, 2H).			
I-1727		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(Nc3nc4ccccc4[nH]3)c12)-c1ccc2ncnn2c1	1H NMR (400 MHz, DMSO-d6) 9.41 (dd, 1.7, 0.9 Hz, 1H), 9.12 (br. s, 1H), 8.57 (s, 1H), 8.40 (d, 1.3 Hz, 1H), 8.35 (br. s, 2H), 8.10 (dd, 9.3, 1.8 Hz, 1H), 7.99 (dd, 9.3, 0.7 Hz, 1H), 7.81 (d, 1.6 Hz, 1H), 7.39 (dd, 8.8, 5.2 Hz, 1H), 7.21 (dd, 5.4, 2.9 Hz, 2H), 7.12 (ddd, 3.1, 8.0, 8.7 Hz, 1H), 7.00-6.87 (m, 2H), 6.61 (br. s, 1H), 6.38 (s, 1H).	510.3	D	
I-1728		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(CS(=O)(=O)c3ccccc3)c12)-c1ccc2ncnn2c1	1H NMR (400 MHz, DMSO-d6) 9.33 (br. s, 1H), 9.23 (dd, 1.7, 0.9 Hz, 1H), 8.58 (s, 1H), 8.21 (s, 1H), 7.99 (d, 9.2 Hz, 1H), 7.83 - 7.74 (m, 1H), 7.83 - 7.74 (m, 1H), 7.74-7.60 (m, 5H), 7.45 (br. s, 1H), 7.30 (br. s, 1H), 6.47 (br. s, 1H), 6.07 (br. s, 1H), 4.71 (br. d, 13.4 Hz, 1H), 3.89 (d, 13.8 Hz, 1H)	533.1	E	
I-1729		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(c12)-c1ccc2ccccc2c1)-c1ccc2ncnn2c1	NMR (400 MHz, DMSO-d6) 9.63 (s, 1H), 9.34 (br s, 1H), 8.58 (s, 1H), 8.27 (d, 9.3 Hz, 1H), 8.21 (d, 1.5 Hz, 1H), 8.13 (s, 1H), 8.06 (s, 1H), 7.97 (d, 9.3 Hz, 1H), 7.87 (t, 7.1 Hz, 2H), 7.82 (d, 8.5 Hz, 1H), 7.63 (d, 9.0 Hz, 1H), 7.56-7.44 (m, 2H), 7.07 (dd, 8.8, 5.2 Hz, 1H), 6.84 (td, 8.7, 2.8 Hz, 1H), 6.64	505	D	




			(br s, 1H), 6.39 (br s, 1H).			
I-1730		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)C(=O)c3ccccc3)c12)-c1ccc2ncnn2c1	NMR (400 MHz, DMSO-d6) 10.91 (br s, 1H), 9.51 (s, 1H), 9.31 (br s, 1H), 8.58 (s, 1H), 8.15 (dd, 9.3, 1.7 Hz, 1H), 8.12 (d, 1.2 Hz, 1H), 8.06 (d, 1.4 Hz, 1H), 7.99 (d, 9.2 Hz, 1H), 7.82-7.71 (m, 3H), 7.66-7.59 (m, 1H), 7.58-7.49 (m, 3H), 7.24 (td, 8.6, 2.9 Hz, 1H), 6.65 (br s, 1H), 6.21 (br s, 1H).	526	D	
I-1731		Fc1cc(cc(c1)C(F)(F)F)C(=O)Nc1ccc2C(=O)NC(C3CCC3)c12	NMR (400 MHz, DMSO-d6) 10.68 (s, 1H), 8.92 (s, 1H), 8.21 (s, 1H), 8.16 (d, 9.1 Hz, 1H), 8.04 (d, 8.4 Hz, 1H), 7.58-7.49 (m, 3H), 4.77 (d, 4.5 Hz, 1H), 2.77-2.64 (m, 1H), 2.07-1.95 (m, 1H), 1.90-1.80 (m, 1H), 1.76-1.66(m, 1H), 1.65-1.53(m, 1H), 1.39-1.30 (m, 2H).	393	E	
I-1732		Fc1cc(cc(c1)C(F)(F)F)C(=O)Nc1ccc2C(=O)NC(CC3CCCCC3)c12	NMR (400 MHz, DMSO-d6) 10.78 (s, 1H), 8.91 (s, 1H), 8.17 (s, 1H), 8.12 (d, 9.0 Hz, 1H), 8.05 (d, 8.4 Hz, 1H), 7.60-7.50 (m, 3H), 4.83 (br, d, 8.0 Hz, 1H), 1.83-1.66 (m, 2H), 1.57-1.37 (m, 5H), 1.18-0.90 (m, 4H), 0.81-0.58 (m, 2H).	435	D	
I-1733		CN1CCCC[C@H]1[C@@H]1NC(=O)c2cccc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	(400 MHz, DMSO-d6) 11.17 (br s, 1H), 8.56 (s, 1H), 8.16 (s, 1H), 8.10 (d, 9.4 Hz, 1H), 8.04 (t, 7.8 Hz, 1H), 7.66 (dd, 7.0, 1.8 Hz, 1H), 7.58-7.50 (m, 2H), 5.26 (d, 3.6 Hz, 1H), 2.86 - 2.77 (app dt, 11.6 Hz, 2.5 H, 1H), 2.29-2.23 (m, 1H), 2.21 (s, 3H), 1.79 (td, 11.5, 2.4 Hz, 1H), 1.56-1.37	436.3	E	




			(m, 2H), 1.36-1.19 (m, 1H), 1.00-0.89 (m, 2H), 0.69 - 0.60 (m, 1H)			
I-1734		Fc1ccc(Cl)c(c1)[C@@H]1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1ccc2nnc(Cl)n2c1		618.09	A	
I-1735		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(OCc3cncnc3)cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12		575.12	A	
I-1736		Nc1ccc(COc2cc3C(=O)NC(c3c(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c2)c2cc(F)ccc2Cl)cn1		589.13	A	
I-1737		Cn1cc(c(n1)C#N)-c1cc2C(=O)N[C@@H](c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl		572.4	E	




I-1738		Cn1cc(c(n1)C#N)-c1cc2C(=O)N[C@H](c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl		572.4	A	
I-1739		FC(F)n1cc(cn1)-c1cc2C(=O)N[C@@H](c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	^{1}H NMR (500 MHz, DMSO-d_6) δ 10.55 (s, 1H), 9.17 (s, 1H), 8.94 (s, 1H), 8.44 (s, 1H), 8.06 (d, J = 1.5 Hz, 1H), 7.99 – 7.69 (m, 5H), 7.32 (dd, J = 8.9, 5.1 Hz, 1H), 7.09 (td, J = 8.4, 3.1 Hz, 1H), 6.92 – 6.41 (m, 1H), 5.99 (s, 1H).	583.4	D	
I-1740		FC(F)n1cc(cn1)-c1cc2C(=O)N[C@H](c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	^{1}H NMR (500 MHz, DMSO-d_6) δ 10.55 (s, 1H), 9.17 (s, 1H), 8.94 (s, 1H), 8.44 (s, 1H), 8.06 (d, J = 1.5 Hz, 1H), 7.99 – 7.69 (m, 5H), 7.32 (dd, J = 8.9, 5.1 Hz, 1H), 7.09 (td, J = 8.4, 3.1 Hz, 1H), 6.92 – 6.41 (m, 1H), 5.99 (s, 1H).	583.4	A	A
I-1741		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1ccn2nc(nc2c1)C#N		609.23	A	
I-1742		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(c12)S(=O)(=O)Cc1ccccc1)-	1H NMR (400 MHz, DMSO-d) 9.59 (br. s, 1H), 9.49 (br. s, 1H), 8.62 (s, 1H), 8.50 (d, 1.5 Hz, 1H), 8.29 (br. s, 1H), 8.16 - 8.09 (m, 1H), 8.02 (d, 8.5 Hz, 1H), 7.62 (br. s, 1H),	533.1	D	




		c1ccc2nc nn2c1	7.40-7.28 (m, 3H), 7.24 (br. s, 1H), 7.02 (d, 6.4 Hz, 2H), 6.42 (br. s, 1H), 6.08 (s, 1H), 4.58 (d, 12.8 Hz, 1H), 4.25 (d, 12.5 Hz, 1H).			
I-1743		CC(=O) N1CCCC (C1)C(= O)Nc1cc(cc2C(=O)NC(c12) c1cc(F)cc c1Cl)- c1ccc2nc nn2c1	NMR (400 MHz, DMSO-d6) 10.01 (br s, 1H), 9.45 (s, 1H), 9.23 (br s, 1H), 8.60-8.54 (m, 1H), 8.14-8.08 (m, 1H), 8.05-7.95 (m, 2H), 7.87-7.76 (m, 1H), 7.63-7.46 (m, 1H), 7.33-7.21 (m, 1H), 6.52 (br s, 1H), 6.12 (s, 1H), 4.35-4.07 (m, 1H), 3.79-3.61 (m, 1H), 3.00-2.81 (m, 1H), 2.28-2.07 (m, 1H), 1.95 (s, 3H), 1.74-1.09 (m, 5H).	547. 2	E	
I-1744		CC(=O) N1CCC(CC1)C(= O)Nc1cc(cc2C(=O)NC(c12) c1cc(F)cc c1Cl)- c1ccc2nc nn2c1	NMR (400 MHz, DMSO-d6) 9.93 (s, 1H), 9.88 (s, 1H), 9.45 (br s, 2H), 9.23 (br s, 2H), 8.57 (s, 2H), 8.25 (s, 1H), 8.10 (dd, 9.3, 1.8 Hz, 2H), 8.02-8.01 (m, 2H), 7.98 (d, 9.3 Hz, 2H), 7.81 (dd, 12.1, 1.5 Hz, 2H), 7.58-7.49 (m, 2H), 7.31-7.20 (m, 2H), 6.61 (br s, 2H), 6.13 (br s, 2H), 4.30-4.13 (m, 2H), 3.81-3.65 (m, 2H), 3.05-2.88 (m, 2H), 2.37-2.26 (m, 2H), 2.46 (m, 1H), 1.98(s, 6H), 1.60-1.06 (m, 9H).	547. 1	E	
I-1745		FC(F)Cc 1cc(F)cc(c1)C(=O) Nc1cc(Br)cc2C(= O)NC(c1 2)c1cc(F) ccc1Cl	1H NMR (400 MHz, DMSO-d6) 10.31 (s, 1H), 9.29 (s, 1H),7.90-7.67 (m, 2H), 7.62-7.27 (m, 3H), 7.25-7.11 (m, 2H), 7.00-7.45 (m,1H), 7.45-6.10 (m,1H), 6.10-5.65 (m,1H), 3.26-3.13 (m, 2H).	540. 95	D	




I-1746		Fc1ccc(Cl)c(c1)C1NC(=O)c2cccc(N3Cc4ccccc4CC3=O)c12	1H NMR (400 MHz, DMSO-d6) 9.08 (s, 1H), 7.77-7.65 (m, 2H), 7.59 (d, 7.5 Hz, 1H), 7.21 (t, 7.4 Hz, 1H), 7.18-7.07 (m, 2H), 6.88 (s, 2H), 6.49 (d, 173.5 Hz, 2H), 5.91-5.84 (m, 1H), 4.98 (d, 14.9 Hz, 1H), 3.86-3.59 (m, 2H), 3.45 (d, 18.3 Hz, 1H).	407.25	E	
I-1747		Fc1cc(cc(c1)C(F)(F)F)C(=O)Nc1ccccc2C(=O)NC(C3CCCNC3)c12	(400 MHz, DMSO-d6) 10.79 (br s, 1H), 8.81 (s, 1H), 8.15 (s, 1H), 8.12 (d, 8.5 Hz, 1H), 8.04 (d, 8.4 Hz, 1H), 7.66 (dd, 6.5, 2.3 Hz, 1H), 7.61-7.50 (m, 2H), 4.78 (s, 1H), 2.78 (br d, 10.9 Hz, 1H), 2.25 (t, 11.3 Hz, 1H), 2.05 - 1.91 (m, 2H), 1.66 (br d, 12.7 Hz, 1H), 1.57 (br d, 12.1 Hz, 1H), 1.52-1.37 (m, 1H), 1.28-1.07 (m, 1H), 0.88-0.67 (m, 1H)	422.3	E	
I-1748		Fc1ccc(Cl)c(c1)[C@@H]1NC(=O)c2cc(Cn3cncc3C#N)cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	1H-NMR (400 MHz, DMSO-d6) 10.63 (br. s, 1H), 9.17 (br. s, 1H), 8.32 (d, 0.5 Hz, 1H), 7.93 (d, 0.8 Hz, 1H), 7.90-7.83 (m, 1H), 7.72 (br. d, 8.8 Hz, 1H), 7.65 (s, 1H), 7.53-7.40 (m, 2H), 7.32 (dd, 8.8, 5.2 Hz, 1H), 7.08 (app. td, 8.4, 3.0 Hz, 1H), 6.59 (br. s, 1H), 5.95 (br. s, 1H), 5.58 (d, A of AB, JAB = 16.1 Hz, 1H), 5.53 (d, B of AB, JAB = 15.9 Hz, 1H).	572.3	A	
I-1749		Fc1ccc(Cl)c(c1)[C@H]1NC(=O)c2cc(Cn3cncc3C#N)cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	1H-NMR (400 MHz, DMSO-d6) 10.67 (br. s, 1H), 9.20 (s, 1H), 8.32 (s, 1H), 7.94 (s, 1H), 7.91 (br. d, 7.6 Hz, 1H), 7.72 (br. d, 9.1 Hz, 1H), 7.64 (s, 1H), 7.52 (s, 1H), 7.44-7.37 (m, 1H), 7.31 (dd, 8.8, 5.1 Hz, 1H), 7.09	572.2	B	





			(app. td, 8.5, 3.0 Hz, 1H), 6.64 (br. s, 1H), 5.96 (br. s, 1H), 5.60 (d, A of AB, JAB = 16.1 Hz, 1H), 5.55 (d, B of AB, JAB = 15.7 Hz, 1H).			
I-1750		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)C3CCCC(F)(F)C3)c12)-c1ccc2ncnn2c1	1H-NMR (400 MHz, DMSO-d6) 9.98 (s, 2H), 9.45 (s, 2H), 9.23 (br. s, 2H), 8.57 (s, 2H), 8.12-8.08 (m, 2H), 8.03-8.01 (m, 2H), 7.98 (d, 9.2 Hz, 2H), 7.82 (dd, 6.8, 1.4 Hz, 2H), 7.56-7.50 (m, 2H), 7.31-7.23 (m, 2H), 6.58 (br. s, 2H), 6.11 (br. s, 2H), 2.42-2.30 (m, 2H), 2.02-1.91 (m, 2H), 1.90-1.58 (m, 8H), 1.56-1.49 (m, 1H), 1.41-1.28 (m, 3H), 1.24-1.08 (m, 2H).	540.3	D	
I-1751		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)C3CCNCC3)c12)-c1ccc2ncnn2c1	NMR (400 MHz, DMSO-d6) 10.13 (br s, 1H), 9.44 (s, 1H), 9.24 (br s, 1H), 8.57 (s, 1H), 8.10 (dd, 9.3, 1.7 Hz, 1H), 8.01 (d, 1.2 Hz, 1H), 7.97 (d, 9.2 Hz, 1H), 7.85 (d, 1.4 Hz, 1H), 7.60-7.47 (m, 1H), 7.24 (td, 8.4, 3.0 Hz, 1H), 6.59 (br s, 1H), 6.14 (br s, 1H), 3.14-2.97 (m, 2H), 2.63 (t, 10.8 Hz, 2H), 2.36-2.22 (m, 1H), 1.62-1.27 (m, 4H).	505	E	
I-1752		Fc1cc(cc(c1)C(F)(F)F)C(=O)Nc1ccc2C(=O)N[C@@H]([C@@H]3CCC(F)(F)C3)c12	1H NMR (400 MHz, DMSOd6) 10.89 (s, 1H), 8.81 (s, 1H), 8.08 (s, 1H), 8.05-7.99 (m, 2H), 7.65-7.53 (m, 3H), 4.88 (s, 1H), 2.25-2.13 (m, 1 H), 2.03-1.83 (m, 2H), 1.77 (d, 13.5 Hz, 1H), 1.69-1.51 (m, 2H), 1.43-1.28 (m, 1H), 1.28-1.11 (m, 2H), 1.06-0.92 (m, 1H).	455.3	D	




I-1753		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(NC(=O)N3CC4CC(F)(C4)C3)c12	1H NMR (400 MHz, DMSO):-′ 9.27 (br s, 1H), 8.38 (s, 1H), 7.63 (d, 1.5 Hz, 1H), 7.50 (br s, 1H), 7.48 (d, 1.7 Hz, 1H), 7.25 (td, 8.2, 2.7 Hz, 1H), 6.55 (br s, 1H), 5.97 (br s, 1H), 3.60-3.41 (m, 3H), 3.28-3.22 (m, 1H), 2.47-2.36 (m, 1H), 2.22 (dd, 18.0, 8.6 Hz, 2H), 1.62 (br s, 2H).	496.2	E	
I-1754		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(NC(=O)N3CC4CCC4(C3)C(F)(F)F)c12	1H NMR (400 MHz, DMSO):-′ 9.21 (br s, 1H), 8.62 (s, 1H), 7.63 (s, 1H), 7.57 (d, 1.7 Hz, 0.5H), 7.56 (d, 1.7 Hz, 0.5H), 7.44 (br s, 1H), 7.22 (2 overlapping td, 8.4, 3.1 Hz, 1H), 6.59 (br s, 1H), 6.02 (br s, 1H), 3.65 (d, 11.4 Hz, 0.5H), 3.46 (d, 11.0 Hz, 0.5H), 3.30 (d, 11.7 Hz, 1H), 3.24 (d, 11.8 Hz, 0.5H), 3.15 (dd, 11.1, 6.4 Hz, 0.5H), 3.05-2.94 (m, 1H), 2.94-2.86 (m, 0.5H), 2.76-2.65 (m, 0.5H), 2.36-2.24 (m, 1H), 2.19-2.05 (m, 1H), 1.90-1.81 (m, 0.5H), 1.81-1.71 (m, 0.5H), 1.66-1.54 (m, 0.5H), 1.51-1.39 (m, 0.5H).	546.2	D	
I-1755		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(NC(=O)NC3(CC(F)(F)F)CC3)c12	1H NMR (400 MHz, DMSO):-′ 9.16 (s, 1H), 8.64 (br s, 0.5H), 8.49 (br s, 0.5H), 7.75 (s, 1H), 7.53 (s, 1H), 7.49-7.41 (m, 1H), 7.35 (s, 1H), 7.20 (td, 8.3, 2.8 Hz, 1H), 6.64 (br s, 1H), 6.11 (s, 1H), 2.49-2.34 (m, 2H), 0.76-0.52 (m, 4H).	520.1	E	





I-1756		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(NC(=O)N3CCC4C(C3)C4C(F)(F)F)c12	1H NMR (400 MHz, DMSO):-′ 9.17 (br s, 1H), 8.40 (s, 0.5H), 8.36 (s, 0.5H), 7.58 (d, 1.7 Hz, 0.5H), 7.57 (d, 1.7 Hz, 0.5H), 7.51 (d, 1.7 Hz, 0.5H), 7.43 (br s and d, 1.7 Hz, 1.5H), 7.27-7.18 (m, 1H), 6.63 (br s, 1H), 5.90 (br s, 1H), 3.61-3.52 (m, 0.5H), 3.48-3.43 (m, 1.5H), 3.19-3.11 (m, 1H), 2.81-2.72 (m, 0.5H), 2.43-2.33 (m, 0.5H), 2.04-1.94 (m, 0.5H), 1.90-1.80 (m, 0.5H), 1.80-1.66 (m, 1H), 1.57-1.33 (m, 3H).	546.1	D	
I-1757		CC(C)(CC(=O)Nc1cc(Br)cc2C(=O)NC(c12)c1cc(F)ccc1Cl)C(F)(F)F	1H NMR (400 MHz, DMSO):-′ 9.95 (s, 1H), 9.27 (s, 1H), 7.74-7.70 (m, 2H), 7.51 (br s, 1H), 7.24 (td, 8.4, 3.1 Hz, 1H), 6.63 (br s, 1H), 6.04 (br s, 1H), 2.21 (2 overlapping d, 13.9 Hz, 2H), 1.01 (br s, 3H), 0.94 (s, 3H).	507	E	
I-1758		CN1CCC(CC1)C(=O)Nc1cc(cc2C(=O)NC(c12)c1cc(F)ccc1Cl)-c1ccc2ncnn2c1	NMR (400 MHz, DMSO-d6) 9.88 (br s, 1H), 9.44 (s, 1H), 9.22 (br s, 1H), 8.57 (s, 1H), 8.09 (dd, 9.3, 1.7 Hz, 1H), 8.00 (d, 1.2 Hz, 1H), 7.97 (d, 9.2 Hz, 1H), 7.81 (d, 1.3 Hz, 1H), 7.60-7.40 (m, 1H), 7.25 (td, 8.4, 3.1 Hz, 1H), 6.56 (br s, 1H), 6.13 (br s, 1H), 2.72 (t, 11.2 Hz, 2H), 2.14 (s, 3H), 2.08-1.93 (m, 1H), 1.86-1.72 (m, 2H), 1.49-1.18 (m, 4H).	519	E	





I-1759		NC1CCC(CC1)C(=O)Nc1cc(cc2C(=O)NC(c12)c1cc(F)ccc1Cl)-c1ccc2ncnn2c1	NMR (400 MHz, DMSO-d6) 9.95 (br s, 1H), 9.44 (s, 1H), 9.21 (br s, 1H), 8.57 (s, 1H), 8.39 (br s, 2H), 8.00 (s, 1H), 7.97 (d, 9.0 Hz, 1H), 7.96 (s, 1H), 7.82 (br d, 4.7 Hz, 1H), 7.58-7.47 (m, 1H), 7.29-7.21 (m, 1H), 6.70 (br s, 1H), 6.11 (br s, 1H), 2.89-2.70 (m, 1H), 2.09-1.95 (m, 1H), 1.93-1.78 (m, 2H), 1.60-1.44 (m, 1H), 1.43-1.30 (m, 1H), 1.30-1.09 (m, 4H).	519	E	
I-1760		ON=C(C(=O)Nc1cc(cc2C(=O)NC(c12)c1cc(F)ccc1Cl)-c1ccc2ncnn2c1)c1ccccc1	NMR (400 MHz, DMSO-d6) 10.62 (br s, 1H), 9.45 (br s, 1H), 9.27 (br s, 1H), 8.59 (s, 1H), 8.15-7.95 (m, 5H), 7.63-7.50 (m, 1H), 7.42-7.37 (m, 1H), 7.32-7.24 (m, 3H), 7.14 (s, 1H), 7.12 (s, 1H), 6.60 (br s, 1H), 6.33 (br s, 1H).	541	E	
I-1761		Fc1cc(cc(c1)C(F)(F)F)C(=O)Nc1ccc2C(=O)NC(CN3CCCC3)c12	NMR (400 MHz, CD3CN) 12.43 (br. s, 1H), 8.45 (dd, 7.3, 1.6 Hz, 1H) 7.93 (s, 1H), 7.77 (br. d, 8.6 Hz, 1H), 7.68 (br. d, 8.6 Hz, 1H), 7.54-7.48 (m, 2H), 6.86 (br. s, 1H), 4.79 (ddd, 8.9, 4.5, 1.0 Hz, 1H), 2.79 (d, 4.9 Hz, 1H), 2.77 (s, 1H) 2.75-2.67 (m, 2H), 2.59-2.51 (m, 2H), 1.35 1.28 (m, 3H), 1.28-1.22 (m, 1H) .	422.2	E	





I-1762		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1ccn2ncc(C#N)c2c1	1H NMR (DMSO-d6, 400 MHz) 10.64 (s, 1H), 9.28 (br s, 1H), 9.07 (d, 7.3 Hz, 1H), 8.70 (s, 1H), 8.39 (d, 1.3 Hz, 1H), 8.24 (d, 1.5 Hz, 1H), 8.08-8.11 (m, 1H), 7.95-8.00 (m, 1H), 7.76-7.81 (m, 1H), 7.71-7.74 (m, 2H), 7.70 (d, 2.0 Hz, 1H), 7.32-7.37 (m, 1H), 7.09-7.15 (m, 1H), 6.02-6.14 (m, 1H)	608.4	A	
I-1763		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1ccn2nccc2n1	1H NMR (DMSO-d6, 400 MHz):-′ = 10.70 (s, 1H), 9.27-9.34 (m, 1H), 9.25 (dd, 7.3, 0.8 Hz, 1H), 8.48 (d, 1.0 Hz, 1H), 8.42 (d, 1.0 Hz, 1H), 8.29 (d, 2.3 Hz, 1H), 7.97 (br d, 8.6 Hz, 1H), 7.84 (d, 7.3 Hz, 1H), 7.80 (br d, 8.8 Hz, 1H), 7.74 (s, 1H), 7.34 (dd, 8.8, 5.3 Hz, 1H), 7.11 (td, 8.4, 3.2 Hz, 1H), 6.81 (dd, 2.3, 0.8 Hz, 1H), 6.02-6.20 (m, 1H)	584.4	A	
I-1764		Fc1ccc(Cl)c(c1)[C@H]1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1ccn2ncnc2c1F	1H NMR (400 MHz, DMSO) δ 10.69 (s, 1H), 9.31 (s, 1H), 8.99 (d, J = 7.1 Hz, 1H), 8.65 (s, 1H), 8.00 (d, J = 1.4 Hz, 1H), 7.95 (dt, J = 8.6, 1.9 Hz, 1H), 7.85 (s, 1H), 7.76 (dd, J = 9.1, 2.5 Hz, 1H), 7.68 (s, 1H), 7.50 (q, J = 7.1 Hz, 1H), 7.34 (dd, J = 8.9, 5.2 Hz, 1H), 7.15 – 7.07 (m, 1H), 6.69 (s, 1H), 6.07 (s, 1H).	602.18	D	





I-1765		Fc1ccc(Cl)c(c1)[C@@H]1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1ccn2ncnc2c1F	1H NMR (400 MHz, DMSO) δ 10.69 (s, 1H), 9.31 (s, 1H), 8.99 (d, J = 7.1 Hz, 1H), 8.65 (s, 1H), 8.00 (d, J = 1.4 Hz, 1H), 7.95 (dt, J = 8.6, 1.9 Hz, 1H), 7.85 (s, 1H), 7.76 (dd, J = 9.1, 2.5 Hz, 1H), 7.68 (s, 1H), 7.50 (q, J = 7.1 Hz, 1H), 7.34 (dd, J = 8.9, 5.2 Hz, 1H), 7.15 – 7.07 (m, 1H), 6.69 (s, 1H), 6.07 (s, 1H).	602.18	A	
I-1766		CC1(C)CC1C1NC(=O)c2ccc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	NMR (400 MHz, DMSO-d6) 10.56 (s, 1H), 8.77 (s, 1H), 8.20 (s, 1H), 8.14 (br. d, 9.2 Hz, 1H), 8.03 (br. d, 8.4 Hz, 1H), 7.66-7.51 (m, 3H), 4.48-4.41 (m, 1H), 1.14 (s, 3H), 0.93 (s, 3H), 0.34-0.24 (m, 3H).	407.2	D	
I-1767		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1cn2c(cnc2cn1)C#N		609.03	A	
I-1768		FC(F)n1cc(ccc1=O)-c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl		610.5	A	





I-1769		CN1CCCC(C1)C1NC(=O)c2cccc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	(400 MHz, DMSO-d6) 10.80 (s, 1H), 8.79 (s, 1H), 8.15 (s, 1H), 8.09 (d, 9.1 Hz, 1H), 8.04 (d, 8.4 Hz, 1H), 7.62 (dd, 6.9, 1.9 Hz, 1H), 7.60-7.52 (m, 2H), 4.81 (d, 1.2 Hz, 1H), 2.60 (d, 10.4 Hz, 1H), 2.15-2.04 (m, 1H), 1.89 (s, 3H), 1.83 (d, 10.8 Hz, 1H), 1.64 - 1.56 (m, 3H), 1.39 (t, 10.9 Hz, 1H), 1.31-1.21 (m, 2H)	436.3	E	
I-1770		Fc1cc(cc(c1)C(F)(F)F)C(=O)Nc1ccc2C(=O)NC(C3CCNCC3)c12	(400 MHz, DMSO-d6) 10.72 (br s, 1H), 8.78 (s, 1H), 8.14 (s, 1H), 8.10 (d, 9.0 Hz, 1H), 8.04 (d, 8.5 Hz, 1H), 7.61 (dd, 7.3, 1.4 Hz, 1H), 7.59-7.50 (m, 2H), 4.77 (d, 1.1 Hz, 1H), 2.98 (d, 11.8 Hz, 1H), 2.82 (d, 11.5 Hz, 1H), 2.35-2.20 (m, 2H), 2.00-1.87 (m, 1H), 1.55-1.43 (m, 2H), 0.93-0.80 (m, 1H), 0.57 (d, 10.8 Hz, 1H)	422.3	D	
I-1771		CC(=O)N1CCCC(C1)C1NC(=O)c2cccc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	(400 MHz, DMSO-d6) 10.96 (br s, 0.5H), 10.85 (br s, 0.5H), 8.89 (s, 0.5H), 8.83 (s, 0.5H), 8.13-7.97 (m, 3H), 7.69-7.52 (m, 3H), 4.87 (d, 0.9 Hz, 0.5H), 4.77 (d, 1.4 Hz, 0.5H), 4.27 (d, 12.3 Hz, 0.5H), 3.68 (d, 12.3 Hz, 0.5H), 3.64 (d, 12.3 Hz, 0.5H), 2.77 (app t, 12.3 Hz, 1H), 2.55 -2.51 (m, 1H), 2.22 (t, 12.1 Hz, 0.5H), 1.94 (t, 12.1 Hz, 1H), 1.89 (s, 1.5H), 1.86-1.64 (m, 2.5H), 1.62 (s, 1.5H), 1.60-1.51 (m, 0.5H), 1.21-1.00 (m, 1H)	464.3	E	




I-1772		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(CC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1ccc2nccnn2c1		583.2	B	
I-1773		OCc1cc(cc(c1)C(F)(F)F)C(=O)Nc1cc(cc2C(=O)NC(c12)c1cc(F)ccc1Cl)-c1ccc2nccnn2c1	NMR (400 MHz, DMSO-d6) 9.35 (s, 1H), 9.07 (s, 1H), 8.54 (s, 1H), 8.12 (s, 1H), 8.02 (dd, 9.3, 1.8 Hz, 1H), 7.99 (s, 1H), 7.89 (d, 9.2 Hz, 1H), 7.70 (s, 1H), 7.54 (dd, 8.3, 5.1 Hz, 1H), 7.40 (d, 1.3 Hz, 1H), 7.24 (td, 8.0, 3.0 Hz, 1H), 7.18 (s, 1H), 6.73 (br s, 1H), 5.96 (s, 1H), 5.69 (t, 6.2 Hz, 1H), 4.71 (dd, 16.1, 6.3 Hz, 1H), 4.53 (dd, 16.0, 5.5 Hz, 1H).	596.3	E	
I-1774		NC(=O)c1cc(cc2C(=O)NC(c12)c1cc(F)ccc1Cl)-c1ccc2nccnn2c1	(400 MHz, DMSO-d6) 9.59 (d, 0.8 Hz, 1 H), 9.30 (s, 1 H), 8.59 (s, 1 H), 8.37 (s, 1 H), 8.29 (d, 1.5 Hz, 1 H), 8.26 (dd, 9.3, 1.8 Hz, 1 H), 8.11 (s, 1 H), 8.01 (d, 9.3 Hz, 1 H), 7.49 (br s, 1 H), 7.45 (s, 1 H), 7.18 (td, 8.4, 3.1 Hz, 1 H), 6.43 (br s, 1 H).	422.1	D	
I-1775		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(ccc12)-c1ccc2nccnn2c1	(400 MHz, DMSO-d6) 9.42 (app d, 0.8 Hz, 1 H), 9.17 (s, 1 H), 8.56 (s, 1 H), 8.13 (d, 1.4 Hz, 1 H), 8.09 (dd, 9.3, 1.8 Hz, 1 H), 8.01 (dd, 8.0, 1.8 Hz, 1 H), 7.95 (dd, 9.3, 0.5 Hz, 1 H), 7.66 (dd, 8.9, 5.1 Hz, 1 H), 7.53 (d, 8.0 Hz, 1 H), 7.28 (ddd, 8.8, 8.1, 3.1 Hz, 1 H), 7.01 (dd, 9.3, 3.0 Hz, 1 H), 6.18 (s, 1 H).	379.2	E	





I-1776		CC(O)C1NC(=O)c2cccc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	NMR (400 MHz, DMSO-d6) 11.29 (br. s, 1H), 8.72 (s, 1H), 8.44 (d, 7.5 Hz, 1H), 8.10 (s, 1H), 8.07-8.00 (m, 2H), 7.55 (t, 7.7 Hz, 1H), 7.48 (dd, 7.4, 0.8 Hz, 1H), 6.88 (br. s, 1H), 4.87 (d, 2.9 Hz, 1H), 4.29-4.22 (m, 1H), 0.73 (d, 6.3 Hz, 3H).	383.2	D	
I-1777		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)CC3CCC3)c12)-c1ccc2ncnn2c1	1H NMR (400 MHz, DMSO-d6) 9.69 (s, 1H), 9.42 (d, 1.6 Hz, 1H), 9.16 (s, 1H), 8.57 (s, 1H), 8.08 (dd, 9.3, 1.9 Hz, 1H), 8.01-7.93 (m, 2H), 7.84 (d, 1.7 Hz, 1H), 7.53 (d, 7.7 Hz, 1H), 7.26 (td, 8.4, 3.1 Hz, 1H), 6.66 (s, 1H), 6.12 (s, 1H), 2.43-2.33 (m, 1H), 2.25-2.09 (m, 2H), 1.95-1.82 (m, 2H), 1.81-1.68 (m, 2H), 1.51 (p, 8.7 Hz, 2H).	490.25	E	
I-1778		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)C3CCC3)c12)-c1ccc2ncnn2c1	1H NMR (400 MHz, DMSO-d6) 9.69 - 9.10 (m, 2H), 8.56 (s, 1H), 8.09 (dd, 9.3, 1.9 Hz, 1H), 8.03 - 7.91 (m, 2H), 7.80 (t, 1.8 Hz, 1H), 7.51 (dd, 9.0, 5.2 Hz, 1H), 7.24 (td, 8.4, 3.1 Hz, 1H), 6.67 (s, 1H), 6.13 (s, 1H), 2.96 (ddt, 12.4, 9.0, 4.9 Hz, 1H), 2.05 - 1.58 (m, 6H).	476.1	E	
I-1779		Fc1ccc(Cl)c(c1)[C@@H]1NC(=O)c2cc(cc(NC(=O)[C@H]3CCCCN3)c12)-c1ccc2ncnn2c1	1H NMR (400 MHz, DMSO-d6) 9.41 (t, 1.3 Hz, 1H), 9.27 (s, 1H), 8.97 (s, 1H), 8.77 (q, 16.4, 13.1 Hz, 1H), 8.59 (s, 1H), 8.18 - 7.92 (m, 4H), 7.55 (t, 7.2 Hz, 2H), 7.28 (td, 8.4, 3.1 Hz, 1H), 6.11 (s, 1H), 3.93 - 3.71 (m, 1H), 3.23 (d, 12.7 Hz, 1H), 3.02 - 2.88 (m, 1H), 1.81 - 1.34 (m,	505.15	E	





			7H), 0.97 (q, 11.7 Hz, 1H).			
I-1780		Fc1ccc(Cl)c(c1)[C@@H]1NC(=O)c2cc(cc(NC(=O)[C@@H]3CCCCN3)c12)-c1ccc2ncnn2c1	1H NMR (400 MHz, DMSO-d6) 9.41 (t, 1.3 Hz, 1H), 9.27 (s, 1H), 8.97 (s, 1H), 8.77 (q, 16.4, 13.1 Hz, 1H), 8.59 (s, 1H), 8.18 - 7.92 (m, 4H), 7.55 (t, 7.2 Hz, 2H), 7.28 (td, 8.4, 3.1 Hz, 1H), 6.11 (s, 1H), 3.93 - 3.71 (m, 1H), 3.23 (d, 12.7 Hz, 1H), 3.02 - 2.88 (m, 1H), 1.81 - 1.34 (m, 7H), 0.97 (q, 11.7 Hz, 1H).	505.15	E	
I-1781		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)CC3CC3)c12)-c1ccc2ncnn2c1	1H NMR (400 MHz, DMSO-d6) 9.80 - 9.14 (m, 2H), 8.57 (s, 1H), 8.09 (dd, 9.3, 1.9 Hz, 1H), 8.02 - 7.92 (m, 2H), 7.85 (t, 1.9 Hz, 1H), 7.52 (dd, 8.9, 5.1 Hz, 1H), 7.24 (td, 8.4, 3.1 Hz, 1H), 6.66 (s, 1H), 6.13 (s, 1H), 2.03 - 1.87 (m, 2H), 0.77 (ddt, 12.4, 7.8, 3.7 Hz, 1H), 0.45 - 0.25 (m, 2H), 0.04 - -0.07 (m, 2H).	476.1	E	
I-1782		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)C3CCCC3)c12)-c1ccc2ncnn2c1	1H NMR (400 MHz, DMSO-d6) 9.84 - 8.98 (m, 2H), 8.57 (s, 1H), 8.10 (dd, 9.3, 1.9 Hz, 1H), 8.03 - 7.93 (m, 2H), 7.81 (d, 1.7 Hz, 1H), 7.52 (dd, 9.1, 5.1 Hz, 1H), 7.25 (td, 8.4, 3.1 Hz, 1H), 6.63 (s, 1H), 6.14 (s, 1H), 2.68 (tt, 3.7, 1.8 Hz, 1H), 1.66 - 1.37 (m, 7H), 1.26 (d, 18.9 Hz, 1H).	490.1	E	
I-1783		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)CN3CCCC3)c12)-	1H NMR (400 MHz, DMSO-d6) 9.45 - 9.40 (m, 1H), 9.30 (d, 59.5 Hz, 1H), 8.57 (s, 1H), 8.21 (dd, 3.5, 1.7 Hz, 1H), 8.09 (dd, 9.3, 1.9 Hz, 1H), 8.02 - 7.95 (m, 2H), 7.57 (s, 1H),	505.15	E	



		c1ccc2nc nn2c1	7.29 (td, 8.4, 3.1 Hz, 1H), 6.67 (s, 1H), 6.18 (s, 1H), 3.11 - 2.94 (m, 2H), 2.38 - 2.11 (m, 4H), 1.72 - 1.59 (m, 4H).			
I-1784		OC(=O)c 1cc(cc2C (=O)NC(c12)c1cc(F)ccc1Cl)- c1ccc2nc nn2c1	1H NMR (400 MHz, DMSO-d6) 9.49 - 9.27 (s, 1H), 8.57 (s, 1H), 8.44 (d, 1.9 Hz, 1H), 8.30 (d, 1.9 Hz, 1H), 8.15 (dd, 9.3, 1.9 Hz, 1H), 7.97 (d, 9.2 Hz, 1H), 7.51 (dd, 9.1, 5.2 Hz, 1H), 7.17 (td, 8.4, 3.1 Hz, 1H), 6.41 (s, 2H).	422. 95	E	
I-1785		[2H]c1nc 2ccc(cn2 n1)- c1cc2C(= O)N[C@ H](c2c(N C(=O)c2 cc(F)cc(c 2)C(F)(F F)c1)c1c c(F)ccc1 Cl	1H NMR (400 MHz, Methanol-d4) 9.27 (dd, 1.9, 0.9 Hz, 1H), 8.22 - 8.12 (m, 2H), 7.99-7.89 (m, 2H), 7.75-7.66 (m, 3H), 7.32 (dd, 8.9, 5.1 Hz, 1H), 7.04 (ddd, 8.8, 7.7, 3.0 Hz, 1H), 6.72 (s, 1H), 6.29 (s, 1H).	585. 05	A	
I-1786		[2H]c1nc 2ccc(cn2 n1)- c1cc2C(= O)N[C@ @H](c2c (NC(=O) c2cc(F)cc (c2)C(F)(F)F)c1)c 1cc(F)ccc 1Cl	1H NMR (400 MHz, Methanol-d4) 9.27 (dd, 1.9, 0.9 Hz, 1H), 8.22 - 8.12 (m, 2H), 7.99 - 7.89 (m, 2H), 7.76 - 7.66 (m, 3H), 7.32 (dd, 8.9, 5.1 Hz, 1H), 7.04 (ddd, 8.9, 7.7, 3.0 Hz, 1H), 6.72 (s, 1H), 6.29 (s, 1H).	585. 1	B	
I-1787		NC(=O) C(C(=O) Nc1cc(cc 2C(=O)N C(c12)c1 cc(F)ccc1 Cl)- c1ccc2nc nn2c1)c1 ccccc1	NMR (400 MHz, DMSO-d6) 10.47 (br s, 0.6H), 10.13 (br s, 0.4H), 9.44-9.42 (m, 0.5H), 9.42-9.40 (m, 0.5H), 9.25 (br s, 0.6H), 9.21 (br s, 0.4H), 8.57 (s, 1H), 8.34 (d, 1.5 Hz, 0.5H), 8.10-8.04 (m, 1.5H), 8.01-7.94 (m, 2H), 7.75 (br s, 0.6H), 7.61 (br s,	555	D	





			0.4H), 7.54-7.36 (m, 2H), 7.31-7.14 (m, 5H), 7.04 (dd, 7.4, 1.5 Hz, 1H), 6.61 (br s, 1H), 6.14 (br s, 1H), 4.36 (br s, 0.6H), 4.35 (br s, 0.4H).			
I-1788		[2H]C([2H])(c1cc2C(=O)N[C@@H](c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl)S(C)(=O)=O	NMR (400 MHz, CD3CN) 8.72 (br, s, 1H), 7.78 (d, 1.4 Hz, 1H), 7.65 (br, d, 8.5 Hz, 1H), 7.63 (s, 1H), 7.60 (br, d, 9.1 Hz, 1H), 7.56 (s, 1H), 7.30 (br, s, 1H), 7.26 (dd, 8.9, 5.1 Hz, 1H), 6.98 (ddd, 8.8, 8.1, 3.1 Hz,1H), 6.66 (br, s, 1H	561	B	
I-1789		[2H]C([2H])(c1cc2C(=O)N[C@H](c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl)S(C)(=O)=O	NMR (400 MHz, CD3CN) 8.72 (br, s, 1H), 7.78 (d, 1.4 Hz, 1H), 7.65 (br, d, 8.5 Hz, 1H), 7.63 (s, 1H), 7.60 (br, d, 9.1 Hz, 1H), 7.56 (s, 1H), 7.30 (br, s, 1H), 7.26 (dd, 8.9, 5.1 Hz, 1H), 6.98 (ddd, 8.8, 8.1, 3.1 Hz,1H), 6.66 (br, s, 1H).	561	A	
I-1790		FC1=C(CCCC1)C1NC(=O)c2cccc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	NMR (400 MHz, DMSO-d6) 10.62 (s, 1H), 8.66 (s, 1H), 8.14 (s, 1H), 8.07-8.00 (m, 2H), 7.62 (dd, 7.4, 1.4 Hz, 1H), 7.58 (t, 7.4 Hz, 1H), 7.51 (dd, 7.5, 1.3 Hz, 1H), 5.73 (s, 1H), 2.10-1.97 (m, , 1H), 1.64-1.40 (m, , 3H), 1.38-1.18 (m, 3H), 1.09 (m, 1H).	437	C	
I-1791		CC1(CC1)C1NC(=O)c2cccc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	NMR (400 MHz, DMSO-d6) 10.59 (s, 1H), 8.72 (s, 1H), 8.24 (s, 1H), 8.16 (d, 9.2 Hz, 1H), 8.04 (d, 8.5 Hz, 1H), 7.63-7.53 (m, 3H), 4.04 (s, 1H), 0.54 (m, 2H), 0.43 (s, 3H), 0.32-0.23 (m, 1H), 0.19-0.11 (m, 1H).	393	E	





I-1792		CN1CCCC(C1)C(=O)Nc1cc(cc2C(=O)NC(c12)c1cc(F)ccc1Cl)-c1ccc2ncnn2c1	NMR (400 MHz, DMSO -d6) 10.01 (br s, 0.5H), 9.97 (br s, 0.5H), 9.46-9.43 (m, 1H), 9.23 (br s, 1H), 8.57 (s, 1H), 8.10 (dt, 9.3, 1.8 Hz, 1H), 8.02-7.92 (m, 2.5H), 7.79 (d, 1.5 Hz, 0.5H), 7.62-7.46 (m, 1H), 7.32-7.22 (m, 1H), 6.50 (br s, 1H), 6.10 (br s, 1H), 2.67-2.54 (m, 1H), 2.44-2.37 (m, 0.5H), 2.36-2.26 (m, 1H), 2.25-2.13 (m, 0.5H), 2.09 (s, 1.5H), 2.06 (s, 1.5H), 1.83-1.59 (m, 2H), 1.57-1.29 (m, 3H), 1.23-1.06 (m, 1H).	519	D	
I-1793		Fc1cnc2ccc(cn12)-c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	1H NMR (500 MHz, DMSO) 10.61 (s, 1H), 9.22 (s, 1H), 8.75 (s, 1H), 8.09 (d, 1.6 Hz, 1H), 7.95 (d, 8.4 Hz, 1H), 7.91 (s, 1H), 7.77 (d, 9.0 Hz, 1H), 7.71 (s, 1H), 7.69 (dd, 9.5, 1.8 Hz, 1H), 7.66 (d, 1.7 Hz, 1H), 7.61 (ddt, 9.7, 6.9, 3.9 Hz, 2H), 7.57-7.52 (m, 1H), 7.42 (d, 7.2 Hz, 1H), 7.33 (dd, 8.9, 5.2 Hz, 1H), 7.10 (td, 8.3, 3.1 Hz, 1H), 6.05 (s, 1H).	601.23	A	
I-1794		Cn1ncc(c1C#N)-c1cc2C(=O)N[C@@H](c2c(NC(=O)c2cc(F)ccc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl		572.4	D	




I-1795		Cn1ncc(c1C#N)-c1cc2C(=O)N[C@H](c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl		572.4	A	
I-1796		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1cnc2ncc(C#N)n2c1		609.08	A	
I-1797		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1cc(F)c2ncc(C#N)n2c1		626.09	A	
I-1798		Fc1ccc(Cl)c(c1)[C@H]1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1ccn2ncc(C#N)c2c1		608.5	D	




I-1799		Fc1ccc(Cl)c(c1)[C@@H]1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1ccn2ncc(C#N)c2c1		608.5	A	
I-1800		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1cnn(c1)C1(CC1)C#N	(400 MHz, DMSO-d6) 10.57 (s, 1 H), 9.16 (s, 1 H), 8.74 (s, 1 H), 8.23 (s, 1 H), 8.01-7.93 (m, 2 H), 7.80 - 7.70 (m, 3 H), 7.32 (dd, 8.9, 5.2 Hz, 1 H), 7.09 (td, 8.5, 2.9 Hz, 1 H), 6.57 (br s, 1 H), 5.98 (s, 1 H), 1.98-1.85 (m, 4 H).	596.3	A	
I-1801		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(C#N)c12)-c1ccc2ncnn2c1	(400 MHz, DMSO-d6) 9.60 (s, 1 H), 9.51 (s, 1 H), 8.63-8.57 (m, 2 H), 8.49 (s, 1 H), 8.22 (dd, 9.3, 1.7 Hz, 1 H), 7.98 (d, 9.3 Hz, 1 H), 7.69-7.49 (m, 1 H), 7.34 (td, 8.4, 2.6 Hz, 1 H), 6.35 (br s, 1 H).	402.2	D	
I-1802		Fc1ccc(Cl)c(c1)C1NC(=O)c2c1c(NC(=O)c1cc(F)cc(c1)C(F)(F)F)cc(-c1ccc3ncnn3c1)c2-c1ccc2ncnn2c1	(400 MHz, CD3CN) 8.83 (br s, 0.5 H), 8.75 - 8.67 (m, 0.5 H), 8.66 (s, 1 H), 8.27 (d, 2.6 Hz, 2 H), 8.10 (s, 1 H), 7.76 (s, 1 H), 7.66 (dd, 17.2, 8.7 Hz, 2 H), 7.61 (s, 1 H), 7.54 (dd, 18.1, 9.1 Hz, 2 H), 7.46 (br s, 1 H), 7.35 (dd, 9.2, 1.7 Hz, 2 H), 7.30 (dd, 8.9, 5.1 Hz, 1 H), 7.03 (td, 8.4, 3.0 Hz, 1 H), 6.84 (br s, 1 H), 6.21 (br s, 1 H)	701.2	B	




I-1803		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)C3CCCCO3)c12)-c1ccc2ncnn2c1	NMR (400 MHz, DMSO-d6) 9.45-9.39 (m, 1H), 9.22 (s, 1H), 9.18 (s, 0.5H), 9.02 (s, 0.5 H), 8.57 (s, 1H), 8.20 (s, 0.5H), 8.17 (d, 1.3 Hz, 1H), 8.09 (d, 1.6 Hz, 1H), 8.09-8.04 (m, 1H), 8.01-7.93 (m, 2H), 7.51 (br s, 1H), 7.34-7.21 (m, 1H), 7.00-6.35 (br s, 1H), 6.19 (br s, 1H), 3.88 (dd, 16.0, 13.5 Hz, 1H), 3.72 (dd, 12.8, 11.4, 2.4 Hz, 1H), 3.52-3.35 (m, 2H), 1.82-1.57 (m, 2H), 1.57-1.29 (m, 3H), 1.11-0.71 (m, 1H).	506.3	E	
I-1804		CC(=O)N1CCCCC1C(=O)Nc1cc(cc2C(=O)NC(c12)c1cc(F)ccc1Cl)-c1ccc2ncnn2c1	NMR (400 MHz, DMSO-d6) 9.87 (s, 0.1H), 9.85 (s, 0.2H), 9.74 (s, 0.3H), 9.65 (s, 0.3H), 9.44-9.42 (s, 0.6H), 9.41-9.39(s, 0.5H), 9.24-9.14 (m, 1H), 8.56-8.51 (m, 1H), 8.10-8.03 (m, 1H), 8.03-7.99 (m, 1H), 7.98-7.91 (m, 2H), 7.86-7.78 (m, 0.5H), 7.57-7.46 (m, 1H), 7.26-7.17 (m, 1H), 6.50 (br s, 1H), 6.20 (br s, 0.6H), 6.16 (br s, 0.4H), 5.08-4.96 (m, 1H), 4.45-3.98 (m, 0.4H), 3.63-3.46 (m, 0.6H), 2.94-2.67 (m, 0.5H), 1.98 (s, 2H), 1.90 (s, 1H), 1.94-1.76 (submerged m, 1H), 1.58-1.45 (m, 0.5 H), 1.43-1.14 (m, 4H), 1.14-0.48 (m, 1H). mixture of diastereomers and possible rotamers	547.2	E	





I-1805		Fc1cc(cc(c1)C(F)(F)F)C(=O)Nc1ccc2C(=O)NC(c12)c1ccccc1	NMR (400 MHz, DMSO-d6) 10.40 (s, 1H), 9.09 (s, 1H), 7.95 (br. d, 8.5 Hz, 1H), 7.69-7.65 (m, 2H), 7.62-7.57 (m, 2H), 7.52 (dd, 7.1, 0.7 Hz, 1H), 7.22-7.11 (m, 3H), 6.99-6.95 (m, 2H), 5.73 (s, 1H).	415.3	D	
I-1806		NC(=O)Cn1nc(Nc2cc(cc3C(=O)NC(c23)c2cc(F)ccc2Cl)-c2ccc3ncnn3c2)c2ccccc12	1H NMR (400 MHz, DMSO-d6) 9.35 (dd, 1.9, 0.9 Hz, 1H), 9.05 (s, 1H), 8.56 (s, 1H), 8.38 (s, 1H), 8.10 - 7.95 (m, 3H), 7.74 (d, 1.6 Hz, 1H), 7.59 (s, 1H), 7.47 (d, 8.4 Hz, 1H), 7.39 - 7.29 (m, 2H), 7.24 (dd, 8.8, 4.9 Hz, 2H), 7.08 - 6.95 (m, 2H), 6.72 (s, 1H), 6.12 (s, 1H), 5.00 - 4.82 (m, 2H).	567.3	D	
I-1807		OCCn1nc(Nc2cc(cc3C(=O)NC(c23)c2cc(F)ccc2Cl)-c2ccc3ncnn3c2)c2ccccc12	1H NMR (400 MHz, DMSO-d6) 9.34 (s, 1H), 9.07 (s, 1H), 8.56 (s, 1H), 8.33 (s, 1H), 8.09 - 8.02 (m, 2H), 7.97 (d, 9.3 Hz, 1H), 7.72 (d, 1.6 Hz, 1H), 7.50 (d, 8.5 Hz, 1H), 7.33 (dt, 9.3, 2.2 Hz, 2H), 7.26 (dd, 8.8, 5.2 Hz, 1H), 7.03 (td, 8.4, 3.2 Hz, 1H), 6.94 (d, 7.5 Hz, 1H), 6.65 (s, 1H), 6.13 (s, 1H), 4.83 (t, 5.4 Hz, 1H), 4.31 (t, 5.7 Hz, 2H), 3.80 (t, 5.8 Hz, 2H).	554.35	D	
I-1808		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(Nc3nn(CC#N)c4cccc34)c12)-c1ccc2ncnn2c1	1H NMR (400 MHz, DMSO-d6) 9.39 (t, 1.4 Hz, 1H), 9.13 (s, 1H), 8.68 (s, 1H), 8.57 (s, 1H), 8.09 (dd, 9.3, 1.9 Hz, 1H), 8.02 (t, 2.1 Hz, 1H), 7.97 (d, 9.2 Hz, 1H), 7.83 (d, 1.6 Hz, 1H), 7.63 (d, 8.8 Hz, 1H), 7.51 - 7.41 (m, 2H), 7.21 (dd, 8.8, 5.1 Hz, 1H), 7.09 (dd,	549.1	D	





			8.2, 6.8 Hz, 1H), 7.00 (td, 8.3, 3.1 Hz, 1H), 6.57 (s, 1H), 6.18 (s, 1H), 5.63 (d, 2.8 Hz, 2H).			
I-1809		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(Nc3nn(C4CC4)c4ccccc34)c12)-c1ccc2ncnn2c1	1H NMR (400 MHz, DMSO-d6) 9.36 (t, 1.4 Hz, 1H), 9.08 (s, 1H), 8.57 (s, 1H), 8.40 (s, 1H), 8.10 - 8.02 (m, 2H), 7.98 (d, 9.0 Hz, 1H), 7.74 (d, 1.6 Hz, 1H), 7.53 (d, 8.4 Hz, 1H), 7.36 (dd, 14.1, 7.2 Hz, 2H), 7.25 - 7.20 (m, 1H), 7.07 - 6.98 (m, 2H), 6.60 (s, 1H), 6.10 (d, 2.8 Hz, 1H), 3.57 (p, 5.3 Hz, 1H), 1.08 (tq, 5.9, 1.9 Hz, 4H).	550.25	D	
I-1810		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(NC(=O)N3CCOC(C3)C(F)(F)F)c12	1H NMR (400 MHz, DMSO-d6) 9.21 (s, 1H), 8.89 (s, 1H), 7.65 (d, 1.7 Hz, 1H), 7.53 (d, 1.7 Hz, 1H), 7.48 (dd, 4.5, 1.7 Hz, 1H), 7.27 (ddt, 11.2, 8.4, 2.7 Hz, 1H), 6.65 (s, 1H), 5.96 (s, 1H), 3.92 (dd, 19.6, 10.6 Hz, 2H), 3.58 (dd, 27.2, 13.5 Hz, 1H), 2.55 (s, 3H).	535.95	D	
I-1812		NC1(CCCC1)C(=O)Nc1cc(cc2C(=O)NC(c12)c1cc(F)ccc1Cl)-c1ccc2ncnn2c1	1H NMR (400 MHz, DMSO-d6) 9.46 (d, 2.1 Hz, 1H), 9.23 (s, 1H), 8.58 (s, 1H), 8.30 - 7.87 (m, 5H), 7.53 (s, 1H), 7.28 (td, 8.4, 3.1 Hz, 1H), 6.08 (s, 1H), 1.82 (d, 73.1 Hz, 8H).	505.15	E	
I-1813		OC1(CCCC1)C(=O)Nc1cc(cc2C(=O)NC(c12)c1cc(F)ccc1Cl)-c1ccc2ncnn2c1	1H NMR (400 MHz, DMSO-d6) 9.58 - 9.35 (m, 2H), 9.20 (s, 1H), 8.57 (s, 1H), 8.20 - 8.06 (m, 2H), 8.03 - 7.94 (m, 2H), 7.54 (d, 8.3 Hz, 1H), 7.26 (ddd, 8.8, 7.9, 3.1 Hz, 1H), 6.67 (s, 1H), 6.25 (s, 1H), 5.49 (s, 1H), 1.83	506.15	E	





			- 1.55 (m, 6H), 1.54 - 1.31 (m, 2H).			
I-1814		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)C3CCCOC3)c12)-c1ccc2ncnn2c1	NMR (400 MHz, DMSO-d6) 9.93 (br s, 0.5H), 9.91 (br s, 0.5H), 9.44 (s, 1H), 9.22 (br s, 1H), 8.57 (s, 1H), 8.09 (dd, 9.3, 1.8 Hz, 1H), 8.01 (s, 1H), 7.97 (d, 9.3 Hz, 1H), 7.81 (dd, 9.4, 1.4 Hz, 1H), 7.62-7.46 (m, 1H), 7.32-7.21 (m, 1H), 6.59 (br s, 1H), 6.09 (br s, 1H), 3.74 (d, 10.6 Hz, 1H), 3.61 (dd, 11.1, 3.7 Hz, 0.5H), 3.25-2.98 (m, 2H), 2.40-2.27 (m, 1H), 1.72-1.59 (m, 0.5H), 1.58-1.32 (m, 4H).	506	E	
I-1815		CN1CCC(CC1)C1NC(=O)c2cccc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	(400 MHz, DMSO-d6) 10.82 (br s, 1H), 8.80 (s, 1H), 8.13 (s, 1H), 8.09 (d, 8.9 Hz, 1H), 8.04 (d, 8.5 Hz, 1H), 7.65-7.48 (m, 3H), 4.79 (d, 1.5 Hz, 1H), 2.79 (d, 7.5 Hz, 1H), 2.65 (d, 11.6 Hz, 2H), 2.06 (s, 3H), 1.86-1.74 (m, 1H), 1.69-1.55 (m, 3H), 1.54-1.44 (m, 1H), 0.98 (qd, 12.4, 3.9 Hz, 1H), 0.59 (d, 12.5 Hz, 1H)	436.3	E	
I-1816		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)[C@H]3CCC[C@@H](C3)C(F)(F)F)c12)-c1ccc2ncnn2c1	1H-NMR (400 MHz, DMSO-d6) 9.90 (br. s, 1H), 9.84 (br. s, 1H), 9.45-9.43 (m, 2H), 9.23 (br. s, 2H), 8.58-8.57 (m, 2H), 8.10 (dd, 9.2, 0.9 Hz, 2H), 8.03-7.98 (m, 3H), 7.95 (dd, 12.1, 1.9 Hz, 2H), 7.82-7.80 (m, 1H), 7.56-7.50 (m, 2H), 7.28-7.20 (m, 2H), 6.51 (br. s, 2H), 6.22 (br. s, 1H), 6.20 (br. s, 1H), 2.61-2.55 (m, 2H), 1.93-1.83 (m, 2H), 1.68-1.59 (m, 2H), 1.56-1.48 (m, 2H), 1.44-1.30 (m, 6H),	572.4	A	




			1.27-1.14 (m, 4H), 1.04-0.77 (m, 2H).			
I-1817		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)[C@H]3CCC[C@H](C3)C(F)(F)F)c12)-c1ccc2ncnn2c1	1H-NMR (400 MHz, DMSO-d6) 10.03 (br. s, 1H), 9.95 (br. s, 1H), 9.44 (s, 2H), 9.22 (br. s, 2H), 8.58-8.56 (m, 2H), 8.10 (dd, 9.3, 1.3 Hz, 2H), 8.01 (d, 1.1 Hz, 2H), 7.97 (d, 9.3 Hz, 2H), 7.80 (dd, 10.6, 0.9 Hz, 2H), 7.53-7.43 (m, 2H), 7.25-7.19 (m, 2H), 6.57 (br. s, 2H), 6.12 (br. s, 2H), 2.31-2.14 (m, 4H), 1.83-1.71 (m, 4H), 1.68-1.53 (m, 2H), 1.43-1.34 (m, 2H), 1.30-1.20 (m, 2H), 1.15-0.98 (m, 6H).	572.3	B	
I-1818		CC(=O)N1CCC(CC1)C1NC(=O)c2cccc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	(400 MHz, DMSO-d6) 10.73 (br s, 1H), 8.76 (s, 0.5H), 8.73 (s, 0.5H), 8.16 (s, 1H), 8.12 (d, 8.9 Hz, 1H), 8.04 (d, 8.5 Hz, 1H), 7.64 (dd, 3.0, 1.6 Hz, 0.5H), 7.62 (dd, 3.2, 1.7 Hz, 0.5H), 7.60-7.51 (m, 2H), 4.83 (s, 1H), 4.41 (d, 12.9 Hz, 0.5H), 4.25 (d, 13.0 Hz, 0.5H), 3.81 (d, 13.4 Hz, 0.5H), 3.67 (d, 13.3 Hz, 0.5H), 2.85-2.68 (m, 1H), 2.29-2.16 (m, 1H), 2.16-2.03 (m, 1H), 1.93 (s, 1.5H), 1.89 (s, 1.5H), 1.64-1.48 (m, 1.5H), 1.48-1.32 (m, 0.5H), 0.94-0.82 (m, 0.5H), 0.81-0.70 (m, 0.5H), 0.69-0.58 (m, 1H)	464.3	E	
I-1819		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(NC(=O)C3(CCCC3)c3cc(F)ccc3F)c12	1H NMR(400 MHz, DMSO):-′ 9.22 (s, 1H), 8.93 (s, 1H), 7.70 (d, 1.4 Hz, 1H), 7.57 (d, 1.4 Hz, 1H), 7.52 (dd, 8.1, 5.1 Hz, 1H), 7.24 (td, 8.4, 3.0 Hz, 1H), 7.19-7.02 (m, 3H), 6.50 (brs, 1H), 6.10 (s, 1H), 2.07-1.93 (m, 2H),	563.2	E	





			1.80-1.64 (m, 2H), 1.54-1.30 (m, 4H)			
I-1820		OC1CCCCC1C1NC(=O)c2cccc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	NMR (400 MHz, DMSO-d6) 10.66 (br. s, 1H), 8.60 (s, 1H), 8.16 (s, 1H), 8.11 (br. d, 9.1 Hz, 1H), 8.00 (br. d, 8.6 Hz, 1H), 7.73 (dd, 7.3, 1.0 Hz, 1H), 7.50-7.43 (m, 2H), 4.97 (d, 1.2 Hz, 1H), 4.34 (br. s, 1H), 3.27-3.16 (m, 1H), 1.82 (app. t, 11.2 Hz, 1H), 1.72-1.62 (m, 1H), 1.58-1.47 (m, 2H), 1.39 (app. d, 12.2 Hz, 1H), 1.29-1.20 (m, 1H), 1.05-0.96 (m, 2H), 0.84-0.71 (m, 1H).	437.2	E	
I-1821		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)C3CCOCC3)c12)-c1ccc2ncnn2c1	NMR (400 MHz, DMSO-d6) 9.88 (s, 1H), 9.45-9.43 (m, 1H), 9.22 (br s, 1H), 8.57 (s, 1H), 8.09 (dd, 9.3, 1.8 Hz, 1H), 8.01 (d, 1.5 Hz, 1H), 7.97 (dd, 9.2, 0.6 Hz, 1H), 7.81 (d, 1.5 Hz, 1H), 7.59-7.46 (m, 1H), 7.25 (td, 8.4, 3.1 Hz, 1H), 6.57 (br s, 1H), 6.13 (br s, 1H), 3.87-3.62 (m, 2H), 3.38-3.07 (m, 2H), 2.41-2.23 (m, 1H), 1.45-1.37 (m, 2H), 1.36-1.16 (m, 2H).	506	E	
I-1822		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1cc(C#N)c2ncnn2c1		609.13	A	




I-1823		FC(F)n1cnc(c1)-c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl		583.4	A	
I-1824		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1cnn2ncnc2c1	1H NMR (500 MHz, DMSO) δ 10.68 (s, 1H), 9.29 (s, 1H), 9.27 (d, J = 2.4 Hz, 1H), 8.88 (d, J = 2.4 Hz, 1H), 8.73 (s, 1H), 8.30 (d, J = 1.6 Hz, 1H), 8.09 (d, J = 1.7 Hz, 1H), 7.96 (dt, J = 8.5, 2.0 Hz, 1H), 7.77 (d, J = 8.7 Hz, 1H), 7.72 (s, 1H), 7.34 (dd, J = 8.9, 5.1 Hz, 1H), 7.11 (td, J = 8.4, 3.1 Hz, 1H), 6.08 (s, 1H).	585.12	A	
I-1825		Cc1c(ccc2ncnn12)-c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl			A	
I-1826		FC(F)n1cc(c(n1)C#N)-c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl		608.5	A	





I-1827		Cc1cc2nc nn2cc1-c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl		598.08	A	
I-1828		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1cc2ncnn2cc1F		602.08	A	
I-1829		Fc1ccc(Cl)c(c1)[C@@H]1NC(=O)c2cc(cc(NC(=O)c3nsc4ccccc34)c12)-c1ccc2ncnn2c1	1H NMR (400 MHz, DMSO-d6) 10.54 (s, 1H), 9.48 (dd, 1.9, 0.9 Hz, 1H), 9.26 (s, 1H), 8.70 (d, 8.2 Hz, 1H), 8.58 (s, 1H), 8.33 (dt, 8.3, 1.1 Hz, 1H), 8.19-8.12 (m, 2H), 8.11 (d, 1.7 Hz, 1H), 8.00 (dd, 9.3, 0.9 Hz, 1H), 7.70 (ddd, 8.3, 6.9, 1.2 Hz, 1H), 7.62 (ddd, 8.1, 7.0, 1.1 Hz, 1H), 7.33-7.24 (m, 1H), 7.04 (td, 8.4, 3.0 Hz, 1H), 6.82 (s, 1H), 6.29 (s, 1H).	555.1	A	
I-1830		Fc1ccc(Cl)c(c1)[C@H]1NC(=O)c2cc(cc(NC(=O)c3nsc4ccccc34)c12)-c1ccc2ncnn2c1	1H NMR (400 MHz, DMSO-d6) 10.54 (s, 1H), 9.48 (dd, 1.9, 0.9 Hz, 1H), 9.26 (s, 1H), 8.70 (d, 8.2 Hz, 1H), 8.58 (s, 1H), 8.33 (dt, 8.3, 1.1 Hz, 1H), 8.19-8.12 (m, 2H), 8.11 (d, 1.7 Hz, 1H), 8.00 (dd, 9.3, 0.9 Hz, 1H), 7.70 (ddd, 8.3, 6.9, 1.2 Hz, 1H), 7.62 (ddd, 8.1, 7.0, 1.1 Hz, 1H), 7.33-7.24 (m, 1H), 7.04 (td, 8.4, 3.0 Hz, 1H), 6.82 (s, 1H), 6.29 (s, 1H).	555.1	D	




I-1831		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)C3CCCO3)c12)-c1ccc2ncnn2c1	NMR (400 MHz, DMSO-d6) 9.57 (s, 1H), 9.445-9.44(m, 0.7H), 9.44-9.42 (m, 0.3H), 9.24 (s, 1H), 8.57 (s, 1H), 8.14-8.06 (m, 1.5H), 8.03 (s, 1.5 H), 8.02-7.94 (m, 1.5H), 7.63-7.49 (m, 1H), 7.33-7.17 (m, 1H), 6.67 (br s, 1H), 6.24 (s, 0.3H), 6.20 (s, 0.7H), 4.26-4.16 (m, 1H), 3.77-3.52 (m, 2H), 2.12-1.95 (m, 1H), 1.81-1.59 (m, 1H), 1.59-1.20 (m, 2H).	492.3	E	
I-1832		CN1CC(C1)C1NC(=O)c2cccc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	NMR (400 MHz, MeCN-d3) 9.46 (br. s, 1H), 8.68 (br. s, 1H), 8.16 (d, 0.4 Hz, 1H), 8.02 (dt, 9.1, 1.7 Hz, 1H), 7.73 (dt, 8.7, 1.5 Hz, 1H), 7.65 (dd, 7.2, 1.3 Hz, 1H), 7.61-7.52 (m , 2H), 5.07 (d, 2.9 Hz, 1H), 4.08 (dd, 10.2, 6.4 Hz, 1H), 3.84 (t, 9.4 Hz, 1H), 3.43 (app. t, 1H), 3.38 (m, 1H), 3.23 (dd, 8.9, 5.8 Hz, 1H), 2.53 (s, 3H)	408.2	E	
I-1833		Fc1cc(cc(c1)C(F)(F)F)C(=O)Nc1ccc2C(=O)NC(C3CNC3)c12	NMR (400 MHz, MeCN-d3) 9.46 (br. s, 1H), 8.83 (br. s, 1H), 8.15 (s, 1H), 8.02 (d, 9.2 Hz, 1H), 7.73 (d, 8.5 Hz, 1H), 7.66 (dd, 7.1, 1.2 Hz, 1H), 7.61-7.51 (m, 2H), 5.07 (d, 1.3 Hz, 1H), 4.21-4.07 (m, 1H), 4.08-3.90 (m, 1H), 3.69-3.52 (m, 1H), 3.50-3.40 (m, 1H), 3.24 (m, 1H).	394.1	E	
I-1834		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)C(C#N)c3ccccc3)c12)-	NMR (400 MHz, DMSO-d6) 10.59 (br s, 1H), 9.44 (br s, 1H), 9.21 (br s, 1H), 8.57 (s, 1H), 8.14-8.02 (m, 2H), 7.96 (d, 9.2 Hz, 1H), 7.86-6.71 (m, 8H), 6.70-6.22 (m, 1H), 6.10	537	D	





		c1ccc2ncnn2c1	(s, 1H), 5.20 (s, 0.3H), 5.13 (s,0.3H).			
I-1835		OC1CCC(CC1)C1NC(=O)c2cccc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	NMR (400 MHz, DMSO-d6) 10.74 (br s, 1H), 8.70 (s, 1H), 8.14 (s, 1H), 8.09 (d, 8.9 Hz, 1H), 8.05 (d, 8.5 Hz, 1H), 7p.61-7.49 (m, 3H), 4.77 (s, 1H), 4.45 (d, 4.2 Hz, 1H), 3.24-3.12 (m, 1H), 1.92-1.68 (m, 2H), 1.64 (d, 11.9 Hz, 1H), 1.57 (d, 13.34 H, 1H), 1.39 (qd, 13.4, 3.2 Hz, 1H), 0.98-0.70 (m, 3H), 0.68-0.60 (m, 1H).	437.1	E	
I-1836		Fc1cc(cc(c1)C(F)(F)F)C(=O)Nc1ccc2C(=O)N[C@@H](C3CCC(F)(F)CC3)c12	NMR (400 MHz, DMSOD6) 10.83 (br s, 1H), 8.79 (s, 1H), 8.15 (s, 1H), 8.13 (d, 9.2 Hz, 1H), 8.03 (d, 8.5 Hz, 1H), 7.64 (dd, 7.3, 1.5 Hz, 1H), 7.59-7.51 (m, 2H), 4.86 (br s, 1H), 2.09-1.95 (m, 2H), 1.90-1.80 (m, 1H), 1.7-1.51 (m, 4H), 1.05-0.90 (qd, 13.7, 3.6 Hz, 1H), 0.73 (app. Br d, 12.7 Hz, 1H).	457.3	E	
I-1837		CC(C#N)n1cc(cn1)-c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)ccc2C(F)(F)F)c1)c1cc(F)ccc1Cl	(400 MHz, DMSO-d6) 10.55 (br s, 1 H), 9.17 (br s, 1 H), 8.62 (s, 1 H), 8.23 (s, 1 H), 7.98 - 7.94 (m, 2 H), 7.79-7.68 (m, 3 H), 7.32 (dd, 8.9, 5.2 Hz, 1 H), 7.09 (td, 8.5, 2.9 Hz, 1 H), 6.58 (br s, 1 H), 5.98 (br s, 1 H), 5.88 (q, 7.1 Hz, 1 H), 1.86 (d, 7.1 Hz, 3 H).	584.3	A	





I-1838		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1cn2c(cnc2cc1F)C#N		626.14	A	
I-1839		Cn1nc(cc1-c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl)C(F)F			A	
I-1840		FC(F)c1nnc2ccc(cn12)-c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl			A	
I-1841		Cn1nc2ccccc2c1Nc1cc(cc2C(=O)NC(c12)c1cc(F)ccc1Cl)-c1ccc2nnnn2c1	1H NMR (400 MHz, DMSO-d6) 9.35 - 9.29 (m, 1H), 9.08 (s, 1H), 8.54 (s, 1H), 8.24 (s, 1H), 7.97 (dd, 9.3, 1.8 Hz, 1H), 7.92 (d, 9.2 Hz, 1H), 7.71 (d, 1.6 Hz, 1H), 7.50 (dd, 8.8, 5.5 Hz, 2H), 7.29 - 7.14 (m, 3H), 7.07 (d, 8.4 Hz, 1H), 6.88 (dd, 8.5, 6.5 Hz, 1H), 6.55 (d, 8.9 Hz, 1H), 5.59 (s, 1H), 3.55 (s, 3H).	524.15	E	





I-1842		CC(=O)N[C@@H]1CCC[C@@H](C1)C(=O)Nc1cc(cc2C(=O)NC(c12)c1cc(F)ccc1Cl)-c1ccc2ncnn2c1	1H NMR (400 MHz, DMSO-d6) 9.85 - 9.56 (m, 1H), 9.44 (s, 1H), 9.19 (s, 1H), 8.57 (s, 1H), 8.14 - 8.06 (m, 1H), 8.03 - 7.94 (m, 2H), 7.82 - 7.77 (m, 1H), 7.67 (dd, 33.9, 7.4 Hz, 1H), 7.50 (s, 1H), 7.32 - 7.15 (m, 1H), 6.56 (s, 1H), 6.14 (s, 1H), 3.93 (s, 1H), 2.37 (s, 1H), 2.16 (t, 12.0 Hz, 1H), 1.86 - 1.76 (m, 3H), 1.69 (s, 1H), 1.62 (d, 17.6 Hz, 1H), 1.43 (s, 3H), 1.24 (s, 1H), 1.22 - 1.08 (m, 1H), 1.07 - 0.97 (m, 2H).	561.2	E	
I-1843		CC(=O)N[C@H]1CCC[C@@H](C1)C(=O)Nc1cc(cc2C(=O)NC(c12)c1cc(F)ccc1Cl)-c1ccc2ncnn2c1	1H NMR (400 MHz, DMSO-d6) 9.82 (s, 1H), 9.43 (dd, 1.9, 0.9 Hz, 1H), 9.18 (s, 1H), 8.57 (s, 1H), 8.09 (dd, 9.4, 1.9 Hz, 1H), 8.02 - 7.94 (m, 2H), 7.79 (d, 1.7 Hz, 1H), 7.70 (d, 8.0 Hz, 1H), 7.48 (td, 8.3, 3.1 Hz, 1H), 7.19 (td, 8.3, 3.1 Hz, 1H), 6.11 (s, 1H), 3.45 (s, 1H), 3.32 (s, 1H), 2.14 (d, 12.9 Hz, 1H), 1.81 (s, 3H), 1.69 (t, 12.3 Hz, 2H), 1.43 (s, 2H), 1.22 (d, 14.9 Hz, 1H), 1.15 (s, 1H), 1.05 (s, 2H).	561.2	E	
I-1844		N[C@@H]1CCC[C@@H](C1)C(=O)Nc1cc(cc2C(=O)NC(c12)c1cc(F)ccc1Cl)-c1ccc2ncnn2c1	1H NMR (400 MHz, DMSO-d6) 9.76 (d, 33.5 Hz, 1H), 9.43 (d, 2.0 Hz, 1H), 9.20 (s, 1H), 8.57 (d, 1.2 Hz, 1H), 8.14 - 8.05 (m, 1H), 8.03 - 7.98 (m, 1H), 7.98 - 7.67 (m, 1H), 7.52 (s, 1H), 7.25 (t, 8.5 Hz, 1H), 6.61 (s, 1H), 6.14 (s, 1H), 2.14 (s, 1H), 2.08 - 1.74 (m, 1H), 1.67 (s, 2H), 1.51 (s, 1H), 1.42 (d, 12.6	519.2	E	





			Hz, 1H), 1.21 (s, 5H), 1.02 - 0.88 (m, 1H).			
I-1845		N[C@H]1CCC[C@@H](C1)C(=O)Nc1cc(cc2C(=O)NC(c12)c1cc(F)ccc1Cl)-c1ccc2ncnn2c1	1H NMR (400 MHz, DMSO-d6) 9.76 (d, 33.5 Hz, 1H), 9.46 - 9.41 (m, 1H), 9.19 (s, 1H), 8.57 (s, 1H), 8.09 (dd, 9.3, 2.0 Hz, 1H), 8.03 - 7.94 (m, 2H), 7.86 - 7.76 (m, 1H), 7.52 (s, 1H), 7.25 (t, 8.6 Hz, 1H), 6.65 (s, 1H), 6.14 (s, 1H), 2.25 - 1.96 (m, 1H), 1.95 - 1.74 (m, 2H), 1.65 (s, 2H), 1.20 (d, 34.2 Hz, 4H), 1.09 - 0.38 (m, 3H).	519.2	E	
I-1846		CNC(=O)c1cc(cc2C(=O)NC(c12)c1cc(F)ccc1Cl)-c1ccc2ncnn2c1	1H NMR (400 MHz, DMSO-d6)9.56 (t, 1.4 Hz, 1H), 9.29 (s, 1H), 8.60 (s, 1H), 8.54 (d, 4.8 Hz, 1H), 8.30-78.10 (m, 3H),8.10-7.90 (s,1H),7.52 (d, 9.1 Hz, 1H), 7.19 (td, 8.4, 3.1 Hz, 1H), 6.41 (s, 2H), 2.61-2.55 (m, 3H).	436	E	
I-1847		Fc1ccc(Cl)c(c1)[C@@H]1NC(=O)c2cc(cc(NC(=O)[C@H]3CCCNC3)c12)-c1ccc2ncnn2c1	1H NMR (400 MHz, DMSO-d6) 10.12 - 9.12 (m, 2H), 8.57 (s, 1H), 8.09 (dd, 9.3, 1.9 Hz, 1H), 8.02 - 7.84 (m, 3H), 7.53 (d, 10.1 Hz, 1H), 7.35 - 7.10 (m, 1H), 6.58 (s, 1H), 6.12 (s, 1H), 2.86 - 2.71 (m, 2H), 2.33 (s, 1H), 2.22 (d, 9.8 Hz, 1H), 1.51 -1.15 (m, 6H).	505.15	E	
I-1848		Fc1ccc(Cl)c(c1)[C@H]1NC(=O)c2cc(cc(NC(=O)[C@H]3CCCNC3)c12)-c1ccc2ncnn2c1	1H NMR (400 MHz, DMSO-d6) 10.12 - 9.12 (m, 2H), 8.57 (s, 1H), 8.09 (dd, 9.3, 1.9 Hz, 1H), 8.02 - 7.84 (m, 3H), 7.53 (d, 10.1 Hz, 1H), 7.35 - 7.10 (m, 1H), 6.58 (s, 1H), 6.12 (s, 1H), 2.86 - 2.71 (m, 2H), 2.33 (s, 1H), 2.22 (d, 9.8 Hz,	505.15	E	




			1H), 1.51 -1.15 (m, 6H).			
I-1849		CC(=O)N[C@H]1CC[C@H](CC1)C(=O)Nc1cc(cc2C(=O)NC(c12)c1cc(F)ccc1Cl)-c1ccc2ncnn2c1	1H NMR (400 MHz, DMSO-d6) 9.45 - 9.40 (m, 1H), 9.38 (s, 1H), 9.23 (s, 1H), 8.57 (s, 1H), 8.21 (dd, 3.5, 1.7 Hz, 1H), 8.09 - 7.95 (m, 2H), 7.93 - 7.82 (s, 1H), 7.79 - 7.68 (s, 1H), 7.57 (s, 1H), 7.29 (td, 8.4, 3.1 Hz, 1H), 6.67 (s, 1H), 6.18 (s, 1H), 3.87 - 3.62 (s, 1H), 2.19 - 2.05 (m, 1H), 1.87 - 1.79 (m, 3H), 1.69 - 1.58 (m, 2H), 1.58 - 1.53 (m,1H), 1.45 - 1.37 (m,2H), 1.37 - 1.29 (m,1H), 1.29 - 1.17(m, 2H).	561.05	E	
I-1850		CC(=O)N[C@H]1CC[C@@H](CC1)C(=O)Nc1cc(cc2C(=O)NC(c12)c1cc(F)ccc1Cl)-c1ccc2ncnn2c1	1H NMR (400 MHz, DMSO-d6) 9.74 (s, 1H), 9.44 (t, 1.3 Hz, 1H), 9.20 (s, 1H), 8.58 (s, 1H), 8.09 (dd, 9.3, 1.9 Hz, 1H), 8.02 - 7.94 (m, 2H), 7.81 (d, 1.7 Hz, 1H), 7.70 (d, 7.8 Hz, 1H), 7.53 (s, 1H), 7.26 (td, 8.4, 3.1 Hz, 1H), 6.13 (s, 1H), 2.06 - 1.96 (m, 1H), 1.87 - 1.65 (m, 5H), 1.53 (dd, 8.8, 4.7 Hz, 1H), 1.36 (s, 1H), 1.32 - 1.23 (m, 3H), 1.21 - 0.98 (m, 2H).	561.1	E	
I-1851		OCc1cc(cc2C(=O)NC(c12)c1cc(F)ccc1Cl)-c1ccc2ncnn2c1	1H NMR (400 MHz, DMSO-d6) 9.43 - 9.38 (m, 1H), 9.18 (s, 1H), 8.56 (s, 1H), 8.10 (dd, 9.3, 1.9 Hz, 1H), 8.05 (d, 1.8 Hz, 1H), 8.02 (d, 1.8 Hz, 1H), 7.97 (d, 9.3 Hz, 1H), 7.60 (s, 1H), 7.28 (td, 8.4, 3.1 Hz, 1H), 6.85 - 6.27 (m, 1H), 6.14 (s, 1H), 5.29 (t, 5.3 Hz, 1H), 4.42 (dd, 14.2, 5.6 Hz,	409.05	E	





			1H), 4.10 (dd, 14.4, 5.1 Hz, 1H).			
I-1852		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(NC3CCc4ccccc34)c12	1H NMR (400 MHz, DMSO-d6) 9.06 (d, 10.4 Hz, 1H), 7.48 (ddd, 24.1, 8.9, 5.2 Hz, 1H), 7.27-6.97 (m, 6H), 6.40 (d, 7.5 Hz, 1H), 5.86 (d, 22.4 Hz, 1H), 5.15-4.81 (m, 2H), 2.97-2.77 (m, 1H), 2.76-2.58 (m, 1H), 2.37-2.18 (m, 1H), 1.80-1.33 (m, 1H).	471	E	
I-1853		Fc1ccc(Cl)c(c1)[C@@H]1NC(=O)c2cc(Br)cc(NC(=O)[C@H]3C[C@H]3C(F)(F)F)c12	1H NMR (400 MHz, DMSO-d6) 10.36 (s, 1H), 9.24 (s, 1H), 7.74 (d, 1.7 Hz, 1H), 7.65 (d, 1.8 Hz, 1H), 7.48 (dd, 9.0, 5.0 Hz, 1H), 7.24 (td, 8.4, 3.1 Hz, 1H), 6.92 - 6.21 (s, 1H), 5.94 (s, 1H), 2.06 (qd, 7.2, 4.2 Hz, 1H), 1.92 (td, 7.1, 4.1 Hz, 1H), 1.16 (t, 7.4 Hz, 2H).	490.85	E	
I-1854		Fc1ccc(Cl)c(c1)[C@H]1NC(=O)c2cc(Br)cc(NC(=O)[C@H]3C[C@H]3C(F)(F)F)c12	1H NMR (400 MHz, DMSO-d6) 10.46 (s, 1H), 9.25 (s, 1H), 7.75 (d, 1.7 Hz, 1H), 7.57 (d, 1.8 Hz, 1H), 7.47 (t, 7.0 Hz, 1H), 7.23 (td, 8.4, 3.1 Hz, 1H), 6.72 (s, 1H), 5.95 (s, 1H), 2.03 (s, 1H), 1.92 (dt, 9.3, 5.0 Hz, 1H), 1.26 - 1.08 (m, 2H).	490.8	E	
I-1855		Fc1ccc(Cl)c(c1)[C@H]1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1cc(F)c2ncc(C#N)n2c1		626.2	C	





I-1856		Fc1ccc(Cl)c(c1)[C@@H]1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1cc(F)c2ncc(C#N)n2c1		626.2	A	
I-1857		CN(C)C(=O)c1cc(cc2C(=O)NC(c12)c1cc(F)ccc1Cl)-c1ccc2ncnn2c1			E	
I-1858		Fc1ccc(Cl)c(c1)[C@H]1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1cnc2ncc(C#N)n2c1		609.2	C	
I-1859		Fc1ccc(Cl)c(c1)[C@@H]1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1cnc2ncc(C#N)n2c1		609.2	A	





I-1860		FC(F)n1cc(ccc1=O)-c1cc2C(=O)N[C@@H](c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl		610.5	D	
I-1861		FC(F)n1cc(ccc1=O)-c1cc2C(=O)N[C@H](c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl		610.5	A	
I-1862		FC(F)n1nccc(c1C#N)-c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl			A	
I-1863		FC(F)n1ccc(cn1)-c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(Cl)c2)c1)c1cc(F)ccc1Cl			A	





I-1864		FC(F)c1cn2cc(ccc2n1)-c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl		633.14	A	
I-1865		Cn1nc(cc1-c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl)C(F)(F)F			A	
I-1866		FC(F)c1cnc2ccc(cn12)-c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl		633.19	A	
I-1867		Fc1ccc(Cl)c(c1)[C@H]1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1cc2ncnn2cc1F	1H NMR (400 MHz, DMSO) δ 10.67 (s, 1H), 9.53 (d, J = 5.3 Hz, 1H), 9.31 (s, 1H), 8.61 (s, 1H), 8.19 (d, J = 7.3 Hz, 1H), 7.97 (d, J = 11.3 Hz, 2H), 7.82 (s, 1H), 7.76 (d, J = 9.2 Hz, 1H), 7.68 (s, 1H), 7.34 (dd, J = 8.9, 5.2 Hz, 1H), 7.15 – 7.09 (m, 1H), 6.08 (s, 1H).	602.08	D	






I-1868		Fc1ccc(Cl)c(c1)[C@@H]1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1cc2ncnn2cc1F	1H NMR (400 MHz, DMSO) δ 10.67 (s, 1H), 9.53 (d, J = 5.3 Hz, 1H), 9.31 (s, 1H), 8.61 (s, 1H), 8.19 (d, J = 7.3 Hz, 1H), 7.97 (d, J = 11.3 Hz, 2H), 7.82 (s, 1H), 7.76 (d, J = 9.2 Hz, 1H), 7.68 (s, 1H), 7.34 (dd, J = 8.9, 5.2 Hz, 1H), 7.15 – 7.09 (m, 1H), 6.08 (s, 1H).	602.08	A	
I-1869		Fc1cnc2ccc(cn12)-c1cc2C(=O)N[C@@H](c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	1H NMR (500 MHz, DMSO) δ 10.61 (s, 1H), 9.22 (s, 1H), 8.75 (s, 1H), 8.09 (d, J = 1.6 Hz, 1H), 7.95 (d, J = 8.4 Hz, 1H), 7.91 (s, 1H), 7.77 (d, J = 9.0 Hz, 1H), 7.71 (s, 1H), 7.69 (dd, J = 9.5, 1.8 Hz, 1H), 7.66 (d, J= 1.7 Hz, 1H), 7.61 (ddt, J = 9.7, 6.9, 3.9 Hz, 2H), 7.57 – 7.52 (m, 1H), 7.42 (d, J = 7.2 Hz, 1H), 7.33 (dd, J = 8.9, 5.2 Hz, 1H), 7.10 (td, J = 8.3, 3.1 Hz, 1H), 6.05 (s, 1H).	601.18	C	
I-1870		Fc1cnc2ccc(cn12)-c1cc2C(=O)N[C@H](c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	1H NMR (500 MHz, DMSO) δ 10.61 (s, 1H), 9.22 (s, 1H), 8.75 (s, 1H), 8.09 (d, J = 1.6 Hz, 1H), 7.95 (d, J = 8.4 Hz, 1H), 7.91 (s, 1H), 7.77 (d, J = 9.0 Hz, 1H), 7.71 (s, 1H), 7.69 (dd, J = 9.5, 1.8 Hz, 1H), 7.66 (d, J= 1.7 Hz, 1H), 7.61 (ddt, J = 9.7, 6.9, 3.9 Hz, 2H), 7.57 – 7.52 (m, 1H), 7.42 (d, J = 7.2 Hz, 1H), 7.33 (dd, J = 8.9, 5.2 Hz, 1H), 7.10 (td, J = 8.3, 3.1 Hz, 1H), 6.05 (s, 1H).	601.18	A	





I-1871		Fc1ccc(Cl)c(c1)[C@H]1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1cnn2ncnc2c1	1H NMR (500 MHz, DMSO) δ 10.68 (s, 1H), 9.29 (s, 1H), 9.27 (d, J = 2.4 Hz, 1H), 8.88 (d, J = 2.4 Hz, 1H), 8.73 (s, 1H), 8.30 (d, J = 1.6 Hz, 1H), 8.09 (d, J = 1.7 Hz, 1H), 7.96 (dt, J = 8.5, 2.0 Hz, 1H), 7.77 (d, J = 8.7 Hz, 1H), 7.72 (s, 1H), 7.34 (dd, J = 8.9, 5.1 Hz, 1H), 7.11 (td, J = 8.4, 3.1 Hz, 1H), 6.08 (s, 1H).	585.12	B	
I-1872		Fc1ccc(Cl)c(c1)[C@@H]1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1cnn2ncnc2c1	1H NMR (500 MHz, DMSO) δ 10.68 (s, 1H), 9.29 (s, 1H), 9.27 (d, J = 2.4 Hz, 1H), 8.88 (d, J = 2.4 Hz, 1H), 8.73 (s, 1H), 8.30 (d, J = 1.6 Hz, 1H), 8.09 (d, J = 1.7 Hz, 1H), 7.96 (dt, J = 8.5, 2.0 Hz, 1H), 7.77 (d, J = 8.7 Hz, 1H), 7.72 (s, 1H), 7.34 (dd, J = 8.9, 5.1 Hz, 1H), 7.11 (td, J = 8.4, 3.1 Hz, 1H), 6.08 (s, 1H).	585.12	A	
I-1873		Cc1cc2ncnn2cc1-c1cc2C(=O)N[C@@H](c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl			D	
I-1874		Cc1cc2ncnn2cc1-c1cc2C(=O)N[C@H](c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl			A	





I-1875		Cc1c(ccc2ncnn12)-c1cc2C(=O)N[C@@H](c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl			D	
I-1876		Cc1c(ccc2ncnn12)-c1cc2C(=O)N[C@H](c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl			A	
I-1877		Fc1cnc2cnc(cn12)-c1cc2C(=O)N[C@@H](c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	1H NMR (400 MHz, DMSO) δ 10.65 (s, 1H), 9.27 (d, J = 1.4 Hz, 1H), 9.26 – 9.21 (m, 1H), 9.17 (t, J = 1.7 Hz, 1H), 8.47 (d, J = 1.6 Hz, 1H), 8.33 (d, J = 1.6 Hz, 1H), 7.96 (d, J = 8.4 Hz, 1H), 7.78 (d, J = 9.1 Hz, 1H), 7.75 – 7.69 (m, 2H), 7.33 (dd, J = 8.9, 5.2 Hz, 1H), 7.10 (td, J = 8.4, 3.0 Hz, 1H).	602.18	D	
I-1878		Fc1cnc2cnc(cn12)-c1cc2C(=O)N[C@H](c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	1H NMR (400 MHz, DMSO) δ 10.65 (s, 1H), 9.27 (d, J = 1.4 Hz, 1H), 9.26 – 9.21 (m, 1H), 9.17 (t, J = 1.7 Hz, 1H), 8.47 (d, J = 1.6 Hz, 1H), 8.33 (d, J = 1.6 Hz, 1H), 7.96 (d, J = 8.4 Hz, 1H), 7.78 (d, J = 9.1 Hz, 1H), 7.75 – 7.69 (m, 2H), 7.33 (dd, J = 8.9, 5.2 Hz, 1H), 7.10 (td, J = 8.4, 3.0 Hz, 1H).	602.18	A	




I-1879		Cn1nc(cc1-c1cc2C(=O)N[C@@H](c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl)C(F)F			D	
I-1880		Fc1ccc(Cl)c(c1)[C@H]1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1cc(C#N)c2ncnn2c1		609.08	C	
I-1881		Cn1nc(cc1-c1cc2C(=O)N[C@H](c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl)C(F)F	1H NMR (500 MHz, DMSO) δ 10.59 (s, 1H), 9.27 (s, 1H), 7.95 (d, J = 8.2 Hz, 1H), 7.85 (d, J = 1.5 Hz, 1H), 7.73 (d, J = 9.0 Hz, 1H), 7.71 – 7.64 (m, 2H), 7.33 (dd, J = 8.9, 5.2 Hz, 1H), 7.15 – 7.06 (m, 2H), 7.02 (s, 1H), 6.83 (d, J = 1.3 Hz, 1H), 4.07 (q, J = 5.3 Hz, 1H), 3.96 (s, 3H), 3.16 (d, J = 5.2 Hz, 3H).	597.18	A	
I-1882		Fc1ccc(Cl)c(c1)[C@@H]1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1cc(C#N)c2ncnn2c1	1H NMR (500 MHz, DMSO) δ 10.65 (s, 1H), 9.83 (d, J = 1.7 Hz, 1H), 9.26 (s, 1H), 8.94 (d, J = 1.7 Hz, 1H), 8.76 (s, 1H), 8.23 (d, J = 1.7 Hz, 1H), 8.03 (d, J = 1.8 Hz, 1H), 7.96 (dt, J = 8.6, 2.0 Hz, 1H), 7.77 (d, J = 8.7 Hz, 1H), 7.73 (s, 1H), 7.34 (dd, J = 8.9, 5.2 Hz, 1H), 7.11 (td, J	609.08	A	




			= 8.4, 3.1 Hz, 1H), 6.07 (s, 1H)			
I-1883		Fc1ccc(Cl)c(c1)[C@H]1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1cn2c(cnc2cc1F)C#N	1H NMR (400 MHz,DMSO) δ 10.66 (s, 1H), 9.31 (s, 1H) ,9.22–9.16 (m, 1H), 8.55 (s, 1H), 8.20 (d, J=7.1 Hz, 1H), 7.97 (d, J=9.2 Hz, 2H), 7.82 (s, 1H), 7.76 (d, J=9.1 Hz, 1H), 7.68 (s, 1H), 7.34 (dd, J=8.9, 5.2 Hz, 1H), 7.12(td, J=8.4, 3.0 Hz,1H)	626.09	D	
I-1884		Fc1ccc(Cl)c(c1)[C@@H]1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1cn2c(cnc2cc1F)C#N	1H NMR (400 MHz, DMSO) δ 10.66 (s, 1H), 9.31 (s, 1H) ,9.22–9.16 (m, 1H), 8.55 (s, 1H), 8.20 (d, J=7.1 Hz, 1H), 7.97 (d, J=9.2 Hz, 2H), 7.82 (s, 1H), 7.76 (d, J=9.1 Hz, 1H), 7.68 (s, 1H), 7.34 (dd, J=8.9, 5.2 Hz, 1H), 7.12(td, J=8.4, 3.0 Hz,1H)	626.09	A	
I-1885		Fc1ccc(Cl)c(c1)[C@H]1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1cnn(c1)C1(CC1)C#N		598.2	C	
I-1886		Fc1ccc(Cl)c(c1)[C@@H]1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1cnn(c1)C1(CC1)C#N		598.2	A	





I-1887		Fc1ccc(Cl)c(c1)[C@H]1NC(=O)c2cc(OCC#N)cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12		523.07	C	
I-1888		Fc1ccc(Cl)c(c1)[C@@H]1NC(=O)c2cc(OCC#N)cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12		523.07	A	
I-1889		FC(F)n1cc(c(n1)C#N)-c1cc2C(=O)N[C@@H](c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	1H NMR (DMSO-d6, 400 MHz): δ = 10.69 (s, 1H), 9.32 (br s, 1H), 9.23 (s, 1H), 7.89-8.22 (m, 3H), 7.86 (s, 1H), 7.74 (br d, J = 8.3 Hz, 1H), 7.66 (s, 1H), 7.34 (dd, J = 8.8, 5.1 Hz, 1H), 7.12 (td, J = 8.4, 2.9 Hz, 1H), 6.38-6.88 (m, 1H), 5.82-6.20 ppm (m, 1H).	608.5	D	
I-1890		FC(F)n1cc(c(n1)C#N)-c1cc2C(=O)N[C@H](c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	1H NMR (DMSO-d6, 400 MHz): δ = 10.69 (s, 1H), 9.32 (br s, 1H), 9.23 (s, 1H), 7.89-8.22 (m, 3H), 7.86 (s, 1H), 7.74 (br d, J = 8.3 Hz, 1H), 7.66 (s, 1H), 7.34 (dd, J = 8.8, 5.1 Hz, 1H), 7.12 (td, J = 8.4, 2.9 Hz, 1H), 6.38-6.88 (m, 1H), 5.82-6.20 ppm (m, 1H).	608.4	A	
I-1891		Oc1cc(cc2C(=O)NC(c12)c1cc(F)ccc1Cl)-c1ccc2nccnn2c1	(400 MHz, CD3CN) 9.01 -8.99 (m, 1 H), 8.35 (br s, 1 H), 7.93 (dd, 9.3, 1.8 Hz, 1 H), 7.82 (dd, 9.2, 0.6 Hz, 1 H), 7.64 (d, 1.4 Hz, 1 H), 7.49 (dd, 8.8, 5.1 Hz, 1 H), 7.32 (d, 1.5 Hz, 1 H), 7.22 (br s, 1	393.3	D	




			H), 7.09 (ddd, 8.8, 8.0, 3.1 Hz, 1 H), 6.76 (dd, 9.4, 3.1 Hz, 1 H), 6.11 (br s, 1 H).			
I-1892		CSc1cc(cc2C(=O)NC(c12)c1cc(F)ccc1Cl)-c1ccc2ncnn2c1		425.05	E	
I-1893		Fc1ccc(Cl)c(c1)[C@@H]1NC(=O)c2cc(Br)cc(N[C@H]3COCc4ccccc34)c12	1H NMR (400 MHz, DMSO-d6) 9.05 (s, 1H), 7.40 (dd, 8.9, 5.2 Hz, 1H), 7.30-7.23 (m, 2H), 7.18 (td, 7.5, 1.3 Hz, 1H), 7.13 (d, 1.5 Hz, 1H), 7.05-6.92 (m, 2H), 6.84 (s, 1H), 6.55 (s, 1H), 5.80 (s, 1H), 4.88 (d, 9.3 Hz, 1H), 4.71 (q, 5.0 Hz, 1H), 4.67 (s, 2H), 3.84 (dd, 11.4, 4.2 Hz, 1H), 3.63 (dd, 11.4, 5.8 Hz, 1H).	487	E	
I-1894		Fc1ccc(Cl)c(c1)[C@@H]1NC(=O)c2cc(Br)cc(N[C@@H]3COCc4ccccc34)c12	1H NMR (400 MHz, DMSO-d6) 9.05 (s, 1H), 7.40 (dd, 8.9, 5.2 Hz, 1H), 7.30-7.23 (m, 2H), 7.18 (td, 7.5, 1.3 Hz, 1H), 7.13 (d, 1.5 Hz, 1H), 7.05-6.92 (m, 2H), 6.84 (s, 1H), 6.55 (s, 1H), 5.80 (s, 1H), 4.88 (d, 9.3 Hz, 1H), 4.71 (q, 5.0 Hz, 1H), 4.67 (s, 2H), 3.99 (dd, 11.4, 4.2 Hz, 1H), 3.70 (dd, 11.4, 5.8 Hz, 1H).	487	E	
I-1895		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(NC3CCOc4ccccc34)c12	1H NMR (400 MHz, DMSO-d6) 9.06 (d, 17.1 Hz, 1H), 7.48 (td, 9.3, 5.2 Hz, 1H), 7.34-7.20 (m, 2H), 7.20-7.10 (m, 2H), 7.10-7.02 (m, 1H), 6.95-6.80 (m, 1H), 6.80-6.36 (m, 2H), 5.88 (s, 1H), 5.10 (d, 7.5 Hz, 1H), 4.74 (dt, 9.3, 4.9 Hz, 1H), 4.00 (ddd, 9.9, 5.7, 3.2 Hz, 1H), 3.52-3.42 (m, 1H), 1.82 (ddd, 13.5, 8.9, 4.5 Hz,	486.95	B	




			1H), 1.62 (d, 13.7 Hz, 1H).			
I-1896		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(Nc3c[nH]c4ccccc34)c12	1H NMR (400 MHz, DMSO-d6) 11.00 (d, 2.7 Hz, 1H), 9.08 (s, 1H), 7.47 (ddd, 8.8, 5.2, 1.4 Hz, 1H), 7.37 (d, 8.2 Hz, 1H), 7.25-7.15 (m, 2H), 7.15-7.03 (m, 3H), 6.98-6.91 (m, 1H), 6.91 (ddd, 7.8, 6.5, 0.9 Hz, 1H), 6.78 (dd, 3.4, 1.7 Hz, 2H), 5.86 (d, 1.2 Hz, 1H).	470	E	
I-1897		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(C(=O)Nc3ccccc3)c12)-c1ccc2nccnn2c1	1H NMR (400 MHz, DMSO-d6) 10.39 (s, 1H), 9.61 (t, 1.3 Hz, 1H), 9.35 (s, 1H), 8.59 (s, 1H), 8.40 (s, 1H), 8.34 (d, 1.7 Hz, 1H), 8.28 (dd, 9.3, 1.9 Hz, 1H), 8.01 (d, 9.3 Hz, 1H), 7.49 - 7.38 (m, 3H), 7.30 (t, 7.9 Hz, 2H), 7.17 - 7.03 (m, 2H), 6.46 (s, 2H).	498.15	E	
I-1898		CS(=O)(=O)Nc1cc(cc2C(=O)NC(c12)c1cc(F)ccc1Cl)-c1ccc2nccnn2c1	1H NMR (400 MHz, DMSO-d6) 9.33 (d, 98.3 Hz, 2H), 8.58 (s, 1H), 8.09 (dd, 9.3, 1.9 Hz, 1H), 7.98 (d, 9.5 Hz, 2H), 7.86 (d, 1.6 Hz, 1H), 7.53 (t, 7.2 Hz, 1H), 7.26 (td, 8.4, 3.1 Hz, 1H), 7.08-6.30 (s, 1H), 6.17 (s, 1H), 2.86 (m, 3H).	472.05	D	
I-1899		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)C3(CCCC3)C#N)c12)-c1ccc2nccnn2c1	1H NMR (400 MHz, DMSO-d6) 10.31 (s, 1H), 9.49 - 9.44 (m, 1H), 9.26 (s, 1H), 8.57 (s, 1H), 8.16 - 8.06 (m, 2H), 7.98 (d, 9.3 Hz, 1H), 7.86 (d, 1.8 Hz, 1H), 7.53 (s, 1H), 7.25 (td, 8.4, 3.1 Hz, 1H), 6.56 (s, 1H), 6.09 (s, 1H), 2.13 - 2.02 (m, 1H), 2.04 (s, 1H), 2.02 - 1.93 (m, 1H), 1.97 - 1.83 (m, 1H), 1.78 - 1.55 (m, 4H).	515.15	E	





I-1900		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)C3CNCCO3)c12)-c1ccc2ncnn2c1	NMR (400 MHz, DMSO-d6) 9.42 (dd, 3.1, 1.3 Hz, 1H), 9.27 (br s, 0.4H), 9.23 (br s, 0.6H), 9.15 (br s, 0.4H), 8.57 (s, 1H), 8.31 (s, 2H), 8.14 (d, 1.4 Hz, 0.4H), 8.10-8.07 (m, 0.6H), 8.06 (d, 1.6 Hz, 0.6H), 8.01 (d, 1.5 Hz, 0.4H), 7.98 (dd, 3.7, 1.3 Hz, 0.5H), 7.96 (dd, 2.3, 0.8 Hz, 0.5H), 7.66-7.45 (m, 1H), 7.32-7.24 (m, 1H), 6.67 (br s, 1H), 6.27-6.08 (m, 1H), 3.84-3.69 (m, 2H), 3.49-3.39 (m, 1H), 2.88 (d, 12.0 Hz, 0.5H), 2.79 (d, 12.0 Hz, 0.5H), 2.67 (d, 12.0 Hz, 1H), 2.57-2.51 (submerged m, 1H), 2.12 (br s, 0.5H), 2.03 (dd, 12.3, 10.3 Hz, 0.5H).	507	E	
I-1901		Fc1cc(cc(c1)C(F)(F)F)C(=O)Nc1ccc2C(=O)N[C@@H]([C@@H]3COCCN3)c12	(400 MHz, CD3CN) 8.61 (dd, 7.9, 1.1 Hz, 1H), 8.04 (s, 1H), 7.92 (d, 9.1 Hz, 1H), 7.69 (d, 8.5 Hz, 1H), 7.57-7.47 (m, 2H), 6.93 (br s, 1H), 4.66 (s, 1H), 3.65 (dd, 11.6, 3.2 Hz, 1H), 3.49 (dd, 11.4, 3.0 Hz, 1H), 3.35 (dt, 10.5, 2.7 Hz, 1H), 3.28 (td, 11.7, 2.4 Hz, 1H), 3.06 (br s, 1H), 2.90 (td, 12.0, 3.4 Hz, 1H), 2.75 (t, 11.0 Hz, 1H), 2.63 (d, 12.0 Hz, 1H)	424.2	E	
I-1902		O[C@H]1CN(C[C@@H]1C(F)(F)F)C(=O)Nc1cc(cc2C(=O)NC(c12)c1cc(F)ccc1Cl)-c1ccc2ncnn2c1	1H-NMR (400 MHz, DMSO-d6) 9.40-9.38 (m, 2H), 9.16 (br. s, 2H), 8.57 (s, 2H), 8.45 (br. s, 1H), 8.39 (br. s, 1H), 8.09-8.04 (m, 2H), 7.99-7.95 (m, 2H), 7.93 (s, 2H), 7.73-7.70 (m, 2H), 7.51-7.44 (m, 2H), 7.28-7.19 (m, 2H), 6.65 (br. s, 2H), 6.09 (br. s, 2H), 5.72 (d, 5.4 Hz, 1H), 5.69 (d, 4.7 Hz,	575.2	D	





			1H), 4.32-4.26 (m, 1H), 4.24-4.18 (m, 1H), 3.72-3.55 (m, 2H), 3.39-3.29 (m, 2H), 3.15-3.09 (m, 2H), 3.02-2.82 (m, 4H).			
I-1903		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)N3CCC(C3)C(F)(F)F)c12)-c1ccc2ncnn2c1	1H-NMR (400 MHz, DMSO-d6) 9.40-9.38 (m, 2H), 9.16 (br. s, 2H), 8.56 (s, 2H), 8.44 (br. s, 1H), 8.40 (br. s, 1H), 8.08-8.04 (m, 2H), 7.99-7.95 (m, 2H), 7.93-7.91 (m, 2H), 7.71-7.69 (m, 2H), 7.52-7.46 (m, 2H), 7.29-7.20 (m, 2H), 6.66 (br. s, 2H), 6.07 (br. s, 2H), 3.58 (dd, 10.5, 8.8 Hz, 1H), 3.49-3.40 (m, 1H), 3.36-3.29 (m, 3H), 3.27-3.12 (m, 3H), 3.01-2.88 (m, 2H), 2.14-2.02 (m, 2H), 1.93-1.77 (m, 2H).	559.3	D	
I-1904		OC1(CCN(C1)C(=O)Nc1cc(cc2C(=O)NC(c12)c1cc(F)ccc1Cl)-c1ccc2ncnn2c1)C(F)(F)F	1H-NMR (400 MHz, DMSO-d6) 9.40-9.38 (m, 2H), 9.15 (br. s, 2H), 8.57 (s, 2H), 8.46 (br. s, 1H), 8.36 (br. s, 1H), 8.08-8.04 (m, 2H), 7.99-7.95 (m, 2H), 7.93-7.91 (m, 2H), 7.73-7.71 (m, 1H), 7.70-7.68 (m,1H), 7.50-7.44 (m, 2H), 7.28-7.18 (m, 2H), 6.69 (br. s, 2H), 6.52 (s, 1H), 6.45 (s, 1H), 6.07 (br. s, 2H), 3.70-3.61 (m, 1H), 3.52 (d, 11.4 Hz, 1H), 3.42-3.35 (m, 3H), 3.25-3.15 (m, 2H), 3.03-2.89 (m, 1H), 2.01-1.90 (m, 4H).	575.3	E	
I-1905		Fc1ccc(Cl)c(c1)[C@H]1NC(=O)c2cc(cc(c12)S(=O)(=O)Cc1ccccc1)-	1H NMR (400 MHz, DMSO-d6) 9.59 (br. s, 1H), 9.49 (br. s, 1H), 8.62 (s, 1H), 8.50 (d, 1.5 Hz, 1H), 8.29 (br. s, 1H), 8.16 - 8.09 (m, 1H), 8.02 (d, 8.5 Hz, 1H), 7.62 (br. s, 1H), 7.40-7.28 (m, 3H), 7.24	533.1	D	





		c1ccc2nc nn2c1	(br. s, 1H), 7.02 (d, 6.4 Hz, 2H), 6.42 (br. s, 1H), 6.08 (s, 1H), 4.58 (d, 12.8 Hz, 1H), 4.25 (d, 12.5 Hz, 1H).			
I-1906		Fc1ccc(C l)c(c1)[C @@H]1 NC(=O)c 2cc(cc(c1 2)S(=O)(=O)Cc1c cccc1)- c1ccc2nc nn2c1		533. 1	E	
I-1907		CC(O)c1 cc(cc2C(=O)NC(c 12)c1cc(F)ccc1Cl)- c1ccc2nc nn2c1	1H NMR (400 MHz, DMSO-d6) 9.43 (br. s, 1H), 9.23 (br. s, 1H), 8.57 (s, 1H), 8.14-8.10 (m, 1H), 8.09 (d, 1.8 Hz, 1H), 8.08-8.01 (m, 2H), 7.98 (br. s, 1H), 7.71 - 7.54 (m, 1H), 7.28 (td, 8.5, 2.9 Hz, 1H), 6.51 (br. s, 1H), 6.22 (br. s, 1H), 5.28 (d, 3.5 Hz, 1H), 4.54 - 4.41 (m, 1H), 1.25 (d, 5.0 Hz, 3H)	423. 1	E	
I-1908		Fc1ccc(C l)c(c1)C1 NC(=O)c 2cc(cc(N 3CCNCC 3)c12)- c1ccc2nc nn2c1	NMR (400 MHz, DMSO-d6) 9.49 (dd- 1.7, 0.8 Hz, 1H), 9.22 (s, 1H), 8.56 (s, 1H), 8.14 (dd, 9.3, 1.8 Hz, 1H), 7.94 (dd, 9.3, 0.7 Hz, 1H), 7.73 (d, 1.4 Hz, 1H), 7.57 (dd, 8.6, 5.5 Hz, 1H), 7.50 (d, 1.4 Hz, 1H), 7.28 (ddd, 8.8, 8.0, 3.1 Hz, 1H), 6.67 (br s, 1H), 6.17 (s, 1H), 3.16-3.05 (m, 2H), 2.78 2.66 (m, 2H), 2.48-2.32 (m, 4H).	463	E	
I-1909		CC(=O) N1CC(C 1)C1NC(=O)c2ccc c(NC(=O)c3cc(F)c c(c3)C(F) (F)F)c12	NMR (400 MHz, DMSO-d6) 10.71 (br. s, 1H), 9.11 (d, 7.2 Hz, 1H), 8.20 (s, 1H), 8.17 (d, 9.0 Hz, 1H), 8.03 (d, 8.3 Hz, 1H), 7.64- 7.54 (m, 3H), 5.00 (2 d, 3.6 Hz, 1H), 4.13 (t, 8.6 Hz, 0.5H), 4.07 (dd,	436. 2	E	





			8.5, 5.9 Hz, 0.5H), 3.92-3.81 (m, 1H), 3.67-3.59 (m, 0.5H), 3.38 (m, 0.5H), 3.18-3.05 (m, 1.5H), 2.93-2.87 (m, 0.5H), 1.67 (s, 1.5H), 1.61 (s, 1.5H).			
I-1910		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)C3COCCO3)c12)-c1ccc2ncnn2c1	NMR (400 MHz, DMSO-d6) 9.54 (br s, 0.5H), 9.43 (s, 1H), 9.43 (br s, 0.5H), 9.23 (br s, 1H), 8.57 (s, 1H), 8.12-7.94 (m, 5H), 7.64-7.46 (m, 1H), 7.29 (ddd, 8.2, 6.4, 4.0 Hz, 1H), 6.61 (br s, 1H), 6.18 (br s, 0.5H), 6.13 (br s, 0.5H), 4.00 (ddd, 19.6, 9.4, 3.1 Hz, 1H), 3.81-3.55 (m, 5H), 3.40-3.30 (m, 0.5H), 2.97-2.88 (m, 0.5H).	508	E	
I-1911		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(N3CCOCC3)c12)-c1ccc2ncnn2c1	NMR (400 MHz, DMSO-d6) 9.50 (dd, 1.7, 0.8 Hz, 1H), 9.25 (s, 1H), 8.56 (s, 1H), 8.21-8.13 (m, 1H), 7.95 (dd, 9.3, 0.7 Hz, 1H), 7.78 (d, 1.4 Hz, 1H), 7.62-7.54 (m, 2H), 7.28 ddd, 8.8, 8.0, 3.1 Hz, 1H), 6.77 (br s, 1H), 6.18 (s, 1H), 3.33-3.26 (m), 4H), 3.21-3.13 (m, 2H), 2.78-2.69 (m, 2H).	464.2	E	
I-1912		Fc1cc(cc(c1)C(F)(F)F)C(=O)Nc1ccccc2C(=O)NC(C3CCCC33CC3)c12	1H NMR (400 MHz, DMSO-d6) 10.77 (s, 0.3H), 10.74 (s, 0.7H), 8.70 (s, 0.3H), 8.61 (s, 0.7H), 8.15 (s, 4.0 Hz, 0.3H), 8.14 (s, 0.7H), 8.11 8.06 (br, d, 9.3Hz, 1H), 8.03 (br, d, 8.5Hz, 1H), 7.62-7.49 (m, 3H), 4.86 (d, 3.0 Hz, 0.3H), 4.63 (s, 0.7H), 1.87-1.75 (m, 0.7H), 1.75-1.61 (m, 0.3H), 1.61-1.45 (m, 1.4H), 1.45-1.31 (m, 2.1H), 1.27-1.19 (m, 0.7H), 1.18-1.06 (m, 0.7H), 1.05-0.96 (m, 0.7H), 0.95-0.85 (m, 1.4H), 0.76-	447	D	




			0.64 (m, 0.3H), 0.59-0.52 (m, 0.7H), 0.34 (dt, 9.0, 4.5 Hz, 0.7H), 0.20 (dt, 9.9, 5.0 Hz, 0.7H), 0.06 (t, 3.8 Hz, 0.3H), -0.01- -0.14 (m, 1.2H), -0.14- -0.21 (m, 0.3H), -0.34 (t, 6.7 Hz, 0.3H).			
I-1913		OC1CCC(CC(=O)Nc2cc(cc3C(=O)NC(c23)c2cc(F)ccc2Cl)-c2ccc3ncnn3c2)CC1	1H NMR (400 MHz, DMSO-d6) 9.75 (br s, 0.2H), 9.74 (br s, 0.8H), 9.42-9.38 (m, 1H), 9.16 (br s, 1H), 8.53 (s, 1H), 8.04 (dt, 10.2, 5.1 Hz, 1H), 7.96 (m, 2H), 7.85-7.81 (m, 1H), 7.57-7.40 (m, 1H), 7.24-7.18 (m, 1H), 6.52 (br s, 1H), 6.16 (br s, 1H), 4.42 (s, 0.8H), 4.21 (s, 0.2H), 3.24-3.14 (m, 1H), 1.94-1.84 (m, 2H), 1.67 (d, 11.2 Hz, 2H), 1.45-1.23 (m, 3H), 1.06-0.90 (m, 2H), 0.82-0.65 (m, 2H).	534.3	E	
I-1914		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(CC(=O)N3CCc4ccccc34)c12)-c1ccc2ncnn2c1	1H NMR (400 MHz, DMSO-d6) 9.44 (dd, 1.1, 0.6 Hz, 1H), 9.25 (br s, 1H), 8.56 (s, 1H), 8.12 (dd, 9.3, 1.8 Hz, 2H), 7.97 (d, 9.4 Hz, 1H), 7.96 (br s, 1H), 7.83 (d, 8.0 Hz, 1H), 7.48 (br s, 1H), 7.23 (d, 7.4 Hz, 1H), 7.10 (t, 7.7 Hz, 1H), 7.07-7.02 (m, 1H), 6.98 (t, 7.4 Hz, 1H), 6.50 (br. d, 7.9 Hz, 1H), 6.17 (br. s, 1H), 4.00 (dd, 18.6, 8.5 Hz, 1H), 3.84 (m, 2H), 3.53 - 3.44 (m, 1H), 3.14 (t, 8.3 Hz, 2H).	538.2	E	
I-1915		C[C@H](C#N)n1cc(cn1)-c1cc2C(=O)N[C@@H](c2cc(NC(=O)c2cc(F)cc(c2)C(F)(			D	





		F)F)c1)c1cc(F)ccc1Cl				
I-1916		C[C@H](C#N)n1cc(cn1)-c1cc2C(=O)N[C@H](c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	1H NMR(400 MHz, DMSO-d6) δ 10.82 (br s, 1 H), 9.16 (s, 1 H), 8.61 (s, 1 H), 8.22 (s, 1 H), 7.96 - 7.93 (m, 2 H), 7.83 – 7.70 (m, 3 H), 7.31 (dd,J = 8.9, 5.2 Hz, 1 H), 7.08 (td,J = 8.3, 3.0 Hz, 1 H), 6.62 (brs, 1 H), 5.99 (brs, 1 H), 5.89 (q,J = 7.1 Hz, 1 H), 1.86 (d,J = 7.1 Hz, 3 H).	586.3	A	
I-1917		CC1(CCCCC1)C1NC(=O)c2cccc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	1H NMR (400 MHz, DMSO-d6) 10.75 (s, 1H), 8.75 (s, 1H), 8.15 (s, 1H), 8.08 (d, 9.0 Hz, 1H), 8.02 (d, 8.5 Hz, 1H), 7.60-7.49 (m, 3H), 4.69 (s, 1H), 1.47-1.10 (m, 9H), 1.06-0.98 (m, 1H), 0.51 (s, 3H).	435	E	
I-1918		FC(F)n1cnc(c1)-c1cc2C(=O)N[C@@H](c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	1H NMR (400 MHz, DMSO) δ 10.56 (s, 1H), 9.18 (s, 1H), 8.94 (s, 1H), 8.43 (s, 1H), 8.06 (d, J = 1.6 Hz, 1H), 8.02 – 7.79 (m, 3H), 7.75 (d, J = 9.1 Hz, 1H), 7.70 (d, J = 2.2 Hz, 1H), 7.31 (dd, J = 8.9, 5.1 Hz, 1H), 7.09 (td, J = 8.3, 3.1 Hz, 1H), 6.86 – 6.58 (m, 1H), 5.98 (s, 1H).	583.2	D	
I-1919		FC(F)n1cnc(c1)-c1cc2C(=O)N[C@H](c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	1H NMR (400 MHz, DMSO) δ 10.56 (s, 1H), 9.18 (s, 1H), 8.94 (s, 1H), 8.43 (s, 1H), 8.06 (d, J = 1.6 Hz, 1H), 8.02 – 7.79 (m, 3H), 7.75 (d, J = 9.1 Hz, 1H), 7.70 (d, J = 2.2 Hz, 1H), 7.31 (dd, J = 8.9, 5.1 Hz, 1H), 7.09 (td, J = 8.3, 3.1 Hz, 1H), 6.86 – 6.58 (m, 1H), 5.98 (s, 1H).	583.2	A	





I-1920		FC(F)n1ncc(c1C#N)-c1cc2C(=O)N[C@@H](c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	1H NMR (400 MHz, DMSO) δ 10.71 (s, 1H), 9.32 (s, 1H), 8.71 (s, 1H), 8.13 (d, J = 1.6 Hz, 1H), 7.97 (d, J = 8.4 Hz, 1H), 7.90 (d, J = 1.6 Hz, 1H), 7.73 (d, J = 9.0 Hz, 1H), 7.65 (s, 1H), 7.33 (dd, J = 8.9, 5.2 Hz, 1H), 7.11 (td, J = 8.8, 8.4, 3.0 Hz, 1H), 6.01 (s, 1H).	608.13	D	
I-1921		FC(F)n1ncc(c1C#N)-c1cc2C(=O)N[C@H](c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	1H NMR (400 MHz, DMSO) δ 10.71 (s, 1H), 9.32 (s, 1H), 8.71 (s, 1H), 8.13 (d, J = 1.6 Hz, 1H), 7.97 (d, J = 8.4 Hz, 1H), 7.90 (d, J = 1.6 Hz, 1H), 7.73 (d, J = 9.0 Hz, 1H), 7.65 (s, 1H), 7.33 (dd, J = 8.9, 5.2 Hz, 1H), 7.11 (td, J = 8.8, 8.4, 3.0 Hz, 1H), 6.01 (s, 1H).	608.13	A	
I-1922		Fc1ccc(Cl)c(c1)[C@H]1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1cn2c(cnc2cn1)C#N	1H NMR (400 MHz, DMSO) δ 10.67 (s, 1H), 9.52 (d, J = 1.5 Hz, 1H), 9.46 (d, J = 1.5 Hz, 1H), 9.24 (s, 1H), 8.67 (s, 1H), 8.55 (d, J = 1.6 Hz, 1H), 8.43 – 8.34 (m, 1H), 7.95 (d, J = 8.6 Hz, 1H), 7.79 (d, J = 9.1 Hz, 1H), 7.72 (s, 1H), 7.33 (dd, J = 8.9, 5.2 Hz, 1H), 7.10 (td, J = 8.4, 3.1 Hz, 1H), 6.62 (s, 1H), 6.06 (s, 1H).	609.18	D	
I-1923		Fc1ccc(Cl)c(c1)[C@@H]1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1cn2c(cnc2cn1)C#N	1H NMR (400 MHz, DMSO) δ 10.67 (s, 1H), 9.52 (d, J = 1.5 Hz, 1H), 9.46 (d, J = 1.5 Hz, 1H), 9.24 (s, 1H), 8.67 (s, 1H), 8.55 (d, J = 1.6 Hz, 1H), 8.43 – 8.34 (m, 1H), 7.95 (d, J = 8.6 Hz, 1H), 7.79 (d, J = 9.1 Hz, 1H), 7.72 (s, 1H), 7.33 (dd, J = 8.9, 5.2 Hz, 1H), 7.10 (td, J =	609.18	A	





			8.4, 3.1 Hz, 1H), 6.62 (s, 1H), 6.06 (s, 1H).			
I-1924		FC(F)c1nnc2ccc(cn12)-c1cc2C(=O)N[C@@H](c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	1H NMR (500 MHz, DMSO) δ 12.67 (s, 1H), 10.64 (s, 1H), 9.26 (s, 1H), 9.03 (t, J = 1.4 Hz, 1H), 8.12 (d, J = 1.7 Hz, 1H), 8.10 – 7.99 (m, 2H), 7.98 – 7.83 (m, 3H), 7.79 – 7.72 (m, 1H), 7.70 (s, 1H), 7.33 (dd, J = 8.9, 5.1 Hz, 1H), 7.10 (td, J = 8.3, 3.0 Hz, 1H), 6.07 (s, 1H)	634.19	D	
I-1925		FC(F)c1nnc2ccc(cn12)-c1cc2C(=O)N[C@H](c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	1H NMR (500 MHz, DMSO) δ 12.67 (s, 1H), 10.64 (s, 1H), 9.26 (s, 1H), 9.03 (t, J = 1.4 Hz, 1H), 8.12 (d, J = 1.7 Hz, 1H), 8.10 – 7.99 (m, 2H), 7.98 – 7.83 (m, 3H), 7.79 – 7.72 (m, 1H), 7.70 (s, 1H), 7.33 (dd, J = 8.9, 5.1 Hz, 1H), 7.10 (td, J = 8.3, 3.0 Hz, 1H), 6.07 (s, 1H)	634.19	A	
I-1926		Fc1ccc(Cl)c(c1)[C@H]1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1cc(F)n2ncnc2c1		602.03	D	
I-1927		Fc1ccc(Cl)c(c1)[C@@H]1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1cc(F)n2ncnc2c1		602.03	A	





I-1928		FC(F)c1cn2cc(ccc2n1)-c1cc2C(=O)N[C@@H](c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	1H NMR (400 MHz, DMSO) δ 10.64 (s, 1H), 9.26 (s, 1H), 9.18 (dd, J = 2.0, 1.1 Hz, 1H), 8.27 (t, J = 1.9 Hz, 1H), 8.04 (d, J = 1.6 Hz, 1H), 7.97 (d, J = 8.5 Hz, 1H), 7.86 (s, 1H), 7.82 (dd, J = 9.5, 1.9 Hz, 1H), 7.79 – 7.69 (m, 3H), 7.33 (dd, J = 5.6, 3.3 Hz, 1H), 7.19 (s, 1H), 7.11 (td, J = 8.4, 3.0 Hz, 1H), 6.05 (s, 1H).	633.24	D	
I-1929		FC(F)c1cn2cc(ccc2n1)-c1cc2C(=O)N[C@H](c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	1H NMR (400 MHz, DMSO) δ 10.64 (s, 1H), 9.26 (s, 1H), 9.18 (dd, J = 2.0, 1.1 Hz, 1H), 8.27 (t, J = 1.9 Hz, 1H), 8.04 (d, J = 1.6 Hz, 1H), 7.97 (d, J = 8.5 Hz, 1H), 7.86 (s, 1H), 7.82 (dd, J = 9.5, 1.9 Hz, 1H), 7.79 – 7.69 (m, 3H), 7.33 (dd, J = 5.6, 3.3 Hz, 1H), 7.19 (s, 1H), 7.11 (td, J = 8.4, 3.0 Hz, 1H), 6.05 (s, 1H).	633.24	A	
I-1930		FC(F)n1cc(cn1)-c1cc2C(=O)N[C@@H](c2c(NC(=O)c2cc(F)cc(Cl)c2)c1)c1cc(F)ccc1Cl	1H NMR (400 MHz, DMSO) δ 10.56 (s, 1H), 9.18 (s, 1H), 8.94 (s, 1H), 8.43 (s, 1H), 8.06 (d, J = 1.6 Hz, 1H), 8.02 – 7.79 (m, 3H), 7.75 (d, J = 9.1 Hz, 1H), 7.70 (d, J = 2.2 Hz, 1H), 7.31 (dd, J = 8.9, 5.1 Hz, 1H), 7.09 (td, J = 8.3, 3.1 Hz, 1H), 6.86 – 6.58 (m, 1H), 5.98 (s, 1H).	583.2	D	
I-1931		FC(F)n1cc(cn1)-c1cc2C(=O)N[C@H](c2c(NC(=O)c2cc(F)cc(Cl)c2)c1)c1cc(F)ccc1Cl	1H NMR (400 MHz, DMSO) δ 10.56 (s, 1H), 9.18 (s, 1H), 8.94 (s, 1H), 8.43 (s, 1H), 8.06 (d, J = 1.6 Hz, 1H), 8.02 – 7.79 (m, 3H), 7.75 (d, J = 9.1 Hz, 1H), 7.70 (d, J = 2.2 Hz, 1H), 7.31 (dd, J = 8.9, 5.1 Hz, 1H), 7.09	583.2	A	





			(td, J = 8.3, 3.1 Hz, 1H), 6.86 – 6.58 (m, 1H), 5.98 (s, 1H).			
I-1932		FC(F)c1ccc(cn1)-c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	1H NMR (DMSO-d6, 400 MHz): δ = 10.66 (s, 1H), 9.28 (br s, 1H), 9.13 (d, J = 2.0 Hz, 1H), 8.43 (dd, J = 8.1, 2.3 Hz, 1H), 8.10 (d, J = 1.3 Hz, 1H), 7.97 (br d, J = 8.6 Hz, 1H), 7.93 (s, 1H), 7.84 (d, J = 8.3 Hz, 1H), 7.77 (br d, J = 9.1 Hz, 1H), 7.70 (s, 1H), 7.34 (dd, J = 8.8, 5.3 Hz, 1H), 6.90-7.22 (m, 2H), 6.46-6.84 (m, 1H), 5.85-6.25 ppm (m, 1H).	594.4	B	
I-1933		FC(F)c1ccc(ccn1)-c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	1H NMR (DMSO-d6, 400 MHz): δ = 10.66 (s, 1H), 9.21-9.41 (m, 1H), 8.81 (d, J = 5.1 Hz, 1H), 8.17 (d, J = 1.3 Hz, 1H), 8.12 (s, 1H), 8.07 (br d, J = 5.3 Hz, 1H), 8.02 (s, 1H), 7.98 (br d, J = 8.6 Hz, 1H), 7.78 (br d, J = 9.1 Hz, 1H), 7.71 (s, 1H), 7.34 (dd, J = 9.0, 5.2 Hz, 1H), 6.90-7.20 (m, 2H), 6.39-6.71 (m, 1H), 5.92-6.26 ppm (m, 1H).	594.4	A	
I-1934		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1cnc2ncc(Cl)n2c1	1H NMR (400 MHz, DMSO) 10.67 (s, 1H), 9.28 (s, 1H), 9.18 (d, 2.5 Hz, 1H), 9.06 (d, 2.5 Hz, 1H), 8.21 (d, 1.6 Hz, 1H), 7.96 (d, 16.9 Hz, 2H), 7.77 (d, 9.4 Hz, 1H), 7.71 (s, 1H), 7.34 (dd, 8.9, 5.2 Hz, 1H), 7.11 (td, 8.3, 3.1 Hz, 1H), 6.06 (s, 1H).	618.13	A	





I-1935		CC(Oc1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl)C#N		523.07	A	
I-1936		FC(F)c1cnc2ccc(cn12)-c1cc2C(=O)N[C@@H](c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	1H NMR (400 MHz, DMSO) δ 10.65 (s, 1H), 9.27 (s, 1H), 8.90 (t, J = 1.4 Hz, 1H), 8.07 (d, J = 1.6 Hz, 1H), 8.00 (s, 1H), 8.01 – 7.85 (m, 3H), 7.89 – 7.80 (m, 2H), 7.76 (d, J = 9.1 Hz, 1H), 7.69 (s, 2H), 7.33 (dd, J = 8.9, 5.2 Hz, 1H), 7.10 (td, J = 8.4, 3.1 Hz, 1H), 6.06 (s, 1H)	633.19	C	
I-1937		FC(F)c1cnc2ccc(cn12)-c1cc2C(=O)N[C@H](c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	1H NMR (400 MHz, DMSO) δ 10.65 (s, 1H), 9.27 (s, 1H), 8.90 (t, J = 1.4 Hz, 1H), 8.07 (d, J = 1.6 Hz, 1H), 8.00 (s, 1H), 8.01 – 7.85 (m, 3H), 7.89 – 7.80 (m, 2H), 7.76 (d, J = 9.1 Hz, 1H), 7.69 (s, 2H), 7.33 (dd, J = 8.9, 5.2 Hz, 1H), 7.10 (td, J = 8.4, 3.1 Hz, 1H), 6.06 (s, 1H)	633.19	A	
I-1938		FC(F)c1nc2ccc(cn2n1)-c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	1H NMR (400 MHz, DMSO) δ 10.65 (s, 1H), 9.56 (dd, J = 1.9, 0.9 Hz, 1H), 9.27 (s, 1H), 8.25 (dd, J = 9.4, 1.8 Hz, 1H), 8.15 (d, J = 1.7 Hz, 1H), 8.07 (dd, J = 9.3, 0.9 Hz, 1H), 8.00 – 7.93 (m, 2H), 7.76 (d, J = 9.1 Hz, 1H), 7.70 (s, 1H), 7.38 – 7.28 (m, 2H), 7.11 (td, J = 8.4, 3.1 Hz, 1H), 3.16 (d, J = 3.5 Hz, 1H).	634.19	A	




I-1939		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)C3OCCc4ccccc34)c12)-c1ccc2ncnn2c1	NMR (400 MHz, DMSO-d6) 9.69 (br s, 1H), 9.56 (br s, 1H), 9.44 (dd, 1.7, 0.8 Hz, 1H), 9.42 (dd, 1.6, 0.8 Hz, 1H), 9.22 (br s, 1H), 9.15 (br s, 1H), 8.58 (s, 1H), 8.57 (s, 1H), 8.16-8.05 (m, 4H), 8.02-7.94 (m, 4H), 7.43-7.34 (m, 2H), 7.27-7.15 (m, 11.2, 5.8 Hz, 6H), 7.14-7.02 (m, 6H), 6.54 (br s, 1H), 6.22 (br s, 1H), 6.14 (br s, 1H), 5.13 (s, 1H), 5.10 (s, 1H), 3.98-3.89 (m, 1H), 3.80-3.71 (m, 2H), 3.71-3.63 (m, 1H), 2.82-2.64 (m, 4H).	554.3	D	
I-1940		CS(=O)c1cc(cc2C(=O)NC(c12)c1cc(F)ccc1Cl)-c1ccc2ncnn2c1	1H NMR (400 MHz, DMSO-d6) 9.61 (d, 17.7 Hz, 1H), 9.42 (s, 1H), 8.59 (s, 1H), 8.43 (s, 1H), 8.33 (d, 7.0 Hz, 1H), 8.20 (dd, 16.4, 9.4 Hz, 1H), 8.00 (d, 9.3 Hz, 1H), 7.62 (s, 1H), 7.33 (d, 12.4 Hz, 1H), 6.68 (s, 1H), 6.43-6.26 (s, 1H), 2.20 (s, 3H).	441.2	E	
I-1941		CS(=O)(=O)c1cc(cc2C(=O)NC(c12)c1cc(F)ccc1Cl)-c1ccc2ncnn2c1	1H NMR (400 MHz, DMSO-d6) 9.67 (s, 1H), 9.58 (s, 1H), 8.61 (s, 1H), 8.51 (s, 2H), 8.26 (d, 9.4 Hz, 1H), 8.02 (d, 9.3 Hz, 1H), 7.62 (s, 1H), 7.26 (s, 1H), 6.53 (s, 1H), 6.47-6.25 (s, 1H), 2.94 (s, 3H).	456.95	E	
I-1942		O[C@@H]1C[C@H](C(=O)Nc2cc(Br)cc3C(=O)NC(c23)c2cc(F)ccc2Cl)c2ccccc12	1H NMR (400 MHz, DMSO-d6) 10.16 (d, 46.4 Hz, 1H), 9.25 (s, 1H), 7.81 (d, 51.4 Hz, 2H), 7.53 (d, 26.0 Hz, 1H), 7.40 - 7.20 (m, 3H), 7.11 (q, 6.8 Hz, 1H), 6.66 (d, 7.6 Hz, 1H), 6.09 (s, 1H), 5.40 (dd, 14.7, 6.9 Hz, 1H), 4.97 (dt, 14.0, 7.0 Hz,	517.05	E	




			1H), 3.63 (dd, 16.2, 8.2 Hz, 1H), 2.30 (dd, 14.3, 7.7 Hz, 1H), 1.98 (s, 1H), 1.80 - 1.65 (m, 1H).			
I-1943		O[C@H]1C[C@H](C(=O)Nc2cc(Br)cc3C(=O)NC(c23)c2cc(F)ccc2Cl)c2ccccc12	1H NMR (400 MHz, DMSO-d6) 10.11 (d, 35.6 Hz, 1H), 9.22 (d, 22.3 Hz, 1H), 7.85 - 7.70 (m, 2H), 7.65 (d, 1.8 Hz, 2H), 7.37 - 7.28 (s, 1H), 7.22 (m, 2H), 7.16 - 7.07 (s, 1H), 6.72 - 6.18 (s, 1H), 6.82 (dd, 25.9, 7.5 Hz, 1H), 6.04 (m, 2H), 5.29 - 5.07 (s, 1H), 2.37 - 2.00 (s, 1H), 1.82 (ddd, 13.1, 8.2, 5.0 Hz, 1H).	517.05	E	
I-1944		Fc1ccc(Cl)c(c1)C1NC(=O)c2cccc(-c3nc4c(F)cc(cc4[nH]3)C(F)(F)F)c12	1H NMR (400 MHz, DMSO-d6) 9.33 (s, 1H), 8.31 (d, 7.6 Hz, 1H), 7.96 (d, 7.5 Hz, 1H), 7.85 (t, 7.6 Hz, 1H), 7.65 (s, 1H), 7.38 (d, 10.6 Hz, 2H), 6.95 (td, 8.4, 3.1 Hz, 1H), 6.69 (s, 1H), 6.21 (s, 1H).	464.05	A	
I-1945		Fc1ccc(Cl)c(c1)[C@@H]1NC(=O)c2cc(Br)cc(NC(=O)Nc3ccccc3)c12	1H NMR (400 MHz, DMSO-d6) 9.26 - 8.26 (m, 2H), 7.85 - 7.76 (m, 1H), 7.62 (d, 1.7 Hz, 1H), 7.46 (dd, 8.9, 5.1 Hz, 1H), 7.39 - 7.31 (m, 2H), 7.31 - 7.14 (m, 3H), 6.98 (td, 7.3, 1.3 Hz, 1H), 6.88 - 6.59 (m, 1H), 6.06 (s, 1H).	476	E	
I-1946		Fc1ccc(Cl)c(c1)[C@H]1NC(=O)c2cc(Br)cc(NC(=O)Nc3ccccc3)c12	1H NMR (400 MHz, DMSO-d6) 9.26 - 8.26 (m, 2H), 7.85 - 7.76 (m, 1H), 7.62 (d, 1.7 Hz, 1H), 7.46 (dd, 8.9, 5.1 Hz, 1H), 7.39 - 7.31 (m, 2H), 7.31 - 7.14 (m, 3H), 6.98 (td, 7.3, 1.3 Hz, 1H), 6.88 - 6.59 (m, 1H), 6.06 (s, 1H).	476	D	




I-1947		CN1CCCC[C@H]1C(=O)Nc1cc(cc2C(=O)N[C@@H](c12)c1cc(F)ccc1Cl)-c1ccc2ncnn2c1	1H NMR (400 MHz, DMSO-d6) 9.43 (d, 1.8 Hz, 2H), 8.57 (s, 1H), 8.18 (d, 1.7 Hz, 1H), 8.09 (dd, 9.3, 1.9 Hz, 1H), 8.03 - 7.94 (m, 2H), 7.55 (s, 1H), 7.26 (td, 8.4, 3.1 Hz, 1H), 6.16 (d, 69.1 Hz, 2H), 5.93 (d, 2H), 3.00 - 2.76 (m, 2H), 1.90 (s, 4H), 1.54 (d, 12.0 Hz, 2H), 1.38 (d, 13.2 Hz, 2H), 1.15 (s, 1H).	519.25	E	
I-1948		CN1CCCC[C@H]1C(=O)Nc1cc(cc2C(=O)N[C@H](c12)c1cc(F)ccc1Cl)-c1ccc2ncnn2c1	1H NMR (400 MHz, DMSO-d6) 9.43 (d, 1.8 Hz, 2H), 8.57 (s, 1H), 8.18 (d, 1.7 Hz, 1H), 8.09 (dd, 9.3, 1.9 Hz, 1H), 8.03 - 7.94 (m, 2H), 7.55 (s, 1H), 7.26 (td, 8.4, 3.1 Hz, 1H), 6.16 (d, 69.1 Hz, 2H), 5.93 (d, 2H), 3.00 - 2.76 (m, 2H), 1.90 (s, 4H), 1.54 (d, 12.0 Hz, 2H), 1.38 (d, 13.2 Hz, 2H), 1.15 (s, 1H).	519.2	E	
I-1949		Fc1ccc(Cl)c(c1)[C@H]1NC(=O)c2cc(Br)cc(NC(=O)N[C@@]3(CC(F)(F)F)CCOC3)c12	1H NMR (400 MHz, DMSO):-′ 9.17 (s, 1H), 8.52 (s, 1H), 7.83 (d, 1.0 Hz, 1H), 7.52 (d, 1.7 Hz, 1H), 7.48 (dd, 8.3, 5.3 Hz, 1H), 7.22 (td, 8.4, 3.1 Hz, 1H), 6.71 (br s, 1H), 6.58 (s, 1H), 6.01 (s, 1H), 3.67-3.49 (m, 4H), 2.85-2.63 (m, 2H), 2.01-1.90 (m, 1H), 1.61-1.49 (m, 1H), 1.47-1.33 (m, 2H).	564.2	E	
I-1950		NCc1cc(cc2C(=O)NC(c12)c1cc(F)ccc1Cl)-c1ccc2ncnn2c1	1H NMR (400 MHz, DMSO-d6) 9.45 (s, 1H), 9.19 (s, 1H), 8.56 (s, 1H), 8.15 (dd, 9.3, 1.9 Hz, 1H), 8.10 (s, 1H), 8.02 (s, 1H), 7.97 (d, 9.3 Hz, 1H), 7.64 (s, 1H), 7.28 (s, 1H), 6.50 (s, 1H), 6.17 (s, 1H), 3.61 (d, 15.6 Hz, 2H).	408.08	E	





I-1951		CN1C(=O)NC(c2cc(F)ccc2Cl)c2c(NC(=O)c3cc(F)cc(c3)C(F)(F)F)cccc12	1H NMR (Chloroform-d, 400 MHz) 7.62 (1H, dt, 8.8, 1.9 Hz), 7.51 (4H, q, 3.5, 2.6 Hz), 7.43 (1H, dd, 8.9, 4.9 Hz), 7.18 (1H, s), 7.03 (2H, ddt, 10.4, 6.0, 3.2 Hz), 6.60 (1H, dd, 8.7, 3.0 Hz), 6.14 (1H, dd, 3.1, 1.3 Hz), 5.55 (1H, d, 3.1 Hz), 3.41 (3H, s)	494.1	D	
I-1952		CN1CCN(CC1)c1cc(cc2C(=O)NC(c12)c1cc(F)ccc1Cl)-c1ccc2ncnn2c1	NMR (400 MHz, CD3CN) 9.09 (br s, 1H), 8.36 (br s, 1H), 8.04 (s, 0.5H), 8.00 (dd, 9.3, 1.9 Hz, 1H), 7.84 (br s, 0.5H), 7.82 (d, 1.5 Hz, 1H), 7.56-7.51 (m, 2H), 7.34-7.29 (m, 1H), 7.14 (ddd, 8.8, 8.0, 3.1 Hz, 1H), 6.62 (br s, 0.5H), 6.60 (br s, 0.5H), 6.20 (s, 1H), 3.41-3.33 (m, 2H), 3.05-2.96 (m, 2H), 2.74-2.54 (m, 4H), 2.44 (s, 3H).	477	E	
I-1953		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(NC(=O)NC3(CC(F)(F)F)CCOCC3)c12	1H NMR (400 MHz, DMSO-d6) 9.19 (s, 1H), 8.07 (s, 1H), 7.76 (d, 1.7 Hz, 1H), 7.54 (d, 1.7 Hz, 1H), 7.49 (dd, 8.7, 5.0 Hz, 1H), 7.27-7.19 (m, 1H), 6.71 (br s, 1H), 6.48 (s, 1H), 6.06 (s, 1H), 3.65-3.50 (m, 2H), 3.30-3.14 (m, 2H), 2.80-2.65 (m, 2H), 1.96-1.86 (m, 2H), 1.67-1.50 (m, 2H).	564.1	E	
I-1954		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(NC(=O)N3CC4CC4(F)C3)c12	1H NMR (400 MHz, DMSO-d6) 9.19 (s, 1H), 8.38 (s, 1H), 7.62 (d, 1.5 Hz, 1H), 7.56-7.42 (m, 2H), 7.30-7.22 (m, 1H), 7.06-6.18 (m, 1H), 5.95 (br s, 1H), 3.95-3.84 (m, 0.5H), 3.81-3.49 (m, 1.5H), 3.24-3.15 (m, 1H), 3.12-2.70 (m, 1H), 2.05-1.92 (m, 1H),	482	E	





			1.55-1.40 (m, 1H), 0.46 (br s, 1H).			
I-1955		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(OCc3ccccc3)c12)-c1ccc2ncnn2c1	(400 MHz, DMSO-d6) 9.52 - 9.50 (m, 1 H), 9.19 (s, 1 H), 8.57 (s, 1 H), 8.16 (dd, 9.3, 1.8 Hz, 1H), 7.96 (d, 9.4 Hz, 1 H), 7.75-7.70 (m, 2 H), 7.52 (dd, 8.9, 5.1 Hz, 1 H), 7.31-7.24 (m, 4 H), 7.02 -- 6.96 (m, 2 H), 6.88 (br s, 1 H), 6.07 (s, 1 H), 5.28-5.18 (m, 2 H).	485.2	E	
I-1956		Fc1cc(cc(c1)C(F)(F)F)C(=O)Nc1ccc2C(=O)NC(C3CCCN3)c12	NMR (400 MHz, DMSO-d6) 8.87 (s, 1H), 8.46 (d, 7.9 Hz, 1H), 8.37 (m, 2H), 8.06 (d, 4.8 Hz, 1H), 8.01 (d, 8.0 Hz), 7.61-7.49 (m, 1H), 7.43 (d, 7.3 Hz, 1H), 4.58 (d, 10.2 Hz, 1H), 3.06-23.00 (m, 1H), 2.89-2.81 (m, 1H), 2.78-2.66 (m, 1H), 1.92-1.81 (m, 2H), 1.60-1.48 (m, 2H).	408.1	E	
I-1957		FC1CCCC(C1)C(=O)Nc1cc(cc2C(=O)NC(c12)c1cc(F)ccc1Cl)-c1ccc2ncnn2c1	NMR (400 MHz, DMSO-d6) 9.92 (br. s, 1H), 9.90-9.87 (m, 1H), 9.45-9.43 (m, 2H), 9.21 (s, 2H), 8.57 (s, 2H), 8.11-8.07 (m, 2H), 8.01-7.99 (m, 2H), 7.99-7.95 (m, 2H), 7.86-7.80 (m, 2H), 7.55-7.49 (m, 2H), 7.29-7.22 (m, 2H), 6.58 (br. s, 2H), 6.13 (br. s, 2H), 4.96-4.90 (m, 1H), 4.84-4.78 (m, 1H), 2.48-2.39 (m, 2H), 1.85-1.65 (m, 4H), 1.61-1.35 (m, 8H), 1.32-1.12 (m, 4H).	522.3	D	
I-1958		Fc1cc(cc(c1)C(F)(F)F)C(=O)Nc1ccc2C(=O)NC(C3CCCOC3)c12	(400 MHz, CD3CN) 9.13 (s, 0.6H), 9.06 (s, 0.4H), 8.11 (s, 1H), 7.96 (d, 9.1 Hz,1H), 7.74 (d, 8.4 Hz,1H), 7.67-7.57 (m , 2H), 7.57-7.51 (m, 7.6 Hz, 1H), 6.97 (s, 0.6H),	423.1	E	




			6.85 (s, 0.4H), 4.83 (s, 1H), 3.85 (dd, 11.1, 2.1 Hz, 0.4H), 3.77-3.63 (m, 1H), 3.32 (t, 10.9 Hz, 0.4H), 3.27-3.11 (m, 1H), 3.11-3.02 (m, 0.6H), 2.95 (t, 10.9 Hz, 0.6H), 2.12 (m, 1H), 1.88-1.78 (m, 0.6H), 1.61-1.32 (m, 3H), 1.12-0.99 (m, 0.6H), 0.96-0.84 (m, 0.4H)			
I-1959		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC3CNCc4ccccc34)c12)-c1ccc2ncnn2c1	1H NMR (400 MHz, DMSO-d6) 9.47-9.42 (m, 1H), 9.01 (s, 1H), 8.55 (s, 1H), 8.14 (dd, 9.3, 1.9 Hz, 1H), 7.94 (d, 9.3 Hz, 1H), 7.48-7.37 (m, 3H), 7.26 (td, 8.4, 3.1 Hz, 1H), 7.13 (td, 7.5, 1.3 Hz, 1H), 7.02 (d, 7.6 Hz, 1H), 6.91 (t, 7.4 Hz, 1H), 6.61 (d, 7.7 Hz, 1H), 5.88 (s, 1H), 4.86-4.77 (m, 2H), 3.86 (s, 2H), 3.24 (dd, 12.0, 4.1 Hz, 1H), 2.87 (dd, 12.5, 5.8 Hz, 1H).	525.1	D	
I-1960		OC1CCCC(CC(=O)Nc2cc(cc3C(=O)NC(c23)c2cc(F)ccc2Cl)-c2ccc3ncnn3c2)C1	NMR (400 MHz, DMSO-d6) 9.79 (br s, 1H), 9.43 (br s, 1H), 9.26-9.13 (m, 1H), 8.57 (d, 2.5 Hz, 1H), 8.13-7.94 (m, 4H), 7.60-7.43 (m, 1H), 7.35-7.17 (m, 1H), 6.59 (br s, 1H), 6.16 (br s, 1H), 4.47 (br s, 1H), 3.81-3.57 (m, 1H), 2.01-1.90 (m, 2H), 1.48-1.08 (m, 9H).	534.2	E	
I-1961		Fc1ccc(Cl)c(c1)[C@@H]1NC(=O)c2cc(Br)cc(NC(=O)N[C@@]3(CC(F)(F)F)CCCOC3)c12	1H NMR (400 MHz, DMSO-d6) 9.18 (s, 1H), 8.49 (s, 1H), 7.77 (d, 1.7 Hz, 1H), 7.53 (d, 1.7 Hz, 1H), 7.48 (dd, 8.6, 5.1 Hz, 1H), 7.21 (td, 8.4, 3.1 Hz, 1H), 6.65 (br s, 1H), 6.58 (s, 1H), 6. (s, 1H), 3.64 (dd, 10.8, 2.5 Hz, 2H), 3.44-3.35 (m, 2H), 2.92-2.75 (m, 1H), 2.69-2.53 (m, 1H),	564.2	E	




			2.17-2.05 (m, 1H), 1.59-1.47 (m, 1H), 1.47-1.32 (m, 2H).			
I-1962		CC(C=CC=C1)=C1C2NCCC3=CC=CC(NC(C4=CC(F)=CC(C(F)(F)F)=C4)=O)=C32		428.2	E	
I-1963		CC(C=CC=C1)=C1C2NCCC3=C(Br)C=CC(NC(C4=CC(F)=CC(C(F)(F)F)=C4)=O)=C32		506.1	E	
I-1964		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)C3CCCN(CC(F)(F)F)C3)c12)-c1ccc2ncnn2c1	1H-NMR (400 MHz, DMSO-d6) as a ca. 1:1 mixture of diastereomers 9.93 (br. s, 1H), 9.91 (br. s, 1H), 9.45-9.43 (m, 2H), 9.21 (br. s, 2H), 8.57 (s, 2H), 8.11-8.07 (m, 2H), 8.01 (d, J = 1.1 Hz, 2H), 7.97 (d, J = 9.3 Hz, 2H), 7.82-7.77 (m, 2H), 7.56-7.49 (m, 2H), 7.28-7.22 (m, 2H), 6.56 (br. s, 2H), 6.09 (br. s, 2H), 3.20-3.06 (m, 3H), 3.03-2.92 (m, 1H), 2.84-2.78 (m, 2H), 2.70-2.65 (m, 1H), 2.55-2.44 (m, 1H), 2.36-2.27 (m, 2H), 2.22 (m, 3H), 2.14-2.06 (m, 1H), 1.59-1.50 (m, 3H), 1.43-1.32 (m, 3H), 1.24-1.05 (m, 2H).	587.3	E	




I-1965		O[C@H]1CN(C[C@H]1O)C(=O)Nc1cc(cc2C(=O)NC(c12)c1cc(F)ccc1Cl)-c1ccc2ncnn2c1	1H-NMR (400 MHz, DMSO-d6) 9.38-9.37 (m, 1H), 9.13 (br. s, 1H), 8.56 (s, 1H), 8.19 (br. s, 1H), 8.05 (dd, J = 9.3, 1.8 Hz, 1H), 7.96 (dd, J = 9.2, 0.6 Hz, 1H), 7.89 (d, J = 1.5 Hz, 1H), 7.72 (br. s, 1H), 7.52-7.45 (m, 1H), 7.24 (app. td, J = 8.6, 3.2 Hz, 1H), 6.66 (br. s, 1H), 6.08 (br. s, 1H), 4.96-4.89 (m, 2H), 3.95-3.89 (m, 1H), 3.89-3.82 (m, 1H), 3.44-3.32 (m, 2H), 3.08 (dd, J = 10.1, 5.6 Hz, 1H), 3.02-2.94 (m, 1H). Multiplet at 3.44-3.32 is partially obscured by the H2O peak.	523	E	
I-1966		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)C34CCC(CC3)O4)c12)-c1ccc2ncnn2c1	NMR (400 MHz, DMSO-d6) 9.46-9.40 (m, 2H), 9.21 (br s, 1H), 8.57 (s, 1H), 8.10 (dd, J = 9.3, 1.8 Hz, 1H), 8.03-8.00 (m, 2H), 7.97 (dd, J = 9.3, 0.5 Hz, 1H), 7.59-7.44 (m, 1H), 7.29-7.21 (m, 1H), 6.61 (br s, 1H), 6.22 (br s, 1H), 4.60 (t, J = 4.9 Hz, 1H), 1.79-1.58 (m, 4H), 1.58-1.48 (m, 2H), 1.39-1.13 (m, 2H). av. 10% impurity	518.3	E	
I-1967		OC1(CCCCC1)C1NC(=O)c2cccc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	NMR (400 MHz, DMSO-d6) 10.70 (br. s, 1H), 8.71 (s, 1H), 8.09 (s, 1H), 8.04 (br. d, J = 9.0 Hz, 1H), 7.99 (br. d, J = 8.4 Hz, 1H), 7.58-7.45 (m, 3H), 4.71 (s, 1H), 4.18 (br. s, 1H), 3.69 (s, 1H), 1.85-1.66 (m, 2H), 1.61 (d, J = 13.4 Hz, 1H), 1.44 (d, J = 11.5 Hz, 1H), 1.28-1.17 (m, 1H), 1.16-1.02 (m, 3H), 0.32 (d, J = 10.8 Hz, 1H).	437.1	E	





I-1968		CN(C)S(=O)(=O)c1cc(cc2C(=O)NC(c12)c1cc(F)ccc1Cl)-c1ccc2ncnn2c1	1H NMR (400 MHz, DMSO-d6) 9.60 (d, J = 2.1 Hz, 1H), 9.57 (s, 1H), 8.61 (s, 1H), 8.47 (s, 1H), 8.24 (s, 1H), 8.19 (dd, J = 9.3, 1.9 Hz, 1H), 8.00 (d, J = 9.3 Hz, 1H), 7.59 (s, 1H), 7.22 (s, 1H), 6.25 (d, J = 103.6 Hz, 1H), 2.62 (s, 6H).	486	E	
I-1969		Fc1cc(cc(c1)C(F)(F)F)C(=O)Nc1ccc2C(=O)NC(c12)C12CC3CC(CC(C3)C1)C2	NMR (400 MHz, DMSOd6) 10.78 (s, 1H), 8.72 (s, 1H), 8.14 (s, 1H), 8.07 (d, J = 9.2 Hz, 1H), 8.02 (d, J = 8.2 Hz, 1H), 7.59-7.50 (m, 3H), 4.50 (s, 1H), 1.81 (br s, 3H), 1.56 (d, J = 13.4 Hz, 3H), 1.52 (m, 3H), 1.44 (d, J = 11.5 Hz, 3H), 1.31 (d, J = 11.8 Hz, 3H). Presence of an impurity at 3.9 10-15% by NMR.	473.3	E	
I-1970		NS(=O)(=O)c1cc(cc2C(=O)NC(c12)c1cc(F)ccc1Cl)-c1ccc2ncnn2c1	1H NMR (400 MHz, DMSO-d6) 9.55 (d, J = 1.8 Hz, 1H), 9.45 (s, 1H), 8.61 (s, 1H), 8.55 (s, 1H), 8.42 (d, J = 1.7 Hz, 1H), 8.20 (dd, J = 9.3, 1.9 Hz, 1H), 8.05 (d, J = 9.3 Hz, 1H), 7.53 (s, 1H), 7.20 (td, J = 8.4, 3.1 Hz, 1H), 7.10 (s, 1H), 6.37 (s, 1H).	458	E	
I-1971		[H][C@]1(CCCC[C@H]1O)C1NC(=O)c2cccc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	(400 MHz, DMSO-d6) 10.74 (s, 1H), 8.12 (s, 1H), 8.08 (d, J = 9.0 Hz, 1H), 8.04 (d, J = 8.5 Hz, 1H), 7.65 (dd, J = 7.4, 1.2 Hz, 1H), 7.59-7.50 (m, 3H), 4.94-4.88 (m, 2H), 3.94-3.88 (m, 1H), 1.92 (d, J = 12.4 Hz, 1H), 1.66 (d, J = 13.6 Hz, 1H), 1.55-1.39 (m, 2H), 1.30-1.20 (m, 2H), 1.15 (d, J = 13.3 Hz, 1H), 1.03-0.89 (m, 1H), 0.47	437.2	E	





			(d, J = 10.5 Hz, 1H) [single diastereomer].			
I-1972		[H][C@@]1(CCCC[C@@H]1O)C1NC(=O)c2cccc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	(400 MHz, DMSO-d6) 10.64 (s, 1H), 8.59 (s, 1H), 8.14 (s, 1H), 8.07 (d, J = 8.8 Hz, 1H), 8.01 (d, J = 8.5 Hz, 1H), 7.59-7.48 (m, 3H), 5.30 (d, J = 1.1 Hz, 1H), 4.70 (d, J = 4.5 Hz, 1H), 3.44-3.35 (m, 1H), 1.85 (d, J = 8.9 Hz, 1H), 1.73 (t, J = 10.5 Hz, 1H), 1.54 (d, J = 12.7 Hz, 1H), 1.42 (d, J = 12.6 Hz, 1H), 1.14-0.86 (m, 3H), 0.75-0.66 (m, 1H), 0.66-0.55 (m, 1H) [single diastereomer] [~5wt% TBSOH as impurity].	437.2	E	
I-1973		COc1cc(cc2C(=O)NC(c12)c1cc(F)ccc1Cl)-c1ccc2nccnn2c1	1H NMR (400 MHz, DMSO-d6) 9.51 (t, J=1.4 Hz, 1H), 9.15 (s, 1H), 8.57 (s, 1H), 8.17 (dd, J=9.3, 1.8 Hz, 1H), 7.96 (dd, J=9.3, 0.9 Hz, 1H), 7.72 (d, J=1.3 Hz, 1H), 7.62-7.53 (m, 2H), 7.24 (td, J=8.4, 3.1 Hz, 1H), 6.81 (s, 1H), 6.04 (s, 1H), 3.82 (s, 3H).	409.05	E	
I-1974		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(Nc3cccc(=O)[nH]3)c12	1H NMR (400 MHz, DMSO-d6) 10.31 (s, 1H), 9.14 (s, 1H), 8.46 (s, 1H), 7.71 (d, J = 4.3 Hz, 1H), 7.53 (s, 1H), 7.41 - 7.23 (m, 2H), 7.13 (td, J = 8.4, 3.1 Hz, 1H), 6.49 (s, 1H), 6.11 (s, 1H), 6.00 (s, 1H), 5.90 (s, 1H).	449.95	D	
I-1975		O[C@H]1CC[C@H](C1)C(=O)Nc1cc(Br)cc2C(=O)NC(c12)c1cc(F)ccc1Cl	1H NMR (400 MHz, DMSO-d6) 9.68 (d, J = 17.2 Hz, 1H), 9.22 (s, 1H), 7.72 - 7.61 (m, 2H), 7.47 (d, J = 7.3 Hz, 1H), 7.24 (td, J = 8.4, 3.1 Hz, 1H), 6.67 (s, 1H), 6.01 (s, 1H), 4.62 (dd, J = 4.7, 2.8 Hz, 1H), 4.03 - 3.96	466.95	E	




			(m, 1H), 2.54 (s, 1H), 1.87 - 1.69 (m, 1H), 1.59 (dt, J = 10.3, 6.9 Hz, 1H), 1.56 - 1.29 (m, 4H).			
I-1976		O[C@@H]1CC[C@H](C1)C(=O)Nc1cc(Br)cc2C(=O)NC(c12)c1cc(F)ccc1Cl	1H NMR (400 MHz, DMSO-d6) 9.75 (s, 1H), 9.23 (s, 1H), 7.69 (d, J = 1.5 Hz, 1H), 7.61 (dt, J = 6.0, 2.0 Hz, 1H), 7.48 (d, J = 6.9 Hz, 1H), 7.29 - 7.19 (m, 1H), 6.67 (s, 1H), 6.02 (s, 1H), 4.47 (t, J = 3.9 Hz, 1H), 4.09 (s, 1H), 2.54 (s, 1H), 1.73 - 1.60 (m, 1H), 1.64 (s, 2H), 1.50 (dd, J = 8.5, 3.9 Hz, 1H), 1.40 (s, 2H).	467.05	E	
I-1977		CNS(=O)(=O)c1cc(cc2C(=O)NC(c12)c1cc(F)ccc1Cl)-c1ccc2ncnn2c1	1H NMR (400 MHz, DMSO-d6) 9.56 (d, J = 1.9 Hz, 1H), 9.50 (s, 1H), 8.61 (s, 1H), 8.45 (s, 1H), 8.40 (s, 1H), 8.19 (dd, J = 9.3, 1.9 Hz, 1H), 8.04 (d, J = 9.3 Hz, 1H), 7.55 (s, 2H), 7.21 (td, J = 8.4, 3.0 Hz, 1H), 6.38 (s, 2H) , 2.33 (s, 3H).	472	E	
I-1978		O[C@H]1CN(C[C@H]1C(F)(F)F)C(=O)Nc1cc(cc2C(=O)NC(c12)c1cc(F)ccc1Cl)-c1ccc2ncnn2c1	1H-NMR (400 MHz, DMSO-d6) as a ca. 1:1 mixture of diastereomers 9.39-9.38 (m, 2H), 9.16 (br. s, 2H), 8.56 (s, 2H), 8.35 (br. s, 1H), 8.27 (br. s, 1H), 8.08-8.04 (m, 2H), 7.99-7.95 (m, 2H), 7.93-7.90 (m, 2H), 7.82-7.78 (m, 1H), 7.74 (d, J = 1.1 Hz, 1H), 7.53-7.46 (m, 2H), 7.23 (app. td, J = 8.4, 3.0 Hz, 2H), 6.68 (br. s, 2H), 6.10 (br. s, 2H), 5.58 (br. d, J = 4.3 Hz, 1H), 5.49 (d, J = 4.5 Hz, 1H), 4.44-4.36 (m, 2H), 3.67-3.51 (m, 1H), 3.47-3.40 (m, 3H), 3.31-3.20 (m, 2H),	575.3	D	




			3.16-3.03 (m, 1H), 3.02-2.86 (m, 3H).			
I-1979		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(C(=O)NCc3ccccc3)c12	1H NMR (400 MHz, DMSO-d6) 9.34 (s, 1H), 9.08 (dd, J = 7.3, 4.7 Hz, 1H), 8.08 (s, 1H), 8.01 (d, J = 1.8 Hz, 1H), 7.49 (s, 1H), 7.30 - 7.17 (m, 4H), 6.87 (dd, J = 6.7, 2.9 Hz, 2H), 6.36 (s, 1H), 4.61 - 4.39 (m, 1H), 4.15 -3.88 (m, 1H).	475	E	
I-1980		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(Cn3ccccc3=O)c12)-c1ccc2ncnn2c1	NMR (400 MHz, DMSO-d6) 9.38 (br. s, 1H), 8.56 (s, 1H), 8.52 (br. s, 2H), 8.13 - 8.10 (m, 1H), 7.90 - 7.92 (m, 2H), 7.68 - 7.56 (m, 2H), 7.43-7.34 (m, 1H), 7.26 (ddd, J = 8.6, 8.0, 2.9 Hz, 1H), 6.51 (br. s, 1H), 6.37 (br. s, 1H), 6.33 (d, J = 9.3 Hz, 1H), 6.19 (app. t, J = 7.0 Hz, 1H), 4.88 (d, J = 14.5 Hz, 1H), 4.72 (d, J = 14.8 Hz, 1H); contains acetonitrile (2.08); contains some impurities (~10% by LC).	486.2	E	
I-1981		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(COc3cc4ccccc4cn3)c12)-c1ccc2ncnn2c1	NMR (400 MHz, DMSO-d6) 9.49 (dd, J = 1.7, 0.8 Hz, 1H), 9.32 (br. s, 1H), 8.98 (s, 1H), 8.57 (s, 1H), 8.21 (br. s, 1H), 8.17 (submerged br. s, 1H), 8.15 (overlapping dd, J = 4.6, 1.8 Hz, 1H), 8.01 (d, J = 8.3 Hz, 1H), 7.97 (d, J = 9.2 Hz, 1H), 7.78 (d, J = 8.1 Hz, 1H), 7.65 (ddd, J = 8.2, 6.8, 1.0, 1H), 7.44 (ddd, J = 8.0, 6.8, 1.0 Hz, 1H), 7.38 (dd, J = 8.8, 5.2 Hz, 1H), 7.13 (br. s, 1H), 7.03 (br. s, 1H), 6.57 (br. s, 1H), 6.35 (br. s, 1H), 5.27 (d, J = 12.2 Hz, 1H), 5.15 (br. s, 1H).	536.2	D	





			contains 8% ammonium formate salt (8.43); contains residual acetonitrile (2.08).			
I-1982		NC1CCCCC1C(=O)Nc1cc(cc2C(=O)NC(c12)c1cc(F)ccc1Cl)-c1ccc2ncnn2c1	1H NMR (400 MHz, DMSO-d6)9.43 (s, 1H), 9.22 (d, J = 9.8 Hz, 1H), 8.58 (s, 1H), 8.40-8.05 (m, 2H),8.05-7.98 (m, 2H), 7.53 (s, 1H), 7.32-7.20 (m, 1H), 6.90-6.35 (m,1H), 6.17 (s, 1H), 3.10-2.90 (m,1H), 2.25-1.90 (m,1H), 1.85-1.50 (m,2H), 1.50-1.35(m,2H),1.35-1.15(m,4H),1.15-0.80(m,2H)	519.1	E	
I-1983		NC(=O)CC(=O)Nc1cc(cc2C(=O)NC(c12)c1cc(F)ccc1Cl)-c1ccc2ncnn2c1	NMR (400 MHz, DMSO-d6) 10.05 (br s, 1H), 9.43 (d, J = 0.7 Hz, 1H), 9.21 (br s, 1H), 8.57 (s, 1H), 8.08 (dd, J = 9.3, 1.5 Hz, 1H), 8.01 (d, J = 0.9 Hz, 1H), 7.98-7.91 (m, 2H), 7.54-7.44 (m, 2H), 7.23 (td, J = 8.3, 3.0 Hz, 1H), 7.17-7.08 (m, 1H), 6.74 (br s, 1H), 6.07 (br s, 1H), 3.00 (d, J = 15.9 Hz, 1H), 2.96 (d, J = 16.2 Hz, 1H).	479	E	
I-1984		Fc1ccc(Cl)c(c1)[C@H]1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1cnc2ncc(Cl)n2c1	1H NMR (400 MHz, DMSO) δ 10.67 (s, 1H), 9.28 (s, 1H), 9.18 (d, J = 2.5 Hz, 1H), 9.06 (d, J = 2.5 Hz, 1H), 8.21 (d, J = 1.6 Hz, 1H), 7.96 (d, J = 16.9 Hz, 2H), 7.77 (d, J = 9.4 Hz, 1H), 7.71 (s, 1H), 7.34 (dd, J = 8.9, 5.2 Hz, 1H), 7.11 (td, J = 8.3, 3.1 Hz, 1H), 6.06 (s, 1H).	619.18	C	




I-1985		Fc1ccc(Cl)c(c1)[C@@H]1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1cnc2ncc(Cl)n2c1	1H NMR (400 MHz, DMSO) δ 10.67 (s, 1H), 9.28 (s, 1H), 9.18 (d, J = 2.5 Hz, 1H), 9.06 (d, J = 2.5 Hz, 1H), 8.21 (d, J = 1.6 Hz, 1H), 7.96 (d, J = 16.9 Hz, 2H), 7.77 (d, J = 9.4 Hz, 1H), 7.71 (s, 1H), 7.34 (dd, J = 8.9, 5.2 Hz, 1H), 7.11 (td, J = 8.3, 3.1 Hz, 1H), 6.06 (s, 1H).	619.18	A	
I-1986		FC(F)c1nc2ccc(cn2n1)-c1cc2C(=O)N[C@@H](c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	1H NMR (400 MHz, DMSO) δ 10.65 (s, 1H), 9.56 (dd, J = 1.9, 0.9 Hz, 1H), 9.27 (s, 1H), 8.25 (dd, J = 9.4, 1.8 Hz, 1H), 8.15 (d, J = 1.7 Hz, 1H), 8.07 (dd, J = 9.3, 0.9 Hz, 1H), 8.00 – 7.93 (m, 2H), 7.76 (d, J = 9.1 Hz, 1H), 7.70 (s, 1H), 7.38 – 7.28 (m, 2H), 7.11 (td, J = 8.4, 3.1 Hz, 1H), 3.16 (d, J = 3.5 Hz, 1H).	634.19	D	
I-1987		FC(F)c1nc2ccc(cn2n1)-c1cc2C(=O)N[C@H](c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	1H NMR (400 MHz, DMSO) δ 10.65 (s, 1H), 9.56 (dd, J = 1.9, 0.9 Hz, 1H), 9.27 (s, 1H), 8.25 (dd, J = 9.4, 1.8 Hz, 1H), 8.15 (d, J = 1.7 Hz, 1H), 8.07 (dd, J = 9.3, 0.9 Hz, 1H), 8.00 – 7.93 (m, 2H), 7.76 (d, J = 9.1 Hz, 1H), 7.70 (s, 1H), 7.38 – 7.28 (m, 2H), 7.11 (td, J = 8.4, 3.1 Hz, 1H), 3.16 (d, J = 3.5 Hz, 1H).	634.19	A	
I-1988		CC#Cc1cc(cc2C(=O)NC(c12)c1cc(F)ccc1Cl)-c1ccc2ncnn2c1	1H NMR (400 MHz, DMSO-d6) 9.47 (d, J = 2.4 Hz, 1H), 9.29 (s, 0H), 8.56 (s, 1H), 8.17-8.08 (m, 2H), 8.00 (d, J = 1.7 Hz, 1H), 7.94 (d, J = 9.3 Hz, 1H), 7.58 (s, 1H), 7.27 (td, J = 8.4, 3.1 Hz, 1H), 6.12	417.05	E	





			(s, 1H), 2.96 (q, J = 2.1 Hz, 1H), 1.87 (s, 3H).			
I-1989		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(NC(=O)[C@H]3C[C@H](C3)C(F)(F)F)c12	1H NMR (400 MHz, DMSO-d6) 9.78 (s, 1H), 9.24 (s, 1H), 7.72 (d, J = 1.8 Hz, 1H), 7.62 (d, J = 1.8 Hz, 1H), 7.47 (d, J = 7.6 Hz, 1H), 7.23 (ddd, J = 8.8, 7.9, 3.1 Hz, 1H), 6.64 (s, 1H), 6.02 (s, 1H), 3.09 (dq, J = 18.2, 9.1 Hz, 1H), 2.91 (p, J = 9.0 Hz, 1H), 2.13-1.86 (m, 4H).	506.9	D	
I-1990		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(N3C(=O)CCC3=O)c12)-c1ccc2ncnn2c1	NMR (400 MHz, DMSO-d6) 9.45 (d, J = 0.8 Hz, 1H), 9.36 (br s, 1H), 8.58 (s, 1H), 8.32 (br s, 1H), 8.06 (dd, J = 9.3, 1.8 Hz, 1H), 8.01-7.95 (m, 2H), 7.70-7.48 (m, 1H), 7.25 (td, J = 8.6, 2.9 Hz, 1H), 6.56 (br s, 1h), 5.96 (br s, H), 2.92-2.76 (m, 1H), 2.76-2.60 (m, 2H), 2.44-2.11 (m, 1H)..	476	E	
I-1991		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)C3COCCN3)c12)-c1ccc2ncnn2c1	NMR (400 MHz, DMSO-d6) 9.67-9.47 (m, 1H), 9.43-9.38 (m, 1H), 9.31-9.19 (m, 1H), 8.58 (s, 1H), 8.29 (s, 1H), 8.25 (s, 1H), 8.16 (d, J = 1.6 Hz, 1H), 8.11-8.03 (m, 1H), 8.02-7.93 (m, 2H), 7.66-7.48(m, 1H), 7.36-7.22 (m, 1H), 6.14 (br s, 1H), 3.58-3.44 (m, 2H), 3.42-3.19 (m, 4H), 3.18-3.07 (m, 1H). mixture of diastereomers (1:1.6)	507.3	E	
I-1992		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)C3CCCC(N3)C(F)(F)F)c12)-	NMR (400 MHz, ACN-d3) 9.05 (s, 1H), 8.43-8.32 (m, 1H), 8.12 (d, J = 9.2 Hz, 1H), 7.96 (d, J = 11.0 Hz, 1H), 7.50 (s, 1H), 7.31 (, 1Hs), 7.23-7.04 (m, 1H), 6.62 (br s, 1H), 6.27 (br , 1H), 3.33-	573.1	D	





		c1ccc2nc nn2c1	3.10 (m, 2H), 1.87-1.59 (m, 4H), 1.46-1.33 (m, 1H), 1.33-1.11 (m, 1H), 0.96-0.78 (m, 1H). Mixture of diastereomers (3:1); major reported			
I-1993		Fc1ccc(C l)c(c1)C1 NC(=O)c 2cc(cc(N c3ccn(n3)C3CC3) c12)-c1ccc2nc nn2c1	1H NMR (400 MHz, DMSO-d6) 9.35-9.30 (m, 1H), 9.06 (s, 1H), 8.56 (s, 1H), 8.03 (dd, J=9.3, 1.8 Hz, 1H), 8.00-7.92 (m, 2H), 7.83 (s, 1H), 7.59 (dd, J=11.8, 1.9 Hz, 2H), 7.48 (dd, J=8.8, 5.2 Hz, 1H), 7.20 (td, J=8.3, 3.1 Hz, 1H), 6.62 (s, 1H), 6.09 (s, 1H), 5.75 (d, J=2.3 Hz, 1H), 3.57 (tt, J=7.3, 3.9 Hz, 1H), 1.02-0.85 (m, 4H).	500.05	E	
I-1994		OCCn1cc c(Nc2cc(cc3C(=O)NC(c23) c2cc(F)cc c2Cl)-c2ccc3nc nn3c2)n1	1H NMR (400 MHz, DMSO-d6) 9.32 (dd, J = 1.8, 1.0 Hz, 1H), 9.05 (s, 1H), 8.56 (s, 1H), 8.02 (dd, J = 9.3, 1.8 Hz, 1H), 8.00 -7.92 (m, 2H), 7.78 (s, 1H), 7.60 (d, J = 1.6 Hz, 1H), 7.53 (d, J = 2.3 Hz, 1H), 7.49 (dd, J = 8.9, 5.2 Hz, 1H), 7.21 (ddd, J = 8.9, 7.9, 3.1 Hz, 1H), 6.69 (s, 1H), 6.11 (s, 1H), 5.76 (d, J = 2.3 Hz, 1H), 4.86 (t, J = 5.3 Hz, 1H), 4.02 (td, J = 5.5, 1.6 Hz, 2H), 3.72 (q, J = 5.7 Hz, 2H).	504	E	
I-1995		CS(=O)(=O)n1cc(cn1)-c1cc2C(= O)N[C@ @H](c2c (NC(=O) c2cc(F)cc (c2)C(F)(F)F)c1)c 1cc(F)ccc 1Cl	(400 MHz, DMSO-d6) 10.58 (br s, 1 H), 9.19 (br s, 1 H), 8.98 (s, 1 H), 8.64 (s, 1 H), 8.13 (s, 1 H), 7.99 - 7.91 (m, 2 H), 7.76 (d, J = 8.9 Hz, 1 H), 7.72 (s, 1 H), 7.32 (dd, J = 8.9, 5.1 Hz, 1 H), 7.10 (td, J = 8.5, 2.9 Hz, 1 H), 6.58 (br s, 1 H), 5.99 (br s, 1 H), 3.61 (s, 3 H).	609.1	C	





I-1996		CS(=O)(=O)n1cc(cn1)-c1cc2C(=O)N[C@H](c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	(400 MHz, DMSO-d6) 10.58 (br s, 1 H), 9.18 (br s, 1 H), 8.97 (s, 1 H), 8.64 (s, 1 H), 8.13 (s, 1 H), 8.00-7.88 (m, 2 H), 7.76 (d, J = 8.9 Hz, 1 H), 7.73 (s, 1 H), 7.32 (dd, J = 8.9, 5.2 Hz, 1 H), 7.10 (td, J = 8.5, 3.0 Hz, 1 H), 6.61 (br s, 1 H), 5.99 (br s, 1 H), 3.61 (s, 3 H).	609.1	A	
I-1997		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(c12)C1=CCNCC1)-c1ccc2ncnn2c1	NMR (400 MHz, DMSO-d6) 9.50 (d, J = 0.7 Hz, 1H), 9.27 (br s, 1H), 8.56 (s, 1H), 8.33 (br s, 1H), 8.16 (dd, J = 9.3, 1.8 Hz, 1H), 8.06 (d, J = 1.4 Hz, 1H), 7.95 (d, J = 9.3 Hz, 1H), 7.83 (s, 1H), 7.62-7.47 (m, 1H), 7.25 (td, J = 8.4, 3.1 Hz, 1H), 6.46 (br s, 1H), 6.29 (br s, 1H), 5.84 (br s, 1H), 3.46-3.08 (m, 2H), 2.98-2.71 (m, 1H), 2.58 (br d, J = 12.3 Hz, 1H), 2.39-2.16 (m, 1H), 1.47 (br d, J = 13.5 Hz, 1H).	460	E	
I-1998		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(c12)C1=CCCNC1)-c1ccc2ncnn2c1	NMR (400 MHz, DMSO-d6) 9.53-9.51 (m, 1H), 9.27 (br s, 1H), 8.56 (s, 1H), 8.18 (dd, J = 9.3, 1.4 Hz, 1H), 8.06 (s, 1H), 7.94 (d, J = 9.3 Hz, 1H), 7.89 (s, 1H), 7.66-7.46 (m, 1H), 7.25 (td, J = 8.4, 3.0 Hz, 1H), 6.41 (br s, 1H), 6.29 (br s, 1H), 5.90 (br s, 1H), 3.69 (br d, J = 18.1 Hz, 1H), 2.92-2.72 (m, 1H), 2.47-2.34 (m, 1H), 2.17-1.87 (m, 3H). One proton missing or submerged.	460	E	




I-1999		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(CN3CCCCC3=O)c12)-c1ccc2ncnn2c1	NMR (400 MHz, DMSO-d6) 9.42 - 9.40 (m, 1H), 9.36-9.18 (m, 1H), 8.57 (s, 1H), 8.10-8.03 (m, 2H), 7.97 (d, J = 9.3 Hz, 1H), 7.64 (s, 2H), 7.30 (td, J = 8.3, 3.1 Hz, 1H), 6.51 (br. s, 1H), 6.23 (br. s, 1H), 4.40 (d, J = 15.3 Hz, 1H), 4.07 (d, J = 15.3 Hz, 1H), 3.23-3.05 (m, 1H), 3.05-2.83 (m, 1H), 2.28-2.21 (m, 2H), 1.85-1.55 (m, 4H)	490.2	E	
I-2000		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)CC#N)c12)-c1ccc2ncnn2c1	NMR (400 MHz, DMSO-d6) 9.45 (s, 1H), 9.24 (br s, H), 8.57 (s, 1H), 8.15-8.05 (m, 2H), 7.97 (d, J = 9.2 Hz, 1H), 7.81 (s, 1H), 7.66-7.44 (m, 1H), 7.25 (td, J = 8.4, 3.0 Hz, 1H), 6.68 (br s, 1H), 6.03 (br s, 1H), 3.66 (d, J = 18.6 Hz, 1H), 3.52 (d, J = 18.6 Hz, 1H). Amide NH missing/submerged.	461	E	
I-2001		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(N(CC(=O)N3CCCCC3)C(=O)C(F)(F)F)c12)-c1ccc2ncnn2c1	NMR (400 MHz, DMSO-d6) 11.47 (s, 1H), 9.98 (s, 1H), 9.58 (s, 1H), 9.40 (br s, 1H), 8.92 (dd, J = 9.4, 1.3 Hz, 1H), 8.56 (d, J = 9.4 Hz, 1H), 8.35 (s, 1H), 8.10 (s, 1H), 7.68-7.39 (m, 1H), 7.27 (td, J = 8.4, 3.1 Hz, 1H), 6.07 (br s, 1H), 5.72 (s, 2H), 3.57-3.40 (m, 4H), 1.75-1.58 (m, 4H), 1.56-1.39 (m, 2H).	615	E	
I-2002		FC(F)c1cc(ccn1)-c1cc2C(=O)N[C@@H](c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c	1H NMR (DMSO-d6, 400 MHz) δ 10.66 (s, 1H), 9.21-9.41 (m, 1H), 8.81 (d, J = 5.1 Hz, 1H), 8.17 (d, J = 1.3 Hz, 1H), 8.12 (s, 1H), 8.07 (br d, J = 5.3 Hz, 1H), 8.02 (s, 1H), 7.98 (br d, J = 8.6 Hz, 1H), 7.78 (br d, J = 9.1 Hz,	594.2	D	





		1cc(F)ccc1Cl	1H), 7.71 (s, 1H), 7.34 (dd, J = 9.0, 5.2 Hz, 1H), 6.90-7.20 (m, 2H), 6.39-6.71 (m, 1H), 5.92-6.26 ppm (m, 1H).			
I-2003		FC(F)c1cc(ccn1)-c1cc2C(=O)N[C@H](c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	1H NMR (DMSO-d6, 400 MHz) δ 10.66 (s, 1H), 9.21-9.41 (m, 1H), 8.81 (d, J = 5.1 Hz, 1H), 8.17 (d, J = 1.3 Hz, 1H), 8.12 (s, 1H), 8.07 (br d, J = 5.3 Hz, 1H), 8.02 (s, 1H), 7.98 (br d, J = 8.6 Hz, 1H), 7.78 (br d, J = 9.1 Hz, 1H), 7.71 (s, 1H), 7.34 (dd, J = 9.0, 5.2 Hz, 1H), 6.90-7.20 (m, 2H), 6.39-6.71 (m, 1H), 5.92-6.26 ppm (m, 1H).	594.4	A	
I-2004		FC(F)c1ccc(cn1)-c1cc2C(=O)N[C@@H](c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	1H NMR (DMSO-d6, 400 MHz) δ 10.66 (s, 1H), 9.28 (br s, 1H), 9.13 (d, J = 2.0 Hz, 1H), 8.43 (dd, J = 8.1, 2.3 Hz, 1H), 8.10 (d, J = 1.3 Hz, 1H), 7.97 (br d, J = 8.6 Hz, 1H), 7.93 (s, 1H), 7.84 (d, J = 8.3 Hz, 1H), 7.77 (br d, J = 9.1 Hz, 1H), 7.70 (s, 1H), 7.34 (dd, J = 8.8, 5.3 Hz, 1H), 6.90-7.22 (m, 2H), 6.46-6.84 (m, 1H), 5.85-6.25 ppm (m, 1H).	594.2	D	
I-2005		C[C@H](Oc1cc2C(=O)N[C@H](c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl)C#N		536.1	D	




I-2006		C[C@@H](Oc1cc2C(=O)N[C@H](c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl)C#N		536.1	A	
I-2007		C[C@H](Oc1cc2C(=O)N[C@@H](c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl)C#N		536.1	D	
I-2008		FC(F)c1ccc(cn1)-c1cc2C(=O)N[C@H](c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	1H NMR (DMSO-d6, 400 MHz): δ = 10.66 (s, 1H), 9.28 (br s, 1H), 9.13 (d, J = 2.0 Hz, 1H), 8.43 (dd, J = 8.1, 2.3 Hz, 1H), 8.10 (d, J = 1.3 Hz, 1H), 7.97 (br d, J = 8.6 Hz, 1H), 7.93 (s, 1H), 7.84 (d, J = 8.3 Hz, 1H), 7.77 (br d, J = 9.1 Hz, 1H), 7.70 (s, 1H), 7.34 (dd, J = 8.8, 5.3 Hz, 1H), 6.90-7.22 (m, 2H), 6.46-6.84 (m, 1H), 5.85-6.25 ppm (m, 1H).	594.5	A	
I-2009		C[C@@H](Oc1cc2C(=O)N[C@@H](c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl)C#N		536.1	A	





I-2010		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC3CCS(=O)(=O)CC3)c12)-c1ccc2ncnn2c1		526	E	
I-2012		[2H]c1nc2cnc(cn2n1)-c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	1H NMR (400 MHz, DMSO-d6) 10.69 (s, 1H), 9.92 (s, 1H), 9.54 (s, 1H), 9.26 (s, 1H), 8.48 (s, 1H), 8.35 (s, 1H), 7.94 (d, J = 8.3 Hz, 1H), 7.77 (d, J = 9.0 Hz, 1H), 7.71 (s, 1H), 7.37 - 7.30 (m, 1H), 7.11 (d, J = 8.7 Hz, 1H), 6.39 (br s, 1H).	586.15	A	
I-2013		Fc1ccc(Cl)c(c1)[C@@H]1NC(=O)c2cc(Br)cc(N[C@@H]3CCOc4ccccc34)c12	1H NMR (400 MHz, DMSO-d6) 9.08 (s, 0H), 7.49 (dd, J = 8.9, 5.1 Hz, 1H), 7.33-7.22 (m, 2H), 7.19-7.12 (m, 2H), 7.06 (ddd, J = 6.7, 4.8, 1.7 Hz, 1H), 6.85 (t, J = 7.5 Hz, 1H), 6.76 (dd, J = 8.3, 1.2 Hz, 2H), 5.89 (s, 1H), 5.10 (d, J = 7.5 Hz, 1H), 4.74 (dt, J = 9.3, 4.7 Hz, 1H), 4.00 (ddd, J = 10.2, 5.9, 3.3 Hz, 1H), 3.53-3.43 (m, 1H), 1.83 (tq, J = 8.0, 3.7 Hz, 1H), 1.63 (d, J = 14.6 Hz, 1H).	486.9	E	
I-2014		Fc1ccc(Cl)c(c1)[C@@H]1NC(=O)c2cc(Br)cc(N[C@H]3CCOc4ccccc34)c12	1H NMR (400 MHz, DMSO-d6) 9.08 (s, 0H), 7.49 (dd, J = 8.9, 5.1 Hz, 1H), 7.33-7.22 (m, 2H), 7.19-7.12 (m, 2H), 7.06 (ddd, J = 6.7, 4.8, 1.7 Hz, 1H), 6.85 (t, J = 7.5 Hz, 1H), 6.76 (dd, J = 8.3, 1.2 Hz, 2H), 5.89 (s, 1H), 5.10 (d, J = 7.5 Hz, 1H), 4.74 (dt, J = 9.3, 4.7 Hz, 1H), 4.00 (ddd, J = 10.2, 5.9, 3.3 Hz, 1H),	486.9	E	





			3.53-3.43 (m, 1H), 1.83 (tq, J = 8.0, 3.7 Hz, 1H), 1.63 (d, J = 14.6 Hz, 1H).			
I-2015		[2H]c1nc2ccc(-c3cc4C(=O)NC(c4c(NC(=O)c4cc(F)cc(c4)C(F)(F)F)c3)c3cc(F)ccc3Cl)c(C#N)n2n1	1H NMR (400 MHz, DMSO-d6) 10.72 (d, J = 2.1 Hz, 1H), 9.35 (s, 1H), 8.34 (s, 1H), 8.08 (s, 1H), 7.96 (s, 2H), 7.85 (dd, J = 9.3, 1.9 Hz, 1H) , 7.69 (s, 1H), 7.38 (s, 1H), 7.22 (s, 1H), 7.14 (s, 1H), 6.64-7.08 (d, J = 9.3 Hz , 1H), 6.10 (br s, 1H).	610	A	
I-2016		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(c12)-n1ccc2c(F)cc(cc2c1=O)C(F)(F)F)-c1ccc2ncnn2c1	1H NMR (400 MHz, DMSO-d6) 9.57 (d, J = 25.7 Hz, 1H), 9.37 (s, 1H), 8.58 (d, J = 4.1 Hz, 1H), 8.36 (d, J = 10.4 Hz, 2H), 8.29 - 8.07 (m, 3H), 7.99 (dd, J = 9.4, 6.2 Hz, 1H), 7.87 (s, 1H), 7.11 (dd, J = 134.1, 73.8 Hz, 3H), 6.52 (d, J = 7.7 Hz, 1H), 6.08 - 5.69 (m, 1H).	608.1	D	
I-2017		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(COc3ccccc3)c12)-c1ccc2ncnn2c1	1H NMR (400 MHz, DMSO-d6) 9.49 (s, 1H), 9.29 (s, 1H), 8.57 (s, 1H), 8.22 - 8.12 (m, 3H), 7.98 (d, J = 9.3 Hz, 1H), 7.46 (s, 1H), 7.24 (t, J = 7.8 Hz, 2H), 7.19 (s, 1H), 6.92 (t, J = 7.3 Hz, 1H), 6.81 (d, J = 8.0 Hz, 2H), 6.57 (s, 1H), 6.27 (s, 1H), 4.91 (d, J = 11.4 Hz, 1H), 4.83 (s, 1H).	485.15	E	
I-2018		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(N3CCn4ncnc4C3)c12)-c1ccc2ncnn2c1	NMR (400 MHz, DMSO-d6) 9.57 (dd, J = 1.7, 0.8 Hz, 1H), 9.32-9.22 (m, 1H), 8.57 (s, 1H), 8.20 (dd, J = 9.3, 1.8 Hz, 1H), 7.97 (dd, J = 9.3, 0.6 Hz, 1H), 7.92 (s, 1H), 7.90 (d, J = 1.3 Hz, 1H), 7.81 (d, J = 1.3 Hz, 1H), 7.44 (dd, J = 8.8, 5.1 Hz, 1H), 7.21-7.15	501	E	




			(m, 1H), 6.85 (br s, 1H), 6.30 (s, 1H), 4.56 (d, J = 15.9 Hz, 1H), 4.09 (d, J = 15.9 Hz, 1H), 3.93-3.81 (m, 1H), 3.79-3.64 (m, 1H), 3.39-3.27 (m, 1H).			
I-2019		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(N3CCn4cnnc4C3)c12)-c1ccc2ncnn2c1	NMR (400 MHz, DMSO-d6) 9.59-9.56 (m, 1H), 9.25 (s, 1H), 8.57 (s, 1H), 8.41 (s, 1H), 8.20 (dd, J = 9.3, 1.8 Hz, 1H), 7.99-7.95 (m, 1H), 7.89 (d, J = 1.3 Hz, 1H), 7.79 (d, J = 1.1 Hz, 1H), 7.44 (dd, J = 8.7, 5.4 Hz, 1H), 7.19 (ddd, J = 11.0, 6.8, 2.3 Hz, 1H), 6.75 (br s, 1H), 6.30 (s, 1H), 4.58 (d, J = 15.4 Hz, 1H), 4.15 (d, J = 15.5 Hz, 1H), 3.81-3.74 (m, 1H), 3.72-3.65 (m, 1H), 3.64- 3.56 (m, 1H), 3.27-3.20 (submerged m, 1H).	501	E	
I-2020		CN1CCC=C(C1)c1cc(cc2C(=O)NC(c12)c1cc(F)ccc1Cl)-c1ccc2ncnn2c1	NMR (400 MHz, DMSO-d6) 9.59-9.47 (m, 1H), 9.25 (br s, 1H), 8.56 (s, 1H), 8.19 (d, J = 9.3 Hz, 1H), 8.06 (s, 1H), 8.02-7.84 (m, 1H), 7.70-7.42 (m, 1H), 7.24 (td, J = 8.4, 2.8 Hz, 1H), 6.41 (br s, 1H), 6.29 (br s, 1H), 5.86 (s, 1H), 3.42 (br d, J = 16.1 Hz, 1H), 2.24-2.08 (m, 2H), 2.04 (s, 3H), 2.04-1.93 (m, 1H), 1.90-1.72 (m, 1H), 1.63-1.47 (m, 1H).	474	E	
I-2021		CN1CCC(=CC1)c1cc(cc2C(=O)NC(c12)c1cc(F)ccc1Cl)-c1ccc2ncnn2c1		474	E	




I-2022		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(OCC#N)c12)-c1ccc2ncnn2c1	NMR (400 MHz, DMSO-d6) 9.52 (br, s, 1H), 9.25 (br, s, 1H), 8.59 (s, 1H), 8.19 (dd, J = 9.3, 1.9 Hz, 1H), 8.00 (dd, J = 9.3, 0.8 Hz, 1H), 7.88 (d, J = 1.2 Hz, 1H), 7.79 (d, J = 1.2 Hz, 1H), 7.57 (dd, J = 8.8, 5.2 Hz, 1H), 7.28-7.22 (m, 1H), 6.87 (br, s, 1H), 6.10 (s, 1H), 5.27 (s, 2H).	434	E	
I-2023		Fc1ccc(Cl)c(c1)[C@@H]1NC(=O)c2cc(cc(N[C@@H]3CCCNC3)c12)-c1ccc2ncnn2c1	NMR (400 MHz, DMSO-d6) 9.43 (s, 1H), 9.06 (s, 1H), 8.55 (s, 1H), 8.11 (d, J = 9.1 Hz, 1H), 7.92 (d, J = 9.2 Hz, 1H), 7.56 (dd, J = 8.3, 5.0 Hz, 1H), 7.38 (s, 1H), 7.32-7.22 (m, 2H), 6.87 (br s, 1H), 5.96 (s, 1H), 4.54 (d, J = 7.7 Hz, 1H), 3.93-3.70 (m, 1H), 3.28-3.07 (m, 1H), 2.99-2.74 (m, 1H), 2.72-2.53 (m, 1H), 1.61-1.17 (m, 4H).	477	E	
I-2024		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC3CCNCC3)c12)-c1ccc2ncnn2c1	NMR (400 MHz, DMSO-d6) 9.41 (s, 1H), 9.06 (s, 1H), 8.57 (s, 1H), 8.09 (d, J = 8.9 Hz, 1H), 7.93 (d, J = 8.7 Hz, 1H), 7.67-7.51 (m, 1H), 7.39 (s, 1H), 7.34-7.19 (m, 2H), 6.82 (br s, 1H), 5.97 (s, 1H), 4.55-4.24 (m, 1H), 3.92-3.55 (m, 1H), 3.49-2.54 (m, 3H), 1.77-0.99 (m, 4H).	477	E	
I-2025		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(Nc3ccncc3)c12	1H NMR (400 MHz, DMS)-d6) 9.23 (s, 1H), 8.47 (br. s, 1H), 8.07 (br. s, 2H), 7.68 (d, J = 1.6 Hz, 1H), 7.57 (d, J = 1.6 Hz, 1H), 7.28 (dd, J = 8.8, 5.2 Hz, 1H), 7.05 (td, J = 8.4, 3.1 Hz, 1H), 6.62 (br. s, 1H), 6.45 (d, J = 4.2 Hz, 2H), 5.86 (s, 1H)	432	E	



I-2026		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(Cn3ccc4ccccc4c3=O)c12)-c1ccc2ncnn2c1	1H NMR (400 MHz, DMSO-d6) 9.38 (s, 1H), 8.54 (s, 1H), 8.14 (d, J = 8.2 Hz, 1H), 8.11 (d, J = 1.1 Hz, 1H), 7.99 (dd, J = 9.3, 1.5 Hz, 1H), 7.92 (dd, J = 9.3, 0.6 Hz, 1H), 7.75 (br. s, 1H), 7.72-7.65 (m, 1H), 7.65-7.58 (m, 1H), 7.59-7.51 (m, 1H), 7.52-7.44 (m, 1H), 7.39 (br. s, 1H), 7.12 (br. s, 1H), 6.60 (d, J = 7.4 Hz, 1H), 6.56-6.27 (m, 1H), 5.54 (m, 2H), 4.94 (dd, J = 34.6, 15.0 Hz, 2H)	536.2	E	
I-2027		O[C@@H]1C[C@@H](C[C@@H](C1)C(F)(F)F)C(=O)Nc1cc(Br)cc2C(=O)NC(c12)c1cc(F)ccc1Cl	1H-NMR (400 MHz, DMSO-d6) as a ca. 1:1 mixture of diastereomers, 9.94 (br. s, 1H), 9.83 (br. s, 1H), 9.25 (br. s, 2H), 7.71 (s, 2H), 7.61 (d, J = 1.4 Hz, 1H), 7.55 (d, J = 0.9 Hz, 1H), 7.49 - 7.41 (m, 2H), 7.22 - 7.16 (m, 2H), 6.51 (br. s, 2H), 6.01 (br. s, 2H), 4.90 - 4.87 (m, 2H), 3.47 - 3.38 (m, 2H), 2.40 - 2.29 (m, 3H), 2.24 - 2.13 (m, 2H), 1.96 - 1.89 (m, 1H), 1.77 - 1.69 (m, 1H), 1.62 - 1.54 (m, 1H), 1.54 - 1.46 (m, 1H), 1.10 - 0.80 (m, 6H).	549.1	E	
I-2028		Fc1ccc(Cl)c(c1)[C@H]1NC(=O)c2cc(cc(NC(=O)[C@H]3CCC[C@H](C3)C(F)(F)F)c12)-c1ccc2ncnn2c1		588.5	D	




I-2029		Fc1ccc(Cl)c(c1)[C@@H]1NC(=O)c2cc(cc(NC(=O)[C@H]3CCC[C@H](C3)C(F)(F)F)c12)-c1ccc2ncnn2c1		588.5	A	A
I-2030		Fc1ccc(Cl)c(c1)[C@@H]1NC(=O)c2cc(cc(NC(=O)[C@@H]3CCC[C@@H](C3)C(F)(F)F)c12)-c1ccc2ncnn2c1		588.5	C	
I-2031		Fc1ccc(Cl)c(c1)[C@H]1NC(=O)c2cc(cc(NC(=O)[C@@H]3CCC[C@@H](C3)C(F)(F)F)c12)-c1ccc2ncnn2c1		588.5	D	
I-2032		Fc1ccc(Cl)c(c1)[C@H]1NC(=O)c2cc(cc(NC(=O)[C@@H]3CCC[C@H](C3)C(F)(F)F)c12)-c1ccc2ncnn2c1		588.5	D	





I-2033		Fc1ccc(Cl)c(c1)[C@H]1NC(=O)c2cc(cc(NC(=O)[C@H]3CCC[C@@H](C3)C(F)(F)F)c12)-c1ccc2nccnn2c1		588.5	D	
I-2034		Fc1ccc(Cl)c(c1)[C@@H]1NC(=O)c2cc(cc(NC(=O)[C@@H]3CCC[C@H](C3)C(F)(F)F)c12)-c1ccc2nccnn2c1		588.5	A	A
I-2035		Fc1ccc(Cl)c(c1)[C@@H]1NC(=O)c2cc(cc(NC(=O)[C@H]3CCC[C@@H](C3)C(F)(F)F)c12)-c1ccc2nccnn2c1		588.5	A	
I-2036		[H][C@]1(CCCCC1=O)[C@@H]1NC(=O)c2cccc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	(400 MHz, DMSO-d6) 10.60 (s, 1H), 8.24 (s, 1H), 8.13 (s, 1H), 8.09 (d, J = 9.1 Hz, 1H), 8.01 (d, J = 8.4 Hz, 1H), 7.62 (dd, J = 7.4, 1.4 Hz, 1H), 7.60-7.51 (m, 2H), 5.43 (s, 1H), 2.93 (dd, J = 11.8, 5.1 Hz, 1H), 2.35-2.20 (m, 2H), 1.95-1.83 (m, 1H), 1.70-1.60 (m, 1H), 1.53-1.38 (m, 2H), 1.27-1.11 (m, 1H), 1.07-0.97 (m, 1H) .	435.3	E	




I-2037		COC1CCCC(C1)C(=O)Nc1cc(cc2C(=O)NC(c12)c1cc(F)ccc1Cl)-c1ccc2ncnn2c1	NMR (400 MHz, DMSO-d6) 9.82 (s, 1H), 9.45-9.41 (m, , 1H), 9.20 (s, 1H), 8.57 (s, 1H), 8.09 (dd, J = 9.3, 1.8 Hz, 1H), 8.01-7.93 (m, 2H), 7.80 (dd, J = 6.6, 1.6 Hz, 1H), 7.56-7.48 (m, 1H), 7.31-7.16 (m, 1H), 6.73 (br s, 1H), 6.12 (s, 1H), 3.21 (s, 3H), 3.08-2.94 (m, 1H), 2.16-2.03 (m, 1H), 1.99-1.80 (m, 1.5H), 1.76-1.59 (m, 1.5H), 1.49-0.83 (m, 5H). 1:1 mixture of diastereomers (one reported); approx.	534.2	E	
I-2038		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NCC(=O)N3CCCCC3)c12)-c1ccc2ncnn2c1	1H NMR (400 MHz, DMSO-d6) 9.28 (s, 1H), 8.54 (s, 1H), 8.00 (d, J = 9.2, 1.5 Hz, 1H), 7.94 (d, J = 9.2 Hz, 1H), 7.68 (dd, J = 10.3, 5.1 Hz, 1H), 7.50-7.13 (m, 4H), 6.49 (d, J = 7.6 Hz, 1H), 6.07 (br. s, 1H), 5.05 - 4.92 (m, 2H), 4.94 (s, 1H), 4.63 (d, J = 17.1 Hz, 1H), 3.62-3.47 (m, 2H), 3.27-3.18 (submerged m, 2H), 1.62-1.38 (m, 6H)	519.2	E	
I-2039		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(N3CCn4cc(nc4C3)C(F)(F)F)c12)-c1ccc2ncnn2c1	NMR (400 MHz, DMSO-d6) 9.55 (dd, J = 1.8, 0.9 Hz, 1H), 9.23 (br s, 1H), 8.57 (s, 1H), 8.19 (dd, J = 9.3, 1.8 Hz, 1H), 7.96 (dd, J = 9.3, 0.7 Hz, 1H), 7.88 (d, J = 1.4 Hz, 1H), 7.76 (d, J = 1.3 Hz, 1H), 7.70 (d, J = 1.3 Hz, 1H), 7.43 (dd, J = 8.8, 5.2 Hz, 1H), 7.18 (ddd, J = 8.8, 8.0, 3.1 Hz, 1H), 6.72 (br s, 1H), 6.29 (br s, 1H), 4.48 (d, J = 15.6 Hz, 1H), 4.05 (d, J = 15.5 Hz, 1H), 3.77 (dd, J = 13.9, 6.4 Hz, 1H), 3.69-	568	E	





			3.59 (m, 2H), 3.30-3.23 (submerged m, 1H).			
I-2040		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(N3CCn4c(C3)nnc4C(F)(F)F)c12)-c1ccc2ncnn2c1	NMR (400 MHz, DMSO-d6) 9.57 (dd, J = 1.7, 0.8 Hz, 1H), 9.23 (br s, 1H), 8.57 (s, 1H), 8.20 (dd, J = 9.3, 1.8 Hz, 1H), 7.97 (dd, J = 9.3, 0.7 Hz, 1H), 7.93 (d, J = 1.4 Hz, 1H), 7.83 (d, J = 1.4 Hz, 1H), 7.37 (dd, J = 8.9, 5.1 Hz, 1H), 7.19-7.13 (m, 1H), 6.76 (br s, 1H), 6.27 (br s, 1H), 4.68 (d, J = 15.9 Hz, 1H), 4.17 (d, J = 15.9 Hz, 1H), 4.02-3.90 (m, 1H), 3.64 (q, J = 6.5 Hz, 2H), 3.40-3.34 (submerged m, 1H).	569	E	
I-2041		Fc1cc(cc(c1)C(F)(F)F)C(=O)Nc1ccccc2C(=O)NC(C(=O)N3CCCCC3)c12	NMR (400 MHz, DMSO-d6) 10.77 (br. s, 1H), 9.08 (s, 1H), 8.14 (s, 1H), 8.08 (br. d, J = 9.2 Hz, 1H), 8.04 (br. d, J = 8.5 Hz, 1H), 7.62-7.52 (m, 3H), 5.74 (s, 1H), 3.52-3.43 (m, 1H), 3.37-3.28 (submerged m, 2H), 3.13-3.04 (m, 1H), 1.50-1.38 (m, 2H), 1.35-1.24 (m, 3H), 0.91-0.80 (m, 1H).	450.2	E	
I-2042		NC1CN(C(=O)Nc2cc(Br)cc3C(=O)NC(c23)c2cc(F)ccc2Cl)c2cccccc12	1H NMR (400 MHz, DMSO-d6) 9.21 (s, 1H), 8.70 (d, J = 51.2 Hz, 1H), 7.78 - 7.56 (m, 3H), 7.43 - 7.33 (m, 2H), 7.17 (dddt, J = 16.9, 11.7, 8.6, 5.4 Hz, 2H), 7.05 - 6.95 (m, 1H), 6.70 (s, 1H), 6.08 - 5.85 (m, 1H), 4.46 (t, J = 7.3 Hz, 1H), 4.00 (dd, J = 10.8, 9.0 Hz, 1H), 3.76 - 3.64 (m, 1H), 3.52 (dd, J = 10.9, 5.8 Hz, 1H), 3.07 - 2.90 (m, 1H).	515.05	D	




I-2043		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(OC3CCOc4ccccc34)c12)-c1ccc2nccnn2c1	NMR (400 MHz, DMSO-d6) 9.56 (br, s, 1H), 9.13 (s, 1H), 8.58 (s, 1H), 8.23-8.18 (m, 1H), 7.97 (dd, J = 9.3, 0.7 Hz, 1H), 7.91 (d, J = 15.1 Hz, 1H), 7.75 (dd, J = 6.9, 1.2 Hz, 1H), 7.41 (dd, J = 8.9, 5.2 Hz, 0.6H), 7.29 (dd, J = 7.6, 1.6 Hz, 0.6H), 7.27-7.20 (m, 1.2H), 7.15 (ddd, J = 9.8, 3.9, 1.6 Hz, 1H), 7.10-7.04 (m, 0.4H), 6.90 (td, J = 7.5, 1.1 Hz, 0.6H), 6.83-6.79 (m, 1H), 6.77 (submerged s, 1H), 6.73 (dd, J = 8.2, 0.9 Hz, 1H), 6.61 (td, J = 7.4, 1.1 Hz, 0.4H), 6.45 (dd, J = 7.6, 1.5 Hz, 0.4H), 5.96 (s, 0.4H), 5.87 (s, 0.6H), 5.84 (t, J = 2.9 Hz, 0.6H), 5.77 (m, 0.4H), 4.21 (m, 1H), 3.86 (m, 0.6H), 3.03 (m, 0.4H), 2.22 (m, 1H), 1.93 (m, 0.6H), 1.72 (m, 0.4H)	527	E	
I-2044		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)CC3(CC3)C(F)(F)F)c12)-c1ccc2nccnn2c1	1H-NMR (400 MHz, DMSO-d6) 9.88 (br. s, 1H), 9.43 (dd, J = 1.7, 0.8 Hz, 1H), 9.20 (br. s, 1H), 8.57 (s, 1H), 8.08 (dd, J = 9.3, 1.8 Hz, 1H), 8.01 (d, J = 1.5 Hz, 1H), 7.97 (dd, J = 9.3, 0.8 Hz, 1H), 7.89 (d, J = 1.5 Hz, 1H), 7.52 (dd, J = 8.0, 4.8 Hz, 1H), 7.24 (ddd, J = 8.7, 8.1, 3.1 Hz, 1H), 6.66 (br. s, 1H), 6.11 (s, 1H), 2.49-2.46 (m, 1H), 2.29 (d, J = 15.3 Hz, 1H), 0.93-0.88 (m, 1H), 0.85-0.78 (m, 3H). Multiplet 2.49-2.46 is a doublet partially obscured by the DMSO peak.	544.3	D	





I-2045		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)C3CCS(=O)(=O)CC3)c12)-c1ccc2ncnn2c1	NMR (400 MHz, DMSO-d6) 10.17-10.01 (m, 1H), 9.44 (d, J = 0.7 Hz, 1H), 9.24 (br s, 1H), 8.57 (s, 1H), 8.10 (dd, J = 9.3, 1.8 Hz, 1H), 8.03 (d, J = 1.5 Hz, 1H), 7.98 (d, J = 9.3 Hz, 1H), 7.82 (s, 1H), 7.58-7.46 (m, 1H), 7.25 (td, J = 8.4, 3.1 Hz, 1H), 6.56 (br s, 1H), 6.16 (br s, 1H), 3.20-3.07 (m, 2H), 3.07-2.95 (m, 2H), 2.48-2.38 (m, 1H), 1.96-1.74 (m, 3H), 1.73-1.62 (m, 1H).	554	E	
I-2046		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(N3CCN(CC3)C(=O)C(F)(F)F)c12)-c1ccc2ncnn2c1	1H NMR (400 MHz, DMSO-d6) 9.51 (dd, J = 1.7, 0.8 Hz, 1H), 9.24 (s, 1H), 8.56 (s, 1H), 8.17 (dd, J = 9.3, 1.8 Hz, 1H), 7.95 (dd, J = 9.3, 0.6 Hz, 1H), 7.87 (d, J = 1.4 Hz, 1H), 7.72 (d, J = 1.3 Hz, 1H), 7.58 (dd, J = 8.3, 5.1 Hz, 1H), 7.27 (ddd, J = 8.9, 8.0, 3.1 Hz, 1H), 6.79 (br. s, 1H), 6.19 (s, 1H), 3.51-3.37 (m, 3H), 3.29-3.14 (m, 3H), 2.89-2.77 (m, 1H), 2.79-2.68 (m, 1H)	559.2	E	
I-2047		CC(=O)N1CCN(CC1)c1cc(cc2C(=O)NC(c12)c1cc(F)ccc1Cl)-c1ccc2ncnn2c1	1H NMR (400 MHz, DMSO-d6) 9.50 (d, J = 0.8 Hz, 1H), 9.24 (s, 1H), 8.56 (s, 1H), 8.16 (dd, J = 9.3, 1.8 Hz, 1H), 7.95 (d, J = 9.3 Hz, 1H), 7.82 (d, J = 1.4 Hz, 1H), 7.62 (d, J = 1.4 Hz, 1H), 7.58 (dd, J = 8.5, 5.2 Hz, 1H), 7.27 (ddd, J = 8.71, 7.03, 3.10 Hz, 1H), 6.74 (br. s, 1H), 6.20 (s, 1H), 3.29-3.04 (m, 6H), 2.85-2.68 (m, 1H), 2.71-2.57 (m, 1H), 1.98 (s, 3H); multiplet at 3.29 - 3.04 6H overlaps	505.2	E	





			with residual water peak			
I-2048		FC(F)n1cc(cn1)-c1cc2C(=O)NC(c2c(c1)-c1nc2cc(cc(F)c2[nH]1)C(F)(F)F)c1cc(F)ccc1Cl	1H NMR (400 MHz, DMSO-d6) 9.31 (s, 1H), 8.98 (s, 1H), 8.71 (s, 1H), 8.52 (s, 1H), 8.23 (s, 1H), 8.07-7.77 (m , 1H), 7.63 (s, 1H), 7.37 (s, 1H), 7.28 (d, J = 10.6 Hz, 1H), 6.95 (td, J = 8.4, 3.1 Hz, 1H), 6.70 (s, 1H), 1.23 (s, 1H).	580	D	
I-2049		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(Nc3n[nH]c4c(cc(F)cc34)C(F)(F)F)c12)-c1ccc2nccnn2c1	1H NMR (400 MHz, DMSO-d6) 12.89 (s, 1H), 9.41 (d, J = 1.7 Hz, 1H), 9.11 (s, 1H), 8.59 (d, J = 6.7 Hz, 2H), 8.10 (dd, J = 9.3, 1.8 Hz, 1H), 8.05 - 7.96 (m, 2H), 7.78 (d, J = 1.6 Hz, 1H), 7.71 (d, J = 8.3 Hz, 1H), 7.40 (d, J = 8.2 Hz, 1H), 7.19 (dd, J = 8.8, 5.2 Hz, 1H), 7.00 (td, J = 8.4, 3.1 Hz, 1H), 6.55 (s, 1H), 6.03 (s, 1H).	596.15	A	
I-2050		Cn1nc(Nc2cc(cc3C(=O)NC(c23)c2cc(F)ccc2Cl)-c2ccc3ncnn3c2)c2cc(F)cc(c12)C(F)(F)F	1H NMR (400 MHz, DMSO-d6) 9.37 (d, J = 1.4 Hz, 1H), 9.13 (s, 1H), 8.55 (s, 1H), 8.36 (s, 1H), 8.06 - 7.99 (m, 1H), 7.93 (d, J = 9.3 Hz, 1H), 7.76 (d, J = 1.5 Hz, 1H), 7.60 (d, J = 8.9 Hz, 1H), 7.45 (dd, J = 9.0, 5.2 Hz, 1H), 7.31 (s, 1H), 7.21 (td, J = 8.3, 3.1 Hz, 1H), 7.08 (d, J = 8.6 Hz, 1H), 6.64 (s, 1H), 5.61 (s, 1H), 3.65 (s, 3H).	610.2	C	
I-2051		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)C3CNCC(C3)C(F)(F)F)c12)-	1H-NMR (400 MHz, DMSO-d6) as a ca. 3:2:1:1 mixture of diastereomers; for the major diastereomer 10.15 (br. s, 1H), 9.44 (s, 1H), 9.23 (br. s, 1H), 8.58 (s, 1H), 8.12-8.08 (m, 1H), 8.06-7.96	573.3	E	






		c1ccc2ncnn2c1	(m, 3H), 7.58-7.49 (m, 1H), 7.27-7.20 (m, 1H), 6.57 (br. s, 1H), 6.19 (br. s, 1H), 6.16 (br. s, 1H), 2.87-2.77 (m, 1H), 2.62-2.47 (m, 2H), 2.44-2.37 (m, 1H), 2.31-2.09 (m, 2H), 1.95-1.82 (m, 1H), 1.63-1.53 (m, 1H).			
I-2052		Fc1cc(cc(c1)C(F)(F)F)C(=O)Nc1ccc2C(=O)N[C@@H](C3CCCCC3)c12	NMR (400 MHz, DMSO-d6) 10.74 (br. s, 1H), 8.74 (s, 1H), 8.13 (s, 1H), 8.08 (br. d, J = 9.0 Hz, 1H), 8.04 (br. d, J = 8.5 Hz, 1H), 7.62-7.49 (m, 3H), 4.73 (d, J = 1.3 Hz, 1H), 1.90-1.80 (m, 1H), 1.73-1.64 (m, 1H), 1.59 - 1.50 (m, 3H), 1.39-1.27 (m, 1H), 1.06-0.86 (m, 3H), 0.79-0.61 (m, 2H).	421.2	D	
I-2053		Fc1cc(cc(c1)C(F)(F)F)C(=O)Nc1ccc2C(=O)N[C@H](C3CCCCC3)c12	NMR (400 MHz, DMSO-d6) 10.74 (br. s, 1H), 8.74 (s, 1H), 8.13 (s, 1H), 8.08 (br. d, J = 9.0 Hz, 1H), 8.04 (br. d, J = 8.5 Hz, 1H), 7.62-7.49 (m, 3H), 4.73 (d, J = 1.3 Hz, 1H), 1.90-1.80 (m, 1H), 1.73-1.64 (m, 1H), 1.59 - 1.50 (m, 3H), 1.39-1.27 (m, 1H), 1.06-0.86 (m, 3H), 0.79-0.61 (m, 2H).	421.2	E	
I-2054		Fc1cc(cc(c1)C(F)(F)F)C(=O)Nc1ccc2C(=O)NC(C(=O)NC3CCCCC3)c12	NMR (400 MHz, DMSO-d6) 11.33 (s, 1H), 8.94 (d, J = 0.6 Hz, 1H), 8.27 (s, 1H), 8.21 (d, J = 8.0 Hz, 1H), 8.17 (br. d, J = 9.3 Hz, 1H), 8.12 (dd, J = 7.6, 1.0 Hz, 1H), 8.04 (br. d, J = 8.7 Hz, 1H), 7.57 (d, J = 7.7 Hz), 7.53 (dd, J = 7.5, 1.2 Hz), 5.43 (d, J = 0.9 Hz, 1H), 3.56-3.41 (m, 1H), 1.62 - 1.46 (m, 4H), 1.24-1.10 (m, 4H),	464.1	E	





			1.09-0.93 (m, 2H). 9:1 mixture of 2 rotamers.			
I-2055		FC(F)S(=O)(=O)n1cc(cn1)-c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	(400 MHz, DMSO-d6) 10.59 (s, 1 H), 9.27 (s, 1 H), 9.22 (br s, 1 H), 8.90 (s, 1 H), 8.23 (s, 1 H), 7.97 (overlapped s, 1 H), 7.97 (overlapped d, J = 10.8 Hz, 1 H), 7.76 (d, J = 9.0 Hz, 1 H), 7.73 (s, 1 H), 7.73 (t, J = 51.4 Hz, 1 H), 7.32 (dd, J = 8.9, 5.2 Hz, 1 H), 7.10 (td, J = 8.5, 3.0 Hz, 1 H), 6.60 (br s, 1 H), 6.01 (br s, 1 H).	645.2	A	
I-2056		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(Nc3cn[nH]c3)c12	1H NMR (400 MHz, DMSO-d6) 12.75 (s, 1H), 9.09 (s, 1H), 7.59 (br. s, 1H), 7.51 (dd, J = 8.8, 5.2 Hz, 1H), 7.23 (ddd, J = 8.8, 8.0, 3.1 Hz, 2H), 7.15 (d, J = 1.6 Hz, 1H), 6.98 - 6.94 (m, 2H), 6.68 (br. s, 1H), 5.82 (s, 1H)	421	E	
I-2057		Fc1cc(cc(c1)C(F)(F)F)C(=O)Nc1ccc2C(=O)N[C@H](CC3CCCCC3)c12	NMR (400 MHz, DMSO-d6) 10.78 (s, 1H), 8.91 (s, 1H), 8.17 (s, 1H), 8.12 (d, J = 9.0 Hz, 1H), 8.05 (d, J = 8.4 Hz, 1H), 7.60-7.50 (m, 3H), 4.83 (br, d, J = 8.0 Hz, 1H), 1.83-1.66 (m, 2H), 1.57-1.37 (m, 5H), 1.18-0.90 (m, 4H), 0.81-0.58 (m, 2H).	435	D	
I-2058		Fc1cc(cc(c1)C(F)(F)F)C(=O)Nc1ccc2C(=O)N[C@@H](CC3CCCCC3)c12	NMR (400 MHz, DMSO-d6) 10.78 (s, 1H), 8.91 (s, 1H), 8.17 (s, 1H), 8.12 (d, J = 9.0 Hz, 1H), 8.05 (d, J = 8.4 Hz, 1H), 7.60-7.50 (m, 3H), 4.83 (br, d, J = 8.0 Hz, 1H), 1.83-1.66 (m, 2H), 1.57-1.37 (m, 5H), 1.18-0.90 (m, 4H), 0.81-0.58 (m, 2H).	435	C	



I-2059		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(Nc3nnc4CCCCn34)c12)-c1ccc2ncnn2c1	1H NMR (400 MHz, DMSO-d6) 9.32 (s, 1H), 8.92 (s, 1H), 8.52 (s), 8.22 (br. s, 1H), 8.04 (dd, J = 9.4, 1.4 Hz, 1H), 7.95 (d, J = 9.3 Hz, 1H), 7.81 - 7.70 (m, 2H), 7.44 (dd, J = 8.9, 5.2 Hz, 1H), 7.20 (td, J = 8.7, 2.9 Hz, 1H), 6.46 (d, J = 8.6 Hz, 1H), 5.92 (s, 1H), 3.53-3.40 (m, 1H), 2.92-2.79 (m, 1H), 2.77-2.69 (m, 2H), 1.87-1.63 (m, 4H).	515.3	E	
I-2060		Fc1cc(cc(c1)C(F)(F)F)C(=O)Nc1ccccc2C(=O)NC(C3CCCCC3=O)c12	(400 MHz, DMSO-d6) 10.62 (br s, 0.65H), 10.37 (s, 0.35H), 8.55 (s, 0.35H), 8.25 (s, 0.65H), 8.15 (s, 0.35H), 8.13 (s, 0.65H), 8.10 (d, J = 10.4, 1.4 Hz, 1H), 8.02 (d, J = 8.5 Hz, 1H), 7.61 (td, J = 7.3, 1.1 Hz, 1H), 7.57-7.48 (m, 2H), 5.43 (s, 0.65H), 5.11 (d, J = 1.2 Hz, 0.35H), 2.97-2.89 (m, 0.65H), 2.84-2.77 (m, 0.35H), 2.30-2.19 (m, 1.3H), 1.96-1.78 (m, 1H), 1.76 - 1.56 (m, 2H), 1.53-1.39 (m, 2H), 1.38-1.27 (m, 0.35H), 1.25-1.11 (m, 1H), 1.07-0.97 (m, 0.65H) [~2:1 ratio of diastereomers].	435.2	E	
I-2061		FC(F)COc1cc2C(=O)N[C@H](c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl			D	





I-2062		FC(F)CO c1cc2C(=O)N[C@@H](c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl		547.1	A	
I-2063		Fc1ccc(Cl)c(c1)[C@@H]1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(Cl)c3)c12)-c1ccc2ncnn2c1C#N		576.2	C	
I-2064		Fc1ccc(Cl)c(c1)[C@H]1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(Cl)c3)c12)-c1ccc2ncnn2c1C#N		576.2	A	
I-2065		FC(F)c1cn2cc(ncc2n1)-c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl			A	




I-2066		[2H]c1nc2ccc(-c3cc4C(=O)N[C@H](c4c(NC(=O)c4cc(F)cc(c4)C(F)(F)F)c3)c3cc(F)ccc3Cl)c(C#N)n2n1		610.00	D	
I-2067		[2H]c1nc2ccc(-c3cc4C(=O)N[C@@H](c4c(NC(=O)c4cc(F)cc(c4)C(F)(F)F)c3)c3cc(F)ccc3Cl)c(C#N)n2n1		610.00	A	
I-2068		[2H]c1nc2cnc(cn2n1)-c1cc2C(=O)N[C@H](c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl		586.15	D	
I-2069		[2H]c1nc2cnc(cn2n1)-c1cc2C(=O)N[C@@H](c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl		586.15	A	





I-2070		Fc1ccc(Cl)c(c1)[C@@H]1NC(=O)c2cc(Br)cc(NC(=O)C3(CCCC3)c3cc(F)cc(c3)C(F)(F)F)c12			E	
I-2071		Fc1ccc(Cl)c(c1)[C@H]1NC(=O)c2cc(Br)cc(NC(=O)C3(CCCC3)c3cc(F)cc(c3)C(F)(F)F)c12			E	
I-2072		Fc1cc(cc(c1)C(F)(F)F)C(=O)Nc1ccc2C(=O)N[C@H](C3CCC(F)(F)CC3)c12		457.3	E	
I-2073		Fc1cc(cc(c1)C(F)(F)F)C(=O)Nc1ccc2C(=O)N[C@@H](C3CCC(F)(F)CC3)c12		457.3	E	
I-2074		Fc1cc(cc(c1)C(F)(F)F)C(=O)Nc1ccc2C(=O)N[C@H](c12)C12C[C@H]3C[C@H](C[C@H](C3)C1)C2		473.3	E	





I-2075		Fc1cc(cc(c1)C(F)(F)F)C(=O)Nc1ccc c2C(=O)N[C@@H](c12)C12C[C@H]3C[C@H](C[C@H](C3)C1)C2		473.3	D	
I-2076		Fc1cc(cc(c1)C(F)(F)F)C(=O)Nc1ccc c2C(=O)NC(C3NC4CCC3C4)c12	NMR (400 MHz, DMSOd6) 8.98 (s, 1H), 8.48 (dd, J = 8.0, 1.0 Hz, 1H), 8.26 (s, 1H), 8.07 (s, 1H), 8.03 (d, J = 8.9 Hz, 1H), 7.52 (t, J = 7.7 Hz, 1H), 7.43 (dd, J = 7.4, 1.0 Hz, 1H), 4.64 (d, J = 10.0 Hz, 1H), 3.21 (s, 1H), 2.79 (d, J = 3.5 Hz, 1H), 2.03 (d, J = 9.4 Hz, 1H), 1.66-1.47 (m, 2H), 1.29 (m, 4H).	434.3	E	
I-2077		Fc1cc(cc(c1)C(F)(F)F)C(=O)Nc1ccc c2C(=O)NC(N3CCC(F)(F)CC3)c12	NMR (400 MHz, DMSO d6) 10.35 (s, 1H), 8.97 (s, 1H), 8.14 - 8.12 (m, 1H), 8.11 (dd, J = 7.9, 0.9 Hz, 2H), 8.11 - 8.07 (submerged broad dt, J = 9.3, 2 Hz, 1H), 8.05 (broad dt, J = 8.5, 1.4 Hz, 1H), 7.60 (t, J = 7.7 Hz, 1H), 7.51 (dd, J = 7.5, 0.9 Hz, 1H), 5.72 (s, 1H), 2.69-2.57 (m, 2H), 2.45-2.34 (m, 2H), 1.93-1.77 (m, 2H), 1.70 (m, 2H).	458.3	D	
I-2078		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC3CCCS(=O)(=O)C3)c12)-c1ccc2ncnn2c1	NMR (400 MHz, DMSO) 9.49-9.47 (m, 0.6H), 9.47-9.45 (m, 0.4H), 9.09 (s, 0.6H), 9.08 (s. 0.4H), 8.56 (s, 1H), 8.12 (d, J = 1.8 Hz, 0.4H), 8.09 (d, J = 1.8 Hz, 0.6H), 7.95 (s, 0.6H), 7.93 (s, 0.4H), 7.62-7.54 (m, 1H), 7.43 (d, J = 1.2 Hz, 0.4H),	526	E	






			7.42 (d, J = 1.1 Hz, 0.6H), 7.31-7.18 (m, 3H), 7.12 (s, 1H), 6.99 (s, 1H), 6.81 (br s, 1H), 5.93 (s, 0.4H), 5.91 (s, 0.6H), 4.67 (d, J = 8.8 Hz, 0.4H), 4.63 (d, J = 9.5 Hz, 0.6H), 4.27-4.09 (m, 1H), 3.55-3.45 (m, 0.6H), 3.21-2.91 (m, 3H), 2.77-2.68 (m, 0.4H), 2.08-1.60 (m, 3H), 1.56-1.29 (m, 1H). ~3:2 mix of diastereomers.			
I-2079		Fc1ccc(Cl)c(c1)C1NC(=O)c2cccc(NC(=O)[C@H]3CCC[C@H](C3)C(F)(F)F)c12	1H-NMR (400 MHz, DMSO-d6) as a ca. 1:1 mixture of diastereomers, 9.82 (br. s, 1H), 9.73 (br. s, 1H), 9.09 (br. s, 2H), 7.63-7.54 (m, 4H), 7.51-7.42 (m, 2H), 7.41-7.34 (m, 2H), 7.25-7.16 (m, 2H), 6.42 (br. s, 2H), 6.04 (br. s, 2H), 2.30-2.08 (m, 4H), 1.85-1.68 (m, 4H), 1.64-1.50 (m, 2H), 1.40-0.92 (m, 10H).	455.3	C	
I-2080		O[C@H]1C[C@@H](C[C@@H](C1)C(F)(F)F)C(=O)Nc1cc(Br)cc2C(=O)NC(c12)c1cc(F)ccc1Cl	1H-NMR (400 MHz, DMSO-d6) as a ca. 1:1 mixture of diastereomers, 9.98 (br. s, 1H), 9.87 (br. s, 1H), 9.25 (br. s, 2H), 7.71 (d, J = 1.5 Hz, 1H), 7.70 (d, J = 1.5 Hz, 1H), 7.65 (d, J = 1.6 Hz, 1H), 7.54 (d, J = 1.5 Hz, 1H), 7.50-7.41 (m, 2H), 7.23-7.17 (m, 2H), 6.53 (br. s, 2H), 6.01 (br. s, 2H), 4.84 (d, J = 2.6 Hz, 1H), 4.80 (d, J = 2.8 Hz, 1H), 4.04 (br. s, 1H), 4.02 (br. s, 1H), 2.61-2.53 (m, 2H), 2.47-2.38 (m, 2H), 1.80-1.72 (m, 2H), 1.58-1.51 (m, 1H), 1.50-1.44 (m, 1H),	549.1	D	





			1.41-1.17 (m, 7H), 1.11-1.00 (m, 1H).			
I-2081		FC(F)n1cc(cn1)-c1cc(N[C@H]2CCOc3ccccc23)c2[C@H](NC(=O)c2n1)c1cc(F)ccc1Cl		526.1	D	
I-2082		FC(F)n1cc(cn1)-c1cc(N[C@H]2CCOc3ccccc23)c2[C@@H](NC(=O)c2n1)c1cc(F)ccc1Cl		526.1	E	
I-2083		Fc1ccc(Cl)c(c1)[C@H]1NC(=O)c2ccccc(NC(=O)[C@H]3CC[C@H](C3)C(F)(F)F)c12	1H NMR (400 MHz, DMSO-d6) Ã¤ 9.80 (s, 1H), 9.08 (s, 1H), 7.61 (dd, J = 7.4, 1.4 Hz, 1H), 7.58 (t, J = 7.5 Hz, 1H), 7.46 (s, 1H), 7.39 (dd, J = 7.5, 1.5 Hz, 1H), 7.22 (ddd, J = 8.9, 8.0, 3.1 Hz, 1H), 6.51 (s, 1H), 6.05 (s, 1H), 2.83 (d, J = 8.3 Hz, 1H), 2.78 (d, J = 8.9 Hz, 1H), 1.84-1.56 (dt, J = 12.9, 7.8 Hz, 4H), 1.55-1.24 (d, J = 12.4 Hz, 2H).	441.05	E	
I-2084		Fc1ccc(Cl)c(c1)[C@H]1NC(=O)c2ccccc(NC(=O)[C@@H]3CC[C@@H](C3)C(F)(F)F)c12	1H NMR (400 MHz, DMSO-d6)9.78 (s, 1H), 9.10-9.06 (m, 1H), 7.61 (dd, J = 7.4, 1.5 Hz, 1H), 7.58 (t, J = 7.4 Hz, 1H), 7.49 (s, 1H), 7.39 (dd, J = 7.4, 1.5 Hz, 1H), 7.22 (ddd, J = 8.8, 8.0, 3.1 Hz, 1H), 6.47 (s, 1H), 6.07 (s, 1H), 2.80 (h, J = 8.9 Hz, 1H), 2.63 (p, J = 8.3 Hz, 1H), 1.87-1.57 (dt, J = 12.9, 7.8 Hz, 4H),	441.05	E	




			1.55-1.24 (d, J = 12.4 Hz, 2H).			
I-2085		Fc1ccc(Cl)c(c1)[C@@H]1NC(=O)c2cccc(NC(=O)[C@H]3CC[C@H](C3)C(F)(F)F)c12	1H NMR (400 MHz, DMSO-d6) Ã¤ 9.81 (s, 1H), 9.08 (s, 1H), 7.65-7.53 (m, 2H), 7.47 (t, J = 7.2 Hz, 1H), 7.39 (dd, J = 7.4, 1.5 Hz, 1H), 7.22 (td, J = 8.4, 3.1 Hz, 1H), 6.43 (s, 1H), 6.05 (s, 1H), 2.81 (dq, J = 18.3, 9.1 Hz, 1H), 2.58 (q, J = 8.8, 8.1 Hz, 1H), 1.86-1.57 (dt, J = 12.9, 7.8 Hz, 4H), 1.56-1.24 (d, J = 12.4 Hz, 2H).	441.05	D	
I-2086		Fc1ccc(Cl)c(c1)[C@@H]1NC(=O)c2cccc(NC(=O)[C@@H]3CC[C@@H](C3)C(F)(F)F)c12	1H NMR (400 MHz, DMSO-d6) Ã¤ 9.78 (s, 1H), 9.08 (s, 1H), 7.61 (dd, J = 7.5, 1.5 Hz, 1H), 7.58 (t, J = 7.4 Hz, 1H), 7.53-7.46 (m, 1H), 7.39 (dd, J = 7.4, 1.5 Hz, 1H), 7.22 (td, J = 8.4, 3.1 Hz, 1H), 6.48 (s, 1H), 6.06 (s, 1H), 2.80 (dq, J = 18.0, 9.0 Hz, 1H), 2.62 (dt, J = 10.1, 7.7 Hz, 1H), 1.84-1.57 (dt, J = 12.9, 7.8 Hz, 4H), 1.56-1.24 (d, J = 12.4 Hz, 2H).	441.05	D	
I-2087		OB(O)c1cc(F)cc(c1)C(=O)Nc1cccc2C(=O)NC(c12)c1cc(F)ccc1Cl	NMR (400 MHz, DMSO-d6) 10.23 (br s, 0.8H), 10.10 (br s, 0.2H), 9.23-9.01 (m, 1H), 8.36 (s, 1H), 7.91 (br s, 0.6H), 7.89-7.83 (m, 0.6H), 7.75-7.39 (m, 5H), 7.33 (dd, J = 8.8, 5.2 Hz, 1H), 7.29-7.22 (m, 1H), 7.10 (td, J = 8.4, 2.4 Hz, 1H), 7.03-6.85 (m, 1H), 6.55 (br s, 1H), 6.10 (br s, 0.5H), 6.03 (br s, 0.5H).	443	E	





I-2088		OC1(CCCC(C1)C(F)(F)F)C(=O)Nc1cccc2C(=O)NC(c12)c1cc(F)ccc1Cl	1H NMR (400 MHz, acetonitrile-d3) 8.61 (br. s, 1H), 7.80 (dd, J = 7.8, 0.6 Hz, 1H), 7.65 (dd, J = 3.0, 1.0 Hz, 1H), 7.58 (ddd, J = 7.6, 1.4 Hz, 1H), 7.47 (dd, J = 8.9, 5.1 Hz, 1H), 7.24 (br. s, 1H), 7.10 (ddd, J = 8.7, 8.1, 3.1 Hz, 1H), 6.57 (br. s, 1H), 6.20 (br. s, 1H), 3.77 (s, 1H), 3.02-2.79 (m, 1H), 1.89-1.79 (m, 1H), 1.68-1.45 (m, 3H), 1.34-1.06 (m, 4H). 1:1 mixture of diastereomers	471.3	E	
I-2089		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(C#N)c12)-c1ccc(=O)[nH]c1			E	
I-2090		Fc1ccc(Cl)c(c1)[C@@H]1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)C1=CN2CCN=C2C=C1	1H NMR (400 MHz, DMSO-d6) 10.30 (s, 1H), 9.13 (s, 1H), 8.12 (s, 1H), 7.93 (d, J = 8.4 Hz, 1H), 7.80-7.70 (m, 3H), 7.66 (s, 1H), 7.53 (d, J = 9.5 Hz, 1H), 7.33 (dd, J = 8.9, 5.1 Hz, 1H), 7.10 (td, J = 8.4, 3.1 Hz, 1H), 6.71 (s, 1H), 6.44 (d, J = 9.6 Hz, 1H), 5.99 (s, 1H), 4.16 (t, J = 10.3 Hz, 2H), 3.83 (t, J = 10.3 Hz, 2H).	585.1	A	
I-2091		Fc1ccc(Cl)c(c1)[C@H]1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)C1=CN2CCN=C2C=C1	1H NMR (400 MHz, DMSO-d6) 10.30 (s, 1H), 9.13 (s, 1H), 8.12 (s, 1H), 7.93 (d, J = 8.4 Hz, 1H), 7.80-7.70 (m, 3H), 7.66 (s, 1H), 7.53 (d, J = 9.5 Hz, 1H), 7.33 (dd, J = 8.9, 5.1 Hz, 1H), 7.10 (td, J = 8.4, 3.1 Hz, 1H), 6.71 (s, 1H), 6.44 (d, J = 9.6 Hz, 1H), 5.99 (s, 1H), 4.16 (t, J = 10.3 Hz,	585.1	C	






			2H), 3.83 (t, J = 10.3 Hz, 2H).			
I-2092		FC(F)S(=O)(=O)n1cc(cn1)-c1cc2C(=O)N[C@@H](c2cc(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	(400 MHz, DMSO-d6) 10.60 (s, 1 H), 9.26 (s, 1 H), 9.22 (s, 1 H), 8.89 (s, 1 H), 8.22 (s, 1 H), 7.98 (s, 1 H), 7.97 (overlapped d, J = 11.0 Hz, 1 H), 7.76 (d, J = 8.9 Hz, 1 H), 7.73 (overlapped app t, J = 51.3 Hz, 1 H)7.73 (s, 1 H), 7.32 (dd, J = 8.9, 5.2 Hz, 1 H), 7.10 (td, J = 8.5, 3.0 Hz, 1 H), 6.61 (br s, 1 H), 6.01 (s, 1 H).	645.2	B	
I-2093		FC(F)S(=O)(=O)n1cc(cn1)-c1cc2C(=O)N[C@H](c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	(400 MHz, DMSO-d6) 10.60 (br s, 1 H), 9.27 (s, 1 H), 9.22 (s, 1 H), 8.90 (s, 1 H), 8.22 (s, 1 H), 7.98 (s, 1 H), 7.97 (overlapped d, J = 11.4 Hz, 1 H), 7.76 (d, J = 8.9 Hz, 1 H), 7.73 (overlapped app t, j = 51.6 Hz, 1 H), 7.73 (s, 1 H), 7.32 (dd, J = 8.9, 5.2 Hz, 1 H), 7.10 (td, J = 8.4, 3.0 Hz, 1 H), 6.61 (br s, 1 H), 6.00 (br s, 1 H).	645.2	A	
I-2094		OC(CCNC(=O)c1cccc2C(=O)NC(c12)c1cc(F)ccc1Cl)C(F)(F)F	1H NMR (400 MHz, DMSO-d6)9.19 (s, 1H), 8.54-8.47 (m, 1H), 7.87 (d, J = 7.4 Hz, 1H), 7.80 (t, J = 7.8 Hz, 1H), 7.68 (t, J = 7.6 Hz, 1H), 7.45 (d, J = 7.7 Hz, 1H), 7.14 (td, J = 8.4, 3.1 Hz, 1H), 6.37-6.31 (m, 2H), 6.10 (dd, J = 8.8, 6.6 Hz, 1H), 3.86-3.79 (m, 1H), 3.27-3.10 (m, 1H), 3.10-2.96 (m, 1H), 1.51-1.20 (m, 2H).	431.15	E	
I-2095		Cn1c(Cl)cc(cc1=O)C(=O)Nc1cc(Br)cc2C(=O)N[C@H](c12)c1cc	1H NMR (400 MHz, DMSO-d6)10.43 (s, 1H), 9.30 (s, 1H), 7.82 (d, J = 1.7 Hz, 1H), 7.71 (d, J = 1.8 Hz, 1H), 7.47-7.39 (m, 1H), 7.19 (ddd, J = 8.8, 7.9,	525.9	E	





		(F)ccc1Cl	3.1 Hz, 1H), 6.66-6.48 (m, 3H), 5.97 (s, 1H), 3.57 (s, 3H).			
I-2096		Cn1c(Cl)cc(cc1=O)C(=O)Nc1cc(Br)cc2C(=O)N[C@@H](c12)c1cc(F)ccc1Cl	1H NMR (400 MHz, DMSO-d6)10.43 (s, 1H), 9.30 (s, 1H), 7.82 (d, J = 1.7 Hz, 1H), 7.71 (d, J = 1.8 Hz, 1H), 7.43 (t, J = 7.1 Hz, 1H), 7.19 (ddd, J = 8.8, 7.9, 3.1 Hz, 1H), 6.70-6.48 (m, 3H), 5.97 (s, 1H), 3.57 (s, 3H).	525.9	E	
I-2097		Fc1ccc(Cl)c(c1)C1NC(=O)c2cccc(C#Cc3ccccc3)c12	1H NMR (400 MHz, DMSO-d6) 9.24 (s, 1H), 7.80 (d, J = 7.5 Hz, 1H), 7.75 (d, J = 7.5 Hz, 1H), 7.63 (t, J = 7.6 Hz, 1H), 7.52 (s, 1H), 7.45 - 7.37 (m, 3H), 7.28 (dt, J = 9.6, 3.2 Hz, 2H), 7.23 (dd, J = 8.6, 3.0 Hz, 1H), 6.16 (s, 1H).	362	E	
I-2098		CN(C)S(=O)(=O)c1cc(cc2C(=O)N[C@H](c12)c1cc(F)ccc1Cl)-c1ccc2ncnn2c1	1H NMR (400 MHz, DMSO-d6) 9.61 (dd, J = 1.9, 0.9 Hz, 1H), 9.57 (s, 1H), 8.61 (s, 1H), 8.47 (s, 1H), 8.26-8.16 (m, 2H), 8.00 (d, J = 9.2 Hz, 1H), 7.60 (s, 1H), 7.22 (s, 1H), 6.39 (s, 1H), 2.62 (s, 6H).	486.05	E	
I-2099		CN(C)S(=O)(=O)c1cc(cc2C(=O)N[C@@H](c12)c1cc(F)ccc1Cl)-c1ccc2ncnn2c1	1H NMR (400 MHz, DMSO-d6) 9.61 (dd, J = 1.9, 0.9 Hz, 1H), 9.57 (s, 1H), 8.61 (s, 1H), 8.47 (s, 1H), 8.26-8.16 (m, 2H), 8.00 (d, J = 9.2 Hz, 1H), 7.60 (s, 1H), 7.22 (s, 1H), 6.39 (s, 1H), 2.62 (s, 6H).	486.05	E	
I-2100		NS(=O)(=O)c1cc(cc2C(=O)N[C@H](c12)c1cc(F)ccc1Cl)-c1ccc2ncnn2c1	1H NMR (400 MHz, DMSO-d6) 9.56 (dd, J = 1.8, 0.9 Hz, 1H), 9.48 (s, 1H), 8.62 (s, 1H), 8.55 (s, 1H), 8.42 (d, J = 1.7 Hz, 1H), 8.20 (dd, J = 9.3, 1.9 Hz, 1H), 8.06 (d, J = 9.3 Hz, 1H), 7.56 (s, 2H),	458	E	




			7.21 (td, J = 8.4, 3.0 Hz, 1H), 6.37 (s, 2H).			
I-2101		NS(=O)(=O)c1cc(cc2C(=O)N[C@@H](c12)c1cc(F)ccc1Cl)-c1ccc2ncnn2c1	1H NMR (400 MHz, DMSO-d6) 9.56 (dd, J = 1.8, 0.9 Hz, 1H), 9.48 (s, 1H), 8.62 (s, 1H), 8.55 (s, 1H), 8.42 (d, J = 1.7 Hz, 1H), 8.20 (dd, J = 9.3, 1.9 Hz, 1H), 8.06 (d, J = 9.3 Hz, 1H), 7.56 (s, 2H), 7.21 (td, J = 8.4, 3.0 Hz, 1H), 6.37 (s, 2H).	458	E	
I-2102		O[C@H]1CC[C@H](C1)C(=O)Nc1cc(Br)cc2C(=O)N[C@H](c12)c1cc(F)ccc1Cl	1H NMR (400 MHz, DMSO-d6) 9.71 (s, 1H), 9.23 (s, 1H), 7.70 (s, 1H), 7.64 (d, J = 1.7 Hz, 1H), 7.49 (s, 1H), 7.24 (td, J = 8.4, 3.1 Hz, 1H), 6.67 (s, 1H), 6.01 (s, 1H), 4.62 (d, J = 4.7 Hz, 1H), 4.04 - 3.96 (m, 1H), 2.42 (q, J = 8.2 Hz, 1H), 1.87 - 1.75 (m, 1H), 1.59 (d, J = 6.6 Hz, 1H), 1.43 (s, 3H), 1.34 (ddd, J = 13.8, 8.7, 6.3 Hz, 1H), 1.24 (s, 1H).	467.05	E	
I-2103		O[C@H]1CC[C@H](C1)C(=O)Nc1cc(Br)cc2C(=O)N[C@@H](c12)c1cc(F)ccc1Cl	1H NMR (400 MHz, DMSO-d6) 9.67 (s, 1H), 9.23 (s, 1H), 7.72 - 7.61 (m, 2H), 7.48 (s, 1H), 7.24 (td, J = 8.5, 3.1 Hz, 1H), 6.67 (s, 1H), 6.01 (s, 1H), 4.61 (d, J = 4.6 Hz, 1H), 4.00 (q, J = 5.6 Hz, 1H), 2.42 (q, J = 8.3 Hz, 1H), 1.75 (dt, J = 13.9, 7.3 Hz, 1H), 1.64 - 1.37 (m, 2H), 1.42 (s, 3H), 1.24 (s, 1H).	467.05	E	
I-2104		O[C@@H]1CC[C@@H](C1)C(=O)Nc1cc(Br)cc2C(=O)N[C@H](c12)c1cc(F)ccc1Cl	1H NMR (400 MHz, DMSO-d6) 9.71 (s, 1H), 9.23 (s, 1H), 7.70 (d, J = 1.7 Hz, 1H), 7.64 (d, J = 1.7 Hz, 1H), 7.49 (s, 1H), 7.24 (td, J = 8.4, 3.0 Hz, 1H), 6.67 (s, 1H), 6.01 (s, 1H), 4.62 (d, J = 4.7 Hz, 1H), 3.99 (q, J =	467.05	E	




			5.6 Hz, 1H), 2.42 (q, J = 8.3 Hz, 1H), 1.81 (ddd, J = 14.0, 8.5, 6.2 Hz, 1H), 1.60 (s, 1H), 1.44 (s, 3H), 1.35 (ddd, J = 12.9, 8.6, 6.1 Hz, 1H).			
I-2105		O[C@@H]1CC[C@@H](C1)C(=O)Nc1cc(Br)cc2C(=O)N[C@@H](c12)c1cc(F)ccc1Cl	1H NMR (400 MHz, DMSO-d6) 9.67 (s, 1H), 9.23 (s, 1H), 7.72 - 7.64 (m, 2H), 7.48 (s, 1H), 7.24 (td, J = 8.4, 3.1 Hz, 1H), 6.68 (s, 1H), 6.01 (s, 1H), 4.62 (d, J = 4.6 Hz, 1H), 4.00 (q, J = 5.6 Hz, 1H), 2.42 (q, J = 8.3 Hz, 1H), 1.75 (dt, J = 13.9, 7.1 Hz, 1H), 1.64 - 1.49 (m, 1H), 1.53 - 1.40 (m, 1H), 1.39 (dd, J = 9.4, 4.9 Hz, 3H), 1.17 (t, J = 7.2 Hz, 1H).	467.05	E	
I-2106		Fc1ccc(Cl)c(c1)C1NC(=O)c2cccc(\C=C\c3ccccc3)c12	1H NMR (400 MHz, DMSO-d6) 9.17 (s, 1H), 7.97 (d, J = 7.7 Hz, 1H), 7.69 (d, J = 7.4 Hz, 1H), 7.60 (m, 2H), 7.42 - 7.32 (m, 4H), 7.28 (td, J = 5.9, 2.6 Hz, 1H), 7.24 - 7.17 (m, 2H), 6.91 (d, J = 16.3 Hz, 1H), 6.76 - 6.40 (s, 1H), 6.28 (s, 1H).	364.1	E	
I-2107		Cc1cc(=O)[nH]cc1C(=O)Nc1cc(Br)cc2C(=O)N[C@@H](c12)c1cc(F)ccc1Cl	1H NMR (400 MHz, DMSO-d6) Ã¤ 11.73 (s, 1H), 10.04 (s, 1H), 9.24 (s, 1H), 7.74 (d, J = 1.7 Hz, 1H), 7.67-7.62 (m, 1H), 7.46 (dd, J = 8.8, 5.1 Hz, 1H), 7.21 (td, J = 8.4, 3.1 Hz, 1H), 6.90 (s, 1H), 6.64 (s, 1H), 6.16 (s, 1H), 5.96 (s, 1H), 2.11 (s, 3H).	492.15	E	





I-2108		Cc1cc(=O)[nH]cc1C(=O)Nc1cc(Br)cc2C(=O)N[C@H](c12)c1cc(F)ccc1Cl	1H NMR (400 MHz, DMSO-d6) Ã¤ 11.72 (s, 1H), 10.05 (s, 1H), 9.24 (s, 1H), 7.74 (d, J = 1.7 Hz, 1H), 7.64 (s, 1H), 7.46 (dd, J = 8.7, 5.1 Hz, 1H), 7.21 (td, J = 8.4, 3.1 Hz, 1H), 6.90 (s, 1H), 6.65 (s, 1H), 6.16 (s, 1H), 5.97 (s, 1H), 2.11 (s, 3H).	492.15	E	
I-2109		Fc1cc(cc(c1)C(F)(F)F)C(=O)Nc1cccc2C(=O)NC(CC3CCCC3)c12	(400 MHz, DMSO-d6) 10.78 (s, 1H), 8.88 (s, 1H), 8.17 (s, 1H), 8.12 (d, J = 8.9 Hz, 1H), 8.04 (d, J = 8.5 Hz, 1H), 7.60-7.50 (m, 3H), 4.77 (d, J = 7.2 Hz, 1H), 1.93-1.81 (m, 1H), 1.81-1.72 (m, 1H), 1.69-1.60 (m, 1H), 1.51-1.41 (m, 1H), 1.39-1.22 (m, 5H), 1.04 (tt, J = 15.2, 7.4 Hz, 1H), 0.94-0.81 (m, 1H) .	421.4	D	
I-2110		O[C@H]1CCCCC1[C@@H]1NC(=O)c2cccc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	(400 MHz, DMSO-d6) 10.90 (s, 1H), 8.53 (s, 1H), 8.10 (s, 1H), 8.03 (t, J = 8.5 Hz, 2H), 7.71 (dd, J = 6.8, 2.1 Hz, 1H), 7.55-7.48 (m, 2H), 4.75 (d, J = 3.9 Hz, 1H), 4.25 (br s, 1H), 3.57 (s, 1H), 1.73-1.41 (m, 5H), 1.32-1.20 (m. 2H), 1.16-1.08 (m, 1H), 1.06 - 0.94 (m, 1H) [single diastereomer]	437.4	E	
I-2111		Fc1ccc(Cl)c(c1)C1NC(=O)c2cccc(NC(=O)N3CCn4c(C3)nnc4C(F)(F)F)c12	NMR (400 MHz, DMSO-d6) 9.05 (br s, 1H), 8.98 (br s, 1H), 7.56 (d, J = 2.2 Hz, 2H), 7.34-7.25 (m, 1H), 7.19 (dd, J = 7.6, 5.4 Hz, 1H), 6.98 (td, J = 8.1, 2.4 Hz, 1H), 6.37 (br s, 1H), 5.95 (br s, 1H), 4.74 (d, J = 17.1 Hz, 1H), 4.43 (d, J = 16.9 Hz, 1H), 4.13-3.98 (m, 1H), 3.97-3.87 (m,	495	E	




			1H), 3.86-3.74 (m, 1H), 3.68-3.55 (m, 1H).			
I-2112		Fc1ccc(Cl)c(c1)C1NC(=O)c2cccc(NC(=O)c3ncc(Br)s3)c12	NMR (400 MHz, DMSO-d6) 10.53 (br s, 1H), 9.13 (br s, 1H), 8.12 (s, 1H), 7.68 (d, J = 7.9 Hz, 1H), 7.64-7.51 (m, 2H), 7.33 (dd, J = 8.7, 4.9 Hz, 1H), 7.09 (td, J = 8.1, 3.1 Hz, 1H), 6.51 (br s, 1H), 6.07 (br s, 1H).	468	E	
I-2113		O[C@@]1(CCCN(C1)C(=O)Nc1cccc2C(=O)N[C@@H](c12)c1cc(F)ccc1Cl)C(F)(F)F		472	E	
I-2114		O[C@]1(CCCN(C1)C(=O)Nc1cccc2C(=O)N[C@H](c12)c1cc(F)ccc1Cl)C(F)(F)F		472.1	E	
I-2115		O[C@]1(CCCN(C1)C(=O)Nc1cccc2C(=O)N[C@@H](c12)c1cc(F)ccc1Cl)C(F)(F)F		472.1	E	
I-2116		O[C@@]1(CCCN(C1)C(=O)Nc1cccc2C(=O)N[C@H](c12)c1cc(F)ccc1Cl)C(F)(F)F		472.1	E	




I-2117		CC(C)(O)C12CC(C1)(C2)C(=O)Nc1cccc2C(=O)NC(c12)c1cc(F)ccc1Cl	NMR (400 MHz, DMSO-d6) 9.38 (s, 1H), 9.05 (br s, 1H), 7.60 (dd, J = 7.4, 0.9 Hz, 1H), 7.55 (app. t, J = 7.5 Hz, 1H), 7.54-7.40 (m, 1H), 7.39 (dd, J = 7.6, 1.1 Hz, 1H), 7.24 (td, J = 8.4, 3.1 Hz, 1H), 6.56 (br s, 1H), 5.98 (br s, 1H), 4.17 (br s, 1H), 1.58 (s, 6H), 0.98 (s, 6H).	429	E	
I-2118		OC(C1CC1)(C1CC1)C12CC(C1)(C2)C(=O)Nc1cccc2C(=O)NC(c12)c1cc(F)ccc1Cl	NMR (400 MHz, DMSO-d6) 9.34 (s, 1H), 9.04 (br s, 1H), 7.59 (dd, J = 7.4, 1.0 Hz, 1H), 7.55 (app. t, J = 7.5 Hz, 1H), 7.51-7.42 (m, 1H), 7.40 (dd, J = 7.6, 1.2 Hz, 1H), 7.27-7.20 (m, 1H), 6.60 (br s, 1H), 5.99 (br s, 1H), 3.51 (s, 1H), 1.70 (s, 6H), 0.72-0.60 (m, 2H), 0.32-0.21 (m, 4H), 0.22-0.09 (m, 4H).	481	E	
I-2119		Fc1ccc(Cl)c(c1)[C@H]1NC(=O)c2cccc(NC(=O)CCC(F)(F)F)c12	1H NMR (400 MHz, DMSO-d6) 9.85 (s, 1H), 9.09 (s, 1H), 7.63 (m, 2H), 7.58 (t, J = 7.5 Hz, 1H), 7.50 (s, 1H), 7.39 (d, J = 7.6 Hz, 1H), 7.24 (td, J = 8.4, 3.1 Hz, 1H), 5.97 (s, 1H), 2.33 (dq, J = 14.9, 10.4, 8.9 Hz, 3H), 2.17 (q, J = 9.3, 8.6 Hz, 1H).	401.15	E	
I-2120		Fc1ccc(Cl)c(c1)[C@@H]1NC(=O)c2cccc(NC(=O)CCC(F)(F)F)c12	1H NMR (400 MHz, DMSO-d6) 9.85 (s, 1H), 9.09 (s, 1H), 7.63 (m, 2H), 7.58 (t, J = 7.5 Hz, 1H), 7.50 (s, 1H), 7.39 (d, J = 7.6 Hz, 1H), 7.24 (td, J = 8.4, 3.1 Hz, 1H), 5.97 (s, 1H), 2.33 (dq, J = 14.9, 10.4, 8.9 Hz, 3H), 2.17 (q, J = 9.3, 8.6 Hz, 1H).	401.2	E	





I-2121		CC(C)(O)c1cc2C(=O)N[C@@H](c2c(NC(=O)N2C[C@H](O)c3ccccc23)c1)c1cc(F)ccc1Cl	1H NMR (400 MHz, DMSO-d6) 9.01 (s, 1H), 8.50 (s, 1H), 7.74 - 7.63 (m, 2H), 7.56 (d, J = 1.7 Hz, 1H), 7.38 - 7.28 (m, 2H), 7.23 - 7.14 (m, 1H), 7.09 (td, J = 8.4, 3.1 Hz, 1H), 6.95 (t, J = 7.4 Hz, 1H), 6.53 (s, 1H), 6.07 (s, 1H), 5.60 (d, J = 5.0 Hz, 1H), 5.26 (s, 1H), 5.15 (dd, J = 8.4, 4.3 Hz, 1H), 3.98 (dd, J = 11.1, 8.0 Hz, 1H), 3.20 (dt, J = 10.7, 5.2 Hz, 1H), 1.50 (s, 6H).	496.2	D	
I-2122		CC(C)(O)c1cc2C(=O)N[C@@H](c2c(NC(=O)N2C[C@@H](O)c3ccccc23)c1)c1cc(F)ccc1Cl	1H NMR (400 MHz, DMSO-d6) 8.99 (s, 1H), 8.63 (s, 1H), 7.84 (d, J = 8.2 Hz, 1H), 7.66 (d, J = 1.5 Hz, 1H), 7.51 (s, 1H), 7.40 - 7.30 (m, 2H), 7.24 (t, J = 7.7 Hz, 1H), 7.16 (td, J = 8.4, 3.1 Hz, 1H), 6.98 (t, J = 7.5 Hz, 1H), 6.54 (s, 1H), 5.98 (s, 1H), 5.64 (d, J = 6.0 Hz, 1H), 5.27 (s, 1H), 5.09 (s, 1H), 3.72 (dd, J = 11.2, 3.5 Hz, 1H), 3.21 (s, 1H), 1.50 (s, 6H).	496.2	E	
I-2123		CC(C)(O)c1cc2C(=O)N[C@H](c2c(NC(=O)N2C[C@H](O)c3ccccc23)c1)c1cc(F)ccc1Cl	1H NMR (400 MHz, DMSO-d6) 9.02 (s, 1H), 8.52 (s, 1H), 7.74 - 7.65 (m, 2H), 7.56 (d, J = 1.6 Hz, 1H), 7.38 - 7.28 (m, 2H), 7.23 - 7.14 (m, 1H), 7.10 (td, J = 8.4, 3.1 Hz, 1H), 6.99 - 6.91 (m, 1H), 6.53 (s, 1H), 6.08 (s, 1H), 5.62 (s, 1H), 5.27 (s, 1H), 5.15 (dd, J = 8.2, 3.9 Hz, 1H), 3.99 (dd, J = 11.1, 8.0 Hz, 1H), 3.21 (s, 1H), 1.50 (s, 6H).	496.2	C	




I-2124		CC(C)(O)c1cc2C(=O)N[C@H](c2cc(NC(=O)N2C[C@@H](O)c3ccccc23)c1)c1cc(F)ccc1Cl	1H NMR (400 MHz, DMSO-d6) 8.99 (s, 1H), 8.63 (s, 1H), 7.84 (d, J = 8.2 Hz, 1H), 7.66 (d, J = 1.5 Hz, 1H), 7.51 (s, 1H), 7.40 - 7.30 (m, 2H), 7.24 (t, J = 7.7 Hz, 1H), 7.16 (td, J = 8.3, 3.1 Hz, 1H), 6.98 (t, J = 7.4 Hz, 1H), 6.53 (s, 1H), 5.98 (s, 1H), 5.65 (s, 1H), 5.27 (s, 1H), 5.08 (s, 1H), 3.72 (dd, J = 11.4, 3.5 Hz, 1H), 3.21 (s, 1H), 1.50 (s, 6H) .	496.2	A	B
I-2125		CNc1nc2ccc(cn2n1)-c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	1H NMR (400 MHz, DMSO-d6) 10.60 (s, 1H), 9.39-8.97 (m, 2H), 8.04 (d, J = 1.6 Hz, 1H), 7.97 (dt, J = 8.7, 2.1 Hz, 1H), 7.93-7.85 (m, 2H), 7.81-7.69 (m, 2H), 7.54-7.47 (m, 1H), 7.34 (dd, J = 8.9, 5.2 Hz, 1H), 7.11 (td, J = 8.4, 3.1 Hz, 1H), 6.58 (q, J = 4.9 Hz, 2H), 6.05 (s, 1H), 2.86 (d, J = 4.9 Hz, 3H)	613.15	A	A
I-2126		O[C@H]1CN(C(=O)Nc2ccccc3C(=O)N[C@H](c23)c2cc(F)ccc2Cl)c2ccc(F)cc12	1H NMR (400 MHz, DMSO-d6) 9.06 (s, 1H), 8.50 (s, 1H), 7.70 (dd, J = 8.8, 4.7 Hz, 1H), 7.60-7.57 (t, J = 7.4 Hz, 2H), 7.44 (dd, J = 7.3, 1.6 Hz, 1H), 7.35 (dd, J = 8.9, 5.2 Hz, 1H), 7.15-7.03 (m, 3H), 6.57 (s, 1H), 6.09 (s, 1H), 5.73 (d, J = 5.1 Hz, 1H), 5.15 (dt, J = 8.4, 4.5 Hz, 1H), 3.97 (dd, J = 11.0, 8.1 Hz, 1H), 3.23 (dd, J = 11.1, 4.1 Hz, 1H).	456.05	C	




I-2127		O[C@@H]1CN(C(=O)Nc2cccc3C(=O)N[C@H](c23)c2cc(F)ccc2Cl)c2ccc(F)cc12	1H NMR (400 MHz, DMSO-d6) 9.04 (s, 1H), 8.62 (s, 1H), 7.83 (dd, J = 8.8, 4.7 Hz, 1H), 7.62-7.52 (m, 2H), 7.37 (dd, J = 8.8, 5.3 Hz, 2H), 7.21-7.10 (m, 2H), 7.08 (td, J = 9.0, 2.8 Hz, 1H), 6.53 (s, 1H), 6.00 (s, 1H), 5.76 (d, J = 6.0 Hz, 1H), 5.08 (s, 1H), 3.71 (dd, J = 11.3, 3.6 Hz, 1H), 3.31 (s, 1H).	456.05	A	A
I-2128		O[C@H]1CN(C(=O)Nc2cccc3C(=O)N[C@@H](c23)c2cc(F)ccc2Cl)c2ccc(F)cc12	1H NMR (400 MHz, DMSO-d6) 9.04 (s, 1H), 8.63 (s, 1H), 7.83 (dd, J = 8.9, 4.7 Hz, 1H), 7.62-7.52 (m, 2H), 7.37 (dd, J = 8.8, 5.6 Hz, 2H), 7.15-7.08 (m, 3H), 6.54 (s, 1H), 6.00 (s, 1H), 5.76 (d, J = 6.0 Hz, 1H), 5.08 (dt, J = 8.2, 4.4 Hz, 1H), 3.71 (dd, J = 11.3, 3.7 Hz, 1H), 3.25 (s, 1H).	456.1	E	
I-2129		O[C@@H]1CN(C(=O)Nc2cccc3C(=O)N[C@@H](c23)c2cc(F)ccc2Cl)c2ccc(F)cc12	1H NMR (400 MHz, DMSO-d6) 9.06 (s, 1H), 8.50 (s, 1H), 7.70 (dd, J = 8.9, 4.7 Hz, 1H), 7.64-7.53 (m, 2H), 7.44 (dd, J = 7.3, 1.6 Hz, 1H), 7.35 (dd, J = 8.9, 5.2 Hz, 1H), 7.12-6.98 (m, 3H), 6.56 (s, 1H), 6.09 (s, 1H), 5.73 (d, J = 5.0 Hz, 1H), 5.15 (dt, J = 8.6, 4.5 Hz, 1H), 3.97 (dd, J = 11.1, 8.1 Hz, 1H), 3.23 (dd, J = 11.0, 4.1 Hz, 1H).	456.05	E	
I-2130		Nc1cc2C(=O)N[C@@H](c2c(NC(=O)N2C[C@H](O)c3ccccc23)c1)c1cc(F)ccc1Cl	1H NMR (400 MHz, DMSO-d6) 8.80 (s, 1H), 8.16 (s, 1H), 7.69 (d, J = 8.1 Hz, 1H), 7.36 - 7.26 (m, 2H), 7.22 - 7.13 (m, 1H), 7.06 (ddd, J = 8.8, 7.9, 3.1 Hz, 1H), 6.93 (td, J = 7.4, 1.1 Hz, 1H), 6.73 (dd, J = 16.6, 2.0 Hz,	453.15	D	





			2H), 6.53 (s, 1H), 5.94 (s, 1H), 5.59 (d, J = 5.3 Hz, 1H), 5.50 (s, 2H), 5.12 (dt, J = 8.7, 4.5 Hz, 1H), 3.85 (dd, J = 11.1, 8.0 Hz, 1H), 3.27 (dd, J = 11.0, 3.9 Hz, 1H).			
I-2131		Nc1cc2C(=O)N[C@@H](c2c(NC(=O)N2C[C@@H](O)c3ccccc23)c1)c1cc(F)ccc1Cl	1H NMR (400 MHz, DMSO-d6) 8.77 (s, 1H), 8.30 (s, 1H), 7.82 (d, J = 8.1 Hz, 1H), 7.37 - 7.28 (m, 2H), 7.26 - 7.17 (m, 1H), 7.12 (td, J = 8.3, 3.1 Hz, 1H), 6.95 (t, J = 7.4 Hz, 1H), 6.74 (d, J = 2.0 Hz, 1H), 6.63 (d, J = 2.0 Hz, 1H), 6.52 (s, 1H), 5.84 (s, 1H), 5.66 (s, 1H), 5.50 (s, 2H), 5.07 (dd, J = 8.1, 3.5 Hz, 1H), 3.63 (dd, J = 11.3, 3.6 Hz, 1H), 3.25 (d, J = 9.9 Hz, 1H).	453.15	D	
I-2132		Nc1cc2C(=O)N[C@H](c2c(NC(=O)N2C[C@H](O)c3ccccc23)c1)c1cc(F)ccc1Cl	1H NMR (400 MHz, DMSO-d6) 8.80 (s, 1H), 8.17 (s, 1H), 7.69 (d, J = 8.1 Hz, 1H), 7.36 - 7.26 (m, 2H), 7.17 (td, J = 7.7, 1.4 Hz, 1H), 7.10 - 7.01 (m, 1H), 6.93 (td, J = 7.4, 1.0 Hz, 1H), 6.73 (dd, J = 16.7, 2.0 Hz, 2H), 6.53 (s, 1H), 5.94 (s, 1H), 5.59 (d, J = 5.3 Hz, 1H), 5.50 (s, 2H), 5.12 (dt, J = 8.4, 4.3 Hz, 1H), 3.85 (dd, J = 11.1, 8.0 Hz, 1H), 3.27 (dd, J = 11.0, 3.9 Hz, 1H).	453.1	A	
I-2133		Nc1cc2C(=O)N[C@H](c2c(NC(=O)N2C[C@@H](O)c3ccccc23)c1)c1cc(F)ccc1Cl	1H NMR (400 MHz, DMSO-d6) 8.76 (s, 1H), 8.28 (s, 1H), 7.82 (d, J = 8.1 Hz, 1H), 7.37 - 7.28 (m, 2H), 7.22 (t, J = 7.7 Hz, 1H), 7.12 (td, J = 8.3, 3.1 Hz, 1H), 7.00 - 6.91 (m, 1H), 6.74 (d, J = 2.0 Hz, 1H), 6.62 (d, J = 2.0 Hz, 1H), 6.52 (s,	453.1	A	A




			1H), 5.84 (s, 1H), 5.60 (d, J = 6.1 Hz, 1H), 5.49 (s, 2H), 5.07 (s, 1H), 3.62 (dd, J = 11.3, 3.6 Hz, 1H), 3.24 (s, 1H).			
I-2134		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(OCC3CC3)cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	1H NMR (400 MHz, DMSO-d6) 10.43 (s, 1H), 9.11 (s, 1H), 7.95 (d, J = 8.4 Hz, 1H), 7.72 (d, J = 9.1 Hz, 1H), 7.64 (s, 1H), 7.31 (dd, J = 8.9, 5.1 Hz, 1H), 7.18 (d, J = 2.3 Hz, 1H), 7.13 - 7.05 (m, 2H), 6.56 (s, 1H), 5.93 (s, 0H), 3.96 (d, J = 7.0 Hz, 2H), 1.27 (dd, J = 12.1, 7.1 Hz, 1H), 0.65 - 0.56 (m, 2H), 0.42 - 0.33 (m, 2H).	537.15	B	
I-2135		FC(F)n1cc(cn1)-c1cc2C(=O)NC(c2c(c1)-c1cn2ccc(cc2n1)C(F)(F)F)c1cc(F)ccc1Cl	1H NMR (400 MHz, DMSO-d6) Ã¤ 9.28 (s, 1H), 9.04 (s, 1H), 8.72 (d, J = 7.2 Hz, 1H), 8.66 (s, 1H), 8.56 (s, 1H), 8.47 (s, 1H), 8.14 (d, J = 1.7 Hz, 1H), 8.06 (s, 0H), 7.91 (s, 0H), 7.79 (d, J = 21.3 Hz, 1H), 7.38 (s, 1H), 7.17 (dd, J = 7.2, 1.9 Hz, 2H), 6.96 (td, J = 8.4, 3.1 Hz, 1H), 6.70 (s, 1H).	562	D	
I-2136		OC1(CCCC(C1)C(=O)Nc1cccc2C(=O)NC(c12)c1cc(F)ccc1Cl)C(F)(F)F		471.2	E	




I-2137		OC(=O)c1cc(ccn1)-c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	1H NMR (400 MHz, DMSO-d6) 10.65 (s, 1H), 9.30 (s, 1H), 8.44 (dd, J=51.6, 28.1 Hz, 2H), 8.26-7.91 (m, 5H), 7.78 (d, J=8.8 Hz, 1H), 7.71 (s, 1H), 7.34 (dd, J=8.9, 5.2 Hz, 1H), 7.12 (d, J=8.1 Hz, 1H), 6.09 (s, 1H).	588.25	A	
I-2138		C[C@@H](CCC(F)(F)F)C(=O)Nc1cccc2C(=O)N[C@@H](c12)c1cc(F)ccc1Cl	1H NMR (400 MHz, DMSO-d6) 9.80 (s, 1H), 9.10 (s, 1H), 7.65-7.55 (m, 2H), 7.47 (td, J = 7.5, 3.0 Hz, 2H), 7.21 (td, J = 8.4, 3.1 Hz, 1H), 6.43 (s, 1H), 6.15 (s, 1H), 2.28 (p, J = 6.9 Hz, 1H), 2.09-1.89 (s, 2H), 1.51-1.38 (m, 1H), 1.32 (tt, J = 12.2, 5.9 Hz, 1H), 0.85 (d, J = 6.8 Hz, 3H).	429.2	D	
I-2139		C[C@H](CCC(F)(F)F)C(=O)Nc1cccc2C(=O)N[C@H](c12)c1cc(F)ccc1Cl	1H NMR (400 MHz, DMSO-d6) 9.82 (s, 1H), 9.10 (s, 1H), 7.65-7.54 (m, 2H), 7.50 (dd, J = 8.9, 5.1 Hz, 1H), 7.43 (dd, J = 7.4, 1.5 Hz, 1H), 7.21 (td, J = 8.4, 3.1 Hz, 1H), 6.46 (s, 1H), 6.10 (s, 1H), 2.27 (dq, J = 13.9, 6.6 Hz, 1H), 2.15-1.85 (m, 2H), 1.60 (dddd, J = 13.1, 11.2, 8.3, 4.9 Hz, 1H), 1.39 (ddt, J = 13.3, 11.2, 5.5 Hz, 1H), 0.77 (d, J = 6.9 Hz, 3H).	429.2	E	
I-2140		C[C@H](CCC(F)(F)F)C(=O)Nc1cccc2C(=O)N[C@@H](c12)c1cc(F)ccc1Cl	1H NMR (400 MHz, DMSO-d6) 9.80 (s, 1H), 9.10 (s, 1H), 7.65-7.55 (m, 2H), 7.47 (td, J = 8.3, 7.2, 3.5 Hz, 2H), 7.21 (ddd, J = 8.8, 8.0, 3.1 Hz, 1H), 6.43 (s, 1H), 6.15 (s, 1H), 2.27 (p, J = 6.9 Hz, 1H), 2.09-1.89 (s, 2H), 1.51-1.38 (m, 1H), 1.32 (tq, J = 12.3, 5.8 Hz,	429.2	E	





			1H), 0.85 (d, J = 6.9 Hz, 3H).			
I-2141		C[C@@H](CCC(F)(F)F)C(=O)Nc1cccc2C(=O)N[C@H](c12)c1cc(F)ccc1Cl	1H NMR (400 MHz, DMSO-d6) 9.82 (s, 1H), 9.10 (s, 1H), 7.65-7.54 (m, 2H), 7.50 (dd, J = 8.9, 5.1 Hz, 1H), 7.43 (dd, J = 7.4, 1.5 Hz, 1H), 7.21 (td, J = 8.4, 3.1 Hz, 1H), 6.46 (s, 1H), 6.10 (s, 1H), 2.27 (dq, J = 13.9, 6.6 Hz, 1H), 2.15-1.85 (m, 2H), 1.60 (dddd, J = 13.1, 11.2, 8.3, 4.9 Hz, 1H), 1.39 (ddt, J = 13.3, 11.2, 5.5 Hz, 1H), 0.77 (d, J = 6.9 Hz, 3H).	429.2	E	
I-2142		O[C@@H]1CN(C(=O)Nc2cccc3C(=O)N[C@H](c23)c2cc(F)ccc2Cl)c2cccc(F)c12	1H NMR (400 MHz, DMSO-d6) 9.05 (s, 1H), 8.71 (s, 1H), 7.74 (d, J = 8.1 Hz, 1H), 7.64-7.53 (m, 2H), 7.43-7.33 (m, 2H), 7.31 (td, J = 8.2, 5.9 Hz, 1H), 7.17 (td, J = 8.4, 3.1 Hz, 1H), 6.78 (t, J = 8.6 Hz, 1H), 6.54 (s, 1H), 6.01 (s, 1H), 5.80 (d, J = 6.8 Hz, 1H), 5.24 (td, J = 7.2, 2.2 Hz, 1H), 3.80 (dd, J = 11.5, 2.3 Hz, 1H), 3.21 (s, 1H).	456.2	A	A
I-2143		O[C@@H]1CN(C(=O)Nc2cccc3C(=O)N[C@@H](c23)c2cc(F)ccc2Cl)c2cccc(F)c12	1H NMR (400 MHz, DMSO-d6) 9.09 (s, 1H), 8.59 (s, 1H), 7.65-7.54 (m, 2H), 7.53-7.42 (m, 2H), 7.35 (dd, J = 8.9, 5.1 Hz, 1H), 7.24 (td, J = 8.2, 5.9 Hz, 1H), 7.09 (td, J = 8.4, 3.1 Hz, 1H), 6.74 (t, J = 8.6 Hz, 1H), 6.56 (s, 1H), 6.10 (s, 1H), 5.75 (d, J = 5.6 Hz, 1H), 5.30 (ddd, J = 7.8, 5.7, 2.4 Hz, 1H), 3.92 (dd, J = 11.3, 7.5 Hz, 1H), 3.38 (dd, J = 11.3, 2.5 Hz, 1H).	456.2	C	




I-2144		O[C@H]1CN(C(=O)Nc2ccccc3C(=O)N[C@H](c23)c2cc(F)ccc2Cl)c2cccc(F)c12	1H NMR (400 MHz, DMSO-d6) 9.08 (s, 1H), 8.59 (s, 1H), 7.61-7.58 (dd, J = 7.5, 1.5 Hz, 2H), 7.50-7.42 (t, J = 7.4 Hz, 2H), 7.35 (dd, J = 8.9, 5.1 Hz, 1H), 7.24 (td, J = 8.2, 5.9 Hz, 1H), 7.09 (td, J = 8.4, 3.1 Hz, 1H), 6.74 (t, J = 8.6 Hz, 1H), 6.56 (s, 1H), 6.10 (s, 1H), 5.75 (d, J = 5.6 Hz, 1H), 5.29 (ddd, J = 7.9, 5.5, 2.4 Hz, 1H), 3.92 (dd, J = 11.3, 7.5 Hz, 1H), 3.37 (dd, J = 11.5, 2.6 Hz, 1H).	456.2	D	
I-2145		O[C@H]1CN(C(=O)Nc2ccccc3C(=O)N[C@@H](c23)c2cc(F)ccc2Cl)c2ccccc(F)c12	1H NMR (400 MHz, DMSO-d6) 9.05 (s, 1H), 8.71 (s, 1H), 7.74 (d, J = 8.1 Hz, 1H), 7.64-7.53 (m, 2H), 7.43-7.35 (m, 2H), 7.31 (td, J = 8.2, 5.9 Hz, 1H), 7.17 (td, J = 8.4, 3.1 Hz, 1H), 6.78 (t, J = 8.6 Hz, 1H), 6.54 (s, 1H), 6.01 (s, 1H), 5.80 (d, J = 6.7 Hz, 1H), 5.28-5.20 (m, 1H), 3.80 (dd, J = 11.6, 2.3 Hz, 1H), 3.21 (s, 1H).	456.2	D	
I-2146		Fc1ccc(Cl)c(c1)[C@@H]1NC(=O)c2cc(cc(NC(=O)[C@H]3CCCCN3)c12)-c1ccc2nccnn2c1	1H NMR (400 MHz, DMSO-d6) Ã¤ 9.40 (dd, J = 1.8, 0.9 Hz, 1H), 9.24 (s, 1H), 8.58 (s, 1H), 8.25 (d, J = 25.7 Hz, 1H), 8.06 (dd, J = 9.3, 1.8 Hz, 1H), 8.03 - 7.94 (m, 2H), 7.56 (s, 1H), 7.30 (td, J = 8.3, 3.1 Hz, 1H), 6.17 (s, 1H), 3.06 (d, J = 9.4 Hz, 1H), 2.82 - 2.64 (m, 1H), 2.43 (d, J = 11.3 Hz, 1H), 1.58 - 1.00 (m, 6H), 0.99 - 0.85 (m, 1H).	505.35	E	



I-2147		Fc1ccc(Cl)c(c1)[C@H]1NC(=O)c2cc(cc(NC(=O)[C@@H]3CCCCN3)c12)-c1ccc2ncnn2c1	1H NMR (400 MHz, DMSO-d6) Ã¤ 9.40 (dd, J = 1.8, 0.9 Hz, 1H), 9.24 (s, 1H), 8.58 (s, 1H), 8.25 (d, J = 25.7 Hz, 1H), 8.06 (dd, J = 9.3, 1.8 Hz, 1H), 8.03 - 7.94 (m, 2H), 7.56 (s, 1H), 7.30 (td, J = 8.3, 3.1 Hz, 1H), 6.17 (s, 1H), 3.06 (d, J = 9.4 Hz, 1H), 2.82 - 2.64 (m, 1H), 2.43 (d, J = 11.3 Hz, 1H), 1.58 - 1.00 (m, 6H), 0.99 - 0.85 (m, 1H).	505.35	E	
I-2148		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-n1ccnn1	1H NMR (400 MHz, DMSO-d6) 10.75 (s, 1H), 9.36 (s, 1H), 9.12 - 9.07 (m, 1H), 8.26 - 8.18 (m, 2H), 8.05 (d, J = 1.2 Hz, 1H), 7.96 (d, J = 8.3 Hz, 1H), 7.77 (d, J = 9.1 Hz, 1H), 7.71 (s, 1H), 7.36 (dd, J = 8.9, 5.2 Hz, 1H), 7.12 (td, J = 8.4, 3.1 Hz, 1H), 6.08 (s, 1H).	534	A	
I-2149		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(NC(=O)C3(CNC3)C#N)cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	(400 MHz,DMSO-d6) 10.84 (br s, 1 H), 10.55 (s, 1 H), 9.20 (br s, 1 H), 8.14 (s, 1 H), 8.00 (d, J = 1.2 Hz, 1 H), 7.95 (d, J = 8.3 Hz, 1 H), 7.82 (d, J = 1.3 Hz, 1 H), 7.72 (d, J = 8.8 Hz, 1 H), 7.63 (s, 1 H), 7.32 (dd, J = 8.9, 5.2 Hz, 1 H), 7.09 (td, J = 8.5, 3.0 Hz, 1 H), 6.60 (br s, 1 H), 5.96 (br s, 1 H), 4.05 (dd, J = 8.2, 3.1 Hz, 2 H), 3.91 (d, J = 8.2 Hz, 2 H).	590.2	A	D
I-2150		O[C@@H]1C[C@H](C[C@H](C1)C(F)(F)F)C(=O)Nc1cc(Br)cc2C(=O)N[C@	1H-NMR (400 MHz, DMSO-d6) 9.89 (br. s, 1H), 9.25 (br. s, 1H), 7.69 (d, J = 1.4 Hz, 1H), 7.65 (d, J = 1.6 Hz, 1H), 7.51-7.44 (m, 1H), 7.20 (app. td, J = 8.3, 3.0 Hz, 1H), 6.55 (br. s, 1H), 6.02 (br. s,	549.3	D	




		H](c12)c1cc(F)ccc1Cl	1H), 4.86 (br. s, 1H), 4.01 (br. s, 1H), 2.57 (tt, J = 12.2, 3.1 Hz, 1H), 2.48-2.39 (m, 1H), 1.80-1.73 (m, 1H), 1.51-1.44 (m, 1H), 1.41-1.34 (m, 1H), 1.34-1.28 (m, 1H), 1.27-1.17 (m, 1H), 1.11-1.00 (m, 1H)..			
I-2151		O[C@@H]1C[C@H](C[C@H](C1)C(F)(F)F)C(=O)Nc1cc(Br)cc2C(=O)N[C@@H](c12)c1cc(F)ccc1Cl	1H-NMR (400 MHz, DMSO-d6) 9.99 (br. s, 1H), 9.25 (br. s, 1H), 7.71 (d, J = 1.7 Hz, 1H), 7.54 (d, J = 1.7 Hz, 1H), 7.44 (dd, J = 8.5, 5.1 Hz, 1H), 7.20 (ddd, J = 8.8, 8.2, 3.1 Hz, 1H), 6.51 (br. s, 1H), 6.01 (br. s, 1H), 4.81 (br. d, J = 2.4 Hz, 1H), 4.04 (br. s, 1H), 2.56 (tt, J = 12.5, 3.3 Hz, 1H), 2.47-2.38 (m, 1H), 1.80-1.72 (m, 1H), 1.57-1.50 (m, 1H), 1.34-1.22 (m, 4H).	549.3	D	
I-2152		O[C@H]1C[C@@H](C[C@@H](C1)C(F)(F)F)C(=O)Nc1cc(Br)cc2C(=O)N[C@H](c12)c1cc(F)ccc1Cl	1H-NMR (400 MHz, DMSO-d6) 9.98 (br. s, 1H), 9.25 (br. s, 1H), 7.71 (d, J = 1.7 Hz, 1H), 7.54 (d, J = 1.7 Hz, 1H), 7.44 (dd, J = 8.5, 5.1 Hz, 1H), 7.20 (ddd, J = 8.7, 8.1, 3.1 Hz, 1H), 6.52 (br. s, 1H), 6.01 (br. s, 1H), 4.80 (br. d, J = 2.8 Hz, 1H), 4.04 (br. s, 1H), 2.56 (tt, J = 12.4, 3.3 Hz, 1H), 2.47-2.38 (m, 1H), 1.80-1.72 (m, 1H), 1.58-1.51 (m, 1H), 1.34-1.23 (m, 4H).	549.3	D	
I-2153		Fc1cc(cc(c1)C(F)(F)F)C(=O)Nc1ccccc2C(=O)N[C@H](CC3CCCC3)c12	(400 MHz, DMSO-d6) 10.78 (s, 1H), 8.88 (s, 1H), 8.17 (s, 1H), 8.12 (d, J = 8.9 Hz, 1H), 8.04 (d, J = 8.5 Hz, 1H), 7.60-7.50 (m, 3H), 4.77 (d, J = 7.2 Hz, 1H), 1.93-1.81 (m, 1H), 1.81-1.72 (m, 1H), 1.69-1.60 (m, 1H),	421.4	D	





			1.51-1.41 (m, 1H), 1.39-1.22 (m, 5H), 1.04 (tt, J = 15.2, 7.4 Hz, 1H), 0.94-0.81 (m, 1H).			
I-2154		Fc1cc(cc(c1)C(F)(F)F)C(=O)Nc1ccc2C(=O)N[C@@H](CC3CCCC3)c12	(400 MHz, DMSO-d6) 10.78 (s, 1H), 8.88 (s, 1H), 8.17 (s, 1H), 8.12 (d, J = 8.9 Hz, 1H), 8.04 (d, J = 8.5 Hz, 1H), 7.60-7.50 (m, 3H), 4.77 (d, J = 7.2 Hz, 1H), 1.93-1.81 (m, 1H), 1.81-1.72 (m, 1H), 1.69-1.60 (m, 1H), 1.51-1.41 (m, 1H), 1.39-1.22 (m, 5H), 1.04 (tt, J = 15.2, 7.4 Hz, 1H), 0.94-0.81 (m, 1H).	421.4	D	
I-2155		OC1(CCC(CC1)C(=O)Nc1cccc2C(=O)NC(c12)c1cc(F)ccc1Cl)C(F)(F)F		471.2	E	
I-2156		Fc1cc(F)cc(c1)C1NC(=O)c2cc(Br)cc(NC(=O)c3cc(F)cc(F)c3)c12	1H NMR (400 MHz, DMSO) 10.33 (s, 1H), 9.28-9.23 (m, 1H), 7.8-7.75 (m, 2H), 7.54 (tt, J = 9.1, 2.4 Hz, 1H), 7.33 (ddd, J = 6.9, 2.4, 1.3 Hz, 2H), 7.10 (tt, J = 9.3, 2.4 Hz, 1H), 6.79-6.69 (m, 2H), 5.75 (d, J = 1.1 Hz, 1H).	480	D	
I-2157		O=C1C2=C(C=C)C=CC(NC(C3=CSC4=C3C=CC=C4)=O)=C2C(C5=C(C)C=CC=C5)N1		425.3		




I-2158		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC3CCCNC3)c12)-c1ccc2ncnn2c1		477.0	E	
I-2159		FC(F)n1cc(cn1)-c1cc(N[C@H]2CCOc3ccccc23)c2[C@H](NC(=O)c2n1)c1cc(F)ccc1Cl		526.1	D	
I-2160		FC(F)n1cc(cn1)-c1cc(N[C@H]2CCOc3ccccc23)c2[C@@H](NC(=O)c2n1)c1cc(F)ccc1Cl		526.1	E	
I-2161		FC(F)n1cc(cn1)-c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(F)c2)c1)c1cc(F)ccc1F	(400 MHz, DMSO) δ 10.33 (s, 1H), 9.15 (d, J = 1.3 Hz, 1H), 8.90 (d, J = 0.7 Hz, 1H), 8.39 (d, J = 0.7 Hz, 1H), 8.02 (d, J = 1.6 Hz, 1H), 7.84 (d, J = 1.6 Hz, 1H), 7.60 – 7.43 (m, 2H), 7.42 – 7.34 (m, 2H), 7.10 (tt, J = 9.3, 2.4 Hz, 1H), 6.76 – 6.68 (m, 2H), 5.75 (s, 1H).	517.0	B	




I-2162		O[C@@H]1C[C@H](CC(F)(F)F)N(C1)C(=O)Nc1ccc2C(=O)N[C@H](c12)c1cc(F)ccc1Cl	(400 MHz, CD3CN) δ 7.62 - 7.58 (m, 1H), 7.57 - 7.49 (m, 2H), 7.45 (dd, J = 8.9, 5.2 Hz, 1H), 7.16 (br s, 1H), 7.09 (ddd, J = 8.9, 8.0, 3.1 Hz, 1H), 6.62 (br s, 1H), 6.62 (br s [submerged peak], 1H), 6.20 (br s, 1H), 4.37 - 4.33 (m, 1H), 4.04 - 3.96 (m, 1H), 3.23 (dd, J = 10.1, 4.7 Hz, 1H), 2.88 (d, J = 10.1 Hz, 1H), 2.85 - 2.75 (m, 1H), 2.54 - 2.42 (m, 1H), 2.03 - 1.97 (m, 2H), 1.91 - 1.84 (m, 1H) ppm	472.2	D	
I-2163		O[C@@H]1C[C@H](CC(F)(F)F)N(C1)C(=O)Nc1ccc2C(=O)N[C@@H](c12)c1cc(F)ccc1Cl	(400 MHz, CD3CN) δ 7.62 - 7.58 (m, 1H), 7.52 (t, J = 7.6 Hz, 1H), 7.46 - 7.38 (m, 1H), 7.35 (d, J = 7.7 Hz, 1H), 7.14 (br s, 1H), 7.07 (ddd, J = 8.8, 8.0, 3.1 Hz, 1H), 6.71 (br s, 1H), 6.62 (br s, 1H), 6.13 (br s, 1H), 4.27 (ddd, J = 7.7, 5.1, 2.7 Hz, 1H), 4.21 (d, J = 8.7 Hz, 1H), 3.05 (d, J = 10.5 Hz, 1H), 2.83 - 2.71 (m, 1H), 2.64 - 2.52 (m, 1H), 2.51 - 2.37 (m, 2H), 2.09 - 1.99 (m, 1H), 1.90 - 1.82 (m, 1H) ppm [~5:1 diastereomeric ratio - major diastereomer described]	472.2	E	
I-2164		O[C@H]1C[C@H](CC(F)(F)F)N(C1)C(=O)Nc1cccc2C(=O)N[C@H](c12)c1cc(F)ccc1Cl	(400 MHz, CD3CN) δ 7.63 - 7.58 (m, 2H), 7.55 (d, J = 7.5 Hz, 1H), 7.46 (dd, J = 8.9, 5.1 Hz, 1H), 7.17 (br s, 1H), 7.10 (ddd, J = 8.8, 8.0, 3.1 Hz, 1H), 6.61 (br s, 1H), 6.61 (br s [submerged], 1H), 6.21 (br s, 1H), 4.31 - 4.25 (m, 1H), 4.09 - 4.00 (m, 1H), 3.14 (dd, J = 9.8,	472.2	D	




			5.0 Hz, 1H), 3.05 - 2.92 (m, 1H), 2.88 (dd, J = 9.8, 3.0 Hz, 1H), 2.12 - 2.08 (m, 1H [submerged under water peak]), 2.03 - 1.97 (m, 1H), 1.92 - 1.83 (m, 2H) ppm			
I-2165		O[C@H]1C[C@H](CC(F)(F)F)N(C1)C(=O)Nc1cccc2C(=O)N[C@@H](c12)c1cc(F)ccc1Cl	(400 MHz, CD3CN) δ 7.62 - 7.58 (m, 1H), 7.52 (t, J = 7.6 Hz, 1H), 7.45 - 7.37 (m, 2H), 7.13 (br s, 1H), 7.10 - 7.01 (m, 1H), 6.68 (br s, 1H), 6.58 (br s, 1H), 6.18 (br s, 1H), 4.33 - 4.25 (m, 1H), 4.20 - 4.12 (m, 1H), 3.30 (dd, J = 10.1, 4.8 Hz, 1H), 2.81 - 2.67 (m, 2H), 2.12 - 2.07 (m, 1H [submerged under water peak]), 2.07 - 1.98 (m, 1H), 1.92 - 1.83 (m, 2H) ppm [~4:1 diastereomeric ratio - major diastereomer described]	472.2	E	
I-2166		OC[C@@]1(O)CN(C(=O)Nc2cccc3C(=O)N[C@H](c23)c2cc(F)ccc2Cl)c2ccccc12	(400 MHz, DMSO-d6) 9.03 (s, 1H), 8.55 (s, 2H), 7.80 (d, J=8.1 Hz, 1H), 7.61-7.51 (m, 2H), 7.41 (dd, J=7.2, 1.8 Hz, 1H), 7.35 (dd, J=8.9, 5.1 Hz, 1H), 7.29 (d, J=7.4 Hz, 1H), 7.21 (t, J=7.7 Hz, 1H), 7.12 (td, J=8.4, 3.1 Hz, 1H), 7.00-6.91 (m, 1H), 6.08 (s, 1H), 5.51 (s, 1H), 4.90 (t, J=5.6 Hz, 1H), 3.68 (d, J=10.9 Hz, 1H), 3.53 (dd, J=11.0, 5.0 Hz, 1H), 3.46-3.36 (m, 2H).	468.1	D	






I-2167		OC[C@]1(O)CN(C(=O)Nc2cccc3C(=O)N[C@@H](c23)c2cc(F)ccc2Cl)c2ccccc12	(400 MHz, DMSO-d6) 9.05 (s, 1H), 8.44 (s, 1H), 7.75 (d, J=8.1 Hz, 1H), 7.57 (d, J=7.2 Hz, 2H), 7.50 (s, 1H), 7.37 (dd, J=8.8, 5.1 Hz, 1H), 7.28 (d, J=7.4 Hz, 1H), 7.19 (t, J=7.8 Hz, 1H), 7.11 (dt, J=8.4, 4.2 Hz, 1H), 6.95 (t, J=7.4 Hz, 1H), 6.14 (s, 1H), 5.43 (s, 1H), 4.92 (s, 1H), 3.93 (d, J=10.9 Hz, 1H), 3.50 (s, 2H), 3.27 (d, J = 10.7 Hz, 2H).	468.1	E	
I-2168		OC[C@@]1(O)CN(C(=O)Nc2cccc3C(=O)N[C@@H](c23)c2cc(F)ccc2Cl)c2ccccc12	(400 MHz, DMSO-d6) 9.03 (s, 1H), 8.56 (s, 1H), 7.80 (d, J=8.1 Hz, 1H), 7.62-7.51 (m, 2H), 7.41 (dd, J=7.2, 1.8 Hz, 1H), 7.35 (dd, J=8.9, 5.2 Hz, 1H), 7.31-7.26 (m, 1H), 7.21 (t, J=7.7 Hz, 1H), 7.12 (td, J=8.3, 3.1 Hz, 1H), 6.95 (t, J=7.4 Hz, 1H), 6.54 (s, 1H), 6.08 (s, 1H), 5.52 (s, 1H), 4.92 (s, 1H), 3.68 (d, J=10.9 Hz, 1H), 3.53 (d, J=10.9 Hz, 1H), 3.41 (t, J=11.7 Hz, 2H).	468.1	E	
I-2169		Fc1ccc(Cl)c(c1)[C@@H]1NC(=O)c2cc(CCC#N)cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	(400 MHz, DMSO-d6) 10.54 (s, 1H), 9.15 (s, 1H), 7.95 (d, J = 8.4 Hz, 1H), 7.74 (d, J = 9.1 Hz, 1H), 7.67 (d, J = 9.8 Hz, 2H), 7.43 (s, 1H), 7.32 (dd, J = 8.9, 5.2 Hz, 1H), 7.10 (td, J = 8.4, 3.1 Hz, 1H), 5.96 (s, 1H), 3.13-2.99 (m, 2H), 2.94 (t, J = 7.1 Hz, 2H).	520.2	A	A





I-2170		Fc1ccc(Cl)c(c1)[C@H]1NC(=O)c2cc(CCC#N)cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	(400 MHz, DMSO-d6) 10.54 (s, 1H), 9.15 (s, 1H), 7.95 (d, J = 8.4 Hz, 1H), 7.74 (d, J = 9.1 Hz, 1H), 7.67 (d, J = 9.8 Hz, 2H), 7.43 (s, 1H), 7.32 (dd, J = 8.9, 5.2 Hz, 1H), 7.10 (td, J = 8.4, 3.1 Hz, 1H), 5.96 (s, 1H), 3.13-2.99 (m, 2H), 2.94 (t, J = 7.1 Hz, 2H).	520.2	E	
I-2171		O[C@@H]1CN(C(=O)Nc2cccc3C(=O)N[C@H](c23)c2cc(F)ccc2Cl)c2cc(F)ccc12	(400 MHz, DMSO-d6) δ9.08 (s, 1H), 8.63 (s, 1H), 7.58 (q, J = 7.9, 7.4 Hz, 2H), 7.49 - 7.26 (m, 4H), 7.09 (td, J = 8.4, 3.1 Hz, 1H), 6.75 (td, J = 8.7, 2.5 Hz, 1H), 6.55 (s, 1H), 6.08 (s, 1H), 5.79 - 5.49 (m, 1H), 5.12 (dd, J = 7.7, 3.4 Hz, 1H), 3.97 (dd, J = 11.1, 7.9 Hz, 1H), 3.29 (dd, J = 11.1, 3.5 Hz, 1H).	456.3	A	A
I-2172		O[C@H]1CN(C(=O)Nc2cccc3C(=O)N[C@H](c23)c2cc(F)ccc2Cl)c2cc(F)ccc12	(400 MHz, DMSO-d6) δ9.08 (s, 1H), 8.63 (s, 1H), 7.58 (q, J = 7.9, 7.4 Hz, 2H), 7.49 - 7.26 (m, 4H), 7.09 (td, J = 8.4, 3.1 Hz, 1H), 6.75 (td, J = 8.7, 2.5 Hz, 1H), 6.55 (s, 1H), 6.08 (s, 1H), 5.79 - 5.49 (m, 1H), 5.12 (dd, J = 7.7, 3.4 Hz, 1H), 3.97 (dd, J = 11.1, 7.9 Hz, 1H), 3.29 (dd, J = 11.1, 3.5 Hz, 1H).	456.3	C	
I-2173		O[C@@H]1CN(C(=O)Nc2cccc3C(=O)N[C@@H](c23)c2cc(F)ccc2Cl)c2cc(F)ccc12	(400 MHz, DMSO-d6) δ9.08 (s, 1H), 8.63 (s, 1H), 7.58 (q, J = 7.9, 7.4 Hz, 2H), 7.49 - 7.26 (m, 4H), 7.09 (td, J = 8.4, 3.1 Hz, 1H), 6.75 (td, J = 8.7, 2.5 Hz, 1H), 6.55 (s, 1H), 6.08 (s, 1H), 5.79 - 5.49 (m, 1H), 5.12 (dd, J = 7.7, 3.4 Hz, 1H), 3.97 (dd, J = 11.1, 7.9 Hz, 1H),	456.3	D	





			3.29 (dd, J = 11.1, 3.5 Hz, 1H).			
I-2174		O[C@H]1CN(C(=O)Nc2ccc c3C(=O)N[C@@H](c23)c2cc(F)ccc2Cl)c2cc(F)ccc12	(400 MHz, DMSO-d6) δ9.08 (s, 1H), 8.63 (s, 1H), 7.58 (q, J = 7.9, 7.4 Hz, 2H), 7.49 - 7.26 (m, 4H), 7.09 (td, J = 8.4, 3.1 Hz, 1H), 6.75 (td, J = 8.7, 2.5 Hz, 1H), 6.55 (s, 1H), 6.08 (s, 1H), 5.79 - 5.49 (m, 1H), 5.12 (dd, J = 7.7, 3.4 Hz, 1H), 3.97 (dd, J = 11.1, 7.9 Hz, 1H), 3.29 (dd, J = 11.1, 3.5 Hz, 1H).	456.3	E	
I-2175		O[C@@H]1C[C@H](C[C@H](C1)C(F)(F)F)C(=O)Nc1cccc2C(=O)N[C@H](c12)c1cc(F)ccc1Cl	(400 MHz, DMSO-d6) δ 9.93 (br. s, 1H), 9.08 (br. s, 1H), 7.62 - 7.54 (m, 2H), 7.44 (dd, J = 8.6, 4.8 Hz, 1H), 7.33 (dd, J = 7.4, 1.3 Hz, 1H), 7.18 (ddd, J = 8.8, 8.1, 3.1 Hz, 1H), 6.41 (br. s, 1H), 6.05 (br. s, 1H), 4.81 (br. s, 1H), 4.05 (br. s, 1H), 2.57 (tt, J = 12.1, 3.3 Hz, 1H), 2.46 - 2.38 (m, 1H), 1.80 - 1.72 (m, 1H), 1.60 - 1.54 (m, 1H), 1.37 - 1.19 (m, 3H), 0.98 - 0.88 (m, 1H).	471.4	E	
I-2176		O[C@@H]1C[C@H](C[C@H](C1)C(F)(F)F)C(=O)Nc1cccc2C(=O)N[C@@H](c12)c1cc(F)ccc1Cl	(400 MHz, DMSO-d6) δ 9.79 (br. s, 1H), 9.08 (br. s, 1H), 7.61 - 7.54 (m, 2H), 7.48 (dd, J = 7.4, 4.8 Hz, 1H), 7.43 (dd, J = 7.2, 0.9 Hz, 1H), 7.19 (app. td, J = 8.3, 3.0 Hz, 1H), 6.44 (br. s, 1H), 6.06 (br. s, 1H), 4.84 (br. s, 1H), 4.01 (br. s, 1H), 2.58 (tt, J = 13.3, 3.8 Hz, 1H), 2.46 - 2.39 (m, 1H), 1.81 - 1.74 (m, 1H), 1.53 - 1.46 (m, 1H), 1.39 - 1.18 (m, 3H), 1.08 (app. q, J = 12.8 Hz, 1H).	471.4	E	




I-2177		O[C@H]1C[C@@H](C[C@@H](C1)C(F)(F)F)C(=O)Nc1ccccc2C(=O)N[C@H](c12)c1cc(F)ccc1Cl	(400 MHz, DMSO-d6) δ 9.77 (br. s, 1H), 9.07 (br. s, 1H), 7.61 - 7.54 (m, 2H), 7.48 (dd, J = 7.7, 5.0 Hz, 1H), 7.43 (dd, J = 7.1, 1.5 Hz, 1H), 7.19 (td, J = 8.4, 3.1 Hz, 1H), 6.45 (br. s, 1H), 6.06 (br. s, 1H), 4.82 (d, J = 2.8 Hz, 1H), 4.01 (br. s, 1H), 2.59 (tt, J = 12.0, 3.4 Hz, 1H), 2.48 - 2.40 (m, 1H), 1.81 - 1.73 (m, 1H), 1.53 - 1.47 (m, 1H), 1.38 - 1.18 (m, 3H), 1.08 (app. q, J = 12.7 Hz, 1H).	471.4	D	
I-2178		O[C@H]1C[C@@H](C[C@@H](C1)C(F)(F)F)C(=O)Nc1ccccc2C(=O)N[C@@H](c12)c1cc(F)ccc1Cl	(400 MHz, DMSO-d6) δ 9.91 (br. s, 1H), 9.08 (br. s, 1H), 7.62 - 7.54 (m, 2H), 7.44 (dd, J = 8.3, 5.1 Hz, 1H), 7.33 (dd, J = 7.4, 1.0 Hz, 1H), 7.19 (ddd, J = 8.8, 8.1, 3.1 Hz, 1H), 6.40 (br. s, 1H), 6.05 (br. s, 1H), 4.78 (br. s, 1H), 4.05 (br. s, 1H), 2.58 (tt, J = 12.4, 3.6 Hz, 1H), 2.47 - 2.37 (m, 1H), 1.80 - 1.73 (m, 1H), 1.60 - 1.53 (m, 1H), 1.38 - 1.19 (m, 2H), 0.93 (app. q, J = 11.8 Hz, 1H).	471.4	E	
I-2179		O[C@H]1C[C@@H](C[C@@H](C1)C(F)(F)F)C(=O)Nc1cc(Br)cc2C(=O)N[C@H](c12)c1cc(F)ccc1Cl	(400 MHz, DMSO-d6) δ 9.88 (br. s, 1H), 9.25 (br. s, 1H), 7.69 (d, J = 1.7 Hz, 1H), 7.65 (d, J = 1.7 Hz, 1H), 7.48 (dd, J = 7.1, 4.6 Hz, 1H), 7.20 (ddd, J = 8.8, 8.1, 3.1 Hz, 1H), 6.56 (br. s, 1H), 6.02 (br. s, 1H), 4.85 (d, J = 2.4 Hz, 1H), 4.01 (br. s, 1H), 2.58 (tt, J = 12.6, 3.6 Hz, 1H), 2.48 - 2.39 (m, 1H), 1.80 - 1.73 (m, 1H), 1.51 - 1.45 (m, 1H), 1.40 - 1.34 (m, 1H), 1.34 - 1.29 (m,	549.3	C	





			1H), 1.28 - 1.20 (m, 1H), 1.11 - 1.00 (m, 1H).			
I-2180		CC(c1nn[nH]c1C(=O)Nc1ccc2C(=O)NC(c12)c1cc(F)ccc1Cl)C(F)(F)F	(400 MHz, DMSO-d6) δ 11.20 (br s, 1H), 10.26 (br s, 1H), 10.18 (br s, 1H), 9.10 (br s, 1H), 9.08 (br s, 1H), 7.69 - 7.63 (m, 2H), 7.63 - 7.54 (m, 4H), 7.35 - 7.28 (m, 2H), 7.13 - 7.00 (m, 2H), 6.62 (br s, 2H), 6.12 (br s, 2H), 4.66 (br s, 1H), 4.55 (br s, 1H), 1.48 (d, J = 7.1 Hz, 3H), 1.42 (d, J = 7.3 Hz, 3H). 1:1 Mixture of diastereomers (both reported)	468.0	E	
I-2181		OCC1CN(CC1C(F)(F)F)C(=O)Nc1cccc2C(=O)NC(c12)c1cc(F)ccc1Cl	(400 MHz, CD3CN) δ 7.59 (overlapping dd J = 7.5, 1.3 Hz, 0.5H), 7.59 (overlapping dd J = 7.5, 1.5 Hz, 0.5H), 7.52 (t, J = 7.6 Hz, 1H), 7.47 - 7.40 (m, 2H), 7.18 (br s, 1H), 7.11 - 7.04 (m, 1H), 6.68 (br s, 0.5H), 6.65 (br s, 0.5H), 6.59 (submerged br s, 1H), 6.15 (br s, 1H), 3.66 - 3.59 (m, 0.5H), 3.60 - 3.33 (m, 5.5H), 3.21 - 3.11 (m, 1H), 2.96 - 2.84 (m, 1H), 2.54 - 2.38 (submerged m, 1H).	472.0	E	
I-2182		Fc1ccc(Cl)c(c1)C1NC(=O)c2cccc(NC(=O)N3CCc4ccncc34)c12	(400 MHz, DMSO-d6) 9.07 (s, 1H), 8.87 (s, 1H), 8.71 (s, 1H), 8.13 (d, J = 4.7 Hz, 1H), 7.65 - 7.53 (m, 2H), 7.42 - 7.33 (m, 2H), 7.29 - 7.23 (m, 1H), 7.15 (ddd, J = 8.9, 7.9, 3.1 Hz, 1H), 6.55 (s, 1H), 6.01 (s, 1H), 3.89 (q, J = 9.8 Hz, 1H), 3.20 - 2.99 (m, 3H).	423.2	E	





I-2183		Fc1ccc(Cl)c(c1)[C@H]1NC(=O)c2cc(Br)cc(Nc3cn[nH]c3)c12	(400 MHz, DMSO-d6) δ 12.75 (s, 1H), 9.09 (s, 1H), 7.59 (br. s, 1H), 7.51 (dd, J = 8.8, 5.2 Hz, 1H), 7.23 (ddd, J = 8.8, 8.0, 3.1 Hz, 2H), 7.15 (d, J = 1.6 Hz, 1H), 6.98 - 6.94 (m, 2H), 6.68 (br. s, 1H), 5.82 (s, 1H); racemic mixture.	421.1	E	
I-2184		Fc1ccc(Cl)c(c1)[C@@H]1NC(=O)c2cc(Br)cc(Nc3cn[nH]c3)c12	(400 MHz, DMSO-d6) δ 12.75 (s, 1H), 9.09 (s, 1H), 7.59 (br. s, 1H), 7.51 (dd, J = 8.8, 5.2 Hz, 1H), 7.23 (ddd, J = 8.8, 8.0, 3.1 Hz, 2H), 7.15 (d, J = 1.6 Hz, 1H), 6.98 - 6.94 (m, 2H), 6.68 (br. s, 1H), 5.82 (s, 1H)	421.1	E	
I-2185		FC(F)c1ccc(F)cc1C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1cn2ncnc2cn1			A	A
I-2186		CC(C)(CN)n1cc(cn1)-c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl		604.3	A	B
I-2187		Fc1ccc(Cl)c(c1)C1NC(=O)c2cccc(C#Cc3cc(F)cc(c3)C(F)(F)F)c12		448.2	E	





I-2188		Fc1ccc(Cl)c(c1)C1NC(=O)c2cccc(C(=O)Nc3ccccc3)c12	(400 MHz, DMSO-d6) 10.32 (s, 1H), 9.25 (s, 1H), 7.93 (dd, J=7.7, 3.9 Hz, 2H), 7.74 (t, J=7.5 Hz, 1H), 7.41 (d, J=8.1 Hz, 3H), 7.27 (t, J=7.9 Hz, 2H), 7.16-7.01 (m, 2H), 6.41 (s, 1H).	381.2	E	
I-2189		Fc1ccc(Cl)c(c1)C1NC(=O)c2cccc(C(=O)Nc3cccc(c3)C(F)(F)F)c12	(400 MHz, DMSO-d6) 10.65 (s, 1H), 9.28 (s, 1H), 7.95 (t, J = 7.3 Hz, 2H), 7.81 (s, 1H), 7.76 (t, J = 7.6 Hz, 1H), 7.65 (d, J = 8.2 Hz, 1H), 7.53 (t, J = 8.0 Hz, 1H), 7.45-7.38 (m, 1H), 7.35 (dd, J = 8.9, 5.2 Hz, 1H), 7.10 (ddd, J = 8.9, 7.9, 3.1 Hz, 1H), 6.40 (s, 1H).	449.2	D	
I-2190		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-n1ncccc1=O	(400 MHz, DMSO-d6) 10.67 (s, 1H), 9.29 (s, 1H), 8.13 (dd, J = 3.8, 1.6 Hz, 1H), 7.92 (dd, J = 12.0, 5.2 Hz, 2H), 7.84 - 7.73 (m, 2H), 7.69 (s, 1H), 7.55 (dd, J = 9.5, 3.8 Hz, 1H), 7.35 (dd, J = 8.9, 5.2 Hz, 1H), 7.13 (ddd, J = 16.8, 9.0, 2.3 Hz, 2H), 6.73 (s, 1H), 6.04 (s, 1H).	561.1	B	
I-2191		Fc1ccc(Cl)c(c1)C1NC(=O)c2cccc(NC(=O)N3CCc4cnccc34)c12	(400 MHz, DMSO-d6) 9.09 (s, 1H), 8.81 (s, 1H), 8.31 - 8.26 (m, 1H), 8.23 (d, J = 5.4 Hz, 1H), 7.66 - 7.60 (m, 1H), 7.63 - 7.54 (m, 2H), 7.43 - 7.35 (m, 2H), 7.16 (ddd, J = 8.8, 7.9, 3.1 Hz, 1H), 6.59 (s, 1H), 6.00 (s, 1H), 3.92 (td, J = 10.1, 7.0 Hz, 1H), 3.19 - 3.08 (m, 2H), 3.08 (s, 1H).	423.1	D	



I-2192		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-n1ccccc1=O	(400 MHz, DMSO-d6) 10.68 (s, 1H), 9.32 (s, 1H), 7.95 (d, J = 8.4 Hz, 1H), 7.82 - 7.71 (m, 2H), 7.71 - 7.65 (m, 2H), 7.62 - 7.53 (m, 2H), 7.36 (dd, J = 8.9, 5.2 Hz, 1H), 7.13 (td, J = 8.4, 3.0 Hz, 1H), 7.00 - 6.76 (s, 1H), 6.55 (dt, J = 9.2, 1.0 Hz, 1H), 6.38 (td, J = 6.7, 1.4 Hz, 1H), 6.06 (s, 1H).	560.1	A	B
I-2193		CCC(CC(=O)Nc1cccc2C(=O)NC(c12)c1cc(F)ccc1Cl)C(C)C(F)(F)F	(400 MHz, DMSO-d6) δ , 9.74 (br. s, 1H), 9.08 (br. s, 1H), 7.65 - 7.52 (m, 2H), 7.53 - 7.46 (m, 1H), 7.42 (dd, J = 7.4, 1.4 Hz, 1H), 7.26 - 7.16 (m, 1H), 6.42 (br. s, 1H), 6.07 (br. s, 1H), 2.48 - 2.28 (m, 1H), 2.21 - 1.74 (m, 3H), 1.24 - 0.95 (m, 2H), 0.94 (d, J = 2.0 Hz, 3H), 0.75 (t, J = 7.3 H, 3Hz)	457.2	D	
I-2194		Fc1ccc(Cl)c(c1)C1NC(=O)c2cccc(NC(=O)c3[nH]nnc3CC(F)(F)F)c12	(400 MHz, DMSO-d6) δ 10.19 (br s, 1H), 9.10 (br s, 1H), 7.68 - 7.62 (m, 1H), 7.62 - 7.56 (m, 2H), 7.31 (dd, J = 8.8, 5.2 Hz, 1H), 7.07 (td, J = 8.4, 3.1 Hz, 1H), 6.62 (br s, 1H), 6.12 (br s, 1H), 4.11 - 3.97 (m, 2H).	454.0	E	
I-2195		CC(C(CC(=O)Nc1cccc2C(=O)NC(c12)c1cc(F)ccc1Cl)C=C)C(F)(F)F	(400 MHz, DMSO-d6) δ 9.67 (br. s, 1H), 9.07 (br. s, 1H), 7.68 - 7.51 (m, 2H), 7.54 - 7.44 (m, 1H), 7.41 (dd, J = 7.5, 1.4 Hz, 1H), 7.32 - 7.10 (m, 1H), 6.59 (br. s, 1H), 6.04 (br. s, 1H), 5.58 (dd, J = 17.6, 8.5 Hz, 1H), 5.04 - 4.87 (m, 2H), 2.87 - 2.63 (m, 1H), 2.35 - 1.88 (m, 2H), 0.99 (d, J = 7.1 Hz, 3H); 1:1 mixture of diastereomers.	455.3	D	



I-2196		CC(C)(C)CCC1NC(=O)c2cccc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	(400 MHz, DMSOd6) δ 10.79 (s, 1H), 8.72 (s, 1H), 8.16 (s, 1H), 8.09 (d, J = 8.9 Hz, 1H), 8.03 (d, J = 8.4 Hz, 1H), 7.60 - 7.51 (m, 3H), 4.79 (dd, J = 6.4, 2.4 Hz, 1H), 1.88 - 1.76 (m, 1H), 1.43 - 1.28 (m, 1H), 0.99 - 0.81 (m, 2H), 0.68 (s, 9H).	423.4	D	
I-2197		CC(C(CO)CC(=O)Nc1ccccc2C(=O)NC(c12)c1cc(F)ccc1Cl)C(F)(F)F	(400 MHz, DMSO-d6) δ 9.72 (s, 1H), 9.07 (s, 1H), 7.68 - 7.53 (m, 2H), 7.52 - 7.44 (m, 1H), 7.39 (dd, J = 7.5, 1.3 Hz, 1H), 7.27 - 7.15 (m, 1H), 6.59 (br. s, 1H), 6.01 (overlapping br. s, 1H), 4.82 (overlapping d, J = 5.0 Hz, 1H), 3.32 - 3.13 (m, 1H), 3.15 - 2.97 (m, 1H), 2.75 - 2.54 (m, 1H), 2.41 - 2.15 (m, 1H), 2.10 - 1.76 (m, 2H), 0.94 (d, J = 3.6 Hz, 3H); 1:1 mixture of diastereomers	459.2	E	
I-2198		CC(O)C(CC(=O)Nc1ccccc2C(=O)NC(c12)c1cc(F)ccc1Cl)C(C)C(F)(F)F	(400 MHz, DMSO-d6) δ 9.64 (br. s, 1H), 9.06 (br. s, 1H), 7.65 - 7.51 (m, 2H), 7.51 - 7.32 (m, 2H), 7.26 - 7.11 (m, 1H), 6.50 (br. s, 1H), 6.06 (br. s, 1H), 4.70 (d, J = 4.2 Hz, 1H), 3.71 - 3.38 (m, 1H), 3.00 - 2.57 (m, 1H), 2.39 - 1.84 (m, 3H), 1.00 - 0.93 (m, 3H), 0.89 (d, J = 6.2 Hz, 3H); 1:1:0.85:0.75 mixture of diastereomers.	473.3	E	



I-2199		OC[C@]1(O)CN(C(=O)Nc2cccc3C(=O)N[C@H](c23)c2cc(F)cc2Cl)c2ccccc12	(400 MHz, DMSO-d6) 9.05 (s, 1H), 8.43 (s, 1H), 7.75 (d, J=8.1 Hz, 1H), 7.62-7.52 (m, 2H), 7.49 (dd, J=7.0, 2.0 Hz, 1H), 7.36 (dd, J=8.9, 5.1 Hz, 1H), 7.28 (d, J=7.4 Hz, 1H), 7.23-7.15 (m, 1H), 7.10 (td, J=8.4, 3.1 Hz, 1H), 6.95 (t, J=7.5 Hz, 1H), 6.14 (s, 1H), 5.41 (s, 1H), 4.90 (t, J=5.4 Hz, 1H), 3.93 (d, J=10.8 Hz, 1H), 3.50 (d, J=5.5 Hz, 2H), 3.27 (d, J=10.7 Hz, 1H).	468.1	E	
I-2200		CN(C)c1nc2cc(ccn2n1)-c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	(DMSO-d6, 400 MHz) 10.61 (1H, s), 9.23 (1H, s), 9.16 (1H, s), 8.04 (1H, s), 7.99-7.86 (3H, m), 7.78 (1H, d, J=9.0 Hz), 7.72 (1H, s), 7.56 (1H, d, J=9.2 Hz), 7.34 (1H, dd, J=8.9, 5.1 Hz), 7.16-7.08 (1H, m), 6.03 (1H, s), 3.08 (6H, s)	627.1	A	A
I-2201		FC(F)c1ccc(F)cc1C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(Cl)c3)c12)-c1cn2ncnc2cn1		567.2	A	B
I-2202		CN1CCO\C1=N/c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl		565.0	B	



I-2203		C[C@]1(O)CN(C(=O)Nc2ccc3C(=O)N[C@@H](c23)c2cc(F)ccc2Cl)c2ccccc12	(400 MHz, DMSO-d6) 9.07 (s, 1H), 8.39 (s, 1H), 7.67 (d, J=8.1 Hz, 1H), 7.61-7.51 (m, 3H), 7.37 (dd, J=8.8, 5.2 Hz, 1H), 7.29 (dd, J=7.5, 1.4 Hz, 1H), 7.21-7.13 (m, 1H), 7.09 (td, J=8.4, 3.1 Hz, 1H), 7.00-6.92 (m, 1H),6.53(s, 1H) 6.14 (s, 1H), 5.46 (s, 1H), 3.59 (d, J=10.6 Hz, 1H), 3.51 (d, J=10.5 Hz, 1H), 1.45 (s, 3H).	452.0	D	
I-2204		C[C@@]1(O)CN(C(=O)Nc2cccc3C(=O)N[C@@H](c23)c2cc(F)ccc2Cl)c2ccccc12		450.0	D	
I-2205		C[C@]1(O)CN(C(=O)Nc2ccc3C(=O)N[C@H](c23)c2cc(F)ccc2Cl)c2ccccc12	(400 MHz, DMSO-d6) 9.04 (s, 1H), 8.58 (s, 1H), 7.84 (d, J = 8.1 Hz, 1H), 7.72-7.51 (m, 2H), 7.42-7.34 (m, 2H), 7.31 (dd, J=7.4, 1.3 Hz, 1H), 7.26-7.12 (m, 3H), 6.98 (td, J=7.4, 1.1 Hz, 1H), 6.58 (s, 1H), 6.01 (s, 1H), 5.52 (s, 1H), 3.84 (d, J=10.8 Hz, 1H), 1.41 (s, 3H).	450.0	A	A
I-2206		C[C@@]1(O)CN(C(=O)Nc2cccc3C(=O)N[C@H](c23)c2cc(F)ccc2Cl)c2ccccc12	(400 MHz, DMSO-d6) 9.04 (s, 1H), 8.58 (s, 1H), 7.84 (d, J=8.0 Hz, 1H), 7.57 (d, J=7.3 Hz, 2H), 7.37 (dd, J=9.0, 5.5 Hz, 2H), 7.31 (d, J=7.4 Hz, 1H), 7.26-7.12 (m, 2H),6.53-6.98 (t, J=7.4 Hz, 1H), 6.01 (s, 1H), 5.51 (s, 1H), 3.84 (d, J=10.8 Hz, 1H), 2.97 (s, 1H), 1.41 (s, 3H).	452.0	E	





I-2207		O[C@H]1CN(C(=O)Nc2cccc3C(=O)N[C@@H](c23)c2cc(F)ccc2Cl)c2c1cccc2F	(400 MHz, DMSO-d6) 9.09 (s, 1H), 9.04 (s, 1H), 7.57 (d, J = 4.3 Hz, 2H), 7.49 (s, 1H), 7.43-7.37 (m, 1H), 7.26 (td, J = 8.4, 3.1 Hz, 1H), 7.16 (dd, J = 5.2, 3.4 Hz, 1H), 7.13-7.04 (m, 2H), 5.94 (s, 1H), 5.77 (d, J = 6.2 Hz, 1H), 5.15 (q, J = 6.7 Hz, 1H), 3.51 (dd, J = 11.3, 6.0 Hz, 1H), 3.24 (t, J = 9.6 Hz, 1H).	456.1	D	
I-2208		O[C@@H]1CN(C(=O)Nc2cccc3C(=O)N[C@@H](c23)c2cc(F)ccc2Cl)c2c1cccc2F	(400 MHz, DMSO-d6) 9.09 (s, 1H), 9.04 (s, 1H), 7.57 (d, J = 4.3 Hz, 2H), 7.49 (s, 1H), 7.43-7.37 (m, 1H), 7.26 (td, J = 8.4, 3.1 Hz, 1H), 7.16 (dd, J = 5.2, 3.4 Hz, 1H), 7.13-7.04 (m, 2H), 5.94 (s, 1H), 5.77 (d, J = 6.2 Hz, 1H), 5.15 (q, J = 6.7 Hz, 1H), 3.51 (dd, J = 11.3, 6.0 Hz, 1H), 3.24 (t, J = 9.6 Hz, 1H).	456.1	E	
I-2209		O[C@H]1CN(C(=O)Nc2cccc3C(=O)N[C@H](c23)c2cc(F)ccc2Cl)c2c1cccc2F	(400 MHz, DMSO-d6) 9.09 (s, 1H), 9.04 (s, 1H), 7.57 (d, J = 4.3 Hz, 2H), 7.49 (s, 1H), 7.43-7.37 (m, 1H), 7.26 (td, J = 8.4, 3.1 Hz, 1H), 7.16 (dd, J = 5.2, 3.4 Hz, 1H), 7.13-7.04 (m, 2H), 5.94 (s, 1H), 5.77 (d, J = 6.2 Hz, 1H), 5.15 (q, J = 6.7 Hz, 1H), 3.51 (dd, J = 11.3, 6.0 Hz, 1H), 3.24 (t, J = 9.6 Hz, 1H).	456.1	E	
I-2210		O[C@@H]1CN(C(=O)Nc2cccc3C(=O)N[C@H](c23)c2cc(F)ccc2Cl)c2c1cccc2F	(400 MHz, DMSO-d6) 9.09 (s, 1H), 9.04 (s, 1H), 7.57 (d, J = 4.3 Hz, 2H), 7.49 (s, 1H), 7.43-7.37 (m, 1H), 7.26 (td, J = 8.4, 3.1 Hz, 1H), 7.16 (dd, J = 5.2, 3.4 Hz, 1H), 7.13-7.04 (m, 2H), 5.94 (s, 1H), 5.77 (d, J = 6.2 Hz, 1H), 5.15 (q, J = 6.7	456.1	E	




			Hz, 1H), 3.51 (dd, J = 11.3, 6.0 Hz, 1H), 3.24 (t, J = 9.6 Hz, 1H).			
I-2211		Fc1ccc(Cl)c(c1)[C@H]1NC(=O)c2cccc(NC(=O)[C@H]3CCC[C@@H](C3)OC(F)(F)F)c12	Mixture (400 MHz, DMSO-d6) δ 9.79 (br s, 0.35H), 9.77 (br s, 0.15H), 9.76 (br s, 0.15H), 9.73 (br s, 0.35H), 9.09 (br s, 1H), 7.63 - 7.54 (m, 2H), 7.52 - 7.44 (m, 1H), 7.43 - 7.35 (m, 1H), 7.25 - 7.16 (m, 1H), 6.46 (br s, 1H), 6.03 (br s, 1H), 4.74 - 4.70 (m, 0.15H), 4.70 - 4.67 (m, 0.15H), 4.33 - 4.27 (m, 0.35H), 4.27 - 4.21 (m, 0.35H), 2.46 - 2.40 (m, 0.15H), 2.39 - 2.30 (m, 0.15H), 2.26-2.20 (m, 0.35H), 2.20-2.14 (m, 0.35H), 1.95 (br s, 1H), 1.84 - 1.38 (m, 4.3H), 1.37 - 1.16 (m, 2H), 1.13 - 1.00 (m, 0.3H), 0.99 - 0.86 (m, 0.3H).	471.0	E	
I-2212		Fc1ccc(Cl)c(c1)[C@@H]1NC(=O)c2cccc(NC(=O)[C@H]3CCC[C@@H](C3)OC(F)(F)F)c12	Mixture (400 MHz, DMSO-d6) δ 9.79 (br s, 0.35H), 9.77 (br s, 0.15H), 9.76 (br s, 0.15H), 9.73 (br s, 0.35H), 9.09 (br s, 1H), 7.63 - 7.54 (m, 2H), 7.52 - 7.44 (m, 1H), 7.43 - 7.35 (m, 1H), 7.25 - 7.16 (m, 1H), 6.46 (br s, 1H), 6.03 (br s, 1H), 4.74 - 4.70 (m, 0.15H), 4.70 - 4.67 (m, 0.15H), 4.33 - 4.27 (m, 0.35H), 4.27 - 4.21 (m, 0.35H), 2.46 - 2.40 (m, 0.15H), 2.39 - 2.30 (m, 0.15H), 2.26-2.20 (m, 0.35H), 2.20-2.14 (m, 0.35H), 1.95 (br s, 1H), 1.84 - 1.38 (m, 4.3H), 1.37 - 1.16 (m, 2H), 1.13 - 1.00 (m, 0.3H), 0.99 - 0.86 (m, 0.3H).	471.0	E	




I-2213		Fc1ccc(Cl)c(c1)[C@H]1NC(=O)c2cccc(NC(=O)[C@@H]3CCC[C@@H](C3)OC(F)(F)F)c12	Mixture (400 MHz, DMSO-d6) δ 9.79 (br s, 0.35H), 9.77 (br s, 0.15H), 9.76 (br s, 0.15H), 9.73 (br s, 0.35H), 9.09 (br s, 1H), 7.63 - 7.54 (m, 2H), 7.52 - 7.44 (m, 1H), 7.43 - 7.35 (m, 1H), 7.25 - 7.16 (m, 1H), 6.46 (br s, 1H), 6.03 (br s, 1H), 4.74 - 4.70 (m, 0.15H), 4.70 - 4.67 (m, 0.15H), 4.33 - 4.27 (m, 0.35H), 4.27 - 4.21 (m, 0.35H), 2.46 - 2.40 (m, 0.15H), 2.39 - 2.30 (m, 0.15H), 2.26-2.20 (m, 0.35H), 2.20-2.14 (m, 0.35H), 1.95 (br s, 1H), 1.84 - 1.38 (m, 4.3H), 1.37 - 1.16 (m, 2H), 1.13 - 1.00 (m, 0.3H), 0.99 - 0.86 (m, 0.3H).	471.0	E	
I-2214		Fc1ccc(Cl)c(c1)[C@@H]1NC(=O)c2cccc(NC(=O)[C@@H]3CCC[C@@H](C3)OC(F)(F)F)c12	Mixture (400 MHz, DMSO-d6) δ 9.79 (br s, 0.35H), 9.77 (br s, 0.15H), 9.76 (br s, 0.15H), 9.73 (br s, 0.35H), 9.09 (br s, 1H), 7.63 - 7.54 (m, 2H), 7.52 - 7.44 (m, 1H), 7.43 - 7.35 (m, 1H), 7.25 - 7.16 (m, 1H), 6.46 (br s, 1H), 6.03 (br s, 1H), 4.74 - 4.70 (m, 0.15H), 4.70 - 4.67 (m, 0.15H), 4.33 - 4.27 (m, 0.35H), 4.27 - 4.21 (m, 0.35H), 2.46 - 2.40 (m, 0.15H), 2.39 - 2.30 (m, 0.15H), 2.26-2.20 (m, 0.35H), 2.20-2.14 (m, 0.35H), 1.95 (br s, 1H), 1.84 - 1.38 (m, 4.3H), 1.37 - 1.16 (m, 2H), 1.13 - 1.00 (m, 0.3H), 0.99 - 0.86 (m, 0.3H).	471.0	E	




I-2215		Fc1ccc(Cl)c(c1)[C@H]1NC(=O)c2cccc(NC(=O)[C@@H]3CCC[C@H](C3)OC(F)(F)F)c12	Mixture (400 MHz, DMSO-d6) δ 9.79 (br s, 0.35H), 9.77 (br s, 0.15H), 9.76 (br s, 0.15H), 9.73 (br s, 0.35H), 9.09 (br s, 1H), 7.63 - 7.54 (m, 2H), 7.52 - 7.44 (m, 1H), 7.43 - 7.35 (m, 1H), 7.25 - 7.16 (m, 1H), 6.46 (br s, 1H), 6.03 (br s, 1H), 4.74 - 4.70 (m, 0.15H), 4.70 - 4.67 (m, 0.15H), 4.33 - 4.27 (m, 0.35H), 4.27 - 4.21 (m, 0.35H), 2.46 - 2.40 (m, 0.15H), 2.39 - 2.30 (m, 0.15H), 2.26-2.20 (m, 0.35H), 2.20-2.14 (m, 0.35H), 1.95 (br s, 1H), 1.84 - 1.38 (m, 4.3H), 1.37 - 1.16 (m, 2H), 1.13 - 1.00 (m, 0.3H), 0.99 - 0.86 (m, 0.3H).	471.0	E	
I-2216		Fc1ccc(Cl)c(c1)[C@@H]1NC(=O)c2cccc(NC(=O)[C@@H]3CCC[C@H](C3)OC(F)(F)F)c12	Mixture (400 MHz, DMSO-d6) δ 9.79 (br s, 0.35H), 9.77 (br s, 0.15H), 9.76 (br s, 0.15H), 9.73 (br s, 0.35H), 9.09 (br s, 1H), 7.63 - 7.54 (m, 2H), 7.52 - 7.44 (m, 1H), 7.43 - 7.35 (m, 1H), 7.25 - 7.16 (m, 1H), 6.46 (br s, 1H), 6.03 (br s, 1H), 4.74 - 4.70 (m, 0.15H), 4.70 - 4.67 (m, 0.15H), 4.33 - 4.27 (m, 0.35H), 4.27 - 4.21 (m, 0.35H), 2.46 - 2.40 (m, 0.15H), 2.39 - 2.30 (m, 0.15H), 2.26-2.20 (m, 0.35H), 2.20-2.14 (m, 0.35H), 1.95 (br s, 1H), 1.84 - 1.38 (m, 4.3H), 1.37 - 1.16 (m, 2H), 1.13 - 1.00 (m, 0.3H), 0.99 - 0.86 (m, 0.3H).	471.0	E	






I-2217		Fc1ccc(Cl)c(c1)[C@H]1NC(=O)c2cccc(NC(=O)[C@H]3CCC[C@H](C3)OC(F)(F)F)c12	Mixture (400 MHz, DMSO-d6) δ 9.79 (br s, 0.35H), 9.77 (br s, 0.15H), 9.76 (br s, 0.15H), 9.73 (br s, 0.35H), 9.09 (br s, 1H), 7.63 - 7.54 (m, 2H), 7.52 - 7.44 (m, 1H), 7.43 - 7.35 (m, 1H), 7.25 - 7.16 (m, 1H), 6.46 (br s, 1H), 6.03 (br s, 1H), 4.74 - 4.70 (m, 0.15H), 4.70 - 4.67 (m, 0.15H), 4.33 - 4.27 (m, 0.35H), 4.27 - 4.21 (m, 0.35H), 2.46 - 2.40 (m, 0.15H), 2.39 - 2.30 (m, 0.15H), 2.26-2.20 (m, 0.35H), 2.20-2.14 (m, 0.35H), 1.95 (br s, 1H), 1.84 - 1.38 (m, 4.3H), 1.37 - 1.16 (m, 2H), 1.13 - 1.00 (m, 0.3H), 0.99 - 0.86 (m, 0.3H).	471.0	E	
I-2218		Fc1ccc(Cl)c(c1)[C@@H]1NC(=O)c2cccc(NC(=O)[C@H]3CCC[C@H](C3)OC(F)(F)F)c12	Mixture (400 MHz, DMSO-d6) δ 9.79 (br s, 0.35H), 9.77 (br s, 0.15H), 9.76 (br s, 0.15H), 9.73 (br s, 0.35H), 9.09 (br s, 1H), 7.63 - 7.54 (m, 2H), 7.52 - 7.44 (m, 1H), 7.43 - 7.35 (m, 1H), 7.25 - 7.16 (m, 1H), 6.46 (br s, 1H), 6.03 (br s, 1H), 4.74 - 4.70 (m, 0.15H), 4.70 - 4.67 (m, 0.15H), 4.33 - 4.27 (m, 0.35H), 4.27 - 4.21 (m, 0.35H), 2.46 - 2.40 (m, 0.15H), 2.39 - 2.30 (m, 0.15H), 2.26-2.20 (m, 0.35H), 2.20-2.14 (m, 0.35H), 1.95 (br s, 1H), 1.84 - 1.38 (m, 4.3H), 1.37 - 1.16 (m, 2H), 1.13 - 1.00 (m, 0.3H), 0.99 - 0.86 (m, 0.3H).	471.0	E	






I-2219		OCC12CC(C1)(C2)C(=O)Nc1cccc2C(=O)NC(c12)c1cc(F)ccc1Cl	(400 MHz, DMSO-d6) δ 9.41 (br. s, 1H), 9.05 (br. s, 1H), 7.60 (dd, J = 7.4, 0.9 Hz, 1H), 7.55 (t, J = 7.5 Hz, 1H), 7.51 - 7.44 (m, 1H), 7.38 (dd, J = 7.6, 1.0 Hz, 1H), 7.24 (ddd, J = 8.8, 8.1, 3.1 Hz, 1H), 6.54 (br. s, 1H), 5.97 (br. s, 1H), 4.53 (t, J = 5.6 Hz, 1H), 3.33 - 3.31 (m, 2H), 1.65 - 1.59 (m, 6H).	401.3	E	
I-2220		Fc1cc(cc(c1)C(F)(F)F)C(=O)Nc1ccccc2C(=O)N[C@H](C3CC3)c12		379.4	E	
I-2221		Fc1cc(cc(c1)C(F)(F)F)C(=O)Nc1ccccc2C(=O)N[C@@H](C3CC3)c12		379.3	E	
I-2222		Fc1ccc(Cl)c(c1)C1NC(=O)c2cccc(NC(=O)N3CCNC(C3)C(F)(F)F)c12	(400 MHz, DMSO-d6) δ 9.03 (br s, 1H), 8.65 (s, 0.6H), 8.63 (s, 0.4H), 7.63 - 7.45 (m, 3H), 7.33 - 7.13 (m, 2H), 6.48 (br s, 1H), 5.99 (br s, 1H), 3.81 (br d, J = 11.4 Hz, 1H), 3.62 (submerged br d, J = 12.0 Hz, 0.6H), 3.20 - 3.04 (m, 0.6H), 2.93 - 2.55 (m, 3.6H), 2.49 - 2.35 (submerged m, 1H), 2.21 - 2.05 (m, 0.4H).	457.0	E	




I-2223		Nc1cc(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c2C(NC(=O)c2c1C#N)c1cc(F)ccc1Cl	(400 MHz, DMSO-d6) δ 10.42 (br s, 1 H), 9.16 (br s, 1 H), 7.94 - 7.82 (m, 1 H), 7.67 (d, J = 9.0 Hz, 1 H), 7.59 (s, 1 H), 7.31 (dd, J = 8.8, 5.2 Hz, 1 H), 7.07 (td, J = 8.4, 3.0 Hz, 1 H), 7.07 (submerged s, 1 H) 6.66 (br s, 1 H), 6.40 (br s, 1 H), 6.40 (submerged br s, 1 H), 5.82 (br s, 1 H).	507.2	A	A
I-2224		O[C@@H]1CCC[C@@H](C1)C1NC(=O)c2cccc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	(400 MHz, DMSO-d6) δ 10.73 (s, 1H), 8.74 (s, 1H), 8.13 (s, 1H), 8.08 (d, J = 9.4 Hz, 1H), 8.04 (d, J = 8.2 Hz, 1H), 7.66 - 7.49 (m, 3H), 4.73 (s, 1H), 4.60 (d, J = 3.9 Hz, 1H), 3.25 - 3.02 (m, 1H), 1.99 - 1.82 (m, 1H), 1.81 - 1.58 (m, 2H), 1.59 - 1.35 (m, 1H), 1.23 (dd, J = 23.9, 12.0 Hz, 1H), 1.09 - 0.73 (m, 2H), 0.75 - 0.43 (m, 2H); 2.5:1 mixture of diastereomers; major diastereomer described.	437.3	E	
I-2225		O[C@H]1CCCC(C1)[C@H]1NC(=O)c2cccc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	(400 MHz, DMSO-d6) δ 10.73 (s, 1H), 8.74 (s, 1H), 8.13 (s, 1H), 8.08 (d, J = 9.4 Hz, 1H), 8.04 (d, J = 8.2 Hz, 1H), 7.66 - 7.49 (m, 3H), 4.73 (s, 1H), 4.60 (d, J = 3.9 Hz, 1H), 3.25 - 3.02 (m, 1H), 1.99 - 1.82 (m, 1H), 1.81 - 1.58 (m, 2H), 1.59 - 1.35 (m, 1H), 1.23 (dd, J = 23.9, 12.0 Hz, 1H), 1.09 - 0.73 (m, 2H), 0.75 - 0.43 (m, 2H); 2.5:1 mixture of diastereomers; major diastereomer described.	437.3	E	





I-2226		O[C@@H]1CCC[C@H](C1)C1NC(=O)c2cccc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	(400 MHz, DMSO-d6) δ 10.73 (s, 1H), 8.74 (s, 1H), 8.13 (s, 1H), 8.08 (d, J = 9.4 Hz, 1H), 8.04 (d, J = 8.2 Hz, 1H), 7.66 - 7.49 (m, 3H), 4.73 (s, 1H), 4.60 (d, J = 3.9 Hz, 1H), 3.25 - 3.02 (m, 1H), 1.99 - 1.82 (m, 1H), 1.81 - 1.58 (m, 2H), 1.59 - 1.35 (m, 1H), 1.23 (dd, J = 23.9, 12.0 Hz, 1H), 1.09 - 0.73 (m, 2H), 0.75 - 0.43 (m, 2H); 2.5:1 mixture of diastereomers; major diastereomer described.	437.3	E	
I-2227		O[C@H]1CCC[C@H](C1)C1NC(=O)c2cccc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12	(400 MHz, DMSO-d6) δ 10.73 (s, 1H), 8.74 (s, 1H), 8.13 (s, 1H), 8.08 (d, J = 9.4 Hz, 1H), 8.04 (d, J = 8.2 Hz, 1H), 7.66 - 7.49 (m, 3H), 4.73 (s, 1H), 4.60 (d, J = 3.9 Hz, 1H), 3.25 - 3.02 (m, 1H), 1.99 - 1.82 (m, 1H), 1.81 - 1.58 (m, 2H), 1.59 - 1.35 (m, 1H), 1.23 (dd, J = 23.9, 12.0 Hz, 1H), 1.09 - 0.73 (m, 2H), 0.75 - 0.43 (m, 2H); 2.5:1 mixture of diastereomers; major diastereomer described.	437.3	E	
I-2228		C[C@H](O)c1cc(cc2C(=O)N[C@@H](c12)c1cc(F)ccc1Cl)-c1ccc2nccnn2c1	(400 MHz, DMSO-d6) δ 9.43 (br. s, 1H), 9.23 (br. s, 1H), 8.57 (s, 1H), 8.14 - 8.10 (m, 1H), 8.09 (d, J = 1.8 Hz, 1H), 8.08 - 8.01 (m, 2H), 7.98 (br. s, 1H), 7.71 - 7.54 (m, 1H), 7.28 (td, J = 8.5, 2.9 Hz, 1H), 6.51 (br. s, 1H), 6.22 (br. s, 1H), 5.28 (d, J = 3.5 Hz, 1H), 4.54 - 4.41 (m, 1H), 1.25 (d, J = 5.0 Hz, 3H); 3:1 mixture of	423.1	E	






			diastereomers; major diastereomer described.			
I-2229		C[C@H](O)c1cc(cc2C(=O)N[C@H](c12)c1cc(F)ccc1Cl)-c1ccc2ncnn2c1	(400 MHz, DMSO-d6) δ 9.43 (br. s, 1H), 9.23 (br. s, 1H), 8.57 (s, 1H), 8.14 - 8.10 (m, 1H), 8.09 (d, J = 1.8 Hz, 1H), 8.08 - 8.01 (m, 2H), 7.98 (br. s, 1H), 7.71 - 7.54 (m, 1H), 7.28 (td, J = 8.5, 2.9 Hz, 1H), 6.51 (br. s, 1H), 6.22 (br. s, 1H), 5.28 (d, J = 3.5 Hz, 1H), 4.54 - 4.41 (m, 1H), 1.25 (d, J = 5.0 Hz, 3H); 3:1 mixture of diastereomers; major diastereomer described	423.1	E	
I-2230		C[C@@H](O)c1cc(cc2C(=O)N[C@@H](c12)c1cc(F)ccc1Cl)-c1ccc2ncnn2c1	(400 MHz, DMSO-d6) δ 9.43 (br. s, 1H), 9.23 (br. s, 1H), 8.57 (s, 1H), 8.14 - 8.10 (m, 1H), 8.09 (d, J = 1.8 Hz, 1H), 8.08 - 8.01 (m, 2H), 7.98 (br. s, 1H), 7.71 - 7.54 (m, 1H), 7.28 (td, J = 8.5, 2.9 Hz, 1H), 6.51 (br. s, 1H), 6.22 (br. s, 1H), 5.28 (d, J = 3.5 Hz, 1H), 4.54 - 4.41 (m, 1H), 1.25 (d, J = 5.0 Hz, 3H); 3:1 mixture of diastereomers; major diastereomer described.	423.1	E	
I-2231		C[C@@H](O)c1cc(cc2C(=O)N[C@H](c12)c1cc(F)ccc1Cl)-c1ccc2ncnn2c1	(400 MHz, DMSO-d6) δ 9.43 (br. s, 1H), 9.23 (br. s, 1H), 8.57 (s, 1H), 8.14 - 8.10 (m, 1H), 8.09 (d, J = 1.8 Hz, 1H), 8.08 - 8.01 (m, 2H), 7.98 (br. s, 1H), 7.71 - 7.54 (m, 1H), 7.28 (td, J = 8.5, 2.9 Hz, 1H), 6.51 (br. s, 1H), 6.22 (br. s, 1H), 5.28 (d, J = 3.5 Hz, 1H), 4.54 - 4.41 (m, 1H), 1.25 (d, J = 5.0 Hz, 3H); 3:1 mixture of diastereomers; major diastereomer described.	423.1	E	




I-2232		Fc1ccc(Cl)c(c1)C1NC(=O)c2cccc(NC(=O)c3noc4CCOCc34)c12			E	
I-2233		FC(F)c1ccc(F)cc1[C@H]1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1cn2ncnc2cn1		601.3	D	
I-2234		FC(F)c1ccc(F)cc1[C@@H]1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1cn2ncnc2cn1		603.1	A	A
I-2235		CC1(C)CCc2scc(C(=O)Nc3ccccc4C(=O)NC(c34)c3cc(F)ccc3Cl)c2C1			D	
I-2236		O[C@@H]1C[C@H](CN(C1)C(=O)Nc1ccccc2C(=O)N[C@@H](c12)c1cc(F)ccc1Cl)C(F)(F)F		472.0	E	






I-2237		O[C@@H]1C[C@H](CN(C1)C(=O)Nc1ccc c2C(=O)N[C@H](c12)c1cc(F)ccc1Cl)C(F)(F)F		472.0	D	
I-2238		Fc1ccc(Cl)c(c1)C1NC(=O)c2cccc(NC(=O)c3noc4CCCCc34)c12			D	
I-2239		Fc1ccc(Cl)c(c1)C1NC(=O)c2cccc(NC(=O)c3csc4CCCCc34)c12			A	B
I-2240		CN1CCN(CC1(C)C)C(=O)Nc1cc(Br)cc2C(=O)N[C@H](c12)c1cc(F)ccc1Cl	(400 MHz, DMSO-d6) δ 9.16 (s, 1H), 8.49 (s, 1H), 7.59 (d, J = 1.4 Hz, 1H), 7.53 (d, J = 1.5 Hz, 1H), 7.51 - 7.44 (m, 1H), 7.23 (td, J = 8.4, 3.0 Hz, 1H), 6.61 (br. s, 1H), 6.01 (br. s, 1H), 3.23 - 3.16 (m, 1H), 3.02 - 2.96 (m, 1H), 2.92 (d, J = 13.4 Hz, 1H), 2.76 (d, J = 12.6 Hz, 1H), 2.32 - 2.20 (m, 2H), 2.06 (s, 3H), 0.84 (s, 3H), 0.69 (s, 3H).	511.3	E	
I-2241		CN1CCN(CC1(C)C)C(=O)Nc1cc(Br)cc2C(=O)N[C@@H](c12)c1cc(F)ccc1Cl	(400 MHz, DMSO-d6) δ 9.16 (s, 1H), 8.49 (s, 1H), 7.59 (d, J = 1.4 Hz, 1H), 7.53 (d, J = 1.5 Hz, 1H), 7.51 - 7.44 (m, 1H), 7.23 (td, J = 8.4, 3.0 Hz, 1H), 6.61 (br. s, 1H), 6.01 (br. s, 1H), 3.23 - 3.16 (m,	511.3	E	






			1H), 3.02 - 2.96 (m, 1H), 2.92 (d, J = 13.4 Hz, 1H), 2.76 (d, J = 12.6 Hz, 1H), 2.32 - 2.20 (m, 2H), 2.06 (s, 3H), 0.84 (s, 3H), 0.69 (s, 3H).			
I-2242		Fc1ccc(Cl)c(c1)[C@@H]1NC(=O)c2cc(Br)cc(NC(=O)N3CCOCC(F)(F)C3)c12	(400 MHz, DMSO-d6) δ 9.22 (s, 1H), 8.66 (s, 1H), 7.66 (d, J = 1.6 Hz, 1H), 7.55 (d, J = 1.7 Hz, 1H), 7.53 - 7.47 (m, 1H), 7.23 (td, J = 8.4, 3.1 Hz, 1H), 6.57 (br. s, 1H), 6.04 (br. s, 1H), 4.17 (dt, J = 15.4, 11.2 Hz, 1H), 3.77 - 3.53 (m, 4H), 3.52 - 3.41 (m, 2H), 3.19 (ddd, J = 14.6, 8.0, 3.6 Hz, 1H).	520.3	E	
I-2243		Fc1ccc(Cl)c(c1)[C@H]1NC(=O)c2cc(Br)cc(NC(=O)N3CCOCC(F)(F)C3)c12	(400 MHz, DMSO-d6) δ 9.22 (s, 1H), 8.66 (s, 1H), 7.66 (d, J = 1.6 Hz, 1H), 7.55 (d, J = 1.7 Hz, 1H), 7.53 - 7.47 (m, 1H), 7.23 (td, J = 8.4, 3.1 Hz, 1H), 6.57 (br. s, 1H), 6.04 (br. s, 1H), 4.17 (dt, J = 15.4, 11.2 Hz, 1H), 3.77 - 3.53 (m, 4H), 3.52 - 3.41 (m, 2H), 3.19 (ddd, J = 14.6, 8.0, 3.6 Hz, 1H).	520.3	E	
I-2244		CN1CCN(CC1)C(=O)Nc1cc(Br)cc2C(=O)N[C@H](c12)c1cc(F)ccc1Cl	(400 MHz, DMSO-d6) δ 9.17 (br. s, 1H), 8.64 (s, 1H), 7.58 (d, J = 1.7 Hz, 1H), 7.54 - 7.48 (m, 1H), 7.47 (d, J = 1.7 Hz, 1H), 7.25 (ddd, J = 8.7, 8.1, 3.1 Hz, 1H), 6.57 (br. s, 1H), 5.97 (br. s, 1H), 3.22 - 3.11 (m, 2H), 3.03 - 2.93 (m, 2H), 2.18 - 2.09 (m, 2H), 2.12 (s, 3H), 2.05 - 1.95 (m, 2H).	483.3	E	






I-2245		CN1CCN(CC1)C(=O)Nc1cc(Br)cc2C(=O)N[C@@H](c12)c1cc(F)ccc1Cl	(400 MHz, DMSO-d6) δ 9.17 (br. s, 1H), 8.64 (s, 1H), 7.58 (d, J = 1.7 Hz, 1H), 7.54 - 7.48 (m, 1H), 7.47 (d, J = 1.7 Hz, 1H), 7.25 (ddd, J = 8.7, 8.1, 3.1 Hz, 1H), 6.57 (br. s, 1H), 5.97 (br. s, 1H), 3.22 - 3.11 (m, 2H), 3.03 - 2.93 (m, 2H), 2.18 - 2.09 (m, 2H), 2.12 (s, 3H), 2.05 - 1.95 (m, 2H).	483.3	E	
I-2246		FC(F)C1CN(C(=O)Nc2cccc3C(=O)NC(c23)c2cc(F)ccc2Cl)c2ccccc12	(400 MHz, DMSO-d6) δ as a ca. 1:1 mixture of diastereomers, δ 9.07 (br. s, 2H), 8.67 (br. s, 1H), 8.66 (br. s, 1H), 7.81 (d, J = 8.0 Hz, 1H), 7.72 (d, J = 8.1 Hz, 1H), 7.61 - 7.54 (m, 4H), 7.43 - 7.34 (m, 4H), 7.30 (dd, J = 7.0, 4.5 Hz, 2H), 7.26 - 7.19 (m, 2H), 7.18 - 7.09 (m, 2H), 6.99 - 6.93 (m, 2H), 6.56 (br. s, 2H), 6.30 - 6.00 (m, 1H), 6.25 (td, J = 55.9, 3.5 Hz, 1H), 6.05 (br. s, 2H), 4.06 - 3.83 (m, 5H), 3.39 (dd, J = 10.2, 4.2 Hz, 1H).	472.4	A	B
I-2247		CC(C)(C)N[C@@H]1NC(=O)c2cccc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12		410.2	E	
I-2248		CC(C)(C)N[C@H]1NC(=O)c2cccc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12		410.2	E	





I-2249		Fc1cc(cc(c1)C(F)(F)F)C(=O)Nc1ccc2C(=O)N[C@H](NC3CCCC3)c12		422.2	E	
I-2250		Fc1cc(cc(c1)C(F)(F)F)C(=O)Nc1ccc2C(=O)N[C@@H](NC3CCCC3)c12		422.3	E	
I-2251		Oc1cc2C(=O)NC(c2c(c1)N(CCC#N)C(=O)c1cc(F)cc(c1)C(F)(F)F)c1cc(F)ccc1Cl	(400 MHz, DMSO-d6) 10.44 (s, 1H), 9.15 (d, J = 53.9 Hz, 1H), 8.00-7.44 (m, 3H), 7.38-6.99 (m, 3H), 6.86 (d, J = 47.8 Hz, 1H), 6.40 (dd, J = 78.9, 38.4 Hz, 1H), 6.02-5.06 (m, 1H), 4.68 (s, 1H), 3.69 (d, J = 151.1 Hz, 1H), 2.95-2.62 (m, 2H).	536.3	E	
I-2252		[H][C@@]1(NC(=O)c2cccc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)[C@@]1([H])CCCC(=O)C1	(400 MHz, DMSO-d6) δ 10.76 (s, 1H), 8.89 (s, 1H), 8.15 - 8.05 (m, 2H), 8.02 (d, J = 8.5 Hz, 1H), 7.66 - 7.51 (m, 3H), 4.96 (s, 1H), 2.40 - 2.13 (m, 3H), 2.14 - 2.01 (m, 1H), 2.02 - 1.89 (m, 1H), 1.89 - 1.61 (m, 2H), 1.52 - 1.19 (m, 1H), 1.20 - 0.99 (m, 1H); ~1.25:1 mixture of diastereomers, major diastereomer described	435.2	E	
I-2253		[H][C@@]1(NC(=O)c2cccc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)[C@]1([	(400 MHz, DMSO-d6) δ 10.76 (s, 1H), 8.89 (s, 1H), 8.15 - 8.05 (m, 2H), 8.02 (d, J = 8.5 Hz, 1H), 7.66 - 7.51 (m, 3H), 4.96 (s, 1H), 2.40 - 2.13 (m, 3H), 2.14 - 2.01 (m, 1H),	435.2	E	






		H])CCC C(=O)C1	2.02 - 1.89 (m, 1H), 1.89 - 1.61 (m, 2H), 1.52 - 1.19 (m, 1H), 1.20 - 0.99 (m, 1H); ~1.25:1 mixture of diastereomers; major diastereomer described.			
I-2254		[H][C@] 1(NC(=O)c2cccc(NC(=O)c 3cc(F)cc(c3)C(F)(F)F)c12)[C@@]1([H])CCC C(=O)C1	(400 MHz, DMSO-d6) δ 10.76 (s, 1H), 8.89 (s, 1H), 8.15 - 8.05 (m, 2H), 8.02 (d, J = 8.5 Hz, 1H), 7.66 - 7.51 (m, 3H), 4.96 (s, 1H), 2.40 - 2.13 (m, 3H), 2.14 - 2.01 (m, 1H), 2.02 - 1.89 (m, 1H), 1.89 - 1.61 (m, 2H), 1.52 - 1.19 (m, 1H), 1.20 - 0.99 (m, 1H); ~1.25:1 mixture of diastereomers; major diastereomer described.	435.2	E	
I-2255		[H][C@] 1(NC(=O)c2cccc(NC(=O)c 3cc(F)cc(c3)C(F)(F)F)c12)[C@]1([H])CCCC(=O)C1	of the mixture of diastereomers: 1H (400 MHz, DMSO-d6) δ 10.76 (s, 1H), 8.89 (s, 1H), 8.15 - 8.05 (m, 2H), 8.02 (d, J = 8.5 Hz, 1H), 7.66 - 7.51 (m, 3H), 4.96 (s, 1H), 2.40 - 2.13 (m, 3H), 2.14 - 2.01 (m, 1H), 2.02 - 1.89 (m, 1H), 1.89 - 1.61 (m, 2H), 1.52 - 1.19 (m, 1H), 1.20 - 0.99 (m, 1H); ~1.25:1 mixture of diastereomers; major diastereomer described.	435.2	E	
I-2256		FC(F)(C 1=CC(F) =CC(C(NC2=C3 C(NC(C3 =CC(NC 4=NCCO 4)=C2)= O)C5=C C(F)=CC =C5Cl)= O)=C1)F	(500 MHz, DMSO) δ 10.44 (s, 1H), 9.01 (s, 1H), 7.93 – 7.88 (m, 1H), 7.77 – 7.67 (m, 2H), 7.61 (s, 1H), 7.28 (dt, J = 8.9, 4.6 Hz, 1H), 7.06 (td, J = 8.3, 3.1 Hz, 1H), 5.87 (s, 1H), 4.30 (t, J = 8.5 Hz, 2H), 3.76 (s, 2H).	551.0	A	B




I-2257		OC1CN(C(=O)Nc2cc(Br)cc3C(=O)NC(c23)c2cc(F)ccc2C(F)F)c2ccc(F)cc12		550.1	A	B
I-2258		FC(F)c1ccc(F)cc1[C@H]1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(Cl)c3)c12)-c1cn2ncncc2cn1		567.3	D	
I-2259		FC(F)c1ccc(F)cc1[C@@H]1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(Cl)c3)c12)-c1cn2ncncc2cn1		567.3	A	A
I-2260		C[C@]1(CCC[C@@H](C1)C(F)(F)F)C(=O)Nc1cc(Br)cc2C(=O)N[C@@H](c12)c1cc(F)ccc1Cl		547.1	C	
I-2261		C[C@@]1(CCC[C@H](C1)C(F)(F)F)C(=O)Nc1cc(Br)cc2C(=O)N[C@@H](c12)c1cc(F)ccc1Cl		547.1	A	A




I-2262		C[C@]1(CCC[C@@H](C1)C(F)(F)F)C(=O)Nc1cc(Br)cc2C(=O)N[C@H](c12)c1cc(F)ccc1Cl		547.1	B	B
I-2263		C[C@@]1(CCC[C@H](C1)C(F)(F)F)C(=O)Nc1cc(Br)cc2C(=O)N[C@H](c12)c1cc(F)ccc1Cl		547.1	D	
I-2264		C[C@]1(CCC[C@@H](C1)C(F)(F)F)C(=O)Nc1cc(Br)cc2C(=O)N[C@@H](c12)c1cc(F)ccc1Cl		547.1	B	
I-2265		Fc1ccc(Cl)c(c1)C1NC(=O)c2cccc(NC(=O)c3coc4COCc34)c12		98.0	E	
I-2266		Fc1ccc(Cl)c(c1)C1NC(=O)c2cccc(NC(=O)c3csc4COCCc34)c12		98.0	B	



I-2267		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(Cl)c3)c12)-c1cn2ncncc2cn1			D	
I-2268		C[C@H](c1nn[nH]c1C(=O)Nc1cccc2C(=O)N[C@@H](c12)c1cc(F)ccc1Cl)C(F)(F)F		468.0	E	
I-2269		C[C@H](c1nn[nH]c1C(=O)Nc1cccc2C(=O)N[C@H](c12)c1cc(F)ccc1Cl)C(F)(F)F		468.0	E	
I-2270		C[C@@H](c1nn[nH]c1C(=O)Nc1cccc2C(=O)N[C@@H](c12)c1cc(F)ccc1Cl)C(F)(F)F		468.0	E	
I-2271		C[C@@H](c1nn[nH]c1C(=O)Nc1cccc2C(=O)N[C@H](c12)c1cc(F)ccc1Cl)C(F)(F)F		468.0	D	





I-2272		O[C@@H]1C[C@@H](C[C@@H](C1)C(F)(F)F)C(=O)Nc1cc(Br)cc2C(=O)N[C@@H](c12)c1cc(F)ccc1Cl		549.0	E	
I-2273		O[C@@H]1C[C@@H](C[C@@H](C1)C(F)(F)F)C(=O)Nc1cc(Br)cc2C(=O)N[C@H](c12)c1cc(F)ccc1Cl		550.9	E	
I-2274		O[C@H]1C[C@H](C[C@H](C1)C(F)(F)F)C(=O)Nc1cc(Br)cc2C(=O)N[C@@H](c12)c1cc(F)ccc1Cl		550.9	E	
I-2275		O[C@H]1C[C@H](C[C@H](C1)C(F)(F)F)C(=O)Nc1cc(Br)cc2C(=O)N[C@H](c12)c1cc(F)ccc1Cl		551.0	E	





I-2276		OC[C@@H]1CN(C[C@H]1C(F)(F)F)C(=O)Nc1cccc2C(=O)N[C@@H](c12)c1cc(F)ccc1Cl		470.2	E	
I-2277		OC[C@@H]1CN(C[C@H]1C(F)(F)F)C(=O)Nc1cccc2C(=O)N[C@H](c12)c1cc(F)ccc1Cl		470.2	D	
I-2278		OC[C@H]1CN(C[C@@H]1C(F)(F)F)C(=O)Nc1ccccc2C(=O)N[C@@H](c12)c1cc(F)ccc1Cl		470.2	E	
I-2279		OC[C@H]1CN(C[C@@H]1C(F)(F)F)C(=O)Nc1ccccc2C(=O)N[C@H](c12)c1cc(F)ccc1Cl		470.2	E	
I-2280		OC1c2ccccc2N(C(=O)Nc2ccc3C(=O)NC(c23)c2cc(F)ccc2Cl)C11CC1	(400 MHz, DMS)-d6) δ 9.23 (s,, 1H), 9.07 (br. s, 1H), 7.52 (m, 2H), 7.38 (d, J = 5.2 Hz, 1H), 7.35 (d, J = 5.2 Hz, 1H), 7.28 - 7.21 (m, 1H), 7.16 - 6.99 (m, 1H), 6.96 - 6.83 (m, 2H), 6.42 (br. s, , 1H),	464.4	E	





			6.13 (br. s, 1H), 6.00 (br. s, 1H), 5.62 (d, J = 6.8 Hz, 1H), 5.04 (d, J = 5.3 Hz, 1H), 1.78 (dt, J = 10.3, 5.2 Hz, 1H), 1.33 (ddd, J = 12.0, 8.1, 4.5 Hz, 1H), 1.10 (dt, J = 9.7, 5.0 Hz, 1H), 0.46 (ddd, J = 10.0, 7.2, 4.7 Hz, 1H); mixture of diastereomers.			
I-2281		Fc1cc(cc(c1)C(F)(F)F)C(=O)Nc1ccc2C(=O)N[C@H](C[C@@H]3CCCCN3)c12		436.4	E	
I-2282		Fc1cc(cc(c1)C(F)(F)F)C(=O)Nc1ccc2C(=O)N[C@@H](C[C@@H]3CCCCN3)c12		426.4	E	
I-2283		Fc1ccc(Cl)c(c1)C1NC(=O)c2cccc(NC(=O)C3CCc4ccccc4C3)c12	(400 MHz, DMSO-d6) δ 9.81 (s, 1H), 9.11 (br. s, 1H), 7.65 - 7.49 (m, 3H), 7.45 (ddd, J = 11.5, 7.2, 1.7 Hz, 1H), 7.34 - 7.23 (m, 1H), 7.11 - 7.03 (m, 3H), 7.02 - 6.88 (m, 1H), 6.48 (br. s, 1H), 6.09 (br. s, 1H), 2.80 - 2.59 (m, 2H), 2.61 - 2.52 (m, 1H), 2.48 - 2.22 (m, 2H), 1.55 (m, 2H); mixture of diastereomers.	435.4	E	






I-2284		Fc1ccc(Cl)c(c1)C1NC(=O)c2cccc(NC(=O)N3CCSc4ccccc34)c12	(400 MHz, DMSO-d6) δ 9.07 (br s, 1H), 8.64 (s, 1H), 7.58 - 7.45 (m, 3H), 7.38 (d, J = 7.3 Hz, 1H), 7.26 (td, J = 8.4, 3.1 Hz, 1H), 7.16 (dd, J = 7.9, 1.4 Hz, 1H), 6.99 (td, J = 7.7, 1.3 Hz, 1H), 6.79 (td, J = 7.7, 1.3 Hz, 1H), 6.46 (br s, 1H), 6.20 (br s, 1H), 6.07 (br s, 1H), 4.37 (br d, J = 11.4 Hz, 1H), 3.20 - 3.04 (m, 2H), 3.03 - 2.91 (m, 1H).	454.0	E	
I-2285		OC(C(F)(F)F)C12CCC(CC1)(C2)C(=O)Nc1ccc2C(=O)NC(c12)c1cc(F)ccc1Cl	(400 MHz, DMSO-d6) δ 9.29 (s, 0.5H), 9.28 (s, 0.5H), 9.08 (br s, 1H), 7.60 (dd, J = 7.4, 1.1 Hz, 1H), 7.56 (t, J = 7.5 Hz, 1H), 7.53 - 7.44 (m, 1H), 7.37 (dd, J = 7.4, 1.0 Hz, 1H), 7.22 (td, J = 8.4, 3.1 Hz, 1H), 6.44 (br s, 1H), 6.25 (d, J = 2.7 Hz, 0.5H), 6.24 (d, J = 2.8 Hz, 0.5H), 6.04 (br s, 1H), 4.02 - 3.93 (m, 1H), 1.82 - 1.68 (m, 1H), 1.62 - 1.15 (m, 9H). 1:1 mix of diastereomers	473.0	E	
I-2286		CC([C@@H]1C[C@@H](O)CN1C(=O)Nc1cccc2C(=O)NC(c12)c1cc(F)ccc1Cl)C(F)(F)F	(400 MHz, CD3CN) δ 7.74 (d, J = 7.6 Hz, 0.4H), 7.65 - 7.44 (m, 3.6H), 7.17 (br s, 1H), 7.14 - 7.06 (m, 1H), 6.66 (br s, 0.4H), 6.57 (br s, 1H), 6.50 (br s, 0.6H), 6.31 - 6.24 (m, 1H), 4.34 - 4.24 (m, 0.6H), 4.16 (p, J = 6.9 Hz, 0.4H), 4.13 - 4.05 (m, 1H), 3.37-3.30 (m, 0.4H), 3.29 - 3.02 (m, 1H), 3.02 - 2.88 (m, 0.6H), 2.83 (dd, J = 10.1, 2.9 Hz, 0.6H), 2.77 (dd, J = 9.7, 6.9 Hz, 0.4H), 2.09 - 2.00 (m, 2H [submerged	486.3	C	





			under H2O]), 1.04 (d, J = 7.3 Hz, 1.2H), 0.89 (d, J = 6.9 Hz, 1.8H) ppm [~1.5-1 mixture of diastereomers]			
I-2287		CC([C@H]1C[C@@H](O)CN1C(=O)Nc1cccc2C(=O)NC(c12)c1cc(F)ccc1Cl)C(F)(F)F	(400 MHz, CD3CN) δ 7.60 (s, 0.4H), 7.58 (s, 0.6H), 7.52 (t, J = 7.6 Hz, 1H), 7.48 - 7.38 (m, 1H), 7.32 (d, J = 8.0 Hz, 0.4H), 7.30 (d, J = 7.8 Hz, 0.6H), 7.15 (br s, 1H), 7.13 - 7.03 (m, 1H), 6.86 (br s, 0.6H), 6.82 (br s, 0.4H), 6.56 (br s, 1H), 6.11 (br s, 1H), 4.36 - 4.26 (m, 0.4H), 4.26 - 4.15 (m, 1H), 3.98 (p, J = 7.3 Hz, 0.4H), 3.22 - 3.08 (m, 0.4H), 3.00 (dd, J = 10.5, 3.0 Hz, 0.4H), 2.96 - 2.87 (m, 1H), 2.82 (dd, J = 9.8, 7.6 Hz, 1H), 2.75 (dd, J = 10.6, 5.9 Hz, 0.4H), 2.13 - 2.04 (m, 1H [submerged under H_2O peak]), 1.74 - 1.63 (m, 1H), 1.00 (d, J = 7.2 Hz, 1.2H), 0.97 (d, J = 7.1 Hz, 1.8H) ppm [~1.5:1 mixture of diastereomers]	486.3	E	
I-2288		CC(O)c1cc2C(=O)NC(c2c(NC(=O)N2CC(O)c3ccccc23)c1)c1cc(F)ccc1Cl	(400 MHz, DMSO-d6) 9.02 (d, J = 10.9 Hz, 1H), 8.62-8.49 (m, 1H), 7.84-7.71 (m, 1H), 7.56 (ddd, J = 11.8, 4.1, 1.4 Hz, 1H), 7.49-7.30 (m, 3H), 7.30-7.05 (m, 2H), 6.96 (dtd, J = 9.8, 7.4, 1.0 Hz, 1H), 6.53 (s, 1H), 6.08-5.99 (m, 1H), 5.62 (ddd, J = 13.7, 5.6, 1.8 Hz, 1H), 5.39 (dd, J = 4.4, 2.6 Hz, 1H), 5.15-5.09 (m, 1H), 4.86 (dp, J = 12.3, 6.3 Hz, 1H), 4.01-3.70 m, 1H),3.30-3.15 (m, 1H), 1.40 (dd, J = 6.4, 2.0 Hz, 3H).	482.3	A	D





I-2289		CC(C#N)c1cc2C(=O)N[C@@H](c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	(400 MHz, DMSO-d6)10.60 (s, 1H), 9.23 (s, 1H), 7.95 (d, J = 8.5 Hz, 1H), 7.74 (d, J = 4.9 Hz, 2H), 7.66 (s, 1H), 7.57 (s, 1H), 7.33 (dd, J = 8.9, 5.1 Hz, 1H), 7.10 (td, J = 8.3, 3.1 Hz, 1H),7.10-5.99 (s, 1H), 5.99 (s, 1H), 4.57 (dd, J = 7.2, 4.1 Hz, 1H), 1.64 (dd, J = 7.3, 4.5 Hz, 3H).	520.1	D	
I-2290		CC(C#N)c1cc2C(=O)N[C@H](c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl	(400 MHz, DMSO-d6) 10.60 (d, J = 10.8 Hz, 1H), 9.24 (s, 1H), 7.96 (d, J = 8.4 Hz, 1H), 7.78-7.71 (m, 2H), 7.66 (s, 1H), 7.56 (d, J = 7.4 Hz, 1H), 7.33 (dd, J = 8.9, 5.1 Hz, 1H), 7.10 (td, J = 8.4, 3.1 Hz, 1H), 6.68 (s, 1H), 5.99 (s, 1H), 4.57 (q, J = 7.2 Hz, 1H), 1.64 (dd, J = 7.2, 4.6 Hz, 3H).	520.1	A	A
I-2291		O[C@H]1CN(C(=O)Nc2ccccc3C(=O)N[C@H](c23)c2cc(F)ccc2Cl)c2cc(F)c(F)cc12	(400 MHz, DMSO-d6) 9.09 (s, 1H), 8.65 (s, 1H), 7.67 - 7.53 (m, 3H), 7.42 (dd, J = 7.6, 1.3 Hz, 1H), 7.39 - 7.30 (m, 2H), 7.14 - 7.05 (m, 1H), 6.56 (s, 1H), 6.08 (s, 1H), 5.76 (dt, J = 4.4, 1.8 Hz, 1H), 5.14 (dt, J = 8.6, 4.3 Hz, 1H), 3.99 (dd, J = 11.0, 8.1 Hz, 1H), 3.23 (dd, J = 11.2, 3.8 Hz, 1H).	474.0	D	
I-2292		O[C@H]1CN(C(=O)Nc2ccccc3C(=O)N[C@@H](c23)c2cc(F)ccc2Cl)c2cc(F)c(F)cc12	(400 MHz, DMSO-d6) 9.09 (s, 1H), 8.64 (s, 1H), 7.67 - 7.54 (m, 3H), 7.42 (dd, J = 7.5, 1.4 Hz, 1H), 7.39 - 7.30 (m, 2H), 7.10 (ddd, J = 8.9, 7.9, 3.1 Hz, 1H), 6.55 (s, 1H), 6.07 (s, 1H), 5.76 (d, J = 5.0 Hz, 1H), 5.14 (dt, J = 8.4, 4.3 Hz, 1H), 3.99 (dd, J = 11.1, 8.0 Hz, 1H), 3.23 (dd, J = 11.0, 3.8 Hz, 1H).	474.0	E	





I-2293		O[C@@H]1CN(C(=O)Nc2cccc3C(=O)N[C@H](c23)c2cc(F)ccc2Cl)c2cc(F)c(F)cc12	(400 MHz, DMSO-d6) 9.07 (s, 1H), 7.79 (s, 1H), 7.64 - 7.53 (m, 2H), 7.42 - 7.33 (m, 3H), 7.16 (td, J = 8.3, 3.1 Hz, 1H), 6.05 (s, 2H), 5.09 - 5.02 (m, 1H), 3.74 (dd, J = 11.3, 3.3 Hz, 1H), 3.34 (s, 2H).	474.0	A	A
I-2294		O[C@H]1CN(C(=O)Nc2cccc3C(=O)N[C@@H](c23)c2cc(F)ccc2Cl)c2cc(F)c(F)cc12	(400 MHz, DMSO-d6) 9.07 (s, 1H), 8.75 (s, 1H), 7.79 (d, J = 6.1 Hz, 1H), 7.64 - 7.57 (m, 1H), 7.57 (t, J = 7.4 Hz, 1H), 7.38 (dt, J = 8.8, 4.9 Hz, 3H), 7.16 (ddd, J = 8.9, 7.9, 3.1 Hz, 1H), 6.54 (s, 1H), 5.98 (d, J = 6.9 Hz, 1H), 5.78 (dd, J = 6.0, 1.3 Hz, 1H), 5.05 (d, J = 8.4 Hz, 1H), 3.74 (dd, J = 11.4, 3.3 Hz, 1H), 3.23 (s, 1H).	474.0	E	
I-2295		Fc1ccc(Cl)c(c1)C1NC(=O)c2cccc(OCc3cc(F)cc(c3)C(F)(F)F)c12	(400 MHz, DMSO-d6) δ9.10 (s, 1H), 7.65 - 7.59 (m, 1H), 7.55 (t, J = 7.8 Hz, 1H), 7.43 (dd, J = 8.9, 5.1 Hz, 1H), 7.37 (d, J = 7.5 Hz, 1H), 7.33 (s, 1H), 7.27 (d, J = 8.1 Hz, 1H), 7.20 (td, J = 8.4, 3.1 Hz, 1H), 7.08 (d, J = 9.5 Hz, 1H), 6.79 (s, 1H), 6.04 (s, 1H), 5.19 (s, 2H).	454.0	E	
I-2296		OCC1(NC(=O)c2cccc(-c3nc4cc(cc(F)c4[nH]3)C(F)(F)F)c12)c1cccc(F)c1	(400 MHz, DMSO-d6) δ9.05 (s, 1H), 8.03 (d, J = 7.6 Hz, 1H), 7.89 (d, J = 7.4 Hz, 1H), 7.73 (d, J = 7.6 Hz, 1H), 7.61 (s, 1H), 7.33 (d, J = 10.6 Hz, 1H), 6.99 (q, J = 7.5 Hz, 1H), 6.89 - 6.75 (m, 3H), 4.75 (d, J = 10.6 Hz, 1H), 4.60 (s, 1H).	460.3	D	



I-2297		FC(F)(C1OC(NC(C=C23)=CC(NC(C4=CC(C(F)(F)F)=CC(F)=C4)=O)=C3C(NC2=O)C5=CC(F)=CC=C5Cl)=NC1)F	(400 MHz, DMSO) δ 10.50 (d, J = 3.8 Hz, 1H), 10.16 – 10.11 (m, 1H), 9.08 (s, 1H), 7.98 (s, 0H), 7.92 (dt, J = 8.5, 1.9 Hz, 2H), 7.78 (s, 1H), 7.73 – 7.66 (m, 2H), 7.63 – 7.58 (m, 1H), 7.28 (ddd, J = 8.9, 5.2, 2.8 Hz, 1H), 7.11 – 7.01 (m, 0H), 7.06 (s, 1H), 6.64 (s, 2H), 5.87 (s, 1H), 5.32 (d, J = 8.4 Hz, 1H), 4.16 (t, J = 11.8 Hz, 1H), 3.98 – 3.90 (m, 1H).	619.0	A	B
I-2298		FC(F)(C1=CC(F)=CC(C(NC2=C3C(NC(C3=CC(NC4=NCCN4C)=C2)=O)C5=CC(F)=CC=C5Cl)=O)=C1)F	(400 MHz, DMSO) δ 10.53 (s, 1H), 9.25 (s, 1H), 7.96 (dt, J = 8.4, 2.1 Hz, 1H), 7.78 (s, 5H), 7.74 – 7.58 (m, 2H), 7.53 (d, J = 1.9 Hz, 1H), 7.39 – 7.28 (m, 2H), 7.27 – 7.10 (m, 1H), 7.08 (s, 2H), 6.62 (s, 1H), 6.02 (s, 1H), 3.75 – 3.65 (m, 2H), 3.65 – 3.49 (m, 3H), 3.03 (s, 3H), 1.25 (dd, J = 7.0, 2.2 Hz, 3H).	564.0	B	
I-2299		OC1CN(C(=O)Nc2cc(cc3C(=O)NC(c23)c2cc(F)ccc2Cl)-c2cnn(c2)C(F)F)c2ccc(F)cc12		572.2	A	B
I-2300		FC(F)n1cc(cn1)-c1cc2C(=O)NC(c2c(NC(=O)N2CCc3cc(F)ccc23)c1)c1cc(F)ccc1Cl		556.2	A	B




I-2301		Fc1ccc(Cl)c(c1)C1NC(=O)c2cccc(NC(=O)c3csc4cocc34)c12		98.0	E	
I-2302		Fc1ccc(Cl)c(c1)C1NC(=O)c2cccc(NC(=O)C3COC4CCCCC34)c12		98.0	E	
I-2303		Fc1ccc(Cl)c(c1)C1NC(=O)c2cccc(NC(=O)C34CC5CC(CC(C5)O3)C4)c12		98.0	E	
I-2304		Fc1ccc(Cl)c(c1)C1NC(=O)c2cccc(NC(=O)c3csc4CNCCc34)c12		97.0	E	
I-2305		Fc1ccc(Cl)c(c1)C1NC(=O)c2cccc(NC(=O)N3CCCc4ccccc4C3)c12	(400 MHz, DMSO-d6) 8.95 (s, 1H), 8.20 (s, 1H), 7.48 (q, J = 3.3, 2.4 Hz, 2H), 7.29 (td, J = 6.2, 5.6, 2.7 Hz, 2H), 7.20 - 7.10 (m, 3H), 7.07 (ddd, J = 11.5, 7.5, 3.4 Hz, 2H), 6.38 (s, 1H), 6.01 (s, 1H), 4.50 (d, J = 14.9 Hz, 1H), 4.25 (d, J = 14.9 Hz, 1H), 3.50 (d, J = 14.3 Hz, 1H), 2.82 (q, J = 6.1 Hz, 2H), 2.50 (p, J = 1.9 Hz, 1H), 1.55 - 1.47 (m, 2H).	450.1	E	




I-2306		Fc1ccc(Cl)c(c1)C1NC(=O)c2cccc(NC(=O)N3CCCCc4ccccc34)c12	(400 MHz, DMSO-d6) 9.04 - 9.00 (m, 1H), 7.55 (s, 5H), 7.49 (d, J = 4.3 Hz, 1H), 7.34 - 7.21 (m, 1H), 7.15 (td, J = 7.5, 1.4 Hz, 1H), 7.00 (s, 1H), 6.41 (s, 2H), 6.11 - 6.06 (m, 1H), 2.68 (d, J = 2.1 Hz, 2H), 2.51 (d, J = 1.9 Hz, 1H), 2.52 - 2.12 (m, 2H), 1.65 (s, 1H), 1.53 (s, 1H), 1.35 (s, 1H).	450.1	E	
I-2307		Fc1ccc(Cl)c(c1)C1NC(=O)c2cccc(NC(=O)N3CCc4ccccc4C3)c12	(400 MHz, DMSO-d6) 9.01 (s, 1H), 8.57 (s, 1H), 7.51 (q, J = 4.4, 3.7 Hz, 2H), 7.32 (dd, J = 5.9, 3.0 Hz, 1H), 7.17 (tdd, J = 9.2, 7.1, 4.3 Hz, 4H), 7.08 - 7.01 (m, 1H), 6.97 (t, J = 9.0 Hz, 1H), 6.40 (s, 1H), 6.01 (s, 1H), 4.41 (d, J = 16.4 Hz, 1H), 4.15 (d, J = 16.4 Hz, 1H), 3.45 (ddd, J = 12.2, 6.7, 4.7 Hz, 1H), 3.22 (ddd, J = 12.6, 7.4, 4.5 Hz, 1H), 2.77 - 2.67 (m, 1H), 2.55 (d, J = 5.6 Hz, 1H).	436.1	E	
I-2308		Fc1ccc(Cl)c(c1)C1NC(=O)c2cccc(NC(=O)N3CCc4ccccc4CC3)c12	(400 MHz, DMSO-d6) 9.04 (s, 1H), 8.56 (s, 1H), 7.53 (q, J = 4.4, 3.5 Hz, 2H), 7.40 - 7.30 (m, 2H), 7.11 (dd, J = 16.8, 3.0 Hz, 5H), 6.49 (s, 1H), 6.13 (s, 1H), 3.34 (s, 2H), 3.32 (s, 2H), 2.68 (d, J = 18.1 Hz, 2H), 2.47 (s, 2H).	450.1	E	
I-2309		NC(=O)CCN(C(=O)c1cc(F)cc(c1)C(F)(F)F)c1cc(O)cc2C(=O)NC(c12)c1cc(F)ccc1Cl	(400 MHz, DMSO-d6) 10.26 (s, 1H), 9.13 (d, J = 53.2 Hz, 1H), 7.86-6.66 (m, 7H), 6.63-5.97 (m, 1H), 5.97-4.24 (m, 1H), 3.58 (d, J = 67.6 Hz, 1H), 2.48-2.12 (m, 2H).	554.2	E	






I-2310		O[C@H]1CN(C(=O)Nc2cccc3C(=O)N[C@@H](c23)c2cc(F)ccc2Cl)c2ccc(F)c(F)c12	(400 MHz, DMSO-d6) 9.05 (s, 1H), 8.73 (s, 1H), 7.68 (s, 1H), 7.58 (d, J = 8.7 Hz, 2H), 7.49 - 7.27 (m, 3H), 7.17 (td, J = 8.4, 3.1 Hz, 1H),6.82 - 6.24 (s, 1H), 5.97 (s, 2H), 5.27 (d, J = 7.2 Hz, 1H), 3.81 (d, J = 11.4 Hz, 1H), 3.23 (s, 1H).	474.1	A	A
I-2311		O[C@@H]1CN(C(=O)Nc2cccc3C(=O)N[C@@H](c23)c2cc(F)ccc2Cl)c2ccc(F)c(F)c12	(400 MHz, DMSO-d6) 9.08 (s, 1H), 8.60 (s, 1H), 7.58 (dd, J = 12.9, 5.6 Hz, 2H), 7.45 (q, J = 6.9, 5.3 Hz, 2H), 7.36 (dd, J = 8.9, 5.1 Hz, 1H), 7.27 (q, J = 9.4 Hz, 1H), 7.10 (td, J = 8.4, 3.1 Hz, 1H), 6.52 (s, 1H), 6.08 (s, 1H), 5.92 (d, J = 4.9 Hz, 1H), 5.34 (s, 1H), 3.96 (dd, J = 11.3, 7.6 Hz, 1H), 3.36 (d, J = 2.9 Hz, 1H).	474.3	D	
I-2312		O[C@H]1CN(C(=O)Nc2cccc3C(=O)N[C@H](c23)c2cc(F)ccc2Cl)c2ccc(F)c(F)c12	(400 MHz, DMSO-d6) 9.09 (s, 1H), 8.59 (s, 1H), 7.64 - 7.51 (m, 2H), 7.48 - 7.40 (m, 2H), 7.36 (dd, J = 8.9, 5.1 Hz, 1H), 7.28 (dt, J = 11.0, 8.6 Hz, 1H), 7.10 (ddd, J = 8.9, 7.9, 3.1 Hz, 1H), 6.55 (s, 1H), 6.08 (s, 1H), 5.93 (d, J = 5.8 Hz, 1H), 5.39 - 5.30 (m, 1H), 3.96 (dd, J = 11.2, 7.7 Hz, 1H), 3.36 (d, J = 2.9 Hz, 1H).	474.3	D	
I-2313		O[C@@H]1CN(C(=O)Nc2cccc3C(=O)N[C@H](c23)c2cc(F)ccc2Cl)c2ccc(F)c(F)c12	(400 MHz, DMSO-d6) 9.06 (s, 1H), 8.73 (s, 1H), 7.69 (d, J = 8.8 Hz, 1H), 7.62 - 7.49 (m, 2H), 7.44 - 7.25 (m, 3H), 7.17 (td, J = 8.3, 3.1 Hz, 1H), 6.50 (s, 1H), 5.98 (m, 2H), 5.28 (t, J = 7.1 Hz, 1H), 3.81 (dd, J = 11.5, 2.4 Hz, 1H), 3.21 (s, 1H).	474.3	D	






I-2314		OCC1CN(C(=O)Nc2cccc3C(=O)NC(c23)c2cc(F)ccc2Cl)c2ccccc12	(400 MHz, DMSO-d6) δ 9.04 (br. s, 1H), 8.58 (br. s, 0.5H), 8.56 (br. s, 0.5H), 7.79 - 7.67 (m, 1H), 7.60 - 7.52 (m, 2H), 7.43 - 7.32 (m, 2H), 7.21 (d, J = 7.3 Hz, 1H), 7.18 - 7.07 (m, 2H), 6.89 (ddd, J = 7.4, 4.1, 0.9 Hz, 1H), 6.48 (br. s, 1H), 6.03 (br. s, 1H), 4.94 (br. s, 1H), 3.93 (t, J = 9.9 Hz, 0.5H), 3.74 (dd, J = 10.0, 4.6 Hz, 0.5H), 3.69 - 3.55 (m, 1H), 3.41 - 3.38 (submerged m, 1H), 3.28 - 3.09 (m, 2H); 1:1 mixture of diastereomers.	452.3	D	
I-2315		Oc1nn(C(=O)Nc2cccc3C(=O)NC(c23)c2cc(F)ccc2Cl)c2ccccc12	(400 MHz, DMSO-d6) δ 9.38 (s, 1H), 9.10 (s, 1H), 8.11 (d, J = 8.4 Hz, 1H), 7.85 (d, J = 8.0 Hz, 1H), 7.68 (dd, J = 7.5, 1.1 Hz, 1H), 7.65 - 7.57 (m, 2H), 7.56 - 7.50 (m, 1H), 7.34 - 7.21 (m, 2H), 7.01 (td, J = 8.5, 3.0 Hz, 1H), 6.66 (br s, 1H), 6.21 (br s, 1H).	437.0	D	
I-2316		Fc1ccc(Cl)c(c1)C1NC(=O)c2cccc(C(=O)Nc3ccc(cc3)C(F)(F)F)c12	(400 MHz, DMSO-d6) δ 10.71 (s, 1 H), 9.28 (s, 1 H), 7.95 (d, J = 7.5 Hz, 1 H), 7.75 (t, J = 7.6 Hz, 1 H), 7.64 (app s, 4 H), 7.37 (dd, J = 8.1, 5.1 Hz, 1 H), 7.14 - 7.07 (m, 1 H), 6.50 (submerged br s, 1 H), 6.41 (overlapped br s, 1 H).	449.2	E	
I-2317		COC(=O)C1CN(C(=O)Nc2cccc3C(=O)NC(c23)c2cc(F)ccc2Cl)c2ccccc12	(400 MHz, DMSO-d6) δ 9.05 (br. s, 1H), 8.71 (br. s, 0.5H), 8.68 (br. s, 0.5H), 7.73 (d, J = 8.0 Hz, 1H), 7.66 - 7.47 (m, 2H), 7.44 - 7.29 (m, 3H), 7.24 - 7.06 (m, 2H), 6.95 (ddd, J = 7.5, 3.3, 1.0	435.4	E	





			Hz, 1H), 6.57 (br. s, 1H), 6.04 (br. s, 1H), 4.41 (dd, J = 10.3, 6.2 Hz, 0.5H), 4.32 (dd, J = 10.3, 6.0 Hz, 0.5H), 4.22 (dd, J = 10.4, 6.1 Hz, 0.5H), 4.06 (t, J = 10.6 Hz, 0.5H), 3.74 - 3.69 (submerged m, 0.5H), 3.74 (s, 1.5H), 3.72 (s, 0.5H), 3.42 - 3.32 (submerged m, 0.5H); 1:1 mixture of diastereomers.			
I-2318		Fc1cc(cc(c1)C(F)(F)F)C(=O)Nc1ccc2C(=O)N[C@@H]([C@H]3CCCCCN3)c12	(400 MHz, CD3CN) δ 8.75 (dd, J = 7.6, 1.5 Hz, 0.5H), 8.55 (dd, J = 7.6, 1.4 Hz, 0.5H), 8.07 (s, 0.5H (formate salt)), 8.03 (s, 0.5H), 8.01 (s, 0.5H), 7.94 - 7.86 (m, 1H), 7.68 (d, J = 8.5 Hz, 1H), 7.53 - 7.45 (m, 2H), 6.95 (br s, 0.5H), 6.87 (br s, 0.5H), 4.72 (d, J = 1.7 Hz, 0.5H), 4.53 (d, J = 9.8 Hz, 0.5H), 3.40 (dt, J = 9.0, 2.5 Hz, 0.5H), 2.77 - 2.69 (m, 1H), 2.65 - 2.36 (m, 2H, submerged under H2O peak)), 1.85 - 1.78 (m, 0.5H), 1.71 - 1.53 (m, 3H), 1.52 - 1.35 (m, 3H) ppm [~1:1 dr, NH protons not observed].	436.4	E	
I-2319		Fc1cc(cc(c1)C(F)(F)F)C(=O)Nc1ccc2C(=O)N[C@@H]([C@@H]3CCCCCN3)c12	(400 MHz, CD3CN) δ 8.55 (dd, J = 7.6, 1.5 Hz, 1H), 8.09 (s, 0.5H, formate salt)), 8.01 (s, 1H), 7.90 (d, J = 9.0 Hz, 1H), 7.68 (d, J = 8.6 Hz, 1H), 7.55 - 7.45 (m, 2H), 6.95 (br s, 1H), 4.53 (dd, J = 9.6, 1.0 Hz, 1H), 2.77 - 2.68 (m, 1H), 2.60 - 2.51 (m, 1H), 2.44 - 2.36 (m, 1H (submerged under H2O peak)), 1.85 - 1.78 (m, 1H), 1.74 - 1.55 (m, 3H), 1.53 - 1.37 (m, 3H) ppm [single	436.4	E	




			diastereomer, NH protons not observed].			
I-2320		Nc1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cccc(F)c1	(400 MHz, DMSO-d6) δ 10.17 (s, 1 H), 8.84 (s, 1 H), 7.93 (d, J = 8.4 Hz, 1 H), 7.70 (d, J = 9.0 Hz, 1 H), 7.62 (s, 1 H), 7.20 - 7.12 (m, 1 H), 6.98 (td, J = 8.5, 2.4 Hz, 1 H), 6.81 (d, J = 1.8 Hz, 1 H), 6.78 (d, J = 7.7 Hz, 1 H), 6.74 - 6.68 (m, 2 H), 5.57 (br s, 2 H), 5.52 (s, 1 H).	448.2	C	
I-2321		Fc1ccc(Cl)c(c1)C1NC(=O)c2cccc(NC(=O)N3CCC3c3ccccc3)c12	(400 MHz, DMSO-d6) δ 9.05 (br s, 0.5H), 9.01 (br s, 0.5H), 8.51 (s, 0.5H), 8.04 (s, 0.5H), 7.58 - 7.53 (m, 1H), 7.53 - 7.47 (m, 2H), 7.38-7.27 (m, 3H), 7.26-7.20 (m, 4H), 6.61 (br s, 1H), 6.08 (br s, 0.5H), 6.03 (submerged br s, 0.5H), 5.21 (t, J = 8.1 Hz, 0.5H), 4.92 (t, J = 7.7 Hz, 0.5H), 3.86 - 3.74 (m, 1H), 3.61 (dd, J = 16.0, 7.7 Hz, 0.5H), 3.04 (dd, J = 14.3, 7.6 Hz, 0.5H), 2.47 (submerged m, 1H), 2.04 - 1.87 (m, 1H). 1:1 Mix of diastereomers	436.0	E	
I-2322		Fc1cc(cc(c1)C(F)(F)F)C(=O)Nc1ccc2C(=O)NC(CC3CC=CC3)c12	(400 MHz, DMSO d6) δ 10.79 (s, 1H), 8.94 (s, 1H), 8.14 (s, 1H), 8.09 (d, J = 9.0 Hz, 1H), 8.03 (d, J = 8.4 Hz, 1H), 7.61 - 7.50 (m, 3H), 5.55 - 5.49 (m, 1H), 5.42-5.37 (m, 1H), 4.80 (d, J = 7.6 Hz, 1H), 2.40 - 2.28 (m, 2H), 2.28 - 2.16 (m, 1H), 2.00 - 1.86 (m, 2H), 1.78 - 1.66 (m, 1H), 1.34 - 1.24 (m, 1H).	419.4	E	





I-2323		FC(F)([C@@H]1OC(NC(C=C23)=CC(NC(C4=CC(C(F)(F)F)=CC(F)=C4)=O)=C3[C@@H](NC2=O)C5=CC(F)=CC=C5Cl)=NC1)F		619.0	B	
I-2324		FC(F)([C@H]1OC(NC(C=C23)=CC(NC(C4=CC(C(F)(F)F)=CC(F)=C4)=O)=C3[C@@H](NC2=O)C5=CC(F)=CC=C5Cl)=NC1)F		619.0	A	A
I-2325		FC(F)([C@@H]1OC(NC(C=C23)=CC(NC(C4=CC(C(F)(F)F)=CC(F)=C4)=O)=C3[C@H](NC2=O)C5=CC(F)=CC=C5Cl)=NC1)F		619.0	D	




I-2326		FC(F)([C@H]1OC(NC(C=C23)=CC(NC(C4=CC(C(F)(F)F)=CC(F)=C4)=O)=C3[C@H](NC2=O)C5=CC(F)=CC=C5Cl)=NC1)F		619.0	D	
I-2327		FC(F)(C1=CC(F)=CC(C(NC2=C3C(NC(C3=CC(NC4=NCC5(CC5)O4)=C2)=O)C6=CC(F)=CC=C6Cl)=O)=C1)F	(500 MHz, DMSO) δ 10.45 (s, 1H), 9.02 (s, 1H), 7.90 (d, J = 8.5 Hz, 1H), 7.70 (d, J = 9.3 Hz, 1H), 7.63 (d, J = 15.0 Hz, 1H), 7.33 – 7.24 (m, 1H), 7.06 (qd, J = 8.1, 4.1 Hz, 1H), 6.67 (s, 2H), 5.87 (s, 1H), 3.87 – 3.80 (m, 2H), 1.15 – 1.09 (m, 2H), 0.77 (s, 2H).	577.0	B	
I-2328		Fc1ccc(Cl)c(c1)C1NC(=O)c2cccc(NC(=O)N3CCC4C3[C@H]4C(F)(F)F)c12		454.3	E	
I-2329		Fc1ccc(Cl)c(c1)C1NC(=O)c2cccc(NC(=O)N3CCC4C3[C@@H]4C(F)(F)F)c12		454.2	D	
I-2330		Fc1cc(cc(c1)C(F)(F)F)C(=O)Nc1ccc2C(=O)NC(c3nc(cs3)C(	(400 MHz, DMSO-d6) δ 10.67 (s, 1H), 9.59 (d, J = 1.3 Hz, 1H), 8.42 (s, 1H), 8.05 - 7.98 (m, 3H), 7.73 - 7.63 (m, 3H), 6.34 (d, J = 1.3 Hz, 1H).	490.2	E	




		F)(F)F)c12				
I-2331		FC(F)[C@@H]1CN(C(=O)Nc2ccc3C(=O)N[C@@H](c23)c2cc(F)ccc2Cl)c2ccccc12		470.2	D	
I-2332		FC(F)[C@H]1CN(C(=O)Nc2cccc3C(=O)N[C@H](c23)c2cc(F)ccc2Cl)c2ccccc12		470.2	D	
I-2333		FC(F)[C@H]1CN(C(=O)Nc2cccc3C(=O)N[C@@H](c23)c2cc(F)ccc2Cl)c2ccccc12		470.2	A	B
I-2334		FC(F)[C@@H]1CN(C(=O)Nc2ccc3C(=O)N[C@H](c23)c2cc(F)ccc2Cl)c2ccccc12		470.2	A	B
I-2335		CC[C@H](CC(=O)Nc1ccc2C(=O)N[C@H](c12)c1cc(F)ccc1Cl)[C@@H](C)C(F)(F)F		455.2	D	




I-2336		CC[C@@H](CC(=O)Nc1cccc2C(=O)N[C@H](c12)c1cc(F)ccc1Cl)[C@H](C)C(F)(F)F		455.2	D	
I-2337		CC[C@@H](CC(=O)Nc1cccc2C(=O)N[C@@H](c12)c1cc(F)ccc1Cl)[C@H](C)C(F)(F)F		455.2	E	
I-2338		CC[C@H](CC(=O)Nc1cccc2C(=O)N[C@@H](c12)c1cc(F)ccc1Cl)[C@@H](C)C(F)(F)F		455.2	E	
I-2339		Fc1ccc(Cl)c(c1)C1NC(=O)c2cccc(NC(=O)N3CC(Nc4ccccc34)C(F)(F)F)c12	(400 MHz, DMSO-d6) δ 9.06 (br s, 1H), 8.76 (s, 0.5H), 8.24 (s, 0.5H), 7.69 - 7.58 (m, 0.5H), 7.58 - 7.41 (m, 3H), 7.32 (d, J = 7.5 Hz, 0.5H), 7.27-7.18 (m, 1H), 6.94 - 6.80 (m, 2H), 6.78-6.74 (m, 1H), 6.40 (t, J = 7.6 Hz, 1H), 6.27 (dd, J = 15.2, 8.0 Hz, 1H), 6.09 (br s, 1H), 5.73 (br s, 1H), 4.79 (br d, J = 14.3 Hz, 0.5H), 4.39 - 4.23 (m, 0.5H), 4.21 - 4.00 (m, 1H), 3.35 (submerged m, 0.5H), 2.75 (br d, J = 12.9 Hz, 0.5H). 1:1 Mix of diastereomers.	505.0	E	





I-2340		Fc1ccc(Cl)c(c1)C1NC(=O)c2cccc(NC(=O)N3CCSC(C3)C(F)(F)F)c12	(400 MHz, DMSO-d6) δ 9.06 (br s, 0.5H), 9.04 (br s, 0.5H), 8.66 (br s, 0.5H), 8.64 (br s, 0.5H) 7.61 - 7.46 (m, 3H), 7.35 - 7.19 (m, 2H), 6.51 (br s, 1H), 6.03 (br s, 0.5H), 5.98 (br s, 0.5H), 4.19 (br d, J = 12.1 Hz, 0.5H), 3.93 (dd, J = 14.1, 2.7 Hz, 0.5H), 3.69 - 3.56 (m, 1H), 3.55 - 3.44 (m, 1H), 3.42 - 3.35 (submerged m, 0.5H), 3.19 (dd, J = 11.3, 9.7 Hz, 0.5H), 3.13 - 2.97 (m, 1H), 2.79 - 2.66 (m, 1H), 2.60 (dd, J = 12.8, 9.0 Hz, 0.5H), 2.26 (br d, J = 12.4 Hz, 0.5H). 1:1 Mix of diastereomers	474.0	E	
I-2341		C[C@H]([C@@H]1C[C@@H](O)CN1C(=O)Nc1ccccc2C(=O)N[C@H](c12)c1cc(F)ccc1Cl)C(F)(F)F	(400 MHz, CD3CN) δ 7.63 - 7.58 (m, 2H), 7.57 - 7.45 (m, 2H), 7.21 (br s, 1H), 7.10 (ddd, J = 8.8, 8.0, 3.1 Hz, 1H), 6.69 (br s, 1H), 6.56 (br s, 1H), 6.28 (s, 1H), 4.16 (p, J = 7.0 Hz, 1H), 4.09 (td, J = 8.1, 3.9 Hz, 1H), 3.34 (dd, J = 9.5, 7.1 Hz. 1H), 3.29 - 3.16 (m, 1H), 2.77 (dd, J = 9.7, 6.9 Hz), 2.13 - 2.04 (m, 1H [submerged under H2O]), 1.73 - 1.63 (m, 1H), 0.89 (d, J = 7.1 Hz, 3H) ppm [95:5 dr, 85% purity].	486.4	B	
I-2342		O[C@H]1CN(C(=O)Nc2cc(cc3C(=O)N[C@H](c23)c2cc(F)ccc2Cl)-n2nccn2)c2ccc(F)cc12	(400 MHz, DMSO-d6) 9.27 (s, 1H), 8.93 (s, 1H), 8.22 (s, 2H), 8.16 (d, J = 2.0 Hz, 1H), 8.08 (d, J = 2.0 Hz, 1H), 7.86 (s, 1H), 7.38 (dd, J = 8.9, 5.1 Hz, 1H), 7.17 (ddd, J = 13.5, 8.1, 2.9 Hz, 2H), 7.10 (td, J = 9.0, 2.8 Hz, 1H), 6.07 (s, 1H),	523.3	B	






			5.78 (d, J = 6.0 Hz, 1H), 5.06 (d, J = 9.2 Hz, 1H), 3.73 (dd, J = 11.4, 3.6 Hz, 1H), 3.24 (s, 1H).			
I-2343		O[C@H]1CN(C(=O)Nc2cc(cc3C(=O)N[C@H](c23)c2cc(F)ccc2Cl)-n2nccn2)c2ccc(F)cc12	(400 MHz, DMSO-d6) 9.29 (s, 1H), 8.77 (s, 1H), 8.23 (d, J = 8.6 Hz, 3H), 8.09 (d, J = 1.9 Hz, 1H), 7.75 (dd, J = 8.7, 4.7 Hz, 1H), 7.37 (dd, J = 8.9, 5.1 Hz, 1H), 7.17-7.10 (m, 2H), 7.12-7.02 (m, 1H), 6.16 (s, 1H), 5.75 (d, J = 5.0 Hz, 1H), 5.15 (s, 1H), 4.03-3.93 (m, 1H), 3.26-3.19 (m, 1H).	523.2	D	
I-2344		O[C@@H]1CN(C(=O)Nc2cc(cc3C(=O)N[C@@H](c23)c2cc(F)ccc2Cl)-n2nccn2)c2ccc(F)cc12		523.1	D	
I-2345		O[C@@H]1CN(C(=O)Nc2cc(cc3C(=O)N[C@@H](c23)c2cc(F)ccc2Cl)-n2nccn2)c2ccc(F)cc12	(400 MHz, DMSO-d6) 9.27 (s, 1H), 8.94 (s, 1H), 8.22 (s, 2H), 8.16 (s, 1H), 8.08 (s, 1H), 7.86 (s, 1H), 7.38 (dd, J = 8.9, 5.1 Hz, 1H), 7.22-7.06 (m, 3H),6.16-5.95(s, 1H), 5.79 (d, J = 6.0 Hz, 1H), 5.07 (s, 1H), 3.77-3.69 (m, 1H).	523.2	D	
I-2346		O[C@H]1CN(C(=O)Nc2cc(CCC#N)cc3C(=O)N[C@H](c23)c2cc(F)ccc2Cl)c2ccc(F)cc12	(400 MHz, DMSO-d6) 9.05 (s, 1H), 8.66 (s, 1H), 7.83 (dd, J = 9.1, 4.7 Hz, 1H), 7.55 (d, J = 1.5 Hz, 1H), 7.37 (dd, J = 8.9, 5.1 Hz, 1H), 7.29 (s, 1H), 7.15 (ddd, J = 13.3, 8.0, 2.9 Hz, 2H), 7.08 (td, J = 9.0, 2.8 Hz, 1H), 6.53 (s, 1H), 5.97 (s, 1H), 5.76	509.1	A	B




			(d, J = 6.0 Hz, 1H), 5.07 (s, 1H), 3.71 (dd, J = 11.4, 3.6 Hz, 1H), 3.23 (s, 1H), 3.11-2.95 (m, 2H), 2.91 (t, J = 7.6 Hz, 2H).			
I-2347		O[C@@H]1CN(C(=O)Nc2cc(CCC#N)cc3C(=O)N[C@H](c23)c2cc(F)ccc2Cl)c2ccc(F)cc12	(400 MHz, DMSO-d6) 9.05 (s, 1H), 8.66 (s, 1H), 7.83 (dd, J = 9.1, 4.7 Hz, 1H), 7.55 (d, J = 1.5 Hz, 1H), 7.37 (dd, J = 8.9, 5.1 Hz, 1H), 7.29 (s, 1H), 7.15 (ddd, J = 13.3, 8.0, 2.9 Hz, 2H), 7.08 (td, J = 9.0, 2.8 Hz, 1H), 6.53 (s, 1H), 5.97 (s, 1H), 5.76 (d, J = 6.0 Hz, 1H), 5.07 (s, 1H), 3.71 (dd, J = 11.4, 3.6 Hz, 1H), 3.23 (s, 1H), 3.11-2.95 (m, 2H), 2.91 (t, J = 7.6 Hz, 2H).	509.1	B	
I-2348		O[C@@H]1CN(C(=O)Nc2cc(CCC#N)cc3C(=O)N[C@@H](c23)c2cc(F)ccc2Cl)c2ccc(F)cc12	(400 MHz, DMSO-d6) 9.05 (s, 1H), 8.66 (s, 1H), 7.83 (dd, J = 9.1, 4.7 Hz, 1H), 7.55 (d, J = 1.5 Hz, 1H), 7.37 (dd, J = 8.9, 5.1 Hz, 1H), 7.29 (s, 1H), 7.15 (ddd, J = 13.3, 8.0, 2.9 Hz, 2H), 7.08 (td, J = 9.0, 2.8 Hz, 1H), 6.53 (s, 1H), 5.97 (s, 1H), 5.76 (d, J = 6.0 Hz, 1H), 5.07 (s, 1H), 3.71 (dd, J = 11.4, 3.6 Hz, 1H), 3.23 (s, 1H), 3.11-2.95 (m, 2H), 2.91 (t, J = 7.6 Hz, 2H).	509.1	D	
I-2349		O[C@H]1CN(C(=O)Nc2cc(CCC#N)cc3C(=O)N[C@@H](c23)c2cc(F)ccc2Cl)c2ccc(F)cc12	(400 MHz, DMSO-d6) 9.05 (s, 1H), 8.66 (s, 1H), 7.83 (dd, J = 9.1, 4.7 Hz, 1H), 7.55 (d, J = 1.5 Hz, 1H), 7.37 (dd, J = 8.9, 5.1 Hz, 1H), 7.29 (s, 1H), 7.15 (ddd, J = 13.3, 8.0, 2.9 Hz, 2H), 7.08 (td, J = 9.0, 2.8 Hz, 1H), 6.53 (s, 1H), 5.97 (s, 1H), 5.76 (d, J = 6.0 Hz, 1H), 5.07 (s, 1H), 3.71 (dd, J	509.1	D	




			= 11.4, 3.6 Hz, 1H), 3.23 (s, 1H), 3.11-2.95 (m, 2H), 2.91 (t, J = 7.6 Hz, 2H).			
I-2350		O[C@H]1CN(C(=O)Nc2cc(cc3C(=O)N[C@H](c23)c2cc(F)ccc2Cl)-n2ccccc2=O)c2ccc(F)cc12	(400 MHz, DMSO-d6)9.23 (s, 1H), 8.84 (s, 1H), 7.85-7.77 (m, 2H), 7.60-7.51 (m, 2H), 7.46-7.36 (m, 2H), 7.15 (dddd, J = 34.3, 18.0, 8.6, 3.0 Hz, 3H), 6.80-6.51 (m, 2H), 6.37 (td, J = 6.7, 1.4 Hz, 1H), 6.09 (s, 1H), 5.77 (d, J = 6.0 Hz, 1H), 5.08 (s, 1H), 3.70 (dd, J = 11.3, 3.6 Hz, 1H), 3.30-3.10 (s, 1H).	531.2	A	C
I-2351		O[C@@H]1CN(C(=O)Nc2cc(cc3C(=O)N[C@H](c23)c2cc(F)ccc2Cl)-n2ccccc2=O)c2ccc(F)cc12	(400 MHz, DMSO-d6) 9.26 (s, 1H), 8.70 (s, 1H), 7.77-7.73 (m, 2H), 7.61-7.50 (m, 3H), 7.39 (dd, J = 8.9, 5.2 Hz, 1H), 7.14 (ddd, J = 11.2, 8.0, 3.0 Hz, 2H), 7.05 (td, J = 9.1, 2.8 Hz, 1H), 6.80-6.54 (m, 2H), 6.37 (td, J = 6.7, 1.3 Hz, 1H), 6.17 (s, 1H), 5.75 (d, J = 5.0 Hz, 1H), 5.15 (dt, J = 8.7, 4.5 Hz, 1H), 3.97 (dd, J = 11.1, 8.1 Hz, 1H), 3.22 (dd, J = 11.1, 4.0 Hz, 1H).	531.1	B	
I-2352		O[C@@H]1CN(C(=O)Nc2cc(cc3C(=O)N[C@@H](c23)c2cc(F)ccc2Cl)-n2ccccc2=O)c2ccc(F)cc12	(400 MHz, DMSO-d6) 9.26 (s, 1H), 8.70 (s, 1H), 7.81-7.69 (m, 2H), 7.60-7.50 (m, 3H), 7.39 (dd, J = 8.9, 5.2 Hz, 1H), 7.14 (ddd, J = 11.5, 8.0, 3.0 Hz, 2H), 7.05 (td, J = 9.0, 2.8 Hz, 1H), 6.80-6.54 (m, 2H), 6.37 (td, J = 6.7, 1.3 Hz, 1H), 6.17 (s, 1H), 5.75 (d, J = 5.0 Hz, 1H), 5.15 (dt, J = 8.7, 4.5 Hz, 1H), 3.97 (dd, J = 11.0, 8.0 Hz, 1H), 3.22 (dd, J = 11.2, 4.0 Hz, 1H).	531.2	D	





I-2353		O[C@H]1CN(C(=O)Nc2cc(cc3C(=O)N[C@@H](c23)c2cc(F)ccc2Cl)-n2ccccc2=O)c2ccc(F)cc12	(400 MHz, DMSO-d6) 9.23 (s, 1H), 8.83 (s, 1H), 7.84 (dd, J = 8.5, 4.6 Hz, 1H), 7.77 (dd, J = 6.9, 2.1 Hz, 1H), 7.60-7.51 (m, 2H), 7.46-7.36 (m, 2H), 7.15 (dddd, J = 34.5, 18.1, 8.6, 3.0 Hz, 3H), 6.80-6.50 (m, 2H), 6.37 (td, J = 6.7, 1.4 Hz, 1H), 6.08 (s, 1H), 5.77 (d, J = 6.0 Hz, 1H), 5.08 (s, 1H), 3.70 (dd, J = 11.3, 3.6 Hz, 1H), 3.25 (s, 1H).	531.2	D	
I-2354		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)\N=C1/OC[C@H]2CCCN12	(500 MHz, DMSO) δ 10.33 (d, J = 3.4 Hz, 1H), 8.98 (s, 1H), 7.90 (dt, J = 8.3, 2.0 Hz, 1H), 7.70 (d, J = 9.1 Hz, 1H), 7.64 (s, 1H), 7.31 – 7.22 (m, 2H), 7.06 (td, J = 8.2, 3.0 Hz, 1H), 7.03 (s, 1H), 5.89 (s, 1H), 5.74 (s, 1H), 4.63 – 4.55 (m, 1H), 4.27 (s, 1H), 3.97 (s, 1H), 3.62 (s, 1H), 3.16 (s, 2H), 2.03 – 1.95 (m, 2H), 1.93 – 1.86 (m, 1H), 1.53 – 1.40 (m, 1H).	591.0	B	
I-2355		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)\N=C1/OC[C@@H]2CCCN12		591.0	B	



I-2356		FC(F)n1cc(cn1)-c1cc2C(=O)N[C@@H](c2c(NC(=O)N2CCc3cc(F)ccc23)c1)c1cc(F)ccc1Cl		556.3	D	
I-2357		FC(F)n1cc(cn1)-c1cc2C(=O)N[C@H](c2c(NC(=O)N2CCc3cc(F)ccc23)c1)c1cc(F)ccc1Cl		556.3	A	A
I-2358		FC(F)(C1=CC(F)=CC(C(NC2=C3C(NC(C3=CC(NC4=NC(C)(C)CO4)=C2)=O)C5=CC(F)=CC=C5Cl)=O)=C1)F	(500 MHz, DMSO) δ 10.43 (s, 1H), 9.01 (s, 1H), 8.13 (s, 1H), 7.91 (dd, J = 8.2, 2.2 Hz, 1H), 7.68 (d, J = 9.2 Hz, 1H), 7.60 (s, 1H), 7.50 (s, 1H), 7.27 (dd, J = 8.8, 5.2 Hz, 1H), 7.06 (tt, J = 8.6, 4.3 Hz, 1H), 6.59 (s, 1H), 5.85 (s, 1H), 3.98 (s, 2H), 1.26 (d, J = 3.3 Hz, 6H).	579.0	B	
I-2359		FC(F)(C1=CC(F)=CC(C(NC2=C3C(NC(C3=CC(NC4=NC5(CC5)CO4)=C2)=O)C6=CC(F)=CC=C6Cl)=O)=C1)F	(500 MHz, DMSO) δ 10.45 (s, 1H), 9.03 (s, 1H), 8.12 (s, 1H), 7.94 – 7.87 (m, 2H), 7.68 (d, J = 9.4 Hz, 1H), 7.58 (s, 2H), 7.27 (dd, J = 8.8, 5.1 Hz, 1H), 7.06 (td, J = 8.4, 3.1 Hz, 1H), 6.50 (s, 1H), 5.84 (s, 1H), 4.25 (s, 2H), 1.22 (s, 0H), 0.95 – 0.90 (m, 2H), 0.75 – 0.68 (m, 2H).	577.0	A	B




I-2360		FC(F)(C1=CC(F)=CC(C(NC2=C3C(NC(C3=CC(NC4=NC(C(F)(F)F)CO4)=C2)=O)C5=CC(F)=CC=C5Cl)=O)=C1)F	(400 MHz, DMSO) δ 10.54 (d, J = 7.4 Hz, 1H), 10.14 (s, 1H), 9.09 (s, 1H), 8.47 (s, 1H), 8.03 (s, 1H), 7.98 – 7.88 (m, 2H), 7.72 – 7.63 (m, 2H), 7.58 (s, 1H), 7.28 (dd, J = 8.9, 5.1 Hz, 1H), 7.06 (s, 1H), 6.84 (s, 3H), 5.85 (s, 1H), 5.74 (s, 1H), 4.89 (s, 1H), 4.51 (t, J = 9.4 Hz, 1H), 4.44 – 4.35 (m, 1H).	619.0	A	C
I-2361		Fc1ccc(Cl)c(c1)C1NC(=O)c2cccc(NC(=O)c3cscc3C(F)(F)F)c12			D	
I-2362		Fc1ccc(Cl)c(c1)C1NC(=O)c2cccc(NC(=O)CCc3ccccc3)c12	(400 MHz, DMSO-d6) 9.70 (s, 1H), 9.09 (s, 1H), 7.61 (dd, J = 7.6, 1.3 Hz, 1H), 7.56 (t, J = 7.5 Hz, 1H), 7.51 (s, 1H), 7.37 (dd, J = 7.5, 1.3 Hz, 1H), 7.32 - 7.10 (m, 6H), 6.02 (s, 1H), 2.70 - 2.57 (s, 1H), 2.57 - 2.52 (s, 1H), 2.34 - 2.16 (m, 2H).	409.3	E	
I-2363		Oc1ccc(cc1C(F)(F)F)C(=O)Nc1cccc2C(=O)NC(c12)c1cc(F)ccc1Cl	(400 MHz, DMSO-d6) 9.95 (s, 1H), 9.09 (s, 1H), 7.61 (p, J = 7.9, 7.5 Hz, 5H), 7.49 (d, J = 7.4 Hz, 1H), 7.31 (dd, J = 8.9, 5.2 Hz, 1H), 7.08 (td, J = 8.5, 3.1 Hz, 1H), 6.81 (s, 1H), 6.60 (s, 1H), 6.02 (s, 1H).	465.1	E	
I-2364		O[C@H]1CN(C(=O)Nc2cc(cc3C(=O)N[C@H](c23)c2cc(F)ccc2Cl)-n2cccn2)	(400 MHz, DMSO-d6) 9.18 (s, 1H), 8.85 (s, 1H), 8.71 (d, J = 2.6 Hz, 1H), 8.03 - 7.95 (m, 2H), 7.88 - 7.79 (m, 2H), 7.38 (dd, J = 9.0, 5.1 Hz, 1H), 7.22 - 7.05 (m, 3H), 6.63 - 6.57 (m, 1H), 6.02 (s, 1H), 5.78 (d, J = 6.0 Hz, 1H),	522.3	A	B





		c2ccc(F)cc12	5.07 (s, 2H), 3.77 - 3.69 (m, 1H), 3.34 (s, 1H).			
I-2365		O[C@@H]1CN(C(=O)Nc2cc(cc3C(=O)N[C@@H](c23)c2cc(F)ccc2Cl)-n2cccn2)c2ccc(F)cc12	(400 MHz, DMSO-d6) 9.21 (s, 1H), 8.74 - 8.68 (m, 2H), 8.07 - 7.99 (m, 2H), 7.81 (d, J = 1.8 Hz, 1H), 7.74 (dd, J = 9.0, 4.7 Hz, 1H), 7.36 (dd, J = 8.9, 5.1 Hz, 1H), 7.11 (td, J = 8.5, 3.0 Hz, 2H), 7.05 (td, J = 9.0, 2.8 Hz, 1H), 6.73 (s, 1H), 6.60 (t, J = 2.1 Hz, 1H), 6.12 (s, 1H), 5.75 (d, J = 5.0 Hz, 1H), 5.16 (dt, J = 8.3, 4.6 Hz, 1H), 3.99 (dd, J = 11.1, 8.1 Hz, 1H), 3.22 (dd, J = 11.2, 4.1 Hz, 1H).	522.4	C	
I-2366		O[C@@H]1CN(C(=O)Nc2cc(cc3C(=O)N[C@H](c23)c2cc(F)ccc2Cl)-n2cccn2)c2ccc(F)cc12	(400 MHz, DMSO-d6) 9.21 (s, 1H), 8.74 - 8.68 (m, 2H), 8.07 - 7.99 (m, 2H), 7.81 (d, J = 1.7 Hz, 1H), 7.74 (dd, J = 8.9, 4.7 Hz, 1H), 7.36 (dd, J = 8.9, 5.1 Hz, 1H), 7.11 (td, J = 8.4, 3.0 Hz, 3H), 6.60 (t, J = 2.1 Hz, 2H), 6.12 (s, 1H), 5.75 (d, J = 5.0 Hz, 1H), 5.16 (dt, J = 8.6, 4.5 Hz, 1H), 3.99 (dd, J = 11.1, 8.1 Hz, 1H), 3.22 (dd, J = 11.0, 4.1 Hz, 1H).	522.3	D	
I-2367		O[C@H]1CN(C(=O)Nc2cc(cc3C(=O)N[C@@H](c23)c2cc(F)ccc2Cl)-n2cccn2)c2ccc(F)cc12	(400 MHz, DMSO-d6) 9.19 (s, 1H), 8.85 (s, 1H), 8.72 (d, J = 2.5 Hz, 1H), 7.99 (dd, J = 11.9, 2.0 Hz, 2H), 7.81 (d, J = 1.7 Hz, 1H), 7.38 (dd, J = 8.9, 5.1 Hz, 1H), 7.22 - 7.11 (m, 2H), 7.11 (dd, J = 8.9, 2.8 Hz, 2H), 6.63 - 6.57 (m, 1H), 6.02 (s, 1H), 5.78 (d, J = 6.0 Hz, 1H), 5.07 (s, 1H), 3.73 (dd, J = 11.3, 3.6 Hz, 1H), 3.24 (s, 1H), 1.13 (s, 1H).	522.4	D	




I-2368		O[C@H]1CN(C(=O)Nc2cc(cc3C(=O)N[C@H](c23)c2cc(F)ccc2Cl)-n2ccnn2)c2ccc(F)cc12	(400 MHz, DMSO-d6)9.30 (s, 1H), 9.07 (d, J = 1.2 Hz, 1H), 8.79 (s, 1H), 8.14 (d, J = 2.0 Hz, 1H), 8.09 (d, J = 2.0 Hz, 1H), 8.03 (d, J = 1.2 Hz, 1H), 7.75 (dd, J = 8.9, 4.7 Hz, 1H), 7.38 (dd, J = 8.9, 5.1 Hz, 1H), 7.20-7.11 (m, 2H), 7.06 (d, J = 2.9 Hz, 1H), 7.00-6.50 (m, 1H), 6.17 (s, 1H), 5.75 (s, 1H), 5.16 (s, 1H), 3.99 (dd, J = 11.1, 8.0 Hz, 1H), 3.24 (dd, J = 11.1, 4.0 Hz, 1H).	523.1	D	
I-2369		O[C@H]1CN(C(=O)Nc2cc(cc3C(=O)N[C@@H](c23)c2cc(F)ccc2Cl)-n2ccnn2)c2ccc(F)cc12	(400 MHz, DMSO-d6) 9.29 (s, 1H), 9.08 (d, J = 1.2 Hz, 1H), 8.96 (s, 1H), 8.17-7.98 (m, 3H), 7.86 (s, 1H), 7.39 (dd, J = 8.9, 5.1 Hz, 1H), 7.27-7.03 (m, 3H), 7.00-6.50 (m, 1H), 6.30-5.90 (m, 1H), 5.79 (d, J = 6.0 Hz, 1H), 5.09 (d, J = 9.0 Hz, 1H), 3.73 (dd, J = 11.4, 3.5 Hz, 1H), 3.17 (d, J = 5.2 Hz, 1H).	523.1	A	B
I-2370		O[C@@H]1CN(C(=O)Nc2cc(cc3C(=O)N[C@H](c23)c2cc(F)ccc2Cl)-n2ccnn2)c2ccc(F)cc12	(400 MHz, DMSO-d6) 9.32 (s, 1H), 9.08 (s, 1H), 8.81 (s, 1H), 8.14 (d, J = 2.0 Hz, 1H), 8.10 (d, J = 1.9 Hz, 1H), 8.04 (s, 1H), 7.75 (dd, J = 8.9, 4.7 Hz, 1H), 7.38 (dd, J = 8.9, 5.1 Hz, 1H), 7.17-7.10 (m, 2H), 7.07 (dd, J = 9.1, 2.8 Hz, 1H), 6.90-6.50 (m, 1H),6.17 (s, 1H), 5.76 (d, J = 4.9 Hz, 1H), 5.16 (dt, J = 8.7, 4.4 Hz, 1H), 4.16-3.90 (m, 1H), 3.23 (dd, J = 11.1, 4.0 Hz, 1H).	523.1	C	





I-2371		O[C@@H]1CN(C(=O)Nc2cc(cc3C(=O)N[C@@H](c23)c2cc(F)ccc2Cl)-n2ccnn2)c2ccc(F)cc12	(400 MHz, DMSO-d6) 9.28 (s, 1H), 9.07 (d, J = 1.2 Hz, 1H), 8.95 (s, 1H), 8.23-8.05 (m, 2H), 8.04 (d, J = 1.2 Hz, 1H), 7.86 (s, 1H), 7.39 (dd, J = 8.9, 5.1 Hz, 1H), 7.28-7.04 (m, 3H), 7.00-6.50 (m, 1H), 6.20-6.10 (m,1H), 5.78 (d, J = 6.0 Hz, 1H), 5.08 (s, 1H), 3.73 (dd, J = 11.3, 3.6 Hz, 1H), 3.30-3.20 (m,1H)	523.1	D	
I-2372		Fc1ccc(Cl)c(c1)C1NC(=O)c2cccc(NC(=O)\C=C\c3ccccc3)c12	(400 MHz, DMSO-d6) 9.95 (s, 1H), 9.08 (s, 1H), 7.67-7.60 (m, 1H), 7.64-7.52 (m, 3H), 7.49-7.39 (m, 5H), 7.39 (s, 1H), 7.14 (td, J = 8.3, 2.9 Hz, 1H), 6.49 (d, J = 15.8 Hz, 1H), 6.06 (s, 1H).	407.1	E	
I-2373		Fc1ccc(Cl)c(c1)C1NC(=O)c2cccc(NC(=O)n3ncc4ccccc34)c12	(400 MHz, DMSO-d6) δ 9.15 (br s, 1H), 8.38 (s, 1H), 8.20 (d, J = 8.4 Hz, 1H), 7.88 (d, J = 7.9 Hz, 1H), 7.78 - 7.54 (m, 4H), 7.37 (t, J = 7.4 Hz, 1H), 7.23 (dd, J = 8.6, 5.1 Hz, 1H), 6.99 (td, J = 7.3, 1.4 Hz, 1H), 6.61 (br s, 1H), 6.21 (br s, 1H).	421.0	B	
I-2374		Fc1ccc(Cl)c(c1)C1NC(=O)c2cccc(NC(=O)C3CCc4ccccc4CC3)c12	(400 MHz, DMSO-d6) δ 9.63 (br. s, 1H), 9.04 (br. s, 1H), 7.58 - 7.49 (m, 2H), 7.49 - 7.41 (m, 1H), 7.37 (dd,J = 7.2, 1.7 Hz, 1H), 7.22 (ddd,J = 8.8, 8.1, 3.1 Hz, 1H), 7.09 - 7.00 (m, 4H), 6.51 (br. s, 1H), 6.01 (br. s, 1H), 2.75 - 2.53 (m, 4H), 2.37 (ddd,J = 11.2, 7.2, 3.0 Hz, 1H), 1.65 - 1.57 (m, 1H), 1.54 - 1.34 (m, 1H), 1.26 - 1.03 (m, 2H).	449.2	E	



I-2375		Fc1ccc(Cl)c(c1)C1NC(=O)c2cccc(NC(=O)C3CCCc4ccccc4C3)c12	(400 MHz, DMSO-d6) δ 9.70 (br. s, 0.5H), 9.68 (br. s, 0.5H), 9.11 (br. s, 1H), 7.67 - 7.51 (m, , 3H), 7.43 (dd, J = 3.2, 1.7 Hz, 0.5H), 7.41 (dd, J = 3.41, 1.6 Hz, 0.5H), 7.28 (two overlapping ddd, J = 7.3, 3.3, 1.7 Hz, 1H), 7.12 - 6.99 (m, 3H), 7.05 - 6.94 (m, 0.5H), 6.93 - 6.80 (m, 0.5H), 6.10 (br. s, 1H), 2.88 - 2.62 (m, 3H), 2.39 (d, J = 14.0 Hz, 0.5H), 2.28 - 2.12 (m, 0.5H), 2.10 - 1.95 (m, 1H), 1.96 - 1.75 (m, 1H), 1.81 - 1.39 (m, 2H), 1.21 - 1.00 (m, 1H);1:1 mixture of isomers.	449.3	E	
I-2376		OC1CN(C(=O)Nc2cccc3C(=O)NC(c23)c2cc(F)ccc2Cl)c2ccc(Cl)cc12	(400 MHz, DMSO-d6) δ 9.08 (br s, 0.5 H), 9.06 (br s, 0.5 H), 8.70 (s, 0.5 H), 8.58 (s, 0.5 H), 7.83 (d, J = 8.5 Hz, 0.5 H), 7.70 (d, J = 8.7 Hz, 0.5 H), 7.64 - 7.52 (m, 2 H), 7.42 (dd, J = 7.4, 1.3 Hz, 0.5 H), 7.39 - 7.26 (m, 3 H), 7.24 (dd, J = 8.7, 2.3 Hz, 0.5 H), 7.19 - 7.13 (m, 0.5 H), 7.09 (td, J = 8.4, 3.1 Hz, 0.5 H), 6.51 (br s, 1 H), 6.07 (br s, 1 H), 5.99 (br s, 1 H), 5.76 (app dd, J = 10.6, 5.4 Hz, 1 H), 5.15 (dt, J = 8.1, 4.2 Hz, 0.5 H), 5.10 - 5.04 (m, 0.5 H), 3.96 (dd, J = 11.0, 8.1 Hz, 0.5 H), 3.71 (dd, J = 11.3, 3.4 Hz, 0.5 H), 3.21 (d, J = 3.8 Hz, 0.5 H), 3.19 (d, J = 3.7 Hz, 0.5 H). Approximately 1:1 mixture of diastereomers.	472.2	D	




I-2377		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(NC(=O)N3CCCC33CCC3)c12		97.0	C	
I-2378		C[C@@H]([C@H]1C[C@H](O)CN1C(=O)Nc1ccccc2C(=O)N[C@H](c12)c1cc(F)ccc1Cl)C(F)(F)F	(400 MHz, CD3CN) δ 7.58 (dd, J = 7.4, 1.1 Hz, 1H), 7.52 (t, J = 7.6 Hz, 1H), 7.45 - 7.39 (m, 2H), 7.12 (br s, 1H), 7.04 (ddd, J = 8.8, 8.0, 3.1 Hz, 1H), 6.67 (br s, 1H), 6.57 (br s, 1H), 6.17 (br s, 1H), 4.36 - 4.30 (m, 1H), 4.26 - 4.19 (m, 1H), 3.31 (dd, J = 10.0, 5.3 Hz, 1H), 2.88 - 2.76 (m, 1H), 2.68 (dd, J = 9.8, 3.6 Hz, 1H), 2.07 - 2.00 (m, 1H), 1.91 - 1.82 (m, 1H), 1.01 (d, J = 7.3 Hz, 3H) ppm [single diastereomer]	486.4	E	
I-2379		C[C@H]([C@H]1C[C@H](O)CN1C(=O)Nc1cccc2C(=O)N[C@H](c12)c1cc(F)ccc1Cl)C(F)(F)F	(400 MHz, CD3CN) δ 7.59 (dd, J = 7.4, 1.0 Hz, 1H), 7.53 (t, J = 7.6 Hz, 1H), 7.45 - 7.38 (m, 2H), 7.15 (br s, 1H), 7.04 (ddd, J = 8.8, 8.1, 3.1 Hz, 1H), 6.73 (br s, 1H), 6.56 (br s, 1H), 6.19 (br s, 1H), 4.34 (td, J = 8.2, 3.7 Hz, 1H), 4.30 - 4.23 (m, 1H), 3.26 (dd, J = 10.4, 4.2 Hz, 1H), 3.21 - 3.00 (m, 1H), 2.88 (d, J = 10.3 Hz, 1H), 2.13 - 2.07 (m, 1H [submerged under H2O peak]), 1.83 - 1.74 (m, 1H), 0.82 (d, J = 7.2 Hz, 3H) ppm.	486.4	E	




I-2380		Cc1nn(C(=O)Nc2cccc3C(=O)NC(c23)c2cc(F)ccc2Cl)c2ccccc12	(400 MHz, DMSO) δ 9.61 (s, 1H), 9.13 (s, 1H), 8.15 (dt, J = 8.4, 0.9 Hz, 1H), 7.84 (dt, J = 8.0, 1.0 Hz, 1H), 7.81 (dd, J = 6.6, 2.3 Hz, 1H), 7.65 – 7.60 (m, 2H), 7.57 (ddd, J = 8.3, 7.1, 1.1 Hz, 1H), 7.35 (ddd, J = 8.0, 7.1, 0.9 Hz, 1H), 7.30 (dd, J = 8.8, 5.1 Hz, 1H), 7.04 (ddd, J = 8.8, 7.9, 3.1 Hz, 1H), 6.82 – 6.50 (m, 1H), 6.21 (s, 1H), 2.54 (s, 3H)	435.0	C	
I-2381		Nc1nn(C(=O)Nc2cccc3C(=O)NC(c23)c2cc(F)ccc2Cl)c2ccccc12	(400 MHz, DMSO) δ 9.10 (s, 1H), 9.08 (s, 1H), 8.09 – 8.03 (m, 1H), 7.86 (dt, J = 8.0, 1.0 Hz, 1H), 7.78 (dd, J = 6.0, 3.0 Hz, 1H), 7.58 (q, J = 3.7, 3.0 Hz, 2H), 7.50 (ddd, J = 8.3, 7.1, 1.2 Hz, 1H), 7.37 (t, J = 6.7 Hz, 1H), 7.24 (ddd, J = 8.0, 7.1, 0.9 Hz, 1H), 7.07 (ddd, J = 8.9, 7.9, 3.1 Hz, 1H), 6.86 – 6.50 (m, 1H), 6.20 (s, 1H), 6.13 (s, 2H)	436.0	B	
I-2382		Fc1ccc(Cl)c(c1)C1NC(=O)c2cccc(NC(=O)Nc3n[nH]c4ccccc34)c12	(500 MHz, DMSO) δ 12.16 (s, 1H), 9.70 (s, 1H), 9.43 (s, 1H), 9.09 (s, 1H), 7.89 (d, J = 8.3 Hz, 1H), 7.85 (d, J = 7.5 Hz, 1H), 7.60 – 7.52 (m, 2H), 7.43 – 7.32 (m, 3H), 7.08 (td, J = 8.4, 3.1 Hz, 1H), 7.02 (ddd, J = 7.9, 6.7, 1.0 Hz, 1H), 6.78 – 6.42 (m, 1H), 6.10 (s, 1H)	436.0	D	
I-2383		O[C@]1(CN(C(=O)Nc2cccc3C(=O)N[C@@H](c23)c2cc(F)ccc2Cl)c2c	(400 MHz, DMSOd6) δ 9.08 (s, 1H), 8.80 (s, 1H), 7.89 (d, J = 8.2 Hz, 1H), 7.64 - 7.55 (m, 2H), 7.39 (m, 3H), 7.31 (dd, J = 8.9, 5.2 Hz, 1H), 7.24 (s, 1H), 7.12 (td, J = 8.5, 3.0 Hz, 1H), 7.06 (t, J = 7.5	506.3	E	




		cccc12)C(F)(F)F	Hz, 1H), 6.52 (br s, 1H), 6.03 (s, 1H), 3.97 (d, J = 12.0 Hz, 1H), 3.48 (d, J = 11.5 H, 1Hz).			
I-2384		O[C@@]1(CN(C(=O)Nc2ccc3C(=O)N[C@H](c23)c2cc(F)ccc2Cl)c2ccccc12)C(F)(F)F	(400 MHz, DMSOd6) δ 9.10 (s, 1H), 8.70 (, 1Hs), 7.81 (d, J = 8.2 H, 1Hz), 7.67 - 7.55 (m, 2H), 7.48 (dd, J = 7.3, 1.5 Hz, 1H), 7.42 (d, J = 7.6 Hz, 1H), 7.36 (td, J = 7.1 , 1.1 Hz, 1H), 7.33 (d, J = 5.3 Hz, 1H), 7.21 (s, 1H), 7.11 (td, J = 8.7, 3.2 Hz, 1H), 7.05 (td, J = 7.9, 0.9 Hz, 1H), 6.53 (br s, 1H), 6.08 (s, 1H), 4.16 (d, J = 12.0 Hz, 1H), 3.44 (d, J = 12.0 Hz, 1H).	506.3	D	
I-2385		O[C@@]1(CN(C(=O)Nc2ccc3C(=O)N[C@@H](c23)c2cc(F)ccc2Cl)c2ccccc12)C(F)(F)F	(400 MHz, DMSOd6) δ 9.10 (s, 1H), 8.70 (, 1Hs), 7.81 (d, J = 8.2 H, 1Hz), 7.67 - 7.55 (m, 2H), 7.48 (dd, J = 7.3, 1.5 Hz, 1H), 7.42 (d, J = 7.6 Hz, 1H), 7.36 (td, J = 7.1 , 1.1 Hz, 1H), 7.33 (d, J = 5.3 Hz, 1H), 7.21 (s, 1H), 7.11 (td, J = 8.7, 3.2 Hz, 1H), 7.05 (td, J = 7.9, 0.9 Hz, 1H), 6.53 (br s, 1H), 6.08 (s, 1H), 4.16 (d, J = 12.0 Hz, 1H), 3.44 (d, J = 12.0 Hz, 1H).	506.3	D	
I-2386		O[C@]1(CN(C(=O)Nc2ccccc3C(=O)N[C@H](c23)c2cc(F)ccc2Cl)c2ccccc12)C(F)(F)F	(400 MHz, DMSOd6) δ 9.08 (s, 1H), 8.80 (s, 1H), 7.89 (d, J = 8.2 Hz, 1H), 7.64 - 7.55 (m, 2H), 7.39 (m, 3H), 7.31 (dd, J = 8.9, 5.2 Hz, 1H), 7.24 (s, 1H), 7.12 (td, J = 8.5, 3.0 Hz, 1H), 7.06 (t, J = 7.5 Hz, 1H), 6.52 (br s, 1H), 6.03 (s, 1H), 3.97 (d, J = 12.0 Hz, 1H), 3.48 (d, J = 11.5 H, 1Hz).	506.3	A	A





I-2387		O=C1C2=CC(NC3=N[C@H](C(F)(F)F)CO3)=CC(NC(C4=CC(F)=CC(C(F)(F)F)=C4)=O)=C2[C@H](C5=C(Cl)C=CC(F)=C5)N1		619.0	A	B
I-2388		O=C1C2=CC(NC3=N[C@@H](C(F)(F)F)CO3)=CC(NC(C4=CC(F)=CC(C(F)(F)F)=C4)=O)=C2[C@H](C5=C(Cl)C=CC(F)=C5)N1		619.0	A	B
I-2389		O=C1C2=CC(NC3=N[C@H](C(F)(F)F)CO3)=CC(NC(C4=CC(F)=CC(C(F)(F)F)=C4)=O)=C2[C@@H](C5=C(Cl)C=CC(F)=C5)N1		619.0	D	
I-2390		O=C1C2=CC(NC3=N[C@@H](C(F)(F)F)CO3)=CC(NC(C4=CC(F)=CC		619.0	D	



		(C(F)(F)F)=C4)=O)=C2[C@@H](C5=C(Cl)C=CC(F)=C5)N1				
I-2391		CCCCc1ccc(Cl)c(c1)C1NC(=O)c2ccc(NC(=O)c3cc(O)cc(c3)C(F)(F)F)c12	(400 MHz, DMSO) δ 10.81 (s, 1H), 10.26 (s, 1H), 8.99 (s, 1H), 8.49 (s, 1H), 7.66 – 7.61 (m, 1H), 7.57 (t, J = 7.6 Hz, 1H), 7.44 (s, 1H), 7.27 (s, 1H), 7.15 (d, J = 8.2 Hz, 2H), 7.08 (s, 1H), 7.00 (dd, J = 8.2, 2.2 Hz, 1H), 6.78 (s, 1H), 5.96 (s, 1H), 2.18 (s, 2H), 1.12 – 1.06 (m, 4H), 0.77 – 0.69 (m, 2H).	503.0	D	
I-2392		CC(C)N1C[C@H](O)C[C@H]1C(=O)Nc1cccc2C(=O)NC(c12)c1cc(F)ccc1Cl	(400 MHz, DMSO-d6) δ 9.23 (br. s, 1H), 9.16 (br. s, 1H), 8.07 (dd, J = 7.5, 1.4 Hz, 0.6H), 7.91 (dd, J = 7.1, 1.8 Hz, 0.3H), 7.69 - 7.43 (m, 3H), 7.33 - 7.29 (m, 0.6H), 7.29 - 7.25 (m, 0.4H), 6.42 (br. s, 1H), 6.14 (br. s, 1H), 4.84 (br. s, 1H), 4.01 - 3.93 (m, 0.3H), 3.70 - 3.61 (m, 0.7H), 3.28 (overlapping dd, J = 5.8, 3.7 Hz, 1H), 3.03 (dd, J = 9.3, 5.3 Hz, 0.3H), 2.83 (dd, J = 9.4, 5.2 Hz, 0.7H), 2.43 (td, J = 12.9, 6.4 Hz, 1H), 2.37 - 2.24 (m, 1H), 1.88 - 1.79 (m, 0.3H), 1.80 - 1.68 (m, 0.7H), 1.65 - 1.48 (m, 0.3H), 1.33 (dt, J = 15.8, 4.8 Hz, 0.7H), 0.89 (overlapping d, J = 5.0 Hz, 4H), 0.71 (d, J = 6.4 Hz, 1H), 0.68 (d, J = 6.3 Hz, 1H); 2:1mixture of diastereomers	432.3	E	




I-2393		C[C@@H]([C@@H]1C[C@H](O)CN1C(=O)Nc1ccccc2C(=O)N[C@H](c12)c1cc(F)ccc1Cl)C(F)(F)F	(400 MHz, CD3CN) δ 7.65 - 7.45 (m, 3H), 7.45 - 7.38 (m, 1H), 7.18 - 7.01 (m, 2H), 6.70 (d, J = 5.1 Hz, 1H), 6.57 (br s, 1H), 6.30 (br s, 0.5H), 6.19 (br s, 0.5H), 4.38 - 4.22 (m, 2H), 3.26 (dd, J = 10.4, 4.2 Hz, 1H), 3.16 (dd, J = 10.3, 4.3 Hz, 1H), 2.99 (d, J = 10.3 Hz, 1H), 2.87 (d, J = 10.1 Hz, 1H), 1.82 - 1.74 (m, 1H), 0.82 (d, J = 7.2 Hz, 1.25H), 0.78 (d, J = 7.2 Hz, 1.75H) ppm [dr = 60:40].	486.3	C	
I-2394		CCC1C(C)CCN1C(=O)Nc1cccc2C(=O)NC(c12)c1cc(F)ccc1Cl	(400 MHz, DMSO-d6) as a ca. 1:1:1:1 mixture of diastereomers δ 9.00 (br. s, 4H), 8.13 (br. s, 1H), 8.08 (br. s, 1H), 7.78 (br. s, 1H), 7.69 (br. s, 1H), 7.55 - 7.44 (m, 14H), 7.30 - 7.18 (m, 6H), 6.59 (br. s, 4H), 6.13 (br. s, 2H), 6.06 (br. s, 1H), 6.02 (br. s, 1H), 3.83 (app. q, J = 6.8 Hz, 1H), 3.51 (dd, J = 12.2, 6.3 Hz, 1H), 3.32 - 3.28 (m, 1H), 3.28 - 3.01 (m, 6H), 3.00 - 2.92 (m, 1H), 2.45 - 2.35 (m, 1H), 2.13 - 1.68 (m, 8H), 1.65 - 1.56 (m, 1H), 1.56 - 1.13 (m, 12H), 0.97 - 0.91 (m, 9H), 0.82 (d, J = 6.8 Hz, 3H), 0.79 - 0.67 (m, 12H).	416.4	D	
I-2395		CCC1CCCN1C(=O)Nc1ccccc2C(=O)NC(c12)c1cc(F)ccc1Cl	(400 MHz, DMSO-d6) as a ca. 1:1 mixture of diastereomers δ 9.00 (br. s, 2H), 8.13 (s, 1H), 7.79 (s, 1H), 7.51 - 7.44 (m, 7H), 7.26 - 7.18 (m, 3H), 6.58 (br. s, 2H), 6.08 (br. s, 1H), 6.01 (br. s, 1H), 3.80 - 3.73 (m, 1H), 3.48 - 3.38 (m,	402.4	D	




			1H), 3.23 - 3.16 (m, 1H), 3.12 (dd, J = 16.5, 8.0 Hz, 1H), 3.00 - 2.93 (m, 1H), 2.60 - 2.52 (m, 1H), 1.79 - 1.54 (m, 10H), 1.15 - 1.00 (m, 2H), 0.75 (t, J = 6.8 Hz, 3H), 0.72 (t, J = 6.7 Hz, 3H).			
I-2396		CC(C)C1CCCN1C(=O)Nc1cccc2C(=O)NC(c12)c1cc(F)ccc1Cl	(400 MHz, DMSO-d6) as a ca. 1:1 mixture of diastereomers, δ 9.01 (br. s, 2H), 8.19 (s, 1H), 7.80 (s, 1H), 7.57 - 7.46 (m, 7H), 7.27 - 7.18 (m, 3H), 6.54 (br. s, 2H), 6.16 (br. s, 1H), 6.00 (br. s, 1H), 3.81 (dd, J = 11.5, 5.6 Hz, 1H), 3.54 - 3.49 (m, 1H), 3.21 - 3.11 (m, 2H), 3.03 (ddd, J = 10.1, 7.6, 4.6 Hz, 1H), 2.06 - 1.96 (m, 1H), 1.90 - 1.79 (m, 1H), 1.77 - 1.49 (m, 9H), 0.79 - 0.73 (m, 6H), 0.67 (d, J = 6.8 Hz, 3H), 0.62 (d, J = 6.8 Hz, 3H).	416.4	D	
I-2397		Fc1ccc(Cl)c(c1)C1NC(=O)c2cccc(NC(=O)c3ncsc3Br)c12	(400 MHz, DMSO-d6) δ 9.97 (br s, 1H), 9.12 (s, 1H), 9.10 (submerged br s, 1H), 7.72 (dd, J = 7.3, 0.6 Hz, 1H), 7.67 - 7.50 (m, 2H), 7.35 (dd, J = 8.3, 5.1 Hz, 1H), 7.11 (td, J = 8.5, 3.0 Hz, 1H), 6.68 (br s, 1H), 6.10 (br s, 1H).	466.0	D	
I-2398		Fc1ccc(Cl)c(c1)C1NC(=O)c2cccc(NC(=O)N3CCC(C3)C3CC3)c12	(400 MHz, DMSO-d6) δ 9.00 (br s, 1H), 8.10 (s, 0.5H), 8.04 (s, 0.5H), 7.55 - 7.40 (m, 3H), 7.33 - 7.26 (m, 1H), 7.26 - 7.19 (m, 1H), 6.58 (br s, 1H), 5.99 (br s, 1H), 3.22 - 3.11 (overlapping m, 1H), 3.10 - 2.65 (submerged m, 2H), 2.94 - 2.84 (overlapping m, 1H),	414.0	E	



			1.94 - 1.73 (m, 1H), 1.58 - 1.29 (m, 2H), 0.68 - 0.51 (m, 1H), 0.47 - 0.33 (m, 2H), 0.22 - 0.02 (m, 2H).			
I-2399		O[C@H]1CN(C(=O)Nc2cc(Cl)cc3C(=O)N[C@@H](c23)c2cc(F)ccc2Cl)c2ccc(F)cc12	(400 MHz, DMSO-d6) δ9.23 (s, 1H), 8.61 (s, 1H), 7.70 (dd, J = 8.9, 4.7 Hz, 1H), 7.56 (d, J = 11.8 Hz, 2H), 7.36 (dd, J = 8.9, 5.1 Hz, 1H), 7.08 (dtd, J = 26.7, 9.0, 8.6, 2.9 Hz, 3H), 6.61 (s, 1H), 6.08 (s, 1H), 5.88 - 5.64 (m, 1H), 5.34 - 4.92 (m, 1H), 3.91 (dd, J = 11.0, 8.1 Hz, 1H), 3.24 (dd, J = 11.1, 3.9 Hz, 1H).	490.0	D	
I-2400		O[C@H]1CN(C(=O)Nc2cc(Cl)cc3C(=O)N[C@H](c23)c2cc(F)ccc2Cl)c2ccc(F)cc12	(400 MHz, DMSO-d6) δ9.23 (s, 1H), 8.61 (s, 1H), 7.70 (dd, J = 8.9, 4.7 Hz, 1H), 7.56 (d, J = 11.8 Hz, 2H), 7.36 (dd, J = 8.9, 5.1 Hz, 1H), 7.08 (dtd, J = 26.7, 9.0, 8.6, 2.9 Hz, 3H), 6.61 (s, 1H), 6.08 (s, 1H), 5.88 - 5.64 (m, 1H), 5.34 - 4.92 (m, 1H), 3.91 (dd, J = 11.0, 8.1 Hz, 1H), 3.24 (dd, J = 11.1, 3.9 Hz, 1H).	490.0	B	
I-2401		O[C@@H]1CN(C(=O)Nc2cc(Cl)cc3C(=O)N[C@H](c23)c2cc(F)ccc2Cl)c2ccc(F)cc12	(400 MHz, DMSO-d6) δ9.23 (s, 1H), 8.61 (s, 1H), 7.70 (dd, J = 8.9, 4.7 Hz, 1H), 7.56 (d, J = 11.8 Hz, 2H), 7.36 (dd, J = 8.9, 5.1 Hz, 1H), 7.08 (dtd, J = 26.7, 9.0, 8.6, 2.9 Hz, 3H), 6.61 (s, 1H), 6.08 (s, 1H), 5.88 - 5.64 (m, 1H), 5.34 - 4.92 (m, 1H), 3.91 (dd, J = 11.0, 8.1 Hz, 1H), 3.24 (dd, J = 11.1, 3.9 Hz, 1H).	490.0	E	




I-2402		O[C@@H]1CN(C(=O)Nc2cc(Cl)cc3C(=O)N[C@@H](c23)c2cc(F)ccc2Cl)c2ccc(F)cc12	(400 MHz, DMSO-d6) δ9.23 (s, 1H), 8.61 (s, 1H), 7.70 (dd, J = 8.9, 4.7 Hz, 1H), 7.56 (d, J = 11.8 Hz, 2H), 7.36 (dd, J = 8.9, 5.1 Hz, 1H), 7.08 (dtd, J = 26.7, 9.0, 8.6, 2.9 Hz, 3H), 6.61 (s, 1H), 6.08 (s, 1H), 5.88 - 5.64 (m, 1H), 5.34 - 4.92 (m, 1H), 3.91 (dd, J = 11.0, 8.1 Hz, 1H), 3.24 (dd, J = 11.1, 3.9 Hz, 1H).	487.9	A	A
I-2403		O[C@H]1CN(C(=O)Nc2cc(cc3C(=O)N[C@H](c23)c2cc(F)ccc2Cl)-n2cc(cn2)C#N)c2ccc(F)cc12	(400 MHz, DMSO-d6) 9.54 (s, 1H), 9.26 (s, 1H), 8.93 (s, 1H), 8.46 (d, J = 24.6 Hz, 1H), 8.29 - 7.70 (m, 3H), 7.45 (d, J = 23.9 Hz, 1H), 7.25 - 7.01 (m, 3H), 6.97 - 6.45 (s, 1H), 6.08 (s, 1H), 5.79 (s, 1H), 5.07 (s, 1H), 3.72 (d, J = 9.9 Hz, 1H), 3.42 (s, 1H) .	547.1	A	B
I-2404		O[C@@H]1CN(C(=O)Nc2cc(cc3C(=O)N[C@@H](c23)c2cc(F)ccc2Cl)-n2cc(cn2)C#N)c2ccc(F)cc12	(400 MHz, DMSO-d6) 9.54 (s, 1H), 9.29 (s, 1H), 8.86 (d, J = 63.1 Hz, 1H), 8.43 (s, 1H), 8.26 - 7.79 (m, 2H), 7.74 (dd, J = 8.8, 4.7 Hz, 1H), 7.38 (dt, J = 9.1, 4.7 Hz, 1H), 7.21 - 7.10 (m, 2H), 7.10 - 6.95 (s, 1H), 6.93 - 6.36 (m, 1H), 6.15 (s, 1H), 5.77 (s, 1H), 5.23 - 5.00 (m, 1H), 3.97 (dd, J = 11.0, 8.1 Hz, 1H), 3.26 - 3.16 (m, 1H).	547.2	B	
I-2405		O[C@@H]1CN(C(=O)Nc2cc(cc3C(=O)N[C@H](c23)c2cc(F)ccc2Cl)-n2cc(cn2)C#N)c2ccc(F)cc12	(400 MHz, DMSO-d6) 9.54 (s, 1H), 9.29 (s, 1H), 8.86 (d, J = 63.1 Hz, 1H), 8.43 (s, 1H), 8.11 - 7.94 (m, 2H), 7.74 (dd, J = 8.8, 4.7 Hz, 1H), 7.38 (dt, J = 9.1, 4.7 Hz, 1H), 7.21 - 6.93 (m, 3H), 6.93 - 6.36 (m, 1H), 6.15 (s, 1H), 5.77 (s, 1H), 5.23 - 5.00 (m, 1H), 3.97	547.2	A	




			(dd, J = 11.0, 8.1 Hz, 1H), 3.26 - 3.16 (m, 1H).			
I-2406		O[C@H]1CN(C(=O)Nc2cc(cc3C(=O)N[C@@H](c23)c2cc(F)ccc2Cl)-n2cc(cn2)C#N)c2ccc(F)cc12	(400 MHz, DMSO-d6) 9.54 (s, 1H), 9.26 (s, 1H), 8.93 (s, 1H), 8.46 (d, J = 24.6 Hz, 1H), 8.02 (d, J = 23.9 Hz, 2H), 7.86 (s, 1H), 7.39 (dd, J = 8.9, 5.1 Hz, 1H), 7.24 - 7.02 (m, 3H), 6.98 - 6.37 (m, 1H), 6.08 (s, 1H), 5.79 (s, 1H), 5.07 (s, 1H), 3.72 (d, J = 9.9 Hz, 1H), 3.17 (d, J = 4.5 Hz, 1H)	547.1	D	
I-2407		CC(N1C[C@H](O)C[C@H]1C(=O)Nc1cccc2C(=O)NC(c12)c1cc(F)ccc1Cl)C(F)(F)F	(400 MHz, DMSO-d6) δ 9.29 (br. s, 1H), 9.16 (br. s, 0.3H), 9.15 (br. s, 0.6H), 9.11 (br. s, 0.3H), 7.95 - 7.80 (m, 0.2H), 7.83 - 7.68 (m, 0.8H), 7.67 - 7.39 (m, 3H), 7.35 - 7.09 (m, 1H), 6.71 (br. s, 0.3H), 6.38 (br. s, 0.7H), 6.15 (br. s, 0.3H), 6.08 (br. s, 0.7H), 4.88 (br. s, 1H), 4.14 - 3.78 (m, 1H), 3.79 - 3.53 (m, 1H), 3.55 - 3.40 (m, 0.2H), 3.28 - 3.07 (m, 1H), 3.08 - 2.91 (m, 0.8H), 2.93 - 2.82 (m, 0.2H), 2.71 - 2.59 (m, 0.2H), 2.60 - 2.52 (m, 0.8H), 1.86 - 1.64 (m, 1H), 1.50 - 1.26 (m, 1H), 1.15 (d, J = 7.0 Hz, 0.7H), 1.08 (d, J = 7.0 Hz, 1.6H), 1.07 (d, J = 6.9 Hz, 0.2H), 1.05 (d, J = 6.8 Hz, 0.5H); 1.4:1:0.9:0.2 mixture of diastereomers according to LCMS	486.3	E	



I-2408		Fc1ccc(Cl)c(c1)C1NC(=O)c2cccc(NC(=O)N3CCCC3C3CC3)c12	(400 MHz, DMSO-d6) δ 9.00 (br s, 1H), 8.18 (br s, 0.6H), 7.74 (br s, 0.4H), 7.56 - 7.38 (m, 3H), 7.29 - 7.17 (m, 2H), 6.57 (submerged br s, 1H), 6.04 (br s, 0.6H), 5.97 (submerged br s, 0.4H), 3.64 (t, J = 7.3 Hz, 0.6H), 3.28 (dt, J = 15.1, 7.6 Hz, 1H), 3.04 (dd, J = 8.5, 5.3 Hz, 1H), 2.41 - 2.27 (m, 0.6H), 1.96 - 1.81 (m, 1H), 1.81 - 1.53 (m, 3.4H), 0.95 - 0.81 (m, 0.4H), 0.81 - 0.66 (m, 0.6H), 0.58 - 0.40 (m, 1H), 0.39 - 0.29 (m, 1H), 0.28 - 0.21 (m, 1H), 0.15 - -0.02 (m, 1H). Mixture 3:2 of diastereomer	414.0	E	
I-2409		FC(F)(C1=CC(F)=CC(C(NC2=C3C(NC(C3=CC(NC4=NC5(CC(F)(F)C5)CO4)=C2)=O)C6=CC(F)=CC=C6Cl)=O)=C1)F	(400 MHz, DMSO) δ 10.49 (s, 1H), 9.84 (s, 1H), 9.08 (s, 1H), 8.02 (s, 2H), 7.92 (d, J = 8.4 Hz, 1H), 7.72 – 7.61 (m, 3H), 7.58 (s, 1H), 7.28 (dd, J = 8.9, 5.1 Hz, 1H), 7.07 (td, J = 8.3, 3.0 Hz, 1H), 5.85 (s, 1H), 4.40 (s, 2H), 2.89 (dd, J = 14.3, 10.7 Hz, 5H), 2.06 (s, 2H), 1.06 (s, 1H).	627.0	A	C
I-2410		Nc1cc2C(=O)N[C@@H](c2c(NC(=O)N2C[C@@H](O)c3cc(F)ccc23)c1)c1cc(F)ccc1Cl	(400 MHz, DMSO-d6) 8.79 (s, 1H), 8.33 (s, 1H), 7.81 (dd, J = 8.9, 4.7 Hz, 1H), 7.33 (dd, J = 8.8, 5.2 Hz, 1H), 7.12 (ddt, J = 8.5, 5.8, 3.1 Hz, 2H), 7.06 (td, J = 9.0, 2.7 Hz, 1H), 6.74 (d, J = 2.0 Hz, 1H), 6.60 (d, J = 2.0 Hz, 1H), 6.51 (s, 1H), 5.82 (s, 1H), 5.74 (d, J = 6.0 Hz, 1H), 5.51 (s, 2H), 5.05 (s, 1H), 3.66 (dd, J = 11.4, 3.6 Hz, 1H), 3.27 - 3.19 (m, 1H).	471.1	A	A







I-2411		Nc1cc2C(=O)N[C@H](c2c(NC(=O)N2C[C@@H](O)c3cc(F)ccc23)c1)c1cc(F)ccc1Cl	(400 MHz, DMSO-d6) 8.81 (s, 1H), 8.20 (s, 1H), 7.70 (dd, J = 9.1, 4.7 Hz, 1H), 7.32 (dd, J = 8.8, 5.2 Hz, 1H), 7.13 - 6.98 (m, 3H), 6.75 (d, J = 2.0 Hz, 1H), 6.67 (d, J = 2.0 Hz, 1H), 6.52 (s, 1H), 5.92 (s, 1H), 5.71 (d, J = 5.2 Hz, 1H), 5.51 (s, 2H), 5.13 (s, 1H), 3.96 - 3.87 (m, 1H), 3.23 (d, J = 8.9 Hz, 1H).	471.1	A	D
I-2412		Nc1cc2C(=O)N[C@@H](c2c(NC(=O)N2C[C@H](O)c3cc(F)ccc23)c1)c1cc(F)ccc1Cl	(400 MHz, DMSO-d6) 8.78 (s, 1H), 8.33 (s, 1H), 7.82 (dd, J = 8.8, 4.8 Hz, 1H), 7.34 (dd, J = 8.8, 5.2 Hz, 1H), 7.12 (ddt, J = 8.5, 5.5, 3.0 Hz, 2H), 7.06 (td, J = 9.1, 2.8 Hz, 1H), 6.74 (d, J = 2.0 Hz, 1H), 6.60 (d, J = 2.0 Hz, 1H), 6.51 (s, 1H), 5.82 (s, 1H), 5.73 (d, J = 6.0 Hz, 1H), 5.51 (s, 2H), 5.05 (s, 1H), 3.66 (dd, J = 11.3, 3.6 Hz, 1H), 3.23 (s, 1H).	471.2	D	
I-2413		Nc1cc2C(=O)N[C@H](c2c(NC(=O)N2C[C@H](O)c3cc(F)ccc23)c1)c1cc(F)ccc1Cl	(400 MHz, DMSO-d6) 8.81 (s, 1H), 8.20 (s, 1H), 7.70 (dd, J = 8.9, 4.8 Hz, 1H), 7.32 (dd, J = 8.8, 5.2 Hz, 1H), 7.13 - 7.07 (m, 1H), 7.06 (dd, J = 8.7, 5.6 Hz, 1H), 7.06 - 6.97 (m, 1H), 6.75 (d, J = 2.0 Hz, 1H), 6.67 (d, J = 2.0 Hz, 1H), 6.53 (s, 1H), 5.92 (s, 1H), 5.71 (d, J = 5.1 Hz, 1H), 5.51 (s, 2H), 5.13 (dt, J = 8.7, 4.6 Hz, 1H), 3.91 (dd, J = 11.1, 8.1 Hz, 1H), 3.23 (dd, J = 11.1, 4.1 Hz, 1H).	471.2	E	






I-2414		OC1CN(C(=O)Nc2cc(cc3C(=O)NC(c23)c2cc(F)ccc2Cl)-n2cncn2)c2ccc(F)cc12	(400 MHz, DMSO-d6) δ 9.51 (br s, 1 H), 9.28 (br s, 1 H), 8.94 (br s, 0.5 H), 8.79 (s, 0.5 H), 8.30 (s, 0.5 H), 8.30 (s, 0.5 H), 8.12 - 8.09 (m, 1 H), 8.03 (d, J = 1.8 Hz, 0.5 H), 7.96 (d, J = 1.6 Hz, 0.5 H), 7.85 (dd, J = 8.0, 4.4 Hz, 0.5 H), 7.73 (dd, J = 8.8, 4.7 Hz, 0.5 H), 7.41 - 7.33 (m, 1 H), 7.21 - 7.00 (m, 3 H), 6.67 (br s, 1 H), 6.14 (br s, 0.5 H), 6.06 (br s, 0.5 H), 5.15 (dd, J = 7.9, 3.9 Hz, 0.5 H), 5.07 (dd, J = 7.7, 3.2 Hz, 0.5 H), 3.98 (dd, J = 10.9, 8.2 Hz, 0.5 H), 3.72 (dd, J = 11.3, 3.4 Hz, 0.5 H), 3.21 (dd, J = 11.0, 3.8 Hz, 0.5 H). 0.5 H submerged under water signal. ~1:1 mixture of diastereomers.	523.3	B	D
I-2415		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)N3CC[C@@H](C3)C#N)c12)-c1ccc2ncnn2c1	(400 MHz, DMSO-d6) δ 9.39 (br s, 1H), 9.17 (br s, 1H), 8.56 (s, 1H), 8.44 (d, J = 7.6 Hz, 1H), 8.06 (dt, J = 9.3, 1.6 Hz, 1H), 7.97 (d, J = 9.2 Hz, 1H), 7.93 (s, 1H), 7.70 (dd, J = 2.4, 1.8 Hz, 1H), 7.51 (br s, 1H), 7.28 - 7.20 (m, 1H), 6.70 (br s, 1H), 6.07 (br s, 1H), 3.58 (dd, J = 10.6, 7.1 Hz, 1H), 3.47 - 3.36 (m, 4H[submerged under H2O peak]), 2.24 - 1.95 (m, 2H) ppm [1:1 mixture of diastereomers].	516.4	E	





I-2416		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(cc(NC(=O)N3CC[C@H](C3)C#N)c12)-c1ccc2ncnn2c1	(400 MHz, DMSO-d6) δ 9.39 (br s, 1H), 9.17 (br s, 1H), 8.56 (s, 1H), 8.44 (d, J = 7.6 Hz, 1H), 8.06 (dt, J = 9.3, 1.6 Hz, 1H), 7.97 (d, J = 9.2 Hz, 1H), 7.93 (s, 1H), 7.70 (dd, J = 2.4, 1.8 Hz, 1H), 7.51 (br s, 1H), 7.28 - 7.20 (m, 1H), 6.70 (br s, 1H), 6.07 (br s, 1H), 3.58 (dd, J = 10.6, 7.1 Hz, 1H), 3.47 - 3.36 (m, 4H[submerged under H2O peak]), 2.24 - 1.95 (m, 2H) ppm [1:1 mixture of diastereomers].	516.4	E	
I-2417		OC1(CN(C1)C(=O)Nc1ccc2C(=O)NC(c12)c1cc(F)ccc1Cl)c1scnc1C(F)(F)F	(400 MHz, DMSO-d6) δ 9.20 (m, 1H), 9.03 (br s, 1H), 8.51 (br s, 1H), 7.60 - 7.48 (m, 2H), 7.43 - 7.32 (m, 1H), 7.18 (dd, J = 8.3, 5.5 Hz, 1H), 6.99 (td, J = 8.4, 2.9 Hz, 1H), 6.90 (br s, 1H), 6.47 (br s, 1H), 6.03 (br s, 1H), 4.10 (d, J = 9.0 Hz, 1H), 4.03 (d, J = 9.1 Hz, 1H), 3.87 (d, J = 9.1 Hz, 1H), 3.66 (d, J = 10.5 Hz, 1H).	527.0	E	
I-2418		OC1(CN(C1)C(=O)Nc1ccc2C(=O)NC(c12)c1cc(F)ccc1Cl)c1nc(cs1)C(F)(F)F	(400 MHz, DMSO-d6) δ 9.05 (br s, 1H), 8.51 (d, J = 0.9 Hz, 1H), 8.39 (br s, 1H), 7.56 - 7.50 (m, 2H), 7.50 - 7.42 (m, 2H), 7.39 (br s, 1H), 7.16 (ddd, J = 8.9, 8.0, 3.1 Hz, 1H), 6.57 (br s, 1H), 6.09 (br s, 1H), 4.11 (d, J = 8.5 Hz, 1H), 3.99 (d, J = 8.5 Hz, 1H), 3.92 (d, J = 8.5 Hz, 1H), 3.70 (d, J = 8.7 Hz, 1H).	527.0	E	





I-2419		CC(C)C1CCN(C1)C(=O)Nc1cccc2C(=O)NC(c12)c1cc(F)ccc1Cl	(400 MHz, DMSO-d6) δ 9.00 (br s, 1H), 8.12 (s, 0.5H), 8.02 (s, 0.5H), 7.65 - 7.36 (m, 3H), 7.43 - 7.15 (m, 2H), 6.56 (br s, 1H), 5.97 (br s, 1H), 3.61 - 3.38 (submerged m, 2H), 3.23 - 3.02 (m, 1H), 2.84 - 2.64 (m, 1H), 1.88 (td, J = 12.2, 6.3 Hz, 1H), 1.77 - 1.51 (m, 1H), 1.47 - 1.16 (m, 2H), 0.89 (dd, J = 6.6, 1.6 Hz, 3H), 0.84 (d, J = 6.5 Hz, 3H). Partial formate salt @8.22 ppm. 1:1 Mixture of diastereomers	416.0	E	
I-2420		CCC1CCN(C1)C(=O)Nc1cccc2C(=O)NC(c12)c1cc(F)ccc1Cl	(400 MHz, DMSO-d6) δ 9.00 (br s, 1H), 8.09 (s, 0.5H), 8.03 (s, 0.5H), 7.55 - 7.42 (m, 3H), 7.35 - 7.17 (m, 2H), 6.55 (br s, 1H), 5.98 (br s, 1H), 3.58 - 3.35 (submerged m, 2H), 3.26 - 3.08 (m, 1H), 2.82 - 2.64 (m, 1H), 2.02 - 1.78 (m, 2H), 1.44 - 1.10 (m, 3H), 0.95 - 0.80 (m, 3H). Partial formate salt @8.23 ppm. 1:1 Mix of diastereomers.	402.0	E	
I-2421		CC(C1CCN(C1)C(=O)Nc1cccc2C(=O)NC(c12)c1cc(F)ccc1Cl)C(F)(F)F	(400 MHz, DMS)-d6) δ 9.01 (br. s, 1H), 8.26 (br. s, 0.2H), 8.24 (br. s, 0.3H), 8.14 (br. s, 0.3H), 8.11 (br. s, 0.2H), 7.54 - 7.42 (m, 3H), 7.33 - 7.15 (m, 2H), 6.59 (br. s, 1H), 5.97 (br. s, 1H), 3.69 - 3.53 (m, 1H), 3.53 - 3.39 (m, 1H), 3.24 - 3.04 (m, 1H), 2.99 - 2.88 (m, 1H), 2.47 - 2.24 (m, 1H), 2.24 - 1.99 (m, 1H), 2.02 - 1.81 (m, 1H), 1.67 - 1.30 (m, 1H), 1.10 (d, J = 6.9 Hz, 0.8H), 1.09	470.2	E	




			(d, J = 6.9 Hz, 0.8H), 1.03 (d, J = 6.7 Hz, 0.7H), 1.02 (d, J = 6.7 Hz, 0.7H); ~1.3 : 1.2 : 1 : 1 mixture of diastereomers; contains ~5% formate salt - due to peak at 8.25 ppm			
1-2422		[H][C@@]12CCN(C(=O)Nc3cccc4C(=O)NC(c34)c3cc(F)ccc3Cl)[C@]1([H])CCCC2	(400 MHz, DMSO-d6) δ as a ca. 1:1 mixture of diastereomers, δ 8.99 (br. s, 2H), 8.04 (br. s, 1H), 7.78 (br. s, 1H), 7.52 - 7.40 (m, 7H), 7.27 - 7.17 (m, 3H), 6.60 (br. s, 2H), 6.05 (br. s, 2H), 3.77 - 3.68 (m, 1H), 3.39 - 3.28 (m, 1H), 3.21 (dd, J = 17.4, 9.1 Hz, 1H), 3.05 - 2.95 (m, 1H), 2.15 - 1.97 (m, 2H), 1.90 - 1.72 (m, 3H), 1.71 - 1.47 (m, 8H), 1.44 - 1.32 (m, 4H), 1.32 - 1.17 (m, 3H), 1.12 - 0.87 (m, 4H). Multiplet at 3.39 - 3.28 ppm is obscured by the peak for residual H2O.	428.4	D	
1-2423		OC1(CN(C(=O)Nc2cccc3C(=O)NC(c23)c2cc(F)ccc2Cl)c2ccccc12)C(F)F	(400 MHz, DMSO-d6) δ as a ca. 1:1 mixture of diastereomers δ 9.11 - 9.04 (m, 2H), 8.72 (br. s, 1H), 8.62 (br. s, 1H), 7.86 (br. d, J = 8.1 Hz, 1H), 7.78 (d, J = 8.3 Hz, 1H), 7.62 - 7.54 (m, 4H), 7.48 (dd, J = 7.3, 1.7 Hz, 1H), 7.42 - 7.37 (m, 3H), 7.37 - 7.26 (m, 4H), 7.14 - 7.08 (m, 2H), 7.01 (tdd, J = 7.5, 5.0, 0.9 Hz, 2H), 6.55 (s, 1H), 6.63 - 6.43 (m, 2H), 6.49 (s, 1H), 6.38 - 6.07 (m, 2H), 6.11 (br. s, 1H), 6.05 (br. s, 1H), 4.06 (d, J = 11.7 Hz, 1H), 3.82 (br. d, J = 12.2 Hz, 1H), 3.45 (br. d, J = 11.3 Hz, 1H), 3.33 - 3.30 (m, 1H). Multiplet	488.3	A	B





			at 3.33 - 3.30 ppm is partially obscured by the peak for residual H2O.			
I-2424		Fc1ccc(Cl)c(c1)C1NC(=O)c2cc(Br)cc(NC(=O)N3CCCC33CCCC3)c12		98.0	C	
I-2425		Fc1ccc(Cl)c(c1)C1NC(=O)c2cccc(NC(=O)N3CCc4c3cccc4C#N)c12		447.1	E	
I-2426		Fc1ccc(Cl)c(c1)C1NC(=O)c2cccc(NC(=O)N3CCc4cc(ccc34)C#N)c12		446.9	E	
I-2427		Fc1ccc(Cl)c(c1)C1NC(=O)c2cccc(NC(=O)N3CCc4ccc(cc34)C#N)c12		447.0	D	
I-2428		Fc1ccc(Cl)c(c1)C1NC(=O)c2cccc(NC(=O)N3CCSC3)c12		391.8	E	
I-2429		Fc1ccc(Cl)c(c1)C1NC(=O)c2cccc(NC(=O)N3CC4C3C3CCC4C3)c12		426.0	E	




I-2430		Fc1ccc(Cl)c(c1)C1NC(=O)c2cccc(NC(=O)N3CCCC33CCCCC3)c12		442.0	C	
I-2431		Nc1nn(C(=O)Nc2cccc3C(=O)NC(c23)c2cc(F)ccc2Cl)c2ccc(F)cc12		453.9	C	
I-2432		CC(C)(C)[C@H]1CCCN1C(=O)Nc1cccc2C(=O)N[C@H](c12)c1cc(F)ccc1Cl	(400 MHz, DMSO-d6) as a ~19:1 mixture of diastereomers, δ 9.02 (br. s, 1H), 7.77 (br. s, 1H), 7.74 (br. d, J = 7.1 Hz, 1H), 7.54 - 7.47 (m, 3H), 7.23 (ddd, J = 8.8, 8.1, 3.1 Hz, 1H), 6.63 (br. s, 1H), 6.16 (br. s, 1H), 3.74 - 3.70 (m, 1H), 3.15 - 3.07 (m, 1H), 3.05 - 2.96 (m, 1H), 1.82 - 1.65 (m, 2H), 1.58 - 1.48 (m, 2H), 0.78 (s, 9H).	430.4	C	
I-2433		CC(C)(C)[C@@H]1CCCN1C(=O)Nc1cccc2C(=O)N[C@H](c12)c1cc(F)ccc1Cl	(400 MHz, DMSO-d6) δ as a ~19:1 mixture of diastereomers, δ 9.00 (br. s, 1H), 8.33 (br. s, 1H), 7.52 - 7.44 (m, 3H), 7.26 - 7.19 (m, 2H), 6.36 (br. s, 1H), 5.98 (br. s, 1H), 3.99 (d, J = 7.9 Hz, 1H), 3.21 - 3.13 (m, 1H), 2.45 - 2.36 (m, 1H), 1.78 - 1.61 (m, 3H), 1.53 - 1.44 (m, 1H), 0.75 (s, 9H).	430.4	D	
I-2434		CCN(C(=O)Nc1cccc2C(=O)NC(c12)c1cc(F)ccc1Cl)c	(400 MHz, DMSO-d6) 9.05 (s, 1H), 7.73 (s, 1H), 7.61 (s, 1H), 7.53-7.43 (m, 2H), 7.35 (ddd, J = 10.9, 7.2, 2.7 Hz, 2H), 7.09 (t, J = 8.6 Hz, 2H), 6.64 (dd, J =	442.3	E	




		1ccc(F)cc1	8.7, 5.0 Hz, 2H), 6.42 (s, 1H), 6.08 (s, 1H), 3.64 (dt, J = 14.2, 7.1 Hz, 1H), 3.42 (dq, J = 13.9, 6.9 Hz, 1H), 0.90 (t, J = 7.0 Hz, 3H).			
I-2435		CN(C(=O)Nc1ccccc2C(=O)NC(c12)c1cc(F)ccc1Cl)c1ccc(F)cc1	(400 MHz, DMSO-d6) 9.04 (s, 1H), 7.91 (s, 1H), 7.58 (s, 1H), 7.54-7.45 (m, 2H), 7.33 (ddd, J = 11.7, 8.6, 4.7 Hz, 2H), 7.10 (t, J = 8.8 Hz, 2H), 6.85-6.75 (m, 2H), 6.43 (s, 1H), 6.04 (s, 1H), 3.05 (s, 3H).	428.2	E	
I-2436		Fc1ccc(Cl)c(c1)C1NC(=O)c2cccc(NC(=O)N3CCc4cc(ccc34)C(F)(F)F)c12	(400 MHz, DMSO-d6) 9.07 (s, 1H), 8.72 (s, 1H), 7.87 (d, J = 8.4 Hz, 1H), 7.62 (d, J = 6.6 Hz, 1H), 7.61-7.54 (m, 2H), 7.54-7.45 (m, 2H), 7.43-7.35 (m, 2H), 7.16 (td, J = 8.4, 3.1 Hz, 1H), 6.01 (s, 1H), 3.95 (td, J = 10.1, 7.0 Hz, 1H), 3.12 (pt, J = 16.8, 7.8 Hz, 2H).	490.3	E	
I-2437		COc1ccc2N(CCc2c1)C(=O)Nc1cccc2C(=O)NC(c12)c1cc(F)ccc1Cl		452.3	E	
I-2438		Cc1cccc2N(CCc12)C(=O)Nc1cccc2C(=O)NC(c12)c1cc(F)ccc1Cl	(400 MHz, DMSO-d6) 9.05 (s, 1H), 8.49 (s, 1H), 7.62 -7.50 (m, 3H), 7.45 -7.36 (m, 2H), 7.16 (td, J = 8.4, 3.1 Hz, 1H), 7.01 (t, J = 7.8 Hz, 1H), 6.73 (d, J = 7.5 Hz, 1H), 6.57 (s, 1H), 6.03 (s, 1H), 3.87 (td, J = 10.1, 7.2 Hz, 1H), 3.27 (s, 1H), 2.96 (tp, J = 14.3, 7.0 Hz, 2H), 2.19 (s, 3H).	436.2	D	




I-2439		COc1ccc2CCN(C(=O)Nc3ccc4C(=O)NC(c34)c3cc(F)ccc3Cl)c2c1	(400 MHz, DMSO-d6) 9.06 (s, 1H), 8.54 (s, 1H), 7.63 - 7.52 (m, 2H), 7.43 - 7.33 (m, 3H), 7.16 (td, J = 8.4, 3.1 Hz, 1H), 7.05 (d, J = 8.2 Hz, 1H), 6.60 (s, 1H), 6.47 (dd, J = 8.2, 2.5 Hz, 1H), 6.02 (s, 1H), 3.87 (td, J = 9.9, 7.4 Hz, 1H), 3.70 (s, 3H), 3.28 (d, J = 17.2 Hz, 1H), 3.04 - 2.85 (m, 2H).	452.2	D	
I-2440		Cc1ccc2N(CCc2c1)C(=O)Nc1cccc2C(=O)NC(c12)c1cc(F)ccc1Cl	(400 MHz, DMSO-d6) 9.03 (s, 1H), 8.47 (s, 1H), 7.56 (q, J = 7.5 Hz, 3H), 7.43-7.34 (m, 2H), 7.15 (td, J = 8.4, 3.1 Hz, 1H), 6.98 (s, 1H), 6.90 (d, J = 8.2 Hz, 1H), 6.58 (s, 1H), 6.02 (s, 1H), 3.83 (td, J = 9.9, 7.4 Hz, 1H), 3.23-3.15 (m, 1H), 2.98 (dt, J = 13.6, 7.0 Hz, 2H), 2.24 (s, 3H).	436.2	E	
I-2441		COc1ccc2N(CCc12)C(=O)Nc1cccc2C(=O)NC(c12)c1cc(F)ccc1Cl	(400 MHz, DMSO-d6) 9.06 (s, 1H), 8.65 (s, 1H), 7.68 (d, J = 8.0 Hz, 1H), 7.64 - 7.53 (m, 2H), 7.39 (td, J = 8.3, 7.4, 2.7 Hz, 2H), 7.22 - 7.12 (m, 2H), 6.97 (d, J = 7.9 Hz, 1H), 6.56 (s, 1H), 6.00 (s, 1H), 3.94 (td, J = 10.3, 7.0 Hz, 1H), 3.25 (s, 1H), 3.08 (tdd, J = 16.5, 10.3, 6.4 Hz, 2H).	456.2	E	
I-2442		Fc1ccc(Cl)c(c1)C1NC(=O)c2cccc(NC(=O)N3CCc4c3cccc4Cl)c12	(400 MHz, DMSO-d6) 9.06 (s, 1H), 8.65 (s, 1H), 7.68 (d, J = 8.0 Hz, 1H), 7.64 - 7.53 (m, 2H), 7.39 (td, J = 8.3, 7.4, 2.7 Hz, 2H), 7.22 - 7.12 (m, 2H), 6.97 (d, J = 7.9 Hz, 1H), 6.56 (s, 1H), 6.00 (s, 1H), 3.94 (td, J = 10.3, 7.0 Hz, 1H), 3.25 (s, 1H), 3.08 (tdd, J = 16.5, 10.3, 6.4 Hz, 2H).	456.2	D	




I-2443		NCCc1cc2C(=O)N[C@@H](c2c(NC(=O)N2C[C@H](O)c3cc(F)ccc23)c1)c1cc(F)ccc1Cl	(400 MHz, DMSO-d6) 9.00 (s, 1H), 8.60 (s, 1H), 7.83 (dd, J = 8.9, 4.7 Hz, 1H), 7.42 (d, J = 1.5 Hz, 1H), 7.36 (dd, J = 8.9, 5.2 Hz, 1H), 7.21 (d, J = 1.5 Hz, 1H), 7.15 (tt, J = 8.2, 2.9 Hz, 2H), 7.08 (td, J = 9.0, 2.8 Hz, 1H), 6.55 (s, 1H), 5.96 (s, 1H), 5.77 (s, 1H), 5.07 (dd, J = 8.4, 3.5 Hz, 1H), 3.71 (dd, J = 11.3, 3.6 Hz, 1H), 3.27 (d, J = 32.4 Hz, 4H), 2.90-2.70 (m, 3H).	499.2	A	D
I-2444		NCCc1cc2C(=O)N[C@@H](c2c(NC(=O)N2C[C@@H](O)c3cc(F)ccc23)c1)c1cc(F)ccc1Cl	(400 MHz, DMSO-d6) 9.00 (s, 1H), 8.60 (s, 1H), 7.83 (dd, J = 8.9, 4.7 Hz, 1H), 7.42 (d, J = 1.5 Hz, 1H), 7.36 (dd, J = 8.9, 5.2 Hz, 1H), 7.21 (d, J = 1.5 Hz, 1H), 7.15 (tt, J = 8.2, 2.9 Hz, 2H), 7.08 (td, J = 9.0, 2.8 Hz, 1H), 6.55 (s, 1H), 5.96 (s, 1H), 5.77 (s, 1H), 5.07 (dd, J = 8.4, 3.5 Hz, 1H), 3.71 (dd, J = 11.3, 3.6 Hz, 1H), 3.27 (d, J = 32.4 Hz, 4H), 2.90-2.70 (m, 3H).	499.2	B	
I-2445		NCCc1cc2C(=O)N[C@H](c2c(NC(=O)N2C[C@H](O)c3cc(F)ccc23)c1)c1cc(F)ccc1Cl	(400 MHz, DMSO-d6) 9.00 (s, 1H), 8.60 (s, 1H), 7.83 (dd, J = 8.9, 4.7 Hz, 1H), 7.42 (d, J = 1.5 Hz, 1H), 7.36 (dd, J = 8.9, 5.2 Hz, 1H), 7.21 (d, J = 1.5 Hz, 1H), 7.15 (tt, J = 8.2, 2.9 Hz, 2H), 7.08 (td, J = 9.0, 2.8 Hz, 1H), 6.55 (s, 1H), 5.96 (s, 1H), 5.77 (s, 1H), 5.07 (dd, J = 8.4, 3.5 Hz, 1H), 3.71 (dd, J = 11.3, 3.6 Hz, 1H), 3.27 (d, J = 32.4 Hz, 4H), 2.90-2.70 (m, 3H).	499.2	D	




I-2446		NCCc1cc2C(=O)N[C@H](c2c(NC(=O)N2C[C@@H](O)c3cc(F)ccc23)c1)c1cc(F)ccc1Cl	(400 MHz, DMSO-d6) 9.00 (s, 1H), 8.60 (s, 1H), 7.83 (dd, J = 8.9, 4.7 Hz, 1H), 7.42 (d, J = 1.5 Hz, 1H), 7.36 (dd, J = 8.9, 5.2 Hz, 1H), 7.21 (d, J = 1.5 Hz, 1H), 7.15 (tt, J = 8.2, 2.9 Hz, 2H), 7.08 (td, J = 9.0, 2.8 Hz, 1H), 6.55 (s, 1H), 5.96 (s, 1H), 5.77 (s, 1H), 5.07 (dd, J = 8.4, 3.5 Hz, 1H), 3.71 (dd, J = 11.3, 3.6 Hz, 1H), 3.27 (d, J = 32.4 Hz, 4H), 2.90-2.70 (m, 3H).	499.2	D	
I-2447		Fc1ccc(Cl)c(c1)C1NC(=O)c2cccc(NC(=O)N3CCc4ccc(cc34)C(F)(F)F)c12	(400 MHz, DMSO-d6) 9.08 (s, 1H), 8.73 (s, 1H), 8.00 (s, 1H), 7.66 - 7.59 (m, 1H), 7.58 (t, J = 7.5 Hz, 1H), 7.43 - 7.32 (m, 3H), 7.25 (d, J = 7.5 Hz, 1H), 7.13 (td, J = 8.4, 3.1 Hz, 1H), 6.56 (s, 1H), 6.03 (s, 1H), 3.95 (td, J = 10.0, 7.0 Hz, 1H), 3.21 (s, 1H), 3.13 (q, J = 10.1 Hz, 2H).	490.2	D	
I-2448		O[C@H]1CN(C(=O)Nc2cc(cc3C(=O)N[C@@H](c23)c2cc(F)ccc2Cl)-c2ccc(=O)n(c2)C(F)F)c2ccc(F)cc12	(400 MHz, DMSO-d6) 9.12 (s, 1H), 8.73 (s, 1H), 8.16 (d, J = 2.6 Hz, 1H), 8.11 - 8.04 (m, 1H), 7.94 - 7.72 (m, 3H), 7.63 (d, J = 1.7 Hz, 1H), 7.38 (dd, J = 8.9, 5.2 Hz, 1H), 7.21 - 7.02 (m, 3H), 6.69 (d, J = 9.7 Hz, 2H), 6.05 (s, 1H), 5.79 (s, 1H), 5.12 - 5.05 (m, 1H), 3.73 (dd, J = 11.4, 3.6 Hz, 1H), 3.25 (dd, J = 11.0, 4.0 Hz, 1H).	599.1	A	B
I-2449		O[C@@H]1CN(C(=O)Nc2cc(cc3C(=O)N[C@@H](c23)c2cc(F)ccc2Cl	(400 MHz, DMSO-d6) 9.14 (s, 1H), 8.59 (s, 1H), 8.15 (d, J = 2.6 Hz, 1H), 8.12 - 8.03 (m, 1H), 7.92 (s, 1H), 7.83 (d, J = 1.6 Hz, 1H), 7.78 - 7.64 (m, 2H), 7.36 (dd, J = 8.9,	599.1	B	





		)-c2ccc(=O)n(c2)C(F)F)c2ccc(F)cc12	5.1 Hz, 1H), 7.18 - 6.96 (m, 3H), 6.68 (d, J = 9.7 Hz, 2H), 6.13 (s, 1H), 5.74 (d, J = 4.9 Hz, 1H), 5.31 - 5.07 (m, 1H), 4.00 (dd, J = 11.1, 8.0 Hz, 1H), 3.25 (dd, J = 11.0, 4.0 Hz, 1H).			
I-2450		O[C@H]1CN(C(=O)Nc2cc(cc3C(=O)N[C@H](c23)c2cc(F)ccc2Cl)-c2ccc(=O)n(c2)C(F)F)c2ccc(F)cc12	(400 MHz, DMSO-d6) 9.14 (s, 1H), 8.60 (s, 1H), 8.15 (d, J = 2.6 Hz, 1H), 8.11 - 8.03 (m, 1H), 7.92 (s, 1H), 7.83 (d, J = 1.6 Hz, 1H), 7.80 - 7.66 (m, 2H), 7.36 (dd, J = 8.9, 5.1 Hz, 1H), 7.18 - 6.95 (m, 3H), 6.68 (m, 2H), 6.13 (s, 1H), 5.75 (s, 1H), 5.16 (dd, J = 8.0, 4.0 Hz, 1H), 4.00 (dd, J = 11.1, 8.1 Hz, 1H), 3.25 (dd, J = 11.0, 4.0 Hz, 1H).	599.0	D	
I-2451		O[C@@H]1CN(C(=O)Nc2cc(cc3C(=O)N[C@H](c23)c2cc(F)ccc2Cl)-c2ccc(=O)n(c2)C(F)F)c2ccc(F)cc12	(400 MHz, DMSO-d6) 9.12 (s, 1H), 8.73 (s, 1H), 8.16 (d, J = 2.6 Hz, 1H), 8.11 - 8.03 (m, 1H), 7.92 (s, 1H), 7.88 - 7.75 (m, 2H), 7.63 (d, J = 1.7 Hz, 1H), 7.38 (dd, J = 8.9, 5.2 Hz, 1H), 7.21 - 7.01 (m, 3H), 6.69 (d, J = 9.7 Hz, 2H), 6.13 (s, 1H), 5.86 (s, 1H), 5.09 (d, J = 7.6 Hz, 1H), 3.73 (dd, J = 11.3, 3.6 Hz, 1H), 3.25 (dd, J = 11.0, 4.0 Hz, 1H).	599.2	D	
I-2452		CC(C)[C@@]1(O)CN(C(=O)Nc2ccc3C(=O)N[C@H](c23)c2cc(F)ccc2Cl)c2ccc(F)cc12	(400 MHz, DMSO-d6) 9.05 (s, 1H), 8.60 (s, 1H), 7.89 (s, 1H), 7.63 - 7.53 (m, 2H), 7.42 (dd, J = 7.1, 1.8 Hz, 1H), 7.34 (dd, J = 8.9, 5.1 Hz, 1H), 7.14 (td, J = 8.4, 3.1 Hz, 1H), 7.09 - 7.02 (m, 2H), 6.55 (s, 1H), 6.11 (s, 1H), 5.54 (s, 1H), 3.64 (d, J = 11.2 Hz, 1H), 3.30 (s,	498.3	D	




			1H), 2.15 - 2.04 (m, 1H), 0.89 (d, J = 6.7 Hz, 3H), 0.55 (d, J = 6.8 Hz, 3H).			
I-2453		CC(C)[C@]1(O)CN(C(=O)Nc2cccc3C(=O)N[C@H](c23)c2cc(F)ccc2Cl)c2ccc(F)cc12	(400 MHz, DMSO-d6) 9.08 (s, 1H), 8.41 (s, 1H), 7.74 (dd, J = 8.8, 4.7 Hz, 1H), 7.58 (d, J = 1.9 Hz, 3H), 7.39 (dd, J = 8.9, 5.1 Hz, 1H), 7.13 (td, J = 8.5, 3.1 Hz, 1H), 7.08 - 6.97 (m, 2H), 6.55 (s, 1H), 6.17 (s, 1H), 5.48 (s, 1H), 3.78 (d, J = 11.1 Hz, 1H), 3.35 (s, 1H), 2.08 (s, 1H), 0.94 (d, J = 6.7 Hz, 3H), 0.57 (d, J = 6.8 Hz, 3H).	498.3	D	
I-2454		CC(C)[C@@]1(O)CN(C(=O)Nc2cccc3C(=O)N[C@@H](c23)c2cc(F)ccc2Cl)c2ccc(F)cc12	(400 MHz, DMSO-d6) 9.05 (s, 1H), 8.60 (s, 1H), 7.89 (s, 1H), 7.63 - 7.53 (m, 2H), 7.42 (dd, J = 7.1, 1.8 Hz, 1H), 7.34 (dd, J = 8.9, 5.2 Hz, 1H), 7.14 (td, J = 8.3, 3.1 Hz, 1H), 7.06 (ddt, J = 6.9, 3.9, 2.1 Hz, 2H), 6.55 (s, 1H), 6.11 (s, 1H), 5.54 (s, 1H), 3.64 (d, J = 11.3 Hz, 1H), 3.35 (s, 1H), 2.15 - 2.04 (m, 1H), 0.89 (d, J = 6.7 Hz, 3H), 0.55 (d, J = 6.8 Hz, 3H).	498.3	B	
I-2455		CC(C)[C@]1(O)CN(C(=O)Nc2cccc3C(=O)N[C@@H](c23)c2cc(F)ccc2Cl)c2ccc(F)cc12	(400 MHz, DMSO-d6) 9.08 (s, 1H), 8.41 (s, 1H), 7.74 (dd, J = 8.8, 4.8 Hz, 1H), 7.58 (d, J = 1.9 Hz, 3H), 7.39 (dd, J = 8.9, 5.1 Hz, 1H), 7.13 (td, J = 8.4, 3.1 Hz, 1H), 7.08 - 7.02 (m, 1H), 7.02 (dd, J = 9.0, 6.3 Hz, 1H), 6.55 (s, 1H), 6.17 (s, 1H), 5.48 (s, 1H), 3.78 (d, J = 11.1 Hz, 1H), 3.29 (s, 1H), 2.07 (q, J = 6.7 Hz, 1H), 0.94 (d, J = 6.7 Hz, 3H), 0.57 (d, J = 6.8 Hz, 3H).	498.3	D	




I-2456		CCC[C@]1(O)CN(C(=O)Nc2cccc3C(=O)N[C@@H](c23)c2cc(F)ccc2Cl)c2ccc(F)cc12	(400 MHz, DMSO-d6) δ 9.05 (s, 1H), 8.62 (s, 1H), 7.86 (s, 1H), 7.62 - 7.52 (m, 2H), 7.41-7.32 (m, 2H), 7.14 (td, J = 8.3, 3.1 Hz, 1H), 7.11 - 7.01 (m, 2H), 6.03 (s, 1H), 5.55 (s, 1H), 3.77 (d, J = 11.0 Hz, 1H), 3.12 (d, J = 11.0 Hz, 1H), 1.77 (td, J = 12.2, 11.2, 4.4 Hz, 1H), 1.52 (td, J = 13.3, 12.6, 4.4 Hz, 1H), 1.26 (d, J = 14.2 Hz, 1H), 1.07 - 0.88 (m, 4H).	498.2	D	
I-2457		CCC[C@@]1(O)CN(C(=O)Nc2cccc3C(=O)N[C@@H](c23)c2cc(F)ccc2Cl)c2ccc(F)cc12	(400 MHz, DMSO-d6) δ 9.05 (s, 1H), 8.62 (s, 1H), 7.86 (s, 1H), 7.62 - 7.52 (m, 2H), 7.41-7.32 (m, 2H), 7.14 (td, J = 8.3, 3.1 Hz, 1H), 7.11 - 7.01 (m, 2H), 6.03 (s, 1H), 5.55 (s, 1H), 3.77 (d, J = 11.0 Hz, 1H), 3.12 (d, J = 11.0 Hz, 1H), 1.77 (td, J = 12.2, 11.2, 4.4 Hz, 1H), 1.52 (td, J = 13.3, 12.6, 4.4 Hz, 1H), 1.26 (d, J = 14.2 Hz, 1H), 1.07 - 0.88 (m, 4H).	498.2	C	
I-2458		CCC[C@]1(O)CN(C(=O)Nc2cccc3C(=O)N[C@H](c23)c2cc(F)ccc2Cl)c2ccc(F)cc12	(400 MHz, DMSO-d6) δ 9.05 (s, 1H), 8.62 (s, 1H), 7.86 (s, 1H), 7.62 - 7.52 (m, 2H), 7.41-7.32 (m, 2H), 7.14 (td, J = 8.3, 3.1 Hz, 1H), 7.11 - 7.01 (m, 2H), 6.03 (s, 1H), 5.55 (s, 1H), 3.77 (d, J = 11.0 Hz, 1H), 3.12 (d, J = 11.0 Hz, 1H), 1.77 (td, J = 12.2, 11.2, 4.4 Hz, 1H), 1.52 (td, J = 13.3, 12.6, 4.4 Hz, 1H), 1.26 (d, J = 14.2 Hz, 1H), 1.07 - 0.88 (m, 4H).	498.2	D	





I-2459		CCC[C@@]1(O)CN(C(=O)Nc2cccc3C(=O)N[C@H](c23)c2cc(F)ccc2Cl)c2ccc(F)cc12	(400 MHz, DMSO-d6) δ 9.05 (s, 1H), 8.62 (s, 1H), 7.86 (s, 1H), 7.62 - 7.52 (m, 2H), 7.41-7.32 (m, 2H), 7.14 (td, J = 8.3, 3.1 Hz, 1H), 7.11 - 7.01 (m, 2H), 6.03 (s, 1H), 5.55 (s, 1H), 3.77 (d, J = 11.0 Hz, 1H), 3.12 (d, J = 11.0 Hz, 1H), 1.77 (td, J = 12.2, 11.2, 4.4 Hz, 1H), 1.52 (td, J = 13.3, 12.6, 4.4 Hz, 1H), 1.26 (d, J = 14.2 Hz, 1H), 1.07 - 0.88 (m, 4H).	498.2	D	
I-2460		CC[C@]1(O)CN(C(=O)Nc2cccc3C(=O)N[C@@H](c23)c2cc(F)ccc2Cl)c2ccc(F)cc12	(400 MHz, DMSO-d6) δ 9.05 (s, 1H), 8.63 (s, 1H), 7.86 (dd, J = 8.7, 4.5 Hz, 1H), 7.64 - 7.52 (m, 2H), 7.42 - 7.33 (m, 2H), 7.15 (td, J = 8.4, 3.1 Hz, 1H), 7.11 - 7.01 (m, 2H), 6.55 (s, 1H), 6.04 (s, 1H), 5.56 (s, 1H), 3.76 (d, J = 11.0 Hz, 1H), 3.13 (d, J = 11.0 Hz, 1H), 1.80 (dq, J = 14.1, 7.1 Hz, 1H), 1.57 (dq, J = 14.6, 7.4 Hz, 1H), 0.76 (t, J = 7.3 Hz, 3H).	484.2	D	
I-2461		CC[C@@]1(O)CN(C(=O)Nc2cccc3C(=O)N[C@@H](c23)c2cc(F)ccc2Cl)c2ccc(F)cc12	(400 MHz, DMSO-d6) δ 9.05 (s, 1H), 8.63 (s, 1H), 7.86 (dd, J = 8.7, 4.5 Hz, 1H), 7.64 - 7.52 (m, 2H), 7.42 - 7.33 (m, 2H), 7.15 (td, J = 8.4, 3.1 Hz, 1H), 7.11 - 7.01 (m, 2H), 6.55 (s, 1H), 6.04 (s, 1H), 5.56 (s, 1H), 3.76 (d, J = 11.0 Hz, 1H), 3.13 (d, J = 11.0 Hz, 1H), 1.80 (dq, J = 14.1, 7.1 Hz, 1H), 1.57 (dq, J = 14.6, 7.4 Hz, 1H), 0.76 (t, J = 7.3 Hz, 3H).	484.2	A	A





I-2462		CC[C@]1(O)CN(C(=O)Nc2cccc3C(=O)N[C@H](c23)c2cc(F)ccc2Cl)c2ccc(F)cc12	(400 MHz, DMSO-d6) δ 9.05 (s, 1H), 8.63 (s, 1H), 7.86 (dd, J = 8.7, 4.5 Hz, 1H), 7.64 - 7.52 (m, 2H), 7.42 - 7.33 (m, 2H), 7.15 (td, J = 8.4, 3.1 Hz, 1H), 7.11 - 7.01 (m, 2H), 6.55 (s, 1H), 6.04 (s, 1H), 5.56 (s, 1H), 3.76 (d, J = 11.0 Hz, 1H), 3.13 (d, J = 11.0 Hz, 1H), 1.80 (dq, J = 14.1, 7.1 Hz, 1H), 1.57 (dq, J = 14.6, 7.4 Hz, 1H), 0.76 (t, J = 7.3 Hz, 3H).	484.2	D	
I-2463		CC[C@@]1(O)CN(C(=O)Nc2cccc3C(=O)N[C@H](c23)c2cc(F)ccc2Cl)c2ccc(F)cc12	(400 MHz, DMSO-d6) δ 9.05 (s, 1H), 8.63 (s, 1H), 7.86 (dd, J = 8.7, 4.5 Hz, 1H), 7.64 - 7.52 (m, 2H), 7.42 - 7.33 (m, 2H), 7.15 (td, J = 8.4, 3.1 Hz, 1H), 7.11 - 7.01 (m, 2H), 6.55 (s, 1H), 6.04 (s, 1H), 5.56 (s, 1H), 3.76 (d, J = 11.0 Hz, 1H), 3.13 (d, J = 11.0 Hz, 1H), 1.80 (dq, J = 14.1, 7.1 Hz, 1H), 1.57 (dq, J = 14.6, 7.4 Hz, 1H), 0.76 (t, J = 7.3 Hz, 3H).	484.2	D	
I-2464		OC1CN(C(=O)Nc2cccc3C(=O)NC(c23)c2cc(F)ccc2Cl)c2cc(Cl)ccc12	(400 MHz, DMSO-d6) δ 9.08 (br s, 1 H), 8.74 (s, 0.5 H), 8.67 (s, 0.5 H), 7.83 (s, 0.5 H), 7.67 - 7.51 (m, 2.5 H), 7.47 - 7.26 (m, 3 H), 7.15 (td, J = 8.4, 3.0 Hz, 0.5 H), 7.08 (td, J = 8.5, 3.0 Hz, 0.5 H), 7.02 (dd, J = 8.1, 1.8 Hz, 0.5 H), 6.99 (dd, J = 8.0, 1.8 Hz, 0.5 H), 6.55 (br s, 1 H), 6.07 (br s, 0.5 H), 6.00 (br s, 0.5 H), 5.72 (s, 1 H), 5.12 (dd, J = 7.7, 3.1 Hz, 0.5 H), 5.06 (dd, J = 7.2, 2.5 Hz, 0.5 H), 3.96 (dd, J = 10.9, 8.0 Hz, 0.5 H), 3.71 (dd, J = 11.3, 3.2 Hz, 0.5 H), 3.26 (dd, J	472.2	A	C




			= 11.1, 3.3 Hz, 0.5 H). ~1:1 mixture of diastereomers			
I-2465		CC(C)c1cc(N)n(n1)C(=O)Nc1cccc2C(=O)NC(c12)c1cc(F)ccc1Cl		428.1	E	
I-2466		CC(C)c1cc(N)nn1C(=O)Nc1cccc2C(=O)NC(c12)c1cc(F)ccc1Cl		428.0	E	
I-2467		Fc1ccc(Cl)c(c1)C1NC(=O)c2cccc(NC(=O)N3CCCC33CC3)c12	(400 MHz, DMSO-d6) δ 8.98 (br s, 1H), 7.97 (s, 1H), 7.70 - 7.37 (m, 3H), 7.37 - 7.15 (m, 2H), 6.61 (br s, 1H), 5.89 (br s, 1H), 3.29 (submerged m, 1H), 2.78 - 2.55 (m, 1H), 1.94 - 1.81 (m, 1H), 1.82 - 1.71 (m, 2H), 1.70 - 1.57 (m, 2H), 1.49 - 1.35 (m, 1H), 0.46 - 0.25 (m, 2H).	400.0	D	
I-2468		Fc1ccc(Cl)c(c1)C1NC(=O)c2cccc(NC(=O)N3CCC4(CC4)C3)c12	(400 MHz, DMSO-d6) δ 9.00 (br s, 1H), 8.06 (br s, 1H), 7.59 - 7.41 (m, 3H), 7.29 (p, J = 3.8 Hz, 1H), 7.24 (td, J = 8.4, 3.1 Hz, 1H), 6.59 (br s, 1H), 6.00 (br s, 1H), 3.39 (submerged m, 1H), 3.17 (d, J = 9.8 Hz, 1H), 2.94 (br s, 1H), 2.70 (br s, 1H), 1.76 - 1.55 (m, 2H), 0.63 - 0.39 (m, 4H).	400.0	E	




I-2469		OC1(CN(C(=O)Nc2cc(cc3C(=O)NC(c23)c2cc(F)ccc2Cl)C#N)c2ccc(F)cc12)C(F)(F)F	(400 MHz, DMSO-d6) δ 9.40 (br. s, 1H), 8.99 (br. s, 2H), 8.05 (s, 2H), 7.92 (s, 2H), 7.85 (dd, J = 8.9, 4.6 Hz, 1H), 7.82 (s, 1H), 7.52 - 7.39 (m, 2H), 7.36 (td, J = 8.3, 5.5 Hz, 2H), 7.31 - 7.25 (m, 2H), 7.25 - 7.18 (m, J = 7.8 Hz, 2H), 7.18 - 7.05 (m, 2H), 6.63 (br. s, 2H), 6.14 (s, 2H), 4.15 (d, J = 11.8 Hz, 1H), 3.97 (d, J = 12.0 Hz, 1H), 3.52 (d, J = 11.8 Hz, 1H), 3.45 (d, J = 11.8 Hz, 1H); 1:1 mixture of diastereomers	547.3	A	A
I-2470		Cc1ccc2CCN(C(=O)Nc3ccc4C(=O)NC(c34)c3cc(F)ccc3Cl)c2c1	(400 MHz, DMSO-d6) 9.05 (s, 1H), 8.55 (s, 1H), 7.61 - 7.52 (m, 2H), 7.46 (s, 1H), 7.42 - 7.34 (m, 2H), 7.15 (td, J = 8.4, 3.1 Hz, 1H), 7.04 (d, J = 7.5 Hz, 2H), 6.75 - 6.68 (m, 1H),6.20(s, 1H) 3.89 - 3.77 (m, 1H), 3.34 (s, 2H), 3.28 (s, 1H), 2.24 (s, 3H).	436.2	B	
I-2471		N[C@]1(CN(C(=O)Nc2ccc3C(=O)N[C@H](c23)c2cc(F)ccc2Cl)c2ccc(F)cc12)C(F)(F)F	(400 MHz, DMSO-d6) δ 9.08 (br s, 1H), 8.68 (s, 1H), 7.78 (dd, J = 8.9, 4.6 Hz, 1H), 7.63 - 7.54 (m, 2H), 7.45 (dd, J = 7.3, 1.4 Hz, 1H), 7.37 (dd, J = 8.7, 5.3 Hz, 1H), 7.28 (dd, J = 8.1, 2.5 Hz, 1H), 7.19 - 7.08 (m, 2H), 6.49 (br s, 1H), 6.06 (br s, 1H), 4.21 (d, J = 11.5 Hz, 1H), 3.30 - 3.25 (m, 1H [submerged under H2O peak-see COSY]), 2.89 - 2.83 (br s, 2H) ppm [dr = 95:5, racemic].	523.4	D	




I-2472		N[C@@]1(CN(C(=O)Nc2ccc3C(=O)N[C@H](c23)c2cc(F)ccc2Cl)c2ccc(F)cc12)C(F)(F)F	(400 MHz, DMSO-d6) δ 9.08 (br s, 1H), 8.77 (s, 1H), 7.81 (dd, J = 8.6, 4.4 Hz, 1H), 7.63 - 7.54 (m, 2H), 7.36 (dd, J = 7.4, 1.3 Hz, 1H), 7.33 (dd, J = 8.9, 5.2 Hz, 1H), 7.26 (dd, J = 8.3, 2.5 Hz, 1H), 7.19 - 7.09 (m, 2H), 6.53 (br s, 1H), 6.04 (br s, 1H), 3.85 (d, J = 11.6 Hz, 1H), 3.54 (d, J = 11.5 Hz, 1H), 2.96 - 2.87 (br s, 2H) ppm [single diasteromer].	523.4	C	
I-2473		OC1(CN(C(=O)Nc2cc(cc3C(=O)NC(c23)c2cc(F)ccc2Cl)C#N)c2ccccc12)C(F)(F)F	(400 MHz, DMSO-d6) δ 9.40 (br. s, 2H), 8.96 (br. s, 2H), 8.04 (s, 2H), 7.95 (d, J = 1.3 Hz, 1H), 7.83 (d, J = 1.3 Hz, 1H), 7.63 (d, J = 1.2 Hz, 1H), 7.60 (d, J = 1.2 Hz, 1H), 7.44 (d, J = 7.7 Hz, 2H), 7.42 - 7.31 (m, 4H), 7.32 - 7.22 (m, 2H), 7.23 - 7.01 (m, 4H), 6.71 (br. s, 2H), 6.16 (br. s, 2H), 4.08 (d, J = 12.0 Hz, 1H), 3.92 (d, J = 11.9 Hz, 1H), 3.50 (d, J = 11.6 Hz, 1H), 3.47 (d, J = 11.6 Hz, 1H) ; 1:1 mixture of diastereomers	529.3	A	A
I-2474		OC1(CN(C(=O)Nc2cccc3C(=O)NC(c23)c2cc(F)ccc2Cl)c2ccc(F)cc12)C(F)(F)F		524.3	A	B





I-2475		O[C@H]1CN(C(=O)Nc2cc(cc3C(=O)N[C@@H](c23)c2cc(F)ccc2Cl)-c2cnn(c2)C(F)F)c2ccc(F)cc12	(400 MHz, DMSO) δ9.08 (s, 1H), 8.87 (s, 1H), 8.68 (s, 1H), 8.38 (s, 1H), 8.01 - 7.65 (m, 4H), 7.37 (dd, J = 8.9, 5.1 Hz, 1H), 7.19 - 7.04 (m, 3H), 6.73 - 6.48 (m, 1H), 6.00 (s, 1H), 5.76 (d, J = 5.9 Hz, 1H), 5.12 - 5.03 (m, 1H), 3.69 (dd, J = 11.4, 3.6 Hz, 1H), 3.29 - 3.27 (m, 1H)	571.9	D	
I-2476		O[C@@H]1CN(C(=O)Nc2cc(cc3C(=O)N[C@@H](c23)c2cc(F)ccc2Cl)-c2cnn(c2)C(F)F)c2ccc(F)cc12	(400 MHz, DMSO) δ9.10 (s, 1H), 8.87 (d, J = 0.8 Hz, 1H), 8.55 (s, 1H), 8.38 (d, J = 0.7 Hz, 1H), 8.00 - 7.68 (m, 4H), 7.34 (dd, J = 8.8, 5.2 Hz, 1H), 7.13 - 6.99 (m, 3H), 6.79 - 6.43 (m, 1H), 6.08 (s, 1H), 5.73 (d, J = 5.0 Hz, 1H), 5.15 (dt, J = 8.6, 4.5 Hz, 1H), 3.96 (dd, J = 11.1, 8.1 Hz, 1H), 3.28 - 3.20 (m, 1H)	571.9	E	
I-2477		O[C@@H]1CN(C(=O)Nc2cc(cc3C(=O)N[C@H](c23)c2cc(F)ccc2Cl)-c2cnn(c2)C(F)F)c2ccc(F)cc12	(400 MHz, DMSO) δ9.08 (s, 1H), 8.87 (d, J = 0.8 Hz, 1H), 8.68 (s, 1H), 8.38 (d, J = 0.8 Hz, 1H), 8.01 - 7.65 (m, 4H), 7.37 (dd, J = 8.9, 5.2 Hz, 1H), 7.18 - 7.03 (m, 3H), 6.76 - 6.40 (m, 1H), 6.00 (s, 1H), 5.76 (d, J = 5.9 Hz, 1H), 5.07 (t, J = 8.6 Hz, 1H), 3.69 (dd, J = 11.4, 3.6 Hz, 1H), 3.30 - 3.20 (m, 1H)	571.9	A	A
I-2478		O[C@H]1CN(C(=O)Nc2cc(cc3C(=O)N[C@H](c23)c2cc(F)ccc2Cl)-c2cnn(c2)C(F)F)c	(400 MHz, DMSO) δ9.10 (s, 1H), 8.87 (d, J = 0.8 Hz, 1H), 8.55 (s, 1H), 8.38 (d, J = 0.7 Hz, 1H), 8.01 - 7.67 (m, 4H), 7.34 (dd, J = 8.9, 5.1 Hz, 1H), 7.14 - 6.99 (m, 3H), 6.75 - 6.48 (m, 1H), 6.08 (s, 1H), 5.73 (d, J = 4.9 Hz, 1H), 5.15 (dt, J =	571.9	B	





		2ccc(F)cc12	8.7, 4.5 Hz, 1H), 3.96 (dd, J = 11.1, 8.1 Hz, 1H), 3.27 - 3.20 (m, 1H)			
I-2479		Fc1ccc(Cl)c(c1)C1NC(=O)c2cccc(NC(=O)N3CCc4cccc34)c12	(400 MHz, DMSO-d6) 9.05 (s, 1H), 8.54 (s, 1H), 7.70 (d, J = 8.0 Hz, 1H), 7.62 - 7.52 (m, 2H), 7.38 (dt, J = 8.3, 3.6 Hz, 2H), 7.20 - 7.11 (m, 2H), 7.14 - 7.05 (m, 1H), 6.89 (td, J = 7.5, 1.1 Hz, 1H), 6.57 (s, 1H), 6.02 (s, 1H), 3.85 (td, J = 10.0, 7.4 Hz, 1H), 3.34 (s, 1H), 3.12 - 2.93 (m, 2H).	422.1	A	B
I-2480		Fc1ccc(Cl)c(c1)C1NC(=O)c2cccc(NC(=O)N3CCc4ccc(OC(F)(F)F)cc34)c12	(400 MHz, DMSO-d6) δ9.07 (s, 1H), 8.68 (s, 1H), 7.70 (s, 1H), 7.64 - 7.53 (m, 2H), 7.43 - 7.34 (m, 2H), 7.26 (d, J = 8.1 Hz, 1H), 7.14 (ddd, J = 8.9, 7.9, 3.1 Hz, 1H), 6.86 (ddd, J = 8.2, 2.4, 1.1 Hz, 1H), 6.55 (s, 1H), 6.02 (s, 1H), 3.94 (td, J = 10.1, 6.8 Hz, 1H), 3.29 (s, 1H), 3.15 - 2.96 (m, 2H).	506.4	D	
I-2481		Fc1ccc(Cl)c(c1)C1NC(=O)c2cccc(NC(=O)N3CCc4cc(OC(F)(F)F)ccc34)c12	(400 MHz, DMSO-d6) δ9.05 (s, 1H), 8.63 (s, 1H), 7.76 (d, J = 8.8 Hz, 1H), 7.63 - 7.54 (m, 2H), 7.39 (dd, J = 8.0, 6.2 Hz, 2H), 7.22 - 7.08 (m, 3H), 6.47 (s, 1H), 6.00 (s, 1H), 3.92 (td, J = 10.1, 7.1 Hz, 1H), 3.25 (s, 1H), 3.09 (td, J = 19.3, 18.0, 8.3 Hz, 2H).	506.2	D	
I-2482		OC1(CN(C(=O)Nc2cc(Cl)cc3C(=O)NC(c23)c2cc(F)ccc2Cl)c2ccc(F)cc	(400 MHz, DMSO-d6) δ 9.26 (br s, 1H), 8.93 (br s, 0.5H), 8.85 (br s, 0.5H), 7.60 (d, J = 1.5 Hz, 1H), 7.57 (d, J = 1.8 Hz, 0.5H), 7.47 (d, J = 1.8 Hz, 0.5H), 7.38 - 7.24 (m, 4H), 7.24 - 7.18 (m, 1H), 7.17 -	558.0	A	A



		12)C(F)(F)F	7.08 (m, 1H), 6.65 (br s, 1H), 6.03 (br s, 1H), 4.14 (d, J = 12.3 Hz, 1H), 3.95 (d, J = 12.0 Hz, 0.5H), 3.48 (submerged dd, J = 28.0, 12.6 Hz, 1H). 1:1 mixture of diastereomers.			
I-2483		OC1(CN(C(=O)Nc2cc(Cl)cc3C(=O)NC(c23)c2cc(F)ccc2Cl)c2ccccc12)C(F)(F)F	(400 MHz, DMSO-d6) δ 9.27 (br s, 1H), 8.91 (br s, 0.5H), 8.81 (br s, 0.5H), 7.60 (d, J = 1.1 Hz, 1H), 7.49 (d, J = 1.8 Hz, 1H), 7.43 (d, J = 7.6 Hz, 1H), 7.40 - 7.30 (m, 3H), 7.19 - 7.02 (m, 3H), 6.68 (br s, 1H), 6.08 (br s, 0.5H), 6.03 (br s, 0.5H), 4.09 (d, J = 12.0 Hz, 0.5H), 3.92 (d, J = 12.0 Hz, 0.5H), 3.49 (submerged overlapped dd, J = 28.0, 12.6 Hz, 1H). 1:1 mixture of diastereomers.	540.0	A	A
I-2484		O[C@]1(CN(C(=O)Nc2ccccc3C(=O)N[C@@H](c23)c2cc(F)ccc2Cl)c2ccccc12)C(F)F		487.9	E	
I-2485		O[C@@]1(CN(C(=O)Nc2ccccc3C(=O)N[C@H](c23)c2cc(F)ccc2Cl)c2ccccc12)C(F)F		487.9	D	




I-2486		O[C@@]1(CN(C(=O)Nc2ccc3C(=O)N[C@@H](c23)c2cc(F)ccc2Cl)c2ccccc12)C(F)F		487.9	E	
I-2487		O[C@]1(CN(C(=O)Nc2ccc3C(=O)N[C@H](c23)c2cc(F)ccc2Cl)c2ccccc12)C(F)F		487.9	A	A
I-2488		OC1(CN(C(=O)Nc2cccc3C(=O)NC(c23)c2cc(F)ccc2Cl)c2ccc(F)cc12)C(F)F	(400 MHz, DMSO-d6) δ as a ca. 1:1 mixture of diastereomers, δ 9.09 (br. s, 1H), 9.07 (br. s, 1H), 8.75 (br. s, 1H), 8.65 (br. s, 1H), 7.88 (dd, J = 8.1, 4.0 Hz, 1H), 7.79 (dd, J = 8.9, 4.7 Hz, 1H), 7.62 - 7.54 (m, 4H), 7.46 (dd, J = 7.4, 1.5 Hz, 1H), 7.40 - 7.28 (m, 3H), 7.28 - 7.21 (m, 2H), 7.21 - 7.08 (m, 4H), 6.70 (s, 1H), 6.64 (s, 1H), 6.55 (br. s, 2H), 6.27 (td, J = 55.3, 3.1 Hz, 2H), 6.08 (br. s, 1H), 6.03 (br. s, 1H), 4.10 (d, J = 11.8 Hz, 1H), 3.86 (d, J = 11.8 Hz, 1H), 3.45 (d, J = 11.7 Hz, 1H), 3.32 - 3.28 (m, 1H). Multiplet at 3.32 - 3.28 ppm is partially obscured by the peak for residual H2O.	506.3	A	B




I-2489		OC1CN(C(=O)Nc2cc(OCC3(CC3)C#N)cc3C(=O)NC(c23)c2cc(F)ccc2Cl)c2ccc(F)cc12	(400 MHz, DMSO-d6) δ 9.05 (br s, 1 H), 8.60 (br s, 1 H), 7.81 (dd, J = 8.5, 4.7 Hz, 0.5 H), 7.69 (dd, J = 8.9, 4.7 Hz, 0.5 H), 7.35 (dt, J = 9.3, 4.8 Hz, 1 H), 7.18 - 6.98 (m, 5 H), 6.57 (br s, 1 H), 6.03 (br s, 0.5 H), 5.94 (br s, 0.5 H), 5.77 (br s, 1 H), 5.13 (dd, J = 7.9, 3.9 Hz, 0.5 H), 5.06 (dd, J = 7.8, 3.2 Hz, 0.5 H), 4.19 (dd, J = 10.4, 3.6 Hz, 1 H), 4.11 (dd, J = 10.4, 2.8 Hz, 1 H), 3.90 (dd, J = 11.0, 8.1 Hz, 0.5 H), 3.66 (dd, J = 11.2, 3.5 Hz, 0.5 H), 3.27 (d, J = 4.0 Hz, 0.5 H), 3.24 (d, J = 3.9 Hz, 0.5 H), 1.39 (app q, J = 4.5 Hz, 2 H), 1.19 (dd, J = 7.0, 4.7 Hz, 2 H). ~1:1 mixture of diastereomers.	551.3	A	C
I-2490		CC1(Cc2cc3C(=O)NC(c3c(NC(=O)N3CC(O)c4cc(F)ccc34)c2)c2cc(F)ccc2Cl)COC1		540.0	C	
I-2491		O[C@H]1CN(C(=O)Nc2cc(cc3C(=O)N[C@H](c23)c2cc(F)ccc2Cl)C#N)c2ccc(F)cc12	(400 MHz, DMSO-d6) 9.37 (s, 1H), 8.76 (s, 1H), 8.02 (d, J = 1.4 Hz, 1H), 7.88 (d, J = 1.4 Hz, 1H), 7.70 (dd, J = 8.9, 4.7 Hz, 1H), 7.37 (dd, J = 8.9, 5.2 Hz, 1H), 7.12 (td, J = 8.3, 3.0 Hz, 2H), 7.05 (td, J = 9.1, 2.8 Hz, 1H), 6.17 (s, 1H), 5.76 (d, J = 5.0 Hz, 1H), 5.15 (dt, J = 8.5, 4.4 Hz, 1H), 3.92 (dd, J = 11.0, 8.0 Hz, 1H), 3.22 (d, J = 3.9	481.1	B	






			Hz, 1H), 3.09 (d, J = 7.0 Hz, 1H).			
I-2492		O[C@@H]1CN(C(=O)Nc2cc(cc3C(=O)N[C@@H](c23)c2cc(F)ccc2Cl)C#N)c2ccc(F)cc12		482.3	C	
I-2493		O[C@@H]1CN(C(=O)Nc2cc(cc3C(=O)N[C@H](c23)c2cc(F)ccc2Cl)C#N)c2ccc(F)cc12	(400 MHz, DMSO-d6) 9.37 (s, 1H), 8.89 (s, 1H), 8.75 (s, 1H), 8.04 - 7.99 (m, 2H), 7.87 (d, J = 1.4 Hz, 1H), 7.82 - 7.77 (m, 1H), 7.70 (dd, J = 8.9, 4.7 Hz, 1H), 7.38 (dt, J = 8.9, 5.5 Hz, 2H), 6.70 (s, 2H), 5.15 (dt, J = 8.6, 4.4 Hz, 1H), 3.92 (dd, J = 11.0, 8.0 Hz, 1H), 3.23 (dd, J = 11.0, 4.0 Hz, 1H).	481.3	B	
I-2494		O[C@@]1(CN(C(=O)Nc2ccc(c3C(=O)N[C@@H](c23)c2cc(F)ccc2Cl)-n2cccn2)c2ccc(F)cc12)C(F)(F)F	(400 MHz, DMSO-d6) 9.28 (s, 1H), 8.74 (s, 1H), 8.69 - 8.64 (m, 1H), 7.89 - 7.81 (m, 2H), 7.78 (d, J = 1.7 Hz, 1H), 7.58 (d, J = 8.6 Hz, 1H), 7.42 (s, 1H), 7.36 (dd, J = 8.9, 5.1 Hz, 1H), 7.30 - 7.19 (m, 2H), 7.18 - 7.09 (m, 1H), 6.76 (s, 1H), 6.51 (t, J = 2.1 Hz, 1H), 6.11 (s, 1H), 4.23 (d, J = 12.0 Hz, 1H), 3.50 (d, J = 11.1 Hz, 1H).	590.2	D	
I-2495		O[C@]1(CN(C(=O)Nc2ccc(c3C(=O)N[C@H](c23)c2cc(F)ccc2Cl)-n2cccn2)c2ccc(F)	(400 MHz, DMSO-d6) 9.26 (s, 1H), 8.82 (s, 1H), 8.65 (s, 1H), 7.93 (s, 1H), 7.85 (d, J = 8.5 Hz, 1H), 7.78 (d, J = 1.8 Hz, 1H), 7.50 (d, J = 8.5 Hz, 1H), 7.42 (s, 1H), 7.39 - 7.18 (m, 3H), 7.16 (td, J = 8.4, 3.1 Hz, 1H), 6.76 (s, 1H), 6.54 - 6.48 (m,	590.2	E	





		cc12)C(F)(F)F	1H), 6.07 (s, 1H), 4.01 (d, J = 12.1 Hz, 1H), 3.54 (d, J = 12.0 Hz, 1H).			
I-2496		O[C@]1(CN(C(=O)Nc2ccc(c3C(=O)N[C@@H](c23)c2cc(F)ccc2Cl)-n2cccn2)c2ccc(F)cc12)C(F)(F)F	(400 MHz, DMSO-d6) 9.27 (s, 1H), 8.73 (s, 1H), 8.66 (s, 1H), 7.89 - 7.81 (m, 2H), 7.78 (d, J = 1.7 Hz, 1H), 7.58 (d, J = 8.6 Hz, 1H), 7.41 (s, 1H), 7.36 (dd, J = 8.9, 5.1 Hz, 1H), 7.30 - 7.19 (m, 2H), 7.18 - 7.09 (m, 1H), 6.84 (s, 1H), 6.51 (dd, J = 2.5, 1.8 Hz, 1H), 6.11 (s, 1H), 4.22 (d, J = 12.0 Hz, 1H), 3.51 (s, 1H).	590.2	D	
I-2497		O[C@@]1(CN(C(=O)Nc2ccc(c3C(=O)N[C@H](c23)c2cc(F)ccc2Cl)-n2cccn2)c2ccc(F)cc12)C(F)(F)F	(400 MHz, DMSO-d6) 9.27 (s, 1H), 8.83 (s, 1H), 8.65 (s, 1H), 7.93 (d, J = 6.6 Hz, 1H), 7.86 (d, J = 8.5 Hz, 1H), 7.78 (d, J = 1.7 Hz, 1H), 7.50 (d, J = 8.5 Hz, 1H), 7.43 (s, 1H), 7.35 (dd, J = 8.9, 5.1 Hz, 1H), 7.32 - 7.12 (m, 3H), 6.76 (s, 1H), 6.54 - 6.48 (m, 1H), 6.07 (s, 1H), 4.02 (d, J = 12.0 Hz, 1H), 3.55 (d, J = 12.1 Hz, 1H).	590.2	A	A
I-2498		Fc1ccc(Cl)c(c1)C1NC(=O)c2cccc(NC(=O)N3CCc4c3cccc4C(F)(F)F)c12	(400 MHz, DMSO-d6) δ9.06 (s, 1H), 8.72 (s, 1H), 8.01 (d, J = 8.1 Hz, 1H), 7.63 - 7.55 (m, 2H), 7.43 - 7.32 (m, 3H), 7.25 - 7.13 (m, 2H), 6.57 (s, 1H), 6.00 (s, 1H), 3.97 (td, J = 10.0, 6.6 Hz, 1H), 3.34 (s, 3H).	490.1	D	
I-2499		C[C@H](Cn1cc(cn1)-c1cc2C(=O)N[C@H](c2c(NC(=O)N2C[C@H](O)c3cc(F)ccc23)	(400 MHz, DMSO-d6) 9.08 (s, 1H), 8.55 (s, 1H), 8.40 (d, J = 0.8 Hz, 1H), 8.10 (d, J = 0.7 Hz, 1H), 7.80 (d, J = 1.5 Hz, 1H), 7.73 (dd, J = 8.9, 4.7 Hz, 1H), 7.64 (d, J = 1.5 Hz, 1H), 7.35 (dd, J = 8.9, 5.2 Hz, 1H), 7.17 - 6.97	589.3	D	





		c1)c1cc(F)ccc1Cl)C#N	(m, 3H), 6.64 (s, 1H), 6.09 (s, 1H), 5.75 (d, J = 5.0 Hz, 1H), 5.16 (dt, J = 8.6, 4.6 Hz, 1H), 4.58 - 4.29 (m, 2H), 3.98 (dd, J = 11.1, 8.1 Hz, 1H), 3.52 - 3.40 (m, 1H), 3.24 (dd, J = 11.0, 4.1 Hz, 1H), 1.28 (d, J = 7.1 Hz, 3H).		
I-2500		C[C@@H](Cn1cc(cn1)-c1cc2C(=O)N[C@@H](c2c(NC(=O)N2C[C@H](O)c3cc(F)ccc23)c1)c1cc(F)ccc1Cl)C#N	(400 MHz, DMSO-d6) 9.08 (s, 1H), 8.54 (s, 1H), 8.40 (s, 1H), 8.10 (s, 1H), 7.80 (d, J = 1.5 Hz, 1H), 7.73 (dd, J = 8.9, 4.7 Hz, 1H), 7.63 (d, J = 1.5 Hz, 1H), 7.35 (dd, J = 8.9, 5.1 Hz, 1H), 7.16 - 6.99 (m, 3H), 6.63 (s, 1H), 6.09 (s, 1H), 5.74 (d, J = 5.0 Hz, 1H), 5.16 (dt, J = 8.6, 4.5 Hz, 1H), 4.53 - 4.31 (m, 2H), 3.98 (dd, J = 11.1, 8.1 Hz, 1H), 3.53 - 3.42 (m, 1H), 3.24 (dd, J = 11.2, 4.1 Hz, 1H), 1.28 (d, J = 7.1 Hz, 3H).	589.3	B
I-2501		C[C@H](Cn1cc(cn1)-c1cc2C(=O)N[C@@H](c2c(NC(=O)N2C[C@H](O)c3cc(F)ccc23)c1)c1cc(F)ccc1Cl)C#N	(400 MHz, DMSO-d6) 9.08 (s, 1H), 8.54 (s, 1H), 8.40 (s, 1H), 8.09 (s, 1H), 7.80 (d, J = 1.5 Hz, 1H), 7.73 (dd, J = 8.9, 4.7 Hz, 1H), 7.63 (d, J = 1.6 Hz, 1H), 7.35 (dd, J = 8.9, 5.1 Hz, 1H), 7.16 - 6.97 (m, 3H), 6.63 (s, 1H), 6.09 (s, 1H), 5.74 (d, J = 5.0 Hz, 1H), 5.16 (dt, J = 8.6, 4.5 Hz, 1H), 4.53 - 4.33 (m, 2H), 3.98 (dd, J = 11.1, 8.1 Hz, 1H), 3.48 (h, J = 7.0 Hz, 1H), 3.25 (dd, J = 11.1, 4.1 Hz, 1H), 1.27 (d, J = 7.1 Hz, 3H).	589.3	B





I-2502		C[C@@H](Cn1cc(cn1)-c1cc2C(=O)N[C@H](c2c(NC(=O)N2C[C@@H](O)c3cc(F)ccc23)c1)c1cc(F)ccc1Cl)C#N	(400 MHz, DMSO-d6) 9.08 (s, 1H), 8.54 (s, 1H), 8.40 (s, 1H), 8.09 (s, 1H), 7.80 (d, J = 1.5 Hz, 1H), 7.73 (dd, J = 8.9, 4.7 Hz, 1H), 7.63 (d, J = 1.5 Hz, 1H), 7.35 (dd, J = 8.9, 5.1 Hz, 1H), 7.16 - 6.93 (m, 3H), 6.63 (s, 1H), 6.09 (s, 1H), 5.74 (d, J = 5.0 Hz, 1H), 5.16 (dt, J = 8.7, 4.5 Hz, 1H), 4.51 - 4.35 (m, 2H), 3.98 (dd, J = 11.1, 8.1 Hz, 1H), 3.48 (p, J = 6.9 Hz, 1H), 3.25 (dd, J = 11.2, 4.1 Hz, 1H), 1.27 (d, J = 7.1 Hz, 3H).	589.3	D	
I-2503		C[C@H](Cn1cc(cn1)-c1cc2C(=O)N[C@H](c2c(NC(=O)N2C[C@@H](O)c3cc(F)ccc23)c1)c1cc(F)ccc1Cl)C#N	(400 MHz, DMSO-d6) 9.06 (s, 1H), 8.67 (s, 1H), 8.40 (s, 1H), 8.10 (d, J = 2.4 Hz, 1H), 7.85 (d, J = 3.9 Hz, 1H), 7.79 (s, 1H), 7.60 - 7.55 (m, 1H), 7.37 (dd, J = 8.9, 5.1 Hz, 1H), 7.20 - 7.05 (m, 3H), 6.64 (s, 1H), 6.00 (s, 1H), 5.77 (d, J = 6.0 Hz, 1H), 5.09 (s, 1H), 4.51 - 4.31 (m, 2H), 3.71 (dd, J = 11.4, 3.6 Hz, 1H), 3.47 (p, J = 7.0 Hz, 1H), 3.28 (s, 1H), 1.28 (dd, J = 7.1, 1.7 Hz, 3H).	589.2	A	C
I-2504		C[C@@H](Cn1cc(cn1)-c1cc2C(=O)N[C@@H](c2c(NC(=O)N2C[C@@H](O)c3cc(F)ccc23)c1)c1cc(F)ccc1Cl)C#N	(400 MHz, DMSO-d6) 9.06 (s, 1H), 8.67 (s, 1H), 8.40 (s, 1H), 8.10 (s, 1H), 7.85 (dd, J = 8.9, 4.7 Hz, 1H), 7.79 (d, J = 1.5 Hz, 1H), 7.58 (d, J = 1.5 Hz, 1H), 7.37 (dd, J = 8.9, 5.1 Hz, 1H), 7.19 - 7.06 (m, 3H), 6.62 (s, 1H),6.00 (s, 1H), 5.77 (d, J = 5.9 Hz, 1H), 5.16 - 4.99 (m, 1H), 4.47 - 4.34 (m, 2H), 3.71 (dd, J = 11.4, 3.6	589.2	D	





			Hz, 1H), 3.54 - 3.41 (m, 1H), 3.27 (s, 1H), 1.28 (d, J = 7.1 Hz, 3H).			
I-2505		C[C@H](Cn1cc(cn1)-c1cc2C(=O)N[C@@H](c2c(NC(=O)N2C[C@@H](O)c3cc(F)ccc23)c1)c1cc(F)ccc1Cl)C#N	(400 MHz, DMSO-d6) 9.06 (s, 1H), 8.67 (s, 1H), 8.40 (s, 1H), 8.09 (s, 1H), 7.85 (dd, J = 8.8, 4.7 Hz, 1H), 7.79 (d, J = 1.5 Hz, 1H), 7.58 (d, J = 1.5 Hz, 1H), 7.38 (dd, J = 8.9, 5.1 Hz, 1H), 7.21 - 7.05 (m, 3H), 6.62 (s, 1H), 6.00 (s, 1H), 5.77 (d, J = 5.9 Hz, 1H), 5.08 (q, J = 5.8, 3.6 Hz, 1H), 4.48 - 4.33 (m, 2H), 3.71 (dd, J = 11.4, 3.6 Hz, 1H), 3.48 (h, J = 7.0 Hz, 1H), 3.28 (s, 1H), 1.28 (d, J = 7.0 Hz, 3H).	589.3	D	
I-2506		O[C@]1(CN(C(=O)Nc2cc(Cl)cc3C(=O)N[C@@H](c23)c2cc(F)ccc2Cl)c2ccccc12)C(F)(F)F			D	
I-2507		O[C@@]1(CN(C(=O)Nc2cc(Cl)cc3C(=O)N[C@H](c23)c2cc(F)ccc2Cl)c2ccccc12)C(F)(F)F			D	




I-2508		O[C@@]1(CN(C(=O)Nc2cc(Cl)cc3C(=O)N[C@@H](c23)c2cc(F)ccc2Cl)c2ccccc12)C(F)(F)F			D	
I-2509		O[C@]1(CN(C(=O)Nc2cc(Cl)cc3C(=O)N[C@H](c23)c2cc(F)ccc2Cl)c2ccccc12)C(F)(F)F			A	A
I-2510		O[C@]1(CN(C(=O)Nc2cc(Cl)cc3C(=O)N[C@@H](c23)c2cc(F)ccc2Cl)c2ccc(F)cc12)C(F)(F)F			D	
I-2511		O[C@@]1(CN(C(=O)Nc2cc(Cl)cc3C(=O)N[C@H](c23)c2cc(F)ccc2Cl)c2ccc(F)cc12)C(F)(F)F			B	
I-2512		O[C@@]1(CN(C(=O)Nc2cc(Cl)cc3C(=O)N[C@@H](c23)c2cc(F)ccc2Cl)c2ccc(F			D	




		)cc12)C(F)(F)F				
I-2513		O[C@]1(CN(C(=O)Nc2cc(Cl)cc3C(=O)N[C@H](c23)c2cc(F)ccc2Cl)c2ccc(F)cc12)C(F)(F)F			A	A
I-2514		O[C@]1(CN(C(=O)Nc2ccccc3C(=O)N[C@@H](c23)c2cc(F)ccc2Cl)c2ccc(F)cc12)C(F)(F)F			E	
I-2515		O[C@@]1(CN(C(=O)Nc2ccccc3C(=O)N[C@H](c23)c2cc(F)ccc2Cl)c2ccc(F)cc12)C(F)(F)F			D	
I-2516		O[C@@]1(CN(C(=O)Nc2ccccc3C(=O)N[C@@H](c23)c2cc(F)ccc2Cl)c2ccc(F)cc12)C(F)(F)F	(400 MHz, DMSO-d6) 9.00 (d, J = 17.4 Hz, 1H), 8.68 (s, 1H), 7.96-7.81 (m, 1H), 7.46 (s, 1H), 7.40-7.17 (m, 6H), 7.11 (td, J = 8.4, 3.1 Hz, 1H), 6.55 (s, 1H), 6.03 (s, 1H), 4.24 (d, J = 12.0 Hz, 1H), 3.41 (d, J = 12.1 Hz, 1H), 2.97-2.74 (m, 4H).	524.1	D	




I-2517		O[C@@]1(CN(C(=O)Nc2ccc3C(=O)N[C@@H](c23)c2cc(F)ccc2Cl)c2ccc(F)cc12)C(F)(F)F	(400 MHz, DMSO-d6) 9.00 (d, J = 17.4 Hz, 1H), 8.68 (s, 1H), 7.96-7.81 (m, 1H), 7.46 (s, 1H), 7.40-7.17 (m, 6H), 7.11 (td, J = 8.4, 3.1 Hz, 1H), 6.55 (s, 1H), 6.03 (s, 1H), 4.24 (d, J = 12.0 Hz, 1H), 3.41 (d, J = 12.1 Hz, 1H), 2.97-2.74 (m, 4H).	524.1		
I-2518		O[C@]1(CN(C(=O)Nc2ccccc3C(=O)N[C@H](c23)c2cc(F)ccc2Cl)c2ccc(F)cc12)C(F)(F)F			A	A
I-2519		O[C@]1(CN(C(=O)Nc2ccccc3C(=O)N[C@H](c23)c2cc(F)ccc2Cl)c2ccc(F)cc12)C(F)(F)F	(400 MHz, DMSO-d6) 9.35 (s, 1H), 8.99 (s, 1H), 8.77 (s, 1H), 7.93-7.88 (m, 2H),7.88-7.70 (m,1H), 7.58 (d, J = 8.4 Hz, 1H), 7.44 (s, 1H), 7.35 (dd, J = 8.9, 5.1 Hz, 1H), 7.29 (td, J = 9.0, 2.8 Hz, 1H), 7.23 (dd, J = 8.1, 2.7 Hz, 1H), 7.17 (td, J = 8.4, 3.1 Hz, 1H), 6.77 (s, 1H), 6.11 (s, 1H), 4.03 (d, J = 12.1 Hz, 1H), 3.54 (d, J = 12.2 Hz, 1H).	591.1		
I-2520		O[C@@]1(CN(C(=O)Nc2ccc(c3C(=O)N[C@H](c23)c2cc(F)ccc2Cl)-n2ccnn2)c2ccc(F)cc12)C(F)(F)F	(400 MHz, DMSO-d6) 9.35 (s, 1H), 8.89 (s, 1H), 8.78 (s, 1H), 7.93-7.81 (m, 3H), 7.66 (d, J = 8.4 Hz, 1H), 7.42-7.37 (m, 2H), 7.26 (qd, J = 8.6, 8.2, 2.8 Hz, 2H), 7.15 (td, J = 8.4, 3.1 Hz, 1H), 6.77 (s, 1H), 4.24 (d, J = 12.0 Hz, 1H), 3.48 (d, J = 12.1 Hz, 1H), 2.87 (s, 1H).	591.1	A	A




I-2521		O[C@@]1(CN(C(=O)Nc2ccc(c3C(=O)N[C@@H](c23)c2cc(F)ccc2Cl)-n2ccnn2)c2ccc(F)cc12)C(F)(F)F			D	
I-2522		O[C@@]1(CN(C(=O)Nc2ccc(c3C(=O)N[C@@H](c23)c2cc(F)ccc2Cl)-n2ccnn2)c2ccc(F)cc12)C(F)(F)F	(400 MHz, DMSO-d6) 9.35 (s, 1H), 8.98 (s, 1H), 8.77 (s, 1H), 7.93-7.84 (m, 2H), 7.80-7.70 (m,1H),7.61-7.54 (m, 1H), 7.44 (s, 1H), 7.40-7.30(m, 1H),7.30-7.25 (m, 1H),7.23 (dd, J = 8.0, 2.8 Hz, 1H), 7.17 (td, J = 8.4, 3.0 Hz, 1H),6.80 (s, 1H), 6.11 (s, 1H), 4.03 (d, J = 12.1 Hz, 1H), 3.54 (d, J = 12.0 Hz, 1H).	591.1		
I-2523		O[C@]1(CN(C(=O)Nc2ccc(c3C(=O)N[C@H](c23)c2cc(F)ccc2Cl)-n2ccnn2)c2ccc(F)cc12)C(F)(F)F	(400 MHz, DMSO-d6) 9.35 (s, 1H), 8.89 (s, 1H), 8.78 (s, 1H), 7.93 (d, J = 1.1 Hz, 1H), 7.90-7.81 (m, 2H), 7.66 (d, J = 8.4 Hz, 1H), 7.42-7.37 (m, 2H), 7.26 (qd, J = 8.7, 2.8 Hz, 2H), 7.15 (td, J = 8.3, 3.1 Hz, 1H), 6.79 (s, 1H), 6.15 (s, 1H), 4.24 (d, J = 12.0 Hz, 1H), 3.48 (d, J = 12.2 Hz, 1H).	591.1	D	
I-2524		O[C@]1(CN(C(=O)Nc2ccc(c3C(=O)N[C@@H](c23)c2cc(F)ccc2Cl)-n2ccnn2)c2ccc(F)cc12)C(F)(F)F	(400 MHz, DMSO-d6) 9.18 (s, 1H), 9.02 (s, 1H), 8.10 (s, 2H), 8.00-7.85(m,1H),7.68 (d, J = 8.3 Hz, 1H), 7.55 (d, J = 8.3 Hz, 1H), 7.43 (s, 1H), 7.36 (dd, J = 8.9, 5.1 Hz, 1H), 7.29 (td, J = 9.0, 2.8 Hz, 1H), 7.25-7.12 (m, 1H),7.12-6.90 (m, 1H), 6.70 (s, 1H), 6.07 (s, 1H), 4.02 (d, J = 12.0 Hz, 1H),	591.1	D	




			3.51 (d, J = 12.0 Hz, 1H).			
I-2525		O[C@@]1(CN(C(=O)Nc2ccc(c3C(=O)N[C@H](c23)c2cc(F)ccc2Cl)-n2nccn2)c2ccc(F)cc12)C(F)(F)F	(400 MHz, DMSO-d6) 9.18 (s, 1H), 9.02 (s, 1H), 8.10 (s, 2H), 7.95 (s, 1H), 7.68 (d, J = 8.3 Hz, 1H), 7.55 (d, J = 8.3 Hz, 1H), 7.44 (s, 1H), 7.36 (dd, J = 8.9, 5.1 Hz, 1H), 7.29 (td, J = 9.1, 2.8 Hz, 1H), 7.22 (dd, J = 8.1, 2.7 Hz, 1H), 7.16 (td, J = 8.3, 3.1 Hz, 1H), 6.69 (s, 1H), 6.07 (s, 1H), 4.02 (d, J = 12.1 Hz, 1H), 3.51 (d, J = 12.0 Hz, 1H), 0.99 (t, J = 7.2 Hz, 1H).	591.1	A	A
I-2526		O[C@@]1(CN(C(=O)Nc2ccc(c3C(=O)N[C@@H](c23)c2cc(F)ccc2Cl)-n2nccn2)c2ccc(F)cc12)C(F)(F)F	(400 MHz, DMSO-d6) 9.19 (s, 1H), 8.91 (s, 1H), 8.10 (s, 2H), 7.87 (dd, J = 9.0, 4.7 Hz, 1H), 7.66 (q, J = 8.4 Hz, 2H), 7.43-7.34 (m, 2H), 7.32-7.20 (m, 2H), 7.15 (td, J = 8.3, 3.1 Hz, 1H), 6.64 (s, 1H), 6.11 (s, 1H), 4.21 (d, J = 12.0 Hz, 1H), 3.44 (d, J = 12.0 Hz, 1H).	591.1	D	
I-2527		O[C@]1(CN(C(=O)Nc2ccc(c3C(=O)N[C@H](c23)c2cc(F)ccc2Cl)-n2nccn2)c2ccc(F)cc12)C(F)(F)F	(400 MHz, DMSO-d6) 9.19 (s, 1H), 8.92 (s, 1H), 8.10 (s, 2H), 7.87 (dd, J = 8.9, 4.7 Hz, 1H), 7.66 (q, J = 8.3 Hz, 2H), 7.44-7.34 (m, 2H), 7.32-7.20 (m, 2H), 7.15 (td, J = 8.3, 3.1 Hz, 1H), 6.71 (s, 1H), 6.11 (s, 1H), 4.21 (d, J = 12.1 Hz, 1H), 3.45 (d, J = 12.0 Hz, 1H).	591.2	D	
I-2528		O[C@]1(CN(C(=O)Nc2ccc(c3C(=O)N[C@@H](c23)c2cc(F)ccc2Cl)-n2nccn2)c2ccc(F)	(400 MHz, DMSO-d6) 9.27 (s, 1H), 9.03 (s, 1H), 7.94 (dd, J = 9.2, 4.6 Hz, 1H), 7.78 (dd, J = 7.0, 2.1 Hz, 1H), 7.61 (d, J = 1.9 Hz, 1H), 7.56 (ddd, J = 9.0, 6.6, 2.1 Hz, 1H), 7.52 - 7.40 (m, 2H), 7.36 (dd, J = 8.9, 5.2 Hz, 1H), 7.29	617.2	D	



		cc12)C(F)(F)F	(td, J = 9.0, 2.8 Hz, 1H), 7.21 (dd, J = 8.1, 2.7 Hz, 1H), 7.16 (td, J = 8.4, 3.1 Hz, 1H), 6.55 (dt, J = 9.4, 1.0 Hz, 2H), 6.38 (td, J = 6.7, 1.4 Hz, 1H), 6.11 (s, 1H), 4.00 (d, J = 12.1 Hz, 1H), 3.52 (d, J = 12.1 Hz, 1H).			
I-2529		O[C@@]1(CN(C(=O)Nc2cc(cc3C(=O)N[C@H](c23)c2cc(F)ccc2Cl)-n2ccccc2=O)c2ccc(F)cc12)C(F)(F)F	(400 MHz, DMSO-d6) 9.27 (s, 1H), 8.92 (s, 1H), 7.87 (dd, J = 9.0, 4.7 Hz, 1H), 7.78 (dd, J = 7.0, 2.1 Hz, 1H), 7.61 (d, J = 1.9 Hz, 1H), 7.59 - 7.51 (m, 2H), 7.45 - 7.35 (m, 2H), 7.31 - 7.19 (m, 2H), 7.16 (td, J = 8.4, 3.1 Hz, 1H), 6.58 - 6.50 (m, 1H), 6.38 (td, J = 6.7, 1.4 Hz, 2H), 6.15 (s, 1H), 4.22 (d, J = 12.0 Hz, 1H), 3.52 (d, J = 12.1 Hz, 1H).	617.2	D	
I-2530		O[C@]1(CN(C(=O)Nc2cc(cc3C(=O)N[C@H](c23)c2cc(F)ccc2Cl)-n2ccccc2=O)c2ccc(F)cc12)C(F)(F)F	(400 MHz, DMSO-d6) 9.27 (s, 1H), 8.92 (s, 1H), 7.87 (dd, J = 9.0, 4.7 Hz, 1H), 7.78 (dd, J = 6.9, 2.1 Hz, 1H), 7.61 (d, J = 1.9 Hz, 1H), 7.60 - 7.51 (m, 2H), 7.43 - 7.35 (m, 2H), 7.31 - 7.11 (m, 3H), 6.63 (s, 1H), 6.58 - 6.51 (m, 1H), 6.38 (td, J = 6.7, 1.4 Hz, 1H), 6.15 (s, 1H), 4.22 (d, J = 12.1 Hz, 1H), 3.43 (d, J = 12.0 Hz, 1H).	617.2	D	
I-2531		O[C@@]1(CN(C(=O)Nc2cc(cc3C(=O)N[C@@H](c23)c2cc(F)ccc2Cl)-n2ccccc2=O)c2ccc(F)cc12)C(F)(F)F	(400 MHz, DMSO-d6) 9.26 (s, 1H), 9.03 (s, 1H), 7.94 (dd, J = 9.1, 4.6 Hz, 1H), 7.78 (dd, J = 6.9, 2.1 Hz, 1H), 7.61 (d, J = 1.9 Hz, 1H), 7.56 (ddd, J = 9.0, 6.6, 2.1 Hz, 1H), 7.48 - 7.40 (m, 2H), 7.36 (dd, J = 8.9, 5.1 Hz, 1H), 7.28 (td, J = 9.1, 2.8 Hz, 1H), 7.24 - 7.12 (m,	617.2	D	





			2H), 6.58 - 6.51 (m, 2H), 6.38 (td, J = 6.7, 1.4 Hz, 1H), 6.11 (s, 1H), 4.00 (d, J = 12.1 Hz, 1H), 3.52 (d, J = 12.1 Hz, 1H).			
I-2532		O[C@]1(CN(C(=O)Nc2cc(cc3C(=O)N[C@@H](c23)c2cc(F)ccc2Cl)-n2ccccc2=O)c2ccc(F)cc12)C(F)(F)F	(400 MHz, DMSO-d6) 9.24 (s, 1H), 9.02 (s, 1H), 8.13 (dd, J = 3.8, 1.7 Hz, 1H), 7.95 (s, 1H), 7.84 (d, J = 1.9 Hz, 1H), 7.66 (d, J = 1.9 Hz, 1H), 7.55 (dd, J = 9.5, 3.8 Hz, 1H), 7.41 (s, 1H), 7.35 (dd, J = 8.9, 5.2 Hz, 1H), 7.29 (td, J = 9.0, 2.8 Hz, 1H), 7.24 - 7.11 (m, 3H), 6.67 (s, 1H), 6.08 (s, 1H), 4.01 (d, J = 12.1 Hz, 1H), 3.52 (d, J = 12.1 Hz, 1H).	618.2	A	A
I-2533		O[C@@]1(CN(C(=O)Nc2cc(cc3C(=O)N[C@H](c23)c2cc(F)ccc2Cl)-n2nccccc2=O)c2ccc(F)cc12)C(F)(F)F	(400 MHz, DMSO-d6) 9.25 (s, 1H), 8.92 (s, 1H), 8.13 (dd, J = 3.8, 1.7 Hz, 1H), 7.92 - 7.81 (m, 2H), 7.74 (d, J = 1.9 Hz, 1H), 7.54 (dd, J = 9.5, 3.8 Hz, 1H), 7.44 - 7.34 (m, 2H), 7.31 - 7.19 (m, 2H), 7.15 (ddd, J = 9.5, 5.3, 2.4 Hz, 2H), 6.63 (s, 1H), 6.12 (s, 1H), 4.24 (d, J = 12.1 Hz, 1H), 3.42 (d, J = 12.2 Hz, 1H).	618.1	D	
I-2534		O[C@]1(CN(C(=O)Nc2cc(cc3C(=O)N[C@H](c23)c2cc(F)ccc2Cl)-n2nccccc2=O)c2ccc(F)cc12)C(F)(F)F	(400 MHz, DMSO-d6) 9.25 (s, 1H), 8.92 (s, 1H), 8.13 (dd, J = 3.8, 1.6 Hz, 1H), 7.92 - 7.81 (m, 2H), 7.74 (d, J = 1.9 Hz, 1H), 7.54 (dd, J = 9.5, 3.8 Hz, 1H), 7.42 - 7.34 (m, 2H), 7.31 - 7.10 (m, 4H), 6.66 (s, 1H), 6.12 (s, 1H), 4.24 (d, J = 12.0 Hz, 1H), 3.42 (d, J = 12.1 Hz, 1H).	618.1	C	





I-2535		O[C@@]1(CN(C(=O)Nc2cc(cc3C(=O)N[C@@H](c23)c2cc(F)ccc2Cl)-n2ncccc2=O)c2ccc(F)cc12)C(F)(F)F	(400 MHz, DMSO-d6) 9.24 (s, 1H), 9.02 (s, 1H), 8.13 (dd, J = 3.8, 1.7 Hz, 1H), 7.94 (d, J = 6.8 Hz, 1H), 7.84 (d, J = 1.9 Hz, 1H), 7.66 (d, J = 1.9 Hz, 1H), 7.55 (dd, J = 9.5, 3.8 Hz, 1H), 7.41 (s, 1H), 7.35 (dd, J = 8.9, 5.1 Hz, 1H), 7.29 (td, J = 9.0, 2.8 Hz, 1H), 7.24 - 7.11 (m, 3H), 6.66 (s, 1H), 6.08 (s, 1H), 4.01 (d, J = 12.1 Hz, 1H), 3.52 (d, J = 12.0 Hz, 1H).	618.2	D	
I-2536		O[C@]1(CN(C(=O)Nc2cc(cc3C(=O)N[C@@H](c23)c2cc(F)ccc2Cl)-n2ncccc2=O)c2ccc(F)cc12)C(F)(F)F	(400 MHz, DMSO-d6) δ9.15 (s, 1H), 8.61 (s, 1H), 7.72 (dd, J = 8.9, 4.7 Hz, 1H), 7.57 (s, 1H), 7.46 (s, 1H), 7.36 (dd, J = 8.9, 5.2 Hz, 1H), 7.07 (dtd, J = 28.1, 9.0, 8.6, 2.9 Hz, 3H), 6.60 (s, 1H), 6.08 (s, 1H), 5.74 (d, J = 4.5 Hz, 1H), 5.16 (dd, J = 8.3, 4.2 Hz, 1H), 4.23 (s, 2H), 3.98 (dd, J = 11.1, 8.1 Hz, 1H), 3.21 (dd, J = 10.9, 4.1 Hz, 1H).	495.2	A	A
I-2537		O[C@@H]1CN(C(=O)Nc2cc(CC#N)cc3C(=O)N[C@H](c23)c2cc(F)ccc2Cl)c2ccc(F)cc12	(400 MHz, DMSO-d6) δ9.15 (s, 1H), 8.61 (s, 1H), 7.72 (dd, J = 8.9, 4.7 Hz, 1H), 7.57 (s, 1H), 7.46 (s, 1H), 7.36 (dd, J = 8.9, 5.2 Hz, 1H), 7.07 (dtd, J = 28.1, 9.0, 8.6, 2.9 Hz, 3H), 6.60 (s, 1H), 6.08 (s, 1H), 5.74 (d, J = 4.5 Hz, 1H), 5.16 (dd, J = 8.3, 4.2 Hz, 1H), 4.23 (s, 2H), 3.98 (dd, J = 11.1, 8.1 Hz, 1H), 3.21 (dd, J = 10.9, 4.1 Hz, 1H).	495.1	A	A






I-2538		O[C@@H]1CN(C(=O)Nc2cc(CC#N)cc3C(=O)N[C@@H](c23)c2cc(F)ccc2Cl)c2ccc(F)cc12	(400 MHz, DMSO-d6) δ9.15 (s, 1H), 8.61 (s, 1H), 7.72 (dd, J = 8.9, 4.7 Hz, 1H), 7.57 (s, 1H), 7.46 (s, 1H), 7.36 (dd, J = 8.9, 5.2 Hz, 1H), 7.07 (dtd, J = 28.1, 9.0, 8.6, 2.9 Hz, 3H), 6.60 (s, 1H), 6.08 (s, 1H), 5.74 (d, J = 4.5 Hz, 1H), 5.16 (dd, J = 8.3, 4.2 Hz, 1H), 4.23 (s, 2H), 3.98 (dd, J = 11.1, 8.1 Hz, 1H), 3.21 (dd, J = 10.9, 4.1 Hz, 1H).	495.1	A	
I-2539		O[C@H]1CN(C(=O)Nc2cc(CC#N)cc3C(=O)N[C@H](c23)c2cc(F)ccc2Cl)c2ccc(F)cc12	(400 MHz, DMSO-d6) δ9.15 (s, 1H), 8.61 (s, 1H), 7.72 (dd, J = 8.9, 4.7 Hz, 1H), 7.57 (s, 1H), 7.46 (s, 1H), 7.36 (dd, J = 8.9, 5.2 Hz, 1H), 7.07 (dtd, J = 28.1, 9.0, 8.6, 2.9 Hz, 3H), 6.60 (s, 1H), 6.08 (s, 1H), 5.74 (d, J = 4.5 Hz, 1H), 5.16 (dd, J = 8.3, 4.2 Hz, 1H), 4.23 (s, 2H), 3.98 (dd, J = 11.1, 8.1 Hz, 1H), 3.21 (dd, J = 10.9, 4.1 Hz, 1H).	495.2	D	
I-2540		O[C@H]1CN(C(=O)Nc2cc(CC#N)cc3C(=O)N[C@@H](c23)c2cc(F)ccc2Cl)c2ccc(F)cc12	(400 MHz, DMSO-d6) 9.09 (s, 1H), 8.86 (s, 1H), 7.93 (s, 1H), 7.54 (s, 1H), 7.43 (s, 1H), 7.38 - 7.23 (m, 3H), 7.20 (dd, J = 8.1, 2.8 Hz, 1H), 7.13 (td, J = 8.4, 3.1 Hz, 1H), 6.53 (s, 1H), 6.01 (s, 1H), 4.56 (s, 2H), 4.01 (d, J = 12.1 Hz, 1H), 3.50 (d, J = 12.0 Hz, 1H), 3.36 (s, 3H).	568.3	B	






I-2541		COCc1cc2C(=O)N[C@@H](c2c(NC(=O)N2C[C@](O)(c3cc(F)ccc23)C(F)(F)F)c1)c1cc(F)ccc1Cl	(400 MHz, DMSO-d6) 9.10 (s, 1H), 8.76 (s, 1H), 7.86 (dd, J = 9.0, 4.7 Hz, 1H), 7.54 (s, 1H), 7.44 (d, J = 1.4 Hz, 1H), 7.40 (s, 1H), 7.35 (dd, J = 8.9, 5.1 Hz, 1H), 7.30 - 7.18 (m, 2H), 7.12 (td, J = 8.3, 3.1 Hz, 1H), 6.53 (s, 1H), 6.06 (s, 1H), 4.56 (s, 2H), 4.24 (d, J = 12.0 Hz, 1H), 3.41 (d, J = 12.0 Hz, 1H), 3.36 (s, 3H).	568.3	A	A
I-2542		COCc1cc2C(=O)N[C@@H](c2c(NC(=O)N2C[C@@](O)(c3cc(F)ccc23)C(F)(F)F)c1)c1cc(F)ccc1Cl	(400 MHz, DMSO-d6) 9.10 (s, 1H), 8.75 (s, 1H), 7.86 (dd, J = 9.0, 4.7 Hz, 1H), 7.54 (s, 1H), 7.44 (d, J = 1.4 Hz, 1H), 7.41 - 7.31 (m, 2H), 7.30 - 7.18 (m, 2H), 7.12 (td, J = 8.4, 3.1 Hz, 1H), 6.54 (s, 1H), 6.05 (s, 1H), 4.56 (s, 2H), 4.24 (d, J = 12.1 Hz, 1H), 3.41 (d, J = 12.0 Hz, 1H), 3.36 (s, 3H).	568.3	D	
I-2543		COCc1cc2C(=O)N[C@H](c2c(NC(=O)N2C[C@](O)(c3cc(F)ccc23)C(F)(F)F)c1)c1cc(F)ccc1Cl	(400 MHz, DMSO-d6) 9.09 (s, 1H), 8.85 (s, 1H), 7.93 (s, 1H), 7.54 (d, J = 1.4 Hz, 1H), 7.41 (s, 1H), 7.36 (d, J = 1.4 Hz, 1H), 7.32 (dd, J = 8.9, 5.2 Hz, 1H), 7.27 (td, J = 9.0, 2.7 Hz, 1H), 7.20 (dd, J = 8.1, 2.8 Hz, 1H), 7.13 (td, J = 8.3, 3.1 Hz, 1H), 6.54 (s, 1H), 6.01 (s, 1H), 4.56 (s, 2H), 4.01 (d, J = 12.1 Hz, 1H), 3.50 (d, J = 12.1 Hz, 1H), 3.36 (s, 3H).	568.3	D	





I-2544		COCc1cc2C(=O)N[C@H](c2c(NC(=O)N2C[C@@](O)(c3cc(F)ccc23)C(F)(F)F)c1)c1cc(F)ccc1Cl	(400 MHz, DMSO-d6) δ 9.26 (br s, 1H), 8.88 (s, 0.5H), 8.78 (s, 0.5H), 7.88 (dd, J = 8.0, 3.9 Hz, 0.5H), 7.81 (dd, J = 8.9, 4.7 Hz, 0.5H), 7.58 (s, 1H), 7.48 (d, J = 1.8 Hz, 1H), 7.39 - 7.30 (m, , 1H), 7.29 - 7.23 (m, 1H), 7.18 (dd, J = 8.9, 2.7 Hz, 1H), 7.16 - 7.08 (m, 1H), 6.66 (br s, 1H), 6.27 (app. t, J = 55.4, 3.6 Hz, 1H), 6.09 (overlapping br s, 0.5H), 6.05 (overlapping br s, 0.5H), 4.04 (d, J = 11.5 Hz, 0.5H), 3.82 (d, J = 11.9 Hz, 0.5H), 3.47 (d, J = 11.6 Hz, 0.5H), 3.33 (d, J = 11.3 Hz, 0.5H). 1:1 Mix of diastereomers.	540.0	D	
I-2545		OC1(CN(C(=O)Nc2cc(Cl)cc3C(=O)NC(c23)c2cc(F)ccc2Cl)c2ccc(F)cc12)C(F)F	(400 MHz,) δ 9.39 (br. s, 2H), 8.99 (s, 1H), 8.89 (s, 1H), 8.03 (br. s, 2H), 7.91 (2 overlapping s, 2H), 7.81 (2 overlapping s, 2H), 7.45 - 7.30 (m, 2H), 7.32 - 7.21 (m, 3H), 7.22 - 7.17 (m, 2H), 7.17 - 7.08 (m, 3H), 6.74 (s, 1H), 6.67 (s, 1H), 6.28 (app. td, J = 55.2, 3.1 Hz, 2H (CHF2 signal)), 6.15 (br. s, 2H), 4.03 (br. d, J = 11.2 Hz, 1H), 3.80 (br. d, J = 11.9 Hz, 1H), 3.46 (br. d, J = 11.4 Hz, 1H), 3.30 (submerged br. d, J = 11.9 Hz, 1H); approximately 1:1 mixture of diastereomers	529.2	A	A





I-2546		OC1(CN(C(=O)Nc2cc(cc3C(=O)NC(c23)c2cc(F)ccc2Cl)C#N)c2ccc(F)cc12)C(F)F	(400 MHz, DMSO-d6) 9.30 (s, 1H), 9.07 (s, 1H), 8.47 (s, 1H), 8.12 (s, 2H), 8.04 (s, 1H), 7.95 (s, 1H), 7.36 (dd, J=8.9, 5.1 Hz, 1H), 7.28 (s, 1H), 7.24-7.13 (m, 2H), 7.17-7.10 (m, 1H), 6.10 (s, 1H), 4.04 (s, 1H), 3.54 (s, 1H).	591.2	A	B
I-2547		O[C@]1(CN(C(=O)Nc2cc(cc3C(=O)N[C@@H](c23)c2cc(F)ccc2Cl)-n2ccnn2)c2ccc(F)cc12)C(F)(F)F	(400 MHz, DMSO-d6) 9.32 (s, 1H), 9.07 (s, 2H), 8.20 (s, 1H), 8.10 (s, 1H), 8.04 (d, J=1.2 Hz, 1H), 7.90 (dd, J=9.0, 4.6 Hz, 1H), 7.38 (dd, J=8.9, 5.1 Hz, 2H), 7.31-7.19 (m, 2H), 7.15 (td, J=8.4, 3.1 Hz, 1H), 6.15 (s, 1H), 4.23 (d, J=12.1 Hz, 1H), 3.45 (d, J=11.7 Hz, 1H).	591.1	A	A
I-2548		O[C@@]1(CN(C(=O)Nc2cc(cc3C(=O)N[C@@H](c23)c2cc(F)ccc2Cl)-n2ccnn2)c2ccc(F)cc12)C(F)(F)F	(400 MHz, DMSO-d6) 9.33 (s, 1H), 9.08 (d, J=1.3 Hz, 1H), 9.03 (s, 1H), 8.19-8.07 (m, 2H), 8.04 (d, J=1.2 Hz, 1H), 7.90 (dd, J=9.0, 4.6 Hz, 1H), 7.42 (s, 1H), 7.38 (dd, J=8.9, 5.1 Hz, 1H), 7.32-7.20 (m, 2H), 7.15 (td, J=8.3, 3.1 Hz, 1H), 6.15 (s, 1H), 4.24 (d, J=12.0 Hz, 1H), 3.43 (d, J=11.8 Hz, 1H).	591.2	D	
I-2549		O[C@]1(CN(C(=O)Nc2cc(cc3C(=O)N[C@H](c23)c2cc(F)ccc2Cl)-n2ccnn2)c2ccc(F)cc12)C(F)(F)F	(400 MHz, DMSO-d6) 9.31 (s, 1H), 9.15 (s, 1H), 9.07 (s, 1H), 8.11 (s, 2H), 8.04 (s, 1H), 7.94 (s, 1H), 7.46 (s, 1H), 7.36 (dd, J=8.9, 5.1 Hz, 1H), 7.28 (s, 1H), 7.22 (d, J=7.9 Hz, 1H), 7.15 (td, J=8.4, 3.1 Hz, 1H), 6.11 (s, 1H), 4.01 (s, 1H), 3.54 (s, 1H).	591.1	B	





I-2550		O[C@@]1(CN(C(=O)Nc2cc(cc3C(=O)N[C@H](c23)c2cc(F)ccc2Cl)-n2ccnn2)c2ccc(F)cc12)C(F)(F)F			D	
I-2551		O[C@@H]1CN(C(=O)Nc2cc(OCC3(CC3)C#N)cc3C(=O)N[C@H](c23)c2cc(F)ccc2Cl)c2ccc(F)cc12			D	
I-2552		O[C@@H]1CN(C(=O)Nc2cc(OCC3(CC3)C#N)cc3C(=O)N[C@@H](c23)c2cc(F)ccc2Cl)c2ccc(F)cc12			A	B
I-2553		O[C@H]1CN(C(=O)Nc2cc(OCC3(CC3)C#N)cc3C(=O)N[C@H](c23)c2cc(F)ccc2Cl)c2ccc(F)cc12			B	





I-2554		O[C@H]1CN(C(=O)Nc2cc(OCC3(CC3)C#N)cc3C(=O)N[C@@H](c23)c2cc(F)ccc2Cl)c2ccc(F)cc12			B	
I-2555		O[C@]1(CN(C(=O)Nc2ccccc3C(=O)N[C@H](c23)c2cc(F)ccc2Cl)c2ccc(F)cc12)C(F)F			D	
I-2556		O[C@]1(CN(C(=O)Nc2ccccc3C(=O)N[C@@H](c23)c2cc(F)ccc2Cl)c2ccc(F)cc12)C(F)F			C	
I-2557		O[C@@]1(CN(C(=O)Nc2ccccc3C(=O)N[C@H](c23)c2cc(F)ccc2Cl)c2ccc(F)cc12)C(F)F			D	
I-2558		O[C@@]1(CN(C(=O)Nc2ccccc3C(=O)N[C@@H](c23)c2cc(F)ccc2Cl)c2ccc(F)cc12)C(F)F			A	A





I-2559		O[C@]1(CN(C(=O)Nc2cc(cc3C(=O)N[C@H](c23)c2cc(F)ccc2Cl)C#N)c2ccc(F)cc12)C(F)(F)F			D	
I-2560		O[C@]1(CN(C(=O)Nc2cc(cc3C(=O)N[C@@H](c23)c2cc(F)ccc2Cl)C#N)c2ccc(F)cc12)C(F)(F)F			A	A
I-2561		O[C@@]1(CN(C(=O)Nc2cc(cc3C(=O)N[C@H](c23)c2cc(F)ccc2Cl)C#N)c2ccc(F)cc12)C(F)(F)F			D	
I-2562		O[C@@]1(CN(C(=O)Nc2cc(cc3C(=O)N[C@@H](c23)c2cc(F)ccc2Cl)C#N)c2ccc(F)cc12)C(F)(F)F			A	A
I-2563		O[C@]1(CN(C(=O)Nc2cc(cc3C(=O)N[C@H](c23)c2cc(F)ccc2Cl)C#			D	



		N)c2cccc c12)C(F) (F)F				
I-2564		O[C@]1(CN(C(= O)Nc2cc (cc3C(= O)N[C@ @H](c23)c2cc(F)c cc2Cl)C# N)c2cccc c12)C(F) (F)F			A	A
I-2565		O[C@@] 1(CN(C(=O)Nc2c c(cc3C(= O)N[C@ H](c23)c 2cc(F)cc c2Cl)C# N)c2cccc c12)C(F) (F)F			D	
I-2566		O[C@@] 1(CN(C(=O)Nc2c c(cc3C(= O)N[C@ @H](c23)c2cc(F)c cc2Cl)C# N)c2cccc c12)C(F) (F)F	(400 MHz, DMSO) δ 9.06 (s, 1H), 8.80 (s, 0.5H), 8.70 (s, 0.5H), 7.90 (dd, J = 8.9, 4.6 Hz, 0.5H), 7.82 (dd, J = 8.9, 4.7 Hz, 0.5H), 7.63 – 7.53 (m, 2H), 7.47 – 7.17 (m, 5H), 7.15 – 7.06 (m, 1H), 6.77 – 6.30 (m, 1H), 6.03 (s, 1H).	526. 3	A	A
I-2567		[2H]C1([2H])N(C (=O)Nc2 cccc3C(= O)NC(c2 3)c2cc(F) ccc2Cl)c 2ccc(F)c c2C1(O) C(F)(F)F	(400 MHz, DMSO d6) δ 9.08 (br. s, 1H), 8.89 (s, 1H), 8.31 (s, 1H), 7.97 - 7.87 (m, 1H), 7.67 (s, 1H), 7.47 (d, J = 3.3 Hz, 1H), 7.39 (d, J = 3.1 Hz, 1H), 7.37-7.29 (m, 1H), 7.28-7.17 (m, 3H), 7.16 - 7.06 (m, 1H), 6.52 (br. s, 1H), 6.04 (br. s, 1H), 4.23 (d, J = 11.6 Hz, 1H), 3.96 (d, J = 2.8 Hz, 2H), 3.50 (d, J = 10.2 Hz, 1H). 1:1 mixture	553. 4	A	A





I-2568		NCc1cc2C(=O)NC(c2c(NC(=O)N2CC(O)(c3cc(F)ccc23)C(F)(F)F)c1)c1cc(F)ccc1Cl		591.1	A	D
I-2569		O[C@]1(CN(C(=O)Nc2cc(cc3C(=O)N[C@@H](c23)c2cc(F)ccc2Cl)-n2nccn2)c2ccc(F)cc12)C(F)(F)F	(400 MHz, DMSO-d6) 9.30 (s, 1H), 8.99 (s, 1H), 8.28-8.20 (m, 3H), 8.12 (d, J=1.9 Hz, 1H), 7.90 (dd, J=8.9, 4.7 Hz, 1H), 7.41-7.33 (m, 2H), 7.32-7.19 (m, 2H), 7.14 (td, J=8.3, 3.1 Hz, 1H), 6.72 (s, 1H), 6.14 (s, 1H), 4.23 (d, J=12.0 Hz, 1H), 3.44 (d, J=12.1 Hz, 1H).	591.1	A	A
I-2570		O[C@@]1(CN(C(=O)Nc2cc(cc3C(=O)N[C@@H](c23)c2cc(F)ccc2Cl)-n2nccn2)c2ccc(F)cc12)C(F)(F)F	(400 MHz, DMSO-d6) 9.30 (s, 1H), 8.99 (s, 1H), 8.28-8.20 (m, 3H), 8.12 (d, J=1.9 Hz, 1H), 7.90 (dd, J=9.0, 4.7 Hz, 1H), 7.41-7.33 (m, 2H), 7.26 (ddd, J=21.4, 8.9, 2.8 Hz, 2H), 7.14 (td, J=8.3, 3.1 Hz, 1H), 6.71 (s, 1H), 6.14 (s, 1H), 4.23 (d, J=12.0 Hz, 1H), 3.44 (d, J=11.9 Hz, 1H).	591.1	D	
I-2571		O[C@]1(CN(C(=O)Nc2cc(cc3C(=O)N[C@H](c23)c2cc(F)ccc2Cl)-n2nccn2)c2ccc(F)cc12)C(F)(F)F	(400 MHz, DMSO-d6) 9.29 (s, 1H), 9.09 (s, 1H), 8.22 (s, 2H), 8.18 (d, J=2.0 Hz, 1H), 8.12 (d, J=1.9 Hz, 1H), 7.96 (d, J=9.0 Hz, 1H), 7.42 (s, 1H), 7.39-7.25 (m, 2H), 7.22 (dd, J=8.0, 2.7 Hz, 1H), 7.14 (td, J=8.4, 3.1 Hz, 1H), 6.71 (s, 1H), 6.10 (s, 1H), 4.03 (d, J=12.2 Hz, 1H), 3.54 (d, J=12.0 Hz, 1H).	591.4	D	





I-2572		O[C@@]1(CN(C(=O)Nc2cc(cc3C(=O)N[C@H](c23)c2cc(F)ccc2Cl)-n2nccn2)c2ccc(F)cc12)C(F)(F)F	(400 MHz, DMSO-d6) 7.86 (s, 1H), 7.79 (s, 1H), 7.67 (dd, J = 6.4, 3.5 Hz, 1H), 7.28 (dt, J = 8.6, 4.2 Hz, 1H), 7.23 (s, 1H), 7.19 (dd, J = 8.1, 2.6 Hz, 1H), 7.07 (s, 1H), 6.58 (s, 1H), 5.91 (s, 1H), 4.00 (s, 1H), 3.42 (d, J = 12.1 Hz, 1H), 2.08 (d, J = 2.6 Hz, 3H).	581.2	D	
I-2573		CC(=O)Nc1cc2C(=O)N[C@@H](c2c(NC(=O)N2C[C@@](O)(c3cc(F)ccc23)C(F)(F)F)c1)c1cc(F)ccc1Cl	(400 MHz, DMSO-d6) 10.26 (s, 1H), 9.05 (s, 1H), 8.73 (s, 1H), 7.89 - 7.81 (m, 2H), 7.79 (d, J = 1.9 Hz, 1H), 7.37 - 7.29 (m, 2H), 7.23 (ddd, J = 18.6, 9.4, 2.8 Hz, 2H), 7.11 (td, J = 8.3, 3.1 Hz, 1H), 6.57 (s, 1H), 5.99 (s, 1H), 4.22 (d, J = 12.0 Hz, 1H), 3.40 (d, J = 12.0 Hz, 1H), 2.11 (s, 3H).	581.2	A	A
I-2574		CC(=O)Nc1cc2C(=O)N[C@H](c2c(NC(=O)N2C[C@@](O)(c3cc(F)ccc23)C(F)(F)F)c1)c1cc(F)ccc1Cl	(400 MHz, DMSO-d6) 10.26 (s, 1H), 9.05 (s, 1H), 8.73 (s, 1H), 7.89 - 7.81 (m, 2H), 7.79 (d, J = 1.9 Hz, 1H), 7.37 - 7.29 (m, 2H), 7.23 (ddd, J = 18.5, 9.3, 2.8 Hz, 2H), 7.11 (td, J = 8.3, 3.1 Hz, 1H), 6.56 (s, 1H), 5.99 (s, 1H), 4.22 (d, J = 12.0 Hz, 1H), 3.40 (d, J = 12.1 Hz, 1H), 2.11 (s, 3H).	581.2	B	
I-2575		CC(=O)Nc1cc2C(=O)N[C@@H](c2c(NC(=O)N2C[C@](O)(c3cc(F)ccc23)C(F)(F)F)c1)c1cc(F)ccc1Cl	(400 MHz, DMSO-d6) 10.26 (s, 1H), 9.04 (s, 1H), 8.84 (s, 1H), 7.93 (dd, J = 9.3, 4.6 Hz, 1H), 7.83 (d, J = 1.8 Hz, 1H), 7.72 (d, J = 1.9 Hz, 1H), 7.36 (s, 1H), 7.35 - 7.23 (m, 2H), 7.20 (dd, J = 8.1, 2.7 Hz, 1H), 7.12 (td, J = 8.4, 3.1 Hz, 1H), 6.57 (s, 1H), 5.95 (s, 1H), 4.02 (d, J = 12.2 Hz, 1H), 3.48 (d, J = 12.1 Hz, 1H), 2.11 (s, 3H).	581.2	D	




I-2576		CC(=O)Nc1cc2C(=O)N[C@H](c2c(NC(=O)N2C[C@](O)(c3cc(F)ccc23)C(F)(F)F)c1)c1cc(F)ccc1Cl	(400 MHz, DMSO-d6) 9.27 (s, 1H), 8.89 (s, 1H), 7.87 (dd, J = 9.0, 4.6 Hz, 1H), 7.78 (s, 1H), 7.70 (s, 1H), 7.42-7.32 (m, 2H), 7.30-7.18 (m, 2H), 7.17-7.07 (m, 1H), 6.90-6.40 (m, 1H), 6.12 (s, 1H), 4.21 (d, J = 12.0 Hz, 1H), 3.43 (d, J = 12.2 Hz, 1H	574.1	D	
I-2577		O[C@]1(CN(C(=O)Nc2cc(cc3C(=O)N[C@@H](c23)c2cc(F)ccc2Cl)C(F)F)c2ccc(F)cc12)C(F)(F)F	(400 MHz, DMSO-d6) 9.28 (s, 1H), 8.90 (s, 1H), 7.87 (dd, J = 9.0, 4.6 Hz, 1H), 7.78 (s, 1H), 7.70 (s, 1H), 7.43-7.33 (m, 2H), 7.32-7.19 (m, 2H), 7.18-7.06 (m, 1H), 6.90-6.12 (m, 1H), 4.21 (d, J = 12.0 Hz, 1H), 3.43 (d, J = 12.1 Hz, 1H).	574.0	D	
I-2578		O[C@]1(CN(C(=O)Nc2cc(cc3C(=O)N[C@H](c23)c2cc(F)ccc2Cl)C(F)F)c2ccc(F)cc12)C(F)(F)F	(400 MHz, DMSO-d6) 9.27 (s, 1H), 9.00 (s, 1H), 7.93 (s, 1H), 7.78 (s, 1H), 7.61 (s, 1H), 7.43 (s, 1H), 7.41-7.18 (m, 4H), 7.15-7.07 (m, 1H), 6.90-6.40 (m, 1H), 6.08 (s, 1H), 4.00 (d, J = 12.1 Hz, 1H), 3.51 (d, J = 12.1 Hz, 1H).	574.1	D	
I-2579		O[C@@]1(CN(C(=O)Nc2cc(cc3C(=O)N[C@@H](c23)c2cc(F)ccc2Cl)C(F)F)c2ccc(F)cc12)C(F)(F)F	(400 MHz, DMSO-d6) 9.26 (s, 1H), 8.99 (s, 1H), 7.93 (s, 1H), 7.78 (s, 1H), 7.61 (s, 1H), 7.42 (s, 1H), 7.37-7.32 (m, 1H), 7.28 (td, J = 9.0, 2.7 Hz, 1H), 7.25-7.07 (m, 3H), 6.90-6.40 (m, 1H), 6.08 (s, 1H), 4.00 (d, J = 12.1 Hz, 1H), 3.52 (d, J = 12.1 Hz, 1H).	574.1	A	A





I-2580		O[C@@]1(CN(C(=O)Nc2cc(cc3C(=O)N[C@H](c23)c2cc(F)ccc2Cl)C(F)F)c2ccc(F)cc12)C(F)(F)F	(400 MHz, DMSO-d6) 9.00 (d, J = 17.4 Hz, 1H), 8.68 (s, 1H), 7.96-7.81 (m, 1H), 7.46 (s, 1H), 7.40-7.17 (m, 6H), 7.11 (td, J = 8.4, 3.1 Hz, 1H), 6.55 (s, 1H), 6.03 (s, 1H), 4.24 (d, J = 12.0 Hz, 1H), 3.41 (d, J = 12.1 Hz, 1H), 2.97-2.74 (m, 4H).	567.2	D	
I-2581		NCCc1cc2C(=O)N[C@H](c2c(NC(=O)N2C[C@](O)(c3cc(F)ccc23)C(F)(F)F)c1)c1cc(F)ccc1Cl	(400 MHz, DMSO-d6) 9.00 (d, J = 17.4 Hz, 1H), 8.68 (s, 1H), 7.96-7.81 (m, 1H), 7.46 (s, 1H), 7.40-7.17 (m, 6H), 7.11 (td, J = 8.4, 3.1 Hz, 1H), 6.55 (s, 1H), 6.03 (s, 1H), 4.24 (d, J = 12.0 Hz, 1H), 3.41 (d, J = 12.1 Hz, 1H), 2.97-2.74 (m, 4H).	567.2	A	D
I-2582		NCCc1cc2C(=O)N[C@H](c2c(NC(=O)N2C[C@@](O)(c3cc(F)ccc23)C(F)(F)F)c1)c1cc(F)ccc1Cl	(400 MHz, DMSO-d6) 9.00 (d, J = 17.4 Hz, 1H), 8.68 (s, 1H), 7.96-7.81 (m, 1H), 7.46 (s, 1H), 7.40-7.17 (m, 6H), 7.11 (td, J = 8.4, 3.1 Hz, 1H), 6.55 (s, 1H), 6.03 (s, 1H), 4.24 (d, J = 12.0 Hz, 1H), 3.41 (d, J = 12.1 Hz, 1H), 2.97-2.74 (m, 4H).	567.2	B	
I-2583		NCCc1cc2C(=O)N[C@@H](c2c(NC(=O)N2C[C@](O)(c3cc(F)ccc23)C(F)(F)F)c1)c1cc(F)ccc1Cl	(400 MHz, DMSO-d6) 9.00 (d, J = 17.4 Hz, 1H), 8.68 (s, 1H), 7.96-7.81 (m, 1H), 7.46 (s, 1H), 7.40-7.17 (m, 6H), 7.11 (td, J = 8.4, 3.1 Hz, 1H), 6.55 (s, 1H), 6.03 (s, 1H), 4.24 (d, J = 12.0 Hz, 1H), 3.41 (d, J = 12.1 Hz, 1H), 2.97-2.74 (m, 4H).	567.1	D	






I-2584		NCCc1cc2C(=O)N[C@@H](c2c(NC(=O)N2C[C@@](O)(c3cc(F)ccc23)C(F)(F)F)c1)c1cc(F)ccc1Cl	(400 MHz, DMSO-d6) as a ca. 1:1 mixture of diastereomers, δ 9.15 (br. s, 1H), 9.13 (br. s, 1H), 8.89 (br. s, 1H), 8.77 (br. s, 1H), 7.90 (br. d, J = 7.8 Hz, 1H), 7.83 (d, J = 8.2 Hz, 1H), 7.59 - 7.57 (m, 1H), 7.51 - 7.49 (m, 1H), 7.45 - 7.29 (m, 7H), 7.22 (s, 1H), 7.20 (s, 1H), 7.14 - 7.04 (m, 4H), 6.58 (br. s, 2H), 6.08 (br. s, 1H), 6.03 (br. s, 1H), 4.24 (s, 4H), 4.17 (d, A of AB, JAB = 12.1 Hz, 1H), 3.97 (d, A of AB, JAB = 12.4 Hz, 1H), 3.48 (d, B of AB, JAB = 11.8 Hz, 1H), 3.43 (d, B of AB, JAB = 11.9 Hz, 1H).	545.4	D	
I-2585		OC1(CN(C(=O)Nc2cc(CC#N)cc3C(=O)NC(c23)c2cc(F)ccc2Cl)c2ccccc12)C(F)(F)F	(400MHz, DMSO-d6) δ as a ca. 3:2 mixture of diastereomers; for both diastereomers, δ 9.16 (br. s, 1H), 9.15 (br. s, 1H), 8.86 (br. s, 1H), 8.75 (br. s, 1H), 7.89 (dd, J = 8.4, 3.9 Hz, 1H), 7.81 (dd, J = 8.9, 4.7 Hz, 1H), 7.57 (br. s, 2H), 7.47 (d, J = 1.2 Hz, 1H), 7.39 (d, J = 1.2 Hz, 1H), 7.37 - 7.30 (m, 2H), 7.28 - 7.21 (m, 2H), 7.20 - 7.16 (m, 2H), 7.15 - 7.08 (m, 2H), 6.71 (s, 1H), 6.64 (s, 1H), 6.58 (br. s, 1H), 6.42 - 6.12 (m, 2H), 6.07 (br. s, 1H), 6.03 (br. s, 1H), 4.23 (s, 4H), 4.11 (d, A of AB, JAB = 11.8 Hz, 1H), 3.86 (d, A of AB, JAB = 11.3 Hz, 1H), 3.44 (d, B of AB JAB = 11.4 Hz, 1H), 3.29 (d, B of AB JAB = 12.3 Hz, 1H).	545.3	A	A





I-2586		OC1(CN(C(=O)Nc2cc(CC#N)cc3C(=O)NC(c23)c2cc(F)ccc2Cl)c2ccc(F)cc12)C(F)F	(400 MHz, DMSO-d6) δ 9.18 (br s, 1 H), 8.85 (br s, 2 H), 7.95 - 7.80 (m, 1 H), 7.35 - 7.23 (m, 2 H), 7.23 - 7.17 (m, 1 H), 7.14 - 7.05 (m, 1 H), 6.81 (s, 0.5 H), 6.74 (s, 0.5 H), 6.65 (br s, 1 H), 6.52 - 6.44 (m, 1 H), 5.90 (br s, 1 H), 4.19 (d, J = 12.0 Hz, 0.5 H), 3.97 (d, J = 12.1 Hz, 0.5 H), 3.45 (submerged d, J = 12.0 Hz, 0.5 H), 3.30 (submerged d, J = 12.2 Hz, 0.5 H), 2.90 - 2.72 (m, 3 H). ~1:1 mixture of diastereomers.	578.3	A	B
I-2587		CNc1cc(NC(=O)N2CC(O)(c3cc(F)ccc23)C(F)(F)F)c2C(NC(=O)c2c1C#N)c1cc(F)ccc1Cl			A	B
I-2588		O[C@]1(CN(C(=O)Nc2cc(Cl)cc3C(=O)N[C@H](c23)c2cc(F)ccc2Cl)c2ccc(F)cc12)C(F)F			D	
I-2589		O[C@]1(CN(C(=O)Nc2cc(Cl)cc3C(=O)N[C@@H](c23)c2cc(F)ccc2Cl)c2ccc(F)cc12)C(F)F			D	





I-2590		O[C@@]1(CN(C(=O)Nc2cc(Cl)cc3C(=O)N[C@H](c23)c2cc(F)ccc2Cl)c2ccc(F)cc12)C(F)F			D	
I-2591		O[C@@]1(CN(C(=O)Nc2cc(Cl)cc3C(=O)N[C@@H](c23)c2cc(F)ccc2Cl)c2ccc(F)cc12)C(F)F		525.9	A	A
I-2592		[2H]C1([2H])N(C(=O)Nc2cccc3C(=O)N[C@@H](c23)c2cc(F)ccc2Cl)c2ccc(F)cc2[C@]1(O)C(F)(F)F		525.9	D	
I-2593		[2H]C1([2H])N(C(=O)Nc2cccc3C(=O)N[C@H](c23)c2cc(F)ccc2Cl)c2ccc(F)cc2[C@@]1(O)C(F)(F)F		525.8	D	




I-2594		[2H]C1([2H])N(C(=O)Nc2cccc3C(=O)N[C@@H](c23)c2cc(F)ccc2Cl)c2ccc(F)cc2[C@@]1(O)C(F)(F)F	(400 MHz, DMSO) δ 9.05 (s, 1H), 8.79 (s, 1H), 7.90 (dd, J = 8.9, 4.7 Hz, 1H), 7.63 – 7.53 (m, 2H), 7.39 – 7.35 (m, 2H), 7.31 (dd, J = 8.9, 5.1 Hz, 1H), 7.25 (td, J = 9.0, 2.8 Hz, 1H), 7.19 (dd, J = 8.1, 2.7 Hz, 1H), 7.15 – 7.08 (m, 1H), 6.65 – 6.38 (m, 1H), 6.01 (s, 1H).	525.9	D	
I-2595		[2H]C1([2H])N(C(=O)Nc2cccc3C(=O)N[C@H](c23)c2cc(F)ccc2Cl)c2ccc(F)cc2[C@]1(O)C(F)(F)F		525.9	A	A
I-2596		OC1(CN(C(=O)Nc2cc(CC#N)cc3C(=O)NC(c23)c2cc(F)ccc2Cl)c2ccc(F)cc12)C(F)(F)F	(400 MHz, DMSO-d6) δ as a ca. 1:1 mixture of diastereomers, δ 9.17 (br. s, 2H), 8.94 (s, 1H), 8.83 (s, 1H), 7.95 - 7.90 (m, 1H), 7.86 (dd, J = 8.9, 4.7 Hz, 1H), 7.59 (br. s, 2H), 7.47 (d, J = 1.3 Hz, 1H), 7.42 - 7.38 (m, 3H), 7.37 - 7.30 (m, 2H), 7.30 - 7.19 (m, 5H), 7.16 - 7.09 (m, 2H), 6.56 (br. s, 2H), 6.11 - 5.97 (m, 2H), 4.24 (s, 4H), 4.23 - 4.20 (m, 1H), 4.01 (d, J = 12.1 Hz, 1H), 3.48 (d, J = 12.0 Hz, 1H), 3.39 (d, J = 12.1 Hz, 1H). Multiplet at 4.23 - 4.20 ppm is partially obscured by 4H singlet at 4.24 ppm.	563.3	A	A





I-2597		NCc1cc2C(=O)NC(c2c(NC(=O)N2CC(O)(C(F)F)c3cc(F)ccc23)c1)c1cc(F)ccc1Cl	(400 MHz, DMSOD6) δ 9.10 (s, 1H), 8.84 (s, 1H), 8.34 (s, 1H), 7.87 (dd, J = 8.4, 4.4 Hz, 1H), 7.67 (s, 1H), 7.49 (s, 1H), 7.34 (dd, J = 8.9, 5.2 Hz, 1H), 7.26 (dd, J = 6.2, 3.0 Hz, 1 H), 7.07-7.21 (m, 2H), 6.51 (br s, 1H), 6.28 (td, J = 55.4, 1.9 Hz, 1H), 6.08 (br. s, 1H), 4.12 (d, J = 11.8 Hz, 1H), 3.99 (s, 2H), 3.46 (d, J = 12.0 Hz, 1H).	535.2	A	D
I-2598		O[C@@]1(CN(C(=O)Nc2cc(CC#N)cc3C(=O)N[C@@H](c23)c2cc(F)ccc2Cl)c2ccc(F)cc12)C(F)F			D	
I-2599		O[C@]1(CN(C(=O)Nc2cc(CC#N)cc3C(=O)N[C@H](c23)c2cc(F)ccc2Cl)c2ccc(F)cc12)C(F)F			B	
I-2600		O[C@]1(CN(C(=O)Nc2cc(CC#N)cc3C(=O)N[C@@H](c23)c2cc(F)ccc2Cl)c2ccc(F)cc12)C(F)F			C	





I-2601		O[C@@]1(CN(C(=O)Nc2cc(CC#N)cc3C(=O)N[C@H](c23)c2cc(F)ccc2Cl)c2ccc(F)cc12)C(F)F			A	A
I-2602		O[C@]1(CN(C(=O)Nc2cc(CC#N)cc3C(=O)N[C@H](c23)c2cc(F)ccc2Cl)c2cccccc12)C(F)(F)F			D	
I-2603		O[C@]1(CN(C(=O)Nc2cc(CC#N)cc3C(=O)N[C@@H](c23)c2cc(F)ccc2Cl)c2ccccc12)C(F)(F)F			D	
I-2604		O[C@@]1(CN(C(=O)Nc2cc(CC#N)cc3C(=O)N[C@H](c23)c2cc(F)ccc2Cl)c2cccccc12)C(F)(F)F			C	
I-2605		O[C@@]1(CN(C(=O)Nc2cc(CC#N)cc3C(=O)N[C@@H](c23)c2cc(F)cc			A	A





		c2Cl)c2ccccc12)C(F)(F)F				
I-2606		CNc1cc(NC(=O)N2C[C@](O)(c3cc(F)ccc23)C(F)(F)F)c2[C@@H](NC(=O)c2c1C#N)c1cc(F)ccc1Cl			D	
I-2607		CNc1cc(NC(=O)N2C[C@](O)(c3cc(F)ccc23)C(F)(F)F)c2[C@H](NC(=O)c2c1C#N)c1cc(F)ccc1Cl			D	
I-2608		CNc1cc(NC(=O)N2C[C@@](O)(c3cc(F)ccc23)C(F)(F)F)c2[C@@H](NC(=O)c2c1C#N)c1cc(F)ccc1Cl			D	
I-2609		CNc1cc(NC(=O)N2C[C@@](O)(c3cc(F)ccc23)C(F)(F)F)c2[C@H](NC(=O)c2c1C#N)c1cc(F)ccc1Cl			A	A






I-2610		CC(C)(C#N)n1cc(cn1)-c1cc2C(=O)N[C@@H](c2c(NC(=O)N2C[C@@](O)(c3cc(F)ccc23)C(F)(F)F)c1)c1cc(F)ccc1Cl	(400 MHz, DMSO-d6) 9.10 (s, 1H), 8.78-8.73 m, 2H), 8.21 (s, 1H), 7.95 (d, J = 1.6 Hz, 1H), 7.88 (dd, J = 9.0, 4.7 Hz, 1H), 7.73 (d, J = 1.5 Hz, 1H), 7.40-7.35 (m, 2H), 7.25 (qd, J = 8.8, 2.8 Hz, 2H), 7.12 (ddd, J = 8.9, 7.8, 3.1 Hz, 1H), 6.59 (s, 1H), 6.06 (s, 1H), 4.27 (d, J = 12.1 Hz, 1H), 3.44 (d, J = 12.0 Hz, 1H), 2.04 (s, 6H).	671.1	D	
I-2611		CC(C)(C#N)n1cc(cn1)-c1cc2C(=O)N[C@H](c2c(NC(=O)N2C[C@@](O)(c3cc(F)ccc23)C(F)(F)F)c1)c1cc(F)ccc1Cl	(400 MHz, DMSO-d6) 9.10 (s, 1H), 8.78-8.73 m, 2H), 8.21 (s, 1H), 7.95 (d, J = 1.6 Hz, 1H), 7.88 (dd, J = 9.0, 4.7 Hz, 1H), 7.73 (d, J = 1.5 Hz, 1H), 7.40 (s, 1H), 7.35 (dd, J = 8.9, 5.2 Hz, 1H), 7.25 (qd, J = 8.8, 2.8 Hz, 2H), 7.12 (ddd, J = 8.9, 7.8, 3.1 Hz, 1H), 6.59 (s, 1H), 6.06 (s, 1H), 4.27 (d, J = 12.1 Hz, 1H), 3.44 (d, J = 12.0 Hz, 1H), 2.04 (s, 6H).	671.2	B	
I-2612		CC(C)(C#N)n1cc(cn1)-c1cc2C(=O)N[C@H](c2c(NC(=O)N2C[C@](O)(c3cc(F)ccc23)C(F)(F)F)c1)c1cc(F)ccc1Cl	(400 MHz, DMSO-d6) 9.09 (s, 1H), 8.85 (s, 1H), 8.73 (s, 1H), 8.20 (s, 1H), 7.95 (d, J = 1.5 Hz, 2H), 7.67 (d, J = 1.5 Hz, 1H), 7.42 (s, 1H), 7.37-7.18 (m, 3H), 7.13 (td, J = 8.4, 3.1 Hz, 1H), 6.60 (s, 1H), 6.03 (s, 1H), 4.00 (d, J = 12.1 Hz, 1H), 3.59 (d, J = 12.1 Hz, 1H), 2.04 (s, 6H).	671.1	D	
I-2613		CC(C)(C#N)n1cc(cn1)-c1cc2C(=O)N[C@@H](c2c(NC(=O)N2C[C@](O)(c3cc	(400 MHz, DMSO-d6)9.09 (s, 1H), 8.85 (s, 1H), 8.73 (s, 1H), 8.20 (s, 1H), 7.95 (d, J = 1.5 Hz, 2H), 7.67 (d, J = 1.5 Hz, 1H), 7.42 (s, 1H), 7.37-7.18 (m, 3H), 7.13 (td, J = 8.4, 3.1 Hz, 1H), 6.60 (s, 1H),	657.1	A	A





		(F)ccc23)C(F)(F)F)c1)c1cc(F)ccc1Cl	6.03 (s, 1H), 4.00 (d, J = 12.1 Hz, 1H), 3.59 (d, J = 12.1 Hz, 1H), 2.04 (s, 6H).			
I-2614		O[C@@]1(CN(C(=O)Nc2ccc(CC#N)c3C(=O)N[C@H](c23)c2cc(F)ccc2Cl)c2ccc(F)cc12)C(F)(F)F	(400 MHz, DMSO-d6) δ9.23 (s, 1H), 8.75 (d, J = 7.2 Hz, 1H), 7.84 (dd, J = 8.9, 4.7 Hz, 1H), 7.58 (d, J = 8.1 Hz, 1H), 7.49 (dd, J = 8.1, 1.9 Hz, 1H), 7.41 - 7.33 (m, 2H), 7.30 - 7.18 (m, 2H), 7.12 (td, J = 8.4, 3.1 Hz, 1H), 6.06 (s, 1H), 4.79 - 4.39 (m, 2H), 4.21 (d, J = 11.9 Hz, 1H), 3.45 (d, J = 12.1 Hz, 1H).	563.4	A	A
I-2615		O[C@@]1(CN(C(=O)Nc2ccc(CC#N)c3C(=O)N[C@@H](c23)c2cc(F)ccc2Cl)c2ccc(F)cc12)C(F)(F)F	(400 MHz, DMSO-d6) δ9.23 (s, 1H), 8.75 (d, J = 7.2 Hz, 1H), 7.84 (dd, J = 8.9, 4.7 Hz, 1H), 7.58 (d, J = 8.1 Hz, 1H), 7.49 (dd, J = 8.1, 1.9 Hz, 1H), 7.41 - 7.33 (m, 2H), 7.30 - 7.18 (m, 2H), 7.12 (td, J = 8.4, 3.1 Hz, 1H), 6.06 (s, 1H), 4.79 - 4.39 (m, 2H), 4.21 (d, J = 11.9 Hz, 1H), 3.45 (d, J = 12.1 Hz, 1H).	563.4	D	
I-2616		O[C@]1(CN(C(=O)Nc2ccc(CC#N)c3C(=O)N[C@H](c23)c2cc(F)ccc2Cl)c2ccc(F)cc12)C(F)(F)F	(400 MHz, DMSO-d6) δ9.23 (s, 1H), 8.75 (d, J = 7.2 Hz, 1H), 7.84 (dd, J = 8.9, 4.7 Hz, 1H), 7.58 (d, J = 8.1 Hz, 1H), 7.49 (dd, J = 8.1, 1.9 Hz, 1H), 7.41 - 7.33 (m, 2H), 7.30 - 7.18 (m, 2H), 7.12 (td, J = 8.4, 3.1 Hz, 1H), 6.06 (s, 1H), 4.79 - 4.39 (m, 2H), 4.21 (d, J = 11.9 Hz, 1H), 3.45 (d, J = 12.1 Hz, 1H).	563.4	D	



I-2617		O[C@]1(CN(C(=O)Nc2ccc(CC#N)c3C(=O)N[C@@H](c23)c2cc(F)ccc2Cl)c2ccc(F)cc12)C(F)(F)F	(400 MHz, DMSO-d6) δ9.23 (s, 1H), 8.75 (d, J = 7.2 Hz, 1H), 7.84 (dd, J = 8.9, 4.7 Hz, 1H), 7.58 (d, J = 8.1 Hz, 1H), 7.49 (dd, J = 8.1, 1.9 Hz, 1H), 7.41 - 7.33 (m, 2H), 7.30 - 7.18 (m, 2H), 7.12 (td, J = 8.4, 3.1 Hz, 1H), 6.06 (s, 1H), 4.79 - 4.39 (m, 2H), 4.21 (d, J = 11.9 Hz, 1H), 3.45 (d, J = 12.1 Hz, 1H).	563.4	D	
I-2618		O[C@@]1(CN(C(=O)Nc2ccc(Cl)c3C(=O)N[C@@H](c23)c2cc(F)ccc2Cl)c2ccc(F)cc12)C(F)(F)F	(400 MHz, DMSO-d6) 9.19 (s, 1H), 8.82 (s, 1H), 7.91 (s, 1H), 7.57 (d, J = 8.4 Hz, 1H), 7.42 - 7.10 (m, 6H), 6.66 (s, 1H), 5.99 (s, 1H), 3.98 (d, J = 12.1 Hz, 1H), 3.50 (d, J = 12.1 Hz, 1H).	558.1	A	A
I-2619		O[C@@]1(CN(C(=O)Nc2ccc(Cl)c3C(=O)N[C@H](c23)c2cc(F)ccc2Cl)c2ccc(F)cc12)C(F)(F)F	(400 MHz, DMSO-d6) 9.20 (s, 1H), 8.72 (s, 1H), 7.83 (dd, J = 8.9, 4.7 Hz, 1H), 7.58 (d, J = 8.4 Hz, 1H), 7.46 (d, J = 8.4 Hz, 1H), 7.41 - 7.31 (m, 2H), 7.29 - 7.18 (m, 2H), 7.13 (td, J = 8.4, 3.1 Hz, 1H), 6.64 (s, 1H), 6.03 (s, 1H), 4.17 (d, J = 12.0 Hz, 1H), 3.44 (d, J = 12.1 Hz, 1H).	558.1	D	
I-2620		O[C@]1(CN(C(=O)Nc2ccc(Cl)c3C(=O)N[C@@H](c23)c2cc(F)ccc2Cl)c2ccc(F)cc12)C(F)(F)F	(400 MHz, DMSO-d6) 9.19 (s, 1H), 8.81 (s, 1H), 7.90 (d, J = 6.3 Hz, 1H), 7.57 (d, J = 8.4 Hz, 1H), 7.42 - 7.34 (m, 2H), 7.34 (dd, J = 8.9, 5.2 Hz, 1H), 7.27 (td, J = 9.0, 2.8 Hz, 1H), 7.21 (dd, J = 8.1, 2.8 Hz, 1H), 7.14 (td, J = 8.4, 3.0 Hz, 1H), 6.63 (s, 1H), 5.99 (s, 1H), 3.97 (d, J = 12.1 Hz, 1H), 3.50 (d, J = 12.1 Hz, 1H).	558.1	D	





I-2621		O[C@]1(CN(C(=O)Nc2ccc(Cl)c3C(=O)N[C@H](c23)c2cc(F)ccc2Cl)c2ccc(F)cc12)C(F)(F)F	(400 MHz, DMSO-d6) 9.20 (s, 1H), 8.72 (s, 1H), 7.83 (dd, J = 8.9, 4.7 Hz, 1H), 7.58 (d, J = 8.4 Hz, 1H), 7.46 (d, J = 8.4 Hz, 1H), 7.42 - 7.31 (m, 2H), 7.29 - 7.18 (m, 2H), 7.13 (ddd, J = 8.8, 7.9, 3.1 Hz, 1H), 6.64 (s, 1H), 6.03 (s, 1H), 4.17 (d, J = 12.0 Hz, 1H), 3.44 (d, J = 12.0 Hz, 1H).	558.1	C	
I-2622		OC1(CN(C(=O)Nc2cc(F)cc3C(=O)NC(c23)c2cc(F)ccc2Cl)c2ccc(F)cc12)C(F)F	(400 MHz, DMSO-d6) δ 9.25 (br s, 1H), 8.85 (br s, 0.5H), 8.74 (br s, 0.5H), 7.87 (br dd, J = 8.1, 4.1 Hz, 0.5H), 7.80 (dd, J = 8.9, 4.5 Hz, 0.5H), 7.42 - 7.30 (m, 3H), 7.30 - 7.21 (m, 2H), 7.19 (dd, J = 8.8, 2.4 Hz, 1H), 7.16 - 7.08 (m, 1H), 6.72 (br s, 0.5H), 6.66 (br s, 0.5H), 6.27 (td, J = 55.3, 4.5 Hz, 1H), 6.04 (br s, 1H), 4.01 (d, J = 11.4 Hz, 0.5H), 3.79 (d, J = 12.0 Hz, 0.5H), 3.48 (d, J = 11.8 Hz, 0.5H). 1:1 mix of diastereomers	524.0	A	B
I-2623		OC1(CN(C(=O)Nc2cc(F)cc3C(=O)NC(c23)c2cc(F)ccc2Cl)c2ccc(F)cc12)C(F)(F)F		542.0	A	A
I-2624		O[C@]1(CN(C(=O)Nc2cc(CC#N)cc3C(=O)N[C@H](c23)c2cc(F)ccc2Cl)c2ccc(			D	




		F)cc12)C(F)(F)F				
I-2625		O[C@@]1(CN(C(=O)Nc2cc(CC#N)cc3C(=O)N[C@H](c23)c2cc(F)ccc2Cl)c2ccc(F)cc12)C(F)(F)F			D	
I-2626		O[C@]1(CN(C(=O)Nc2cc(CC#N)cc3C(=O)N[C@@H](c23)c2cc(F)ccc2Cl)c2ccc(F)cc12)C(F)(F)F			C	
I-2627		O[C@@]1(CN(C(=O)Nc2cc(CC#N)cc3C(=O)N[C@@H](c23)c2cc(F)ccc2Cl)c2ccc(F)cc12)C(F)(F)F			A	A
I-2628		O[C@]1(CN(C(=O)Nc2cc(F)cc3C(=O)N[C@H](c23)c2cc(F)ccc2Cl)c2ccc(F)cc12)C(F)(F)F			D	




I-2629		O[C@]1(CN(C(=O)Nc2cc(F)cc3C(=O)N[C@@H](c23)c2cc(F)ccc2Cl)c2ccc(F)cc12)C(F)(F)F			D	
I-2630		O[C@@]1(CN(C(=O)Nc2cc(F)cc3C(=O)N[C@H](c23)c2cc(F)ccc2Cl)c2ccc(F)cc12)C(F)(F)F			D	
I-2631		O[C@@]1(CN(C(=O)Nc2cc(F)cc3C(=O)N[C@@H](c23)c2cc(F)ccc2Cl)c2ccc(F)cc12)C(F)(F)F			A	A
I-2632		O[C@]1(CN(C(=O)Nc2cc(F)cc3C(=O)N[C@@H](c23)c2cc(F)ccc2Cl)c2ccc(F)cc12)C(F)(F)F			D	
I-2633		O[C@]1(CN(C(=O)Nc2cc(F)cc3C(=O)N[C@H](c23)c2cc(F)ccc2Cl)c2			D	





		ccc(F)cc 12)C(F)F				
I-2634		O[C@@] 1(CN(C(=O)Nc2c c(F)cc3C (=O)N[C @@H](c 23)c2cc(F)ccc2Cl)c2ccc(F) cc12)C(F)F			D	
I-2635		O[C@@] 1(CN(C(=O)Nc2c c(F)cc3C (=O)N[C @H](c23)c2cc(F)c cc2Cl)c2 ccc(F)cc 12)C(F)F			A	A
I-2636		Cc1cn(cn 1)- c1cc2C(= O)N[C@ @H](c2c (NC(=O) N2C[C@](O)(c3cc (F)ccc23) C(F)(F)F)c1)c1cc(F)ccc1Cl	(400 MHz, DMSO-d6) 9.23 (s, 1H), 8.96 (s, 1H), 8.26 (d, J = 1.5 Hz, 1H), 7.90 (d, J = 14.8 Hz, 1H), 7.82 (d, J = 2.0 Hz, 1H), 7.62 (d, J = 2.0 Hz, 1H), 7.56 (t, J = 1.3 Hz, 1H), 7.44 (s, 1H), 7.34 (dd, J = 8.9, 5.1 Hz, 1H), 7.28 (td, J = 9.0, 2.8 Hz, 1H), 7.22 (dd, J = 8.0, 2.7 Hz, 1H), 7.14 (td, J = 8.4, 3.1 Hz, 1H), 6.77 (d, J = 81.8 Hz, 1H), 6.06 (s, 1H), 3.98 (d, J = 12.1 Hz, 1H), 3.57 (d, J = 11.9 Hz, 1H), 2.19 (d, J = 1.0 Hz, 3H).	604. 1	D	
I-2637		Cc1cn(cn 1)- c1cc2C(= O)N[C@ @H](c2c (NC(=O) N2C[C@ @](O)(c3 cc(F)ccc 23)C(F)(F)F)c1)c	(400 MHz, DMSO-d6) 9.23 (s, 1H), 8.96 (s, 1H), 8.26 (d, J = 1.5 Hz, 1H), 7.90 (d, J = 14.8 Hz, 1H), 7.82 (d, J = 2.0 Hz, 1H), 7.62 (d, J = 2.0 Hz, 1H), 7.56 (t, J = 1.3 Hz, 1H), 7.44 (s, 1H), 7.34 (dd, J = 8.9, 5.1 Hz, 1H), 7.28 (td, J = 9.0, 2.8 Hz, 1H), 7.22	604. 4	A	A




		1cc(F)cc c1Cl	(dd, J = 8.0, 2.7 Hz, 1H), 7.14 (td, J = 8.4, 3.1 Hz, 1H), 6.77 (d, J = 81.8 Hz, 1H), 6.06 (s, 1H), 3.98 (d, J = 12.1 Hz, 1H), 3.57 (d, J = 11.9 Hz, 1H), 2.19 (d, J = 1.0 Hz, 3H).			
I-2638		Cc1cn(cn 1)-c1cc2C(=O)N[C@H](c2c(NC(=O)N2C[C@](O)(c3cc(F)ccc23)C(F)(F)F)c1)c1cc(F)ccc1Cl	(400 MHz, DMSO-d6) 9.23 (s, 1H), 8.96 (s, 1H), 8.26 (d, J = 1.5 Hz, 1H), 7.90 (d, J = 14.8 Hz, 1H), 7.82 (d, J = 2.0 Hz, 1H), 7.62 (d, J = 2.0 Hz, 1H), 7.56 (t, J = 1.3 Hz, 1H), 7.44 (s, 1H), 7.34 (dd, J = 8.9, 5.1 Hz, 1H), 7.28 (td, J = 9.0, 2.8 Hz, 1H), 7.22 (dd, J = 8.0, 2.7 Hz, 1H), 7.14 (td, J = 8.4, 3.1 Hz, 1H), 6.77 (d, J = 81.8 Hz, 1H), 6.06 (s, 1H), 3.98 (d, J = 12.1 Hz, 1H), 3.57 (d, J = 11.9 Hz, 1H), 2.19 (d, J = 1.0 Hz, 3H).	604.1	D	
I-2639		Cc1cn(cn 1)-c1cc2C(=O)N[C@H](c2c(NC(=O)N2C[C@@](O)(c3cc(F)ccc23)C(F)(F)F)c1)c1cc(F)ccc1Cl	(400 MHz, DMSO-d6) 9.23 (s, 1H), 8.96 (s, 1H), 8.26 (d, J = 1.5 Hz, 1H), 7.90 (d, J = 14.8 Hz, 1H), 7.82 (d, J = 2.0 Hz, 1H), 7.62 (d, J = 2.0 Hz, 1H), 7.56 (t, J = 1.3 Hz, 1H), 7.44 (s, 1H), 7.34 (dd, J = 8.9, 5.1 Hz, 1H), 7.28 (td, J = 9.0, 2.8 Hz, 1H), 7.22 (dd, J = 8.0, 2.7 Hz, 1H), 7.14 (td, J = 8.4, 3.1 Hz, 1H), 6.77 (d, J = 81.8 Hz, 1H), 6.06 (s, 1H), 3.98 (d, J = 12.1 Hz, 1H), 3.57 (d, J = 11.9 Hz, 1H), 2.19 (d, J = 1.0 Hz, 3H).	604.4	E	




I-2640		CNc1cc2C(=O)N[C@@H](c2c(NC(=O)N2C[C@](O)(c3cc(F)ccc23)C(F)(F)F)c1)c1cc(F)ccc1Cl	(400 MHz, DMSO-d6) 8.83 (s, 1H), 8.57 (s, 1H), 7.90 (dd, J = 9.1, 4.7 Hz, 1H), 7.35 (s, 1H), 7.31-7.21 (m, 2H), 7.18 (dd, J = 8.1, 2.8 Hz, 1H), 7.09 (td, J = 8.3, 3.1 Hz, 1H), 6.70 (d, J = 2.1 Hz, 1H), 6.58 (d, J = 2.1 Hz, 1H), 6.52 (s, 1H), 6.21-6.05 (m, 1H), 5.87 (s, 1H), 3.98 (d, J = 12.1 Hz, 1H), 3.50 (d, J = 12.0 Hz, 1H), 2.75 (d, J = 4.9 Hz, 3H).	553.1	A	A
I-2641		CNc1cc2C(=O)N[C@@H](c2c(NC(=O)N2C[C@@](O)(c3cc(F)ccc23)C(F)(F)F)c1)c1cc(F)ccc1Cl	(400 MHz, DMSO-d6) 8.85 (s, 1H), 8.49 (s, 1H), 7.84 (dd, J = 9.0, 4.7 Hz, 1H), 7.35-7.27 (m, 2H), 7.26-7.17 (m, 2H), 7.08 (ddd, J = 8.8, 7.8, 3.1 Hz, 1H), 6.68 (dd, J = 17.1, 2.1 Hz, 2H), 6.50 (s, 1H), 6.14 (d, J = 5.2 Hz, 1H), 5.91 (s, 1H), 4.20 (d, J = 12.0 Hz, 1H), 3.41 (d, J = 12.1 Hz, 1H), 2.75 (d, J = 4.9 Hz, 3H).	553.1	C	
I-2642		CNc1cc2C(=O)N[C@H](c2c(NC(=O)N2C[C@](O)(c3cc(F)ccc23)C(F)(F)F)c1)c1cc(F)ccc1Cl	(400 MHz, DMSO-d6) 8.85 (s, 1H), 8.49 (s, 1H), 7.84 (dd, J = 9.0, 4.7 Hz, 1H), 7.35-7.28 (m, 2H), 7.27-7.15 (m, 2H), 7.08 (ddd, J = 8.9, 7.9, 3.2 Hz, 1H), 6.68 (dd, J = 17.1, 2.1 Hz, 2H), 6.51 (s, 1H), 6.13 (d, J = 5.1 Hz, 1H), 5.91 (s, 1H), 4.20 (d, J = 12.1 Hz, 1H), 3.41 (d, J = 12.1 Hz, 1H), 2.75 (d, J = 4.9 Hz, 3H).	553.1	B	
I-2643		CNc1cc2C(=O)N[C@H](c2c(NC(=O)N2C[C@@](O)(c3cc(F)ccc23)C(F)(F)F)c1)	(400 MHz, DMSO-d6) 8.83 (s, 1H), 8.57 (s, 1H), 7.90 (dd, J = 9.1, 4.6 Hz, 1H), 7.35 (s, 1H), 7.31-7.21 (m, 2H), 7.18 (dd, J = 8.1, 2.8 Hz, 1H), 7.09 (td, J = 8.3, 3.1 Hz, 1H), 6.70 (d, J = 2.0 Hz, 1H),	553.1	D	




		c1cc(F)ccc1Cl	6.58 (d, J = 2.1 Hz, 1H), 6.51 (s, 1H), 6.14 (d, J = 5.1 Hz, 1H), 5.87 (s, 1H), 3.98 (d, J = 12.1 Hz, 1H), 3.50 (d, J = 12.1 Hz, 1H), 2.75 (d, J = 4.9 Hz, 3H).			
I-2644		CNc1cc(NC(=O)N2C[C@@](O)(c3cc(F)ccc23)C(F)(F)F)c2[C@H](NC(=O)c2n1)c1cc(F)ccc1Cl	(400 MHz, DMSO-d6) 9.07 - 9.03 (m, 1H), 8.84 (s, 1H), 7.90 (dd, J = 9.0, 4.6 Hz, 1H), 7.38 (s, 1H), 7.34 - 7.23 (m, 2H), 7.19 (dd, J = 8.1, 2.7 Hz, 1H), 7.08 (td, J = 8.4, 3.1 Hz, 1H), 6.96 (d, J = 5.1 Hz, 1H), 6.66 (s, 1H), 6.49 (s, 1H), 5.87 (s, 1H), 3.93 (d, J = 12.1 Hz, 1H), 3.52 (d, J = 12.0 Hz, 1H), 2.86 (d, J = 4.8 Hz, 3H).	554.4	A	A
I-2645		CNc1cc(NC(=O)N2C[C@](O)(c3cc(F)ccc23)C(F)(F)F)c2[C@H](NC(=O)c2n1)c1cc(F)ccc1Cl	(400 MHz, DMSO-d6) 9.06 (s, 1H), 8.74 (s, 1H), 7.85 (dd, J = 9.0, 4.6 Hz, 1H), 7.37 - 7.30 (m, 2H), 7.30 - 7.17 (m, 2H), 7.10 (ddd, J = 8.9, 7.9, 3.1 Hz, 1H), 6.96 (d, J = 4.9 Hz, 1H), 6.66 (s, 1H), 6.59 (s, 1H), 5.89 (s, 1H), 4.11 (d, J = 12.0 Hz, 1H), 3.38 (d, J = 12.0 Hz, 1H), 2.86 (d, J = 4.7 Hz, 3H).	554.4	D	
I-2646		CNc1cc(NC(=O)N2C[C@](O)(c3cc(F)ccc23)C(F)(F)F)c2[C@@H](NC(=O)c2n1)c1cc(F)ccc1Cl	(400 MHz, DMSO-d6) 9.07 (s, 1H), 8.74 (s, 1H), 7.86 (dd, J = 9.0, 4.7 Hz, 1H), 7.37 - 7.30 (m, 2H), 7.26 (td, J = 9.0, 2.8 Hz, 1H), 7.21 (dd, J = 8.0, 2.7 Hz, 1H), 7.10 (td, J = 8.4, 3.1 Hz, 1H), 6.96 (q, J = 4.8 Hz, 1H), 6.66 (s, 1H), 6.59 (s, 1H), 5.89 (s, 1H), 4.11 (d, J = 12.0 Hz, 1H), 3.38 (d, J = 12.0 Hz, 1H), 2.86 (d, J = 4.7 Hz, 3H).	554.1	C	





I-2647		CNc1cc(NC(=O)N2C[C@@](O)(c3cc(F)ccc23)C(F)(F)F)c2[C@@H](NC(=O)c2n1)c1cc(F)ccc1Cl	(400 MHz, DMSO-d6) 9.05 (s, 1H), 8.84 (s, 1H), 7.90 (dd, J = 9.1, 4.7 Hz, 1H), 7.37 (s, 1H), 7.34 - 7.28 (m, 1H), 7.31 - 7.23 (m, 1H), 7.20 (d, J = 8.1 Hz, 1H), 7.08 (td, J = 8.3, 3.1 Hz, 1H), 6.96 (s, 1H), 6.66 (s, 1H), 6.49 (s, 1H), 5.86 (s, 1H), 3.92 (d, J = 12.2 Hz, 1H), 3.52 (d, J = 12.0 Hz, 1H), 2.85 (d, J = 4.7 Hz, 3H).	554.3	B	
I-2648		[2H]C1(NC(=O)c2cccc(NC(=O)N3CC(O)(c4cc(F)ccc34)C(F)(F)F)c12)c1cc(F)ccc1Cl	(400 MHz, DMSO-d6) δ 8.60 (br s, 1H), 8.36 (d, J = 8.1 Hz, 0.5H), 8.19 (d, J = 7.9 Hz, 0.5H), 7.88 (td, J = 10.1, 5.5 Hz, 1H), 7.47 – 7.36 (m, 1H), 7.17 (t, J = 7.9 Hz, 1H), 7.08 (ddd, J = 16.8, 8.5, 2.9 Hz, 1H), 6.98 – 6.80 (m, 3H), 6.70 (br s, 1H), 6.36 (br s, 1H), 3.98 (d, J = 14.0 Hz, 0.5H), 3.77 (d, J = 13.9 Hz, 0.5H), 3.56 (d, J = 12.6 Hz, 0.5H), 3.26 (submerged d, J = 13.6 Hz, 0.5H).	525.0	A	A
I-2649		CC(C)(CN)n1cc(cn1)-c1cc2C(=O)N[C@@H](c2cc(NC(=O)N2C[C@](O)(c3cc(F)ccc23)C(F)(F)F)c1)c1cc(F)ccc1Cl	(400 MHz, DMSO-d6)9.04 (s, 1H), 8.81 (s, 1H), 8.44 (s, 1H), 8.00 (s, 1H), 7.96-7.86 (m, 2H), 7.64-7.56 (m, 1H), 7.41 (s, 1H), 7.33-7.27 (m, 2H), 7.25-7.17 (m, 1H), 7.12 (td, J = 8.4, 3.1 Hz, 1H), 6.80-6.30 (s,1H), 6.01 (s, 1H),4.01 (d, J = 12.1 Hz, 1H), 3.58 (d, J = 12.1 Hz, 1H), 2.89 (s, 2H), 2.00 (s, 1H), 1.52 (s, 6H),1.25(m,1H).	661.2	A	B




I-2650		CC(C)(CN)n1cc(cn1)-c1cc2C(=O)N[C@@H](c2c(NC(=O)N2C[C@@](O)(c3ccc(F)ccc23)C(F)(F)F)c1)c1cc(F)ccc1Cl	(400 MHz, DMSO-d6) 9.04 (s, 1H), 8.81 (s, 1H), 8.44 (s, 1H), 8.00 (s, 1H), 7.96-7.86 (m, 2H), 7.64-7.56 (m, 1H), 7.41 (s, 1H), 7.33-7.27 (m, 2H), 7.25-7.17 (m, 1H), 7.12 (td, J = 8.4, 3.1 Hz, 1H), 6.80-6.30 (s,1H), 6.01 (s, 1H), 4.01 (d, J = 12.1 Hz, 1H),3.58 (d, J = 12.1 Hz, 1H), 2.89 (s, 2H), 2.00 (s, 1H), 1.52 (s, 6H),1.25(m,1H).	661.2	C	
I-2651		CC(C)(CN)n1cc(cn1)-c1cc2C(=O)N[C@H](c2c(NC(=O)N2C[C@](O)(c3cc(F)ccc23)C(F)(F)F)c1)c1cc(F)ccc1Cl	(400 MHz, DMSO-d6)9.04 (s, 1H), 8.81 (s, 1H), 8.44 (s, 1H), 8.00 (s, 1H), 7.96-7.86 (m, 2H), 7.64-7.56 (m, 1H), 7.41 (s, 1H), 7.33-7.27 (m, 2H), 7.25-7.17 (m, 1H), 7.12 (td, J = 8.4, 3.1 Hz, 1H),6.80-6.30(s,1H),6.01 (s, 1H),4.01 (d, J = 12.1 Hz, 1H),3.58 (d, J = 12.1 Hz, 1H), 2.89 (s, 2H), 2.00 (s, 1H), 1.52 (s, 6H),1.25(m,1H).	661.1	D	
I-2652		CC(C)(CN)n1cc(cn1)-c1cc2C(=O)N[C@H](c2c(NC(=O)N2C[C@@](O)(c3cc(F)ccc23)C(F)(F)F)c1)c1cc(F)ccc1Cl	(400 MHz, DMSO-d6)9.04 (s, 1H), 8.81 (s, 1H), 8.44 (s, 1H), 8.00 (s, 1H), 7.96-7.86 (m, 2H), 7.64-7.56 (m, 1H), 7.41 (s, 1H), 7.33-7.27 (m, 2H), 7.25-7.17 (m, 1H), 7.12 (td, J = 8.4, 3.1 Hz, 1H),6.80-6.30(s,1H),6.01 (s, 1H),4.01 (d, J = 12.1 Hz, 1H),3.58 (d, J = 12.1 Hz, 1H), 2.89 (s, 2H), 2.00 (s, 1H), 1.52 (s, 6H),1.25(m,1H).	661.1	D	
I-2653		O[C@@]1(CN(C(=O)Nc2cc(cc3C(=O)N[C@@H](c23)c2cc(F)ccc2Cl)C2	(400 MHz, DMSO-d6) 9.11 (s, 1H), 8.77 (s, 1H), 7.87 (dd, J = 8.9, 4.7 Hz, 1H), 7.63-7.59 (m, 1H), 7.54 (d, J = 1.6 Hz, 1H), 7.41-7.31 (m, 2H), 7.24 (ddd, J = 18.3, 9.2, 2.7 Hz, 2H),	580.1	E	





		COC2)c2ccc(F)cc12)C(F)(F)F	7.12 (td, J = 8.4, 3.1 Hz, 1H), 6.56 (s, 1H), 6.06 (s, 1H), 5.02 (dd, J = 8.3, 6.0 Hz, 2H), 4.67 (dt, J = 11.3, 6.3 Hz, 2H), 4.41 (p, J = 7.4 Hz, 1H), 4.26 (d, J = 12.1 Hz, 1H), 3.41 (d, J = 12.0 Hz, 1H).			
I-2654		O[C@]1(CN(C(=O)Nc2cc(cc3C(=O)N[C@@H](c23)c2cc(F)ccc2Cl)C2COC2)c2ccc(F)cc12)C(F)(F)F	(400 MHz, DMSO-d6) 9.09 (s, 1H), 8.86 (s, 1H), 7.92 (dd, J = 9.0, 4.6 Hz, 1H), 7.61 (d, J = 1.6 Hz, 1H), 7.47 (d, J = 1.6 Hz, 1H), 7.41 (s, 1H), 7.32 (dd, J = 8.9, 5.2 Hz, 1H), 7.28 (td, J = 9.0, 2.8 Hz, 1H), 7.21 (dd, J = 8.0, 2.7 Hz, 1H), 7.13 (td, J = 8.4, 3.1 Hz, 1H), 6.56 (s, 1H), 6.02 (s, 1H), 5.02 (ddd, J = 8.3, 6.0, 1.1 Hz, 2H), 4.66 (dt, J = 10.8, 6.3 Hz, 2H), 4.46-4.35 (m, 1H), 4.02 (d, J = 12.1 Hz, 1H), 3.52 (d, J = 12.0 Hz, 1H).	580.1	D	
I-2655		O[C@@]1(CN(C(=O)Nc2cc(cc3C(=O)N[C@H](c23)c2cc(F)ccc2Cl)C2COC2)c2ccc(F)cc12)C(F)(F)F	(400 MHz, DMSO-d6)9.08 (s, 1H), 8.85 (s, 1H), 7.92 (dd, J = 9.1, 4.6 Hz, 1H), 7.61 (d, J = 1.5 Hz, 1H), 7.47 (d, J = 1.6 Hz, 1H), 7.40 (s, 1H), 7.36-7.18 (m, 3H), 7.12 (td, J = 8.3, 3.1 Hz, 1H), 6.56 (s, 1H), 6.02 (s, 1H), 5.02 (ddd, J = 8.3, 5.9, 1.1 Hz, 2H), 4.66 (dt, J = 10.6, 6.3 Hz, 2H), 4.40 (p, J = 7.2 Hz, 1H), 4.02 (d, J = 12.1 Hz, 1H), 3.53 (d, J = 12.0 Hz, 1H), 1.45-1.20 (m, 1H).	580.1	A	A
I-2656		O[C@]1(CN(C(=O)Nc2cc(cc3C(=O)N[C@H](c23)c2cc(F)ccc2Cl)C2	(400 MHz, DMSO-d6)9.09 (s, 1H), 8.76 (s, 1H), 7.87 (dd, J = 9.0, 4.7 Hz, 1H), 7.61 (d, J = 1.6 Hz, 1H), 7.53 (d, J = 1.5 Hz, 1H), 7.40-7.31 (m, 2H), 7.30-7.21 (m, 1H), 7.25-7.18 (m,	580.1	C	




		COC2)c2ccc(F)cc12)C(F)(F)F	1H), 7.12 (ddd, J = 8.9, 7.9, 3.1 Hz, 1H), 6.56 (s, 1H), 6.06 (s, 1H), 5.02 (dd, J = 8.3, 6.0 Hz, 2H), 4.67 (dt, J = 11.2, 6.3 Hz, 2H), 4.40 (ddd, J = 14.8, 8.4, 6.7 Hz, 1H), 4.26 (d, J = 12.0 Hz, 1H), 3.41 (d, J = 12.1 Hz, 1H).			
I-2657		CC1(Cc2cc3C(=O)N[C@@H](c3c(NC(=O)N3C[C@@](O)(c4cc(F)ccc34)C(F)(F)F)c2)c2cc(F)ccc2Cl)COC1	(400 MHz, DMSO-d6) 9.03 (s, 1H), 8.76 (s, 1H), 7.92 (dd, J = 8.8, 4.6 Hz, 1H), 7.44 - 7.35 (m, 2H), 7.35 - 7.23 (m, 2H), 7.20 (dd, J = 8.7, 2.2 Hz, 2H), 7.12 (td, J = 8.4, 3.1 Hz, 1H), 6.56 (s, 1H), 5.99 (s, 1H), 4.58 (t, J = 5.7 Hz, 2H), 4.24 (dd, J = 5.6, 3.3 Hz, 2H), 4.00 (d, J = 12.1 Hz, 1H), 3.51 (d, J = 12.1 Hz, 1H), 3.14 - 2.92 (m, 2H), 1.24 (s, 3H).	608.4	A	A
I-2658		CC1(Cc2cc3C(=O)N[C@@H](c3c(NC(=O)N3C[C@](O)(c4cc(F)ccc34)C(F)(F)F)c2)c2cc(F)ccc2Cl)COC1	(400 MHz, DMSO-d6) 9.05 (s, 1H), 8.68 (s, 1H), 7.85 (dd, J = 8.9, 4.7 Hz, 1H), 7.41 (d, J = 1.3 Hz, 1H), 7.37 - 7.31 (m, 2H), 7.29 - 7.18 (m, 3H), 7.11 (ddd, J = 8.9, 7.9, 3.1 Hz, 1H), 6.56 (s, 1H), 6.02 (s, 1H), 4.57 (t, J = 5.9 Hz, 2H), 4.33 - 4.02 (m, 3H), 3.41 (d, J = 12.0 Hz, 1H), 3.10 (d, J = 13.4 Hz, 1H), 3.01 (d, J = 13.4 Hz, 1H), 1.24 (s, 3H).	608.4	D	
I-2659		CC1(Cc2cc3C(=O)N[C@H](c3c(NC(=O)N3C[C@@](O)(c4cc(F)ccc34)C(F)(F)F)c2)c2cc(	(400 MHz, DMSO-d6) 9.05 (s, 1H), 8.69 (s, 1H), 7.85 (dd, J = 9.0, 4.7 Hz, 1H), 7.41 (d, J = 1.4 Hz, 1H), 7.38 - 7.30 (m, 2H), 7.30 - 7.17 (m, 3H), 7.11 (td, J = 8.3, 3.1 Hz, 1H), 6.56 (s, 1H), 6.02 (s, 1H), 4.57 (t, J = 5.9 Hz, 2H), 4.28 - 4.10 (m,	608.4	D	




	F)ccc2Cl)COC1	3H), 3.40 (d, J = 12.0 Hz, 1H), 3.10 (d, J = 13.4 Hz, 1H), 3.01 (d, J = 13.4 Hz, 1H), 1.24 (s, 3H).			
I-2660	 CC1(Cc2cc3C(=O)N[C@H](c3c(NC(=O)N3C[C@](O)(c4cc(F)ccc34)C(F)(F)F)c2)c2cc(F)ccc2Cl)COC1	(400 MHz, DMSO-d6) 9.04 (s, 1H), 8.77 (s, 1H), 7.92 (dd, J = 9.0, 4.7 Hz, 1H), 7.40 (d, J = 10.1 Hz, 2H), 7.35 - 7.23 (m, 2H), 7.22 - 7.16 (m, 2H), 7.12 (td, J = 8.4, 3.1 Hz, 1H), 6.95 - 6.14 (m, 1H), 5.98 (s, 1H), 4.58 (t, J = 5.8 Hz, 2H), 4.24 (dd, J = 5.6, 3.4 Hz, 2H), 4.00 (d, J = 12.1 Hz, 1H), 3.51 (d, J = 12.1 Hz, 1H), 3.10 (d, J = 13.5 Hz, 1H), 3.01 (d, J = 13.4 Hz, 1H), 1.24 (s, 3H).	608.1	E	
I-2661	 Cc1nccn1-c1cc2C(=O)N[C@@H](c2c(NC(=O)N2C[C@](O)(c3cc(F)ccc23)C(F)(F)F)c1)c1cc(F)ccc1Cl	(400 MHz, DMSO-d6) 9.28 (s, 1H), 8.99 (s, 1H), 7.92 (t, J = 6.0 Hz, 1H), 7.61 (d, J = 1.9 Hz, 1H), 7.51-7.39 (m, 3H), 7.43-7.32 (m, 1H), 7.29 (td, J = 9.0, 2.7 Hz, 1H), 7.22 (dd, J = 8.1, 2.7 Hz, 1H), 7.15 (td, J = 8.4, 3.1 Hz, 1H), 6.98 (d, J = 1.5 Hz, 1H), 6.74 (s, 2H), 6.11 (s, 1H), 3.99 (d, J = 11.8 Hz, 1H), 3.55 (d, J = 12.0 Hz, 1H), 2.37 (s, 3H).	604.1	A	A
I-2662	 Cc1nccn1-c1cc2C(=O)N[C@@H](c2c(NC(=O)N2C[C@@](O)(c3cc(F)ccc23)C(F)(F)F)c1)c1cc(F)ccc1Cl	(400 MHz, DMSO-d6) 9.29 (s, 1H), 8.89 (s, 1H), 7.86 (dd, J = 9.0, 4.6 Hz, 1H), 7.61 (d, J = 1.9 Hz, 1H), 7.54 (d, J = 1.9 Hz, 1H), 7.43 (d, J = 1.4 Hz, 1H), 7.43-7.34 (m, 2H), 7.31-7.19 (m, 2H), 7.19-7.10 (m, 1H), 6.96 (d, J = 1.4 Hz, 1H), 6.72 (s, 1H), 6.15 (s, 1H), 4.18 (d, J = 12.0 Hz, 1H), 3.46 (d, J =	604.1	D	





			12.0 Hz, 1H), 2.37 (s, 3H).			
I-2663		Cc1nccn1-c1cc2C(=O)N[C@H](c2c(NC(=O)N2C[C@](O)(c3cc(F)ccc23)C(F)(F)F)c1)c1cc(F)ccc1Cl	(400 MHz, DMSO-d6) 9.28 (s, 1H), 8.88 (s, 1H), 7.86 (dd, J = 9.0, 4.7 Hz, 1H), 7.61 (d, J = 1.9 Hz, 1H), 7.54 (d, J = 1.9 Hz, 1H), 7.43 (d, J = 1.5 Hz, 1H), 7.41-7.34 (m, 2H), 7.31-7.19 (m, 2H), 7.15 (td, J = 8.4, 3.1 Hz, 1H), 6.96 (d, J = 1.4 Hz, 1H), 6.14 (s, 1H), 4.18 (d, J = 11.9 Hz, 1H), 3.46 (d, J = 12.0 Hz, 1H), 2.37 (s, 3H).	604.1	D	
I-2664		Cc1nccn1-c1cc2C(=O)N[C@H](c2c(NC(=O)N2C[C@@](O)(c3cc(F)ccc23)C(F)(F)F)c1)c1cc(F)ccc1Cl	(400 MHz, DMSO-d6) 9.28 (s, 1H), 8.99 (s, 1H), 7.93 (dd, J = 8.9, 4.6 Hz, 1H), 7.61 (d, J = 1.9 Hz, 1H), 7.43 (dd, J = 14.4, 1.9 Hz, 3H), 7.41-7.19 (m, 3H), 7.15 (td, J = 8.4, 3.1 Hz, 1H), 6.96 (d, J = 1.4 Hz, 1H), 6.11 (s, 1H), 4.00 (d, J = 12.0 Hz, 1H), 3.55 (d, J = 12.0 Hz, 1H), 2.37 (s, 3H).	604.1	D	
I-2665		O[C@]1(CN(C(=O)Nc2cc(cc3C(=O)N[C@@H](c23)c2cc(F)ccc2Cl)N2CCCC2=O)c2ccc(F)cc12)C(F)(F)F	(400 MHz, DMSO-d6) 9.11 (s, 1H), 8.95 (s, 1H), 7.93 (s, 1H), 7.85 (d, J = 2.0 Hz, 1H), 7.81 (d, J = 2.0 Hz, 1H), 7.40 (s, 1H), 7.36 - 7.24 (m, 2H), 7.21 (d, J = 8.2 Hz, 1H), 7.13 (td, J = 8.3, 3.1 Hz, 1H), 6.54 (s, 1H), 5.99 (s, 1H), 4.09 - 3.85 (m, 3H), 2.56 (d, J = 8.5 Hz, 3H), 2.11 (p, J = 7.5 Hz, 2H).	607.2	A	A
I-2666		O[C@@]1(CN(C(=O)Nc2cc(cc3C(=O)N[C@@H](c23)c2cc(F)ccc2Cl)N2CCCC2=	(400 MHz, DMSO-d6) 9.10 (s, 1H), 8.83 (s, 1H), 7.91 - 7.80 (m, 3H), 7.38 - 7.30 (m, 2H), 7.30 - 7.19 (m, 2H), 7.11 (td, J = 8.3, 3.1 Hz, 1H), 6.54 (s, 1H), 6.01 (s, 1H), 4.29 (d, J = 12.0 Hz, 1H),	607.1	D	






		O)c2ccc(F)cc12)C(F)(F)F	4.01 ¨C 3.86 (m, 2H), 3.32 (s, 1H), 2.57 (t, J = 8.0 Hz, 2H), 2.17 ¨C 2.05 (m, 2H).			
I-2667		O[C@]1(CN(C(=O)Nc2cc(cc3C(=O)N[C@H](c23)c2cc(F)ccc2Cl)N2CCCC2=O)c2ccc(F)cc12)C(F)(F)F	(400 MHz, DMSO-d6) 9.10 (s, 1H), 8.83 (s, 1H), 7.91 - 7.80 (m, 3H), 7.38 - 7.30 (m, 2H), 7.30 - 7.18 (m, 2H), 7.11 (td, J = 8.4, 3.1 Hz, 1H), 6.55 (s, 1H), 6.01 (s, 1H), 4.29 (d, J = 12.1 Hz, 1H), 4.01 - 3.86 (m, 2H), 3.32 (s, 1H), 2.57 (t, J = 8.0 Hz, 2H), 2.17 ¨C 2.05 (m, 2H).	607.2	D	
I-2668		O[C@@]1(CN(C(=O)Nc2cc(cc3C(=O)N[C@H](c23)c2cc(F)ccc2Cl)N2CCCC2=O)c2ccc(F)cc12)C(F)(F)F	(400 MHz, DMSO-d6) 9.09 (s, 1H), 8.93 (s, 1H), 7.93 (s, 1H), 7.83 (dd, J = 18.0, 2.0 Hz, 2H), 7.38 (s, 1H), 7.33 (d, J = 5.2 Hz, 1H), 7.34 - 7.23 (m, 1H), 7.23 - 7.17 (m, 1H), 7.12 (td, J = 8.2, 3.0 Hz, 1H), 6.58 (s, 1H), 5.99 (s, 1H), 4.05 (d, J = 12.3 Hz, 1H), 4.02 - 3.85 (m, 2H), 3.51 - 3.41 (m, 1H), 2.58 (d, J = 8.0 Hz, 2H), 2.11 (dd, J = 14.4, 6.9 Hz, 2H).	607.1	E	
I-2669		O[C@@]1(CN(C(=O)Nc2cc(Cn3cc(cn3)C#N)cc3C(=O)N[C@@H](c23)c2cc(F)ccc2Cl)c2ccc(F)cc12)C(F)(F)F	(400 MHz, DMSO-d6) 9.14 (s, 1H), 8.87 (s, 1H), 8.79 (s, 1H), 8.15 (s, 1H), 7.91 (s, 1H), 7.53 (s, 1H), 7.41 (s, 1H), 7.36 - 7.23 (m, 3H), 7.20 (d, J = 8.2 Hz, 1H), 7.13 (td, J = 8.4, 3.0 Hz, 1H), 6.51 (s, 1H), 6.00 (s, 1H), 5.58 (s, 2H), 4.00 (d, J = 12.0 Hz, 1H), 3.46 (d, J = 12.0 Hz, 1H)	629.2	A	A





I-2670		O[C@]1(CN(C(=O)Nc2cc(Cn3cc(cn3)C#N)cc3C(=O)N[C@@H](c23)c2cc(F)ccc2Cl)c2ccc(F)cc12)C(F)(F)F	(400 MHz, DMSO-d6) 9.15 (s, 1H), 8.78 (d, J = 3.6 Hz, 2H), 8.15 (s, 1H), 7.84 (dd, J = 9.0, 4.7 Hz, 1H), 7.52 (s, 1H), 7.39 (s, 1H), 7.37 - 7.30 (m, 2H), 7.30 - 7.19 (m, 2H), 7.12 (td, J = 8.3, 3.0 Hz, 1H), 6.51 (s, 1H), 6.04 (s, 1H), 5.57 (s, 2H), 4.22 (d, J = 12.0 Hz, 1H), 3.34 (s, 1H).	629.2	C	
I-2671		O[C@@]1(CN(C(=O)Nc2cc(Cn3cc(cn3)C#N)cc3C(=O)N[C@H](c23)c2cc(F)ccc2Cl)c2ccc(F)cc12)C(F)(F)F	(400 MHz, DMSO-d6) 9.15 (s, 1H), 8.78 (d, J = 3.6 Hz, 2H), 8.15 (s, 1H), 7.84 (dd, J = 8.9, 4.7 Hz, 1H), 7.52 (s, 1H), 7.42 - 7.30 (m, 3H), 7.24 (ddd, J = 18.5, 9.3, 2.8 Hz, 2H), 7.12 (td, J = 8.3, 3.1 Hz, 1H), 6.51 (s, 1H), 6.03 (s, 1H), 5.57 (s, 2H), 4.22 (d, J = 12.1 Hz, 1H), 3.37 (s, 1H).	629.2	C	
I-2672		O[C@]1(CN(C(=O)Nc2cc(Cn3cc(cn3)C#N)cc3C(=O)N[C@H](c23)c2cc(F)ccc2Cl)c2ccc(F)cc12)C(F)(F)F	(400 MHz, DMSO-d6) 9.14 (s, 1H), 8.87 (s, 1H), 8.79 (s, 1H), 8.15 (s, 1H), 7.91 (s, 1H), 7.53 (s, 1H), 7.40 (s, 1H), 7.36 - 7.23 (m, 3H), 7.21 (d, J = 8.0 Hz, 1H), 7.13 (td, J = 8.3, 3.0 Hz, 1H), 6.51 (s, 1H), 6.00 (s, 1H), 5.58 (s, 2H), 3.99 (d, J = 12.1 Hz, 1H), 3.46 (d, J = 11.7 Hz, 1H).	629.2	E	
I-2673		O[C@]1(CN(C(=O)Nc2cc(cc3C(=O)N[C@@H](c23)c2cc(F)ccc2Cl)N2CCOC2=O)c2ccc(F)cc12)C(F)(F)F	(400 MHz, DMSO-d6) 9.13 (s, 1H), 8.98 (s, 1H), 7.75 (d, J = 2.1 Hz, 1H), 7.69 (d, J = 2.1 Hz, 1H), 7.40 (s, 1H), 7.36-7.24 (m, 2H), 7.21 (dd, J = 8.0, 2.7 Hz, 1H), 7.13 (td, J = 8.3, 3.1 Hz, 1H), 6.56 (s, 1H), 5.99 (s, 1H), 4.50 (t, J = 8.0 Hz, 2H), 4.17 (dq, J = 27.7, 8.3 Hz, 2H), 4.06 (d, J =	609.4	A	A





			12.2 Hz, 1H), 3.46 (d, J = 12.1 Hz, 1H).			
I-2674		O[C@@]1(CN(C(=O)Nc2cc(cc3C(=O)N[C@@H](c23)c2cc(F)ccc2Cl)N2CCOC2=O)c2ccc(F)cc12)C(F)(F)F	(400 MHz, DMSO-d6) 9.13 (s, 1H), 8.98 (s, 1H), 7.75 (d, J = 2.1 Hz, 1H), 7.69 (d, J = 2.1 Hz, 1H), 7.40 (s, 1H), 7.36-7.24 (m, 2H), 7.21 (dd, J = 8.0, 2.7 Hz, 1H), 7.13 (td, J = 8.3, 3.1 Hz, 1H), 6.56 (s, 1H), 5.99 (s, 1H), 4.50 (t, J = 8.0 Hz, 2H), 4.17 (dq, J = 27.7, 8.3 Hz, 2H), 4.06 (d, J = 12.2 Hz, 1H), 3.46 (d, J = 12.1 Hz, 1H).	609.4	D	
I-2675		O[C@]1(CN(C(=O)Nc2cc(cc3C(=O)N[C@H](c23)c2cc(F)ccc2Cl)N2CCOC2=O)c2ccc(F)cc12)C(F)(F)F	(400 MHz, DMSO-d6) 9.13 (s, 1H), 8.98 (s, 1H), 7.75 (d, J = 2.1 Hz, 1H), 7.69 (d, J = 2.1 Hz, 1H), 7.40 (s, 1H), 7.36-7.24 (m, 2H), 7.21 (dd, J = 8.0, 2.7 Hz, 1H), 7.13 (td, J = 8.3, 3.1 Hz, 1H), 6.56 (s, 1H), 5.99 (s, 1H), 4.50 (t, J = 8.0 Hz, 2H), 4.17 (dq, J = 27.7, 8.3 Hz, 2H), 4.06 (d, J = 12.2 Hz, 1H), 3.46 (d, J = 12.1 Hz, 1H).	609.2	D	
I-2676		O[C@@]1(CN(C(=O)Nc2cc(cc3C(=O)N[C@H](c23)c2cc(F)ccc2Cl)N2CCOC2=O)c2ccc(F)cc12)C(F)(F)F	(400 MHz, DMSO-d6) 9.13 (s, 1H), 8.98 (s, 1H), 7.75 (d, J = 2.1 Hz, 1H), 7.69 (d, J = 2.1 Hz, 1H), 7.40 (s, 1H), 7.36-7.24 (m, 2H), 7.21 (dd, J = 8.0, 2.7 Hz, 1H), 7.13 (td, J = 8.3, 3.1 Hz, 1H), 6.56 (s, 1H), 5.99 (s, 1H), 4.50 (t, J = 8.0 Hz, 2H), 4.17 (dq, J = 27.7, 8.3 Hz, 2H), 4.06 (d, J = 12.2 Hz, 1H), 3.46 (d, J = 12.1 Hz, 1H).	609.2	E	





I-2677		CNc1cc2C(=O)N[C@@H](c2c(NC(=O)N2C[C@](O)(C(F)F)c3cc(F)ccc23)c1)c1cc(F)ccc1Cl	(400 MHz, DMSO-d6) 8.82 (s, 1H), 8.49 (s, 1H), 7.87 (dd, J = 8.9, 4.7 Hz, 1H), 7.29 (dd, J = 8.9, 5.2 Hz, 1H), 7.24 (dd, J = 8.3, 2.8 Hz, 1H), 7.17 (td, J = 9.0, 2.8 Hz, 1H), 7.08 (td, J = 8.3, 3.1 Hz, 1H), 6.69 (d, J = 2.1 Hz, 1H), 6.65 (s, 1H), 6.59 (d, J = 2.1 Hz, 1H), 6.45 (d, J = 47.5 Hz, 1H), 6.25 (s, 1H), 6.15 - 6.07 (m, 1H), 5.89 (s, 1H), 3.87 - 3.79 (m, 1H), 3.46 (d, J = 11.7 Hz, 1H), 2.75 (d, J = 5.0 Hz, 3H).	535.1	A	A
I-2678		CNc1cc2C(=O)N[C@H](c2c(NC(=O)N2C[C@](O)(C(F)F)c3cc(F)ccc23)c1)c1cc(F)ccc1Cl	(400 MHz, DMSO-d6) 8.84 (s, 1H), 8.40 (s, 1H), 7.80 (dd, J = 9.0, 4.7 Hz, 1H), 7.32 (dd, J = 8.9, 5.2 Hz, 1H), 7.22 (dd, J = 8.2, 2.8 Hz, 1H), 7.15 (td, J = 9.1, 2.8 Hz, 1H), 7.08 (td, J = 8.3, 3.1 Hz, 1H), 6.70 - 6.64 (m, 2H), 6.60 (s, 1H), 6.45 (d, J = 47.1 Hz, 1H), 6.25 (s, 1H), 6.16 - 6.08 (m, 1H), 5.93 (s, 1H), 4.09 (d, J = 11.7 Hz, 1H), 3.30 (d, J = 3.6 Hz, 1H), 2.75 (d, J = 4.9 Hz, 3H).	535.1	D	
I-2679		CNc1cc2C(=O)N[C@@H](c2c(NC(=O)N2C[C@@](O)(C(F)F)c3cc(F)ccc23)c1)c1cc(F)ccc1Cl	(400 MHz, DMSO-d6) 8.84 (s, 1H), 8.40 (s, 1H), 7.80 (dd, J = 9.0, 4.7 Hz, 1H), 7.32 (dd, J = 8.8, 5.1 Hz, 1H), 7.22 (dd, J = 8.3, 2.8 Hz, 1H), 7.15 (td, J = 9.0, 2.8 Hz, 1H), 7.08 (td, J = 8.4, 3.1 Hz, 1H), 6.71 - 6.64 (m, 2H), 6.60 (s, 1H), 6.39 (s, 1H), 6.25 (s, 1H), 6.15 - 6.05 (m, 1H), 5.93 (s, 1H), 4.09 (d, J = 11.7 Hz, 1H), 3.29 (s, 1H), 2.75 (d, J = 5.0 Hz, 3H).	535.1	E	





I-2680		CNc1cc2C(=O)N[C@H](c2c(NC(=O)N2C[C@@](O)(C(F)F)c3cc(F)ccc23)c1)c1cc(F)ccc1Cl	(400 MHz, DMSO-d6) 8.82 (s, 1H), 8.49 (s, 1H), 7.87 (dd, J = 8.9, 4.7 Hz, 1H), 7.29 (dd, J = 8.9, 5.1 Hz, 1H), 7.23 (dd, J = 8.2, 2.8 Hz, 1H), 7.17 (td, J = 9.1, 2.8 Hz, 1H), 7.08 (td, J = 8.4, 3.1 Hz, 1H), 6.69 (d, J = 2.1 Hz, 1H), 6.65 (s, 1H), 6.59 (d, J = 2.1 Hz, 1H), 6.45 (d, J = 46.0 Hz, 1H), 6.25 (s, 1H), 6.12 (d, J = 5.6 Hz, 1H), 5.89 (s, 1H), 3.83 (d, J = 11.8 Hz, 1H), 3.46 (d, J = 11.8 Hz, 1H), 2.75 (d, J = 4.9 Hz, 3H).	535.2	E	
I-2681		[2H][C@]1(NC(=O)c2cccc(NC(=O)N3C[C@@](O)(c4cc(F)ccc34)C(F)(F)F)c12)c1cc(F)ccc1Cl			D	
I-2682		[2H][C@]1(NC(=O)c2cccc(NC(=O)N3C[C@](O)(c4cc(F)ccc34)C(F)(F)F)c12)c1cc(F)ccc1Cl			A	A
I-2683		[2H][C@@]1(NC(=O)c2cccc(NC(=O)N3C[C@](O)(c4cc(F)ccc34)C(F)(F)F)c12)c1cc(F)ccc1Cl			D	




I-2684		[2H][C@@]1(NC(=O)c2cccc(NC(=O)N3C[C@@](O)(c4cc(F)ccc34)C(F)(F)F)c12)c1cc(F)ccc1Cl			E	
I-2685		O[C@]1(CN(C(=O)Nc2cccc3C(=O)N[C@H](c23)c2ccccc2Cl)c2ccc(F)cc12)C(F)(F)F			E	
I-2686		O[C@@]1(CN(C(=O)Nc2cccc3C(=O)N[C@H](c23)c2ccccc2Cl)c2ccc(F)cc12)C(F)(F)F			E	
I-2687		O[C@@]1(CN(C(=O)Nc2cccc3C(=O)N[C@@H](c23)c2ccccc2Cl)c2ccc(F)cc12)C(F)(F)F			D	
I-2688		O[C@]1(CN(C(=O)Nc2cccc3C(=O)N[C@@H](c23)c2ccccc2Cl)c2ccc(F)cc12)C(F)(F)F			A	A

I-2689		OC1(CN(C(=O)Nc2cccc3C(=O)NC(c23)c2ccccc2Cl)c2ccc(F)cc12)C(F)(F)F	(400 MHz, DMSO-d6) δ 9.06 (br s, 1H), 8.75 (s, 0.5H), 8.66 (s, 0.5H), 7.90 (dd, J = 8.7, 4.7 Hz, 0.5H), 7.85 (dd, J = 8.4, 4.5 Hz, 0.5H), 7.59 (t, J = 7.0 Hz, 1H), 7.55 (d, J = 7.4 Hz, 1H), 7.48 – 7.34 (m, 2H), 7.32 – 7.17 (m, 5H), 7.17 – 7.05 (m, 1H), 6.09 (br s, 1H), 4.17 (d, J = 11.9 Hz, 0.5H), 3.97 (d, J = 12.1 Hz, 0.5H), 3.43 (d, J = 11.5 Hz, 0.5H), 3.31 (submerged d, 0.5H). 1:1 mix of diastereomers.	506.0		
I-2690		CN(C)c1cc(NC(=O)N2C[C@@](O)(c3cc(F)ccc23)C(F)(F)F)c2[C@@H](NC(=O)c2n1)c1cc(F)ccc1Cl	(400 MHz, DMSO-d6) 9.13 (s, 1H), 8.98 (s, 1H), 7.90 (dd, J = 9.1, 4.7 Hz, 1H), 7.41 (s, 1H), 7.34- 7.24 (m, 2H), 7.20 (dd, J = 8.1, 2.7 Hz, 1H), 7.08 (td, J = 8.3, 3.1 Hz, 1H), 6.60 (s, 2H), 5.90 (s, 1H), 3.98 (d, J = 12.1 Hz, 1H), 3.52 (d, J = 12.1 Hz, 1H), 3.11 (s, 6H).	568.4	A	A
I-2691		CN(C)c1cc(NC(=O)N2C[C@](O)(c3cc(F)ccc23)C(F)(F)F)c2[C@@H](NC(=O)c2n1)c1cc(F)ccc1Cl	(400 MHz, DMSO-d6) 9.14 (s, 1H), 8.89 (s, 1H), 7.88 (dd, J = 9.0, 4.6 Hz, 1H), 7.36 (s, 1H), 7.33 (dd, J = 8.8, 5.1 Hz, 2H), 7.32 - 7.18 (m, 2H), 7.10 (ddd, J = 8.9, 7.8, 3.1 Hz, 1H), 6.68 (s, 1H), 5.91 (s, 1H), 4.21 (d, J = 12.1 Hz, 2H), 3.12 (s, 6H).	568.4	D	
I-2692		CN(C)c1cc(NC(=O)N2C[C@@](O)(c3cc(F)ccc23)C(F)(F)F)c2[C@H](NC(=O)c2n1)c1cc	(400 MHz, DMSO-d6) 9.14 (s, 1H), 8.90 (s, 1H), 7.88 (dd, J = 9.1, 4.6 Hz, 1H), 7.37 (s, 1H), 7.33 (dd, J = 8.8, 5.2 Hz, 1H), 7.26 (ddd, J = 16.8, 8.4, 2.8 Hz, 2H), 7.21 (d, J = 2.8 Hz, 1H), 7.10 (td, J = 8.3, 3.1 Hz, 1H), 6.74	568.4	E	

		(F)ccc1Cl	(s, 1H), 6.68 (s, 1H), 5.92 (s, 1H), 4.21 (d, J = 12.1 Hz, 1H), 3.12 (s, 6H).			
I-2693		CN(C)c1cc(NC(=O)N2C[C@](O)(c3cc(F)ccc23)C(F)(F)F)c2[C@H](NC(=O)c2n1)c1cc(F)ccc1Cl	(400 MHz, DMSO-d6) 9.13 (s, 1H), 8.98 (s, 1H), 7.89 (dd, J = 9.1, 4.7 Hz, 1H), 7.40 (s, 1H), 7.34 - 7.24 (m, 2H), 7.20 (dd, J = 8.1, 2.7 Hz, 1H), 7.07 (ddd, J = 8.8, 7.9, 3.1 Hz, 1H), 6.60 (s, 2H), 5.90 (s, 1H), 3.97 (d, J = 12.0 Hz, 1H), 3.52 (d, J = 12.0 Hz, 1H), 3.11 (s, 6H).	568.0	E	
I-2694		NCc1cc2C(=O)N[C@@H](c2c(NC(=O)N2C[C@@](O)(C(F)F)c3cc(F)ccc23)c1)c1cc(F)ccc1Cl		533.3	A	B
I-2695		NCc1cc2C(=O)N[C@@H](c2c(NC(=O)N2C[C@](O)(C(F)F)c3cc(F)ccc23)c1)c1cc(F)ccc1Cl		533.3	D	
I-2696		NCc1cc2C(=O)N[C@H](c2c(NC(=O)N2C[C@@](O)(C(F)F)c3cc(F)ccc23)c1)c1cc(F)ccc1Cl		533.3	D	

I-2697		NCc1cc2C(=O)N[C@H](c2c(NC(=O)N2C[C@](O)(C(F)F)c3cc(F)ccc23)c1)c1cc(F)ccc1Cl		533.3	D	
I-2698		O[C@]1(CN(C(=O)Nc2ccnc3C(=O)N[C@@H](c23)c2cc(F)ccc2Cl)c2ccc(F)cc12)C(F)(F)F	(400 MHz, DMSO-d6)9.41 (s, 1H), 9.27 (s, 1H), 8.68 (s, 1H), 7.92 (d, J = 6.8 Hz, 1H), 7.42 (s, 2H), 7.34 - 7.29 (m, 2H), 7.21 (d, J = 7.5 Hz, 1H), 7.11 (td, J = 8.4, 3.1 Hz, 1H), 6.73 (s, 1H), 6.02 (s, 1H), 3.98 (s, 1H), 3.54 (d, J = 12.2 Hz, 1H).	525.0	A	B
I-2699		O[C@@]1(CN(C(=O)Nc2ccnc3C(=O)N[C@@H](c23)c2cc(F)ccc2Cl)c2ccc(F)cc12)C(F)(F)F	(400 MHz, DMSO-d6) 9.42 (s, 1H), 9.17 (s, 1H), 8.70 (s, 1H), 7.88 (dd, J = 9.2, 4.5 Hz, 1H), 7.49 (d, J = 5.4 Hz, 1H), 7.40-7.32 (m, 2H), 7.28 (t, J = 8.9 Hz, 1H), 7.23 (d, J = 7.8 Hz, 1H), 7.12 (td, J = 8.9, 8.5, 3.1 Hz, 1H), 6.79 (s, 1H), 6.04 (s, 1H), 4.17 (d, J = 12.1 Hz, 1H), 3.37 (d, J = 11.9 Hz, 1H).	525.0	D	
I-2700		O[C@]1(CN(C(=O)Nc2ccnc3C(=O)N[C@H](c23)c2cc(F)ccc2Cl)c2ccc(F)cc12)C(F)(F)F	(400 MHz, DMSO-d6) 9.42 (s, 1H), 9.18 (s, 1H), 8.70 (d, J = 5.4 Hz, 1H), 7.88 (dd, J = 9.1, 4.6 Hz, 1H), 7.49 (d, J = 5.4 Hz, 1H), 7.40-7.20 (m, 4H), 7.12 (td, J = 8.4, 3.1 Hz, 1H), 6.82 (s, 1H), 6.05 (s, 1H), 4.18 (d, J = 12.1 Hz, 1H), 3.37 (d, J = 12.1 Hz, 1H).	525.0	D	

I-2701		O[C@@]1(CN(C(=O)Nc2ccnc3C(=O)N[C@H](c23)c2cc(F)ccc2Cl)c2ccc(F)cc12)C(F)(F)F	(400 MHz, DMSO-d6) 9.42 (s, 1H),9.27 (s, 1H), 8.70 (d, J = 5.3 Hz,1H),7.92 (s, 1H),7.50-7.40 (m,1H),7.40-7.37 (m, 1H),7.37-7.26 (m, 2H),7.22 (d, J = 8.4 Hz, 1H), 7.10 (td, J = 8.4, 3.0 Hz, 1H), 6.81 (s, 1H), 6.03 (s, 1H), 4.00 (d, J = 12.1 Hz, 1H), 3.52 (d, J = 12.0 Hz, 1H).	524.9	D	
I-2702		O[C@@]1(CN(C(=O)Nc2cc(Cl)nc3C(=O)N[C@@H](c23)c2cc(F)ccc2Cl)c2ccc(F)cc12)C(F)(F)F	(400 MHz, DMSO-d6) 9.57 (s, 1H), 9.34 (s, 1H), 7.88 (s, 1H), 7.63 (s, 1H), 7.38 (s, 2H), 7.28 (s, 1H), 7.22 (s, 1H), 7.14 (td, J = 8.4, 3.1 Hz, 1H), 7.01- 6.03 (s, 1H), 6.04 (s, 1H), 4.06 (s, 1H), 3.45 (s, 1H).	559.1	D	
I-2703		O[C@]1(CN(C(=O)Nc2cc(Cl)nc3C(=O)N[C@@H](c23)c2cc(F)ccc2Cl)c2ccc(F)cc12)C(F)(F)F	(400 MHz, DMSO-d6) 9.58 (s, 1H), 9.43 (s, 1H), 7.90 (s, 1H), 7.51 (s, 1H), 7.46 (s, 1H), 7.33 (s, 2H), 7.22 (s, 1H), 7.11 (t, J = 7.8 Hz, 1H), 6.27 (s, 2H), 3.90 (s, 1H), 3.58 (s, 1H).	559.1	A	A
I-2704		O[C@@]1(CN(C(=O)Nc2cc(Cl)nc3C(=O)N[C@H](c23)c2cc(F)ccc2Cl)c2ccc(F)cc12)C(F)(F)F		559.1	A	A

I-2705		O[C@]1(CN(C(=O)Nc2cc(Cl)nc3C(=O)N[C@H](c23)c2cc(F)ccc2Cl)c2ccc(F)cc12)C(F)(F)F		559.1	D	
I-2706		Fc1cccc(c1)C1NC(=O)c2cc(cc(NC(=O)c3cc(F)cc(c3)C(F)(F)F)c12)-c1ccc2ncnn2c1C#N				
I-2707		NC(=O)c1c(ccc2ncnn12)-c1cc2C(=O)NC(c2c(NC(=O)c2cc(F)cc(c2)C(F)(F)F)c1)c1cc(F)ccc1Cl				

[0603] In chemical structures in Table 1, above, and the Examples, below, stereogenic centers are described according to the Enhanced Stereo Representation format (MDL/Biovia, e.g. using labels “or1”, “or2”, “abs”, “and1”). (See, for example, the structures of Compounds I-1, I-2, I-4, I-5, I-292, and I-293.)

[0604] In some embodiments, the present invention provides a compound in Table 1, above, wherein the compound is denoted as having an ADP-Glo IC_{50} of “A”. In some embodiments, the present invention provides a compound in Table 1, above, wherein the compound is denoted as having an ADP-Glo IC_{50} of “A” or “B”. In some embodiments, the present invention provides a compound in Table 1, above, wherein the compound is denoted as having an ADP-Glo IC_{50} of “A” or “B” or “C”. In some embodiments, the present invention provides a compound in Table 1, above, wherein the compound is denoted as having an ADP-Glo IC_{50} of “A” or “B” or “C” or “D”.

[0605] In some embodiments, the present invention provides a compound in Table 1, above, wherein the compound is denoted as having an MCF10A IC_{50} of "A". In some embodiments, the present invention provides a compound in Table 1, above, wherein the compound is denoted as having an MCF10A IC_{50} of "A" or "B". In some embodiments, the present invention provides a compound in Table 1, above, wherein the compound is denoted as having an MCF10A IC_{50} of "A" or "B" or "C". In some embodiments, the present invention provides a compound in Table 1, above, wherein the compound is denoted as having an MCF10A IC_{50} of "A" or "B" or "C" or "D".

[0606] In some embodiments, the present invention comprises a compound of formula I selected from those depicted in Table 1, above, or a pharmaceutically acceptable salt, stereoisomer, or mixture of stereoisomers thereof. In some embodiments, the present invention provides a compound of formula I selected from those depicted in Table 1, above, or a pharmaceutically acceptable salt thereof. In some embodiments, the present invention provides a compound of formula I selected from those depicted in Table 1, above.

[0607] In some embodiments, the present invention comprises a compound of formula II selected from those depicted in Table 1, above, or a pharmaceutically acceptable salt, stereoisomer, or mixture of stereoisomers thereof. In some embodiments, the present invention provides a compound of formula II selected from those depicted in Table 1, above, or a pharmaceutically acceptable salt thereof. In some embodiments, the present invention provides a compound of formula II selected from those depicted in Table 1, above.

[0608] In some embodiments, the present invention comprises a compound of formula III selected from those depicted in Table 1, above, or a pharmaceutically acceptable salt, stereoisomer, or mixture of stereoisomers thereof. In some embodiments, the present invention provides a compound of formula III selected from those depicted in Table 1, above, or a pharmaceutically acceptable salt thereof. In some embodiments, the present invention provides a compound of formula III selected from those depicted in Table 1, above.

[0609] In some embodiments, the present invention comprises a compound of formula IV selected from those depicted in Table 1, above, or a pharmaceutically acceptable salt, stereoisomer, or mixture of stereoisomers thereof. In some embodiments, the present invention provides a compound of formula IV selected from those depicted in Table 1, above, or a pharmaceutically acceptable salt thereof. In some embodiments, the present invention provides a compound of formula IV selected from those depicted in Table 1, above.

[0610] In some embodiments, the present invention comprises a compound of formula V, VI, VII, VIII, IX, X, XI, XII, XIII, XIV, XV, XVI, XVII, XVIII, XIX, XX, XXI, XXII, XXIII, XXIV, XXV, XXVI, XXVII, XXVIII, XXIX, XXX, XXXI, XXXII, XXXIII, XXXIV, XXXV, XXXVI, XXXVII, XXXVIII, XXXIX, or XXXX, selected from those depicted in Table 1, above, or a pharmaceutically acceptable salt, stereoisomer, or mixture of stereoisomers thereof. In some embodiments, the present invention provides a compound of formula V, VI, VII, VIII, IX, X, XI, XII, XIII, XIV, XV, XVI, XVII, XVIII, XIX, XX, XXI, XXII, XXIII, XXIV, XXV, XXVI, XXVII, XXVIII, XXIX, XXX, XXXI, XXXII, XXXIII, XXXIV, XXXV, XXXVI, XXXVII, XXXVIII, XXXIX, or XXXX, selected from those depicted in Table 1, above, or a pharmaceutically acceptable salt thereof. In some embodiments, the present invention provides a compound of formula V, VI, VII, VIII, IX, X, XI, XII, XIII, XIV, XV, XVI, XVII, XVIII, XIX, XX, XXI, XXII, XXIII, XXIV, XXV, XXVI, XXVII, XXVIII, XXIX, XXX, XXXI, XXXII, XXXIII, XXXIV, XXXV, XXXVI, XXXVII, XXXVIII, XXXIX, or XXXX, selected from those depicted in Table 1, above.


4. General Methods of Providing the Present Compounds

[0611] The compounds of this invention may be prepared or isolated, in general, by synthetic and/or semi-synthetic methods known to those skilled in the art, methods illustrated in the following Schemes, and by methods described in detail in the Examples, below. The scope of the disclosure is not to be construed as limited to specific embodiments disclosed in these Schemes, however, which are illustrative only. At least some of the compounds identified herein as "Intermediates", e.g. compounds with numbers preceded by "Int-", are contemplated as compounds of the disclosure.

[0612] In the Schemes, it is understood by one skilled in the art of organic synthesis that the functionality present on various portions of the molecule should be compatible with the reagents and reactions proposed. Substituents not compatible with the reaction conditions will be apparent to one skilled in the art, and alternate methods are therefore indicated (for example, use of protecting groups or alternative reactions). Protecting group chemistry and strategy is well known in the art, for example, as described in detail in "Protecting Groups in Organic Synthesis", T. W. Greene and P. G. M. Wuts, 3rd edition, John Wiley & Sons, 1999, the entire contents of which are hereby incorporated by reference. The starting materials for the Schemes are either commercially available or are readily prepared by one skilled in the art of organic synthesis from known materials using standard methods.

[0613] General principles of organic chemistry and synthesis, well known in the art, are described in, for example, "Organic Chemistry", Thomas Sorrell, University Science Books, Sausalito: 1999; "March's Advanced Organic Chemistry", 5th Ed., Ed.: Smith, M.B. and March, J., John Wiley & Sons, New York: 2001; and "Comprehensive Organic Synthesis", 2nd Ed., Ed.: Knochel, P. and Molander, G.A., Elsevier, Amsterdam: 2014; the entire contents of each of which are hereby incorporated by reference. For example, certain embodiments below refer to leaving groups. Suitable leaving groups are well known in the art, as described in, for example, the preceding references. Such leaving groups include, but are not limited to, halogen, alkoxy, sulphonyloxy, optionally substituted alkylsulphonyloxy, optionally substituted alkenylsulfonyloxy, optionally substituted arylsulfonyloxy, and diazonium moieties. Examples of suitable leaving groups include chloro, iodo, bromo, fluoro, methanesulfonyl (mesyl), tosyl, triflate, nitro-phenylsulfonyl (nosyl), and bromo-phenylsulfonyl (brosyl).

Scheme 1



[0614] In some embodiments, compounds of formula A (i.e. compounds of formula I, wherein Q is CH, and R^2 is -N(H)C(O)-R^{2A}) are prepared according to the general procedure depicted in Scheme 1, above. In some embodiments, Step 1 comprises the condensation of Int-1 with a primary amine of formula PG-NH_2, thereby forming a compound of formula Int-

2, wherein X, Y, and Z are as defined in embodiments herein, LG^1 and LG^2 are leaving groups, and PG is a protecting group. In some embodiments, LG^1 and LG^2 taken together are -O- (i.e. Int-1 is a bicyclic anhydride). In some embodiments, LG^1 and LG^2 are Cl. In some embodiments, PG is *p*-methoxybenzyl (PMB). In some embodiments, PG is 2,4-dimethoxybenzyl (DMB).

[0615] In some embodiments, Step 2 comprises the reduction of a compound of formula Int-2, thereby forming a compound of formula Int-3, wherein X, Y, and Z are as defined in embodiments herein and PG is a protecting group. In some embodiments, the reduction is conducted with iron and ammonium chloride.

[0616] In some embodiments, Step 3 comprises the nucleophilic addition of an organometallic reagent of formula R^1-M with Int-3, thereby forming a compound of formula Int-4, wherein X, Y, Z, and R^1 are as defined in embodiments herein and PG is a protecting group. In some embodiments, the organometallic reagent of formula R^1-M is a Grignard reagent of formula R^1-MgBr or R^1-MgCl. In some embodiments, the organometallic reagent of formula R^1-M is a Grignard reagent of formula R^1-MgBr. In some embodiments, the R^1 is phenyl substituted with r^1 instances of R^{1C}.

[0617] In some embodiments, Step 4 comprises the reduction of a compound of formula Int-4, thereby forming a compound of formula Int-5, wherein X, Y, Z, and R^1 are as defined in embodiments herein and PG is a protecting group. In some embodiments, the reduction is conducted with a silane and acid. In some embodiments, the reduction is conducted with a trialkylsilane and trifluoroacetic acid.

[0618] In some embodiments, Step 5 comprises the coupling of Int-5 with a reagent comprising R^{2A}, thereby forming a compound of formula Int-6, wherein X, Y, Z, R^1, and R^{2A} are as defined in embodiments herein and PG is a protecting group.

[0619] In some embodiments, the reagent comprising R^{2A} is a compound of formula R^{2A}-C(O)Cl. In some embodiments, the reagent comprising R^{2A} is a compound of formula R^{2A}-C(O)OH, and Step 5 further comprises an amide-coupling reagent. In some embodiments, the amide-coupling reagent is 1-[bis(dimethylamino)methylene]-1*H*-1,2,3-triazolo[4,5-*b*]pyridinium 3-oxid hexafluorophosphate (HATU) or tetramethylchloroformamidinium hexafluorophosphate (TCFH) and *N*-methylimidazole (NMI). In some embodiments, the amide-coupling reagent is tetramethylchloroformamidinium hexafluorophosphate (TCFH) and *N*-methylimidazole (NMI). In some embodiments, the amide-coupling reagent is 1-


[bis(dimethylamino)methylene]-1*H*-1,2,3-triazolo[4,5-*b*]pyridinium 3-oxid hexafluorophosphate (HATU).

[0620] In some embodiments, the reagent comprising R^{2A} comprises a primary or secondary amine, and Step 5 further comprises a carbonyl-equivalent reagent. In some embodiments, the carbonyl-equivalent reagent is triphosgene.

[0621] In some embodiments, Step 6 comprises the deprotection of a compound of formula Int-6, thereby forming a compound of formula A, wherein X, Y, Z, R^1, and R^{2A} are as defined in embodiments herein. In some embodiments, the deprotection is conducted with an acid. In some embodiments, the deprotection is conducted with trifluoroacetic acid. In some embodiments, the deprotection is conducted with trifluoroacetic acid and trifluoromethanesulfonic acid. In some embodiments, the deprotection is conducted with an oxidant. In some embodiments, the deprotection is conducted with cerium (IV) ammonium nitrate.

[0622] In some embodiments, the order of performing Step 5 and Step 6 is reversed.

Scheme 2



[0623] In some embodiments, compounds of formula Int-5 are prepared according to the general procedure depicted in Scheme 2, above. In some embodiments, Step 1 comprises the Ugi reaction condensation of Int-26 with an aldehyde of formula R^1-CHO, a primary amine of formula PG-NH_2, and *t*-butyl isocyanide, thereby forming a compound of formula Int-7, wherein R^1, X, Y, and Z are as defined in embodiments herein, LG is a leaving group, and PG is a protecting group. In some embodiments, LG is a halogen. In some embodiments,


LG is F. In some embodiments, LG is Cl. In some embodiments, PG is *p*-methoxybenzyl (PMB). In some embodiments, PG is 2,4-dimethoxybenzyl (DMB).

[0624] In some embodiments, Step 2 comprises the cyclization of a compound of formula Int-7, thereby forming a compound of formula Int-8, wherein R^1, X, Y, and Z are as defined in embodiments herein and PG is a protecting group. In some embodiments, the cyclization is conducted with a base. In some embodiments, the cyclization is conducted with an organic base. In some embodiments, the cyclization is conducted with 2-(*t*-butyl)-1,1,3,3-tetramethylguanidine. In some embodiments, the cyclization is conducted with an inorganic base. In some embodiments, the cyclization is conducted with potassium carbonate. In some embodiments, the cyclization is catalyzed by a phase-transfer reagent. In some embodiments, the cyclization is catalyzed by a tetraalkylammonium phase-transfer reagent.

[0625] In some embodiments, Step 3 comprises the reduction of a compound of formula Int-8, thereby forming a compound of formula Int-9, wherein R^1, X, Y, and Z are as defined in embodiments herein and PG is a protecting group. In some embodiments, the reduction is conducted with a silane and acid. In some embodiments, the reduction is conducted with a trialkylsilane and trifluoroacetic acid.

[0626] In some embodiments, Step 4 comprises the reduction of a compound of formula Int-9, thereby forming a compound of formula Int-5, wherein R^1, X, Y, and Z are as defined in embodiments herein and PG is a protecting group. In some embodiments, the reduction is conducted with iron and ammonium chloride.

Scheme 3



[0627] In some embodiments, compounds of formula A (i.e. compounds of formula I, wherein Q is CH, and R^2 is -N(H)C(O)-R^{2A}) are prepared according to the general procedure depicted in Scheme 4, above. In some embodiments, Step 1 comprises the reduction of a compound of formula Int-10, thereby forming a compound of formula Int-11, wherein X, Y, and Z, are as defined in embodiments herein. In some embodiments, the reduction is conducted with a metal hydride. In some embodiments, the reduction is conducted with sodium borohydride.

[0628] In some embodiments, Step 2 comprises the reduction of a compound of formula Int-11, thereby forming a compound of formula Int-12, wherein X, Y, and Z are as defined in embodiments herein. In some embodiments, the reduction is conducted with iron and ammonium chloride.

[0629] In some embodiments, Step 3 comprises the activation of a compound of formula Int-12, thereby forming a compound of formula Int-13, wherein X, Y, and Z are as defined in embodiments herein and LG is a leaving group. In some embodiments, the activation is an alcoholysis reaction. In some embodiments, the leaving group is an alkoxy group. In some embodiments, the activation is a methanolysis. In some embodiments, the leaving group is a methoxy group.


[0630] In some embodiments, Step 4 comprises the nucleophilic addition of an organometallic reagent of formula R^1-M with Int-13, thereby forming a compound of formula Int-14, wherein X, Y, Z, and R^1 are as defined in embodiments herein. In some embodiments, the organometallic reagent of formula R^1-M is a Grignard reagent of formula R^1-MgBr or R^1-MgCl.

[0631] In some embodiments, Step 5 comprises the coupling of Int-14 with a reagent comprising R^{2A}, thereby forming a compound of formula A, wherein X, Y, Z, R^1, and R^{2A} are as defined in embodiments herein.

[0632] In some embodiments, the reagent comprising R^{2A} is a compound of formula R^{2A}-C(O)Cl. In some embodiments, the reagent comprising R^{2A} is a compound of formula R^{2A}-C(O)OH, and Step 5 further comprises an amide-coupling reagent. In some embodiments, the amide-coupling reagent is tetramethylchloroformamidinium hexafluorophosphate (TCFH) and *N*-methylimidazole (NMI) or 1-[bis(dimethylamino)methylene]-1*H*-1,2,3-triazolo[4,5-*b*]pyridinium 3-oxid hexafluorophosphate (HATU).

[0633] In some embodiments, the reagent comprising R^{2A} comprises a primary or secondary amine, and Step 5 further comprises a carbonyl-equivalent reagent. In some embodiments, the carbonyl-equivalent reagent is triphosgene.

Scheme 4



[0634] In some embodiments, compounds of formula Int-5 or Int-6 are prepared according to the general procedure depicted in Scheme 4, above. In some embodiments, Step 1 comprises the coupling of Int-15 with a primary amine of formula PG-NH_2, thereby forming a compound of formula Int-16, wherein X, Y, and Z are as defined in embodiments herein, LG^1 is a leaving group, and PG is a protecting group. In some embodiments, one or more of X, Y, or Z is nitrogen. In some embodiments, X is nitrogen. In some embodiments, Z is nitrogen. In some embodiments, LG^1 is a halogen. In some embodiments, LG^1 is Cl. In some embodiments, PG is 2,4-dimethoxybenzyl (DMB). In some embodiments, PG is *p*-methoxybenzyl (PMB).

[0635] In some embodiments, Step 2 comprises the condensation of Int-16 with a compound of formula R^1–C(O)–LG^2, thereby forming a compound of formula Int-17, wherein R^1, X, Y, and Z are as defined in embodiments herein, LG^1 is a leaving group, and PG is a protecting group. In some embodiments, LG^2 is Cl. In some embodiments, the condensation is

conducted with a strong base. In some embodiments, the condensation is conducted with butyl lithium. In some embodiments, the condensation is conducted with LHMDS.

[0636] In some embodiments, Step 3 comprises the reduction of a compound of formula Int-17, thereby forming a compound of formula Int-18, wherein R^1, X, Y, and Z are as defined in embodiments herein, LG^1 is a leaving group, and PG is a protecting group. In some embodiments, the reduction is conducted with a silane and acid. In some embodiments, the reduction is conducted with a trialkylsilane and trifluoroacetic acid.


[0637] In some embodiments, Step 4 comprises the coupling of Int-18 with a compound of formula PG^2–N(H) –PG^3, thereby forming a compound of formula Int-19, wherein R^1, X, Y, and Z are as defined in embodiments herein, and PG, PG^2, and PG^3 are protecting groups. In some embodiments, PG^2 is 2,4-dimethoxybenzyl (DMB). In some embodiments, PG^2 is *p*-methoxybenzyl (PMB). In some embodiments, PG^3 is H. In some embodiments, PG^3 is 2,4-dimethoxybenzyl (DMB). In some embodiments, PG^3 is *p*-methoxybenzyl (PMB). In some embodiments, PG^2–N–PG^3 is taken together to represent azide (N_3).

[0638] In some embodiments, the coupling is conducted with a base. In some embodiments, the coupling is conducted with an organic base. In some embodiments, the coupling is conducted with a trialkylamine base. In some embodiments, the coupling is conducted with an inorganic base. In some embodiments, the coupling is conducted with a transition-metal catalyst. In some embodiments, the coupling is conducted with a palladium catalyst.

[0639] In some embodiments, Step 5 comprises the deprotection of a compound of formula Int-19, thereby forming a compound of formula Int-5, wherein R^1, X, Y, and Z are as defined in embodiments herein, and PG is a protecting group. In some embodiments, the deprotection is conducted with an acid. In some embodiments, the deprotection is conducted with hydrochloric acid. In some embodiments, the deprotection is conducted with trifluoroacetic acid. In some embodiments, the deprotection is conducted with a reductant (for example, when PG^2–N–PG^3 is taken together to represent azide). In some embodiments, the deprotection is conducted with a phosphine reductant.

[0640] In some embodiments, Step 6 comprises the coupling of Int-18 with a compound of formula R^{2A}–$C(O)NH_2$, thereby forming a compound of formula Int-6, wherein R^1, R^{2A}, X, Y, and Z are as defined in embodiments herein, and PG is a protecting group. In some embodiments, the coupling is a transition-metal-mediated coupling reaction. In some embodiments, the coupling is a Pd-catalyzed coupling reaction.

Scheme 5



[0641] In some embodiments, compounds of formula Int-5 are prepared according to the general procedure depicted in Scheme 5, above. In some embodiments, Step 1 comprises the Ugi reaction condensation of Int-20 with an aldehyde of formula R^1-CHO, a primary amine of formula PG-NH_2, and *t*-butyl isocyanide, thereby forming a compound of formula Int-21, wherein R^1, X, Y, and Z are as defined in embodiments herein, LG is a leaving group, and PG is a protecting group. In some embodiments, LG is a halogen. In some embodiments, LG is Br. In some embodiments, LG is Cl. In some embodiments, PG is 2,4-dimethoxybenzyl (DMB). In some embodiments, PG is *p*-methoxybenzyl (PMB).


[0642] In some embodiments, Step 2 comprises the cyclization of a compound of formula Int-21, thereby forming a compound of formula Int-22, wherein R^1, X, Y, and Z are as defined in embodiments herein, LG is a leaving group, and PG is a protecting group. In some embodiments, the cyclization is conducted with a base. In some embodiments, the cyclization is conducted with an inorganic base. In some embodiments, the cyclization is conducted with sodium hydride. In some embodiments, the cyclization is conducted with potassium carbonate. In some embodiments, the cyclization is catalyzed by a phase-transfer reagent. In some embodiments, the cyclization is catalyzed by a tetraalkylammonium phase-transfer reagent. In some embodiments, the cyclization is conducted with an organic base. In some embodiments, the cyclization is conducted with 2-(*t*-butyl)-1,1,3,3-tetramethylguanidine.

[0643] In some embodiments, Step 3 comprises the reduction of a compound of formula Int-22, thereby forming a compound of formula Int-23, wherein R^1, X, Y, and Z are as defined in

embodiments herein, LG is a leaving group, and PG is a protecting group. In some embodiments, the reduction is conducted with a silane and a Lewis acid. In some embodiments, the reduction is conducted with a trialkylsilane and trifluoroboron diethyletherate. In some embodiments, the reduction is conducted with a silane and acid. In some embodiments, the reduction is conducted with a trialkylsilane and trifluoroacetic acid.

[0644] In some embodiments, Step 4 comprises the coupling of a compound of formula Int-23, thereby forming a compound of formula Int-5, wherein R^1, X, Y, and Z are as defined in embodiments herein and PG is a protecting group. In some embodiments, the coupling is a transition-metal-mediated coupling reaction. In some embodiments, the coupling is a Pd-catalyzed coupling reaction. In some embodiments, the coupling is a Pd-catalyzed coupling reaction conducted with benzophenone imine.

Scheme 6



[0645] In some embodiments, compounds of formula B (i.e. compounds of formula I, wherein Q is $C(R^Q)$, and R^2 is $-N(H)C(O)-R^{2A}$) are prepared according to the general procedure depicted in Scheme 6, above. In some embodiments, Step 1 comprises the nucleophilic addition of an organometallic reagent of formula R^Q-M with Int-4, thereby forming a compound of formula Int-24, wherein X, Y, Z, R^1, and R^Q are as defined in embodiments herein and PG is a protecting group. In some embodiments, PG is *p*-methoxybenzyl (PMB). In some embodiments, PG is 2,4-dimethoxybenzyl (DMB). In some embodiments, the organometallic reagent of formula R^Q-M is a Grignard reagent of formula R^Q-MgBr or R^Q-MgCl. In some embodiments, the nucleophilic addition is conducted with a Lewis acid. In some embodiments, the nucleophilic addition is conducted with trifluoroboron diethyletherate.

[0646] In some embodiments, Step 2 comprises the coupling of Int-24 with a reagent comprising R^{2A}, thereby forming a compound of formula Int-25, wherein X, Y, Z, R^1, R^Q, and R^{2A} are as defined in embodiments herein and PG is a protecting group.

[0647] In some embodiments, the reagent comprising R^{2A} is a compound of formula R^{2A}-C(O)Cl. In some embodiments, the reagent comprising R^{2A} is a compound of formula R^{2A}-C(O)OH, and Step 2 further comprises an amide-coupling reagent. In some embodiments, the amide-coupling reagent is tetramethylchloroformamidinium hexafluorophosphate (TCFH) and *N*-methylimidazole (NMI). In some embodiments, the amide-coupling reagent is 1-[bis(dimethylamino)methylene]-1*H*-1,2,3-triazolo[4,5-*b*]pyridinium 3-oxid hexafluorophosphate (HATU).


[0648] In some embodiments, the reagent comprising R^{2A} comprises a primary or secondary amine, and Step 2 further comprises a carbonyl-equivalent reagent. In some embodiments, the carbonyl-equivalent reagent is triphosgene.

[0649] In some embodiments, Step 3 comprises the deprotection of a compound of formula Int-25, thereby forming a compound of formula B, wherein X, Y, Z, R^1, R^Q, and R^{2A} are as defined in embodiments herein. In some embodiments, the deprotection is conducted with an acid. In some embodiments, the deprotection is conducted with trifluoroacetic acid. In some embodiments, the deprotection is conducted with trifluoroacetic acid and trifluoromethanesulfonic acid. In some embodiments, the deprotection is conducted with an oxidant. In some embodiments, the deprotection is conducted with cerium (IV) ammonium nitrate.

[0650] In some embodiments, the order of performing Step 2 and Step 3 is reversed.

[0651] Additional compounds of Formula B may be prepared by conducting nucleopilic addition, as described for Step 1 of Scheme 6 above, instead of the reduction Step 3 in Scheme 2, Scheme 4, and Scheme 5 above. The remainder of the steps are conducted as described in Scheme 2, Scheme 4, and Scheme 5 to prepare compounds of Int-24 (rather than Int-5) or Int-25 (rather than Int-6).

Scheme 7



[0652] In some embodiments, compounds of formula C (i.e. compounds of formula I, wherein Q is N, and R^2 is -N(H)C(O)-R^{2A}) are prepared according to the general procedure depicted in Scheme 7, above. In some embodiments, Step 1 comprises the coupling of Int-26 with a hydrazine of formula R^1-N(H)-NH_2, thereby forming a compound of formula Int-27, wherein R^1, X, Y, and Z are as defined in embodiments herein and LG is a leaving group. In some embodiments, LG is a halogen. In some embodiments, LG is Cl. In some embodiments, LG is F. In some embodiments, Step 5 further comprises an amide-coupling reagent. In some embodiments, the amide-coupling reagent is 1-[bis(dimethylamino)methylene]-1*H*-1,2,3-triazolo[4,5-*b*]pyridinium 3-oxid hexafluorophosphate (HATU).

[0653] In some embodiments, Step 2 comprises the cyclization of a compound of formula Int-27, thereby forming a compound of formula Int-28, wherein R^1, X, Y, and Z are as defined in embodiments herein. In some embodiments, the cyclization is conducted with a base. In some embodiments, the cyclization is conducted with an inorganic base. In some embodiments, the cyclization is conducted with potassium *tert*-butoxide. In some embodiments, the cyclization is conducted with potassium carbonate. In some embodiments, the cyclization is catalyzed by a phase-transfer reagent. In some embodiments, the cyclization is catalyzed by a tetraalkylammonium phase-transfer reagent. In some embodiments, the cyclization is conducted with an organic base. In some embodiments, the cyclization is conducted with 2-(*t*-butyl)-1,1,3,3-tetramethylguanidine.

[0654] In some embodiments, Step 3 comprises the reduction of a compound of formula Int-28, thereby forming a compound of formula Int-29, wherein R^1, X, Y, and Z are as defined in embodiments herein. In some embodiments, the reduction is conducted with iron and ammonium chloride.

[0655] In some embodiments, Step 4 comprises the coupling of Int-29 with a reagent comprising R^{2A}, thereby forming a compound of formula C, wherein X, Y, Z, R^1, and R^{2A} are as defined in embodiments herein.

[0656] In some embodiments, the reagent comprising R^{2A} is a compound of formula R^{2A}-C(O)Cl. In some embodiments, the reagent comprising R^{2A} is a compound of formula R^{2A}-C(O)OH, and Step 4 further comprises an amide-coupling reagent. In some embodiments, the amide-coupling reagent is tetramethylchloroformamidinium hexafluorophosphate (TCFH) and *N*-methylimidazole (NMI). In some embodiments, the amide-coupling reagent is 1-[bis(dimethylamino)methylene]-1*H*-1,2,3-triazolo[4,5-*b*]pyridinium 3-oxid hexafluorophosphate (HATU).

[0657] In some embodiments, the reagent comprising R^{2A} comprises a primary or secondary amine, and Step 4 further comprises a carbonyl-equivalent reagent. In some embodiments, the carbonyl-equivalent reagent is triphosgene.

[0658] In some embodiments, the coupling of Step 4 also results in acylation of the indazalonyl nitrogen atom. In said embodiments, the undesired acyl substituent may be selectively removed under basic conditions. Accordingly, in some embodiments, the coupling of Step 4 is followed by treatment of the product with a base, thereby forming a compound of Formula C, wherein X, Y, Z, R^1, and R^{2A} are as defined in embodiments herein. In some embodiments, the coupling of Step 4 is followed by treatment of the product with an inorganic base in an alcohol solvent. In some embodiments, the coupling of Step 4 is followed by treatment with potassium carbonate in methanol.

Functional Group Transformations

[0659] In some embodiments, the synthesis of compounds of formula I further comprises a functional group transformation. Functional group transformations are well known in the art, as described in, for example, "Organic Chemistry", Thomas Sorrell, University Science Books, Sausalito: 1999; "March's Advanced Organic Chemistry", 5th Ed., Ed.: Smith, M.B. and March, J., John Wiley & Sons, New York: 2001; and "Comprehensive Organic Synthesis", 2nd Ed., Ed.: Knochel, P. and Molander, G.A., Elsevier, Amsterdam: 2014.

[0660] In some embodiments, the functional group transformation is conducted on Int-5. In some embodiments, the functional group transformation is conducted on Int-6. In some embodiments, the functional group transformation is conducted on a compound of formula A. In some embodiments, the functional group transformation is conducted on Int-14. In some embodiments, the functional group transformation is conducted on Int-24. In some embodiments, the functional group transformation is conducted on Int-25. In some embodiments, the functional group transformation is conducted on a compound of formula B. In some embodiments, the functional group transformation is conducted on Int-28. In some embodiments, the functional group transformation is conducted on Int-29. In some embodiments, the functional group transformation is conducted on a compound of formula C.

[0661] In some embodiments, when X, Y, or Z is carbon substituted with a halogen, the synthesis of compounds of formula I further comprises a functional group transformation of the halogen. In some embodiments, the halogen is bromine.

[0662] In some embodiments, the functional group transformation is a transition-metal-mediated coupling reaction. In some embodiments, the functional group transformation is a Suzuki coupling. In some embodiments, the functional group transformation is a Ni-mediated photoredox coupling. In some embodiments, the functional group transformation is a Pd-mediated C-N coupling. In some embodiments, the functional group transformation is a Stille coupling. In some embodiments, the functional group transformation is a Pd-mediated cyanation. In some embodiments, the functional group transformation is a Heck coupling. In some embodiments, the functional group transformation is a carbonylation. In some embodiments, the carbonylation is conducted in the presence of an alcohol and forms an ester. In some embodiments, the carbonylation is conducted in the presence of an amine and forms an amide. In some embodiments, the carbonylation is Pd-catalyzed. In some embodiments, the carbonylation is Co-mediated.

[0663] In some embodiments, when X, Y, or Z is carbon substituted with a group comprising an alkene, the synthesis of compounds of formula I further comprises a functional group transformation of the alkene. In some embodiments, the functional group transformation is an oxidation of the alkene. In some embodiments, the functional group transformation is a hydroboration of the alkene. In some embodiments, the functional group transformation is a dihydroxylation of the alkene. In some embodiments, the functional group transformation is an oxidative cleavage of the alkene. In some embodiments, the functional group transformation is a reduction of the alkene.

[0664] In some embodiments, when X, Y, or Z is carbon substituted with a group comprising an ester, the synthesis of compounds of formula I further comprises a functional group transformation of the ester. In some embodiments, the functional group transformation is a reduction of the ester to an alcohol. In some embodiments, the functional group transformation is a saponifcation of the ester to a carboxylic acid. In some embodiments, the resulting carboxylic acid is further converted to an amide. In some embodiments, the functional group transformation is a cyclopropanation of the ester.

[0665] In some embodiments, when X, Y, or Z is carbon substituted with a group comprising an aldehyde or ketone, the synthesis of compounds of formula I further comprises a functional group transformation of the aldehyde or ketone. In some embodiments, the functional group transformation is a nucleophilic addition to the aldehyde or ketone. In some embodiments, the functional group transformation is an organometallic addition to the aldehyde or ketone. In some embodiments, the functional group transformation is a Grignard addition to the aldehyde or ketone. In some embodiments, the functional group transformation is a reduction of the aldehyde or ketone to an alcohol. In some embodiments, the functional group transformation is a reductive amination of the aldehyde or ketone.

5. Uses, Formulation, and Administration

Pharmaceutically Acceptable Compositions

[0666] According to another embodiment, the invention provides a composition comprising a compound of this invention, or a pharmaceutically acceptable derivative thereof, and a pharmaceutically acceptable carrier, adjuvant, or vehicle. In some embodiments, the invention provides a pharmaceutical composition comprising a compound of this invention, and a pharmaceutically acceptable carrier. The amount of compound in compositions of this invention is such that is effective to measurably inhibit a PI3Kα protein kinase, or a mutant thereof, in a biological sample or in a patient. In certain embodiments, the amount of compound in compositions of this invention is such that it is effective to measurably inhibit a PI3Kα protein kinase, or a mutant thereof, in a biological sample or in a patient. In certain embodiments, a composition of this invention is formulated for administration to a patient in need of such composition. In some embodiments, a composition of this invention is formulated for oral administration to a patient.

[0667] The terms "subject" and "patient," as used herein, means an animal (i.e., a member of the kingdom animal), preferably a mammal, and most preferably a human. In some

embodiments, the subject is a human, mouse, rat, cat, monkey, dog, horse, or pig. In some embodiments, the subject is a human. In some embodiments, the subject is a mouse, rat, cat, monkey, dog, horse, or pig.

[0668] The term "pharmaceutically acceptable carrier, adjuvant, or vehicle" refers to a non-toxic carrier, adjuvant, or vehicle that does not destroy the pharmacological activity of the compound with which it is formulated. Pharmaceutically acceptable carriers, adjuvants or vehicles that may be used in the compositions of this invention include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, polyethylene glycol and wool fat.

[0669] A "pharmaceutically acceptable derivative" means any non-toxic salt, ester, salt of an ester or other derivative of a compound of this invention that, upon administration to a recipient, is capable of providing, either directly or indirectly, a compound of this invention or an inhibitorily active metabolite or residue thereof.

[0670] As used herein, the term "inhibitorily active metabolite or residue thereof" means that a metabolite or residue thereof is also an inhibitor of a PI3Kα protein kinase, or a mutant thereof.

[0671] Compositions of the present invention may be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, vaginally or via an implanted reservoir. The term "parenteral" as used herein includes subcutaneous, intravenous, intramuscular, intra-articular, intra-synovial, intrasternal, intrathecal, intrahepatic, intralesional and intracranial injection or infusion techniques. Preferably, the compositions are administered orally, intraperitoneally or intravenously.

[0672] Sterile injectable forms of the compositions of this invention may be aqueous or oleaginous suspension. These suspensions may be formulated according to techniques known in the art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally acceptable diluent or solvent, for example as a solution in 1,3-butanediol. Among

the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium.

[0673] For this purpose, any bland fixed oil may be employed including synthetic mono- or di-glycerides. Fatty acids, such as oleic acid and its glyceride derivatives are useful in the preparation of injectables, as are natural pharmaceutically-acceptable oils, such as olive oil or castor oil, especially in their polyoxyethylated versions. These oil solutions or suspensions may also contain a long-chain alcohol diluent or dispersant, such as carboxymethyl cellulose or similar dispersing agents that are commonly used in the formulation of pharmaceutically acceptable dosage forms including emulsions and suspensions. Other commonly used surfactants, such as Tweens, Spans and other emulsifying agents or bioavailability enhancers which are commonly used in the manufacture of pharmaceutically acceptable solid, liquid, or other dosage forms may also be used for the purposes of formulation.

[0674] Pharmaceutically acceptable compositions of this invention may be orally administered in any orally acceptable dosage form including, but not limited to, capsules, tablets, aqueous suspensions or solutions. In the case of tablets for oral use, carriers commonly used include lactose and corn starch. Lubricating agents, such as magnesium stearate, are also typically added. For oral administration in a capsule form, useful diluents include lactose and dried cornstarch. When aqueous suspensions are required for oral use, the active ingredient is combined with emulsifying and suspending agents. If desired, certain sweetening, flavoring or coloring agents may also be added.

[0675] Alternatively, pharmaceutically acceptable compositions of this invention may be administered in the form of suppositories for rectal or vaginal administration. These can be prepared by mixing the agent with a suitable non-irritating excipient that is solid at room temperature but liquid at rectal or vaginal temperature and therefore will melt in the rectum or vagina to release the drug. Such materials include cocoa butter, beeswax and polyethylene glycols.

[0676] Pharmaceutically acceptable compositions of this invention may also be administered topically, especially when the target of treatment includes areas or organs readily accessible by topical application, including diseases of the eye, the skin, or the lower intestinal tract. Suitable topical formulations are readily prepared for each of these areas or organs.

[0677] Topical application for the lower intestinal tract can be effected in a rectal suppository formulation (see above) or in a suitable enema formulation. Topically-transdermal patches may also be used.

[0678] For topical applications, provided pharmaceutically acceptable compositions may be formulated in a suitable ointment containing the active component suspended or dissolved in one or more carriers. Carriers for topical administration of compounds of this invention include, but are not limited to, mineral oil, liquid petrolatum, white petrolatum, propylene glycol, polyoxyethylene, polyoxypropylene compound, emulsifying wax and water. Alternatively, provided pharmaceutically acceptable compositions can be formulated in a suitable lotion or cream containing the active components suspended or dissolved in one or more pharmaceutically acceptable carriers. Suitable carriers include, but are not limited to, mineral oil, sorbitan monostearate, polysorbate 60, cetyl esters wax, cetearyl alcohol, 2-octyldodecanol, benzyl alcohol and water.

[0679] For ophthalmic use, provided pharmaceutically acceptable compositions may be formulated as micronized suspensions in isotonic, pH adjusted sterile saline, or, preferably, as solutions in isotonic, pH adjusted sterile saline, either with or without a preservative such as benzylalkonium chloride. Alternatively, for ophthalmic uses, the pharmaceutically acceptable compositions may be formulated in an ointment such as petrolatum.

[0680] Pharmaceutically acceptable compositions of this invention may also be administered by nasal aerosol or inhalation. Such compositions are prepared according to techniques well-known in the art of pharmaceutical formulation and may be prepared as solutions in saline, employing benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability, fluorocarbons, and/or other conventional solubilizing or dispersing agents.

[0681] Preferably, pharmaceutically acceptable compositions of this invention are formulated for oral administration. Such formulations may be administered with or without food. In some embodiments, pharmaceutically acceptable compositions of this invention are administered without food. In other embodiments, pharmaceutically acceptable compositions of this invention are administered with food.

[0682] The amount of compounds of the present invention that may be combined with the carrier materials to produce a composition in a single dosage form will vary depending upon the patient treated, the particular mode of administration. Preferably, provided compositions

should be formulated so that a dosage of between 0.01 - 100 mg/kg body weight/day of the inhibitor can be administered to a patient receiving these compositions.

[0683] It should also be understood that a specific dosage and treatment regimen for any particular patient will depend upon a variety of factors, including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, rate of excretion, drug combination, and the judgment of the treating physician and the severity of the particular disease being treated. The amount of a compound of the present invention in the composition will also depend upon the particular compound in the composition.

[0684] The precise dose to be employed in the compositions will also depend on the route of administration, and should be decided according to the judgment of the practitioner and each subject's circumstances. In specific embodiments of the disclosure, suitable dose ranges for oral administration of the compounds of the disclosure are generally about 1 mg/day to about 1000 mg/day. In some embodiments, the oral dose is about 1 mg/day to about 800 mg/day. In some embodiments, the oral dose is about 1 mg/day to about 500 mg/day. In some embodiments, the oral dose is about 1 mg/day to about 250 mg/day. In some embodiments, the oral dose is about 1 mg/day to about 100 mg/day. In some embodiments, the oral dose is about 5 mg/day to about 50 mg/day. In some embodiments, the oral dose is about 5 mg/day. In some embodiments, the oral dose is about 10 mg/day. In some embodiments, the oral dose is about 20 mg/day. In some embodiments, the oral dose is about 30 mg/day. In some embodiments, the oral dose is about 40 mg/day. In some embodiments, the oral dose is about 50 mg/day. In some embodiments, the oral dose is about 60 mg/day. In some embodiments, the oral dose is about 70 mg/day. In some embodiments, the oral dose is about 100 mg/day. It will be recognized that any of the dosages listed herein may constitute an upper or lower dosage range, and may be combined with any other dosage to constitute a dosage range comprising an upper and lower limit.

[0685] In some embodiments, pharmaceutically acceptable compositions contain a provided compound and/or a pharmaceutically acceptable salt thereof at a concentration ranging from about 0.01 to about 90 wt%, about 0.01 to about 80 wt%, about 0.01 to about 70 wt%, about 0.01 to about 60 wt%, about 0.01 to about 50 wt%, about 0.01 to about 40 wt%, about 0.01 to about 30 wt%, about 0.01 to about 20 wt%, about 0.01 to about 2.0 wt%, about 0.01 to about 1 wt%, about 0.05 to about 0.5 wt%, about 1 to about 30 wt%, or about 1 to about 20 wt%. The composition can be formulated as a solution, suspension, ointment, or a capsule, and the like. The pharmaceutical composition can be prepared as an aqueous solution and can contain

additional components, such as preservatives, buffers, tonicity agents, antioxidants, stabilizers, viscosity-modifying ingredients and the like.

[0686] Pharmaceutically acceptable carriers are well-known to those skilled in the art, and include, *e.g.*, adjuvants, diluents, excipients, fillers, lubricants and vehicles. In some embodiments, the carrier is a diluent, adjuvant, excipient, or vehicle. In some embodiments, the carrier is a diluent, adjuvant, or excipient. In some embodiments, the carrier is a diluent or adjuvant. In some embodiments, the carrier is an excipient.

[0687] Examples of pharmaceutically acceptable carriers may include, *e.g.*, water or saline solution, polymers such as polyethylene glycol, carbohydrates and derivatives thereof, oils, fatty acids, or alcohols. Non-limiting examples of oils as pharmaceutical carriers include oils of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like. The pharmaceutical carriers may also be saline, gum acacia, gelatin, starch paste, talc, keratin, colloidal silica, urea, and the like. In addition, auxiliary, stabilizing, thickening, lubricating and coloring agents may be used. Other examples of suitable pharmaceutical carriers are described in *e.g.*, Remington's: The Science and Practice of Pharmacy, 22nd Ed. (Allen, Loyd V., Jr ed., Pharmaceutical Press (2012)); Modern Pharmaceutics, 5th Ed. (Alexander T. Florence, Juergen Siepmann, CRC Press (2009)); Handbook of Pharmaceutical Excipients, 7th Ed. (Rowe, Raymond C.; Sheskey, Paul J.; Cook, Walter G.; Fenton, Marian E. eds., Pharmaceutical Press (2012)) (each of which hereby incorporated by reference in its entirety).

[0688] The pharmaceutically acceptable carriers employed herein may be selected from various organic or inorganic materials that are used as materials for pharmaceutical formulations and which are incorporated as analgesic agents, buffers, binders, disintegrants, diluents, emulsifiers, excipients, extenders, glidants, solubilizers, stabilizers, suspending agents, tonicity agents, vehicles and viscosity-increasing agents. Pharmaceutical additives, such as antioxidants, aromatics, colorants, flavor-improving agents, preservatives, and sweeteners, may also be added. Examples of acceptable pharmaceutical carriers include carboxymethyl cellulose, crystalline cellulose, glycerin, gum arabic, lactose, magnesium stearate, methyl cellulose, powders, saline, sodium alginate, sucrose, starch, talc and water, among others. In some embodiments, the term "pharmaceutically acceptable" means approved by a regulatory agency of the Federal or a state government or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in animals, and more particularly in humans.

[0689] Surfactants such as, *e.g.*, detergents, are also suitable for use in the formulations. Specific examples of surfactants include polyvinylpyrrolidone, polyvinyl alcohols, copolymers of vinyl acetate and of vinylpyrrolidone, polyethylene glycols, benzyl alcohol, mannitol, glycerol, sorbitol or polyoxyethylenated esters of sorbitan; lecithin or sodium carboxymethylcellulose; or acrylic derivatives, such as methacrylates and others, anionic surfactants, such as alkaline stearates, in particular sodium, potassium or ammonium stearate; calcium stearate or triethanolamine stearate; alkyl sulfates, in particular sodium lauryl sufate and sodium cetyl sulfate; sodium dodecylbenzenesulphonate or sodium dioctyl sulphosuccinate; or fatty acids, in particular those derived from coconut oil, cationic surfactants, such as water-soluble quaternary ammonium salts of formula $N^+R'R''R'''R''''Y^-$, in which the R radicals are identical or different optionally hydroxylated hydrocarbon radicals and Y^- is an anion of a strong acid, such as halide, sulfate and sulfonate anions; cetyltrimethylammonium bromide is one of the cationic surfactants which can be used, amine salts of formula $N^+R'R''R'''$, in which the R radicals are identical or different optionally hydroxylated hydrocarbon radicals; octadecylamine hydrochloride is one of the cationic surfactants which can be used, non-ionic surfactants, such as optionally polyoxyethylenated esters of sorbitan, in particular Polysorbate 80, or polyoxyethylenated alkyl ethers; polyethylene glycol stearate, polyoxyethylenated derivatives of castor oil, polyglycerol esters, polyoxyethylenated fatty alcohols, polyoxyethylenated fatty acids or copolymers of ethylene oxide and of propylene oxide, amphoteric surfactants, such as substituted lauryl compounds of betaine.

[0690] Suitable pharmaceutical carriers may also include excipients such as starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene, glycol, polyethylene glycol 300, water, ethanol, polysorbate 20, and the like. The present compositions, if desired, may also contain wetting or emulsifying agents, or pH buffering agents.

[0691] Tablets and capsule formulations may further contain one or more adjuvants, binders, diluents, disintegrants, excipients, fillers, or lubricants, each of which are known in the art. Examples of such include carbohydrates such as lactose or sucrose, dibasic calcium phosphate anhydrous, corn starch, mannitol, xylitol, cellulose or derivatives thereof, microcrystalline cellulose, gelatin, stearates, silicon dioxide, talc, sodium starch glycolate, acacia, flavoring agents, preservatives, buffering agents, disintegrants, and colorants. Orally

administered compositions may contain one or more optional agents such as, *e.g.*, sweetening agents such as fructose, aspartame or saccharin; flavoring agents such as peppermint, oil of wintergreen, or cherry; coloring agents; and preservative agents, to provide a pharmaceutically palatable preparation.

Uses of Compounds and Pharmaceutically Acceptable Compositions

[0692] Compounds and compositions described herein are generally useful for the inhibition of a kinase or a mutant thereof. In some embodiments, the kinase inhibited by the compounds and compositions described herein is a phosphatidylinositol 3-kinase (PI3K). In some embodiments, the kinase inhibited by the compounds and compositions described herein is one or more of a PI3Kα, PI3Kδ, and PI3Kγ. In some embodiments, the kinase inhibited by the compounds and compositions described herein is a PI3Kα. In some embodiments, the kinase inhibited by the compounds and compositions described herein is a PI3Kα containing at least one of the following mutations: H1047R, E542K, and E545K.

[0693] Compounds or compositions of the disclosure can be useful in applications that benefit from inhibition of PI3K enzymes. For example, PI3K inhibitors of the present invention are useful for the treatment of cellular proliferative diseases generally. Compounds or compositions of the disclosure can be useful in applications that benefit from inhibition of PI3Kα enzymes. For example, PI3Kα inhibitors of the present invention are useful for the treatment of cellular proliferative diseases generally.

[0694] Aberrant regulation of PI3K, which often increases survival through Aid activation, is one of the most prevalent events in human cancer and has been shown to occur at multiple levels. The tumor suppressor gene PTEN, which dephosphorylates phosphoinositides at the 3' position of the inositol ring, and in so doing antagonizes PI3K activity, is functionally deleted in a variety of tumors. In other tumors, the genes for the p110 alpha isoform, PIK3CA, and for Akt are amplified, and increased protein expression of their gene products has been demonstrated in several human cancers. Furthermore, mutations and translocation of p85 alpha that serve to up-regulate the p85-p110 complex have been described in human cancers. Finally, somatic missense mutations in PIK3CA that activate downstream signaling pathways have been described at significant frequencies in a wide diversity of human cancers (Kang et el., Proc. Natl. Acad. Sci. USA 102:802 (2005); Samuels et al., Science 304:554 (2004); Samuels et al., Cancer Cell 7:561-573 (2005)). These observations show that deregulation of phosphoinositol-3 kinase, and the upstream and downstream components of this signaling

pathway, is one of the most common deregulations associated with human cancers and proliferative diseases (Parsons et al., Nature 436:792 (2005); Hennessey at el., Nature Rev. Drug Disc. 4:988-1004 (2005)).

[0695] The activity of a compound utilized in this invention as an inhibitor of a PI3K kinase, for example, a PI3Kα, or a mutant thereof, may be assayed *in vitro*, *in vivo* or in a cell line. *In vitro* assays include assays that determine inhibition of either the phosphorylation activity and/or the subsequent functional consequences, or ATPase activity of an activated PI3Kα, or a mutant thereof. Alternative *in vitro* assays quantitate the ability of the inhibitor to bind to a a PI3Kα. Inhibitor binding may be measured by radiolabeling the inhibitor prior to binding, isolating the inhibitor/PI3Kα complex and determining the amount of radiolabel bound. Alternatively, inhibitor binding may be determined by running a competition experiment where new inhibitors are incubated with a PI3Kα bound to known radioligands. Representative *in vitro* and *in vivo* assays useful in assaying a PI3Kα inhibitor include those described and disclosed in the patent and scientific publications described herein. Detailed conditions for assaying a compound utilized in this invention as an inhibitor of a PI3Kα, or a mutant thereof, are set forth in the Examples below.

Treatment of Disorders

[0696] Provided compounds are inhibitors of PI3Kα and are therefore useful for treating one or more disorders associated with activity of PI3Kα or mutants thereof. Thus, in certain embodiments, the present invention provides a method of treating a PI3Kα-mediated disorder in a subject, comprising administering a therapeutically effective amount of a compound of the present invention, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable composition of either of the foregoing, to a subject in need thereof. In certain embodiments, the present invention provides a method of treating a PI3Kα-mediated disorder in a subject comprising administering a therapeutically effective amount of a compound of the present invention, or a pharmaceutically acceptable composition thereof, to a subject in need thereof. In some embodiments, the subject has a mutant PI3Kα. In some embodiments, the subject has PI3Kα containing at least one of the following mutations: H1047R, E542K, and E545K.

[0697] As used herein, the term "PI3Kα-mediated" disorders, diseases, and/or conditions means any disease or other deleterious condition in which PI3Kα or a mutant thereof is

known to play a role. Accordingly, another embodiment of the present invention relates to treating or lessening the severity of one or more diseases in which PI3Kα, or a mutant thereof, is known to play a role. Such PI3Kα-mediated disorders include, but are not limited to, cellular proliferative disorders (e.g. cancer). In some embodiments, the PI3Kα-mediated disorder is a disorder mediated by a mutant PI3Kα. In some embodiments, the PI3Kα-mediated disorder is a disorder mediated by a PI3Kα containing at least one of the following mutations: H1047R, E542K, and E545K.

[0698] In some embodiments, the present invention provides a method for treating a cellular proliferative disease, said method comprising administering to a patient in need thereof a therapeutically effective amount of a compound of the present invention, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable composition of either of the foregoing. In some embodiments, the present invention provides a method for treating a cellular proliferative disease, said method comprising administering to a patient in need thereof, a therapeutically effective amount of a compound of the present invention, or a pharmaceutically acceptable composition thereof.

[0699] In some embodiments, the method of treatment comprises the steps of: i) identifying a subject in need of such treatment; (ii) providing a disclosed compound, or a pharmaceutically acceptable salt thereof; and (iii) administering said provided compound in a therapeutically effective amount to treat, suppress and/or prevent the disease state or condition in a subject in need of such treatment. In some embodiments, the subject has a mutant PI3Kα. In some embodiments, the subject has PI3Kα containing at least one of the following mutations: H1047R, E542K, and E545K.

[0700] In some embodiments, the method of treatment comprises the steps of: i) identifying a subject in need of such treatment; (ii) providing a composition comprising a disclosed compound, or a pharmaceutically acceptable salt thereof; and (iii) administering said composition in a therapeutically effective amount to treat, suppress and/or prevent the disease state or condition in a subject in need of such treatment. In some embodiments, the subject has a mutant PI3Kα. In some embodiments, the subject has PI3Kα containing at least one of the following mutations: H1047R, E542K, and E545K.

[0701] Another aspect of the invention provides a compound according to the definitions herein, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of either of the foregoing, for use in the treatment of a disorder described herein. Another

aspect of the invention provides the use of a compound according to the definitions herein, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of either of the foregoing, for the treatment of a disorder described herein. Similarly, the invention provides the use of a compound according to the definitions herein, or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for the treatment of a disorder described herein.

Cellular Proliferative Diseases

[0702] In some embodiments, the disorder is a cellular proliferative disease. In some embodiments, the cellular proliferative disease is cancer. In some embodiments, the cancer is a tumor. In some embodiments, the cancer is a solid tumor. In some embodiments, the cellular proliferative disease is a tumor and/or cancerous cell growth. In some embodiments, the cellular proliferative disease is a tumor. In some embodiments, the cellular proliferative disease is a solid tumor. In some embodiments, the cellular proliferative disease is a cancerous cell growth.

[0703] In some embodiments, the cancer is selected from sarcoma; lung; bronchus; prostate; breast (including sporadic breast cancers and sufferers of Cowden disease); pancreas; gastrointestinal; colon; rectum; carcinoma; colon carcinoma; adenoma; colorectal adenoma; thyroid; liver; intrahepatic bile duct; hepatocellular; adrenal gland; stomach; gastric; glioma; glioblastoma; endometrial; melanoma; kidney; renal pelvis; urinary bladder; uterine corpus; uterine cervix; vagina; ovary (including clear cell ovarian cancer); multiple myeloma; esophagus; a leukemia; acute myelogenous leukemia; chronic myelogenous leukemia; lymphocytic leukemia; myeloid leukemia; brain; a carcinoma of the brain; oral cavity and pharynx; larynx; small intestine; non-Hodgkin lymphoma; villous colon adenoma; a neoplasia; a neoplasia of epithelial character; lymphoma; a mammary carcinoma; basal cell carcinoma; squamous cell carcinoma; actinic keratosis; neck; head; polycythemia vera; essential thrombocythemia; myelofibrosis with myeloid metaplasia; and Waldenstrom macroglobulinemia.

[0704] In some embodiments, the cancer is selected from lung; bronchus; prostate; breast (including sporadic breast cancers and Cowden disease); pancreas; gastrointestinal; colon; rectum; thyroid; liver; intrahepatic bile duct; hepatocellular; adrenal gland; stomach; gastric; endometrial; kidney; renal pelvis; urinary bladder; uterine corpus; uterine cervix; vagina; ovary (including clear cell ovarian cancer); esophagus; a leukemia; acute myelogenous

leukemia; chronic myelogenous leukemia; lymphocytic leukemia; myeloid leukemia; brain; oral cavity and pharynx; larynx; small intestine; neck; and head. In some embodiments, the cancer is selected from sarcoma; carcinoma; colon carcinoma; adenoma; colorectal adenoma; glioma; glioblastoma; melanoma; multiple myeloma; a carcinoma of the brain; non-Hodgkin lymphoma; villous colon adenoma; a neoplasia; a neoplasia of epithelial character; lymphoma; a mammary carcinoma; basal cell carcinoma; squamous cell carcinoma; actinic keratosis; polycythemia vera; essential thrombocythemia; myelofibrosis with myeloid metaplasia; and Waldenstrom macroglobulinemia.

[0705] In some embodiments, the cancer is selected from lung; bronchus; prostate; breast (including sporadic breast cancers and Cowden disease); pancreas; gastrointestinal; colon; rectum; thyroid; liver; intrahepatic bile duct; hepatocellular; adrenal gland; stomach; gastric; endometrial; kidney; renal pelvis; urinary bladder; uterine corpus; uterine cervix; vagina; ovary (including clear cell ovarian cancer); esophagus; brain; oral cavity and pharynx; larynx; small intestine; neck; and head. In some embodiments, the cancer is a leukemia. In some embodiments, the cancer is acute myelogenous leukemia; chronic myelogenous leukemia; lymphocytic leukemia; or myeloid leukemia.

[0706] In some embodiments, the cancer is breast cancer (including sporadic breast cancers and Cowden disease). In some embodiments, the cancer is breast cancer. In some embodiments, the cancer is ER+/HER2- breast cancer. In some embodiments, the cancer is ER+/HER2- breast cancer, and the subject is intolerant to, or ineligible for, treatment with alpelisib. In some embodiments, the cancer is sporadic breast cancer. In some embodiments, the cancer is Cowden disease.

[0707] In some embodiments, the cancer is ovarian cancer. In some embodiments, the ovarian cancer is clear cell ovarian cancer.

[0708] In some embodiments, the cellular proliferative disease has mutant PI3Kα. In some embodiments, the cancer has mutant PI3Kα. In some embodiments, the breast cancer has mutant PI3Kα. In some embodiments, the ovarian cancer has mutant PI3Kα. In some embodiments, the clear cell ovarian cancer has mutant PI3Kα.

[0709] In some embodiments, the cellular proliferative disease has PI3Kα containing at least one of the following mutations: H1047R, E542K, and E545K. In some embodiments, the cancer has PI3Kα containing at least one of the following mutations: H1047R, E542K, and E545K. In some embodiments, the breast cancer has PI3Kα containing at least one of the

following mutations: H1047R, E542K, and E545K. In some embodiments, the ovarian cancer has PI3Kα containing at least one of the following mutations: H1047R, E542K, and E545K. In some embodiments, the clear cell ovarian cancer has PI3Kα containing at least one of the following mutations: H1047R, E542K, and E545K.

[0710] In some embodiments, the cancer is adenoma; carcinoma; sarcoma; glioma; glioblastoma; melanoma; multiple myeloma; or lymphoma. In some embodiments, the cancer is a colorectal adenoma or avillous colon adenoma. In some embodiments, the cancer is colon carcinoma; a carcinoma of the brain; a mammary carcinoma; basal cell carcinoma; or a squamous cell carcinoma. In some embodiments, the cancer is a neoplasia or a neoplasia of epithelial character. In some embodiments, the cancer is non-Hodgkin lymphoma. In some embodiments, the cancer is actinic keratosis; polycythemia vera; essential thrombocythemia; myelofibrosis with myeloid metaplasia; or Waldenstrom macroglobulinemia.

[0711] In some embodiments, the cellular proliferative disease displays overexpression or amplification of PI3Kα, somatic mutation of PIK3CA, germline mutations or somatic mutation of PTEN, or mutations and translocation of p85α that serve to up-regulate the p85-p110 complex. In some embodiments, the cellular proliferative disease displays overexpression or amplification of PI3Kα. In some embodiments, the cellular proliferative disease displays somatic mutation of PIK3CA. In some embodiments, the cellular proliferative disease displays germline mutations or somatic mutation of PTEN. In some embodiments, the cellular proliferative disease displays mutations and translocation of p85α that serve to up-regulate the p85-p110 complex.

Additional Disorders

[0712] In some embodiments, the PI3Kα-mediated disorder is selected from the group consisting of: polycythemia vera, essential thrombocythemia, myelofibrosis with myeloid metaplasia, asthma, COPD, ARDS, PROS (PI3K-related overgrowth syndrome), venous malformation, Loffler's syndrome, eosinophilic pneumonia, parasitic (in particular metazoan) infestation (including tropical eosinophilia), bronchopulmonary aspergillosis, polyarteritis nodosa (including Churg-Strauss syndrome), eosinophilic granuloma, eosinophil-related disorders affecting the airways occasioned by drug-reaction, psoriasis, contact dermatitis, atopic dermatitis, alopecia greata, erythema multiforme, dermatitis herpetiformis, scleroderma, vitiligo, hypersensitivity angiitis, urticaria, bullous pemphigoid, lupus erythematosus, pemphisus, epidermolysis bullosa acquisita, autoimmune haematogical

disorders (e.g. haemolytic anaemia, aplastic anaemia, pure red cell anaemia and idiopathic thrombocytopenia), systemic lupus erythematosus, polychondritis, Wegener granulomatosis, dermatomyositis, chronic active hepatitis, myasthenia gravis, Steven-Johnson syndrome, idiopathic sprue, autoimmune inflammatory bowel disease (e.g. ulcerative colitis and Crohn's disease), endocrine opthalmopathy, Graves' disease, sarcoidosis, alveolitis, chronic hypersensitivity pneumonitis, multiple sclerosis, primary biliary cirrhosis, uveitis (anterior and posterior), interstitial lung fibrosis, psoriatic arthritis, glomerulonephritis, cardiovascular diseases, atherosclerosis, hypertension, deep venous thrombosis, stroke, myocardial infarction, unstable angina, thromboembolism, pulmonary embolism, thrombolytic diseases, acute arterial ischemia, peripheral thrombotic occlusions, and coronary artery disease, reperfusion injuries, retinopathy, such as diabetic retinopathy or hyperbaric oxygen-induced retinopathy, and conditions characterized by elevated intraocular pressure or secretion of ocular aqueous humor, such as glaucoma.

[0713] In some embodiments, the PI3Kα-mediated disorder is polycythemia vera, essential thrombocythemia, or myelofibrosis with myeloid metaplasia. In some embodiments, the PI3Kα-mediated disorder is asthma, COPD, ARDS, PROS (PI3K-related overgrowth syndrome), venous malformation, Loffler's syndrome, eosinophilic pneumonia, parasitic (in particular metazoan) infestation (including tropical eosinophilia), or bronchopulmonary aspergillosis. In some embodiments, the PI3Kα-mediated disorder is polyarteritis nodosa (including Churg-Strauss syndrome), eosinophilic granuloma, eosinophil-related disorders affecting the airways occasioned by drug-reaction, psoriasis, contact dermatitis, atopic dermatitis, alopecia greata, erythema multiforme, dermatitis herpetiformis, or scleroderma. In some embodiments, the PI3Kα-mediated disorder is vitiligo, hypersensitivity angiitis, urticaria, bullous pemphigoid, lupus erythematosus, pemphisus, epidermolysis bullosa acquisita, or autoimmune haematogical disorders (e.g. haemolytic anaemia, aplastic anaemia, pure red cell anaemia and idiopathic thrombocytopenia). In some embodiments, the PI3Kα-mediated disorder is systemic lupus erythematosus, polychondritis, scleroderma, Wegener granulomatosis, dermatomyositis, chronic active hepatitis, myasthenia gravis, Steven-Johnson syndrome, idiopathic sprue, or autoimmune inflammatory bowel disease (e.g. ulcerative colitis and Crohn's disease).

[0714] In some embodiments, the PI3Kα-mediated disorder is endocrine opthalmopathy, Graves' disease, sarcoidosis, alveolitis, chronic hypersensitivity pneumonitis, multiple sclerosis, primary biliary cirrhosis, uveitis (anterior and posterior), interstitial lung fibrosis, or

psoriatic arthritis. In some embodiments, the PI3Kα-mediated disorder is glomerulonephritis, cardiovascular diseases, atherosclerosis, hypertension, deep venous thrombosis, stroke, myocardial infarction, unstable angina, thromboembolism, pulmonary embolism, thrombolytic diseases, acute arterial ischemia, peripheral thrombotic occlusions, and coronary artery disease, or reperfusion injuries. In some embodiments, the PI3Kα-mediated disorder is retinopathy, such as diabetic retinopathy or hyperbaric oxygen-induced retinopathy, and conditions characterized by elevated intraocular pressure or secretion of ocular aqueous humor, such as glaucoma.

Routes of Administration and Dosage Forms

[0715] The compounds and compositions, according to the methods of the present invention, may be administered using any amount and any route of administration effective for treating or lessening the severity of the disorder (e.g. a proliferative disorder). The exact amount required will vary from subject to subject, depending on the species, age, and general condition of the subject, the severity of the infection, the particular agent, its mode of administration, and the like. Compounds of the invention are preferably formulated in unit dosage form for ease of administration and uniformity of dosage. The expression "unit dosage form" as used herein refers to a physically discrete unit of agent appropriate for the patient to be treated. It will be understood, however, that the total daily usage of the compounds and compositions of the present invention will be decided by the attending physician within the scope of sound medical judgment. The specific effective dose level for any particular patient or organism will depend upon a variety of factors including the disorder being treated and the severity of the disorder; the activity of the specific compound employed; the specific composition employed; the age, body weight, general health, sex and diet of the patient; the time of administration, route of administration, and rate of excretion of the specific compound employed; the duration of the treatment; drugs used in combination or coincidental with the specific compound employed, and like factors well known in the medical arts.

[0716] Pharmaceutically acceptable compositions of this invention can be administered to humans and other animals orally, rectally, parenterally, intracisternally, intravaginally, intraperitoneally, topically (as by powders, ointments, or drops), bucally, as an oral or nasal spray, or the like. In certain embodiments, the compounds of the invention may be administered orally or parenterally at dosage levels of about 0.01 mg/kg to about 50 mg/kg and preferably from about 1 mg/kg to about 25 mg/kg, of subject body weight per day, one or more times a day, to obtain the desired therapeutic effect.

[0717] Liquid dosage forms for oral administration include, but are not limited to, pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs. In addition to the active compounds, the liquid dosage forms may contain inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor, and sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof. Besides inert diluents, the oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.

[0718] Injectable preparations, for example, sterile injectable aqueous or oleaginous suspensions may be formulated according to the known art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution, suspension or emulsion in a nontoxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution, U.S.P. and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil can be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid are used in the preparation of injectables.

[0719] Injectable formulations can be sterilized, for example, by filtration through a bacterial-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable medium prior to use.

[0720] In order to prolong the effect of a compound of the present invention, it is often desirable to slow the absorption of the compound from subcutaneous or intramuscular injection. This may be accomplished by the use of a liquid suspension of crystalline or amorphous material with poor water solubility. The rate of absorption of the compound then depends upon its rate of dissolution that, in turn, may depend upon crystal size and crystalline form. Alternatively, delayed absorption of a parenterally administered compound form is accomplished by dissolving or suspending the compound in an oil vehicle. Injectable depot forms are made by forming microencapsule matrices of the compound in biodegradable polymers such as polylactide-polyglycolide. Depending upon the ratio of compound to

polymer and the nature of the particular polymer employed, the rate of compound release can be controlled. Examples of other biodegradable polymers include poly(orthoesters) and poly(anhydrides). Depot injectable formulations are also prepared by entrapping the compound in liposomes or microemulsions that are compatible with body tissues.

[0721] Compositions for rectal or vaginal administration are preferably suppositories which can be prepared by mixing the compounds of this invention with suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol or a suppository wax which are solid at ambient temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active compound.

[0722] Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules. In such solid dosage forms, the active compound is mixed with at least one inert, pharmaceutically acceptable excipient or carrier such as sodium citrate or dicalcium phosphate and/or a) fillers or extenders such as starches, lactose, sucrose, glucose, mannitol, and silicic acid, b) binders such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidinone, sucrose, and acacia, c) humectants such as glycerol, d) disintegrating agents such as agar--agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate, e) solution retarding agents such as paraffin, f) absorption accelerators such as quaternary ammonium compounds, g) wetting agents such as, for example, cetyl alcohol and glycerol monostearate, h) absorbents such as kaolin and bentonite clay, and i) lubricants such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof. In the case of capsules, tablets and pills, the dosage form may also comprise buffering agents.

[0723] Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like. The solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings and other coatings well known in the pharmaceutical formulating art. They may optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner. Examples of embedding compositions that can be used include polymeric substances and waxes. Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polethylene glycols and the like.

[0724] The active compounds can also be in micro-encapsulated form with one or more excipients as noted above. The solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings, release controlling coatings and other coatings well known in the pharmaceutical formulating art. In such solid dosage forms the active compound may be admixed with at least one inert diluent such as sucrose, lactose or starch. Such dosage forms may also comprise, as is normal practice, additional substances other than inert diluents, e.g., tableting lubricants and other tableting aids such a magnesium stearate and microcrystalline cellulose. In the case of capsules, tablets and pills, the dosage forms may also comprise buffering agents. They may optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner. Examples of embedding compositions that can be used include polymeric substances and waxes.

[0725] Dosage forms for topical or transdermal administration of a compound of this invention include ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalants or patches. The active component is admixed under sterile conditions with a pharmaceutically acceptable carrier and any needed preservatives or buffers as may be required. Ophthalmic formulation, ear drops, and eye drops are also contemplated as being within the scope of this invention. Additionally, the present invention contemplates the use of transdermal patches, which have the added advantage of providing controlled delivery of a compound to the body. Such dosage forms can be made by dissolving or dispensing the compound in the proper medium. Absorption enhancers can also be used to increase the flux of the compound across the skin. The rate can be controlled by either providing a rate controlling membrane or by dispersing the compound in a polymer matrix or gel.

Dosage Amounts and Regimens

[0726] In accordance with the methods of the present disclosure, the compounds of the disclosure are administered to the subject in a therapeutically effective amount, *e.g.,* to reduce or ameliorate symptoms of the disorder in the subject. This amount is readily determined by the skilled artisan, based upon known procedures, including analysis of titration curves established *in vivo* and methods and assays disclosed herein.

[0727] In some embodiments, the methods comprise administration of a therapeutically effective dosage of the compounds of the disclosure. In some embodiments, the

therapeutically effective dosage is at least about 0.0001 mg/kg body weight, at least about 0.001 mg/kg body weight, at least about 0.01 mg/kg body weight, at least about 0.05 mg/kg body weight, at least about 0.1 mg/kg body weight, at least about 0.25 mg/kg body weight, at least about 0.3 mg/kg body weight, at least about 0.5 mg/kg body weight, at least about 0.75 mg/kg body weight, at least about 1 mg/kg body weight, at least about 2 mg/kg body weight, at least about 3 mg/kg body weight, at least about 4 mg/kg body weight, at least about 5 mg/kg body weight, at least about 6 mg/kg body weight, at least about 7 mg/kg body weight, at least about 8 mg/kg body weight, at least about 9 mg/kg body weight, at least about 10 mg/kg body weight, at least about 15 mg/kg body weight, at least about 20 mg/kg body weight, at least about 25 mg/kg body weight, at least about 30 mg/kg body weight, at least about 40 mg/kg body weight, at least about 50 mg/kg body weight, at least about 75 mg/kg body weight, at least about 100 mg/kg body weight, at least about 200 mg/kg body weight, at least about 250 mg/kg body weight, at least about 300 mg/kg body weight, at least about 350 mg/kg body weight, at least about 400 mg/kg body weight, at least about 450 mg/kg body weight, at least about 500 mg/kg body weight, at least about 550 mg/kg body weight, at least about 600 mg/kg body weight, at least about 650 mg/kg body weight, at least about 700 mg/kg body weight, at least about 750 mg/kg body weight, at least about 800 mg/kg body weight, at least about 900 mg/kg body weight, or at least about 1000 mg/kg body weight. It will be recognized that any of the dosages listed herein may constitute an upper or lower dosage range, and may be combined with any other dosage to constitute a dosage range comprising an upper and lower limit.

[0728] In some embodiments, the therapeutically effective dosage is in the range of about 0.1 mg to about 10 mg/kg body weight, about 0.1 mg to about 6 mg/kg body weight, about 0.1 mg to about 4 mg /kg body weight, or about 0.1 mg to about 2 mg/kg body weight.

[0729] In some embodiments the therapeutically effective dosage is in the range of about 1 to 500 mg, about 2 to 150 mg, about 2 to 120 mg, about 2 to 80 mg, about 2 to 40 mg, about 5 to 150 mg, about 5 to 120 mg, about 5 to 80 mg, about 10 to 150 mg, about 10 to 120 mg, about 10 to 80 mg, about 10 to 40 mg, about 20 to 150 mg, about 20 to 120 mg, about 20 to 80 mg, about 20 to 40 mg, about 40 to 150 mg, about 40 to 120 mg or about 40 to 80 mg.

[0730] In some embodiments, the methods comprise a single dosage or administration (*e.g.*, as a single injection or deposition). Alternatively, in some embodiments, the methods comprise administration once daily, twice daily, three times daily or four times daily to a subject in need thereof for a period of from about 2 to about 28 days, or from about 7 to about

10 days, or from about 7 to about 15 days, or longer. In some embodiments, the methods comprise chronic administration. In yet other embodiments, the methods comprise administration over the course of several weeks, months, years or decades. In still other embodiments, the methods comprise administration over the course of several weeks. In still other embodiments, the methods comprise administration over the course of several months. In still other embodiments, the methods comprise administration over the course of several years. In still other embodiments, the methods comprise administration over the course of several decades.

[0731] The dosage administered can vary depending upon known factors such as the pharmacodynamic characteristics of the active ingredient and its mode and route of administration; time of administration of active ingredient; age, sex, health and weight of the recipient; nature and extent of symptoms; kind of concurrent treatment, frequency of treatment and the effect desired; and rate of excretion. These are all readily determined and may be used by the skilled artisan to adjust or titrate dosages and/or dosing regimens.

Inhibition of Protein Kinases

[0732] According to one embodiment, the invention relates to a method of inhibiting protein kinase activity in a biological sample comprising the step of contacting said biological sample with a compound of this invention, or a composition comprising said compound. According to another embodiment, the invention relates to a method of inhibiting activity of a PI3K, or a mutant thereof, in a biological sample comprising the step of contacting said biological sample with a compound of this invention, or a composition comprising said compound. According to another embodiment, the invention relates to a method of inhibiting activity of PI3Kα, or a mutant thereof, in a biological sample comprising the step of contacting said biological sample with a compound of this invention, or a composition comprising said compound. In some embodiments, the PI3Kα is a mutant PI3Kα. In some embodiments, the PI3Kα contains at least one of the following mutations: H1047R, E542K, and E545K.

[0733] In another embodiment, the invention provides a method of selectively inhibiting PI3Kα over one or both of PI3Kδ and PI3Kγ. In some embodiments, a compound of the present invention is more than 5-fold selective over PI3Kδ and PI3Kγ. In some embodiments, a compound of the present invention is more than 10-fold selective over PI3Kδ and PI3Kγ. In some embodiments, a compound of the present invention is more than 50-fold

selective over PI3Kδ and PI3Kγ. In some embodiments, a compound of the present invention is more than 100-fold selective over PI3Kδ and PI3Kγ. In some embodiments, a compound of the present invention is more than 200-fold selective over PI3Kδ and PI3Kγ. In some embodiments, the PI3Kα is a mutant PI3Kα. In some embodiments, the PI3Kα contains at least one of the following mutations: H1047R, E542K, and E545K.

[0734] In another embodiment, the invention provides a method of selectively inhibiting a mutant PI3Kα over a wild-type PI3Kα. In some embodiments, a compound of the present invention is more than 5-fold selective for mutant PI3Kα over wild-type PI3Kα. In some embodiments, a compound of the present invention is more than 10-fold selective for mutant PI3Kα over wild-type PI3Kα. In some embodiments, a compound of the present invention is more than 50-fold selective for mutant PI3Kα over wild-type PI3Kα. In some embodiments, a compound of the present invention is more than 100-fold selective for mutant PI3Kα over wild-type PI3Kα. In some embodiments, a compound of the present invention is more than 200-fold selective for mutant PI3Kα over wild-type PI3Kα. In some embodiments, the mutant PI3Kα contains at least one of the following mutations: H1047R, E542K, and E545K.

[0735] The term "biological sample", as used herein, includes, without limitation, cell cultures or extracts thereof; biopsied material obtained from a mammal or extracts thereof; and blood, saliva, urine, feces, semen, tears, or other body fluids or extracts thereof.

[0736] Inhibition of activity of a PI3K (for example, PI3Kα, or a mutant thereof) in a biological sample is useful for a variety of purposes that are known to one of skill in the art. Examples of such purposes include, but are not limited to, blood transfusion, organ-transplantation, biological specimen storage, and biological assays.

[0737] Another embodiment of the present invention relates to a method of inhibiting protein kinase activity in a patient comprising the step of administering to said patient a compound of the present invention, or a composition comprising said compound.

[0738] According to another embodiment, the invention relates to a method of inhibiting activity of a PI3K, or a mutant thereof, in a patient comprising the step of administering to said patient a compound of the present invention, or a composition comprising said compound. In some embodiments, the invention relates to a method of inhibiting activity of PI3Kα, or a mutant thereof, in a patient comprising the step of administering to said patient a compound of the present invention, or a composition comprising said compound. In some

embodiments, the PI3Kα is a mutant PI3Kα. In some embodiments, the PI3Kα contains at least one of the following mutations: H1047R, E542K, and E545K.

[0739] According to another embodiment, the present invention provides a method for treating a disorder mediated by a PI3K, or a mutant thereof, in a patient in need thereof, comprising the step of administering to said patient a compound according to the present invention or pharmaceutically acceptable composition thereof. In some embodiments, the present invention provides a method for treating a disorder mediated by PI3Kα, or a mutant thereof, in a patient in need thereof, comprising the step of administering to said patient a compound according to the present invention or pharmaceutically acceptable composition thereof. In some embodiments, the PI3Kα is a mutant PI3Kα. In some embodiments, the PI3Kα contains at least one of the following mutations: H1047R, E542K, and E545K.

[0740] According to another embodiment, the present invention provides a method of inhibiting signaling activity of PI3Kα, or a mutant thereof, in a subject, comprising administering a therapeutically effective amount of a compound according to the present invention, or a pharmaceutically acceptable composition thereof, to a subject in need thereof. In some embodiments, the present invention provides a method of inhibiting PI3Kα signaling activity in a subject, comprising administering a therapeutically effective amount of a compound according to the present invention, or a pharmaceutically acceptable composition thereof, to a subject in need thereof. In some embodiments, the PI3Kα is a mutant PI3Kα. In some embodiments, the PI3Kα contains at least one of the following mutations: H1047R, E542K, and E545K. In some embodiments, the subject has a mutant PI3Kα. In some embodiments, the subject has PI3Kα containing at least one of the following mutations: H1047R, E542K, and E545K.

[0741] The compounds described herein can also inhibit PI3Kα function through incorporation into agents that catalyze the destruction of PI3Kα. For example, the compounds can be incorporated into proteolysis targeting chimeras (PROTACs). A PROTAC is a bifunctional molecule, with one portion capable of engaging an E3 ubiquitin ligase, and the other portion having the ability to bind to a target protein meant for degradation by the cellular protein quality control machinery. Recruitment of the target protein to the specific E3 ligase results in its tagging for destruction (i.e., ubiquitination) and subsequent degradation by the proteasome. Any E3 ligase can be used. The portion of the PROTAC that engages the E3 ligase is connected to the portion of the PROTAC that engages

the target protein via a linker which consists of a variable chain of atoms. Recruitment of PI3Kα to the E3 ligase will thus result in the destruction of the PI3Kα protein. The variable chain of atoms can include, for example, rings, heteroatoms, and/or repeating polymeric units. It can be rigid or flexible. It can be attached to the two portions described above using standard techniques in the art of organic synthesis.

Combination Therapies

[0742] Depending upon the particular disorder, condition, or disease, to be treated, additional therapeutic agents, that are normally administered to treat that condition, may be administered in combination with compounds and compositions of this invention. As used herein, additional therapeutic agents that are normally administered to treat a particular disease, or condition, are known as "appropriate for the disease, or condition, being treated."

[0743] Additionally, PI3K serves as a second messenger node that integrates parallel signaling pathways, and evidence is emerging that the combination of a PI3K inhibitor with inhibitors of other pathways will be useful in treating cancer and cellular proliferative diseases.

[0744] Accordingly, in certain embodiments, the method of treatment comprises administering the compound or composition of the invention in combination with one or more additional therapeutic agents. In certain other embodiments, the methods of treatment comprise administering the compound or composition of the invention as the only therapeutic agent.

[0745] Approximately 20-30% of human breast cancers overexpress Her-2/neu-ErbB2, the target for the drug trastuzumab. Although trastuzumab has demonstrated durable responses in some patients expressing Her2/neu-ErbB2, only a subset of these patients respond. Recent work has indicated that this limited response rate can be substantially improved by the combination of trastuzumab with inhibitors of PI3K or the PI13K/AKT pathway (Chan et al., Breast Can. Res. Treat. 91:187 (2005), Woods Ignatoski et al., Brit. J. Cancer 82:666 (2000), Nagata et al., Cancer Cell 6:117 (2004)). Accordingly, in certain embodiments, the method of treatment comprises administering the compound or composition of the invention in combination with trastuzumab. In certain embodiments, the cancer is a human breast cancer that overexpresses Her-2/neu-ErbB2.

[0746] A variety of human malignancies express activating mutations or increased levels of Her1/EGFR and a number of antibody and small molecule inhibitors have been developed

against this receptor tyrosine kinase including tarceva, gefitinib and erbitux. However, while EGFR inhibitors demonstrate anti-tumor activity in certain human tumors (e.g., NSCLC), they fail to increase overall patient survival in all patients with EGFR-expressing tumors. This may be rationalized by the fact that many downstream targets of Her1/EGFR are mutated or deregulated at high frequencies in a variety of malignancies, including the PI3K/Akt pathway.

[0747] For example, gefitinib inhibits the growth of an adenocarcinoma cell line in in vitro assays. Nonetheless, sub-clones of these cell lines can be selected that are resistant to gefitinib that demonstrate increased activation of the PI3/Akt pathway. Down-regulation or inhibition of this pathway renders the resistant sub-clones sensitive to gefitinib (Kokubo et al., Brit. J. Cancer 92:1711 (2005)). Furthermore, in an in vitro model of breast cancer with a cell line that harbors a PTEN mutation and over-expresses EGFR inhibition of both the PI3K/Akt pathway and EGFR produced a synergistic effect (She et al., Cancer Cell 8:287-297 (2005)). These results indicate that the combination of gefitinib and PI3K/Akt pathway inhibitors would be an attractive therapeutic strategy in cancer.

[0748] Accordingly, in certain embodiments, the method of treatment comprises administering the compound or composition of the invention in combination with an inhibitor of Her1/EGFR. In certain embodiments, the method of treatment comprises administering the compound or composition of the invention in combination with one or more of tarceva, gefitinib, and erbitux. In certain embodiments, the method of treatment comprises administering the compound or composition of the invention in combination with gefitinib. In certain embodiments, the cancer expresses activating mutations or increased levels of Her1/EGFR.

[0749] The combination of AEE778 (an inhibitor of Her-2/neu/ErbB2, VEGFR and EGFR) and RAD001 (an inhibitor of mTOR, a downstream target of Akt) produced greater combined efficacy that either agent alone in a glioblastoma xenograft model (Goudar et al., Mol. Cancer. Ther. 4:101-112 (2005)).

[0750] Anti-estrogens, such as tamoxifen, inhibit breast cancer growth through induction of cell cycle arrest that requires the action of the cell cycle inhibitor p27Kip. Recently, it has been shown that activation of the Ras-Raf-MAP Kinase pathway alters the phosphorylation status of p27Kip such that its inhibitory activity in arresting the cell cycle is attenuated, thereby contributing to anti-estrogen resistance (Donovan, et al, J. Biol. Chem. 276:40888,

(2001)). As reported by Donovan et al., inhibition of MAPK signaling through treatment with MEK inhibitor reversed the aberrant phosphorylation status of p27 in hormone refractory breast cancer cell lines and in so doing restored hormone sensitivity. Similarly, phosphorylation of p27Kip by Aid also abrogates its role to arrest the cell cycle (Viglietto et al., Nat. Med. 8:1145 (2002)).

[0751] Accordingly, in certain embodiments, the method of treatment comprises administering the compound or composition of the invention in combination with a treatment for a hormone-dependent cancer. In certain embodiments, the method of treatment comprises administering the compound or composition of the invention in combination with tamoxifen. In certain embodiments, the cancer is a hormone dependent cancer, such as breast and prostate cancers. By this use, it is aimed to reverse hormone resistance commonly seen in these cancers with conventional anticancer agents.

[0752] In hematological cancers, such as chronic myelogenous leukemia (CML), chromosomal translocation is responsible for the constitutively activated BCR-Abl tyrosine kinase. The afflicted patients are responsive to imatinib, a small molecule tyrosine kinase inhibitor, as a result of inhibition of Abl kinase activity. However, many patients with advanced stage disease respond to imatinib initially, but then relapse later due to resistance-conferring mutations in the Abl kinase domain. In vitro studies have demonstrated that BCR-Ab1 employs the Ras-Raf kinase pathway to elicit its effects. In addition, inhibiting more than one kinase in the same pathway provides additional protection against resistance-conferring mutations.

[0753] Accordingly, in another aspect, the compounds and compositions of the invention are used in combination with at least one additional agent selected from the group of kinase inhibitors, such as imatinib, in the treatment of hematological cancers, such as chronic myelogenous leukemia (CML). By this use, it is aimed to reverse or prevent resistance to said at least one additional agent.

[0754] Because activation of the PI3K/Akt pathway drives cell survival, inhibition of the pathway in combination with therapies that drive apoptosis in cancer cells, including radiotherapy and chemotherapy, will result in improved responses (Ghobrial et al., CA Cancer J. Clin 55:178-194 (2005)). As an example, combination of PI3 kinase inhibitor with carboplatin demonstrated synergistic effects in both in vitro proliferation and apoptosis

assays as well as in in vivo tumor efficacy in a xenograft model of ovarian cancer (Westfall and Skinner, Mol. Cancer Ther. 4:1764-1771 (2005)).

[0755] In some embodiments, the one or more additional therapeutic agents is selected from antibodies, antibody-drug conjugates, kinase inhibitors, immunomodulators, and histone deacetylase inhibitors. Synergistic combinations with PIK3CA inhibitors and other therapeutic agents are described in, for example, Castel et al., Mol. Cell Oncol. (2014)1(3) e963447.

[0756] In some embodiments, the one or more additional therapeutic agent is selected from the following agents, or a pharmaceutically acceptable salt thereof: BCR-ABL inhibitors (see e.g. Ultimo et al. Oncotarget (2017) 8 (14) 23213-23227.): e.g. imatinib, inilotinib, nilotinib, dasatinib, bosutinib, ponatinib, bafetinib, danusertib, saracatinib, PF03814735; ALK inhibitors (see e.g. Yang et al. Tumour Biol. (2014) 35 (10) 9759-67): e.g. crizotinib, NVP-TAE684, ceritinib, alectinib, brigatinib, entrecinib, lorlatinib; BRAF inhibitors (see e.g. Silva et al. Mol. Cancer Res. (2014) 12, 447-463): e.g. vemurafenib, dabrafenib; FGFR inhibitors (see e.g. Packer et al. Mol. Cancer Ther. (2017) 16(4) 637-648): e.g. infigratinib, dovitinib, erdafitinib, TAS-120, pemigatinib, BLU-554, AZD4547; FLT3 inhibitors: e.g. sunitinib, midostaurin, tanutinib, sorafenib, lestaurtinib, quizartinib, and crenolanib; MEK Inhibitors (see e.g. Jokinen et al. Ther. Adv. Med. Oncol. (2015) 7(3) 170-180): e.g. trametinib, cobimetinib, binimetinib, selumetinib; ERK inhibitors: e.g. ulixertinib, MK 8353, LY 3214996; KRAS inhibitors: e.g. AMG-510, MRTX849, ARS-3248; Tyrosine kinase inhibitors (see e.g. Makhov et al. Mol. Cancer. Ther. (2012) 11(7) 1510-1517): e.g. erlotinib, linifanib, sunitinib, pazopanib; Epidermal growth factor receptor (EGFR) inhibitors (see e.g. She et al. BMC Cancer (2016) 16, 587): gefitnib, osimertinib, cetuximab, panitumumab; HER2 receptor inhibitors (see e.g. Lopez et al. Mol. Cancer Ther. (2015) 14(11) 2519-2526): e.g. trastuzumab, pertuzumab, neratinib, lapatinib, lapatinib; MET inhibitors (see e.g. Hervieu et al. Front. Mol. Biosci. (2018) 5, 86): e.g. crizotinib, cabozantinib; CD20 antibodies: e.g. rituximab, tositumomab, ofatumumab; DNA Synthesis inhibitors: e.g. capecitabine, gemcitabine, nelarabine, hydroxycarbamide; Antineoplastic agents (see e.g. Wang et al. Cell Death & Disease (2018) 9, 739): e.g. oxaliplatin, carboplatin, cisplatin;; Immunomodulators: e.g. afutuzumab, lenalidomide, thalidomide, pomalidomide; CD40 inhibitors: e.g. dacetuzumab; Pro-apoptotic receptor agonists (PARAs): e.g. dulanermin; Heat Shock Protein (HSP) inhibitors (see e.g. Chen et al. Oncotarget (2014) 5 (9). 2372-2389): e.g. tanespimycin; Hedgehog antagonists (see e.g. Chaturvedi et al. Oncotarget (2018) 9 (24), 16619-16633):

e.g. vismodegib; Proteasome inhibitors (see e.g. Lin et al. Int. J. Oncol. (2014) 44 (2), 557-562): e.g. bortezomib; PI3K inhibitors: e.g. pictilisib, dactolisib, alpelisib, buparlisib, taselisib, idelalisib, duvelisib, umbralisib; SHP2 inhibitors (see e.g. Sun et al. Am. J. Cancer Res. (2019) 9 (1), 149-159: e.g. SHP099, RMC-4550, RMC-4630);; BCL-2 inhibitors (see e.g. Bojarczuk et al. Blood (2018) 133 (1), 70-80): e.g. venetoclax; Aromatase inhibitors (see e.g. Mayer et al. Clin. Cancer Res. (2019) 25 (10), 2975-2987): exemestane, letrozole, anastrozole, fulvestrant, tamoxifen; mTOR inhibitors (see e.g. Woo et al. Oncogenesis (2017) 6, e385): e.g. temsirolimus, ridaforolimus, everolimus, sirolimus; CTLA-4 inhibitors (see e.g. O'Donnell et al. (2018) 48, 91-103): e.g. tremelimumab, ipilimumab; PD1 inhibitors (see O'Donnell, supra): e.g. nivolumab, pembrolizumab; an immunoadhesin; Other immune checkpoint inhibitors (see e.g. Zappasodi et al. Cancer Cell (2018) 33, 581-598, where the term "immune checkpoint" refers to a group of molecules on the cell surface of CD4 and CD8 T cells. Immune checkpoint molecules include, but are not limited to, Programmed Death 1 (PD-1), Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4), B7H1, B7H4, OX-40, CD 137, CD40, and LAG3. Immunotherapeutic agents which can act as immune checkpoint inhibitors useful in the methods of the present disclosure, include, but are not limited to, inhibitors of PD-L1, PD-L2, CTLA4, TIM3, LAG3, VISTA, BTLA, TIGIT, LAIR1, CD 160, 2B4 and/or TGFR beta): e.g. pidilizumab, AMP-224; PDL1 inhibitors (see e.g. O'Donnell supra): e.g. MSB0010718C; YW243.55.S70, MPDL3280A; MEDI-4736, MSB-0010718C, or MDX-1105;; Histone deacetylase inhibitors (HDI, see e.g. Rahmani et al. Clin. Cancer Res. (2014) 20(18), 4849-4860): e.g. vorinostat;; Androgen Receptor inhibitors (see e.g. Thomas et al. Mol. Cancer Ther. (2013) 12(11), 2342-2355): e.g. enzalutamide, abiraterone acetate, orteronel, galeterone, seviteronel, bicalutamide, flutamide; Androgens: e.g. fluoxymesterone; CDK4/6 inhibitors (see e.g. Gul et al. Am. J. Cancer Res. (2018) 8(12), 2359-2376): e.g. alvocidib, palbociclib, ribociclib, trilaciclib, abemaciclib.

[0757] In some embodiments, the one or more additional therapeutic agent is selected from the following agents: anti-FGFR antibodies; FGFR inhibitors, cytotoxic agents; Estrogen Receptor-targeted or other endocrine therapies, immune-checkpoint inhibitors, CDK inhibitors, Receptor Tyrosine Kinase inhibitors, BRAF inhibitors, MEK inhibitors, other PI3K inhibitors, SHP2 inhibitors, and SRC inhibitors. (See Katoh, Nat. Rev. Clin. Oncol. (2019), 16:105-122; Chae, et al. Oncotarget (2017), 8:16052-16074; Formisano et al., Nat. Comm. (2019), 10:1373-1386; and references cited therein.)

[0758] The structure of the active compounds identified by code numbers, generic or trade names may be taken from the actual edition of the standard compendium "The Merck Index" or from databases, e.g. Patents International (e.g. IMS World Publications).

[0759] A compound of the current invention may also be used in combination with known therapeutic processes, for example, the administration of hormones or radiation. In certain embodiments, a provided compound is used as a radiosensitizer, especially for the treatment of tumors which exhibit poor sensitivity to radiotherapy.

[0760] A compound of the current invention can be administered alone or in combination with one or more other therapeutic compounds, possible combination therapy taking the form of fixed combinations or the administration of a compound of the invention and one or more other therapeutic compounds being staggered or given independently of one another, or the combined administration of fixed combinations and one or more other therapeutic compounds. A compound of the current invention can besides or in addition be administered especially for tumor therapy in combination with chemotherapy, radiotherapy, immunotherapy, phototherapy, surgical intervention, or a combination of these. Long-term therapy is equally possible as is adjuvant therapy in the context of other treatment strategies, as described above. Other possible treatments are therapy to maintain the patient's status after tumor regression, or even chemopreventive therapy, for example in patients at risk.

[0761] Those additional agents may be administered separately from an inventive compound-containing composition, as part of a multiple dosage regimen. Alternatively, those agents may be part of a single dosage form, mixed together with a compound of this invention in a single composition. If administered as part of a multiple dosage regime, the two active agents may be submitted simultaneously, sequentially or within a period of time from one another normally within five hours from one another.

[0762] As used herein, the term “combination,” “combined,” and related terms refers to the simultaneous or sequential administration of therapeutic agents in accordance with this invention. For example, a compound of the present invention may be administered with another therapeutic agent simultaneously or sequentially in separate unit dosage forms or together in a single unit dosage form. Accordingly, the present invention provides a single unit dosage form comprising a compound of the current invention, an additional therapeutic agent, and a pharmaceutically acceptable carrier, adjuvant, or vehicle.

[0763] The amount of both an inventive compound and additional therapeutic agent (in those compositions which comprise an additional therapeutic agent as described above) that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration. Preferably, compositions of this invention should be formulated so that a dosage of between 0.01 - 100 mg/kg body weight/day of an inventive compound can be administered.

[0764] In those compositions which comprise an additional therapeutic agent, that additional therapeutic agent and the compound of this invention may act synergistically. Therefore, the amount of additional therapeutic agent in such compositions will be less than that required in a monotherapy utilizing only that therapeutic agent. In such compositions a dosage of between 0.01 – 1,000 μg/kg body weight/day of the additional therapeutic agent can be administered.

[0765] The amount of additional therapeutic agent present in the compositions of this invention will be no more than the amount that would normally be administered in a composition comprising that therapeutic agent as the only active agent. Preferably the amount of additional therapeutic agent in the presently disclosed compositions will range from about 50% to 100% of the amount normally present in a composition comprising that agent as the only therapeutically active agent.

[0766] The compounds of this invention, or pharmaceutical compositions thereof, may also be incorporated into compositions for coating an implantable medical device, such as prostheses, artificial valves, vascular grafts, stents and catheters. Vascular stents, for example, have been used to overcome restenosis (re-narrowing of the vessel wall after injury). However, patients using stents or other implantable devices risk clot formation or platelet activation. These unwanted effects may be prevented or mitigated by pre-coating the device with a pharmaceutically acceptable composition comprising a kinase inhibitor. Implantable devices coated with a compound of this invention are another embodiment of the present invention.

[0767] Any of the compounds and/or compositions of the disclosure may be provided in a kit comprising the compounds and/or compositions. Thus, in some embodiments, the compound and/or composition of the disclosure is provided in a kit.

[0768] The disclosure is further described by the following non-limiting Examples.

EXAMPLES

[0769] Examples are provided herein to facilitate a more complete understanding of the disclosure. The following examples serve to illustrate the exemplary modes of making and practicing the subject matter of the disclosure. However, the scope of the disclosure is not to be construed as limited to specific embodiments disclosed in these examples, which are illustrative only.

[0770] As depicted in the Examples below, in certain exemplary embodiments, compounds are prepared according to the following general procedures. It will be appreciated that, although the general methods depict the synthesis of certain compounds of the present invention, the following general methods, and other methods known to one of ordinary skill in the art, can be applied to other classes and subclasses and species of each of these compounds, as described herein. Additional compounds of the invention were prepared by methods substantially similar to those described herein in the Examples and methods known to one skilled in the art.

[0771] In the description of the synthetic methods described below, unless otherwise stated, it is to be understood that all reaction conditions (for example, reaction solvent, atmosphere, temperature, duration, and workup procedures) are selected from the standard conditions for that reaction, unless otherwise indicated. The starting materials for the Examples are either commercially available or are readily prepared by standard methods from known materials.

List of Abbreviations

aq: aqueous
Ac: acetyl
ACN or MeCN: acetonitrile
AmF: ammonium formate
anhyd.: anhydrous
BINAP: (±)-2,2′-Bis(diphenylphosphino)-1,1′-binaphthalene
Bn: Benzyl
conc.: concentrated
DBU: 1,8-Diazabicyclo[5.4.0]undec-7-ene
DCE: Dichloroethane
DCM: Dichloromethane
DIPEA: Diisopropylamine
DMF: N,N-dimethylformamide

DMP: Dess-Martin periodinane

DMPU: N,N′-Dimethylpropyleneurea

DMSO: dimethylsulfoxide

DIPEA: diisopropylethylamine

EA or EtOAc: ethyl acetate

EDCI, EDC, or EDAC: 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide

equiv or eq: molar equivalents

Et: ethyl

HATU: 1-[Bis(dimethylamino)methylene]-1*H*-1,2,3-triazolo[4,5-*b*]pyridinium 3-oxid Hexafluorophosphate

HPLC: high pressure liquid chromatography

LCMS or LC-MS: liquid chromatography-mass spectrometry

Ms: methanesulfonyl

NBS: N-bromosuccinimide

NMR: nuclear magnetic resonance

PE: petroleum ether

PMB: *p*-methoxybenzyl

rt or RT: room temperature

sat: saturated

TBS: *tert*-butyldimethylsilyl

TEA: triethylamine

Tf: trifluoromethanesulfonate

TFA: trifluoroacetic acid

THF: tetrahydrofuran

TLC: thin layer chromatography

Tol: toluene

UV: ultra violet

LC-MS Method Summaries

LCMS Method 1

Instrumentation

LC: Waters Acquity UPLC

UV Detection: Waters Acquity PDA (198-360nm), 20 pts/sec, 220 and 254nm

MS Detection: Waters SQD, ESI (ES+/ES-, 120-1200 amu)

Mobile Phase

Eluent A1: Milli-Q H_2O + 10mM Ammonium Formate pH: 3.8 (AmF)

Eluent B1: ACN

Column Waters Acquity UPLC CSH C18, 1.8µm, 2.1 x 30mm at 40°C

Gradient 5% to 100% B in 2.0 minutes; hold 100% B for 0.7 minute

Flow 0.9 mL/min

Run Time 2.7 minutes

LCMS Method 2

Instrumentation

LC: Waters Acquity UPLC

UV Detection: Waters Acquity PDA (198-360nm), 20 pts/sec, 220 and 254nm

MS Detection: Waters SQD, ESI (ES+/ES-, 120-1200 amu)

Mobile Phase

Eluent A1: Milli-Q H_2O + 10mM Ammonium Formate pH: 3.8 (AmF)

Eluent B1: ACN

Column Waters Acquity UPLC CSH C18, 1.8µm, 2.1 x 30mm at 40°C


Gradient 5% to 100% B in 5.2 minutes; hold 100% B for 1.2 minutes

Flow 0.9 mL/min


Run Time 7 minutes

Example 1

N-(1-Oxo-3-(*o*-tolyl)isoindolin-4-yl)benzo[*b*]thiophene-3-carboxamide (I-1)




2-(4-methoxybenzyl)-4-nitroisoindoline-1,3-dione



[0772] Step 1: To a mixture of 4-nitroisobenzofuran-1,3-dione (40.0 g, 207 mmol, 1.00 eq.) in HOAc (500 mL) was added $PMBNH_2$ (36.9 g, 269 mmol, 34.9 mL, 1.30 eq.) at 25°C, then heated to 85°C and stirred at 85°C for 10 hrs. Two batches of the mixture were poured into water (1.00 L), then filtered and the filter cake was washed with petroleum ether (200 mL), dried in vacuum to afford 2-(4-methoxybenzyl)-4-nitroisoindoline-1,3-dione (120 g, 383 mmol, 92.6% yield, 100% purity) as a light yellow solid. MS: m/z = 334.9 $[M+Na]^+$; ^1H NMR (400 MHz, DMSO-d_6) δ 8.28 (d, J = 8.0 Hz, 1H), 8.17 (d, J = 7.2 Hz, 1H), 8.05 (t, J = 8.0 Hz, 1H), 7.27 (d, J = 8.4 Hz, 2H), 6.88 (d, J = 8.4 Hz, 2H), 4.70 (s, 2H), 3.72 (s, 3H).


4-amino-2-(4-methoxybenzyl)isoindoline-1,3-dione



[0773] Step 2: To a solution of 2-(4-methoxybenzyl)-4-nitroisoindoline-1,3-dione (48.8 g, 156 mmol, 1.00 equiv.) in EtOH (700 mL)/H_2O (200 mL) was added NH_4Cl (33.4 g, 625 mmol, 4.00 eq.) at 25°C. The mixture was heated to 40°C and Fe (26.2 g, 469 mmol, 3.00 eq.) was added into the mixture at 40°C. Then the mixture was heated to 80°C and stirred at 80°C for 1 hr. Two batches of the mixture were filtered, and the filter cake was washed with


ethyl acetate (5 x 800 mL). The filtrate was concentrated in vacuum to afford a residue. To the residue was added water (400 mL) and extracted with ethyl acetate (3 x 800 mL). The combined organic layer was washed with brine (800 mL), dried over Na_2SO_4, and filtered. The filtrate was concentrated to afford 4-amino-2-(4-methoxybenzyl)isoindoline-1,3-dione (85.5 g, 298 mmol, 95.5% yield, 98.5% purity) as a yellow solid. MS: m/z = 283.1 $[M+H]^+$; ^{1}H NMR (400 MHz, DMSO-d_6) δ 7.43 (t, J = 6.0 Hz, 1H), 7.22 (d, J = 8.4Hz, 2H), 6.99-6.96 (m, 2H), 6.87 (d, J = 8.4 Hz, 2H), 6.46 (s, 2H), 4.61 (s, 2H), 3.71 (s, 3H).

4-amino-3-hydroxy-2-(4-methoxybenzyl)-3-(*o*-tolyl)isoindolin-1-one



[0774] Step 3: To a solution of 4-amino-2-(4-methoxybenzyl)isoindoline-1,3-dione (50.0 g, 174 mmol, 1.00 eq.) in DCM (1.50 L) was added *o*-tolylmagnesium bromide (1.00 M in Et_2O, 436 mL, 2.50 eq.) dropwise at 0°C, then warmed to 20°C and stirred at 20°C for 1 hr. The mixture was poured into a saturated aqueous solution of NH_4Cl (1.50 L) and extracted with ethyl acetate (3 x 800 mL). The combined organic layer was washed with brine (800 mL), dried over Na_2SO_4, and filtered. The filtrate was concentrated to afford 4-amino-3-hydroxy-2-(4-methoxybenzyl)-3-(*o*-tolyl)isoindolin-1-one (72.4 g, crude) as a yellow solid. MS: m/z = 357.4 $[M-OH]^+$.


4-amino-2-(4-methoxybenzyl)-3-(*o*-tolyl)isoindolin-1-one



[0775] Step 4: To a solution of 4-amino-3-hydroxy-2-(4-methoxybenzyl)-3-(*o*-tolyl)isoindolin-1-one (67.4 g, 180 mmol, 1.00 eq.) in DCM (680 mL) was added TFA (205 g, 1.80 mol, 133 mL, 10.0 eq.) at 25°C. The mixture was cooled to 0°C, then triethylsilane (41.9 g, 360 mmol, 57.5 mL, 2.00 eq.) was added at 0°C. The mixture was warmed to 25°C and stirred at 25°C for 1 hr. The mixture was concentrated in vacuum to afford a residue. To


the residue was added water (500 mL), the pH was adjusted to 8 by addition of ammonia, and the mixture was extracted with DCM (3 x 500 mL). The combined organic layer was washed with brine (500 mL), dried over Na_2SO_4, and filtered. The filtrate was concentrated to afford a crude product. The crude product was purified by column chromatography (SiO_2, petroleum ether/ethyl acetate=1:0 to 0:1) to afford 4-amino-2-(4-methoxybenzyl)-3-(*o*-tolyl)isoindolin-1-one (30.0 g, 81.7 mmol, 45.4% yield, 97.6% purity) as a yellow solid. MS: *m/z* = 359.1 $[M+H]^+$; ^1H NMR (400 MHz, DMSO-d_6) δ 7.56-7.55 (m, 1H), 7.28-7.24 (m, 6H), 7.10-7.00 (m, 8H), 6.99-6.74 (m, 6H), 6.48 (d, *J* = 7.6 Hz, 1H), 5.52 (s, 1H), 5.39 (s, 1H), 5.00-4.94 (m, 2H), 4.56 (s, 2H), 4.43 (s, 2H), 3.72 (s, 6H), 3.57 (d, *J* = 14.8 Hz, 1H), 3.48 (d, *J* = 15.2 Hz, 1H), 2.26 (s, 3H), 1.50 (s, 2H).

***N*-{2-[(4-methoxyphenyl)methyl]-3-(2-methylphenyl)-1-oxo-2,3-dihydro-1*H*-isoindol-4-yl}-1-benzothiophene-3-carboxamide**



[0776] Step 5: To a solution of 4-amino-2-[(4-methoxyphenyl)methyl]-3-(2-methylphenyl)-2,3-dihydro-1H-isoindol-1-one (50 mg, 0.14 mmol) in DCM (2.0 mL) was added pyridine (56 μL, 0.70 mmol, 5 eq.), 1-benzothiophene-3-carbonyl chloride (27 mg, 0.14 mmol, 1 eq.) at RT, and the mixture was stirred at RT for 1.5 hrs. The solution was concentrated by rotary evaporation. The resulting crude mixture was purified by prep-HPLC (40-80% ACN/water) to provide the desired product as a white solid (45 mg, 63% yield). MS: *m/z* = 519.3 $[M+H]^+$.


***N*-[3-(2-methylphenyl)-1-oxo-2,3-dihydro-1H-isoindol-4-yl]-1-benzothiophene-3-carboxamide (I-1)**




[0777] Step 6: *N*-{2-[(4-methoxyphenyl)methyl]-3-(2-methylphenyl)-1-oxo-2,3-dihydro-1*H*-isoindol-4-yl}-1-benzothiophene-3-carboxamide (40 mg, 0.077 mmol) was dissolved in TFA (2.0 mL). The solution was stirred at 100°C for 45 min in a microwave reactor. The solution was concentrated by rotary evaporation. The resulting crude mixture was purified by prep-HPLC (30-70% ACN/water) to provide the desired product as a white solid (18 mg, 60% yield). MS: *m/z* = 399.2 $[M+H]^+$; ^{1}H NMR (400 MHz, DMSO-d_6) δ 10.09 (s, 1H), 9.02 (s, 1H), 7.94-8.07 (m, 2H), 7.52-7.72 (m, 4H), 7.32-7.46 (m, 2H), 7.04-7.15 (m, 1H), 6.91-7.00 (m, 2H), 6.62 (br s, 1H), 6.02 (s, 1H), 2.07-2.30 (m, 3H).

Example 2

***N*-(1-Oxo-3-(*o*-tolyl)isoindolin-4-yl)bicyclo[2.2.2]octane-1-carboxamide (I-179)**




***N*-(2-(4-Methoxybenzyl)-1-oxo-3-(*o*-tolyl)isoindolin-4-yl)bicyclo[2.2.2]octane-1-carboxamide**



[0778] Step 1: A flame-dried, round-bottomed flask equipped with a magnetic stirrer bar was charged with a solution of 4-amino-2-(4-methoxybenzyl)-3-(*o*-tolyl)isoindolin-1-one (50.0 mg, 139 μmol) in dry pyridine (0.70 mL) under nitrogen, and the solution was cooled to 0 °C with stirring. A solution of bicyclo[2.2.2]octane-1-carbonyl chloride (47.9 mg, 278 μmol) in DCM (1.30 mL) was then added dropwise, and the reaction mixture warmed to ambient temperature and stirred for 16 hours. The reaction mixture was then partitioned between saturated aqueous $NaHCO_3$ solution (10 mL) and DCM (10 mL), and the mixture passed through a phase separator. The organic phase was then concentrated *in vacuo* to afford the

crude product. Purification by reverse-phase chromatography on C18 (eluting with 55–80% ACN in 10 mmol aqueous AmF) furnished *N*-(2-(4-methoxybenzyl)-1-oxo-3-(*o*-tolyl)isoindolin-4-yl)bicyclo[2.2.2]octane-1-carboxamide (43 mg, 86.4 µmol, 62% yield) as an amorphous orange solid. LC-MS (Method 1): 1.60 min, *m/z* = 495.4 $[M+H]^+$.


***N*-(1-oxo-3-(*o*-tolyl)isoindolin-4-yl)bicyclo[2.2.2]octane-1-carboxamide (I-179)**




[0779] Step 2: A solution of *N*-(2-(4-methoxybenzyl)-1-oxo-3-(*o*-tolyl)isoindolin-4-yl)bicyclo[2.2.2]octane-1-carboxamide (40.0 mg, 80.8 µmol) in TFA (0.54 mL) was heated at 90 °C with stirring in a sealed tube for 18 hours. The reaction mixture was then cooled to ambient temperature and concentrated *in vacuo*. The residue was purified directly by reverse-phase flash chromatography on C18 (eluting with 40–65% ACN in 10 mmol aqueous AmF) to afford *N*-(1-oxo-3-(*o*-tolyl)isoindolin-4-yl)bicyclo[2.2.2]octane-1-carboxamide (21.0 mg, 56.0 µmol, 70% yield) as an amorphous orange solid. LC-MS (Method 2): 2.45 min, *m/z* = 375.3 $[M+H]^+$; ^{1}H NMR (400 MHz, DMSO-d_6) δ 8.97 (s, 1H), 8.75 (s, 1H), 7.57-7.54 (m, 1H), 7.53–7.49 (m, 1H), 7.45 (dd, *J* = 7.5, 1.4 Hz, 1H), 7.18 (d, *J* = 4.0 Hz, 2H), 7.06–6.98 (m, 1H), 6.47 (br. s, 1H), 5.94 (s, 1H), 2.32 (br. s, 3H), 1.50–1.45 (m, 1H), 1.42–1.33 (m, 6H), 1.32–1.21 (m, 6H).

Example 3

***N*-(1-Oxo-3-(*o*-tolyl)isoindolin-4-yl)-[1,2,4]triazolo[4,3-*a*]pyridine-3-carboxamide (I-328)**




[1,2,4]Triazolo[4,3-*a*]pyridine-3-carbonyl chloride




[0780] Step 1: Thionyl chloride (20.0 µL, 275 µmol) was added dropwise to a stirring solution of [1,2,4]triazolo[4,3-*a*]pyridine-3-carboxylic acid (34.0 mg, 208 µmol) and DIPEA (0.15 mL, 858 µmol) in DCM (0.83 mL) at 0 °C. The reaction mixture was stirred at this temperature for 15 mins, then warmed to ambient temperature and stirred for a further 1.5 hours. The volatiles were then removed *in vacuo*, and the crude [1,2,4]triazolo[4,3-*a*]pyridine-3-carbonyl chloride was used directly in the next step, assuming quantitative yield.

***N*-(2-(4-Methoxybenzyl)-1-oxo-3-(*o*-tolyl)isoindolin-4-yl)-[1,2,4]triazolo[4,3-*a*]pyridine-3-carboxamide**



[0781] Step 2: A flame-dried, round-bottomed flask equipped with a magnetic stirrer bar was charged with a solution of 4-amino-2-(4-methoxybenzyl)-3-(*o*-tolyl)isoindolin-1-one (50 mg, 139 µmol) in dry pyridine (0.70 mL) under nitrogen, and the solution cooled to 0 °C with stirring. A solution of [1,2,4]triazolo[4,3-*a*]pyridine-3-carbonyl chloride (37.7 mg, 208 µmol) in DCM (1.30 mL) was then added dropwise. The reaction mixture was warmed to ambient temperature and stirred for 16 hours. The reaction mixture was then partitioned between saturated aqueous $NaHCO_3$ solution (10 mL) and DCM (10 mL), and the mixture was passed through a phase separator. The organic phase was then concentrated *in vacuo* to afford the crude product. Purification by reverse-phase chromatography on C18 (eluting with 37–57% ACN in 10 mmol aqueous AmF) afforded *N*-(2-(4-methoxybenzyl)-1-oxo-3-(*o*-tolyl)isoindolin-4-yl)-[1,2,4]triazolo[4,3-*a*]pyridine-3-carboxamide (39 mg, 58.0 µmol, 56% yield) as an amorphous yellow solid. LC-MS (Method 1): 1.20 min, *m/z* = 504.3 $[M+H]^+$.

***N*-(1-oxo-3-(*o*-tolyl)isoindolin-4-yl)-[1,2,4]triazolo[4,3-*a*]pyridine-3-carboxamide (I-328)**




[0782] Step 3: A solution of *N*-(2-(4-methoxybenzyl)-1-oxo-3-(*o*-tolyl)isoindolin-4-yl)-[1,2,4]triazolo[4,3-*a*]pyridine-3-carboxamide (39.0 mg, 58.0 µmol) in TFA (0.55 mL) was heated at 90 °C with stirring in a sealed tube for 42 hours. The reaction mixture was then cooled to ambient temperature and concentrated *in vacuo*. The residue was purified directly by reverse-phase flash chromatography on C18 (eluting with 18–38% ACN in 10 mmol aqueous AmF) to afford *N*-(1-oxo-3-(*o*-tolyl)isoindolin-4-yl)-[1,2,4]triazolo[4,3-*a*]pyridine-3-carboxamide (16.7 mg, 43.5 µmol, 75% yield) as an amorphous white solid.


[0783] LC-MS (Method 2): 1.51 min, *m/z* = 384.3 $[M+H]^+$; ^{1}H NMR (400 MHz, DMSO-d_6) δ 10.61 (br. s, 1H), 9.07 (dt, *J* = 7.0, 1.1 Hz, 1H), 9.05 (s, 1H), 7.98 (dt, *J* = 9.3, 1.1 Hz, 1H), 7.69 (dd, *J* = 2.7, 1.2 Hz, 1H), 7.67 (dd, *J* = 3.0, 1.2 Hz, 1H), 7.64–7.58 (m, 2H), 7.24 (td, *J* = 6.9, 1.1 Hz, 1H), 6.93–6.86 (m, 2H), 6.82 (br. s, 1H), 6.66 (br. s, 1H), 6.09 (s, 1H), 2.19 (br. s, 3H). The compound appeared to have been isolated as a partial formate salt, based on the presence of a singlet at 8.42 ppm.

Example 4

7-Chloro-*N*-[3-(2-methylphenyl)-1-oxo-2,3-dihydro-1*H*-isoindol-4-yl]imidazo[1,5-*a*]pyridine-1-carboxamide (I-258)




Methyl 2-(4-chloropyridin-2-yl)-2-(hydroxyimino)acetate



[0784] Step 1: A solution of sodium nitrite (242 mg, 3.51 mmol) in water (1.10 mL) was added dropwise to a stirring solution of methyl 2-(4-chloropyridin-2-yl)acetate (652 mg, 3.51 mmol) in acetic acid (4.30 mL) at ambient temperature, and the reaction mixture was stirred at ambient temperature for 4 hours. The volatiles were then removed *in vacuo*, and the residue was suspended in water (25 mL). The pH was adjusted to 7-8 by addition of solid K_2CO_3, and the resulting suspension was poured into a separatory funnel and extracted into EtOAc (3 x 10 mL). The combined organic phases were washed with saturated NaCl solution, dried (anhydrous $MgSO_4$), filtered, and concentrated *in vacuo* to afford methyl 2-(4-chloropyridin-2-yl)-2-(hydroxyimino)acetate (762 mg, 3.55 mmol) as a yellow-green gum in quantitative yield as a 3:1 mixture of geometric isomers. The crude product was used directly in the next step without further purification. LC-MS (Method 1): 0.68 min (minor isomer), 0.80 min (major isomer), *m/z* = 215.1 $[M+H]^+$; Minor Isomer ^{1}H NMR (400 MHz, $CDCl_3$) δ 8.53 (d, *J* = 5.5 Hz, 1H), 7.87 (d, *J* = 1.8 Hz, 1H), 7.34 (dd, *J* = 5.4, 2.0 Hz, 1H), 3.99 (s, 3H); Major Isomer ^{1}H NMR (400 MHz, $CDCl_3$) δ 8.49–8.46 (m, 1H), 8.24 (dd, *J* = 2.0, 0.5 Hz, 1H), 7.53 (dd, *J* = 5.5, 2.0 Hz, 1H), 3.96 (s, 3H).


Methyl 2-amino-2-(4-chloropyridin-2-yl)acetate



[0785] Step 2: To a vigorously stirring solution of methyl 2-(4-chloropyridin-2-yl)-2-(hydroxyimino)acetate (762 mg, 3.55 mmol) in acetic acid (18.0 mL) at ambient temperature was added zinc dust (1.15 g, 17.7 mmol) in one portion. The reaction mixture was stirred at ambient temperature for 2.5 hours. The volatiles were then removed *in vacuo*, and the residue was partitioned between EtOAc (20 mL) and saturated aqueous $NaHCO_3$ solution (25 mL). The biphasic supernatant was decanted into a separatory funnel, and the phases were separated. The aqueous phase was extracted with EtOAc (2 x 20 mL). The combined organics were washed with saturated NaCl solution, dried (anhydrous $MgSO_4$), filtered, and concentrated *in vacuo* to afford crude methyl 2-amino-2-(4-chloropyridin-2-yl)acetate, which


was used immediately in the next step without further purification, assuming quantitative yield.

Methyl 7-chloroimidazo[1,5-*a*]pyridine-1-carboxylate




[0786] Step 3: A microwave vial equipped with a magnetic stirring bar was charged with a mixture of methyl 2-amino-2-(4-chloropyridin-2-yl)acetate (712 mg, 3.55 mmol) and triethyl orthoformate (0.88 mL, 5.29 mmol). The vial was sealed, and the reaction mixture irradiated in a microwave reactor at 150 °C for 10 minutes before cooling to ambient temperature. The reaction mixture was concentrated *in vacuo*, and the residue was purified by reverse-phase flash chromatography on C18 (eluting with 18–38% ACN in 10 mmol aqueous AmF) to furnish methyl 7-chloroimidazo[1,5-*a*]pyridine-1-carboxylate (17 mg, 80.7 µmol, 2.3% yield) as an amorphous beige solid. LC-MS (Method 1): 0.75 min, *m/z* = 211.0 $[M+H]^+$.

7-Chloroimidazo[1,5-*a*]pyridine-1-carboxylic acid




[0787] Step 4: Aqueous 2M NaOH solution (0.05 mL, 0.10 mmol) was added in one portion to a stirring suspension of methyl 7-chloroimidazo[1,5-*a*]pyridine-1-carboxylate (17.0 mg, 80.7 µmol) in methanol (0.12 mL) and water (0.12 mL), and the mixture stirred at ambient temperature for 20 hours. The reaction mixture was then concentrated *in vacuo* to remove the volatiles, and the residue was diluted with water (10 mL). The mixture was acidified to pH 2-3 with concentrated HCl, and extracted with a 4:1 mixture of $CHCl_3$:IPA (3 x 10 mL). The combined organic phases were washed with saturated aqueous NaCl solution, dried (anhydrous $MgSO_4$), filtered, and concentrated *in vacuo* to afford crude 7-chloroimidazo[1,5-*a*]pyridine-1-carboxylic acid (13.0 mg, 66.1 µmol, 82% yield) as a pale yellow solid. The crude acid was used directly in the next step without further purification. LC-MS (Method 1): 0.55 min, *m/z* = 415.2 $[2M+Na]^+$.

7-Chloroimidazo[1,5-*a*]pyridine-1-carbonyl chloride




[0788] Step 5: Thionyl chloride (10.0 µL, 137 µmol) was added dropwise to a stirring solution of 7-chloroimidazo[1,5-*a*]pyridine-1-carboxylic acid (13.0 mg, 66.1 µmol) and DIPEA (40.0 µL, 230 µmol) in DCM (0.27 mL) at 0 °C. The reaction mixture was stirred at this temperature for 15 mins, then warmed to ambient temperature and stirred for a further 1.5 hours. The volatiles were then removed *in vacuo*, and the crude 7-chloroimidazo[1,5-*a*]pyridine-1-carbonyl chloride was used directly in the next step, assuming quantitative yield.

7-Chloro-*N*-(2-(4-methoxybenzyl)-1-oxo-3-(*o*-tolyl)isoindolin-4-yl)imidazo[1,5-*a*]pyridine-1-carboxamide



[0789] Step 6: A flame-dried round-bottomed flask equipped with a magnetic stirrer bar was charged with a solution of 4-amino-2-(4-methoxybenzyl)-3-(*o*-tolyl)isoindolin-1-one (28.4 mg, 79.3 µmol) in dry pyridine (0.33 mL) under nitrogen, and the solution was cooled to 0 °C with stirring. A solution of 7-chloroimidazo[1,5-*a*]pyridine-1-carbonyl chloride (14.2 mg, 66.1 µmol) in DCM (0.80 mL) was then added dropwise, and the reaction mixture was warmed to ambient temperature and stirred for 16 hours. The reaction mixture was then partitioned between saturated aqueous $NaHCO_3$ solution (10 mL) and DCM (10 mL), and the mixture passed through a phase separator. The organic phase was then concentrated *in vacuo* to afford the crude product. Purification by reverse-phase flash chromatography on C18 (eluting with 50–75% ACN in 10 mmol aqueous AmF) furnished 7-chloro-*N*-(2-(4-methoxybenzyl)-1-oxo-3-(*o*-tolyl)isoindolin-4-yl)imidazo[1,5-*a*]pyridine-1-carboxamide (8.0 mg, 14.8 µmol, 23% yield) as an amorphous orange-brown solid. LC-MS (Method 1): 1.46 min, *m/z* = 537.3 $[M+H]^+$.


7-chloro-*N*-[3-(2-methylphenyl)-1-oxo-2,3-dihydro-1*H*-isoindol-4-yl]imidazo[1,5-*a*]pyridine-1-carboxamide (I-258)




[0790] Step 7: A solution of 7-chloro-*N*-(2-(4-methoxybenzyl)-1-oxo-3-(*o*-tolyl)isoindolin-4-yl)imidazo[1,5-*a*]pyridine-1-carboxamide (8.0 mg, 14.8 μmol) in TFA (0.10 mL) was heated at 90 °C with stirring in a sealed tube for 18 hours. The reaction mixture was then cooled to ambient temperature and concentrated *in vacuo*. The residue was purified directly by reverse-phase flash chromatography on C18 (eluting with 35–55% ACN in 10 mmol aqueous AmF) to afford 7-chloro-*N*-(1-oxo-3-(*o*-tolyl)isoindolin-4-yl)imidazo[1,5-*a*]pyridine-1-carboxamide (5.0 mg, 11.9 μmol, 81% yield) as an amorphous off-white solid. LC-MS (Method 2): 2.17 min, *m/z* = 417.2 $[M+H]^+$; ^{1}H NMR (400 MHz, DMSO-d_6) δ 9.29 (s, 1H), 9.02 (s, 1H), 8.52 (dd, *J* = 7.4, 0.8 Hz, 1H), 8.42 (s, 1H), 8.03–7.98 (m, 2H), 7.56 (d, *J* = 1.7 Hz, 1H), 7.55 (s, 1H), 7.09–7.02 (m, 2H), 7.01–6.94 (m, 2H), 6.69 (br. s, 1H), 6.15 (s, 1H), 2.35 (br. s, 3H).

Example 5

7-Chloro-*N*-(1-oxo-3-(*o*-tolyl)isoindolin-4-yl)-3-methylimidazo[1,5-*a*]pyridine-1-carboxamide (I-277)




***N*-((4-Chloropyridin-2-yl)methyl)acetamide**




[0791] Step 1: Acetyl chloride (0.43 mL, 6.05 mmol) was added dropwise to a stirring solution of (4-chloropyridin-2-yl)methanamine (684 mg, 4.79 mmol) and pyridine (0.78 mL, 9.64 mmol) at 0 °C. The reaction mixture was stirred at 0 °C for 15 minutes, then warmed to ambient temperature and stirred for 2 hours. The reaction mixture was then concentrated *in vacuo* and the crude *N*-((4-chloropyridin-2-yl)methyl)acetamide was used directly in the next step without further purification, assuming quantitative yield. LC-MS (Method 1): 0.47 min, m/z = 185.0 $[M+H]^+$.

1-(7-Chloro-3-methylimidazo[1,5-*a*]pyridin-1-yl)-2,2,2-trifluoroethanone



[0792] Step 2: Crude *N*-((4-chloropyridin-2-yl)methyl)acetamide (884 mg, 4.78 mmol) was dissolved in DCM (16.0 mL), pyridine (1.20 mL, 14.7 mmol) was added, and the resulting solution was cooled to –5 °C with stirring. Trifluoroacetic anhydride (1.50 mL, 10.7 mmol) was then added slowly dropwise. The reaction mixture was allowed to slowly warm to ambient temperature with stirring over 3 hours. The reaction was then quenched with saturated aqueous $NaHCO_3$ solution (20 mL), and the mixture was extracted with DCM (3 x 20 mL). The combined organics were washed with saturated aqueous NaCl solution, dried (anhydrous $MgSO_4$), filtered, and concentrated *in vacuo*. Purification of the residue by reverse-phase flash chromatography on C18 (eluting with 30-55% ACN in 10 mmol aqueous AmF) furnished 1-(7-chloro-3-methylimidazo[1,5-*a*]pyridin-1-yl)-2,2,2-trifluoroethanone (1.02 g, 3.89 mmol, 82% yield over two steps) as a yellow solid. ^{1}H NMR (400 MHz, $CDCl_3$) δ 8.41 (dd, J = 2.0, 0.9 Hz, 1H), 7.91 (dd, J = 7.3, 0.8 Hz, 1H), 7.00 (dd, J = 7.3, 2.1 Hz, 1H), 2.74 (s, 3H).


7-Chloro-3-methylimidazo[1,5-*a*]pyridine-1-carboxylic acid



[0793] Step 3: A microwave vial equipped with a magnetic stirrer bar was charged with a suspension of 1-(7-chloro-3-methylimidazo[1,5-*a*]pyridin-1-yl)-2,2,2-trifluoroethanone (400 mg, 1.52 mmol) in 2M aqueous NaOH solution (4.50 mL, 9.00 mmol). The vial was sealed


and irradiated in a microwave reactor at 110 °C for 10 minutes. The reaction mixture was cooled to ambient temperature, diluted with water (30 mL), and extracted with EtOAc (2 x 10 mL). The aqueous phase was then acidified to pH 2-3 with conc. HCl, during which a precipitate was evolved. The precipitate was collected by vacuum filtration, washed with water, and dried by suction to furnish 7-chloro-3-methylimidazo[1,5-*a*]pyridine-1-carboxylic acid (260 mg, 1.23 mmol, 81% yield) as an amorphous beige solid. LC-MS (Method 1): 0.58 min, *m/z* = 211.1 $[M+H]^+$.

7-Chloro-3-methylimidazo[1,5-*a*]pyridine-1-carbonyl chloride



[0794] Step 4: Thionyl chloride (20.0 µL, 275 µmol) was added dropwise to a stirring solution of 7-chloro-3-methylimidazo[1,5-*a*]pyridine-1-carboxylic acid (44.0 mg, 0.21 mmol) and DIPEA (0.15 mL, 0.86 mmol) in DCM (1.10 mL) at 0 °C. The reaction mixture was stirred at this temperature for 15 mins, then warmed to ambient temperature and stirred for a further 1.5 hours. The volatiles were then removed *in vacuo*, and the crude 7-chloro-3-methylimidazo[1,5-*a*]pyridine-1-carbonyl chloride used directly in the next step, assuming quantitative yield.


7-Chloro-*N*-(2-(4-methoxybenzyl)-1-oxo-3-(*o*-tolyl)isoindolin-4-yl)-3-methylimidazo[1,5-*a*]pyridine-1-carboxamide



[0795] Step 5: A flame-dried round-bottomed flask equipped with a magnetic stirrer bar was charged with a solution of 4-amino-2-(4-methoxybenzyl)-3-(o-tolyl)isoindolin-1-one (50.0 mg, 139 µmol) in dry pyridine (0.70 mL) under nitrogen, and the solution cooled to 0 °C with stirring. A solution of 7-chloro-3-methylimidazo[1,5-*a*]pyridine-1-carbonyl chloride (47.6 mg, 208 µmol) in DCM (1.40 mL) was then added dropwise, and the reaction mixture was

warmed to ambient temperature and stirred for 16 hours. The reaction mixture was then partitioned between saturated aqueous $NaHCO_3$ solution (10 mL) and DCM (10 mL), and the mixture was passed through a phase separator. The organic phase was then concentrated *in vacuo* to afford the crude product. Purification by reverse-phase flash chromatography on C18 (eluting with 55–75% ACN in 10 mmol aqueous AmF) furnished 7-chloro-*N*-(2-(4-methoxybenzyl)-1-oxo-3-(*o*-tolyl)isoindolin-4-yl)-3-methylimidazo[1,5-*a*]pyridine-1-carboxamide (62 mg, 0.11 mmol, 79% yield) as an amorphous orange-brown solid. LC-MS (Method 1): 1.54 min, *m/z* = 551.3 $[M+H]^+$.

7-Chloro-*N*-(1-oxo-3-(*o*-tolyl)isoindolin-4-yl)-3-methylimidazo[1,5-*a*]pyridine-1-carboxamide (I-277)



[0796] Step 6: A solution of 7-chloro-*N*-(2-(4-methoxybenzyl)-1-oxo-3-(*o*-tolyl)isoindolin-4-yl)-3-methylimidazo[1,5-*a*]pyridine-1-carboxamide (62 mg, 109 μmol) in TFA (0.73 mL) was heated at 90 °C with stirring in a sealed tube for 18 hours. The reaction mixture was then cooled to ambient temperature and concentrated *in vacuo*. The residue was purified directly by reverse-phase flash chromatography on C18 (eluting with 36–56% ACN in 10 mmol aqueous AmF) to afford 7-chloro-*N*-(1-oxo-3-(*o*-tolyl)isoindolin-4-yl)imidazo[1,5-*a*]pyridine-1-carboxamide (6.0 mg, 13.9 μmol, 13% yield) as an amorphous off-white solid. LC-MS (Method 2): 2.17 min, *m/z* = 417.2 $[M+H]^+$; ^1H NMR (400 MHz, DMSO-d_6) δ 9.05 (s, 1H), 9.04 (s, 1H), 8.33 (dd, *J* = 7.6, 0.5 Hz, 1H), 8.17 (dd, *J* = 7.4, 1.3 Hz, 1H), 7.98 (dd, *J* = 2.1, 0.7 Hz, 1H), 7.59–7.50 (m, 2H), 7.17 (br. d, *J* = 7.4 Hz, 1H), 7.14–7.08 (m, 1H), 7.03 (br. t, *J* = 7.2 Hz, 1H), 6.97 (dd, *J* = 7.5, 2.1 Hz, 1H), 6.72 (br. s, 1H), 6.12 (s, 1H), 2.61 (s, 3H), 2.45 (br. s, 3H). The broad singlet at 2.45 ppm overlaps with the DMSO-d_5 peak.

[0797] Additional compounds prepared according to the methods of Examples 1-5 are listed in Table 2 below. Corresponding ^1H NMR and mass spectrometry characterization for these compounds are described in Table 1. Certain compounds in Table 2 below were prepared by replacing 4-amino-2-(4-methoxybenzyl)-3-(o-tolyl)isoindolin-1-one, as described in


Examples 1-5, with other compounds whose preparation is described further below in the Examples.

Table 2. Additional Exemplary Compounds


Compound	Compound	Compound
I-2	I-61	I-216
I-4	I-62	I-279
I-5	I-67	I-292
I-11	I-69	I-316
I-16	I-74	I-317
I-19	I-78	I-318
I-20	I-79	I-340
I-21	I-81	I-341
I-25	I-86	I-369
I-26	I-97	I-376
I-30	I-98	I-377
I-36	I-105	I-378
I-37	I-107	I-387
I-38	I-109	I-388
I-42	I-111	I-612
I-46	I-112	I-638
I-47	I-124	I-693
I-48	I-144	I-752
I-54	I-198	I-850
I-58	I-203	I-1610
I-59	I-206	I-1617

Example 6

6,8-Difluoro-*N*-(1-oxo-3-(*o*-tolyl)isoindolin-4-yl)imidazo[1,5-a]pyridine-3-carboxamide (I-180)




Ethyl 2-(((3,5-difluoropyridin-2-yl)methyl)amino)-2-oxoacetate




[0798] Step 1: A flame-dried, round-bottomed flask equipped with a magnetic stirrer bar was charged with a solution of (3,5-difluoropyridin-2-yl)methanamine (500 mg, 3.46 mmol) and triethylamine (0.97 mL, 6.95 mmol) in DCM (7.00 mL), and the mixture was cooled to 0 °C with stirring. Ethyl chlorooxoacetate (0.39 mL, 3.49 mmol) was added slowly dropwise, and the reaction mixture was allowed to warm to ambient temperature and stirred for 3 days. The reaction was quenched with water (20 mL) and the mixture was extracted with DCM (3 x 20 mL). The combined organic phases were washed with saturated aqueous NaCl solution, dried (anhyd. $MgSO_4$), filtered, and concentrated *in vacuo*. Purification by flash chromatography on silica gel (eluting with 5–80% EtOAc in hexanes) furnished ethyl 2-(((3,5-difluoropyridin-2-yl)methyl)amino)-2-oxoacetate (452 mg, 1.85 mmol, 53% yield) as a yellow gum. LC-MS (Method 1): 0.61 min, *m/z* = 245.1 $[M+H]^+$; ^1H NMR (400 MHz, $CDCl_3$) δ 8.32 (d, 2.3 Hz, 1H), 8.21 (br. s, 1H), 7.27–7.22 (m, 1H), 4.69 (dt, 5.1, 1.6 Hz, 1H), 4.39 (q, 7.1 Hz, 2H), 1.40 (t, 7.2 Hz, 3H).

Ethyl 6,8-difluoroimidazo[1,5-*a*]pyridine-3-carboxylate




[0799] Step 2: A round-bottomed flask equipped with a magnetic stirrer bar and a reflux condenser was charged with a solution of ethyl 2-(((3,5-difluoropyridin-2-yl)methyl)amino)-2-oxoacetate (412 mg, 1.68 mmol) in DCE (4.10 mL), then $POCl_3$ (1.50 mL, 16.0 mmol) was added dropwise at ambient temperature with stirring. The reaction mixture was then heated to 120 °C with stirring for 18 hours, before cooling to ambient temperature. The volatiles were removed *in vacuo*, and the residue carefully quenched by addition of saturated aqueous $NaHCO_3$ solution (20 mL). The mixture was extracted with EtOAc (3 x 25 mL), and the combined organic phases were dried (anhyd. $MgSO_4$), filtered, and concentrated *in vacuo*. Purification of the residue by flash chromatography on silica gel (eluting with 5–20% EtOAc in hexanes) afforded ethyl 6,8-difluoroimidazo[1,5-*a*]pyridine-3-carboxylate (306 mg, 1.35 mmol, 80% yield) as a very pale yellow solid. LC-MS (Method 1): 0.94 min, *m/z* = 227.7 $[M+H]^+$.

6,8-Difluoroimidazo[1,5-*a*]pyridine-3-carboxylic acid




[0800] Step 3: Aqueous 2M NaOH solution (0.25 mL, 0.50 mmol) was added in one portion to a stirring solution of ethyl 6,8-difluoroimidazo[1,5-*a*]pyridine-3-carboxylate (100 mg, 0.44 mmol) in ethanol (0.67 mL) and water (0.67 mL), and the mixture was stirred at ambient temperature for 18 hours. The reaction mixture was then concentrated *in vacuo* to remove the volatiles, and the residue diluted with water (10 mL). The mixture was acidified to pH 2-3 with concentrated HCl. The resulting precipitate was collected by vacuum filtration, washed with water, and dried by suction to afford 6,8-difluoroimidazo[1,5-*a*]pyridine-3-carboxylic acid (73 mg, 0.37 mmol, 83% yield) as a pale yellow solid. LC-MS (Method 1): 0.48 min, *m/z* = 197.1 $[M-H]^-$.

6,8-Difluoroimidazo[1,5-*a*]pyridine-3-carbonyl chloride



[0801] Step 4: Thionyl chloride (30.0 µL, 41.4 µmol) was added dropwise to a stirring solution of 6,8-difluoroimidazo[1,5-*a*]pyridine-3-carboxylic acid (55.0 mg, 278 µmol) and DIPEA (0.20 mL, 1.14 mmol) in DCM (1.10 mL) at 0 °C. The reaction mixture was stirred at this temperature for 15 mins, then warmed to ambient temperature and stirred for a further 1.5 hours. The volatiles were then removed *in vacuo*, and the crude 6,8-difluoroimidazo[1,5-*a*]pyridine-3-carbonyl chloride was used directly in the next step, assuming quantitative yield.


6,8-Difluoro-*N*-(2-(4-methoxybenzyl)-1-oxo-3-(*o*-tolyl)isoindolin-4-yl)imidazo[1,5-*a*]pyridine-3-carboxamide



[0802] Step 5: A flame-dried, round-bottomed flask equipped with a magnetic stirrer bar was charged with a solution of 4-amino-2-(4-methoxybenzyl)-3-(*o*-tolyl)isoindolin-1-one (50 mg, 139 µmol) in dry pyridine (0.70 mL) under nitrogen, and the solution was cooled to 0 °C with stirring. A solution of 6,8-difluoroimidazo[1,5-*a*]pyridine-3-carbonyl chloride (60.2 mg, 278 µmol) in DCM (1.30 mL) was then added dropwise, and the reaction mixture was warmed to ambient temperature and stirred for 16 hours. The reaction mixture was then partitioned between saturated aqueous $NaHCO_3$ solution (10 mL) and DCM (10 mL), and the mixture passed through a phase separator. The organic phase was then concentrated *in vacuo* to afford the crude product. Purification by flash chromatography on silica gel (eluting with 10% EtOAc in hexanes) furnished 6,8-difluoro-*N*-(2-(4-methoxybenzyl)-1-oxo-3-(*o*-tolyl)isoindolin-4-yl)imidazo[1,5-*a*]pyridine-3-carboxamide (77 mg, 142 µmol, quantitative

yield) as an amorphous orange-brown solid. LC-MS (Method 1): 1.60 min, *m/z* = 539.3 $[M+H]^+$.

6,8-Difluoro-*N*-(1-oxo-3-(*o*-tolyl)isoindolin-4-yl)imidazo[1,5-a]pyridine-3-carboxamide (I-180)



[0803] Step 6: A solution of 6,8-difluoro-*N*-(2-(4-methoxybenzyl)-1-oxo-3-(*o*-tolyl)isoindolin-4-yl)imidazo[1,5-*a*]pyridine-3-carboxamide (57.0 mg, 105 µmol) in TFA (0.70 mL) was heated at 75 °C with stirring in a sealed tube for 40 hours. The reaction mixture was then cooled to ambient temperature and concentrated *in vacuo*. The residue was purified directly by reverse-phase flash chromatography on C18 (eluting with 40–65% ACN in 10 mmol aqueous AmF) to afford 6,8-difluoro-*N*-(1-oxo-3-(*o*-tolyl)isoindolin-4-yl)imidazo[1,5-*a*]pyridine-3-carboxamide (17.0 mg, 40.6 µmol, 39% yield) as an amorphous orange solid. LC-MS (Method 2): 2.51 min, *m/z* = 419.3 $[M+H]^+$; ^{1}H NMR (400 MHz, DMSO-d_6) δ 10.02 (br. s, 1H), 9.14 (d, 4.0 Hz, 1H), 9.03 (s, 1H), 7.84 (d, 0.8 Hz, 1H), 7.78 (dd, 7.6, 1.2 Hz, 1H), 7.65–7.62 (m, 1H), 7.62–7.57 (m, 1H), 7.44 (ddd, 10.6, 8.8, 1.8 Hz, 1H), 6.99–6.92 (m, 2H), 6.90–6.85 (m, 1H), 6.68 (br. s, 1H), 6.10 (s, 1H), 2.23 (br. s, 3H).


[0804] Additional compounds prepared according to the methods of Example 6 are listed in Table 3 below.

Table 3. Additional Exemplary Compounds


Compound
I-151
I-285
I-342

Example 7

***N*-(1-Oxo-3-(*o*-tolyl)isoindolin-4-yl)-1,2,3,4-tetrahydro-1,4-methanonaphthalene-1-carboxamide (I-226)**




***N*-(2-(4-Methoxybenzyl)-1-oxo-3-(*o*-tolyl)isoindolin-4-yl)-1,2,3,4-tetrahydro-1,4-methanonaphthalene-1-carboxamide**



[0805] Step 1: A screw-top glass reaction tube equipped with a magnetic stirrer bar was charged with a vigorously stirring mixture of 4-amino-2-(4-methoxybenzyl)-3-(*o*-tolyl)isoindolin-1-one (50.0 mg, 139 μmol) and 1,2,3,4-tetrahydro-1,4-methanonaphthalene-1-carboxylic acid (31.2 mg, 166 μmol) in DCM (0.50 mL) at ambient temperature. *N*-methylimidazole (40.0 μL, 500 μmol) was added dropwise, followed by tetramethylchloroformamidinium hexafluorophosphate (TCFH, 46.5 mg, 166 μmol) in one portion, and the reaction mixture stirred at ambient temperature for 24 hours. The reaction mixture was then partitioned between DCM (10 mL) and water (10 mL), and the mixture passed through a phase separator. The organic phase was concentrated *in vacuo*, and the residue was purified by reverse-phase flash chromatography on C18 (eluting with 55–80% ACN in 10 mmol aqueous AmF) to afford *N*-(2-(4-methoxybenzyl)-1-oxo-3-(*o*-tolyl)isoindolin-4-yl)-1,2,3,4-tetrahydro-1,4-methanonaphthalene-1-carboxamide (57.0 mg, 107 μmol, 78% yield) as an amorphous off-white solid. LC-MS (Method 1): 1.58 min, *m/z* = 529.4 $[M+H]^+$.


***N*-(1-oxo-3-(*o*-tolyl)isoindolin-4-yl)-1,2,3,4-tetrahydro-1,4-methanonaphthalene-1-carboxamide (I-226)**




[0806] Step 2: A solution of *N*-(2-(4-methoxybenzyl)-1-oxo-3-(*o*-tolyl)isoindolin-4-yl)-1,2,3,4-tetrahydro-1,4-methanonaphthalene-1-carboxamide (57.0 mg, 107 µmol) in TFA (0.71 mL) was heated at 90 °C with stirring in a sealed tube for 18 hours. The reaction mixture was then cooled to ambient temperature and concentrated *in vacuo*. The residue was purified directly by reverse-phase flash chromatography on C18 (eluting with 40–60% ACN in 10 mmol aqueous AmF) to afford *N*-(1-oxo-3-(*o*-tolyl)isoindolin-4-yl)-1,2,3,4-tetrahydro-1,4-methanonaphthalene-1-carboxamide (37.0 mg, 90.5 µmol, 85% yield) as an amorphous off-white solid. LC-MS (Method 2): 2.49 min, *m/z* = 409.4 $[M+H]^+$; ^{1}H NMR (400 MHz, DMSO-d_6) as a 1:1 mixture of diastereomers δ 9.02 (br. s, 1H), 8.99 (br. s, 1H), 8.80 (br. s, 2H), 7.67–7.53 (m, 6H), 7.23–7.10 (m, 6H), 7.09–6.91 (m, 6H), 6.85 (d, *J* = 7.2 Hz, 1H), 6.66–6.58 (m, 3H), 6.07 (s, 2H), 3.31 (dd, *J* = 11.4, 3.4 Hz, 2H), 2.29 (br. s, 6H), 1.93–1.84 (m, 2H), 1.81–1.76 (m, 1H), 1.76–1.64 (m, 3H), 1.44 (d, *J* = 8.7 Hz, 1H), 1.36 (d, *J* = 8.7 Hz, 1H), 1.22–1.14 (m, 1H), 1.14–1.08 (m, 1H), 1.08–0.99 (m, 2H). The spectrum was recorded at 70 °C (343K).

Example 8

***N*-(1-oxo-3-(*o*-tolyl)isoindolin-4-yl)benzo[*d*]isothiazole-3-carboxamide (I-13)**




***N*-(2-(4-methoxybenzyl)-1-oxo-3-(*o*-tolyl)isoindolin-4-yl)benzo[*d*]isothiazole-3-carboxamide**



[0807] Step 1: To a solution of 4-amino-2-(4-methoxybenzyl)-3-(*o*-tolyl)isoindolin-1-one (100 mg, 0.278 mmol), 1-[bis(dimethylamino)methylene]-1*H*-1,2,3-triazolo[4,5-*b*]pyridinium 3-oxid hexafluorophosphate (HATU, 127 mg, 0.336 mmol), and 1,2-benzothiazole-3-carboxylic acid (50 mg, 0.27 mmol) in anhydrous DMF (1.5 mL), was added $NaHCO_3$ (70 mg, 0.83 mmol). The resulting mixture was stirred under an atmosphere of nitrogen at 22 °C. After 18 h, the reaction mixture was treated with a saturated aqueous $NaHCO_3$ solution and extracted with EtOAc (3 x 10 mL). The combined organic layers were dried over sodium sulfate, filtered, and concentrated by rotary evaporation. The resulting material was purified by C18 column chromatography (eluting with 20% to 100% MeCN/10 mM AmF). The product-containing fractions were combined and lyophilized to obtain the title compound as a white powder (105 mg, 72 % yield). *m/z* = 520.4 $[M+H]^+$.

***N*-(1-Oxo-3-(*o*-tolyl)isoindolin-4-yl)benzo[*d*]isothiazole-3-carboxamide (I-13)**



[0808] Step 2: *N*-(2-(4-methoxybenzyl)-1-oxo-3-(*o*-tolyl)isoindolin-4-yl)benzo[*d*]isothiazole-3-carboxamide (105 mg, 0.202 mmol) was treated with trifluoroacetic acid (5.0 mL), and the resulting mixture was stirred at 120 °C. After 2 h, the reaction mixture was concentrated by rotary evaporation, and the resulting material was purified by C18 column chromatography (eluting with 20% to 100% MeCN/10 mM AmF). The product-containing fractions were combined and lyophilized to obtain the title compound as a white

powder (45 mg, 58% yield). *m/z* = 400.3 $[M+H]^+$; ^1H NMR (400 MHz, DMSO-d_6) 10.15 (s, 1H), 9.05 (s, 1H), 8.58 (d, *J* = 8.2 Hz, 1H), 8.29 (d, *J* = 8.2 Hz, 1H), 7.80 (dd, *J* = 7.6, 1.2 Hz, 1H), 7.74–7.55 (m, 4H), 7.06–6.93 (m, 2H), 6.89 (t, *J* = 13.3 Hz, 1H), 6.68 (br s, 1H), 6.12 (s, 1H), 2.40–2.10 (br s, 3H).

[0809] Additional compounds prepared according to the methods of Examples 7 and 8 are listed in Table 4 below. Certain compounds in Table 4 below were prepared by replacing 4-amino-2-(4-methoxybenzyl)-3-(o-tolyl)isoindolin-1-one, as described in Examples 7 and 8, with other compounds whose preparation is described further below in the Examples.

Table 4. Additional Exemplary Compounds

Compound	Compound	Compound
I-12	I-2177	I-2225
I-17	I-2178	I-2226
I-24	I-2179	I-2227
I-41	I-2180	I-2232
I-63	I-2193	I-2235
I-72	I-2194	I-2238
I-73	I-2195	I-2239
I-129	I-2196	I-2247
I-133	I-2197	I-2248
I-197	I-2198	I-2249
I-200	I-2211	I-2250
I-256	I-2212	I-2252
I-337	I-2213	I-2253
I-612	I-2214	I-2254
I-638	I-2215	I-2255
I-693	I-2216	I-2260
I-752	I-2217	I-2261
I-850	I-2218	I-2262
I-1610	I-2219	I-2263
I-1617	I-2220	I-2264
I-2175	I-2221	I-2265
I-2176	I-2224	I-2266


Compound
I-2268
I-2269
I-2270
I-2271
I-2272
I-2273
I-2274
I-2275
I-2281
I-2282
I-2283
I-2285

Compound
I-2301
I-2302
I-2303
I-2304
I-2318
I-2319
I-2322
I-2330
I-2335
I-2336
I-2337


Compound
I-2338
I-2361
I-2362
I-2363
I-2372
I-2374
I-2375
I-2391
I-2392
I-2397
I-2407

Example 9

***N*-[3-(2-methylphenyl)-1-oxo-2,3-dihydro-1*H*-isoindol-4-yl]-2,3-dihydro-1*H*-indole-1-carboxamide (I-43)**




***N*-{2-[(4-methoxyphenyl)methyl]-3-(2-methylphenyl)-1-oxo-2,3-dihydro-1*H*-isoindol-4-yl}-2,3-dihydro-1*H*-indole-1-carboxamide**



[0810] Step 1: To a solution of 4-amino-2-(4-methoxybenzyl)-3-(*o*-tolyl)isoindolin-1-one (50 mg, 139 μmol, 1.00 eq.) in anhydrous THF (0.7 mL) was added DIPEA (19.2 μL, 139 μmol, 1.00 eq.). The mixture was stirred and cooled to 0°C. A solution of triphosgene (41.8 mg, 141 μmol, 1.01 eq.) in anhydrous THF (0.7 mL) was added dropwise at 0°C. The mixture was stirred overnight at room temperature. The solution was then added to a solution of 2,3-dihydro-1*H*-indole (116 mg, 973 μmol, 7.00 eq.) in pyridine (1.5 mL) and DMAP (catalytic amount). The resulting mixture was stirred at room temperature overnight. The reaction mixture was diluted with aqueous NH_4Cl and extracted with dichloromethane. The organic layer was concentrated to obtain *N*-{2-[(4-methoxyphenyl)methyl]-3-(2-methylphenyl)-1-oxo-2,3-dihydro-1*H*-isoindol-4-yl}-2,3-dihydro-1*H*-indole-1-carboxamide as a brown oil (35 mg), which was used in the next step without further purification. LC-MS (Method 1): 1.42 min, *m/z* = 504.4 $[M+H]^+$.

***N*-[3-(2-methylphenyl)-1-oxo-2,3-dihydro-1*H*-isoindol-4-yl]-2,3-dihydro-1*H*-indole-1-carboxamide (I-43)**



[0811] Step 2: A solution of *N*-{2-[(4-methoxyphenyl)methyl]-3-(2-methylphenyl)-1-oxo-2,3-dihydro-1*H*-isoindol-4-yl}-2,3-dihydro-1*H*-indole-1-carboxamide (35 mg, crude) in trifluoroacetic acid (10 ml, 130 mmol) was stirred overnight at 80 °C. The reaction mixture was concentrated. The resulting residue was purified by reverse-phase column chromatography (C18: 12 g column; 10mM AmF in water/acetonitrile) and lyophilized to give *N*-[3-(2-methylphenyl)-1-oxo-2,3-dihydro-1*H*-isoindol-4-yl]-2,3-dihydro-1*H*-indole-1-carboxamide (18.8 mg, 49.0 μmol, 35% yield) as a white solid. LC-MS (Method 1): 1.51 min, >99% purity, *m/z* = 383.9 $[M+H]^+$; ^1H NMR (400 MHz, DMSO-d_6) δ 8.95 (s, 1H), 8.37 (s, 1H), 7.68 (d, *J* = 8.0 Hz, 1H), 7.60–7.50 (m, 2H), 7.47–7.35 (m, 1H), 7.19–7.06 (m, 3H), 7.02 (d, *J* = 7.3 Hz, 1H), 6.95 (t, *J* = 7.1 Hz, 1H), 6.88 (td, *J* = 7.4, 1.0 Hz, 1H), 6.54 (s, 1H), 5.88 (s, 1H), 3.68–3.50 (m, 1H), 3.01–2.80 (m, 3H), 2.07 (s, 3H).

[0812] Additional compounds prepared according to the methods of Example 9 are listed in Table 5 below. Certain compounds in Table 5 below were prepared by replacing 4-amino-2-(4-methoxybenzyl)-3-(o-tolyl)isoindolin-1-one, as described in Example 9, with other compounds whose preparation is described further below in the Examples.

Table 5. Additional Exemplary Compounds

Compound	Compound	Compound
I-43	I-597	I-1051
I-44	I-598	I-1176
I-45	I-612	I-1256
I-55	I-638	I-1257
I-60	I-642	I-1269
I-95	I-661	I-1270
I-96	I-685	I-1294
I-104	I-686	I-1318
I-110	I-693	I-1382
I-308	I-698	I-1383
I-309	I-713	I-1429
I-405	I-714	I-1459
I-430	I-716	I-1462
I-432	I-720	I-1507
I-433	I-722	I-1508
I-481	I-752	I-1509
I-482	I-766	I-1510
I-491	I-769	I-1511
I-542	I-772	I-1512
I-543	I-988	I-1513
I-544	I-989	I-1514
I-574	I-990	I-1576
I-576	I-992	I-1577
I-577	I-1050	I-1578
I-1579	I-2121	I-2204
I-1610	I-2122	I-2205

Compound
I-1663
I-1715
I-1716
I-1717
I-1718
I-1720
I-1721
I-1722
I-1753
I-1754
I-1755
I-1756
I-1810
I-1902
I-1903
I-1904
I-1945
I-1946
I-1949
I-1953
I-1954
I-1961
I-1965
I-1978
I-2042
I-2111
I-2113
I-2114
I-2115
I-2116
I-2300
I-2305

Compound
I-2123
I-2124
I-2126
I-2127
I-2128
I-2129
I-2130
I-2131
I-2132
I-2133
I-2142
I-2143
I-2144
I-2145
I-2162
I-2163
I-2164
I-2165
I-2166
I-2167
I-2168
I-2171
I-2172
I-2173
I-2174
I-2181
I-2182
I-2191
I-2199
I-2203
I-2352
I-2353

Compound
I-2206
I-2207
I-2208
I-2209
I-2210
I-2222
I-2236
I-2237
I-2240
I-2241
I-2242
I-2243
I-2244
I-2245
I-2246
I-2257
I-2276
I-2277
I-2278
I-2279
I-2280
I-2284
I-2286
I-2287
I-2288
I-2291
I-2292
I-2293
I-2294
I-2299
I-2402
I-2403

Compound
I-2306
I-2307
I-2308
I-2310
I-2311
I-2312
I-2313
I-2314
I-2315
I-2317
I-2321
I-2328
I-2329
I-2331
I-2332
I-2333
I-2334
I-2339
I-2340
I-2341
I-2342
I-2343
I-2344
I-2345
I-2346
I-2347
I-2348
I-2349
I-2350
I-2351
I-2436
I-2437

Compound
I-2356
I-2357
I-2364
I-2365
I-2366
I-2367
I-2368
I-2369
I-2370
I-2371
I-2373
I-2376
I-2377
I-2378
I-2379
I-2380
I-2381
I-2382
I-2383
I-2384
I-2385
I-2386
I-2393
I-2394
I-2395
I-2396
I-2398
I-2399
I-2400
I-2401
I-2468
I-2469

Compound
I-2404
I-2405
I-2406
I-2408
I-2410
I-2411
I-2412
I-2413
I-2414
I-2415
I-2416
I-2417
I-2418
I-2419
I-2420
I-2421
I-2422
I-2423
I-2424
I-2425
I-2426
I-2427
I-2428
I-2429
I-2430
I-2431
I-2432
I-2433
I-2434
I-2435
I-2500
I-2501

Compound
I-2438
I-2439
I-2440
I-2441
I-2442
I-2443
I-2444
I-2445
I-2446
I-2447
I-2448
I-2449
I-2450
I-2451
I-2452
I-2453
I-2454
I-2455
I-2456
I-2457
I-2458
I-2459
I-2460
I-2461
I-2462
I-2463
I-2464
I-2465
I-2466
I-2467
I-2532
I-2533

Compound
I-2470
I-2471
I-2472
I-2473
I-2474
I-2475
I-2476
I-2477
I-2478
I-2479
I-2480
I-2481
I-2482
I-2483
I-2484
I-2485
I-2486
I-2487
I-2488
I-2489
I-2490
I-2491
I-2492
I-2493
I-2494
I-2495
I-2496
I-2497
I-2498
I-2499
I-2564
I-2565

Compound
I-2502
I-2503
I-2504
I-2505
I-2506
I-2507
I-2508
I-2509
I-2510
I-2511
I-2512
I-2513
I-2514
I-2515
I-2516
I-2517
I-2518
I-2519
I-2520
I-2521
I-2522
I-2523
I-2524
I-2525
I-2526
I-2527
I-2528
I-2529
I-2530
I-2531
I-2596
I-2597

Compound
I-2534
I-2535
I-2536
I-2537
I-2538
I-2539
I-2540
I-2541
I-2542
I-2543
I-2544
I-2545
I-2546
I-2547
I-2548
I-2549
I-2550
I-2551
I-2552
I-2553
I-2554
I-2555
I-2556
I-2557
I-2558
I-2559
I-2560
I-2561
I-2562
I-2563
I-2628
I-2629

Compound
I-2566
I-2567
I-2568
I-2569
I-2570
I-2571
I-2572
I-2573
I-2574
I-2575
I-2576
I-2577
I-2578
I-2579
I-2580
I-2581
I-2582
I-2583
I-2584
I-2585
I-2586
I-2587
I-2588
I-2589
I-2590
I-2591
I-2592
I-2593
I-2594
I-2595
I-2653
I-2654

Compound
I-2598
I-2599
I-2600
I-2601
I-2602
I-2603
I-2604
I-2605
I-2606
I-2607
I-2608
I-2609
I-2610
I-2611
I-2612
I-2613
I-2614
I-2615
I-2616
I-2617
I-2618
I-2619
I-2620
I-2621
I-2622
I-2623
I-2624
I-2625
I-2626
I-2627
I-2674
I-2675


Compound
I-2630
I-2631
I-2632
I-2633
I-2634
I-2635
I-2636
I-2637
I-2638
I-2639
I-2640
I-2641
I-2642
I-2643
I-2648
I-2649
I-2650
I-2651
I-2652


Compound
I-2655
I-2656
I-2657
I-2658
I-2659
I-2660
I-2661
I-2662
I-2663
I-2664
I-2665
I-2666
I-2667
I-2668
I-2669
I-2670
I-2671
I-2672
I-2673

Compound
I-2676
I-2677
I-2678
I-2679
I-2680
I-2681
I-2682
I-2683
I-2684
I-2685
I-2686
I-2687
I-2688
I-2689
I-2694
I-2695
I-2696
I-2697


Example 10

***N*-[6-bromo-3-(2-methylphenyl)-1-oxo-2,3-dihydro-1*H*-isoindol-4-yl]-1-benzothiophene-3-carboxamide (I-29) and *N*-[6-(1-methyl-1*H*-pyrazol-4-yl)-3-(2-methylphenyl)-1-oxo-2,3-dihydro-1*H*-isoindol-4-yl]-1-benzothiophene-3-carboxamide (I-115)**






5-Bromo-3-nitrophthalic acid




[0813] Step 1: To a solution of 5-bromo-2-methyl-3-nitrobenzoic acid (290 g, 1.12 mol, 1.00 eq) in H_2O (2.90 L) was added KOH (313 g, 5.58 mol, 5.00 eq) at 25°C. To the mixture was added $KMnO_4$ (881 g, 5.58 mol, 5.00 eq) at 70°C, and then the reaction mixture was stirred at 70°C for 16 hrs. To the reaction mixture was added Na_2SO_3 (10%, 3.00 L), then the mixture was filtered. To the filtrate was added 6 M HCl to adjust the pH to 1, and the aqueous phase was extracted three times with ethyl acetate. The combined organic phases were dried over Na_2SO_4, filtered, and concentrated under reduced pressure to give 5-bromo-3-nitrophthalic acid (173 g) as a yellow solid. LC-MS (Method 1, 220 nm): 1.73 min, 73.4% purity; ^{1}H NMR (400 MHz, DMSO-d_6) δ 8.53 (s, 1H), 8.34 (s, 1H).

5-Bromo-3-nitrophthaloyl dichloride




[0814] Step 2: To a solution of 5-bromo-3-nitrophthalic acid (75.0 g, 259 mmol, 1.00 eq) in toluene (130 mL) was added $SOCl_2$ (245 g, 2.06 mol, 149 mL, 7.97 eq) at 25°C, then the mixture was heated to 100°C and stirred at 100°C for 3.5 hrs. Two batches of the mixture were concentrated and then dissolved in, and concentrated from, toluene (3 x 100 mL) to give 5-bromo-3-nitrophthaloyl dichloride (165 g) as a brown oil. The product was used in the next step without further purification. For LC-MS analysis, the product was quenched with MeOH: LC-MS (Method 1, 220 nm): 0.21 min, *m/z* = 318.0 $[M+H]^+$.

6-Bromo-2-(4-methoxybenzyl)-4-nitroisoindoline-1,3-dione




[0815] Step 3: To a solution of 5-bromo-3-nitrophthaloyl dichloride (82.3 g, 252 mmol, 1.00 eq) in THF (140 mL) was added a mixture of $PMBNH_2$ (41.4 g, 302 mmol, 39.1 mL, 1.20 eq) and Et_3N (83.7 g, 827 mmol, 115 mL, 3.28 eq) in THF (50 mL) dropwise at 0°C, then the mixture was heated to 70°C, and stirred at 70°C for 15 hrs. The mixture was concentrated and then dissolved in AcOH (189 g, 3.15 mol, 180 mL, 12.5 eq). The mixture was heated to 90°C and stirred at 90°C for 4.5 hrs. Two batches of the mixture were diluted with DCM (200 mL) and concentrated. The residue was dissolved in, then concentrated from, toluene (2 x 200 mL) to give a residue. The residue was dissolved in ethyl acetate (500 mL) and poured into water (500 mL). The aqueous phase was extracted with ethyl acetate (3 x 500 mL). The combined organic layer was washed with brine (500 mL), dried over Na_2SO_4, and filtered. The filtrate was concentrated to afford 6-bromo-2-(4-methoxybenzyl)-4-nitroisoindoline-1,3-dione (204 g) as a yellow solid. LC-MS (Method 1, 220 nm): 0.99 min, *m/z* = 415.2 $[M+Na]^+$; ^1H NMR (400 MHz, DMSO-d_6) δ 8.58 (d, *J* = 1.6 Hz, 1H), 8.41 (d, *J* = 1.6 Hz, 1H), 7.27 (d, *J* = 8.8 Hz, 2H), 6.88 (d, *J* = 8.8 Hz, 2H), 4.69 (s, 2H), 3.72 (s, 3H).

4-amino-6-bromo-2-(4-methoxybenzyl)isoindoline-1,3-dione




[0816] Step 4: To a solution of 6-bromo-2-(4-methoxybenzyl)-4-nitroisoindoline-1,3-dione (100 g, 256 mmol, 1.00 eq) in EtOH (1.00 L) / H_2O (200 mL) was added NH_4Cl (54.7 g, 1.02 mol, 4.00 eq) at 25°C. The mixture was heated to 40°C, and then Fe (42.8 g, 767 mmol, 3.00 eq) was added into the mixture at 40°C. The resulting mixture was heated to 80°C and stirred at 80°C for 1.5 hrs. Two batches of the mixture were poured into water (200 mL), filtered, and the filtrate was concentrated in vacuum. The resulting residue was extracted with ethyl acetate (3 x 200 mL). The combined organic layer was washed with brine (200 mL), dried over Na_2SO_4, filtered, and the filtrate was concentrated. The residue was purified by column chromatography (SiO_2, petroleum ether/ethyl acetate=1/0 to 0/1, Product R_f = 0.5 in 3/1 petroleum ether/ethyl acetate) to afford 4-amino-6-bromo-2-(4-methoxybenzyl)isoindoline-1,3-dione (63.3 g, 145.5 mmol, 83.0% purity) as a yellow solid. LC-MS (Method 1, 220 nm): 0.99 min, *m/z* = 361.1 $[M+H]^+$; ^1H NMR (400 MHz, DMSO-d_6) δ 7.22-7.18 (m, 3H), 7.06 (d, *J* = 2.0 Hz, 1H), 6.87 (d, *J* = 8.8 Hz, 2H), 6.65 (s, 2H), 4.61 (s, 2H), 3.71 (s, 3H).

4-Amino-6-bromo-3-hydroxy-2-(4-methoxybenzyl)-3-(*o*-tolyl)isoindolin-1-one



[0817] Step 5: To a solution of 4-amino-6-bromo-2-(4-methoxybenzyl)isoindoline-1,3-dione (77.3 g, 178 mmol, 1.00 eq) in DCM (1.00 L) was added *o*-tolylmagnesium bromide (0.9 M in diethyl ether, 493 mL, 2.50 eq) dropwise at 0°C, then the mixure was warmed to 25°C and stirred at 25°C for 1.5 hrs. The mixture was poured into a saturated aqueous solution of NH_4Cl (800 mL) and extracted with ethyl acetate (3 x 800 mL). The combined organic layer was washed with brine (800 mL), dried over Na_2SO_4, and filtered. The filtrate was concentrated to afford 4-amino-6-bromo-3-hydroxy-2-(4-methoxybenzyl)-3-(*o*-tolyl)isoindolin-1-one (145.4 g, crude) as a black-brown oil. The product was used in the next step without further purification. LC-MS (Method 1, 220 nm): 0.99 min, *m/z* = 437.2 $[M\text{-}OH]^+$.

4-Amino-6-bromo-2-(4-methoxybenzyl)-3-(*o*-tolyl)isoindolin-1-one




[0818] Step 6: To a solution of 4-amino-6-bromo-3-hydroxy-2-(4-methoxybenzyl)-3-(*o*-tolyl)isoindolin-1-one (131 g, 289 mmol, 1.00 eq) in DCM (1.00 L) was added TFA (330 g, 2.89 mol, 214 mL, 10.0 eq) at 25°C, then to the mixture was added triethylsilane (67.2 g, 578 mmol, 92.3 mL, 2.00 eq) at 0°C. The mixture was warmed to 25°C and stirred at 25°C for 1 hr. Two batches of the mixture were concentrated in vacuum to afford a residue. To the residue was added water (500 mL), and the pH was adjusted to 8 with the addition of ammonia. The mixture was extracted with DCM (3 x 500 mL). The combined organic layer was washed with brine (500 mL), dried over Na_2SO_4, filtered, and the filtrate was concentrated. The residue was purified by column chromatography (SiO_2, petroleum ether/ethyl acetate=1/0 to 0/1) and prep-HPLC to afford 4-amino-6-bromo-2-(4-

methoxybenzyl)-3-(*o*-tolyl)isoindolin-1-one (41.0 g, 86.3 mmol, 94.4% purity) as a red-brown solid and 7-amino-5-bromo-2-(4-methoxybenzyl)-3-(*o*-tolyl)isoindolin-1-one (29.0 g, 61.7 mmol, 93.1% purity) as a yellow solid.


[0819] Characterization data for 4-amino-6-bromo-2-(4-methoxybenzyl)-3-(*o*-tolyl)isoindolin-1-one: LC-MS (Method 1, 220 nm): 1.00 min, *m/z* = 437.2 $[M+H]^+$; ^1H NMR (400 MHz, DMSO-d_6) δ 7.54 - 7.53 (m, 1H), 7.28 -7.23 (m, 4H), 7.15 (d, *J* = 1.2 Hz, 1H), 6.99 - 6.97 (m, 8H), 6.93 - 6.83 (m, 5H), 6.48 (d, *J* = 7.6 Hz, 1H), 5.52 (s, 1H), 5.39 (s, 1H), 4.95 - 4.87 (m, 3H), 4.74 (s, 1H), 3.71 (s, 6H), 3.58 (d, *J* = 14.8 Hz 1H), 3.49 (d, *J* = 15.6 Hz, 1H), 2.25 (s, 3H), 1.51 (s, 2H).

***N*-[6-bromo-3-(2-methylphenyl)-1-oxo-2,3-dihydro-1*H*-isoindol-4-yl]-1-benzothiophene-3-carboxamide (I-29)**



[0820] Steps 7 and 8: According to the procedures of Example 1, Steps 5 and 6, 4-amino-6-bromo-2-(4-methoxybenzyl)-3-(*o*-tolyl)isoindolin-1-one was converted to *N*-[6-bromo-3-(2-methylphenyl)-1-oxo-2,3-dihydro-1*H*-isoindol-4-yl]-1-benzothiophene-3-carboxamide. MS: *m/z* = 477.0 $[M+H]^+$; ^1H NMR (400 MHz, DMSO-d_6) δ 10.12-10.35 (m, 1H), 9.13-9.35 (m, 1H), 7.96-8.08 (m, 2H), 7.80-7.87 (m, 1H), 7.71-7.78 (m, 1H), 7.56-7.68 (m, 1H), 7.32-7.49 (m, 2H), 7.05-7.14 (m, 1H), 6.88-7.05 (m, 2H), 6.44-6.82 (m, 1H), 5.91-6.11 (m, 1H), 1.82-2.38 (m, 3H).

_N_-[6-(1-methyl-1_H_-pyrazol-4-yl)-3-(2-methylphenyl)-1-oxo-2,3-dihydro-1_H_-isoindol-4-yl]-1-benzothiophene-3-carboxamide (I-115)



[0821] Step 9: _N_-[6-bromo-3-(2-methylphenyl)-1-oxo-2,3-dihydro-1_H_-isoindol-4-yl]-1-benzothiophene-3-carboxamide (40 mg, 83.7 μmol), 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1_H_-pyrazole (19.1 mg), and Na_2CO_3 (26 mg) were suspended in dioxane (0.5 mL) in a screw-top glass reaction tube equipped with stir bar. The suspension was subjected to freeze-pump-thaw cycle (3 cycles), and then nitrogen was bubbled through the suspension for 10 mins. Palladium (II) bis(triphenylphosphine) dichloride (1.8 mg, 2.56 μmol) was then added to the suspension. The glass reaction tube was sealed and placed in a pre-heated oil bath (110 °C, external) for 5 h with stirring. The reaction mixture was filtered through Celite and washed with ethyl acetate. The combined filtrate was concentrated under reduced pressure, and the residue was purified by reverse-phase flash column chromatography (eluting with 0-100% acetonitrile in water with 10 mM AmF) to furnish after lyophilization _N_-[6-(1-methyl-1_H_-pyrazol-4-yl)-3-(2-methylphenyl)-1-oxo-2,3-dihydro-1_H_-isoindol-4-yl]-1-benzothiophene-3-carboxamide (3.3 mg, 7.8% yield) as a white solid. MS: _m/z_ = 479.3 $[M+H]^+$; ^1H NMR (400 MHz, $CDCl_3$) δ 8.46 (br s, 1H), 8.26 (br s, 1H), 7.88 (s, 1H), 7.86 (d, _J_ = 1.4 Hz, 1H), 7.76 (s, 1H), 7.49 – 7.40 (m, 3H), 7.36 (d, _J_ = 7.3 Hz, 1H), 7.24 – 7.21 (m, 1H), 6.85 (s, 1H), 6.35 (s, 1H), 5.87 (s, 1H), 3.97 (s, 3H), 1.55 (s, 3H).


[0822] Additional compounds prepared according to the methods of Example 10 are listed in Table 6 below. Certain compounds in Table 6 below were prepared by replacing _N_-[6-bromo-3-(2-methylphenyl)-1-oxo-2,3-dihydro-1_H_-isoindol-4-yl]-1-benzothiophene-3-carboxamide, as described in Example 10, with other compounds whose preparation is described further below in the Examples.

Table 6. Additional Exemplary Compounds


Compound
I-220
I-141

Example 11

3-Fluoro-*N*-[3-(2-methylphenyl)-6-(isopropyl)-1-oxo-2,3-dihydro-1*H*-isoindol-4-yl]-5-(trifluoromethyl)benzamide (I-266)




4-Amino-2-[(4-methoxyphenyl)methyl]-3-(2-methylphenyl)-6-(propan-2-yl)-2,3-dihydro-1*H*-isoindol-1-one



[0823] Step 1: A stock solution of nickel(II) dichloride 1,2-dimethoxyethane (6.25 mg) and 4,4′-di-*tert*-butyl-2,2′-dipyridyl (8.75 mg) in dioxane (0.5 mL) in a 4-mL vial was sparged with nitrogen for 15 mins (until the solution turned light blue). In a separate 4-mL vial with a stir bar, a solution of 4-amino-6-bromo-2-[(4-methoxyphenyl)methyl]-3-(2-methylphenyl)-2,3-dihydro-1H-isoindol-1-one (50 mg, 114 μmol) and $[Ir\{dFCF_3ppy\}_2(bpy)]PF_6$ (28.3 mg, 1.0 eq) in dioxane (0.6 mL) was purged with nitrogen with stirring. To this solution were added, in order, 1,1,1,3,3,3-hexamethyl-2-(trimethylsilyl)trisilane (35.1 μL, 1.0 eq), lithium hydroxide (5.46 mg, 2 eq), 100 μL of the nickel/ligand stock solution, and 2-bromopropane (12.7 μL, 1.2 eq). The reaction mixture was sparged for 10 minutes, then sealed. The reaction mixture was placed 6 cm in front of a Blue LED light with stirring for 72 hours. The reaction mixture was concentrated, and the residue was purified by silica gel column chromatography

(eluting with 0-100% EtOAc in heptane) to yield 4-amino-2-[(4-methoxyphenyl)methyl]-3-(2-methylphenyl)-6-(propan-2-yl)-2,3-dihydro-1*H*-isoindol-1-one (30 mg, 74.9 µmol, 65.7%).

3-Fluoro-*N*-[3-(2-methylphenyl)-6-(isopropyl)-1-oxo-2,3-dihydro-1*H*-isoindol-4-yl]-5-(trifluoromethyl)benzamide (I-266)



[0824] Step 2: To a suspension of 3-fluoro-5-(trifluoromethyl)benzoic acid (39.9 mg, 192 µmol) in DCE (0.2 mL) was added 1-chloro-*N*,*N*,2-trimethyl-1-propenylamine (25.3 µL, 2 eq). The mixture was stirred at RT for 5 mins, until the solution became clear, then added to a solution of 4-amino-2-[(4-methoxyphenyl)methyl]-3-(isopropyl)-6-(2-methylpropyl)-2,3-dihydro-1*H*-isoindol-1-one (40 mg, 96.4 µmol), DMAP (3.70 mg, 9.64 µmol), and pyridine (38.9 µL, 5 eq) in 1,1-dichloroethane (1 mL). The reaction mixture was stirred for approximately 20 minutes, then concentrated.

[0825] The residue was treated with 1 mL of TFA and stirred at 100°C for 2 hours. The reaction was diluted with toluene, then concentrated, three times. The residue was purified prep-HPLC to yield 3-fluoro-*N*-[3-(2-methylphenyl)-6-(isopropyl)-1-oxo-2,3-dihydro-1*H*-isoindol-4-yl]-5-(trifluoromethyl)benzamide (9.7 mg, 20.0 µmol, 20.7 %). MS: *m/z* = 471.4 $[M+H]^+$; ^{1}H NMR (400 MHz, DMSO-d_6) δ 1.29 (d, *J* = 6.82 Hz, 6H), 2.17 (br d, *J* = 1.26 Hz, 3H), 3.02-3.14 (m, 1H), 5.85 (s, 1H), 6.60 (s, 1H), 6.87-6.99 (m, 2H), 7.01-7.09 (m, 1H), 7.33-7.41 (m, 2H), 7.49 (br d, 8.84 Hz, 1H), 7.55 (d, *J* = 1.26 Hz, 1H), 7.87 (br d, *J* = 8.59 Hz, 1H), 8.99 (s, 1H), 10.33 (s, 1H).


[0826] Additional compounds prepared according to the methods of Example 11 are listed in Table 7 below. Certain compounds in Table 7 below were prepared with other compounds whose preparation is described elsewhere in the Examples.

Table 7. Additional Exemplary Compounds

Compound
I-268
I-293

Example 12

***N*-(6-Bromo-3-(2-chloro-5-fluorophenyl)-1-oxoisoindolin-4-yl)-3-fluoro-5-(trifluoromethyl)benzamide**



[0827] Step 1: To a solution of Compound 1 (185 g, 999 mmol) in H_2SO_4 (1.20 L) was added 1,3-dibromo-5,5-dimethylhydantoin (143 g, 500 mmol) at 20 °C, the mixture was stirred at 85 °C for 2 h. The mixture was cooled to 20 °C, which was then poured to ice water (5.00 L) and filtered. The filtered cake was concentrated under vacuum to afford

Compound 2 (240 g, 84.5% yield) as a yellow solid. ^{1}H NMR (400 MHz, DMSO-d_6) δ 14.15 (br, 1H), 8.55 (d, J = 3.2 Hz, 1H), 8.32 - 8.29 (m, 1H).

[0828] Step 2: To a solution of 2-chloro-5-fluorobenzaldehyde (67.0 g, 423 mmol) in MeOH (1.20 L) was sequentially added the following reagents, (4-methoxyphenyl)methanamine (58.0 g, 423 mmol), Compound 2 (120 g, 423 mmol), and tert-butyl isocyanide (35.1 g, 423 mmol) at 20 °C under N_2. The mixture was stirred at 20 °C for 2 h. The mixture was directly concentrated. The residue was purified by column chromatography (SiO_2, Petroleum ether/Ethyl acetate = 50:1 to 5:1, R_f = 0.40) to afford Compound 3 (248 g, 88.6% yield) as a yellow solid. MS: m/z = 648.1 $[M+Na]^+$; ^{1}H NMR (400 MHz, DMSO-d_6) δ 8.52 (br, 1H), 8.26 - 8.20 (m, 1H), 7.90 (s, 1H), 7.61 - 7.51 (m, 1H), 7.28 - 7.08 (m, 3H), 6.89 - 6.77 (m, 2H), 6.62 - 6.60 (m, 2H), 5.39 - 5.13 (m, 1H), 4.55 - 4.27 (m, 1H), 3.65 (s, 3H), 1.30 - 1.25 (m, 9H).

[0829] Step 3: To a solution of Compound 3 (243 g, 367 mmol) in ACN (1.50 L) was added 2-tert-butyl-1,1,3,3-tetramethylguanidine (94.3 g, 550 mmol) at 20 °C. The mixture was stirred at 50 °C for 2 h. The mixture was concentrated to give Compound 4 (191 g, crude) as a black oil. MS: m/z = 522.9 $[M+H]^+$.

[0830] Step 4: To a solution of Compound 4 (191 g, 367 mmol) in TFA (1.50 L) was added triethylsilane (213 g, 1.83 mol) at 20 °C. The mixture was stirred at 90 °C for 5 h. The mixture was directly concentrated to give Compound 5 (186 g, crude) as a green oil. MS: m/z = 505.9 $[M+H]^+$.

[0831] Step 5: To a solution of Compound 5 (186 g, 367 mmol) in EtOH (1.20 L) and AcOH (150 mL) was added NH_4Cl (137 g, 2.57 mol) at 20 °C. The mixture was heated to 50 °C and added Fe (143 g, 2.57 mol) in portions. The mixture was stirred at 80 °C for 1 h. The mixture was diluted with MeOH (2.00 L) and ethyl acetate (2.00 L). Then the mixture was poured into water (4.00 L). The mixture was extracted with ethyl acetate (2.00 L x 3). The combined organic layers were washed with brine (2.50 L), dried over Na_2SO_4, filtered, and concentrated. The crude product was purified by silica gel column chromatography (Petroleum ether/Ethyl acetate=50/1 to 5/1, R_f = 0.40). Then the crude product was purified by prep-HPLC (column: Phenomenex luna C18 250, 50mm, 10 um; mobile phase: [water(0.225%FA)-ACN]; B%: 40%-70%, 30min) to afford Compound 6 (30.5 g, 14.2% yield) as an off-white solid. MS: m/z = 476.8 $[M+H]^+$; ^{1}H NMR (400 MHz, $CDCl_3$) δ 7.49 (d, J = 1.6 Hz, 1H), 7.45 - 7.41 (m, 1H), 7.12 - 7.08 (m, 2H), 7.05 - 7.00 (m, 1H), 6.88 (d, J =

1.6 Hz, 1H), 6.83 - 6.79 (m, 2H), 6.52 (dd, *J* = 3.2, 3.2 Hz, 1H), 5.70 (d, *J* = 1.6 Hz, 1H), 5.17 (d, *J* = 14.8 Hz, 1H), 3.79 (s, 3H), 3.68 (d, *J* = 14.8 Hz, 1H).

[0832] Step 6: 4-Amino-6-bromo-3-(2-chloro-5-fluorophenyl)-2-[(4-methoxyphenyl)methyl]-2,3-dihydro-1H-isoindol-1-one (7.0 g, 14.7 mmol) was dissolved in 500 mL of ACN and treated with pyridine (2.32 g, 29.4 mmol) and 3-fluoro-5-(trifluoromethyl)benzoyl chloride (3.33 g, 14.7 mmol). After an hour, a second aliquot of 3-fluoro-5-(trifluoromethyl)benzoyl chloride (0.833 g, 3.67 mmol) was added and the reaction was allowed to stir for 72 h. The mixture was diluted with EtOAc and water. The organic layer was washed with brine, dried over sodium sulfate, filtered, then concentrated to yield N-[6-bromo-3-(2-chloro-5-fluorophenyl)-2-[(4-methoxyphenyl)methyl]-1-oxo-2,3-dihydro-1H-isoindol-4-yl]-3-fluoro-5-(trifluoromethyl)benzamide (11 g, 16.5 mmol)

[0833] Step 7: Compound 7 (8.5 g, 12.7 mmol) was added to a flask and dissolved in methane sulfonic acid (35 mL) and heated to 60°C for 16 h. Aqueous sodium carbonate (10%) was added to the mixture. The aqueous layer was extracted with EtOAc, the organics were then washed with brine, dried over sodium sulfate, filtered, and concentrated to afford *N*-[6-bromo-3-(2-chloro-5-fluorophenyl)-1-oxo-2,3-dihydro-1H-isoindol-4-yl]-3-fluoro-5-(trifluoromethyl)benzamide (6 g, 86.5% yield).

[0834] Additional compounds prepared according to the methods of Example 12 are listed in Table 8 below. Certain compounds in Table 8 were prepared with other compounds whose preparation is described elsewhere in the Examples.

Table 8. Additional Exemplary Compounds


Compound
I-49
I-57
I-83
I-84
I-85
I-99
I-101
I-102
I-122
I-137

Compound
I-138
I-157
I-158
I-159
I-160
I-167
I-168
I-169
I-170

Compound
I-221
I-241
I-281
I-325
I-330
I-331
I-332
I-371
I-372

Example 13

N-[4-Chloro-1-(2-methylphenyl)-3-oxo-1H,2H,3H-pyrrolo[3,4-c]pyridin-7-yl]-3-fluoro-5-(trifluoromethyl)benzamide (I-232)



[0835] Step 1: To a solution of Compound 1 (30.0 g, 127 mmol) and 2,4-dimethoxybenzylamine (22.3 g, 133 mmol) in DMF (180 mL) was added HOBt (25.7 g, 190 mmol), EDCI (36.5 g, 190 mmol) and DIPEA (41.0 g, 317 mmol) at 0 °C. The mixture was stirred at 10-20 °C for 4 h. The mixture was poured into 900 mL water with stirring and extracted with ethyl acetate (1.00 L × 3). The organic layer was adjusted pH to 6-7 with 0.5 N HCl, washed with saturated $NaHCO_3$ solution (200 mL) and brine (200 mL × 2), dried and concentrated. The residue was triturated with petroleum ether/ethyl acetate = 20/1 (300 mL) for 2 h. The mixture was filtered, and the filter cake was dried to give Compound 2 (32.0 g, crude) as a light yellow solid. ^1H NMR (400 MHz, $CDCl_3$) δ 8.47 (d, J = 2.4 Hz, 1H), 8.23

(d, J = 2.8 Hz, 1H), 7.25 (d, J = 8.0 Hz, 1H), 7.07 (br, s, 1H), 6.48 - 6.45 (m, 2H), 4.57 (d, J = 5.6 Hz, 2H), 3.85 (s, 3H), 3.81 (s, 3H).

[0836] Step 2: To a solution of Compound 2 (32.0 g, 83.0 mmol) in THF (320 mL) was added NaH (4.98 g, 124 mmol, 60% purity, 1.50 eq) at 0 °C. The mixture was stirred for 0.5 hours at 0 °C and followed by dropwise addition of *p*-toluoyl chloride (17.5 g, 113 mmol, 14.7 mL, 1.36 eq). The mixture was stirred for additional 2 h at 0-25 °C. The mixture was quenched by addition of 150 mL of NH_4Cl aqueous solution and extracted with ethyl acetate (150 mL × 3). The organic layer was dried and concentrated. The residue was purified by column chromatography (SiO2, petroleum ether/ethyl acetate = 1/0 to 5/1, R_f = 0.50) to give compound 3 (12.8 g) as a yellow solid. ^{1}H NMR (400 MHz, $CDCl_3$) δ 8.24 (d, J = 2.4 Hz, 1H), 7.43 (d, J = 2.4 Hz, 1H), 7.31 (d, J = 8.4 Hz, 1H), 7.25 - 7.19 (m, 2H), 7.13 (d, J = 7.2 Hz, 1H), 7.00 (d, J = 7.6 Hz, 1H), 6.50 - 6.47 (m, 1H), 6.43 (d, J = 2.4 Hz, 1H), 5.12 (s, 2H), 3.81 (s, 3H), 3.69 (s, 3H), 2.20 (s, 3H).

[0837] Step 3: To a solution of compound 3 (12.8 g, 25.4 mmol, 1.00 eq) in THF (128 mL) at -50 °C was added LiHMDS (1 M, 38.1 mL, 1.50 eq). The mixture was stirred at -50 °C for additional 4 hours. The mixture was quenched by 650 mL of saturated NH_4Cl solution and extracted with 650 mL × 2 of ethyl acetate. The organic layers were combined, washed with brine (650 mL), dried and concentrated to give compound 4 (12.0 g, crude) as a yellow solid. ^{1}H NMR (400 MHz, $CDCl_3$) δ 8.48 (s, 1H), 8.21 (d, J = 7.6 Hz, 1H), 7.43 (d, J = 8.4 Hz, 1H), 7.39 (t, J = 7.2 Hz, 1H), 7.30 (t, J = 7.0 Hz, 1H), 7.02 (d, J = 7.6 Hz, 1H), 6.43 - 6.41 (m, 1H), 6.34 (d, J = 2.0 Hz, 1H), 5.34 (br, s, 1H), 4.54 (d, J = 14.4 Hz, 1H), 4.05 (d, J = 14.8 Hz, 1H), 3.79 (s, 3H), 3.75 (s, 3H), 1.63 (s, 3H).


[0838] Step 4: To a solution of compound 4 (12.0 g, 23.8 mmol) and TFA (67.9 g, 596 mmol) in DCM (120 mL) was added Et_3SiH (27.7 g, 238 mmol, 38.1 mL, 10.0 eq). The mixture was stirred at 10-20 °C for 16 h. The mixture was adjusted pH to 7-8 with saturated Na_2CO_3 solution and extracted with DCM (200 mL × 3). The organic layer was washed with brine (100 mL), dried over Na_2SO_4, filtered, and concentrated. The residue was triturated with a solution of petroleum ether/ethyl acetate = 20/1 (50.0 mL) for 12 h, and then filtered to give a filter cake. The cake was dried under vacuum to give compound 5 (8.58 g, 66.2% yield) as a yellow solid. MS: m/z = 488.9 $[M+H]^+$; ^{1}H NMR (400 MHz, $CDCl_3$) δ 8.48 - 8.47 (m, 1H), 7.24 - 7.19 (m, 2H), 7.12 - 7.08 (m, 1H), 7.04 (d, J = 8.0 Hz, 1H), 6.54 (d, J = 7.6 Hz, 1H), 6.44 - 6.41 (m, 2H), 5.59 (s, 1H), 5.03 - 4.96 (m, 1H), 3.84 - 3.80 (m, 4H), 3.74 - 3.72 (m, 3H), 2.33 (s, 3H).

[0839] Step 5: A reaction vial was charged with 7-bromo-4-chloro-2-[(2,4-dimethoxyphenyl)methyl]-1-(2-methylphenyl)-1H,2H,3H-pyrrolo[3,4-c]pyridin-3-one (250 mg, 0.512 mmol), 3-fluoro-5-(trifluoromethyl)benzamide (81.6 mg, 0.394 mmol), sodium tert-butoxide (56.8 mg, 0.591 mmol), $Pd_2(dba)_3$ (21.6 mg, 23.6 umol), and Xanthphos (4.56 mg, 7.88 umol). The reaction vessel was evacuated and backfilled with nitrogen 3x followed by the addition of dry toluene (5 mL). Heated to 100 °C for 16h. Quenched with 1N HCl. Diluted with water (5 mL) and extracted with EtOAc (2x10 mL), dried over sodium sulfate and dried onto SiO2. Purified on a CombiFlash® EZ Prep flash column using 0-60% EtOAc in heptanes (40 mm column). Combined fractions were concentrated to give N-{4-chloro-2-[(2,4-dimethoxyphenyl)methyl]-1-(2-methylphenyl)-3-oxo-1H,2H,3H-pyrrolo[3,4-c]pyridin-7-yl}-3-fluoro-5-(trifluoromethyl)benzamide (321 mg, 25.6%) as an orange solid. MS: m/z = 614.28 $[M+H]^+$.

[0840] Step 6: A solution of N-{4-chloro-2-[(2,4-dimethoxyphenyl)methyl]-1-(2-methylphenyl)-3-oxo-1H,2H,3H-pyrrolo[3,4-c]pyridin-7-yl}-3-fluoro-5-(trifluoromethyl)benzamide (15 mg, 0.02443 mmol) in TFA (500 uL) was heated at 100 °C for 16 h. The mixture was concentrated and purified by reverse-phase HPLC purification (20-40% acetonitrile/water w/ 0.1% formic acid) to afford N-[4-chloro-1-(2-methylphenyl)-3-oxo-1H,2H,3H-pyrrolo[3,4-c]pyridin-7-yl]-3-fluoro-5-(trifluoromethyl)benzamide (5 mg, 0.01078 mmol).

Example 14

N-(4-Amino-3-oxo-1-(*o*-tolyl)-2,3-dihydro-1*H*-pyrrolo[3,4-c]pyridin-7-yl)-3-fluoro-5-(trifluoromethyl)benzamide (I-262)




[0841] Step 1: Dissolved N-{4-chloro-2-[(2,4-dimethoxyphenyl)methyl]-1-(2-methylphenyl)-3-oxo-1H,2H,3H-pyrrolo[3,4-c]pyridin-7-yl}-3-fluoro-5-(trifluoromethyl)benzamide (75 mg, 0.1221 mmol) in DMF. Bubbled with N_2 for 5 min.

Added 1-(2,4-dimethoxyphenyl)methanamine (20.1 μL, 0.1343 mmol) followed by ethylbis(propan-2-yl)amine (31.8 μL, 0.1831 mmol). Stirred at 100 °C for 16 h. The mixture was diluted with EtOAc, extracted with water (2x), washed with brine, dried over Na_2SO_4, and concentrated. The concentrate was purified on prep-HPLC using 0-50% EtOAc in heptanes to give N-{2-[(2,4-dimethoxyphenyl)methyl]-4-{[(2,4-dimethoxyphenyl)methyl]amino}-1-(2-methylphenyl)-3-oxo-1H,2H,3H-pyrrolo[3,4-c]pyridin-7-yl}-3-fluoro-5-(trifluoromethyl)benzamide (59.0 mg, 65%). MS: *m/z* = 745.53 $[M+H]^+$.

[0842] Step 2: N-{2-[(2,4-dimethoxyphenyl)methyl]-4-{[(2,4-dimethoxyphenyl)methyl]amino}-1-(2-methylphenyl)-3-oxo-1H,2H,3H-pyrrolo[3,4-c]pyridin-7-yl}-3-fluoro-5-(trifluoromethyl)benzamide (59.0 mg, 0.07922 mmol) was dissolved in TFA (1 mL) and stirred at RT for 1 h. The mixture was heated to 100 °C for 16 h, and concentrated. The concentrate was dissolved in DCM (1 mL) and to the solution was added Et_3SiH (3 eq) and TFA (10 eq), which was stirred at 80 °C for 1 h. Purified by reverse-phase HPLC to give N-(4-amino-3-oxo-1-(o-tolyl)-2,3-dihydro-1*H*-pyrrolo[3,4-c]pyridin-7-yl)-3-fluoro-5-(trifluoromethyl)benzamide (5 mg, 0.011 mmol).

Example 15

***N*-[3-(2-Methylphenyl)-1-oxo-1H,2H,3H-pyrrolo[3,4-c]pyridin-4-yl]-1,2-benzothiazole-3-carboxamide (I-176)**



[0843] Step 1: To a stirred -50 °C solution under N_2 atmosphere of 2,6-dichloro-N-[(4-methoxyphenyl)methyl]pyridine-4-carboxamide (2.0 g, 6.42 mmol) in THF (32.0 mL) was slowly added LiHMDS (7.05 mL of a 1.0 M solution in THF). The orange solution was stirred at -78°C for 1 h. To the reaction was added dropwise over 2 min a solution of 2-methylbenzoyl chloride (919 µL, 7.06 mmol). The reaction was stirred 0.5 h at -78 °C and then 16 h at ambient temperature. The mixture was cooled back between -50 to -78 °C and 1.1 equiv. of 1M LiHMDS in THF (7.05mL) was slowly added. The reaction was stirred at -50 to -78 °C for 1 hour. The mixture was slowly quenched with water and concentrated to remove THF. The suspension was diluted with EtOAc. The layers were separated, and the aqueous layer was extracted twice with EtOAc. The organic layers were combined, washed with brine, dried over Na_2SO_4 and filtered. The crude product was purified by flash chromatography (50 g, solid loading, 0-50% EtOAc/hexanes) to afford 4,6-dichloro-3-hydroxy-2-[(4-methoxyphenyl)methyl]-3-(2-methylphenyl)-1H,2H,3H-pyrrolo[3,4-c]pyridin-1-one (812 mg, 29.5% yield).

[0844] Step 2: To a stirred 0 °C solution of 4,6-dichloro-3-hydroxy-2-[(4-methoxyphenyl)methyl]-3-(2-methylphenyl)-1H,2H,3H-pyrrolo[3,4-c]pyridin-1-one (812.8 mg, 1.89 mmol) in DCM (8.45 mL) under nitrogen was added TFA (2.89 mL) followed by triethylsilane (3.00 mL, 18.9 mmol). The reaction was then allowed to warm to ambient temperature and stirred for 16 h. The mixture was diluted with DCM (20 mL) and quenched with saturated aq. $NaHCO_3$ until pH 6-7. The organic layer was extracted once more, washed with brine, dried over Na_2SO_4, filtered, and concentrated. The crude product was purified by normal phase chromatography (50 g, 30-70% EtOAc/hexanes). Fractions were concentrated to yield 4,6-dichloro-2-[(4-methoxyphenyl)methyl]-3-(2-methylphenyl)-1H,2H,3H-pyrrolo[3,4-c]pyridin-1-one (502 mg, 64.2% yield).

[0845] Step 3: A tube containing 4,6-dichloro-2-[(4-methoxyphenyl)methyl]-3-(2-methylphenyl)-1H,2H,3H-pyrrolo[3,4-c]pyridin-1-one (243 mg, 0.5879 mmol), bis[(2,4-dimethoxyphenyl)methyl]amine (205 mg, 0.6466 mmol), ethylbis(propan-2-yl)amine (1.52 mL, 8.81 mmol) and 2-propanol (2.35 mL) was sealed and stirred at 150 °C for 30 h and then cooled to ambient temperature. The mixture was diluted in water/EtOAc. The pH of aqueous layer was adjusted with NH_4Cl to pH 7-8. The aqueous layer was extracted twice with EtOAc. The organic layers were combined, washed with brine, and concentrated. The crude product was purified by reverse phase chromatography (30 g, 30%-100% ACN/Ammonium formate (aq)). Fractions containing product were concentrated to yield 4-{bis[(2,4-dimethoxyphenyl)methyl]amino}-6-chloro-2-[(4-methoxyphenyl)methyl]-3-(2-methylphenyl)-1H,2H,3H-pyrrolo[3,4-c]pyridin-1-one (24 mg, 6.1% yield).

[0846] Step 4: 4-{Bis[(2,4-dimethoxyphenyl)methyl]amino}-6-chloro-2-[(4-methoxyphenyl)methyl]-3-(2-methylphenyl)-1H,2H,3H-pyrrolo[3,4-c]pyridin-1-one (25 mg, 0.03601 mmol) and NaOAc anhydrous (12.3 mg) were dissolved in methanol (1.2 mL). The solution was purged with N_2 and 9.6 mg of Pd/C 10% wt was added. The mixture was purged again with N_2 and then with H_2. The mixture was stirred at RT under a H_2 atmosphere for 16 h. The mixture was purged with N_2 and 5 mg of Pd/C 10% wt was added. The mixture was purged again with N_2 and then with H_2. The mixture was stirred at RT under a H_2 atmosphere for 16 h. The mixture was filtered through Celite®, washed with EtOAc/MeOH, concentrated and dried on vacuum to yield 4-{bis[(2,4-dimethoxyphenyl)methyl]amino}-2-[(4-methoxyphenyl)methyl]-3-(2-methylphenyl)-1H,2H,3H-pyrrolo[3,4-c]pyridin-1-one (3 mg).

[0847] Step 5: Solid 4-{bis[(2,4-dimethoxyphenyl)methyl]amino}-2-[(4-methoxyphenyl)methyl]-3-(2-methylphenyl)-1H,2H,3H-pyrrolo[3,4-c]pyridin-1-one (24 mg,


0.03637 mmol) was treated with trifluoroacetic acid (0.70 mL, 0.08289 mmol) and stirred at ambient temperature. After 20 min, the mixture was concentrated. The crude mixture containing 4-amino-2-[(4-methoxyphenyl)methyl]-3-(2-methylphenyl)-1H,2H,3H-pyrrolo[3,4-c]pyridin-1-one (13 mg) was used directly for the next step.

[0848] Step 6: 4-Amino-2-[(4-methoxyphenyl)methyl]-3-(2-methylphenyl)-1H,2H,3H-pyrrolo[3,4-c]pyridin-1-one (13.0 mg, 0.03616 mmol) was dissolved in pyridine (0.36 mL) and 1,2-benzothiazole-3-carbonyl chloride (10.7 mg, 0.05424 mmol) was added. The mixture was stirred at ambient temperature for 2 h. Approximately 10.7 mg of 1,2-benzothiazole-3-carbonyl chloride was added to the mixture, and it was stirred one more hour. Water (0.4 mL) and 5 mg of K_2CO_3 were added to the reaction. The mixture was stirred 0.5 h at ambient temperature. The mixture was concentrated, diluted in DCM and water. The pH was adjusted to 7-8 and the layers were separated. The aqueous layer was was extracted twice with DCM. The organic layers were combined, washed with brine, dried over Na_2SO_4, filtered and concentrated. Crude product containing N-(2-(4-methoxybenzyl)-1-oxo-3-(o-tolyl)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-4-yl)benzo[d]isothiazole-3-carboxamide (18.8 mg) was used directly in the next step.

[0849] Step 7: To a stirred 0 °C solution of N-(2-(4-methoxybenzyl)-1-oxo-3-(o-tolyl)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-4-yl)benzo[d]isothiazole-3-carboxamide (19.4 mg, 0.03615 mmol) in DCM (0.18 mL) under nitrogen was added TFA with 0.2% triflic acid (55.3 uL) followed by triethylsilane (57.6 µL, 0.3615 mmol). The reaction was allowed to warm to ambient temperature and stirred for 16 h. The mixture was concentrated, diluted with DCM/water and slowly quenched with saturated aq. $NaHCO_3$ until pH 6-7. The organic layer was extracted once more, washed with brine, and concentrated. The crude product was purified by reverse-phase chromatography (10 g, 10-75% ACN/Ammonium formate 10mM). The pure fractions were combined, concentrated, and lyophilized to yield N-[3-(2-methylphenyl)-1-oxo-1H,2H,3H-pyrrolo[3,4-c]pyridin-4-yl]-1,2-benzothiazole-3-carboxamide (1 mg, 6.6% yield).

Example 16

N-[5-(2-Chlorophenyl)-2-(methylsulfanyl)-7-oxo-5H,6H,7H-pyrrolo[3,4-d]pyrimidin-4-yl]-3-fluoro-5-(trifluoromethyl)benzamide



[0850] Step 1: To a round bottom flask was added 6-hydroxy-2-(methylsulfanyl)pyrimidine-4-carboxylic acid (1.29 g, 6.95 mmol), which was suspended in $POCl_3$ (15 mL) and heated to 95 °C. After 2 h the reaction was cooled, concentrated, and redissolved in THF (10 mL). In a separate flask, 2-chloro-N-[(4-methoxyphenyl)methyl]benzamide (1.6 g, 5.80 mmol) in THF (15 mL) was cooled to -78 °C and charged with lithiobis(trimethylsilyl)amine (5.80 mL, 5.80 mmol). The solution from flask one was added to the second flask dropwise. After 30 min, the reaction was quenched with water and extracted with ethyl acetate. The organic layers were concentrated to yield 6-chloro-N-(2-chlorobenzoyl)-N-[(4-methoxyphenyl)methyl]-2-(methylsulfanyl)pyrimidine-4-carboxamide (550 mg, 20.5% yield).

[0851] Step 2: A mixture of 6-chloro-N-(2-chlorobenzoyl)-N-[(4-methoxyphenyl)methyl]-2-(methylsulfanyl)pyrimidine-4-carboxamide (547 mg, 1.18 mmol) in THF was cooled to -78

°C and charged with lithiobis(trimethylsilyl)amine (1.18 mL, 1.18 mmol). The reaction was stirred at -78 °C for 1 h, and the solution was allowed to warm to -20 °C. The reaction was then quenched with saturated with NH_4Cl, and the aqueous layer was extracted with ethyl acetate. The organic layer was concentrated to yield 4-chloro-5-(2-chlorophenyl)-5-hydroxy-6-[(4-methoxyphenyl)methyl]-2-(methylsulfanyl)-5H,6H,7H-pyrrolo[3,4-d]pyrimidin-7-one (418 mg, 0.90 mmol, 76%).

[0852] Step 3: To a vial was added 4-chloro-5-(2-chlorophenyl)-5-hydroxy-6-[(4-methoxyphenyl)methyl]-2-(methylsulfanyl)-5H,6H,7H-pyrrolo[3,4-d]pyrimidin-7-one (350 mg, 0.7570 mmol) in THF (5 mL), which was then charged with triethylamine (315 µL, 2.27 mmol) and 1-(2,4-dimethoxyphenyl)methanamine (151 mg, 0.9084 mmol) and stirred at ambient temperature. After 6 h, the reaction was poured into a brine solution and extracted with ethyl acetate. The organic layer was concentrated to yield 5-(2-chlorophenyl)-4-{[(2,4-dimethoxyphenyl)methyl]amino}-5-hydroxy-6-[(4-methoxyphenyl)methyl]-2-(methylsulfanyl)-5H,6H,7H-pyrrolo[3,4-d]pyrimidin-7-one (484 mg, crude).


[0853] Step 4: To a vial was added 5-(2-chlorophenyl)-4-{[(2,4-dimethoxyphenyl)methyl]amino}-5-hydroxy-6-[(4-methoxyphenyl)methyl]-2-(methylsulfanyl)-5H,6H,7H-pyrrolo[3,4-d]pyrimidin-7-one (450mg, 0.7587 mmol), then TFA (4 mL), then triethylsilane (1.21 mL, 7.58 mmol) and the mixture was heated to 80 °C. After 4 h the reaction was concentrated. The crude material was dissolved in DCM, washed with saturated sodium bicarbonate, then dried over sodium sulfate. The organic layer was filtered and concentrated to yield 4-amino-5-(2-chlorophenyl)-6-[(4-methoxyphenyl)methyl]-2-(methylsulfanyl)-5H,6H,7H-pyrrolo[3,4-d]pyrimidin-7-one (265 mg, 82% yield).

[0854] Step 5: To a vial containing 3-fluoro-5-(trifluoromethyl)benzoic acid (36.5 mg, 0.1756 mmol) in toluene (1 mL) was added (1-chloro-2-methylprop-1-en-1-yl)dimethylamine (23.1 µL, 0.1756 mmol), and the mixture was stirred at ambient temperature for 30 min to create a stock solution. In a separate vial, 4-amino-5-(2-chlorophenyl)-6-[(4-methoxyphenyl)methyl]-2-(methylsulfanyl)-5H,6H,7H-pyrrolo[3,4-d]pyrimidin-7-one (50 mg, 0.1171 mmol) in THF (3mL) was cooled to 0 °C, and was charged with lithiobis(trimethylsilyl)amine (175 µL, 0.1756 mmol). After 15 min, the stock solution of acid chloride was added and stirred for 30 min. The solvent was removed, and the residue was purified by prep-HPLC to yield N-[5-(2-chlorophenyl)-6-[(4-methoxyphenyl)methyl]-2-(methylsulfanyl)-7-oxo-5H,6H,7H-pyrrolo[3,4-d]pyrimidin-4-yl]-3-fluoro-5-(trifluoromethyl)benzamide (15 mg, 20% yield).

[0855] Step 6: To a microwave vial was added N-[5-(2-chlorophenyl)-6-[(4-methoxyphenyl)methyl]-2-(methylsulfanyl)-7-oxo-5H,6H,7H-pyrrolo[3,4-d]pyrimidin-4-yl]-3-fluoro-5-(trifluoromethyl)benzamide (15 mg, 0.02431 mmol) in TFA + 1% TfOH (1.5 mL), which was heated in a microwave at 75 °C for 50 min. The solvent was removed, and the residue was purified by prep-HPLC to yield N-[5-(2-chlorophenyl)-2-(methylsulfanyl)-7-oxo-5H,6H,7H-pyrrolo[3,4-d]pyrimidin-4-yl]-3-fluoro-5-(trifluoromethyl)benzamide (6.5 mg, 54% yield).

Example 17

3-Fluoro-N-[1-(1-methylcyclohexyl)-3-oxo-2,3-dihydro-1H-indazol-7-yl]-5-(trifluoromethyl)benzamide



[0856] Step 1: To a solution of 2-chloro-3-nitrobenzoic acid (1 g, 4.96 mmol), (1-methylcyclohexyl)hydrazine (635 mg, 4.96 mmol) and HATU (2.82 g, 7.44 mmol) in DMF (50 mL) was added sodium bicarbonate (1.24 g, 14.8 mmol). The mixture was stirred at ambient temperature overnight, and then the mixture was washed with sat. $NaHCO_3$ and brine. The reaction mixture was concentrated and purified by reverse-phase chromatography (30 g column, 10 mM ammonium formate in water/acetonitrile system (5-100%)) and lyophilized to give 2-chloro-N'-(1-methylcyclohexyl)-3-nitrobenzohydrazide (500 mg, 26.9 % yield).

[0857] Step 2: To a round bottomed flask was added 2-chloro-N'-(1-methylcyclohexyl)-3-nitrobenzohydrazide (500 mg, 1.60 mmol), sodium tert-butoxide (230 mg, 2.40 mmol), and DMF (20 mL). The mixture was stirred at 90 ºC for 2 h under inert atmosphere. The reaction

mixture was concentrated and purified by reverse-phase chromatography (30 g column, 10 mM ammonium formate in water/acetonitrile system (5-100%)) and fractions were lyophilized to give 1-(1-methylcyclohexyl)-7-nitro-2,3-dihydro-1H-indazol-3-one (180 mg, 39.9 % yield).

[0858] Step 3: A 30-mL vial was charged with 1-(1-methylcyclohexyl)-7-nitro-2,3-dihydro-1H-indazol-3-one (180 mg, 653 μmol), iron (364 mg, 6.52 mmol) and acetic acid (668 μL, 11.7 mmol). The mixture was suspended in 4:1 MeOH/water (15 mL) and vigorously stirred at 90 °C for 30 min. The mixture was filtered through a pad of Celite®. The filtrate was concentrated under reduced pressure to give 7-amino-1-(1-methylcyclohexyl)-2,3-dihydro-1H-indazol-3-one (70 mg, 43.7 % yield).

[0859] Step 4: To a solution of 7-amino-1-(1-methylcyclohexyl)-2,3-dihydro-1H-indazol-3-one (70 mg, 285 μmol) in DCM (5 mL) were added pyridine (112 mg, 1.42 mmol) and 3-fluoro-5-(trifluoromethyl)benzoyl chloride (129 mg, 570 μmol), and the resulting mixture was stirred at ambient temperature for 1 hour. Reaction mixture was concentrated, washed with aq. NH_4Cl, extracted with DCM. The organic layer was concentrated to obtain the crude sticky residue (150 mg) which was used in the next step without further purification. Yield was assumed quantitative.

[0860] Step 5: 3-Fluoro-N-{2-[3-fluoro-5-(trifluoromethyl)benzoyl]-1-(1-methylcyclohexyl)-3-oxo-2,3-dihydro-1H-indazol-7-yl}-5-(trifluoromethyl)benzamide (180 mg, 287 μmol) was dissolved in methanol (10 mL), then potassium carbonate (395 mg, 2.86 mmol) was added, and the reaction mixture was stirred at 60°C for 1 hour. The reaction mixture was concentrated and purified by reverse-phase chromatography (30 g column, 10mM ammonium formate in water/acetonitrile system (5-100%)) to give 3-fluoro-N-[1-(1-methylcyclohexyl)-3-oxo-2,3-dihydro-1H-indazol-7-yl]-5-(trifluoromethyl)benzamide (80 mg, 181 μmol, 63.8%).


[0861] Additional compounds prepared according to the methods of Example 17 are listed in Table 9 below. Certain compounds in Table 9 were prepared with other compounds whose preparation is described elsewhere in the Examples.

Table 9. Additional Exemplary Compounds

Compound	Compound	Compound
I-68	I-152	I-252
I-117	I-178	I-323

Example 18

N-(1,1-Dioxido-3-(o-tolyl)-2,3-dihydrobenzo[d]isothiazol-4-yl)-3-fluoro-5-(trifluoromethyl)benzamide



[0862] Step 1: (A) To water (36 mL) cooled to 0°C was added thionyl chloride (6.08 mL, 4.3 eq, 14.2 mmol) keeping the temperature at 0 - 7 °C (very exothermic, slow careful addition with dropping funnel). The mixture allowed to warm to room temperature for 1 hour after which CuCl (191 mg, 0.1 eq) was added and the solution cooled to -3 °C using a brine/ice bath. (B) Concentrated hydrogen chloride (30 mL, 1.0 eq, 36% w/w) was added to methyl 2-amino-6-nitrobenzoate (3.8 g, 19.3 mmol) keeping the temperature below 30 °C with ice/brine mixture cooling, and the mixture was cooled to -5 °C. Sodium nitrite (1.52 g, 1.15 eq) was dissolved in water (5 mL) (exothermic, slow careful addition with dropping funnel required) was added dropwise keeping the temperature between -5 and 0 °C and stirred for an additional 15 min. The slurry from (B) was added dropwise to solution (A) while keeping the temperature of both solutions between 0 and -5 °C and this mixture stirred

for 30 min, filtered, rinsed with water, and air dried, which resulted in a wet cake. Material was dried under vacuum to give methyl 2-(chlorosulfonyl)-6-nitrobenzoate (5.34 g, 99% yield).

[0863] Step 2: A round bottom flask was charged with methyl 2-(chlorosulfonyl)-6-nitrobenzoate (1 g, 3.57 mmol) and dioxane (5 mL), and the mixture was cooled to 0 °C using an ice bath. Ammonium hydroxide (5 mL, conc. 35 wt%) was added dropwise, and the mixture was allowed to warm to RT over 90 min. The mixture was cooled to 0 °C, and conc. HCl (ca. 4 mL) was added to reach pH 1. Water (30 mL) was added and the reaction mixture was filtered on a fritted funnel, which was rinsed with water and air dried to afford 4-nitrobenzo[d]isothiazol-3(2H)-one 1,1-dioxide (560 mg, 68.7 % yield) as an off-white solid.

[0864] Step 3: A reaction vial was loaded with 4-nitrobenzo[d]isothiazol-3(2H)-one 1,1-dioxide (500 mg, 2.19 mmol), palladium hydroxide, 20 wt. % Pd on carbon, wet (100 mg, 0.429 eq) and purged with nitrogen. Anhydrous methanol (8 mL) was added and nitrogen purging was continued for 2 minutes, followed by purging with hydrogen (from a ballon) for 5 minutes. The mixture was stirred at ambient temperature for 16 hours. The mixture was purged with nitrogen and filtered through a small celite pad on a fritted funnel. The filtrate was concentrated to dryness to afford 4-aminobenzo[d]isothiazol-3(2H)-one 1,1-dioxide (368 mg, 1.81 mmol, 82.9 %) as a tan powder.

[0865] Step 4: A round bottom flask was charged with 4-aminobenzo[d]isothiazol-3(2H)-one 1,1-dioxide (236 mg, 1.19 mmol), 4-dimethylaminopyridine (14.5 mg, 0.1 eq) and anhydrous pyridine (3 mL), followed by dropwise addition of 3-fluoro-5-(trifluoromethyl)benzoyl chloride (403 mg, 1.78 mmol). The mixture was stirred at ambient temperature for 1 hour. The reaction mixture was diluted with DCM (50 mL) and water (10 mL) and acidified to pH 1 with 1 M HCl (ca. 30 mL). The DCM phase was separated out, and the aqueous phase was extracted with EtOAc (30 mL). The organic phases were combined, dried over sodium sulfate, and concentrated to dryness. The crude mixture was triturated with DCM (ca. 8 mL) and filtered to afford N-(1,1-dioxido-3-oxo-2,3-dihydrobenzo[d]isothiazol-4-yl)-3-fluoro-5-(trifluoromethyl)benzamide (355 mg, 0.9142 mmol, 76.8 %) as a tan solid.


[0866] Step 5: A dry round bottom flask under nitrogen was charged with N-(1,1-dioxido-3-oxo-2,3-dihydrobenzo[d]isothiazol-4-yl)-3-fluoro-5-(trifluoromethyl)benzamide (100 mg, 0.2575 mmol) and anhydrous tetrahydrofuran (1.03 mL), and the mixture was cooled to 0°C. Bromo(2-methylphenyl)magnesium (772 µL, 0.7725 mmol, 1 M in THF) was added

dropwise and warmed to ambient temperature over 1 hour. After 1 hour, a second portion of bromo(2-methylphenyl)magnesium (257 ul, 257 uM, 1 M in THF) was added, and stirred at ambient temperature for 3 hours, followed by a third portion of bromo(2-methylphenyl)magnesium (257 ul, 257 uM, 1 M in THF) and the mixture was stirred at ambient temperature overnight. The reaction mixture was quenched with saturated NH_4Cl (5 mL), diluted with water (5 mL), and extracted with EtOAc (3x12 mL), dried over sodium sulfate and concentrated to dryness to afford N-(1,1-dioxido-3-(o-tolyl)benzo[d]isothiazol-4-yl)-3-fluoro-5-(trifluoromethyl)benzamide (120 mg, 0.1038 mmol, 40.3 %). The crude product was used directly for the next step.

[0867] Step 6: A round bottom flask was charged with crude N-(1,1-dioxido-3-(o-tolyl)benzo[d]isothiazol-4-yl)-3-fluoro-5-(trifluoromethyl)benzamide (60 mg, 0.1297 mmol) and anhydrous methanol (1.29 mL), then sodium borohydride (14.7 mg, 3 eq) was added (instant gas evolution). The reaction mixture was stirred for 3 hours. The reaction mixture was concentrated to dryness and purified by reverse-phase flash chromatography (12 g C18 cartridge, 10 to 80% ACN in ammonium formate (aq)). An impurity (Rt = 1.80 min) co-eluted with the desired product. All fractions containing desired product were concentrated together and re-purified by normal-phase flash chromatography (12 g cartridge, 0 to 25% EtOAc in DCM) to afford N-(1,1-dioxido-3-(o-tolyl)-2,3-dihydrobenzo[d]isothiazol-4-yl)-3-fluoro-5-(trifluoromethyl)benzamide (17 mg, 28.2%) as a white solid after lyophilization.

Example 19

(Z)-N-[3-(2-Chloro-5-fluorophenyl)-1-sulfanylidene-2,3-dihydro-1H-isoindol-4-yl]-3-fluoro-N'-hydroxy-5-(trifluoromethyl)benzimidamide




[0868] Step 1: A suspension of N-[3-(2-chloro-5-fluorophenyl)-1-oxo-2,3-dihydro-1H-isoindol-4-yl]-3-fluoro-5-(trifluoromethyl)benzamide (0.065 g, 139 µmol) in toluene (2 mL) was treated with bis(4-methoxyphenyl)-1,3,2,4-dithiadiphosphetane-2,4-dithione (60.2 mg). The mixture was stirred at 100 °C for 3 h and then purified by silica-gel chromatography (0-100% EtOAc/hexanes) to provide N-[3-(2-chloro-5-fluorophenyl)-1-oxo-2,3-dihydro-1H-

isoindol-4-yl]-3-fluoro-5-(trifluoromethyl)benzene-1-carbothioamide (0.038 g, 78.6 μmol, 56%).

[0869] Step 2: A solution of N-[3-(2-chloro-5-fluorophenyl)-1-oxo-2,3-dihydro-1H-isoindol-4-yl]-3-fluoro-5-(trifluoromethyl)benzene-1-carbothioamide (0.038 g, 78.6 μmol) in ethanol (3 mL) was treated with $NaHCO_3$ (2 eq) and hydroxylamine hydrochloride (2 eq). The mixture was stirred at 70 °C for 48 h and then purified by reverse-phase HPLC (20-70% ACN/water) to provide (Z)-N-[3-(2-chloro-5-fluorophenyl)-1-sulfanylidene-2,3-dihydro-1H-isoindol-4-yl]-3-fluoro-N'-hydroxy-5-(trifluoromethyl)benzimidamide (0.005 g, 7.02 μmol, 9% yield) as light-yellow powder.

Example 20

5-Bromo-4-(2-methylphenyl)-3,4-dihydro-2H-1,3-benzoxazin-2-one



[0870] Step 1: To 2-bromo-6-hydroxybenzaldehyde (1.72 g, 8.55 mmol) and 2-methylpropane-2-sulfinamide (1.23 g, 10.2 mmol) in THF (25 mL) was added tetraethoxytitanium (5.35 mL, 25.6 mmol). The mixture was stirred at ambient temperature for 2 hours. The solution was then quenched with aqueous sodium bicarbonate. The aqueous layer was extracted with DCM. The organic layer was concentrated to afford N-[(E)-(2-bromo-6-hydroxyphenyl)methylidene]-2-methylpropane-2-sulfinamide (2.6 g, 8.55 mmol, 99%).


[0871] Step 2: To a solution of N-[(E)-(2-bromo-6-hydroxyphenyl)methylidene]-2-methylpropane-2-sulfinamide (200 mg, 0.6574 mmol) in THF (3 mL) at 0°C was added bromo(2-methylphenyl)magnesium (985 μL, 1.97 mmol, 2 M in THF). Reaction was allowed to warm to ambient temperature after 5 minutes of stirring at 0°C. Mixture was stirred for 15 minutes before quenching with saturated NH_4Cl. The aqueous layer was extracted with ethyl acetate, and the organic layer was concentrated to yield N-[(2-bromo-6-hydroxyphenyl)(2-methylphenyl)methyl]-2-methylpropane-2-sulfinamide (260 mg, 0.650 mmol, 99%).

[0872] Step 3: To N-[(2-bromo-6-hydroxyphenyl)(2-methylphenyl)methyl]-2-methylpropane-2-sulfinamide (210 mg, 0.5298 mmol) in 2-MeTHF (3 mL) was added 1-(1H-

imidazole-1-carbonyl)-1H-imidazole (170 mg, 1.05 mmol) and heated to 90 °C for 16 h. The solution was cooled, then MTBE was added dropwise until solid started to precipitate. The solid was then filtered and dried to afford 5-bromo-4-(2-methylphenyl)-3,4-dihydro-2H-1,3-benzoxazin-2-one (95 mg, 0.538 mmol, 56.5%).

Example 21

N-(4-(2-Chlorophenyl)-2-oxo-1,2,3,4-tetrahydroquinazolin-5-yl)-3-fluoro-5-(trifluoromethyl)benzamide



[0873] Step 1: A round bottom flask was charged with 3-aminobenzamide (500 mg, 3.67 mmol) and 4-dimethylaminopyridine (22.4 mg, 0.05 eq) and flushed with nitrogen. Anhydrous pyridine (7.34 mL) was added followed by 3-fluoro-5-(trifluoromethyl)benzoyl chloride (837 µL, 5.50 mmol), and the reaction mixture was stirred at ambient temperature for 1.5 hours. Water (20 mL) was added, and the reaction mixture was stirred for 10 minutes. The mixture was filtered through a fritted funnel, and the precipitate was rinsed with water and a small amount of acetonitrile, then air dried to afford N-(3-carbamoylphenyl)-3-fluoro-5-(trifluoromethyl)benzamide (726 mg, 2.22 mmol, 61.0 %) as a white powder.


[0874] Step 2: A solution of N-(3-carbamoylphenyl)-3-fluoro-5-(trifluoromethyl)benzamide (175 mg, 0.5867 mmol) and N,N-diisopropylethylamine (107 µL, 1.05 eq) in anhydrous THF (2.93 mL) under nitrogen was cooled to 0 °C using an ice bath, and a solution of triphosgene (174 mg, 0.5867 mmol) in THF (3 mL) was added dropwise. The reaction mixture was stirred at 0 °C for 1 hour followed by the dropwise addition of ammonium hydroxide (390 µL, 5.86 mmol, 25 wt% in water) and stirred for 10

minutes. The reaction mixture was diluted with water (15 mL), extracted with EtOAc (2 x 15 mL), washed with saturated NH_4Cl, dried over sodium sulfate, filtered, and concentrated to afford N-[3-(carbamoylamino)phenyl]-3-fluoro-5-(trifluoromethyl)benzamide (210 mg, 0.5845 mmol, 99.5 %) as a tan solid.

[0875] Step 3: A reaction vial was charged with N-[3-(carbamoylamino)phenyl]-3-fluoro-5-(trifluoromethyl)benzamide (100 mg, 0.2930 mmol) and 2-chlorobenzaldehyde (49.4 mg, 0.3515 mmol), and phosphorus pentoxide in MeOH (7.7 % weight, 0.5 mL, 1.0 eq) was added. The reaction mixture was heated to 80 °C for 45 min, then poured into sat. $NaHCO_3$. The mixture was extracted with EtOAc (2 x 15 mL), washed with saturated $NaHCO_3$ (10 mL), dried over sodium sulfate and concentrated to dryness. Purification via reverse-phase chromatography (12 g C18 cartridge, 5 to 70 % ACN in AmF) afforded N-(4-(2-chlorophenyl)-2-oxo-1,2,3,4-tetrahydroquinazolin-5-yl)-3-fluoro-5-(trifluoromethyl)benzamide (8 mg, 5.65%) as a white solid.

Example 22

N-[1-(2-Chlorophenyl)-3-oxo-1,2,3,4-tetrahydroisoquinolin-8-yl]-3-fluoro-5-(trifluoromethyl)benzamide




[0876] Step 1: A round bottom flask was charged with 2-(3-aminophenyl)acetamide (250 mg, 1.66 mmol) and 4-dimethylaminopyridine (10.1 mg, 0.05 eq) and flushed with nitrogen. Anh. pyridine (5.53 mL) was added followed by 3-fluoro-5-(trifluoromethyl)benzoyl chloride (379 µL, 2.48 mmol), and the reaction mixture was stirred at ambient temperature for 16 hours. Water (20 mL) was added to the reaction mixture, stirred for 10 min, and the precipitate was filtered and air dried. The residue was dried under high vacuum to afford N-[3-(carbamoylmethyl)phenyl]-3-fluoro-5-(trifluoromethyl)benzamide (570 mg, 1.40 mmol, 84.7 %) as a tan powder.

[0877] Step 2: A reaction vial was charged with N-[3-(carbamoylmethyl)phenyl]-3-fluoro-5-(trifluoromethyl)benzamide (100 mg, 0.2938 mmol) and 2-chlorobenzaldehyde (45.4 mg, 0.3231 mmol), then P_2O_5 in MeOH (7.7 % weight, 0.5 mL, 1.0 eq) was added, and the

reaction mixture was heated to 80 °C for 2 h. Once cooled, the reaction mixture was slowly poured into sat. $NaHCO_3$ (20 mL). The precipitate was filtered-off, dissolved in EtOAc and concentrated to dryness. Purification by reverse-phase chromatography (12 g C18 cartridge, 10 to 70% ACN in AmF) afforded N-[1-(2-chlorophenyl)-3-oxo-1,2,3,4-tetrahydroisoquinolin-8-yl]-3-fluoro-5-(trifluoromethyl)benzamide (24 mg, 0.05185 mmol, 17.7 %) as white powder after lyophilisation.

Example 23

N-[5-(2-Chloro-5-fluorophenyl)-1-methyl-2,7-dioxo-1H,2H,5H,6H,7H-pyrrolo[3,4-b]pyridin-4-yl]-3-fluoro-5-(trifluoromethyl)benzamide



[0878] Step 1: To a solution of 4,6-dichloropicolinic acid (58.0 g, 302 mmol) in dichloromethane (1.80 L) was added CDI (73.4 g, 453 mmol, 1.50 eq) and DMAP (1.11 g, 9.06 mmol, 0.03 eq) at 15 °C, and the mixture was stirred for 12 h. Then to the reaction mixture was added (4-methoxyphenyl)methanamine (41.4 g, 302 mmol, 39.1 mL) at 25 °C, and the mixture was stirred for 1.5 h. The mixture was poured into water (2.00 L). The

organic layers were washed with water (500 mL × 2) and brine (500 mL), dried over Na_2SO_4, filtered, and concentrated. The residue from two batches of the preceding procedure was purified by column chromatography on silica gel eluted with petroleum ether:ethyl acetate = 1:0 to 10:1 (Product: P1: R_f = 0.50) to afford 4,6-dichloro-N-(4-methoxybenzyl)picolinamide (165 g, 453 mmol, 75.1% yield) as a brown solid.

[0879] Step 2: To a mixture of 4,6-dichloro-N-(4-methoxybenzyl)picolinamide (88.0 g, 282 mmol, 1.00 eq) in THF (800 mL) was added NaH (22.6 g, 565 mmol) at 25 °C, and the mixture was stirred for 2 h. Then to the mixture was added a solution of 2-chloro-5-fluorobenzoyl chloride (81.8 g, 424 mmol) in THF (80.0 mL) at 25 °C, and the mixture was stirred for 2 h. Two batches of the preceding reaction mixture were combined and quenched with water (2.00 L). The resulting solution was extracted with ethyl acetate (1.00 L × 2). The combined organic layers were washed with brine (500 mL), dried over Na_2SO_4, filtered and concentrated. The residue was purified by column chromatography on silica gel eluted with petroleum ether:ethyl acetate = 1:0 to 80:1 (product: P1: R_f = 0.60) to afford 4,6-dichloro-*N*-(2-chloro-5-fluorobenzoyl)-*N*-(4-methoxybenzyl)picolinamide (160 g, 57.4% yield) as a yellow solid.

[0880] Step 3: To a solution of 4,6-dichloro-N-(2-chloro-5-fluorobenzoyl)-N-(4-methoxybenzyl)picolinamide (72.0 g, 153 mmol, 1.00 eq) in THF (720 mL) was added LiHMDS (1.00 M, 230 mL, 1.50 eq) at -50 °C. The mixture was stirred at -50 °C for 3 h. Two batches of the preceding mixture were combined and quenched with water (3.00 L). The resulting solution was extracted with ethyl acetate (1.50 L × 2). The combined organic layers were washed with brine (1.00 L), dried over Na_2SO_4, filtered and concentrated. The residue was purified by column chromatography on silica gel eluted with petroleum ether:ethyl acetate = 1:0 to 1:1 (Product: P1: R_f = 0.30) to afford 2,4-dichloro-5-(2-chloro-5-fluorophenyl)-5-hydroxy-6-(4-methoxybenzyl)-5,6-dihydro-7H-pyrrolo[3,4-b]pyridin-7-one (34.0 g, 68.3 mmol, 14.8% yield) as a white solid.

[0881] Step 4: To a solution of 2,4-dichloro-5-(2-chloro-5-fluorophenyl)-5-hydroxy-6-(4-methoxybenzyl)-5,6-dihydro-7H-pyrrolo[3,4-b]pyridin-7-one (34.0 g, 68.3 mmol) in dichloromethane (340 mL) was added Et_3SiH (79.4 g, 683 mmol, 109 mL) and $BF_3 \cdot Et_2O$ (31.0 g, 218 mmol) at 25 °C. Then the mixture was stirred at 40 °C for 15 h. The mixture was adjusted pH 6~7 with saturated $NaHCO_3$ solution. The resulting mixture was extracted with dichloromethane (400 mL × 2). The combined organic layers were washed with brine (300 mL), dried over Na_2SO_4, filtered and concentrated. The residue was purified by column

chromatography on silica gel eluted with petroleum ether:ethyl acetate = 1:0 to 10:1 (Product: P1: R_f = 0.50) to afford 2,4-dichloro-5-(2-chloro-5-fluorophenyl)-6-(4-methoxybenzyl)-5,6-dihydro-7H-pyrrolo[3,4-b]pyridin-7-one (32.0 g, 64.4 mmol, 95.8% yield) as a white solid.

[0882] Step 5: To a solution of 2,4-dichloro-5-(2-chloro-5-fluorophenyl)-6-(4-methoxybenzyl)-5,6-dihydro-7H-pyrrolo[3,4-b]pyridin-7-one (6.40 g, 13.5 mmol) in i-PrOH (40.3 mL) was added (2,4-dimethoxyphenyl)methanamine (3.40 g, 20.3 mmol) and DIEA (5.26 g, 40.7 mmol) in a sealed tube. The mixture was stirred at 190 °C for 5 h. The reaction mixture was combined and concentrated to afford the crude product. Then the crude product was dissolved in 100 mL DCM, washed with hydrochloric acid (0.50 M, 50.0 mL) and brine (100 mL), dried over Na_2SO_4, filtered and concentrated. The residue was purified by prep-HPLC (column: Phenomenex luna c18 250mm*100mm*10.0um; mobile phase: [water (0.225%FA)-ACN]; B%: 45.0%-75.0%, 20min) to afford 4-chloro-5-(2-chloro-5-fluorophenyl)-2-((2,4-dimethoxybenzyl)amino)-6-(4-methoxybenzyl)-5,6-dihydro-7H-pyrrolo[3,4-b]pyridin-7-one (2.6 g, 4.4 mmol, 32.9% yield).

[0883] Step 6: A supension of 4-chloro-5-(2-chloro-5-fluorophenyl)-2-((2,4-dimethoxybenzyl)amino)-6-(4-methoxybenzyl)-5,6-dihydro-7H-pyrrolo[3,4-b]pyridin-7-one (13.0 g, 22.3 mmol, 1.00 eq) in TFA (120 g, 1.05 mol, 78.0 mL, 47.2 eq) was stirred at 25 °C for 7 hours. The rection mixture was adjusted pH 9.00 with saturated $NaHCO_3$ solution. The resulting mixture was extracted with ethyl acetate (1.00 L × 3). The combined organic layers were washed with brine (500 mL), dried over Na_2SO_4, filtered and concentrated to afford 2-amino-4-chloro-5-(2-chloro-5-fluorophenyl)-6-[(4-methoxyphenyl)methyl]-5H,6H,7H-pyrrolo[3,4-b]pyridin-7-one (9.97 g, 17.3 mmol, 77.9% yield) as an off-white solid.

[0884] Step 7: To a solution of 2-amino-4-chloro-5-(2-chloro-5-fluorophenyl)-6-[(4-methoxyphenyl)methyl]-5H,6H,7H-pyrrolo[3,4-b]pyridin-7-one (1 g, 2.31 mmol) in MeOH (10 mL) at 0°C was added TFA (880 uL) followed by *tert*-butyl nitrite (1.35 mL, 11.5 mmol). The mixture was stirred at ambient temperature for 5 hours, and then a saturated aqueous solution of $NaHCO_3$ was added. The mixture was extracted with AcOEt (3x), and the combined organic layers were washed with brine, dried over Na_2SO_4, filtered, and concentrated under reduced pressure. Purification by silica gel chromatography (0 to 30% acetone/heptanes) afforded 4-chloro-5-(2-chloro-5-fluorophenyl)-2-methoxy-6-[(4-methoxyphenyl)methyl]-5H,6H,7H-pyrrolo[3,4-b]pyridin-7-one (725 mg, 70%) as a white foam/solid.

[0885] Step 8: 4-Chloro-5-(2-chloro-5-fluorophenyl)-2-methoxy-6-[(4-methoxyphenyl)methyl]-5H,6H,7H-pyrrolo[3,4-b]pyridin-7-one (525 mg, 1.17 mmol) was dissolved in a solution of HCl in dioxane (4M, 15 mL). The mixture was stirred at ambient temperature for 24 hours, and a saturated aqueous solution of $NaHCO_3$ was added with caution. The mixture was extracted with DCM (3x), and the combined organic layers were washed with brine, dried over Na_2SO_4, filtered and concentrated under reduced pressure, affording 4-chloro-5-(2-chloro-5-fluorophenyl)-6-(4-methoxybenzyl)-4a,5,6,7a-tetrahydro-1H-pyrrolo[3,4-b]pyridine-2,7-dione (506 mg, 1.17 mmol, 100%) as a clear oil.

[0886] Step 9: To a solution of 4-chloro-5-(2-chloro-5-fluorophenyl)-6-(4-methoxybenzyl)-4a,5,6,7a-tetrahydro-1H-pyrrolo[3,4-b]pyridine-2,7-dione (506 mg, 1.17 mmol) in dry and degassed DMF (5.8 mL) at ambient temperature was added iodomethane (88.5 µL, 1.75 mmol), followed by dipotassium carbonate (485 mg, 3.51 mmol). The mixture was stirred at ambient temperature for 12 hours, and a degassed saturated aqueous solution of NH_4Cl was then added. The mixture was extracted with DCM (3x), and the combined organic layers were washed with brine, dried over $MgSO_4$, filtered and concentrated under reduced pressure. Purification by silica gel chromatography (0 to 20% acetone/heptanes) afforded 4-chloro-5-(2-chloro-5-fluorophenyl)-6-(4-methoxybenzyl)-1-methyl-5,6-dihydro-1H-pyrrolo[3,4-b]pyridine-2,7-dione (432 mg, 83%) as an oil.

[0887] Step 10: 4-Chloro-5-(2-chloro-5-fluorophenyl)-6-(4-methoxybenzyl)-1-methyl-5,6-dihydro-1H-pyrrolo[3,4-b]pyridine-2,7-dione (432 mg, 0.9658 mmol) was diluted in 1-(4-methoxyphenyl)methanamine (6.5 mL, 49.7 mmol) and the mixture was stirred at 120°C for 12 hours (sealed tube). The mixture was then diluted with AcOEt and washed with a 1N solution of HCl. The layers were separated, and the aqueous layer was extracted with AcOEt (3x). The combined organic layers were washed with 1N HCl, then with brine, dried over $MgSO_4$, filtered, and concentrated under reduced pressure. Purification by silica gel chromatography (0 to 40% acetone/hexanes) afforded 5-(2-chloro-5-fluorophenyl)-6-(4-methoxybenzyl)-4-((4-methoxybenzyl)amino)-1-methyl-5,6-dihydro-1H-pyrrolo[3,4-b]pyridine-2,7-dione (489 mg, 92%) as a white solid foam.


[0888] Step 11: 5-(2-Chloro-5-fluorophenyl)-6-(4-methoxybenzyl)-4-((4-methoxybenzyl)amino)-1-methyl-5,6-dihydro-1H-pyrrolo[3,4-b]pyridine-2,7-dione (425 mg, 0.7755 mmol) was dissolved in TFA (0.6 mL) and stirred at 120 °C for 4 h. Four drops of TfOH were added and stirring was continued at 80 °C for 12 h. The mixture was carefully poured into a saturated aqueous solution of $NaHCO_3$ and extracted with DCM (3x) and

2MeTHF (3x). The combined organic layers were washed with brine, dried over Na_2SO_4, filtered and concentrated under reduced pressure. The resulting solid was precipitated in MeOH and recovered by filtration, affording 4-amino-5-(2-chloro-5-fluorophenyl)-1-methyl-1H,2H,5H,6H,7H-pyrrolo[3,4-b]pyridine-2,7-dione (260 mg, crude) as an orange solid.

[0889] Step 12: To a solution of 4-amino-5-(2-chloro-5-fluorophenyl)-1-methyl-1H,2H,5H,6H,7H-pyrrolo[3,4-b]pyridine-2,7-dione (50 mg, 0.1624 mmol) in dry DCM (2 mL) at ambient temperature were added 3-fluoro-5-(trifluoromethyl)benzoic acid (40.5 mg, 0.1948 mmol), 1-methyl-1H-imidazole (40.0 mg, 0.4872 mmol) and [chloro(dimethylamino)methylidene]dimethylazanium hexafluorophosphate (68.3 mg, 0.2436 mmol). The mixture was stirred at ambient temperature for 12 h. The reaction mixture was then diluted with DCM (10 mL) and H_2O (10 mL) and passed through a phase separator cartridge. The organic portion was then concentrated *in vacuo*. Product was purified by reverse-phase chromatography (12 g column, water/ACN; water solvent is 10 mM ammonium formate) to yield N-[5-(2-chloro-5-fluorophenyl)-1-methyl-2,7-dioxo-1H,2H,5H,6H,7H-pyrrolo[3,4-b]pyridin-4-yl]-3-fluoro-5-(trifluoromethyl)benzamide (8.79 mg, 10.8%).

Example 24

4-Amino-3-methoxyisoindolin-1-one



[0890] Step 1: To a solution of 4-nitro-2,3-dihydro-1H-isoindole-1,3-dione (15 g, 78.0 mmol) in a mixture of DCM (150 mL) and methanol (150 mL) at 0°C was added $NaBH_4$ (2.95 g, 78.0 mmol) by portions. The mixture was allowed to warm to RT and stirred for 1h. The mixture was concentrate to approximately 100 mL and filtered on a Büchner funnel, affording 8.6 g of 3-hydroxy-4-nitroisoindolin-1-one as a white powder. The filtrate was recovered and re-concentrated, then filtered again. Repetition of this procedure afforded an additional 4.7 g of 3-hydroxy-4-nitroisoindolin-1-one (13.3 g, 88%) as a white solid. LC-MS (Method 1): 0.4 min, *m/z* = 193.1 $[M-H]^-$.


[0891] Step 2: To a suspension of 3-hydroxy-4-nitroisoindolin-1-one (7 g, 36 mmol) in methanol (150 mL) was added Pd/C (10% on carbon, 2.5 g) followed by $NaHCO_3$ (5 g). The

mixture was degassed with hydrogen (vacuum and fill) and stirred at room temperature under a pressure of hydrogen for 12 h. The mixture was then filtered on a plug of Celite® (washed with MeOH) and concentrated under reduced pressure. The crude 4-amino-3-hydroxyisoindolin-1-one was carried to next step without further purification.

[0892] Step 3: The crude 4-amino-3-hydroxyisoindolin-1-one was diluted in MeOH (150 mL) and a 4N solution of HCL (10 mL) was then added. The mixture was stirred at 60°C for 15 min and then allowed to cool to room temperature. Volatiles were removed under reduced pressure and the mixture was treated with a sat. aq. solution of $NaHCO_3$. The mixture was extracted with DCM (3X) and MeTHF (3X). The combined organic layers were washed with brine, dried over Na_2SO_4, filtered and concentrated under reduced pressure. Purification by silica gel chromatography (0 to 80% acetone/hexanes) afforded 4-amino-3-methoxyisoindolin-1-one (1 g, 22%) as an orange solid. LC-MS (Method 1): 0.38 min, *m/z* = 179.2 $[M+H]^+$.

Example 25

6-([1,2,4]Triazolo[1,5-a]pyridin-6-yl)-4-bromo-3-(2-chloro-5-fluorophenyl)-2-(4-methoxybenzyl)isoindolin-1-one



[0893] Step 1: To a solution of 4-amino-6-bromo-3-(2-chloro-5-fluorophenyl)-2-(4-methoxybenzyl)isoindolin-1-one (125 g, 263 mmol) in DCM (1.25 L) was added DMAP (38.5 g, 315 mmol) and Boc_2O (86.0 g, 394 mmol) at 20 °C, and the mixture was stirred at 20 °C for 12 h. The reaction was poured into H_2O (2.00 L) and divided. The combined organic layers were washed with saturated NH_4Cl solution (1.50 mL * 3), washed with brine (1.50 L), dried over Na_2SO_4, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO_2, petroleum ether/ethyl acetate = 100/1 to 10/1, R_f = 0.55) to give Compound 1 & 1a (196 g, crude) as a yellow solid.


[0894] Step 2: To a solution of Compound 1 & 1a (98.0 g, crude) in DMF (980 mL) was added 6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-[1,2,4]triazolo[1,5-a]pyridine (50.1 g, 204 mmol) and K_2CO_3 (2 M, 255 mL). The mixture was purged with N_2 for three times. Then $Pd(dppf)Cl_2$ (6.23 g, 8.51 mmol, 0.05 eq) was added to the mixture at 20 °C. The mixture was purged with N_2 for three times again. Then the mixture was heated to 90 °C and stirred at 90 °C for 1 h. The reaction was poured into H_2O (5.00 L), stirred and filtered. The filter cake was diluted with ethyl acetate (3.00 L) and filtered. The combined organic layers were washed with saturated NH_4Cl solution (1.50 L), washed with brine (1.50 L), dried over Na_2SO_4, filtered and concentrated under reduced pressure to give compound 2 & 2a (85.0 g, crude) as a black brown solid.

[0895] Step 3: To a solution of compound 2 & 2a (85.0 g, crude) in DCM (850 mL) was added TFA (655 g, 5.74 mol) at 20 °C, then the mixture was stirred at 20 °C for 3 h. The reaction was concentrated under reduced pressure to give oil. The oil was diluted with DCM (1.00 L), poured into 2 N NaOH (2.00 L) and ice, and extracted with DCM (1.00 L * 3). The combined organic layers were washed with brine (2.00 L), dried over Na_2SO_4, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO_2, petroleum ether/ethyl acetate = 10/1 to ethyl acetate/dichloromethane = 4/1, R_f = 0.40) to give 6-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-amino-3-(2-chloro-5-fluorophenyl)-2-(4-methoxybenzyl)isoindolin-1-one (57.5 g) as a yellow amorphous solid.

[0896] Step 4: To a solution of 6-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-amino-3-(2-chloro-5-fluorophenyl)-2-(4-methoxybenzyl)isoindolin-1-one (11.6 g, 22.6 mmol) in ACN (110 mL) and HBr (173 g, 705 mmol) was added $NaNO_2$ (1.71 g, 24.8 mmol, 1.10 eq) at 0 °C. The diazonium solution was stirred for a further 30 min at 0 °C, and then CuBr (3.89 g, 27.1 mmol) was added to the mixture and stirred at 0 °C for 1 h. The mixture was poured into ice-water (2.00 L) and extracted with DCM (1.00 L*3). The combined organic layers were dried over Na_2SO_4, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO_2, petroleum ether/ethyl acetate = 1/1 to 0/1, R_f = 0.50). The resulting product was triturated with ethyl acetate (200 mL) at 25 °C for 16 h to give 6-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-bromo-3-(2-chloro-5-fluorophenyl)-2-(4-methoxybenzyl)isoindolin-1-one (8.3 g, 12.8 mmol, 56.7% yield) as a green solid.

Example 26


N-(3-(2-Chloro-5-fluorophenyl)-1-oxo-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isoindolin-4-yl)-3-fluoro-5-(trifluoromethyl)benzamide



[0897] To a solution of N-(6-bromo-3-(2-chloro-5-fluorophenyl)-1-oxoisoindolin-4-yl)-3-fluoro-5-(trifluoromethyl)benzamide (160 g, 261 mmol) and B_2Pin_2 (79.5 g, 313 mmol, 1.20 eq) in dioxane (1.60 L) was added KOAc (76.8 g, 783 mmol) and $Pd(dppf)Cl_2$ (9.55 g, 13.1 mmol, 0.05 eq) at 25 °C. The mixture was purged with N_2 three times, heated to 90 °C, and stirred at 90 °C for 14 hrs. To the reaction mixture was added half saturated brine (0.50 L) followed by saturated $Na_2S_2O_3$ aqueous solution (0.80 L). The aqueous layer was extracted with EtOAc (1.0 L), then the mixture was filtered. After separating the organic layer, the aqueous layer was extracted EtOAc (1.00 L) again. The combined organic layer was washed with brine (0.50 L), dried over Na_2SO_4, filtered, and concentrated. The crude product was dissolved in MTBE (3.00 V of crude, 600 mL), which was slowly dropped into heptanes (10.0 V of crude, 2.00 L), then the mixture was stirred at 25 °C for 2 h. The mixture was filtered, and the filter cake was dried under vacuum. The resulting product was triturated with petroleum ether: ethyl acetate = 5: 1 (600 mL) at 25 °C for 10 hrs. The mixture was filtered, and the filter cake was dried under vacuum. N-(3-(2-chloro-5-fluorophenyl)-1-oxo-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isoindolin-4-yl)-3-fluoro-5-(trifluoromethyl)benzamide (157 g, 96.3% yield) was obtained as a tan amorphous solid.

Example 27


N-(3-(2-Chloro-5-fluorophenyl)-6-hydroxy-1-oxoisoindolin-4-yl)-3-fluoro-5-(trifluoromethyl)benzamide



[0898] To a solution of N-(3-(2-chloro-5-fluorophenyl)-1-oxo-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isoindolin-4-yl)-3-fluoro-5-(trifluoromethyl)benzamide (97.0 g, 0.164 mol, 1.00 *eq*) in ACN (1.00 L) was added H_2O_2-urea (28.9 g, 0.307 mol, 1.88 *eq*) at 25 °C under N_2 atmosphere, then the mixture was stirred at 25 °C for 12 hrs. To the mixture was added half saturated brine (0.50 L) followed by saturated $Na_2S_2O_3$ aqueous solution (0.80 L). The aqueous layer was extracted with ethyl acetate (1.00 L), and then the mixture was filtered. After separating the organic layer, the aqueous layer was extracted again with ethyl acetate (1.00 L). The combined organic layer was washed with brine (0.50 L), dried over Na_2SO_4, filtered and concentrated. The crude product was purified by column chromatography (SiO_2, ethyl acetate: dichloromethane = 1:10 - 1:4 - 1:1, R_f = 0.30). The crude product was dissolved in MTBE (150 mL, 3.00 V of crude), which was slowly dropped into heptanes (520 mL, 10.0 V of crude), then the mixture was heated to 50 °C, and stirred at 50 °C for 1 hr. The mixture was cooled to 25 °C and filtered, and the filter cake was dried under vacuum to afford N-(3-(2-chloro-5-fluorophenyl)-6-hydroxy-1-oxoisoindolin-4-yl)-3-fluoro-5-(trifluoromethyl)benzamide (51.0 g, 61.7% yield) as a yellow solid.

Example 28


Methyl 1-(2-chloro-5-fluorophenyl)-7-(3-fluoro-5-(trifluoromethyl)benzamido)-3-oxoisoindoline-5-carboxylate



[0899] To a solution of N-(6-bromo-3-(2-chloro-5-fluorophenyl)-1-oxoisoindolin-4-yl)-3-fluoro-5-(trifluoromethyl)benzamide (120 g, 220 mmol) in MeOH (1.00 L) was added Et_3N (44.5 g, 440 mmol, 61.2 mL) and $Pd(dppf)Cl_2$ (16.1 g, 22.0 mmol) at 25 °C. The mixture was degassed and purged with CO three times. The mixture was heated to 80 °C and stirred at 80 °C for 16 hrs under CO (50 psi). The mixture was concentrated, and the residue was purified by column chromatography (SiO_2, petroleum ether: ethyl acetate= 50: 1 - 0: 1, R_f= 0.1) to give methyl 1-(2-chloro-5-fluorophenyl)-7-(3-fluoro-5-(trifluoromethyl)benzamido)-3-oxoisoindoline-5-carboxylate (58.0 g, 103 mmol, 47.0% yield, 93.6% purity) as a pink solid.

Example 29

N-(6-(Bromomethyl)-3-(2-chloro-5-fluorophenyl)-1-oxoisoindolin-4-yl)-3-fluoro-5-(trifluoromethyl)benzamide




[0900] Step 1: To a solution of lithium aluminum hydride (7.16 g, 188 mmol, 2.20 eq) in THF (100 mL) was added methyl 1-(2-chloro-5-fluorophenyl)-7-(3-fluoro-5-(trifluoromethyl) benzamido)-3-oxoisoindoline-5-carboxylate (45.0 g, 85.7 mmol, 1.00 eq) dissolved in THF (300 mL) at 0 °C. The mixture was warmed to 25 °C and stirred at 25 °C for 2 hours. The mixture was cooled to -10 °C and poured into Na_2SO_4*$10H_2O$ (110 g) under stirring, then filtered under reduced pressure and the filtrate was concentrated under pressure. The residue was triturated with mixture solution (petroleum ether: ethyl acetate = 5:1, 300 mL) at 25 °C for 30 mins and filtered under pressure to obtain N-(3-(2-chloro-5-fluorophenyl)-6-(hydroxymethyl)-1-oxoisoindolin-4-yl)-3-fluoro-5-(trifluoromethyl)benzamide (50.0 g, crude) as a brown solid.

[0901] Step 2: To a solution of N-(3-(2-chloro-5-fluorophenyl)-6-(hydroxymethyl)-1-oxoisoindolin-4-yl)-3-fluoro-5-(trifluoromethyl)benzamide (36.0 g, 72.5 mmol) in THF (1200 mL) was added PBr_3 (23.5 g, 86.96 mmol) at -20 °C, then the mixture was warmed to 0 °C and stirred at 0 °C for 2 h. The mixture was slowly warmed to 10 °C and stirred at 10 °C for 10 h. The mixture was dropped into saturated NH_4Cl (200 mL) at -20 °C, then extracted with ethyl acetate (500 mL * 3). The combined organic layers were washed with

brine (200 mL * 3), dried over Na_2SO_4, filtered and concentrated under reduced pressure. The residue was triturated with mixture solvent (petroleum ether: ethyl acetate = 3:1, 100 mL) at 10 °C for 30 mins to obtain N-(6-(bromomethyl)-3-(2-chloro-5-fluorophenyl)-1-oxoisoindolin-4-yl)-3-fluoro-5-(trifluoromethyl)benzamide (27.6 g, 46.9 mmol, 64.7% yield) as a white solid.

Example 30


(1-(2-Chloro-5-fluorophenyl)-7-(3-fluoro-5-(trifluoromethyl)benzamido)-3-oxoisoindolin-5-yl)methanesulfonyl chloride



[0902] A 100 mL round bottom flask was charged with N-(6-(bromomethyl)-3-(2-chloro-5-fluorophenyl)-1-oxoisoindolin-4-yl)-3-fluoro-5-(trifluoromethyl)benzamide (1.05 g, 1.0 eq.) and thiourea (149 mg, 1.05 eq.). Ethanol (30 mL) was added, and the reaction media was heated to 80 °C and kept under stirring for 3 h. The reaction media was cooled to ambient temperature, and ethanol was removed under reduced pressure to afford a white powder. The mixture was dissolved in MeCN (6 mL) and cooled to 0 C. Hydrochloric acid (1N, 1.3 mL) was added dropwise to the reaction mixture, which was kept under stirring at 0 °C for 20 min, at which point *N*-chlorosuccinimide (998 mg, 4 eq.) was added portionwise. The reaction media was allowed to warm to ambient temperature. After 30 min of stirring, the reaction mixture was concentrated to yield (1-(2-chloro-5-fluorophenyl)-7-(3-fluoro-5-(trifluoromethyl)benzamido)-3-oxoisoindolin-5-yl)methanesulfonyl chloride as an orange solid (1.01 g, 92% yield)

Example 31

N-(3-(2-Chloro-5-fluorophenyl)-6-formyl-1-oxoisoindolin-4-yl)-3-fluoro-5-(trifluoromethyl)benzamide (I-333)




[0903] Step 1: To a solution of N-(6-bromo-3-(2-chloro-5-fluorophenyl)-1-oxoisoindolin-4-yl)-3-fluoro-5-(trifluoromethyl)benzamide (200 g, 367 mmol) in dioxane (2.00 L) and H_2O (400 mL) was added vinylboronic acid pinacol ester (113 g, 733 mmol), $Pd(dppf)Cl_2$ (26.8 g, 36.7 mmol) and $NaHCO_3$ (154 g, 1.83 mol) at 25 °C, then the mixture was heated to 80 °C and stirred at 80 °C for 12 h. The mixture was poured into water (2.50 L) and extracted with ethyl acetate (1.00 L * 2). The combined organic phase was washed with brine (1.00 L * 2), dried with anhydrous Na_2SO_4, filtered, and concentrated in vacuum. The resulting residue was purified by column chromatography (SiO_2, petroleum ether: ethyl acetate = 50: 1 - 0: 1, R_f= 0.25) to give N-(3-(2-chloro-5-fluorophenyl)-1-oxo-6-vinylisoindolin-4-yl)-3-fluoro-5-(trifluoromethyl)benzamide (135 g, 70.1% yield) as a brown solid.

[0904] Step 2: Ozone was bubbled into a solution of N-(3-(2-chloro-5-fluorophenyl)-1-oxo-6-vinylisoindolin-4-yl)-3-fluoro-5-(trifluoromethyl)benzamide (52.0 g, 106 mmol) in DCM (2.00 L) at -78 °C for 0.5 h. After excess O_3 was purged with N_2, Me_2S (7.21 g, 116 mmol) was added at -78 °C, and the mixture was stirred at -78 °C for 0.5 hr. Two batches of the reaction mixture were quenched with saturated $NaHCO_3$ solution (2.00 L), and the mixture was extracted with DCM (1.20 L * 3). The combined organic layers were washed with brine (1.00 L), dried over Na_2SO_4, filtered, and concentrated. The resulting residue was purified by prep-HPLC (column: Phenomenex luna C18 (250*70mm, 15 um); mobile phase: [water(0.225%FA)-ACN]; B%: 43ACN%-63ACN%, 20 min) to give N-(3-(2-chloro-5-fluorophenyl)-6-formyl-1-oxoisoindolin-4-yl)-3-fluoro-5-(trifluoromethyl)benzamide (42.0 g, 40.1% yield) as an off-white solid.

Example 32

N-(2-([1,2,4]Triazolo[1,5-a]pyridin-6-yl)-5-(2-chloro-5-fluorophenyl)-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-4-yl)-3-fluoro-5-(trifluoromethyl)benzamide



[0905] Step 1: 2,4-Dichloro-5-(2-chloro-5-fluorophenyl)-6-(4-methoxybenzyl)-5,6-dihydro-7H-pyrrolo[3,4-b]pyridin-7-one (6.000 g, 13.2 mmol) was slurried in a mixture of dimethoxyethane (60 mL) and ethanol (30 mL). To this was added 6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-[1,2,4]triazolo[1,5-a]pyridine (3.23 g, 13.2 mmol), followed by 25 mL of 1.5 M aqueous sodium carbonate. The mixture was degassed for 10 min by bubbling N_2 directly into the slurry. Palladium(2+) bis(triphenylphosphine) dichloride (370 mg, 528 μmol) was added, and the mixture was heated to 80 °C for 3 h. The reaction mixture was cooled to RT and diluted with ethyl acetate (150 mL) and water (50 mL). The mixture was extracted with ethyl acetate (100 mL). The combined organic layers were washed with brine (100 mL), dried over Na_2SO_4, filtered, and concentrated. The residue was purified by column chromatography on silica gel eluted with heptanes:ethyl acetate = 1:1 to 0:100 (Product: P1: R_f = 0.50) to afford 2-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-chloro-5-(2-chloro-5-fluorophenyl)-6-(4-methoxybenzyl)-5,6-dihydro-7H-pyrrolo[3,4-b]pyridin-7-one (3.1 g, 42.9% yield) as an off-white solid.

[0906] Step 2: 2-([1,2,4]Triazolo[1,5-a]pyridin-6-yl)-4-chloro-5-(2-chloro-5-fluorophenyl)-6-(4-methoxybenzyl)-5,6-dihydro-7H-pyrrolo[3,4-b]pyridin-7-one (2.0 g, 3.74 mmol) was dissolved in 3 mL of NMP and treated with 1-(2,4-dimethoxyphenyl)methanamine (2.8 mL, 18.7 mmol). The mixture was heated to 150 °C for 30 min. The reaction was cooled to room temperature, diluted with ethyl acetate (50 mL) and aqueous LiCl (25 mL). The organic layer was washed with 4 x 25 mL aqueous LiCl, dried over Na_2SO_4, filtered, and concentrated to afford 2-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-5-(2-chloro-5-fluorophenyl)-4-((2,4-dimethoxybenzyl)amino)-6-(4-methoxybenzyl)-5,6-dihydro-7H-pyrrolo[3,4-b]pyridin-7-one (2.5 g, 3.60 mmol, 96.7% yield) as an off-white solid.

[0907] Step 3: 2-([1,2,4]Triazolo[1,5-a]pyridin-6-yl)-5-(2-chloro-5-fluorophenyl)-4-((2,4-dimethoxybenzyl)amino)-6-(4-methoxybenzyl)-5,6-dihydro-7H-pyrrolo[3,4-b]pyridin-7-one (2.5 g, 3.75 mmol) was dissolved in DCM (2 mL) and dropped into trifluoroacetic acid (5.7 mL, 75 mmol, 20 eq). The mixture was stirred at room temperature for 16 h. The mixture was concentrated *in vacuo* then diluted with dichloromethane (50 mL). This was slowly added to an ice cold, stirring mixture of saturated aqueous sodium bicarbonate (50 mL). The pH was then adjusted to pH 10 via addition of 2N sodium hydroxide. The mixture was stirred for 5 h. The organic layer was washed with water (50 mL), brine (50 mL), dried over Na_2SO_4, filtered and concentrated. The resulting residue was triturated with MTBE (25 mL) for 60 mins and then filtered to afford 2-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-amino-5-(2-chloro-5-fluorophenyl)-6-(4-methoxybenzyl)-5,6-dihydro-7H-pyrrolo[3,4-b]pyridin-7-one (1.6 g, 82.9% yield) as an off-white solid.


[0908] Step 4: 2-([1,2,4]Triazolo[1,5-a]pyridin-6-yl)-4-amino-5-(2-chloro-5-fluorophenyl)-6-(4-methoxybenzyl)-5,6-dihydro-7H-pyrrolo[3,4-b]pyridin-7-one (2.50 g, 4.85 mmol) was dissolved in acetonitrile (30 mL). Pyridine (3.9 mL, 48.5 mmol) was added, followed by 3-fluoro-5-(trifluoromethyl)benzoyl chloride (1.31 g, 5.81 mmol, 1.2eq). The reaction was heated to 80 °C for 16 h. The reaction was cooled to room temperature and diluted with ethyl acetate (100 mL). This was carefully washed with 10% aqueous sodium carbonate (3 x 50 mL), followed by brine (50 mL). The solution was dried over Na_2SO_4, filtered and concentrated. The residue was triturated in MTBE (25 mL) for 2 h and filtered to afford N-(2-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-5-(2-chloro-5-fluorophenyl)-6-(4-methoxybenzyl)-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-4-yl)-3-fluoro-5-(trifluoromethyl)benzamide (2.5 g, 73.3% yield).

[0909] Step 5: N-(2-([1,2,4]Triazolo[1,5-a]pyridin-6-yl)-5-(2-chloro-5-fluorophenyl)-6-(4-methoxybenzyl)-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-4-yl)-3-fluoro-5-

(trifluoromethyl)benzamide (1.00 g, 1.41 mmol) was dissolved in acetonitrile (18 mL). Ceric ammonium nitrate (1.54 g, 2.82 mmol) was added as a solution in water (2 mL). The reaction was warmed to 40 °C for 30 min. The reaction was cooled to RT and carefully quenched with a solution of sodium bisulfite in water. The mixture was extracted with MeTHF (3 x 20 mL). The combined organics were then washed with water (20 mL), brine (30 mL), dried over Na_2SO_4, filtered and concentrated. The residue was purified by column chromatography on silica gel eluted with dichloromethane:methanol = 100:0 to 85:15 to afford N-(2-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-5-(2-chloro-5-fluorophenyl)-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-4-yl)-3-fluoro-5-(trifluoromethyl)benzamide (514 mg, 62.3% yield) as a white solid.

Example 33


N-[3-(2-Chloro-5-fluorophenyl)-6-(1H-indol-2-yl)-1-oxo-2,3-dihydro-1H-isoindol-4-yl]-3-fluoro-5-(trifluoromethyl)benzamide



[0910] To an 8-mL vial was added N-[6-bromo-3-(2-chloro-5-fluorophenyl)-1-oxo-2,3-dihydro-1H-isoindol-4-yl]-3-fluoro-5-(trifluoromethyl)benzamide (100 mg, 183 μmol), 2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indole (44.4 mg, 1 eq), sodium carbonate (48.4 mg, 2.5 eq), and palladium bis(triphenylphosphine) dichloride (10.5 mg, 0.15 eq). The vial was purged with nitrogen and sealed. The solids were then dissolved in dioxane (1.6 mL) and water (0.4 mL). The reaction was then stirred and heated to 90°C for 1 hour before checking the reaction progress via LCMS. The reaction mixture was cooled and filtered through a pad of silica. The filtrate was concentrated, and the resulting material was purified on the AccQ Prep system eluting with 30-60% water with 0.1% formic acid. Product-containing fractions were concentrated to yield N-[3-(2-chloro-5-fluorophenyl)-6-(1H-indol-2-yl)-1-oxo-2,3-dihydro-1H-isoindol-4-yl]-3-fluoro-5-(trifluoromethyl)benzamide (87.6 mg, 82.6%).

Example 34

N-[3-(2-Chloro-5-fluorophenyl)-6-[3-(difluoromethyl)imidazo[1,2-a]pyridin-6-yl]-1-oxo-2,3-dihydro-1H-isoindol-4-yl]-3-fluoro-5-(trifluoromethyl)benzamide



[0911] To a vial was added N-[3-(2-chloro-5-fluorophenyl)-1-oxo-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2,3-dihydro-1H-isoindol-4-yl]-3-fluoro-5-(trifluoromethyl)benzamide (381 mg, 644 μmol), 6-bromo-3-(difluoromethyl)imidazo[1,2-a]pyridine (145 mg, 586 μmol), palladium(2+) bis(triphenylphosphane) dichloride (61.6 mg, 87.8 μmol), and disodium carbonate (185 mg, 1.75 mmol). The vial was purged and back filled with nitrogen, and then water (250 μL) and dioxane (1 mL) were added. The reaction mixure was then heated to 90°C for 20 mins. The reaction progress was then checked via LCMS, which showed complete conversion to product. The mixture was then cooled, filtered, and placed on the AccQ prep system. Fractions containing product were concentrated to yield N-[3-(2-chloro-5-fluorophenyl)-6-[3-(difluoromethyl)imidazo[1,2-a]pyridin-6-yl]-1-oxo-2,3-dihydro-1H-isoindol-4-yl]-3-fluoro-5-(trifluoromethyl)benzamide (145 mg, 39.1%).

[0912] Additional compounds prepared according to the methods of Example 33 and Example 34 are listed in Table 10 below. Certain compounds in Table 10 were prepared with other compounds whose preparation is described elsewhere in the Examples.

Table 10. Additional Exemplary Compounds

Compound	Compound	Compound
I-705	I-741	I-822
I-712	I-782	I-823
I-732	I-783	I-824
I-736	I-784	I-825
I-737	I-815	I-826
I-738	I-821	I-827

Compound
I-838
I-849
I-851
I-852
I-853
I-854
I-855
I-865
I-866
I-881
I-882
I-883
I-884
I-885
I-886
I-887
I-888
I-890
I-891
I-892
I-893
I-894
I-895
I-896
I-902
I-905
I-906
I-915
I-918
I-919
I-921
I-927

Compound
I-928
I-929
I-930
I-931
I-932
I-933
I-934
I-940
I-941
I-943
I-945
I-946
I-948
I-949
I-967
I-969
I-970
I-971
I-972
I-975
I-979
I-980
I-981
I-982
I-984
I-985
I-986
I-987
I-996
I-1000
I-1003
I-1004

Compound
I-1006
I-1007
I-1008
I-1009
I-1010
I-1011
I-1012
I-1023
I-1024
I-1025
I-1026
I-1027
I-1028
I-1030
I-1032
I-1033
I-1034
I-1035
I-1036
I-1037
I-1038
I-1039
I-1041
I-1042
I-1043
I-1044
I-1045
I-1047
I-1048
I-1049
I-1053
I-1054

Compound
I-1055
I-1056
I-1057
I-1059
I-1061
I-1062
I-1063
I-1065
I-1089
I-1090
I-1091
I-1092
I-1093
I-1094
I-1095
I-1098
I-1101
I-1102
I-1103
I-1105
I-1106
I-1107
I-1108
I-1111
I-1116
I-1117
I-1121
I-1122
I-1123
I-1124
I-1136
I-1137

Compound
I-1150
I-1151
I-1152
I-1156
I-1163
I-1165
I-1166
I-1167
I-1168
I-1169
I-1170
I-1171
I-1172
I-1173
I-1174
I-1190
I-1193
I-1195
I-1197
I-1207
I-1208
I-1214
I-1215
I-1216
I-1217
I-1219
I-1220
I-1222
I-1231
I-1232
I-1264
I-1265

Compound
I-1272
I-1303
I-1329
I-1330
I-1331
I-1332
I-1335
I-1340
I-1342
I-1343
I-1368
I-1369
I-1373
I-1374
I-1390
I-1405
I-1406
I-1407
I-1408
I-1409
I-1410
I-1411
I-1413
I-1415
I-1416
I-1419
I-1437
I-1438
I-1439
I-1440
I-1441
I-1442

Compound
I-1443
I-1444
I-1445
I-1448
I-1449
I-1452
I-1453
I-1454
I-1455
I-1456
I-1458
I-1464
I-1474
I-1482
I-1483
I-1492
I-1499
I-1500
I-1506
I-1529
I-1530
I-1531
I-1537
I-1538
I-1539
I-1540
I-1542
I-1544
I-1547
I-1549
I-1550
I-1552

Compound
I-1553
I-1573
I-1574
I-1583
I-1584
I-1585
I-1586
I-1589
I-1598
I-1599
I-1600
I-1601
I-1602
I-1603
I-1604
I-1605
I-1609
I-1624
I-1627
I-1628
I-1630
I-1631
I-1645
I-1646
I-1647
I-1648
I-1649
I-1650
I-1652
I-1653
I-1662
I-1664

Compound
I-1665
I-1667
I-1676
I-1684
I-1685
I-1688
I-1690
I-1692
I-1693
I-1694
I-1696
I-1700
I-1701
I-1702
I-1703
I-1704
I-1707
I-1708
I-1723
I-1724
I-1730
I-1734
I-1743
I-1744
I-1750
I-1751
I-1758
I-1759
I-1760
I-1767
I-1773
I-1777

Compound
I-1778
I-1779
I-1780
I-1781
I-1782
I-1783
I-1785
I-1786
I-1787
I-1792
I-1793
I-1796
I-1797
I-1802
I-1803
I-1804
I-1812
I-1813
I-1814
I-1816
I-1817
I-1821
I-1822
I-1825
I-1827
I-1829
I-1830
I-1831
I-1834
I-1838
I-1839
I-1840

Compound
I-1842
I-1843
I-1844
I-1845
I-1847
I-1848
I-1849
I-1850
I-1855
I-1856
I-1858
I-1859
I-1864
I-1865
I-1866
I-1869
I-1870
I-1873
I-1874
I-1875
I-1876
I-1877
I-1878
I-1879
I-1880
I-1881
I-1882
I-1883
I-1884
I-1899
I-1900
I-1910

Compound
I-1913
I-1922
I-1923
I-1924
I-1925
I-1928
I-1929
I-1932
I-1933
I-1934
I-1936
I-1937
I-1938
I-1939
I-1947
I-1948
I-1957
I-1960
I-1964
I-1966
I-1982
I-1983
I-1984
I-1985
I-1986
I-1987
I-1990
I-1991
I-1992
I-2000
I-2001
I-2002


Compound
I-2003
I-2004
I-2008
I-2012
I-2015
I-2028
I-2029
I-2030
I-2031
I-2032
I-2033
I-2034
I-2035
I-2037
I-2044

Compound
I-2045
I-2051
I-2063
I-2064
I-2065
I-2066
I-2067
I-2068
I-2069
I-2125
I-2137
I-2146
I-2147
I-2161
I-2169

Compound
I-2170
I-2185
I-2185
I-2186
I-2200
I-2201
I-2233
I-2234
I-2258
I-2259
I-2267
I-2289
I-2290
I-2706
I-2707

Example 35

N-[3-(2-Chloro-5-fluorophenyl)-6-[(oxetan-2-yl)methyl]-1-oxo-2,3-dihydro-1H-isoindol-4-yl]-3-fluoro-5-(trifluoromethyl)benzamide



[0913] To a 4-mL vial were added 4,4′-di-*tert*-butyl-2,2′-dipyridyl (3.67 mg, 0.05 eq) and $NiCl_2$ (3.07 mg, 0.01 eq), and dioxane (1.0 mL). The solution was stirred and sparged with nitrogen for 15 mins, until it turned light blue. While the nickel ligand stock solution was stirring, to an 8-mL vial with a stir bar was added N-[6-bromo-3-(2-chloro-5-fluorophenyl)-1-oxo-2,3-dihydro-1H-isoindol-4-yl]-3-fluoro-5-(trifluoromethyl)benzamide (150 mg, 274 μmol) and $[Ir\{dF(CF_3)ppy\}_2(dtbpy)]PF_6$ (3.07 mg, 0.01 eq) dissolved in dioxane (2.73 mL).

The mixture was purged with nitrogen and stirred. To the Ir-containing mixture were added, in order, lutidine (95.1 μL, 3 eq), 1,1,1,3,3,3-hexamethyldisilazane (68.1 mg, 1.0 eq), the nickel ligand stock solution, then 2-(bromomethyl)oxetane (39.5 μL, 1.5 eq). The reaction was sparged for 10 minutes before sealing with parafilm and vacuum grease. The reaction was placed in the Merck photoreactor to run at 100% intensity (wavelengths: 365nm to 450nm) for 3 hours before checking reaction progress via LCMS. The reaction was concentrated and purified on the AccQ system eluting with 30-60 % water with 0.1% formic acid. Product-containing fractions were lyophilized to yield N-[3-(2-chloro-5-fluorophenyl)-6-[(oxetan-2-yl)methyl]-1-oxo-2,3-dihydro-1H-isoindol-4-yl]-3-fluoro-5-(trifluoromethyl)benzamide (94 mg, 63.9%).


[0914] Additional compounds prepared according to the methods of Example 35 are listed in Table 11 below. Certain compounds in Table 11 were prepared with other compounds whose preparation is described elsewhere in the Examples.

Table 11. Additional Exemplary Compounds

Compound
I-529
I-1376

Example 36

N-[3-(2-Chloro-5-fluorophenyl)-1-oxo-6-(5-oxo-5,6-dihydro-1,6-naphthyridin-6-yl)-2,3-dihydro-1H-isoindol-4-yl]-3-fluoro-5-(trifluoromethyl)benzamide




[0915] A resealable reaction vial was charged with 5,6-dihydro-1,6-naphthyridin-5-one (20 mg, 0.1368 mmol), N-[6-bromo-3-(2-chloro-5-fluorophenyl)-1-oxo-2,3-dihydro-1H-isoindol-4-yl]-3-fluoro-5-(trifluoromethyl)benzamide (74.6 mg, 0.1368 mmol), copper (I) iodide (3.90

mg, 0.15 eq), dipotassium carbonate (8.50 mg, 0.45 eq), and a stirbar before being evacuated and purged with nitrogen three times. Dimethylformamide (0.5 mL) was added, and the mixture was stirred at 130 °C overnight. Reaction mixture was then cooled and diluted with water. The aqueous layer was extracted with ethyl acetate 3 times. The organic layer was washed with brine, dried over sodium sulfate, filtered, and concentrated. The resulting material was purified by prep-HPLC (acetonitrile/water/0.1% formic acid). Product-containing fractions were lyophilized to yield product N-[3-(2-chloro-5-fluorophenyl)-1-oxo-6-(5-oxo-5,6-dihydro-1,6-naphthyridin-6-yl)-2,3-dihydro-1H-isoindol-4-yl]-3-fluoro-5-(trifluoromethyl)benzamide (3.91 mg, 4.4%).

Example 37

N-[3-(2-Chloro-5-fluorophenyl)-1-oxo-6-[(pyrimidin-5-yl)methoxy]-2,3-dihydro-1H-isoindol-4-yl]-3-fluoro-5-(trifluoromethyl)benzamide



[0916] To a 20-mL vial was added N-[3-(2-chloro-5-fluorophenyl)-6-hydroxy-1-oxo-2,3-dihydro-1H-isoindol-4-yl]-3-fluoro-5-(trifluoromethyl)benzamide (100 mg, 207 μmol), (pyrimidin-5-yl)methanol (22.7 mg, 207 μmol), triphenylphosphine (70.5 mg, 1.3 eq), and diisopropyl azodicarboxylate (52.8 μL, 1.3 eq) dissolved in tetrahydrofuran (5 mL). The reaction was stirred and heated at reflux for 20 mins. Reaction progress was checked via LCMS and showed complete conversion to product. The reaction mixture was purified with AccQ prep system to yield N-[3-(2-chloro-5-fluorophenyl)-1-oxo-6-[(pyrimidin-5-yl)methoxy]-2,3-dihydro-1H-isoindol-4-yl]-3-fluoro-5-(trifluoromethyl)benzamide (46.4 mg, 38.9%).

[0917] Additional compounds prepared according to the methods of Example 37 are listed in Table 12 below. Certain compounds in Table 12 were prepared with other compounds whose preparation is described elsewhere in the Examples.

Table 12. Additional Exemplary Compounds

Compound	Compound	Compound
I-708	I-1132	I-1366
I-709	I-1135	I-1375
I-735	I-1149	I-1378
I-739	I-1160	I-1412
I-740	I-1184	I-1414
I-748	I-1192	I-1421
I-773	I-1198	I-1431
I-812	I-1205	I-1432
I-819	I-1210	I-1457
I-873	I-1221	I-1466
I-977	I-1234	I-1467
I-1064	I-1239	I-1468
I-1113	I-1251	I-1517
I-1129	I-1252	I-1518
I-1131	I-1253	I-1519
I-1132	I-1289	I-1520
I-1135	I-1295	I-1521
I-1149	I-1298	I-1522
I-1160	I-1304	I-1523
I-1184	I-1305	I-1524
I-1192	I-1320	I-1525
I-1198	I-1322	I-1526
I-1205	I-1333	I-1527
I-1210	I-1334	I-1541
I-873	I-1338	I-1566
I-977	I-1341	I-1567
I-1064	I-1346	I-1568
I-1113	I-1347	I-1569
I-1129	I-1348	I-1735
I-1131	I-1357	I-1736


Compound
I-1887
I-1888
I-1935
I-2005

Compound
I-2006
I-2007
I-2009

Compound
I-2061
I-2062
I-2134

Example 38

N-[3-(2-Chloro-5-fluorophenyl)-1-oxo-6-{[(1r*,3r)-3-hydroxycyclobutyl]amino}-2,3-dihydro-1H-isoindol-4-yl]-3-fluoro-5-(trifluoromethyl)benzamide**



[0918] In a microwave vial, a solution of N-[6-bromo-3-(2-chloro-5-fluorophenyl)-1-oxo-2,3-dihydro-1H-isoindol-4-yl]-3-fluoro-5-(trifluoromethyl)benzamide (70 mg, 128 µmol), (1r*,3r**)-3-aminocyclobutan-1-ol hydrochloride (31.6 mg) and BrettPhos Pd G4 (35.3 mg) in toluene (1.5 mL) was degassed by passing nitrogen through the solution. To the reaction mixture, lithium bis(trimethylsilyl)azanide (512 µL, 512 µmol) was added. The tube was sealed and heated at 110 °C for 1 hour. The reaction was quenched with water (2 mL) and the mixture was passed through Celite®. The crude mixture was purified on C18 reverse-phase column (12 g cartridge) using water with ACN 5-60% as an eluent. The fractions containing the desired product were collected and lyophilized to yield N-[3-(2-chloro-5-fluorophenyl)-1-oxo-6-{[(1r*,3r**)-3-hydroxycyclobutyl]amino}-2,3-dihydro-1H-isoindol-4-yl]-3-fluoro-5-(trifluoromethyl)benzamide (2 mg, 2.8%).

[0919] Additional compounds prepared according to the methods of Example 38 are listed in Table 13 below. Certain compounds in Table 13 were prepared with other compounds whose preparation is described elsewhere in the Examples.

Table 13. Additional Exemplary Compounds


Compound
I-39
I-51
I-53
I-275
I-284
I-288
I-304
I-311
I-312
I-310
I-321
I-329
I-338
I-343
I-359
I-370
I-375
I-478
I-530
I-532
I-540
I-541
I-609
I-613
I-695
I-707
I-721

Compound
I-723
I-728
I-729
I-730
I-780
I-781
I-814
I-830
I-848
I-868
I-869
I-899
I-900
I-960
I-1015
I-1040
I-1069
I-1070
I-1082
I-1086
I-1125
I-1126
I-1127
I-1128
I-1140
I-1146

Compound
I-1164
I-1181
I-1189
I-1227
I-1233
I-1236
I-1237
I-1248
I-1249
I-1250
I-1260
I-1261
I-1262
I-1263
I-1267
I-1273
I-1291
I-1299
I-1301
I-1309
I-1310
I-1354
I-1387
I-1388
I-2148
I-2192

Example 39

***N*-(6-(Aminomethyl)-1-oxo-3-(*o*-tolyl)isoindolin-4-yl)benzo[*b*]thiophene-3-carboxamide (I-88)**



[0920] A reaction vessel was charged with *N*-[6-bromo-3-(2-methylphenyl)-1-oxo-2,3-dihydro-1*H*-isoindol-4-yl]-1-benzothiophene-3-carboxamide (20 mg, 0.04189 mmol), 2-{[(tert-butoxy)carbonyl]amino}acetic acid (22.0 mg, 0.1256 mmol), Cs_2CO_3 (40.8 mg, 0.1256 mmol), $NiCl_2$·DME (1.37 mg, 0.006283 mmol), 4,4′-di-*tert*-butyl-2,2′-dipyridyl (1.68 mg, 0.006283 mmol), and $[Ir\{dF(CF_3)ppy\}_2(dtbpy)]PF_6$ (0.02 mol%). The reaction vessel was sealed, evacuated, and purged with N_2. Then 0.3 mL of DMAC was added, and the mixture was stirred for 16 hrs at ambient temperature while irradiating with a Kessel lamp. The reaction mixture was diluted with EtOAc and filtered through a plug of silica.

[0921] The filtrate was concentrated, then diluted with 1:1 TFA and DCM and stirred for 4 hrs. The reaction was concentrated, and the product was purified by reverse phase HPLC using a gradient of water (0.1% FA) and acetonitrile (0.1% FA) 80/20 to 30/70 in 13 minutes then 5/95. Product-containing fractions were combined and lyophilized to provide *N*-(6-(aminomethyl)-1-oxo-3-(*o*-tolyl)isoindolin-4-yl)benzo[*b*]thiophene-3-carboxamide (2 mg, 10%).

[0922] Additional compounds prepared according to the methods of Example 39 are listed in Table 14 below. Certain compounds in Table 14 below were prepared with other compounds whose preparation is described elsewhere in the Examples.

Table 14. Additional Exemplary Compounds


Compound
I-87
I-89
I-90

Compound
I-126
I-140
I-155

Compound
I-207
I-223
I-260

Example 40

_N_-[6-Amino-3-(2-methylphenyl)-1-oxo-2,3-dihydro-1_H_-isoindol-4-yl]-1,2-benzothiazole-3-carboxamide (I-50)



[0923] A reaction vessel was charged with _N_-[6-bromo-3-(2-methylphenyl)-1-oxo-2,3-dihydro-1H-isoindol-4-yl]-1,2-benzothiazole-3-carboxamide (50 mg, 0.1 mmol) and Pd(tBu)$_3$P-G4 (13.7 mg, 0.017 mmol). The reaction vessel was evacuated and purged with N_2. Then 0.6 mL of toluene was added, and the mixture was stirred for 5 min at ambient temperature. Then LiHMDS (0.5 mL, 0.5 mmol) was added, and the mixture was stirred for 16 hours at 50°C. The mixture was diluted with 2 mL of MeOH (0.1% FA), stirred, and then concentrated. The resulting residue was diluted with 2 mL of DMSO and purified by reverse phase HPLC using a gradient of water (0.1% FA) and acetonitrile (0.1% FA) 70/30 to 35/65 in 13 minutes, then 5/95. Product-containing fractions were combined and lyophilized to provide _N_-[6-amino-3-(2-methylphenyl)-1-oxo-2,3-dihydro-1_H_-isoindol-4-yl]-1,2-benzothiazole-3-carboxamide (10 mg, 20 %).

[0924] Additional compounds prepared according to the methods of Example 40 are listed in Table 15 below. Certain compounds in Table 15 below were prepared with other compounds whose preparation is described elsewhere in the Examples.

Table 15. Additional Exemplary Compounds


Compound
I-34
I-40
I-65
I-66

Compound
I-91
I-92
I-125
I-213

Compound
I-217
I-218
I-289

Example 41


***N*-[6-Ethenyl-3-(2-methylphenyl)-1-oxo-2,3-dihydro-1*H*-isoindol-4-yl]-1-benzothiophene-3-carboxamide (I-100)**



[0925] To a screw-top glass reaction vial equipped with a stir bar was added *N*-[6-bromo-3-(2-methylphenyl)-1-oxo-2,3-dihydro-1*H*-isoindol-4-yl]-1-benzothiophene-3-carboxamide (80 mg, 167.0 μmol), 1,4-dioxane (1.5 mL), tributyl(vinyl)tin (80 μL, 273 umol), DABCO (2.00 mg, 17.8 μmol), and TBAF (500 μL). The suspension was degassed by freeze-pump-thaw cycle (3 cycles), followed by bubbling with nitrogen gas for 10 min. Palladium acetate (2.00 mg, 8.90 μmol) was then introduced into the suspension. The suspension was sealed, and the vial was placed in a pre-heated oil bath (110 °C, external) until the reaction was deemed complete (ca. 16 h). The reaction mixture was filtered through Celite and washed with ethyl acetate. The combined organic fraction was evaporated under reduced pressure to afford the crude residue. This crude residue was filtered through a small pad of silica, and eluted first with hexanes, and then with ethyl acetate. The combined organic fraction was evaporated under reduced pressure to afford a crude product. Approximately half of this crude product was purified by normal-phase flash column chromatography (eluting with 20% EtOAc in Hexanes to 100% ethyl acetate in gradient) to afford *N*-[6-ethenyl-3-(2-methylphenyl)-1-oxo-2,3-dihydro-1*H*-isoindol-4-yl]-1-benzothiophene-3-carboxamide (9 mg) as an off-white solid.

Example 42

***N*-[6-(2-Hydroxyethyl)-3-(2-methylphenyl)-1-oxo-2,3-dihydro-1*H*-isoindol-4-yl]-1-benzothiophene-3-carboxamide (I-181)**



[0926] Step 1: A round bottom flask equipped with a stir bar was charged with a solution of crude *N*-[6-ethenyl-3-(2-methylphenyl)-1-oxo-2,3-dihydro-1*H*-isoindol-4-yl]-1-benzothiophene-3-carboxamide (~25 mg, ~59 μmol) in THF (1.0 mL). To this solution was added an excess of BH_3·THF (1.0 M THF solution, 0.2 mL, 200 μmol) at room temperature. The solution was then stirred for 4 hours at room temperature. To this solution was added sodium perborate tetrahydrate (30.7 mg, 200 μmol), and the mixture was stirred for 5 minutes. To the solution was then added water (1.0 mL), and the mixture was stirred overnight. The solution was evaporated under reduced pressure to afford a crude residue. The crude residue was purified by reverse-phase flash column chromatography (12 g, C18, eluting with increasing amount of acetonitrile (0-100%) from initial 10 mM ammonium bicarbonate in water) to afford a mixture of the desired alcohol and a minor impurity as white powder after lyophilization. This white powder was purified further using prep-HPLC (gradient 20% to 100% acetonitrile in 0.1% FA in water) to afford, after lyophilization of pure fractions, 3.2 mg of *N*-[6-(2-hydroxyethyl)-3-(2-methylphenyl)-1-oxo-2,3-dihydro-1*H*-isoindol-4-yl]-1-benzothiophene-3-carboxamide as a white solid.

[0927] Additional compounds prepared according to the methods of Example 42 are listed in Table 16 below. Certain compounds in Table 16 below were prepared with other compounds whose preparation is described elsewhere in the Examples.


Table 16. Additional Exemplary Compounds

Compound
I-119
I-434

Compound
I-579

Example 43

***N*-[6-(1,2-Dihydroxyethyl)-3-(2-methylphenyl)-1-oxo-2,3-dihydro-1*H*-isoindol-4-yl]-1-benzothiophene-3-carboxamide (I-139)**



[0928] Step 1: A round bottom flask equipped with a stir bar was charged with a solution of crude *N*-[6-ethenyl-3-(2-methylphenyl)-1-oxo-2,3-dihydro-1*H*-isoindol-4-yl]-1-benzothiophene-3-carboxamide (~25 mg, ~59 μmol) in THF (1.5 mL) and water (0.4 mL). To this reaction mixture was added NMO (6.6 mg, 56 μmol) and potassium osmate(VI) dihydrate (1.9 mg, 5 μmol). The solution was stirred for two hours. The volatiles were evaporated under reduced pressure to afford a residue, which was purified by normal-phase flash column chromatography (eluting with 20% EtOAc/Hexanes to 100% EtOAc in gradient, then 10% MeOH in EtOAc), to afford the 1:1 mixture of desired diol diastereomers from the MeOH/EtOAc fractions. The solvent was evaporated under reduced pressure to afford a concentrated diol mixture. The diol mixture was purified further by reverse-phase flash column chromatography (eluting with 10mM ammonium bicarbonate in water to 100% acetonitrile in gradient). Lyophilization of the pure fractions afforded 4.8 mg of the desired diol *N*-[6-(1,2-dihydroxyethyl)-3-(2-methylphenyl)-1-oxo-2,3-dihydro-1*H*-isoindol-4-yl]-1-benzothiophene-3-carboxamide as a 1:1 mixture of diastereomers as a white solid.


[0929] Additional compounds prepared according to the methods of Example 43 are listed in Table 17 below. Certain compounds in Table 17 below were prepared with other compounds whose preparation is described elsewhere in the Examples.

Table 17. Additional Exemplary Compounds


Compound
I-120
I-382


Example 44

***N*-[6-(Hydroxymethyl)-3-(2-methylphenyl)-1-oxo-2,3-dihydro-1*H*-isoindol-4-yl]-1,2-benzothiazole-3-carboxamide (I-131)**



Methyl 7-amino-2-(4-methoxybenzyl)-3-oxo-1-(*o*-tolyl)isoindoline-5-carboxylate and Methyl 2-(4-methoxybenzyl)-7-((methoxycarbonyl)amino)-3-oxo-1-(*o*-tolyl)isoindoline-5-carboxylate






[0930] Step 1: To a solution of 4-amino-6-bromo-2-(4-methoxybenzyl)-3-(*o*-tolyl)isoindolin-1-one (17.1 g, 39.1 mmol, 1.00 equiv.) in MeOH (500 mL) was added DPPF (2.17 g, 3.91 mmol, 0.10 equiv.), $Pd(OAc)_2$ (1.76 g, 7.82 mmol, 0.20 equiv.), and KOAc (11.5 g, 117 mmol, 3.00 equiv.). The mixture was degassed and purged with CO three times. The mixture was heated to 80°C and stirred at 80°C for 10 hrs under CO (50 psi). LCMS showed significant unconsumed 4-amino-6-bromo-2-(4-methoxybenzyl)-3-(*o*-tolyl)isoindolin-1-one. The mixture was stirred at 80°C for 120 hrs. The mixture was filtered, and the filtrate was concentrated in vacuum to give the crude product. The crude product was purified by column chromatography (SiO_2, petroleum ether/ethyl acetate=1/0 to 0/1) to afford methyl 7-amino-2-(4-methoxybenzyl)-3-oxo-1-(*o*-tolyl)isoindoline-5-carboxylate (MS: *m/z* = 417.2 $[M+H]^+$)

and methyl 2-(4-methoxybenzyl)-7-((methoxycarbonyl)amino)-3-oxo-1-(*o*-tolyl)isoindoline-5-carboxylate (11.5 g, 22.9 mmol, 58.6% yield, 94.5% purity) as a light yellow solid.


[0931] Characterization data for methyl 2-(4-methoxybenzyl)-7-((methoxycarbonyl)amino)-3-oxo-1-(*o*-tolyl)isoindoline-5-carboxylate: MS: *m/z* = 475.3 $[M+H]^+$; ^1H NMR (400 MHz, DMSO-d_6) δ 9.17 (d, *J* = 16.4 Hz, 1H), 8.13 (dd, *J* = 23.6, 1.2 Hz, 1H), 7.94 (d, *J* = 1.2 Hz, 1H), 7.60 (d, *J* = 19.4 Hz, 1H), 6.93 - 6.83 (d, *J* = 19.4 Hz, 1H), 7.45 (d, *J* = 24 Hz, 1H), 7.28 - 7.22 (m, 5H), 7.07 - 7.00 (m, 6H), 6.91 - 6.87 (m, 4H), 6.46 (d, *J* = 7.6 Hz, 1H), 6.29 (d, *J* = 7.6 Hz, 1H), 5.97 (s, 1H), 5.73 (s, 1H), 5.63 (s, 1H), 5.50 (s, 1H), 5.01 - 4.91 (m, 2H), 4.77 (s, 1H), 3.92 (d, *J* = 4.8 Hz, 4H), 3.87 (d, *J* = 4.8 Hz, 2H), 3.74 (d, *J* = 8.0 Hz, 6H), 3.62(d, *J* = 14.8 Hz, 1H), 3.49 (d, *J* = 9.6 Hz, 5H), 2.25 (d, *J* = 18.4 Hz, 3H), 1.48 (s, 1H), 1.34 (s, 2H).

4-Amino-6-(hydroxymethyl)-2-[(4-methoxyphenyl)methyl]-3-(2-methylphenyl)-2,3-dihydro-1*H*-isoindol-1-one



[0932] Step 2: A solution of methyl 7-amino-2-(4-methoxybenzyl)-3-oxo-1-(*o*-tolyl)isoindoline-5-carboxylate (516 mg, 1.24 mmol) in THF (6.19 mL) was stirred under nitrogen atmosphere and cooled to 0 °C using an ice bath. Then a solution of borane lithium hydride (930 µL, 1.86 mmol, 2 M in THF) was added, and the mixture was warmed to room temperature overnight. The reaction mixture was quenched with water (20 mL), extracted with DCM (3 x 20 mL), and the combined organic phases were concentrated under reduced pressure. The resulting residue was purified by reverse-phase chromatography (60g column C18, 10 to 100% ACN/AmF 10mM) to afford after lyophilisation 4-amino-6-(hydroxymethyl)-2-[(4-methoxyphenyl)methyl]-3-(2-methylphenyl)-2,3-dihydro-1*H*-isoindol-1-one (188 mg, 0.484 mmol, 39% yield) as a white powder. MS: *m/z* = 389.3 $[M+H]^+$.


***N*-[6-(Hydroxymethyl)-2-[(4-methoxyphenyl)methyl]-3-(2-methylphenyl)-1-oxo-2,3-dihydro-1*H*-isoindol-4-yl]-1,2-benzothiazole-3-carboxamide**



[0933] Step 3: To a solution of 4-amino-6-(hydroxymethyl)-2-[(4-methoxyphenyl)methyl]-3-(2-methylphenyl)-2,3-dihydro-1*H*-isoindol-1-one (150 mg, 0.3861 mmol) in DCM (1.93 mL) was added 1*H*-imidazole (65.7 mg, 0.9652 mmol), and the reaction mixture was cooled to 0°C using an ice bath. Then *tert*-butyl(chloro)dimethylsilane (69.8 mg, 0.4633 mmol) was added, and the reaction mixture was stirred for 2h at room temperature.

[0934] To the reaction mixture was added 1,2-benzothiazole-3-carbonyl chloride (76.3 mg, 0.3861 mmol), and the reaction mixture was stirred for 3 days at room temperature. The reaction mixture was concentrated to dryness and purified by reverse phase chromatography (60g C18 column, 10 to 100% ACN/AmF 10mM) to afford after lyophilisation *N*-[6-(hydroxymethyl)-2-[(4-methoxyphenyl)methyl]-3-(2-methylphenyl)-1-oxo-2,3-dihydro-1*H*-isoindol-4-yl]-1,2-benzothiazole-3-carboxamide (80.5 mg, 0.1466 mmol, 38% yield) as an orange powder. MS: *m/z* = 550.3 $[M+H]^+$; ^{1}H NMR (400 MHz, DMSO-d_6) δ 10.18 (s, 0.31H), 10.06 (s, 0.48H), 8.58 (d, *J* = 8.2 Hz, 0.32H), 8.52 (d, *J* = 8.2 Hz, 0.53H), 8.29 (d, *J* = 8.3 Hz, 1H), 7.72 (d, *J* = 4.5 Hz, 1H), 7.71 – 7.67 (m, 1H), 7.67 – 7.63 (m, 1H), 7.60 – 7.52 (m, 1H), 7.27 (d, *J* = 7.0 Hz, 0.38H), 7.11 – 6.81 (m, 7H), 6.74 (t, *J* = 6.7 Hz, 0.36H), 6.42 – 6.35 (m, 0.57H), 5.96 (s, 0.51H), 5.76 (s, 0.33H), 5.45 (td, *J* = 5.8, 2.9 Hz, 1H), 5.00 (dd, *J* = 15.0, 11.1 Hz, 1H), 4.65 (t, *J* = 5.2 Hz, 2H), 3.73 (s, 3H), 3.61 (d, *J* = 14.9 Hz, 0.40H), 3.47 (d, *J* = 15.5 Hz, 0.71H), 2.10 (s, 2H), 1.44 (s, 1H). The compound appears to exist as non-interconverting rotamers in DMSO solution at ambient temperature.

***N*-[6-(Hydroxymethyl)-3-(2-methylphenyl)-1-oxo-2,3-dihydro-1*H*-isoindol-4-yl]-1,2-benzothiazole-3-carboxamide**



[0935] Step 4: In a sealed tube *N*-[6-(hydroxymethyl)-2-[(4-methoxyphenyl)methyl]-3-(2-methylphenyl)-1-oxo-2,3-dihydro-1*H*-isoindol-4-yl]-1,2-benzothiazole-3-carboxamide (231 mg, 0.420 mmol) was dissolved in trifluoroacetic acid (6.42 mL, 84.0 mmol). The resulting mixture was heated at 90°C for 24 h. The reaction was diluted with DCM (50 mL), the organic layer was washed with water (2 x 5 mL), and the organic phase was concentrated under reduced pressure. The residue was purified by reverse phase chromatography (60g C18 cartridge, 10 to 100% ACN/AmF 10mM) to afford *N*-[6-(hydroxymethyl)-3-(2-methylphenyl)-1-oxo-2,3-dihydro-1*H*-isoindol-4-yl]-1,2-benzothiazole-3-carboxamide (123 mg, 0.288 mmol, 68% yield) as a brown powder after lyophilisation.

[0936] Additional compounds prepared according to the methods of Example 44 are listed in Table 18 below. Certain compounds in Table 18 below were prepared with other compounds whose preparation is described elsewhere in the Examples.

Table 18. Additional Exemplary Compounds


Compound
I-154
I-185
I-224

Compound
I-306
I-307


Compound
I-314
I-373

Example 45

***N*-(6-((Methylsulfonyl)methyl)-1-oxo-3-(*o*-tolyl)isoindolin-4-yl)benzo[*d*]isothiazole-3-carboxamide (I-202)**




***N*-(6-(Bromomethyl)-1-oxo-3-(*o*-tolyl)isoindolin-4-yl)benzo[*d*]isothiazole-3-carboxamide**



[0937] Step 1: A flask was charged with *N*-(6-(hydroxymethyl)-1-oxo-3-(*o*-tolyl)isoindolin-4-yl)benzo[*d*]isothiazole-3-carboxamide (7 mg, 0.0163 mmol), dichloromethane (0.13 mL) triphenylphosphine (4.69 mg, 0.0179 mmol), and tetrabromomethane (5.93 mg, 0.0179 mmol). The reaction mixture was stirred for 1.5 h at room temperature. The reaction mixture was concentrated under reduced pressure and purified by reverse phase chromatography (30 g C18 cartridge, 10 to 100% ACN/AmF 10mM) to afford *N*-(6-(bromomethyl)-1-oxo-3-(*o*-tolyl)isoindolin-4-yl)benzo[*d*]isothiazole-3-carboxamide (9.00 mg, 0.0183 mmol) as a beige powder. MS: *m/z* = 492.2 $[M+H]^+$.

***N*-(6-((Methylsulfonyl)methyl)-1-oxo-3-(*o*-tolyl)isoindolin-4-yl)benzo[*d*]isothiazole-3-carboxamide**



[0938] Step 2: A sealed tube was charged with *N*-(6-(bromomethyl)-1-oxo-3-(*o*-tolyl)isoindolin-4-yl)benzo[*d*]isothiazole-3-carboxamide (9.00 mg, 0.01827 mmol), DMF (0.09 mL), and sodium methanesulfinate (4.66 mg, 0.04567 mmol). The reaction mixture was heated to 70°C for 6 h. The reaction mixture was cooled to room temperature then directly purified on reverse phase chromatography (30 g C18 cartridge, 10 to 100% ACN/AmF 10 mM) to afford after lyophilisation *N*-(6-((methylsulfonyl)methyl)-1-oxo-3-(*o*-tolyl)isoindolin-4-yl)benzo[*d*]isothiazole-3-carboxamide (5.44 mg, 0.0111 mmol, 60% yield) as a white powder. MS: *m/z* = 492.3 $[M+H]^+$; ^{1}H NMR (400 MHz, $CDCl_3$) δ 8.90 (d, *J* = 7.7 Hz, 1H), 8.87 (s, 1H), 8.59 (s, 1H), 7.94 (d, *J* = 7.8 Hz, 1H), 7.79 (d, *J* = 1.2 Hz, 1H), 7.72 – 7.62 (m, 1H), 7.60 – 7.50 (m, 3H), 7.46 (td, *J* = 7.4, 3.0 Hz, 1H), 7.17 (br s, 1H), 6.65 (s, 1H), 6.00 (br s, 1H), 4.41 (s, 2H), 2.89 (s, 3H), 2.16 (s, 1H), 1.24 (br s, 3H).


[0939] Additional compounds prepared according to the methods of Example 45 are listed in Table 19 below. Certain compounds in Table 19 below were prepared with other compounds whose preparation is described elsewhere in the Examples.

Table 19. Additional Exemplary Compounds


Compound
I-231
I-310

Example 46

N-(6-(Methoxymethyl)-1-oxo-3-(*o*-tolyl)isoindolin-4-yl)-*N*-methylbenzo[*d*]isothiazole-3-carboxamide (I-134)




***N*-(2-(4-Methoxybenzyl)-6-(methoxymethyl)-1-oxo-3-(*o*-tolyl)isoindolin-4-yl)-*N*-methylbenzo[*d*]isothiazole-3-carboxamide**



[0940] Step 1: To a solution of *N*-(6-(hydroxymethyl)-2-(4-methoxybenzyl)-1-oxo-3-(*o*-tolyl)isoindolin-4-yl)benzo[*d*]isothiazole-3-carboxamide (20 mg, 0.036 mmol) in DMF (0.18 mL) cooled to 0°C using an ice bath, was added sodium hydride (3.05 mg, 0.0764 mmol) and the mixture was stirred for 30 minutes. Iodomethane (2.71 µL, 0.0437 mmol) was added, and the reaction mixture was warmed to room temperature for 2 h. The reaction was quenched with water (10 mL), the aqueous layer was extracted with DCM (3 x 10mL), and the combined organic layers were concentrated under reduced pressure. The residue was purified by reverse phase chromatography (30 g C18 Biotage, 10 to 100% ACN/AmF 10mM) to afford after lyophilisation *N*-(2-(4-methoxybenzyl)-6-(methoxymethyl)-1-oxo-3-(*o*-tolyl)isoindolin-4-yl)-*N*-methylbenzo[*d*]isothiazole-3-carboxamide (10.5 mg, 0.0183 mmol, 50% yield) as a beige powder. MS: *m/z* = 578.4 $[M+H]^+$.

***N*-(6-(Methoxymethyl)-1-oxo-3-(*o*-tolyl)isoindolin-4-yl)-*N*-methylbenzo[*d*]isothiazole-3-carboxamide**




[0941] Step 2: A sealed tube was charged with *N*-(2-(4-methoxybenzyl)-6-(methoxymethyl)-1-oxo-3-(*o*-tolyl)isoindolin-4-yl)-*N*-methylbenzo[*d*]isothiazole-3-carboxamide (10.5 mg, 0.0183 mmol) and trifluoroacetic acid (317 µL, 4.15 mmol), and the reaction mixture was heated to 90°C for 24 h. The resulting mixture was diluted with DCM (20 mL), washed with water (2 x 50 mL), and concentrated under reduced pressure. The residue was purified by


reverse-phase chromatography (30 g C18 cartridge, 10 to 100% ACN/AmF 10mM) affording after lyophilisation *N*-(6-(methoxymethyl)-1-oxo-3-(*o*-tolyl)isoindolin-4-yl)-*N*-methylbenzo[*d*]isothiazole-3-carboxamide (3.84 mg, 0.00839 mmol, 40% yield) as a beige powder.

Example 47

***N*-(6-(Methoxymethyl)-1-oxo-3-(*o*-tolyl)isoindolin-4-yl)benzo[*d*]isothiazole-3-carboxamide (I-146)**




(7-(Benzo[*d*]isothiazole-3-carboxamido)-2-(4-methoxybenzyl)-3-oxo-1-(*o*-tolyl)isoindolin-5-yl)methyl methanesulfonate




[0942] Step 1: To a solution of *N*-(6-(hydroxymethyl)-2-(4-methoxybenzyl)-1-oxo-3-(*o*-tolyl)isoindolin-4-yl)benzo[*d*]isothiazole-3-carboxamide (25 mg, 0.036 mmol) in anhydrous DCM (0.23 mL) was added triethylamine (19.0 µL, 0.14 mmol), and the mixture was cooled to 0°C using an ice bath. Methanesulfonyl methanesulfonate (11.8 mg, 0.0682 mmol) was added, and the reaction mixture was stirred for 30 minutes at room temperature. The mixture was quenched with water (20 mL). The layers were separated, and the aqueous layer was further extracted with DCM (3 x 20 mL). The combined organics were washed with brine, dried over sodium sulfate, and concentrated to provide (7-(benzo[*d*]isothiazole-3-carboxamido)-2-(4-methoxybenzyl)-3-oxo-1-(*o*-tolyl)isoindolin-5-yl)methyl methanesulfonate which was used directly in the next step. MS: *m/z* = 628.2 $[M+H]^+$.

***N*-(2-(4-Methoxybenzyl)-6-(methoxymethyl)-1-oxo-3-(*o*-tolyl)isoindolin-4-yl)benzo[*d*]isothiazole-3-carboxamide**



[0943] Step 2: To a solution of (7-(benzo[*d*]isothiazole-3-carboxamido)-2-(4-methoxybenzyl)-3-oxo-1-(*o*-tolyl)isoindolin-5-yl)methyl methanesulfonate in methanol (1 mL) was added sodium methanolate (1.0 mL, 4.36 mmol, 25% w/w in MeOH), and the mixture was stirred for 18 h at room temperature. The mixture was concentrated under reduced pressure, and the crude was purified by reverse-phase chromatography (30 g C18 cartridge, 10 to 100% ACN/AmF 10mM) to afford after lyophilisation *N*-(2-(4-methoxybenzyl)-6-(methoxymethyl)-1-oxo-3-(*o*-tolyl)isoindolin-4-yl)benzo[*d*]isothiazole-3-carboxamide (13.0 mg, 0.0231 mmol, 50% yield over two steps) as a beige powder. MS: *m/z* = 564.3 $[M+H]^+$.

***N*-(6-(Methoxymethyl)-1-oxo-3-(*o*-tolyl)isoindolin-4-yl)benzo[*d*]isothiazole-3-carboxamide**




[0944] Step 3: A sealed tube was charged with *N*-(2-(4-methoxybenzyl)-6-(methoxymethyl)-1-oxo-3-(*o*-tolyl)isoindolin-4-yl)benzo[*d*]isothiazole-3-carboxamide (13.0 mg, 0.0231 mmol) and trifluoroacetic acid (352 µL, 4.61 mmol), and the reaction mixture was heated to 90°C for 24 h. The resulting mixture was diluted with DCM (20 mL), washed with water (2 x 50 mL), and concentrated under reduced pressure. The residue was purified by reverse-phase chromatography (30 g C18 cartridge, 10 to 100% ACN/AmF 10mM) affording after


lyophilisation *N*-(6-(methoxymethyl)-1-oxo-3-(*o*-tolyl)isoindolin-4-yl)benzo[*d*]isothiazole-3-carboxamide (6 mg, 0.013 mmol, 55% yield) as a beige powder.

Example 48

7-(Benzo[*b*]thiophene-3-carboxamido)-*N*-methyl-3-oxo-1-(*o*-tolyl)isoindoline-5-carboxamide (I-6), (*R*)-7-(Benzo[*b*]thiophene-3-carboxamido)-*N*-methyl-3-oxo-1-(*o*-tolyl)isoindoline-5-carboxamide (I-75), and (*S*)-7-(Benzo[*b*]thiophene-3-carboxamido)-*N*-methyl-3-oxo-1-(*o*-tolyl)isoindoline-5-carboxamide (I-76)




7-Amino-2-(4-methoxybenzyl)-3-oxo-1-(*o*-tolyl)isoindoline-5-carboxylic acid



[0945] Step 1: To a mixture of methyl 2-(4-methoxybenzyl)-7-((methoxycarbonyl)amino)-3-oxo-1-(*o*-tolyl)isoindoline-5-carboxylate (10.0 g, 19.9 mmol, 1.00 equiv.) in MeOH (200 mL) was added NaOH (2 M, 99.6 mL, 10.0 equiv.) at 25°C. Then the mixture was heated to 60°C and stirred at 60°C for 4 h. The mixture was concentrated in vacuum to afford a residue. The residue was diluted with water (200 mL), and washed with ethyl acetate (3 x 200 mL). The aqueous layer was adjusted to pH = 3, then extracted with ethyl acetate (3 x 20.0 mL). The combined organic layers were washed with brine (20.0 mL), dried over Na_2SO_4, filtered, and the filtrate was concentrated. The crude product was purified by column chromatography (SiO_2, 0 to 5% MeOH in DCM) to afford 7-amino-2-(4-methoxybenzyl)-3-oxo-1-(*o*-tolyl)isoindoline-5-carboxylic acid (3.50 g, 7.89 mmol, 39.6% yield, 90.7% purity) as a yellow solid. MS: *m/z* = 401.1 $[M-H]^-$; ^1H NMR (400 MHz, DMSO-d_6) δ 12.93 (s, 1H), 7.60 -7.54 (m, 3H), 7.44 - 7.39 (m, 2H), 7.31 - 7.21(m, 4H), 7.03 - 6.99 (m, 6H), 6.88 - 6.86 (m, 4H), 6.46 (d, *J* = 8.0 Hz, 1H), 5.60 (s, 1H), 5.48 (s, 1H), 4.99 - 4.93 (m, 1H), 4.85 (s, 1H),


4.71 (s, 2H), 3.73 (s, 6H), 3.65 (d, J = 8.0 Hz, 1H), 3.60 (d, J = 14.8 Hz, 1H), 3.51 (d, J = 15.6 Hz, 1H), 2.26 (s, 3H), 1.48 (s, 2H).

7-Amino-2-(4-methoxybenzyl)-*N*-methyl-3-oxo-1-(*o*-tolyl)isoindoline-5-carboxamide




[0946] Step 2: To a solution of 7-amino-2-(4-methoxybenzyl)-3-oxo-1-(*o*-tolyl)isoindoline-5-carboxylic acid (844 mg, 2.10 mmol, 1.00 equiv.) in DMF (10 mL) was added DIPEA (2.17 g, 16.8 mmol, 2.92 mL, 8.00 equiv.) at 25°C. The mixture was cooled to 0°C, then HOBt (567 mg, 4.19 mmol, 2.00 equiv.) and EDCI (804 mg, 4.19 mmol, 2.00 equiv.) were added at 0°C. The mixture was warmed to 25°C and stirred at 25°C for 0.5 hr. Then $MeNH_2$·HCl (708 mg, 10.5 mmol, 5.00 equiv.) was added to the reaction mixture, and the mixture was stirred at 25°C for 4 hrs. The mixture was poured into water (40.0 mL) and extracted with ethyl acetate (3 x 40.0 mL). The combined organic layer was washed with brine (40.0 mL), dried over Na_2SO_4, filtered, and concentrated. The residue was purified by column chromatography (SiO_2, Petroleum ether/Ethyl acetate = 1:0 to 0:1) to afford compound 7-amino-2-(4-methoxybenzyl)-*N*-methyl-3-oxo-1-(*o*-tolyl)isoindoline-5-carboxamide (340 mg) as a light yellow solid. MS: m/z = 414.3 $[M+H]^+$; ^{1}H NMR (400 MHz, DMSO-d_6) δ 8.50 - 8.47 (m, 2H), 7.57 - 7.52 (m, 2H), 7.44 (d, J = 1.2 Hz, 1H), 7.37 - 7.20 (m, 7H), 7.10 - 7.00 (m, 4H), 6.90 - 6.85 (m, 7H), 6.62 (d, J = 8.4 Hz, 2H), 6.46 (d, J = 8.0 Hz, 1H), 5.58 (s, 1H), 5.45 (s, 1H), 5.00 – 4.94 (m, 1H), 4.68 (t, J = 19.2 Hz, 4H), 3.72 (s, 3H), 3.65 (s, 3H), 3.59 (d, J = 14.8 Hz, 1H), 3.51 (d, J = 15.2 Hz, 1H), 2.78 - 2.75 (m, 6H), 2.26 (s, 2H), 1.30 (s, 2H).

7-(Benzo[*b*]thiophene-3-carboxamido)-2-(4-methoxybenzyl)-*N*-methyl-3-oxo-1-(*o*-tolyl)isoindoline-5-carboxamide




[0947] Step 3: To a mixture of 7-amino-2-(4-methoxybenzyl)-*N*-methyl-3-oxo-1-(*o*-tolyl)isoindoline-5-carboxamide (340 mg, 818 μmol, 1.00 equiv.) and benzo[*b*]thiophene-3-carbonyl chloride (241 mg, 1.23 mmol, 1.50 equiv.) in THF (8.00 mL) was added Et_3N (248.42 mg, 2.45 mmol, 342 μL, 3.00 equiv.). The mixture was stirred at 50°C for 8 hrs. The mixture was concentrated in vacuum to afford the crude product. The crude product was purified by prep-HPLC (Column: Waters X bridge BEH C18 250*50mm*10μm; Mobile phase: 42%-72% ACN in water (10mM NH_4HCO_3)) to afford 7-(benzo[*b*]thiophene-3-carboxamido)-2-(4-methoxybenzyl)-*N*-methyl-3-oxo-1-(*o*-tolyl)isoindoline-5-carboxamide (130 mg, 224 μmol, 99.2% purity) as a white solid. MS: *m/z* = 576.4 $[M+H]^+$; ^1H NMR (400 MHz, DMSO-d_6) δ 10.18 (d, *J* = 43.2 Hz, 1H), 8.80 - 8.77 (m, 1H), 8.24 (d, *J* = 21.2 Hz, 1H), 8.16 - 8.13 (m, 1H), 8.07 - 7.96 (m, 3H), 7.79 (d, *J* = 20.0 Hz, 7H), 6.62 (d, *J* = 8.4 Hz, 2H), 6.46 (d, *J* = 8.0 Hz, 1H), 5.58 (s, 1H), 5.45 (s, 1H), 5.00 - 4.94 (m, 1H), 7.42 - 7.36 (m, 2H), 7.18 - 7.00 (m, 5H), 6.92 - 6.86 (m, 3H), 6.34 (d, *J* = 7.2 Hz, 1H), 5.94 (s, 1H), 5.71 (s, 1H), 5.00 (dd, *J* = 14.8, 3.6 Hz, 1H), 3.73 (s, 3H), 3.63 (d, *J* = 15.2 Hz, 1H), 3.53 (d, *J* = 15.6 Hz, 1H), 2.83 (t, *J* = 4.8 Hz, 3H), 1.94 (s, 2H), 1.39 (s, 1H).

7-(Benzo[*b*]thiophene-3-carboxamido)-*N*-methyl-3-oxo-1-(*o*-tolyl)isoindoline-5-carboxamide



[0948] Step 4: A solution of 7-(benzo[*b*]thiophene-3-carboxamido)-2-(4-methoxybenzyl)-*N*-methyl-3-oxo-1-(*o*-tolyl)isoindoline-5-carboxamide (130 mg, 226 μmol, 1.00 equiv.) in TFA (4.00 g, 35.1 mmol, 2.60 mL, 156 equiv.) was stirred at 100°C for 75 hrs. The mixture was concentrated in vacuum to afford the residue. The residue was dissolved in ethyl acetate (20.0 mL), poured into saturated aqueous solution of $NaHCO_3$ (20.0 mL), extracted with ethyl acetate (3 x 20.0 mL). The combined organic layer was washed with brine (20.0 mL), dried over Na_2SO_4, filtered, and concentrated. The crude product was purified by prep-HPLC (Column: Waters Xbridge 150*25mm* 5μm; Mobile phase: 28%-58% ACN in water (10mM NH_4HCO_3)) to afford 7-(benzo[*b*]thiophene-3-carboxamido)-*N*-methyl-3-oxo-1-(*o*-tolyl)isoindoline-5-carboxamide (76.0 mg, 167 μmol, 73.8% yield, 100% purity) as a white solid. MS: *m/z* = 456.2 $[M+H]^+$; ^1H NMR (400 MHz, CD_3OD) δ 8.18 (d, *J* = 1.2 Hz, 1H), 8.13 (t, *J* = 5.6 Hz, 1H), 8.02 (d, *J* = 1.6 Hz, 1H), 7.92 -7.89 (m, 1H), 7.42 -7.39 (m, 3H), 7.16 - 7.12 (m, 1H), 7.03 - 7.00 (m, 2H), 6.15 (s, 1H), 2.98(s, 3H), 2.21 - 2.18 (m, 3H).

(*R*)-7-(Benzo[*b*]thiophene-3-carboxamido)-*N*-methyl-3-oxo-1-(*o*-tolyl)isoindoline-5-carboxamide and (*S*)-7-(Benzo[*b*]thiophene-3-carboxamido)-*N*-methyl-3-oxo-1-(*o*-tolyl)isoindoline-5-carboxamide



[0949] Step 5: The enantiomers of 7-(benzo[*b*]thiophene-3-carboxamido)-*N*-methyl-3-oxo-1-(*o*-tolyl)isoindoline-5-carboxamide were resolved by SFC (Column: REGIS (*S*,*S*)-WHELK-O1 (250 mm*50 mm,10 μm); Mobile phase: 50% [0.1%NH_3H_2O in MeOH]) to afford (*S*)-7-(benzo[*b*]thiophene-3-carboxamido)-*N*-methyl-3-oxo-1-(*o*-tolyl)isoindoline-5-carboxamide (27.7 mg, 60.2 μmol, 36.0% yield, 99.0% purity, 99.6% *ee*) as a white solid and (*R*)-7-(benzo[*b*]thiophene-3-carboxamido)-*N*-methyl-3-oxo-1-(*o*-tolyl)isoindoline-5-carboxamide (25.8 mg, 55.9 μmol, 33.4% yield, 98.5% purity, 99.8% *ee*) as an off-white solid.

[0950] Additional compounds prepared according to the methods of Example 48 are listed in Table 20 below. Certain compounds in Table 20 below were prepared with other compounds whose preparation is described elsewhere in the Examples.

Table 20. Additional Exemplary Compounds


Compound
I-121
I-123
I-156

Compound
I-163
I-164
I-165


Compound
I-166
I-211
I-212

Example 49

***N*-[6-(1-hydroxycyclopropyl)-3-(2-methylphenyl)-1-oxo-2,3-dihydro-1*H*-isoindol-4-yl]-1,2-benzothiazole-3-carboxamide (I-315)**




Methyl 7-(1,2-benzothiazole-3-amido)-2-[(4-methoxyphenyl)methyl]-1-(2-methylphenyl)-3-oxo-2,3-dihydro-1*H*-isoindole-5-carboxylate



[0951] Step 1: A solution of 1,2-benzothiazole-3-carbonyl chloride (110 mg, 0.56 mmol) in DCM (2.0 mL) was added to a solution of methyl 7-amino-2-(4-methoxybenzyl)-3-oxo-1-(*o*-tolyl)isoindoline-5-carboxylate (154 mg, 0.372 mmol) in DCM (2.0 mL) at 0 °C. The reaction mixture was stirred at 0 °C for 10-15 min, then allowed to reach room temperature overnight. The reaction mixture was quenched with saturated sodium bicarbonate (1.0 mL), and stirred for 30 minutes. The reaction mixture was diluted with DCM (10 mL), and washed with saturated sodium bicarbonate (15 mL x 3), water (15 mL), and then brine (15 mL). The organic layer was dried with Na_2SO_4, and filtered. The filtrate was evaporated under reduced


pressure to afford methyl 7-(1,2-benzothiazole-3-amido)-2-[(4-methoxyphenyl)methyl]-1-(2-methylphenyl)-3-oxo-2,3-dihydro-1*H*-isoindole-5-carboxylate, which was used in the next step without further purification. MS: *m/z* = 578.2 $[M+H]^+$.

Methyl 7-(benzo[*d*]isothiazole-3-carboxamido)-3-oxo-1-(*o*-tolyl)isoindoline-5-carboxylate



[0952] Step 2: Methyl 7-(1,2-benzothiazole-3-amido)-2-[(4-methoxyphenyl)methyl]-1-(2-methylphenyl)-3-oxo-2,3-dihydro-1*H*-isoindole-5-carboxylate was dissolved in trifluoroacetic acid (2.0 mL, 17.5 μmol) at room temperature in a screw-top glass reaction vial equipped with a stir bar and septum under nitrogen atmosphere. Excess triethylsilane (100 μL, 625 μmol) was added, and the solution was stirred at room temperature for 30 min. The septa was quickly replaced with a plastic cap, and the reaction mixture was sealed from the oxygen atmosphere. The reaction mixture was placed in a pre-heated oil bath (105 °C, external) and stirred overnight. The reaction mixture was diluted with DCM (10 mL), and then all volatiles were evaporated to furnish a crude residue. To the crude residue was added diethyl ether (3 mL) and MeOH (10 mL). The resulting suspension was shaken, and the insoluble fraction was allowed to settle. The supernatant was slowly filtered followed by the solid, and the remaining solid was washed with MeOH (3 mL x 3). The washing and filtration steps were repeated two more times to afford 93 mg of methyl 7-(benzo[*d*]isothiazole-3-carboxamido)-3-oxo-1-(*o*-tolyl)isoindoline-5-carboxylate as a light brown solid, which was used in the next step without further purification. MS: *m/z* = 458.1 $[M+H]^+$.


***N*-[6-(1-hydroxycyclopropyl)-3-(2-methylphenyl)-1-oxo-2,3-dihydro-1*H*-isoindol-4-yl]-1,2-benzothiazole-3-carboxamide**




[0953] Step 3: A flame-dried, round-bottom flask equipped with a stir bar was charged with methyl 7-(benzo[*d*]isothiazole-3-carboxamido)-3-oxo-1-(*o*-tolyl)isoindoline-5-carboxylate (30 mg, 65.5 μmol). The solid was suspended in THF (5.0 mL), and stirrred vigorously at room temperature for 10 minutes. Titanium tetraisopropoxide (50 μL, 168 μmol) was added, and the mixture was stirred for 10 minutes at room temperature. To the resulting solution was added dropwise over 3 hours ethylmagnesium bromide (0.8 mL, 3.0 M, 2.40 mmol). The solution was quenched with dropwise addition of 1M HCl (1 mL), then diluted with DCM (20 mL). The mixture was washed with water (20 mL x 3), then with brine (20 mL x 3). The solvent was evaporated. The resulting residue was purified by reverse-phase flash column chromatography (eluting with 0 to 100% acetonitrile in 10 mM AmF in water) to afford after lyophilization *N*-[6-(1-hydroxycyclopropyl)-3-(2-methylphenyl)-1-oxo-2,3-dihydro-1*H*-isoindol-4-yl]-1,2-benzothiazole-3-carboxamide (13 mg) as a white powder.

Example 50

***N*-(7-Cyano-1-oxo-3-(*o*-tolyl)isoindolin-4-yl)benzo[*b*]thiophene-3-carboxamide (I-132)**




6-Bromo-2-methyl-3-nitrobenzoic acid




[0954] Step 1: To a solution of 2-bromo-6-methylbenzoic acid (240 g, 1.12 mol, 1.00 equiv.) in H_2SO_4 (1.20 L) at 0°C was added dropwise a mixture of HNO_3 (76.5 g, 1.21 mol, 54.7 mL, 1.09 equiv.) in H_2SO_4 (100 mL). The mixture was stirred at 0°C for 45 min. The mixture was poured into ice water (5.00 L), and solids precipitated. The suspension was filtered. The filter cake was dried under reduced pressure to afford an approximately equimolar mixture of 6-bromo-2-methyl-3-nitrobenzoic acid and a regioisomer (339 g, crude) as a light yellow solid. MS: *m/z* = 261.9 $[M+H]^+$; ^1H NMR (400 MHz, $CDCl_3$) δ 7.84 (d, *J* = 8.8 Hz, 1H), 7.81 (d, *J* = 8.0 Hz, 0.5H), 7.65 (d, *J* = 8.8 Hz, 1H), 7.37 (d, *J* = 8.4 Hz, 0.9H), 2.61 (s, 3H), 2.52 (s, 1.5H).

4-Amino-7-bromo-2-(4-methoxybenzyl)-3-(*o*-tolyl)isoindolin-1-one




[0955] Steps 2 through 7: Using the procedures described in Example 10, Steps 1 through 6, 6-bromo-2-methyl-3-nitrobenzoic acid was converted to 4-amino-7-bromo-2-(4-methoxybenzyl)-3-(*o*-tolyl)isoindolin-1-one in 2% yield over the six steps. (The undesired regioisomer generated in Step 1 was removed by reverse-phase chromatography after the iron-mediated nitro-group reduction of Step 5.) The 4-amino-7-bromo-2-(4-methoxybenzyl)-3-(*o*-tolyl)isoindolin-1-one product was isolated as a white solid following purification by reverse-phase HPLC. MS: *m/z* = 439.2 $[M+H]^+$; ^1H NMR (400 MHz, DMSO-d_6) δ 7.57 - 7.55 (m, 0.5H), 7.39 - 7.34 (m, 1H), 7.30 - 7.20 (m, 2H), 7.11 - 6.99 (m, 3H), 6.88 - 6.85(m, 2H) 6.76 - 6.68(m, 1H), 6.49 (d, *J* = 7.6 Hz, 0.5H), 5.50 (s, 0.5H), 5.38 (s, 0.5H), 4.96 - 4.90 (m, 1H), 4.72 (s, 1H), 4.57 (s, 1H), 3.72 (s, 3H), 3.58 (d, *J* = 14.8 Hz, 0.5H), 3.48 (d, *J* = 15.2 Hz, 0.5H), 2.25 (s, 1.7H), 1.52 (s, 1.3H).

***N*-(7-Bromo-1-oxo-3-(*o*-tolyl)isoindolin-4-yl)benzo[*b*]thiophene-3-carboxamide**



[0956] Steps 8 and 9: According to the procedures of Example 1, Steps 5 and 6, 4-amino-7-bromo-2-(4-methoxybenzyl)-3-(*o*-tolyl)isoindolin-1-one was converted to *N*-(7-bromo-1-oxo-3-(*o*-tolyl)isoindolin-4-yl)benzo[*b*]thiophene-3-carboxamide.

***N*-(7-Cyano-1-oxo-3-(*o*-tolyl)isoindolin-4-yl)benzo[*b*]thiophene-3-carboxamide**



[0957] Step 10: A microwave vial equipped with a Teflon-coated stir bar and rubber septum was charged with *N*-(7-bromo-1-oxo-3-(*o*-tolyl)isoindolin-4-yl)benzo[*b*]thiophene-3-carboxamide (30 mg, 0.0628 mmol), followed by $Pd_2(dba)_3$ (11.5 mg, 0.0126 mmol), dppf (6.96 mg, 0.0126 mmol), $Zn(CN)_2$ (14.7 mg, 0.126 mmol), zinc (821 μg, 0.0126 mmol), DMF (1.9 mL), and water (0.1 mL). The dark turbid solution, under moderate stirring, at room temperature, was degassed by bubbling with nitrogen gas for about 5 minutes. The vial was then placed in a pre-heated oil bath (105 °C, external), and vigorously stirred for 3 hours. The mixture was cooled to room temperature and directly loaded onto a C18 column (24 g), which was eluted with 10–60% acetonitrile in 10 mM aq. AmF. Fractions containing pure product were combined, acetonitrile was removed under reduced pressure, and the remaining aqueous solution was lyophilized to afford *N*-(7-cyano-1-oxo-3-(*o*-tolyl)isoindolin-4-yl)benzo[*b*]thiophene-3-carboxamide as a tan, amorphous solid (18 mg).


[0958] Additional compounds prepared according to the methods of Example 50 are listed in Table 21 below. Certain compounds in Table 21 below were prepared with other compounds whose preparation is described elsewhere in the Examples.

Table 21. Additional Exemplary Compounds

Compound
I-116
I-237
I-313

Example 51

***N*-[7-Ethenyl-3-(2-methylphenyl)-1-oxo-2,3-dihydro-1*H*-isoindol-4-yl]-1-benzothiophene-3-carboxamide (I-2157)**



[0959] A 50 mL round-bottomed flask equipped with a Teflon-coated stir bar and rubber septum was charged with *N*-(7-bromo-1-oxo-3-(*o*-tolyl)isoindolin-4-yl)benzo[*b*]thiophene-3-carboxamide (100 mg, 0.209 mmol), followed by potassium vinyltrifluoroborate (139 mg, 1.04 mmol), K_2CO_3 (201 mg, 1.46 mmol), and THF:water (10 mL, 9:1). The brown color turbid solution, under slow stirring, was degassed by bubbling with nitrogen gas for about five minutes. Then $Pd(dppf)Cl_2$ (29 mg, 0.042 mmol) was added, and the rubber septum was quickly exchanged for a reflux condenser. The system was evacuated under house vacuum, and back-filled with nitrogen gas. The flask was then placed in a pre-heated oil bath (63 °C, external), and the mixture stirred for 40 hours. The mixture was diluted with ethyl acetate (20 mL), and washed with water (2 x 20 mL). The combined aqueous layers were extracted with ethyl acetate (20 mL). The combined organics were washed with brine (20 mL), dried over sodium sulfate, filtered, and solvents removed under reduced pressure to afford a tan paste. The residue was purified by silica gel flash chromatography (ethyl acetate/hexanes) to afford *N*-[7-ethenyl-3-(2-methylphenyl)-1-oxo-2,3-dihydro-1*H*-isoindol-4-yl]-1-benzothiophene-3-carboxamide (65 mg) as a tan powder. MS: m/z = 425.3 $[M+H]^+$.


[0960] Additional compounds prepared according to the methods of Example 51 are listed in Table 22 below. Certain compounds in Table 22 below were prepared with other compounds whose preparation is described elsewhere in the Examples.

Table 22. Additional Exemplary Compounds

Compound
I-205

Example 52

7-(Benzo[*b*]thiophene-3-carboxamido)-3-oxo-1-(*o*-tolyl)isoindoline-4-carboxamide (I-149)



[0961] A microwave vial equipped with a Teflon-coated stir bar and rubber septum was charged with *N*-(7-bromo-1-oxo-3-(*o*-tolyl)isoindolin-4-yl)benzo[*b*]thiophene-3-carboxamide (20 mg, 0.0419 mmol), followed by $Pd(OAc)_2$ (1.88 mg, 0.00838 mmol), Xantphos (4.84 mg, 0.00838 mmol), 4-dimethylaminopyridine (10.2 mg, 0.0838 mmol), $Co_2(CO)_8$ (3.6 mg, 0.010 mmol), and dioxane (2 mL). This dark color turbid solution, under moderate stirring, was degassed by bubbling with nitrogen gas for five minutes, and then a 2M solution of ammonia in isopropanol (0.1 mL, 0.20 mmol) was added. The rubber septum was quickly exchanged for a microwave vial cap and sealed. The vial was then placed in a Biotage microwave reactor and irradiated at 90°C for one hour. The mixture was directly loaded onto a C18 column (24 g, 1 mL of DMF was used to rinse the vial), and the column was eluted with 10-60% acetonitrile in 10mM aq. AmF. The fractions containing pure product were lyophilized to afford 7-(benzo[*b*]thiophene-3-carboxamido)-3-oxo-1-(*o*-tolyl)isoindoline-4-carboxamide as an off-white amorphous solid (9 mg).

[0962] Additional compounds prepared according to the methods of Example 52 are listed in Table 23 below. Certain compounds in Table 23 below were prepared with other compounds whose preparation is described elsewhere in the Examples.

Table 23. Additional Exemplary Compounds


Compound
I-150
I-219
I-225

Compound
I-261
I-276

Compound
I-278
I-339

Example 53


***N*-(7-Methyl-1-oxo-3-(*o*-tolyl)isoindolin-4-yl)benzo[*b*]thiophene-3-carboxamide (I-153)**



[0963] A microwave vial equipped with a Teflon-coated stir bar and rubber septum was charged with *N*-(7-bromo-1-oxo-3-(*o*-tolyl)isoindolin-4-yl)benzo[*b*]thiophene-3-carboxamide (20 mg, 0.0419 mmol), followed by $Pd_2(dba)_3$ (3.83 mg, 0.00419 mmol), DABAL-Me3 (10.7 mg, 0.0419 mmol), Xphos (3.99 mg, 0.00838 mmol), and THF (2 mL). The dark color reaction mixture was then heated to reflux and vigorously stirred for 9 hours. The mixture was cooled to RT, and additional DABAL-Me3 (5 mg) was added. The mixture was again heated to reflux and vigorously stirred for 18 hours. The mixture was cooled to RT, diluted with ethyl acetate (20 mL), and washed with water (2 x 20 mL). The combined aqueous layers were extracted with ethyl acetate (10 mL). The combined organics were dried over sodium sulfate, filtered, and solvents removed under reduced pressure. The resulting residue was purified by reverse phase chromatography (load in DMF, C18 column, 24 g, 10-50% Acetonitrile in 10mM aq. AmF). The fractions containing pure product were lyophilized to afford *N*-(7-methyl-1-oxo-3-(*o*-tolyl)isoindolin-4-yl)benzo[*b*]thiophene-3-carboxamide (2.6 mg) as a white amorphous solid.

Example 54

***N*-(6-Acetyl-3-(2-chloro-5-fluorophenyl)-1-oxoisoindolin-4-yl)-3-fluoro-5-(trifluoromethyl)benzamide (I-127)**




[0964] *N*-[6-Bromo-3-(2-chloro-5-fluorophenyl)-1-oxo-2,3-dihydro-1*H*-isoindol-4-yl]-3-fluoro-5-(trifluoromethyl)benzamide (600 mg, 1.09 mmol), tributyl(1-ethoxyethenyl)stannane (787 mg, 2.18 mmol) and bis(triphenylphosphine)palladium(II) dichloride (153 mg, 0.218 mmol) were combined and evacuated/purged with nitrogen. Dioxane (4 mL) was added, and the mixture was heated to 90 °C for 4 hrs. The mixture was diluted with EtOAc, filtered through a plug of silica, and the filtrate was concentrated to provide *N*-(3-(2-chloro-5-fluorophenyl)-6-(1-ethoxyvinyl)-1-oxoisoindolin-4-yl)-3-fluoro-5-(trifluoromethyl)benzamide.

[0965] The resulting residue was stirred in TFA (2.5 mL) and water (0.5 mL) for 2 hr, then concentrated and purified by reverse phase HPLC to provide *N*-(6-acetyl-3-(2-chloro-5-fluorophenyl)-1-oxoisoindolin-4-yl)-3-fluoro-5-(trifluoromethyl)benzamide (0.42 g, 72%).

Example 55

***N*-(3-(2-chloro-5-fluorophenyl)-6-(2-hydroxypropan-2-yl)-1-oxoisoindolin-4-yl)-3-fluoro-5-(trifluoromethyl)benzamide (I-128)**



[0966] To a solution of *N*-(6-acetyl-3-(2-chloro-5-fluorophenyl)-1-oxoisoindolin-4-yl)-3-fluoro-5-(trifluoromethyl)benzamide (400 mg, 0.7 mmol) in THF (5 mL) at 0 °C was

dropwise added MeMgBr, 3.0 M in Et_2O (3.5 mmol, 1.16 mL). After completion of the reaction, the reaction was quenched with aq NH_4Cl, and the mixture was extracted with EtOAc. The organics were washed with brine, dried, and concentrated. The residue was purified by reverse phase HPLC using a gradient of water (0.1% FA) and acetonitrile (0.1% FA) 70/30 to 35/65 in 13 minutes then 5/95. Product-containing fractions were combined and lyophilized to provide *N*-(3-(2-chloro-5-fluorophenyl)-6-(2-hydroxypropan-2-yl)-1-oxoisoindolin-4-yl)-3-fluoro-5-(trifluoromethyl)benzamide (0.25 g, 67%).


[0967] Additional compounds prepared according to the methods of Examples 54 and 55 are listed in Table 24 below.

Table 24. Additional Exemplary Compounds

Compound	Compound	Compound
I-135	I-238	I-272
I-136	I-239	I-280
I-189	I-242	I-290
I-190	I-250	I-298
I-191	I-263	I-299
I-192	I-264	I-308
I-214	I-267	I-355
I-215	I-271	I-356

Example 56

***N*-(3-(2-chloro-5-fluorophenyl)-1-oxo-6-(2,2,2-trifluoro-1-hydroxyethyl)isoindolin-4-yl)-3-fluoro-5-(trifluoromethyl)benzamide (I-270)**



[0968] To *N*-[3-(2-chloro-5-fluorophenyl)-6-formyl-1-oxo-2,3-dihydro-1*H*-isoindol-4-yl]-3-fluoro-5-(trifluoromethyl)benzamide (110 mg, 0.2223 mmol) in 0.5 mL of DMF was added K_2CO_3 (28 mg, 0.2 mmol) and trimethyl(trifluoromethyl)silane (80 mg, 0.5626 mmol). The

mixture was stirred at RT for 16 hrs. The mixture was then taken in 1 mL of MeOH and added 50 μL of conc. HCl and stirred for 1 hr. The mixture was taken in 2 mL of DMSO and purified by reverse-phase HPLC using a gradient of water (0.1% FA) and acetonitrile (0.1% FA) 70/30 to 35/65 in 13 minutes, then 5/95. Product-containing fractions were combined and lyophilized to provide *N*-(3-(2-chloro-5-fluorophenyl)-1-oxo-6-(2,2,2-trifluoro-1-hydroxyethyl)isoindolin-4-yl)-3-fluoro-5-(trifluoromethyl)benzamide (35 mg, 27%).


[0969] Additional compounds prepared according to the method of Example 56 are listed in Table 25 below.

Table 25. Additional Exemplary Compounds

Compound
I-297
I-334

Example 57

***N*-(3-(2-Chloro-5-fluorophenyl)-6-((3,3-difluoroazetidin-1-yl)methyl)-1-oxoisoindolin-4-yl)-3-fluoro-5-(trifluoromethyl)benzamide (I-348)**



[0970] A solution of *N*-[3-(2-chloro-5-fluorophenyl)-6-formyl-1-oxo-2,3-dihydro-1*H*-isoindol-4-yl]-3-fluoro-5-(trifluoromethyl)benzamide (15 mg, 0.030 mmol) in THF (1 mL) was treated with 3,3-difluoroazetidine hydrochloride (8 mg, 0.061 mmol) and polymer-bound Biotage® MP-Triacetoxyborohydride (2 mmol/g, 40 mg). The mixture was stirred at 45 °C for 12 h and then diluted with EtOAc. It was filtered and then concentrated by rotary evaporation. The residue was subjected to reverse-phase HPLC purification (15-60% acetonitrile/water) to afford *N*-(3-(2-chloro-5-fluorophenyl)-6-((3,3-difluoroazetidin-1-yl)methyl)-1-oxoisoindolin-4-yl)-3-fluoro-5-(trifluoromethyl)benzamide (5 mg, 29% yield) as an off-white powder.


[0971] Additional compounds prepared according to the method of Example 57 are listed in Table 26 below.

Table 26. Additional Exemplary Compounds


Compound
I-349
I-350
I-352
I-353

Example 58

***N*-[3-(2-chloro-5-fluorophenyl)-6-(1-hydroxycyclopropyl)-1-oxo-2,3-dihydro-1*H*-isoindol-4-yl]-3-fluoro-5-(trifluoromethyl)benzamide (I-374)**




Methyl 1-(2-chloro-5-fluorophenyl)-7-[3-fluoro-5-(trifluoromethyl)benzamido]-3-oxo-2,3-dihydro-1*H*-isoindole-5-carboxylate



[0972] Step 1: A screw-top glass reaction vial equipped with a stir bar and a rubber septa was charged with *N*-[6-bromo-3-(2-chloro-5-fluorophenyl)-1-oxo-2,3-dihydro-1*H*-isoindol-4-yl]-3-fluoro-5-(trifluoromethyl)benzamide (90 mg, 164 μmol), palladium(II) acetate (7.36 mg, 32.8 μmol), methanol (1.58 g, 49.3 mmol), $Co_2(CO)_8$ (16.6 mg, 48.8 μmol), Xantphos (18.8 mg, 32.6 μmol), and 4-dimethylaminopyridine (20 mg, 164 μmol). The reaction mixture was

degassed by bubbling with nitrogen gas (balloon) under vigorous stirring for two minutes, the rubber septa was quickly replaced with a plastic cap, and the reaction mixture was sealed from the atmosphere. The vial was then placed in a pre-heated oil bath (85 °C, external), and the mixture was vigorously stirred for 7 h. The volatiles were evaporated under reduced pressure to afford a residue, which was purified by normal-phase flash column chromatography (eluted with 0-100% EtOAc/heptanes in gradient) to furnish methyl 1-(2-chloro-5-fluorophenyl)-7-[3-fluoro-5-(trifluoromethyl)benzamido]-3-oxo-2,3-dihydro-1*H*-isoindole-5-carboxylate (73 mg) as an off-white solid. MS: *m/z* = 525.3 $[M+H]^+$; ^{1}H NMR (400 MHz, DMSO-d_6) δ 10.66 (s, 1H), 9.35 (br s, 1H), 8.13 (dd, *J* = 16.4, 1.2 Hz, 2H), 7.96 (d, *J* = 8.3 Hz, 1H), 7.76 (d, *J* = 8.8 Hz, 1H), 7.68 (s, 1H), 7.33 (dd, *J* = 8.9, 5.2 Hz, 1H), 7.10 (td, *J* = 8.5, 3.1 Hz, 1H), 6.04 (br s, 1H), 3.93 (s, 3H). One proton expected at ca. 6.8 ppm was not observed.


_N_-[3-(2-chloro-5-fluorophenyl)-6-(1-hydroxycyclopropyl)-1-oxo-2,3-dihydro-1*H*-isoindol-4-yl]-3-fluoro-5-(trifluoromethyl)benzamide




[0973] Step 2: According to the procedure of Example 49, Step 3, methyl 1-(2-chloro-5-fluorophenyl)-7-[3-fluoro-5-(trifluoromethyl)benzamido]-3-oxo-2,3-dihydro-1*H*-isoindole-5-carboxylate was converted to *N*-[3-(2-chloro-5-fluorophenyl)-6-(1-hydroxycyclopropyl)-1-oxo-2,3-dihydro-1*H*-isoindol-4-yl]-3-fluoro-5-(trifluoromethyl)benzamide, which was isolated as an off-white solid following reverse-phase chromatography (10 mM AmF in a gradient of 0-100% CH_3CN in water).

Example 59

N-(3-Cyclohexyl-1-oxoisoindolin-4-yl)benzo[*d*]isothiazole-3-carboxamide (I-204)




4-Amino-3-cyclohexylisoindolin-1-one



[0974] Step 1: To a solution of 4-amino-3-methoxyisoindolin-1-one (50 mg, 0.28 mmol) in dry THF (0.35 mL) at 0 °C under a nitrogen atmosphere was added a 1M solution of bromo(cyclohexyl)magnesium (841 µL, 0.841 mmol) in THF. The mixture was stirred at R.T. for 15 min. Another portion of 1M solution of bromo(cyclohexyl)magnesium (560 uL, 0.56 mmol) was added and stirring was continuied at R.T. for 15 min. A sat. aq solution of NH_4Cl was then added, and the mixture was extracted with EtOAct (3x). The combined organic layers were washed with brine, dried over Na_2SO_4, filtered, and concentrated under reduced pressure. The resulting 4-amino-3-cyclohexylisoindolin-1-one, as a brown oil, was used in the next step without further purification.

N-(3-Cyclohexyl-1-oxoisoindolin-4-yl)benzo[*d*]isothiazole-3-carboxamide



[0975] Step 2: The 4-amino-3-cyclohexylisoindolin-1-one from the previous step was dissolved in dry DMF (0.94 mL) at room temperature under a nitrogen atmosphere, and 1,2-

benzothiazole-3-carboxylic acid (60.3 mg, 0.337 mmol) was added, followed by HATU (159 mg, 0.421 mmol) and finally DIPEA (197 µL, 1.12 mmol). The mixture was stirred at room temperature for 12h. The mixture was then diluted with water and extracted with AcOEt (3x). The combined organic layers were washed with brine, dried over Na_2SO_4, filtered and concentrated under reduced pressure. Purification by reverse phase chromatography (5 to 70% ACN/aqueous AmF 10 mM) followed by purification by normal phase chromatography (0 to 60% acetone/hexanes) afforded *N*-(3-cyclohexyl-1-oxoisoindolin-4-yl)benzo[*d*]isothiazole-3-carboxamide (10 mg, 10%) as a yellow powder after lyophilisation.

[0976] Additional compounds prepared according to the methods of Example 59 are listed in Table 27 below.


Table 27. Additional Exemplary Compounds

Compound
I-8
I-18
I-106


Compound
I-259
I-327

Example 60

***N*-(7-oxo-5-(*o*-tolyl)-6,7-dihydro-5*H*-pyrrolo[3,4-*b*]pyridin-4-yl)indoline-1-carboxamide (I-147)**




4-Chloro-*N*-(2,4-dimethoxybenzyl)picolinamide




[0977] Step 1: To a solution of 4-chloropicolinic acid (200 g, 1.27 mol, 1.00 eq) in DCM (2.00 L) was added CDI (216 g, 1.33 mol, 1.05 eq) and DMAP (4.65 g, 38.1 mmol, 0.03 eq) at 15 °C for 0.5 h. Then a solution of (2,4-dimethoxyphenyl)methanamine (212 g, 1.27 mol, 191 mL, 1.00 eq) in DCM (400 mL) was added, and the mixture was stirred at 25 °C for 1 h. The reaction mixture was concentrated. The residue was purified by fast flash column chromatography (SiO_2, petroleum ether/ethyl acetate = 3/1), to obtain 4-chloro-*N*-(2,4-dimethoxybenzyl)picolinamide (316 g, 1.03 mol, 81.1% yield) as a white solid.

4-Chloro-6-(2,4-dimethoxybenzyl)-5-hydroxy-5-(*o*-tolyl)-5,6-dihydro-7*H*-pyrrolo[3,4-*b*]pyridin-7-one




[0978] Step 2: To a solution of *n*-BuLi (2.50 M, 391 mL, 3.00 eq) in THF (1.20 L) at -78 °C was added a solution of 4-chloro-*N*-(2,4-dimethoxybenzyl)picolinamide (100 g, 326 mmol, 1.00 eq) in THF (200 mL). The mixture was stirred at -40 to -50 °C for nearly 3 h. The reaction was then cooled back to -78 °C. To the reaction was added dropwise over 15 minutes a solution of 2-methylbenzoyl chloride (101 g, 652 mmol, 84.7 mL, 2.00 eq) in THF (200 mL). The reaction was stirred for 1 h at -78 °C, before removal of the dry ice/ethyl acetate bath. The reaction was then stirred at 25 °C for 2 h. The mixture was poured into water (2.00 L) and extracted with ethyl acetate (3 x 500 mL). The combined organic layer was washed with brine (500 mL), dried over Na_2SO_4, and concentrated. The resulting yellow oil was purified once by column chromatography (SiO_2, petroleum ether/ethyl acetate = 50/1 to 1/1) and twice by column chromatography (SiO_2, DCM/MeOH = 1/0 to 50/1), to obtain 4-chloro-6-(2,4-dimethoxybenzyl)-5-hydroxy-5-(*o*-tolyl)-5,6-dihydro-7*H*-pyrrolo[3,4-*b*]pyridin-7-one (125 g) as a white solid. MS: *m/z* = 425.0 $[M+H]^+$; ^1H NMR (400 MHz, DMSO-d_6) δ 9.02 (t, *J* = 6.4 Hz, 1H), 8.73 (d, *J* = 5.2 Hz, 1H), 7.94 (d, *J* = 5.2 Hz, 1H), 7.44 - 7.47 (m, 1H), 7.36 (d, *J* = 7.2 Hz, 1H), 7.21 (d, *J* = 4.0 Hz, 1H), 6.91 (d, *J* = 8.4 Hz, 1H), 6.52 (d, *J* = 2.4 Hz, 1H), 6.39 (dd, *J* =2.4, 8.4 Hz, 1H), 4.25 (d, *J* = 6.0 Hz, 2H), 3.76 (s, 3H), 3.72 (s, 3H), 2.65 (s, 3H).

4-Chloro-6-(2,4-dimethoxybenzyl)-5-(*o*-tolyl)-5,6-dihydro-7*H*-pyrrolo[3,4-*b*]pyridin-7-one



[0979] Step 3: To a stirred solution of 4-chloro-6-(2,4-dimethoxybenzyl)-5-hydroxy-5-(*o*-tolyl)-5,6-dihydro-7*H*-pyrrolo[3,4-*b*]pyridin-7-one (75.0 g, 177 mmol, 1.00 eq) in DCM (1.10 L) was added TFA (503 g, 4.41 mol, 327 mL, 25.0 eq) at 25 °C. The mixture was cooled to 0 °C, then triethylsilane (205 g, 1.77 mol, 282 mL, 10.0 eq) was added. The mixture was warmed to 25 °C, stirred at 25 °C for 12 h, and then concentrated. The residue was purified by reverse-phase HPLC (0.1% FA condition) to afford 4-chloro-6-(2,4-dimethoxybenzyl)-5-(*o*-tolyl)-5,6-dihydro-7*H*-pyrrolo[3,4-*b*]pyridin-7-one (62.0 g, 152 mmol, 85.9% yield) as a white solid. MS: *m/z* = 409.1 $[M+H]^+$; ^1H NMR (400 MHz, DMSO-d_6) δ 8.73 (d, *J* = 5.2 Hz, 1H), 7.66 (d, *J* = 5.6 Hz, 1H), 7.20 - 7.28 (m, 2H), 7.04 - 7.08 (m, 1H), 6.95 (d, *J* = 8.4 Hz, 1H), 6.45 – 6.50 (m, 4H), 5.78 (s, 1H), 4.82 (dd, *J* =3.6, 14.8 Hz, 1H), 3.73 (s, 3H), 3.64 (s, 3H), 2.24 (s, 3H).


6-(2,4-Dimethoxybenzyl)-4-((2,4-dimethoxybenzyl)amino)-5-(*o*-tolyl)-5,6-dihydro-7*H*-pyrrolo[3,4-*b*]pyridin-7-one



[0980] Step 4: A mixture of 4-chloro-6-(2,4-dimethoxybenzyl)-5-(*o*-tolyl)-5,6-dihydro-7*H*-pyrrolo[3,4-*b*]pyridin-7-one (70.0 g, 171 mmol, 1.00 eq), (2,4-dimethoxyphenyl) methanamine (42.9 g, 256 mmol, 38.6 mL, 1.50 eq), Cs_2CO_3 (55.7 g, 171 mmol, 1.00 eq), $Pd_2(dba)_3$ (15.6 g, 17.1 mmol, 0.10 eq), and BRETTPHOS (18.3 g, 34.2 mmol, 0.20 eq) in dioxane (700 mL) was degassed and purged with N_2 three times, and then the mixture was stirred at 90 °C for 12 h under N_2 atmosphere. Additional (2,4-dimethoxyphenyl)

methanamine (14.3 g, 85.6 mmol, 12.8 mL, 0.50 eq) was added, the mixture was purged with N_2 three times, and then the mixture was stirred at 90 °C for 18 h under N_2 atmosphere. The reaction mixture was diluted with H_2O (600 mL) and extracted with ethyl acetate (3 x 400 mL). The combined organic layers were washed with satd. aq. NaCl (800 mL), dried over Na_2SO_4, filtered, and concentrated under reduced pressure. The resulting residue was purified by column chromatography (SiO_2, petroleum ether/ethyl acetate = 1/0 to 0/1, ethyl acetate/methanol = 20/1) to afford 6-(2,4-dimethoxybenzyl)-4-((2,4-dimethoxybenzyl) amino)-5-(*o*-tolyl)-5,6-dihydro-7*H*-pyrrolo[3,4-*b*]pyridin-7-one (60.0 g, 94.1 mmol, 55.0% yield, 84.7% purity) as a brown oil. MS: *m/z* = 540.0 $[M+H]^+$; ^1H NMR (400 MHz, $CDCl_3$) δ 8.39 – 8.42 (m, 1H), 7.29 – 7.30 (m, 1H), 7.21 – 7.23 (m, 1H), 7.17 – 7.18 (m, 1H), 7.14 (s, 1H), 7.12 (s, 1H), 7.07 – 7.09 (m, 1H), 6.91 – 6.94 (m, 1H), 6.78 – 6.80 (m, 1H), 6.70 (d, *J* = 8.4 Hz, 1H), 6.54 (d, *J* = 6.0 Hz, 1H), 6.29 – 6.32 (m, 2H), 5.36 (s, 1H), 3.76 – 3.80 (m, 12H), 3.66 (s, 2H), 3.63 (s, 2H), 2.08 (s, 3H).


4-Amino-6-(2,4-dimethoxybenzyl)-5-(*o*-tolyl)-5,6-dihydro-7*H*-pyrrolo[3,4-*b*]pyridin-7-one



[0981] Step 5: A solution of 6-(2,4-dimethoxybenzyl)-4-((2,4-dimethoxybenzyl) amino)-5-(*o*-tolyl)-5,6-dihydro-7*H*-pyrrolo[3,4-*b*]pyridin-7-one (60.0 g, 111 mmol, 1.00 eq) in HCl/MeOH (4.00 M, 600 mL, 21.6 eq) was stirred at 35 °C for 7 h. Additional HCl/MeOH (4.00 M, 600 mL, 21.6 eq) was added to the mixture, then the mixture was stirred at 35 °C for 16 h. Additional HCl/MeOH (4.00 M, 600 mL, 21.6 eq) was added to the mixture, then the mixture was stirred at 35 °C for 22 h. The reaction mixture was concentrated under vacuum, and the residue was dissolved in DCM (2.00 L). The mixture was adjusted to pH = 8 with saturated $NaHCO_3$ (1.00 L) and stirred at 25 °C for 0.5 h. The mixture was extracted with DCM (2 x 2.00 L). The combined organic layers were washed with brine (2 x 200 mL), dried over Na_2SO_4, filtered, and concentrated. The resulting brown gum was purified by reversed-phase HPLC (0.1% FA condition) to afford 4-amino-6-(2,4-dimethoxybenzyl)-5-(*o*-tolyl)-5,6-dihydro-7*H*-pyrrolo[3,4-*b*]pyridin-7-one (20.4 g, 50.4 mmol, 45.3% yield, 96.0% purity)


as a white solid. MS: *m/z* = 390.2 $[M+H]^+$; ^{1}H NMR (400 MHz, DMSO-d_6) δ 8.17 – 8.23 (m, 1H), 7.52 - 7.54 (m, 1H), 7.18 - 7.27 (m, 2H), 7.06 – 7.09 (m, 1H), 6.97 (d, *J* = 8.4 Hz, 1H), 6.84 (d, *J* = 8.4 Hz, 1H), 6.59 – 6.65 (m, 1H), 6.44 – 6.53 (m, 3H), 5.39 - 5.48 (m, 2H), 4.69 - 4.82 (m, 1H), 3.69 - 3.78 (m, 6H), 2.25 (s, 2H), 1.15 (s, 1H).

***N*-(6-(2,4-Dimethoxybenzyl)-7-oxo-5-(*o*-tolyl)-6,7-dihydro-5*H*-pyrrolo[3,4-*b*]pyridin-4-yl)indoline-1-carboxamide**



[0982] Step 6: 4-Amino-6-(2,4-dimethoxybenzyl)-5-(*o*-tolyl)-5*H*-pyrrolo[3,4-*b*]pyridine-7(6*H*)-one (1.00 g, 1.87 mmol) and carbonyldiimidazole (457 mg, 2.82 mmol) were dissolved in DCM (25 mL). To the resulting mixture were added *N,N*-diisopropylethylamine (0.54 mL, 3.08 mmol) and 4-dimethylaminopyridine (2.5 mg, 0.020 mmol). The resulting mixture was stirred at 40 °C. After 24 h, the reaction mixture was cooled to 22 °C, and indoline (457 mg, 3.84 mmol) was added to the solution. The resulting mixture was stirred at 22 °C for 1 h and then diluted with a saturated aqueous NH_4Cl solution and extracted with DCM. The organic layer was dried over sodium sulfate, filtered, and concentrated by rotary evaporation. The resulting *N*-(6-(2,4-dimethoxybenzyl)-7-oxo-5-(*o*-tolyl)-6,7-dihydro-5*H*-pyrrolo[3,4-*b*]pyridin-4-yl)indoline-1-carboxamide was directly subjected to the subsequent reaction without further purification.

***N*-(7-Oxo-5-(*o*-tolyl)-6,7-dihydro-5*H*-pyrrolo[3,4-*b*]pyridin-4-yl)indoline-1-carboxamide**



[0983] Step 7: The *N*-(6-(2,4-dimethoxybenzyl)-7-oxo-5-(*o*-tolyl)-6,7-dihydro-5*H*-pyrrolo[3,4-*b*]pyridin-4-yl)indoline-1-carboxamide (ca. 1.00 mmol) from the preceding step was treated with trifluoroacetic acid (14.2 mL) and trifluoromethanesulfonic acid (0.41 mL, 4.67 mmol). The resulting mixture was stirred at 40 °C. After 1 h, the reaction mixture was concentrated, diluted with saturated aqueous $NaHCO_3$, and extracted with DCM. The organic layer was dried over sodium sulfate, filtered, and concentrated by rotary evaporation. The resulting mixture was purified by C18 silica gel column chromatography (20% to 100% MeCN/10 mM AmF (aq)). The product-containing fractions were combined and lyophilized to obtain *N*-(7-oxo-5-(*o*-tolyl)-6,7-dihydro-5*H*-pyrrolo[3,4-*b*]pyridin-4-yl)indoline-1-carboxamide (38 mg, 5.3% over two steps) as a white powder.


[0984] Additional compounds prepared according to the methods of Example 60 are listed in Table 28 below.

Table 28. Additional Exemplary Compounds


Compound	Compound	Compound
I-148	I-245	I-282
I-177	I-246	I-296
I-199	I-247	I-300
I-227	I-248	I-301
I-228	I-249	I-302
I-229	I-251	I-303
I-230	I-257	I-324

Example 61

***N*-(5-(2,3-Difluorophenyl)-7-oxo-6,7-dihydro-5*H*-pyrrolo[3,4-*b*]pyridin-4-yl)benzo[*b*]thiophene-3-carboxamide (I-15)**




4-Amino-5-(2,3-difluorophenyl)-6-(2,4-dimethoxybenzyl)-5,6-dihydro-7*H*-pyrrolo[3,4-*b*]pyridin-7-one



[0985] Steps 1 to 5: According to the procedures of Example 60, Steps 1 to 5, 4-amino-5-(2,3-difluorophenyl)-6-(2,4-dimethoxybenzyl)-5,6-dihydro-7*H*-pyrrolo[3,4-*b*]pyridin-7-one was synthesized.


***N*-(5-(2,3-Difluorophenyl)-6-(2,4-dimethoxybenzyl)-7-oxo-6,7-dihydro-5*H*-pyrrolo[3,4-*b*]pyridin-4-yl)benzo[*b*]thiophene-3-carboxamide**



[0986] Step 6: To a stirred solution of (1-chloro-2-methylprop-1-en-1-yl)dimethylamine (257 mg, 1.93 mmol, 4 eq) in toluene (1.6 mL) was added 1-benzothiophene-3-carboxylic acid (343 mg, 1.93 mmol, 4 eq). The suspension quickly turned into a clear, light pink solution, which was stirred for 30 minutes. About 0.4 mL of this solution was added to a stirred solution of 4-amino-5-(2,3-difluorophenyl)-6-(2,4-dimethoxybenzyl)-5,6-dihydro-7*H*-pyrrolo[3,4-*b*]pyridin-7-one (200 mg, 0.483 mmol) in pyridine (1 mL). To this solution was added catalytic DMAP (24 mg, 0.19 mmol, 0.4 eq). The mixture was stirred at room temperature for 5 minutes and then at 75-80 °C for 5 hours. Every hour an additional 0.4 mL of the preformed acid chloride solution in toluene was added to the mixture until the reaction was nearly completed. The mixture was cooled to room temperature and quenched with methanol (2 mL). The mixture was stirred 10 minutes after quenching and was then concentrated. The residue was eluted on 12 g column eluted with a gradient of 10:90:1

MeOH/DCM/NH_4OH in DCM, to afford *N*-(5-(2,3-difluorophenyl)-6-(2,4-dimethoxybenzyl)-7-oxo-6,7-dihydro-5*H*-pyrrolo[3,4-*b*]pyridin-4-yl)benzo[*b*]thiophene-3-carboxamide (214 mg, ~95% purity, 73.5% yield) as a light yellow, foamy solid. A small amount of residual pyridine was still present after purification. MS: *m/z* = 572.5 $[M+H]^+$.

N-(5-(2,3-Difluorophenyl)-7-oxo-6,7-dihydro-5*H*-pyrrolo[3,4-*b*]pyridin-4-yl)benzo[*b*] thiophene-3-carboxamide



[0987] Step 7: To a solution of *N*-(5-(2,3-difluorophenyl)-6-(2,4-dimethoxybenzyl)-7-oxo-6,7-dihydro-5*H*-pyrrolo[3,4-*b*]pyridin-4-yl)benzo[*b*]thiophene-3-carboxamide (197 mg, 0.342 mmol) in acetonitrile (6.8 mL) was added a solution of ammonium cerium (IV) nitrate (559 mg, 1.02 mmol, 3.0 eq). The mixture was stirred for 15 minutes at RT. The mixture was carefully treated with saturated aqueous $NaHCO_3$ (25 mL). The resulting solid was isolated by filtration, dried, and loaded as a silica gel slurry onto a 24 gram silica gel column, which was eluted with a gradient of 10:90:1 MeOH/DCM/NH_4OH in DCM. Product-containing fractions (eluting between 6.7% and 7.5% MeOH/DCM) were combined, concentrated, and dried. The resulting yellow solid (93 mg) was then treated with dichloromethane (2 mL). A light yellow solid was isolated by filtration and dried to yield *N*-(5-(2,3-difluorophenyl)-7-oxo-6,7-dihydro-5*H*-pyrrolo[3,4-*b*]pyridin-4-yl)benzo[*b*] thiophene-3-carboxamide (84.5 mg, 58% yield).

[0988] Additional compounds prepared according to the methods of Example 60 and 61 are listed in Table 29 below.

Table 29. Additional Exemplary Compounds

Compound
I-7
I-9
I-22

Compound
I-71
I-142
I-171

Compound
I-208
I-209
I-210


Compound
I-23
I-32
I-33
I-70

Compound
I-172
I-173
I-174
I-175


Compound
I-234
I-235
I-240
I-305

Example 62

3-Fluoro-*N*-(4-methyl-3-oxo-1-(*o*-tolyl)-2,3-dihydro-1*H*-pyrrolo[3,4-*c*]pyridin-7-yl)-5-(trifluoromethyl)benzamide (I-244)




***N*-(2-(2,4-Dimethoxybenzyl)-4-methyl-3-oxo-1-(*o*-tolyl)-2,3-dihydro-1*H*-pyrrolo[3,4-*c*]pyridin-7-yl)-3-fluoro-5-(trifluoromethyl)benzamide**



[0989] Step 1: To a solution of *N*-(4-chloro-2-(2,4-dimethoxybenzyl)-3-oxo-1-(*o*-tolyl)-2,3-dihydro-1*H*-pyrrolo[3,4-*c*]pyridin-7-yl)-3-fluoro-5-(trifluoromethyl)benzamide (50 mg, 0.0814 mmol) in dioxane (500 µL) and water (50 µL) was added potassium carbonate (33.7 mg, 0.2442 mmol), trimethyl-1,3,5,2,4,6-trioxatriborinane (12.4 µL, 0.0896 mmol), and tetrakis(triphenylphosphine) palladium (4.70 mg, 0.00407 mmol). The mixture was stirred at 100 °C for 16 h, then quenched with 1N HCl (100 µL), then diluted with water. The resulting mixture was extracted with EtOAc three times. The combined organics were dried over

Na_2SO_4, filtered, and concentrated. The resulting residue was used directly in the next step without further purification.


3-Fluoro-*N*-(4-methyl-3-oxo-1-(*o*-tolyl)-2,3-dihydro-1*H*-pyrrolo[3,4-*c*]pyridin-7-yl)-5-(trifluoromethyl)benzamide




[0990] Step 2: According to the procedures of Example 13, Step 6, *N*-(2-(2,4-dimethoxybenzyl)-4-methyl-3-oxo-1-(*o*-tolyl)-2,3-dihydro-1*H*-pyrrolo[3,4-*c*]pyridin-7-yl)-3-fluoro-5-(trifluoromethyl)benzamide was converted to 3-fluoro-*N*-(4-methyl-3-oxo-1-(*o*-tolyl)-2,3-dihydro-1*H*-pyrrolo[3,4-*c*]pyridin-7-yl)-5-(trifluoromethyl)benzamide.

Example 63

***N*-(1-Chloro-1-(2-chloro-5-fluorophenyl)-4-(3,3-difluoroazetidin-1-yl)-3-oxo-2,3-dihydro-1*H*-pyrrolo[3,4-*c*]pyridin-7-yl)-3-fluoro-5-(trifluoromethyl)benzamide (I-274)**




***N*-[4-Chloro-1-(2-chloro-5-fluorophenyl)-3-oxo-1*H*,2*H*,3*H*-pyrrolo[3,4-*c*]pyridin-7-yl]-3-fluoro-5-(trifluoromethyl)benzamide**



[0991] Steps 1-6: By analogy to the procedures of Example 13, Steps 1-6, *N*-[4-chloro-1-(2-chloro-5-fluorophenyl)-3-oxo-1*H*,2*H*,3*H*-pyrrolo[3,4-*c*]pyridin-7-yl]-3-fluoro-5-(trifluoromethyl)benzamide was prepared.

***N*-(1-Chloro-1-(2-chloro-5-fluorophenyl)-4-(3,3-difluoroazetidin-1-yl)-3-oxo-2,3-dihydro-1*H*-pyrrolo[3,4-*c*]pyridin-7-yl)-3-fluoro-5-(trifluoromethyl)benzamide**



[0992] Step 7: A conical microwave reaction tube was charged with *N*-[4-chloro-1-(2-chloro-5-fluorophenyl)-3-oxo-1*H*,2*H*,3*H*-pyrrolo[3,4-*c*]pyridin-7-yl]-3-fluoro-5-(trifluoromethyl)benzamide (11 mg, 21.9 µmol, 1.0 eq.), 3,3-difluoroazetidine hydrochloride (3.65 mg, 28.4 µmol, 1.3 eq.), and cesium carbonate (17.8 mg, 54.7 µmol, 2.5 eq.) and purged with nitrogen for 5 minutes. Dry DMF (0.5 mL) was then added to the reaction media, which was sealed and stirred at 85 °C for 2 h. The reaction media was allowed to cool to room temperature, diluted with EtOAc (4 mL), and the organic phase was washed 4 times with half-saturated $NaHCO_3$ (aq). The organic layer was then dried over anhydrous $MgSO_4$ and concentrated under vacuum. The crude mixture was purified over C18 column, eluting with water (10mM formate): acetonitrile 95:5 to 0:100. The pure fractions were lyophilized to afford *N*-(1-chloro-1-(2-chloro-5-fluorophenyl)-4-(3,3-difluoroazetidin-1-yl)-3-oxo-2,3-dihydro-1*H*-pyrrolo[3,4-*c*]pyridin-7-yl)-3-fluoro-5-(trifluoromethyl)benzamide (3.2 mg).

MS: *m/z* = 593.1 $[M+H]^+$; ^{1}H NMR (400 MHz, CD_3OD) δ 8.71 (s, 1H), 7.87 (s, 1H), 7.77 (d, *J* = 8.6 Hz, 1H), 7.68 – 7.58 (m, 2H), 7.49 – 7.32 (m, 1H), 7.14 – 6.97 (m, 1H), 3.82 – 3.56 (m, 4H).

[0993] Additional compounds prepared by analogy to the methods of Examples 13, 14, 62, 63, and other Examples herein, are listed in Table 30 below.

Table 30. Additional Exemplary Compounds


Compound
I-143
I-233
I-236
I-243

Compound
I-253
I-254
I-255


Compound
I-265
I-287
I-320

Example 64

***N*-(3-(2-(Difluoromethyl)-5-fluorophenyl)-5-fluoro-1-oxoisoindolin-4-yl)-3-fluoro-5-(trifluoromethyl)benzamide (I-283)**




2-[1-(3-Bromo-2,4-difluorophenyl)-*N*-[(2,4-dimethoxyphenyl)methyl]formamido]-*N*-*tert*-butyl-2-[2-(difluoromethyl)-5-fluorophenyl]acetamide



[0994] Step 1: To a solution of 2-(difluoromethyl)-5-fluorobenzaldehyde (405 mg, 2.33 mmol) in methanol (5 mL) was added 1-(2,4-dimethoxyphenyl)methanamine (350 µL, 2.33 mmol), followed by 3-bromo-2,4-difluorobenzoic acid (500 mg, 2.10 mmol), and 2-isocyano-2-methylpropane (193 mg, 2.33 mmol). The mixture was stirred at room temperature overnight. The reaction mixture was concentrated *in vacuo* to obtain a yellow solid. The resulting 2-[1-(3-bromo-2,4-difluorophenyl)-*N*-[(2,4-dimethoxyphenyl)methyl]formamido]-*N*-*tert*-butyl-2-[2-(difluoromethyl)-5-fluorophenyl]acetamide was used in the next step without further purification. LC-MS (Method 1): 1.62 min, *m/z* = 644.2 $[M+H]^+$.

4-Bromo-3-[2-(difluoromethyl)-5-fluorophenyl]-2-[(2,4-dimethoxyphenyl)methyl]-5-fluoro-2,3-dihydro-1*H*-isoindol-1-one




[0995] Step 2: A solution of 2-[1-(3-bromo-2,4-difluorophenyl)-*N*-[(2,4-dimethoxyphenyl)methyl]formamido]-*N*-tert-butyl-2-[2-(difluoromethyl)-5-fluorophenyl]acetamide (1.0 g, 1.55 mmol) in DMF (6.2 mL) was evacuated and purged with nitrogen three times, and the reaction mixture was stirred at -78 °C for 5 minutes. Then NaH (92.8 mg, 3.87 mmol) was added under nitrogen atmosphere, and the reaction was stirred overnight from -78 °C to 22 °C. The reaction mixture was neutralized with sat. NH_4Cl and then extracted with EtOAc (10 mL). The aqueous phase was extracted with EtOAc (3 x 5 mL). The combined organic layers were washed with brine solution, dried over sodium sulfate, filtered, and concentrated *in vacuo*. The resulting residue contained both 4-bromo-3-[2-(difluoromethyl)-5-fluorophenyl]-2-[(2,4-dimethoxyphenyl)methyl]-5-fluoro-2,3-dihydro-1*H*-isoindol-1-one and oxidized product 4-bromo-3-[2-(difluoromethyl)-5-fluorophenyl]-2-[(2,4-dimethoxyphenyl)methyl]-5-fluoro-3-hydroxy-2,3-dihydro-1H-isoindol-1-one. The mixture was purified by normal phase chromatography (50 g column, hexane/acetone). The purified desired 4-bromo-3-[2-(difluoromethyl)-5-fluorophenyl]-2-[(2,4-dimethoxyphenyl)methyl]-5-fluoro-2,3-dihydro-1*H*-isoindol-1-one was used in Step 3.

[0996] The purified oxidized product was subjected to a reduction reaction: A solution of 4-bromo-3-[2-(difluoromethyl)-5-fluorophenyl]-2-[(2,4-dimethoxyphenyl)methyl]-5-fluoro-3-


hydroxy-2,3-dihydro-1*H*-isoindol-1-one (500 mg, 0.9253 mmol) in DCM (2 mL) was cooled to -78 °C and $BF_3{\cdot}OEt_2$ (182 µL, 1.48 mmol) was added. After 15 min, triethylsilane (1.46 mL, 9.25 mmol) was added. The mixture was stirred at - 78 °C for additional 15 minutes and then warmed to 22 °C and stirred for 3 h. The mixture was diluted with aq. $NaHCO_3$ and extracted with DCM. The organics were dried over sodium sulfate, filtered, and concentrated *in vacuo*. The resulting 4-bromo-3-[2-(difluoromethyl)-5-fluorophenyl]-2-[(2,4-dimethoxyphenyl)methyl]-5-fluoro-2,3-dihydro-1*H*-isoindol-1-one was combined with the previous portion and used in the next step without further purification.

4-Amino-3-[2-(difluoromethyl)-5-fluorophenyl]-2-[(2,4-dimethoxyphenyl)methyl]-5-fluoro-2,3-dihydro-1*H*-isoindol-1-one




[0997] Step 3: To a solution of 4-bromo-3-[2-(difluoromethyl)-5-fluorophenyl]-2-[(2,4-dimethoxyphenyl)methyl]-5-fluoro-2,3-dihydro-1*H*-isoindol-1-one (20 mg, 0.03814 mmol) in toluene (0.4 mL) was added diphenylmethanimine (8.29 mg, 0.04576 mmol), followed by (*S*)-BINAP (7.12 mg, 0.01144 mmol), $Pd_2(dba)_3$ (3.49 mg, 0.003814 mmol), and NaO*t*Bu (5.49 mg, 0.05721 mmol). The mixture was stirred at 80 °C for 16 h. The reaction mixture was quenched with 1 M HCl and stirred at 22 °C overnight. Then, the reaction mixture was diluted with DCM (10 mL) and $NaHCO_3$ (15 mL), and the aqueous phase was extracted with DCM (3 x 5 mL). The combined organic layers were washed with brine solution, dried over sodium sulfate, filtered, and concentrated *in vacuo*. The residue was purified by reverse phase chromatography (30 g column, water/ACN; water solvent is 10mM ammonium formate) to afford 4-amino-3-[2-(difluoromethyl)-5-fluorophenyl]-2-[(2,4-dimethoxyphenyl)methyl]-5-fluoro-2,3-dihydro-1*H*-isoindol-1-one. LC-MS (Method 1): 1.30 min, *m/z* = 461.3 $[M+H]^+$.

***N*-{3-[2-(difluoromethyl)-5-fluorophenyl]-2-[(2,4-dimethoxyphenyl)methyl]-5-fluoro-1-oxo-2,3-dihydro-1*H*-isoindol-4-yl}-3-fluoro-5-(trifluoromethyl)benzamide**



[0998] Step 4: To a solution of 4-amino-3-[2-(difluoromethyl)-5-fluorophenyl]-2-[(2,4-dimethoxyphenyl)methyl]-5-fluoro-2,3-dihydro-1*H*-isoindol-1-one (10 mg, 0.0217 mmol) in DCM (1 mL) was added 3-fluoro-5-(trifluoromethyl)benzoyl chloride (7.37 mg, 0.0326 mmol) and K_2CO_3 (15 mg, 0.108 mmol). The reaction mixture was stirred for 3 hrs at 50 °C. The reaction mixture was diluted with EtOAc (10 mL) and $NaHCO_3$ (15 mL), and the aqueous phase was extracted with EtOAc (3 x 5 mL). The combined organic layers were washed with brine solution, dried over sodium sulfate, filtered, and concentrated *in vacuo*. The resulting residue was purified by reverse-phase chromatography (30 g column, water/ACN; water solvent is 10mM ammonium formate). LC-MS (Method 1): 1.52 min, *m/z* = 651.7 $[M+H]^+$.

***N*-(3-(2-(Difluoromethyl)-5-fluorophenyl)-5-fluoro-1-oxoisoindolin-4-yl)-3-fluoro-5-(trifluoromethyl)benzamide**




[0999] Step 5: A mixture of *N*-{3-[2-(difluoromethyl)-5-fluorophenyl]-2-[(2,4-dimethoxyphenyl)methyl]-5-fluoro-1-oxo-2,3-dihydro-1H-isoindol-4-yl}-3-fluoro-5-(trifluoromethyl)benzamide (10 mg, 0.01537 mmol) in TFA (2 mL) was heated to 40 °C in a sealed tube for 1 hour. The reaction mixture was then cooled to ambient temperature and concentrated *in vacuo*. The resulting residue was purified by reverse-phase chromatography (30 g column, water/ACN; water solvent is 10mM ammonium formate) to afford *N*-(3-(2-


(difluoromethyl)-5-fluorophenyl)-5-fluoro-1-oxoisoindolin-4-yl)-3-fluoro-5-(trifluoromethyl)benzamide (0.79 mg, 5 % yield over 2 steps).

Example 65

***N*-(3-Methyl-1-oxo-3-(*o*-tolyl)isoindolin-4-yl)benzo[*b*]thiophene-3-carboxamide (I-80)**




4-Amino-2-(4-methoxybenzyl)-3-methyl-3-(*o*-tolyl)isoindolin-1-one




[1000] Step 1: To a solution of 4-amino-3-hydroxy-2-(4-methoxybenzyl)-3-(*o*-tolyl)isoindolin-1-one (300 mg, 0.801 mmol) in dry THF (3 mL) at room temperature under a nitrogen atmosphere was added $BF_3{\cdot}OEt_2$ (295 µL, 2.40 mmol). The purple solution was then stirred at room temperature for 12h, then a solution of chloro(methyl)magnesium (4.8 mL, 3M in THF, 14.3 mmol) was added. The mixture was stirred for another 1 h, and then a saturated (aq) solution of NH_4Cl (20 mL) was added slowly. The mixture was diluted with EtOAc and extracted with EtOAc (3x). The combined organic layers were washed with brine, dried over Na_2SO_4, filtered, and concentrated under reduced pressure to yield an orange foam. The resulting 4-amino-2-(4-methoxybenzyl)-3-methyl-3-(*o*-tolyl)isoindolin-1-one was used without further purification. LC-MS (Method 1): 1.24 min, *m/z* = 373.3 $[M+H]^+$.

4-Amino-3-methyl-3-(*o*-tolyl)isoindolin-1-one



[1001] Step 2: A solution of 4-amino-2-(4-methoxybenzyl)-3-methyl-3-(o-tolyl)isoindolin-1-one (150 mg, 0.282 mmol) in TFA (15 mL) was heated at 170°C for 80 min under microwave irradiation. Analysis indicated the major product was 2,2,2-trifluoro-*N*-(3-methyl-1-oxo-3-(*o*-tolyl)isoindolin-4-yl)acetamide. The mixture was then concentrated under reduced pressure and dissolved in MeOH (10 mL). Potassium carbonate (500 mg, 3.56 mmol) was added, and the mixture was heated at 60°C for 12 h. The mixture was then diluted with a satd. (aq) solution of NH_4Cl and extracted with DCM (4x). The combined organic layers were washed with brine, dried over Na_2SO_4, filtered, and concentrated under reduced pressure to afford 4-amino-3-methyl-3-(*o*-tolyl)isoindolin-1-one, which was used in the next step without further purification.

***N*-(3-Methyl-1-oxo-3-(*o*-tolyl)isoindolin-4-yl)benzo[*b*]thiophene-3-carboxamide**



[1002] Step 3: The 4-amino-3-methyl-3-(*o*-tolyl)isoindolin-1-one from the previous step was dissolved in pyridine (6 mL) and 1-benzothiophene-3-carbonyl chloride (110 mg, 0.563 mmol) was added. The mixture was stirred at room temperature for 12 h. The mixture was then diluted with a satd. (aq) solution of $CuSO_4$ and extracted with EtOAc (3x). The combined organic layers were washed with water, then satd. $NaHCO_3$ (aq), and finally with brine, then dried over Na_2SO_4, filtered, and concentrated under reduced pressure. Purification by reverse phase chromatography (5 to 70% ACN / Water [AmF 10 mM]) followed by purification by normal phase chromatography (0 to 60% acetone / heptanes) afforded *N*-(3-

methyl-1-oxo-3-(*o*-tolyl)isoindolin-4-yl)benzo[*b*]thiophene-3-carboxamide (43 mg, 37% over two steps) as a white powder after lyophilisation.


[1003] Additional compounds prepared by analogy to the methods of Example 65, and other Examples herein, are listed in Table 31 below.

Table 31. Additional Exemplary Compounds


Compound
I-130

Example 66

***N*-(1-(2-chlorophenyl)-6-methoxy-3-oxo-2,3-dihydro-1*H*-pyrrolo[3,4-*c*]pyridin-7-yl)-3-fluoro-5-(trifluoromethyl)benzamide (I-335)**




2-Chloro-*N*-(2,4-dimethoxybenzyl)benzamide




[1004] Step 1: To a solution of 1-(2,4-dimethoxyphenyl)methanamine (4.76 g, 28.5 mmol) in DCM (30 mL) was added DIPEA (9.91 mL, 57.0 mmol). The solution was cooled to 0-5 °C, then 2-chlorobenzoyl chloride (3.61 mL, 28.5 mmol) was added dropwise. The mixture was warmed to RT and stirred for 2 h. The mixture was diluted with DCM and washed with water. The organic layer was dried and concentrated. Heptane was added, and the mixture was sonicated until solid separated. The mixture was filtered and air dried to afford 2-chloro-*N*-(2,4-dimethoxybenzyl)benzamide (7.89 g, 25.8 mmol, 90.5% yield) as a white solid. MS: *m/z* = 306.3 $[M+H]^+$.

1-(2-Chlorophenyl)-2-(2,4-dimethoxybenzyl)-6-methoxy-7-nitro-1,2-dihydro-3*H*-pyrrolo[3,4-*c*]pyridin-3-one



[1005] Step 2: To a solution of 2-chloro-*N*-(2,4-dimethoxybenzyl)benzamide (1.51 g, 4.97 mmol) in THF (25 mL) at -50 °C was added LHMDS (4.97 mL, 4.97 mmol) dropwise over 15 min, keeping temperature at -50 °C. The mixture was stirred at -50 °C for 15 min, then 6-chloro-5-nitropyridine-3-carbonyl chloride (1.1 g, 4.97 mmol) was added dropwise over 15 min. Upon completion of addition, the mixture was warmed to -20 °C over 30 min. After 30 min, the mixture was cooled to -50 °C and a second equivalent of LHMDS (4.97 mL, 4.97 mmol) was added dropwise over 15 min. The mixture was warmed to room temperature over 45 min. The reaction mixture was quenched at room temperature with MeOH (25 mL). The solution was concentrated onto SiO2 and purified by normal phase chromatography (0-100% ethyl acetate in heptanes) to afford 1-(2-chlorophenyl)-2-(2,4-dimethoxybenzyl)-6-methoxy-7-nitro-1,2-dihydro-3*H*-pyrrolo[3,4-*c*]pyridin-3-one (1.24 g, 0.638 mmol, 12.8%, 30% pure by HPLC). MS: m/z = 486.12 $[M+H]^+$.


7-Amino-1-(2-chlorophenyl)-2-(2,4-dimethoxybenzyl)-1-hydroxy-6-methoxy-1,2-dihydro-3*H*-pyrrolo[3,4-*c*]pyridin-3-one



[1006] Step 3: A solution of 1-(2-chlorophenyl)-2-(2,4-dimethoxybenzyl)-6-methoxy-7-nitro-1,2-dihydro-3H-pyrrolo[3,4-c]pyridin-3-one as prepared in the previous step (300 mg, 0.6174 mmol) in MeOH (4 mL) and AcOH (2 mL) was cooled to 0 °C, and iron (172 mg, 3.08 mmol) was added. The mixture was warmed to RT, then heated at 80 °C for 1 h. The mixture was partitioned between EtOAc and water, then filtered through a pad of celite to


remove any solids. The layers were separated layers, and the organic layer was washed with brine, dried over Na_2SO_4, filtered, and concentrated. The resulting 7-amino-1-(2-chlorophenyl)-2-(2,4-dimethoxybenzyl)-1-hydroxy-6-methoxy-1,2-dihydro-3*H*-pyrrolo[3,4-*c*]pyridin-3-one (35% pure by LCMS) was used directly in the next step without further purification.

_N_-(1-(2-Chlorophenyl)-2-(2,4-dimethoxybenzyl)-1-hydroxy-6-methoxy-3-oxo-2,3-dihydro-1*H*-pyrrolo[3,4-*c*]pyridin-7-yl)-3-fluoro-5-(trifluoromethyl)benzamide



[1007] Step 4: A suspension of 3-fluoro-5-(trifluoromethyl)benzoic acid (94.6 mg, 0.4546 mmol) in DCE (5 mL) was treated with (1-chloro-2-methylprop-1-en-1-yl)dimethylamine (60.7 mg, 0.4546 mmol). The mixture was stirred at RT for 15 min, before it was transferred to a solution of 7-amino-1-(2-chlorophenyl)-2-(2,4-dimethoxybenzyl)-1-hydroxy-6-methoxy-1,2-dihydro-3*H*-pyrrolo[3,4-*c*]pyridin-3-one as prepared in the previous step (100 mg, 0.2273 mmol), DMAP (8.74 mg, 0.0227 mmol), and pyridine (90.9 µL, 1.13 mmol) in DCE (5 mL). The mixture was stirred at 60 °C for 16 h. The mixture was concentrated and the resulting *N*-(1-(2-chlorophenyl)-2-(2,4-dimethoxybenzyl)-1-hydroxy-6-methoxy-3-oxo-2,3-dihydro-1*H*-pyrrolo[3,4-*c*]pyridin-7-yl)-3-fluoro-5-(trifluoromethyl)benzamide was used in the next step without further purification.


_N_-(1-(2-chlorophenyl)-6-methoxy-3-oxo-2,3-dihydro-1*H*-pyrrolo[3,4-*c*]pyridin-7-yl)-3-fluoro-5-(trifluoromethyl)benzamide




[1008] Step 5: *N*-(1-(2-chlorophenyl)-2-(2,4-dimethoxybenzyl)-1-hydroxy-6-methoxy-3-oxo-2,3-dihydro-1*H*-pyrrolo[3,4-*c*]pyridin-7-yl)-3-fluoro-5-(trifluoromethyl)benzamide as prepared in the previous step was dissolved in TFA (1 mL) and stirred at 80 °C for 30 min. The mixture was cooled to room temperature, triethylsilane (108 µL, 0.682 mmol) was added, and the mixture was heated at 80 °C for 30 min. The mixture was concentrated, and the residue was purified by reverse phase purification to give *N*-(1-(2-chlorophenyl)-6-methoxy-3-oxo-2,3-dihydro-1*H*-pyrrolo[3,4-*c*]pyridin-7-yl)-3-fluoro-5-(trifluoromethyl)benzamide (6 mg, 0.01250 mmol, 5.50 % from step 2) as a white solid.

Example 67

6-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-3-(2-chloro-5-fluorophenyl)-4-(piperidin-3-ylamino)isoindolin-1-one (I-2158)




tert-butyl 3-((6-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-3-(2-chloro-5-fluorophenyl)-2-(4-methoxybenzyl)-1-oxoisoindolin-4-yl)amino)piperidine-1-carboxylate



[1009] Step 1: .A 25 mL microwave vial equipped with a stir bar was charged with 4-bromo-3-(2-chloro-5-fluorophenyl)-2-[(4-methoxyphenyl)methyl]-6-{[1,2,4]triazolo[1,5-a]pyridin-6-yl}-2,3-dihydro-1H-isoindol-1-one (300 mg, 0.5191 mmol), Pd_2dba_3 (47.5 mg, 0.05191 mmol), DavePhos (40.8 mg, 0.1038 mmol), sodium tert-butoxide (148 mg, 1.55 mmol) and tert-butyl 3-aminopiperidine-1-carboxylate (187 µL, 2 eq) before diluting with toluene (4

mL). The mixture was sparged with nitrogen before sealing and heating at 110 °C for 1 h. After concentration in vacuo, the mixture was subjected to reverse phase C18 chromotography and lyophilized to afford tert-butyl 3-((6-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-3-(2-chloro-5-fluorophenyl)-2-(4-methoxybenzyl)-1-oxoisoindolin-4-yl)amino)piperidine-1-carboxylate (150 mg, 0.22 mmol, 41.5% yield).

6-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-3-(2-chloro-5-fluorophenyl)-4-(piperidin-3-ylamino)isoindolin-1-one




[1010] Step 2: A 20 mL sealed tube equipped with a stir bar was charged with tert-butyl 3-{[3-(2-chloro-5-fluorophenyl)-2-[(4-methoxyphenyl)methyl]-1-oxo-6-{[1,2,4]triazolo[1,5-a]pyridin-6-yl}-2,3-dihydro-1H-isoindol-4-yl]amino}piperidine-1-carboxylate (150 mg, 0.2151 mmol) followed by dilution in trifluoroacetic acid (20 mL) and addition of trifluoromethanesulfonic acid (28.4 µL, 1.5 eq). The vial was sealed and heated at 90°C for 1 h. The mixture was diluted with DCM and concentrated, subjected to reverse-phase chromotography (C18-30g), and lyophilized to afford 6-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-3-(2-chloro-5-fluorophenyl)-4-(piperidin-3-ylamino)isoindolin-1-one (20 mg, 0.042 mmol, 19.6% yield). MS: *m/z* = 477.0 $[M+H]^+$.


Example 68

(S)-N-[3-(2-chloro-5-fluorophenyl)-1-oxo-6-{[1,2,4]triazolo[1,5-a]pyridin-6-yl}-2,3-dihydro-1H-isoindol-4-yl]-3-fluoro-5-(trifluoromethyl)benzamide (I-943) and (R)- N-[3-

(2-chloro-5-fluorophenyl)-1-oxo-6-{[1,2,4]triazolo[1,5-a]pyridin-6-yl}-2,3-dihydro-1H-isoindol-4-yl]-3-fluoro-5-(trifluoromethyl)benzamide (I-945)



N-[3-(2-chloro-5-fluorophenyl)-1-oxo-6-{[1,2,4]triazolo[1,5-a]pyridin-6-yl}-2,3-dihydro-1H-isoindol-4-yl]-3-fluoro-5-(trifluoromethyl)benzamide



[1011] Step 1: A N_2-degassed mixture of N-[6-bromo-3-(2-chloro-5-fluorophenyl)-1-oxo-2,3-dihydro-1H-isoindol-4-yl]-3-fluoro-5-(trifluoromethyl)benzamide (32.1 mg), 6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-[1,2,4]triazolo[1,5-a]pyridine (23.0 mg), palladium(II) bis(triphenylphosphane) dichloride (6.18 mg), disodium carbonate (18.6 mg) in acetonitrile (1.17 mL) / water (0.4 mL) was stirred in a sealed tube for 40 minutes at 110°C. The mixture was cooled, diluted with THF (10 mL) and brine (8 mL), and the layers were separated. The organic layer was concentrated. The crude was loaded as a silica gel slurry onto a 12 g silica gel column, which was eluted with DCM to 10:90:1 MeOH/DCM/NH_4OH gradient over 25 minutes. The product eluted between 5.5% and 6.2% MeOH/DCM. The fractions containing product were combined, concentrated in vacuo, and dried to yield a foamy, white solid (25.0 mg). MS: *m/z* = 584.0 $[M+H]^+$. ^1H NMR (400 MHz, DMSO-d_6) δ 10.65 (s, 1H), 9.48 (s, 1H), 9.34 – 9.26 (br s, 1H), 8.58 (s, 2H), 8.34 (s, 2H), 8.00 (m, 3H), 7.97 (m, 1H), 7.76 (d, J = 7.6 Hz, 1H), 7.59 (s, 1H), 7.42(t, J = 7.7 Hz, 1H), 6.04 (br s, 1H).

(S)-N-[3-(2-chloro-5-fluorophenyl)-1-oxo-6-{[1,2,4]triazolo[1,5-a]pyridin-6-yl}-2,3-dihydro-1H-isoindol-4-yl]-3-fluoro-5-(trifluoromethyl)benzamide (I-943) and (R)- N-[3-

(2-chloro-5-fluorophenyl)-1-oxo-6-{[1,2,4]triazolo[1,5-a]pyridin-6-yl}-2,3-dihydro-1H-isoindol-4-yl]-3-fluoro-5-(trifluoromethyl)benzamide (I-945)


[1012] Step 2: 90.3 mg of the racemate from step 1 (combined over multiple reaction runs) was subjected to chiral separation by SFC (method: Column: ChiralPak AS-H 30 x 250 mm Mobile Phase: 55% methanol in CO_2; Flow Rate: 80 mL/min; Sample: 90.3 mg of sample was dissolved in 10 mL methanol + 10 mL dichloromethane; Injection: 2.5 mL; Detection: 220 nm). Separation yielded two peaks.


[1013] Peak1 (retention time: 0.66 min): (S)-N-[3-(2-chloro-5-fluorophenyl)-1-oxo-6-{[1,2,4]triazolo[1,5-a]pyridin-6-yl}-2,3-dihydro-1H-isoindol-4-yl]-3-fluoro-5-(trifluoromethyl)benzamide was isolated as a white solid in 100% LC purity and 100% in chiral purity (38.8 mg). MS: *m/z* = 584.3 $[M+H]^+$. ^{1}H NMR (DMSO-d_6, 400 MHz): δ = 10.64 (s, 1H), 9.48 (s, 1H), 9.26 (br s, 1H), 8.58 (s, 1H), 8.10-8.19 (m, 2H), 7.99 (br d, J = 9.9 Hz, 3H), 7.75-7.83 (m, 1H), 7.73 (s, 1H), 7.35 (dd, J = 8.8, 5.3 Hz, 1H), 7.12 (td, J = 8.3, 3.0 Hz, 1H), 6.51-6.97 (m, 1H), 6.07 (br s, 1H).

[1014] Peak 2 (retention time: 2.48 min): (R)-N-[3-(2-chloro-5-fluorophenyl)-1-oxo-6-{[1,2,4]triazolo[1,5-a]pyridin-6-yl}-2,3-dihydro-1H-isoindol-4-yl]-3-fluoro-5-(trifluoromethyl)benzamide was isolated as a white solid in 100% LC purity and 99.89% in chiral purity (37.6 mg). MS: *m/z* = 584.3 $[M+H]^+$. ^{1}H NMR (DMSO-d_6, 400 MHz): δ = 10.64 (s, 1H), 9.48 (s, 1H), 9.26 (br s, 1H), 8.58 (s, 1H), 8.10-8.19 (m, 2H), 7.99 (br d, J = 9.9 Hz, 3H), 7.75-7.83 (m, 1H), 7.73 (s, 1H), 7.35 (dd, J = 8.8, 5.3 Hz, 1H), 7.12 (td, J = 8.3, 3.0 Hz, 1H), 6.51-6.97 (m, 1H), 6.07 ppm (br s, 1H).


Example 69

(S)-N-(3-(2-chloro-5-fluorophenyl)-6-(5-cyano-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1-oxoisoindolin-4-yl)-3-fluoro-5-(trifluoromethyl)benzamide (I-1647) and (R)-N-(3-(2-chloro-5-fluorophenyl)-6-(5-cyano-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1-oxoisoindolin-4-yl)-3-fluoro-5-(trifluoromethyl)benzamide (I-1648)





N-(3-(2-chloro-5-fluorophenyl)-6-(5-cyano-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1-oxoisoindolin-4-yl)-3-fluoro-5-(trifluoromethyl)benzamide



[1015] Step 1: To a sealed tube fitted with stir bar were added [1-(2-chloro-5-fluorophenyl)-7-[3-fluoro-5-(trifluoromethyl)benzamido]-3-oxo-2,3-dihydro-1H-isoindol5-yl]boronic acid (50 mg, 0.09792 mmol), 6-bromo-[1,2,4]triazolo[1,5-a]pyridine-5-carbonitrile (21.8 mg, 0.09792 mmol), palladium(II) bis(triphenylphosphane) dichloride (10.3 mg, 0.01468 mmol), acetonitrile (2 mL, 0.05M), and a solution of disodium carbonate (31.1 mg, 0.2937 mmol) in water (0.65 mL). The mixture was degassed with nitrogen for 30 seconds, and the tube was sealed. The reaction was heated at 90°C for 45 min. The reaction was cooled to RT, filtered through a pad of Celite®, and concentrated. The residue was purified on prep-HPLC (AccQ Prep; eluting with 30-60% acetonitrile in water w/ 0.1% formic acid). Combined fractions containing product were concentrated in vacuo to yield a solid (10 mg, 15.9 % yield). MS: *m/z* = 609.08 $[M+H]^+$. ^{1}H NMR (500 MHz, DMSO-d_6) δ 10.71 (s, 1H), 9.33 (s, 1H), 8.79 (s, 1H), 8.33 (d, J = 9.2 Hz, 1H), 8.06 (s, 1H), 7.98 (d, J = 9.3 Hz, 1H), 7.95 (d, J = 7.7 Hz, 1H), 7.83 (s, 1H), 7.75 (d, J = 9.1 Hz, 1H), 7.68 (s, 1H), 7.35 (dd, J = 8.9, 5.1 Hz, 1H), 7.12 (td, J = 8.4, 3.1 Hz, 1H), 6.54 (s, 1H), 6.08 (s, 1H).

(S)-N-(3-(2-chloro-5-fluorophenyl)-6-(5-cyano-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1-oxoisoindolin-4-yl)-3-fluoro-5-(trifluoromethyl)benzamide (I-1647) and (R)-N-(3-(2-chloro-5-fluorophenyl)-6-(5-cyano-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1-oxoisoindolin-4-yl)-3-fluoro-5-(trifluoromethyl)benzamide (I-1648)


[1016] Step 2: 100.0 mg of the racemate from step 1 (combined over multiple reaction runs) was subjected to chiral separation by SFC (method: UniChiral AS-5H 21 x 250 mm; Mobile Phase: 60% ethanol in CO_2; Flow Rate: 70 mL/min; Sample: 100.0 mg of sample was dissolved in 5 mL methanol + 5 mL dichloromethane; Injection: 2.5 mL; Detection: 254 nm). Separation yielded two peaks.

[1017] Peak 1 (retention time: 0.83 min): (S)-N-(3-(2-chloro-5-fluorophenyl)-6-(5-cyano-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1-oxoisoindolin-4-yl)-3-fluoro-5-(trifluoromethyl)benzamide was isolated as a solid (40 mg). MS: *m/z* = 609.1 $[M+H]^+$. ^1H NMR (500 MHz, DMSO-d_6) δ 10.71 (s, 1H), 9.33 (s, 1H), 8.80 (s, 1H), 8.34 (d, J = 9.2 Hz, 1H), 8.07 (s, 1H), 7.97 (t, J = 9.9 Hz, 2H), 7.83 (s, 1H), 7.75 (d, J = 9.2 Hz, 1H), 7.68 (s, 1H), 7.35 (dd, J = 8.8, 5.1 Hz, 1H), 7.13 (d, J = 8.0 Hz, 1H).


[1018] Peak 2 (retention time: 3.11 min): (R)-N-(3-(2-chloro-5-fluorophenyl)-6-(5-cyano-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1-oxoisoindolin-4-yl)-3-fluoro-5-(trifluoromethyl)benzamide was isolated as a solid (43 mg). MS: *m/z* = 609.1 $[M+H]^+$. ^1H NMR (500 MHz, DMSO-d_6) δ 10.71 (s, 1H), 9.33 (s, 1H), 8.80 (s, 1H), 8.34 (d, J = 9.2 Hz, 1H), 8.07 (s, 1H), 7.97 (t, J = 9.9 Hz, 2H), 7.83 (s, 1H), 7.75 (d, J = 9.2 Hz, 1H), 7.68 (s, 1H), 7.35 (dd, J = 8.8, 5.1 Hz, 1H), 7.13 (d, J = 8.0 Hz, 1H).

Example 70

(S)-N-(3-(2-chloro-5-fluorophenyl)-6-(1-(difluoromethyl)-1H-pyrazol-4-yl)-1-oxoisoindolin-4-yl)-3-fluoro-5-(trifluoromethyl)benzamide (I-1739) and (R)-N-(3-(2-chloro-5-fluorophenyl)-6-(1-(difluoromethyl)-1H-pyrazol-4-yl)-1-oxoisoindolin-4-yl)-3-fluoro-5-(trifluoromethyl)benzamide (I-1740)



N-(3-(2-chloro-5-fluorophenyl)-6-(5-cyano-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1-oxoisoindolin-4-yl)-3-fluoro-5-(trifluoromethyl)benzamide



[1019] **Step 1**: To a sealed tube fitted with stir bar were added N-[6-bromo-3-(2-chloro-5-fluorophenyl)-1-oxo-2,3-dihydro-1H-isoindol-4-yl]-3-fluoro-5-(trifluoromethyl)benzamide (350 mg, 0.641 mmol, 1 eq), 1-(difluoromethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (211 mg, 0.865 mmol, 1.35 eq), bis(triphenylphosphine)palladium (II) dichloride (67.4 mg, 0.096 mmol, 0.15 eq), dioxane (4.3 mL, 0.15M), and a solution of sodium carbonate (203 mg, 1.92 mmol, 3.0 eq) in water (1.4 mL). The mixture was degassed with nitrogen for 30 seconds, and the tube was sealed. The reaction was stirred at 100 °C for a total of 55 minutes. The reaction was cooled to R.T. and treated with water (30 mL). A dark brown solid was isolated by filtration. The crude (>400 mg) was loaded as a silica gel slurry on a 24 g silica gel column, which was eluted with DCM to 10:90:1 MeOH/DCM/NH_4OH gradient over 25 minutes. The product eluted at ~3.8% MeOH / DCM. The fractions containing desired product were combined, concentrated, and dried to yield a tan solid (94.0 mg). MS: *m/z* = 583.4 $[M+H]^+$. ^1H NMR (400 MHz, DMSO-d_6) δ 10.56 (s, 1H), 9.18 (s, 1H), 8.94 (s, 1H), 8.43 (s, 1H), 8.06 (d, J = 1.6 Hz, 1H), 8.02 – 7.79 (m, 3H), 7.75 (d, J = 9.1 Hz, 1H), 7.70 (d, J = 2.2 Hz, 1H), 7.31 (dd, J = 8.9, 5.1 Hz, 1H), 7.09 (td, J = 8.3, 3.1 Hz, 1H), 6.86 – 6.58 (m, 1H), 5.98 (s, 1H).

(S)-N-(3-(2-chloro-5-fluorophenyl)-6-(1-(difluoromethyl)-1H-pyrazol-4-yl)-1-oxoisoindolin-4-yl)-3-fluoro-5-(trifluoromethyl)benzamide (I-1739) and (R)-N-(3-(2-chloro-5-fluorophenyl)-6-(1-(difluoromethyl)-1H-pyrazol-4-yl)-1-oxoisoindolin-4-yl)-3-fluoro-5-(trifluoromethyl)benzamide (I-1740)

[1020] **Step 2**: 85.1 mg of the racemate from step 1 was subjected to chiral separation by SFC (Column: UniChiral AS-5H 21 x 250 mm; Mobile Phase: 45% methanol in CO_2; Flow Rate: 70 mL/min; Sample: 85.1 mg of sample was dissolved in 10 mL methanol + 5 mL dichloromethane; Injection: 2.5 mL; Detection: 254 nm). Separation yielded two peaks.


[1021] Peak 1 (retention time: 0.45 min): (S)-N-(3-(2-chloro-5-fluorophenyl)-6-(1-(difluoromethyl)-1H-pyrazol-4-yl)-1-oxoisoindolin-4-yl)-3-fluoro-5-(trifluoromethyl)benzamide was isolated as a solid (42.8 mg). MS: *m/z* = 583.4 $[M+H]^+$. ^1H NMR (500 MHz, DMSO-d_6) δ 10.55 (s, 1H), 9.17 (s, 1H), 8.94 (s, 1H), 8.44 (s, 1H), 8.06 (d, J = 1.5 Hz, 1H), 7.99 – 7.69 (m, 5H), 7.32 (dd, J = 8.9, 5.1 Hz, 1H), 7.09 (td, J = 8.4, 3.1 Hz, 1H), 6.92 – 6.41 (m, 1H), 5.99 (s, 1H).

[1022] Peak 2 (retention time: 0.74 min): (R)-N-(3-(2-chloro-5-fluorophenyl)-6-(1-(difluoromethyl)-1H-pyrazol-4-yl)-1-oxoisoindolin-4-yl)-3-fluoro-5-


(trifluoromethyl)benzamide as a solid (23.4 mg). MS: *m/z* = 583.4 $[M+H]^+$. ^1H NMR (500 MHz, DMSO-d_6) δ 10.55 (s, 1H), 9.17 (s, 1H), 8.94 (s, 1H), 8.44 (s, 1H), 8.06 (d, J = 1.5 Hz, 1H), 7.99 – 7.69 (m, 5H), 7.32 (dd, J = 8.9, 5.1 Hz, 1H), 7.09 (td, J = 8.4, 3.1 Hz, 1H), 6.92 – 6.41 (m, 1H), 5.99 (s, 1H).

Example 71

(*S*)-N-(3-(2-chloro-5-fluorophenyl)-6-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-1-oxoisoindolin-4-yl)-3-fluoro-5-(trifluoromethyl)benzamide (I-701) and (*R*)-N-(3-(2-chloro-5-fluorophenyl)-6-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-1-oxoisoindolin-4-yl)-3-fluoro-5-(trifluoromethyl)benzamide (I-702)




N-[3-(2-chloro-5-fluorophenyl)-2-[(4-methoxyphenyl)methyl]-6-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-1-oxo-2,3-dihydro-1H-isoindol-4- yl]-3-fluoro-5-(trifluoro methyl)benzamide



[1023] Step 1: A N_2-degassed mixture of N-[6-bromo-3-(2-chloro-5-fluorophenyl)-2-[(4-methoxyphenyl)methyl]-1-oxo-2,3-dihydro-1H-isoindol-4-yl]-3-fluoro-5-(trifluoromethyl)benzamide (140 mg), 1-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,2-dihydropyridin-2-one (83.6 mg), palladium(II) bis(triphenylphosphane) dichloride (22.0 mg), disodium carbonate (66.7 mg) in acetonitrile (4.19 mL) / water (1.40 mL) was stirred in a sealed tube for 40 minutes at 105 °C. The mixture was cooled, diluted with THF

(7-8 mL) and brine (10 mL), and the layers were separated. The organic layer was concentrated . The crude was loaded as a silica gel slurry onto a 24 g silica gel column, which was eluted with DCM to 10:90:1 MeOH/DCM/NH_4OH gradient over 20 minutes. The product eluted between 4.7% and 5.2% MeOH/DCM. The combined fractions were concentrated in vacuo and dried to yield an off-white / light gray-green, foamy solid weighing 114.1 mg. MS: *m/z* = 694.7 $[M+H]^+$.

N-[3-(2-chloro-5-fluorophenyl)-6-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-1-oxo-2,3-dihydro-1H-isoindol-4-yl]-3-fluoro-5-(trifluoromethyl)benzamide



[1024] Step 2: A mixture of N-[3-(2-chloro-5-fluorophenyl)-2-[(4-methoxyphenyl)methyl]-6-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-1-oxo-2,3-dihydro-1H-isoindol-4-yl]-3-fluoro-5-(trifluor methyl)benzamide (114.1 mg) and 10% TFA in DCM (5.5 mL) was heated for 14 hours at 100 °C in microwave. After cooling, the mixture was concentrated and eluted on 12 gram silica gel column with DCM to 10:90:1 MeOH / DCM / NH_4OH. The product eluted between 6.1% and 6.7% MeOH/DCM, which was concentrated in vacuo and dried to yield 61.6 mg. MS: *m/z* = 574.5 $[M+H]^+$; ^1H NMR (400 MHz, DMSO-d_6) δ 10.90 (s, 1H), 9.52 (s, 1H), 8.62 (d, *J* = 1.5 Hz, 1H), 8.18 (dd, *J* = 8.6, 1.6 Hz, 1H), 7.98 (d, *J* = 8.7, 1H), 7.87 (s, 1H), 7.75 (d, *J* = 8.5, 1H), 7.67 (s, 1H), 7.35 (m, 1H), 7.10 (td, 8.6, 1.6 Hz, 1H), 6.57 (d, *J* = 8.8 Hz, 1H), 6.02 (s, 1H), 3.59 (s, 3H).

(*S*)-N-(3-(2-chloro-5-fluorophenyl)-6-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-1-oxoisoindolin-4-yl)-3-fluoro-5-(trifluoromethyl)benzamide (I-701) and (*R*)-N-(3-(2-chloro-5-fluorophenyl)-6-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-1-oxoisoindolin-4-yl)-3-fluoro-5-(trifluoromethyl)benzamide (I-702)

[1025] Step 3: 55 mg of the racemate from step 2 was subjected to chiral separation by SFC (method: Column: ChiralPak IC-H 21 x 250 mm; Mobile Phase: 40% methanol in CO_2; Flow


Rate: 70 mL/min; Sample: 54.8 mg of sample was dissolved in 4 mL methanol + 4 mL dichloromethane; Injection: 1 mL; Detection: 220 nm). Separation yielded two peaks.

[1026] Peak1 (retention time: 2.4 min): (*S*)-N-(3-(2-chloro-5-fluorophenyl)-6-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-1-oxoisoindolin-4-yl)-3-fluoro-5-(trifluoromethyl)benzamide was isolated as a white solid in 100% LC purity and 100% in chiral purity (20.2 mg). MS: *m/z* = 574.3 $[M+H]^+$; ^1H NMR (400 MHz, DMSO-d_6) δ 10.90 (s, 1H), 9.52 (s, 1H), 8.62 (d, *J* = 1.5 Hz, 1H), 8.18 (dd, *J* = 8.6, 1.6 Hz, 1H), 7.98 (d, *J* = 8.7, 1H), 7.87 (s, 1H), 7.75 (d, *J* = 8.5, 1H), 7.67 (s, 1H), 7.35 (m, 1H), 7.10 (td, 8.6, 1.6 Hz, 1H), 6.57 (d, *J* = 8.8 Hz, 1H), 6.02 (s, 1H), 3.59 (s, 3H).


[1027] Peak2 (retention time: 3.72 min): (*R*)-N-(3-(2-chloro-5-fluorophenyl)-6-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-1-oxoisoindolin-4-yl)-3-fluoro-5-(trifluoromethyl)benzamide was isolated as a white solid in 100% LC purity and 100% in chiral purity (20.1 mg). MS: *m/z* = 574.2 $[M+H]^+$; ^1H NMR (400 MHz, DMSO-d_6) δ 10.90 (s, 1H), 9.52 (s, 1H), 8.62 (d, *J* = 1.5 Hz, 1H), 8.18 (dd, *J* = 8.6, 1.6 Hz, 1H), 7.98 (d, *J* = 8.7, 1H), 7.87 (s, 1H), 7.75 (d, *J* = 8.5, 1H), 7.67 (s, 1H), 7.35 (m, 1H), 7.10 (td, 8.6, 1.6 Hz, 1H), 6.57 (d, *J* = 8.8 Hz, 1H), 6.02 (s, 1H), 3.59 (s, 3H).

Example 72

4-Amino-2-chloro-6-(2,4-dimethoxybenzyl)-5-(*o*-tolyl)-5,6-dihydro-7*H*-pyrrolo[3,4-*b*]pyridin-7-one




4,6-Dichloro-*N*-(2,4-dimethoxybenzyl)picolinamide



[1028] Step 1: To a solution of 4,6-dichloropicolinic acid (50.0 g, 260 mmol, 1.00 eq) in DCM (250 mL) was added CDI (44.3 g, 273 mmol, 1.05 eq) and DMAP (1.59 g, 13.02


mmol, 0.05 eq), and the mixture was stirred at 45 °C for 2 h. Then the mixture was cooled to 15 °C, and a solution of 2,4-dimethoxybenzylamine (43.5 g, 260 mmol, 39.2 mL, 1.00 eq) in DCM (50 mL) was added. The mixture was stirred at 15 °C for 5 h. Water (700 mL) was added, and the mixture was extracted with DCM (3 x 300 mL). The organic phase was adjusted to pH = 4 with 1M HCl, and extracted with DCM (300 mL). The combined organic layers were washed with satd. NaCl (50 mL), dried over Na_2SO_4, filtered, and concentrated under reduced pressure to afford 4,6-dichloro-*N*-(2,4-dimethoxybenzyl)picolinamide (68.0 g, 165 mmol, 63.5% yield, 83.0% purity) as a white solid. MS: *m/z* = 341.0 $[M+H]^+$; ^1H NMR (400 MHz, $CDCl_3$) δ 8.15 (s, 1H), 8.14 (s, 1H), 7.45 (d, *J* = 0.8 Hz, 1H), 7.26 (t, *J* = 7.2 Hz, 1H), 6.50 - 6.42 (m, 2H), 3.88 (s, 3H), 3.80 (s, 3H).

4,6-Dichloro-*N*-(2,4-dimethoxybenzyl)-*N*-(2-methylbenzoyl)picolinamide




[1029] Step 2: To a suspension of NaH (10.6 g, 264 mmol, 60% purity, 1.50 eq) in THF (300 mL) at 0 °C under N_2 was added 4,6-dichloro-*N*-(2,4-dimethoxybenzyl)picolinamide (60.0 g, 176 mmol, 1.00 eq) in THF (100 mL). The mixture was stirred at 0 °C for 0.5 h. Then, 2-methylbenzoyl chloride (28.8 g, 186 mmol, 24.2 mL, 1.06 eq) was added dropwise at 0 °C, and the mixture was stirred at 0 °C for 2 h. The mixture was quenched with 1.0 L of NH_4Cl and extracted with ethyl acetate (3 x 500 mL). The combined organic layers were washed with brine, dried over Na_2SO_4, and concentrated. The residue was purified by silica gel column chromatography (petroleum ether:ethyl acetate = 100:0 to 100:6) to afford 4,6-dichloro-*N*-(2,4-dimethoxybenzyl)-*N*-(2-methylbenzoyl)picolinamide (35.0 g, 64.7 mmol, 36.8 yield, 84.9% purity) as a brown oil. MS: *m/z* = 483.1 $[M+Na]^+$; ^1H NMR (400 MHz, $CDCl_3$) δ 7.40 (d, *J* = 4.2 Hz, 1H), 7.37 (d, *J* = 0.8 Hz, 1H), 7.18 - 7.16 (m, 3H), 7.02 - 7.00 (m, 2H), 6.48 (d, *J* = 4.2 Hz, 1H), 6.41 (d, *J* = 1.2 Hz, 1H), 5.12 (s, 2 H), 3.80 (s, 3H), 3.66 (s, 3H), 2.44 (s, 3H).

2,4-Dichloro-6-(2,4-dimethoxybenzyl)-5-hydroxy-5-(*o*-tolyl)-5,6-dihydro-7*H*-pyrrolo[3,4-*b*]pyridin-7-one



[1030] Step 3: To a solution of 4,6-dichloro-*N*-(2,4-dimethoxybenzyl)-*N*-(2-methylbenzoyl)picolinamide (44.8 g, 97.4 mmol, 1.00 eq) in THF (450 mL) at -50 °C was added LiHMDS (1 M, 146 mL, 1.50 eq). The solution was stirred at -50 °C for 3 h. The mixture was quenched with saturated NH_4Cl solution (1.0 L) and extracted with ethyl acetate (2 x 500 mL). The organic layers were combined, washed with brine (500 mL), dried, and concentrated. The residue was purified by silica gel column chromatography (petroleum ether:ethyl acetate = 100:1 to 100:11) to afford 2,4-dichloro-6-(2,4-dimethoxybenzyl)-5-hydroxy-5-(*o*-tolyl)-5,6-dihydro-7*H*-pyrrolo[3,4-*b*]pyridin-7-one (29.0 g, 33.5 mmol, 34.3% yield, 53.0% purity) as a yellow oil. MS: *m/z* = 459.0 $[M+H]^+$; ^1H NMR (400 MHz, DMSO-d_6) δ 8.99 (t, *J* = 6.2 Hz, 1H), 8.21 (s, 1H), 7.35 (s, 1H), 7.23 (d, *J* = 3.6 Hz, 1H), 7.16 (d, *J* = 4.0 Hz, 1H) 6.88 (d, *J* = 4.0 Hz, 1H), 6.55 (d, *J* = 1.2 Hz, 1H), 6.53 - 6.50 (m, 3H), 4.24 (d, *J* = 3.2 Hz, 2H), 3.80 (s, 3H), 3.70 (s, 3H), 2.64 (s, 3H).


2,4-Dichloro-6-(2,4-dimethoxybenzyl)-5-(*o*-tolyl)-5,6-dihydro-7*H*-pyrrolo[3,4-*b*]pyridin-7-one




[1031] Step 4: To a solution of 2,4-dichloro-6-(2,4-dimethoxybenzyl)-5-hydroxy-5-(*o*-tolyl)-5,6-dihydro-7*H*-pyrrolo[3,4-*b*]pyridin-7-one (28.0 g, 32.3 mmol, 1.00 eq) and TFA (92.1 g, 808 mmol, 59.8 mL, 25.0 eq) in DCM (280 mL) was added Et_3SiH (37.6 g, 323 mmol, 51.6 mL, 10.0 eq) at 20 °C. The solution was stirred at 25 °C for 12 h. The mixture was concentrated. The crude product was purified by prep-HPLC (TFA condition) to give 2,4-

dichloro-6-(2,4-dimethoxybenzyl)-5-(*o*-tolyl)-5,6-dihydro-7*H*-pyrrolo[3,4-*b*]pyridin-7-one (7.85 g, 17.5 mmol, 54.3% yield, 99.0% purity) as a brown solid. MS: *m/z* = 443.0 $[M+H]^+$; ^{1}H NMR (400 MHz, DMSO-d_6) δ 7.95 (s, 1H), 7.23, (s, 1H), 7.09 - 7.08 (m, 1H), 6.95 (d, *J* = 4.2 Hz, 1H), 6.57 (d, *J* = 5.8 Hz, 1H) 6.51 (s, 1H), 6.50 - 6.44 (m, 1H), 5.78 (s, 1H), 4.80 (d, *J* = 7.6 Hz, 1H), 3.77 (s, 1H), 3.74 (s, 3H), 3.65 (s, 3H), 2.22 (s, 3H).

2-Chloro-6-(2,4-dimethoxybenzyl)-4-((2,4-dimethoxybenzyl)amino)-5-(*o*-tolyl)-5,6-dihydro-7*H*-pyrrolo[3,4-*b*]pyridin-7-one and 4-Chloro-6-(2,4-dimethoxybenzyl)-2-((2,4-dimethoxybenzyl)amino)-5-(*o*-tolyl)-5,6-dihydro-7*H*-pyrrolo[3,4-*b*]pyridin-7-one






[1032] Step 5: To a solution of 2,4-dichloro-6-(2,4-dimethoxybenzyl)-5-(*o*-tolyl)-5,6-dihydro-7*H*-pyrrolo[3,4-*b*]pyridin-7-one (3.92 g, 8.84 mmol, 1.00 eq) in i-PrOH (25.0 mL) was added compound 2,4-dimethoxybenzylamine (2.22 g, 13.3 mmol, 2.00 mL, 1.50 eq) and DIPEA (3.43 g, 26.5 mmol, 4.62 mL, 3.00 eq) in a sealed tube. The mixture was stirred at 160 °C for 5 h. The mixture was concentrated. The residue was purified by prep-HPLC (Column: Phenomenex Luna C18 (250*80 mm*15 μm); Mobile phase: 56% - 86% CH_3CN in water (0.1% TFA) over 20 min) to afford 2-chloro-6-(2,4-dimethoxybenzyl)-4-((2,4-dimethoxybenzyl)amino)-5-(*o*-tolyl)-5,6-dihydro-7*H*-pyrrolo[3,4-*b*]pyridin-7-one (4.79 g, 8.20 mmol, 46.4% yield, 98.24% purity) as a light yellow solid and 4-chloro-6-(2,4-dimethoxybenzyl)-2-((2,4-dimethoxybenzyl)amino)-5-(*o*-tolyl)-5,6-dihydro-7*H*-pyrrolo[3,4-*b*]pyridin-7-one (1.35 g, 2.28 mmol, 12.9% yield, 97.0% purity) as a yellow solid.

[1033] 2-Chloro-6-(2,4-dimethoxybenzyl)-4-((2,4-dimethoxybenzyl)amino)-5-(*o*-tolyl)-5,6-dihydro-7*H*-pyrrolo[3,4-*b*]pyridin-7-one: MS: *m/z* = 574.2 $[M+H]^+$; ^{1}H NMR (400 MHz, DMSO-d_6) δ 7.50 (d, *J* = 3.4 Hz, 1H), 7.29 - 7.25 (m, 2H), 7.14 - 7.10 (m, 1H), 7.00 - 6.84 (m, 1H), 6.70 - 6.63 (m, 2H) 6.52 - 6.43 (m, 4H), 5.76 - 5.38 (m, 2H), 4.79 - 4.67 (m, 1H), 4.16 - 4.14 (m,2H), 3.74 (s, 3H), 3.70 (s, 3H), 3.69 (s, 3H), 3.66 (s, 3H), 2.21 (s, 2H), 1.55 (s, 1H).

[1034] 4-Chloro-6-(2,4-dimethoxybenzyl)-2-((2,4-dimethoxybenzyl)amino)-5-(*o*-tolyl)-5,6-dihydro-7*H*-pyrrolo[3,4-*b*]pyridin-7-one: MS: *m/z* = 574.4 $[M+H]^+$; ^1H NMR (400 MHz, DMSO-d_6) δ 7.41 (s, 1H), 8.21 (s, 1H), 7.20 - 7.18 (m, 3H), 7.11 - 7.07 (m, 1H), 6.78 (d, *J* = 3.2 Hz, 1H), 6.58 (s, 1H), 6.54 (s, 1H), 6.52 - 6.50 (m, 4H), 5.52 (s, 1H), 4.75 (d,, *J* = 7.6 Hz, 3H), 4.43 (s, 2H), 3.81 (s, 3H), 3.77 (s, 3H), 3.73 (s, 3H), 3.65 (s, 3H), 2.19 (s, 2H), 1.61 (s, 1H).


4-Amino-2-chloro-6-(2,4-dimethoxybenzyl)-5-(*o*-tolyl)-5,6-dihydro-7*H*-pyrrolo[3,4-*b*]pyridin-7-one




[1035] Step 6: A solution of 2-chloro-6-(2,4-dimethoxybenzyl)-4-((2,4-dimethoxybenzyl)amino)-5-(*o*-tolyl)-5,6-dihydro-7*H*-pyrrolo[3,4-*b*]pyridin-7-one (3.60 g, 6.27 mmol, 1.00 eq) and TFA (17.9 g, 157 mmol, 11.6 mL, 25.0 eq) was stirred at 25 °C for 2 h. The mixture was poured into satd. Na_2CO_3 (200 mL) and filtered. The filtrate was extracted with ethyl acetate (2 x 150 mL). The combined organics were dried over Na_2SO_4 and concentrated. The residue was purified by reversed-phase HPLC (0.1% NH_3 H_2O) to afford 4-amino-2-chloro-6-(2,4-dimethoxybenzyl)-5-(*o*-tolyl)-5,6-dihydro-7*H*-pyrrolo[3,4-*b*]pyridin-7-one (1.18 g, 2.76 mmol, 43.9% yield, 99.1% purity) as a white solid. MS: *m/z* = 424.3 $[M+H]^+$; ^1H NMR (400 MHz, DMSO-d_6) δ 7.51 (t, *J* = 2.6 Hz, 1H), 7.28 - 7.20 (m, 2H), 7.11 - 7.08 (s, 1H), 6.98 - 6.84 (m, 1H), 6.86 (d, *J* = 9.0 Hz, 1H) 6.53 - 6.51 (m, 1H), 6.46 - 6.44 (m, 1H), 5.87 - 5.80 (m, 2H), 5.48 (d, *J* = 10.8 Hz, 1H), 4.80 - 4.66 (m, 1H), 3.74 (s, 3H), 3.70 (s, 3H), 2.24 (s, 2H), 1.59 (s, 1H).

Example 73

_N_-(5-(2-Chlorophenyl)-7-oxo-2-(1_H_-pyrazol-4-yl)-6,7-dihydro-5_H_-pyrrolo[3,4-_b_]pyridin-4-yl)benzo[_d_]isothiazole-3-carboxamide (I-94)




4-Amino-2-chloro-5-(2-chlorophenyl)-6-(4-methoxybenzyl)-5,6-dihydro-7H-pyrrolo[3,4-b]pyridin-7-one




[1036] Step 1 to 6: According to the procedures of Example 68, Steps 1 to 6, 4,6-dichloropicolinic acid, 4-methoxybenzylamine, and 2-chlorobenzoyl chloride were converted to 4-amino-2-chloro-5-(2-chlorophenyl)-6-(4-methoxybenzyl)-5,6-dihydro-7H-pyrrolo[3,4-b]pyridin-7-one. MS: m/z = 414.3 $[M+H]^+$.

N-[2-Chloro-5-(2-chlorophenyl)-6-[(4-methoxyphenyl)methyl]-7-oxo-5H,6H,7H-pyrrolo[3,4-b]pyridin-4-yl]-1,2-benzothiazole-3- carboxamide




[1037] Step 7: To a stirred solution of (1-chloro-2-methylprop-1-en-1-yl)dimethylamine (624 mg, 4.67 mmol) in toluene (3.89 mL) was added 1,2-benzothiazole-3-carboxylic acid (836 mg, 4.67 mmol). The suspension very quickly turned into a clear, light pink solution, which was stirred for 30 minutes before addition of 1.3 mL to a solution of 4-amino-2-chloro-5-(2-chlorophenyl)-6-[(4- methoxyphenyl)methyl]-5H,6H,7H-pyrrolo[3,4-b]pyridin-7-one (323 mg, 0.779 mmol) in pyridine (2.6 mL). To this reaction solution was added catalytic DMAP. The solution was stirred at room temperature for 5 minutes and then at 65°C for 30 minutes. A total of 6 equivalents of acid chloride was added in several portions. The reaction was eventually cooled to R.T. and quenched with MeOH (3 mL), then concentrated and loaded onto a 12 g silica gel column eluted with DCM to 10:90:1 MeOH/DCM/NH_4OH gradient over 25 minutes. The product eluted between 3% and 3.5% MeOH/DCM to yield a light yellow, foamy solid (316 mg, 70.5% yield). MS: *m/z* = 575.5 $[M+H]^+$.

***N*-[2-Chloro-5-(2-chlorophenyl)-7-oxo-5*H*,6*H*,7*H*-pyrrolo[3,4-*b*]pyridin-4-yl]-1,2-benzothiazole-3-carboxamide (I-93)**



[1038] Step 8: To a solution of N-[2-chloro-5-(2-chlorophenyl)-6-[(4-methoxyphenyl)methyl]-7-oxo-5H,6H,7H-pyrrolo[3,4-b]pyridin-4-yl]-1,2-benzothiazole-3-carboxamide (251 mg, 0.436 mmol) in acetonitrile (8.7 mL) was added a solution of cerium ammonium nitrate (712 mg, 1.30 mmol) in water (0.87 mL). The mixture was stirred 1 hour at RT. The reaction was treated with saturated aqueous $NaHCO_3$ (25 mL). A yellow precipitate was isolated by filtration, dried, and eluted on a 12 g silica gel column with a DCM to 10:90:1 MeOH/DCM/NH_4OH gradient over 25 minutes. The major product peak eluted between 5.5% and 6.7% MeOH/DCM. The fractions containing pure product were combined, concentrated, and dried to yield N-[2-chloro-5-(2-chlorophenyl)-7-oxo-5H,6H,7H-pyrrolo[3,4-b]pyridin-4-yl]-1,2-benzothiazole-3-carboxamide (44 mg, 21.8% yield). MS: *m/z* = 455.3 $[M+H]^+$; ^1H NMR (400 MHz, DMSO-d_6) δ 10.53 (s, 1H), 9.65 (s, 1H), 8.67 (d, 1H), 8.32 (d, 1H), 7.98 (s, 1H), 7.69 (t, 1H), 7.62 (t, 1H), 7.33 (d, 1H), 7.22 (t, 1H), 7.14 (t, 1H).

***N*-(5-(2-Chlorophenyl)-7-oxo-2-(1*H*-pyrazol-4-yl)-6,7-dihydro-5*H*-pyrrolo[3,4-*b*]pyridin-4-yl)benzo[*d*]isothiazole-3-carboxamide (I-94)**



[1039] Step 9: To a mixture of N-[2-chloro-5-(2-chlorophenyl)-7-oxo-5H,6H,7H-pyrrolo[3,4-b]pyridin-4-yl]-1,2-benzothiazole-3-carboxamide (18.3 mg, 0.04 mmol), tert-butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole-1-carboxylate (17.6 mg, 0.06 mmol, 1.5 eq), bis(triphenylphosphine) palladium (II) dichloride (4.2 mg, 0.006 mmol, 0.15 eq) in a sealed tube were added acetonitrile (0.8 mL) and a solution of sodium carbonate (12.7 mg, 0.12 mmol, 3 eq) in water (0.27 mL). The reaction mixture was briefly degassed with nitrogen before sealing the tube. The reaction mixture was then stirred at 115°C for 20 minutes before cooling back to RT. The reaction mixture was diluted with THF (5 mL) and brine (3 mL), and the layers were separated. The organic layer was dried over sodium sulfate, filtered, and concentrated. The crude was loaded as a silica gel slurry onto a 12 gram silica gel column and eluted with a gradient of DCM to 10:90:1 MeOH/DCM/NH_4OH over 20 minutes. The fractions eluting between 7% and 9% MeOH/DCM were combined, concentrated, and dried to yield racemic N-[5-(2-chlorophenyl)-7-oxo-2-(1H-pyrazol-4-yl)-5H,6H,7Hpyrrolo[3,4-b]pyridin-4-yl]-1,2-benzothiazole-3-carboxamide as a light yellow solid (6.8 mg, 35% yield). MS: m/z = 487.3 $[M+H]^+$; ^{1}H NMR (400 MHz, DMSO-d_6) δ 13.20 (br s, 1H), 10.48 (s, 1H), 9.46 (s, 1H), 8.69 (d, J = 8.1 Hz, 1H), 8.41 (br s, 1H), 8.33 (d, J = 8.1 Hz, 1H), 8.10 (br s, 1H), 8.07 (s, 1H), 7.60-7.73 (m, 3H), 7.30 (d, J = 7.8 Hz, 1H), 7.15-7.21 (m, 1H), 7.09-7.14 (m, 1H), 6.29 ppm (br s, 1H).

[1040] Additional compounds prepared according to the method of Examples 68 and 69 are listed in Table 32 below.

Table 32. Additional Exemplary Compounds


Compound
I-108
I-113
I-114
I-161
I-162
I-182

Compound
I-186
I-187
I-193
I-194
I-195
I-196


Compound
I-379
I-380
I-381
I-384
I-386

Example 74

***N*-[5-(2-Chloro-5-fluorophenyl)-2-(3,3-difluoroazetidin-1-yl)-7-oxo-5*H*,6*H*,7*H*-pyrrolo[3,4-*b*]pyridin-4-yl]-3-fluoro-5-(trifluoromethyl)benzamide (I-286)**




4-Amino-2-chloro-5-(2-chloro-5-fluorophenyl)-6-(2,4-dimethoxybenzyl)-5,6-dihydro-7*H*-pyrrolo[3,4-*b*]pyridin-7-one




[1041] Step 1 to 6: According to the procedures of Example 68, Steps 1 to 6, 4,6-dichloropicolinic acid, 2,4-dimethoxybenzylamine, and 2-chloro-5-fluorobenzoyl chloride were converted to 4-amino-2-chloro-5-(2-chloro-5-fluorophenyl)-6-(2,4-dimethoxybenzyl)-5,6-dihydro-7*H*-pyrrolo[3,4-*b*]pyridin-7-one.

***N*-(2-Chloro-5-(2-chloro-5-fluorophenyl)-6-(2,4-dimethoxybenzyl)-7-oxo-6,7-dihydro-5*H*-pyrrolo[3,4-*b*]pyridin-4-yl)-3-fluoro-5-(trifluoromethyl)benzamide**



[1042] Step 7: To a mixture of 4-amino-2-chloro-5-(2-chloro-5-fluorophenyl)-6-(2,4-dimethoxybenzyl)-5,6-dihydro-7*H*-pyrrolo[3,4-*b*]pyridin-7-one (1.00 g, 2.31 mmol) in dry pyridine (14.7 mL) under nitrogen was added dropwise 3-fluoro-5-(trifluoromethyl)benzoyl chloride (530.4 μL, 3.47 mmol). Then 4-dimethylaminopyridine (14 mg, 0.115 mmol) was added, and the mixture was stirred at ambient temperature for 6 h. The mixture was quenched with water, and the pH was adjusted with a saturated aqueous $NaHCO_3$ solution. The product was extracted with DCM. The organic phase was then dried over sodium sulfate, filtered, and concentrated by rotary evaporation. Purification by normal-phase silica chromatography (0% to 70% EtOAc/hexanes) furnished *N*-(2-chloro-5-(2-chloro-5-fluorophenyl)-6-(2,4-dimethoxybenzyl)-7-oxo-6,7-dihydro-5*H*-pyrrolo[3,4-*b*]pyridin-4-yl)-3-fluoro-5-(trifluoromethyl)benzamide as a white solid (67% yield).


***N*-(5-(2-Chloro-5-fluorophenyl)-2-(3,3-difluoroazetidin-1-yl)-6-(2,4-dimethoxybenzyl)-7-oxo-6,7-dihydro-5*H*-pyrrolo[3,4-*b*]pyridin-4-yl)-3-fluoro-5-(trifluoromethyl)benzamide**



[1043] Step 8: A vial containing *N*-(2-chloro-5-(2-chloro-5-fluorophenyl)-6-(2,4-dimethoxybenzyl)-7-oxo-6,7-dihydro-5*H*-pyrrolo[3,4-*b*]pyridin-4-yl)-3-fluoro-5-

(trifluoromethyl)benzamide (1.00 g, 1.61 mmol), 3,3-difluoroazetidine hydrochloride (416.24 mg, 3.21 mmol), and BrettPhos Pd Gen.4 (728.3 mg, 0.803 mmol) was evacuated under vacuum and purged with nitrogen. Toluene (10.7 mL, 0.15 M) was added, and the mixture was purged once more with nitrogen. Then LiHMDS (1M in THF, 8.03 mL, 8.03 mmol) was added to the mixture, and the mixture was stirred at 105 °C for 2 h. The mixture was cooled to 22 °C and quenched with DCM and water under inert atmosphere. The bi-phasic solution was then diluted with a saturated aqueous NH_4Cl solution and extracted with DCM. The organic layer was dried over sodium sulfate, filtered, and concentrated by rotary evaporation. The resulting product mixture was directly subjected to the subsequent reaction without further purification.

_N_-[5-(2-Chloro-5-fluorophenyl)-2-(3,3-difluoroazetidin-1-yl)-7-oxo-5_H_,6_H_,7_H_-pyrrolo[3,4-_b_]pyridin-4-yl]-3-fluoro-5-(trifluoromethyl)benzamide (I-286)



[1044] Step 9: The product mixture from the previous step containing _N_-(5-(2-Chloro-5-fluorophenyl)-2-(3,3-difluoroazetidin-1-yl)-6-(2,4-dimethoxybenzyl)-7-oxo-6,7-dihydro-5_H_-pyrrolo[3,4-_b_]pyridin-4-yl)-3-fluoro-5-(trifluoromethyl)benzamide (ca. 1.00 mmol) was treated with trifluoroacetic acid (22 mL) and trifluoromethanesulfonic acid (0.1 mL, 1 mmol). The resulting mixture was stirred at 90 °C for 1 h. The mixture was cooled to room temperature and concentrated. The residue was purified by C18 silica gel column chromatography (30% to 80% MeCN/10 mM Ammonium Bicarbonate aq.). The product-containing fractions were combined and lyophilized to obtain _N_-[5-(2-chloro-5-fluorophenyl)-2-(3,3-difluoroazetidin-1-yl)-7-oxo-5_H_,6_H_,7_H_-pyrrolo[3,4-_b_]pyridin-4-yl]-3-fluoro-5-(trifluoromethyl)benzamide as a white powder (64.8 mg, 11.5% over two steps). MS: m/z = 559.3 $[M+H]^+$; ^1H NMR (400 MHz, DMSO-d_6) δ 10.72 (br s, 1H), 9.30 (br s, 1H), 7.94 (d, J = 6.5 Hz, 1H), 7.71 (d, J = 9.0 Hz, 1H), 7.62 (s, 1H), 7.34 (dd, J = 8.9, 5.2 Hz, 1H), 7.17 – 6.97 (m, 1H), 6.94 – 6.56 (m, 2H), 5.91 (br s, 1H), 4.65 – 4.33 (m, 4H).


[1045] Additional compounds prepared according to the method of Examples 68-70 are listed in Table 33 below.

Table 33. Additional Exemplary Compounds


Compound	Compound	Compound
I-273	I-321	I-357
I-284	I-322	I-356
I-288	I-329	I-366
I-291	I-338	I-367
I-319	I-354	I-368

Example 75

Methyl 4-(1,2-benzothiazole-3-amido)-5-(2-chlorophenyl)-7-oxo-5*H*,6*H*,7*H*-pyrrolo[3,4-*b*]pyridine-2-carboxylate (I-222)




4-Chloro-6-(methoxycarbonyl)pyridine-2-carboxylic acid



[1046] Step 1: 4-Chloropyridine-2,6-dicarboxylic acid (8.15 g, 40.4 mmol) was mixed with thionyl chloride (58.8 mL, 807 mmol) and warmed to reflux. After 5 hours of stirring, the mixture was cooled to room temperature and stirred for 16 hours. The excess thionyl chloride was removed by rotary evaporation. The residue was dissolved with anhydrous dichloroethane (161 mL) and then cooled to 0-5 °C. Methanol (1.87 mL, 46.4 mmol) and DIPEA (8.07 mL, 46.4 mmol) were added dropwise to the mixture (exothermic). The mixture was stirred for 2.5 hours at room temperature. The volatiles were removed by rotary


evaporation. The residue containing a mixture of monomethyl ester, dimethyl ester, and starting material was purified by normal phase chromatography (0-50% acetonitrile/DCM). The pure fractions were combined, concentrated, and dried under vacuum to afford 4-chloro-6-(methoxycarbonyl)pyridine-2-carboxylic acid as an off-white solid (2.28 g, 26% yield, 90% purity by LC/MS).

Methyl 4-chloro-6-{[(4-methoxyphenyl)methyl]carbamoyl}pyridine-2-carboxylate




[1047] Step 2: Thionyl chloride (15.2 mL, 10 mmol) was added dropwise to a stirred suspension of 4-chloro-6-(methoxycarbonyl)pyridine-2-carboxylic acid (2.28 g, 10.5 mmol) in DMF (10 mL) at room temperature. After 25 mins and following gas evolution, the mixture was warmed to 40 °C for 20 mins. The excess of thionyl chloride was removed by rotary evaporation, and the residue was dissolved in dry dichloroethane (42.0 mL) and cooled to 0°C. Triethylamine (3.12 mL, 22.5 mmol) and 1-(4-methoxyphenyl)methanamine (2.04 mL, 15.7 mmol) were added to the solution. The mixture was stirred at room temperature for 1 hour. The mixture was slowly quenched with water. The layers were separated, and the aqueous layer was extracted with EtOAc. The organic layers were combined, dried over Na_2SO_4, and the solvents were evaporated. The residue was purified through normal phase silica gel chromatography (20-75% EtOAc/hexanes) to afford methyl 4-chloro-6-{[(4-methoxyphenyl)methyl]carbamoyl}pyridine-2-carboxylate as a yellow solid (2.56 g, 73% yield).

Methyl 4-chloro-5-(2-chlorophenyl)-5-hydroxy-6-[(4-methoxyphenyl)methyl]-7-oxo-5*H*,6*H*,7*H*-pyrrolo[3,4-*b*]pyridine-2-carboxylate



[1048] Step 3: To a stirred -50 °C solution of methyl 4-chloro-6-{[(4-methoxyphenyl) methyl]carbamoyl}pyridine-2-carboxylate (1.53 g, 4.57 mmol) in THF (22.8 mL) under nitrogen atmosphere was slowly added LiHMDS (1.0 M solution in THF, 5.0 mL, 5.0 mmol). The solution was stirred at -78°C for 1 hour. To the mixture was added dropwise 2-chlorobenzoyl chloride (635 µL, 5.02 mmol) over 2 minutes. The mixture was stirred 0.5 hour at -78°C and then 2.5 hours at room temperature. The mixture was cooled back between -50°C and -78°C, and then LiHMDS (1M in THF, 5.0 mL, 5.0 mmol) was slowly added. The mixture was stirred between -50°C and -78°C for 1 hour. The mixture was slowly quenched with a solution of AcOH (0.6 mL) in MeOH (25 mL). The solution was then diluted in water and EtOAc. The layers were separated, and the aqueous layer was extracted three times with EtOAc. The organic layers were combined, washed with brine, dried over Na_2SO_4, filtered, and concentrated. The residue was purified by normal phase silica chromatography (0-60% acetone/heptanes) to afford methyl 4-chloro-5-(2-chlorophenyl)-5-hydroxy-6-[(4-methoxyphenyl)methyl]-7-oxo-5*H*,6*H*,7*H*-pyrrolo[3,4-*b*]pyridine-2-carboxylate as an off-white solid (1.03 g, 38% yield).


Methyl 4-chloro-5-(2-chlorophenyl)-6-[(4-methoxyphenyl)methyl]-7-oxo-5*H*,6*H*,7*H*-pyrrolo[3,4-*b*]pyridine-2-carboxylate



[1049] Step 4: To a stirred 0°C solution of methyl 4-chloro-5-(2-chlorophenyl)-5-hydroxy-6-[(4-methoxyphenyl)methyl]-7-oxo-5*H*,6*H*,7*H*-pyrrolo[3,4-*b*]pyridine-2-carboxylate (1.03 g, 2.17 mmol) in DCM (10.8 mL) under nitrogen was added TFA (3.31 mL, 43.4 mmol) followed by triethylsilane (3.46 mL, 21.7 mmol). The mixture was then allowed to warm to room temperature and stirred for 16 hours. The mixture was cooled to 0°C and a second portion of TFA (1.65 mL, 21.7 mmol) and triethylsilane (1.73 mL, 10.9 mmol) were added. The mixture was warmed to room temperature and stirred for 16 hours. The mixture was diluted with DCM and quenched with saturated aqueous solution of $NaHCO_3$ until pH 6-7 was obtained. The layers were separated, and the aqueous layer was extracted once with DCM. The organic layers were combined, washed with brine, dried over Na_2SO_4, filtered,


and concentrated. The residue was purified by normal phase silica gel column (30-100% acetone/hexanes) to afford methyl 4-chloro-5-(2-chlorophenyl)-6-[(4-methoxyphenyl) methyl]-7-oxo-5*H*,6*H*,7*H*-pyrrolo[3,4-*b*]pyridine-2-carboxylate as a yellow solid (684.8 mg, 69% yield).

Methyl 4-azido-5-(2-chlorophenyl)-5-hydroxy-6-[(4-methoxyphenyl)methyl]-7-oxo-5*H*,6*H*,7*H*-pyrrolo[3,4-*b*]pyridine-2-carboxylate



[1050] Step 5: To a round bottom flask was added methyl 4-chloro-5-(2-chlorophenyl)-6-[(4-methoxyphenyl)methyl]-7-oxo-5*H*,6*H*,7*H*-pyrrolo[3,4-*b*]pyridine-2-carboxylate (500 mg, 1.09 mmol) in DMF (5.7 mL). Sodium azide (105 mg, 1.63 mmol) was added, and the mixture was stirred at 70°C for 1.5 hours. The mixture was cooled to room temperature, then diluted with water and extracted with DCM. The aqueous layer was extracted once more with DCM. The organic layers were combined, washed with brine, dried over Na_2SO_4, filtered, and concentrated. The resulting methyl 4-azido-5-(2-chlorophenyl)-5-hydroxy-6-[(4-methoxyphenyl)methyl]-7-oxo-5*H*,6*H*,7*H*-pyrrolo[3,4-*b*]pyridine-2-carboxylate was directly subjected to the subsequent reaction without further purification.


Methyl 4-amino-5-(2-chlorophenyl)-5-hydroxy-6-[(4-methoxyphenyl)methyl]-7-oxo-5*H*,6*H*,7*H*-pyrrolo[3,4-*b*]pyridine-2-carboxylate



[1051] Step 6: To a solution of methyl 4-azido-5-(2-chlorophenyl)-5-hydroxy-6-[(4-methoxyphenyl)methyl]-7-oxo-5*H*,6*H*,7*H*-pyrrolo[3,4-*b*]pyridine-2-carboxylate (505 mg, 1.05 mmol) in THF (10.5 mL) and water (2.10 mL) was added triphenylphosphine (826 mg,


3.15 mmol). The mixture was heated at 60°C for 2 hours. The mixture was cooled to room temperature and concentrated hydrochloric acid (2.62 mL, 31.5 mmol) was added dropwise (exothermic addition). The mixture was heated at 60°C for 2 hours and then cooled to room temperature. The volatiles were concentrated by rotary evaporation, and the residue was diluted in DCM and water. The aqueous layer was basified with a saturated aqueous solution of $NaHCO_3$. The layers were separated, and the aqueous layer was extracted twice with DCM. The organic layers were combined, washed with brine, dried over Na_2SO_4, filtered, and concentrated. The residue was purified by normal-phase silica chromatography (0-15% MeOH/DCM) follow by a second purification by normal phase silica chromatography (0-80% acetone/heptanes) to afford methyl 4-amino-5-(2-chlorophenyl)-5-hydroxy-6-[(4-methoxyphenyl)methyl]-7-oxo-5*H*,6*H*,7*H*-pyrrolo[3,4-*b*]pyridine-2-carboxylate as a yellow solid (100.7 mg, 21% yield over 2 steps).

Methyl 4-amino-5-(2-chlorophenyl)-6-[(4-methoxyphenyl)methyl]-7-oxo-5*H*,6*H*,7*H*-pyrrolo[3,4-*b*]pyridine-2-carboxylate




[1052] Step 7: To a stirred solution of methyl 4-amino-5-(2-chlorophenyl)-5-hydroxy-6-[(4-methoxyphenyl)methyl]-7-oxo-5*H*,6*H*,7*H*-pyrrolo[3,4-*b*]pyridine-2-carboxylate (87.6 mg, 0.193 mmol) in DCE (2.57 mL) under nitrogen was added trifluoroborane diethyl etherate (76.1 µL, 0.618 mmol) followed by triethylsilane (307 µL, 1.93 mmol). The mixture was heated to 80°C, stirred for 15 hours, and then cooled to room temperature. A second portion of trifluoroborane diethyl etherate (76.1 µL, 0.618 mmol) and triethylsilane (307 µL, 1.93 mmol) was added, and the mixture was heated to 80°C and stirred 15 hours. The mixture was cooled to room temperature and diluted with DCM and water. The pH was adjusted to 8-9 with a saturated aqueous solution of $NaHCO_3$. The layers were separated, and the aqueous layer was extracted with DCM twice. The organic layers were combined, washed with brine, dried over Na_2SO_4, filtered, and concentrated. The residue was directly used for the next step without any further purification.

Methyl 4-(1,2-benzothiazole-3-amido)-5-(2-chlorophenyl)-6-[(4-methoxyphenyl)methyl]-7-oxo-5*H*,6*H*,7*H*-pyrrolo[3,4-*b*]pyridine-2-carboxylate



[1053] Step 8: The residue from the previous step containing methyl 4-amino-5-(2-chlorophenyl)-6-[(4-methoxyphenyl)methyl]-7-oxo-5*H*,6*H*,7*H*-pyrrolo[3,4-*b*]pyridine-2-carboxylate (84.5 mg, 0.193 mmol) and 1,2-benzothiazole-3-carboxylic acid (44.9 mg, 0.251 mmol) were dissolved in DCM (0.96mL). *N*-Methylimidazole (53.7 uL, 0.675 mmol) was added, followed by tetramethylchloroformamidinium hexafluorophosphate (64.9 mg, 0.231 mmol). The mixture was stirred at room temperature for 16 hours and then diluted with DCM and water. The pH was adjusted to 7-8 with a saturated aqueous solution of $NaHCO_3$. The layers were separated, and the aqueous layer was extracted with DCM. The combined organics were washed with brine, dried with Na_2SO_4, filtered, and concentrated. The resulting residue was directly subjected to the subsequent reaction without further purification.

Methyl 4-(1,2-benzothiazole-3-amido)-5-(2-chlorophenyl)-7-oxo-5*H*,6*H*,7*H*-pyrrolo[3,4-*b*]pyridine-2-carboxylate (I-222)



[1054] Step 9: According to the procedures of Example 37, Step 7, methyl 4-(1,2-benzothiazole-3-amido)-5-(2-chlorophenyl)-6-[(4-methoxyphenyl)methyl]-7-oxo-5*H*,6*H*,7*H*-pyrrolo[3,4-*b*]pyridine-2-carboxylate was converted to methyl 4-(1,2-benzothiazole-3-amido)-5-(2-chlorophenyl)-7-oxo-5*H*,6*H*,7*H*-pyrrolo[3,4-*b*]pyridine-2-carboxylate. The residue was purified by normal-phase silica chromatography (0% to 10% MeOH/DCM). The

residue was suspended in water and the precipitate filtered. The solid was then dissolved with a mixture of acetonitrile/water and lyophilized to obtain methyl 4-(1,2-benzothiazole-3-amido)-5-(2-chlorophenyl)-7-oxo-5*H*,6*H*,7*H*-pyrrolo[3,4-*b*]pyridine-2-carboxylate as an off-white powder (4.62 mg, 13% yield over 3 steps). MS: *m/z* = 479.2 $[M+H]^+$; ^{1}H NMR (400 MHz, DMSO-d_6) δ 10.61 (br s, 1H), 9.70 (br s, 1H), 8.70 (d, *J* = 7.9 Hz, 1H), 8.60 (s, 1H), 8.33 (d, *J* = 8.2 Hz, 1H), 7.70 (ddd, *J* = 8.3, 7.0, 1.2 Hz, 1H), 7.67 – 7.52 (m, 1H), 7.33 (d, *J* = 7.7 Hz, 1H), 7.23 (td, *J* = 7.9, 1.6 Hz, 1H), 7.15 (td, *J* = 7.4, 1.1 Hz, 1H), 6.40 (br s, 1H), 3.97 (s, 3H).

Example 76

[1055] Selected compounds of the present invention were tested in an ADP-Glo Biochemical PIK3CA Kinase Assay. Compounds to be assayed were plated in 16 doses of 1:2 serial dilutions (20 nL volume each well) on a 1536-well plate, and the plate warmed to room temperature. PIK3CA enzyme (e.g. H1047R, E542K, E545K, or wild-type) (1 µL of 2 nM solution in Enzyme Assay Buffer (comprising 50 mM HEPES pH 7.4, 50mM NaCl, 6mM $MgCl_2$, 5mM DTT and 0.03% CHAPS)) was added and shaken for 10 seconds and preincubated for 30 minutes. To the well was added 1 µL of 200 µM ATP and 20 µM of diC8-PIP2 in Substrate Assay Buffer (50 mM HEPES pH7.4, 50mM NaCl, 5mM DTT and 0.03% CHAPS) to start the reaction, and the plate was shaken for 10 seconds, then spun briefly at 1500 rpm, and then incubated for 60 minutes at room temperature. The reaction was stopped by adding 2 µL of ADP-Glo reagent (Promega), and spinning briefly at 1500 rpm, and then incubating for 40 minutes. ADP-Glo Detection reagent (Promega) was added and the plate spun briefly at 1500 rpm, then incubated for 30 minutes. The plate was read on an Envision 2105 (Perkin Elmer), and the IC_{50} values were calculated using Genedata software.

[1056] Results of the ADP-Glo Biochemical PIK3CA Kinase Assay using H1047R PIK3CA enzyme are presented in Table 1. Compounds having an IC_{50} less than or equal to 100 nM are represented as "A"; compounds having an IC_{50} greater than 100 nM but less than or equal to 500 nM are represented as "B"; compounds having an IC_{50} greater than 500 nM but less than or equal to1 µM are represented as "C"; compounds having an IC_{50} greater than 1 µM but less than or equal to10 µM are represented as "D"; and compounds having an IC_{50} greater than 10 µM but less than or equal to 100 µM are represented as "E".

Example 77

[1057] Selected compounds of the present invention were tested in a MCF10A Cell-Based PIK3CA Kinase Assay, namely the CisBio Phospho-AKT (Ser473) HTRF assay, to measure the degree of PIK3CA-mediated AKT phosphorylation. MCF10A cells (immortalized non-transformed breast cell line) overexpressing hotspot PIK3CA mutations (including H1047R, E542K, and E545K mutations) were used. Cells were seeded at 5,000 cells per well in DMEM/F12 (Thermo Fisher Scientific) supplemented with 0.5 mg/mL hydrocortisone, 100ng/mL Cholera Toxin, 10μg/mL insulin, and 0.5% horse serum. Once plated, cells were placed in a 5% CO_2, 37 °C incubator to adhere overnight.

[1058] The following day, compounds were added to the cell plates in 12 doses of 1:3 serial dilutions. The dose response curves were run in duplicate. Compound addition was carried out utilizing an Echo 55 Liquid Handler acoustic dispenser (Labcyte). The cell plates were incubated for 2 hours in a 5% CO_2, 37 °C incubator. Following compound incubation, the cells were lysed for 60 min at room temperature. Finally, a 4-hour incubation with the HTRF antibodies was performed at room temperature. All reagents, both lysis buffer and antibodies, were used from the CisBio pAKT S473 HTRF assay kit, as per the manufacturers protocol. Plates were read on an Envision 2105 (Perkin Elmer), and the IC_{50} values were calculated using Genedata software.

[1059] Results of the MCF10A Cell-Based PIK3CA Kinase Assay are presented in Table 1. Compounds having an IC_{50} less than or equal to 1 μM are represented as "A"; compounds having an IC_{50} greater than 1 μM but less than or equal to 5 μM are represented as "B"; compounds having an IC_{50} greater than 5 μM but less than or equal to10 μM are represented as "C"; compounds having an IC_{50} greater than 10 μM but less than or equal to36 μM are represented as "D"; and compounds having an IC_{50} greater than 36 μM but less than or equal to 100 μM are represented as "E".

INCORPORATION BY REFERENCE

[1060] All publications and patents mentioned herein are hereby incorporated by reference in their entirety for all purposes as if each individual publication or patent was specifically and individually incorporated by reference. In case of conflict, the present application, including any definitions herein, will control.


EQUIVALENTS

[1061] While specific embodiments of the subject disclosure have been discussed, the above specification is illustrative and not restrictive. Many variations of the present disclosure will become apparent to those skilled in the art upon review of this specification. The full scope of the disclosure should be determined by reference to the claims, along with their full scope of equivalents, and the specification, along with such variations.

[1062] Unless otherwise indicated, all numbers expressing quantities of ingredients, reaction conditions, and so forth used in the specification and claims are to be understood as being modified in all instances by the term "about." Accordingly, unless indicated to the contrary, the numerical parameters set forth in this specification and attached claims are approximations that may vary depending upon the desired properties sought to be obtained by the present disclosure.

What is claimed is:

1. A compound of formula I-1:



I-1

or a pharmaceutically acceptable salt thereof, wherein:

E is -C(O)-, -C(R^E)$_2$-, -C(R^E)$_2$C(R^E)$_2$-, -C(S)-, -S(O)$_2$-, -OC(O)-, -N(R^E)C(O)-, -C(O)N(R^E)-, or -C(R^E)$_2$C(O)-;

Q is CH, C(R^Q), or N;

X is CH, C(R^X), or N;

Y is CH, C(R^Y), or N;

Z is CH, C(R^Z), or N;

R^1 is -L^1-R^{1A};

R^2 is -L^2-R^{2A};

each instance of R^E is independently H or -L^E-R^{EA};

R^Q is -L^Q-R^{QA};

R^X is -L^X-R^{XA};

R^Y is -L^Y-R^{YA};

R^Z is -L^Z-R^{ZA}; or

two instances of R^E are taken together with their intervening atoms to form a 3-8 membered saturated or partially unsaturated monocyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or an 8-12 membered saturated or partially unsaturated bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein each ring is substituted with n instances of R^{EEC};

R^Q and R^1 are taken together with their intervening atoms to form a 4-8 membered saturated or partially unsaturated monocyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or an 8-12 membered saturated or partially

unsaturated bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein each ring is substituted with p instances of R^{Q1C};

R^Y and R^Z are taken together with their intervening atoms to form a 4-7 membered partially unsaturated or aromatic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said ring is substituted with q instances of R^{YZC};

each of L^1, L^2, L^E, L^Q, L^X, L^Y, and L^Z is independently a covalent bond, or a C_{1-4} bivalent saturated or unsaturated, straight or branched hydrocarbon chain wherein one or two methylene units of the chain are optionally and independently replaced by $-CH(R^L)-$, $-C(R^L)_2-$, C_{3-6} cycloalkylene, C_{3-6} heterocycloalkylene, -N(R)-, -N(R)C(O)-, -N(R)C(NR)-, -N(R)C(NOR)-, -N(R)C(NCN)-, -C(O)N(R)-, $-N(R)S(O)_2-$, $-S(O)_2N(R)-$, -O-, -C(O)-, -OC(O)-, -C(O)O-, -S-, -S(O)- , or $-S(O)_2-$;

R^{1A} is R^A or R^B substituted by r^1 instances of R^{1C};

R^{2A} is R^A or R^B substituted by r^2 instances of R^{2C};

R^{EA} is R^A or R^B substituted by r^3 instances of R^{EC};

R^{QA} is R^A or R^B substituted by r^4 instances of R^{QC};

R^{XA} is R^A or R^B substituted by r^5 instances of R^{XC};

R^{YA} is R^A or R^B substituted by r^6 instances of R^{YC};

R^{ZA} is R^A or R^B substituted by r^7 instances of R^{ZC};

R^L is R^A or R^B substituted by r^8 instances of R^{LC};

each instance of R^A is independently oxo, deuterium, halogen, -CN, $-NO_2$, -OR, $-SF_5$, -SR, $-NR_2$, $-S(O)_2R$, $-S(O)_2NR_2$, $-S(O)_2F$, -S(O)R, $-S(O)NR_2$, -S(O)(NR)R, -S(O)(NCN)R, -S(NCN)R, -C(O)R, -C(O)OR, $-C(O)NR_2$, -C(O)N(R)OR, -OC(O)R, $-OC(O)NR_2$, -N(R)C(O)OR, -N(R)C(O)R, $-N(R)C(O)NR_2$, $-N(R)C(NR)NR_2$, $-N(R)S(O)_2NR_2$, $-N(R)S(O)_2R$, $-P(O)R_2$, -P(O)(R)OR, or $-B(OR)_2$;

each instance of R^B is independently a C_{1-6} aliphatic chain; phenyl; naphthyl; cubanyl; adamantyl; a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; an 8-10 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring; a 5-12 membered saturated or partially unsaturated bicyclic carbocyclic ring; a 3-7 membered

saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or a 7-12 membered saturated or partially unsaturated bicyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;


each instance of R^{1C}, R^{2C}, R^{EC}, R^{QC}, R^{XC}, R^{YC}, R^{ZC}, R^{LC}, R^{EEC}, R^{Q1C}, and R^{YZC} is independently oxo, deuterium, halogen, -CN, $-NO_2$, -OR, $-SF_5$, -SR, $-NR_2$, $-S(O)_2R$, $-S(O)_2NR_2$, $-S(O)_2F$, -S(O)R, $-S(O)NR_2$, -S(O)(NR)R, -C(O)R, -C(O)OR, $-C(O)NR_2$, -C(O)N(R)OR, -OC(O)R, $-OC(O)NR_2$, -N(R)C(O)OR, -N(R)C(O)R, $-N(R)C(O)NR_2$, $-N(R)C(NR)NR_2$, $-N(R)S(O)_2NR_2$, $-N(R)S(O)_2R$, $-P(O)R_2$, -P(O)(R)OR, $-B(OR)_2$, or an optionally substituted group selected from C_{1-6} aliphatic, phenyl, a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;

each instance of R is independently hydrogen, or an optionally substituted group selected from C_{1-6} aliphatic, phenyl, a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or

two R groups on the same nitrogen are taken together with their intervening atoms to form a 4-7 membered saturated, partially unsaturated, or heteroaryl ring having 0-3 heteroatoms, in addition to the nitrogen, independently selected from nitrogen, oxygen, and sulfur; and

each of n, p, q, r^1, r^2, r^3, r^4, r^5, r^6, r^7, and r^8 is independently 0, 1, 2, 3, 4, or 5.

2. A compound of formula I:



I

or a pharmaceutically acceptable salt thereof, wherein:

E is -C(O)-, -C(R^E)$_2$-, -C(R^E)$_2$C(R^E)$_2$-, -C(S)-, -S(O)$_2$-, -OC(O)-, -N(R^E)C(O)-, -C(O)N(R^E)-, or -C(R^E)$_2$C(O)-;

Q is CH, C(R^Q), or N;

X is CH, C(R^X), or N;

Y is CH, C(R^Y), or N;

Z is CH, C(R^Z), or N;

R^1 is -L^1-R^{1A};

R^2 is -L^2-R^{2A};

each instance of R^E is independently H or -L^E-R^{EA};

R^Q is -L^Q-R^{QA};

R^X is -L^X-R^{XA};

R^Y is -L^Y-R^{YA};

R^Z is -L^Z-R^{ZA}; or

two instances of R^E are taken together with their intervening atoms to form a 3-8 membered saturated or partially unsaturated monocyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or an 8-12 membered saturated or partially unsaturated bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein each ring is substituted with n instances of R^{EEC};

R^Q and R^1 are taken together with their intervening atoms to form a 4-8 membered saturated or partially unsaturated monocyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or an 8-12 membered saturated or partially unsaturated bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein each ring is substituted with p instances of R^{Q1C};

R^Y and R^Z are taken together with their intervening atoms to form a 4-7 membered partially unsaturated or aromatic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said ring is substituted with q instances of R^{YZC};

each of L^1, L^2, L^E, L^Q, L^X, L^Y, and L^Z is independently a covalent bond, or a C_{1-4} bivalent saturated or unsaturated, straight or branched hydrocarbon chain wherein one or two methylene units of the chain are optionally and independently replaced by -CH(R^L)-,

$-C(R^L)_2-$, C_{3-6} cycloalkylene, C_{3-6} heterocycloalkylene, -N(R)-, -N(R)C(O)-, -N(R)C(NR)-, -N(R)C(NOR)-, -N(R)C(NCN)-, -C(O)N(R)-, $-N(R)S(O)_2-$, $-S(O)_2N(R)-$, -O-, -C(O)-, -OC(O)-, -C(O)O-, -S-, -S(O)- , or $-S(O)_2-$;

R^{1A} is R^A or R^B substituted by r^1 instances of R^{1C};

R^{2A} is R^A or R^B substituted by r^2 instances of R^{2C};

R^{EA} is R^A or R^B substituted by r^3 instances of R^{EC};

R^{QA} is R^A or R^B substituted by r^4 instances of R^{QC};

R^{XA} is R^A or R^B substituted by r^5 instances of R^{XC};

R^{YA} is R^A or R^B substituted by r^6 instances of R^{YC};

R^{ZA} is R^A or R^B substituted by r^7 instances of R^{ZC};

R^L is R^A or R^B substituted by r^8 instances of R^{LC};

each instance of R^A is independently oxo, deuterium, halogen, -CN, $-NO_2$, -OR, $-SF_5$, -SR, $-NR_2$, $-S(O)_2R$, $-S(O)_2NR_2$, $-S(O)_2F$, -S(O)R, $-S(O)NR_2$, -S(O)(NR)R, -C(O)R, -C(O)OR, $-C(O)NR_2$, -C(O)N(R)OR, -OC(O)R, $-OC(O)NR_2$, -N(R)C(O)OR, -N(R)C(O)R, $-N(R)C(O)NR_2$, $-N(R)C(NR)NR_2$, $-N(R)S(O)_2NR_2$, $-N(R)S(O)_2R$, $-P(O)R_2$, -P(O)(R)OR, or $-B(OR)_2$;

each instance of R^B is independently a C_{1-6} aliphatic chain; phenyl; naphthyl; cubanyl; adamantyl; a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; an 8-10 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring; a 5-12 membered saturated or partially unsaturated bicyclic carbocyclic ring; a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or a 7-12 membered saturated or partially unsaturated bicyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;

each instance of R^{1C}, R^{2C}, R^{EC}, R^{QC}, R^{XC}, R^{YC}, R^{ZC}, R^{LC}, R^{EEC}, R^{Q1C}, and R^{YZC} is independently oxo, deuterium, halogen, -CN, $-NO_2$, -OR, $-SF_5$, -SR, $-NR_2$, $-S(O)_2R$, $-S(O)_2NR_2$, $-S(O)_2F$, -S(O)R, $-S(O)NR_2$, -S(O)(NR)R, -C(O)R, -C(O)OR, $-C(O)NR_2$, -C(O)N(R)OR, -OC(O)R, $-OC(O)NR_2$, -N(R)C(O)OR, -N(R)C(O)R, $-N(R)C(O)NR_2$,

-N(R)C(NR)NR_2, -N(R)$S(O)_2NR_2$, -N(R)$S(O)_2R$, -$P(O)R_2$, -P(O)(R)OR, -$B(OR)_2$, or an optionally substituted group selected from C_{1-6} aliphatic, phenyl, a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;

each instance of R is independently hydrogen, or an optionally substituted group selected from C_{1-6} aliphatic, phenyl, a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or

two R groups on the same nitrogen are taken together with their intervening atoms to form a 4-7 membered saturated, partially unsaturated, or heteroaryl ring having 0-3 heteroatoms, in addition to the nitrogen, independently selected from nitrogen, oxygen, and sulfur; and

each of n, p, q, r^1, r^2, r^3, r^4, r^5, r^6, r^7, and r^8 is independently 0, 1, 2, 3, or 4.


3. The compound of claim 1 or 2, wherein the compound is a compound of formula III:



III

or a pharmaceutically acceptable salt thereof.


4. The compound of claim 1 or 2, wherein the compound is a compound of formula IV:




IV

or a pharmaceutically acceptable salt thereof.


5. The compound of claim 1 or 2, wherein the compound is a compound of formula V, VI, or VII:



V




VI




VII

or a pharmaceutically acceptable salt thereof.


6. The compound of claim 1 or 2, wherein the compound is a compound of formula VIII, IX, or X:



VIII



IX




X

or a pharmaceutically acceptable salt thereof.


7. The compound of claim 1 or 2, wherein the compound is a compound of formula XI, XII, or XIII:



XI



XII



XIII

or a pharmaceutically acceptable salt thereof.

8. The compound of claim 1 or 2, wherein the compound is a compound of formula XIV, XV, or XVI:



XIV



XV



XVI

or a pharmaceutically acceptable salt thereof.

9. The compound of any one of the preceding claims, wherein X is CH.

10. The compound of claim 1 or 2, wherein the compound is a compound of formula XXVIII:



XXVIII

or a pharmaceutically acceptable salt thereof.


11. The compound of any one of the preceding claims, wherein Z is CH or N.

12. The compound of any one of the preceding claims, wherein L^1 is a covalent bond.

13. The compound of any one of the preceding claims, wherein R^{1A} is R^B substituted by r^1 instances of R^{1C}.

14. The compound of any one of the preceding claims, wherein R^{1A} is phenyl or an 8-10 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein R^{1A} is substituted by r^1 instances of R^{1C}.

15. The compound of any one of the preceding claims, wherein R^{1A} is phenyl substituted by r^1 instances of R^{1C}.

16. The compound of any one of the preceding claims, wherein R^1 is .

17. The compound of any one of the preceding claims, wherein each instance of R^{1C} is independently halogen, -CN, -O-(C_{1-6} aliphatic), or C_{1-6} aliphatic; wherein each C_{1-6} aliphatic is optionally substituted with one or more halogen atoms.





18. The compound of any one of the preceding claims, wherein each instance of R^{1C} is independently halogen or C_{1-3} aliphatic optionally substituted with 1-3 halogen.



19. The compound of any one of the preceding claims, wherein R^2 is -N(H)C(O)-R^{2A}, -N(H)C(O)N(H)-R^{2A}, -C(O)N(H)-R^{2A}, -N(H)-R^{2A}, -$S(O)_2CH_2$-R^{2A}, -$CH_2S(O)_2$-R^{2A}, or -C(H)(CH_3)OH.


20. The compound of any one of the preceding claims, wherein R^2 is -N(H)C(O)-R^{2A}.

21. The compound of any one of the preceding claims, wherein R^{2A} is R^B substituted by r^2 instances of R^{2C}.

22. The compound of any one of the preceding claims, wherein R^{2A} is phenyl; naphthyl; an 8-10 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or a 7-12 membered saturated or partially unsaturated bicyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein R^{2A} is substituted by r^2 instances of R^{2C}.

23. The compound of any one of claims 1-20, wherein R^{2A} is , , , or .

24. The compound of any one of claims 1-18, wherein R^2 is , .



25. The compound of any one of the preceding claims, wherein each instance of R^{2C} is independently halogen, -CN, -O-(C_{1-6} aliphatic), or C_{1-6} aliphatic; wherein each C_{1-6} aliphatic is optionally substituted with one or more halogen atoms.











26. The compound of any one of the preceding claims, wherein each instance of R^{2C} is independently halogen or C_{1-3} aliphatic optionally substituted with 1-3 halogen.

27. The compound of any one of the preceding claims, wherein Y is $C(R^{YA})$.

28. The compound of any one of the preceding claims, wherein R^{YA} is a C_{1-4} aliphatic chain; a 3-5 membered saturated or partially unsaturated monocyclic carbocyclic ring; or a 3-5 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein R^{YA} is substituted by r^6 instances of a group independently selected from halogen, -CN, -OH, -O-(optionally substituted C_{1-3} aliphatic), and an optionally substituted C_{1-3} aliphatic.

29. The compound of any one of claims 1-27, wherein R^{YA} is an 8-10 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said ring is substituted by r^6 instances of R^{YC}.

30. The compound of any one of claims 1-27, wherein R^{YA} is a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is substituted by r^6 instances of R^{YC}.

31. The compound of any one of claims 1-27, wherein R^{YA} is , , , , , , , , , or .

32. The compound of any one of claims 1-27 or 29-31, wherein each instance of R^{YC} is independently oxo, halogen, -CN, -OH, -O-(C_{1-3} aliphatic), or C_{1-3} aliphatic, wherein each C_{1-3} aliphatic is optionally substituted with one or more halogen atoms.

33. A compound selected from those set forth in Table 1, or a pharmaceutically acceptable salt thereof.

34. A pharmaceutical composition, comprising a compound of any one of the preceding claims, and a pharmaceutically acceptable carrier.

35. A method of inhibiting PI3Kα signaling activity in a subject, comprising administering a therapeutically effective amount of a compound of any of claims 1-33, or the pharmaceutical composition of claim 34, to a subject in need thereof.

36. A method of treating a PI3Kα-mediated disorder in a subject, comprising administering a therapeutically effective amount of a compound of any of claims 1-33, or the pharmaceutical composition of claim 34, to a subject in need thereof.

37. A method of treating a cellular proliferative disease in a subject, comprising administering a therapeutically effective amount of a compound of any of claims 1-33, or the pharmaceutical composition of claim 34, to a subject in need thereof.

38. The method of claim 37, wherein the cellular proliferative disease is cancer.

39. The method of claim 38, wherein the cancer is breast cancer.

40. The method of claim 38, wherein the cancer is ovarian cancer.

41. The method of claim 40, wherein the ovarian cancer is clear cell ovarian cancer.

42. The method of any one of claims 35-41, wherein the subject has PI3Kα containing at least one of the following mutations: H1047R, E542K, and E545K.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 21/29882

A. CLASSIFICATION OF SUBJECT MATTER

IPC - A61K 31/4035; C07D 209/46 (2021.01)

CPC - A61K 31/4035; C07D 209/46

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
See Search History document

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched
See Search History document

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
See Search History document

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	PUBCHEM-SID:381053983 Deposit Date: 30 January 2019 (30.01.2019) pages 1-6; pg 6	1-3, 5, 7, 10
A	PUBCHEM-SID:368778762 Deposit Date: 25 May 2018 (25.05.2018) pages 1-5; pg 2	1-3, 5, 7, 10
A	US 2014/0038936 A1 (VERTEX PHARMACEUTICALS INCORPORATED) 06 February 2014 (06.02.2014) para [0002], [0037], [0075]-[0083]	1-3, 5, 7, 10
A	US 2019/0016708 A1 (ASTEX THERAPEUTICS LIMITED et al.) 17 January 2019 (17.01.2019) para [1654] deuter	1-3, 5, 7, 10

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:
"A" document defining the general state of the art which is not considered to be of particular relevance
"D" document cited by the applicant in the international application
"E" earlier application or patent but published on or after the international filing date
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
"O" document referring to an oral disclosure, use, exhibition or other means
"P" document published prior to the international filing date but later than the priority date claimed
"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
29 June 2021 (29.06.2021)	SEP 24 2021
Name and mailing address of the ISA/US Mail Stop PCT, Attn: ISA/US, Commissioner for Patents P.O. Box 1450, Alexandria, Virginia 22313-1450 Facsimile No. 571-273-8300	Authorized officer Kari Rodriquez Telephone No. PCT Helpdesk: 571-272-4300

Form PCT/ISA/210 (second sheet) (July 2019)

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 21/29882

Attachment to Box.No.III:

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1. In order for all inventions to be searched, the appropriate additional search fees must be paid.

Group I+: Claims 1-8, 10 and 33, directed to a compound according to Formula I-1 or Formula I or a pharmaceutically acceptable salt thereof, as described in claims 1 and 2 and further represented by Formula III, IV, V, VI, VII, VIII, IX, X, XI, XII, XIII, XIV, XV, XVI or XXVIII or a pharmaceutically acceptable salt thereof and selected from the compounds listed in Table 1 [see para [0602] of the specification for structures].
The compound will be searched to the extent that the compound encompasses the first species of claim 1, represented by Formula I-1, wherein
E is -C(O)-; Q, X, Y and Z are each CH;
R1 is L1-R1A and R2 is L2-R2A, wherein L1 and L2 are each a covalent bond;
R1A is RA substituted by r1 instances of R1C, wherein RA is deuterium (first monovalent substituent) and r1 is 0;
R2A is RA substituted by r2 instances of R2C, wherein RA is deuterium (first monovalent substituent) and r2 is 0.
It is believed that claims 1-3, 5, 7 and 10 read on this first named invention, and thus this claim will be searched without fee to the extent that it encompasses the first species of claim 1, described above.
Applicant is invited to elect additional compound(s) wherein each additional compound elected will require one additional invention fee. Applicants must specify the claims that encompass any additionally elected compound. Applicants must further indicate, if applicable, the claims which encompass the first named invention, if different than what was indicated above for this group. Failure to clearly identify how any paid additional invention fees are to be applied to the '+' group(s) will result in only the first claimed invention to be searched.
Additionally, an exemplary election wherein different actual variables are selected is suggested. An exemplary election would be the first -listed compound of Table 1, [see para [0602] of the specification for structure] represented by Formula (I), wherein
E is -C(O)-; Q, X, Y and Z are each CH;
R1 is L1-R1A, where L1 is a covalent bond and R1A is RB, substituted with r1 instances of R1C, wherein RB is phenyl; r1 is 1 and R1C is Ci-aliphatic which is unsubstituted;
R2 is L2-R2A, wherein L2 is C2-bivalent saturated straight hydrocarbon chain, wherein two methylene units are replaced by -NR and -C(O)-, where R is H;
R2A is RB substituted by r2 instances of R2C, wherein RB is a 9-membered bicyclic heteroaryl, having one heteroatom, which is sulfur; and r2 is 0 (i.e., claims 1-3, 5, 7 and 33).

The group of inventions listed above do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

Special Technical Features:

Group I+ includes the technical feature of a unique compound, which is not required by any other invention of Group I+.

Common technical features:

The inventions of Group I+ share the technical features of a compound of Formula (I-1) or Formula I.

This shared technical feature, however, does not provide a contribution over the prior art, as being anticipated by PUBCHEM-SID: 368778762 Deposit date: 25 May 2018 (hereinafter Pubchem), which discloses a compound of Formula (I-1) or Formula I, wherein
E is -C(O)-; Q, X, Y and Z are each CH;
R1 is L1-R1A and R2 is L2-R2A, wherein L1 and L2 are each a covalent bond;
R1A is RB substituted by r1 instances of R1C, wherein RB is C1-aliphatic and r1 is 0; and
R2A is RB substituted by r2 instances of R2C, wherein RB is C1-aliphatic and r2 is 0 (pg 2, structure).

As said compound was known in the art at the time of the invention, this cannot be considered a special technical feature, that would otherwise unify the inventions of Group I+.

The inventions of Groups I+, thus lack unity under PCT Rule 13.

Item 4(contd.): Claims 9, 11-32 and 34-42 are unsearchable because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a). These claims are, therefore, not included in the above analysis.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 21/29882

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☒ Claims Nos.: 9, 11-32 and 34-42
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:
---Please see attached sheet--

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.

2. ☐ As all searchable claims could be searched without effort justifying additional fees, this Authority did not invite payment of additional fees.

3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
1-3, 5, 7 and 10

Remark on Protest

☐ The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.

☐ The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.

☐ No protest accompanied the payment of additional search fees.